PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Andegeko, Y; Moyal, L; Mittelman, L; Tsarfaty, I; Shiloh, Y; Rotman, G				Andegeko, Y; Moyal, L; Mittelman, L; Tsarfaty, I; Shiloh, Y; Rotman, G			Nuclear retention of ATM at sites of DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELANGIECTASIA GENE-PRODUCT; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; DAMAGE RESPONSE; IN-VIVO; PROTEIN; PHOSPHORYLATION; LOCALIZATION; ACTIVATION; COMPLEX	The ATM protein kinase mediates a rapid induction of cellular responses to DNA double strand breaks (DSBs). ATM kinase activity is enhanced immediately after exposure of cells to DSB-inducing agents, but no changes in its amount or subcellular location following that activation have been reported. We speculated that some of the ATM molecules associate with sites of DSBs, while the rest of the nuclear ATM pool remains in the nucleoplasm, masking detection of the damage-associated ATM fraction. Using detergent extraction to remove nucleoplasmic proteins, we show here that immediately following induction of DSBs, a fraction of the ATM pool becomes resistant to extraction and is detected in nuclear aggregates. Colocalization of the retained ATM with the phosphorylated form of histone H2AX (gamma -H2AX) and with foci of the Nbs1 protein suggests that ATM associates with sites of DSBs. The striking correlation between the appearance of retained ATM and of gamma -H2AX, and the rapid association of a fraction of ATM with gamma -H2AX foci, are consistent with a major role for ATM in the early detection of DSBs and subsequent induction of cellular responses.	Tel Aviv Univ, Sackler Sch Med, David & Inez Myers Lab Genet Res, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Interdept Core Facil, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Shiloh, Y (corresponding author), Tel Aviv Univ, Sackler Sch Med, David & Inez Myers Lab Genet Res, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel.			Tsarfaty, Ilan/0000-0002-5230-7093	NINDS NIH HHS [R01 NS 31763] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn JY, 2000, CANCER RES, V60, P5934; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HOLMES TJ, 1992, J OPT SOC AM A, V9, P1052, DOI 10.1364/JOSAA.9.001052; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Michelson RJ, 2000, BIOESSAYS, V22, P966, DOI 10.1002/1521-1878(200011)22:11<966::AID-BIES2>3.3.CO;2-C; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Ronen D, 1999, CELL GROWTH DIFFER, V10, P131; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sarkaria JN, 1998, CANCER RES, V58, P4375; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	33	215	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38224	38230						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11454856				2022-12-25	WOS:000171526500068
J	Krogh, BO; Shuman, S				Krogh, BO; Shuman, S			Vaccinia topoisomerase mutants illuminate conformational changes during closure of the protein clamp and assembly of a functional active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-DNA TOPOISOMERASE; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; DUPLEX DNA; CATALYTIC MECHANISM; COVALENT CATALYSIS; KINETIC-ANALYSIS; FLP RECOMBINASE; STRAND CLEAVAGE; RESIDUES	We present a mutational analysis of vaccinia topoisomerase that highlights the contributions of five residues in the catalytic domain (Phe-88 and Phe-101 in helix alpha1, Ser-204 in alpha5, and Lys-220 and Asn-228 in alpha6) to the DNA binding and transesterification steps. When augmented by structural information from exemplary type IB topoisomerases and tyrosine recombinases in different functional states, the results suggest how closure of the protein clamp around duplex DNA and assembly of a functional active site might be orchestrated by internal conformational changes in the catalytic domain. Lys-220 is a constituent of the active site, and a positive charge at this position is required for optimal DNA cleavage. Ser-204 and Asn-228 appear not to be directly involved in reaction chemistry at the scissile phosphodiester. We propose that (i) Asn-228 recruits the Tyr-274 nucleophile to the active site by forming a hydrogen bond to the main chain of the tyrosine-containing alpha8 helix and that (ii) contacts between Ser-204 and the DNA backbone upstream of the cleavage site trigger a separate conformational change required for active site assembly. Mutations of Phe-88 and Phe-101 affect DNA binding, most likely at the clamp closure step, which we posit to entail a distortion of helix alpha1.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGIN AB, 1995, NUCLEIC ACIDS RES, V15, P2973; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P11367; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hwang Y, 1999, J BIOL CHEM, V274, P9160, DOI 10.1074/jbc.274.14.9160; KLEMPERER N, 1993, J BIOL CHEM, V268, P15887; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; Sekiguchi J, 1997, J BIOL CHEM, V272, P15721, DOI 10.1074/jbc.272.25.15721; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P29760; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Wang LK, 1997, BIOCHEMISTRY-US, V36, P7944, DOI 10.1021/bi970498q; Wittschieben J, 1998, NUCLEIC ACIDS RES, V26, P490, DOI 10.1093/nar/26.2.490; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	43	7	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36091	36099		10.1074/jbc.M102609200	http://dx.doi.org/10.1074/jbc.M102609200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11441004	hybrid			2022-12-25	WOS:000171194500008
J	Ohtsubo, Y; Delawary, M; Kimbara, K; Takagi, M; Ohta, A; Nagata, Y				Ohtsubo, Y; Delawary, M; Kimbara, K; Takagi, M; Ohta, A; Nagata, Y			BphS, a key transcriptional regulator of bph genes involved in polychlorinated biphenyl/biphenyl degradation in Pseudomonas sp KKS102	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN KKS102; BIPHENYL DEGRADATION; NEGATIVE REGULATOR; TRANSPOSON TN4371; IDENTIFICATION; OPERON; DNA; INITIATION; REPRESSION; EXPRESSION	The bph genes in Pseudomonas sp. KKS102, which are involved in the degradation of polychlorinated biphenyl/biphenyl, are induced in the presence of biphenyl. In this study our goal was to understand the regulatory mechanisms involved in the inducible expression. The bph genes (bphEGF(orf4)A1A2A3BCD(orf1)A4R) constitute an operon, and its expression is strongly dependent on the pE promoter located upstream of the bphE gene. A bphS gene, whose deduced amino acid sequence showed homology with the GntR family transcriptional repressors, was identified at the upstream region of the bphE gene. Disruption of the bphS gene resulted in constitutive expression of bph genes, suggesting that the bphS gene product negatively regulated the pE promoter. The gel retardation and DNase footprinting analyses demonstrated specific binding of BphS to the pE promoter region and identified four BphS binding sites that were located within and immediately downstream of the - 10 box of the pE promoter. The four binding sites were functional in repression because their respective elimination resulted in derepression of the pE promoter. The binding of BphS was abolished in the presence of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid, an intermediate compound in the biphenyl degradation pathway. We concluded that the negative regulator BphS plays a central role in the regulation of bph gene expression through its action at the pE promoter.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Railway Tech Res Inst, Kokubunji, Tokyo 1858540, Japan; Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 9808577, Japan	University of Tokyo; Tohoku University	Ohtsubo, Y (corresponding author), RIKEN, Inst Phys & Chem Res, Microbiol Lab, Hirosawa 2-1, Wako, Saitama 3510198, Japan.	yohtsubo@postman.riken.go.jp						ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; Arai H, 1999, MOL MICROBIOL, V33, P1132, DOI 10.1046/j.1365-2958.1999.01554.x; Brenner Vladimir, 1994, Biodegradation, V5, P359, DOI 10.1007/BF00696470; FUJITA Y, 1987, P NATL ACAD SCI USA, V84, P4524, DOI 10.1073/pnas.84.13.4524; FUKUDA M, 1994, BIOCHEM BIOPH RES CO, V202, P850, DOI 10.1006/bbrc.1994.2008; Furukawa Kensuke, 1994, Biodegradation, V5, P289, DOI 10.1007/BF00696466; HAWLEY DK, 1985, J BIOL CHEM, V260, P8618; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; Hopwood D. A., 1985, GENETIC MANIPULATION; KIKUCHI Y, 1994, J BACTERIOL, V176, P1689, DOI 10.1128/jb.176.6.1689-1694.1994; KIKUCHI Y, 1994, J BACTERIOL, V176, P4269, DOI 10.1128/jb.176.14.4269-4276.1994; KIMBARA K, 1988, AGR BIOL CHEM TOKYO, V52, P2885, DOI 10.1080/00021369.1988.10869161; KIMBARA K, 1989, J BACTERIOL, V171, P2740, DOI 10.1128/jb.171.5.2740-2747.1989; Lewis DEA, 1999, MOL MICROBIOL, V31, P451, DOI 10.1046/j.1365-2958.1999.01186.x; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Merlin C, 1997, MOL GEN GENET, V253, P499; Mouz S, 1999, MOL GEN GENET, V262, P790, DOI 10.1007/s004380051142; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Ohtsubo Y, 2000, GENE, V256, P223, DOI 10.1016/S0378-1119(00)00349-8; Rodionov DA, 2000, MOL MICROBIOL, V38, P673, DOI 10.1046/j.1365-2958.2000.02115.x; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; Seah SYK, 1998, J BIOL CHEM, V273, P22943, DOI 10.1074/jbc.273.36.22943; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SPRINGAEL D, 1993, J BACTERIOL, V175, P1674, DOI 10.1128/JB.175.6.1674-1681.1993; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Watanabe T, 2000, J BIOL CHEM, V275, P31016, DOI 10.1074/jbc.M003023200	29	38	43	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36146	36154		10.1074/jbc.M100302200	http://dx.doi.org/10.1074/jbc.M100302200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11459836	hybrid			2022-12-25	WOS:000171194500015
J	Tomita, T; Ogo, S; Egawa, T; Shimada, H; Okamoto, N; Imai, Y; Watanabe, Y; Ishimura, Y; Kitagawa, T				Tomita, T; Ogo, S; Egawa, T; Shimada, H; Okamoto, N; Imai, Y; Watanabe, Y; Ishimura, Y; Kitagawa, T			Elucidation of the differences between the 430-and 455-nm absorbing forms of P450-isocyanide adducts by resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE REDUCTASE; CRYSTAL-STRUCTURE; FUSARIUM-OXYSPORUM; LIVER-MICROSOMES; BOUND FORMS; CYTOCHROME-P-450; RESOLUTION; COMPLEXES; MYOGLOBIN; PURIFICATION	Alkylisocyanide adducts of microsomal P450 exist in two interconvertible forms, each giving the Soret maximum around 430 or 455 nm. This is demonstrated with a rabbit liver P450 2B4. Resonance Raman spectra of the 430- and 455-nm forms were examined for typical P450s of the two types as well as for P450 2B4 because the 430-nm form of P450 2B4 is liable to change into P420. P450cam and P450nor were selected as a model of the 430- and 455-nm forms, respectively. For the n-butyl isocyanide (CNBu) adduct, the Fe(Il)-CN-Bu stretching band was observed for the first time at 480/467 cm(-1) for P450cam and at 471/459 cm(-1) for P450nor with their (CNBu)-C-12/(CNBu)-C-13 derivatives. For P450cam, but not P450nor, other C-13 isotope-sensitive bands were observed at 412/402, 844/835, and 940/926 cm(-1). The C-N stretching mode was identified by Fourier transform IR spectroscopy at 2116/2080 cm(-1) for P450cam and at 2148/2108 cm(-1) for P450nor for the C-12/C-13 derivatives. These findings suggest that the binding geometry of isocyanide differs between the two forms bent and linear structures for P450cam-CNBu and P450nor-CNBu, respectively. In contrast, in the ferric state, the Raman C-13 isotopic frequency shifts, and the IR C-N stretching frequencies (2213/2170 and 2215/2172 cm(-1)) were similar between P450cam and P450nor, suggesting similar bent structures for both.	Okazaki Natl Res Inst, Inst Mol Sci, Okazaki, Aichi 4448585, Japan; Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan; Univ Osaka Prefecture, Dept Vet Sci, Sakai, Osaka 5998531, Japan	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB); Keio University; Osaka Metropolitan University	Kitagawa, T (corresponding author), Okazaki Natl Res Inst, Inst Mol Sci, Okazaki, Aichi 4448585, Japan.			Tomita, Takeshi/0000-0001-6815-2244				CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DEATHERAGE JF, 1976, J MOL BIOL, V104, P687, DOI 10.1016/0022-2836(76)90129-7; DENT T, 2001, J AM CHEM SOC, V123, P269; GRIFFIN B, 1971, ARCH BIOCHEM BIOPHYS, V145, P220, DOI 10.1016/0003-9861(71)90029-4; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HASHIMOTOYUTSUDO C, 1980, J BIOCHEM-TOKYO, V88, P505, DOI 10.1093/oxfordjournals.jbchem.a132997; HENRY ER, 1985, BIOCHEMISTRY-US, V24, P5907, DOI 10.1021/bi00342a033; Hirota S, 1996, J PHYS CHEM-US, V100, P15274, DOI 10.1021/jp953190m; HU SZ, 1993, BIOCHEMISTRY-US, V32, P10125, DOI 10.1021/bi00089a031; ICHIKAWA Y, 1968, BIOCHIM BIOPHYS ACTA, V153, P753, DOI 10.1016/0005-2728(68)90003-0; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; Imai Y, 1997, BBA-PROTEIN STRUCT M, V1337, P66, DOI 10.1016/S0167-4838(96)00151-3; IMAI Y, 1994, BBA-PROTEIN STRUCT M, V1207, P49, DOI 10.1016/0167-4838(94)90050-7; IMAI Y, 1980, J BIOCHEM-TOKYO, V88, P489, DOI 10.1093/oxfordjournals.jbchem.a132996; IMAI Y, 1974, J BIOCHEM-TOKYO, V75, P689, DOI 10.1093/oxfordjournals.jbchem.a130441; IMAI Y, 1967, J BIOCHEM-TOKYO, V62, P464, DOI 10.1093/oxfordjournals.jbchem.a128690; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KITAGAWA T, 1976, J AM CHEM SOC, V98, P5169, DOI 10.1021/ja00433a019; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; Lee DS, 2001, BIOCHEMISTRY-US, V40, P2669, DOI 10.1021/bi002225s; LOPEZGARRIGA JJ, 1990, BIOCHEMISTRY-US, V29, P9387, DOI 10.1021/bi00492a012; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; Okamoto N, 1997, ARCH BIOCHEM BIOPHYS, V337, P338, DOI 10.1006/abbi.1996.9786; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SHIRO Y, 1994, BIOCHEMISTRY-US, V33, P8673, DOI 10.1021/bi00195a007; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SIMIANU MC, 1995, J AM CHEM SOC, V117, P4628, DOI 10.1021/ja00121a020; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P9777, DOI 10.1021/bi00451a035; WEBER WP, 1972, TETRAHEDRON LETT, V17, P1637; YU NT, 1984, P NATL ACAD SCI-BIOL, V81, P5106, DOI 10.1073/pnas.81.16.5106	37	7	7	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36261	36267		10.1074/jbc.M104932200	http://dx.doi.org/10.1074/jbc.M104932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11459844	hybrid			2022-12-25	WOS:000171194500029
J	Hufner, K; Higgs, HN; Pollard, TD; Jacobi, C; Aepfelbacher, M; Linder, S				Hufner, K; Higgs, HN; Pollard, TD; Jacobi, C; Aepfelbacher, M; Linder, S			The Verprolin-like Central (VC) region of Wiskott-Aldrich syndrome protein induces Arp2/3 complex-dependent actin nucleation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-WASP; WASP/SCAR PROTEINS; ACTIVATION; SIGNALS; CDC42; POLYMERIZATION; IDENTIFICATION; MACROPHAGES; PROFILIN; SCAR	Wiskott-Aldrich Syndrome protein (WASp) and related proteins stimulate actin filament nucleation by Arp2/3 complex. The isolated C-terminal VCA domain of WASp (containing Yerprolin-like, Central and Acidic regions) is constitutively active but autoinhibited in the full-length protein. This study compared the ability of parts of VCA fused to the C terminus of glutathione S-transferase (GST) to bind actin and Arp2/3 complex in vitro and to activate actin polymerization in vitro and in cells. Fluorescence anisotropy measurements showed that GST-CA and GST-A bound Arp2/3 complex with K-d values of 0.11 muM and 1.0 muM, respectively, whereas GST-VC displayed almost undetectable binding (K-d > I mm). However, GST-VC activated actin nucleation through Arp2/3 complex in vitro, though requiring 70-fold higher concentration than GST-VCA while neither GST-CA nor GST-A activated Arp2/3 complex in vitro, though both GST-CA and GST-A inhibited Arp2/3 complex activation by WASp VCA. None of these constructs bound WASp from macrophage lysates. Both GST-VC and GST-CA induced actin accumulations when microinjected into primary human macrophages or human endothelial vein cells. However, only microinjection of GST-VC led to a significant increase of cellular polymerized actin. Additionally, endogenous Arp2/3 complex, but not WASp, colocalized with these GST-VC-induced actin accumulations. These data suggest that WASp constructs lacking the A region, previously thought to be indispensable for actin nucleation, are able to bind and activate Arp2/3 complex in vitro and in vivo.	Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, D-80336 Munich, Germany; Univ Munich, Max Von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munich, Germany; Salk Inst Biol Studies, La Jolla, CA 92037 USA	University of Munich; University of Munich; Salk Institute	Linder, S (corresponding author), Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.	stefan.linder@klp.med.uni-muenchen.de		Higgs, Henry/0000-0002-2917-9644; Hufner, Katharina/0000-0002-5453-8792	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Linder S, 2000, J IMMUNOL, V165, P221, DOI 10.4049/jimmunol.165.1.221; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MAREHAND JB, 2001, NATURE CELL BIOL, V3, P76; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Ochs HD, 1998, SEMIN HEMATOL, V35, P332; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sasaki N, 2000, BIOCHEM BIOPH RES CO, V272, P386, DOI 10.1006/bbrc.2000.2785; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	27	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35761	35767		10.1074/jbc.M106520200	http://dx.doi.org/10.1074/jbc.M106520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11459849	hybrid			2022-12-25	WOS:000171109300073
J	Jonas, JC; Laybutt, DR; Steil, GM; Trivedi, N; Pertusa, JG; Van de Casteele, M; Weir, GC; Henquin, JC				Jonas, JC; Laybutt, DR; Steil, GM; Trivedi, N; Pertusa, JG; Van de Casteele, M; Weir, GC; Henquin, JC			High glucose stimulates early response gene c-Myc expression in rat pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; CHRONIC HYPERGLYCEMIA; TRANSCRIPTION FACTOR; GROWTH; ACTIVATION; APOPTOSIS; ISLETS; INHIBITION; RELEASE; TARGET	Glucose-induced insulin secretion from hyperglycemic 90% pancreatectomized rats is markedly impaired, possibly because of loss of beta cell differentiation. Association of these changes with beta cell hypertrophy, increased mRNA levels of the transcription factor c-Myc, and their complete normalization by phlorizin treatment suggested a link between chronic hyperglycemia, increased c-Myc expression, and altered beta cell function. In this study, we tested the effect of hyperglycemia on rat pancreatic islet c-Myc expression both in vivo and in vitro. Elevation of plasma glucose for 1-4 days (glucose infusion/clamp) was followed by parallel increases in islet mRNA levels (relative to TATA-binding protein) of c-Myc and two of its target genes, ornithine decarboxylase and lactate dehydrogenase A. Similar changes were observed in vitro upon stimulation of cultured islets or purified beta cells with 20 and 30 mmol(.)liter(-1) glucose for 18 h. These effects of high glucose were reproduced by high potassium-induced depolarization or dibutyryl-cAMP and were inhibited by agents decreasing cytosolic Ca2+ or cAMP concentrations. In conclusion, the expression of the early response gene c-Myc in rat pancreatic beta cells is stimulated by high glucose in a Ca2+ -dependent manner and by cAMP. c-Myc could therefore participate to the regulation of beta cell growth, apoptosis, and differentiation under physiological or pathophysiological conditions.	Univ Catholique Louvain, Unit Endocrinol & Metab, B-1200 Brussels, Belgium; Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA; Free Univ Brussels, Diabet Res Ctr, Brussels, Belgium	Universite Catholique Louvain; Harvard University; Joslin Diabetes Center, Inc.; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Jonas, JC (corresponding author), Ave Hippocrate 55, B-1200 Brussels, Belgium.		Jonas, Jean-Christophe/C-6766-2011; Steil, Garry/R-7673-2019	Jonas, Jean-Christophe/0000-0001-9882-5438; Van De Casteele, mark/0000-0002-8594-9260	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035449] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Dang CV, 1999, MOL CELL BIOL, V19, P1; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GILON P, 1993, J BIOL CHEM, V268, P22265; HENQUIN JC, 1982, DIABETES, V31, P776, DOI 10.2337/diab.31.9.776; HENQUIN JC, 1994, JOSLINS DIABETES MEL, P56; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Jonas JC, 2001, DIABETES, V50, pS137, DOI 10.2337/diabetes.50.2007.S137; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; Leahy Jack L., 1996, P103; LEAHY JL, 1993, DIABETOLOGIA, V36, P1238, DOI 10.1007/BF00400800; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; NILSSON T, 1988, J BIOL CHEM, V263, P1855; Paraskevas S, 1999, FEBS LETT, V455, P203, DOI 10.1016/S0014-5793(99)00882-0; Pelengaris S, 2000, DIABETOLOGIA, V43, pA57; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; VALVERDE I, 1979, SCIENCE, V206, P225, DOI 10.1126/science.225798; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; YAMASHITA S, 1988, ENDOCRINOLOGY, V123, P1825, DOI 10.1210/endo-123-4-1825; YAMAZAKI S, 1982, MOL PHARMACOL, V21, P648	35	85	90	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35375	35381		10.1074/jbc.M105020200	http://dx.doi.org/10.1074/jbc.M105020200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457846	hybrid			2022-12-25	WOS:000171109300024
J	Mizutani, K; Muralidhara, BK; Yamashita, H; Tabata, S; Mikami, B; Hirose, M				Mizutani, K; Muralidhara, BK; Yamashita, H; Tabata, S; Mikami, B; Hirose, M			Anion-mediated Fe3+ release mechanism in ovotransferrin C-lobe - A structurally identified SO42- binding site and its implications for the kinetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL MONOFERRIC TRANSFERRIN; INDUCED CONFORMATIONAL CHANGE; HUMAN SERUM TRANSFERRIN; IRON-RELEASE; N-LOBE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; X-RAY; 3-DIMENSIONAL STRUCTURE; ACETOHYDROXAMIC ACID	The differential properties of anion-mediated Fe2+ release between the N- and C-lobes of transferrins have been a focus in transferrin biochemistry. The structural and kinetic characteristics for isolated lobe have, however, been documented with the N-lobe only. Here we demonstrate for the first time the quantitative Fe3+ release kinetics and the anion-binding structure for the isolated C-lobe of ovotransferrin. In the presence of pyrophosphate, sulfate, and nitrilotriacetate anions, the C-lobe released Fe3+ with a decelerated rate in a single exponential progress curve, and the observed first order rate constants displayed a hyperbolic profile as a function of the anion concentration. The profile was consistent with a newly derived single-pathway Fe3+ release model in which the holo form is converted depending on the anion concentration into a "mixed ligand" intermediate that releases Fe3+. The apo C-lobe was crystallized in ammonium sulfate solution, and the structure determined at 2.3 A resolution demonstrated the existence of a single bound SO42- in the interdomain cleft, which interacts directly with Thr(461) -OG1, Tyr(431)-OH, and HiS(592)-NE2 and indirectly with Tyr(524)-OH. The latter three groups are Fe3+-coordinating ligands, strongly suggesting the facilitated Fe3+ release upon the anion occupation at this site. The SO42- binding structure supported the single-pathway kinetic model.	Kyoto Univ, Grad Sch Agr, Food Sci Res Inst, Uji, Kyoto 6110011, Japan	Kyoto University	Hirose, M (corresponding author), Kyoto Univ, Grad Sch Agr, Food Sci Res Inst, Uji, Kyoto 6110011, Japan.			Hirose, Masaaki/0000-0003-2672-4384				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; Bailey CT, 1997, BIOCHEMISTRY-US, V36, P10105, DOI 10.1021/bi961430y; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BALDWIN DA, 1981, BIOCHEM BIOPH RES CO, V99, P1101, DOI 10.1016/0006-291X(81)90732-4; BALI PK, 1989, J AM CHEM SOC, V111, P4457, DOI 10.1021/ja00194a047; BALI PK, 1991, INORG CHEM, V30, P502, DOI 10.1021/ic00003a030; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG YG, 1995, BIOCHEMISTRY-US, V34, P14879, DOI 10.1021/bi00045a032; CHEUK MS, 1987, J INORG BIOCHEM, V30, P121, DOI 10.1016/0162-0134(87)80048-X; COWART RE, 1982, J BIOL CHEM, V257, P7560; COWART RE, 1986, J BIOL CHEM, V261, P4607; DAY CL, 1993, J MOL BIOL, V232, P1084, DOI 10.1006/jmbi.1993.1462; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; EGAN TJ, 1993, BIOCHEMISTRY-US, V32, P8162, DOI 10.1021/bi00083a016; EGAN TJ, 1992, INORG CHEM, V31, P1994, DOI 10.1021/ic00037a005; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GROSSMANN JG, 1993, J MOL BIOL, V229, P585, DOI 10.1006/jmbi.1993.1063; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; Grossmann JG, 1998, J MOL BIOL, V279, P461, DOI 10.1006/jmbi.1998.1787; HARIDAS M, 1995, ACTA CRYSTALLOGR D, V51, P629, DOI 10.1107/S0907444994013521; HARRIS WR, 1999, BIOCHIM BIOPHYS ACTA, V1430, P267; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; He QY, 1999, BIOCHEMISTRY-US, V38, P9704, DOI 10.1021/bi990134t; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRETCHMAR SA, 1986, J AM CHEM SOC, V108, P6212, DOI 10.1021/ja00280a017; KRETCHMAR SA, 1988, INORG CHEM, V27, P1436, DOI 10.1021/ic00281a028; Kurokawa H, 1999, J BIOL CHEM, V274, P28445, DOI 10.1074/jbc.274.40.28445; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; Li YJ, 1998, BBA-PROTEIN STRUCT M, V1387, P89, DOI 10.1016/S0167-4838(98)00109-5; Li YJ, 1998, BIOCHEMISTRY-US, V37, P14157, DOI 10.1021/bi9810454; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; MARQUES HM, 1995, J INORG BIOCHEM, V57, P11, DOI 10.1016/0162-0134(94)00009-Y; Mason AB, 1996, BIOCHEM J, V319, P361, DOI 10.1042/bj3190361; MASON AB, 1987, J BIOL CHEM, V262, P9011; Mason AB, 1984, J BIOL CHEM, V259, P1866; Mecklenburg SL, 1997, J MOL BIOL, V270, P739, DOI 10.1006/jmbi.1997.1126; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizutani K, 2000, BIOCHEMISTRY-US, V39, P3258, DOI 10.1021/bi992574q; Mizutani K, 2001, J MOL BIOL, V309, P937, DOI 10.1006/jmbi.2001.4719; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; Muralidhara BK, 2000, J BIOL CHEM, V275, P12463, DOI 10.1074/jbc.275.17.12463; NGUYEN SAK, 1993, J AM CHEM SOC, V115, P6758; OE H, 1989, J BIOCHEM-TOKYO, V106, P858, DOI 10.1093/oxfordjournals.jbchem.a122942; OE H, 1988, J BIOCHEM-TOKYO, V103, P1066, DOI 10.1093/oxfordjournals.jbchem.a122381; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Rawas A, 1996, ACTA CRYSTALLOGR D, V52, P631, DOI 10.1107/S0907444996000212; Rawas A, 1997, ACTA CRYSTALLOGR D, V53, P464, DOI 10.1107/S0907444997000838; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182; Sharma AK, 1999, J MOL BIOL, V289, P303, DOI 10.1006/jmbi.1999.2767; Steinlein LM, 1998, BIOCHEMISTRY-US, V37, P13696, DOI 10.1021/bi980318s; THIBODEAU SN, 1978, J BIOL CHEM, V253, P3771; Zak O, 1997, BIOCHEMISTRY-US, V36, P11036, DOI 10.1021/bi970628v	59	21	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35940	35946		10.1074/jbc.M102590200	http://dx.doi.org/10.1074/jbc.M102590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466309	hybrid			2022-12-25	WOS:000171109300095
J	Stachelek, SJ; Tuft, RA; Lifsehitz, LM; Leonard, DM; Farwell, AP; Leonard, JL				Stachelek, SJ; Tuft, RA; Lifsehitz, LM; Leonard, DM; Farwell, AP; Leonard, JL			Real-time visualization of processive myosin 5a-mediated vesicle movement in living astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II IODOTHYRONINE 5'-DEIODINASE; SUBSTRATE-BINDING SUBUNIT; STIMULATED GLIAL-CELLS; THYROID-HORMONE; ACTIN POLYMERIZATION; CULTURED ASTROCYTES; ORGANELLE TRANSPORT; MELANOSOME DYNAMICS; MEMBRANE-PROTEINS; MOUSE MELANOCYTES	Recycling endosomes in astrocytes show hormone-regulated, actin fiber-dependent delivery to the endosomal sorting pool. Recycling vesicle trafficking was followed in real time using a fusion protein composed of green florescent protein coupled to the 29-kDa subunit of the short-lived, membrane-bound enzyme type 2 deiodinase. Primary endosomes budded from the plasma membrane and oscillated near the cell periphery for 1-4 min. The addition of thyroid hormone triggered the processive, centripetal movement of the recycling vesicle in linear bursts at velocities of up to 200 nm/s. Vesicle migration was hormone-specific and blocked by inhibitors of actin polymerization and myosin ATPase. Domain mapping confirmed that the hormone-dependent vesicle-binding domain was located at the C terminus of the motor. In addition, the interruption of normal dimerization of native myosin 5a monomers inactivated vesicle transport, indicating that single-headed myosin 5a motors do not transport cargo in situ. This is the first demonstration of processive hormone-dependent myosin 5a movement in living cells.	Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Leonard, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cellular & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.			Farwell, Alan/0000-0001-7716-2719				Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Catlett NL, 1998, P NATL ACAD SCI USA, V95, P14799, DOI 10.1073/pnas.95.25.14799; Catlett NL, 2000, J CELL BIOL, V150, P513, DOI 10.1083/jcb.150.3.513; DEKKEROHNO K, 1993, LAB ANIM SCI, V43, P370; Evans LL, 1998, J CELL SCI, V111, P2055; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Huang JD, 1998, GENETICS, V148, P1963; Lambert T, 1998, J INVEST DERMATOL, V111, P835, DOI 10.1046/j.1523-1747.1998.00395.x; Leonard DM, 2000, J BIOL CHEM, V275, P25194, DOI 10.1074/jbc.M002036200; LEONARD JL, 1990, J BIOL CHEM, V265, P940; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; Maienschein V, 1999, GLIA, V26, P233, DOI 10.1002/(SICI)1098-1136(199905)26:3<233::AID-GLIA5>3.0.CO;2-2; Marxen M, 1999, NEUROSCIENCE, V94, P985, DOI 10.1016/S0306-4522(99)00351-6; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Molyneaux BJ, 2000, CELL MOTIL CYTOSKEL, V46, P108, DOI 10.1002/1097-0169(200006)46:2<108::AID-CM3>3.0.CO;2-P; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rodionov VI, 1998, CURR BIOL, V8, P165, DOI 10.1016/S0960-9822(98)70064-8; Rogers SL, 1999, J CELL BIOL, V146, P1265, DOI 10.1083/jcb.146.6.1265; Rogers SL, 2000, CURR OPIN CELL BIOL, V12, P57, DOI 10.1016/S0955-0674(99)00057-5; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; SAFRAN M, 1991, ENDOCRINOLOGY, V129, P2011, DOI 10.1210/endo-129-4-2011; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Schott D, 1999, J CELL BIOL, V147, P791, DOI 10.1083/jcb.147.4.791; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; Stachelek SJ, 2000, J BIOL CHEM, V275, P31701, DOI 10.1074/jbc.M004221200; TITUS MA, 1997, CURR BIOL, V7, P301; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wu XF, 1997, J CELL SCI, V110, P847; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2000, PIGM CELL RES, V13, P241, DOI 10.1034/j.1600-0749.2000.130405.x; Yin HW, 2000, NATURE, V406, P1013, DOI 10.1038/35023024	46	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35652	35659		10.1074/jbc.M103331200	http://dx.doi.org/10.1074/jbc.M103331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11470781	hybrid			2022-12-25	WOS:000171109300060
J	Hvitved, AN; Trent, JT; Premer, SA; Hargrove, MS				Hvitved, AN; Trent, JT; Premer, SA; Hargrove, MS			Ligand binding and hexacoordination in Synechocystis hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FACILITATED DIFFUSION; ASCARIS HEMOGLOBIN; OXYGEN-BINDING; HEME; MYOGLOBIN; KINETICS; NO; LEGHEMOGLOBIN; OXIDATION	A large and phylogenetically diverse group of organisms contain truncated hemoglobins, including the unicellular cyanobacterium Synechocystis (Pesce, A., Couture, M., Dewilde, S., Guertin, M., Yamauchi, K., Ascenzi, P., Moens, L., and Bolognesi, M. (2000) EMBO J. 19,2424-2434). Synechocystis hemoglobin is also hexacoordinate, with a heme pocket histidine that reversibly coordinates the ligand binding site. Hexacoordinate hemoglobins are ubiquitous in plants and are now being identified in a diverse array of organisms including humans (Arredondo-Peter, R., Hargrove, M. S., Moran, J. F., Sarath, G., and Klucas, R. V. (1998) Plant Physiol. 118, 1121-1125; Trent, J. T., III, Watts, R. A., and Hargrove, M. S. (2001) J. Biol. Chem. 276, 30106-30110). Rate constants for association and dissociation of the hexacoordinating amino acid side chain in Synechocystis hemoglobin have been measured along with bimolecular rate constants for association of oxygen and carbon monoxide following laser flash photolysis. These values were compared with ligand binding initiated by rapid mixing. Site-directed mutagenesis was used to determine the roles of several heme pocket amino acids in facilitating hexacoordination and stabilizing bound oxygen. It is demonstrated that Synechocystis hemoglobin contains a very reactive binding site and that ligand migration through the protein is rapid. Rate constants for hexacoordination by His(46) are also large and facilitated by other heme pocket amino acids including Gln(43).	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Hargrove, MS (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	msh@iastate.edu						APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; Arredondo-Peter R, 1998, PLANT PHYSIOL, V118, P1121, DOI 10.1104/pp.118.4.1121; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; CARVER TE, 1990, J BIOL CHEM, V265, P20007; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Das TK, 1999, BIOCHEMISTRY-US, V38, P15360, DOI 10.1021/bi991237e; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dikshit KL, 1998, ARCH BIOCHEM BIOPHYS, V349, P161, DOI 10.1006/abbi.1997.0432; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; GIBSON QH, 1986, J BIOL CHEM, V261, P228; Goodman MD, 2001, J BIOL CHEM, V276, P6834, DOI 10.1074/jbc.M009254200; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LECOMTE J, 2001, IN PRESS BIOCHEMISTR; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MURRAY JD, 1971, J BIOL CHEM, V246, P5903; Olson J S, 1981, Methods Enzymol, V76, P631; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; ROHLFS RJ, 1988, J BIOL CHEM, V263, P1803; Scott NL, 2000, PROTEIN SCI, V9, P587; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Thorsteinsson MV, 1999, BIOCHEMISTRY-US, V38, P2117, DOI 10.1021/bi9819172; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; WHITAKER TL, 1995, BIOCHEMISTRY-US, V34, P8221, DOI 10.1021/bi00026a002; WYMAN J, 1966, J BIOL CHEM, V241, P115; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224	34	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34714	34721		10.1074/jbc.M105175200	http://dx.doi.org/10.1074/jbc.M105175200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11438545	hybrid			2022-12-25	WOS:000171024600051
J	Rebres, RA; Vaz, LE; Green, JM; Brown, EJ				Rebres, RA; Vaz, LE; Green, JM; Brown, EJ			Normal ligand binding and signaling by CD47 (integrin-associated protein) requires a long range disulfide bond between the extracellular and membrane-spanning domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; REGULATORY PROTEIN; CHEMOKINE BINDING; COUPLED RECEPTOR; TERMINAL DOMAIN; MYELOID CELLS; THROMBOSPONDIN; FAMILY; MUTAGENESIS; EXPRESSION	CD47 is a unique member of the Ig superfamily with a single extracellular Ig domain followed by a multiply membrane-spanning (AIMS) domain with five transmembrane segments, implicated in both integrin-dependent and -independent signaling cascades. Essentially all functions of CD47 require both the Ig and AMS domains, raising the possibility that interaction between the two domains is required for normal function. Conservation of Cys residues among CD47 homologues suggested the existence of a disulfide bond between the Ig and MMS domains that was confirmed by chemical digestion and mapped to Cys(33) and Cys(263). Subtle changes in CD47 conformation in the absence of the disulfide were suggested by decreased binding of two anti-Ig domain monoclonal antibodies, decreased SIRP alpha1 binding, and reduced CD47/SIRP alpha1-mediated cell adhesion. Mutagenesis to prevent formation of this disulfide completely disrupted CD47 signaling independent of effects on ligand binding, as assessed by T cell interleukin-2 secretion and Ca2+ responses. Loss of the disulfide did not affect membrane raft localization of CD47 or its association with alpha (v)beta (3) integrin. Thus, a disulfide bond between the Ig and MMS domains of CD47 is required for normal ligand binding and signal transduction.	Univ Calif San Francisco, Program Microbial Pathogenesis & Host Defense, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Brown, EJ (corresponding author), Univ Calif San Francisco, Program Microbial Pathogenesis & Host Defense, Box 0654,513 Parnassus Ave, San Francisco, CA 94143 USA.				NIAID NIH HHS [AI24674] Funding Source: Medline; NIGMS NIH HHS [GM38330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024674, R01AI024674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; Adams S, 1998, J IMMUNOL, V161, P1853; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Rebres RA, 2001, J BIOL CHEM, V276, P7672, DOI 10.1074/jbc.M008858200; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; Reinhold MI, 1999, INT IMMUNOL, V11, P707, DOI 10.1093/intimm/11.5.707; ROSALES C, 1992, J IMMUNOL, V149, P2759; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Tournamille C, 1997, J BIOL CHEM, V272, P16274, DOI 10.1074/jbc.272.26.16274; Vernon-Wilson EF, 2000, EUR J IMMUNOL, V30, P2130; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	37	41	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34607	34616		10.1074/jbc.M106107200	http://dx.doi.org/10.1074/jbc.M106107200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454874	hybrid			2022-12-25	WOS:000171024600037
J	Bajgar, R; Seetharaman, S; Kowaltowski, AJ; Garlid, KD; Paucek, P				Bajgar, R; Seetharaman, S; Kowaltowski, AJ; Garlid, KD; Paucek, P			Identification and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium channel in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BEEF-HEART MITOCHONDRIA; K+ CHANNELS; SODIUM 5-HYDROXYDECANOATE; PARTIAL-PURIFICATION; ADENINE-NUCLEOTIDES; MYOCARDIAL-ISCHEMIA; ENERGY-METABOLISM; CATION-TRANSPORT; OPENERS	Protection of heart against ischemia-reperfusion injury by ischemic preconditioning and K-ATP channel openers is known to involve the mitochondrial ATP-sensitive K+ channel (mitoK(ATP)). Brain is also protected by ischemic preconditioning and K-ATP channel openers, and it has been suggested that mitoK(ATP) may also play a key role in brain protection. However, it is not known whether mitoK(ATP) exists in brain mitochondria, and, if so, whether its properties are similar to or different from those of heart mitoK(ATP). We report partial purification and reconstitution of a new mitoK(ATP) from rat brain mitochondria. We measured K+ flux in proteoliposomes and found that brain mitoK(ATP) is regulated by the same ligands as those that regulate mitoK(ATP) from heart and liver. We also examined the effects of opening and closing mitoK(ATP) on brain mitochondrial respiration, and we estimated the amount of mitoK(ATP) by means of green fluorescence probe BODIPY-FL-glyburide labeling of the sulfonylurea receptor of mitoK(ATP) from brain and liver. Three independent methods indicate that brain mitochondria contain six to seven times more mitoK(ATP) per milligram of mitochondrial protein than liver or heart.	Oregon Hlth Sci Univ, OGI Sch Sci & Engn, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA	Oregon Health & Science University	Paucek, P (corresponding author), Oregon Hlth Sci Univ, OGI Sch Sci & Engn, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.		Kowaltowski, Alicia J/H-8698-2012	Garlid, Keith/0000-0002-6777-1235	NIGMS NIH HHS [GM55324] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; AUCHAMPACH JA, 1992, CARDIOVASC RES, V26, P1054, DOI 10.1093/cvr/26.11.1054; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1987, J BIOL CHEM, V262, P6165; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Domoki F, 1999, STROKE, V30, P2713, DOI 10.1161/01.STR.30.12.2713; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Downey JM, 1997, ADV EXP MED BIOL, V430, P39; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; GARLID KD, 1991, J BIOL CHEM, V266, P6518; Garlid KD, 1997, CIRC RES, V81, P1072; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; GARLID KD, 1988, INTEGRATION MITOCHON, P257; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Grover GJ, 2000, J MOL CELL CARDIOL, V32, P677, DOI 10.1006/jmcc.2000.1111; GROVER GJ, 1991, J PHARMACOL EXP THER, V257, P156; GROVER GJ, 1994, CARDIOVASC RES, V28, P778, DOI 10.1093/cvr/28.6.778; Grover GJ, 1997, CAN J PHYSIOL PHARM, V75, P309, DOI 10.1139/cjpp-75-4-309; GROVER GJ, 1989, J PHARMACOL EXP THER, V251, P98; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; Hide EJ, 1996, CARDIOVASC RES, V31, P941; Hu H, 1999, MOL PHARMACOL, V55, P1000, DOI 10.1124/mol.55.6.1000; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Kowaltowski AJ, 2001, BIOPHYS J, V80, p498A; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; KRAMER W, 1994, BBA-BIOMEMBRANES, V1191, P278, DOI 10.1016/0005-2736(94)90178-3; Laclau MN, 2001, J MOL CELL CARDIOL, V33, P947, DOI 10.1006/jmcc.2001.1357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; MCPHERSON CD, 1993, AM J PHYSIOL, V265, pH1809, DOI 10.1152/ajpheart.1993.265.5.H1809; Mironova G D, 1997, Membr Cell Biol, V10, P583; MIRONOVA GD, 1981, BIOFIZIKA+, V26, P451; MIRONOVA GD, 1996, MEMBR CELL BIOL, V10, P429; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; NELSON DA, 1992, J BIOL CHEM, V267, P14928; Pain T, 2000, CIRC RES, V87, P460; Paucek P, 1996, J BIOL CHEM, V271, P32084, DOI 10.1074/jbc.271.50.32084; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Perez-Pinzon MA, 1999, NEUROSCIENCE, V89, P453, DOI 10.1016/S0306-4522(98)00560-0; Reshef A, 1998, NEUROSCI LETT, V250, P111, DOI 10.1016/S0304-3940(98)00458-3; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Sanada S, 2001, AM J PHYSIOL-HEART C, V280, pH256, DOI 10.1152/ajpheart.2001.280.1.H256; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; SOLS A, 1947, NATURE, V160, P89, DOI 10.1038/160089a0; Szewczyk A, 1999, TRENDS PHARMACOL SCI, V20, P157, DOI 10.1016/S0165-6147(99)01301-2; Takeo S, 1999, CARDIOVASC RES, V43, P32, DOI 10.1016/S0008-6363(99)00079-6; Toyoda Y, 2000, AM J PHYSIOL-HEART C, V279, pH2694, DOI 10.1152/ajpheart.2000.279.6.H2694; Wang S, 2001, AM J PHYSIOL-HEART C, V280, pH246, DOI 10.1152/ajpheart.2001.280.1.H246; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wind T, 1997, BRAIN RES, V751, P295, DOI 10.1016/S0006-8993(96)01419-9; YarovYarovoy V, 1997, BBA-BIOENERGETICS, V1321, P128, DOI 10.1016/S0005-2728(97)00051-0	60	233	255	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33369	33374		10.1074/jbc.M103320200	http://dx.doi.org/10.1074/jbc.M103320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11441006	hybrid			2022-12-25	WOS:000170910200013
J	Blaiseau, PL; Lesuisse, E; Camadro, JM				Blaiseau, PL; Lesuisse, E; Camadro, JM			Aft2p, a novel iron-regulated transcription activator that modulates, with Aft1p, intracellular iron use and resistance to oxidative stress in yeast.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; GENE; PROTEIN; EXPRESSION; OXIDASE; COPPER; TRANSPORT; IDENTIFICATION; METABOLISM	The yeast, Saccharomyces cerevisiae, contains a transcription activator, Aft1p, that regulates the transcription of the high affinity iron transport system genes. This report describes the properties of Aft2p, a protein 39% homologous to Aft1p. Aft2p was found to activate transcription. Overproduction of Aft2p activates the transcription of the AFT1 target gene FET3. The double aft1aft2 mutant was unable to grow in iron-deprived conditions. Because a fet3 mutant does not show this deficiency, the defect is not solely caused by mis-regulation of iron transport but also involves defective iron use by the cells. The aft1 cells were unable to grow in aerobic conditions on plates containing raffinose as the sole carbon source. The inability to grow on raffinose is not caused by the cell iron content being too low to sustain respiratory metabolism, because the oxygen consumption of aft1 mutants showed that their respiratory activity is 2-fold higher than that of controls. The double aft1aft2 mutant also has many phenotypes related to oxidative stress such as H2O2 hypersensitivity, oxygen-dependent copper toxicity, and oxygen-dependent methionine auxotrophy, which are suppressed in anaerobiosis. These results suggest that Aft2p and Aft1p have overlapping roles in the control of iron-regulated pathway(s) connected to oxidative stress resistance in yeast.	Univ Paris 06, CNRS, Lab Ingn Prot & Control Metab, Inst Jacques Monod,Dept Biol Genomes,UMR 7592, F-75251 Paris 05, France; Univ Paris 07, CNRS, Lab Ingn Prot & Control Metab, Inst Jacques Monod,Dept Biol Genomes,UMR 7592, F-75251 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Blaiseau, PL (corresponding author), Univ Paris 06, CNRS, Lab Ingn Prot & Control Metab, Inst Jacques Monod,Dept Biol Genomes,UMR 7592, 2 Pl Jussieu, F-75251 Paris 05, France.	blaiseau@jjm.jussieu.fr		Camadro, Jean-Michel/0000-0002-8549-2707				ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; Yun CW, 2001, J BIOL CHEM, V276, P10218, DOI 10.1074/jbc.M010065200	39	157	161	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34221	34226		10.1074/jbc.M104987200	http://dx.doi.org/10.1074/jbc.M104987200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448968	hybrid			2022-12-25	WOS:000170910200124
J	Leipelt, M; Warnecke, D; Zahringer, U; Ott, C; Muller, F; Hube, B; Heinz, E				Leipelt, M; Warnecke, D; Zahringer, U; Ott, C; Muller, F; Hube, B; Heinz, E			Glucosylceramide synthases, a gene family responsible for the biosynthesis of glucosphingolipids in animals, plants, and fungi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICHIA-PASTORIS; UDP-GLUCOSE; ACYL (E)-DELTA(3)-UNSATURATION; CERAMIDE GLUCOSYLTRANSFERASE; CANDIDA-ALBICANS; HUMAN PATHOGEN; EXPRESSION; CEREBROSIDES; SPHINGOLIPIDS; GLYCOSYLTRANSFERASES	Glucosylceramides are membrane lipids in most eukaryotic organisms and in a few bacteria. The physiological functions of these glycolipids have only been documented in mammalian cells, whereas very little information is available of their roles in plants, fungi, and bacteria. In an attempt to establish appropriate experimental systems to study glucosylceramide functions in these organisms, we performed a systematic functional analysis of a glycosyltransferase gene family with members of animal, plant, fungal, and bacterial origin. Deletion of such putative glycosyltransferase genes in Candida albicans and Pichia pastoris resulted in the complete loss of glucosylceramides. When the corresponding knock-out strains were used as host cells for homologous or heterologous expression of candidate glycosyltransferase genes, five novel glucosylceramide synthase (UDP-glucose:ceramide glucosyltransferase) genes were identified from the plant Gossypium arboreum (cotton), the nematode Caenorhabditis elegans, and the fungi Magnaporthe grisea, Candida albicans, and P. pastoris. The glycosyltransferase gene expressions led to the biosynthesis of different molecular species of glucosylceramides that contained either C18 or very long chain fatty acids. The latter are usually channeled exclusively into inositol-containing sphingolipids known from Saccharomyces cerevisiae and other yeasts. Implications for the biosynthesis, transport, and function of sphingolipids will be discussed.	Univ Hamburg, Inst Allgemeine Bot, D-22609 Hamburg, Germany; Zentrum Med & Biowissensch, D-23845 Borstel, Germany; Robert Koch Inst, D-13353 Berlin, Germany	University of Hamburg; Robert Koch Institute	Warnecke, D (corresponding author), Univ Hamburg, Inst Allgemeine Bot, Ohnhorststr 18, D-22609 Hamburg, Germany.	warnecke@botanik.uni-hamburg.de		Hube, Bernhard/0000-0002-6028-0425				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BASU S, 1968, J BIOL CHEM, V243, P5802; BOAS MHSV, 1994, CHEM PHYS LIPIDS, V70, P11; Brade L, 2000, GLYCOBIOLOGY, V10, P629, DOI 10.1093/glycob/10.6.629; CAHOON EB, 1991, PLANT PHYSIOL, V95, P58, DOI 10.1104/pp.95.1.58; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Coutinho PM, 1999, ROY SOC CH, P3; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Dunn TM, 2000, METHOD ENZYMOL, V312, P317; FONZI WA, 1993, GENETICS, V134, P717; Fujimoto H, 2000, J BIOL CHEM, V275, P22623, DOI 10.1074/jbc.C000200200; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; Guillas I, 2000, METHOD ENZYMOL, V312, P506; HEINZ E, 1996, ADV LIPID METHODOLOG, P211; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Jennemann R, 2001, EUR J BIOCHEM, V268, P1190, DOI 10.1046/j.1432-1327.2001.01963.x; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Kawahara K, 2000, EUR J BIOCHEM, V267, P1837, DOI 10.1046/j.1432-1327.2000.01189.x; KAWAI G, 1989, BIOCHIM BIOPHYS ACTA, V1001, P185; Koga J, 1998, J BIOL CHEM, V273, P31985, DOI 10.1074/jbc.273.48.31985; Leipelt M, 2000, BIOCHEM SOC T, V28, P751, DOI 10.1042/BST0280751; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Lynch Daniel V., 1993, P285; Lynch DV, 1997, ARCH BIOCHEM BIOPHYS, V340, P311, DOI 10.1006/abbi.1997.9928; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; Marks DL, 2001, J BIOL CHEM, V276, P26492, DOI 10.1074/jbc.M102612200; MATSUBARA T, 1987, CHEM PHYS LIPIDS, V43, P1, DOI 10.1016/0009-3084(87)90012-0; NAKAYAMA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1882, DOI 10.1271/bbb.59.1882; REECE KS, 1995, GENE, V165, P141, DOI 10.1016/0378-1119(95)00529-F; Rodrigues ML, 2000, INFECT IMMUN, V68, P7049, DOI 10.1128/IAI.68.12.7049-7060.2000; Sakaki T, 2001, YEAST, V18, P679, DOI 10.1002/yea.720; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Toledo MS, 1999, BIOCHEMISTRY-US, V38, P7294, DOI 10.1021/bi982898z; Toledo MS, 2001, GLYCOBIOLOGY, V11, P105, DOI 10.1093/glycob/11.2.105; Toledo MS, 2001, GLYCOBIOLOGY, V11, P113, DOI 10.1093/glycob/11.2.113; Toledo MS, 2001, FEBS LETT, V493, P50, DOI 10.1016/S0014-5793(01)02275-X; Umemura K, 2000, PLANT CELL PHYSIOL, V41, P676, DOI 10.1093/pcp/41.6.676; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WAGNER H, 1966, BIOCHEM Z, V346, P333; Warnecke D, 1999, J BIOL CHEM, V274, P13048, DOI 10.1074/jbc.274.19.13048; Wu KJ, 1999, BIOCHEM J, V341, P395, DOI 10.1042/0264-6021:3410395; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142	53	135	147	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33621	33629		10.1074/jbc.M104952200	http://dx.doi.org/10.1074/jbc.M104952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443131	hybrid			2022-12-25	WOS:000170910200046
J	Neuss, M; Monticone, R; Lundberg, MS; Chesley, AT; Fleck, E; Crow, MT				Neuss, M; Monticone, R; Lundberg, MS; Chesley, AT; Fleck, E; Crow, MT			The apoptotic regulatory protein ARC (apoptosis repressor with caspase recruitment domain) prevents oxidant stress-mediated cell death by preserving mitochondrial function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PERMEABILITY TRANSITION; KINASE; CYTOTOXICITY; ACTIVATION; INHIBITORS; INTERACTS; RECEPTOR; NECROSIS; PATHWAY	ARC is an apoptotic regulatory protein expressed almost exclusively in myogenic cells. It contains a caspase recruitment domain (CARD) through which it has been shown to block the activation of some initiator caspases. Because ARC also blocks caspase-independent events associated with apoptosis, such as hypoxia-induced cytochrome c release, we examined its role in cell death triggered by exposure to hydrogen peroxide (H2O2) in the myogenic cell line, H9c2. Cell death in this model was caspase-independent and characterized by dose-dependent reduction in ARC expression accompanied by disruption of the mitochondrial membrane potential (Delta psi (m)) and loss of plasma membrane integrity, typical of necrotic cell death. Ectopic expression of ARC prevented both H2O2-induced mitochondrial dysfunction and cell death without affecting the stress kinase response, suggesting that ARCs protective effects were downstream of early signaling events and not due to quenching of H2O2. ARC was also effective in blocking H2O2-induced loss of membrane integrity and/or disruption of Delta psi (m) in two human cell lines in which it is not normally expressed. These results demonstrate that, in addition to its ability to block caspase-dependent and -independent events in apoptosis, ARC also prevents necrosis-like cell death via the preservation of mitochondrial function.	NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA; German Heart Inst, Dept Med Cardiol, D-13353 Berlin, Germany	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); German Heart Center Berlin	Crow, MT (corresponding author), NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.							BELLOMO G, 1983, FEBS LETT, V163, P136, DOI 10.1016/0014-5793(83)81180-6; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOLLI R, 1989, P NATL ACAD SCI USA, V86, P4695, DOI 10.1073/pnas.86.12.4695; Constantini P., 1996, J BIOL CHEM, V271, P6746; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ekhterae D, 1999, CIRC RES, V85, pE70; GU J, 1994, BIOTECHNIQUES, V17, P257; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LI P, 1997, CELL, V91, P4799; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; Rimpler MM, 1999, BIOCHEM J, V340, P291, DOI 10.1042/0264-6021:3400291; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Shimizu S, 1996, ONCOGENE, V12, P2045; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Single B, 2001, EXP CELL RES, V262, P8, DOI 10.1006/excr.2000.5059; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Stoss O, 1999, J BIOL CHEM, V274, P10951, DOI 10.1074/jbc.274.16.10951; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; ZORATTI M, 1995, BIOCHIM BIOPHYS ACTA, V1241, P136; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	37	98	102	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33915	33922		10.1074/jbc.M104080200	http://dx.doi.org/10.1074/jbc.M104080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438535	hybrid			2022-12-25	WOS:000170910200085
J	Marignani, PA; Kanai, F; Carpenter, CL				Marignani, PA; Kanai, F; Carpenter, CL			LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEUTZ-JEGHERS-SYNDROME; CELL-CYCLE ARREST; SERINE/THREONINE PROTEIN-KINASE; CHROMATIN REMODELING COMPLEX; SERINE-THREONINE KINASE; SWI-SNF COMPLEX; GLUCOCORTICOID RECEPTOR; SOMATIC MUTATIONS; DROSOPHILA-BRAHMA; ESTROGEN-RECEPTOR	Inactivating mutations in the serine-threonine kinase LKB1 (STK11) are found in most patients with Peutz-Jeghers syndrome; however the function of LKB1 is unknown. We found that TK I binds to and regulates brahma-related gene I (Brg1), an essential component of chromatin remodeling complexes. The association requires the N terminus of LKB1 and the helicase domain of Brg1 and LKB1 stimulates the ATPase activity of Brg1. Brg1 expression in SW13 cells induces the formation of flat cells indicative of cell cycle arrest and senescence. Expression of a kinase-dead mutant of LKB1, SL26, in SW13 cells blocks the formation of Brg1-induced flat cells, indicating that LKB1 is required for Brg1-dependent growth arrest. The inability of mutants of LKB1 to mediate Brg1-dependent growth arrest may explain the manifestations of Peutz-Jeghers syndrome.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Cell Biol,Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Marignani, PA (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.	marignan@uhnres.utoronto.ca; ccarpent@caregroup.harvard.edu		Marignani, Paola/0000-0001-8070-905X	NIGMS NIH HHS [GM 54389] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Churchman M, 1999, DNA SEQUENCE, V10, P255, DOI 10.3109/10425179909033954; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Entius MM, 2001, J CLIN PATHOL, V54, P126, DOI 10.1136/jcp.54.2.126; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nezu J, 1999, BIOCHEM BIOPH RES CO, V261, P750, DOI 10.1006/bbrc.1999.1047; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Watts JL, 2000, DEVELOPMENT, V127, P1467; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	45	100	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32415	32418		10.1074/jbc.C100207200	http://dx.doi.org/10.1074/jbc.C100207200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11445556	hybrid			2022-12-25	WOS:000170746000007
J	Prasad, R; Lavrik, OI; Kim, SJ; Kedar, P; Yang, XP; Vande Berg, BJ; Wilson, SH				Prasad, R; Lavrik, OI; Kim, SJ; Kedar, P; Yang, XP; Vande Berg, BJ; Wilson, SH			DNA polymerase beta-mediated long patch base excision repair - Poly(ADP-ribose) polymerase-1 stimulates strand displacement DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; SITE; RECONSTITUTION; PROTEINS; BINDING; DOMAIN; FEN1; STEP; ATP	Recently, photoaffinity labeling experiments with mouse cell extracts suggested that PARP-1 functions as a surveillance protein for a stalled DER intermediate. To further understand the role of PARP-1 in DER, we examined the DNA synthesis and flap excision steps in long patch DER using a reconstituted system containing a 34-base pair DER substrate and five purified human enzymes: uracil-DNA glycosylase, apurinic/apyrimidinic endonuclease, DNA polymerase beta, flap endonuclease-1 (FEN-1), and PARP-1. PARP-1 stimulates strand displacement DNA synthesis by DNA polymerase 13 in this system; this stimulation is dependent on the presence of FEN-1. PARP-1 and FEN-1, therefore, cooperate to activate long patch DER. The results are discussed in the context of a model for DER sub-pathway choice, illustrating a dual role for PARP-1 as a surveillance protein for a stalled DER intermediate and an activating factor for long patch DER DNA synthesis.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Lavrik, Olga I/G-4641-2013; Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050158, ZIAES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beard WA, 1995, METHOD ENZYMOL, V262, P98; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	24	162	168	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32411	32414		10.1074/jbc.C100292200	http://dx.doi.org/10.1074/jbc.C100292200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11440997	hybrid			2022-12-25	WOS:000170746000006
J	Sibley, K; Stern, P; Knowles, MA				Sibley, K; Stern, P; Knowles, MA			Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours	ONCOGENE			English	Article						FGFR3; mutation; tumour	HUMAN PROSTATIC-CARCINOMA; CELL-LINE; ACTIVATING MUTATIONS; CERVICAL-CARCINOMA; MULTIPLE-MYELOMA; FGFR3; TRANSLOCATION; GENE; TRANSFORMATION; CHROMOSOME	Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma, In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours, Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FCFR3, suggesting that these mutations are important only in the development of certain types of tumour.	St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England; Paterson Inst Canc Res, CRC, Immunol Grp, Manchester M20 4BX, Lancs, England	Saint James's University Hospital; Paterson Institute for Cancer Research	Knowles, MA (corresponding author), St James Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657				BLOOM ET, 1972, CANCER RES, V32, P960; Brady CS, 1999, J GEN VIROL, V80, P3233, DOI 10.1099/0022-1317-80-12-3233; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; JONES PA, 1975, INT J CANCER, V16, P616, DOI 10.1002/ijc.2910160411; KAIGHN ME, 1979, INVEST UROL, V17, P16; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Wu R, 2000, ONCOGENE, V19, P5543, DOI 10.1038/sj.onc.1203934; Wuchner C, 1997, HUM GENET, V100, P215, DOI 10.1007/s004390050493; Yee CJ, 2000, JNCI-J NATL CANCER I, V92, P1848, DOI 10.1093/jnci/92.22.1848	22	71	71	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4416	4418		10.1038/sj.onc.1204543	http://dx.doi.org/10.1038/sj.onc.1204543			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466624				2022-12-25	WOS:000169912600017
J	Shigemitsu, K; Sekido, Y; Usami, N; Mori, S; Sato, M; Horio, Y; Hasegawa, Y; Bader, SA; Gazdar, AF; Minna, JD; Hida, T; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K				Shigemitsu, K; Sekido, Y; Usami, N; Mori, S; Sato, M; Horio, Y; Hasegawa, Y; Bader, SA; Gazdar, AF; Minna, JD; Hida, T; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K			Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion	ONCOGENE			English	Article						beta-catenin; lung cancer; malignant mesothelioma; chromosome 3; homozygous deletion; breakpoint cloning	CELL-LINES; HEPATOCELLULAR CARCINOMAS; GROWTH SUPPRESSION; HUMAN SEMAPHORIN; E-CADHERIN; MUTATIONS; EXPRESSION; ACTIVATION; REGION; CHROMOSOME-3	The beta -catenin gene (CTNNB1) has been shown to be genetically mutated in various human malignancies. To determine whether the beta -catenin gene is responsible for oncogenesis in thoracic malignancies, we searched for the mutation in 166 lung cancers (90 primary tumors and 76 cell lines), one blastoma and 10 malignant mesotheliomas (two primary tumors and eight cell lines). Among the lung cancers, including 43 small cell lung cancers (SCLCs) and 123 non-small cell lung cancers (NSCLCs), we identified four alterations in exon 3, which is the target region of mutation for stabilizing beta -catenin. One primary adenocarcinoma had a somatic mutation from C to G, leading to an amino acid substitution from Ser to Cys at codon 37. Among the cell lines, SCLC NCI-H1092 had a mutation from A to G, leading to an Asp to Cry substitution at codon 6, NSCLC HCC15 had a mutation from C to T, leading to a Ser to Phe substitution at codon 45, and NSCLC NCI-H358 had a mutation from A to G, leading to a Thr to Ala substitution at codon 75. One blastoma also had a somatic mutation from C to C, leading to a Ser to Cys substitution at codon 37. Among the 10 malignant mesotheliomas, we identified a homozygous deletion in the NCI-H28 cell line. Cloning of the rearranged fragment from NCI-H28 indicated that all the exons except exon 1 of the beta -catenin gene are deleted and that the deletion junction is 13 kb downstream from exon 1. Furthermore, Northern blot analysis of 26 lung cancer and eight mesothelioma cell line RNAs detected ubiquitous expression of the beta -catenin messages except NCI-H28, although Western blot analysis showed that relatively less amounts of protein products were expressed in some of lung cancer cell lines, Our findings suggest that the beta -catenin gene is infrequently mutated in lung cancer and that the NCI-H28 homozygous deletion of the beta -catenin gene might indicate the possibility of a new tumor suppressor gene residing in this region at 3p21.3, where various types of human cancers show frequent allelic loss.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol 2, Nagoya, Aichi 4668550, Japan; Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Aichi Canc Ctr, Dept Internal Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University; Aichi Cancer Center	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan.		Sekido, Yoshitaka/P-9756-2015; Hasegawa, Yoshinori/I-1277-2012; Sato, MITSUO/I-7280-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Sato, MITSUO/0000-0001-5458-9576; Takahashi, Masahide/0000-0002-2803-2683; Horio, Yoshitsugu/0000-0003-4661-6399; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bell DW, 1997, CANCER RES, V57, P4057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; CHENG JQ, 1994, CANCER RES, V54, P5547; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; Fukuchi T, 1998, CANCER RES, V58, P3526; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; GIBAS Z, 1986, CANCER GENET CYTOGEN, V20, P191, DOI 10.1016/0165-4608(86)90074-9; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; Hidaka N, 1998, MODERN PATHOL, V11, P1039; Iwao K, 1998, CANCER RES, V58, P1021; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kase S, 2000, CLIN CANCER RES, V6, P4789; LU YY, 1994, GENE CHROMOSOME CANC, V9, P76, DOI 10.1002/gcc.2870090114; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nawrocki B, 1998, AM J PATHOL, V153, P1521, DOI 10.1016/S0002-9440(10)65740-9; Palacios J, 1998, CANCER RES, V58, P1344; Park WS, 1999, CANCER RES, V59, P4257; POPESCU NC, 1988, CANCER RES, V48, P142; Retera JMAM, 1998, J CLIN PATHOL, V51, P891, DOI 10.1136/jcp.51.12.891; Roche J, 1996, ONCOGENE, V12, P1289; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SEKIDO Y, 1994, CANCER RES, V54, P4988; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smythe WR, 1999, LUNG CANCER-J IASLC, V24, P157, DOI 10.1016/S0169-5002(99)00032-X; Sparks AB, 1998, CANCER RES, V58, P1130; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; TAGUCHI T, 1993, CANCER RES, V53, P4349; TIAINEN M, 1989, BRIT J CANCER, V60, P618, DOI 10.1038/bjc.1989.326; Voeller HJ, 1998, CANCER RES, V58, P2520; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	45	85	88	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4249	4257		10.1038/sj.onc.1204557	http://dx.doi.org/10.1038/sj.onc.1204557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464291				2022-12-25	WOS:000169857200015
J	Chung, KS; Won, M; Lee, SB; Jang, YJ; Hoe, KL; Kim, DU; Lee, JW; Kim, KW; Yoo, HS				Chung, KS; Won, M; Lee, SB; Jang, YJ; Hoe, KL; Kim, DU; Lee, JW; Kim, KW; Yoo, HS			Isolation of a novel gene from Schizosaccharomyces pombe: stm1(+) encoding a seven-transmembrane loop protein that may couple with the heterotrimeric G alpha 2 protein, Gpa2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CELL-CYCLE PROGRESSION; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; SEXUAL DEVELOPMENT; STATIONARY-PHASE; ADENYLYL-CYCLASE; MAP KINASE; TRANSCRIPTION FACTOR; PHOSPHOLIPASE-C	A putative seven transmembrane protein gene, stm1(+), which is required for proper recognition of nitrogen starvation signals, was isolated as a multicopy suppressor of a ras1 synthetic lethal mutant in Schizosaccharomyces pombe. Under nitrogen-deficient conditions, transcription of the stm1 gene was induced; deletion of stm1 was associated with early entry into G, arrest. Under nutritionally sufficient conditions, overexpression of Stm1 inhibited vegetative cell growth, resulted in decreased intracellular cAMP levels, increased the expression of the meiosis-specific genes ste11, mei2, and mam2, and facilitated sexual development in homothallic cells. However inhibition of vegetative cell growth and reduction of cAMP levels were not observed in a deletion mutant of the heterotrimeric G protein G alpha2 gene, gpa2, that is responsible for regulating intracellular cAMP levels, a key factor in determining the sexual development in S. pombe. Stm1 protein was shown to interact with Gpa2 through its C-terminal transmembrane domains 5-7. Mutation at Lys(199) in the C-terminal domain (stm1(K199A)) abolished the Stm1 overexpression effect on lowering cAMP levels. Induction of ste11, a meiosis-specific gene transcription factor, by Stm1 overexpression was enhanced in gpa2-deleted cells but was absent in a deletion mutant of sty1, a key protein kinase that links mitotic control with environmental signals and induces stress-responsive genes. Moreover, deletion of both stm1 and ras1 caused delayed entry into G, arrest in S. pombe when the cells were grown in a nitrogen-deficient medium. Thus we consider that the stm1 gene can function through Gpa2-dependent and/or -independent pathways and may play a role in providing the prerequisite state for entering the pheromone-dependent differentiation cycle in which heterotrimeric Gal protein, Gpa1, and Ras1 play major roles. Stm1 could function as a sentinel molecule sensing the nutritional state of the cells, stopping the proliferative cell cycle, and preparing the cell to enter meiosis under nutritionally deficient conditions.	KRIBB, Cell Cycle & Signal Transduct Res Unit, Taejon 305606, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 600738, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Pusan National University	Yoo, HS (corresponding author), KRIBB, Cell Cycle & Signal Transduct Res Unit, POB 115, Taejon 305606, South Korea.	yoohyang@mail.kribb.re.kr		Hoe, Kwang Lae/0000-0002-3943-4549				Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CANNON JF, 1986, GENETICS, V113, P247; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHODER M, 1991, GENE DEV, V5, P2315, DOI 10.1101/gad.5.12a.2315; Chung KS, 1998, GENE, V210, P143, DOI 10.1016/S0378-1119(98)00061-4; Chung KS, 1997, MOL CELLS, V7, P800; CLARK CD, 1994, J BIOL CHEM, V269, P8831; DEVINSON AD, 1986, TRENDS GENET, V2, P81; FASANO O, 1986, RAS GENES GROWTH CON, P200; FAURE M, 1994, J BIOL CHEM, V269, P7851; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; FUKUI Y, 1986, EMBO J, V5, P1991, DOI 10.1002/j.1460-2075.1986.tb04454.x; Gutz H., 1974, HDB GENETICS, V1, P395; Harlow E., 1988, ANTIBODIES LAB MANUA; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISSHIKI T, 1992, GENE DEV, V6, P2455, DOI 10.1101/gad.6.12b.2455; Jang YJ, 1997, BBA-MOL CELL RES, V1358, P229, DOI 10.1016/S0167-4889(97)00078-5; Jang YJ, 1997, J BIOL CHEM, V272, P19993, DOI 10.1074/jbc.272.32.19993; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kim DU, 1996, MOL GEN GENET, V252, P20, DOI 10.1007/BF02173201; KITAMURA K, 1991, EMBO J, V10, P3743, DOI 10.1002/j.1460-2075.1991.tb04943.x; LEE CH, 1992, J BIOL CHEM, V267, P16044; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; MAEDA T, 1990, P NATL ACAD SCI USA, V87, P7814, DOI 10.1073/pnas.87.20.7814; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Miller JH., 1972, EXPT MOL GENETICS; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NARDINDAVIS SA, 1988, EMBO J, V7, P985; NARDINDAVIS SA, 1986, EMBO J, V5, P2963; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NIELSEN O, 1992, EMBO J, V11, P1391, DOI 10.1002/j.1460-2075.1992.tb05184.x; OBARA T, 1991, P NATL ACAD SCI USA, V88, P5877, DOI 10.1073/pnas.88.13.5877; PLESSET J, 1987, J BACTERIOL, V169, P779, DOI 10.1128/jb.169.2.779-784.1987; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satoh T, 1992, Semin Cancer Biol, V3, P169; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Song KW, 1996, J CELL BIOL, V133, P1307, DOI 10.1083/jcb.133.6.1307; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TODA T, 1981, J CELL SCI, V52, P271; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x; WERNERWASHBURNE M, 1989, J BACTERIOL, V171, P2680, DOI 10.1128/jb.171.5.2680-2688.1989; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996	69	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40190	40201		10.1074/jbc.M100341200	http://dx.doi.org/10.1074/jbc.M100341200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11461899	hybrid			2022-12-25	WOS:000171789200091
J	Ameloot, P; Fiers, W; De Bleser, P; Ware, CF; Vandenabeele, P; Brouckaert, P				Ameloot, P; Fiers, W; De Bleser, P; Ware, CF; Vandenabeele, P; Brouckaert, P			Identification of tumor necrosis factor (TNF) amino acids crucial for binding to the murine p75 TNF receptor and construction of receptor-selective mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; P55; SPECIFICITY; RESOLUTION; EXPRESSION; TOXICITY	The bioactivity of tumor necrosis factor (TNF) is mediated by two TNF receptors (TNF-Rs), more particularly TNF-RI and TNF-RII. Although human TNF (hTNF) and murine TNTF (mTNF) are very homologous, hTNF binds only to mTNF-RI. By measuring the binding of a panel of mTNF/hTNF chimeras to both mTNF-R, we pinpointed the TNF region that mediates the interaction with mTNF-RII. Using site-specific mutagenesis, we identified amino acids 71-73 and 89 as the main interacting residues. Mutein hTNF-S71D/T72Y/H73 Delta /T89E interacts with both types of mTNF-R and is active in CT6 cell proliferation assays mediated by mTNF-RII. Mutein mTNF-D71S/Y72T/Delta 73H/E89T binds to mTNF-RI only and is no longer active on CT6 cells. However, the L929s cytotoxicity of this mutein (an effect mediated by mTNF-RI triggering) was also 100-fold lower than that of wild-type mTNF due to enhanced dissociation during incubation at subnanomolar concentrations. The additional mutation of amino acid 102, resulting in the mutein mTNF-D71S/Y72T/Delta 73H/E89T/P102Q, restored the trimer stability, which led to an enhanced specific activity on L929s cells. Hence the specific activity of a TNF species is governed not only by its receptor binding characteristics but also by its trimer stability after incubation at subnanomolar concentrations. In conclusion, the mutation of TNF amino acids 71-73,89, and 102 is sufficient to obtain a mTNF mutein selective for mTNF-RI and a hTNF mutein that, unlike wild-type hTNF, also acts on mTNF-RII.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Unit Mol Pathophysiol & Expt Therapy, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Unit Mol Signaling Cell Death, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium; Univ Calif San Diego, La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92103 USA	Ghent University; La Jolla Institute for Immunology; University of California System; University of California San Diego	Brouckaert, P (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		De Bleser, Pieter/C-3489-2011; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022; De Bleser, Pieter/AAB-2968-2021	De Bleser, Pieter/0000-0003-4762-8770; Vandenabeele, Peter/0000-0002-6669-8822; 	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; Baeyens KJ, 1999, ACTA CRYSTALLOGR D, V55, P772, DOI 10.1107/S0907444998018435; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Beutler B, 1998, BLOOD CELL MOL DIS, V24, P216, DOI 10.1006/bcmd.1998.0187; Brouckaert P, 1996, J INFLAMM, V47, P18; BROUCKAERT P, 1994, CIRC SHOCK, V43, P185; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Fiers W, 1995, BIOL THERAPY CANC, P295; GUNSTEREN WF, 1987, BIOMOS BIOMOLECULAR; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Ksontini R, 1998, ARCH SURG-CHICAGO, V133, P558, DOI 10.1001/archsurg.133.5.558; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MOHLER KM, 1993, J IMMUNOL, V151, P1548; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; RANGES GE, 1989, J IMMUNOL, V142, P1203; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TAVERNIER J, 1990, J MOL BIOL, V211, P493, DOI 10.1016/0022-2836(90)90367-U; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; VANOSTADE X, 1993, NATURE, V361, P266; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VANZEE KJ, 1994, J EXP MED, V179, P1185, DOI 10.1084/jem.179.4.1185	28	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37426	37430		10.1074/jbc.M102020200	http://dx.doi.org/10.1074/jbc.M102020200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11448951	hybrid			2022-12-25	WOS:000171375700075
J	Kozak, KR; Crews, BC; Ray, JL; Tai, HH; Morrow, JD; Marnett, LJ				Kozak, KR; Crews, BC; Ray, JL; Tai, HH; Morrow, JD; Marnett, LJ			Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(+)-DEPENDENT 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE-2; HYDROLYSIS; BIOLOGY; DISEASE; BINDING	Prostaglandin glycerol esters (PG-Gs) and prostaglandin ethanolamides (PG-EAs) are generated by the action of cyclooxygenase-2 on the endocannabinoids 2-arachidonylglycerol (2-AG) and arachidonylethanolamide, respectively. These novel eicosanoids may have unique pharmacological properties and/or serve as latent sources of prostaglandins at sites remote from their tissue of origin. Therefore, we investigated the metabolism of PG-Gs and PG-EAs in vitro and in vivo. PGE(2)-G was rapidly hydrolyzed in rat plasma to generate PGE(2) (t(1/2) = 14 s) but was only slowly metabolized in human plasma (t(1/2) > 10 min). An intermediate extent of metabolism of PGE(2)-G was observed in human whole blood (t(1/2) approximate to 7 min). The parent arachidonylglycerol, 2-AG, and the more stable regioisomer, 1-AG, also were much more rapidly metabolized in rat plasma compared with human plasma. PGE(2)-EA was not significantly hydrolyzed in plasma, undergoing slow dehydration/isomerization to PGB(2)-EA. Both PGE(2)-G and PGE(2)-EA were stable in canine, bovine, and human cerebrospinal fluid. Human 15-hydroxyprostaglandin dehydrogenase, the enzyme responsible for the initial step in PG inactivation in vivo, oxidized both PGE(2)-G and PGE(2)-EA less efficiently than the free acid. The sterically hindered glyceryl prostaglandin was the poorest substrate examined in the E series. Minimal 15-hydroxyprostaglandin dehydrogenase oxidation of PGF(2 alpha)-G was observed. PGE(2)-G and PGE(2)-EA pharmacokinetics were assessed in rats. PGE(2)-G was not detected in plasma 5 min following an intravenous dose of 2 mg/kg. However, PGE(2)-EA was detectable up to 2 h following an identical dose, displaying a large apparent volume of distribution and a half-life of over 6 min. The results suggest that endocannabinoid-derived PG-like compounds may be sufficiently stable in humans to exert actions systemically. Furthermore, these results suggest that the rat is not an adequate model for investigating the biological activities of 2-arachidonylglycerol or glyceryl prostaglandins in humans.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Kentucky	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.				NCI NIH HHS [CA77839] Funding Source: Medline; NHLBI NIH HHS [HL46296] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGGARD E, 1966, ACTA PHYSIOL SCAND, V66, P509, DOI 10.1111/j.1748-1716.1966.tb03231.x; ANGGARD E, 1971, ACTA PHYSIOL SCAND, V81, P396, DOI 10.1111/j.1748-1716.1971.tb04914.x; CALVO R, 1980, CLIN PHARMACOL THER, V27, P179, DOI 10.1038/clpt.1980.27; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COOK CS, 1995, PHARMACEUT RES, V12, P1158, DOI 10.1023/A:1016259826037; COSTELLO PB, 1984, ARTHRITIS RHEUM, V27, P422, DOI 10.1002/art.1780270409; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; ENSOR CM, 1994, BBA-PROTEIN STRUCT M, V1208, P151, DOI 10.1016/0167-4838(94)90172-4; Ericsson H, 1999, EUR J PHARM SCI, V8, P29, DOI 10.1016/S0928-0987(98)00058-X; FITZPATRICK FA, 1981, BIOCHEMISTRY-US, V20, P6129, DOI 10.1021/bi00524a033; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1971, J BIOL CHEM, V246, P6713; HARRIS PA, 1967, J PHARM SCI-US, V56, P713, DOI 10.1002/jps.2600560610; HAYASHI M, 1973, J ORG CHEM, V38, P1250, DOI 10.1021/jo00946a052; HORECKER BL, 1948, J BIOL CHEM, V175, P385; JARABAK J, 1983, PROSTAGLANDINS, V26, P849, DOI 10.1016/0090-6980(83)90149-1; Jarai Z, 2000, HYPERTENSION, V35, P679, DOI 10.1161/01.HYP.35.2.679; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; KUNGCHAO DTY, 1980, BIOCHIM BIOPHYS ACTA, V614, P1, DOI 10.1016/0005-2744(80)90161-8; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; MILLER OV, 1974, PROSTAGLANDINS, V7, P29, DOI 10.1016/S0090-6980(74)80075-4; MINAGAWA T, 1995, BIOCHEM PHARMACOL, V49, P1361, DOI 10.1016/0006-2952(95)00071-7; NAKANO J, 1969, EUR J BIOCHEM, V11, P386, DOI 10.1111/j.1432-1033.1969.tb00784.x; Needleman P, 1997, J RHEUMATOL, V24, P6; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; OHNO H, 1978, J BIOCHEM-TOKYO, V84, P1485, DOI 10.1093/oxfordjournals.jbchem.a132272; QUON CY, 1985, DRUG METAB DISPOS, V13, P420; SAMUELSSON B, 1971, ANN NY ACAD SCI, V180, P138; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; THALERDAO H, 1976, ADV PROSTAG THROMB R, V1, P177; WESTWICK J, 1976, BRIT J PHARMACOL, V58, pP297; WOODWARD DF, 1989, OPHTHALMIC RES, V21, P428, DOI 10.1159/000266933; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181; Zhou HP, 1999, BIOCHEM BIOPH RES CO, V257, P414, DOI 10.1006/bbrc.1999.0356	35	116	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36993	36998		10.1074/jbc.M105854200	http://dx.doi.org/10.1074/jbc.M105854200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11447235	hybrid			2022-12-25	WOS:000171375700019
J	Anglana, M; Debatisse, M				Anglana, M; Debatisse, M			Dual control of replication timing - Stochastic onset but programmed completion of mammalian chromosome duplication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; FLUORESCENCE INSITU HYBRIDIZATION; DNA-REPLICATION; REPLICON CLUSTERS; NUCLEAR-ORGANIZATION; SPINDLE DISRUPTION; GENE-EXPRESSION; LIVING CELLS; S-PHASE; CHECKPOINT	In mammalian cells, DNA replication proceeds according to a precise temporal order during the S phase, but how this program is controlled remains poorly understood. We analyzed the replication-dependent bromodeoxyuridine banding of chromosomes in Chinese hamster cells treated with the spindle poison nocodazole. In these cells, nocodazole induces a transient mitotic arrest, followed by DNA re-replication without intervening cell division. Nuclear fragmentation is often observed in tetraploid derivatives, and previous studies suggest that replication timing of chromosomes could be affected when they are segregated into different micronuclei. Here we show that the onset of replication is frequently asynchronous on individual chromosomes during the re-replication process. Moreover, fluorescence in situ hybridization analysis revealed that replication synchrony is equally altered in fragmented and non-fragmented nuclei, indicating that asynchronous onset of replication is not dependent on physical separation of the chromosomes into isolated compartments. We also show that the ordered program of replication is always preserved along individual chromosomes. Our results demonstrate that the onset of replication of individual chromosomes in the same nuclear compartment can be uncoupled from the time of S-phase entry and from the programmed replication of chromosome sub-domains, revealing that multi-level controls contribute to establish replication timing in mammalian cells.	Inst Curie, CNRS, UMR147, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Debatisse, M (corresponding author), Inst Curie, CNRS, UMR147, Batiment Trouillet Rossignol,26 Rue Ulm, F-75248 Paris, France.	Michelle.Debatisse@curie.fr						ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Baron B, 1996, MAMM GENOME, V7, P429, DOI 10.1007/s003359900127; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; Bridger JM, 2000, CURR BIOL, V10, P149, DOI 10.1016/S0960-9822(00)00312-2; Cardoso MC, 1999, J CELL BIOCHEM, P15; Cimbora DM, 2001, CELL, V104, P643, DOI 10.1016/S0092-8674(01)00260-4; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEBATISSE M, 1988, MOL CELL BIOL, V8, P17, DOI 10.1128/MCB.8.1.17; DEBATISSE M, 1981, J CELL PHYSIOL, V106, P1, DOI 10.1002/jcp.1041060102; DePamphilis ML, 2000, J STRUCT BIOL, V129, P186, DOI 10.1006/jsbi.2000.4219; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; EPHRUSSI B, 1967, DEVELOP BIOL       S, V1, P136; Ferreira J, 1997, J CELL BIOL, V139, P1597, DOI 10.1083/jcb.139.7.1597; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GALLOWAY SM, 1975, CYTOGENET CELL GENET, V15, P17, DOI 10.1159/000130495; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Khan SH, 1998, CANCER RES, V58, P396; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Laskey RA, 1996, EXP CELL RES, V229, P204, DOI 10.1006/excr.1996.0361; Lemaitre JM, 1998, J CELL BIOL, V142, P1159, DOI 10.1083/jcb.142.5.1159; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; Leonhardt H, 1999, CRIT REV EUKAR GENE, V9, P345, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.190; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; Marshall WF, 1997, CURR OPIN GENET DEV, V7, P259, DOI 10.1016/S0959-437X(97)80136-0; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Moir RD, 2000, J CELL BIOL, V149, P1179, DOI 10.1083/jcb.149.6.1179; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Ricoul M, 1998, MUTAT RES-FUND MOL M, V403, P177, DOI 10.1016/S0027-5107(98)00078-5; Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHAY JW, 1977, J ULTRASTRUCT RES, V2, P155; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; SPARVOLI E, 1994, J CELL SCI, V107, P3097; Stein GS, 2000, J CELL SCI, V113, P2527; Stevenson JB, 1999, GENE DEV, V13, P146, DOI 10.1101/gad.13.2.146; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STUBBLEFIELD ELTON, 1964, SYMP INT SOC CELL BIOL, V3, P223; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; TOLEDO F, 1992, MUTAT RES, V276, P261, DOI 10.1016/0165-1110(92)90012-X; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; VOGEL W, 1986, HUM GENET, V72, P129; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Zink D, 1999, EXP CELL RES, V247, P176, DOI 10.1006/excr.1998.4311	58	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36639	36646		10.1074/jbc.M104501200	http://dx.doi.org/10.1074/jbc.M104501200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11454865	hybrid			2022-12-25	WOS:000171194500078
J	Glaser, W; Cencic, R; Skern, T				Glaser, W; Cencic, R; Skern, T			Foot-and-mouth disease virus leader proteinase - Involvement of C-terminal residues in self-processing and cleavage of eIF4GI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICORNAVIRUS RNA TRANSLATION; INITIATION-FACTOR 4G; CAP-BINDING PROTEIN; RETICULOCYTE LYSATE; P220 CLEAVAGE; 2A PROTEASE; IN-VITRO; INFECTION; EXPRESSION; SEQUENCE	The leader proteinase (L-pro) of foot-and-mouth disease virus frees itself from the nascent polyprotein, cleaving between its own C terminus and the N terminus of VP4 at the sequence Lys-Leu-Lys- down arrow -Gly-Ala-Gly. Subsequently, the L-pro impairs protein synthesis from capped mRNAs in the infected cell by processing a host protein, eukaryotic initiation factor 4GI, at the sequence Asn-Leu-Gly- down arrow -Arg-Thr-Thr. A rabbit reticulocyte lysate system was used to examine the substrate specificity of L-pro and the relationship of the two cleavage reactions. We show that L-pro requires a basic residue at one side of the scissile bond to carry out efficient self-processing. This reaction is abrogated when leucine and lysine prior to the cleavage site are substituted by serine and glutamine, respectively. However, the cleavage of eIF4GI is unaffected by the inhibition of self-processing. Removal of the 18-amino acid C-terminal extension of Lpr, slowed eIF4GI cleavage; replacement of the C-terminal extension by unrelated amino acid sequences further delayed this cleavage. Surprisingly, wild-type L-pro and the C-terminal variants all processed the polyprotein cleavage site in an intermolecular reaction at the same rate. However, when the polyprotein cleavage site was part of the same polypeptide chain as the wild-type Lb(pro), the rate of processing was much more rapid. These experiments strongly suggest that self-processing is an intramolecular reaction.	Univ Vienna, Inst Med Biochem, Div Biochem, Vienna BioCtr, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Skern, T (corresponding author), Univ Vienna, Inst Med Biochem, Div Biochem, Vienna BioCtr, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.		Skern, Tim/AAC-1732-2022	Skern, Tim/0000-0001-8865-5500				Belsham GJ, 2000, J VIROL, V74, P272, DOI 10.1128/JVI.74.1.272-280.2000; BELSHAM GJ, 1990, VIROLOGY, V176, P524, DOI 10.1016/0042-6822(90)90022-J; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; Bovee ML, 1998, VIROLOGY, V245, P241, DOI 10.1006/viro.1998.9172; Bovee ML, 1998, VIROLOGY, V245, P229, DOI 10.1006/viro.1998.9171; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P6485, DOI 10.1093/nar/17.16.6485; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; FORSS S, 1984, NUCLEIC ACIDS RES, V12, P6587, DOI 10.1093/nar/12.16.6587; Glaser W, 2000, FEBS LETT, V480, P151, DOI 10.1016/S0014-5793(00)01928-1; GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Guarne A, 2000, J MOL BIOL, V302, P1227, DOI 10.1006/jmbi.2000.4115; Guarne A, 1998, EMBO J, V17, P7469, DOI 10.1093/emboj/17.24.7469; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; MADER S, 1995, MOL CELL BIOL, V15, P4900; MEDINA M, 1993, VIROLOGY, V194, P355, DOI 10.1006/viro.1993.1267; Ohlmann T, 1997, EMBO J, V16, P844, DOI 10.1093/emboj/16.4.844; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; RUECKERT RR, 1996, FIELDS VIROLOGY, V1, P609; SANGAR DV, 1988, J GEN VIROL, V69, P2327, DOI 10.1099/0022-1317-69-9-2327; Svitkin YV, 1999, J VIROL, V73, P3467, DOI 10.1128/JVI.73.4.3467-3472.1999; Turk B, 1997, BIOL CHEM, V378, P141; WYCKOFF EE, 1992, J VIROL, V66, P2943, DOI 10.1128/JVI.66.5.2943-2951.1992; YAN RQ, 1992, J BIOL CHEM, V267, P23226	32	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35473	35481		10.1074/jbc.M104192200	http://dx.doi.org/10.1074/jbc.M104192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11459842	hybrid			2022-12-25	WOS:000171109300037
J	Lu, B; Ennis, D; Lai, R; Bogdanovic, E; Nikolov, R; Salamon, L; Fantus, C; Le-Tien, H; Fantus, IG				Lu, B; Ennis, D; Lai, R; Bogdanovic, E; Nikolov, R; Salamon, L; Fantus, C; Le-Tien, H; Fantus, IG			Enhanced sensitivity of insulin-resistant adipocytes to vanadate is associated with oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; GLUCOSE-TRANSPORT SYSTEM; PROTEIN-KINASE-C; PHOSPHOTYROSINE PHOSPHATASE INHIBITORS; RECEPTOR TYROSINE KINASE; RAT ADIPOCYTES; ENDOTHELIAL-CELLS; PHOSPHOINOSITIDE 3-KINASE; PEROXOVANADIUM COMPOUNDS; N-ACETYLCYSTEINE	Vanadate (sodium orthovanadate), an inhibitor of phosphotyrosine phosphatases (PTPs), mimics many of the metabolic actions of insulin in vitro and in vivo. The potential of vanadate to stimulate glucose transport independent of the early steps in insulin signaling prompted us to test its effectiveness in an in vitro model of insulin resistance. In primary rat adipocytes cultured for 18 h in the presence of high glucose (15 mM) and insulin (10(-7) M), sensitivity to insulin-stimulated glucose transport was decreased. In contrast, there was a paradoxical enhanced sensitivity to vanadate of the insulin-resistant cells (EC50 for control, 325 +/- 7.5 muM; EC50 for insulin-resistant, 171 +/- 32 muM; p < 0.002). Enhanced sensitivity was also present for vanadate stimulation of insulin receptor kinase activity and autophosphorylation and Akt/protein kinase B Ser-473 phosphorylation consistent with more effective PTP inhibition in the resistant cells. Investigation of this phenomenon revealed that 1) depletion of GSH with buthionine sulfoximine reproduced the enhanced sensitivity to vanadate while preincubation of resistant cells with N-acetyleysteine (NAC) prevented it, 2) intracellular GSH was decreased in resistant cells and normalized by NAC, 3) exposure to high glucose and insulin induced an increase in reactive oxygen species, which was prevented by NAC, 4) EPR (electron paramagnetic resonance) spectroscopy showed a decreased amount of vanadyl (+4) in resistant and buthionine sulfoximine-treated cells, which correlated with decreased GSH and increased vanadate sensitivity, while total vanadium uptake was not altered, and 5) inhibition of recombinant PTP1B in vitro was more sensitive to vanadate (+5) than vanadyl (+4). In conclusion, the parodoxical increased sensitivity to vanadate in hyperglycemia-induced insulin resistant adipocytes is due to oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4). Thus, sensitivity of PTP inhibition and glucose transport to vanadate is regulated by cellular redox state.	Mt Sinai Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Fantus, IG (corresponding author), Mt Sinai Hosp, Dept Med, Banting & Best Diabet Ctr, 600 Univ Ave,Suite 780, Toronto, ON M5G 1X5, Canada.	fantus@mshri.on.ca	Nikolov, Rumen/AAP-6517-2021	Nikolov, Rumen/0000-0001-6977-9073				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; ATKINSON TP, 1993, J IMMUNOL, V151, P1448; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; BRICHARD SM, 1992, ENDOCRINOLOGY, V131, P311, DOI 10.1210/en.131.1.311; BRICHARD SM, 1988, ENDOCRINOLOGY, V123, P2048, DOI 10.1210/endo-123-4-2048; BRICHARD SM, 1995, TRENDS PHARMACOL SCI, V16, P265, DOI 10.1016/S0165-6147(00)89043-4; BRUCK R, 1991, HEPATOLOGY, V14, P540; Ceriello A, 1996, DIABETES, V45, P471, DOI 10.2337/diabetes.45.4.471; CHASTEEN ND, 1986, INORG CHEM, V25, P2754, DOI 10.1021/ic00236a021; Chasteen ND, 1986, FRONTIERS BIOINORGAN, P133; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CIARALDI TP, 1982, DIABETES, V31, P1016, DOI 10.2337/diacare.31.11.1016; COHEN N, 1995, J CLIN INVEST, V95, P2501, DOI 10.1172/JCI117951; Crans DC, 1995, MOL CELL BIOCHEM, V153, P17, DOI 10.1007/BF01075914; CRANS DC, 1994, COMMENT INORG CHEM, V16, P1; Cuncic C, 1999, J BIOL INORG CHEM, V4, P354, DOI 10.1007/s007750050322; DEGANI H, 1981, BIOCHEMISTRY-US, V20, P5795, DOI 10.1021/bi00523a023; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; DONOFRIO F, 1994, FEBS LETT, V340, P269, DOI 10.1016/0014-5793(94)80152-5; ELBERG G, 1994, J BIOL CHEM, V269, P9521; Elberg G, 1997, DIABETES, V46, P1684, DOI 10.2337/diabetes.46.11.1684; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FANTUS IG, 1990, ENDOCRINOLOGY, V127, P2716; FANTUS IG, 1994, DIABETES, V43, P375, DOI 10.2337/diabetes.43.3.375; Fantus IG, 1996, DIABETES, V45, P1084, DOI 10.2337/diabetes.45.8.1084; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GIL J, 1988, J BIOL CHEM, V263, P1868; GOLDFINE AB, 1995, J CLIN ENDOCR METAB, V80, P3311, DOI 10.1210/jc.80.11.3311; GREEN A, 1986, BIOCHEM J, V238, P663, DOI 10.1042/bj2380663; Halberstam M, 1996, DIABETES, V45, P659, DOI 10.2337/diabetes.45.5.659; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; Hiort C, 1996, BIOCHEMISTRY-US, V35, P12354, DOI 10.1021/bi9606253; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ida M, 1996, BIOCHEM PHARMACOL, V51, P1061, DOI 10.1016/0006-2952(95)02438-7; KADOTA S, 1987, J BIOL CHEM, V262, P8252; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; KASHIWAGI A, 1994, DIABETOLOGIA, V37, P264, DOI 10.1007/BF00398053; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li JP, 1996, BIOCHEMISTRY-US, V35, P8314, DOI 10.1021/bi960209i; MACARA IG, 1980, BIOCHIM BIOPHYS ACTA, V629, P95, DOI 10.1016/0304-4165(80)90268-8; McNeill JH, 1995, MOL CELL BIOCHEM, V153, P175, DOI 10.1007/BF01075935; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; ODoherty R, 1997, DIABETOLOGIA, V40, pB10, DOI 10.1007/BF03168180; OLEFSKY JM, 1978, BIOCHEM J, V172, P137, DOI 10.1042/bj1720137; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; ORVIG C, 1995, MET IONS BIOL SYST, V31, P575; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; POSNER BI, 1994, J BIOL CHEM, V269, P4596; PUGAZHENTHI S, 1993, MOL CELL BIOCHEM, V128, P211, DOI 10.1007/BF01076772; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SABBIONI E, 1993, CARCINOGENESIS, V14, P2565, DOI 10.1093/carcin/14.12.2565; SCHULZ LO, 1988, ANN NUTR METAB, V32, P289, DOI 10.1159/000177469; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Shaver A, 1995, MOL CELL BIOCHEM, V153, P5, DOI 10.1007/BF01075913; SHECHTER Y, 1980, NATURE, V284, P556, DOI 10.1038/284556a0; SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; Stankiewicz Paul J., 1995, V31, P249; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SWARUP G, 1982, J BIOL CHEM, V257, P7298; TAKAYUKI A, 1995, DIABETES, V44, P520; TAMURA S, 1984, J BIOL CHEM, V259, P6650; Tang SG, 2001, DIABETES, V50, P83, DOI 10.2337/diabetes.50.1.83; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TOLMAN EL, 1979, LIFE SCI, V25, P1159, DOI 10.1016/0024-3205(79)90138-3; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; TROCINO RA, 1995, DIABETES, V44, P992, DOI 10.2337/diabetes.44.8.992; Tsiani E, 1998, DIABETES, V47, P1676, DOI 10.2337/diabetes.47.11.1676; Tsiani E, 1997, TRENDS ENDOCRIN MET, V8, P51, DOI 10.1016/S1043-2760(96)00262-7; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Worm D, 1996, DIABETOLOGIA, V39, P1208, DOI 10.1007/BF02658508; ZIERATH JR, 1994, DIABETOLOGIA, V37, P270, DOI 10.1007/BF00398054	93	88	94	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35589	35598		10.1074/jbc.M106783200	http://dx.doi.org/10.1074/jbc.M106783200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11463798	hybrid			2022-12-25	WOS:000171109300052
J	Thorey, IS; Roth, J; Regenbogen, J; Halle, JP; Bittner, M; Vogl, T; Kaesler, S; Bugnon, P; Reitmaier, B; Durka, S; Graf, A; Wockner, M; Rieger, N; Konstantinow, A; Wolf, E; Goppelt, A; Werner, S				Thorey, IS; Roth, J; Regenbogen, J; Halle, JP; Bittner, M; Vogl, T; Kaesler, S; Bugnon, P; Reitmaier, B; Durka, S; Graf, A; Wockner, M; Rieger, N; Konstantinow, A; Wolf, E; Goppelt, A; Werner, S			The Ca2+-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; EPIDERMAL DIFFERENTIATION COMPLEX; GLUCOCORTICOID-TREATED MICE; MYELOMONOCYTIC ANTIGEN L1; GROWTH-FACTOR EXPRESSION; WOUND REPAIR; INFLAMMATORY DERMATOSES; MYELOID DIFFERENTIATION; GLUTATHIONE-PEROXIDASE; INTERMEDIATE FILAMENTS	To gain insight into the molecular mechanisms underlying cutaneous wound repair, we performed a large scale screen to identify novel injury-regulated genes. Here we show a strong up-regulation of the RNA and protein levels of the two Ca2+-binding proteins S100A8 and S100A9 in the hyperthickened epidermis of acute murine and human wounds and of human ulcers. Furthermore, both genes were expressed by inflammatory cells in the wound. The increased expression of S100A8 and S100A9 in wound keratinocytes is most likely related to the activated state of the keratinocytes an not secondary to the inflammation of the skin, since we also found up-regulation of S100A8 and S100A9 in the epidermis of activin-overexpressing mice, which develop a hyperproliferative and abnormally differentiated epidermis in the absence of inflammation. Furthermore, S100A8 and S100A9 expression was found to be associated with partially differentiated keratinocytes in vitro. Using confocal microscopy, both proteins were shown to be at least partially associated with the keratin cytoskeleton. In addition, cultured keratinocytes efficiently secreted the S100A8/A9 dimer. These results together with previously published data suggest that S100A8 and S100A9 are novel players in wound repair, where they might be involved in the reorganization of the keratin cytoskeleton in the wounded epidermis, in the chemoattraction of inflammatory cells, and/or in the defense against microorganisms.	ETH Zurich, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Munster, Inst Expt Dermatol, D-48129 Munster, Germany; SWITCH BIOTECH AG, D-82152 Martinsried, Germany; Univ Munich, Inst Mol Tierzucht & Biotechnol, D-81377 Munich, Germany; Tech Univ Munich, Klin Dermatol & Allergol, D-80802 Munich, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Munster; University of Munich; Technical University of Munich	Werner, S (corresponding author), ETH Zurich, Inst Cell Biol, HPM D42, CH-8093 Zurich, Switzerland.			Halle, Joern-Peter/0000-0002-1178-5275; Wolf, Eckhard/0000-0002-0430-9510; Werner, Sabine/0000-0001-7397-8710				Abe M, 1999, J NEUROL, V246, P358, DOI 10.1007/s004150050363; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BRANDTZAEG P, 1987, AM J CLIN PATHOL, V87, P700, DOI 10.1093/ajcp/87.6.700; BRANDTZAEG P, 1995, ADV EXP MED BIOL, V371, P201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AF, 1996, MOL CELLULAR BIOL WO, P195; Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185; DiSepio D, 1997, J BIOL CHEM, V272, P25555, DOI 10.1074/jbc.272.41.25555; DORIN JR, 1987, NATURE, V326, P614, DOI 10.1038/326614a0; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; Frosch M, 2000, ARTHRITIS RHEUM-US, V43, P628, DOI 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X; GABRIELSEN TO, 1986, J AM ACAD DERMATOL, V15, P173, DOI 10.1016/S0190-9622(86)70152-7; Garbuglia M, 1999, BIOCHEM BIOPH RES CO, V254, P36, DOI 10.1006/bbrc.1998.9881; GOEBELER M, 1995, BIOCHEM J, V309, P419, DOI 10.1042/bj3090419; GOEBELER M, 1993, J LEUKOCYTE BIOL, V53, P11, DOI 10.1002/jlb.53.1.11; Hardas BD, 1996, J INVEST DERMATOL, V106, P753, DOI 10.1111/1523-1747.ep12345807; Harrison CA, 1999, J BIOL CHEM, V274, P8561, DOI 10.1074/jbc.274.13.8561; HOGG N, 1989, EUR J IMMUNOL, V19, P1053, DOI 10.1002/eji.1830190615; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Katz AB, 1999, J INVEST DERMATOL, V112, P818, DOI 10.1046/j.1523-1747.1999.00572.x; KELLY SE, 1989, J PATHOL, V159, P17, DOI 10.1002/path.1711590107; KELLY SE, 1991, BRIT J DERMATOL, V124, P403, DOI 10.1111/j.1365-2133.1991.tb00616.x; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; KOMMINOTH P, 1992, HISTOCHEMISTRY, V98, P217, DOI 10.1007/BF00271035; KUNZ M, 1992, ARCH DERMATOL RES, V284, P386, DOI 10.1007/BF00372067; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAGASSE E, 1992, BLOOD, V79, P1907; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Munz B, 1999, J BIOL CHEM, V274, P13305, DOI 10.1074/jbc.274.19.13305; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; Nagpal S, 1996, CELL GROWTH DIFFER, V7, P1783; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Passey RJ, 1999, J IMMUNOL, V163, P2209; Propper C, 1999, J BIOL CHEM, V274, P183, DOI 10.1074/jbc.274.1.183; Rammes A, 1997, J BIOL CHEM, V272, P9496; ROTH J, 1992, INT ARCH ALLERGY IMM, V98, P140, DOI 10.1159/000236177; ROTH J, 1993, BLOOD, V82, P1875; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; SAINTIGNY G, 1992, J INVEST DERMATOL, V99, P639, DOI 10.1111/1523-1747.ep12668098; SOHNLE PG, 1991, J INFECT DIS, V163, P187, DOI 10.1093/infdis/163.1.187; South AP, 1999, J INVEST DERMATOL, V112, P910, DOI 10.1046/j.1523-1747.1999.00613.x; Steiling H, 1999, EXP CELL RES, V247, P484, DOI 10.1006/excr.1998.4366; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WILKINSON MM, 1988, J CELL SCI, V91, P221; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	58	185	204	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35818	35825		10.1074/jbc.M104871200	http://dx.doi.org/10.1074/jbc.M104871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11463791	hybrid			2022-12-25	WOS:000171109300080
J	Wang, X; Pei, DQ				Wang, X; Pei, DQ			Shedding of membrane type matrix metalloproteinase 5 by a furin-type convertase - A potential mechanism for down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND TRANSCRIPTION FACTOR; PROPROTEIN CONVERTASES; ACTIVATION; EXPRESSION; CLEAVAGE; CELLS; PROTEINS; COMPLEX; SIGNALS; REGION	The shedding of membrane-associated proteins has been recognized as a regulatory mechanism to either up-regulate or down-regulate cellular functions by releasing membrane-bound growth factors or removing ectodomains of adhesion molecules and receptors. We have reported previously that the ectoenzyme of membrane type matrix metalloproteinase 5 (MT5-MMP) is shed into extracellular milieu (Pei, D. (1999) J. BioL Chem. 274, 8925-8932). Here we present evidence that MT5-MMP is shed by a furin-type convertase activity in the trans-Golgi network. Among proteinase inhibitors screened, only decanoyl-Arg-Val-Lys-Arg-chloromethylketone, a known inhibitor for furin-type convertases, blocked the shedding of MT5-MMP in a dose-dependent manner. As expected, decanoyl-Arg-Val-Lys-Arg-chloromethylketone also prevented the activation of MT5-MMP, raising the possibility that the observed shedding could be autolytic. However, an active site mutant devoid of any catalytic activity, is also shed efficiently, thus ruling out the autolytic pathway. The shedding cleavage was subsequently mapped to the stem region immediately upstream of the transmembrane domain, where a cryptic furin recognition site, (RRKERR)-R-545, was recognized. Indeed, MT5-MMP and furin are co-localized in the trans-Golgi network and the shed species could be detected inside the cells. Furthermore, deletion mutations removing this cryptic site prevented MT5-MMP from shedding. The resulting mutants express a gain-of-function phenotype by mediating more robust activation of proMMP-2 than the wild type molecule. Thus, shedding provides a potential mechanism to regulate proteolytic activity of membrane-bound MMPs.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.		Wang, Xing/G-2917-2015					Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gazitt Y, 2000, STEM CELLS, V18, P390, DOI 10.1634/stemcells.18-6-390; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Leto G., 1994, In Vivo (Attiki), V8, P231; Llano E, 1999, CANCER RES, V59, P2570; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; ROEBROEK AJM, 1994, BIOCHIMIE, V76, P210, DOI 10.1016/0300-9084(94)90148-1; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Wang X, 1999, FEBS LETT, V462, P261, DOI 10.1016/S0014-5793(99)01534-3; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	41	43	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35953	35960		10.1074/jbc.M103680200	http://dx.doi.org/10.1074/jbc.M103680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11470782	hybrid			2022-12-25	WOS:000171109300097
J	Honda, A; Salen, G; Matsuzaki, Y; Batta, AK; Xu, GR; Leitersdorf, E; Ting, GS; Erickson, SK; Tanaka, N; Shefer, S				Honda, A; Salen, G; Matsuzaki, Y; Batta, AK; Xu, GR; Leitersdorf, E; Ting, GS; Erickson, SK; Tanaka, N; Shefer, S			Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27(-/-) mice but not in cerebrotendinous xanthomatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL 27-HYDROXYLASE GENE; PERFORMANCE LIQUID-CHROMATOGRAPHY; RAT-LIVER MITOCHONDRIA; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7-ALPHA-HYDROXYLASE; ALCOHOL GLUCURONIDES; MASS-SPECTROMETRY; 25-HYDROXYLATION; MICROSOMES; MUTATIONS	The accumulation of various 25-hydroxylated C-27-bile alcohols in blood and their excretion in urine are characteristic features of cerebrotendinous xanthomatosis (CTX) a recessively inherited inborn error of bile acid synthesis caused by mutations in the mitochondrial sterol 27-hydroxylase (CYP27) gene. These bile alcohols may be intermediates in the alternative cholic acid side chain cleavage pathway. The present study was undertaken to identify enzymes and reactions responsible for the formation of these bile alcohols and to explain why Cyp27(-/-) mice do not show CTX-related abnormalities. Microsomal activities of 5 beta -cholestane-3 alpha ,7 alpha ,12 alpha -triol 25- and 26-hydroxylases, 5 beta -cholestane-3 alpha ,7 alpha ,12 alpha ,25-tetrol 23R-, 24S-, and 27-hydroxylases and testosterone 6 beta -hydroxylase, a marker enzyme for CYP3A, in Cyp27(-/-) mice livers were markedly up-regulated (5.5-, 3.5-, 6.5-, 7.5-, 2.9-, and 5.4-fold, respectively). In contrast, these enzyme activities were not increased in CTX. The activities of 5 beta -cholestane-3 alpha ,7 alpha ,12 alpha -triol 25- and 26-hydroxylases and 5p-cholestane-3a,7a,12a,25-tetrol 23R-, 24R-, 24S-, and 27-hydroxylases were strongly correlated with the activities of testosterone 6 beta -hydroxylase in control human liver microsomes from eight unrelated donors. Troleandomycin, a specific inhibitor of CYP3A, markedly suppressed these microsomal side chain hydroxylations in both mouse and human livers in a dose-dependent manner. In addition, experiments using recombinant overexpressed human CYP3A4 confirmed that these microsomal side chain hydroxylations were catalyzed by a single enzyme, CYP3A4. The results demonstrate that microsomal 25- and 26-hydroxylations of 5 beta -cholestane-3 alpha ,7 alpha ,12 alpha -triol and microsomal 23R-, 24R-, 24S-, and 27-hydroxylations of 5 beta -cholestane-3 alpha ,7 alpha ,12 alpha ,25-tetrol are mainly catalyzed by CYP3A in both mice and humans. Unlike Cyp27(-/-) mice, CYP3A activity was not up-regulated despite marked accumulation of 5 beta -cholestane-3 alpha ,7 alpha ,12 alpha -triol in CTX.	Univ Tsukuba, Dept Gastroenterol, Tsukuba, Ibaraki 3058575, Japan; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Gastrointestinal Div, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Liver, Newark, NJ 07103 USA; Hadassah Univ Hosp, Dept Med, Ctr Res Prevent & Treatment Atherosclerosis, IL-91120 Jerusalem, Israel; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of Tsukuba; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Hebrew University of Jerusalem; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Salen, G (corresponding author), Vet Affairs Med Ctr, GI Lab 15A, 385 Tremont Ave, E Orange, NJ 07018 USA.			Honda, Akira/0000-0003-0902-8272	NICHD NIH HHS [HD-31932] Funding Source: Medline; NIDDK NIH HHS [DK-26756] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026756, R37DK026756] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1983, J BIOL CHEM, V258, P6777; BATTA AK, 1987, J LIPID RES, V28, P1006; BATTA AK, 1985, J LIPID RES, V26, P690; BERGSTROM S, 1957, ACTA CHEM SCAND, V11, P1067, DOI 10.3891/acta.chem.scand.11-1067; BJORKHEM I, 1976, J BIOL CHEM, V251, P3495; BJORKHEM I, 1969, EUR J BIOCHEM, V8, P337, DOI 10.1111/j.1432-1033.1969.tb00533.x; BORNHEIM LM, 1990, MOL PHARMACOL, V38, P319; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CHENG FW, 1977, J LIPID RES, V18, P6; DAYAL B, 1976, J LIPID RES, V17, P74; Furster C, 1999, BBA-MOL CELL BIOL L, V1437, P46, DOI 10.1016/S0005-2760(98)00175-1; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015; Haehner BD, 1996, MOL PHARMACOL, V50, P52; HAYASHI S, 1986, J BIOCHEM-TOKYO, V99, P1753, DOI 10.1093/oxfordjournals.jbchem.a135653; Honda A, 1999, J LIPID RES, V40, P1520; Honda A, 2000, J LIPID RES, V41, P442; HONDA A, 1991, J CHROMATOGR-BIOMED, V565, P53, DOI 10.1016/0378-4347(91)80370-R; Honda A, 2001, J LIPID RES, V42, P291; HOSHITA T, 1962, J BIOCHEM-TOKYO, V52, P176, DOI 10.1093/oxfordjournals.jbchem.a127593; HOSHITA T, 1980, J LIPID RES, V21, P1015; KIM HS, 1989, J LIPID RES, V30, P247; KIM KS, 1994, J LIPID RES, V35, P1031; Lee MH, 2001, J LIPID RES, V42, P159; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; LEITERSDORF E, 1993, J CLIN INVEST, V91, P2488, DOI 10.1172/JCI116484; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Murray GI, 1999, BRIT J CANCER, V79, P1836, DOI 10.1038/sj.bjc.6690292; NOSHIRO M, 1985, STEROIDS, V45, P539, DOI 10.1016/0039-128X(85)90018-2; OGISHIMA T, 1986, ANAL BIOCHEM, V158, P228, DOI 10.1016/0003-2697(86)90613-5; OKUDA K, 1988, J BIOL CHEM, V263, P18138; Ono S, 1996, XENOBIOTICA, V26, P681, DOI 10.3109/00498259609046742; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; SALEN G, 1985, J CLIN INVEST, V76, P744, DOI 10.1172/JCI112030; SALEN G, 1979, J CLIN INVEST, V63, P38, DOI 10.1172/JCI109275; SALEN G, 1983, METABOLIC BASIS INHE, P713; SHEFER S, 1975, J LIPID RES, V16, P280; SHEFER S, 1976, J CLIN INVEST, V57, P897, DOI 10.1172/JCI108366; SHEFER S, 1978, J BIOL CHEM, V253, P6386; SHIMASUE A, 1974, HIROSHIMA J MED SCI, V23, P265; SHODA J, 1993, STEROIDS, V58, P119, DOI 10.1016/0039-128X(93)90048-R; TANIGUCHI S, 1973, EUR J BIOCHEM, V40, P607, DOI 10.1111/j.1432-1033.1973.tb03233.x; TINT GS, 1978, J LIPID RES, V19, P956; Toide K, 1997, ARCH BIOCHEM BIOPHYS, V338, P43, DOI 10.1006/abbi.1996.9792; USUI E, 1990, FEBS LETT, V274, P175, DOI 10.1016/0014-5793(90)81357-T	46	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34579	34585		10.1074/jbc.M103025200	http://dx.doi.org/10.1074/jbc.M103025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454857	hybrid			2022-12-25	WOS:000171024600033
J	Lee, H; Kang, SH; Bae, SH; Choi, BS; Hwang, DS				Lee, H; Kang, SH; Bae, SH; Choi, BS; Hwang, DS			SeqA protein aggregation is necessary for SeqA function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION INITIATION; ESCHERICHIA-COLI; CHROMOSOMAL REPLICATION; DAM METHYLTRANSFERASE; COMPLEXES; METHYLASE; MIGRATION; PROMOTER; DOMAINS; BINDING	The binding of SeqA protein to hemimethylated GATC sequences is important in the negative modulation of chromosomal initiation at oriC, and in the formation of SeqA foci necessary for Escherichia coli chromosome segregation. Using gel-filtration chromotography and glycerol gradient sedimentation, we demonstrate that SeqA exists as a homotetramer. SeqA tetramers are able to aggregate or multimerize in a reversible, concentration-dependent manner. Using a bacterial two-hybrid system, we demonstrate that the N-terminal region of SeqA, especifically the 9th amino acid residue, glutamic acid, is required for functional SeqA-SeqA interaction. Although the SeqA(E9K) mutant protein, containing lysine rather than glutamic acid at the 9th amino acid residue, exists as a tetramer, the mutant protein binds to hemimethylated DNA with altered binding patterns as compared with wild-type SeqA. Aggregates of SeqA(E9K) are defective in hemimethylated DNA binding. Here we demonstrate that proper interaction between SeqA tetramers is required for both hemimethylated DNA binding and formation of active aggregates. SeqA tetramers and aggregates might be involved in the formation of SeqA foci required for the segregation of chromosomal DNA as well as the regulation of chromosomal initiation.	Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea; Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr, Taejon 305701, South Korea	Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Hwang, DS (corresponding author), Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea.		Choi, Byong-Seok/C-1937-2011; Bae, Sung-Ho/AAK-7350-2020	Kang, Sukhyun/0000-0002-7567-0231				Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Boye E, 1996, P NATL ACAD SCI USA, V93, P12206, DOI 10.1073/pnas.93.22.12206; Brendler T, 2000, EMBO J, V19, P6249, DOI 10.1093/emboj/19.22.6249; Brendler T, 1999, EMBO J, V18, P2304, DOI 10.1093/emboj/18.8.2304; CADWELL R, 1995, PCR PRIMER LAB MANUA, P581; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P560; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hiraga S, 1998, MOL CELL, V1, P381, DOI 10.1016/S1097-2765(00)80038-6; HWANG DS, 1992, J BIOL CHEM, V267, P2209; Kang S, 1999, J BIOL CHEM, V274, P11463, DOI 10.1074/jbc.274.17.11463; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; KORNBERG A, 1992, DNA REPLICATION, P521; Lee H, 2001, MOL GEN GENET, V264, P931, DOI 10.1007/PL00008701; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MARIANS KJ, 1996, ESCHERICHIA COLI SAL, P753; MESSER W, 1996, ESCHERICHIA COLI SAL, P1580; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; Onogi T, 1999, MOL MICROBIOL, V31, P1775, DOI 10.1046/j.1365-2958.1999.01313.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sian AK, 2000, BIOCHEM J, V349, P299, DOI 10.1042/0264-6021:3490299; Skarstad K, 2000, MOL MICROBIOL, V36, P1319, DOI 10.1046/j.1365-2958.2000.01943.x; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitao T, 2000, EMBO REP, V1, P494; Zlotnick A, 2000, VIROLOGY, V277, P450, DOI 10.1006/viro.2000.0619	31	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34600	34606		10.1074/jbc.M101339200	http://dx.doi.org/10.1074/jbc.M101339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457824	hybrid			2022-12-25	WOS:000171024600036
J	Paunola, E; Qiao, MQ; Shmelev, A; Makarow, M				Paunola, E; Qiao, MQ; Shmelev, A; Makarow, M			Inhibition of translocation of beta-lactamase into the yeast endoplasmic reticulum by covalently bound benzylpenicillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL PROTEIN-TRANSPORT; ACYL-ENZYME INTERMEDIATE; SACCHAROMYCES-CEREVISIAE; ER MEMBRANE; PRECURSOR POLYPEPTIDES; SIGNAL SEQUENCES; MITOCHONDRIA; COMPLEX; BINDING; IMPORT	We found recently that beta -lactamase folds in the yeast cytosol to a native-like, catalytically active, and trypsin-resistant conformation, and is thereafter translocated into the ER and secreted to the medium. Previously, it was thought that pre-folded proteins cannot be translocated. Here we have studied in living yeast cells whether beta -lactamase, a tight globule in authentic form, must be unfolded for ER translocation. A beta -lactamase mutant (E166A) binds irreversibly benzylpenicillin via Ser(70) in the active site. We fused E166A to the C terminus of a yeast-derived polypeptide having a post-translational signal peptide. In the presence of benzylpenicillin, the E166A fusion protein was not translocated into the endoplasmic reticulum, whereas translocation of the unmutated variant was not affected. The benzylpenicillin-bound protein adhered to the endoplasmic reticulum. membrane, where it prevented translocation of BiP, carboxypeptidase Y, and secretory proteins. Although the 321-amino acid-long N-terminal fusion partner adopts no regular secondary structure and should have no constraints for pore penetration, the benzylpenicillin-bound protein remained fully exposed to the cytosol, maintaining its signal peptide. Our data suggest that the beta -lactamase portion must unfold for translocation, that the unfolding machinery is cytosolic, and that unfolding of the remote C-terminal. P-lactamase is required for initiation of pore penetration.	Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki	Makarow, M (corresponding author), Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, POB 56,Valimotie 7, FIN-00014 Helsinki, Finland.							ADACHI H, 1991, J BIOL CHEM, V266, P3186; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CITRI N, 1982, BIOCHEM J, V201, P425, DOI 10.1042/bj2010425; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1986, NATURE, V322, P800; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanninen AL, 1999, MOL BIOL CELL, V10, P3623, DOI 10.1091/mbc.10.11.3623; Holkeri H, 1998, J CELL SCI, V111, P749; JACKSON CL, 1994, GENETICS, V137, P423; JAMSA E, 1995, YEAST, V11, P1381, DOI 10.1002/yea.320111406; JELSCH C, 1992, FEBS LETT, V299, P135, DOI 10.1016/0014-5793(92)80232-6; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Merlin A, 1999, J CELL BIOL, V145, P961, DOI 10.1083/jcb.145.5.961; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Paunola E, 1998, MOL BIOL CELL, V9, P817, DOI 10.1091/mbc.9.4.817; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; SIMONEN M, 1994, J BIOL CHEM, V269, P13889; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Suntio T, 1999, J CELL SCI, V112, P3889; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566	34	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34553	34559		10.1074/jbc.M102056200	http://dx.doi.org/10.1074/jbc.M102056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11447216	hybrid			2022-12-25	WOS:000171024600029
J	See, V; Loeffler, JP				See, V; Loeffler, JP			Oxidative stress induces neuronal death by recruiting a protease and phosphatase-gated mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; CEREBELLAR GRANULE NEURONS; FAMILY TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; CELL-DEATH; PARKINSONS-DISEASE; KINASE-IV; CREB PHOSPHORYLATION; SUPEROXIDE-DISMUTASE; CALCINEURIN ACTIVITY	Reactive oxygen species (ROS) cause death of cerebellar granule neurons. Here, a 15-min pulse of H2O2 (100 gm) induced an active process of neuronal death distinct from apoptosis. Oxidative stress activated a caspase-independent but calpain-dependent decline of calcium/calmodulin-dependent protein kinase IV and cAMP-responsive element-binding protein (CREB). Calpain inhibitors restored calcium/calmodulin-dependent protein kinase IV and CREB but did not influence phosphorylated CREB levels or survival, indicating recruitment of an additional dephosphorylation process. Co-treatment with calpain and serine/threonine phosphatase inhibitors restored pCREB levels and rescued neurons. This phosphatase-activated signaling pathway was shown to be dependent on de novo protein synthesis. Further, gene transfer studies revealed that CREB is a common final effector of both apoptosis and ROS-induced death. Our data indicate that dephosphorylation and proteolytic signaling mechanisms underlie ROS-induced programmed cell death.	Univ Strasbourg 1, Fac Med, EA Mol Signaling & Neurodegenerat, F-67000 Strasbourg, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Loeffler, JP (corresponding author), Univ Strasbourg 1, Fac Med, EA Mol Signaling & Neurodegenerat, 11 Rue Humann, F-67000 Strasbourg, France.		LOEFFLER, Jean-Philippe/AAS-4401-2020					Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Behl C, 1997, CELL TISSUE RES, V290, P471, DOI 10.1007/s004410050955; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Boutillier AL, 1999, EUR J NEUROSCI, V11, P441, DOI 10.1046/j.1460-9568.1999.00451.x; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Brugg B, 1996, J NEUROCHEM, V66, P733; Carballo M, 1999, J BIOL CHEM, V274, P93, DOI 10.1074/jbc.274.1.93; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Ciani E, 1996, BRAIN RES, V728, P1; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Ferri A, 2000, J NEUROCHEM, V75, P606, DOI 10.1046/j.1471-4159.2000.0750606.x; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; Gringhuis SI, 1997, J BIOL CHEM, V272, P31809, DOI 10.1074/jbc.272.50.31809; Hill IE, 2000, EXP NEUROL, V162, P73, DOI 10.1006/exnr.2000.7322; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Ishihara I, 2000, NEUROSCI LETT, V279, P97, DOI 10.1016/S0304-3940(99)00960-X; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.0.CO;2-S; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Lee JE, 2000, EXP MOL MED, V32, P42, DOI 10.1038/emm.2000.8; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Lutz-Bucher B, 1999, NEUROENDOCRINOLOGY, V69, P377, DOI 10.1159/000054440; Marini M, 1996, BIOCHEM BIOPH RES CO, V229, P910, DOI 10.1006/bbrc.1996.1901; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; Palomba L, 1996, FEBS LETT, V390, P91, DOI 10.1016/0014-5793(96)00634-5; Palomba L, 1999, BIOCHEM PHARMACOL, V58, P1743, DOI 10.1016/S0006-2952(99)00271-3; Przywara DA, 1998, J NEUROCHEM, V71, P1889; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Schulz JB, 1996, J NEUROSCI, V16, P4696; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Springer JE, 2000, J NEUROSCI, V20, P7246; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Walton M, 1999, J NEUROCHEM, V73, P1836; Walton M, 1996, MOL BRAIN RES, V43, P21, DOI 10.1016/S0169-328X(96)00144-1; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Wei TT, 2000, PHARMACOL RES, V41, P427, DOI 10.1006/phrs.1999.0604; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; YAN GZ, 1994, MOL CELL ENDOCRINOL, V101, pR25, DOI 10.1016/0303-7207(94)90255-0	65	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35049	35059		10.1074/jbc.M104988200	http://dx.doi.org/10.1074/jbc.M104988200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11443132	hybrid			2022-12-25	WOS:000171024600094
J	Zelphati, O; Wang, Y; Kitada, S; Reed, JC; Felgner, PL; Corbeil, J				Zelphati, O; Wang, Y; Kitada, S; Reed, JC; Felgner, PL; Corbeil, J			Intracellular delivery of proteins with a new lipid-mediated delivery system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CATIONIC LIPOSOMES; CELL-DEATH; MAMMALIAN-CELLS; GENE-TRANSFER; TRANSDUCTION; MECHANISM; EFFICIENT; LYMPHOCYTE; PEPTIDE	There are many very effective methods to introduce transcriptionally active DNA into viable cells but approaches to deliver functional proteins are limited. We have developed a lipid-mediated delivery system that can deliver functional proteins or other bioactive molecules into living cells. This delivery system is composed of a new trifluoroacetylated lipopolyamine (TFA-DODAPL) and dioleoyl phosphatidylethanolamine (DOPE). This cationic formulation successfully delivered antibodies, dextran sulfates, phycobiliproteins, albumin, and enzymes (beta -galactosidase and proteases) into the cytoplasm of numerous adherent and suspension cells. Two systems were used to demonstrate that the proteins were delivered in a functionally active form. First, intracellular beta -galactosidase activity was clearly demonstrated within X-gal-stained cells after TFA-DODAPL:DOPE-mediated delivery of the enzyme. Second, the delivery system mediated delivery of several caspases (caspase 3, caspase 8, and granzyme B) into cultured cell lines and primary cells triggering apoptosis. Mechanistic studies showed that up to 100% of the protein mixed with the lipid formulation was captured into a lipid-protein complex, and up to 50% of the input protein associated with cells. This lipid-mediated transport system makes protein delivery into cultured cells as convenient, effective, and reliable as DNA transfection.	Gene Therapy Syst Inc, San Diego, CA 92121 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; San Diego Vet Adm Healthcare Syst, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Zelphati, O (corresponding author), Gene Therapy Syst Inc, 10190 Telesis Court, San Diego, CA 92121 USA.		Corbeil, Jacques/AAW-9739-2020	Corbeil, Jacques/0000-0002-9973-2740	NCI NIH HHS [CA55164] Funding Source: Medline; NIAID NIH HHS [AI47703, AI46237, AI36214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R21AI047703, R01AI046237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABARZUA P, 1995, CANCER RES, V55, P3490; Arrigo AP, 1998, BIOL CHEM, V379, P19; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FARHOOD H, 1995, ANAL BIOCHEM, V225, P89, DOI 10.1006/abio.1995.1112; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fenton M, 1998, J IMMUNOL METHODS, V212, P41, DOI 10.1016/S0022-1759(97)00208-1; Gao X, 1995, GENE THER, V2, P710; Guillaume C, 2000, J PHARM SCI, V89, P639, DOI 10.1002/(SICI)1520-6017(200005)89:5<639::AID-JPS9>3.0.CO;2-L; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang L, 1995, BIOCHEM BIOPH RES CO, V217, P761, DOI 10.1006/bbrc.1995.2838; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PEREZ F, 1992, J CELL SCI, V102, P717; Reed JC, 2000, CURR OPIN BIOTECH, V11, P586, DOI 10.1016/S0958-1669(00)00148-8; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SELLS MA, 1995, BIOTECHNIQUES, V19, P72; Trapani JA, 2000, CURR OPIN IMMUNOL, V12, P323, DOI 10.1016/S0952-7915(00)00094-7; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; WALKER C, 1992, P NATL ACAD SCI USA, V89, P7915, DOI 10.1073/pnas.89.17.7915; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195; Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493	33	184	218	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35103	35110		10.1074/jbc.M104920200	http://dx.doi.org/10.1074/jbc.M104920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11447231	hybrid			2022-12-25	WOS:000171024600100
J	Catimel, B; Teh, T; Fontes, MRM; Jennings, IG; Jans, DA; Howlett, GJ; Nice, EC; Kobe, B				Catimel, B; Teh, T; Fontes, MRM; Jennings, IG; Jans, DA; Howlett, GJ; Nice, EC; Kobe, B			Biophysical characterization of interactions involving importin-alpha during nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; T-ANTIGEN NLS; PROTEIN IMPORT; LOCALIZATION SEQUENCE; KARYOPHERIN-ALPHA; CRYSTALLOGRAPHIC ANALYSIS; ENHANCES RECOGNITION; SIGNAL RECOGNITION; IN-VIVO; BETA	Proteins containing the classical nuclear localization sequences (NLSs) are imported into the nucleus by the importin-alpha/beta heterodimer. Importin-alpha contains the NLS binding site, whereas importin-beta mediates the translocation through the nuclear pore. We characterized the interactions involving importin-alpha during nuclear import using a combination of biophysical techniques (biosensor, crystallography, sedimentation equilibrium, electrophoresis, and circular dichroism). Importin-alpha is shown to exist in a monomeric autoinhibited state (association with NLSs undetectable by biosensor). Association with importin-beta (stoichiometry, 1:1; K-D = 1.1 x 10(-8) m) increases the affinity for NLSs; the importin-alpha/beta complex binds representative monopartite NLS (simian virus 40 large T-antigen) and bipartite NLS (nucleoplasmin) with affinities (K-D = 3.5 x 10(-8) m and 4.8 x 10(-8) m, respectively) comparable with those of a truncated importin-alpha lacking the autoinhibitory domain (T-antigen NLS, K-D = 1.7 x 10(-8) m; nucleoplasmin NLS, K-D = 1.4 x 10(-8) m). The autoinhibitory domain (as a separate peptide) binds the truncated importin-alpha, and the crystal structure of the complex resembles the structure of full-length importin-alpha. Our results support the model of regulation of nuclear import mediated by the intrasteric autoregulatory sequence of importin-alpha and provide a quantitative description of the binding and regulatory steps during nuclear import.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; St Vincents Inst Med Res, Struct Biol Lab, Fitzroy, Vic 3065, Australia; Univ Queensland, Inst Mol Biosci, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signaling Lab, Canberra, ACT 2601, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; St. Vincent's Institute of Medical Research; University of Queensland; Australian National University; John Curtin School of Medical Research; University of Melbourne			Fontes, Marcos Roberto/B-1941-2009; Nice, Edouard C/B-1026-2011; Kobe, Bostjan/D-1292-2009	Fontes, Marcos Roberto/0000-0002-4634-6221; Kobe, Bostjan/0000-0001-9413-9166; Jans, David/0000-0001-5115-4745; Jennings, Ian/0000-0002-4781-9465; CATIMEL, Bruno/0000-0002-4350-6875				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Catimel B, 1996, J BIOL CHEM, V271, P25664, DOI 10.1074/jbc.271.41.25664; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Cingolani G, 2000, FEBS LETT, V484, P291, DOI 10.1016/S0014-5793(00)02154-2; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Fridman M, 2000, BIOCHEMISTRY-US, V39, P15603, DOI 10.1021/bi001224x; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Hubner S, 1999, J BIOL CHEM, V274, P22610, DOI 10.1074/jbc.274.32.22610; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kohler M, 1999, MOL CELL BIOL, V19, P7782; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee SJ, 2000, J MOL BIOL, V302, P251, DOI 10.1006/jmbi.2000.4055; Mathieu MN, 2001, J PEPT RES, V57, P374, DOI 10.1034/j.1399-3011.2001.00853.x; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Percipalle P, 1999, J MOL BIOL, V292, P263, DOI 10.1006/jmbi.1999.3077; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; STENBERG E, 1990, J COLLOID INTERF SCI, V43, P513; Stewart M, 1999, NAT STRUCT BIOL, V6, P301, DOI 10.1038/7529; Sweitzer TD, 2000, CURR TOP CELL REGUL, V36, P77; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	53	135	137	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34189	34198		10.1074/jbc.M103531200	http://dx.doi.org/10.1074/jbc.M103531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448961	hybrid			2022-12-25	WOS:000170910200120
J	Dussault, I; Lin, M; Hollister, K; Wang, EH; Synold, TW; Forman, BM				Dussault, I; Lin, M; Hollister, K; Wang, EH; Synold, TW; Forman, BM			Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE X RECEPTOR; NUCLEAR; METABOLISM; DRUGS	The orphan nuclear receptor SXR coordinately regulates drug clearance in response to a wide variety of xenobiotic compounds. This signaling system protects the body from exposure to toxic compounds; however, it can also pose a severe barrier to drug therapy. We now demonstrate that the human immunodeficiency virus (HIV) protease inhibitor ritonavir binds SXR and activates its target genes. This represents an example of a commonly used therapeutic agent that effectively activates SXR. We also show that other protease inhibitors are weaker (saquinavir) or unable to activate SXR (nelfinavir, indinavir) thus defining analogs that fail to induce SXR-regulated clearance pathways. Interestingly, HIV protease inhibitors are distinct from previously known SXR ligands in that they are peptide mimetic compounds. This expands the ligand specificity of SXR to include this unique chemical class whose pharmaceutical significance is expanding. Finally, we show that SXR ligands activate expression of multiple resistance protein 2, a critical regulator of bile flow and biliary drug excretion. These findings have important implications for the role of SXR in regulating drug clearance and hepatic disorders associated with impaired bile flow.	City Hope Natl Med Ctr, Gonda Diabet & Genet Res Ctr, Div Mol Med, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; City of Hope; Beckman Research Institute of City of Hope	Forman, BM (corresponding author), City Hope Natl Med Ctr, Gonda Diabet & Genet Res Ctr, Div Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.	bmforman@earthlink.net		Synold, Timothy/0000-0002-4075-2544				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Glass CK, 2000, GENE DEV, V14, P121; Gutmann H, 1999, MOL PHARMACOL, V56, P383, DOI 10.1124/mol.56.2.383; Hsu A, 1997, ANTIMICROB AGENTS CH, V41, P898, DOI 10.1128/AAC.41.5.898; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Keppler D, 2000, SEMIN LIVER DIS, V20, P265, DOI 10.1055/s-2000-9391; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Miller DS, 2000, MOL PHARMACOL, V58, P1357, DOI 10.1124/mol.58.6.1357; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Pan-Zhou XR, 1998, BIOCHEM PHARMACOL, V55, P757, DOI 10.1016/S0006-2952(97)00538-8; Piscitelli SC, 2001, NEW ENGL J MED, V344, P984, DOI 10.1056/NEJM200103293441307; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; van Heeswijk RPG, 2000, AIDS, V14, pF103, DOI 10.1097/00002030-200006160-00003; von Bergmann K, 1975, Naunyn Schmiedebergs Arch Pharmacol, V287, P33; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; ZSIGMOND G, 1974, P SOC EXP BIOL MED, V145, P631	22	154	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33309	33312		10.1074/jbc.C100375200	http://dx.doi.org/10.1074/jbc.C100375200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11466304	hybrid			2022-12-25	WOS:000170910200005
J	Hatters, DM; Lindner, RA; Carver, JA; Howlett, GJ				Hatters, DM; Lindner, RA; Carver, JA; Howlett, GJ			The molecular chaperone, alpha-crystallin, inhibits amyloid formation by apolipoprotein C-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; B-CRYSTALLIN; PROTEINS; AMYLOIDOGENESIS; AGGREGATION; SEPARATION	Under lipid-free conditions, human apolipoprotein C-II (apoC-II) exists in an unfolded conformation that over several days forms amyloid ribbons. We examined the influence of the molecular chaperone, alpha -crystallin, on amyloid formation by apoC-II. Time-dependent changes in apoC-II turbidity (at 0.3 mg/ml) were suppressed potently by substoichiometric subunit concentrations of a-crystallin (1-10 mug/ml). alpha -Crystallin also inhibits time-dependent changes in the CD spectra, thioflavin T binding, and sedimentation coefficient of apoC-II. This contrasts with stoichiometric concentrations of a-crystallin required to suppress the amorphous aggregation of stressed proteins such as reduced alpha -lactalbumin. Two pieces of evidence suggest that alpha -crystallin directly interacts with amyloidogenic intermediates. First, sedimentation equilibrium and velocity experiments exclude high affinity interactions between alpha -crystallin and unstructured monomeric apoC-II. Second, the addition of alpha -crystallin does not lead to the accumulation of intermediate sized apoC-II species between monomer and large aggregates as indicated by gel filtration and sedimentation velocity experiments, suggesting that alpha -crystallin does not inhibit the relatively rapid fibril elongation upon nucleation. We propose that alpha -crystallin interacts stoichiometrically with partly structured amyloidogenic precursors, inhibiting amyloid formation at nucleation rather than the elongation phase. In doing so, alpha -crystallin forms transient complexes with apoC-II, in contrast to its chaperone behavior with stressed proteins.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia	University of Melbourne; University of Wollongong	Howlett, GJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.		Carver, John Adrian/J-3825-2014	Carver, John Adrian/0000-0002-2441-8108; Hatters, Danny/0000-0002-9965-2847				Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; Ferrone F, 1999, METHOD ENZYMOL, V309, P256; Hatters DM, 2001, FEBS LETT, V494, P220, DOI 10.1016/S0014-5793(01)02355-9; Hatters DM, 2000, BIOCHEMISTRY-US, V39, P8276, DOI 10.1021/bi000002w; HAVEL RJ, 1973, BIOCHEMISTRY-US, V12, P1828, DOI 10.1021/bi00733a026; HIGUCHI K, 1991, BIOCHEM J, V279, P427, DOI 10.1042/bj2790427; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; JACKSON RL, 1986, METHOD ENZYMOL, V128, P288; Kudva YC, 1997, FEBS LETT, V416, P117, DOI 10.1016/S0014-5793(97)01180-0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lindner RA, 1997, J BIOL CHEM, V272, P27722, DOI 10.1074/jbc.272.44.27722; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Lindner RA, 2001, BIOCHEM J, V354, P79, DOI 10.1042/0264-6021:3540079; Loutas J, 1996, EXP EYE RES, V62, P613, DOI 10.1006/exer.1996.0072; MacRaild CA, 2001, BIOCHEMISTRY-US, V40, P5414, DOI 10.1021/bi002821m; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schuck P, 1998, BIOPHYS J, V74, P466, DOI 10.1016/S0006-3495(98)77804-X; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SLINGSBY C, 1990, EXP EYE RES, V51, P21, DOI 10.1016/0014-4835(90)90165-Q; Stege GJJ, 1999, BIOCHEM BIOPH RES CO, V262, P152, DOI 10.1006/bbrc.1999.1167; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; TAJIMA S, 1982, J BIOCHEM-TOKYO, V91, P1273, DOI 10.1093/oxfordjournals.jbchem.a133812; Treweek TM, 2000, BBA-PROTEIN STRUCT M, V1481, P175, DOI 10.1016/S0167-4838(00)00109-6; Wang CS, 1996, BBA-LIPID LIPID MET, V1302, P224, DOI 10.1016/0005-2760(96)00065-3; WESTERMARK P, 1995, AM J PATHOL, V147, P1186; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; WISNIEWSKI T, 1995, AM J PATHOL, V147, P238	36	86	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33755	33761		10.1074/jbc.M105285200	http://dx.doi.org/10.1074/jbc.M105285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11447233	hybrid			2022-12-25	WOS:000170910200064
J	Missero, C; Pirro, MT; Simeone, S; Pischetola, M; Di Lauro, R				Missero, C; Pirro, MT; Simeone, S; Pischetola, M; Di Lauro, R			The DNA glycosylase T : G mismatch-specific thymine DNA glycosylase represses thyroid transcription factor-1-activated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; FACTOR-I TTF-1; HEART DEVELOPMENT; FOLLICULAR CELLS; GENE-EXPRESSION; LIM PROTEIN; BOX GENE; HOMEODOMAIN; PROMOTER; LUNG	The transcription factor thyroid transcription factor-1 (TTF-1) is a homeodomain-containing protein that belongs to the NK2 family of genes involved in organogenesis. TTF-1 is required for normal development of the forebrain, lung, and thyroid. In a search for factors that regulate TTF-1 transcriptional activity, we isolated three genes (T:G mismatch-specific thymine DNA glycosylase (TDG), homeodomain-interacting protein kinase 2 (HIPK2), and Ajuba), whose products can interact with TTF-1 in yeast and in mammalian cells. TDG is an enzyme involved in base excision repair. In the present paper, we show that TDG acts as a strong repressor of TTF-1 transcriptional activity in a dose-dependent manner, while HIPK2 and Ajuba display no effect on TTF-1 activity, at least under the tested conditions. TDG-mediated inhibition occurs specifically on TTF-1-responsive promoters in thyroid and non thyroid cells. TDG associates with TTF-1 in mammalian cells through the TTF-1 carboxyl-terminal activation domain and is independent of the homeodomain. These findings reveal a previously unsuspected role for the repair enzyme TDG as a transcriptional repressor and open new routes toward the understanding of the regulation of TTF-1 transcriptional activity.	Staz Zool Anton Dohrn, I-80121 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli	Missero, C (corresponding author), TIGEM, Telethon Inst Genet & Med, Via P Castellino 111, I-80131 Naples, Italy.	missero@tigem.it	Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; Missero, Caterina/0000-0003-0905-5123	Telethon [D.067, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CIVITAREALE D, 1993, MOL ENDOCRINOL, V7, P1589, DOI 10.1210/me.7.12.1589; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; De Felice M, 1998, NAT GENET, V19, P395, DOI 10.1038/1289; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Endo T, 1997, MOL ENDOCRINOL, V11, P1747, DOI 10.1210/me.11.11.1747; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; Kanungo J, 2000, MOL BIOL CELL, V11, P3299, DOI 10.1091/mbc.11.10.3299; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LINTS TJ, 1993, DEVELOPMENT, V119, P969; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Niederreither K, 1998, ONCOGENE, V17, P1577, DOI 10.1038/sj.onc.1202072; OHMORI M, 1995, ENDOCRINOLOGY, V136, P269, DOI 10.1210/en.136.1.269; Pellizzari L, 2000, NUCLEIC ACIDS RES, V28, P2503, DOI 10.1093/nar/28.13.2503; POLEEV A, 1992, DEVELOPMENT, V116, P611; Reecy JM, 1997, DEV BIOL, V188, P295, DOI 10.1006/dbio.1997.8641; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; Sussel L, 1998, DEVELOPMENT, V125, P2213; Sussel L, 1999, DEVELOPMENT, V126, P3359; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	54	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33569	33575		10.1074/jbc.M104963200	http://dx.doi.org/10.1074/jbc.M104963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438542	hybrid			2022-12-25	WOS:000170910200039
J	Tomsic, M; Tsujikawa, L; Panaghie, G; Wang, Y; Azok, J; deHaseth, PL				Tomsic, M; Tsujikawa, L; Panaghie, G; Wang, Y; Azok, J; deHaseth, PL			Different roles for basic and aromatic amino acids in conserved region 2 of Escherichia coli sigma(70) in the nucleation and maintenance of the single-stranded DNA bubble in open RNA polymerase-promoter complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONTEMPLATE STRAND; CRYSTAL-STRUCTURE; MECHANISM; RECOGNITION; GLYCOSYLASE; BINDING; TRANSCRIPTION; TEMPERATURE; MUTATIONS; KINETICS	Amino acid residues in region 2 of sigma (70) have been shown to play an important role in the strand separation step that is necessary for formation of the functional or open RNA polymerase-promoter complex. Here we present a comparison of the roles of basic and aromatic amino acids in the accomplishment of this process, using RNA polymerase bearing alanine substitutions for both types of amino acids in region 2. We determined the effects of the substitutions on the kinetics of open complex formation, as well as on the ability of the RNA polymerase to form complexes with single-stranded DNA, and with forked DNA duplexes carrying a single-stranded overhang consisting of bases in the -10 region. We concluded that two basic amino acids (Lys(414) and Lys(418)) are important for promoter binding and demonstrated distinct roles, at a subsequent step, for two aromatic amino acids (Tyr(430) and Trp(433)). It is likely that these four amino acids, which are close to each other in the structure of sigma (70), together are involved in the nucleation of the strand separation process.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	deHaseth, PL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	pld2@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031808] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Fedoriw AM, 1998, BIOCHEMISTRY-US, V37, P11971, DOI 10.1021/bi980980o; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Gussin GN, 1996, METHOD ENZYMOL, V273, P45; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Panaghie G, 2000, J MOL BIOL, V299, P1217, DOI 10.1006/jmbi.2000.3808; Pues H, 1999, BIOCHEMISTRY-US, V38, P1426, DOI 10.1021/bi9818016; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; Severinova E, 1998, J MOL BIOL, V279, P9, DOI 10.1006/jmbi.1998.1742; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Xiao GY, 1999, PROTEINS, V35, P13; Zaychikov E, 1997, J BIOL CHEM, V272, P2259	31	62	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31891	31896		10.1074/jbc.M105027200	http://dx.doi.org/10.1074/jbc.M105027200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11443133	hybrid			2022-12-25	WOS:000170613500059
J	Hu, JD; Ma, XR; Lindner, DJ; Karra, S; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV				Hu, JD; Ma, XR; Lindner, DJ; Karra, S; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV			Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the interferon-retinoid combination	ONCOGENE			English	Article						cytokines; vitamin; growth suppression; apoptosis; redox state	HUMAN TUMOR-CELLS; REDOX REGULATION; DNA-BINDING; MOLECULAR-CLONING; SUPPRESSES GROWTH; INDUCED APOPTOSIS; VITAMIN-A; CANCER; RECEPTOR; PROTEIN	We have shown earlier that the IFN-P and all-trans retinoic acid (RA) combination, but not the single agents, induces death in several tumor cell lines. Employing a genetic technique we have identified several Genes associated with Retinoid-IFN induced Mortality (GRIM), One of the GRIMs was human thioredoxin reductase (TR), a redox enzyme. Since the overexpressed TR augments IFN/RA stimulated cell death, we explored the mechanisms of TR-mediated death, Here we show that TR augments cell death by upregulating the transcriptional activity of p53 tumor suppressor. This process does not involve a physical increase in levels of p53, Using redox inactive mutants of TR and its substrate, thioredoxin (Trx), we demonstrate that IFN/ RA-induced regulation of p53 dependent gene expression requires TR and Trx, In contrast-over-expression of wildtype TR or Trx augment the p53 dependent gene expression in response to IFN/RA treatment. Consistent with these results an increased DNA binding activity of p53 was noted in the presence of TR, These studies identify a novel mechanism of p53 mediated cell death regulation involving redox enzymes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Greenebaum Canc Ctr,Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Greenebaum Canc Ctr,Mol & Cellular Biol Program, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 71401, CA 78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Di Leonardo A, 1997, CANCER RES, V57, P1013; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; FAN SJ, 1995, CANCER RES, V55, P1649; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAINAUT P, 1993, CANCER RES, V53, P4469; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MA X, 2001, IN PRESS J BIOL CHEM; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; MIYASHITA T, 1995, CELL, V80, P293; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALZ HK, 1994, GENETICS, V136, P1075; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Tanioka A, 1997, COLLOID SURFACE B, V9, P17, DOI 10.1016/S0927-7765(97)00006-4; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TSUKADA T, 1993, ONCOGENE, V8, P3313; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103	69	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4235	4248		10.1038/sj.onc.1204585	http://dx.doi.org/10.1038/sj.onc.1204585			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464290				2022-12-25	WOS:000169857200014
J	Rohn, TA; Wagenknecht, B; Roth, W; Naumann, U; Gulbins, E; Krammer, PH; Walczak, H; Weller, M				Rohn, TA; Wagenknecht, B; Roth, W; Naumann, U; Gulbins, E; Krammer, PH; Walczak, H; Weller, M			CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release	ONCOGENE			English	Article						brain; apoptosis; neuroimmunology; cytokines; immunotherapy	MALIGNANT GLIOMA; CD95 LIGAND; LETHAL WEAPON; APO2 LIGAND; IN-VIVO; DEATH; EXPRESSION; CYTOTOXICITY; MODULATION; RECEPTORS	Death ligands such as CD95 ligand (CD95L) or tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) induce apoptosis in radiochemotherapy-resistant human malignant glioma cell lines. The death-signaling TRAIL receptors 2 (TRAIL-R2/death receptor (DR) 5) and TRAIL-R1/ DR4 were expressed more abundantly than the non-death-inducing (decoy) receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 in 12 human glioma cell lines. Four of the 12 cell lines were TRAIL/Apo2L-sensitive in the absence of a protein synthesis inhibitor, cycloheximide (CHX), Three of the 12 cell lines were still TRAIL/ Apo2L-resistant in the presence of CHX, TRAIL-R2 expression predicted sensitivity to apoptosis. Coexposure to TRAIL/Apo2L and cytotoxic drugs such as topotecan, lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, CCNU) or temozolomide resulted in synergistic killing. Synergistic killing was more often observed in cell lines retaining wild-type p53 activity (U87MG, LN-229) than in p53 mutant cell lines (LN-18, T98G, U373MG). Drug exposure resulted in enhanced TRAIL-R2 expression, but decreased TRAIL-R4 expression in U87MG cells. Ectopic expression of dominant-negative p53(V135A) abrogated the drug-induced changes in TRAIL-R2 and TRAIL-R4 expression, but had no effect on synergy. Thus, neither wildtype p53 function nor changes in TRAIL receptor expression were required for synergy, In contrast, synergy resulted possibly from drug-induced cytochrome c release from mitochondria, serving as an amplifier of the TRAIL/Apo2L-mediated cascade of caspase activation. These data provide novel insights into the role of the TRAIL/Apo2L system in malignant gliomas and illustrate that TRAIL/Apo2L-based immunochemotherapy may be an effective therapeutic strategy for these lethal neoplasms.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Univ Tubingen, Sch Med, Inst Physiol, D-72076 Tubingen, Germany; German Canc Res Ctr, Dept Immunogenet, D-6900 Heidelberg, Germany; German Canc Res Ctr, Dept Apoptosis Regulat, D-6900 Heidelberg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Walczak, Henning/AAV-2214-2020; Gulbins, Erich/L-6989-2014	Walczak, Henning/0000-0002-6312-4591; Gulbins, Erich/0000-0002-3117-1342; Weller, Michael/0000-0002-1748-174X				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; GLASER T, 2001, IN PRESS ONCOGENE; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hermisson M, 2000, ONCOGENE, V19, P2338, DOI 10.1038/sj.onc.1203554; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Nagane M, 2000, CANCER RES, V60, P847; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schmidt F, 2001, EUR J PHARMACOL, V412, P21, DOI 10.1016/S0014-2999(00)00923-7; Sheikh MS, 1998, CANCER RES, V58, P1593; VAN MEIR EG, 1994, CANCER RES, V54, P649; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	27	85	90	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4128	4137		10.1038/sj.onc.1204534	http://dx.doi.org/10.1038/sj.onc.1204534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464279				2022-12-25	WOS:000169857200003
J	Wang, JY; Del Valle, L; Gordon, J; Rubini, M; Romano, G; Croul, S; Peruzzi, F; Khalili, K; Reiss, K				Wang, JY; Del Valle, L; Gordon, J; Rubini, M; Romano, G; Croul, S; Peruzzi, F; Khalili, K; Reiss, K			Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas	ONCOGENE			English	Article						IGF-IR; medulloblastoma; IRS-1; cell proliferation; tyrosine phosphorylation	INSULIN-RECEPTOR SUBSTRATE-1; DOMINANT-NEGATIVE MUTANT; NEUROTROPIC JC VIRUS; CELL-LINE; IN-VIVO; EMBRYO FIBROBLASTS; INDUCED APOPTOSIS; TUMOR-GROWTH; C-MYC; TRANSFORMATION	Insulin-like growth factor I receptor (IGF-IR) has been implicated in the normal and malignant growth of many cell types including cells from the central nervous system. In the cerebellar cortex ICF-IR mRNA is found in granular cells and IGF-I stimulation is mitogenic and protects cells from low-potassium-induced apoptosis, Since primitive neuroectodermal tumers/medulloblastomas (PNETs/medulloblastomas) are suspected to originate from the external cerebellar granular layer, it is reasonable to postulate that IGF-IR and/or its signaling molecules may contribute to the transformation of these poorly differentiated cells. To study activation of the IGF-IR system in medulloblastomas, we have utilized an antibody (anti-pY1316) that specifically recognizes the phosphorylated (active) form of the IGF-IR, Medulloblastoma biopsy specimens were positive when examined immunohistochemically with anti-Y1316 antibody. Further analysis of the IGF-IR system was performed in three human (Daoy, TE-671, D283 Med) and four mouse (BsB8, BsB13, Bs-lb, Bs-lc) medulloblastoma cell lines. All the murine cell lines examined express IGF-IR and PI3-kinase at relatively normal levels, and grossly overexpress IRS-I, when compared with normal mouse cerebellum. Within 15 min following IGF-I stimulation both mouse and human cell lines phosphorylate the P subunit of the IGF-IR, IRS-1, Akt, and MAP kinases, They respond with cell proliferation when stimulated solely with IGF-I and are strongly inhibited when challenged with a dominant negative mutant of the IGF-IR (486/STOP), or with antisense oligonucleotides against the IGF-IR mRNA.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Ferrara; Jefferson University	Reiss, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,Biol Life Sci Bldg,Room 238, Philadelphia, PA 19122 USA.		Rubini, Michele/AFF-8477-2022; Peruzzi, Francesca/M-9804-2014; Del Valle, Luis/J-4085-2015	Rubini, Michele/0000-0003-1448-9516; Del Valle, Luis/0000-0003-3894-9206; Croul, Sidney/0000-0002-2224-5485	NINDS NIH HHS [P0-1 NS 36466] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BASERGA R, 1995, CANCER RES, V55, P240; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAmbrosio C, 1996, CANCER RES, V56, P4013; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; Dunn SE, 1998, CANCER RES, V58, P3353; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; FULTS D, 1989, BRAIN RES, V503, P281, DOI 10.1016/0006-8993(89)91675-2; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; KALEBIC T, 1994, CANCER RES, V54, P5531; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; MIURA M, 1995, CANCER RES, V55, P663; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Morrione A, 2000, CANCER RES, V60, P2263; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Pappas IS, 1996, CELL GROWTH DIFFER, V7, P797; Patti R, 2000, INT J ONCOL, V16, P577; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PORCU P, 1994, ONCOGENE, V9, P2125; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; REISS K, 1995, AM J PHYSIOL-HEART C, V269, pH943, DOI 10.1152/ajpheart.1995.269.3.H943; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; RESNICOFF M, 1994, CANCER RES, V54, P2218; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Rubini M, 1999, EXP CELL RES, V251, P22, DOI 10.1006/excr.1999.4562; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Steller MA, 1996, CANCER RES, V56, P5087; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; WATERS SB, 1993, J BIOL CHEM, V268, P22231	51	74	76	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3857	3868		10.1038/sj.onc.1204532	http://dx.doi.org/10.1038/sj.onc.1204532			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439349				2022-12-25	WOS:000169494700011
J	Mohanam, S; Jasti, SL; Kondraganti, SR; Chandrasekar, N; Lakka, SS; Kin, Y; Fuller, GN; Yung, AWK; Kyritsis, AP; Dinh, DH; Olivero, WC; Gujrati, M; Ali-Osman, F; Rao, JS				Mohanam, S; Jasti, SL; Kondraganti, SR; Chandrasekar, N; Lakka, SS; Kin, Y; Fuller, GN; Yung, AWK; Kyritsis, AP; Dinh, DH; Olivero, WC; Gujrati, M; Ali-Osman, F; Rao, JS			Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells	ONCOGENE			English	Article						glioblastoma; invasion; cathepsin B	HUMAN GLIOMAS; CYSTATIN-C; PROTEASE INHIBITORS; TUMOR PROGRESSION; CANCER METASTASIS; PROGNOSTIC FACTOR; BREAST-CANCER; ANGIOGENESIS; LOCALIZATION; LINES	Increases in abundance of cathepsin B transcript and protein correlate with increases in tumor grade and alterations in subcellular localization and activity of cathepsin B, The enzyme is able to degrade the components of the extracellular matrix (ECM) and activate other proteases capable of degrading ECM, To investigate the role played by this protease in the invasion of brain tumor cells, we transfected SNB19 human glioblastoma cells with a plasmid containing cathepsin B cDNA in antisense orientation. Control cells were transfected with vector alone. Clones expressing antisense cathepsin B cDNA exhibited significant reductions in cathepsin B mRNA, enzyme activity and protein compared to controls. Matrigel Invasion assay showed that the antisense-transfected cells had markedly diminished invasiveness compared with controls. When tumor spheroids containing antisense transfected SNB19 cells expressing reduced cathepsin B were co-cultured with fetal rat brain aggregates, invasion of fetal rat brain aggregates was significantly reduced. Green Fluorescent Protein (GFP) expressing parental cells and antisense transfectants were generated for detection in mouse brain tissue without any post-chemical treatment. Intracerebral injection of SNB19 stable antisense transfectants resulted in reduced tumor formation in nude mice. These results strongly support a role for cathepsin B in the invasiveness of human glioblastoma cells and suggest cathepsin B antisense may prove useful in cancer therapy.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neuropathol, Houston, TX 77030 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA.			Fuller, Gregory/0000-0001-9447-2647	NCI NIH HHS [P30 CA-16672, CA 76350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA076350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cox JL, 1999, MELANOMA RES, V9, P369, DOI 10.1097/00008390-199908000-00005; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013; Friedrich B, 1999, EUR J CANCER, V35, P138, DOI 10.1016/S0959-8049(98)00273-1; Go Y, 1996, CANCER LETT, V110, P225, DOI 10.1016/S0304-3835(96)04515-6; Goldbrunner RH, 1998, MICROSC RES TECHNIQ, V43, P250, DOI 10.1002/(SICI)1097-0029(19981101)43:3<250::AID-JEMT7>3.0.CO;2-C; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Heidtmann HH, 1997, CLIN EXP METASTAS, V15, P368, DOI 10.1023/A:1018494020001; Hirai K, 1999, HUM PATHOL, V30, P680, DOI 10.1016/S0046-8177(99)90094-1; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; Kostoulas G, 1999, FEBS LETT, V455, P286, DOI 10.1016/S0014-5793(99)00897-2; Kruger S, 1999, CANCER RES, V59, P6010; Lah TT, 1998, BIOL CHEM, V379, P125; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maguire TM, 1998, INT J BIOL MARKER, V13, P139, DOI 10.1177/172460089801300303; MCCORMICK D, 1993, NEUROPATH APPL NEURO, V19, P146, DOI 10.1111/j.1365-2990.1993.tb00420.x; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Navab R, 1997, CLIN EXP METASTAS, V15, P121, DOI 10.1023/A:1018496625936; Nygaard SJT, 1995, INVAS METAST, V15, P179; PEDERSEN PH, 1993, CANCER RES, V53, P5158; REMPEL SA, 1994, CANCER RES, V54, P6027; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; Sinha AA, 1998, ANAT REC, V252, P281; SIVAPARVATHI M, 1995, CLIN EXP METASTAS, V13, P49, DOI 10.1007/BF00144018; Sivaparvathi M, 1996, CLIN EXP METASTAS, V14, P27, DOI 10.1007/BF00157683; SPIESS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917, DOI 10.1177/42.7.8014475; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Van Noorden CJF, 1998, CLIN EXP METASTAS, V16, P159; Werle B, 1999, BRIT J CANCER, V81, P510, DOI 10.1038/sj.bjc.6690723	39	71	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3665	3673		10.1038/sj.onc.1204480	http://dx.doi.org/10.1038/sj.onc.1204480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439329				2022-12-25	WOS:000169400200007
J	Adhikari, P; Bachhawat-Sikder, K; Thomas, CJ; Ravishankar, R; Jeyaprakash, AA; Sharma, V; Vijayan, M; Surolia, A				Adhikari, P; Bachhawat-Sikder, K; Thomas, CJ; Ravishankar, R; Jeyaprakash, AA; Sharma, V; Vijayan, M; Surolia, A			Mutational analysis at Asn-41 in peanut agglutinin - A residue critical for the binding of the tumor-associated Thomsen-Friedenreich antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING; CRYSTAL-STRUCTURE; ARACHIS-HYPOGAEA; LECTIN; SPECIFICITY; COMPLEX; CELLS; SITE; ASP	Peanut agglutinin is a clinically important lectin due to its application in the screening of mature and immature thymocytes as well as in the detection of cancerous malignancies. The basis for these applications is the remarkably strong affinity of the lectin for the tumor-associated Thomsen-Friedenreich antigen (T-antigen) and more so due to its ability to distinguish T-antigen from its cryptic forms. The crystal structure of the complex of peanut agglutinin with T-antigen reveals the basis of this specificity. Among the contacts involved in providing this specificity toward T-antigen is the water-mediated interaction between the side chain of Asn-41 and the carbonyl oxygen of the acetamido group of the second hexopyranose ring of the sugar molecule. Site directed mutational changes were introduced at this residue with the objective of probing the role of this residue in T-antigen binding and possibly engineering an altered species with increased specificity for T-antigen. Of the three mutants tested, i.e. N41A, N41D, and N41Q, the last one shows improved potency for recognition of T-antigen. The affinities of the mutants can be readily explained on the basis of the crystal structure of the complex and simple modeling. In particular, the change of asparagine to glutamine could lead to a direct interaction of the side chain with the sugar while at the same time retaining the water bridge. This study strengthens the theory that in lectins the nonprimary contacts generally made through water bridges are involved in imparting exquisite specificity.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009; Arulanandam, Arockia Jeyaprakash/Y-5885-2019	Arulanandam, Arockia Jeyaprakash/0000-0002-1889-8635; Ramachandran, Ravishankar/0000-0002-0723-9861				Ausubel F. M., 1993, CURRENT PROTOCOLS MO, P3; BANNERJEE R, 1994, P NATL ACAD SCI USA, V91, P227; BANNERJEE R, 1996, J MOL BIOL, V259, P281; BOVIN NV, 1993, GLYCOCONJUGATE J, V10, P142, DOI 10.1007/BF00737711; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; JONNSON U, 1991, BIOTECHNIQUES, V11, P620; Liener I.E., 1986, LECTINS PROPERTIES F; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MIRKOV TE, 1993, GLYCOBIOLOGY, V3, P581, DOI 10.1093/glycob/3.6.581; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; Ravishankar R, 1999, ACTA CRYSTALLOGR D, V55, P1375, DOI 10.1107/S0907444999006587; Ravishankar R, 1997, CURR SCI INDIA, V72, P855; REISNER Y, 1979, P NATL ACAD SCI USA, V76, P447, DOI 10.1073/pnas.76.1.447; RINDERLE SJ, 1989, J BIOL CHEM, V264, P16123; Sambrook J, 1989, MOL CLONING LABORATO, P10; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARMA V, 1994, GENE, V148, P299, DOI 10.1016/0378-1119(94)90702-1; Sharma V, 1996, J BIOL CHEM, V271, P21209, DOI 10.1074/jbc.271.35.21209; SHARMA V, 1997, J MOL BIOL, V267, P21209; SHARON N, 1989, LECTINS; SWAMY MJ, 1991, CARBOHYD RES, V213, P59; VANEIJSDEN RR, 1992, PLANT MOL BIOL, V20, P1049, DOI 10.1007/BF00028892; ZEBDA N, 1994, J CELL BIOCHEM, V54, P161, DOI 10.1002/jcb.240540205	27	28	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40734	40739		10.1074/jbc.M103040200	http://dx.doi.org/10.1074/jbc.M103040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11447220	hybrid			2022-12-25	WOS:000171925600049
J	Lamminmaki, U; Kankare, JA				Lamminmaki, U; Kankare, JA			Crystal structure of a recombinant anti-estradiol Fab fragment in complex with 17 beta-estradiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; MOLECULAR-BASIS; BINDING-SITE; SPECIFICITY; REGION; CLASSIFICATION; CONFORMATIONS; SEQUENCE; CLONING; DOMAIN	The crystal structure of a Fab fragment of an anti-17 beta -estradiol. antibody 57-2 was determined in the absence and presence of the steroid ligand, 17 beta -estradiol (E2), at 2.5 and 2.15-Angstrom resolutions, respectively. The antibody binds the steroid in a deep hydrophobic pocket formed at the interface between the variable domains. No major structural rearrangements take place upon ligand binding;, however, a large part of the heavy chain variable domain near the binding pocket is unusually flexible and is partly stabilized when the steroid is bound. The nonpolar steroid skeleton of E2 is recognized by a number of hydrophobic interactions, whereas the two hydroxyl groups of E2 are hydrogen-bonded to the protein. Especially, the 17-hydroxyl group of E2 is recognized by an intricate hydrogen bonding network in which the 17-hydroxyl itself forms a rare four-center hydrogen bond with three polar amino acids; this hydrogen bonding arrangement accounts for the low cross-reactivity of the antibody with other estrogens such as estrone. The CDRH3 loop plays a prominent role in ligand binding. All the complementarity-determining regions of the light chain make direct contacts with the steroid, even CDRL2, which is rarely directly involved in the binding of haptens.	Univ Turku, Dept Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, Turku 20521, Finland	University of Turku; University of Turku	Lamminmaki, U (corresponding author), Univ Turku, Dept Biotechnol, Tykistokatu 6,6th Floor, FIN-20520 Turku, Finland.	urpo.lamminmaki@utu.fi						Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulun SE, 2000, J MOL ENDOCRINOL, V25, P35, DOI 10.1677/jme.0.0250035; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; *IUPAC IUB JCBN, 1989, EUR J BIOCHEM, V86, P429; JEFFREY AG, 1997, INTRO HYDROGEN BONDI, P25; JEFFREY PD, 1995, J MOL BIOL, V248, P344, DOI 10.1016/S0022-2836(95)80055-7; JEFFREY PD, 1993, P NATL ACAD SCI USA, V90, P10310, DOI 10.1073/pnas.90.21.10310; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABAT AS, 1991, SEQUENCES PROTEINS I, P91; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lamminmaki U, 1997, MOL IMMUNOL, V34, P1215, DOI 10.1016/S0161-5890(97)00085-0; Lamminmaki U, 1999, J MOL BIOL, V291, P589, DOI 10.1006/jmbi.1999.2981; Lamminmaki U, 2000, ACTA CRYSTALLOGR D, V56, P1670, DOI 10.1107/S0907444900013317; Lim K, 1998, J BIOL CHEM, V273, P28576, DOI 10.1074/jbc.273.44.28576; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAX EE, 1981, J BIOL CHEM, V256, P5116; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Mylvaganam SE, 1998, J MOL BIOL, V281, P301, DOI 10.1006/jmbi.1998.1942; Oliva B, 1998, J MOL BIOL, V279, P1193, DOI 10.1006/jmbi.1998.1847; OTWINOSWKI Z, 1993, DENZO SCALEPACK DATA; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; Pajunen M, 1997, BBA-GENE STRUCT EXPR, V1351, P192, DOI 10.1016/S0167-4781(96)00202-3; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; Saviranta P, 1998, PROTEIN ENG, V11, P143, DOI 10.1093/protein/11.2.143; SEIDMAN JG, 1978, P NATL ACAD SCI USA, V75, P3881, DOI 10.1073/pnas.75.8.3881; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; Tegoni M, 1999, J MOL BIOL, V289, P1375, DOI 10.1006/jmbi.1999.2845; Thomas L, 1998, CLIN LAB DIAGNOSTICS; Trinh CH, 1997, STRUCTURE, V5, P937, DOI 10.1016/S0969-2126(97)00247-5; VARGASMADRAZO E, 1995, J MOL BIOL, V254, P497, DOI 10.1006/jmbi.1995.0633; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4	54	27	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36687	36694		10.1074/jbc.M102367200	http://dx.doi.org/10.1074/jbc.M102367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11451948	hybrid			2022-12-25	WOS:000171194500084
J	Ostlund, P; Lindegren, H; Pettersson, C; Bedecs, K				Ostlund, P; Lindegren, H; Pettersson, C; Bedecs, K			Up-regulation of functionally impaired insulin-like growth factor-1 receptor in scrapie-infected neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; FACTOR-I RECEPTOR; PRION PROTEIN; SIGNAL-TRANSDUCTION; DOLICHYL-PHOSPHATE; BINDING-PROTEINS; OXIDATIVE STRESS; NITRIC-OXIDE; AGING RATS; IGF-I	A growing body of evidence suggests that an altered level or function of the neurotrophic insulin-like growth factor-1 receptor (IGF-1R), which supports neuronal survival, may underlie neurodegeneration. This study has focused on the expression and function of the IGF-1R in scrapie-infected neuroblastoma cell lines. Our results show that scrapie infection induces a 4-fold increase in the level of IGF-1R in two independently scrapie-infected neuroblastomas, ScN2a and ScN1E-115 cells, and that the increased IGF-1R level was accompanied by increased IGF-1R mRNA levels. In contrast to the elevated IGF-IR expression in ScN2a, receptor binding studies revealed an 80% decrease in specific I-125-IGF-1-binding sites compared with N2a cells. This decrease in IGF-1R-binding sites was shown to be caused by a 7-fold decrease in IGF-1R affinity. Furthermore, ScN2a showed no significant difference in IGF-1 induced proliferative response, despite the noticeable elevated IGF-1R expression, putatively explained by the reduced IGF-1R binding affinity. Additionally, IGF-1 stimulated IGF-1R beta tyrosine phosphorylation showed no major change in the dose-response between the cell types, possibly due to altered tyrosine kinase signaling in scrapie-infected neuroblastoma cells. Altogether these data indicate that scrapie infection affects the expression, binding affinity, and signal transduction mediated by the IGF-1R in neuroblastoma cells. Altered IGF-1R expression and function may weaken the trophic support in scrapie-infected neurons and thereby contribute to neurodegeneration in prion diseases.	Univ Stockholm, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden	Stockholm University	Bedecs, K (corresponding author), Univ Stockholm, Dept Neurochem & Neurotoxicol, Svante Arrhenius V 21A, S-10691 Stockholm, Sweden.	coco@neurochem.su.se						ADEM A, 1994, J NEURAL TRANSM-GEN, V97, P73, DOI 10.1007/BF01277964; Anlar B, 1999, HORM METAB RES, V31, P120, DOI 10.1055/s-2007-978708; Averbukh E, 1998, METABOLISM, V47, P1331, DOI 10.1016/S0026-0495(98)90300-6; Bosque PJ, 2000, J VIROL, V74, P4377, DOI 10.1128/JVI.74.9.4377-4386.2000; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Carlberg M, 1996, J BIOL CHEM, V271, P17453, DOI 10.1074/jbc.271.29.17453; CastroAlamancos MA, 1996, NEUROSCIENCE, V70, P843, DOI 10.1016/0306-4522(95)00472-6; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; Damon SE, 2001, ENDOCRINOLOGY, V142, P21, DOI 10.1210/en.142.1.21; DCOSTA AP, 1995, NEUROSCIENCE, V65, P805, DOI 10.1016/0306-4522(94)00495-Q; Delafontaine P, 1997, CARDIOVASC RES, V33, P216, DOI 10.1016/S0008-6363(96)00179-4; DEPABLO F, 1995, TRENDS NEUROSCI, V18, P143, DOI 10.1016/0166-2236(95)93892-2; Diez M, 1997, P NATL ACAD SCI USA, V94, P13267, DOI 10.1073/pnas.94.24.13267; Dore S, 1997, TRENDS NEUROSCI, V20, P326; DOYLE JW, 1993, J CELL PHYSIOL, V155, P171, DOI 10.1002/jcp.1041550122; Dricu A, 1999, GLYCOBIOLOGY, V9, P571, DOI 10.1093/glycob/9.6.571; Du J, 1999, ARTERIOSCL THROM VAS, V19, P2119, DOI 10.1161/01.ATV.19.9.2119; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Guan ZZ, 1996, J NEUROCHEM, V66, P277; Guentchev M, 2000, NEUROBIOL DIS, V7, P270, DOI 10.1006/nbdi.2000.0290; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000; Keshet GI, 1999, J NEUROCHEM, V72, P1224, DOI 10.1046/j.1471-4159.1999.0721224.x; Levresse V, 2000, J NEUROSCI RES, V62, P799; Loddick SA, 1998, P NATL ACAD SCI USA, V95, P1894, DOI 10.1073/pnas.95.4.1894; Matthews CC, 1997, NEUROSCIENCE, V79, P525, DOI 10.1016/S0306-4522(96)00611-2; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; NILSSON L, 1988, NEUROSCI LETT, V88, P221, DOI 10.1016/0304-3940(88)90130-9; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; RUBINI M, 1994, EXP CELL RES, V211, P374, DOI 10.1006/excr.1994.1101; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; Sonntag WE, 1999, NEUROSCIENCE, V88, P269, DOI 10.1016/S0306-4522(98)00192-4; Sortino MA, 1996, ENDOCRINOLOGY, V137, P1418, DOI 10.1210/en.137.4.1418; Stenvers KL, 1996, NEUROSCIENCE, V72, P505, DOI 10.1016/0306-4522(95)00524-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tatzelt J, 1998, CELL MOL NEUROBIOL, V18, P721, DOI 10.1023/A:1020282205041; Torres-Aleman I, 1999, HORM METAB RES, V31, P114, DOI 10.1055/s-2007-978707; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Wang JM, 2000, BRAIN RES, V859, P381, DOI 10.1016/S0006-8993(00)02008-4; Werther GA, 1998, HORM RES, V49, P37, DOI 10.1159/000053066; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Wong K, 1996, NEUROLOGY, V47, P741, DOI 10.1212/WNL.47.3.741; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	61	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36110	36115		10.1074/jbc.M105710200	http://dx.doi.org/10.1074/jbc.M105710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11461928	hybrid			2022-12-25	WOS:000171194500010
J	Ko, KS; Arora, PD; McCulloch, CAG				Ko, KS; Arora, PD; McCulloch, CAG			Cadherins mediate intercellular mechanical signaling in fibroblasts by activation of stretch-sensitive calcium-permeable channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GINGIVAL FIBROBLASTS; CELL-CELL ADHESION; ADHERENS JUNCTIONS; ION CHANNELS; COLLAGEN PHAGOCYTOSIS; SMOOTH-MUSCLE; GAP-JUNCTIONS; ACTIN; COMMUNICATION; CYTOSKELETON	Cells in mechanically active environments form extensive, cadherin-mediated intercellular junctions that are important in tissue remodeling and differentiation. Currently, it is unknown whether adherens junctions in connective tissue fibroblasts transmit mechanical signals and coordinate multicellular adaptations to physical forces. We hypothesized that cadherins mediate intercellular mechanotransduction by activating calcium-permeable, stretch-sensitive channels. Human gingival fibroblasts in suspension were plated on established homotypic monolayer cultures. The cells formed intercellular adherens junctions. Controlled mechanical forces were applied to intercellular junctions by electromagnets acting on cells containing internalized magnetite beads. At early but not later stages of intercellular attachment, force application visibly displaced magnetite bead-loaded cells and induced robust Ca2+ transients (65 +/- 9.4 nm above base line). Similar Ca2+ transients were induced by force application to anti-N-cadherin antibody-coated magnetite beads. Ca2+ responses depended on influx of extracellular Ca2+ through mechanosensitive channels because both Ca2+ chelation and gadolinium chloride abolished the response and MnCl2 quenched fura-2 fluorescence after force application. Force application induced accumulation of microinjected rhodamine-actin at intercellular contacts; actin assembly was inhibited by buffering intracellular calcium fluxes. Our results indicate that mechanical forces applied to adherens junctions activate stretch-sensitive calcium-permeable channels and increase actin polymerization. We suggest that N-cadherins in fibroblasts are intercellular mechanotransducers.	Univ Toronto, Inst Canc, Hlth Res Grp Matrix Dynam, Fac Dent, Toronto, ON M5S 3E2, Canada	University of Toronto	Ko, KS (corresponding author), Univ Toronto, Inst Canc, Hlth Res Grp Matrix Dynam, Fac Dent, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.							Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; ARORA PD, 1994, J CELL PHYSIOL, V161, P187, DOI 10.1002/jcp.1041610202; BEERTSEN W, 1980, J PERIODONTAL RES, V16, P524; BOITANO S, 1994, J CELL SCI, V107, P3037; Brock J, 1996, J CELL BIOL, V135, P1097, DOI 10.1083/jcb.135.4.1097; BYERS SW, 1995, J CELL SCI, V108, P2053; CHAYTOR AT, 1997, J PHYSIOL-LONDON, V503, P109; Danjo Y, 1998, J CELL SCI, V111, P3323; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; Dora KA, 1999, BIOCHEM BIOPH RES CO, V254, P27, DOI 10.1006/bbrc.1998.9877; Gabbiani G, 1981, HDB INFLAMMATION, V3, P1; Galbraith CG, 1997, P NATL ACAD SCI USA, V94, P9114, DOI 10.1073/pnas.94.17.9114; Girard P. R., 1993, PHYSICAL FORCES MAMM, P193; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Glogauer M, 1997, J CELL SCI, V110, P11; Glogauer M, 1998, PFLUG ARCH EUR J PHY, V435, P320; Gloushankova NA, 1998, P NATL ACAD SCI USA, V95, P4362, DOI 10.1073/pnas.95.8.4362; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guan XJ, 1996, MOL CARCINOGEN, V16, P157; HANSEN M, 1995, J CELL SCI, V108, P2583; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Hurst V, 1999, AM J PHYSIOL-LUNG C, V276, pL582, DOI 10.1152/ajplung.1999.276.4.L582; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIRBER MT, 1988, PFLUG ARCH EUR J PHY, V412, P339, DOI 10.1007/BF01907549; KNOWLES GC, 1991, J CELL SCI, V98, P551; Ko K, 2000, AM J PHYSIOL-CELL PH, V279, pC147, DOI 10.1152/ajpcell.2000.279.1.C147; Ko KS, 2001, J CELL SCI, V114, P1155; Ko KSC, 1998, INFECT IMMUN, V66, P703, DOI 10.1128/IAI.66.2.703-709.1998; KULKARNI GV, 1994, J CELL SCI, V107, P1169; Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; Levenberg S, 1998, J CELL SCI, V111, P347; MASSEY BS, 1968, MECH FLUIDS, P154; MCKEOWN M, 1990, CELL TISSUE RES, V262, P523, DOI 10.1007/BF00305249; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; Noria S, 1999, CIRC RES, V85, P504, DOI 10.1161/01.RES.85.6.504; PENDER N, 1991, J CELL SCI, V100, P187; Ragsdale GK, 1997, BIOPHYS J, V73, P2798, DOI 10.1016/S0006-3495(97)78309-7; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SHORE RC, 1981, J ANAT, V133, P67; Spanakis SG, 1998, INVEST OPHTH VIS SCI, V39, P1320; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Wang XJ, 1999, J MOL CELL CARDIOL, V31, P333, DOI 10.1006/jmcc.1998.0886; XIA SL, 1992, BIOCHEM BIOPH RES CO, V186, P1212, DOI 10.1016/S0006-291X(05)81535-9; Xu J, 1998, AM J PHYSIOL-LUNG C, V275, pL545, DOI 10.1152/ajplung.1998.275.3.L545; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	48	117	122	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35967	35977		10.1074/jbc.M104106200	http://dx.doi.org/10.1074/jbc.M104106200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466312	hybrid			2022-12-25	WOS:000171109300099
J	Newton, A; Mackay, J; Crossley, M				Newton, A; Mackay, J; Crossley, M			The N-terminal zinc finger of the erythroid transcription factor GATA-1 binds GATC motifs in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; FAMILY; COFACTOR; FOG-2; SPECIFICITY; REGULATORS; MUTATION; COMPLEX; CLONING; DOMAIN	The mammalian transcription factor GATA-1 is required for normal erythroid and megakaryocytic development. GATA-1 contains two zinc fingers, the C-terminal finger, which is known to bind (A/T)GATA(A/G) motifs in DNA and the N-finger, which is important for interacting with co-regulatory proteins such as Friend of GATA (FOG). We now show that, like the C-finger, the N-finger of GATA-1 is also capable of binding DNA but recognizes distinct sequences with the core GATC. We demonstrate that the GATA-1 N-finger can bind these sequences in vitro and that in cellular assays, GATA-1 can activate promoters containing GATC motifs. Experiments with mutant GATA-1 proteins confirm the importance of the N-finger, as the C-finger is not required for transactivation from GATC sites. Recently four naturally occurring mutations in GATA-1 have been shown to be associated with familial blood disorders. These mutations all map to the N-finger domain. We have investigated the effect of these mutations on the recognition of GATC sites by the N-finger and show that one mutation R216Q abolishes DNA binding, whereas the others have only minor effects.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Sydney	Crossley, M (corresponding author), Univ Sydney, Dept Biochem, G08, Sydney, NSW 2006, Australia.	M.Crossley@biochem.usyd.edu.au	Crossley, Merlin/D-7888-2011; Mackay, Joel P/D-6834-2011	Crossley, Merlin/0000-0003-2057-3642; Mackay, Joel P/0000-0001-7508-8033				Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DRACHMAN JG, 2001, IN PRESS BLOOD; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Freson K, 2001, BLOOD, V98, P85, DOI 10.1182/blood.V98.1.85; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; Kramer MF, 2000, GENE, V247, P153, DOI 10.1016/S0378-1119(00)00103-7; LACRONIQUE V, 1995, J BIOL CHEM, V270, P14989, DOI 10.1074/jbc.270.25.14989; Liew CK, 2000, STRUCTURE, V8, P1157, DOI 10.1016/S0969-2126(00)00527-X; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Minami T, 1998, EUR J BIOCHEM, V258, P879, DOI 10.1046/j.1432-1327.1998.2580879.x; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Teakle GR, 1998, TRENDS BIOCHEM SCI, V23, P100, DOI 10.1016/S0968-0004(98)01174-8; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Trainor CD, 2000, J BIOL CHEM, V275, P28157; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Yu CN, 2000, BLOOD, V96, p495A; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	38	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35794	35801		10.1074/jbc.M106256200	http://dx.doi.org/10.1074/jbc.M106256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11445591	hybrid			2022-12-25	WOS:000171109300077
J	Oberg, C; Li, JH; Pauley, A; Wolf, E; Gurney, M; Lendahl, U				Oberg, C; Li, JH; Pauley, A; Wolf, E; Gurney, M; Lendahl, U			The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian sel-10 homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; NUCLEAR ACCESS; DROSOPHILA; LIN-12; PROTEOLYSIS; DEGRADATION; PRESENILIN; PROTEINS; RELEASE; GENES	The Caenorhabditis elegans sel-10 protein is structurally similar to E3 ubiquitin ligases and is a negative regulator of Notch (lin-12) and presenilin signaling. In this report, we characterize the mammalian Sel-10 homolog (mSel-10) and analyze its effects on Notch signaling. We find that mSel-10 localizes to the cell nucleus, and that it physically interacts with the Notch 1 intracellular domain (IC) and reduces Notch 1 IC-mediated activation of the HES 1 promoter. Notch 1 IC is ubiquitinated by mSel-10, and ubiquitination requires the presence of the most carboxyl-terminal region of the Notch IC, including the PEST domain. In the presence of the proteasome inhibitor MG132, the amount of Notch 1 IC and its level of ubiquitination are increased. Interestingly, this accumulation of Notch 1 IC in the presence of MG132 is accompanied by decreased activation of the RES 1 promoter, suggesting that ubiquitinated Notch 1 IC is a less potent transactivator. Finally, we show that mSel-10 itself is ubiquitinated and degraded by the proteasome. In conclusion, these data reveal the importance of ubiquitination and proteasome-mediated degradation for the activity and turnover of Notch ICs, and demonstrate that mSel-10 plays a key role in this process.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Pharmacia Corp, Dept Neurobiol, Kalamazoo, MI 49001 USA	Karolinska Institutet; Pfizer	Lendahl, U (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden.			Lendahl, Urban/0000-0001-9543-8141				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Beatus P, 1999, DEVELOPMENT, V126, P3925; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kadesch T, 2000, EXP CELL RES, V260, P1, DOI 10.1006/excr.2000.4921; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Levitan D, 1998, DEVELOPMENT, V125, P3101; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; QUI L, 2000, J BIOL CHEM, V275, P35734; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SUNDARAM M, 1993, GENETICS, V135, P765; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	23	320	327	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35847	35853		10.1074/jbc.M103992200	http://dx.doi.org/10.1074/jbc.M103992200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461910	hybrid			2022-12-25	WOS:000171109300084
J	Rontein, D; Nishida, I; Tashiro, G; Yoshioka, K; Wu, WI; Voelker, DR; Basset, G; Hanson, AD				Rontein, D; Nishida, I; Tashiro, G; Yoshioka, K; Wu, WI; Voelker, DR; Basset, G; Hanson, AD			Plants synthesize ethanolamine by direct decarboxylation of serine using a pyridoxal phosphate enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-PHOSPHATE-DEPENDENT HISTIDINE-DECARBOXYLASE; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLSERINE DECARBOXYLASE; PHOSPHATIDYLCHOLINE SYNTHESIS; METABOLITE CONCENTRATIONS; SUBCELLULAR VOLUMES; CHOLINE SYNTHESIS; SPINACH LEAVES; BIOSYNTHESIS	The established pathways from serine to ethanolamine are indirect and involve decarboxylation of phosphatidylserine. Here we show that plants can decarboxylate serine directly. Using a radioassay based on ethanolamine (Etn) formation, pyridoxal 5'-phosphate-dependent L-serine decarboxylase (SDC) activity was readily detected in soluble extracts from leaves of diverse species, including spinach, Arabidopsis, and rapeseed. A putative Arabidopsis SDC cDNA was identified by searching GenBank (TM) for sequences homologous to other amino acid decarboxylases and shown by expression in Escherichia coli to encode a soluble protein with SDC activity. This cDNA was further authenticated by complementing the Etn requirement of a yeast psd1 psd2 mutant. In a parallel approach, a cDNA was isolated from a rapeseed library by its ability to complement the Etn requirement of a yeast cho1 mutant and shown by expression in E. coli to specify SDC. The deduced Arabidopsis and rapeseed SDC polypeptides are 90% identical, lack obvious targeting signals, and belong to amino acid decarboxylase group II. Recombinant Arabidopsis SDC was shown to exist as a tetramer and to contain pyridoxal 5'-phosphate. It does not attack D-serine, L-phosphoserine, other L-amino acids, or phosphatidylserine and is not inhibited by Etn, choline, or their phosphoesters. As a soluble, pyridoxal 5-phosphate enzyme, SDC contrasts sharply with phosphatidylserine decarboxylases, which are membrane proteins that have a pyruvoyl cofactor.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Natl Jewish Ctr Immunol & Resp Med, Dept Med, Cell Biol Program, Denver, CO 80206 USA	State University System of Florida; University of Florida; University of Tokyo; National Jewish Health	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.		Nishida, Ikuo/W-8007-2019; Nishida, Ikuo/E-3339-2010	Nishida, Ikuo/0000-0002-9669-4005; RONTEIN, Denis/0000-0002-3288-3800				Abe M, 2001, J BIOL CHEM, V276, P26923, DOI 10.1074/jbc.M102179200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIRECKA H, 1985, PLANT PHYSIOL, V79, P509, DOI 10.1104/pp.79.2.509; Bourgis F, 1999, PLANT CELL, V11, P1485, DOI 10.1105/tpc.11.8.1485; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINE K, 1986, J BIOL CHEM, V261, P4804; CROCOMO OJ, 1970, PHYTOCHEMISTRY, V9, P537, DOI 10.1016/S0031-9422(00)85685-X; CRONAN CE, 1996, ESCHERICHIA COLI SAL, P612; DATKO AH, 1988, PLANT PHYSIOL, V88, P854, DOI 10.1104/pp.88.3.854; Delhaize E, 1999, J BIOL CHEM, V274, P7082, DOI 10.1074/jbc.274.11.7082; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; HAMAMATSU S, 1994, FEBS LETT, V348, P33, DOI 10.1016/0014-5793(94)00576-1; HAYASHI H, 1986, J BIOL CHEM, V261, P1003; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HIKIJI T, 1988, J BIOCHEM-TOKYO, V104, P894, DOI 10.1093/oxfordjournals.jbchem.a122579; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KINNEY AJ, 1987, PLANT PHYSIOL, V84, P78, DOI 10.1104/pp.84.1.78; Kocsis MG, 2000, PLANT PHYSIOL, V123, P1153, DOI 10.1104/pp.123.3.1153; Manoharan K, 2000, PLANT CELL PHYSIOL, V41, P1143, DOI 10.1093/pcp/pcd041; MARSHALL MO, 1974, CAN J BIOCHEM CELL B, V52, P469, DOI 10.1139/o74-071; MARSHALL MO, 1973, FEBS LETT, V31, P199, DOI 10.1016/0014-5793(73)80102-4; MARTIN BA, 1983, PLANT PHYSIOL, V73, P464, DOI 10.1104/pp.73.2.464; MAZELIS M, 1962, J BIOL CHEM, V237, P109; McNeil SD, 2000, PLANT PHYSIOL, V123, P371, DOI 10.1104/pp.123.1.371; MILLS WR, 1980, PLANTA, V148, P75, DOI 10.1007/BF00385445; MINET M, 1992, PLANT J, V2, P417; MORINO Y, 1984, METHOD ENZYMOL, V106, P116; MUDD SH, 1989, PLANT PHYSIOL, V91, P587, DOI 10.1104/pp.91.2.587; Nishida I, 1996, PLANT MOL BIOL, V31, P205, DOI 10.1007/BF00021784; NISHIDA I, 1998, ADV PLANT LIPID RES, P255; Nuccio ML, 2000, J BIOL CHEM, V275, P14095, DOI 10.1074/jbc.275.19.14095; Ohlrogge J, 2000, CURR OPIN PLANT BIOL, V3, P224, DOI 10.1016/S1369-5266(00)00068-6; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; PICTON S, 1993, PLANT MOL BIOL, V23, P627, DOI 10.1007/BF00019310; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; SUMMERS PS, 1993, PLANT PHYSIOL, V103, P1269, DOI 10.1104/pp.103.4.1269; TANASE S, 1985, J BIOL CHEM, V260, P6738; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; VAALER GL, 1986, J BIOL CHEM, V261, P1010; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Vincent P, 1999, FEBS LETT, V464, P80, DOI 10.1016/S0014-5793(99)01682-8; Voelker DR, 1997, BBA-LIPID LIPID MET, V1348, P236, DOI 10.1016/S0005-2760(97)00101-X; WINTER H, 1993, PLANTA, V191, P180, DOI 10.1007/BF00199748; WINTER H, 1994, PLANTA, V193, P530, DOI 10.1007/BF02411558	49	106	120	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35523	35529		10.1074/jbc.M106038200	http://dx.doi.org/10.1074/jbc.M106038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461929	hybrid			2022-12-25	WOS:000171109300043
J	Yehia, G; Schlotter, F; Razavi, R; Alessandrini, A; Molina, CA				Yehia, G; Schlotter, F; Razavi, R; Alessandrini, A; Molina, CA			Mitogen-activated protein kinase phosphorylates and targets inducible cAMP early repressor to ubiquitin-mediated destruction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; CYCLIC-AMP; GENE-EXPRESSION; TRANSCRIPTION FACTORS; MICE LACKING; CELL-CYCLE; MAP KINASE; CREM GENE; ICER; PATHWAY	Inducible cAMP early repressor (ICER) is an important mediator of cAMP antiproliferative activity that acts as a putative tumor suppressor gene product. In this study, we examined the regulation of ICER protein by phosphorylation and ubiquitination in human choriocarcinoma JEG-3 and mouse pituitary AtT20 cells. We found that cAMP stabilized ICER protein by inhibiting the mitogen-activated protein kinase (MAPK) cascade. Activation of the MAPK pathway increased ICER phosphorylation. ICER phosphorylation was abrogated by inhibition of the MAPK pathway either by cAMP or directly by the MAPK inhibitor PD098059. The MAPKs extracellular signal-regulated kinases 1 and 2 physically interact with ICER and mediated the phosphorylation of ICER on a critical serine residue (Ser-41). A mutant form of ICER in which Ser-41 was substituted by alanine had a half-life 4-5 h longer than its wild-type counterpart. This alteration in stability was due to the inability of the Ser-41-mutant ICER to be efficiently ubiquitinated and degraded via the ubiquitin-proteasome pathway. These results present a novel cell signaling crosstalk mechanism at the cell nucleus between the MAPK and cAMP pathways, whereby MAPK targets a repressor of the cAMP-dependent gene expression for ubiquitination and proteasomal degradation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Obstet Gynecol & Womens Hlth, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Massachusetts Gen Hosp, Med Serv, Charlestown, MA 02129 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Massachusetts General Hospital	Molina, CA (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Obstet Gynecol & Womens Hlth, 185 S Orange Ave, Newark, NJ 07103 USA.	molinaca@umdnj.edu			NATIONAL CANCER INSTITUTE [R29CA069316] Funding Source: NIH RePORTER; NCI NIH HHS [CA69316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bakin Robert Edward, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P835; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Folco EJ, 1997, BIOCHEM J, V328, P37; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Lamas M, 1997, MOL ENDOCRINOL, V11, P1415, DOI 10.1210/me.11.10.1415; Lamas M, 1997, MOL ENDOCRINOL, V11, P1425, DOI 10.1210/me.11.10.1425; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE AG, 1993, LIPOSOME TECHNOLOGY, V2, P1; MASQUILIER D, 1993, CELL GROWTH DIFFER, V4, P931; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Mukherjee A, 1998, MOL ENDOCRINOL, V12, P785, DOI 10.1210/me.12.6.785; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Pati D, 1999, MOL CELL BIOL, V19, P5001; Razavi R, 1998, ONCOGENE, V17, P3015, DOI 10.1038/sj.onc.1202225; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Seite P, 2000, CELL DEATH DIFFER, V7, P1081, DOI 10.1038/sj.cdd.4400730; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yehia G, 2001, CANCER RES, V61, P6055; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137	42	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35272	35279		10.1074/jbc.M105404200	http://dx.doi.org/10.1074/jbc.M105404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466319	hybrid			2022-12-25	WOS:000171109300011
J	Etter, EF; Eto, M; Wardle, RL; Brautigan, DL; Murphy, RA				Etter, EF; Eto, M; Wardle, RL; Brautigan, DL; Murphy, RA			Activation of myosin light chain phosphatase in intact arterial smooth muscle during nitric oxide-induced relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INDUCED CA2+ SENSITIZATION; SWINE CAROTID-ARTERY; CYCLIC-GMP; SIGNAL-TRANSDUCTION; INHIBITORY PROTEIN; ARACHIDONIC-ACID; CONTRACTILE ELEMENTS; RHO-KINASE; PHOSPHORYLATION	We investigated whether myosin light chain phosphatase activity changes during nitric oxide-induced relaxation of contracted intact carotid media and how changes in phosphatase activity mediate this relaxation. We also investigated one mechanism for regulating this phosphatase. Myosin phosphatase activity, myosin light chain phosphorylation, guanosine 3',5'-cyclic monophosphate (cGMP) concentration, and phosphorylation of the inhibitory protein CPI-17 were all assayed in homogenates of one carotid media ring at each time point during nitric oxide-induced relaxation. The application of sodium nitroprusside to histamine-contracted media caused rapid declines in light chain phosphorylation and force. These were temporally correlated with a rapid elevation of cGMP and a large transient increase in myosin phosphatase activity. During the early response to nitroprusside, when force declined, increases in myosin phosphatase activity, concurrent with cGMP-mediated decreases in calcium and myosin light chain kinase activity, could accelerate light chain dephosphorylation. CPI-17 was dephosphorylated upon application of nitroprusside at the same time that myosin phosphatase activity increased, suggesting that the removal of inhibition by phospho-CPI-17 contributed to the increase in myosin phosphatase activity. After 20 min of nitroprusside, myosin phosphatase activity had declined to basal levels, however low force was sustained. Additional light chain phosphorylation-independent mechanisms may be involved in sustaining the relaxation.	Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Etter, EF (corresponding author), Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.		Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056034] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40024] Funding Source: Medline; NHLBI NIH HHS [P01 HL-19242] Funding Source: Medline; NIDDK NIH HHS [DK-56034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BARANY M, 1993, ARCH BIOCHEM BIOPHYS, V305, P202, DOI 10.1006/abbi.1993.1412; BARANY M, 1996, BIOCH SMOOTH MUSCLE, P321; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chuang AT, 1998, LIFE SCI, V63, P185, DOI 10.1016/S0024-3205(98)00259-8; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; ERDODI F, 1996, BIOCH SMOOTH MUSCLE, P131; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Eto M, 2000, CELL MOTIL CYTOSKEL, V46, P222, DOI 10.1002/1097-0169(200007)46:3<222::AID-CM6>3.3.CO;2-2; Gailly P, 1997, J PHYSIOL-LONDON, V500, P95, DOI 10.1113/jphysiol.1997.sp022002; GONG MC, 1995, J PHYSIOL-LONDON, V486, P113, DOI 10.1113/jphysiol.1995.sp020795; GONG MC, 1992, J BIOL CHEM, V267, P21492; GONG MC, 1992, J BIOL CHEM, V267, P14662; Hamaguchi T, 2000, BIOCHEM BIOPH RES CO, V274, P825, DOI 10.1006/bbrc.2000.3225; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; ITOH H, 1993, AM J PHYSIOL, V265, pC1319; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kitazawa T, 1999, J PHYSIOL-LONDON, V520, P139, DOI 10.1111/j.1469-7793.1999.00139.x; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MCDANIEL NL, 1992, AM J PHYSIOL, V263, pC461, DOI 10.1152/ajpcell.1992.263.2.C461; MCDONALD LJ, 1995, NITRIC OXIDE BIOCH M, P263; Murphy RA, 1998, ACTA PHYSIOL SCAND, V164, P373; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; PFITZER G, 1986, PFLUG ARCH EUR J PHY, V407, P87, DOI 10.1007/BF00580726; Rembold CM, 2001, J APPL PHYSIOL, V91, P1460, DOI 10.1152/jappl.2001.91.3.1460; Rembold CM, 2000, J PHYSIOL-LONDON, V524, P865, DOI 10.1111/j.1469-7793.2000.00865.x; REMBOLD CM, 1986, CIRC RES, V58, P803, DOI 10.1161/01.RES.58.6.803; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Sward K, 2000, J PHYSIOL-LONDON, V522, P33, DOI 10.1111/j.1469-7793.2000.0033m.x; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; VanRiper DA, 1997, BBA-MOL CELL RES, V1355, P323, DOI 10.1016/S0167-4889(96)00144-9; Walker JS, 2000, ANAL BIOCHEM, V284, P173, DOI 10.1006/abio.2000.4704; Walker LA, 2001, J BIOL CHEM, V276, P24519, DOI 10.1074/jbc.M103560200; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WINGARD CJ, 1995, J PHYSIOL-LONDON, V488, P729, DOI 10.1113/jphysiol.1995.sp021004; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760	58	110	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34681	34685		10.1074/jbc.M104737200	http://dx.doi.org/10.1074/jbc.M104737200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11461918	hybrid			2022-12-25	WOS:000171024600046
J	Azriel, R; Gazit, E				Azriel, R; Gazit, E			Analysis of the structural and functional elements of the minimal active fragment of islet amyloid polypeptide (IAPP) - An experimental support for the key role of the phenylalanine residue in amyloid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PEPTIDE POLYMERIZATION; TYPE-2 DIABETES-MELLITUS; FIBRIL FORMATION; CONGO RED; PRION PROTEIN; AMYLIN; AGGREGATION; SEQUENCE; DISEASE; FIBRILLOGENESIS	The development of type Il diabetes was shown to be associated with the formation of amyloid fibrils consisted of the islet amyloid polypeptide (IAPP or amylin). Recently, a short functional hexapeptide fragment of IAPP (NH2-NFGAIL-COOH) was found to form fibrils that are very similar to those formed by the full-length polypeptide. To better understand the specific role of the residues that compose the fragment, we performed a systematic alanine scan of the LAPP "basic amyloidogenic units." Turbidity assay experiments demonstrated that the wild-type peptide and the Asn(1) --> Ala and Gly(3) --> Ala peptides had the highest rate of aggregate formation, whereas the Phe(2) --> Ala peptide did not form any detectable aggregates. Dynamic light-scattering experiments demonstrated that all peptides except the Phe(2) --> Ala form large multimeric structures. Electron microscopy and Congo red staining confirmed that the structures formed by the various peptides are indeed amyloid fibrils. Taken together, the results of our study provide clear experimental evidence for the key role of phenylalanine residue in amyloid formation by IAPP. In contrast, glycine, a residue that was suggested to facilitate amyloid formation in other systems, has only a minor role, if any, in this case. Our results are discussed in the context, of the remarkable occurrence of aromatic residues in short functional fragments and potent inhibitors of amyloid-related polypeptides. We hypothesize that pi-pi interactions may play a significant role in the molecular recognition and self-assembly processes that lead to amyloid formation.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	ehudg@post.tau.ac.il	Gazit, Ehud/M-8026-2019; Gazit, Ehud/C-3715-2011; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; 				ASHBURN TT, 1993, J AM CHEM SOC, V115, P11012, DOI 10.1021/ja00076a078; CLARK A, 1987, LANCET, V2, P231; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; COHEN AS, 1982, ELECTRON MICROS, V3, P165; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; COOPER JH, 1974, LAB INVEST, V31, P232; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Haggqvist B, 1999, P NATL ACAD SCI USA, V96, P8669, DOI 10.1073/pnas.96.15.8669; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hoppener JWM, 2000, NEW ENGL J MED, V343, P411; HUNTER CA, 1993, ANGEW CHEM INT EDIT, V32, P1584, DOI 10.1002/anie.199315841; HUNTER CA, 1994, CHEM SOC REV, V23, P101, DOI 10.1039/cs9942300101; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kapurniotu A, 1998, EUR J BIOCHEM, V251, P208, DOI 10.1046/j.1432-1327.1998.2510208.x; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; LANSBURY PT, 1992, BIOCHEMISTRY-US, V31, P6865, DOI 10.1021/bi00145a001; Larson JL, 2000, PROTEIN SCI, V9, P427; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; LUSKEY KL, 1992, DIABETES CARE, V15, P297, DOI 10.2337/diacare.15.2.297; MAURY CPJ, 1992, BIOCHEM BIOPH RES CO, V183, P227, DOI 10.1016/0006-291X(92)91632-Z; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Moriarty DF, 1999, BIOCHEMISTRY-US, V38, P1811, DOI 10.1021/bi981658g; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; RINK TJ, 1993, TRENDS PHARMACOL SCI, V14, P113, DOI 10.1016/0165-6147(93)90081-T; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Sun S, 1996, J PHYS CHEM-US, V100, P13348, DOI 10.1021/jp960739o; TAYLOR DL, 1974, J HISTOCHEM CYTOCHEM, V22, P1105, DOI 10.1177/22.12.1105; Tenidis K, 2000, J MOL BIOL, V295, P1055, DOI 10.1006/jmbi.1999.3422; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tuite MF, 2000, CELL, V100, P289, DOI 10.1016/S0092-8674(00)80663-7; Twyman LJ, 1999, TETRAHEDRON LETT, V40, P9383, DOI 10.1016/S0040-4039(99)02030-4; WESTERMARK GT, 1992, BIOCHEM BIOPH RES CO, V182, P27, DOI 10.1016/S0006-291X(05)80107-X; WESTERMARK P, 1987, AM J PATHOL, V127, P414; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; WESTERMARK P, 1986, BIOCHEM BIOPH RES CO, V140, P827, DOI 10.1016/0006-291X(86)90708-4; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I	49	366	382	2	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34156	34161		10.1074/jbc.M102883200	http://dx.doi.org/10.1074/jbc.M102883200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445568	hybrid			2022-12-25	WOS:000170910200115
J	Blackwell, LJ; Bjornson, KP; Allen, DJ; Modrich, P				Blackwell, LJ; Bjornson, KP; Allen, DJ; Modrich, P			Distinct MutS DNA-binding modes that are differentially modulated by ATP binding and hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR PROTEIN; REPLICATION FIDELITY; SLIDING CLAMP; STRAND BREAK; HMUTS-ALPHA; COMPLEX; HETERODIMER; MSH6	The role of MutS ATPase in mismatch repair is controversial. To clarify further the function of this activity, we have examined adenine nucleotide effects on interactions of Escherichia coli MutS with homoduplex and heteroduplex DNAs. In contrast to previous results with human MutS alpha, we find that a physical block at one end of a linear heteroduplex is sufficient to support stable MutS complex formation in the presence of ATP(.)Mg(2+). Surface plasmon resonance analysis at low ionic strength indicates that the lifetime of MutS complexes with heteroduplex DNA depends on the nature of the nucleotide present when MutS binds. Whereas complexes prepared in the absence of nucleotide or in the presence of ADP undergo rapid dissociation upon challenge with ATP(.)Mg(2+), complexes produced in the presence of ATP(.)Mg(2+), adenosine 5 '-(beta,gamma -imino)triphosphate (AMPPNP)Mg-.(2+), or ATP (no Mg2+) are resistant to dissociation upon ATP challenge. AMPPNP(.)Mg(2+) and ATP (no Mg2+) reduce MutS affinity for heteroduplex but have little effect on homoduplex affinity, resulting in abolition of specificity for mispaired DNA at physiological salt concentrations. Conversely, the highest mismatch specificity is observed in the absence of nucleotide or in the presence of ADP. ADP has only a limited effect on heteroduplex affinity but reduces MutS affinity for homoduplex DNA.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Modrich, P (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	modrich@biochem.duke.edu		Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Biswas I, 1999, J BIOL CHEM, V274, P23673, DOI 10.1074/jbc.274.33.23673; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2000, STRUCTURE, V8, pR237, DOI 10.1016/S0969-2126(00)00545-1; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x	33	82	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34339	34347		10.1074/jbc.M104256200	http://dx.doi.org/10.1074/jbc.M104256200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11454861	hybrid			2022-12-25	WOS:000170910200138
J	Katz, RA; DiCandeloro, P; Kukolj, G; Skalka, AM				Katz, RA; DiCandeloro, P; Kukolj, G; Skalka, AM			Role of DNA end distortion in catalysis by avian sarcoma virus integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION SIGNAL SEQUENCES; VIRAL-DNA; RETROVIRAL INTEGRASE; HIV-1 INTEGRASE; V(D)J RECOMBINATION; C-TERMINUS; IN-VITRO; PROTEIN; BINDING; RECOGNITION	Retroviral integrase (IN) recognizes linear viral DNA ends and introduces nicks adjacent to a highly conserved CA dinucleotide usually located two base pairs from the 3 ' -ends of viral DNA (the "processing" reaction). In a second step, the same IN active site catalyzes the insertion of these ends into host DNA (the "joining" reaction). Both DNA sequence and DNA structure contribute to specific recognition of viral DNA ends by IN. Here we used potassium permanganate modification to show that the avian sarcoma virus IN catalytic domain is able to distort viral DNA ends in vitro. This distortion activity is consistent with both unpairing and unstacking of the three terminal base pairs, including the processing site adjacent to the conserved CA. Furthermore, the introduction of mismatch mutations that destabilize the viral DNA ends were found to stimulate the IN processing reaction as well as IN-mediated distortion. End-distortion activity was also observed with mutant or heterologous DNA substrates. However, further analyses showed that using Mn2+ as a cofactor, processing site specificity of these substrates was also maintained. Our results support a model whereby unpairing and unstacking of the terminal base pairs is a required step in the processing reaction. Furthermore, these results are consistent with our previous observations indicating that unpairing of target DNA promotes the joining reaction.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Katz, RA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA71515, CA06927] Funding Source: Medline; NIAID NIH HHS [AI40385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA071515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; ANDRAKE MD, 1995, J BIOL CHEM, V270, P29299, DOI 10.1074/jbc.270.49.29299; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; BROWN PO, 1998, RETROVIRUSES; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Declais AC, 2000, J MOL BIOL, V296, P421, DOI 10.1006/jmbi.1999.3479; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Holstege FCP, 1997, METHODS, V12, P203, DOI 10.1006/meth.1997.0472; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Kale SB, 2001, MOL CELL BIOL, V21, P459, DOI 10.1128/MCB.21.2.459-466.2001; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KUKOLJ G, 1992, J BIOL CHEM, V267, P17827; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEROY JL, 1988, J MOL BIOL, V200, P223, DOI 10.1016/0022-2836(88)90236-7; Lubkowski J, 1998, J BIOL CHEM, V273, P32685, DOI 10.1074/jbc.273.49.32685; MULLER B, 1995, J VIROL, V69, P5631; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; SENIOR M, 1988, BIOCHEMISTRY-US, V27, P3879, DOI 10.1021/bi00410a053; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; Wlodawer A, 1999, ADV VIRUS RES, V52, P335, DOI 10.1016/S0065-3527(08)60305-X; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463	43	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34213	34220		10.1074/jbc.M104632200	http://dx.doi.org/10.1074/jbc.M104632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11441016	hybrid			2022-12-25	WOS:000170910200123
J	Langsetmo, K; Stafford, WF; Mabuchi, K; Tao, T				Langsetmo, K; Stafford, WF; Mabuchi, K; Tao, T			Recombinant small subunit of smooth muscle myosin light chain phosphatase - Molecular properties and interactions with the targeting subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE-1; SIGNAL-TRANSDUCTION; BOUNDARY ANALYSIS; RHO-KINASE; EXPRESSION; CLONING; DOMAINS; 1M	We expressed the small subunit of smooth muscle myosin light chain phosphatase (MPs) in Escherichia coli, and have studied its molecular properties as well as its interaction with the targeting subunit (MPt). MPs (M-r = 18,500) has an anomalously low electrophoretic mobility, running with an apparent M-r of similar to 21,000 in sodium dodecyl sulfate-gel electrophoresis. CD spectroscopy shows that it is similar to 45% alpha -helix and undergoes a cooperative temperature-induced unfolding with a transition midpoint of 73 degreesC. Limited proteolysis rapidly degrades MPs to a stable G-terminal fragment (M-r = 10,000) that retains most of the helical content. Rotary shadowing electron microscopy reveals that it is an elongated protein with two domains. Sedimentation velocity measurements show that recombinant MPt (M-r = 107,000), intact MPs, and the 10-kDa. MPs fragment are all dimeric, and that MPs and MPt form a complex with a molar mass consistent with a 1:1 heterodimer. Sequence analysis predicts that regions in the C-terminal portions of both MPs and MPt have high probabilities for coiled coil formation. A synthetic peptide from a region of MPs encompassing, residues 77-116 was found to be 100% alpha -helical, dimeric, and formed a complex with MPt with a molecular mass corresponding to a heterodimer. Based on these results, we propose that MPs is an elongated molecule with an N-terminal head and a C-terminal stalk domain. It dimerizes via a coiled coil interaction in the stalk domain, and interacts with MPt via heterodimeric coiled coil formation. Since other proteins with known regulatory function toward MP also have predicted coiled coil regions, our results suggest that these regulatory proteins target MP via the same coiled coil strand exchange mechanism with MPt.	Boston Biomed Res Inst, Muscle & Motil Grp, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Tufts University	Tao, T (corresponding author), Boston Biomed Res Inst, Muscle & Motil Grp, 64 Grove St, Watertown, MA 02472 USA.	Tao@BBRI.org	Stafford, Walter/ABC-6553-2020		NHLBI NIH HHS [HL64187] Funding Source: Medline; NIAMS NIH HHS [AR41637] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; COHEN PT, 1991, METHODS ENZYMOL, V201, P408; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; ERDODI F, 1996, MYOSIN LIGHT CHAIN P; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; GONG MC, 1995, J PHYSIOL-LONDON, V486, P113, DOI 10.1113/jphysiol.1995.sp020795; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, BIOCH CONTRACTILE PR; Haystead CMM, 1995, FEBS LETT, V377, P123, DOI 10.1016/0014-5793(95)01318-0; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; MABUCHI K, 1990, J STRUCT BIOL, V103, P249, DOI 10.1016/1047-8477(90)90043-C; Mabuchi K, 1999, BBA-PROTEIN STRUCT M, V1434, P296, DOI 10.1016/S0167-4838(99)00182-X; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SILBER KR, 1994, MOL GEN GENET, V242, P237, DOI 10.1007/BF00391018; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; STULL JT, 1996, MYOSIN LIGHT CHAIN K; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takizawa N, 1999, BIOPHYS J, V76, pA290; Tanford C., 1961, PHYS CHEM MACROMOLEC; TARTOF KD, 1987, FOCUS, V9, P12; Zhang Y, 1997, BBA-PROTEIN STRUCT M, V1343, P51, DOI 10.1016/S0167-4838(97)00120-9; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301; Zhou YB, 1999, BIOCHEM BIOPH RES CO, V254, P158, DOI 10.1006/bbrc.1998.9915	42	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34318	34322		10.1074/jbc.M103255200	http://dx.doi.org/10.1074/jbc.M103255200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448958	hybrid			2022-12-25	WOS:000170910200135
J	Mansson, B; Wenglen, C; Morgelin, M; Saxne, T; Heinegard, D				Mansson, B; Wenglen, C; Morgelin, M; Saxne, T; Heinegard, D			Association of chondroadherin with collagen type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN; ELECTRON-MICROSCOPY; SMALL PROTEOGLYCAN; SKIN FRAGILITY; CORE PROTEINS; CARTILAGE; LOCALIZATION; EXPRESSION; LUMICAN; DECORIN	Chondroadherin is a cell binding, leucine-rich repeat protein found in the territorial matrix of articular cartilage. Several members of the leucine-rich repeat protein family present in the extracellular matrix of e.g. cartilage. have been shown to interact with collagen and influence collagen fibrillogenesis. We show that complexes of monomeric collagen type II and chondroadherin can be released under non-denaturing conditions from articular cartilage treated with p-aminophenylmercuric acetate to activate resident matrix metalloproteinases. Purified complexes as well as complexes formed in vitro between recombinant chondroadherin and collagen type II were studied by electron microscopy. Chondroadherin was shown to bind to two sites on collagen type II. The interaction was characterized by surface plasmon resonance analysis showing KD values in the nanomolar range. Both chondroadherin and collagen interact with chondrocytes, partly via the same receptor, but give rise to different cellular responses. By also interacting with each other, a complex system is created which may be of functional importance for the communication between the cells and its surrounding matrix and/or in the regulation of collagen fibril assembly.	Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, BMC, SE-22184 Lund, Sweden; Univ Lund Hosp, Dept Rheumatol, SE-22185 Lund, Sweden	Lund University; Lund University; Skane University Hospital	Heinegard, D (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, BMC, C12, SE-22184 Lund, Sweden.							BASCHONG W, 1990, J ELECTRON MICR TECH, V14, P313, DOI 10.1002/jemt.1060140405; BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; COLLAWN JF, 1989, CURRENT PROTOCOLS MO; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DURR J, 1993, EXP CELL RES, V207, P235, DOI 10.1006/excr.1993.1189; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Ganu V, 1998, ARTHRITIS RHEUM, V41, P2143, DOI 10.1002/1529-0131(199812)41:12<2143::AID-ART9>3.0.CO;2-P; Grover J, 1997, GENOMICS, V45, P379, DOI 10.1006/geno.1997.4951; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; Heinegard D, 1998, OSTEOARTHRITIS, P74; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Landgren C, 1998, GENOMICS, V47, P84, DOI 10.1006/geno.1997.5085; LARSSON T, 1991, J BIOL CHEM, V266, P20428; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; MIOSGE N, 1994, HISTOCHEM J, V26, P939; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PAULSSON M, 1983, BIOCHEM J, V212, P659, DOI 10.1042/bj2120659; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Shen ZX, 1998, BIOCHEM J, V330, P549, DOI 10.1042/bj3300549; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WOODS VL, 1994, ARTHRITIS RHEUM, V37, P537, DOI 10.1002/art.1780370414; YOUNG JM, 1988, GENE, V62, P171, DOI 10.1016/0378-1119(88)90556-2	32	57	59	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32883	32888		10.1074/jbc.M101680200	http://dx.doi.org/10.1074/jbc.M101680200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11445564	hybrid			2022-12-25	WOS:000170746000069
J	Chen, RY; Kim, O; Yang, JB; Sato, K; Eisenmann, KM; McCarthy, J; Chen, HG; Qiu, Y				Chen, RY; Kim, O; Yang, JB; Sato, K; Eisenmann, KM; McCarthy, J; Chen, HG; Qiu, Y			Regulation of Akt/PKB activation by tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; AKT; SRC; GROWTH; CELLS; MECHANISM; INSULIN	Activation of Akt/PHB by growth factors requires multiple phosphorylation events. Phosphorylation of Thr(308) and Ser(473) of Akt by its upstream kinase(s) or autophosphorylation is critical for optimal activation of its kinase activity. Here, we present evidence that tyrosine phosphorylation is required for Akt activation. Epidermal growth factor treatment induces tyrosine phosphorylation of Akt in COS1 and PC3M cells, which is abrogated by PP2, a selective inhibitor for Src family tyrosine kinases. Elevated Akt activity is observed in v-Src transformed NIH3T3 cells, which is accompanied with increased tyrosine phosphorylation of Akt. Akt activity induced by growth factors is significantly reduced in SYF cells lacking Src, Yes, and Fyn, which can be restored by introducing c-Src, but not the kinase-inactive Src, back to these cells. Furthermore, we have identified two tyrosine residues near the activation loop of Akt that are important for its activation. Substitution of these residues with phenylalanine abolishes Akt kinase activity stimulated by growth factors. These two YF mutants fail to block Forkhead transcription factor activity in 293 cells and are unable to prevent apoptosis induced by matrix detachment. Our data suggest that, in addition to phosphorylation of Thr(308) and Ser(473), tyrosine phosphorylation of Akt may be essential for its biological function.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Qiu, Y (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, MMC 609,420 Delaware St SE, Minneapolis, MN 55455 USA.			Eisenmann, Kathryn/0000-0002-5337-5928	NCI NIH HHS [CA85380] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; LI WQ, 1994, J BIOL CHEM, V269, P2349; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301	25	198	206	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31858	31862		10.1074/jbc.C100271200	http://dx.doi.org/10.1074/jbc.C100271200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11445557	hybrid			2022-12-25	WOS:000170613500054
J	Struss, AK; Romeike, BFM; Munnia, A; Nastainczyk, W; Steudel, WI; Konig, J; Ohgaki, H; Feiden, W; Fischer, U; Meese, E				Struss, AK; Romeike, BFM; Munnia, A; Nastainczyk, W; Steudel, WI; Konig, J; Ohgaki, H; Feiden, W; Fischer, U; Meese, E			PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme	ONCOGENE			English	Article						humoral immune response; SEREX; glioblastoma multiforme; polyclonal antibody; PHD finger; PHF3	HUMAN TUMOR-ANTIGENS; SEROLOGIC RESPONSES; IMMUNE-RESPONSES; PHD FINGER; CANCER; GENE; P53; AUTOANTIBODIES; IDENTIFICATION; LOCALIZATION	Glioblastoma multiforme (GBM), a malignant astrocytic tumour, represents the most frequent tumour of the human brain. Nevertheless, its molecular pathology is not well understood. We utilized the immune system, which contributes to cancer protection, to help identify new GEM-related genes. By screening a human GEM cDNA library with autologous patient serum (SEREX-approach), we isolated a gene termed PHF3 (PHD finger protein 3), The gene product of PHF3 is immunogenic in GEM as tested in an allogenic patient serum screening demonstrating antibodies in 24 of 39 (61.53%) sera, whereas none of the 14 healthy persons had antibodies against PHF3, While previous SEREX studies revealed allogenic antibody responses up to 40%, our results for PHF3 represent the highest reported rate for a specific antibody response. We show that GEM patients with an antibody response against PHF3 show significant better survival than patients without PHF3-specific antibodies. Because the amino acid sequence of PHF3 contains a PHD finger (also termed LAP motif), a TFIIS homology, a proline rich region and nuclear localization signals, it supposedly functions as a transcription factor. A polyclonal antibody generated against PHF3 shows nuclear expression in most investigated formalin-fixed, paraffin embedded tissues. In GEM, PHF3 expression is concentrated in cells surrounding necroses.	Univ Saarlandes Kliniken, Inst Humangenet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Neurochirurg Klin, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Bioinformat, D-66421 Homburg, Germany; Int Agcy Res Canc, F-69372 Lyon 8, France	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; World Health Organization; International Agency for Research on Cancer (IARC)	Meese, E (corresponding author), Univ Saarland, Sch Med, Inst Humangenet, Bldg 60, D-66421 Homburg, Germany.	hgemee@med-rz.uni-sb.de	König, Jochem/T-3500-2019; Romeike, Bernd/K-8516-2019; , PD Dr. med. Bernd FM Romeike/Q-2600-2019; Meese, Eckart Ulrich/ABD-1983-2021	König, Jochem/0000-0003-4683-0360; , PD Dr. med. Bernd FM Romeike/0000-0002-9693-3870; 				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Biernat W, 1997, ACTA NEUROPATHOL, V94, P303, DOI 10.1007/s004010050711; Blaes F, 2000, ANN THORAC SURG, V69, P254, DOI 10.1016/S0003-4975(99)01198-4; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CHINOT O, 1996, BIOL TUMEURS CEREBRA; Coulson M, 1998, GENOMICS, V48, P381, DOI 10.1006/geno.1997.5201; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Dietrich PY, 1997, ANN NY ACAD SCI, V824, P124, DOI 10.1111/j.1749-6632.1997.tb46215.x; FOLEY EJ, 1953, CANCER RES, V13, P835; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Hampton TA, 2000, CANCER GENE THER, V7, P446, DOI 10.1038/sj.cgt.7700124; Harlow E, 1998, ANTIBODIES LAB MANUA; Hasenpusch-Theil K, 1999, MAMM GENOME, V10, P294, DOI 10.1007/s003359900989; Heckel D, 1997, HUM MOL GENET, V6, P2031, DOI 10.1093/hmg/6.12.2031; Jung V, 1999, J NEUROPATH EXP NEUR, V58, P993, DOI 10.1097/00005072-199909000-00009; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; KORNBLITH PL, 1983, CANCER, V52, P2230, DOI 10.1002/1097-0142(19831215)52:12<2230::AID-CNCR2820521211>3.0.CO;2-7; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OLD LJ, 1981, CANCER RES, V41, P361; PREHN RT, 1957, J NATL CANCER I, V18, P769; Rainov NG, 1995, CLIN CANCER RES, V1, P775; Robinson C, 2000, AM J RESP CELL MOL, V22, P550, DOI 10.1165/ajrcmb.22.5.3930; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1999, INT J CANCER, V83, P456, DOI 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5; Scarcella DL, 1999, CLIN CANCER RES, V5, P335; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; Shrikant P, 1996, J IMMUNOL, V157, P1819; Soussi T, 2000, CANCER RES, V60, P1777; Suresh MR, 1996, ANTICANCER RES, V16, P2273; Tureci O, 1997, MOL MED TODAY, V3, P342, DOI 10.1016/S1357-4310(97)01081-2; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WELLER RO, 1992, BRAIN PATHOL, V2, P277, DOI 10.1111/j.1750-3639.1992.tb00704.x; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	37	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4107	4114		10.1038/sj.onc.1204552	http://dx.doi.org/10.1038/sj.onc.1204552			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464277				2022-12-25	WOS:000169857200001
J	Trauzold, A; Wermann, H; Arlt, A; Schutze, S; Schafer, H; Oestern, S; Roder, C; Ungefroren, H; Lampe, E; Heinrich, M; Walczak, H; Kalthoff, H				Trauzold, A; Wermann, H; Arlt, A; Schutze, S; Schafer, H; Oestern, S; Roder, C; Ungefroren, H; Lampe, E; Heinrich, M; Walczak, H; Kalthoff, H			CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappa B contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells	ONCOGENE			English	Article						apoptosis; CD95; TRAIL; PKC; NF-kappa B; pancreatic adenocarcinoma	SIGNALING PATHWAYS; TNF-ALPHA; DEATH; FAMILY; LIGAND; INHIBITION; INDUCTION; MEMBER; FAS; MU	The molecular alterations in tumour cells leading to resistance towards apoptosis induced by CD95 and TRAIL-receptors are not fully understood. We report here that the stimulation of the CD95- and TRAIL-resistant human pancreatic adenocarcinoma cell line PancTuI with an agonistic anti-CDW antibody or TRAIL resulted in activation of protein kinase C and NF-kappaB, Inhibition of protein kinase C by Go6983 sensitized these cells to apoptotic challenges and strongly diminished activation of NF-kappaB by anti-CD95 and TRAIL. Similarly, inhibition of NF-kappaB by MG132 or by transient transfection with a dominant negative mutant of I kappaB alpha restored the responsiveness of PancTuI cells to both death ligands. In the CD95 and TRAIL-sensitive cell line Colo357 the induction of protein kinase C and NF-KB following activation of CD95 and TRAIL-R was very moderate compared with PancTuI cells. However, pre-incubation of these cells with PMA strongly reduced their apoptotic response to anti-CD95 and TRAIL. Taken together, we show that activation of protein kinase C operates directly in a death receptor-dependent manner in PancTuI cells and protect pancreatic tumour cells from anti-CD95 and TRAIL-mediated apoptosis by preventing the loss Delta Psim and Cytochrome c release as well as by induction of NF-kappaB.	Univ Kiel, Clin Gen Surg, D-24105 Kiel, Germany; Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; German Canc Res Ctr, Dept Apoptosis Regulat, D-6900 Heidelberg, Germany	University of Kiel; University of Kiel; University of Kiel; Helmholtz Association; German Cancer Research Center (DKFZ)	Kalthoff, H (corresponding author), Univ Kiel, Clin Gen Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Kalthoff, Holger/B-1618-2010; Arlt, Alexander/G-7308-2019; Schäfer, Heiner/C-1055-2011; Walczak, Henning/AAV-2214-2020; Schütze, Stefan/C-8596-2011; Roeder, Christian/F-1068-2010; Trauzold, Anna/P-4398-2014	Arlt, Alexander/0000-0002-6160-1059; Walczak, Henning/0000-0002-6312-4591; Roeder, Christian/0000-0001-7881-9110; 				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kobayashi D, 1997, CHEMOTHERAPY, V43, P415, DOI 10.1159/000239600; Krammer P H, 1999, Adv Immunol, V71, P163; KUMUDA CD, 1997, J BIOL CHEM, V272, P14914; Leverkus M, 2000, CANCER RES, V60, P553; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Packham G, 1997, CELL DEATH DIFFER, V4, P130, DOI 10.1038/sj.cdd.4400217; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PETER ME, 1998, APOPTOSIS PROBLEMS D, P25; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Ravi R, 1998, CANCER RES, V58, P882; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sawai H, 1997, J BIOL CHEM, V272, P2452; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Ungefroren H, 1998, CANCER RES, V58, P1741; von Reyher U, 1998, CANCER RES, V58, P526; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	40	143	144	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4258	4269		10.1038/sj.onc.1204559	http://dx.doi.org/10.1038/sj.onc.1204559			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464292				2022-12-25	WOS:000169857200016
J	Bensaad, K; Rouillard, D; Soussi, T				Bensaad, K; Rouillard, D; Soussi, T			Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line	ONCOGENE			English	Article						p53; DNA damage; Xenopus laevis; cell cycle	XENOPUS-LAEVIS P53; WILD-TYPE P53; HUMAN CANCER; PROTEIN; BINDING; MUTATIONS; GENE; TRANSACTIVATION; MDM2; PHOSPHORYLATION	In mammalian cells, the p53 protein is a kev regulator of the cell cycle following DNA damage. In the present study, we investigated the function of p53 in the A6 amphibian cell line. Using various specific Xenopus p53 monoclonal antibodies, we showed that Xenopus p53 accumulates after DNA damage, including gamma and UV irradiation or treatment with adriamycin, Such accumulation is accompanied by an increase in the apparent molecular weight of the protein. This change was shown to be the result of a phosphorylation event that occurs after DNA damage. Accumulation of Xenopus p53 is parallel to a drastic change in the cell cycle distribution. Brief exposure to adriamycin or gamma irradiation induces reversible growth arrest, whereas long-term exposure to adriamycin leads to apoptosis, Taken together, these results indicate that p53 has a similar behaviour in frog cells and mammalian cells, and that it conserves two activities, cell cycle arrest and apoptosis.	Inst Curie, Lab Genotoxicol Tumeurs, F-75005 Paris, France; Inst Curie, Serv Cytometrie, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Soussi, T (corresponding author), Inst Curie, Lab Genotoxicol Tumeurs, 26 Rue Ulm, F-75005 Paris, France.			soussi, thierry/0000-0001-8184-3293				Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DEQUIEDT F, 1995, VIROLOGY, V209, P676, DOI 10.1006/viro.1995.1303; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; HARDYBESSARD AC, 1998, ONCOGENE, V16, P883; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; Mayr B, 2000, RES VET SCI, V68, P63, DOI 10.1053/rvsc.1999.0339; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; RAFFERTY KA, 1969, BIOL AMPHIBIAN TUMOR, P52; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SOUSSI T, 1987, ONCOGENE, V1, P71; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; Tchang F, 1999, EXP CELL RES, V251, P46, DOI 10.1006/excr.1999.4570; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Veldhoen N, 1998, ONCOGENE, V16, P249, DOI 10.1038/sj.onc.1201489; WANG Y, 1995, ONCOGENE, V10, P779; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	37	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3766	3775		10.1038/sj.onc.1204492	http://dx.doi.org/10.1038/sj.onc.1204492			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439340				2022-12-25	WOS:000169494700002
J	Hemenway, CS; de Erkenez, AC; Gould, GCD				Hemenway, CS; de Erkenez, AC; Gould, GCD			The polycomb protein MPc3 interacts with AF9, an MLL fusion partner in t(9;11)(p22;q23) acute leukemias	ONCOGENE			English	Article						polycomb group proteinsMLL fusion genes; fluorescent protein tagging	TRANSCRIPTIONAL REPRESSOR; DROSOPHILA-MELANOGASTER; GENE-EXPRESSION; GROUP-COMPLEXES; TRITHORAX-GROUP; GAGA-FACTOR; MOUSE; CHROMATIN; IDENTIFICATION; BINDING	Polycomb group (PcG) proteins assemble to form large multiprotein complexes involved in gene silencing, Evidence suggests that PcG complexes are heterogeneous with respect to both protein composition and specific function, MPc3 is a recently described mouse Polycomb (Pc) protein that shares structural homology with at least two other Pc proteins, M33 and MPc2, All three Pc proteins bind another PcG protein, RING1, through a conserved carboxy-terminal C-box motif, Here, data are presented demonstrating that MPc3 also interacts with AF9, a transcriptional activator implicated in the development of acute leukemias. The carboxy-terminus of AF9 is fused to the MLL protein in leukemias characterized by t(9;11)(p22;q23) chromosomal translocations, importantly, it is the carboxy-terminus of AF9 to which MPc,7 binds, The AF9 binding site of MPc3 maps to a central, non-conserved, region of the polypeptide sequence. In contrast to MPc3, data indicate that the Pc protein M33 does not interact with AF9, This finding suggests a potentially unique role for MPc3 in linking a PcG silencing complex to a transcriptional activator protein.	Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA	Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.				NATIONAL CANCER INSTITUTE [K01CA078318] Funding Source: NIH RePORTER; NCI NIH HHS [1K01 CA78318-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; Bel S, 1998, DEVELOPMENT, V125, P3543; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Hashimoto N, 1998, BIOCHEM BIOPH RES CO, V245, P356, DOI 10.1006/bbrc.1998.8438; Hemenway CS, 2000, GENE, V242, P31, DOI 10.1016/S0378-1119(99)00540-5; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; IIDA S, 1993, ONCOGENE, V8, P3085; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; Morgan H, 2000, FASEB J, V14, P1109, DOI 10.1096/fasebj.14.9.1109; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RUBNITZ JE, 1994, BLOOD, V84, P1747; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Takihara Y, 1997, DEVELOPMENT, V124, P3673; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	38	62	66	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3798	3805		10.1038/sj.onc.1204478	http://dx.doi.org/10.1038/sj.onc.1204478			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439343				2022-12-25	WOS:000169494700005
J	Baumann, SW; Baur, R; Sigel, E				Baumann, SW; Baur, R; Sigel, E			Subunit arrangement of gamma-aminobutyric acid type a receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; FUNCTIONAL-PROPERTIES; XENOPUS-OOCYTES; ION CHANNELS; CELL-SURFACE; BINDING-SITE; RAT-BRAIN; STOICHIOMETRY; EXPRESSION; SUBTYPES	The GABA(A) receptors are ligand-gated chloride channels. The subunit stoichiometry of the receptors is controversial; four, five, or six subunits per receptor molecule have been proposed for alpha beta receptors, whereas alpha beta gamma receptors are assumed to be pentamers. In this study, alpha-beta and beta-alpha tandem cDNAs from the alpha1 and beta2 subunits of the GABA(A) receptor were constructed. We determined the minimal length of the linker that is required between the two subunits for functional channel expression for each of the tandem constructs. 10- and 23-amino acid residues are required for alpha-beta and beta-alpha, respectively. The tandem constructs either alone or in combination with each other failed to express functional channels in Xenopus oocytes. Therefore, we can exclude tetrameric or hexameric alpha beta GABA(A) receptors. We can also exclude proteolysis of the tandem constructs. In addition, the tandem constructs were combined with single alpha, beta, or gamma subunits to allow formation of pentameric arrangements. In contrast to the combination with alpha subunits, the combination with either beta or gamma subunits led to expression of functional channels. Therefore, a pentameric arrangement containing two alpha1 and three beta2 subunits is proposed for the receptor composed of alpha and beta subunits. Our findings also favor an arrangement beta alpha gamma beta alpha for the receptor composed of alpha, beta, and gamma subunits.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.		Sigel, Erwin/F-7736-2015					ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1418; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; BENKE D, 1994, J BIOL CHEM, V269, P27100; Chang YC, 1996, J NEUROSCI, V16, P5415; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; Gorrie GH, 1997, J NEUROSCI, V17, P6587; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Hevers W, 1998, MOL NEUROBIOL, V18, P35, DOI 10.1007/BF02741459; HURST RS, 1992, J BIOL CHEM, V267, P23742; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KANEDA M, 1995, J PHYSIOL-LONDON, V485, P419, DOI 10.1113/jphysiol.1995.sp020739; Kellenberger S, 1996, NEUROPHARMACOLOGY, V35, P1403, DOI 10.1016/S0028-3908(96)00034-2; Knight AR, 1998, RECEPTOR CHANNEL, V6, P1; Kuhn FJP, 1999, J GEN PHYSIOL, V114, P167, DOI 10.1085/jgp.114.2.167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMART TG, 1991, BRIT J PHARMACOL, V103, P1837, DOI 10.1111/j.1476-5381.1991.tb12337.x; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; Sukharev SI, 1999, J MEMBRANE BIOL, V171, P183, DOI 10.1007/s002329900570; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tretter V, 1997, J NEUROSCI, V17, P2728; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; Whiting PJ, 1997, J NEUROSCI, V17, P5027; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627	40	182	183	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36275	36280		10.1074/jbc.M105240200	http://dx.doi.org/10.1074/jbc.M105240200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11466317	hybrid			2022-12-25	WOS:000171194500031
J	Bill, RM; Hedfalk, K; Karlgren, S; Mullins, JGL; Rydstrom, J; Hohmann, S				Bill, RM; Hedfalk, K; Karlgren, S; Mullins, JGL; Rydstrom, J; Hohmann, S			Analysis of the pore of the unusual major intrinsic protein channel, yeast Fps1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL FACILITATOR; ESCHERICHIA-COLI; SECONDARY-STRUCTURE; WATER CHANNEL; AQUAPORINS; TRANSPORT; ANTIMONITE; PREDICTION; ALGORITHM; MODEL	Fps1p is a glycerol efflux channel from Saccharomyces cerevisiae. In this atypical major intrinsic protein neither of the signature NPA motifs of the family, which are part of the pore, is preserved. To understand the functional consequences of this feature, we analyzed the pseudo-NPA motifs of Fps1p by site-directed mutagenesis and assayed the resultant mutant proteins in vivo. In addition, we took advantage of the fact that the closest bacterial homolog of Fps1p, Escherichia coli GlpF, can be functionally expressed in yeast, thus enabling the analysis in yeast cells of mutations that make this typical major intrinsic protein more similar to Fps1p. We observed that mutations made in Fps1p to "restore" the signature NPA motifs did not substantially affect channel function. In contrast, when GlpF was mutated to resemble Fps1p, all mutants had reduced activity compared with wild type. We rationalized these data by constructing models of one GlpF mutant and of the transmembrane core of Fps1p. Our model predicts that the pore of Fps1p is more flexible than that of GlpF. We discuss the fact that this may accommodate the divergent NPA motifs of Fps1p and that the different pore structures of Fps1p and GlpF may reflect the physiological roles of the two glycerol facilitators.	Gothenburg Univ, Dept Cell & Mol Biol Microbiol, S-40530 Gothenburg, Sweden; Chalmers Univ Technol, Dept Mol Biotechnol, S-40530 Gothenburg, Sweden; Univ Luton, Dept Biol & Hlth Sci, Luton LU1 3JU, Beds, England; Gothenburg Univ, Dept Biochem & Biophys, S-40530 Gothenburg, Sweden	University of Gothenburg; Chalmers University of Technology; University of Bedfordshire; University of Gothenburg	Bill, RM (corresponding author), Gothenburg Univ, Dept Cell & Mol Biol Microbiol, S-40530 Gothenburg, Sweden.	roslyn.bill@gmm.gu.se	Rydström, Jan/A-7683-2010; Bill, Roslyn M/D-4554-2012; Hedfalk, Kristina/A-8244-2010; Hohmann, Stefan/K-9895-2013	Bill, Roslyn M/0000-0003-1331-0852; Hohmann, Stefan/0000-0002-0809-1985; Mullins, Jonathan/0000-0003-0144-2962				BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Cain SM, 2000, J MEMBRANE BIOL, V176, P159, DOI 10.1007/s002320001085; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Deen PMT, 1998, CURR OPIN NEPHROL HY, V7, P37; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; Hohmann S, 2000, TRENDS MICROBIOL, V8, P33, DOI 10.1016/S0966-842X(99)01645-5; Holst B, 2000, MOL MICROBIOL, V37, P108, DOI 10.1046/j.1365-2958.2000.01968.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johansson I, 2000, BBA-BIOMEMBRANES, V1465, P324, DOI 10.1016/S0005-2736(00)00147-4; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kaldenhoff R, 1998, PLANT J, V14, P121, DOI 10.1046/j.1365-313X.1998.00111.x; Kjellbom P, 1999, TRENDS PLANT SCI, V4, P308, DOI 10.1016/S1360-1385(99)01438-7; Kuwahara M, 1998, AM J PHYSIOL-CELL PH, V275, pC1459, DOI 10.1152/ajpcell.1998.275.6.C1459; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders OI, 1997, J BACTERIOL, V179, P3365, DOI 10.1128/jb.179.10.3365-3367.1997; SARAKINOU KS, 2001, BIOCHEM SOC T, V29, P36; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sherman F., 1983, METHODS YEAST GENETI; Sutherland FCW, 1997, J BACTERIOL, V179, P7790, DOI 10.1128/jb.179.24.7790-7795.1997; SWEET G, 1990, J BACTERIOL, V172, P424, DOI 10.1128/JB.172.1.424-430.1990; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Tao W, 1999, J BIOL CHEM, V274, P360, DOI 10.1074/jbc.274.1.360; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VOEGELE RT, 1993, J BACTERIOL, V175, P1087, DOI 10.1128/JB.175.4.1087-1094.1993; Wysocki R, 2001, MOL MICROBIOL, V40, P1391, DOI 10.1046/j.1365-2958.2001.02485.x	36	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36543	36549		10.1074/jbc.M105045200	http://dx.doi.org/10.1074/jbc.M105045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11445582	Green Accepted, hybrid			2022-12-25	WOS:000171194500067
J	Mant, A; Woolhead, CA; Moore, M; Henry, R; Robinson, C				Mant, A; Woolhead, CA; Moore, M; Henry, R; Robinson, C			Insertion of PsaK into the thylakoid membrane in a "horseshoe" conformation occurs in the absence of signal recognition particle, nucleoside triphosphates, or functional Albino3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; PSI-K SUBUNIT; ESCHERICHIA-COLI; POSTTRANSLATIONAL INTEGRATION; INDEPENDENT INSERTION; PROTEIN-TRANSPORT; INNER MEMBRANE; PHOTOSYSTEM-I; SEC; MITOCHONDRIAL	The photosystem I subunit PsaK spans the thylakoid membrane twice, with the N and C termini both located in the lumen. The insertion mechanism of a thylakoid membrane protein adopting this type of topology has not been studied before, and we have used in vitro assays to determine the requirements for PsaK insertion into thylakoids. PsaK inserts with high efficiency and we show that one transmembrane span (the C-terminal region) can insert independently of the other, indicating that a "hairpin"-type mechanism is not essential. Insertion of PsaK does not require stromal extract, indicating that signal recognition particle (SRP) is not involved. Removal of nucleoside triphosphates inhibits insertion only slightly, both in the presence and absence of stroma, suggesting a mild stimulatory effect of a factor in the translation system and again ruling out an involvement of SRP or its partner protein, FtsY. We, furthermore, rind no evidence for the involvement of known membrane-bound translocation apparatus; proteolysis of thylakoids destroys the See and Tat translocons but does not block PsaK insertion, and antibodies against the Oxa1/YidC homolog, Alb3, block the SRP-dependent insertion of Lhcb1 but again have no effect on PsaK insertion. Because YidC is required for the efficient insertion of every membrane protein tested in Escherichia coli (whether SRP-dependent or -independent), PsaK is the first protein identified as being independent of YidC/Alb3-type factors in either thylakoids or bacteria. The data raise the possibility of a wholly spontaneous insertion pathway.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA	University of Warwick; University of Warwick; University of Arkansas System; University of Arkansas Fayetteville	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	Crobinson@bio.warwick.ac.uk		Mant, Alexandra/0000-0001-7169-209X				ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; BREYTON C, 1994, J BIOL CHEM, V269, P7597; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; DeLille J, 2000, P NATL ACAD SCI USA, V97, P1926, DOI 10.1073/pnas.030395197; DOUCE R, 1996, ADV PHOTOSYNTH, V4, P69; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; JAMES HE, 1989, J BIOL CHEM, V264, P19573; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KJAERULFF S, 1993, J BIOL CHEM, V268, P18912; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Thompson SJ, 1999, J BIOL CHEM, V274, P4059, DOI 10.1074/jbc.274.7.4059; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Tu CJ, 2000, J BIOL CHEM, V275, P13187, DOI 10.1074/jbc.C000108200; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	33	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36200	36206		10.1074/jbc.M102914200	http://dx.doi.org/10.1074/jbc.M102914200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11451950	hybrid			2022-12-25	WOS:000171194500022
J	Meyer, LA; Durley, AP; Prohaska, JR; Harris, ZL				Meyer, LA; Durley, AP; Prohaska, JR; Harris, ZL			Copper transport and metabolism are normal in aceruloplasminemic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED FORM; HUMAN CERULOPLASMIN; PROTEIN; DEFICIENCY; YEAST; IRON; GENE; APOCERULOPLASMIN; HEMOSIDEROSIS; BIOSYNTHESIS	Ceruloplasmin is an abundant serum glycoprotein containing greater than 95% of the copper found in the plasma of vertebrate species. Although this protein is known to function as an essential ferroxidase, the role of ceruloplasmin in copper transport and metabolism remains unclear. To elucidate the role of ceruloplasmin in copper metabolism, the kinetics of copper absorption, transport, distribution, and excretion were examined utilizing Cu-64 in wild-type and aceruloplasminemic mice. No differences in gastrointestinal absorption, hepatic uptake, or biliary excretion were observed in these animals. Furthermore, steady state measurements of tissue copper content utilizing Cu-64 and atomic absorption spectroscopy revealed no differences in the copper content of the brain, heart, spleen, and kidney. Consistent with these findings, the activity of copper-zinc superoxide dismutase in these tissues was equivalent in wildtype and ceruloplasmin-deficient mice. Hepatic iron was elevated 3.5-fold in aceruloplasminemic mice because of the loss of ferroxidase function. Hepatic copper content was markedly increased in aceruloplasminemic mice. As no differences were observed in copper absorption or biliary copper excretion, these data suggest that in these animals, hepatocyte copper intended for ceruloplasmin incorporation is trafficked into a compartment that is less available for biliary copper excretion. Taken together, these data reveal no essential role for ceruloplasmin in copper metabolism and suggest a previously unappreciated complexity to the subcellular distribution of this metal within the hepatocyte secretory pathway.	Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Div Pediat Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Univ Minnesota, Dept Biochem & Mol Biol, Duluth, MN 55812 USA	Johns Hopkins University; Washington University (WUSTL); University of Minnesota System; University of Minnesota Duluth	Harris, ZL (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Div Pediat Anesthesiol & Crit Care Med, 600 N Wolfe St,Blalock 904B, Baltimore, MD 21287 USA.	zharris@jhmi.edu		Harris, Zena Leah/0000-0003-0110-8438	NICHD NIH HHS [HD39708] Funding Source: Medline; NIDDK NIH HHS [DK58086, DK02464] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002464, R01DK058086] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL CH, 1981, BIOCHIM BIOPHYS ACTA, V678, P27; Cordano A, 1998, AM J CLIN NUTR, V67, p1012S, DOI 10.1093/ajcn/67.5.1012S; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Fortna RR, 1999, BIOL REPROD, V61, P1042, DOI 10.1095/biolreprod61.4.1042; GITLIN D, 1960, NATURE, V185, P693, DOI 10.1038/185693a0; GITLIN D, 1960, NATURE, V188, P150, DOI 10.1038/188150a0; GITLIN JD, 1992, BIOCHEM J, V282, P835, DOI 10.1042/bj2820835; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Harris ZL, 1996, AM J CLIN NUTR, V63, P836; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2354; HSIEH HS, 1975, BIOCHEM BIOPH RES CO, V67, P1326; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; MARCEAU N, 1973, BIOCHIM BIOPHYS ACTA, V328, P351, DOI 10.1016/0005-2795(73)90268-7; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; OWEN CA, 1965, AM J PHYSIOL, V209, P900, DOI 10.1152/ajplegacy.1965.209.5.900; OWEN CA, 1968, DEFECTS ORIG ARTIC S, V2, P1; Patel BN, 2000, J BIOL CHEM, V275, P4305, DOI 10.1074/jbc.275.6.4305; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; PROHASKA JR, 1983, J NUTR, V113, P2048, DOI 10.1093/jn/113.10.2048; Salzer JL, 1998, J NEUROSCI RES, V54, P147, DOI 10.1002/(SICI)1097-4547(19981015)54:2<147::AID-JNR3>3.0.CO;2-E; SATO M, 1991, J BIOL CHEM, V266, P5128; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; STEVENS MD, 1984, BIOCHEMISTRY-US, V23, P261, DOI 10.1021/bi00297a014; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; TANAKA K, 1978, J BIOCHEM-TOKYO, V84, P937, DOI 10.1093/oxfordjournals.jbchem.a132207; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267	36	96	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36857	36861		10.1074/jbc.M105361200	http://dx.doi.org/10.1074/jbc.M105361200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11461924	hybrid			2022-12-25	WOS:000171194500106
J	Wynn, RM; Chuang, JL; Sansaricq, C; Mandel, H; Chuang, DT				Wynn, RM; Chuang, JL; Sansaricq, C; Mandel, H; Chuang, DT			Biochemical basis of type IB (E1 beta) mutations in maple syrup urine disease - A prevalent allele in patients from the Druze kindred in Israel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOACID DEHYDROGENASE; HETERODIMERIC INTERMEDIATE; CHAPERONINS GROEL; E1-ALPHA LOCUS; MESSENGER-RNA; COMPLEX; ALPHA(2)BETA(2); DECARBOXYLASE; GROEL/GROES; DEFECT	Maple syrup urine disease (MSUD) is a metabolic disorder associated with often-fatal ketoacidosis, neurological derangement, and mental retardation. In this study, we identify and characterize two novel type ID MSUD mutations in Israeli patients, which affect the E1 beta subunit in the decarboxylase (El) component of the branched-chain a-ketoacid dehydrogenase complex. The recombinant mutant El carrying the prevalent S289L-beta (TCG --> TTG) mutation in the Druze kindred exists as a stable inactive alpha beta heterodimer. Based on the human El structure, the S289L-beta mutation disrupts the interactions between Ser-289-beta and Glu-290-beta', and between Arg-309-beta and Glu-290-beta', which are essential for native alpha (2)beta (2) heterotetrameric assembly. The R133P-beta (CGG --> CCG) mutation, on the other hand, is inefficiently expressed in Escherichia coli as heterotetramers in a temperature-dependent manner. The R133P-beta mutant El exhibits significant residual activity but is markedly less stable than the wild-type, as measured by thermal inactivation and free energy change of denaturation. The R133P-beta substitution abrogates the coordination of Arg-133-beta to Ala-95-beta, Glu-96-beta, and Ile-97-beta, which is important for strand-strand interactions and K+ ion binding in the beta subunit. These findings provide new insights into folding and assembly of human El and will facilitate DNA-based diagnosis for MSUD in the Israeli population.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Rambam Med Ctr, Dept Pediat, IL-31906 Haifa, Israel	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Icahn School of Medicine at Mount Sinai; Rambam Health Care Campus; Technion Israel Institute of Technology	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Bldg, Dallas, TX 75390 USA.	David.Chuang@UTSouthwestern.edu		Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; CHUANG JL, 1994, AM J HUM GENET, V55, P297; CHUANG JL, 1995, J CLIN INVEST, V95, P954, DOI 10.1172/JCI117804; Chuang JL, 2000, METHOD ENZYMOL, V324, P413; Chuang JL, 1999, J BIOL CHEM, V274, P10395, DOI 10.1074/jbc.274.15.10395; CHUANG JL, 1990, FEBS LETT, V262, P305, DOI 10.1016/0014-5793(90)80215-5; FISHER CR, 1991, J CLIN INVEST, V88, P1034, DOI 10.1172/JCI115363; FISHER CW, 1989, J BIOL CHEM, V264, P3448; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HENNIG J, 1966, BIOCH PHYSL THIAMIN, P243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDA I, 1990, BIOCHEM BIOPH RES CO, V172, P646, DOI 10.1016/0006-291X(90)90723-Z; MENKES JH, 1954, PEDIATRICS, V14, P462; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; SCRIVER CR, 1971, LANCET, V1, P310; Song JL, 2000, J BIOL CHEM, V275, P22305, DOI 10.1074/jbc.M002038200; TAYLOR J, 1978, PEDIATR RES, V12, P60, DOI 10.1203/00006450-197801000-00019; Wynn RM, 2000, METHOD ENZYMOL, V324, P179; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Wynn RM, 2000, J BIOL CHEM, V275, P2786, DOI 10.1074/jbc.275.4.2786; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200	26	12	12	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36550	36556		10.1074/jbc.M105862200	http://dx.doi.org/10.1074/jbc.M105862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11448970	hybrid			2022-12-25	WOS:000171194500068
J	Chung, NJ; Mao, CG; Heitman, J; Hannun, YA; Obeid, LM				Chung, NJ; Mao, CG; Heitman, J; Hannun, YA; Obeid, LM			Phytosphingosine as a specific inhibitor of growth and nutrient import in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE SYNTHASE; INDUCED APOPTOSIS; ALKALINE CERAMIDASE; GENE; YEAST; SPHINGOLIPIDS; BIOSYNTHESIS; STRESS; INVOLVEMENT; PHOSPHATASE	In the yeast Saccharomyces cerevisiae, we have demonstrated a necessary role for sphingolipids in the heat stress response through inhibition of nutrient import (Chung, N., Jenkins, G. M., Hannun, Y. A., Heitman, J., and Obeid, L. M. (2000) J. Biol Chem. 275,17229-17232). In this study, we used a combination of pharmacological and genetic approaches to determine which endogenous sphingolipid is the likely mediator of growth inhibition. When cells were treated with exogenous phytosphin-gosine (PHS, 20 muM) or structurally similar or metabolically related molecules, including 3-ketodihydrosphin-gosine, dihydrosphingosine, C-2-phytoceramide (PHC), and stearylamine, only PHS inhibited growth. Also, PHS was shown to inhibit uptake of uracil, tryptophan, leucine, and histidine. Again this effect was specific to PHS. Because of the dynamic nature of sphingolipid metabolism, however, it was difficult to conclude that growth inhibition was caused by PHS itself. By using mutant yeast strains defective in various steps in sphingolipid metabolism, we further determined the specificity of PHS. The elo2 Delta strain, which is defective in the conversion of PHS to PHC, was shown to have slower biosynthesis of ceramides and to be hypersensitive to PHS (5 muM), suggesting that PHS does not need to be converted to PHC. The lcb4 Delta lcb5 Delta strain is defective in the conversion of PHS to PHS 1-phosphate, and it was as sensitive to PHS as the wild-type strain. The syr2 Delta mutant strain was defective in the conversion of DHS to PHS. Interestingly, this strain was resistant to high concentrations of DHS (40 muM) that inhibited the growth of an isogenic wild-type strain, demonstrating that DHS needs to be converted to PHS to inhibit growth. Together, these data demonstrate that the active sphingolipid species that inhibits yeast growth is PHS or a closely related and yet unidentified metabolite.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet Microbiol & Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Medical University of South Carolina; Medical University of South Carolina; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.		Heitman, Joseph/ABC-6006-2021	obeid, lina/0000-0002-0734-0847	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43707] Funding Source: Medline; NIAID NIH HHS [AI41937] Funding Source: Medline; NIA NIH HHS [AG16583] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballou L.R, 1997, SPHINGOLIPID MEDIATE, P35; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chung N, 2000, METHOD ENZYMOL, V311, P319; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Guthrie C, 1991, METHODS ENZYMOL, V194; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HASSLER DF, 1993, ADV LIPID RES, V26, P49; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; MERRILL AH, 1993, ADV LIPID RES, V26, P215; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WELLS GB, 1983, J BIOL CHEM, V258, P200; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521	36	78	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35614	35621		10.1074/jbc.M105653200	http://dx.doi.org/10.1074/jbc.M105653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11468289	hybrid			2022-12-25	WOS:000171109300055
J	Qi, JF; Isupov, MN; Littlechild, JA; Anderson, LE				Qi, JF; Isupov, MN; Littlechild, JA; Anderson, LE			Chloroplast glyceraldehyde-3-phosphate dehydrogenase contains a single disulfide bond located in the C-terminal extension to the B subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADP-MALATE DEHYDROGENASE; CALVIN CYCLE ACTIVITY; CYSTEINE RESIDUES; CHEMICAL CLEAVAGE; LIGHT REGULATION; REDOX REGULATION; STRUCTURAL BASIS; ENZYME; PROTEINS; MODULATION	Mass mapping analysis based on cyanylation and CN-induced cleavage indicates that the two cysteine residues in the C-terminal extension of the B subunit of the light-activated pea leaf chloroplast glyceraldehyde-3-phosphate dehydrogenase form a disulfide bond. No evidence was found for a disulfide bond in the A subunit, nor was there any indication of a second disulfide bond in the B subunit. The availability of the structure of the extended glyceraldehyde-3-phosphate dehydrogenase from the archaeon Sulfolobus solfataricus allows modeling of the B subunit. As modeled, the two cysteine residues in the extension are positioned to form an interdomain disulfide cross-link.	Univ Illinois, Dept Biol Sci MC 066, Chicago, IL 60607 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Univ Exeter, Sch Chem Sci, Exeter EX4 4QG, Devon, England; Univ Exeter, Sch Biol Sci, Exeter EX4 4QG, Devon, England	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Michigan State University; University of Exeter; University of Exeter	Anderson, LE (corresponding author), Univ Illinois, Dept Biol Sci MC 066, 845 W Taylor St, Chicago, IL 60607 USA.	louise@uic.edu	Isupov, Mikhail/AAA-8280-2019; Littlechild, Jenny/AAE-4096-2020	Isupov, Michail/0000-0001-6842-4289				ANDERSON LE, 1986, ADV BOT RES, V12, P1, DOI 10.1016/S0065-2296(08)60192-5; ANDERSON LE, 1995, PLANTA, V196, P245; Baalmann E, 1996, PLANT MOL BIOL, V32, P505, DOI 10.1007/BF00019102; Buchanan BB, 1980, ANNU REV PLANT PHYS, V288, P1; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; Chiadmi M, 1999, EMBO J, V18, P6809, DOI 10.1093/emboj/18.23.6809; Fleming TM, 1998, ACTA CRYSTALLOGR D, V54, P671, DOI 10.1107/S0907444997018076; HILBERT M, 1993, PROTEINS, V17, P138, DOI 10.1002/prot.340170204; Hutchison RS, 2000, BIOCHEMISTRY-US, V39, P6679, DOI 10.1021/bi0001978; Isupov MN, 1999, J MOL BIOL, V291, P651, DOI 10.1006/jmbi.1999.3003; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li AD, 1997, PHOTOSYNTH RES, V51, P167; Li AD, 1997, PLANT PHYSIOL, V115, P1201, DOI 10.1104/pp.115.3.1201; LI D, 1994, BIOPHYS J, V67, P29, DOI 10.1016/S0006-3495(94)80484-9; Muslin EH, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P3583; Qi JF, 2001, BIOCHEMISTRY-US, V40, P4531, DOI 10.1021/bi002229x; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SKARZYNSKI T, 1988, J MOL BIOL, V203, P1097, DOI 10.1016/0022-2836(88)90130-1; WAKSELMAN M, 1976, J CHEM SOC CHEM COMM, P21, DOI 10.1039/c39760000021; Wedel N, 1997, P NATL ACAD SCI USA, V94, P10479, DOI 10.1073/pnas.94.19.10479; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; Wu J, 1998, ANAL BIOCHEM, V258, P268, DOI 10.1006/abio.1998.2596; Wu J, 1996, ANAL BIOCHEM, V235, P161, DOI 10.1006/abio.1996.0108	27	30	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35247	35252		10.1074/jbc.M103855200	http://dx.doi.org/10.1074/jbc.M103855200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11438534	hybrid			2022-12-25	WOS:000171109300007
J	Homma, K; Saito, J; Ikebe, R; Ikebe, M				Homma, K; Saito, J; Ikebe, R; Ikebe, M			Motor function and regulation of myosin X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; LIGHT-CHAIN; CALMODULIN; ACTIN; BINDING; EXPRESSION; MECHANISM; FAMILY	Myosin X is a member of the diverse myosin superfamily that is ubiquitously expressed in various mammalian tissues. Although its association with actin in cells has been shown, little is known about its biochemical and mechanoenzymatic function at the molecular level. We expressed bovine myosin X containing the entire head, neck, and coiled-coil domain and purified bovine myosin X in Sf9 cells. The Mg2+-ATPase activity of myosin X was significantly activated by actin with low K-ATP. The actin-activated ATPase activity was reduced at Ca2+ concentrations above pCa 5 in which 1 mol of calmodulin light chain dissociates from the heavy chain. Myosin X translocates F-actin filaments with the velocity of 0.3 mum/s with the direction toward the barbed end. The actin translocating activity was inhibited at concentrations of Ca2+ at pCa 6 in which no calmodulin dissociation takes place, suggesting that the calmodulin dissociation is not required for the inhibition of the motility. Unlike class V myosin, which shows a high affinity for F-actin in the presence of ATP, the K-actin of the myosin X ATPase was much higher than that of myosin V. Consistently nearly all actin dissociated from myosin X in the presence of ATP. ADP did not significantly inhibit the actin-activated ATPase activity of myosin X, suggesting that the ADP release step is not rate-limiting. These results suggest that myosin X is a nonprocessive motor. Consistently myosin X failed to support the actin translocation at low density in an in vitro motility assay where myosin V, a processive motor, supports the actin filament movement.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu			NHLBI NIH HHS [HL 60381] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline; NIGMS NIH HHS [GM 55834] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; Berg JS, 2000, J CELL SCI, V113, P3439; Chen LF, 2001, BIOPHYS J, V80, p573A; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Homma K, 2001, BIOPHYS J, V80, p573A; IKEBE M, 1989, J BIOL CHEM, V264, P6967; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Perreault-Micale C, 2000, J BIOL CHEM, V275, P21618, DOI 10.1074/jbc.M000363200; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rock RS, 2000, METHODS, V22, P373, DOI 10.1006/meth.2000.1089; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers J. R., 1999, MYOSINS; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Yonezawa S, 2000, BIOCHEM BIOPH RES CO, V271, P526, DOI 10.1006/bbrc.2000.2669; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	36	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34348	34354		10.1074/jbc.M104785200	http://dx.doi.org/10.1074/jbc.M104785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11457842	hybrid			2022-12-25	WOS:000170910200139
J	Moldes, M; Lasnier, F; Gauthereau, X; Klein, C; Pairault, J; Feve, B; Chambaut-Guerin, AM				Moldes, M; Lasnier, F; Gauthereau, X; Klein, C; Pairault, J; Feve, B; Chambaut-Guerin, AM			Tumor necrosis factor-alpha-induced adipose-related protein (TIARP), a cell-surface protein that is highly induced by tumor necrosis factor-alpha and adipose conversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT H2O2 GENERATION; ADIPOCYTE PLASMA-MEMBRANES; INSULIN-RESISTANCE; GENE-EXPRESSION; TNF-ALPHA; POTASSIUM CHANNELS; LIPOPROTEIN-LIPASE; 3T3-L1 CELLS; H2O2-GENERATING SYSTEM; MOLECULAR-CLONING	Tumor necrosis factor-alpha (TNF alpha) is involved in the physiological and biological abnormalities found in two opposite metabolic situations: cachexia and obesity. In an attempt to identify novel genes and proteins that could mediate the effects of TNFa alpha on adipocyte metabolism, and development, we have used a differential display technique comparing 3T3-L1 cells exposed or not to the cytokine. We have isolated a novel adipose cDNA encoding a TNF alpha -inducible 470-amino acid protein termed TIARP, with six putative transmembrane regions flanked by a large amino-terminal and a short carboxyl-terminal domain, a structure reminiscent of channel and transporter proteins. Commitment into the differentiation process is required for cytokine responsiveness. The differentiation process per se is accompanied by a sharp emergence of TIARP m-RNA transcripts, in parallel with the expression of the protein at the plasma membrane. Transcripts are present at high levels in white and brown adipose tissues, and are also detectable in liver, kidney, heart, and skeletal muscle. Whereas the biological function of TIARP is presently unknown, its pattern of expression during adipose conversion and in response to TNF alpha exposure as a transmembrane protein mainly located at the cell surface suggest that TIARP might participate in adipocyte development and metabolism and mediate some TNF alpha effects on the fat cell as a channel or a transporter.	Univ Paris 06, Ctr Rech Biomed Cordeliers, UMR 7079, CNRS, F-75270 Paris 06, France; Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM, IFR58, F-75270 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Chambaut-Guerin, AM (corresponding author), Univ Paris 06, Ctr Rech Biomed Cordeliers, UMR 7079, CNRS, 15 Rue Ecole Med, F-75270 Paris 06, France.		Moldes-Garnaud, Marthe/E-4817-2017	Moldes-Garnaud, Marthe/0000-0002-9950-2267; klein, christophe/0000-0001-8015-287X; Feve, Bruno/0000-0001-6577-9009				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Argiles JM, 1997, FASEB J, V11, P743, DOI 10.1096/fasebj.11.10.9271359; BEUTLER B, 1988, ENDOCR REV, V9, P57, DOI 10.1210/edrv-9-1-57; Biou V, 1997, EMBO J, V16, P3405, DOI 10.1093/emboj/16.12.3405; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; CARPET F, 1988, NUCLEIC ACIDS RES, V16, P10881; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Choe S, 1999, TRENDS BIOCHEM SCI, V24, P345, DOI 10.1016/S0968-0004(99)01440-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Derst C, 1998, J EXP BIOL, V201, P2791; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DUNNE MJ, 1988, J MEMBRANE BIOL, V102, P205, DOI 10.1007/BF01925714; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Gasic S, 1999, J BIOL CHEM, V274, P6770, DOI 10.1074/jbc.274.10.6770; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Grey ST, 1998, INT J HEMATOL, V67, P53; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; KALVAKOLANU DVR, 1993, P NATL ACAD SCI USA, V90, P3167, DOI 10.1073/pnas.90.8.3167; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kishida K, 2000, J BIOL CHEM, V275, P20896, DOI 10.1074/jbc.M001119200; Krieger-Brauer HI, 2000, J BIOL CHEM, V275, P2486, DOI 10.1074/jbc.275.4.2486; Krieger-Brauer HI, 2000, J BIOL CHEM, V275, P35920, DOI 10.1074/jbc.M002490200; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDAT MH, 1972, BIOCHIM BIOPHYS ACTA, V255, P1005, DOI 10.1016/0005-2736(72)90413-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; MUKHERJEE SP, 1977, ARCH BIOCHEM BIOPHYS, V184, P69, DOI 10.1016/0003-9861(77)90327-7; Nietsch HH, 2000, J BIOL CHEM, V275, P20556, DOI 10.1074/jbc.M002535200; Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881; PAPONNE PA, 1993, AM J PHYSIOL, V264, P1014; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; Porras A, 1997, FEBS LETT, V416, P324, DOI 10.1016/S0014-5793(97)01204-0; Prins JB, 1997, DIABETES, V46, P1939, DOI 10.2337/diabetes.46.12.1939; RamirezPonce MP, 1996, BIOCHEM BIOPH RES CO, V223, P250, DOI 10.1006/bbrc.1996.0880; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sebestyen A, 2000, CYTOKINE, V12, P1557, DOI 10.1006/cyto.2000.0754; SOKOLOV BP, 1994, NUCLEIC ACIDS RES, V22, P4009, DOI 10.1093/nar/22.19.4009; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Steiner MS, 2000, CANCER RES, V60, P4419; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; TengkuMuhammad TS, 1996, CYTOKINE, V8, P525, DOI 10.1006/cyto.1996.0071; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; Wilson SM, 1999, J GEN PHYSIOL, V113, P125, DOI 10.1085/jgp.113.1.125; Zemel MB, 1998, MOL CELL BIOCHEM, V188, P129, DOI 10.1023/A:1006880708475; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	67	83	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33938	33946		10.1074/jbc.M105726200	http://dx.doi.org/10.1074/jbc.M105726200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443137	hybrid			2022-12-25	WOS:000170910200088
J	Ohnishi, N; Takahashi, Y				Ohnishi, N; Takahashi, Y			PsbT polypeptide is required for efficient repair of photodamaged photosystem II reaction center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; CHLOROPLAST GENOME; GENE ORGANIZATION; COMPLETE SEQUENCE; PROTEIN DAMAGE; SUBUNIT; PHOTOINHIBITION; LIGHT; INACTIVATION; TURNOVER	PsbT is a small chloroplast-encoded hydrophobic polypeptide associated with the photosystem. II (PSII) core complex. A psbT-deficient mutant (Delta psbT) of the green alga Chlamydomonas reinhardtii grows photoautotrophically, whereas its growth is significantly impaired in strong light. To understand the photosensitivity of Delta psbT, we have studied the effect of strong illumination on PSH activity and proteins. It is shown that the level of PSII activity and proteins is reduced in the Delta psbT more significantly than in wild type under strong light. When recovery of the photodamaged PSII is inhibited by a chloroplast protein synthesis inhibitor, the light-induced inactivation and degradation of PSH occur similarly in wild-type and mutant cells. On the contrary, the recovery of PSII activity after partial photoinactivation is remarkably delayed in the Delta psbT cells, suggesting that PsbT is required for efficient recovery of the photodamaged PSII complex. These results therefore present the first evidence for involvement of this small PSII polypeptide in the recovery process. Partial disintegration of the purified PSII core complex and localization of PSII proteins in the resulting PSII subcore complexes have revealed that PsbT is associated with D1/D2 heterodimer. A possible role of PsbT in the recovery process is discussed.	Okayama Univ, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan; Okayama Univ, Fac Sci, Dept Biol, Okayama 7008530, Japan	Okayama University; Okayama University	Takahashi, Y (corresponding author), Okayama Univ, Grad Sch Nat Sci & Technol, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.		Takahashi, Yuichiro/B-2062-2011	Takahashi, Yuichiro/0000-0001-6410-0447				ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Hagman A, 1997, BIOCHEMISTRY-US, V36, P12666, DOI 10.1021/bi970685o; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HONG L, 1995, MOL GEN GENET, V247, P180, DOI 10.1007/BF00705648; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; JOHNSON CH, 1993, PLANT MOL BIOL, V22, P645, DOI 10.1007/BF00047405; KUNSTNER P, 1995, J BIOL CHEM, V270, P9651; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MONOD C, 1992, MOL GEN GENET, V231, P449, DOI 10.1007/BF00292715; MONOD C, 1994, EMBO J, V13, P2724; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; Rhee KH, 1998, NATURE, V396, P283, DOI 10.1038/24421; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; Takahashi Y, 1998, J PLANT RES, V111, P101, DOI 10.1007/BF02507156; Takahashi Y, 1996, PLANT CELL PHYSIOL, V37, P161, DOI 10.1093/oxfordjournals.pcp.a028927; Telfer A, 1999, J PHOTOCH PHOTOBIO B, V48, P89, DOI 10.1016/S1011-1344(99)00028-7; YAMAGUCHI N, 1988, PLANT CELL PHYSIOL, V29, P123; Yamamoto Y, 2001, PLANT CELL PHYSIOL, V42, P121, DOI 10.1093/pcp/pce022; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	34	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33798	33804		10.1074/jbc.M104454200	http://dx.doi.org/10.1074/jbc.M104454200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11451956	hybrid			2022-12-25	WOS:000170910200069
J	Sampson, NS; Ryan, ST; Enke, DA; Cosgrove, D; Koteliansky, V; Gotwals, P				Sampson, NS; Ryan, ST; Enke, DA; Cosgrove, D; Koteliansky, V; Gotwals, P			Global gene expression analysis reveals a role for the alpha(1) integrin in renal pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; RECESSIVE ALPORT SYNDROME; TRANSFORMING GROWTH-FACTOR-BETA-1; OLIGONUCLEOTIDE ARRAYS; TGF-BETA; IN-VIVO; COLLAGEN; IDENTIFICATION; ALPHA-1-BETA-1; MUTATIONS	Kidney fibrosis is the hallmark of most types of progressive kidney disease, including the genetic disorder Alport's syndrome. We undertook gene expression analysis in Alport's syndrome mouse kidneys using microchip arrays to characterize the development of fibrosis. La addition to matrix and matrix-remodeling genes, consistent with interstitial fibrosis, macrophage-related genes show elevated expression levels in Alport's syndrome kidneys. Immunohistochemical analysis of kidney sections illustrated that macrophages as well as myofibroblasts accumulate in the tubular interstitium. Deletion of alpha (1) integrin results in decreased accumulation of both myofibroblasts and macrophages in the tubular interstitium in Alport's syndrome mice and delays disease progression. Transforming growth factor beta antagonism, although reducing interstitial fibrosis, does not limit macrophage accumulation in the tubular interstitium and disease progression. In this study, we identified previously overlooked inflammatory events that occur in the tubulointerstitial region. We propose that in addition to the previously suggested role for the alpha (1)beta (1) integrin in mesangial expansion and abnormal laminin deposition, this integrin may be critical for monocyte accumulation that, in turn, may lead directly to renal failure. Our gene expression and immunohistochemical data indicate that macrophage accumulation is dependent on alpha (1) integrin expression on the macrophage cell surface and that anti-alpha (1) integrin strategies may be employed as therapeutics in the treatment of chronic inflammatory and fibrotic diseases.	Biogen Inc, Cambridge, MA 02142 USA; Boys Town Natl Res Inst, Omaha, NE 68131 USA	Biogen	Cosgrove, D (corresponding author), Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.		Sampson, Nicole/C-4598-2014	Sampson, Nicole/0000-0002-2835-7760				ADAMS MD, 1995, NATURE, V377, P3; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; CHAMPSI J, 1995, IMMUNOLOGY, V84, P549; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981; Cosgrove D, 2000, AM J PATHOL, V157, P1649, DOI 10.1016/S0002-9440(10)64802-X; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; de Saizieu A, 1998, NAT BIOTECHNOL, V16, P45, DOI 10.1038/nbt0198-45; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Flinter F, 1997, J MED GENET, V34, P326, DOI 10.1136/jmg.34.4.326; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Khalil N, 1996, AM J RESP CELL MOL, V15, P252, DOI 10.1165/ajrcmb.15.2.8703482; LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MIYAKE S, 1994, EUR J IMMUNOL, V24, P2000, DOI 10.1002/eji.1830240910; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; Pozzi M, 1998, J CELL BIOL, V142, P587; RUBIO MA, 1995, EUR J IMMUNOL, V25, P2701, DOI 10.1002/eji.1830250945; SALOMON GD, 1990, SURGERY, V108, P318; Sayers R, 1999, KIDNEY INT, V56, P1662, DOI 10.1046/j.1523-1755.1999.00744.x; Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939; WAHL SM, 1990, J IMMUNOL, V145, P2514; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	25	50	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34182	34188		10.1074/jbc.M102859200	http://dx.doi.org/10.1074/jbc.M102859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11447218	hybrid			2022-12-25	WOS:000170910200119
J	Ammanamanchi, S; Brattain, MG				Ammanamanchi, S; Brattain, MG			5-AzaC treatment enhances expression of transforming growth factor-beta receptors through down-regulation of Sp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; HUMAN GASTRIC-CANCER; TGF-BETA; II RECEPTOR; DNA METHYLATION; SP-FAMILY; TRANSCRIPTION; ACTIVATION; PROMOTER; RESISTANCE	We have previously reported that Sp3 acts as a transcriptional repressor of transforming growth factor-P receptors type I (RI) and type II (RII). We now present data suggesting that treatment of MCF-7L, breast and GEO colon cancer cells with 5-aza cytidine (5-azaC) leads to down-regulation of Sp3 and the concomitant induction of RI and RII. Western blot and gel shift analyses on 5-azaC-treated MCF-7L and GEO nuclear extracts indicated reduced Sp3 protein levels and decreased binding of Sp3 protein to radiolabeled consensus Sp1 oligonucleotide. Southwestern analysis detected decreased binding of Sp3 to RI and RH promoters in 5-azaC-treated MCF-7L and GEO cells, suggesting a correlation between decreased Sp3 binding and enhanced RI and RII expression in these cells. Reverse transcription-polymerase chain reaction and nuclear run-on data from 5-azaC-treated MCF-7L and GEO cells indicated down-regulation of Sp3 mRNA as a result of decreased transcription of Sp3. We reported earlier that 5-azaC treatment induces RI and RII expression through increased Sp1 protein levels/activities in these cells. These studies demonstrate that the effect of 5-azaC involves a combination of effects on Sp1 and Sp3.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA050457, R01CA038173, R01CA072001, R37CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA50457, CA38173, CA72001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kim DH, 1997, J BIOL CHEM, V272, P688; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, GENE DEV, V14, P627; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	27	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32854	32859		10.1074/jbc.M103951200	http://dx.doi.org/10.1074/jbc.M103951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11443124	hybrid			2022-12-25	WOS:000170746000065
J	Barnakov, AN; Barnakova, LA; Hazelbauer, GL				Barnakov, AN; Barnakova, LA; Hazelbauer, GL			Location of the receptor-interaction site on CheB, the methylesterase response regulator of bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; COVALENT MODIFICATION; SENSORY TRANSDUCER; ASPARTATE RECEPTOR; PROTEIN METHYLTRANSFERASE; FLAGELLAR SWITCH; DOCKING SITE; GENE-PRODUCT; METHYLATION	Sensory adaptation in bacterial chemotaxis is mediated by covalent modification of chemoreceptors, specifically methylation and demethylation of glutamates catalyzed by methyltransferase CheR and methylesterase CheB. The methylesterase is a two-domain response regulator in which phosphorylation of the regulatory domain enhances activity of the catalytic domain. In Escherichia coli and Salmonella typhimurium, a crucial determinant of efficient methylation and demethylation is a specific pentapeptide sequence at the chemoreceptor carboxyl terminus, a position distant from sites of enzymatic action. Each enzyme binds pentapeptide, but the site of binding has been located only for CheR. Here we locate the pentapeptide-binding site on CheB by assessing catalytic activity and pentapeptide binding of CheB fragments, protection of CheB from proteolysis by pentapeptide, and interference with pentapeptide-CheB interaction by a CheB segment. The results place the binding site near the hinge between regulatory and catalytic domains, in a segment spanning the carboxyl-terminal end of the regulatory domain and the beginning of the linker that stretches to the catalytic domain. This location is quite different from the catalytic domain location of the pentapeptide-binding site on CheR and is likely to reflect the rather different ways in which pentapeptide binding enhances enzymatic action for the methyltransferase and the methylesterase.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Hazelbauer, GL (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand GS, 2000, PROTEIN SCI, V9, P898, DOI 10.1110/ps.9.5.898; BARAK R, 1992, BIOCHEMISTRY-US, V31, P10099, DOI 10.1021/bi00156a033; Barnakov AN, 1999, P NATL ACAD SCI USA, V96, P10667, DOI 10.1073/pnas.96.19.10667; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; Djordjevic S, 1998, NAT STRUCT BIOL, V5, P446, DOI 10.1038/nsb0698-446; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Feng XH, 1999, J BACTERIOL, V181, P3164, DOI 10.1128/JB.181.10.3164-3171.1999; Feng XH, 1997, J BACTERIOL, V179, P6714, DOI 10.1128/jb.179.21.6714-6720.1997; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HAZELBAUER GL, 1989, P NATL ACAD SCI USA, V86, P1448, DOI 10.1073/pnas.86.5.1448; HAZELBAUER GL, 1980, NATURE, V283, P98, DOI 10.1038/283098a0; HAZELBAUER GL, 1999, ENCY NEUROSCIENCE, P181; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hughes CA, 2001, J MOL BIOL, V307, P967, DOI 10.1006/jmbi.2001.4523; Jasuja R, 1999, BIOPHYS J, V76, P1706, DOI 10.1016/S0006-3495(99)77329-7; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; Kim C, 2001, J MOL BIOL, V307, P119, DOI 10.1006/jmbi.2000.4389; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; LeMoual H, 1997, BIOCHEMISTRY-US, V36, P13441, DOI 10.1021/bi9713207; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MESIBOV R, 1972, J BACTERIOL, V112, P315, DOI 10.1128/JB.112.1.315-326.1972; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NOWLIN DM, 1988, PROTEINS, V3, P102, DOI 10.1002/prot.340030205; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; Okumura H, 1998, J BACTERIOL, V180, P1862, DOI 10.1128/JB.180.7.1862-1868.1998; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RICE MS, 1991, J BIOL CHEM, V266, P9746; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHAPIRO MJ, 1995, P NATL ACAD SCI USA, V92, P1053, DOI 10.1073/pnas.92.4.1053; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; TERWILLIGER TC, 1986, P NATL ACAD SCI USA, V83, P6707, DOI 10.1073/pnas.83.18.6707; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; Weerasuriya S, 1998, J BACTERIOL, V180, P914, DOI 10.1128/JB.180.4.914-920.1998; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; YAMAMOTO K, 1990, J BACTERIOL, V172, P383, DOI 10.1128/JB.172.1.383-388.1990; 2000, LIFE SCI NEWS, V6, P10	46	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32984	32989		10.1074/jbc.M105925200	http://dx.doi.org/10.1074/jbc.M105925200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435446	hybrid			2022-12-25	WOS:000170746000082
J	Daiho, T; Yamasaki, K; Saino, T; Kamidochi, M; Satoh, K; Iizuka, H; Suzuki, H				Daiho, T; Yamasaki, K; Saino, T; Kamidochi, M; Satoh, K; Iizuka, H; Suzuki, H			Mutations of either or both Cys(876) and Cys(888) residues of sarcoplasmic reticulum Ca2+-ATPase result in a complete loss of Ca2+ transport activity without a loss of Ca2+-dependent ATPase activity - Role of the Cys(876)-Cys(888) disulfide bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR LINKED FUNCTIONS; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; MOLECULAR-CLONING; SKELETAL-MUSCLE; PHOSPHOENZYME INTERMEDIATE; INORGANIC-PHOSPHATE; COMPLEMENTARY-DNA; CA-2+ ATPASE	Disulfide-containing peptides in pepsin digest of sarcoplasmic reticulum vesicles were identified by using a fluorogenic thiol-specific reagent 4-fluoro-7-sulfamoylbenzofurazan and a reductant tributylphosphine. Sequencing of the purified peptides revealed the presence of a Cys(876)-Cys(888) disulfide bond on the luminal loop connecting the 7th and 8th transmembrane helices (loop 7-8) of the Ca2+-ATPase (SERCA1a). We substituted either or both of these cysteine residues with alanine and made three mutants (C876A, C888A, C876A/C888A), in which the disulfide bond is disrupted. The mutants and the wild type were expressed in COS-1 cells, and functional analysis was performed with the microsomes isolated from the cells. Electrophoresis performed under reducing and non-reducing conditions confirmed the presence of Cys(876)-Cys(888) disulfide bond in the expressed wild type. All the three mutants possessed high Ca2+-ATPase activity. In contrast, no Ca2+ transport activity was detected with these mutants. These mutants formed almost the same amount of phosphoenzyme intermediate as the wild type from ATP and from Pi. Detailed kinetic analysis showed that the three mutants hydrolyze ATP in the mechanism well accepted for the Ca2+-ATPase; activation of the catalytic site upon high affinity Ca2+ binding, formation of ADP-sensitive phosphoenzyme, subsequent rate-limiting transition to ADP-insensitive phosphoenzyme, and hydrolysis of the latter phosphoenzyme. It is likely that the pathway for delivery of Ca2+ from the binding sites into the lumen of vesicles is disrupted by disruption of the Cys(876)-Cys(888) disulfide bond, and therefore that the loop 7-8 having the disulfide bond is important for formation of the proper structure of the Ca2+ pathway.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Daiho, T (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	daiho@asahikawa-med.ac.jp						ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; DAIHO T, 1994, J BIOL CHEM, V269, P11060; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; Dixon M, 1923, P R SOC LOND B-CONTA, V94, P266, DOI 10.1098/rspb.1923.0005; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; GREEN NM, 1985, BIOCHEM J, V231, P425, DOI 10.1042/bj2310425; HASHIMOTOGOTOH T, 1995, GENE, V152, P271, DOI 10.1016/0378-1119(94)00750-M; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; INESI G, 1992, ANN NY ACAD SCI, V671, P32, DOI 10.1111/j.1749-6632.1992.tb43782.x; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V68, P593, DOI 10.1093/oxfordjournals.jbchem.a129392; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KIRLEY TL, 1989, ANAL BIOCHEM, V180, P231, DOI 10.1016/0003-2697(89)90422-3; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; Ruegg U T, 1977, Methods Enzymol, V47, P111; Ruiz-Perez VL, 1999, HUM MOL GENET, V8, P1621, DOI 10.1093/hmg/8.9.1621; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SPACKMAN DH, 1960, J BIOL CHEM, V235, P648; THORLEYLAWSON DA, 1977, BIOCHEM J, V167, P739, DOI 10.1042/bj1670739; TOYOOKA T, 1984, ANAL CHEM, V56, P2461, DOI 10.1021/ac00277a044; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Webb RJ, 2000, J BIOL CHEM, V275, P977, DOI 10.1074/jbc.275.2.977; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; Yamasaki K, 1997, J BIOL CHEM, V272, P30627, DOI 10.1074/jbc.272.49.30627	56	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32771	32778		10.1074/jbc.M101229200	http://dx.doi.org/10.1074/jbc.M101229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438520	hybrid			2022-12-25	WOS:000170746000054
J	Zhong, SP; Jansen, C; She, QB; Goto, H; Inagaki, M; Bode, AM; Ma, WY; Dong, ZG				Zhong, SP; Jansen, C; She, QB; Goto, H; Inagaki, M; Bode, AM; Ma, WY; Dong, ZG			Ultraviolet B-induced phosphorylation of histone H3 at serine 28 is mediated by MSK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CHROMOSOME CONDENSATION; CHROMATIN-STRUCTURE; MAP KINASE; C-FOS; H3; MITOSIS; ACTIVATION; CLONING; SITE	N-terminal tail phosphorylation of histone H3 plays an important role in gene expression, chromatin remodeling, and chromosome condensation. Phosphorylation of histone H3 at serine 10 was shown to be mediated by RSK2, mitogen- and stress-activated protein kinase-1 (MSK1), and mitogen-activated protein kinases depending on the specific stimulation or stress. Our previous study showed that mitogen-activated protein kinases MAP kinases are involved in ultraviolet B-induced phosphorylation of histone H3 at serine 28 (Zhong, S., Zhong, Z., Jansen, J., Goto, H., Inagaki, M., and Dong, Z., J. BioL Chem. 276, 12932-12937). However, downstream effectors of MAP kinases remain to be identified. Here, we report that H89, a selective inhibitor of the nucleosomal response, totally inhibits ultraviolet B-induced phosphorylation of histone H3 at serine 28. H89 blocks MSK1 activity but does not inhibit ultraviolet B-induced activation of MAP kinases p70/85(S6K), p90(RSK), Akt, and protein kinase A. Furthermore, MSK1 markedly phosphorylated serine 28 of histone H3 and chromatin in vitro. Transfection experiments showed that an N-terminal mutant MSK1 or a C-terminal mutant MSK1 markedly blocked MSK1 activity. Compared with wild-type MSKI, cells transfected with N-terminal or C-terminal mutant MSK1 strongly blocked ultraviolet B-induced phosphorylation of histone H3 at serine 28 in vivo. These data illustrate that MSK1 mediates ultraviolet B-induced phosphorylation of histone H3 at serine 28.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Aichi 4648681, Japan	University of Minnesota System; Aichi Cancer Center	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@smig.net	Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467; She, Qing-Bai/0000-0002-7207-0599	NATIONAL CANCER INSTITUTE [R01CA081064, R37CA081064, R01CA077646] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA81064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJIRO K, 1985, J BIOL CHEM, V260, P5379; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; AJIRO K, 1983, J BIOL CHEM, V258, P4534; Ajiro K, 1996, EUR J BIOCHEM, V241, P923, DOI 10.1111/j.1432-1033.1996.00923.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALHORN R, 1975, BIOCHEMISTRY-US, V14, P2504, DOI 10.1021/bi00682a033; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; GREENGARD P, 1978, SCIENCE, V199, P146, DOI 10.1126/science.22932; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; WALSH DA, 1968, J BIOL CHEM, V243, P3763; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	40	66	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33213	33219		10.1074/jbc.M103973200	http://dx.doi.org/10.1074/jbc.M103973200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11441012	hybrid			2022-12-25	WOS:000170746000107
J	Mende, I; Malstrom, S; Tsichlis, PN; Vogt, PK; Aoki, M				Mende, I; Malstrom, S; Tsichlis, PN; Vogt, PK; Aoki, M			Oncogenic transformation induced by membrane-targeted Akt2 and Akt3	ONCOGENE			English	Article						Akt; transformation; serine/threonine kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; TUMOR-SUPPRESSOR; B-GAMMA; ACTIVATION; EXPRESSION; OVARIAN	The kinases Akt2, Akt3 and their myristylated variants, Myr-Akt2 and Myr-Akt3 were expressed by the RCAS vector in chicken embryo fibroblasts (CEF), Myr-Akt2 and Myr-Akt3 were strongly oncogenic, inducing multilayered foci of transformed cells. In contrast, wild-type Akt2 and Akt3 were only poorly transforming, their efficiencies of focus formation were more than 100-fold lower; foci appeared later and showed less multilayering, Addition of the myristylation signal not only enhanced oncogenic potential hut also increased kinase activities. Myr-Akt2 and Myr-Akt3 also induced hemangiosarcomas in the animal, whereas wild type Akt2 and Akt3 were not oncogenic in vivo. Furthermore, Akt2, driven by the lck (lymphocyte specific kinase) promoter in transgenic mice, induced lymphomas, The oncogenic effects of Akt2 and Akt3 described here are indistinguishable from those of Akt1, The downstream targets relevant to oncogenic transformation are therefore probably shared by the three Akt kinases.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Scripps Research Institute; Jefferson University	Vogt, PK (corresponding author), 10550 N Torrey Pines Rd,BCC-239, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490	NCI NIH HHS [CA 79616, CA 42564, CA 78230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564, R01CA079616, R01CA078230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; CECI JD, 1991, ONCOGENE, V6, P323; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Liu AX, 1998, CANCER RES, V58, P2973; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PELES E, 1992, J BIOL CHEM, V267, P12266; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SIRACUSA LD, 1987, GENETICS, V117, P85; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	48	86	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4419	4423		10.1038/sj.onc.1204486	http://dx.doi.org/10.1038/sj.onc.1204486			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466625				2022-12-25	WOS:000169912600018
J	Xi, HK; Goodwin, B; Shepherd, AT; Blanck, G				Xi, HK; Goodwin, B; Shepherd, AT; Blanck, G			Impaired class II transactivator expression in mice lacking interferon regulatory factor-2	ONCOGENE			English	Article						IRF; CIITA; MHC class II; IFN-gamma; mice	BARE LYMPHOCYTE SYNDROME; CREB BINDING-PROTEIN; MHC GENE-EXPRESSION; IFN-GAMMA; DERMAL FIBROBLASTS; CIITA INTERACTS; CHAIN GENE; INDUCTION; ACTIVATION; PROMOTER	Class II transactivator (CIITA) is required for both constitutive and inducible expression of MHC class II genes. IFN-gamma induced expression of CIITA in various cell types is directed by CIITA type IV promoter. The two transactivators, STAT1 and IRF-1, mediate the IFN-gamma activation of the type IV promoter by binding to the GAS and IRF-E of the promoter, respectively. In addition to IRF-1, IRF-2, another member of the IRF family, also activates the human CIITA type IV promoter, and IRF-2 cooperates with IRF-1 to activate the promoter in transient transfection assays, IRF-1 and IRF-2 can co-occupy the IRF-E of the human CIITA type IV promoter. To understand the effect of loss of IRF-2 on the endogenous CIITA expression, we assayed for CIITA expression in IRF-2 knock-out mice. Both basal and IFN-gamma induced CIITA expression were reduced in IRF-2 knock-out mice. At least half of the amount of inducible CIITA mRNA depends on IRF-2, The reduction of IFN-gamma induced CIITA mRNA in IRF-2: knock-out mice was due to the reduction of the type IV CIITA mRNA induction. The reduction of basal CIITA mRNA was apparently due to the reduction of CIITA mRNA originating from other promoters. These data indicate that IRF-2, like IRF-1, plays a critical role in the regulation of the endogenous CIITA gene. The implications in understanding the previously described phenotypes of IRF-2 defective mice are discussed.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Blanck, George/A-5365-2012		NCI NIH HHS [R01CA81497-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASTA PV, 1987, J IMMUNOL, V138, P1275; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; Bradley MB, 1997, J IMMUNOL, V159, P1086; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOES N, 1995, J IMMUNOL, V155, P4559; Grieder FB, 1999, VIROLOGY, V257, P106, DOI 10.1006/viro.1999.9662; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Hobart M, 1997, J IMMUNOL, V158, P4260; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Lu YM, 1996, J IMMUNOL, V156, P2495; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Merediz SAK, 2000, NUCLEIC ACIDS RES, V28, P4219, DOI 10.1093/nar/28.21.4219; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nikcevich KM, 1999, J NEUROIMMUNOL, V99, P195, DOI 10.1016/S0165-5728(99)00117-4; O'Keefe GM, 1999, EUR J IMMUNOL, V29, P1275, DOI 10.1002/(SICI)1521-4141(199904)29:04<1275::AID-IMMU1275>3.0.CO;2-T; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Rohn WM, 1996, CRIT REV IMMUNOL, V16, P311, DOI 10.1615/CritRevImmunol.v16.i3.40; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; Schoneboom BA, 2000, J INTERF CYTOK RES, V20, P205, DOI 10.1089/107999000312621; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Xi HK, 1999, ONCOGENE, V18, P5889, DOI 10.1038/sj.onc.1202969; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000	44	16	16	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4219	4227		10.1038/sj.onc.1204556	http://dx.doi.org/10.1038/sj.onc.1204556			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464288				2022-12-25	WOS:000169857200012
J	Thompson, DA; Zacny, V; Belinsky, GS; Classon, M; Jones, DL; Schlegel, R; Munger, K				Thompson, DA; Zacny, V; Belinsky, GS; Classon, M; Jones, DL; Schlegel, R; Munger, K			The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts	ONCOGENE			English	Article						apoptosis; tumor necrosis factor-alpha; caspase 8; human papillomavirus	HUMAN-PAPILLOMAVIRUS TYPE-16; SIGNALING COMPLEX DISC; TNF RECEPTOR; CELL-DEATH; GROWTH ARREST; KAPPA-B; KINASE RIP; PROTEIN; ACTIVATION; PATHWAY	Tumor necrosis factor-alpha (TNF) is a cytokine that induces programmed cell death, apoptosis, in a number of cell types and is employed by cytotoxic T cells to eliminate virus infected cells. Consequently, many viruses have acquired mechanisms to undermine these host cell defense mechanisms and cause resistance to TNF-mediated apoptosis, Here we show that normal human diploid fibroblasts that express the human papillomavirus type 16 E7 oncoprotein have a decreased propensity to undergo apoptosis in response to TNF treatment. The ability of E7 to undermine TNF-mediated apoptosis correlates with cellular transformation. While E7 does not generally subvert signaling by tumor necrosis factor receptor I, pro-caspase 8 activation is decreased in E7-expressing cells, E7 also provides some protection from apoptosis caused by stimulation of the TNF receptor 1-related cytokine receptor Fas, where induction of apoptosis occurs much slower in this cell type. Hence, E7-expressing normal human fibroblasts exhibit specific defect that obstructs cytokine-mediated activation of pro-caspase 8 and apoptosis.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Ctr Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Canc Cell BIol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Munger, Karl/0000-0003-3288-9935; Thompson, David/0000-0003-2372-7766	NATIONAL CANCER INSTITUTE [T32CA072320, R01CA081135] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81135, T32 CA72320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTWERP DJV, 1996, SCIENCE, V274, P787; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baker SJ, 1996, ONCOGENE, V12, P1; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boyer SN, 1996, CANCER RES, V56, P4620; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DARCY A, 1993, J MOL BIOL, V229, P555, DOI 10.1006/jmbi.1993.1055; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1999, VIROLOGY, V258, P406, DOI 10.1006/viro.1999.9733; KIRSTEIN M, 1986, J IMMUNOL, V137, P2277; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; PFIZENMAIER K, 1987, BLUT, V55, P1, DOI 10.1007/BF00319635; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ramshaw IA, 1997, IMMUNOL REV, V159, P119, DOI 10.1111/j.1600-065X.1997.tb01011.x; REID TR, 1989, J BIOL CHEM, V264, P4583; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; WAKABAYASHI T, 1990, J BIOL CHEM, V265, P7604; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8; Wong GHW, 1992, TUMOR NECROSIS FACTO, P371; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806	55	43	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3629	3640		10.1038/sj.onc.1204483	http://dx.doi.org/10.1038/sj.onc.1204483			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439326				2022-12-25	WOS:000169400200004
J	Wallace, M; Coates, PJ; Wright, EG; Ball, KL				Wallace, M; Coates, PJ; Wright, EG; Ball, KL			Differential post-translational modification of the tumour suppressor proteins Rb and p53 modulate the rates of radiation-induced apoptosis in vivo	ONCOGENE			English	Article						Rb; p21; p53; apoptosis; genetic variation; radiation	CELL-CYCLE ARREST; RETINOBLASTOMA GENE-PRODUCT; DRUG-RESISTANT CELLS; HUMAN CANCER-CELLS; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; THYMOCYTE APOPTOSIS; MEDIATED APOPTOSIS; HEPATOMA-CELLS; G(1) ARREST	Ionizing radiation induces p53-dependent apoptosis in the spleen, providing a model system to study p53 regulated events in a normal cell type. We have developed an in vivo model that identifies genetic differences in the regulation of p53-mediated apoptosis and addresses whether altered post-translational events in the p53-p21/Rb axis modulate the sensitivity of cells to radiation-induced cell death in vivo. Splenocytes from mice with distinct genetic backgrounds (DBA/2 and C57BL/6) exhibit differences in the rate of apoptosis, Whilst no obvious strain differences in protein levels of Bcl-2 or the cyclin-CDKs were observed, early posttranslational regulatory events in the p53-p21/Rb axis showed striking differences in the two mouse strains. Cells from C57BL/6 animals undergo more rapid apoptosis after irradiation resulting from elevated levels and rapid induction of p53, pronounced Rb-cleavage, and the absence of a sustained induction of p21, In contrast, cells from DBA/2 animals have a reduced rate of apoptosis following irradiation with elevated levels of hyperphosphorylated Rb and a sustained induction of the p21 protein that is coincident with the C-terminal phosphorylation of p53, These data suggest that quantitative differences in the level of p21 protein can affect the rate of apoptosis in vivo, consistent with the view that p21 is an anti-apoptotic effector of p53, However, striking differences in the Rb protein-caspase cleavage or hyperphosphorylation - in the same cell type, but in different genetic backgrounds, demonstrates that p53-dependent apoptosis can be modulated in vivo by genetic factors that impinge upon the pro- or antiapoptotic potential of Rh, In addition, we show that Rb cleavage is p53-dependent and that its phosphorylation status can be uncoupled from p21 expression. This study highlights the possibility that genetic factors can be identified that affect differential sensitivity of cells to ionizing radiation in vivo.	Univ Dundee, Sch Med, Dept Surg & Mol Oncol, CRC Labs, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Med, Dept Mol & Cellular Pharmacol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Ball, KL (corresponding author), Univ Dundee, Sch Med, Dept Surg & Mol Oncol, CRC Labs, Dundee DD1 9SY, Scotland.		Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; An B, 1996, CANCER RES, V56, P438; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Ball KL, 1996, EUR J BIOCHEM, V237, P854, DOI 10.1111/j.1432-1033.1996.0854p.x; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Bowen C, 1998, CANCER RES, V58, P3275; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DEDEIRY WS, 1994, CANCER RES, V54, P1169; DOU QP, 1995, CANCER RES, V55, P5222; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Dou QP, 1997, J CELL BIOCHEM, V64, P586; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Fan GS, 1996, ONCOGENE, V12, P1909; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HAUPT Y, 1995, ONCOGENE, V10, P1563; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MIYASHITA T, 1995, CELL, V80, P293; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; NOMURA T, 1992, J RADIAT RES, V33, P109, DOI 10.1269/jrr.33.SUPPLEMENT_109; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; RODERICK TH, 1963, RADIAT RES, V20, P631, DOI 10.2307/3571354; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Tian H, 2000, CANCER RES, V60, P679; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang H, 1996, ONCOGENE, V13, P373; Wang J, 1997, CANCER RES, V57, P351; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Weil MM, 1997, GENOMICS, V45, P626, DOI 10.1006/geno.1997.4999; Whitaker LL, 1997, ONCOGENE, V15, P1069, DOI 10.1038/sj.onc.1201277; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	68	47	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3597	3608		10.1038/sj.onc.1204496	http://dx.doi.org/10.1038/sj.onc.1204496			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439323				2022-12-25	WOS:000169400200001
J	Hawtin, SR; Tobin, AB; Patel, S; Wheatley, M				Hawtin, SR; Tobin, AB; Patel, S; Wheatley, M			Palmitoylation of the vasopressin V-1a receptor reveals different conformational requirements for signaling, agonist-induced receptor phosphorylation, and sequestration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIOGONADOTROPIN RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; SITE-DIRECTED MUTAGENESIS; CYSTEINE RESIDUES; CYTOPLASMIC TAIL; BETA(2)-ADRENERGIC RECEPTOR; THYROTROPIN RECEPTOR; HORMONE RECEPTOR; CLATHRIN ADAPTER; DOWN-REGULATION	In this study, we establish that the V-1a vasopressin receptor (V1aR) is palmitoylated, and we show that this modification has an important functional role. Palmitoylation of the V1aR occurs within the Cys(371)/Cys(372) couplet located in the proximal C-terminal tail domain. Substitution of these residues in a [C371G/C372G]V1aR construct effectively disrupted receptor palmitoylation. Our data also indicate an additional palmitoylation site at another locus in the receptor, as yet undefined. [H-3]Palmitate incorporation was agonist-sensitive and increased following exposure to [Arg(8)]vasopressin (AVP). Given the hydrophobic nature of the acyl chain, palmitoylation of the C terminus of G-protein-coupled receptors has been proposed to form an additional intracellular loop. Consequently, palmitoylation/depalmitoylation will have a profound effect on the local conformation of this domain. The V1aR palmitoylation status regulated both phosphorylation and sequestration of the receptor, and furthermore, palmitoylation, phosphorylation, and sequestration were all regulated by AVP. The palmitoylation-defective construct [C371G/C372G]V1aR exhibited decreased phosphorylation compared to wild-type V1aR, under both basal and AVP-stimulated conditions, and was sequestered at a faster rate. In contrast, the binding of four different classes of ligand and intracellular signaling were not affected by palmitoylation. This study therefore establishes that there are different conformational requirements for signaling, agonist-induced phosphorylation, and sequestration of the V1aR.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England	University of Birmingham; University of Leicester; Merck & Company	Wheatley, M (corresponding author), Univ Birmingham, Sch Biosci, Edgbaston, Birmingham B15 2TT, W Midlands, England.	m.wheatley@bham.ac.uk		Wheatley, Mark/0000-0001-6261-5682				ALALUF S, 1995, J NEUROCHEM, V64, P1548; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BONATTI S, 1989, J BIOL CHEM, V264, P12590; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chen CG, 1998, FEBS LETT, V441, P148, DOI 10.1016/S0014-5793(98)01547-6; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DAVIDSON JS, 1994, MOL CELL ENDOCRINOL, V100, P9, DOI 10.1016/0303-7207(94)90271-2; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Gao ZH, 1999, BIOCHEM J, V342, P387, DOI 10.1042/0264-6021:3420387; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRUNEWALD S, 1990, BIOCHEMISTRY-US, V35, P15149; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAWKIN SR, 2001, BIOCHEM J, V357, P73; Hawtin SR, 2001, BIOCHEM J, V354, P465, DOI 10.1042/0264-6021:3540465; Hawtin SR, 2000, BIOCHEMISTRY-US, V39, P13524, DOI 10.1021/bi0013400; Hawtin Stuart R., 1997, Biochemical Society Transactions, V25, p437S; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; HOWL J, 1995, GEN PHARMACOL-VASC S, V26, P1143, DOI 10.1016/0306-3623(95)00016-T; HOWL J, 1995, ENDOCRINOLOGY, V136, P2206, DOI 10.1210/en.136.5.2206; Howl J, 1997, FASEB J, V11, P582, DOI 10.1096/fasebj.11.7.9212082; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Jin H, 1999, EUR J PHARMACOL, V386, P305, DOI 10.1016/S0014-2999(99)00727-X; KAWATE N, 1994, J BIOL CHEM, V269, P30651; Kawate N, 1997, MOL CELL ENDOCRINOL, V127, P211, DOI 10.1016/S0303-7207(97)04010-0; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; Kosugi S, 1996, BIOCHEM BIOPH RES CO, V221, P636, DOI 10.1006/bbrc.1996.0648; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Loisel TP, 1999, J BIOL CHEM, V274, P31014, DOI 10.1074/jbc.274.43.31014; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Ponimaskin EG, 2001, BIOCHEM J, V353, P627, DOI 10.1042/0264-6021:3530627; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; Wheatley M, 1997, Methods Mol Biol, V73, P305; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	57	57	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38139	38146						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11466323				2022-12-25	WOS:000171526500056
J	Dierks, H; Kolanus, J; Kolanus, W				Dierks, H; Kolanus, J; Kolanus, W			Actin cytoskeletal association of cytohesin-1 is regulated by specific phosphorylation of its carboxyl-terminal polybasic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PH DOMAIN; T-CELL; SIGNALING MOLECULES; NUCLEOTIDE EXCHANGE; STRUCTURAL BASIS; PLECKSTRIN; INTEGRINS; MEMBRANE; ADHESION	Cell adhesion mediated by integrin receptors is controlled by intracellular signal transduction cascades. Cytohesin-1 is an integrin-binding protein and guanine nucleotide exchange factor that activates binding of the leukocyte integrin leukocyte function antigen-1 to its ligand, intercellular adhesion molecule 1. Cytohesin-1 bears a carboxyl-terminal pleckstrin homology domain that aids in reversible membrane recruitment and functional regulation of the protein. Although phosphoinositide-dependent membrane attachment of cytohesin-1 is mediated primarily by the pleckstrin homology domain, this function is further strengthened by a short carboxyl-terminal polybasic amino acid sequence. We show here that a serine/threonine motif within the short polybasic stretch of cytohesin-1 is phosphorylated by purified protein kinase CS in vitro. Furthermore the respective residues are also found to be phosphorylated after phorbol ester stimulation in vivo. Biochemical and functional analyses show that phosphorylated cytohesin-1 is able to tightly associate with the actin cytoskeleton, and we further demonstrate that phosphorylation of the protein is required for maximal leukocyte function antigen-1-mediated adhesion of Jurkat cells to intercellular adhesion molecule 1. These data suggest that both phosphatidylinositol 3-kinase and protein kinase C-dependent intracellular pathways that stimulate beta (2)-integrin-mediated adhesion of T lymphocytes converge on cytohesin-1 as functional integrator.	Univ Munich, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany	University of Munich	Kolanus, W (corresponding author), Univ Munich, Genzentrum, Mol Biol Lab, Feodor Lynen Str 25, D-81377 Munich, Germany.	kolanus@lmb.uni-muenchen.de						AUSUBEL FM, 1987, CURRENT PROTOCOL S15, V1; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; DANIELIAN S, 1990, BIOCHIMIE, V72, P315, DOI 10.1016/0300-9084(90)90026-D; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FORCHHAMMER K, 1994, J BACTERIOL, V176, P84, DOI 10.1128/JB.176.1.84-91.1994; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Kolanus W, 1998, CURR TOP MICROBIOL, V231, P33; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Meller N, 1996, MOL CELL BIOL, V16, P5782; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; Venkateswarlu K, 1999, J CELL SCI, V112, P1957	44	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37472	37481		10.1074/jbc.M101502200	http://dx.doi.org/10.1074/jbc.M101502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11438522	hybrid			2022-12-25	WOS:000171375700081
J	Faradji, RN; Havari, E; Chen, Q; Gray, J; Tornheim, K; Corkey, BE; Mulligan, RC; Lipes, MA				Faradji, RN; Havari, E; Chen, Q; Gray, J; Tornheim, K; Corkey, BE; Mulligan, RC; Lipes, MA			Glucose-induced toxicity in insulin-producing pituitary cells that coexpress GLUT2 and glucokinase - Implications for metabolic engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELL; NON-ISLET CELLS; TURBO DESIGN; EXPRESSION; SECRETION; GLYCOLYSIS; RELEASE; PHOSPHORYLATION; CYCLE; LIVER	We have shown that intermediate lobe (IL) pituitary cells can be engineered to produce sufficient amounts of insulin (ins) to cure diabetes in nonobese diabetic mice but, unlike transplanted islets, ILins cells evade immune attack. To confer glucose-sensing capabilities into these cells, they were further modified with recombinant adenoviruses to express high levels of GLUT2 and the beta -cell isoform of glucokinase (GK). Although expression of GLUT2 alone had negligible effects on glucose usage and lactate production, expression of GK alone resulted in similar to2-fold increase in glycolytic flux within the physiological (3-20 mM) glucose range. GLUT2/GK coexpression further increased glycolytic flux at 20 mM glucose but disproportionately increased flux at 3 mM glucose. Despite enhanced glycolytic fluxes, GLUT2/GK-coexpressing cells showed glucose dose-dependent accumulation of hexose phosphates, depletion of intracellular ATP, and severe apoptotic cell death. These studies demonstrate that glucose-sensing properties can be introduced into non-islet cells by the single expression of GK and that glucose responsiveness can be augmented by the coexpression of GLUT2. However, in the metabolic engineering of surrogate beta cells, it is critical that the levels of the components be closely optimized to ensure their physiological function and to avoid the deleterious consequences of glucose-induced toxicity.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Med, Boston, MA 02215 USA; Boston Univ, Med Ctr, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Med Ctr, Obes Res Ctr, Boston, MA 02118 USA; Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Boston University; Boston University; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Lipes, MA (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Med, 1 Joslin Pl,Rm 495, Boston, MA 02215 USA.		Gray, John T/D-2916-2016; Corkey, Barbara/E-7712-2015	Gray, John T/0000-0002-1888-4612; Tornheim, Keith/0000-0002-6235-5128; Corkey, Barbara/0000-0002-5467-1630	NIDDK NIH HHS [DK53281, DK53064, DK35914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053281, R01DK035914, R37DK035914, R01DK053064, R56DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; Bakker BM, 2000, P NATL ACAD SCI USA, V97, P2087, DOI 10.1073/pnas.030539197; Chen R, 2000, GENE THER, V7, P1802, DOI 10.1038/sj.gt.3301306; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Clark SA, 1997, DIABETES, V46, P958, DOI 10.2337/diabetes.46.6.958; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Feng S, 1999, TRANSPLANTATION, V67, P1607, DOI 10.1097/00007890-199906270-00016; Garnier M, 1998, ENDOCRINOLOGY, V139, P3525, DOI 10.1210/en.139.8.3525; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GITZELMAN R, 1995, METABOLIC MOL BASIS, P904; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Iynedjian PB, 1998, TRENDS BIOCHEM SCI, V23, P467, DOI 10.1016/S0968-0004(98)01317-6; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; LIANG Y, 1991, J BIOL CHEM, V266, P6999; Lipes MA, 1996, P NATL ACAD SCI USA, V93, P8595, DOI 10.1073/pnas.93.16.8595; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P955, DOI 10.1016/0020-711X(91)90085-2; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORITA H, 1994, J CLIN INVEST, V94, P1373, DOI 10.1172/JCI117472; Motoyoshi S, 1998, DIABETOLOGIA, V41, P1492, DOI 10.1007/s001250051096; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Passonneau OH, 1972, FLEXIBLE SYSTEM ENZY, P68, DOI 10.1016/B978-0-12-457950-7.50007%26%23x2013%3B3; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Sweet IR, 1997, DIABETOLOGIA, V40, P112, DOI 10.1007/s001250050652; Teusink B, 1998, TRENDS BIOCHEM SCI, V23, P162, DOI 10.1016/S0968-0004(98)01205-5; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; Thorens B, 1996, J BIOL CHEM, V271, P8075, DOI 10.1074/jbc.271.14.8075; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; Wang HY, 1997, J BIOL CHEM, V272, P25731, DOI 10.1074/jbc.272.41.25731; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372	39	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36695	36702		10.1074/jbc.M102542200	http://dx.doi.org/10.1074/jbc.M102542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11443115	hybrid			2022-12-25	WOS:000171194500085
J	Handrick, R; Reinhardt, S; Focarete, ML; Scandola, M; Adamus, G; Kowalczuk, M; Jendrossek, D				Handrick, R; Reinhardt, S; Focarete, ML; Scandola, M; Adamus, G; Kowalczuk, M; Jendrossek, D			A new type of thermoalkalophilic hydrolase of Paucimonas lemoignei with high specificity for amorphous polyesters of short chain-length hydroxyalkanoic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC ATACTIC POLY(3-HYDROXYBUTYRATE); CRYSTALLINITY-INDUCED BIODEGRADATION; BIOCHEMICAL-PROPERTIES; PSEUDOMONAS-LEMOIGNEI; EXTRACELLULAR LIPASE; BACILLUS-SUBTILIS; MOLECULAR-CLONING; BACTERIAL LIPASES; PHB-DEPOLYMERASE; INCLUSION-BODIES	A novel type of hydrolase was purified from culture fluid of Paucimonas (formerly Pseudomonas) lemoignei. Biochemical characterization revealed an unusual substrate specificity of the purified enzyme for amorphous poly((R)-3-hydroxyalkanoates) (PHA) such as native granules of natural poly((R)-3-hydroxybutyrate) (PHB) or poly((R)-3-hydroxyvalerate) (PHV), artificial cholate-coated granules of natural PHB or PHV, atactic poly((R,S)3-hydroxybutyrate), and oligomers of (R)-3-hydroxybutyrate (3HB) with six or more 3HB units. The enzyme has the unique property to recognize the physical state of the polymeric substrate by discrimination between amorphous PHA (good substrate) and denatured, partially crystalline PHA (no substrate). The pentamers of 3HB or 3HV were identified as the main products of enzymatic hydrolysis of native PHB or PHV, respectively. No activity was found with any denatured PHA, oligomers of (R)-3HB with five or less 3HB units, poly(6-hydroxyhexanoate), substrates of lipases such as tributyrin or triolein, substrates for amidases/nitrilases, DNA, RNA, casein, N-alpha -benzoyl-L-arginine-4-nitranilide, or starch. The purified enzyme (M-r 36,209) was remarkably stable and active at high temperature (60 degreesC), high pH (up to 12.0), low ionic strength (distilled water), and in solvents (e.g. n-propyl alcohol). The depolymerase contained no essential SH groups or essential disulfide bridges and was insensitive to high concentrations of ionic (SDS) and nonionic (Triton and Tween) detergents. Characterization of the cloned structural gene (phaZ7) and the DNA-deduced amino acid sequence revealed no homologies to any PUB depolymerase or any other sequence of data banks except for a short sequence related to the active site serine of serine hydrolases. A classification of the enzyme into a new family (family 9) of carboxyesterases (Arpigny, J. L., and Jaeger, YL-E. (1999) Biochem J. 343, 177-183) is suggested.	Univ Stuttgart, Inst Mikrobiol, D-70569 Stuttgart, Germany; Univ Bologna, Dept Chem G Ciamician, I-40126 Bologna, Italy; Univ Bologna, Ctr Studio Fis Macromol, CNR, I-40126 Bologna, Italy; Polish Acad Sci, Ctr Polymer Chem, PL-41800 Zabrze, Poland	University of Stuttgart; University of Bologna; Consiglio Nazionale delle Ricerche (CNR); University of Bologna; Polish Academy of Sciences	Handrick, R (corresponding author), Univ Stuttgart, Inst Mikrobiol, Allandring 31, D-70569 Stuttgart, Germany.		Focarete, Maria Letizia/B-2369-2009	Focarete, Maria Letizia/0000-0002-0458-7836; Adamus, Grazyna/0000-0001-5439-7400; Kowalczuk, Marek/0000-0002-2877-7466				Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; Bachmann BM, 1998, HELV CHIM ACTA, V81, P2430, DOI 10.1002/(SICI)1522-2675(19981216)81:12<2430::AID-HLCA2430>3.0.CO;2-W; Bachmann BM, 1999, MACROMOLECULES, V32, P1777, DOI 10.1021/ma981496w; BARHAM PJ, 1984, J MATER SCI, V19, P2781, DOI 10.1007/BF01026954; Behrends A, 1996, FEMS MICROBIOL LETT, V143, P191, DOI 10.1016/0378-1097(96)00305-9; Briese Bernd Holger, 1994, Journal of Environmental Polymer Degradation, V2, P75, DOI 10.1007/BF02074776; CORNIBERT J, 1975, MACROMOLECULES, V8, P296, DOI 10.1021/ma60045a011; Eggert T, 2000, EUR J BIOCHEM, V267, P6459, DOI 10.1046/j.1432-1327.2000.01736.x; Focarete ML, 1998, MACROMOLECULES, V31, P8485, DOI 10.1021/ma981115e; GILBERT EJ, 1993, ENZYME MICROB TECH, V15, P634, DOI 10.1016/0141-0229(93)90062-7; Handrick R, 2000, J BACTERIOL, V182, P5916, DOI 10.1128/JB.182.20.5916-5918.2000; HOROWITZ DM, 1994, J AM CHEM SOC, V116, P2695, DOI 10.1021/ja00086a001; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; JEDLINSKI Z, 1995, J MACROMOL SCI PURE, VA32, P797, DOI 10.1080/10601329508010290; Jendrossek D, 2001, INT J SYST EVOL MICR, V51, P905, DOI 10.1099/00207713-51-3-905; Jendrossek D, 1996, APPL MICROBIOL BIOT, V46, P451, DOI 10.1007/s002530050844; Jendrossek Dieter, 2001, V71, P293; KAWAGUCHI Y, 1990, FEMS MICROBIOL LETT, V70, P151, DOI 10.1016/S0378-1097(05)80030-8; Khalameyzer V, 1999, BIOTECHNOL LETT, V21, P101, DOI 10.1023/A:1005445214284; Kim HK, 1998, BIOSCI BIOTECH BIOCH, V62, P66, DOI 10.1271/bbb.62.66; KOUKER G, 1987, APPL ENVIRON MICROB, V53, P211, DOI 10.1128/AEM.53.1.211-213.1987; KOWALECZUK M, 2000, ACS POLYM PREP, V41, P1626; Krebsfanger N, 1998, J BIOTECHNOL, V60, P105, DOI 10.1016/S0168-1656(97)00192-2; KURCOK P, 1992, MACROMOLECULES, V25, P2017, DOI 10.1021/ma00033a027; Lee DW, 1999, FEMS MICROBIOL LETT, V179, P393, DOI 10.1016/S0378-1097(99)00440-1; LESUISSE E, 1993, EUR J BIOCHEM, V216, P155, DOI 10.1111/j.1432-1033.1993.tb18127.x; Madison LL, 1999, MICROBIOL MOL BIOL R, V63, P21, DOI 10.1128/MMBR.63.1.21-53.1999; Manco G, 1998, BIOCHEM J, V332, P203, DOI 10.1042/bj3320203; Mayer F, 1996, J GEN APPL MICROBIOL, V42, P445, DOI 10.2323/jgam.42.445; MERRICK JM, 1965, J BACTERIOL, V89, P234, DOI 10.1128/JB.89.1.234-239.1965; NAKAYAMA K, 1985, BIOCHIM BIOPHYS ACTA, V827, P63, DOI 10.1016/0167-4838(85)90101-3; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Saegusa H, 2001, J BACTERIOL, V183, P94, DOI 10.1128/JB.183.1.94-100.2001; Sambrook J., 2002, MOL CLONING LAB MANU; Scandola M, 1997, MACROMOLECULES, V30, P2568, DOI 10.1021/ma961431y; Scandola M, 1997, MACROMOLECULES, V30, P7743, DOI 10.1021/ma970989i; SCANDOLA M, 1988, INT J BIOL MACROMOL, V10, P373, DOI 10.1016/0141-8130(88)90032-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SchmidtDannert C, 1996, BBA-LIPID LIPID MET, V1301, P105, DOI 10.1016/0005-2760(96)00027-6; STEINBUCHEL A, 1995, CAN J MICROBIOL, V41, P94, DOI 10.1139/m95-175; STINSON MW, 1974, J BACTERIOL, V119, P152, DOI 10.1128/JB.119.1.152-161.1974; STUART ES, 1995, CAN J MICROBIOL, V41, P84, DOI 10.1139/m95-174; STUER W, 1986, J BACTERIOL, V168, P1070, DOI 10.1128/jb.168.3.1070-1074.1986; SVENDSEN A, 1995, BBA-LIPID LIPID MET, V1259, P9, DOI 10.1016/0005-2760(95)00117-U; WICZOREK R, 1995, J BACTERIOL, V177, P2425	46	111	116	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36215	36224		10.1074/jbc.M101106200	http://dx.doi.org/10.1074/jbc.M101106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11457823	hybrid			2022-12-25	WOS:000171194500024
J	Kataoka, K; Shioda, S; Yoshitomo-Nakagawa, K; Handa, H; Nishizawa, M				Kataoka, K; Shioda, S; Yoshitomo-Nakagawa, K; Handa, H; Nishizawa, M			Maf and Jun nuclear oncoproteins share downstream target genes for inducing cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER TRANSCRIPTION FACTOR; C-MAF; EMBRYO FIBROBLASTS; CRYSTALLIN GENE; BASIC DOMAIN; V-MAF; EXPRESSION; ONCOGENE; FAMILY; LENS	The Maf oncoprotein is a basic leucine zipper (bZip)-bearing transcriptional activator that recognizes the Maf recognition element (MARE) DNA sequence. In this study, we investigated the role of Maf's transactivation function in cell transformation. Replacement of the conserved amino terminus transactivator domain of Maf by a heterologous and stronger transactivator domain (the acidic transactivator domain of VP16) resulted in enhanced transformation of chicken embryo fibroblast cells. In contrast, the fusing of a transcriptional repressor domain (Sin3 interaction domain of Mxi1) with the whole Maf protein masked the transactivator function of Maf, which in turn inhibited its transforming activity. Furthermore, the leucine zipper domain of Maf, which defines its dimer-forming specificity, was exchangeable with that of GCN4 yeast protein in terms of its transactivating and cell transforming activities. Thus, heterodimer formation with other bZip factors is not required for Maf's ability to transform. These results together suggest that transactivation through MARE is necessary for Maf-induced transformation and that there exist downstream target gene(s) for transformation. Since the MARE sequence overlaps with the recognition element of another bZip oncoprotein Jun, we assessed whether Jun and Maf induce cell transformation through activating the same genes. We thus constructed a mutated version of Jun that has a GCN4 leucine zipper and lacks the transactivator domain. This mutant repressed the cell transformation not only by Jun but also by Maf. Thus, Maf and Jun share downstream target gene(s) that are involved in cell transformation.	Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Univ Tokyo, Inst Med Sci, Dept Virol, Minato Ku, Tokyo 1088639, Japan; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Tokyo Institute of Technology; University of Tokyo; Scripps Research Institute	Kataoka, K (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.							Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; Kataoka K, 1996, ONCOGENE, V12, P53; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Li MF, 1999, J VIROL, V73, P9178, DOI 10.1128/JVI.73.11.9178-9186.1999; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUO I, 1992, NUCLEIC ACIDS RES, V20, P3701, DOI 10.1093/nar/20.14.3701; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; PENN MD, 1984, MOL CELL BIOL, V4, P520, DOI 10.1128/MCB.4.3.520; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; SAKAI M, 1995, CANCER RES, V55, P5370; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36849	36856		10.1074/jbc.M102234200	http://dx.doi.org/10.1074/jbc.M102234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11461901	hybrid			2022-12-25	WOS:000171194500105
J	Coulie, B; Matsuura, B; Dong, MQ; Hadac, EM; Pinon, DI; Feighner, SD; Howard, AD; Miller, LJ				Coulie, B; Matsuura, B; Dong, MQ; Hadac, EM; Pinon, DI; Feighner, SD; Howard, AD; Miller, LJ			Identification of peptide ligand-binding domains within the human motilin receptor using photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE SECRETAGOGUE; AMINO-ACID; CHOLECYSTOKININ; ANALOGS; SITE; ERYTHROMYCIN; STOMACH; PORTION	The cDNA encoding the human motilin receptor was recently cloned and found to represent a G protein-coupled receptor that is structurally related to the growth hormone secretagogue receptors. Together, these represent a new Class I receptor family. Our aim in the present work is to gain insight into the molecular basis of binding of motilin to its receptor using photoaffinity labeling. To achieve this, we developed a Chinese hamster ovary cell line that overexpressed functional motilin receptor (CHO-MtIR; 175,000 sites per cell, with K-i = 2.3 +/- 0.4 nM motilin and EC50 = 0.3 +/- 0.1 nM motilin) and a radioiodinatable peptide analogue of human motilin that incorporated a photolabile p-benzoyl-L-phenyl-alanine (Bpa) residue into its pharmacophoric domain. This probe, [Bpa(1),Ile(13)]motilin, was a full agonist at the motilin receptor that increased intracellular calcium in a concentration-dependent manner (EC50 = 1.5 0.4 nm). This photolabile ligand bound specifically and with high affinity to the motilin receptor (K-i = 12.4 +/- 1.0 nM), and covalently labeled that molecule within its M-r = 45,000 deglycosylated core. Cyanogen bromide cleavage demonstrated its covalent attachment to fragments of the receptor having apparent M-r = 6,000 and M-r = 31,000. These were demonstrated to represent fragments that included both the first and the large second extracellular loop domains, with the latter representing a unique structural feature of this receptor. The spatial approximation of the pharmacophoric domain of motilin with these receptor domains support their functional importance as well.	Mayo Clin & Mayo Fdn, Dept Internal Med, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem Mol Biol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA	Mayo Clinic; Mayo Clinic; Merck & Company	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, Ctr Basic Res Digest Dis, Guggenheim 17,200 1st St SW, Rochester, MN 55905 USA.							BOULANGER Y, 1995, INT J PEPT PROT RES, V46, P527; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Hosoda H, 2000, J BIOL CHEM, V275, P21995, DOI 10.1074/jbc.M002784200; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Itoh Z, 1997, PEPTIDES, V18, P593, DOI 10.1016/S0196-9781(96)00333-6; JANSSENS J, 1983, REGUL PEPTIDES, V6, P363, DOI 10.1016/0167-0115(83)90265-3; JANSSENS J, 1990, NEW ENGL J MED, V322, P1028, DOI 10.1056/NEJM199004123221502; KAUER JC, 1986, J BIOL CHEM, V261, P695; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; MILLER P, 1995, PEPTIDES, V16, P11, DOI 10.1016/0196-9781(94)00148-Y; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAMOTO C, 1995, BIOCHEMISTRY-US, V34, P10546, DOI 10.1021/bi00033a029; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEETERS TL, 1992, PEPTIDES, V13, P1103, DOI 10.1016/0196-9781(92)90014-T; PEETERS TL, 1993, GASTROENTEROLOGY, V105, P1886, DOI 10.1016/0016-5085(93)91089-Z; POITRAS P, 1992, BIOCHEM BIOPH RES CO, V183, P36, DOI 10.1016/0006-291X(92)91605-P; POITRAS P, 1994, BIOCHEM BIOPH RES CO, V205, P449, DOI 10.1006/bbrc.1994.2686; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	26	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35518	35522		10.1074/jbc.M104489200	http://dx.doi.org/10.1074/jbc.M104489200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461914	hybrid			2022-12-25	WOS:000171109300042
J	Ensenberger, MG; Tomasini-Johansson, BR; Sottile, J; Ozeri, V; Hanski, E; Mosher, DF				Ensenberger, MG; Tomasini-Johansson, BR; Sottile, J; Ozeri, V; Hanski, E; Mosher, DF			Specific interactions between F1 adhesin of Streptococcus pyogenes and N-terminal modules of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; STAPHYLOCOCCUS-AUREUS; BINDING-PROTEIN; I MODULES; EPITHELIAL-CELLS; CROSS-LINKING; FACTOR-XIIIA; MATRIX; FIBROBLASTS; FRAGMENT	Protein F1 is a surface protein of Streptococcus pyogenes that mediates high affinity binding to fibronectin (Fn) and facilitates S. pyogenes adherence and penetration into cells. The smallest portion of F1 known to retain the full binding potential of the intact protein is a stretch of 49 amino acids known as the functional upstream domain (FUD). Synthetic and recombinant versions of FUD were labeled with fluorescein isothiocyanate and used in fluorescence anisotropy experiments. These probes bound to Fn or the 70-kDa fragment of Fn with dissociation constants of 8-30 nM. Removal of the N-terminal seven residues of FUD did not cause a change in binding affinity. Further N- or C-terminal truncations resulted in complete loss of binding activity. Analysis of recombinant versions of the 70-kDa fragment that lacked one or several type I modules indicates that residues 1-7 of the 49-mer bind to type I modules I1 and I2 of the 27-kDa subfragment and the C-terminal residues bind to modules I4 and I5. Fluorescein isothiocyanate-labeled 49-mer also bound with lower affinity to large Fn fragments that lack the five type I modules of the 27-kDa fragment but contain the other seven type I modules of Fn. These results indicate that, although FUD has a general affinity for type I modules, high affinity binding of FUD to Fn is mediated by specific interactions with N-terminal type I modules.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14624 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Clin Microbiol, IL-91010 Jerusalem, Israel	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Rochester; Hebrew University of Jerusalem	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, 4285 MSC,1300 Univ Ave, Madison, WI 53706 USA.		hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050549, R01HL021644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50549, HL21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; Burton-Wurster N, 1999, BIOCHEM J, V341, P555, DOI 10.1042/0264-6021:3410555; Cleary P P, 2000, Subcell Biochem, V33, P137; Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897; GRECO R, 1995, RES MICROBIOL, V146, P551, DOI 10.1016/0923-2508(96)80561-4; Hanski E, 1996, ADV EXP MED BIOL, V408, P141; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; HUFF S, 1994, J BIOL CHEM, V269, P15563; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; Hynes RO, 1990, FIBRONECTINS; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; Kishore R, 1997, J BIOL CHEM, V272, P17078, DOI 10.1074/jbc.272.27.17078; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; Mosher, 1989, FIBRONECTIN, P1; MOSHER DF, 1980, J BIOL CHEM, V255, P1181; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; Neeman R, 1998, LANCET, V352, P1974, DOI 10.1016/S0140-6736(97)12452-7; Okada N, 1997, J BIOL CHEM, V272, P26978, DOI 10.1074/jbc.272.43.26978; Osterlund A, 1997, LARYNGOSCOPE, V107, P640; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Penkett CJ, 2000, BIOCHEMISTRY-US, V39, P2887, DOI 10.1021/bi992267k; Potts JR, 1996, MATRIX BIOL, V15, P313, DOI 10.1016/S0945-053X(96)90133-X; Potts JR, 1999, BIOCHEMISTRY-US, V38, P8304, DOI 10.1021/bi990202b; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SMITH DE, 1982, J BIOL CHEM, V257, P5831; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; Sottile J, 1997, BIOCHEM J, V323, P51, DOI 10.1042/bj3230051; Tomasini-Johansson BR, 2001, J BIOL CHEM, V276, P23430, DOI 10.1074/jbc.M103467200; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; Yamada KM, 1989, FIBRONECTIN, P47	36	32	34	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35606	35613		10.1074/jbc.M105417200	http://dx.doi.org/10.1074/jbc.M105417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11468286	hybrid			2022-12-25	WOS:000171109300054
J	Garrison, S; Hojgaard, A; Patillo, D; Weis, JJ; Weis, JH				Garrison, S; Hojgaard, A; Patillo, D; Weis, JJ; Weis, JH			Functional characterization of pactolus, a beta-integrin-like protein preferentially expressed by neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; A-DOMAIN; COMPLEMENT; RECEPTOR; DISTINCT; ANTIGEN; IDENTIFICATION; LOCALIZATION; CD11B/CD18; MUTATIONS	Murine Pactolus is a beta -integrin-like molecule expressed exclusively on the surface of granulocytes. Cell surface expression of Pactolus is dramatically increased following activation of bone marrow neutrophils with known agonists, and cross-linking of cell surface Pactolus, suggesting the bulk of the protein is in intracellular stores. The mature protein is found in two forms depending upon the extent of N-linked glycosylation. There is no evidence to suggest that Pactolus requires an associated a chain for expression. In some mouse strains, a truncated form of the protein is predicted based upon alternative splicing: this form, however, is unstable and rapidly degraded after synthesis. Differences in the quantities of these Pactolus mRNA isoforms have defined two alleles. BALB/c and C3H/HeJ mice possess allele B and preferentially express the truncated, unstable product, whereas C57BL/6 mice possess allele A and only produce the membrane-bound form. Sequence analysis has shown the difference between these two alleles is due to a single base pair difference at the splice acceptor site for the truncated product. The increased expression of the membrane form of Pactolus by granulocytes of C57BL/6 mice suggests a compensatory adhesion function that is reduced in cells from the low producing strains.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Weis, JH (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	john.weis@path.utah.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042032, R01AI024158, R01AI032223, R56AI032223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043521] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24158, AI-42032, AI-32223] Funding Source: Medline; NIAMS NIH HHS [AR-43521] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAJT ML, 1994, J BIOL CHEM, V269, P20913; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Chen YY, 1998, J BIOL CHEM, V273, P8711, DOI 10.1074/jbc.273.15.8711; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; HATHCOCK KS, 1992, J IMMUNOL, V149, P2286; HESTDAL K, 1991, J IMMUNOL, V147, P22; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; Kumar A, 1997, BLOOD, V89, P4555, DOI 10.1182/blood.V89.12.4555; Lander E S, 1997, Harvey Lect, V93, P35; Margraf RL, 1999, MAMM GENOME, V10, P1075, DOI 10.1007/s003359901164; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Mulligan MS, 1998, INFLAMMATION, V22, P327, DOI 10.1023/A:1022356301181; O'Neil JP, 1998, MUTAT RES-REV MUTAT, V411, P179, DOI 10.1016/S1383-5742(98)00013-1; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; SENGELOV H, 1994, J IMMUNOL, V153, P804; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; Tan S S, 1992, PCR Methods Appl, V2, P137; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; WILSON RW, 1989, NUCLEIC ACIDS RES, V17, P5397, DOI 10.1093/nar/17.13.5397; Wolfe PC, 1996, J BIOL CHEM, V271, P6658, DOI 10.1074/jbc.271.12.6658	27	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35500	35511		10.1074/jbc.M104369200	http://dx.doi.org/10.1074/jbc.M104369200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461913	hybrid			2022-12-25	WOS:000171109300040
J	Goitsuka, R; Tatsuno, A; Ishiai, M; Kurosaki, T; Kitamura, D				Goitsuka, R; Tatsuno, A; Ishiai, M; Kurosaki, T; Kitamura, D			MIST functions through distinct domains in immunoreceptor signaling in the presence and absence of LAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; BRUTONS TYROSINE KINASE; ADAPTER PROTEIN SLP-76; T-CELL; PHOSPHOLIPASE C-GAMMA-2; MEDIATED ACTIVATION; B-CELLS; CATALYTIC ACTIVITY; MOLECULAR-CLONING; LINKER PROTEIN	MIST (also termed Clnk) is an adaptor protein structurally related to SLP-76 and BLNY./BASWSLP-65 hematopoietic cell-specific adaptor proteins. By using the BLNK-deficient DT40 chicken B cell system, we demonstrated MIST functions through distinct intramolecular domains in immunoreceptor signaling depending on the availability of linker for activation of T cells (LAT). MIST can partially restore the B cell antigen receptor (BCR) signaling in the BLNK-deficient cells, which requires phosphorylation of the two N-terminal tyrosine residues. Co-expression of LAT with MIST fully restored the BCR signaling and dispenses with the requirement of the two tyrosines in MIST for BCR signaling. However, some other tyrosine(s), as well as the Src homology (SH) 2 domain and the two proline-rich regions in MIST is still required for full reconstitution of the BCR signaling, in cooperation with LAT. The C-terminal proline-rich region of MIST is dispensable for the LAT-aided full restoration of MAP kinase activation, although it is responsible for the interaction with LAT and for the localization in glycolipid-enriched microdomains. On the other hand, the N-terminal proline-rich region, which is a binding site of the SH3 domain of phospholipase Cy, is essential for BCR signaling. These results revealed a marked plasticity of MIST function as an adaptor in the cell contexts with or without LAT.	Sci Univ Tokyo, Res Inst Biol Sci, Div Mol Biol, Noda, Chiba 2780022, Japan; Japan Sci Technol Corp, Precursory Res Embryon Sci & Technol, Inheritance & Variat Grp, Noda, Chiba 278, Japan; Kansai Univ, Sch Med, Inst Hepatol, Div Mol Genet, Moriguchi, Osaka 5708506, Japan	Tokyo University of Science; Japan Science & Technology Agency (JST); Kansai University	Goitsuka, R (corresponding author), Sci Univ Tokyo, Res Inst Biol Sci, Div Mol Biol, 2669 Yamazaki, Noda, Chiba 2780022, Japan.							Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Cao MY, 1999, J EXP MED, V190, P1527, DOI 10.1084/jem.190.10.1527; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Goitsuka R, 2000, INT IMMUNOL, V12, P573, DOI 10.1093/intimm/12.4.573; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; Horstman DA, 1999, ARCH BIOCHEM BIOPHYS, V361, P149, DOI 10.1006/abbi.1998.0978; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Peterson EJ, 1999, EUR J IMMUNOL, V29, P2223, DOI 10.1002/(SICI)1521-4141(199907)29:07<2223::AID-IMMU2223>3.0.CO;2-6; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Pivniouk VI, 1999, J CLIN INVEST, V103, P1737; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	49	14	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					36043	36050		10.1074/jbc.M106390200	http://dx.doi.org/10.1074/jbc.M106390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11463797	hybrid			2022-12-25	WOS:000171109300109
J	Kotani, M; Detheux, M; Vandenbbogaerde, A; Communi, D; Vanderwinden, JM; Le Poul, E; Brezillon, S; Tyldesley, R; Suarez-Huerta, N; Vandeput, F; Blanpain, C; Schiffmann, SN; Vassart, G; Parmentier, M				Kotani, M; Detheux, M; Vandenbbogaerde, A; Communi, D; Vanderwinden, JM; Le Poul, E; Brezillon, S; Tyldesley, R; Suarez-Huerta, N; Vandeput, F; Blanpain, C; Schiffmann, SN; Vassart, G; Parmentier, M			The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN-RELEASING PEPTIDE; BINDING; NEUROPEPTIDE; PROMOTER; CELLS	Natural peptides displaying agonist activity on the orphan G protein-coupled receptor GPR54 were isolated from human placenta. These 54-, 14,- and 13-amino acid peptides, with a common RF-amide C terminus, derive from the product of KiSS-1, a metastasis suppressor gene for melanoma cells, and were therefore designated kisspeptins. They bound with low nanomolar affinities to rat and human GPR54 expressed in Chinese hamster ovary K1 cells and stimulated PIP2 hydrolysis, Ca2+ mobilization, arachidonic acid release, ERK1/2 and p38 MAP kinase phosphorylation, and stress fiber formation but inhibited cell proliferation. Human GPR54 was highly expressed in placenta, pituitary, pancreas, and spinal cord, suggesting a role in the regulation of endocrine function. Stimulation of oxytocin secretion after kisspeptin administration to rats confirmed this hypothesis.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Free Univ Brussels, Gen Med Serv, B-1070 Brussels, Belgium; Euroscreen SA, B-1070 Brussels, Belgium; Micromass Ltd, Manchester M23 9LZ, Lancs, England; Free Univ Brussels, Neurophysiol Lab, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), Free Univ Brussels, IRIBHN, Campus Erasme,Route Lennik 808, B-1070 Brussels, Belgium.	mparment@ulb.ac.be	Blanpain, Cedric/ABD-8392-2021	BREZILLON, stephane/0000-0001-7954-8340; Parmentier, Marc/0000-0001-8081-4685; Schiffmann, Serge/0000-0002-0118-9816				Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Civelli O, 2001, TRENDS NEUROSCI, V24, P230, DOI 10.1016/S0166-2236(00)01763-X; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Guillemot L, 2000, J BIOL CHEM, V275, P26349, DOI 10.1074/jbc.M001614200; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kotani M, 2001, BRIT J PHARMACOL, V133, P138, DOI 10.1038/sj.bjp.0704038; Langmead CJ, 2000, BRIT J PHARMACOL, V131, P683, DOI 10.1038/sj.bjp.0703617; Lee DK, 1999, FEBS LETT, V446, P103, DOI 10.1016/S0014-5793(99)00009-5; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Thibonnier M, 2000, AM J PHYSIOL-HEART C, V279, pH2529, DOI 10.1152/ajpheart.2000.279.5.H2529; West A, 1998, GENOMICS, V54, P145, DOI 10.1006/geno.1998.5566; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200	23	1146	1231	0	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34631	34636		10.1074/jbc.M104847200	http://dx.doi.org/10.1074/jbc.M104847200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457843	hybrid			2022-12-25	WOS:000171024600040
J	Li, J; Zhang, S; Wang, CC				Li, J; Zhang, S; Wang, CC			Effects of macromolecular crowding on the refolding of glucose-6-phosphate dehydrogenase and protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROEL; INTERMEDIATE; CONSEQUENCES; BINDING; VOLUME	The effects of polysaccharide, polyethylene glycol, and protein-crowding agents on the refolding of glucose-6-phosphate dehydrogenase (G6PDH) and protein disulfide isomerase have been examined. By increasing concentration during refolding, the reactivation yields of the two proteins decrease with the formation of soluble aggregates. In the presence of high concentrations of crowding agents the reactivation yields remain constant but with decreased refolding rates. The refolding of G6PDH changes from monophasic to biphasic first-order reactions in the presence of crowding agents, and the amplitude of the new slow phase increases with increasing concentrations of crowding agents. The molecular chaperone GroEL reverses the refolding kinetics of G6PDH from biphase back to monophase and accelerates the refolding process. Our results display the complexity and diversity of the effects of macromolecular crowding on both the thermodynamics and kinetics of protein folding.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, CC (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Creighton TE, 1997, BIOL CHEM, V378, P731; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; ELLIS RJ, 1997, CURR BIOL, V7, P531; Galan A, 2001, J BIOL CHEM, V276, P957, DOI 10.1074/jbc.M006861200; Gervasoni P, 1998, J MOL BIOL, V275, P663, DOI 10.1006/jmbi.1997.1481; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HU CH, 1988, CHIN BIOCH J, V4, P61; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; Li J, 1999, J BIOL CHEM, V274, P10790, DOI 10.1074/jbc.274.16.10790; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; MINTON AP, 1992, BIOPHYS J, V63, P1090, DOI 10.1016/S0006-3495(92)81663-6; MINTON AP, 1992, P NATL ACAD SCI USA, V89, P10504, DOI 10.1073/pnas.89.21.10504; MORJANA NA, 1993, P NATL ACAD SCI USA, V90, P2107, DOI 10.1073/pnas.90.6.2107; PLOMER JJ, 1993, BIOCHIM BIOPHYS ACTA, V1163, P89, DOI 10.1016/0167-4838(93)90283-W; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; van den Berg B, 2000, EMBO J, V19, P3870, DOI 10.1093/emboj/19.15.3870; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; YUE RH, 1969, J BIOL CHEM, V244, P1353; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	24	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34396	34401		10.1074/jbc.M103392200	http://dx.doi.org/10.1074/jbc.M103392200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11445570	hybrid			2022-12-25	WOS:000171024600007
J	Rizzo, MA; Kraft, CA; Watkins, SC; Levitan, ES; Romero, G				Rizzo, MA; Kraft, CA; Watkins, SC; Levitan, ES; Romero, G			Agonist-dependent traffic of Raft-associated Ras and Raf-1 is required for activation of the mitogen-activated protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; RECEPTOR ENDOCYTOSIS; PHOSPHATIDIC-ACID; LIPID RAFTS; CHOLESTEROL; LOCALIZATION; RECRUITMENT; PATHWAYS; VESICLES	Stimulation of HIRcB fibroblasts with insulin leads to accumulation of active components of the mitogen-activated protein kinase cascade in endocytic compartments. However, the factors that regulate the mobilization of these components through the endocytic pathway and the relevance of this event to cellular signaling remain unclear. Here we report that Ras proteins are associated with lipid rafts in resting HIRcB fibroblasts. Ras is rapidly internalized into the endocytic compartment following stimulation with insulin. The redistribution of Ras is independent of its activation. Attachment of the C-terminal 20 amino acids of Ha-Ras to green fluorescent protein was sufficient to target this construct to the same loci as the endogenous Ras protein, indicating that Ras distribution is a consequence of the association of its lipid modified C terminus with membranes. Depletion of plasma membrane cholesterol delocalized Ras and blocked insulin-dependent Ras traffic. Cholesterol depletion also blocked insulin-dependent phosphorylation of MEK and mitogen-activated protein kinase (MAPK) but had no effects on the translocation and activation of Raf-1. A second inhibitor of endocytosis, cytochalasin D, also blocked insulin-dependent MAPK phosphorylation. Taken together, these results suggest that mobilization of active Raf-1 through the endocytic compartment is required for completion of the MAPK cascade.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Romero, G (corresponding author), Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA.	ggr@pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054782, R01DK051183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054813] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK54782, R01-DK51183] Funding Source: Medline; NIGMS NIH HHS [T32-GM54813] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD D, 1989, METHOD CELL BIOL, V30, P245; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Chiariello M, 1999, FEBS LETT, V453, P20, DOI 10.1016/S0014-5793(99)00686-9; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GODDETTE DW, 1986, J BIOL CHEM, V261, P5974; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mobius W, 1999, J HISTOCHEM CYTOCHEM, V47, P1005; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROMERO G, 1990, P NATL ACAD SCI USA, V87, P1476, DOI 10.1073/pnas.87.4.1476; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Stewart S, 1999, MOL CELL BIOL, V19, P5523; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang TY, 2000, BIOPHYS J, V79, P919, DOI 10.1016/S0006-3495(00)76347-8; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	46	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34928	34933		10.1074/jbc.M105918200	http://dx.doi.org/10.1074/jbc.M105918200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11466321	hybrid			2022-12-25	WOS:000171024600078
J	Wang, YX; Kauffman, EJ; Duex, JE; Weisman, LS				Wang, YX; Kauffman, EJ; Duex, JE; Weisman, LS			Fusion of docked membranes requires the armadillo repeat protein Vac8p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOTYPIC VACUOLE FUSION; SEMLIKI-FOREST-VIRUS; SACCHAROMYCES-CEREVISIAE; SNARE COMPLEX; T-SNARE; SEC18P NSF; SYNAPTIC VESICLES; YEAST VACUOLES; GTPASE YPT7P; ALPHA-SNAP	The discovery of molecules required for membrane fusion has revealed a remarkably conserved mechanism that centers upon the formation of a complex of SNARE proteins. However, whether the SNARE proteins or other components catalyze the final steps of membrane fusion in vivo remains unclear. Understanding this last step depends on the identification of molecules that act late in the fusion process. Here we demonstrate that in Saccharomyces cerevisiae, Vac8p, a myristoylated and palmitoylated armadillo repeat protein, is required for homotypic vacuole fusion. Vac8p is palmitoylated during the fusion reaction, and the ability of Vac8p to be palmitoylated appears to be necessary for its function in fusion. Both in vivo and in vitro analyses show that Vac8p functions after both Rab-dependent vacuole docking and the formation of trans-SNARE pairs. We propose that Vac8p may bind the fusion machinery through its armadillo repeats and that palmitoylation brings this machinery to a specialized lipid domain that facilitates bilayer mixing.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Weisman, LS (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.				NIGMS NIH HHS [GM50403] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050403] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; Catlett NL, 1998, P NATL ACAD SCI USA, V95, P14799, DOI 10.1073/pnas.95.25.14799; Chatterjee PK, 2000, J VIROL, V74, P1623, DOI 10.1128/JVI.74.4.1623-1631.2000; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DEMESQUITA DSG, 1991, J GEN MICROBIOL, V137, P2447, DOI 10.1099/00221287-137-10-2447; Fleckenstein D, 1998, J CELL SCI, V111, P3109; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; HAAS A, 1995, METHODS CELL SCI, V17, P238; KIELIAN MC, 1984, J VIROL, V52, P281, DOI 10.1128/JVI.52.1.281-283.1984; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Lonart G, 2000, J BIOL CHEM, V275, P27703; Mayer A, 2000, MOL BIOL CELL, V11, P807, DOI 10.1091/mbc.11.3.807; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Pan XZ, 2000, MOL BIOL CELL, V11, P2445, DOI 10.1091/mbc.11.7.2445; Pan XZ, 1998, J CELL SCI, V111, P2137; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; Price A, 2000, J CELL BIOL, V148, P1223, DOI 10.1083/jcb.148.6.1223; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Wang YX, 1996, MOL BIOL CELL, V7, P1375, DOI 10.1091/mbc.7.9.1375; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	56	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35133	35140		10.1074/jbc.M103937200	http://dx.doi.org/10.1074/jbc.M103937200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11441010	hybrid			2022-12-25	WOS:000171024600103
J	Brodt, P; Fallavollita, L; Khatib, AM; Samani, AA; Zhang, DL				Brodt, P; Fallavollita, L; Khatib, AM; Samani, AA; Zhang, DL			Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; BREAST-CARCINOMA CELLS; SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION; ANTISENSE RNA; TYROSINE PHOSPHORYLATION; ALPHA-V-BETA-3 INTEGRIN; TRANSFORMING ACTIVITY; GLIOBLASTOMA CELLS; LIGAND OCCUPANCY	The receptor for the type 1 insulin-like growth factor (IGF-1) regulates multiple cellular functions impacting on the metastatic phenotype of tumor cells, including cellular proliferation, anchorage-independent growth, survival, migration, synthesis of the 72-kDa type IV collagenase and invasion. We have used site-directed mutagenesis to generate domain-specific mutants of the receptor beta subunit to analyze the role of specific tyrosines in the regulation of the invasive/metastatic phenotype. Poorly invasive M-27 carcinoma cells expressing low receptor numbers were transfected with a plasmid vector expressing IGF-1 receptor cDNA in which single or multiple tyrosine codons in the kinase domain, namely Tyr-1131, Tyr-1135, and Tyr-1136 or the C-terminal tyrosines 1250 and 1251 were substituted with phenylalanine. Changes in the invasive and metastatic properties, were analyzed relative to M-27 cells expressing the wild type receptor. We found that cells expressing the Y1131F,Y1135F,Y1136F or Y1135F receptor mutants lost all IGF-ER.-dependent functions and their phenotypes were indistinguishable from, or suppressed relative to, the parent line. The Y1250F,Y1251F substitution abolished anchorage-independent growth, cell spreading, and the anti-apoptotic effect of IGF-I whereas all other IGF-IR-dependent phenotypes were either unperturbed (i.e. mitogenicity) or only partially reduced (migration and invasion). The results identify three types of receptor-dependent functions in this model: those dependent only on an intact kinase domain (DNA synthesis), those dependent equally on kinase domain and Tyr-1250/1251 signaling (e.g. apoptosis, soft agar cloning) and those dependent on kinase domain and enhanced through Tyr-1250/1251 signaling (migration, invasion). They suggest that signals derived from both regions of the receptor cooperate to enhance tumor metastasis.	McGill Univ, Ctr Hlth, Royal Victoria Hosp, Dept Surg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Brodt, P (corresponding author), Royal Victoria Hosp, Div Surg Res, 687 Pine Ave W,Rm H6-25, Montreal, PQ H3A 1A1, Canada.		KHATIB, Abdel-Majid/A-9948-2015	KHATIB, Abdel-Majid/0000-0001-6957-0384				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; Baserga R, 1997, ENDOCRINOLOGY, V138, P2217, DOI 10.1210/en.138.6.2217; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Blakesley VA, 1998, J BIOL CHEM, V273, P18411, DOI 10.1074/jbc.273.29.18411; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; BRODT P, 1986, CANCER RES, V46, P2442; BRODT P, 1996, CELL ADHESION INVASI, P167; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; FERNANDEZSANCHE.C, 1995, J BIOL CHEM, V270, P29176; Filardo EJ, 1996, J CELL SCI, V109, P1615; Fornaro M, 2000, MOL BIOL CELL, V11, P2235, DOI 10.1091/mbc.11.7.2235; GOHEL AR, 1995, J HISTOCHEM CYTOCHEM, V43, P1085, DOI 10.1177/43.11.7560891; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; LI SW, 1994, J BIOL CHEM, V269, P32558; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1994, CANCER RES, V54, P3732; LONG L, 1995, CANCER RES, V55, P1006; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; PHILLIPS PD, 1987, J CELL PHYSIOL, V133, P135, DOI 10.1002/jcp.1041330117; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; RUBIN R, 1995, LAB INVEST, V73, P311; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tawil NJ, 1996, INT J CANCER, V66, P703, DOI 10.1002/(SICI)1097-0215(19960529)66:5<703::AID-IJC20>3.0.CO;2-3; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	55	81	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33608	33615		10.1074/jbc.M102754200	http://dx.doi.org/10.1074/jbc.M102754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445567	hybrid			2022-12-25	WOS:000170910200044
J	Chen, ZS; Lee, K; Kruh, GD				Chen, ZS; Lee, K; Kruh, GD			Transport of cyclic nucleotides and estradiol 17-beta-D-glueuronide by multidrug resistance protein 4 - Resistance to 6-mercaptopurine and 6-thioguanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT VESICLES; EMBRYONIC KIDNEY 293-CELLS; ATRIAL NATRIURETIC FACTOR; DEPENDENT EXPORT PUMP; EPITHELIAL-CELL LINE; HUMAN ERYTHROCYTES; LEUKOTRIENE C-4; MEMBRANE-VESICLES; ANTICANCER AGENTS; DRUG-RESISTANCE	Human multidrug resistance protein 4 (MRP4) has recently been determined to confer resistance to the antiviral purine analog 9-(2-phosphonylmethoxyethy-1)adenine and methotrexate. However, neither its substrate selectivity nor physiological functions have been determined. Here we report the results of investigations of the in vitro transport properties of MRP4 using membrane vesicles prepared from insect cells infected with MRP4 baculovirus. It is shown that expression of MRP4 is specifically associated with the MgATP-dependent transport of cGMP, cAMP, and estradiol 17-beta -D-glucuronide (E(2)17 betaG). cGMP, cAMP, and E(2)17 betaG are transported with K-m and V-max values of 9.7 +/- 2.3 muM and 2.0 +/- 0.3 pmol/mg/min, 44.5 +/- 5.8 muM and 4.1 +/- 0.4 pmol/mg/min, and 30.3 +/- 6.2 muM and 102 +/- 16 pmol/mg/min, respectively. Consistent with its ability to transport cyclic nucleotides, it is demonstrated that the MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purine analogs that are converted in the cell to nucleotide analogs. On the basis of its capacity to transport cyclic nucleotides and E(2)17 betaG, it is concluded that MRP4 may influence diverse cellular processes regulated by cAMP and cGMP and that its substrate range is distinct from that of any other characterized MRP family member.	Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kruh, GD (corresponding author), Fox Chase Canc Ctr, Div Med Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Chen, Zhe-Sheng/0000-0002-8289-097X	NATIONAL CANCER INSTITUTE [U01CA073728, F32CA074518, R01CA073728] Funding Source: NIH RePORTER; NCI NIH HHS [CA74518, CA73728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHMAN DF, 1963, BIOCHEM BIOPH RES CO, V11, P330, DOI 10.1016/0006-291X(63)90566-7; AWASTHI YC, 1981, BLOOD, V58, P733; Belinsky MG, 1998, J NATL CANCER I, V90, P1735, DOI 10.1093/jnci/90.22.1735; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BREUNINGER LM, 1995, CANCER RES, V55, P5342; BROADUS AE, 1970, J CLIN INVEST, V49, P2222, DOI 10.1172/JCI106441; BRUNTON LL, 1988, METHOD ENZYMOL, V159, P83; BRUNTON LL, 1979, J BIOL CHEM, V254, P9714; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; Cui YH, 1999, MOL PHARMACOL, V55, P929; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; FEHR TF, 1990, J BIOL CHEM, V265, P10974; Flens MJ, 1996, AM J PATHOL, V148, P1237; FRIEDLANDER G, 1992, J CLIN INVEST, V90, P848, DOI 10.1172/JCI115960; GOLDENBAUM PE, 1979, J BACTERIOL, V140, P459, DOI 10.1128/JB.140.2.459-467.1979; GRANT CE, 1994, CANCER RES, V54, P357; HAMET P, 1989, J BIOL CHEM, V264, P12364; HEASLEY LE, 1985, MOL PHARMACOL, V27, P60; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hooijberg JH, 1999, CANCER RES, V59, P2532; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; HUANG CL, 1986, P NATL ACAD SCI USA, V83, P8015, DOI 10.1073/pnas.83.20.8015; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kawabe T, 1999, FEBS LETT, V456, P327, DOI 10.1016/S0014-5793(99)00979-5; Keppler D, 1996, Prog Liver Dis, V14, P55; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1997, CANCER RES, V57, P3537; KRUH GD, 1995, J NATL CANCER I, V87, P1256, DOI 10.1093/jnci/87.16.1256; KRUH GD, 1994, CANCER RES, V54, P1649; KUBLER D, 1989, J BIOL CHEM, V264, P14549; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; Lee K, 1998, CANCER RES, V58, P2741; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Madon J, 1997, FEBS LETT, V406, P75, DOI 10.1016/S0014-5793(97)00245-7; MARQUARDT D, 1990, CANCER RES, V50, P1426; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; McAleer MA, 1999, J BIOL CHEM, V274, P23541, DOI 10.1074/jbc.274.33.23541; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; Millul V, 1996, AM J PHYSIOL-CELL PH, V270, pC1051, DOI 10.1152/ajpcell.1996.270.4.C1051; Ortiz DF, 1999, AM J PHYSIOL-GASTR L, V276, pG1493, DOI 10.1152/ajpgi.1999.276.6.G1493; PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16; Pisarev VM, 1997, MOL PHARMACOL, V52, P63, DOI 10.1124/mol.52.1.63; PODEVIN RA, 1980, BIOCHIM BIOPHYS ACTA, V629, P135, DOI 10.1016/0304-4165(80)90272-X; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; ROBBINS BL, 1995, MOL PHARMACOL, V47, P391; Sager G, 1996, SCAND J CLIN LAB INV, V56, P289, DOI 10.3109/00365519609090579; SAIER MH, 1975, J BIOL CHEM, V250, P7593; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schultz C, 1998, BIOCHEMISTRY-US, V37, P1161, DOI 10.1021/bi9713409; SORBERA LA, 1991, SCIENCE, V253, P1286, DOI 10.1126/science.1653970; STEINBERG RA, 1979, J CELL PHYSIOL, V100, P579, DOI 10.1002/jcp.1041000319; STREWLER GJ, 1984, AM J PHYSIOL, V246, pC224, DOI 10.1152/ajpcell.1984.246.3.C224; Sundkvist E, 2000, BBA-BIOMEMBRANES, V1463, P121, DOI 10.1016/S0005-2736(99)00184-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Aubel RAMH, 1998, MOL PHARMACOL, V53, P1062; Vaskinn S, 1999, MOL MEMBR BIOL, V16, P181; WEN SC, 1985, ENDOCRINOLOGY, V116, P935, DOI 10.1210/endo-116-3-935; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; WOODS M, 1991, BIOCHEM PHARMACOL, V41, P385, DOI 10.1016/0006-2952(91)90535-D; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zeng H, 1999, CANCER RES, V59, P5964; Zeng H, 2000, CANCER RES, V60, P4779	73	332	341	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33747	33754		10.1074/jbc.M104833200	http://dx.doi.org/10.1074/jbc.M104833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11447229	hybrid			2022-12-25	WOS:000170910200063
J	Quick, M; Stevens, BR				Quick, M; Stevens, BR			Amino acid transporter CAATCH1 is also an amino acid-gated cation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NA+; CURRENTS; STOICHIOMETRY; COOPERATIVITY; EXCHANGE; WATER; PH	CAATCH1 (cation-(a) under bar mino (a) under bar cid (t) under bar ransporter/(c) under bar hannel) is a recently cloned insect epithelial membrane protein related to mammalian Na+-, Cl--coupled neurotransmitter transporters (Feldman, D. H., Harvey, W. R., and Stevens, B. R. (2000) J. BioL Chem. 275,24518-24526). In the present study we analyze the relationship between CAATCH1-mediated amino acid transport and ion fluxes by utilizing the Xenopus oocyte expression system in conjunction with electrophysiology and radiotracer uptake. Simultaneous flux measurements reveal that electrical currents and amino acid transport are thermodynamically uncoupled. This observation is supported by measuring significant uptake even in the absence of external alkali cations. Remarkably, CAATCH1-associated Na+ or K+ currents are large and do not saturate with voltage nor with cation concentration. These currents reverse in Nernstian fashion, thereby conferring channel activity in CAATCH1. Upon step-changes in the membrane potential, CAATCH1-expressing oocytes exhibit transient currents. Detailed analyses of these transients in the absence and presence of amino acids reveal direct ligand-protein interaction, demonstrating that binding by different amino acids (e.g. proline, threonine, methionine) differentially affects the state probability of CAATCH1 but has no effect on the maximal charge movement (Q(max)). Together these data suggest that CAATCH1 is a multifunction membrane protein that mediates thermodynamically uncoupled amino acid uptake but functions predominantly as an,amino acid-gated alkali cation channel.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; State University System of Florida; University of Florida	Quick, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	mquick@mednet.ucla.edu			NIAID NIH HHS [AI30464] Funding Source: Medline; NIDDK NIH HHS [DK19567] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030464, R56AI030464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSI E, 2000, PFLUGGERS ARCH, V438, P788; BOSSI E, 2000, J PHYSL, V515, P729; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Broer A, 1999, J NEUROCHEM, V73, P2184; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Diez-Sampedro A, 2001, AM J PHYSIOL-RENAL, V280, pF278, DOI 10.1152/ajprenal.2001.280.2.F278; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Feldman DH, 2000, J BIOL CHEM, V275, P24518, DOI 10.1074/jbc.M907582199; FORSEN S, 1995, TRENDS BIOCHEM SCI, V20, P495, DOI 10.1016/S0968-0004(00)89115-X; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Forster IC, 1999, AM J PHYSIOL-RENAL, V276, pF644, DOI 10.1152/ajprenal.1999.276.4.F644; Galli A, 1997, J NEUROSCI, V17, P3401; GERENCSER GA, 1994, J EXP BIOL, V196, P59; GUIDOTTI GG, 1992, MAMMALIAN AMINO ACID TRANSPORT, P3; LEONARDI MG, 1998, AM J PHYSIOL, V274, P1372; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 1999, J PHYSIOL-LONDON, V518, P195, DOI 10.1111/j.1469-7793.1999.0195r.x; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; MONTICELLI G, 1985, COMP BIOCHEM PHYS A, V80, P425, DOI 10.1016/0300-9629(85)90062-3; Nelson N, 1998, J NEUROCHEM, V71, P1785; Peres A, 2000, J PHYSIOL-LONDON, V525, P83, DOI 10.1111/j.1469-7793.2000.t01-1-00083.x; QUICK M, 2001, J BIOL CHEM, V276, P1278; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Sonders MS, 1997, J NEUROSCI, V17, P960; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; Taylor PM, 1996, J EXP BIOL, V199, P923; Torres-Zamorano V, 1998, BIOCHEM BIOPH RES CO, V245, P824, DOI 10.1006/bbrc.1998.8434; TREHERNE JE, 1962, NATURE, V193, P750, DOI 10.1038/193750a0; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	34	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33413	33418		10.1074/jbc.M104438200	http://dx.doi.org/10.1074/jbc.M104438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445577	hybrid			2022-12-25	WOS:000170910200018
J	Sadoski, RC; Zaslavsky, D; Gennis, RB; Durham, B; Millett, F				Sadoski, RC; Zaslavsky, D; Gennis, RB; Durham, B; Millett, F			Exposure of bovine cytochrome c oxidase to high Triton X-100 or to alkaline conditions causes a dramatic change in the rate of reduction of compound F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; PROTON-TRANSFER; DIOXYGEN; STATE; BEEF; FORM; PH	The final step in the catalytic cycle of cytochrome oxidase, the reduction of oxyferryl heme a(3) in compound F, was investigated using a binuclear polypyridine ruthenium complex ([Ru(bipyridine)(2)](2)(1,4-bis[2-(4 ' -methyl-2, 2 ' -bipyrid-4-yl)ethenyl]benzene)(PF6)(4)) as a photoactive reducing agent. In the untreated dimeric enzyme, the rate constant for reduction of compound F decreased from 700 s(-1) to 200 s(-1) as the pH was increased from 7.5 to 9.5. Incubation of dimeric enzyme at pH 10 led to an increase in the rate constant to 1650 s(-1), which was independent of pH between pH 7.4 and 10. This treatment resulted in a decrease in the sedimentation coefficient consistent with the irreversible conversion of the enzyme to a monomeric form. Similar results were obtained when the enzyme was incubated with Triton X-100 at pH 8.0. These treatments, which have traditionally been used to convert dimeric enzyme to monomeric form, have no effect on the steady state activity. The data indicate that either the conversion of the bovine oxidase to a monomeric form or some structural change coincident with this conversion strongly influences the rate constant of this step in the catalytic cycle, perhaps by influencing the proton access to the heme-copper binuclear center.	Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Illinois System; University of Illinois Urbana-Champaign	Millett, F (corresponding author), Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA.	millett@uark.edu			NCRR NIH HHS [RR15569] Funding Source: Medline; NHLBI NIH HHS [HL16101] Funding Source: Medline; NIGMS NIH HHS [GM20488] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016101, R37HL016101] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABA AI, 1995, INORG CHEM, V34, P1198, DOI 10.1021/ic00109a030; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BLAIR DF, 1982, BIOCHEMISTRY-US, V21, P6928, DOI 10.1021/bi00269a048; BLAIR DF, 1983, CHEM SCRIPTA, V21, P43; BOLLI R, 1985, ARCH BIOCHEM BIOPHYS, V240, P102, DOI 10.1016/0003-9861(85)90012-8; CAPALDI RA, 1972, FEBS LETT, V26, P261, DOI 10.1016/0014-5793(72)80587-8; ESTEY LA, 1993, BIOCHEMISTRY-US, V32, P13270, DOI 10.1021/bi00211a040; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; GEORGEVICH G, 1983, BIOCHEMISTRY-US, V22, P1317, DOI 10.1021/bi00275a001; HALL J, 1988, J BIOL CHEM, V263, P8142; HALLEN S, 1992, BIOCHEMISTRY-US, V31, P11853, DOI 10.1021/bi00162a025; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; LOVE B, 1970, J BIOL CHEM, V245, P6664; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; OLIVEBERG M, 1989, BIOCHIM BIOPHYS ACTA, V977, P322, DOI 10.1016/S0005-2728(89)80087-8; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; ROBINSON NC, 1986, BIOCHEMISTRY-US, V25, P2328, DOI 10.1021/bi00357a005; SHOWEN KBJ, 1978, TRANSITION STATES BI, P225; SUAREZ MD, 1984, J BIOL CHEM, V259, P3791; THOMPSON DA, 1985, J INORG BIOCHEM, P23357; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Verkhovsky MI, 1996, P NATL ACAD SCI USA, V93, P12235, DOI 10.1073/pnas.93.22.12235; VYGODINA TV, 1988, ANN NY ACAD SCI, V550, P124, DOI 10.1111/j.1749-6632.1988.tb35329.x; Wang KF, 1999, J BIOL CHEM, V274, P38042, DOI 10.1074/jbc.274.53.38042; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; ZASLAVSKY D, 1993, FEBS LETT, V336, P389, DOI 10.1016/0014-5793(93)80843-J; Zaslavsky D, 1998, BIOCHEMISTRY-US, V37, P14910, DOI 10.1021/bi981490z	28	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33616	33620		10.1074/jbc.M103640200	http://dx.doi.org/10.1074/jbc.M103640200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443122	hybrid			2022-12-25	WOS:000170910200045
J	Scheuermann, S; Hambsch, B; Hesse, L; Stumm, J; Schmidt, C; Beher, D; Bayer, TA; Beyreuther, K; Multhaup, G				Scheuermann, S; Hambsch, B; Hesse, L; Stumm, J; Schmidt, C; Beher, D; Bayer, TA; Beyreuther, K; Multhaup, G			Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; CELL-SURFACE; EXTRACELLULAR DOMAIN; HIPPOCAMPAL-NEURONS; NEURITE OUTGROWTH; APP; BETA-A4; COPPER; PHOSPHORYLATION; IDENTIFICATION	We reported previously that the carbohydrate domain of the amyloid precursor protein is involved in amyloid precursor protein (APP)-APP interactions. Functional in vitro studies suggested that this interaction occurs through the collagen binding site of APP. The physiological significance remained unknown, because it is not understood whether and how APP dimerization occurs in vivo. Here we report that cellular APP exists as homodimers matching best with a two-site model. Consistent with our published crystallographic data, we show that a deletion of the entire sequence after the kunitz protease inhibitor domain did not abolish APP homodimerization, suggesting that two domains are criticaIly involved but that neither is essential for homodimerization. Finally, we generated stabilized dimers by expressing mutant APP with a single cysteine in the ectodomain juxtamembrane region. Mutation of Lys(624) to cysteine produced similar to6-8-fold more A beta than cells expressing normal APP. Our results suggest that amyloid A beta production can in principle be positively regulated by dimerization in vivo. We suggest that dimerization could be a physiologically important mechanism for regulating the proposed signal activity of APP.	Heidelberg Univ, ZMBH, Ctr Mol Biol, D-69120 Heidelberg, Germany; Univ Bonn, Med Ctr, Dept Psychiat, D-53105 Bonn, Germany	Ruprecht Karls University Heidelberg; University of Bonn	Multhaup, G (corresponding author), Heidelberg Univ, ZMBH, Ctr Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	g.multhaup@zmbh.uni-heidelberg.de		Beher, Dirk/0000-0001-8005-5359				Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Beher D, 1999, J NEUROCHEM, V72, P1564, DOI 10.1046/j.1471-4159.1999.721564.x; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; Borchardt T, 2000, CELL MOL BIOL, V46, P785; Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Coulson EJ, 2000, NEUROCHEM INT, V36, P175, DOI 10.1016/S0197-0186(99)00125-4; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; Enya M, 1999, AM J PATHOL, V154, P271, DOI 10.1016/S0002-9440(10)65273-X; Freedman RB, 1998, CURR BIOL, V8, pR468, DOI 10.1016/S0960-9822(98)70295-7; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Heber S, 2000, J NEUROSCI, V20, P7951; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Jensen M, 2000, MOL MED, V6, P291, DOI 10.1007/BF03401938; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNOPS J, 1993, BIOCHEM BIOPH RES CO, V197, P380, DOI 10.1006/bbrc.1993.2490; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; McLoughlin DM, 2001, J BIOL CHEM, V276, P9303, DOI 10.1074/jbc.M010023200; Meyer RK, 2000, J BIOL CHEM, V275, P38081, DOI 10.1074/jbc.M007114200; MULTHAUP G, 1994, BIOCHIMIE, V76, P304, DOI 10.1016/0300-9084(94)90163-5; MULTHAUP G, 1994, FEBS LETT, V355, P151, DOI 10.1016/0014-5793(94)01176-1; Neve RL, 2000, BRAIN RES, V886, P54, DOI 10.1016/S0006-8993(00)02869-9; Nishimoto I, 1998, NEUROBIOL AGING, V19, pS33, DOI 10.1016/S0197-4580(98)00040-2; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Peraus GC, 1997, J NEUROSCI, V17, P7714; Perez RG, 1997, J NEUROSCI, V17, P9407; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; Seraphin B, 1996, NUCLEIC ACIDS RES, V24, P3276, DOI 10.1093/nar/24.16.3276; SMALL DH, 1994, J NEUROSCI, V14, P2117; Storey E, 1996, BRAIN RES, V735, P59; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Walter J, 2000, J BIOL CHEM, V275, P23523, DOI 10.1074/jbc.M002850200; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349	51	182	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33923	33929		10.1074/jbc.M105410200	http://dx.doi.org/10.1074/jbc.M105410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438549	hybrid			2022-12-25	WOS:000170910200086
J	Yeagley, D; Guo, SD; Unterman, T; Quinn, PG				Yeagley, D; Guo, SD; Unterman, T; Quinn, PG			Gene- and activation-specific mechanisms for insulin inhibition of basal and glucocorticoid-induced insulin-like growth factor binding protein-1 and phosphoenolpyruvate carboxykinase transcription - Roles of forkhead and insulin response sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC NUCLEAR FACTOR-3; MULTIHORMONAL REGULATION; PROMOTER ACTIVITY; FACTOR FKHR; KINASE-B; FACTOR BINDING-PROTEIN-1; MEDIATED EXPRESSION; BETA ENHANCEOSOME; DOMINANT ROLE; PEPCK GENE	The insulin response sequence (IRS) of the phosphoenolpyruvate carboxykinase (PEPCK) promoter, located within the glucocorticoid response unit, was first characterized by its ability to mediate insulin inhibition when inserted into a thymidine kinase promoter. The IRSs of the PEPCK and insulin-like growth factor binding protein-1 (IGFBP-1) promoters have been proposed to contribute to regulation by glucocorticoids and insulin. Forkhead (FKHR) recognizes IRS sequences, is phosphorylated in response to insulin, and mediates insulin inhibition of basal IGFBP-1 transcription in an IRS-dependent manner. Here, we investigate the contributions of FKHR and IRSs to insulin inhibition of basal and glucocorticoid-induced transcription of PEPCK and IGFBP-1. Expression of T/S/S, in which three putative protein kinase B (PKB) sites in FKHR are mutated, reduced insulin inhibition of basal expression of IGFBP-1 but not PEPCK Mutation of the IGFBP-1 IRSs abolished insulin inhibition in the presence of T/S/S. Mutation of the PEPCK IRS had no effect on insulin inhibition in the presence of T/S/S, indicating that insulin inhibits PEPCK transcription independently of the IRS or of the putative PKB phosphorylation sites in FKHR. Mutations in the IRS or FKHR had no effect on insulin inhibition of glucocorticoid-induced transcription of either the PEPCK or IGFBP-1 gene. Thus, insulin uses gene- and activation-specific mechanisms to regulate the basal and glucocorticoid-induced activity of these genes.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Univ Illinois, Coll Med, Chicago, IL 60612 USA; Chicago Area Vet Hlth Care Syst, W Side Div, Chicago, IL 60612 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Quinn, PG (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, H-166,500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430, R29DK041430] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41430] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHU DTW, 1988, J BIOL CHEM, V263, P13007; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Ellwood K, 1999, MOL CELL BIOL, V19, P2613; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GRANNER D, 1990, J BIOL CHEM, V265, P10173; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Kaestner KH, 2000, GENE DEV, V14, P142; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; Pierreux CE, 1999, MOL CELL ENDOCRINOL, V147, P1, DOI 10.1016/S0303-7207(98)00238-X; Pierreux CE, 1998, MOL ENDOCRINOL, V12, P1343, DOI 10.1210/me.12.9.1343; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Powell David R., 1995, Progress in Growth Factor Research, V6, P93, DOI 10.1016/0955-2235(95)00034-8; POWELL DR, 1991, J BIOL CHEM, V266, P18868; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; SHORT JM, 1986, J BIOL CHEM, V261, P9721; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; SUH DS, 1994, MOL ENDOCRINOL, V8, P794, DOI 10.1210/me.8.6.794; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30335; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Unterman T., 1995, Progress in Growth Factor Research, V6, P119, DOI 10.1016/0955-2235(95)00020-8; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; Waltner-Law M, 2000, J BIOL CHEM, V275, P31847, DOI 10.1074/jbc.M003656200; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108	66	83	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33705	33710		10.1074/jbc.M101215200	http://dx.doi.org/10.1074/jbc.M101215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445561	hybrid			2022-12-25	WOS:000170910200057
J	Haines, WR; Migita, K; Cox, JA; Egan, TM; Voigt, MM				Haines, WR; Migita, K; Cox, JA; Egan, TM; Voigt, MM			The first transmembrane domain of the P2X receptor subunit participates in the agonist-induced gating of the channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP; IDENTIFICATION; NUCLEOTIDES; EFFICACY; BINDING; CELLS	Based on pharmacological properties, the P2X receptor family can be subdivided into those homo-oligomers that are sensitive to the ATP analog alpha beta -methylene ATP(alpha beta meATP) (P2X(1) and P2X(3)) and those that are not (P2X(2), P2X(4), P2X(5), P2X(6), and P2X(7)). We exploited this dichotomy through the construction of chimeric receptors and site-directed mutagenesis in order to identify domains responsible for these differences in the abilities of extracellular agonists to gate P2X receptors. Replacement of the extracellular domain of the alpha beta meATP-sensitive rat P2X(1) subunit with that of the alpha beta meATP-insensitive rat P2X2 subunit resulted in a receptor that was still alpha beta meATP-sensitive, suggesting a non-extracellular domain was responsible for the differential gating of P2X receptors by various agonists. Replacement of the first transmembrane domain of the rat P2X2 subunit with one from an alpha beta meATP-sensitive subunit (either rat P2X(1) or P2X3 subunit) converted the resulting chimera to alpha beta meATP sensitivity. This conversion did not occur when the first transmembrane domain came from a non-alpha beta meATP-sensitive subunit. Site-directed mutagenesis indicated that the C-terminal portion of the first transmembrane domain was important in determining the agonist selectivity of channel gating for these chimeras. These results suggest that the first transmembrane domain plays an important role in the agonist operation of the P2X receptor.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Voigt, MM (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Migita, Keisuke/E-8274-2013	Egan, Terrance/0000-0002-7249-3161	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035534] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56236] Funding Source: Medline; NINDS NIH HHS [NS35534] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Burnstock G, 1996, CIBA F SYMP, V198, P1; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Egan TM, 1998, J NEUROSCI, V18, P2350; Egan TM, 2000, FEBS LETT, V475, P287, DOI 10.1016/S0014-5793(00)01685-9; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Evans RJ, 1996, J PHYSIOL-LONDON, V497, P413, DOI 10.1113/jphysiol.1996.sp021777; FRIEL DD, 1988, J GEN PHYSIOL, V91, P1, DOI 10.1085/jgp.91.1.1; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; Haines WR, 1999, MOL PHARMACOL, V56, P720; HAINES WR, 2001, IN PRESS J NEUROSCI, V21; HORN R, 1992, METHOD ENZYMOL, V207, P149; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Khakh BS, 2001, PHARMACOL REV, V53, P107; Le KT, 1998, J NEUROSCI, V18, P7152; MIGITA KM, 2001, IN PRESS J BIOL CHEM, V276; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; O'Shea SM, 2000, J BIOL CHEM, V275, P22764, DOI 10.1074/jbc.M001299200; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Virginio C, 1998, MOL PHARMACOL, V53, P969	23	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32793	32798		10.1074/jbc.M104216200	http://dx.doi.org/10.1074/jbc.M104216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438537	hybrid			2022-12-25	WOS:000170746000057
J	Orelli, BJ; Logsdon, JM; Bishop, DK				Orelli, BJ; Logsdon, JM; Bishop, DK			Nine novel conserved motifs in BRCA1 identified by the chicken orthologue	ONCOGENE			English	Article						avian; DT40; breast cancer; BRCA1	DNA-DAMAGE RESPONSE; TRANSCRIPTION-COUPLED REPAIR; SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; SEQUENCE-ANALYSIS; MEIOTIC CELLS; MOUSE BRCA1; IN-VIVO; PHOSPHORYLATION; AMPLIFICATION	The breast cancer susceptibility gene BRCA1 encodes a multifunctional protein that is mutated in many hereditary breast and ovarian cancers. We have cloned a homologue of the human BRCA1 gene from chicken; the gene encodes a 1749 amino acid protein that is 33% identical to human BRCA1, Phylogenetic analyses of the chicken and mammalian proteins indicate that the chicken gene is a bona fide BRCA1 orthologue, the first to be described from a non-mammal. Most of the chicken protein has diverged considerably from its mammalian orthologues, although the RING and BRCT repeat regions are highly conserved. This marked overall sequence divergence has allowed us to identify nine additional highly-conserved motifs (ranging from 8-56 amino acids in length) which are likely important for BRCA1 function.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	University of Chicago; Emory University	Bishop, DK (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 920 E 58th St, Chicago, IL 60637 USA.		Logsdon, John M/B-7812-2009					ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Bennett LM, 1999, MAMM GENOME, V10, P19, DOI 10.1007/s003359900935; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Le Page F, 2000, CANCER RES, V60, P5548; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 2001, PAUP PHYLOGENETIC AN; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	40	35	38	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4433	4438		10.1038/sj.onc.1204485	http://dx.doi.org/10.1038/sj.onc.1204485			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466627				2022-12-25	WOS:000169912600020
J	Zhang, YW; Morita, I; Ikeda, M; Ma, KW; Murota, S				Zhang, YW; Morita, I; Ikeda, M; Ma, KW; Murota, S			Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27	ONCOGENE			English	Article						gap junction; connexin 43; tumor suppressive effect; p27; Rb; cell cycle	JUNCTIONAL INTERCELLULAR COMMUNICATION; ANTI-HYPOXIA/REOXYGENATION AGENTS; VEIN ENDOTHELIAL-CELLS; TYROSINE KINASE; GROWTH-CONTROL; TRANSFORMED-CELLS; GAP-JUNCTIONS; NEOPLASTIC PHENOTYPE; EPITHELIAL-CELLS; GENE-EXPRESSION	Many lines of evidence indicate that connexin genes expressing gap junction (GJ) proteins inhibit tumor cell proliferation. However, the precise molecular mechanisms remain unclear, In this study, we show that overexpression of connexin43 (Cx43) suppressed proliferation of human osteosarcoma U2OS cells through inhibition of the cell cycle transition from G1 to S phase. This inhibition was attributed to a significant accumulation of the hypophosphorylated retinoblastoma (Rb) protein, which was causally related to decreases in the kinase activities of cyclin-dependent kinases (CDKs) 2 and 4, Enforced Cx43 expression markedly increased the level of the CDK inhibitor p27, This increase resulted from an increased synthesis and a reduced degradation of the p27 proteins, but not influence of the p27 mRNA, Moreover, we show that the Cx43-modulated GJ function was the main contributor to the elevation in p27 levels, in which cAMP was involved. These data suggest that Cx43 appears to inhibit proliferation of U2OS cells by increasing the levels of p27 proteins via post-transcriptional regulatory mechanisms.	Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Morita, I (corresponding author), Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADSHAW SL, 1993, GROWTH REGULAT, V3, P26; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FITZGERALD DJ, 1990, TERATOGEN CARCIN MUT, V10, P89; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Huang RP, 1998, CANCER RES, V58, P5089; Kandel ER, 2000, BRAIN RES REV, V32, P3, DOI 10.1016/S0165-0173(99)00062-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MARTIN W, 1991, CANCER RES, V51, P5348; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; Mehta PP, 1996, MOL CARCINOGEN, V15, P18, DOI 10.1002/(SICI)1098-2744(199601)15:1<18::AID-MC4>3.0.CO;2-O; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MESNIL M, 1995, CANCER RES, V55, P629; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; Rae RS, 1998, MOL CARCINOGEN, V22, P120, DOI 10.1002/(SICI)1098-2744(199806)22:2<120::AID-MC7>3.0.CO;2-Q; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Statuto M, 1997, J BIOL CHEM, V272, P24710, DOI 10.1074/jbc.272.39.24710; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; TROSKO JE, 1993, LIFE SCI, V53, P1, DOI 10.1016/0024-3205(93)90606-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Yamasaki H, 1995, MUTAT RES-FUND MOL M, V333, P181, DOI 10.1016/0027-5107(95)00144-1; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang YW, 2000, PLANTA MED, V66, P119, DOI 10.1055/s-2000-11126; Zhang YW, 2000, PLANTA MED, V66, P114, DOI 10.1055/s-2000-11128; Zhang YW, 1999, PROSTAG LEUKOTR ESS, V61, P33, DOI 10.1054/plef.1999.0070; Zhang YW, 1999, J CELL PHYSIOL, V180, P305, DOI 10.1002/(SICI)1097-4652(199909)180:3<305::AID-JCP1>3.0.CO;2-Z; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	45	106	113	1	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4138	4149		10.1038/sj.onc.1204563	http://dx.doi.org/10.1038/sj.onc.1204563			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464280				2022-12-25	WOS:000169857200004
J	Mattoon, D; Gupta, K; Doyon, J; Loll, PJ; DiMaio, D				Mattoon, D; Gupta, K; Doyon, J; Loll, PJ; DiMaio, D			Identification of the transmembrane dimer interface of the bovine papillomavirus E5 protein	ONCOGENE			English	Article						coiled-coil; papillomavirus; platelet-derived growth factor receptor; transmembrane domain; viral oncogene	FACTOR-BETA RECEPTOR; GROWTH-FACTOR RECEPTOR; TRANSFORMING PROTEIN; TYROSINE KINASE; C127 CELLS; ACTIVATION; DOMAIN; PHOSPHORYLATION; REQUIRES; REVEALS	We have developed a genetic method to determine the active orientation of dimeric transmembrane protein helices, The bovine papillomavirus E5 protein, a 44-amino acid homodimeric protein that appears to traverse membranes as a left-handed foiled-coil, transforms fibroblasts by binding and activating the platelet-derived growth factor (PDCF) beta receptor, A heterologous dimerization domain was used to force E5 monomers to adopt all seven possible symmetric coiled-coil registries relative to one another within the dimer, Focus formation assays demonstrated that dimerization of the E5 protein is required for transformation and identified a single preferred orientation of the monomers, The essential glutamine residue at position 17 resided in the dimer interface in this active orientation, The active chimera formed complexes with the PDGF beta receptor and induced receptor tyrosine phosphorylation, We also identified ES-like structures that underwent non-productive interactions with the receptor.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	Yale University; University of Pennsylvania	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.		Gupta, Kushol/GOE-5620-2022	Gupta, Kushol/0000-0002-7006-2667	NATIONAL CANCER INSTITUTE [R01CA037157, R37CA037157] Funding Source: NIH RePORTER; NCI NIH HHS [CA37157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; Surti T, 1998, PROTEINS, V33, P601; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001	25	35	37	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3824	3834		10.1038/sj.onc.1204523	http://dx.doi.org/10.1038/sj.onc.1204523			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439346				2022-12-25	WOS:000169494700008
J	Crostella, L; Lidder, S; Williams, R; Skouteris, GG				Crostella, L; Lidder, S; Williams, R; Skouteris, GG			Hepatocyte Growth Factor/Scatter Factor-induces phosphorylation of cortactin in A431 cells in a Src kinase-independent manner	ONCOGENE			English	Article						tyrosine phosphorylation; MET; F-actin binding proteins	RECEPTOR TYROSINE KINASE; GRB2 BINDING-SITE; SCATTER FACTOR; MET RECEPTOR; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; CARCINOMA-CELLS; V-SRC; MOTILITY	The Hepatocyte Growth Factor receptor transduces proliferating and scattering signals in epithelial and endothelial cells. We have explored potential interactions of the HGF/SF receptor beta-subunit (p145(beta MET)) with F-actin binding partners aiming to identify novel downstream effecters implicated in HGF/SF pluripotent signalling. Cortactin, a p80/85 F-actin binding protein, was found phosphorylated on tyrosine in response to HGF-SF in A431 human epidermoid carcinoma cells, expressing the HGF/SF receptor (c-MET). The HGF/SF receptor was enriched in the detergent-insoluble fraction and was found to co-precipitate with cortactin and to associate in vitro with cortactin, The Grb2 small adapter protein known to associate via its Src homology 2 domain (SH2) with the MET C-terminus, was also associated with cortactin, Transient transfection of A431 cells with dominant-negative Grb2 constructs has revealed that the Grb2-C-SH3 domain possesses central role in cortactin phosphorylation in response to HGF/SF, Finally, tyrosine phosphorylation of cortactin was found uncoupled of endogenous c-Src kinase activity, thus further supporting the hypothesis that cortactin is a direct target of the MET kinase, We propose that cortactin may constitute a docking site for MET-derived signals within the cytoskeleton.	Royal Free & UCL, Sch Med, Dept Med, Inst Hepatol,Lab Cell Biol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Skouteris, GG (corresponding author), Royal Free & UCL Med Sch, Dept Med, Ctr Hepatol, Lab Cellular & Mol Biol, Upper 3rd Floor,Rowland Hill St,Royal Free Campus, London NW3 2PF, England.	g.skouteris@rfc.ucl.ac.uk						BARDELLI A, 1992, ONCOGENE, V7, P1973; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAY D, 1986, J CELL SCI, P71; BRUNATI AM, 1995, EUR J BIOCHEM, V229, P164, DOI 10.1111/j.1432-1033.1995.0164l.x; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; DUGINA VB, 1995, J CELL SCI, V108, P1659; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; Skouteris GG, 1996, J BIOL CHEM, V271, P27266, DOI 10.1074/jbc.271.44.27266; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VANITALLIE CM, 1995, J CELL SCI, V108, P1735; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weed SA, 1998, J CELL SCI, V111, P2433; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221	50	35	37	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3735	3745		10.1038/sj.onc.1204474	http://dx.doi.org/10.1038/sj.onc.1204474			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439336				2022-12-25	WOS:000169400200014
J	Liu, BL; Fan, Z				Liu, BL; Fan, Z			The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway	ONCOGENE			English	Article						apoptosis; caspase; TNF receptor family; EGF receptor; monoclonal antibody	EPIDERMAL GROWTH-FACTOR; FAS-MEDIATED APOPTOSIS; CYTOCHROME-C RELEASE; ANTICANCER DRUGS; CD95 FAS/APO-1; DEATH DOMAIN; CANCER-CELLS; G(1) ARREST; LIGAND; FADD	We previously reported that the anti-epidermal growth factor (EGF) receptor monoclonal antibody (mAb) 225 induces DiFi colon cancer cells to undergo apoptosis, and this apoptosis was accompanied by activation of the two apoptosis initiation caspases, caspase-8 and caspase-9, In the current study, we found that pretreatment of DiFi cells with the caspase-8-specific inhibitor z-IETD-fmk but not pretreatment with the caspase-9-specific inhibitor z-LEHD-fmk inhibited mAb 225-induced apoptosis, indicating that caspase-8 plays an essential role in initiating mAb 225-induced apoptosis, Because caspase-8 is activated primarily by the members of the tumor necrosis factor (TNF) receptor family, such as Fas, TNF receptor-1 (TNFR1), or receptors for TNF-related apoptosis-inducing ligand (TRAIL), we investigated whether mAb 225 activated caspase-8 by regulating one or more of these known pathways, Exposure of DiFi cells to TNF alpha or TRAIL activated caspase-8 and induced apoptosis in the cells. A TNFR1-antagonistic mAb or a TRAIL decoy receptor inhibited the activation of caspase-8 and the subsequent apoptosis induced by TNF alpha or TRAIL, respectively, in the cells. However, neither the TNFR1-antagonistic mAb nor the TRAIL decoy receptor inhibited mAb 225-induced activation of caspase-8 and apoptosis in DiFi cells, DiFi cells express detectable level of Fas but are not sensitive to the treatment by the Fas-agonistic mAb CH-II, A Fas-antagonistic mAb (ZB-4) inhibited the Fas-agonistic mAb CH-ll-induced caspase-8 activation and apoptosis in Jurkat T-leukemic cells (used as positive control), but had no effect on mAb 225-induced activation of caspase-8 and apoptosis in DiFi cells. Taken together, our results suggest that mAb 225 does not interact with or regulate these known death receptor pathways, An exploration is therefore warranted for a novel mechanism by which mAb 225 activates caspase-8 and triggers apoptosis in DiFi cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 36,1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Bantel H, 1999, CANCER RES, V59, P2083; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1994, J BIOL CHEM, V269, P27595; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Fellenberg J, 1997, INT J CANCER, V72, P536, DOI 10.1002/(SICI)1097-0215(19970729)72:3<536::AID-IJC25>3.0.CO;2-8; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Liu B, 2000, BRIT J CANCER, V82, P1991; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MENDELSOHN J, 1999, P AN M AM SOC CLIN, V18, pA389; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Milas L, 2000, CLIN CANCER RES, V6, P701; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peng D, 1996, CANCER RES, V56, P3666; PEREZSOLER R, 1998, P AN M AM SOC CLIN, V17, pA393; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sato J D, 1983, Mol Biol Med, V1, P511; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ungefroren H, 1998, CANCER RES, V58, P1741; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu XP, 1996, ONCOGENE, V12, P1397; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	63	35	36	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3726	3734		10.1038/sj.onc.1204490	http://dx.doi.org/10.1038/sj.onc.1204490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439335				2022-12-25	WOS:000169400200013
J	Derkinderen, P; Toutant, M; Kadare, G; Ledent, C; Parmentier, M; Girault, JA				Derkinderen, P; Toutant, M; Kadare, G; Ledent, C; Parmentier, M; Girault, JA			Dual role of Fyn in the regulation of FAK(+)6,7 by cannabinoids in hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL-ADHESION-KINASE; LONG-TERM POTENTIATION; MEDIATED SIGNAL-TRANSDUCTION; BOVINE ADRENOCORTICAL-CELLS; TYROSINE-PHOSPHATASE SHP-2; SRC-FAMILY KINASES; PROTEIN-KINASE; DIFFERENTIAL REGULATION; SYNAPTIC-TRANSMISSION; SELECTIVE ANTAGONIST	In hippocampus endocannabinoids modulate synaptic function and plasticity and increase tyrosine phosphorylation of several proteins, including focal adhesion kinase (FAK). Autophosphorylation of FAK on Tyr-397 is generally a critical step for its activation, allowing the recruitment of Src family kinases, and phosphorylation of FAK and associated proteins. We have examined the mechanisms of the regulation of FAK by cannabinoids in rat and mouse hippocampal slices. Anandamide and 2-arachidonoylglycerol, two endocannabinoids, and Delta9-tetrahydrocannabinol, stimulated tyrosine phosphorylation of FAK(+)6,7, a neuronal splice isoform of FAK, on several residues including Tyr-397. Cannabinoids increased phosphorylation of p130-Cas, a protein associated with FAK, but had no effect on PYK2, a tyrosine kinase related to FAK and enriched in hippocampus. Pharmacological experiments and the use of knockout mice demonstrated that the effects of cannabinoids were mediated through CB1 receptors. These effects were sensitive to manipulation of cAMP-dependent protein kinase, suggesting that they were mediated by inhibition of a cAMP pathway. PP2, an Sre family kinase inhibitor, prevented the effects of cannabinoids on p130-Cas and on FAK(+)6,7 tyrosines 577 and 925, but not 397, indicating that FAK autophosphorylation was upstream of Src family kinases in response to CB1-R stimulation. Endocannabinoids increased the association of Fyn, but not Sre, with FAK(+)6,7. In hippocampal slices from Fyn -/- mice, the levels of p130-Cas were increased, and the effects of endocannabinoids on tyrosine phosphorylation, including of Tyr-397, were completely abolished. These results demonstrate the specific functional association of Fyn with FAK(+)6,7 in a pathway regulated by endocannabinoids, in which Fyn may play roles dependent and independent of its catalytic activity.	Inst Fer Moulin, INSERM U536, F-75005 Paris, France; Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Nucl, B-1070 Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Girault, JA (corresponding author), Inst Fer Moulin, INSERM U536, 17 Rue Fer Moulin, F-75005 Paris, France.	girault@infobiogen.fr	Girault, Jean-Antoine/F-7518-2013; Derkinderen, Pascal/K-2393-2015	Girault, Jean-Antoine/0000-0002-7900-1705; Kadare, Gress/0000-0002-8865-5743; Parmentier, Marc/0000-0001-8081-4685				Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BIDAUTRUSSELL M, 1991, J NEUROCHEM, V57, P1769, DOI 10.1111/j.1471-4159.1991.tb06379.x; Burgaya F, 1997, J BIOL CHEM, V272, P28720, DOI 10.1074/jbc.272.45.28720; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COLLINS DR, 1994, EUR J PHARMACOL, V259, pR7, DOI 10.1016/0014-2999(94)90666-1; DEADWYLER SA, 1993, RECEPTOR CHANNEL, V1, P121; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Derkinderen P, 1998, EUR J NEUROSCI, V10, P1667, DOI 10.1046/j.1460-9568.1998.00174.x; Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Frisch SM, 2000, NAT CELL BIOL, V2, pE167, DOI 10.1038/35023650; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Hajos N, 2000, EUR J NEUROSCI, V12, P3239, DOI 10.1046/j.1460-9568.2000.00217.x; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Hoffman AF, 2000, J NEUROSCI, V20, P2470; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Howlett AC, 2000, CHEM PHYS LIPIDS, V108, P53, DOI 10.1016/S0009-3084(00)00187-0; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Katona I, 1999, J NEUROSCI, V19, P4544; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; Lauri SE, 2000, NEUROREPORT, V11, P997, DOI 10.1097/00001756-200004070-00020; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Manes S, 1999, MOL CELL BIOL, V19, P3125; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Menegon A, 1999, EUR J NEUROSCI, V11, P3777, DOI 10.1046/j.1460-9568.1999.00798.x; Misner DL, 1999, J NEUROSCI, V19, P6795, DOI 10.1523/JNEUROSCI.19-16-06795.1999; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Ohno-Shosaku T, 2001, NEURON, V29, P729, DOI 10.1016/S0896-6273(01)00247-1; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Padmanabhan J, 1999, J NEUROBIOL, V39, P407, DOI 10.1002/(SICI)1097-4695(19990605)39:3<407::AID-NEU7>3.0.CO;2-S; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Rocchi S, 2000, BIOCHEM J, V352, P483, DOI 10.1042/0264-6021:3520483; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Shen MX, 1998, BRAIN RES, V783, P77, DOI 10.1016/S0006-8993(97)01195-5; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; SICILIANO JC, 1994, J NEUROCHEM, V62, P950; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sullivan JM, 1999, J NEUROPHYSIOL, V82, P1286, DOI 10.1152/jn.1999.82.3.1286; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TERRANOVA JP, 1995, N-S ARCH PHARMACOL, V352, P576, DOI 10.1007/BF00169393; Toutant M, 2000, BIOCHEM J, V348, P119, DOI 10.1042/0264-6021:3480119; Troyer DA, 1996, J AM SOC NEPHROL, V7, P415; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Tsou K, 1999, NEUROSCIENCE, V93, P969, DOI 10.1016/S0306-4522(99)00086-X; Twitchell W, 1997, J NEUROPHYSIOL, V78, P43, DOI 10.1152/jn.1997.78.1.43; Ueki K, 1998, FEBS LETT, V432, P197, DOI 10.1016/S0014-5793(98)00862-X; Vilgrain I, 1998, BIOCHEM J, V332, P533, DOI 10.1042/bj3320533; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; Voth EA, 1997, ANN INTERN MED, V126, P791, DOI 10.7326/0003-4819-126-10-199705150-00008; Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	80	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38289	38296						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11468287				2022-12-25	WOS:000171526500077
J	Morel, N; Leroy, J; Ayon, A; Massoulie, J; Bon, S				Morel, N; Leroy, J; Ayon, A; Massoulie, J; Bon, S			Acetylcholinesterase H and T dimers are associated through the same contact - Mutations at this interface interfere with the C-terminal T peptide, inducing degradation rather than secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY ASSOCIATIONS; ATTACHMENT DOMAIN; CAUDATE-NUCLEUS; COLLAGEN TAIL; SUBUNIT; CHOLINESTERASES; EXPRESSION; DISTINCT; PROTEIN; FORMS	Acetylcholinesterase (AChE) exists as AChE(H) and AChE(T) subunits, which differ by their C-terminal H or T peptides, generating glycophosphatidylinositol-anchored dimers and various oligomers, respectively. We introduced mutations in the four-helix bundle interface of glycophosphatidylinositol-anchored dimers, and analyzed their effect on the production and oligomerization of AChE(H), of AChE(T), and of truncated subunits, AChE(C) (without H or T peptide). Dimerization was reduced for all types of subunits, showing that they interact through the same contact zone; the formation of amphiphilic tetramers (Torpedo AChE(T)) and 13.5 S oligomers (rat AChE(T)) was also suppressed. Oligomerization appeared totally blocked by introduction of an N-linked glycan on the surface of helix alpha (7,8). Other point mutations did not affect the synthesis or the catalytic properties of AChE but reduced or blocked the secretion of AChE(T) subunits. Secretion of AChE(T) was partially restored by coexpression with Q(N), a secretable protein containing a proline-rich attachment domain (PRAD); Q(N) organized PRAD-linked tetramers, except for the N-glycosylated mutants. Thus, the simultaneous presence of an abnormal four-helix bundle zone and an exposed T peptide targeted the enzyme toward degradation, indicating a cross-talk between the catalytic and tetramerization domains.	Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, UMR 8544, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Massoulie, J (corresponding author), Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, UMR 8544, 46 Rue Ulm, F-75005 Paris, France.		Morel, Nathalie/O-9012-2016					Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BON S, 1988, J NEUROCHEM, V51, P786, DOI 10.1111/j.1471-4159.1988.tb01813.x; Bourne Y, 1999, J BIOL CHEM, V274, P30370, DOI 10.1074/jbc.274.43.30370; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Coussen F, 2001, J BIOL CHEM, V276, P27881, DOI 10.1074/jbc.M010817200; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; Giles K, 1997, PROTEIN ENG, V10, P677, DOI 10.1093/protein/10.6.677; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; Krejci E, 1997, J BIOL CHEM, V272, P22840, DOI 10.1074/jbc.272.36.22840; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perrier AL, 2000, J BIOL CHEM, V275, P34260, DOI 10.1074/jbc.M004289200; RAVES M, 1998, THESIS WEIZMANN I RE; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; VELAN B, 1991, J BIOL CHEM, V266, P23977	24	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37379	37389		10.1074/jbc.M103192200	http://dx.doi.org/10.1074/jbc.M103192200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11443120	hybrid			2022-12-25	WOS:000171375700070
J	Swarts, HGP; Koenderink, JB; Hermsen, HPH; Willems, PHGM; De Pont, JJHHM				Swarts, HGP; Koenderink, JB; Hermsen, HPH; Willems, PHGM; De Pont, JJHHM			K+-independent gastric H+,K+-ATPase activity - Dissociation of K+-independent dephosphorylation and preference for the E-1 conformation by combined mutagenesis of transmembrane glutamate residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CATION-BINDING; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; SF9 CELLS; NA,K-ATPASE; NA+,K+-ATPASE; H,K-ATPASE; MUTATION	Several mutations of residues Glu(795) and Glu(820) present in M5 and M6 of the catalytic subunit of gastric H+,K+-ATPase have resulted in a K+-independent, SCH 28080-sensitive ATPase activity, caused by a high spontaneous dephosphorylation rate. The mutants with this property also have a preference for the E-1 conformation. This paper investigates the question of whether these two phenomena are coupled. This possibility was studied by combining mutations in residue Glu(343), present in M4, with those in residues 795 and 820. When in combined mutants Glu and/or Gln residues were present at positions 343, 795, and 820, the residue at position 820 dominated the behavior: a Glu giving K+-activated ATPase activity and an E-2 preference and a Gln giving K+-independent ATPase activity and an E-1 preference. With an Asp at position 343, the enzyme could be phosphorylated, but the dephosphorylation was blocked, independent of the presence of either a Glu or a Gln at positions 795 and 820. However, in these mutants, the direction of the E-2 <-> E-1 equilibrium was still dominated by the 820 residue: a Glu giving E-2 and a Gln giving E-1. This indicates that the preference for the E-1 conformation of the E820Q mutation is independent of an active dephosphorylation process.	Univ Nijmegen, Inst Cellular Signalling, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Univ Nijmegen, Inst Cellular Signalling, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.depont@bioch.kun.nl	Koenderink, Jan/N-3578-2014; Willems, P.H.G.M./L-4759-2015	Willems, P.H.G.M./0000-0002-0915-1599				ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; Asano S, 2000, J BIOCHEM, V127, P993, DOI 10.1093/oxfordjournals.jbchem.a022716; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; Hermsen HPH, 2001, BIOCHEMISTRY-US, V40, P6527, DOI 10.1021/bi002456z; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KLAASSEN CHW, 1995, BIOCHEM BIOPH RES CO, V210, P907, DOI 10.1006/bbrc.1995.1743; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Swarts HGP, 1999, MOL PHARMACOL, V55, P541; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Vetter IR, 1996, PROTEIN SCI, V5, P2399, DOI 10.1002/pro.5560051203; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048	31	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36909	36916		10.1074/jbc.M103945200	http://dx.doi.org/10.1074/jbc.M103945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11470785	hybrid			2022-12-25	WOS:000171375700009
J	Rohl, T; van Wijk, KJ				Rohl, T; van Wijk, KJ			In vitro reconstitution of insertion and processing of cytochrome f in a homologous chloroplast translation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE; CHLAMYDOMONAS-REINHARDTII; PEA-CHLOROPLASTS; MESSENGER-RNAS; SPINACH-CHLOROPLASTS; PROTEIN-TRANSPORT; LARGE SUBUNIT; SECA HOMOLOG; IN-VIVO; GENE	Using a homologous chloroplast translation system, we have reconstituted insertion and processing of the chloroplast-encoded thylakoid protein cytochrome f (pCytf). Cross-linking demonstrated that pCytf nascent chains when attached to the 70 S ribosome tightly interact with cpSecA, but this is strictly dependent on thylakoid membranes and a functional signal peptide. This indicates that cpSecA is only operative in pCytf biogenesis when it is bound to the membrane, most likely as part of the See translocon. No evidence for interaction between the 54-kDa subunit of the chloroplast signal recognition particle (cpSRP) and the pCytf nascent chain could be detected, suggesting that pCytf, in contrast to the polytopic D1 protein, does not require cpSRP for targeting. Insertion of pCytf occurred only co-translationally, resulting in processing and accumulation of both the processed signal peptide and the mature protein in the thylakoid. This co-translational membrane insertion and processing required a functional signal peptide and was inhibited by azide, demonstrating that cpSecA is essential for translocation of the soluble luminal domain. pCytf also associated posttranslationally with thylakoids, but the soluble N-terminal domain could not be translocated into the lumen. This is the first study in which synthesis, targeting, and insertion of a chloroplast-encoded thylakoid membrane protein is reconstituted from exogenous transcripts and using the chloroplast translational machinery.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA	Cornell University	van Wijk, KJ (corresponding author), Cornell Univ, Dept Plant Biol, Emerson Hall,3rd Floor,Tower Rd, Ithaca, NY 14853 USA.							Adam Z, 2000, BIOCHIMIE, V82, P647, DOI 10.1016/S0300-9084(00)00612-X; BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; Choquet Y, 1998, P NATL ACAD SCI USA, V95, P4380, DOI 10.1073/pnas.95.8.4380; Choquet Y, 2000, BIOCHIMIE, V82, P615, DOI 10.1016/S0300-9084(00)00609-X; ELLIS RJ, 1997, BIOCHIM BIOPHYS ACTA, V463, P185; FRIEMANN A, 1988, PLANTA, V175, P50, DOI 10.1007/BF00402881; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; Hamel P, 2000, J BIOL CHEM, V275, P17072, DOI 10.1074/jbc.M001468200; Hashimoto A, 1996, FEBS LETT, V391, P29; HATTORI T, 1986, ARCH BIOCHEM BIOPHYS, V244, P630; Haward SR, 1997, EUR J BIOCHEM, V248, P724, DOI 10.1111/j.1432-1033.1997.00724.x; High S, 1997, J BIOL CHEM, V272, P11622; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; Houben E, 1999, PLANT CELL, V11, P1553; HOWE G, 1994, J BIOL CHEM, V269, P5824; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KIM J, 1994, PLANT PHYSIOL, V104, P907, DOI 10.1104/pp.104.3.907; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; KURAS R, 1995, BIOCHEMISTRY-US, V34, P7468, DOI 10.1021/bi00022a021; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUI JW, 1993, PLANT MOL BIOL REP, V11, P48; MINAMI EI, 1984, ARCH BIOCHEM BIOPHYS, V235, P562, DOI 10.1016/0003-9861(84)90230-3; Mould RM, 1997, PLANT J, V11, P1051, DOI 10.1046/j.1365-313X.1997.11051051.x; Muhlbauer SK, 1999, EUR J BIOCHEM, V261, P784, DOI 10.1046/j.1432-1327.1999.00337.x; NAGANO Y, 1991, CURR GENET, V20, P431, DOI 10.1007/BF00317074; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; Nohara T, 1996, BIOCHEM BIOPH RES CO, V224, P474, DOI 10.1006/bbrc.1996.1051; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; ROTHSTEIN SJ, 1985, P NATL ACAD SCI USA, V82, P7955, DOI 10.1073/pnas.82.23.7955; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; vanWijk KJ, 1996, J BIOL CHEM, V271, P9627, DOI 10.1074/jbc.271.16.9627; Voelker R, 1997, GENETICS, V145, P467; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; WILLEY DL, 1990, PLANT MOL BIOL, V15, P347, DOI 10.1007/BF00036920; Wollman F. A., 1998, MOL BIOL CHLOROPLAST, P459; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; Zerges W, 1998, J CELL BIOL, V140, P101, DOI 10.1083/jcb.140.1.101	43	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35465	35472		10.1074/jbc.M103005200	http://dx.doi.org/10.1074/jbc.M103005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11459839	hybrid			2022-12-25	WOS:000171109300036
J	Wu, GC; Lai, HL; Lin, YW; Chu, YT; Chern, Y				Wu, GC; Lai, HL; Lin, YW; Chu, YT; Chern, Y			N-glycosylation and residues Asn(805) and Asn(890) are involved in the functional properties of type VI adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCOSYLATION; RECEPTOR; EXPRESSION; CLONING; SITES; GENE; IDENTIFICATION; INHIBITION; FORSKOLIN; PHOSPHORYLATION	In this study, we demonstrate that type VI adenylyl cyclase (ACVI) is glycosylated in vivo. Treating HEK293 cells expressing ACVI with tunicamycin to block the addition of N-linked oligosaccharide or removing the N-linked oligosaccharide by in vitro peptidyl-N-glycosidase F digestion reduced the molecular mass of ACVI. Furthermore, tunicamycin treatment suppressed the forskolin-stimulated activity of ACVI. Mutation of either one or both potential N-glycosylation sites (Asn(805) and Asn(890), located on extracellular loops 5 and 6, respectively) also reduced the molecular mass of ACVI. Therefore, ACVI was glycosylated at both Asn(805) and Asn(890). Confocal analysis indicated that glycosylation was not required for the delivery of ACVI to the cell surface. Although no significant alterations in K-m values for ATP or sensitivity to divalent cations were detected, the glycosylation-deficient ACNI mutant N805Q/NS890Q-ACVI exhibited much lower forskolin-, Mn2+, and Mg2+-stimulated cyclase activities than did wild-type ACVI. By contrast, the G alpha (8)-stimulated cyclase activities of wildtype ACVI and N805Q/NS90Q-ACVI were indistinguishable. Furthermore, compared with wild-type ACVI, N805Q/NS90Q-ACVI was less sensitive to inhibition mediated by dopamine D2 receptors or by protein kinase C. Collectively, glycosylation of ACVI not only affected its catalytic activity in an activator-dependent manner, but also altered its ability to be regulated by a G alpha (i) protein-coupled receptor or by protein kinase C.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Def Med Ctr, Inst Life Sci, Taipei 104, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Chern, Y (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.	bmychern@ibms.sinica.edu.tw	chern, yijuang/S-7013-2018	chern, yijuang/0000-0002-5842-5429				ALBERT PR, 1990, J BIOL CHEM, V265, P2098; Bol GF, 1997, BBA-MOL CELL RES, V1358, P307, DOI 10.1016/S0167-4889(97)00073-6; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; BROOKER G, 1979, ADV CYCLIC NUCLEOTID, V10, P2; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Chen Z, 2001, CURR BIOL, V11, P1874, DOI 10.1016/S0960-9822(01)00596-6; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; CHERN YJ, 1992, BIOCHEM BIOPH RES CO, V185, P304, DOI 10.1016/S0006-291X(05)90000-4; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; ELBEIN AD, 1997, METHOD ENZYMOL, V138, P661; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; GUASCH R, 1992, ALCOHOL CLIN EXP RES, V16, P942, DOI 10.1111/j.1530-0277.1992.tb01897.x; Harry A, 1997, J BIOL CHEM, V272, P19017, DOI 10.1074/jbc.272.30.19017; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Henry H, 1999, CLIN CHEM, V45, P1408; Hirsch B, 1999, HORM METAB RES, V31, P645, DOI 10.1055/s-2007-978814; Huang CL, 1999, J NEUROCHEM, V72, P2437, DOI 10.1046/j.1471-4159.1999.0722437.x; Karpa KD, 1999, MOL PHARMACOL, V56, P1071, DOI 10.1124/mol.56.5.1071; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; Kohne C, 1999, J CELL BIOCHEM, V75, P446; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lai HL, 1999, MOL PHARMACOL, V56, P644, DOI 10.1124/mol.56.3.644; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Liu FC, 1998, FEBS LETT, V436, P92, DOI 10.1016/S0014-5793(98)01098-9; MASIBAY AS, 1991, BIOCHIM BIOPHYS ACTA, V1090, P230, DOI 10.1016/0167-4781(91)90106-V; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Ramanathan VK, 1999, J BIOL CHEM, V274, P20513, DOI 10.1074/jbc.274.29.20513; ROTH JA, 1991, J NEUROCHEM, V57, P708, DOI 10.1111/j.1471-4159.1991.tb03803.x; Rudd PM, 1999, GLYCOBIOLOGY, V9, P443, DOI 10.1093/glycob/9.5.443; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; STANGL D, 1993, ENDOCRINOLOGY, V132, P744, DOI 10.1210/en.132.2.744; STEUBE K, 1985, BIOCHEMISTRY-US, V24, P5587, DOI 10.1021/bi00341a045; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; WONG YH, 1994, METHOD ENZYMOL, V238, P81; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	48	29	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35450	35457		10.1074/jbc.M009704200	http://dx.doi.org/10.1074/jbc.M009704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461898	hybrid			2022-12-25	WOS:000171109300034
J	Dick, GM; Rossow, CF; Smirnov, S; Horowitz, B; Sanders, KM				Dick, GM; Rossow, CF; Smirnov, S; Horowitz, B; Sanders, KM			Tamoxifen activates smooth muscle BK channels through the regulatory beta 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE COLONIC MYOCYTES; RAT CEREBRAL-ARTERIES; HIGH-DOSE TAMOXIFEN; PHASE-I TRIAL; NONGENOMIC ACTIONS; POTASSIUM CHANNEL; K-CHANNELS; INHIBITION; CA2+; COMBINATION	Estrogen (17 beta -estradiol; 17 betaE) and xenoestrogens, estrogenic compounds that are not steroid hormones, have nongenomic actions at plasma membrane receptors unrelated to the nuclear estrogen receptor. The open probability (P-o) of large conductance Ca2+/voltage-sensitive k(+)(BK) channels is increased by 17 betaE through the regulatory beta1 subunit. The pharmacological nature of the putative membrane binding site is unclear. We probed the site by determining whether tamoxifen ((Z)-1-(p-dimethylaminoethoxy-phenyl)-1,2-diphenyl-1-butene; Tx), a chemotherapeutic xenoestrogen, increased P-o in clinically relevant concentrations (0.1-10 muM). In whole cell patch clamp recordings on canine colonic myocytes, which express the beta1 subunit, Tx activated charybdotoxin-sensitive K+ current. In single channel experiments, Tx increased the NPo (P-o x number channel; N) and decreased the unitary conductance (gamma) of BK channels. Tx increased NPo (EC50 = 0.65 muM) in excised membrane patches independent of Ca2+ changes. The Tx mechanism of action requires the beta1 subunit, as Tx increased the NPo of Slo alpha expressed in human embryonic kidney cells only in the presence of the beta1 subunit. Tx decreased gamma of the alpha subunit expressed alone, without effect on NTPo. Our data indicate that Tx increases BK channel activity in therapeutic concentrations and reveal novel pharmacological properties attributable to the a and beta1 subunits. These data shed light on BK channel structure and function, non-genomic mechanisms of regulation, and physiologically and therapeutically relevant effects of xenoestrogens.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA; Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of Bath	Dick, GM (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA.		Dick, Gregory/G-3032-2010	Dick, Gregory/0000-0003-1444-6436; Smirnov, Sergey/0000-0003-2651-7545	NIDDK NIH HHS [F32 DK09947, DK41315] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041315, F32DK009947] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen MC, 1998, EUR J PHARMACOL, V354, P261, DOI 10.1016/S0014-2999(98)00454-3; Behrens R, 2000, FEBS LETT, V474, P99, DOI 10.1016/S0014-5793(00)01584-2; Bergan RC, 1999, CLIN CANCER RES, V5, P2366; BERMAN E, 1995, LEUKEMIA, V9, P1631; BERS DM, 1982, AM J PHYSIOL, V242, P404; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; CARL A, 1989, AM J PHYSIOL, V257, pC470, DOI 10.1152/ajpcell.1989.257.3.C470; COLE WC, 1989, AM J PHYSIOL, V257, pC461, DOI 10.1152/ajpcell.1989.257.3.C461; Decensi A, 1999, J CLIN ONCOL, V17, P2633, DOI 10.1200/JCO.1999.17.9.2633; Dick GM, 1999, BRIT J PHARMACOL, V127, P1819, DOI 10.1038/sj.bjp.0702730; Doughty JM, 1998, J PHYSIOL-LONDON, V507, P433, DOI 10.1111/j.1469-7793.1998.433bt.x; Fukao M, 2001, MOL PHARMACOL, V59, P16, DOI 10.1124/mol.59.1.16; Hardy SP, 1998, FEBS LETT, V434, P236, DOI 10.1016/S0014-5793(98)00974-0; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; JORDAN VC, 1976, CANCER TREAT REP, V60, P1409; Kostrzewska A, 1997, AM J OBSTET GYNECOL, V176, P381, DOI 10.1016/S0002-9378(97)70503-9; KROEGER EA, 1985, BIOCHEM BIOPH RES CO, V131, P750, DOI 10.1016/0006-291X(85)91302-6; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842; MARSHALL K, 1987, BRIT J PHARMACOL, V92, P429, DOI 10.1111/j.1476-5381.1987.tb11339.x; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Nelson MT, 1997, J PHYSIOL-LONDON, V502, P259, DOI 10.1111/j.1469-7793.1997.259bk.x; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; OBRIAN CA, 1985, CANCER RES, V45, P2462; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; THORNEYCROFT IH, 1971, AM J OBSTET GYNECOL, V111, P947, DOI 10.1016/0002-9378(71)90951-3; TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Welsh DG, 2000, J PHYSIOL-LONDON, V527, P139, DOI 10.1111/j.1469-7793.2000.t01-1-00139.x	32	110	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34594	34599		10.1074/jbc.M104689200	http://dx.doi.org/10.1074/jbc.M104689200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454866	hybrid			2022-12-25	WOS:000171024600035
J	Eppelmann, K; Doekel, S; Marahiel, MA				Eppelmann, K; Doekel, S; Marahiel, MA			Engineered biosynthesis of the peptide antibiotic bacitracin in the surrogate host Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC COMPETENCE; ABC TRANSPORTER; SYNTHETASES; RESISTANCE; SURFACTIN; DOMAINS; COMS; IDENTIFICATION; POLYKETIDES; SEQUENCE	Nonribosomal peptides are processed on multifunctional enzymes called nonribosomal peptide synthetases (NRPSs), whose modular multidomain arrangement allowed the rational design of new peptide products. However, the lack of natural competence and efficient transformation methods for most of nonribosomal peptide producer strains prevented the in vivo manipulation of these biosynthetic gene clusters. In this study, we present methods for the construction of a genetically engineered Bacillus subtilis surrogate host for the integration and heterologous expression of foreign NRPS genes. In the B. subtilis surrogate host, we deleted the resident 26-kilobase srfA gene cluster encoding the surfactin synthetases and subsequently used the same chromosomal location for integration of the entire 49-kilobase bacitracin biosynthetic gene cluster from Bacillus licheniformis by a stepwise homologous recombination method. Synthesis of the branched cyclic peptide antibiotic bacitracin in the engineered B. subtilis strain was achieved at high level, indicating a functional production and proper posttranslational modification of the bacitracin synthetases BacABC, as well as the expression of the associated bacitracin self-resistance genes. This engineered and genetically amenable B. subtilis strain will facilitate the rational design of new bacitracin derivatives.	Univ Marburg, Dept Chem, D-35032 Marburg, Germany	Philipps University Marburg	Marahiel, MA (corresponding author), Univ Marburg, Dept Chem, D-35032 Marburg, Germany.	marahiel@chemie.uni-marburg.de						BRON S, 1991, RES MICROBIOL, V142, P875, DOI 10.1016/0923-2508(91)90068-L; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; COOPER DG, 1981, APPL ENVIRON MICROB, V42, P408, DOI 10.1128/AEM.42.3.408-412.1981; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; CUTTING SM, 1990, MOL BIOL METHODS BAC, P34; deFerra F, 1997, J BIOL CHEM, V272, P25304, DOI 10.1074/jbc.272.40.25304; Doekel S, 2000, CHEM BIOL, V7, P373, DOI 10.1016/S1074-5521(00)00118-6; Doekel S, 2001, METAB ENG, V3, P64, DOI 10.1006/mben.2000.0170; DSOUZA C, 1994, P NATL ACAD SCI USA, V91, P9397, DOI 10.1073/pnas.91.20.9397; Dubnau David, 1993, P555; EHRLICH SD, 1986, GENETIC ENG, V8, P71; Gaidenko T. A., 1988, MOL GENET MIKROBIOL, V2, P24; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; IKAI Y, 1992, J ANTIBIOT, V45, P1325, DOI 10.7164/antibiotics.45.1325; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; ISHIHARA H, 1974, BIOCHIM BIOPHYS ACTA, V338, P588, DOI 10.1016/0304-4165(74)90322-5; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KLEIN C, 1992, APPL ENVIRON MICROB, V58, P132, DOI 10.1128/AEM.58.1.132-142.1992; Konz D, 1997, CHEM BIOL, V4, P927, DOI 10.1016/S1074-5521(97)90301-X; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Liu L, 1996, J BACTERIOL, V178, P5144, DOI 10.1128/jb.178.17.5144-5152.1996; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Mootz HD, 2000, P NATL ACAD SCI USA, V97, P5848, DOI 10.1073/pnas.100075897; Mootz HD, 1999, CURR OPIN BIOTECH, V10, P341, DOI 10.1016/S0958-1669(99)80062-7; NAKANO MM, 1988, J BACTERIOL, V170, P5662, DOI 10.1128/jb.170.12.5662-5668.1988; Neumuller AM, 2001, EUR J BIOCHEM, V268, P3180, DOI 10.1046/j.1432-1327.2001.02203.x; Ogura M, 1999, MOL MICROBIOL, V32, P799, DOI 10.1046/j.1365-2958.1999.01399.x; Pfeifer BA, 2001, MICROBIOL MOL BIOL R, V65, P106, DOI 10.1128/MMBR.65.1.106-118.2001; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; PODLESEK Z, 1995, MOL MICROBIOL, V16, P969, DOI 10.1111/j.1365-2958.1995.tb02322.x; Podlesek Z, 2000, FEMS MICROBIOL LETT, V188, P103, DOI 10.1111/j.1574-6968.2000.tb09176.x; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Rieder H, 1975, Methods Enzymol, V43, P548; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider A, 1998, MOL GEN GENET, V257, P308, DOI 10.1007/s004380050652; Schneider A, 1998, ARCH MICROBIOL, V169, P404, DOI 10.1007/s002030050590; Stachelhaus T, 1996, BIOCHEM PHARMACOL, V52, P177, DOI 10.1016/0006-2952(96)00111-6; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; STEINMETZ M, 1994, GENE, V142, P79, DOI 10.1016/0378-1119(94)90358-1; Symmank H, 1999, J BIOL CHEM, V274, P21581, DOI 10.1074/jbc.274.31.21581; Turgay K, 1997, GENE DEV, V11, P119, DOI 10.1101/gad.11.1.119; Yakimov MM, 2000, J MOL MICROB BIOTECH, V2, P217	46	75	83	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34824	34831		10.1074/jbc.M104456200	http://dx.doi.org/10.1074/jbc.M104456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11448966	hybrid			2022-12-25	WOS:000171024600065
J	Harper, N; Farrow, SN; Kaptein, A; Cohen, GM; MacFarlane, M				Harper, N; Farrow, SN; Kaptein, A; Cohen, GM; MacFarlane, M			Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING RECEPTOR; TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; TNF-INDUCED APOPTOSIS; DEATH-DOMAIN; KINASE RIP; MEDIATING RECEPTOR; TERMINAL KINASE; DECOY RECEPTOR; APO-2 LIGAND	Tumor necrosis factor (TNF) apoptosis-inducing ligand (TRAIL), a member of the TNF family, induces apoptosis in many transformed cells. We report TRAIL-induced NF-kappaB activation, concomitant with production of the pro-inflammatory cytokine Interleukin-8 in the relatively TRAIL-insensitive cell line, HEK293. In contrast, TRAIL-induced NF-kappaB activation occurred in HeLa cells only upon pretreatment with the caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp-(OMe) fluoromethyl ketone (z-VAD.fmk), indicating that this was due to a caspase-sensitive component of TRAIL-induced NF-kappaB activation. NF-kappaB activation was mediated by the death receptors, TRAIL-R1 and -R2, but not by TRAIL-R3 or -R4 and was only observed in HeLa cells in the presence of z-VAD.fmk. Receptor-interacting protein, an obligatory component of TNF-alpha -induced NF-kappaB activation, was cleaved during TRAIL-induced apoptosis. We show that receptor-interacting protein is recruited to the native TRAIL death-inducing signaling complex (DISC) and that recruitment is enhanced in the presence of z-VAD.fmk, thus providing an explanation for the potentiation of TRAIL-induced NF-kappaB activation by z-VAD.fmk in TRAIL-sensitive cell lines. Examination of the TRAIL DISC in sensitive and resistant cells suggests that a high ratio of c-FLIP to caspase-8 may partially explain cellular resistance to TRAIL-induced apoptosis. Sensitivity to TRAIL-induced apoptosis was also modulated by inhibition or activation of NF-kappaB. Thus, in some contexts, modulation of NF-kappaB activation possibly at the level of apical caspase activation at the DISC may be a key determinant of sensitivity to TRAIL-induced apoptosis.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Glaxo SmithKline Med Res Ctr, Stevenage SG1 2NY, Herts, England	University of Leicester; GlaxoSmithKline	MacFarlane, M (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.		Cohen, Gerald M/A-1687-2008					Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Moore JT, 1997, ANAL BIOCHEM, V247, P203, DOI 10.1006/abio.1997.2092; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tsang TC, 1997, BIOTECHNIQUES, V22, P68, DOI 10.2144/97221bm13; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	62	134	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34743	34752		10.1074/jbc.M105693200	http://dx.doi.org/10.1074/jbc.M105693200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11461927	hybrid			2022-12-25	WOS:000171024600055
J	Avery, AM; Avery, SV				Avery, AM; Avery, SV			Saccharomyces cerevisiae expresses three phospholipid hydroperoxide glutathione peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ADAPTIVE RESPONSE; STRESS; YEAST; SENSITIVITY; PROTECTION; INDUCTION; TOXICITY; DAMAGE; ENZYME	The GPX1, GPX2, and GPX3 genes of Saccharomyces cerevisiae have been reported previously to encode glutathione peroxidases (GPxs). We re-examined the sequence alignments of these proteins with GPxs from higher eukaryotes. Sequence identities, particularly with phospholipid hydroperoxide glutathione peroxidases (PHGPxs), were enhanced markedly by introduction to the yeast sequences of gaps that are characteristic of PHGPxs. PHGPx-like activity was detectable in extracts from wild-type S. cerevisiae and was diminished in extracts from gpx1 Delta, gpx2 Delta, and gpx3 Delta deletion mutants; PHGPx activity was almost absent in a gpx1 Delta /gpx2 Delta /gpx3 Delta triple mutant. Studies with cloned GPX1, GPX2, and GPX3 expressed heterologously in Escherichia coli confirmed that these genes encode proteins with PHGPx activity. An S. cerevisiae gpx1 Delta /gpx2 Delta/ gpx3 Delta mutant was defective for growth in medium supplemented with the oxidation-sensitive polyunsaturated fatty acid linolenate (18:3). This sensitivity to 18:3 was more marked than sensitivity to H2O2. Unlike H2O2 toxicity, delayed toxicity of 18:3 toward gpx1 Delta /gpx2 Delta/ gpx3 Delta cells was correlated with the gradual incorporation of 18:3 into S. cerevisiae membrane lipids and was suppressible with a-tocopherol, an inhibitor of lipid peroxidation. The results show that the GPX genes of S. cerevisiae, previously reported to encode GPxs, encode PHGPxs (PHGPx1, PHGPx2, and PHGPx3) and that these enzymes protect yeast against phospholipid hydroperoxides as well as nonphospholipid peroxides during oxidative stress. This is the first report of an organism that expresses PHGPx from more than one gene and produces PHGPx in the absence of a GPx.	Univ Nottingham, Sch Life & Environm Sci, Nottingham NG7 2RD, England	University of Nottingham	Avery, SV (corresponding author), Univ Nottingham, Sch Life & Environm Sci, Univ Pk, Nottingham NG7 2RD, England.		Avery, Simon/U-5816-2019; Avery, Simon/AAS-5291-2021	Avery, Simon/0000-0002-2102-2255	NIGMS NIH HHS [R01 GM57945] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057945] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; AUSUBEL FM, 2001, CURRENT PROTOCOLS MO; Avery SV, 2000, J BACTERIOL, V182, P76, DOI 10.1128/JB.182.1.76-80.2000; Avery SV, 1996, APPL ENVIRON MICROB, V62, P3960, DOI 10.1128/AEM.62.11.3960-3966.1996; Avery SV, 2001, ADV APPL MICROBIOL, V49, P111, DOI 10.1016/S0065-2164(01)49011-3; Bao YP, 2000, PROG NAT SCI-MATER, V10, P321; BILINSKI T, 1989, BIOCHIM BIOPHYS ACTA, V177, P358; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; CHEESEMAN KH, 1993, DNA FREE RADICALS, P109; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; DAWES IW, 1999, METABOLISM MOL PHYSL, P277; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; Evans MV, 1998, J BACTERIOL, V180, P483, DOI 10.1128/JB.180.3.483-490.1998; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GALIAZZO F, 1987, BIOCHEM BIOPH RES CO, V147, P1200, DOI 10.1016/S0006-291X(87)80197-3; Hazebrouck S, 2000, J BIOL CHEM, V275, P28715, DOI 10.1074/jbc.M004985200; Howlett NG, 1997, APPL ENVIRON MICROB, V63, P2971, DOI 10.1128/AEM.63.8.2971-2976.1997; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; JACOB HS, 1965, J CLIN INVEST, V44, P1187, DOI 10.1172/JCI105225; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; SANTORO N, 1997, YEAST STRESS RESPONS, P171; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; Turton HE, 1997, J BACTERIOL, V179, P1096, DOI 10.1128/jb.179.4.1096-1101.1997; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1995, METHOD ENZYMOL, V252, P38; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; Wonisch W, 1997, FEBS LETT, V405, P11, DOI 10.1016/S0014-5793(97)00123-3; [No title captured]	35	148	156	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33730	33735		10.1074/jbc.M105672200	http://dx.doi.org/10.1074/jbc.M105672200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445588	hybrid			2022-12-25	WOS:000170910200060
J	Iwasaki, T; Chin, WW; Ko, L				Iwasaki, T; Chin, WW; Ko, L			Identification and characterization of RRM-containing coactivator activator (CoAA) as TRBP-interacting protein, and its splice variant as a coactivator modulator (CoAM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR; RNA-BINDING PROTEINS; MESSENGER-RNA; HNRNP A1; TRANSCRIPTION; SEQUENCE; DOMAINS; CANCER; FAMILY; GENES	We previously cloned and characterized thyroid hormone receptor-binding protein (TRBP) as an LXXLL-containing general coactivator that associates with coactivator complexes through its C terminus. To identify protein cofactors for TRBP action, a Sos-Ras yeast two hybrid cDNA library was screened using TRBP C terminus as bait. A novel coactivator was isolated, coactivator activator (CoAA), that specifically associates with TRBP. Human CoAA is composed of 669 amino acids with a TRBP-interacting domain and two highly conserved RNA recognition motifs (RRM) commonly found in ribonucleoproteins. A splice variant lacking the entire TRBP-interacting domain was also isolated as a coactivator modulator (CoAM), a 156-amino acid protein containing only the RRM region. Human CoAA and CoAM mRNAs are encoded by a single gene located on chromosome 11q13; alternative splicing in exon 2 of CoAA yields CoAM. CoAA interacts with both TRBP and p300 in vitro. In addition, CoAA potently coactivates transcription mediated by multiple hormone-response elements and acts synergistically with TRBP and CREB-binding protein (CBP). Furthermore, CoAA is associated with the DNA-dependent protein kinase-poly(ADP-ribose) polymerase complex. Strikingly, CoAM, which lacks a TRBP-interacting domain, strongly represses both TRBP and CBP action suggesting that CoAM may modulate endogenous CoAA function. These data suggest that CoAA may serve as a mediator of coactivators such as TRBP in gene activation.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Dept Gene Regulat Bone & Inflammat Res, Indianapolis, IN 46285 USA	Eli Lilly	Ko, L (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Dept Gene Regulat Bone & Inflammat Res, Bldg 98-C,Drop Code 0434, Indianapolis, IN 46285 USA.			Ko, Lan/0000-0002-0089-9090				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Barrett TJ, 1999, VITAM HORM, V55, P127; Berezney R, 1995, INT REV CYTOL, V162A, P1; BIAMONTI G, 1994, NUCLEIC ACIDS RES, V22, P1996, DOI 10.1093/nar/22.11.1996; Biggiogera M, 2000, FASEB J, V14, P828, DOI 10.1096/fasebj.14.5.828; Bode J, 1995, INT REV CYTOL, V162A, P389; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Hubsman M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e18; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nickerson JA, 1995, INT REV CYTOL, V162A, P67; ONATE SA, 1995, SCIENCE, V270, P1354; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510	34	107	112	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33375	33383		10.1074/jbc.M101517200	http://dx.doi.org/10.1074/jbc.M101517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443112	hybrid			2022-12-25	WOS:000170910200014
J	Blackwell, LJ; Wang, ST; Modrich, P				Blackwell, LJ; Wang, ST; Modrich, P			DNA chain length dependence of formation and dynamics of hMutS alpha(.)hMutL alpha(.)heteroduplex complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; MUTS-ENCODED PROTEIN; MISMATCH REPAIR; ESCHERICHIA-COLI; TRANSLOCATION MECHANISM; SLIDING CLAMP; HMUTS-ALPHA; TUMOR-CELLS; BASE PAIRS; BINDING	Formation of a ternary complex between human MutS alpha, MutL alpha, and heteroduplex DNA has been demonstrated by surface plasmon resonance spectroscopy and electrophoretic gel shift methods. Formation of the hMutL alpha (.)-hMutS alpha -heteroduplex complex requires a mismatch and ATP hydrolysis, and depends on DNA chain length. Ternary complex formation was supported by a 200-base pair G-T heteroduplex, a 100-base pair substrate was somewhat less effective, and a 41-base pair heteroduplex was inactive. As judged by surface plasmon resonance spectroscopy, ternary complexes produced with the 200-base pair G-T DNA contained similar to0.8 mol of hMutL alpha /mol of heteroduplex-bound hMutS alpha. Although the steady-state levels of the hMutL alpha (.)hMutS alpha (.)heteroduplex were substantial, this complex was found to turn over, as judged by surface plasmon resonance spectroscopy and electrophoretic gel shift analysis. With the former method, the majority of the complexes dissociated rapidly upon termination of protein flow, and dissociation occurred in the latter case upon challenge with competitor DNA. However, ternary complex dissociation as monitored by gel shift assay was prevented if both ends of the heteroduplex were physically blocked with streptavidin-biotin complexes. This observation suggests that, like hMutSa, the hMutL alpha (.)hMutS alpha complex can migrate along the helix contour to dissociate at DNA ends.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Modrich, P (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fisher Robert J., 1994, Methods (Orlando), V6, P121, DOI 10.1006/meth.1994.1015; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Li GM, 1999, ONCOL RES, V11, P393; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; SCHOFIELD MJ, 2001, IN PRESS J BIOL CHEM, V22; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829	37	88	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33233	33240		10.1074/jbc.M105076200	http://dx.doi.org/10.1074/jbc.M105076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11441019	hybrid			2022-12-25	WOS:000170746000109
J	Saito, H; Santoni, MJ; Arsanto, JP; Jaulin-Bastard, F; Le Bivic, A; Marchetto, S; Audebert, S; Isnardon, D; Adelaide, J; Birnbaum, D; Borg, JP				Saito, H; Santoni, MJ; Arsanto, JP; Jaulin-Bastard, F; Le Bivic, A; Marchetto, S; Audebert, S; Isnardon, D; Adelaide, J; Birnbaum, D; Borg, JP			Lano, a novel LAP protein directly connected to MAGUK proteins in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; PAPILLOMAVIRUS E6 PROTEINS; INTERACTS; HOMOLOG; BINDING; GENE; LOCALIZATION; ERBIN; CYCLE; DLG	Protein networks asymetrically distributed to basolateral and apical epithelial membranes maintain cell polarity and homeostasis of epithelial tissues. Genetic studies in non-vertebrates assigned two families of basolateral proteins, MAGUK (Membrane-associated and guanylate kinase) and LAP (leucine-rich repeats and PDZ) proteins, to a common pathway crucial for the epithelial architecture and acting as a gatekeeper to malignancy. In mammals, three LAP proteins have been described, Densin-180, Erbin, and hScribble. Here, we identify a protein called Lano (LAP and no PDZ) only present in vertebrates and presenting strong identities with LAP proteins. Despite the lack of PDZ domain, Lano is located at the basolateral side of epithelial cells in a similar manner to Erbin and hScribble. Using in vitro and in vivo experiments, we demonstrate that Lano directly interacts with the PDZ domains of MAGUK proteins, including hDLG (human disc large), in epithelial cells. A second pool of Lano is complexed to Erbin. These LAP-MAGUK protein complexes coexist at the basolateral side of epithelial cells. We provide evidence for a direct interaction between LAP and MAGUK proteins, and we propose that various LAP-MAGUK networks targeted to the basolateral side of epithelial cells participate to homeostasis of epithelial tissues and tumor growth.	INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Fac Sci Luminy, Inst Dev Biol, F-13288 Marseille 09, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Borg, JP (corresponding author), INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.	borg@marseille.inserm.fr	Borg, Jean-Paul/AAX-8096-2020; ADELAIDE, José JA/O-4390-2017; Jaulin, Fanny/D-7152-2017	Borg, Jean-Paul/0000-0001-8418-3382; ADELAIDE, José JA/0000-0003-4364-9857; Jaulin, Fanny/0000-0002-5110-1800; Audebert, Stephane/0000-0002-9409-2588; Santoni, Marie-Josee/0000-0002-2619-7257				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bilder D, 2000, NAT CELL BIOL, V2, pE114, DOI 10.1038/35017119; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; JOUANNEAU J, 1991, CANCER CELL-MON REV, V3, P525; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MCMAHON L, 2001, IN PRESS J CELL SCI; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 1998, J CELL SCI, V111, P2365	29	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32051	32055		10.1074/jbc.C100330200	http://dx.doi.org/10.1074/jbc.C100330200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11440998	hybrid			2022-12-25	WOS:000170613500080
J	Liu, B; Shuai, K				Liu, B; Shuai, K			Induction of apoptosis by protein inhibitor of activated Stat1 through c-jun NH2-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; RECEPTOR COREGULATOR; TRANSCRIPTION FACTOR; GENE ACTIVATION; GROWTH-FACTOR; DNA-DAMAGE; STRESS; JNK; GADD45	Members of the protein inhibitor of activated signal transducer and activator of transcription (STAT) family (PIAS family) of proteins act as negative regulators of STATs in cytokine signaling. We report here that PIAS proteins have proapoptotic activity. PIAS1 induced apoptosis in both human 293T cells and human osteosarcoma U2OS cells. PIAS1 is localized in the nucleus as distinct nuclear dots. Ectopic expression of PIAS1 in U2OS cells activated JNK1 (c-Jun NH2-terminal kinase). A dominant-negative JNK1, capable of inhibiting PIAS1-induced JNK1 activation, blocked PIAS1-mediated apoptosis. Furthermore, a mutant PIAS1, lacking the first 9 amino acid residues, failed to repress Stat1-mediated gene activation although it retained its ability to activate JNK and to trigger apoptosis. Our results identify a novel function of PIAS1 in the induction of JNK-dependent apoptosis, independent of the previously known inhibitory activity of PIAS1 in STAT-mediated gene activation.	Univ Calif Los Angeles, Div Hematol Oncol, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Shuai, K (corresponding author), Univ Calif Los Angeles, Div Hematol Oncol, Dept Med, 11-934 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039612, R21AI043438, R01AI043438] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39612, AI43438] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mohr SE, 1999, GENE, V229, P109, DOI 10.1016/S0378-1119(99)00033-5; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4	41	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36624	36631		10.1074/jbc.M101085200	http://dx.doi.org/10.1074/jbc.M101085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11451946	hybrid			2022-12-25	WOS:000171194500076
J	Ueda, N; Yamanaka, K; Yamamoto, S				Ueda, N; Yamanaka, K; Yamamoto, S			Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID-RECEPTOR-LIGAND; RAT-BRAIN MICROSOMES; ANANDAMIDE AMIDOHYDROLASE; ENZYMATIC-SYNTHESIS; ACYLETHANOLAMINES; ACYLPHOSPHATIDYLETHANOLAMINE; PHOSPHODIESTERASE; IDENTIFICATION; BIOSYNTHESIS; DEGRADATION	N-Arachidonoylethanolamine (anandamide) is canna-bimimetic, and N-palmitoylethanolamine is anti-inflammatory and immunosuppressive. We found an amidase that is more active with the latter than the former in contrast to the previously known anandamide amidohydrolase for which N-palmitoylethanolamine is a poor substrate. Proteins solubilized by freezing and thawing from the 12,000 x g pellet of various rat organs hydrolyzed [C-14]N-palmitoylethanolamine to palmitic acid and ethanolamine. The specific enzyme activity was higher in the order of lung > spleen > small intestine > thymus > cecum, and high activity was found in peritoneal and alveolar macrophages. The enzyme with a molecular mass of 31 kDa was purified from rat lung to a specific activity of 1.8 mu mol/min/mg protein. Relative reactivities of the enzyme with various N-acylethanolamines (100 muM) were as follows: N-palmitoylethanolamine, 100%; N-myristoylethanolamine, 48%; N-stearoylethanolamine, 21%; N-oleoylethanolamine, 20%; N-linoleoylethanolamine, 13%; anandamide, 8%. The enzyme was the most active at pH 5 and was activated 7-fold by Triton X-100. The enzyme was almost insensitive to methyl arachidonyl fluorophosphonate, which inhibited anandamide amidohydrolase potently. Thus, the new enzyme referred to as N-palmitoylethanolamine hydrolase was clearly distinguishable from anandamide amidohydrolase.	Kagawa Med Univ, Dept Biochem, Miki, Kagawa 7610793, Japan; Univ Tokushima, Sch Med, Dept Biochem, Tokushima 7708503, Japan; Kyoto Womens Univ, Fac Home Econ, Dept Food & Nutr, Higashiyama Ku, Kyoto 6058501, Japan	Kagawa University; Tokushima University; Kyoto Womens University	Yamamoto, S (corresponding author), Kagawa Med Univ, Dept Biochem, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.							BACHUR NR, 1965, J BIOL CHEM, V240, P1019; BERDYSHEV E, 1998, LIFE SCI, V63, pL125; Berdyshev EV, 1997, EUR J PHARMACOL, V330, P231, DOI 10.1016/S0014-2999(97)01007-8; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 1998, EUR J BIOCHEM, V254, P634, DOI 10.1046/j.1432-1327.1998.2540634.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DePetrocellis L, 1997, BIOCHEM BIOPH RES CO, V231, P82, DOI 10.1006/bbrc.1997.6000; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; EPPS DE, 1979, BIOCHEM BIOPH RES CO, V90, P628, DOI 10.1016/0006-291X(79)91281-6; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; GATT S, 1966, J BIOL CHEM, V241, P3724; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; Gulaya NM, 1998, CHEM PHYS LIPIDS, V97, P49, DOI 10.1016/S0009-3084(98)00093-0; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; Katayama K, 1999, BBA-MOL CELL BIOL L, V1440, P205, DOI 10.1016/S1388-1981(99)00124-9; Katayama K, 1997, BBA-LIPID LIPID MET, V1347, P212, DOI 10.1016/S0005-2760(97)00078-7; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kondo S, 1998, ARCH BIOCHEM BIOPHYS, V354, P303, DOI 10.1006/abbi.1998.0688; Kurahashi Y, 1997, BIOCHEM BIOPH RES CO, V237, P512, DOI 10.1006/bbrc.1997.7180; Lambert DM, 1999, BBA-MOL CELL BIOL L, V1440, P266, DOI 10.1016/S1388-1981(99)00132-8; Lambert DM, 1999, CURR MED CHEM, V6, P757; Matsuda S, 1997, EXP EYE RES, V64, P707, DOI 10.1006/exer.1996.0265; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; Schmid PC, 1997, CHEM PHYS LIPIDS, V87, P103, DOI 10.1016/S0009-3084(97)00032-7; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Schmid PC, 1998, CHEM PHYS LIPIDS, V92, P27, DOI 10.1016/S0009-3084(97)00109-6; Schmid PC, 1996, FEBS LETT, V385, P125; Sheskin T, 1997, J MED CHEM, V40, P659, DOI 10.1021/jm960752x; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; SPENCE MW, 1986, BIOCHEM CELL BIOL, V64, P400, DOI 10.1139/o86-056; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V221, P206; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; Ueda N, 2001, BBA-MOL CELL BIOL L, V1532, P121, DOI 10.1016/S1388-1981(01)00120-2; Ueda N, 1999, FEBS LETT, V454, P267, DOI 10.1016/S0014-5793(99)00820-0; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	50	203	219	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35552	35557		10.1074/jbc.M106261200	http://dx.doi.org/10.1074/jbc.M106261200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11463796	hybrid			2022-12-25	WOS:000171109300047
J	Lu, HS; Chai, JJ; Li, M; Huang, BR; He, CH; Bi, RC				Lu, HS; Chai, JJ; Li, M; Huang, BR; He, CH; Bi, RC			Crystal structure of human epidermal growth factor and its dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRELIMINARY-X-RAY; B-LOOP; CRYSTALLIZATION; NMR; ACTIVATION; MOLECULES; COMPLEX; PROTEIN	Epidermal growth factor (EGF) is a typical growth-stimulating peptide and functions by binding to specific cell-surface receptors and inducing dimerization of the receptors. Little is known about the molecular mechanism of EGF-induced dimerization of EGF receptors. The crystal structure of human EGF has been determined at pH 8.1. There are two human EGF molecules A and B in the asymmetric unit of the crystals, which form a potential dimer. Importantly, a number of residues known to be indispensable for EGF binding to its receptor are involved in the interface between the two EGF molecules, suggesting a crucial role of EGF dimerization in the EGF-induced dimerization of receptors. In addition, the crystal structure of EGF shares the main features of the NMR structure of mouse EGF determined at pH 2.0, but structural comparisons between different models have revealed new detailed features and properties of the EGF structure.	Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China; Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100005, Peoples R China; Beijing Union Med Coll, Beijing 100005, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Bi, RC (corresponding author), Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China.	rebi@iname.com	lankarani, kamran b/D-5901-2012; Lankarani, Kamran B/P-5336-2019; Lankarani, Kamran Bagheri/P-2066-2017	Lankarani, Kamran B/0000-0002-7524-9017; Lankarani, Kamran Bagheri/0000-0002-7524-9017; Chai, Jijie/0000-0001-7591-3873				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Blanco-Aparicio C, 1998, J BIOL CHEM, V273, P12370, DOI 10.1074/jbc.273.20.12370; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Campbell I D, 1989, Prog Growth Factor Res, V1, P13, DOI 10.1016/0955-2235(89)90038-0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1978, NATURE, V276, P409, DOI 10.1038/276409a0; Chai JJ, 2000, ACTA CRYSTALLOGR D, V56, P62, DOI 10.1107/S0907444999012615; COLMAN PM, 1976, CRYSTALLOGRAPHIC COM, P248; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; Degenhardt M, 1998, ACTA CRYSTALLOGR D, V54, P999, DOI 10.1107/S0907444998001851; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HIGUCHI Y, 1988, J BIOCHEM-TOKYO, V103, P905, DOI 10.1093/oxfordjournals.jbchem.a122385; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P741, DOI 10.1093/oxfordjournals.jbchem.a122338; KRAULIS PJ, 1993, J APPL CRYSTALLOGR, V26, P283; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P56; PHILO J, 1994, J BIOL CHEM, V269, P27840; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Van Zoelen E J, 2000, Vitam Horm, V59, P99, DOI 10.1016/S0083-6729(00)59005-0; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; 黄秉仁, 1998, 中国生物化学与分子生物学报, V14, P512	33	60	66	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34913	34917		10.1074/jbc.M102874200	http://dx.doi.org/10.1074/jbc.M102874200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11438527	hybrid			2022-12-25	WOS:000171024600076
J	Castrillo, A; Mojena, M; Hortelano, S; Bosca, L				Castrillo, A; Mojena, M; Hortelano, S; Bosca, L			Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449 - Comparison with the effects of 15-deoxy-Delta(12,14)-prostaglandin J(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; PPAR-GAMMA; CYCLOPENTENONE PROSTAGLANDINS; BACTERIAL LIPOPOLYSACCHARIDE; TERMINAL KINASE; IN-VITRO; APOPTOSIS; ALPHA; INFLAMMATION	The effects of L-796,449 (3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)phenylacetic acid; referred to henceforth as compound G), a thiazolidinedione-unrelated peroxisome proliferator activated-receptor-gamma (PPAR-gamma) agonist, on early signaling in lipopolysaccharide-activated RAW 264.7 macrophages were analyzed and compared with those elicited by 15-deoxy-Delta (12,14)-prostaglandin J(2) and the thiazolidinedione rosiglitazone. Compound G inhibited the activation of nuclear factor kappaB through the impairment of the targeting and degradation of I kappaB proteins and promoted a redistribution of I kappaB alpha and I kappaB beta in the nucleus of activated cells. Compound G inhibited I kappaB kinase (IKK) activity both in vivo and in vitro, suggesting a direct mechanism of interaction between this molecule and the IKK complex. The effect of compound G on IKK activity was independent of PPAR-gamma engagement because RAW 264.7 cells expressed negligible levels of this nuclear receptor, and rosiglitazone failed to mimic these actions. Moreover, treatment of activated macrophages with compound G enhanced the synthesis of superoxide anion, which, in combination with the NO produced under activation conditions, triggered apoptosis through the intracellular synthesis of peroxynitrite. These results suggest that compound G might contribute to the resolution of inflammation by favoring the induction of apoptosis through mechanisms independent of PPAR-gamma engagement.	Univ Complutense Madrid, Fac Farm, CSIC, Ctr Mixto,Inst Bioquim, E-28040 Madrid, Spain; Merck Sharp & Dohme Ltd, CIBE, Madrid 28027, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Merck & Company	Bosca, L (corresponding author), Univ Complutense Madrid, Fac Farm, CSIC, Ctr Mixto,Inst Bioquim, E-28040 Madrid, Spain.		Bosca, Lisardo/A-2059-2008; Hortelano, Sonsoles/A-7954-2010	Bosca, Lisardo/0000-0002-0253-5469; Hortelano, Sonsoles/0000-0003-2528-0072; Mojena, Marina/0000-0002-5371-8118				Albina JE, 1998, CANCER METAST REV, V17, P39, DOI 10.1023/A:1005904704618; Anderson GP, 1996, TRENDS PHARMACOL SCI, V17, P438, DOI 10.1016/S0165-6147(96)01004-8; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; Eguchi Y, 1997, P NATL ACAD SCI USA, V94, P14689, DOI 10.1073/pnas.94.26.14689; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Glass CK, 2000, GENE DEV, V14, P121; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hanley K, 1997, J CLIN INVEST, V100, P705, DOI 10.1172/JCI119583; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Hortelano S, 1999, BRIT J PHARMACOL, V126, P1139, DOI 10.1038/sj.bjp.0702422; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Procyk KJ, 2000, BLOOD, V96, P2592; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tontonoz P, 1999, CURR OPIN LIPIDOL, V10, P485, DOI 10.1097/00041433-199912000-00002; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	54	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34082	34088		10.1074/jbc.M102472200	http://dx.doi.org/10.1074/jbc.M102472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438523	hybrid			2022-12-25	WOS:000170910200106
J	Whistler, JL; Tsao, P; von Zastrow, M				Whistler, JL; Tsao, P; von Zastrow, M			A phosphorylation-regulated brake mechanism controls the initial endocytosis of opioid receptors but is not required for post-endocytic sorting to lysosomes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; NG108-15 HYBRID-CELLS; DOWN-REGULATION; OPIATE RECEPTOR; MOLECULAR MECHANISMS; KINASE-C; DESENSITIZATION; ARRESTIN; RESENSITIZATION	The delta -opioid receptor (DOR) can undergo proteolytic down-regulation by endocytosis of receptors followed by sorting of internalized receptors to lysosomes. Although phosphorylation of the receptor is thought to play an important role in controlling receptor downregulation, previous studies disagree on whether phosphorylation is actually required for the agonist-induced endocytosis of opioid receptors. Furthermore, no previous studies have determined whether phosphorylation is required for subsequent sorting of internalized receptors to lysosomes. We have addressed these questions by examining the endocytic trafficking of a series of mutant versions of DOR expressed in stably transfected HEK 293 cells. Our results confirm that phosphorylation is not required for agonist-induced endocytosis of truncated mutant receptors that lack the distal carboxyl-terminal cytoplasmic domain containing sites of regulatory phosphorylation. However, phosphorylation is required for endocytosis of full-length receptors. Mutation of all serine/threonine residues located in the distal carboxyl-terminal tail domain of the full-length receptor to alanine creates functional mutant receptors that exhibit no detectable agonist-induced endocytosis. Substitution of these residues with aspartate restores the ability of mutant receptors to undergo agonist-induced endocytosis. Studies using green fluorescent protein-tagged versions of arrestin-3 suggest that the distal tail domain, when not phosphorylated, inhibits receptor-mediated recruitment of beta -arrestins to the plasma membrane. Biochemical and radioligand binding studies indicate that, after endocytosis occurs, phosphorylation-defective mutant receptors traffic to lysosomes with similar kinetics as wild type receptors. We conclude that phosphorylation controls endocytic trafficking of opioid receptors primarily by regulating a "brake" mechanism that prevents endocytosis of full-length receptors in the absence of phosphorylation. After endocytosis occurs, subsequent steps of membrane trafficking mediating sorting and transport to lysosomes do not require receptor phosphorylation.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Program Cell Biol, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Cell Biol, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Cell Biol, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Whistler, JL (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	shooz2@itsa.ucsf.edu			NIDA NIH HHS [DA12864] Funding Source: Medline; NIGMS NIH HHS [T32GM08120] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012864] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chaturvedi K, 2000, MOL BRAIN RES, V80, P166, DOI 10.1016/S0169-328X(00)00134-0; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; GUCKER S, 1992, MOL PHARMACOL, V42, P656; Guo J, 2000, MOL PHARMACOL, V58, P1050, DOI 10.1124/mol.58.5.1050; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Malbon C C, 1991, Chin J Physiol, V34, P105; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Roth BL, 1998, DRUG ALCOHOL DEPEN, V51, P73, DOI 10.1016/S0376-8716(98)00067-2; Trapaidze N, 2000, DNA CELL BIOL, V19, P93, DOI 10.1089/104454900314609; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28	41	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34331	34338		10.1074/jbc.M104627200	http://dx.doi.org/10.1074/jbc.M104627200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443128	hybrid			2022-12-25	WOS:000170910200137
J	Kang, MG; Chen, CC; Felix, R; Letts, VA; Frankel, WN; Mori, Y; Campbell, KP				Kang, MG; Chen, CC; Felix, R; Letts, VA; Frankel, WN; Mori, Y; Campbell, KP			Biochemical and biophysical evidence for gamma(2) subunit association with neuronal voltage-activated Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL; N-TYPE; SKELETAL-MUSCLE; XENOPUS OOCYTES; BETA-SUBUNIT; FUNCTIONAL-CHARACTERIZATION; AUXILIARY SUBUNITS; ION CHANNELS; BRAIN; IDENTIFICATION	A novel gene (Cacng2; gamma (2)) encoding a protein similar to the voltage-activated Ca2+ channel gamma (1) subunit was identified as the defective gene in the epileptic and ataxic mouse, stargazer. In this study, we analyzed the association of this novel neuronal gamma (2) subunit with Ca2+ channels of rabbit brain, and the function of the gamma (2) subunit in recombinant neuronal Ca2+ channels expressed in Xenopus oocytes. Our results showed that the gamma (2) subunit and a closely related protein (called gamma (3)) co-sedimented and co-immunoprecipitated with neuronal Ca2+ channel subunits in vivo. Electrophysiological analyses showed that y2 co-expression caused a significant decrease in the current amplitude of both alpha (1B)(alpha (1)2.2)-class (36.8%) and alpha (1A)(alpha (1)2.1)-class (39.7%) Ca2+ channels (alpha (1)beta (3)alpha (2)delta)- Interestingly, the inhibitory effects of the gamma (2) subunit on current amplitude were dependent on the co-expression of the alpha (2)delta subunit. In addition, co-expression of gamma (2) or gamma (1) also significantly decelerates the activation kinetics of a IB-class Ca2+ channels. Taken together, these results suggest that the gamma (2) subunit is an important constituent of the neuronal Ca2+ channel complex and that it down-regulates neuronal Ca2+ channel activity. Furthermore, the gamma (2) subunit likely contributes to the fine-tuning of neuronal Ca2+ channels by counterbalancing the effects of the alpha (2)delta subunit.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Phys & Biophys,Dept Neurol, Iowa City, IA 52242 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 4448585, Japan	Howard Hughes Medical Institute; University of Iowa; Jackson Laboratory; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Phys & Biophys,Dept Neurol, 400 EMRB, Iowa City, IA 52242 USA.		Felix, Ricardo/A-6989-2008; Chen, Chien-Chang/D-2023-2015	Felix, Ricardo/0000-0002-5383-7176; Chen, Chien-Chang/0000-0001-8850-4278; Kang, Myoung-Goo/0000-0003-2649-219X; Campbell, Kevin/0000-0003-2066-5889				Ahern C A, 2001, BMC Physiol, V1, P8, DOI 10.1186/1472-6793-1-8; BALAGUERO N, 2000, SOC NEUR 30 ANN M NE, P365; Black JL, 1999, MAYO CLIN PROC, V74, P357, DOI 10.4065/74.4.357; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Burgess DL, 1999, MOL CELL NEUROSCI, V13, P293, DOI 10.1006/mcne.1999.0748; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; De Waard M, 1996, Ion Channels, V4, P41; Eberst R, 1997, PFLUG ARCH EUR J PHY, V433, P633, DOI 10.1007/s004240050324; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Freise D, 2000, J BIOL CHEM, V275, P14476, DOI 10.1074/jbc.275.19.14476; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; Harlow E., 1999, USING ANTIBODIES LAB; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Lerche H, 1996, PFLUG ARCH EUR J PHY, V431, P461, DOI 10.1007/s004240050021; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Mori Y, 2000, J NEUROSCI, V20, P5654, DOI 10.1523/JNEUROSCI.20-15-05654.2000; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; SuhKim H, 1996, MOL PHARMACOL, V50, P1330; Wakamori M, 1999, J PHYSIOL-LONDON, V517, P659, DOI 10.1111/j.1469-7793.1999.0659s.x; WEI XY, 1991, J BIOL CHEM, V266, P21943; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; WITCHER DR, 1994, METHOD ENZYMOL, V238, P335; ZHANG Y, 2000, SOC NEUR 30 ANN M NE, P364; Zwingman TA, 2001, J NEUROSCI, V21, P1169	35	95	101	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32917	32924		10.1074/jbc.M100787200	http://dx.doi.org/10.1074/jbc.M100787200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11441000	hybrid			2022-12-25	WOS:000170746000073
J	Gerber, SH; Rizo, J; Sudhof, TC				Gerber, SH; Rizo, J; Sudhof, TC			The top loops of the C-2 domains from synaptotagmin and phospholipase A(2) control functional specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOSOLIC PHOSPHOLIPASE-A2; CRYSTAL-STRUCTURE; MEMBRANE-DOCKING; BINDING DOMAIN; CA2+; MOTIF; SITE	The phospholipid-binding specificities of C-2 domains, widely distributed Ca2+-binding modules, differ greatly despite similar three-dimensional structures. To understand the molecular basis for this specificity, we have examined the synaptotagmin 1 C(2)A domain, which interacts in a primarily electrostatic, Ca2+-dependent reaction with negatively charged phospholipids, and the cytosolic phospholipase A(2) (cPLA(2)) C-2 domain, which interacts by a primarily hydrophobic Ca2+-dependent mechanism with neutral phospholipids. We show that grafting the short Ca2+-binding loops from the tip of the cPLA(2) C-2 domain onto the top of the synaptotagmin I C(2)A domain confers onto the synaptotagmin I C(2)A domain the phospholipid binding specificity of the cPLA(2) C-2 domain, indicating that the functional specificity of C-2 domains is determined by their short top loops.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040944] Funding Source: NIH RePORTER; NINDS NIH HHS [NS40944] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Ubach J, 1999, NAT CELL BIOL, V1, P106, DOI 10.1038/10076; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Williams RL, 1996, STRUCTURE, V4, P1387, DOI 10.1016/S0969-2126(96)00146-3; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512	26	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32288	32292		10.1074/jbc.C100108200	http://dx.doi.org/10.1074/jbc.C100108200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11447211	hybrid			2022-12-25	WOS:000170613500110
J	Klarlund, JK; Holik, J; Chawla, A; Park, JG; Buxton, J; Czech, MP				Klarlund, JK; Holik, J; Chawla, A; Park, JG; Buxton, J; Czech, MP			Signaling complexes of the FERM domain-containing protein GRSP1 bound to ARF exchange factor GRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; ADP-RIBOSYLATION FACTOR-6; PLECKSTRIN-HOMOLOGY DOMAINS; PLASMA-MEMBRANE; FACTOR MSEC7-1; 3-KINASE; CYTOHESIN-1; ARNO; TRANSLOCATION; DOWNSTREAM	GRP1 is a member of a family of proteins that contain a coiled-coil region, a Sec7 homology domain with guanosine nucleotide exchange activity for the ARF GTP-binding proteins, and a pleckstrin homology domain at the C terminus. The pleckstrin homology domain of GRP1 binds phosphatidylinositol (3,4,5) trisphosphate and mediates the translocation of GRP1 to the plasma membrane upon agonist stimulation of PI 3-kinase activity. Using a P-32-labeled GRP1 probe to screen a mouse brain cDNA expression library, we isolated a cDNA clone encoding a GRP1-binding partner (GRSP1) that exists as two different splice variants in brain and lung. The GRSP1 protein contains a FERM protein interaction domain as well as two coiled coil domains and may therefore function as a scaffolding protein. Mapping experiments revealed that the interaction of GRP1 and GRSP1 occurs through the coiled coil domains in the two proteins. Immunodepletion experiments indicate that virtually all of the endogenous GRSP1 protein exists as a complex with GRP1 in lung. When co-expressed in Chinese hamster ovary cells expressing the human insulin receptor, both proteins display a diffuse, cytoplasmic localization. Acute translocation and co-localization of GRSP1 and GRP1 to ruffles in the plasma membrane was evident after insulin stimulation. These results identify GRSP1 as a novel member of GRP1 signaling complexes that are acutely recruited to plasma membrane ruffles in response to insulin receptor signaling.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Pittsburgh, Ophthalmol & Visual Sci Res Ctr, Pittsburgh, PA 15213 USA	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.				NEI NIH HHS [EY 08098] Funding Source: Medline; NIDDK NIH HHS [DK 30648] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashery U, 1999, P NATL ACAD SCI USA, V96, P1094, DOI 10.1073/pnas.96.3.1094; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; Grifman M, 1998, P NATL ACAD SCI USA, V95, P13935, DOI 10.1073/pnas.95.23.13935; Hinchliffe K, 2000, CURR BIOL, V10, pR104, DOI 10.1016/S0960-9822(00)00303-1; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Klarlund JK, 2001, METHOD ENZYMOL, V329, P279; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Ogasawara M, 2000, J BIOL CHEM, V275, P3221, DOI 10.1074/jbc.275.5.3221; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Venkateswarlu K, 2000, BIOCHEM J, V345, P719, DOI 10.1042/0264-6021:3450719; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2	32	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40065	40070		10.1074/jbc.M105260200	http://dx.doi.org/10.1074/jbc.M105260200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11445584	hybrid			2022-12-25	WOS:000171789200076
J	Kalo, MS; Yu, HH; Pasquale, EB				Kalo, MS; Yu, HH; Pasquale, EB			In vivo tyrosine phosphorylation sites of activated ephrin-B1 and EphB2 from neural tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE LIGANDS; MASS-SPECTROMETRY; VISUAL-SYSTEM; SH2 DOMAINS; IN-VITRO; RECEPTORS; KINASES; BINDING; PDZ; EXPRESSION	EphB2 is a receptor tyrosine kinase of the Eph family and ephrin-B1 is one of its transmembrane ligands. In the embryo, EphB2 and ephrin-B1 participate in neuronal axon guidance, neural crest cell migration, the formation of blood vessels, and the development of facial structures and the inner ear. Interestingly, EphB2 and ephrin-B1 can both signal through their cytoplasmic domains and become tyrosine-phosphorylated when bound to each other. Tyrosine phosphorylation regulates EphB2 signaling and likely also ephrin-B1 signaling. Embryonic retina is a tissue that highly expresses both ephrin-B1 and EphB2. Although the expression patterns of EphB2 and ephrin-B1 in the retina are different, they partially overlap, and both proteins are substantially tyrosine-phosphorylated. To understand the role of ephrin-B1 phosphorylation, we have identified three tyrosines of ephrin-B1 as in vivo phosphorylation sites in transfected 293 cells stimulated with soluble EphB2 by using mass spectrometry and site-directed mutagenesis. These tyrosines are also physiologically phosphorylated in the embryonic retina, although the extent of phosphorylation at each site may differ. Furthermore, many of the tyrosines of EphB2 previously identified as phosphorylation sites in 293 cells (Kalo, M. S., and Pasquale, E. B. (1999) Biochemistry 38,14396-14408) are also phosphorylated in retinal tissue. Our data underline the complexity of ephrin-Eph bidirectional signaling by implicating many tyrosine phosphorylation sites of the ligand-receptor complex.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [F32CA073195] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY010576] Funding Source: NIH RePORTER; NCI NIH HHS [CA73195] Funding Source: Medline; NEI NIH HHS [EY10576] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams RH, 2001, CELL, V104, P57, DOI 10.1016/S0092-8674(01)00191-X; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; [Anonymous], 1997, Cell, V90, P403; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; Braisted JE, 1997, DEV BIOL, V191, P14, DOI 10.1006/dbio.1997.8706; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Chong LD, 2000, MOL CELL BIOL, V20, P724, DOI 10.1128/MCB.20.2.724-734.2000; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Connor RJ, 1998, DEV BIOL, V193, P21, DOI 10.1006/dbio.1997.8786; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; De Corte V, 1999, PROTEIN SCI, V8, P234; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; Kalo MS, 1999, BIOCHEMISTRY-US, V38, P14396, DOI 10.1021/bi991628t; Kalo MS, 1999, CELL TISSUE RES, V298, P1, DOI 10.1007/PL00008807; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Watty A, 2000, P NATL ACAD SCI USA, V97, P4585, DOI 10.1073/pnas.080061997; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	43	71	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38940	38948		10.1074/jbc.M105815200	http://dx.doi.org/10.1074/jbc.M105815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11466320	hybrid			2022-12-25	WOS:000171673200081
J	Fortea, MI; Soler, F; Fernandez-Belda, F				Fortea, MI; Soler, F; Fernandez-Belda, F			Unravelling the interaction of thapsigargin with the conformational states of Ca2+-ATPase from skeletal sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S3 STALK SEGMENT; INORGANIC-PHOSPHATE; THAPSIA-GARGANICA; TUMOR PROMOTER; CALCIUM-PUMP; ATPASE; INHIBITION; PROTEINS; CA-2+; MECHANISM	Preincubation of thapsigargin with sarcoplasmic reticulum vesicles in the presence of high Ca2+ or the addition of high Ca2+ to microsomal vesicles preincubated with thapsigargin in the absence of Ca2+ allowed full enzyme phosphorylation by ATP. However, the enzyme activity was not protected by high Ca2+ even when the samples were subjected to gel filtration before ATP addition. Our data indicate that: (i) the enzyme in the Ca2+-bound conformation can be stabilized in the presence of thapsigargin; (ii) the conformational transition from the Ca2+-free to the Ca2+-bound state can be elicited by Ca2+ when thapsigargin is present; (iii) thapsigargin binding occurs whether or not the enzyme is in the presence of Ca2+, and so a ternary complex enzyme-Ca2+-thapsigargin may be formed; (iv) thapsigargin can be dissociated from the enzyme with a slow kinetics after dilution under drastic conditions; (v) the kinetics of Ca2+ binding is clearly slowed down by thapsigargin; and (vi) thapsigargin does not affect the hydrolysis rate of phosphorylating substrates when measured in the absence of Ca2+, indicating that thapsigargin specifically inhibits the Ca2+-dependent activity.	Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol A, E-30071 Murcia, Spain	University of Murcia	Fernandez-Belda, F (corresponding author), Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol A, E-30071 Murcia, Spain.	fbelda@um.es						BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; CHRISTENSEN SB, 1980, TETRAHEDRON LETT, V21, P3829, DOI 10.1016/0040-4039(80)80191-2; CHRISTENSEN SB, 1982, J ORG CHEM, V47, P649; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fernandez-Belda F, 2001, J BIOL CHEM, V276, P7998, DOI 10.1074/jbc.M008648200; HUA SM, 1995, BIOCHEMISTRY-US, V34, P5137, DOI 10.1021/bi00015a026; Hua SM, 1997, BIOCHEMISTRY-US, V36, P11865, DOI 10.1021/bi970105n; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	27	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37266	37272		10.1074/jbc.M103949200	http://dx.doi.org/10.1074/jbc.M103949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11445572	hybrid			2022-12-25	WOS:000171375700055
J	Navarro, JA; Myshkin, E; De la Rosa, MA; Bullerjahn, GS; Hervas, M				Navarro, JA; Myshkin, E; De la Rosa, MA; Bullerjahn, GS; Hervas, M			The unique proline of the Prochlorothrix hollandica plastocyanin hydrophobic patch impairs electron transfer to photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLASH KINETIC-ANALYSIS; CYTOCHROME C(6); PHOTOSYNTHETIC PROKARYOTE; SIMULATION; REDUCTION; OXIDATION; DYNAMICS	A number of surface residues of plastocyanin from Prochlorothrix hollandica have been modified by site-directed mutagenesis. Changes have been made in amino acids located in the amino-terminal hydrophobic patch of the copper protein, which presents a variant structure as compared with other plastocyanins. The single mutants Y12G, Y12F, Y12W, P14L, and double mutant Y12G/P14L have been produced. Their reactivity toward photosystem I has been analyzed by laser flash absorption spectroscopy. Plots of the observed rate constant with all mutants versus plastocyanin concentration show a saturation profile similar to that with wildtype plastocyanin, thus suggesting the formation of a plastocyanin-photosystem I transient complex. The mutations do not induce relevant changes in the equilibrium constant for complex formation but induce significant variations in the electron transfer rate constant mainly with the two mutants at proline 14. Additionally: molecular dynamics calculations indicate that mutations at position 14 yield small changes in the geometry of the copper center. The comparative kinetic analysis of the reactivity of plastocyanin mutants toward photosystem I from different organisms (plants and cyanobacteria) reveals that reversion of the unique proline of Prochlorothrix plastocyanin to the conserved leucine of all other plastocyanins at this position enhances the reactivity of the Prochlorothrix protein.	Univ Seville, Ctr Invest Cient Isl Cartuja, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain; Bowling Green State Univ, Dept Biol Sci, Ctr Photochem Sci, Bowling Green, OH 43403 USA	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC); University System of Ohio; Bowling Green State University	Hervas, M (corresponding author), Univ Seville, Ctr Invest Cient Isl Cartuja, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio S-N, Seville 41092, Spain.	marosa@cica.es	Hervas, Manuel/K-9279-2014; Bullerjahn, George S/F-4428-2010; De la Rosa, Miguel/B-2545-2014; navarro, jose a/B-6354-2015	Hervas, Manuel/0000-0003-4523-8891; De la Rosa, Miguel/0000-0003-1187-5737; navarro, jose a/0000-0002-0536-6074; Bullerjahn, George/0000-0001-5319-7896				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Babu CR, 1997, BIOCHEM BIOPH RES CO, V235, P631, DOI 10.1006/bbrc.1997.6846; Babu CR, 1999, BIOCHEMISTRY-US, V38, P4988, DOI 10.1021/bi983024f; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; Downard AJ, 1996, INORG CHEM, V35, P7684, DOI 10.1021/ic960642g; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; Kolthoff IM, 1935, J PHYS CHEM-US, V39, P945, DOI 10.1021/j150367a004; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MATTHIJS HCP, 1994, MOL BIOL CYANOBACTER, P49; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; Navarro JA, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1605; NELISSEN B, 1995, MOL BIOL EVOL, V12, P1166; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sigfridsson K, 1998, PHOTOSYNTH RES, V57, P1, DOI 10.1023/A:1006067631076; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; Ungar LW, 1997, BIOPHYS J, V72, P5, DOI 10.1016/S0006-3495(97)78642-9	26	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37501	37505		10.1074/jbc.M105367200	http://dx.doi.org/10.1074/jbc.M105367200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11457853	hybrid			2022-12-25	WOS:000171375700084
J	Kim, YM; Ye, LW; Maloney, PC				Kim, YM; Ye, LW; Maloney, PC			Helix proximity in OxlT, the oxalate : formate antiporter of Oxalobacter formigenes - Cross-linking between TM2 and TM11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE PERMEASE; ESCHERICHIA-COLI; BACTERIAL CHEMORECEPTOR; EXCHANGE PROTEIN; TRANSMEMBRANE; MEMBRANE; TRANSPORTER; RECEPTOR	Experiments were designed to evaluate the proximity of transmembrane helices two (TM2) and eleven (TM11) in the tertiary structure of Ox1T, the oxalate-formate exchange transporter of Oxalobacter formigenes. A tandem duplication of the Factor Xa protease cleavage site (IE-GRIEGR) was inserted into the central cytoplasmic loop of an Ox1T cysteine-less derivative in which an endogenous cleavage site had been eliminated by mutagenesis (R248Q). Using this host, double cysteine derivatives were constructed so as to pair one of seventeen positions in TM2 with one of four positions in TM11. Following treatment of membrane vesicles with Cu(Il)(1,10-phenanthroline)(3), molecular iodine, or NN'-o-phenylenedimaleimide, samples were exposed to Factor Xa, and disulfide bond formation was assessed after SDS-polyacrylamide gel electrophoresis by staining with antibody directed against the Ox1T C terminus. In the absence of disulfide bond formation, exposure to Factor Xa revealed the expected C-terminal 22-kDa fragment, a result unaffected by the presence of reductant. By contrast, after disulfide formation, Ox1T mobility remained at 35 kDa, and appearance of the 22-kDa fragment required addition of 200 mM dithiothreitol prior to electrophoresis. The four TM11 positions chosen for cysteine substitution lie on a helical face known to interact with substrate. Similarly, TM2 positions supporting disulfide trapping were also confined to a single helical face. We conclude that TM2 and TM11 are in close juxtaposition to one another in the tertiary structure of Ox1T.	Johns Hopkins Med Sch, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Maloney, PC (corresponding author), Johns Hopkins Med Sch, Dept Physiol, Baltimore, MD 21205 USA.	pmaloney@bs.jhmi.edu						Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; Beckwith J, 2000, METHOD ENZYMOL, V326, P3; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; LEE GF, 1994, J BIOL CHEM, V269, P29920; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; Wolin CD, 2000, BIOCHEMISTRY-US, V39, P6130, DOI 10.1021/bi0001269; Wu JH, 1998, J MOL BIOL, V282, P959, DOI 10.1006/jmbi.1998.2065; Ye LW, 2001, J BACTERIOL, V183, P2490, DOI 10.1128/JB.183.8.2490-2496.2001; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	20	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36681	36686		10.1074/jbc.M106079200	http://dx.doi.org/10.1074/jbc.M106079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11457863	hybrid			2022-12-25	WOS:000171194500083
J	Bachelder, RE; Wendt, MA; Fujita, N; Tsuruo, T; Mercurio, AM				Bachelder, RE; Wendt, MA; Fujita, N; Tsuruo, T; Mercurio, AM			The cleavage of Akt/protein kinase B by death receptor signaling is an important event in detachment-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-KINASE; MEDIATED APOPTOSIS; CELLULAR-SURVIVAL; AKT2 ONCOGENE; PHOSPHORYLATION; EXPRESSION; ACTIVATION; ANOIKIS	Epithelial cells undergo death receptor-dependent apoptosis when detached from matrix, a process termed anoikis. Activation of Akt/protein kinase B (PKB) by matrix attachment protects cells from anoikis. In this study, we establish a link between anoikis and Akt/PKB-mediated survival by demonstrating that Akt/PKB is cleaved by caspases in matrix-detached epithelial cells by a mechanism that involves death receptors. Reduced levels of Akt/PKB protein were observed in detached Madin-Darby canine kidney cells relative to cells attached to collagen. Equivalent levels of Akt/PKB, however, were detected in matrix-adherent and detached cells after inhibition of caspase activity or expression of an Akt/PKB mutant (D108+119A) that is resistant to caspase cleavage. The contribution of death domain-containing proteins to Akt/PKB cleavage was evidenced by the ability of dominant negative Fas-associated death domain to restore normal levels of Akt/PKB; in matrix-detached cells. Importantly, expression of a cleavage-resistant Akt/PKB mutant protected matrix-detached cells from apoptosis. These studies suggest that members of the death receptor family promote the caspase-mediated cleavage of Akt/PKB and that this event contributes to anoikis.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1130032, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Tokyo; Japanese Foundation for Cancer Research	Bachelder, RE (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, 330 Brookline Ave, Boston, MA 02215 USA.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264	NCI NIH HHS [CA81697, CA89209, CA80789] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080789, R01CA089209, F32CA081697] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Fenton RG, 1998, CANCER RES, V58, P3391; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271	37	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34702	34707		10.1074/jbc.M102806200	http://dx.doi.org/10.1074/jbc.M102806200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11463786	hybrid			2022-12-25	WOS:000171024600049
J	Palanche, T; Ilien, B; Zoffmann, S; Reck, MP; Bucher, B; Edelstein, SJ; Galzi, JL				Palanche, T; Ilien, B; Zoffmann, S; Reck, MP; Bucher, B; Edelstein, SJ; Galzi, JL			The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; NUCLEOTIDE-BINDING PROTEINS; MAP KINASE ACTIVATION; SUBSTANCE-P RECEPTOR; BETA-GAMMA-SUBUNITS; CONSTITUTIVE ACTIVITY; BETA(2)-ADRENERGIC RECEPTOR; STRUCTURAL INSTABILITY; COUPLED RECEPTORS; NK2 RECEPTOR	G protein-coupled receptors are thought to mediate agonist-evoked signal transduction by interconverting between discrete conformational states endowed with different pharmacological and functional properties. In order to address the question of multiple receptor states, we monitored rapid kinetics of fluorescent neurokinin A (NKA) binding to tachykinin NK2 receptors, in parallel with intracellular calcium, using rapid mixing equipment connected to real time fluorescence detection. Cyclic AMP accumulation responses were also monitored. The naturally truncated version of neurokinin A (NKA-(4-10)) binds to the receptor with a single rapid phase and evokes only calcium responses. In contrast, full-length NKA binding exhibits both a rapid phase that correlates with calcium responses and a slow phase that correlates with cAMP accumulation. Furthermore, activators (phorbol esters and forskolin) and inhibitors (Ro 31-8220 and H89) of protein kinase C or A, respectively, exhibit differential effects on NKA binding and associated responses; activated protein kinase C facilitates a switch between calcium and cAMP responses, whereas activation of protein kinase A diminishes cAMP responses. NK2 receptors thus adopt multiple activatable, active, and desensitized conformations with low, intermediate, or high affinities and with distinct signaling specificities.	Ecole Super Biotechnol Strasbourg, CNRS, UPR 9050, F-67400 Illkirch Graffenstaden, France; Fac Pharm, F-67401 Illkirch Graffenstaden, France; Inst Federatif Rech, IFR 85, F-67400 Illkirch Graffenstaden, France; Inst Federatif Rech, FR 2059, F-67400 Illkirch Graffenstaden, France; Dept Biochem, CH-1211 Geneva 4, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Geneva	Galzi, JL (corresponding author), Ecole Super Biotechnol Strasbourg, CNRS, UPR 9050, Blvd Sebastien Brant, F-67400 Illkirch Graffenstaden, France.							ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Alblas J, 1996, EMBO J, V15, P3351, DOI 10.1002/j.1460-2075.1996.tb00700.x; Alewijnse AE, 1998, J NEUROCHEM, V71, P799; Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; ARKINSTALL S, 1994, FEBS LETT, V338, P75, DOI 10.1016/0014-5793(94)80119-3; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; Catalioto RM, 1998, N-S ARCH PHARMACOL, V358, P395, DOI 10.1007/PL00005270; Charpentier S, 1996, J BIOL CHEM, V271, P28071, DOI 10.1074/jbc.271.45.28071; Claeysen S, 2000, MOL PHARMACOL, V58, P136, DOI 10.1124/mol.58.1.136; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Edelstein SJ, 1996, BIOL CYBERN, V75, P361, DOI 10.1007/s004220050302; EGUCHI S, 1993, ENDOCRINOLOGY, V132, P524, DOI 10.1210/en.132.2.524; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Galzi JL, 1996, P NATL ACAD SCI USA, V93, P1853, DOI 10.1073/pnas.93.5.1853; GARCIA M, 1994, BIOCHEM PHARMACOL, V48, P1735, DOI 10.1016/0006-2952(94)90459-6; HEIDMANN T, 1980, BIOCHEM BIOPH RES CO, V97, P889, DOI 10.1016/0006-291X(80)91460-6; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUANG RRC, 1995, BIOCHEMISTRY-US, V34, P10048, DOI 10.1021/bi00031a029; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Lecci A, 2000, NEUROPEPTIDES, V34, P303, DOI 10.1054/npep.2000.0825; Leff P, 1997, TRENDS PHARMACOL SCI, V18, P355, DOI 10.1016/S0165-6147(97)90664-7; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Maggi CA, 1997, CAN J PHYSIOL PHARM, V75, P696, DOI 10.1139/cjpp-75-6-696; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Murtra P, 2000, NATURE, V405, P180, DOI 10.1038/35012069; NEMETH K, 1995, J BIOL CHEM, V270, P27601, DOI 10.1074/jbc.270.46.27601; NEUBIG RR, 1993, MOL PHARMACOL, V43, P734; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pommier B, 1999, J NEUROCHEM, V73, P281, DOI 10.1046/j.1471-4159.1999.0730281.x; POSNER RG, 1994, MOL PHARMACOL, V45, P65; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Roush ED, 1999, MOL PHARMACOL, V55, P855; Sagan S, 1996, J PHARMACOL EXP THER, V276, P1039; Sagan S, 1999, J BIOL CHEM, V274, P23770, DOI 10.1074/jbc.274.34.23770; THEODORSSONNORHEIM E, 1987, EUR J BIOCHEM, V166, P693, DOI 10.1111/j.1432-1033.1987.tb13567.x; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; Torrens Y, 1998, J NEUROCHEM, V70, P2091; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; Wang L, 1996, AM J PHYSIOL-GASTR L, V271, pG613, DOI 10.1152/ajpgi.1996.271.4.G613; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5	52	107	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34853	34861		10.1074/jbc.M104363200	http://dx.doi.org/10.1074/jbc.M104363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11459843	hybrid			2022-12-25	WOS:000171024600069
J	Yokouchi, M; Kondo, T; Sanjay, A; Houghton, A; Yoshimura, A; Komiya, S; Zhang, H; Baron, R				Yokouchi, M; Kondo, T; Sanjay, A; Houghton, A; Yoshimura, A; Komiya, S; Zhang, H; Baron, R			Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; NEGATIVE REGULATOR; BINDING DOMAIN; RING FINGER; PROTOONCOGENE PRODUCT; SIGNALING PATHWAY; CSF-1 RECEPTOR; ACTIVE SRC; ACTIVATION	The protooncogene c-Cbl has recently emerged as an E3 ubiquitin ligase for activated receptor tyrosine kinases. We report here that c-Cbl also mediates the ubiquitination of another protooncogene, the non-receptor tyrosine kinase c-Src, as well as of itself. The c-Cbl-dependent ubiquitination of Src and c-Cbl requires c-Cbl's RING finger, Src kinase activity, and c-Cbl's tyrosine phosphorylation, probably on Tyr-371.. In vitro, c-Cbl forms a stable complex with the ubiquitin-conjugating enzyme UbcH7, but active Src destabilizes this interaction. In contrast, Src inhibition stabilizes the c-Cbl.UbcH7.Src complex. Finally, c-Cbl reduces v-Src protein levels and suppresses v-Src-induced STAT3 activation. Thus, in addition to mediating the ubiquitination of activated receptor tyrosine kinases, c-Cbl also acts as a ubiquitin ligase for the non-receptor tyrosine kinase Src, thereby down-regulating Src.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06511 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06511 USA; Kagoshima Univ, Fac Med, Dept Orthopaed Surg, Kagoshima 8908520, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8930861, Japan	Yale University; Yale University; Yale University; Kagoshima University; Kurume University	Baron, R (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.		Kondo, Takeshi/G-2103-2012; Yoshimura, Akihiko/K-5515-2013	Kondo, Takeshi/0000-0001-7455-5824; 	NATIONAL CANCER INSTITUTE [R01CA072878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-72878] Funding Source: Medline; NIAMS NIH HHS [AR-42927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Sambrooke J., 1989, MOL CLONING LAB MANU; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; van Leeuwen JEM, 1999, MOL CELL BIOL, V19, P6652; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	54	181	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35185	35193		10.1074/jbc.M102219200	http://dx.doi.org/10.1074/jbc.M102219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11448952	hybrid			2022-12-25	WOS:000171024600109
J	Collingwood, TN; Urnov, FD; Chatterjee, VKK; Wolffe, AP				Collingwood, TN; Urnov, FD; Chatterjee, VKK; Wolffe, AP			Chromatin remodeling by the thyroid hormone receptor in regulation of the thyroid-stimulating hormone alpha-subunit promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; TUMOR VIRUS PROMOTER; BETA-A GENE; NUCLEAR RECEPTOR; POSITIONED NUCLEOSOMES; TRANSCRIPTION FACTOR; IN-VIVO; HYPERSENSITIVE SITES; BASAL TRANSCRIPTION; NEGATIVE REGULATION	The chromatin architecture of a promoter is an important determinant of its transcriptional response. For most target genes, the thyroid hormone receptor (TR) activates gene expression in response to thyroid hormone (T-3). In contrast, the thyroid-stimulating hormone a-subunit (TSH alpha) gene promoter is down-regulated by TR in the presence of T-3. Here we utilize the capacity for the Xenopus oocyte to chromatinize exogenous nuclear-injected DNA to analyze the chromatin architecture of the TSHa promoter and how this changes upon TR-mediated regulation. Interestingly, in the oocyte, the TSH alpha promoter was positively regulated by T-3. In the inactive state, the promoter contained six loosely positioned nucleosomes. The addition of TR/retinoid X receptor together had no effect on the chromatin structure, but the inclusion of T-3 induced strong positioning of a dinucleosome in the TSHa proximal promoter that was bordered by regions that were hypersensitive to cleavage by methidiumpropyl EDTA. We identified a novel thyroid response element that coincided with the proximal hypersensitive region. Furthermore, we examined the consequences of mutations in TR that impaired coactivator recruitment. In a comparison with the Xenopus TR betaA promoter, we found that the effects of these mutations on transactivation and chromatin remodeling were significantly more severe on the TSH alpha promoter.	NIH, Mol Embryol Lab, Bethesda, MD 20892 USA; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England	National Institutes of Health (NIH) - USA; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Collingwood, TN (corresponding author), Sangamo Biosci, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.	tcollingwood@sangamo.com		Chatterjee, Vengalil Krishna/0000-0002-2654-8854				Abel ED, 1999, J CLIN INVEST, V104, P291, DOI 10.1172/JCI6397; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; Belikov S, 2000, EMBO J, V19, P1023, DOI 10.1093/emboj/19.5.1023; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; FENSTERMAKER RA, 1990, MOL ENDOCRINOL, V4, P1480, DOI 10.1210/mend-4-10-1480; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Greenspan FS, 1997, BASIC CLIN ENDOCRINO, P192; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GURDON JB, 1968, J EMBRYOL EXP MORPH, V20, P401; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345; Tagami T, 1998, MOL ENDOCRINOL, V12, P1888, DOI 10.1210/me.12.12.1888; TONE Y, 1994, J BIOL CHEM, V269, P31157; Urnov FD, 2001, J BIOL CHEM, V276, P19753, DOI 10.1074/jbc.M100924200; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WONG CW, 1995, MOL ENDOCRINOL, V9, P551, DOI 10.1210/me.9.5.551; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; Wong JM, 1998, J BIOL CHEM, V273, P14186, DOI 10.1074/jbc.273.23.14186; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zorn AM, 1997, GENE DEV, V11, P2176, DOI 10.1101/gad.11.17.2176	64	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34227	34234		10.1074/jbc.M105172200	http://dx.doi.org/10.1074/jbc.M105172200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11454868	hybrid			2022-12-25	WOS:000170910200125
J	Kokura, K; Kaul, SC; Wadhwa, R; Nomura, T; Khan, MM; Shinagawa, T; Yasukawa, T; Colmenares, C; Ishii, S				Kokura, K; Kaul, SC; Wadhwa, R; Nomura, T; Khan, MM; Shinagawa, T; Yasukawa, T; Colmenares, C; Ishii, S			The ski protein family is required for MeCP2-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING-PROTEIN; HISTONE DEACETYLASE COMPLEX; TRANSFORMING-GROWTH-FACTOR; THYROID-HORMONE RECEPTOR; DNA METHYLATION; CO-REPRESSOR; N-COR; COREPRESSOR COMPLEX; MEDIATED REPRESSION; MECP2	DNA methylation is essential for development in the mouse and plays an important role in inactivation of the X chromosome and genomic imprinting. MeCP2 is the founder member of a family of methyl-CpG-binding proteins. MeCP2 directly binds to the co-repressor mSin3, which interacts with class I histone deacetylase, recruiting them to methyl-CpG regions to suppress transcription. Here, we report that MeCP2 directly binds to two co-repressors, c-Ski and N-CoR, in addition to mSin3A, and that the c-Ski, which is encoded by the c-ski proto-onocogene, is required for MeCP2-mediated transcriptional repression. The two regions of c-Ski, including the C-terminal coiled-coil region, interact with the transcriptional repression domain in the center of the MeCP2 molecule. The immunostaining signals for c-Ski and MeCP2 overlap in the nuclear heterochromatin region, suggesting the co-localization of the two proteins. The degree of transcriptional repression mediated by a Gal4-MeCP2 fusion protein was abrogated by overexpression of the putative dominant negative form of c-Ski. Furthermore, injection of antibodies against c-Ski and Sno almost completely abolished the transcriptional repression mediated by the Gal4-MeCP2 fusion protein. These results suggest that the ski gene family is involved in methyl CpG-mediated transcriptional repression.	RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Corp, CREST Project, Tsukuba, Ibaraki 3050074, Japan; Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3050046, Japan; Chugai Res Inst Mol Med, Niihari, Ibaraki 300101, Japan; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	RIKEN; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Cleveland Clinic Foundation	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Kaul, Sunil C/L-8671-2018; Ishii, Shunsuke/A-5271-2016	Kaul, Sunil C/0000-0002-0046-3916; Ishii, Shunsuke/0000-0002-6530-2478	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD030728, R29HD030728] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30728] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; Guenther MG, 2000, GENE DEV, V14, P1048; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang EY, 2000, GENE DEV, V14, P45; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kao HY, 2000, GENE DEV, V14, P55; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; NAGASE T, 1993, J BIOL CHEM, V268, P13710; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	49	156	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34115	34121		10.1074/jbc.M105747200	http://dx.doi.org/10.1074/jbc.M105747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11441023	hybrid			2022-12-25	WOS:000170910200110
J	Wang, GQ; Gastman, BR; Wieckowski, E; Goldstein, LA; Gambotto, A; Kim, TH; Fang, BL; Rabinovitz, A; Yin, XM; Rabinowich, H				Wang, GQ; Gastman, BR; Wieckowski, E; Goldstein, LA; Gambotto, A; Kim, TH; Fang, BL; Rabinovitz, A; Yin, XM; Rabinowich, H			A role for mitochondrial Bak in apoptotic response to anticancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; BCL-2 FAMILY MEMBERS; CELL-DEATH; IN-VIVO; CASPASE ACTIVATION; DEFICIENT MICE; HOMOLOG BAK; EXPRESSION; GENE	In the present study a clonal Jurkat cell line deficient in expression of Bak was used to analyze the role of Bak in cytochrome c release from mitochondria. The Bak-deficient T leukemic cells were resistant to apoptosis induced by UV, staurosporin, VP-16, bleomycin, or cisplatin. In contrast to wild type Jurkat cells, these Bak-deficient cells did not respond to UV or treatment with these anticancer drugs by membranous phosphatidylserine exposure, DNA breaks, activation of caspases, or release of mitochondrial cytochrome c. The block in the apoptotic cascade was in the mitochondrial mechanism for cytochrome c release because purified mitochondria from Bak-deficient cells failed to release cytochrome c or apoptosis-inducing factor in response to recombinant Bax or truncated Bid. The resistance of Bak-deficient cells to VP-16 was reversed by transduction of the Bak gene into these cells. Also, the cytochrome c releasing capability of the Bak-deficient mitochondria was restored by insertion of recombinant Bak protein into purified mitochondria. Following mitochondrial localization, low dose recombinant Bak restored the mitochondrial release of cytochrome c in response to Bax; at increased doses it induced cytochrome c release itself. The function of Bak is independent of Bid and Bax because recombinant Bak induced cytochrome c release from mitochondria purified from Bax(-/-), Bid(-/-), or Bid(-/-) Bax(-/-) mice. Together, our findings suggest that Bak plays a key role in the apoptotic machinery of cytochrome c release and thus in the chemoresistance of human T leukemic cells.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center	Rabinowich, H (corresponding author), Univ Pittsburgh, Inst Canc, W952 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R01CA084134, R01CA083817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012321] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 84134-01, R01 CA83817-01] Funding Source: Medline; NIDCR NIH HHS [P01DE 12321-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eguchi H, 2000, CELL DEATH DIFFER, V7, P439, DOI 10.1038/sj.cdd.4400675; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fang BL, 1998, J BIOL CHEM, V273, P4972, DOI 10.1074/jbc.273.9.4972; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Iwamoto KS, 1999, MOL CARCINOGEN, V25, P113, DOI 10.1002/(SICI)1098-2744(199906)25:2<113::AID-MC6>3.0.CO;2-D; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Johnson DE, 2000, CANCER RES, V60, P1818; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 2001, CANCER RES, V61, P659; Kondo S, 2000, CANCER RES, V60, P4328; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V148, P1567; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pataer A, 2000, CANCER RES, V60, P788; Pearson AS, 2000, CLIN CANCER RES, V6, P887; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yin XM, 2000, J MOL MED-JMM, V78, P203, DOI 10.1007/s001090000099; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	59	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34307	34317		10.1074/jbc.M103526200	http://dx.doi.org/10.1074/jbc.M103526200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11447222	hybrid			2022-12-25	WOS:000170910200134
J	Wu, SY; Chiang, CA				Wu, SY; Chiang, CA			TATA-binding protein-associated factors enhance the recruitment of RNA polymerase II by transcriptional activators.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE EARLY PROTEIN; TBP-ASSOCIATED FACTORS; PREINITIATION COMPLEX; BASAL TRANSCRIPTION; FUNCTIONAL-CHARACTERIZATION; EUKARYOTIC ACTIVATORS; LACKING TAF(II)S; TFIID COMPLEX; CELL-LINES; IN-VITRO	Transcription factor (TF) IID, comprised of the TATA-binding protein (TBP) and TBP-associated factors (TAFs), is a general transcription factor required for RNA polymerase II (pol II) transcription on most eukaryotic genes. Recent findings that TAFs may not be globally required for activator-dependent transcription in vivo and in vitro and that both TAF-dependent and TAF-independent promoters are found in yeast suggest that transcriptional activation can occur through at least two different pathways, depending on the presence or absence of TAFs. Using order-of-addition and template challenge assays performed in a human cell-free transcription system reconstituted with recombinant general transcription factors (TFIIB, TBP, TFIIE, TFIIF), a recombinant general cofactor (PC4), and highly purified epitope-tagged multiprotein complexes (TFIID, TFIIH, pol II), we demonstrate that when TBP is used as the TATA-binding factor transcriptional activators such as Gal4-VP16 and human papillomavirus E2 mainly function by facilitating pol II entry to the promoter region. In contrast, when TFIID is used as the TATA-binding factor, promoter recognition by TFIID appears to be the rate-limiting step facilitated by transcriptional activators during preinitiation complex assembly. Using protein-protein pull-down and far-Western analyses, we further show that the presence of TAFs in MID facilitates the recruitment of pol II by transcriptional activators, thereby switching the rate-limiting step from pol II entry to promoter recognition. Our findings thus provide distinct molecular mechanisms for TAF-independent and TAF-dependent activation.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Chiang, CA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NCI NIH HHS [CA81017] Funding Source: Medline; NIGMS NIH HHS [GM59643] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059643] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; ASO T, 1994, J BIOL CHEM, V269, P26575; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burley SK, 1998, CELL, V94, P551, DOI 10.1016/S0092-8674(00)81596-2; Chen Z, 2000, MOL CELL BIOL, V20, P5064, DOI 10.1128/MCB.20.14.5064-5076.2000; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dorris DR, 2000, MOL CELL BIOL, V20, P4350, DOI 10.1128/MCB.20.12.4350-4358.2000; Enzenauer C, 1998, INTERVIROLOGY, V41, P80, DOI 10.1159/000024918; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hou SY, 2000, MOL CELL BIOL, V20, P113, DOI 10.1128/MCB.20.1.113-125.2000; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Kershnar E, 1998, J BIOL CHEM, V273, P34444, DOI 10.1074/jbc.273.51.34444; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nishimura A, 2000, J VIROL, V74, P3752, DOI 10.1128/JVI.74.8.3752-3760.2000; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; Wu SY, 1996, BIOTECHNIQUES, V21, P718; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Wu SY, 1999, J BIOL CHEM, V274, P23480, DOI 10.1074/jbc.274.33.23480; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478	65	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34235	34243		10.1074/jbc.M102463200	http://dx.doi.org/10.1074/jbc.M102463200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11457828	hybrid			2022-12-25	WOS:000170910200126
J	Liu, XJ; Xie, Q; Zhu, YF; Chen, C; Ling, N				Liu, XJ; Xie, Q; Zhu, YF; Chen, C; Ling, N			Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR	Insulin-like growth factor-I (IGF-I) has both metabolic and mitogenic activities mediated through interaction with the type I IGF receptor. The circulation of IGF-I in blood and interstitial fluid is not free but bound mostly to a family of six high affinity IGF-binding proteins, which form stable complexes with IGF and neutralize its bioactivity. Therefore, displacement of this large pool of endogenous IGF from the binding proteins could elevate "free" IGF levels to elicit beneficial effects in diabetes and other IGF-responsive diseases comparable with those produced by administration of exogenous IGF-I. We report here the identification of a nonpeptide ligand NBI-31772, which displaces IGF-I from all six IGF-binding proteins at low nanomolar concentrations from screening of the in-house chemical libraries. Furthermore, the released free IGF-I was shown to be biologically active in an in vitro bioassay. Thus, NBI-31772 could serve as a valuable lead molecule for the design of novel therapeutics to treat diabetes and other IGF-responsive diseases.	Neurocrine Biosci Inc, Dept Peptide Chem, San Diego, CA 92121 USA; Neurocrine Biosci Inc, Med Chem, San Diego, CA 92121 USA	Neurocrine Biosciences; Neurocrine Biosciences	Ling, N (corresponding author), Neurocrine Biosci Inc, Dept Peptide Chem, 10555 Sci Ctr Dr, San Diego, CA 92121 USA.				NIDDK NIH HHS [R43-DK52243] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK052243] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Dunger DB, 1997, DIABETIC MED, V14, P723, DOI 10.1002/(SICI)1096-9136(199709)14:9<723::AID-DIA480>3.0.CO;2-S; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KOLACZYNSKI JW, 1994, ANN INTERN MED, V120, P47, DOI 10.7326/0003-4819-120-1-199401010-00009; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; Loddick SA, 1998, P NATL ACAD SCI USA, V95, P1894, DOI 10.1073/pnas.95.4.1894; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SCHOENLE EJ, 1991, DIABETOLOGIA, V34, P675, DOI 10.1007/BF00400998; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; ZENOBI PD, 1992, J CLIN INVEST, V90, P2234, DOI 10.1172/JCI116109	15	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32419	32422		10.1074/jbc.C100299200	http://dx.doi.org/10.1074/jbc.C100299200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11445558	hybrid			2022-12-25	WOS:000170746000008
J	Smith, ER; Allis, CD; Lucchesi, JC				Smith, ER; Allis, CD; Lucchesi, JC			Linking global histone acetylation to the transcription enhancement of X-chromosomal genes in Drosophila males	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; DOSAGE COMPENSATION; ACETYLTRANSFERASE ACTIVITY; NUCLEOSOMAL ARRAYS; MSL COMPLEX; CHROMATIN; YEAST; ACTIVATION; H4; EMBRYOGENESIS	It has become well established for several genes that targeting of histone acetylation to promoters is required for the activation of transcription. In contrast, global patterns of acetylation have not been ascribed to any particular regulatory function. In Drosophila, a specific modification of H4, acetylation at lysine 16, is enriched at hundreds of sites on the male X chromosome due to the activity of the male-specific lethal (MSL) dosage compensation complex. Utilizing chromatin immunoprecipitation, we have determined that H4Ac16 is present along the entire length of X-linked genes targeted by the MSL complex with relatively modest levels of acetylation at the promoter regions and high levels in the middle and/or 3 ' end of the transcription units. We propose that global acetylation by the MSL complex increases the expression of X-linked genes by facilitating transcription elongation rather than by enhancing promoter accessibility. We have also determined that H4Ac16 is absent from a region of the X chromosome that includes a gene known to be dosage-compensated by a MSL-independent mechanism. This study represents the first biochemical interpretation of the very large body of cytological observations on the chromosomal distribution of the MSL complex.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Emory University; University of Virginia	Lucchesi, JC (corresponding author), Emory Univ, Dept Biol, 1510 Clifton Rd, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053512, R01GM053512] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53512, GM15961] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Elefant F, 2000, J BIOL CHEM, V275, P13827, DOI 10.1074/jbc.275.18.13827; GERGEN JP, 1987, GENETICS, V117, P477; Gu WG, 2000, EMBO J, V19, P5202, DOI 10.1093/emboj/19.19.5202; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Jansa P, 2001, NUCLEIC ACIDS RES, V29, P423, DOI 10.1093/nar/29.2.423; Kageyama Y, 2001, EMBO J, V20, P2236, DOI 10.1093/emboj/20.9.2236; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; Meller VH, 2000, CURR BIOL, V10, P136, DOI 10.1016/S0960-9822(00)00311-0; Ohba R, 1999, MOL CELL BIOL, V19, P2061; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Protacio RU, 2000, MOL CELL BIOL, V20, P8866, DOI 10.1128/MCB.20.23.8866-8878.2000; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Schubeler D, 2000, GENE DEV, V14, P940; SCOTT MJ, 1991, GENE, V109, P177, DOI 10.1016/0378-1119(91)90607-D; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	36	130	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31483	31486		10.1074/jbc.C100351200	http://dx.doi.org/10.1074/jbc.C100351200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11445559	hybrid			2022-12-25	WOS:000170613500003
J	Schell, MJ; Erneux, C; Irvine, RF				Schell, MJ; Erneux, C; Irvine, RF			Inositol 1,4,5-trisphosphate 3-kinase A associates with F-actin and dendritic spines via its N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; PROTEIN-KINASE-II; RAT-BRAIN; HIPPOCAMPAL-NEURONS; MEMBRANE ASSOCIATION; CALCIUM INFLUX; EXPRESSION; CA1; PURIFICATION; NMDA	The consequences of the rapid 3-phosphorylation of inositol 1,4,5-trisphosphate (IP3) to produce inositol 1,3,4,5-tetrakisphosphate (IP4) via the action of IP3 3-kinases involve the control of calcium signals. Using green fluorescent protein constructs of full-length and truncated IP3 3-kinase isoform A expressed in HeLa cells, COS-7 cells, and primary neuronal cultures, we have defined a novel N-terminal 66-amino acid F-actin-binding region that localizes the kinase to dendritic spines. The region is necessary and sufficient for binding F-actin and consists of a proline-rich stretch followed by a predicted alpha -helix. We also localized endogenous IP3 3-kinase A to the dendritic spines of pyramidal neurons in primary hippocampal cultures, where it is co-localized postsynaptically with calcium/calmodulin-dependent protein kinase II. Our experiments suggest a link between inositol phosphate metabolism, calcium signaling, and the actin cytoskeleton in dendritic spines. The phosphorylation of IP3 in dendritic spines to produce IP4 is likely to be important for modulating the compartmentalization of calcium at synapses.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England; Free Univ Brussels, B-1070 Brussels, Belgium	University of Cambridge; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schell, MJ (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.			Schell, Michael/0000-0003-1553-3582				Allison DW, 2000, J NEUROSCI, V20, P4545, DOI 10.1523/JNEUROSCI.20-12-04545.2000; Allison DW, 1998, J NEUROSCI, V18, P2423; BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; BROCKE L, 1995, J NEUROSCI, V15, P6797; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; Communi D, 1999, J BIOL CHEM, V274, P14734, DOI 10.1074/jbc.274.21.14734; Communi D, 1997, EMBO J, V16, P1943, DOI 10.1093/emboj/16.8.1943; Cozier GE, 2000, J BIOL CHEM, V275, P28261; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; DENNY JB, 1990, BRAIN RES, V534, P317, DOI 10.1016/0006-8993(90)90148-5; DEWAARD M, 1992, NEURON, V9, P497, DOI 10.1016/0896-6273(92)90187-I; Dewaste V, 2000, BIOCHEM J, V352, P343, DOI 10.1042/0264-6021:3520343; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; GO M, 1993, NEUROSCI LETT, V158, P135, DOI 10.1016/0304-3940(93)90247-I; Halpain S, 1998, J NEUROSCI, V18, P9835; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; Jun KS, 1998, LEARN MEMORY, V5, P317; Kaech S, 1997, J NEUROSCI, V17, P9565; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; LEE SY, 1990, J BIOL CHEM, V265, P9434; MAILLEUX P, 1991, BRAIN RES, V539, P203, DOI 10.1016/0006-8993(91)91622-8; MAILLEUX P, 1992, NEUROSCI LETT, V148, P177, DOI 10.1016/0304-3940(92)90833-S; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; MOON KH, 1989, BIOCHEM BIOPH RES CO, V164, P370, DOI 10.1016/0006-291X(89)91728-2; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Shen K, 1998, NEURON, V21, P593, DOI 10.1016/S0896-6273(00)80569-3; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; Smith PM, 2000, BIOCHEM J, V347, P77, DOI 10.1042/0264-6021:3470077; Soriano S, 1997, BIOCHEM J, V324, P579, DOI 10.1042/bj3240579; Szinyei C, 1999, J PHYSIOL-LONDON, V516, P855, DOI 10.1111/j.1469-7793.1999.0855u.x; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1989, BIOCHEM J, V261, P483, DOI 10.1042/bj2610483; Tsubokawa H, 1996, J PHYSIOL-LONDON, V497, P67, DOI 10.1113/jphysiol.1996.sp021750; VANWEYENBERG V, 1995, BIOCHEM J, V306, P429, DOI 10.1042/bj3060429; Woodring PJ, 1997, J BIOL CHEM, V272, P30447, DOI 10.1074/jbc.272.48.30447; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yakunin AF, 1998, ANAL BIOCHEM, V258, P146, DOI 10.1006/abio.1998.2571; YAMADA M, 1993, BRAIN RES, V606, P335, DOI 10.1016/0006-8993(93)91004-C; Yuste R, 2000, NAT NEUROSCI, V3, P653, DOI 10.1038/76609	50	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37537	37546		10.1074/jbc.M104101200	http://dx.doi.org/10.1074/jbc.M104101200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11468283	hybrid			2022-12-25	WOS:000171375700089
J	Kessler, D; Dethlefsen, S; Haase, I; Plomann, M; Hirche, F; Krieg, T; Eckes, B				Kessler, D; Dethlefsen, S; Haase, I; Plomann, M; Hirche, F; Krieg, T; Eckes, B			Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE CELLS; VASCULAR ENDOTHELIAL-CELLS; HUMAN-SKIN FIBROBLASTS; AMINO-ACID SEQUENCE; FLUID SHEAR-STRESS; DERMAL FIBROBLASTS; EXPRESSION; CONTRACTION	Fibroblasts are subjected to changes of the mechanical force balance during physiological as well as pathological situations, such as wound healing, development of hypertrophic scars, and fibrogenesis. However, the molecular response and the changes in fibroblast gene expression upon mechanical stimulation remain poorly understood. As an in vitro model, human dermal fibroblasts were cultured within a three-dimensional network of fibrillar collagen either under high (stressed) or low tension (relaxed). cDNA microarray technology in combination with Northern blot analysis led to identification of mechano-responsive genes coding for extracellular matrix proteins, fibrogenic growth factors, protease inhibitors, components of focal adhesions, and the cytoskeleton. Application of biaxial strain to fibroblasts cultured on flexible silicone membranes revealed that the type of strain as well as the properties of the substrate induced different patterns of gene regulation. The transcriptional profile of mechanically induced genes in collagen lattices suggests that mechanical stimuli lead to a "synthetic" fibroblast phenotype characterized by induction of connective tissue synthesis while simultaneously inhibiting matrix degradation.	Univ Cologne, Dept Dermatol, D-50931 Cologne, Germany; Univ Cologne, Inst Biochem 2, D-50931 Cologne, Germany; Univ Cologne, Inst Physiol, D-50931 Cologne, Germany	University of Cologne; University of Cologne; University of Cologne	Eckes, B (corresponding author), Univ Cologne, Dept Dermatol, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	beate.eckes@uni-koeln.de						ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BELLOWS CG, 1981, J CELL SCI, V50, P299; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brown RA, 1998, J CELL PHYSIOL, V175, P323, DOI 10.1002/(SICI)1097-4652(199806)175:3<323::AID-JCP10>3.0.CO;2-6; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; Chiquet M, 1996, BIOCHEM CELL BIOL, V74, P737, DOI 10.1139/o96-080; CHIQUETEHRISMANN R, 1994, J CELL BIOL, V127, P2093, DOI 10.1083/jcb.127.6.2093; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1988, J BIOL CHEM, V263, P18601; DELVOYE P, 1991, J INVEST DERMATOL, V97, P898, DOI 10.1111/1523-1747.ep12491651; Eckes B, 1998, J CELL SCI, V111, P1897; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Feng YJ, 1999, CIRC RES, V85, P1118; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gabbiani G, 1981, Prog Clin Biol Res, V54, P183; Gimond C, 1996, CELL ADHES COMMUN, V3, P527, DOI 10.3109/15419069609081028; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Gruden G, 1997, P NATL ACAD SCI USA, V94, P12112, DOI 10.1073/pnas.94.22.12112; GUIDRY C, 1985, J CELL SCI, V79, P67; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IYER VR, 1999, SCIENE, V283, P33; Kershaw DB, 1997, J BIOL CHEM, V272, P15708, DOI 10.1074/jbc.272.25.15708; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAMBERT CA, 1992, LAB INVEST, V66, P444; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lee E, 1996, CIRC RES, V78, P44, DOI 10.1161/01.RES.78.1.44; LEUNG DYM, 1976, SCIENCE, V191, P475; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MAUCH C, 1988, EXP CELL RES, V178, P493, DOI 10.1016/0014-4827(88)90417-X; MAUCH C, 1989, FEBS LETT, V250, P301, DOI 10.1016/0014-5793(89)80743-4; Mercier I, 1996, EXP CELL RES, V225, P245, DOI 10.1006/excr.1996.0174; MONTESANO R, 1988, P NATL ACAD SCI USA, V85, P4894, DOI 10.1073/pnas.85.13.4894; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Parizi M, 2000, EXP CELL RES, V254, P210, DOI 10.1006/excr.1999.4754; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Schaefer BM, 1996, ARCH DERMATOL RES, V288, P122, DOI 10.1007/BF02505820; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TOMASEK JJ, 1992, ANAT REC, V232, P359, DOI 10.1002/ar.1092320305; Trachslin J, 1999, EXP CELL RES, V247, P320, DOI 10.1006/excr.1998.4363; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Witte M H, 1997, EXS, V79, P65; Wlaschek M, 2000, J INVEST DERMATOL, V115, P909, DOI 10.1046/j.1523-1747.2000.00120.x; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301; Yamadori T, 1999, P NATL ACAD SCI USA, V96, P6341, DOI 10.1073/pnas.96.11.6341; Yamamoto T, 2000, J IMMUNOL, V164, P6174, DOI 10.4049/jimmunol.164.12.6174	61	295	314	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36575	36585		10.1074/jbc.M101602200	http://dx.doi.org/10.1074/jbc.M101602200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11468280	hybrid			2022-12-25	WOS:000171194500071
J	Coux, F; Vachon, V; Rang, C; Moozar, K; Masson, L; Royer, M; Bes, M; Rivest, S; Brousseau, R; Schwartz, JL; Laprade, R; Frutos, R				Coux, F; Vachon, V; Rang, C; Moozar, K; Masson, L; Royer, M; Bes, M; Rivest, S; Brousseau, R; Schwartz, JL; Laprade, R; Frutos, R			Role of interdomain salt bridges in the pore-forming ability of the Bacillus thuringiensis toxins Cry1Aa and Cry1Ac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER-MEMBRANE; INSECTICIDAL CRYSTAL PROTEINS; SITE-DIRECTED MUTAGENESIS; AMINOPEPTIDASE-N RECEPTOR; SURFACE-EXPOSED LOOPS; AMINO-ACID-RESIDUES; DELTA-ENDOTOXIN; DOMAIN-III; MANDUCA-SEXTA; ION-CHANNEL	The four salt bridges (Asp(222)-Arg(281), Arg(233) -Glu(288), Arg(234)-Glu(274), and Asp(242)-Arg(265)) linking domains I and II in Cry1Aa were abolished individually in alpha -helix 7 mutants D222A, R233A, R234A, and D242A. Two additional mutants targeting the fourth salt bridge (R265A) and the double mutant (D242A/R265A) were rapidly degraded during trypsin activation. Mutations were also introduced in the corresponding Cry1Ac salt bridge (D242E, D242K, D242N, and D242P), but only D242N and D242P could be produced. All toxins tested, except D242A, were shown by light-scattering experiments to permeabilize Manduca sexta larval midgut brush border membrane vesicles. The three active Cry1Aa mutants at pH 10.5, as well as D222A at pH 7.5, demonstrated a faster rate of pore formation than Cry1Aa, suggesting that increases in molecular flexibility due to the removal of a salt bridge facilitated toxin insertion into the membrane. However, all mutants were considerably less toxic to M. sexta larvae than to the respective parental toxins, suggesting that increased flexibility made the toxins more susceptible to proteolysis in the insect midgut. Interdomain salt bridges, especially the Asp(242)- Arg(265) bridge, therefore contribute greatly to the stability of the protein in the larval midgut, whereas their role in intrinsic pore-forming ability is relatively less important.	Univ Montreal, Grp Rech Transport Membranaire, Montreal, PQ H3C 3J7, Canada; CIRAD, IGEPAM, Montpellier, France; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Universite de Montreal; CIRAD; National Research Council Canada	Laprade, R (corresponding author), Univ Montreal, Grp Rech Transport Membranaire, POB 6128,Ctr Ville Stn, Montreal, PQ H3C 3J7, Canada.		schwartz, jean-louis/D-9938-2011					ARONSON AI, 1995, J BACTERIOL, V177, P4059, DOI 10.1128/jb.177.14.4059-4065.1995; BOSCH D, 1994, BIO-TECHNOL, V12, P915, DOI 10.1038/nbt0994-915; BOURGOUIN C, 1990, APPL ENVIRON MICROB, V56, P340, DOI 10.1128/AEM.56.2.340-344.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bravo A, 1997, J BACTERIOL, V179, P2793, DOI 10.1128/jb.179.9.2793-2801.1997; Burton SL, 1999, J MOL BIOL, V287, P1011, DOI 10.1006/jmbi.1999.2649; Carroll J, 1997, EUR J BIOCHEM, V245, P797, DOI 10.1111/j.1432-1033.1997.00797.x; CARROLL J, 1993, EUR J BIOCHEM, V214, P771, DOI 10.1111/j.1432-1033.1993.tb17979.x; CUMMINGS CE, 1994, MOL MEMBR BIOL, V11, P87, DOI 10.3109/09687689409162225; de Maagd RA, 1999, MOL MICROBIOL, V31, P463, DOI 10.1046/j.1365-2958.1999.01188.x; Dean DH, 1996, GENE, V179, P111, DOI 10.1016/S0378-1119(96)00442-8; DeMaagd RA, 1996, APPL ENVIRON MICROB, V62, P2753, DOI 10.1128/AEM.62.8.2753-2757.1996; deMaagd RA, 1996, APPL ENVIRON MICROB, V62, P1537, DOI 10.1128/AEM.62.5.1537-1543.1996; DOW JAT, 1992, J EXP BIOL, V172, P355; DOW JAT, 1984, AM J PHYSIOL, V246, pR633, DOI 10.1152/ajpregu.1984.246.4.R633; FEITELSON JS, 1992, BIO-TECHNOL, V10, P271, DOI 10.1038/nbt0392-271; Finney D.J., 1971, PROBIT ANAL; Fiuza LM, 1996, APPL ENVIRON MICROB, V62, P1544, DOI 10.1128/AEM.62.5.1544-1549.1996; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; GAZIT E, 1994, BIOCHEM J, V304, P895, DOI 10.1042/bj3040895; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P3429, DOI 10.1021/bi00064a029; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOFTE H, 1988, APPL ENVIRON MICROB, V54, P2010; HOFTE H, 1989, MICROBIOL REV, V53, P242; Jenkins JL, 1999, FEBS LETT, V462, P373, DOI 10.1016/S0014-5793(99)01559-8; Jenkins JL, 2000, J BIOL CHEM, V275, P14423, DOI 10.1074/jbc.275.19.14423; KNOWLES BH, 1994, ADV INSECT PHYSIOL, V24, P275, DOI 10.1016/S0065-2806(08)60085-5; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LECADET MM, 1980, J GEN MICROBIOL, V121, P203; Lee MK, 1996, BIOCHEM BIOPH RES CO, V229, P139, DOI 10.1006/bbrc.1996.1770; LEE MK, 1995, BIOCHEM BIOPH RES CO, V216, P306, DOI 10.1006/bbrc.1995.2625; Lee MK, 1999, APPL ENVIRON MICROB, V65, P4513; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LU H, 1994, J BACTERIOL, V176, P5554, DOI 10.1128/JB.176.17.5554-5559.1994; Luo K, 1999, APPL ENVIRON MICROB, V65, P457; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; MASSON L, 1994, MOL MICROBIOL, V14, P851, DOI 10.1111/j.1365-2958.1994.tb01321.x; MASSON L, 1989, BIOCHEM J, V269, P507; Meza R, 1996, FEMS MICROBIOL LETT, V145, P333, DOI 10.1111/j.1574-6968.1996.tb08597.x; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Peyronnet O, 1997, APPL ENVIRON MICROB, V63, P1679, DOI 10.1128/AEM.63.5.1679-1684.1997; Rajamohan F, 1996, J BIOL CHEM, V271, P2390, DOI 10.1074/jbc.271.5.2390; Rajamohan F, 1996, J BIOL CHEM, V271, P25220, DOI 10.1074/jbc.271.41.25220; Rajamohan F, 1996, P NATL ACAD SCI USA, V93, P14338, DOI 10.1073/pnas.93.25.14338; Rang C, 1999, APPL ENVIRON MICROB, V65, P2918; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; Smedley DP, 1996, MICROBIOL-SGM, V142, P1617, DOI 10.1099/13500872-142-7-1617; SMITH GP, 1994, BIOCHEM J, V302, P611, DOI 10.1042/bj3020611; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; VONTERSCH MA, 1994, APPL ENVIRON MICROB, V60, P3711, DOI 10.1128/AEM.60.10.3711-3717.1994; WALTERS FS, 1993, BIOCHEM BIOPH RES CO, V196, P921, DOI 10.1006/bbrc.1993.2337; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Wu SJ, 1996, J MOL BIOL, V255, P628, DOI 10.1006/jmbi.1996.0052	57	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35546	35551		10.1074/jbc.M101887200	http://dx.doi.org/10.1074/jbc.M101887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466307	hybrid			2022-12-25	WOS:000171109300046
J	Fournier, B; Gutzwiller, S; Dittmar, T; Matthias, G; Steenbergh, P; Matthias, P				Fournier, B; Gutzwiller, S; Dittmar, T; Matthias, G; Steenbergh, P; Matthias, P			Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEIN; OSTEOBLAST-ENRICHED CULTURES; FETAL-RAT BONE; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; INTERLEUKIN-6 PROMOTER; IGF-I; ALPHA; HORMONE; EXPRESSION	The importance of insulin-like growth factor I (IGF-I) on maintenance of skeletal integrity has been widely recognized. Although osteoblasts secrete some IGF-I, the liver is the primary endocrine source for IGF-L We have studied the regulation of the human IGF-l promoter in the hepatocyte cell line Hep3B, and we have shown that the IGF-I promoter, when co-transfected in Hep3B cells together with an estrogen receptor (ER)-alpha expression vector, was transcriptionally regulated by raloxifene or raloxifene-like molecules but not by 17 beta -estradiol and 4(OH)-tamoxifen. The induction mediated by raloxifene is antagonized by 17 beta -estradiol and mediated selectively by ER-alpha, but not by ER-beta. Transfer of IGF-I promoter sequences from -733 to -65 or from -375 to -65 to a minimal Fos promoter resulted in a comparable responsiveness to raloxifene. This region contains two CAAT/enhancer-binding protein sites and an activator protein 1 site, both of which have been shown to be involved in estrogen receptor-mediated transactivation. When the CAAT/enhancer-binding protein sites were mutated in a construct bearing the sequence from -375 to -65 in front of the minimal Fos promoter, raloxifene induction was reduced, whereas mutation of the other elements did not affect induction. In addition, using chimeric proteins, we delineated the domains of ER-alpha that confer to ER-alpha transactivation abilities on the IGF-l promoter that are not exhibited by ER-beta These data shed new light on the mechanism of action of antiestrogens and might help explain, at least in part, the bone-protective effects observed for some antiestrogens in ovariectomized animals.	Novartis Pharma AG, Arthrit & Bone Metab Therapeut Area, Novartis Pharma Res, CH-4002 Basel, Switzerland; Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 Utrecht, Netherlands; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Novartis; Utrecht University; Friedrich Miescher Institute for Biomedical Research	Fournier, B (corresponding author), Novartis Pharma AG, Arthrit & Bone Metab Therapeut Area, Novartis Pharma Res, WK-125-9-17, CH-4002 Basel, Switzerland.							Ammann P, 1999, OSTEOPOROSIS INT, V10, P369, DOI 10.1007/s001980050242; Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Calkhoven CF, 1997, EUR J BIOCHEM, V249, P113, DOI 10.1111/j.1432-1033.1997.t01-2-00113.x; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Decensi A, 1999, EUR J CANCER, V35, P596, DOI 10.1016/S0959-8049(98)00428-6; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713; Garnero P, 2000, LANCET, V355, P898, DOI 10.1016/S0140-6736(99)05463-X; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; JANSEN E, 1992, BIOCHEM BIOPH RES CO, V187, P1219, DOI 10.1016/0006-291X(92)90433-L; Jones PS, 1999, J BIOL CHEM, V274, P32008, DOI 10.1074/jbc.274.45.32008; Kassem M, 1998, CALCIFIED TISSUE INT, V62, P60, DOI 10.1007/s002239900395; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; KUIPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5295; Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Mitlak BH, 1997, HORM RES, V48, P155, DOI 10.1159/000185507; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Pfeilschifter J, 1998, EUR J ENDOCRINOL, V138, P617, DOI 10.1530/eje.0.1380617; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; ROSEN CJ, 1994, P SOC EXP BIOL MED, V206, P83; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; Sibonga JD, 1998, ENDOCRINOLOGY, V139, P3736, DOI 10.1210/en.139.9.3736; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Yang NN, 1997, SCIENCE, V275, P1249	40	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35444	35449		10.1074/jbc.M105418200	http://dx.doi.org/10.1074/jbc.M105418200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457856	hybrid			2022-12-25	WOS:000171109300033
J	Chen, X; Resh, MD				Chen, X; Resh, MD			Activation of mitogen-activated protein kinase by membrane-targeted Raf chimeras is independent of raft localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PLASMA-MEMBRANE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; TYROSINE KINASE; FATTY ACYLATION; LIPID BODIES; CAVEOLAE; SRC	Binding of proteins to the plasma membrane can be achieved with various membrane targeting motifs, including combinations of fatty acids, isoprenoids, and basic domains. In this study, we investigate whether attachment of different membrane targeting motifs influences the signaling capacity of membrane-bound signal transduction proteins by directing the proteins to different membrane microdomains. We used c-Raf-1 as a model for a signaling protein that is activated when membrane-bound. Three different membrane targeting motifs from K-Ras, Fyn, and Src proteins were fused to the N or C terminus of Raf-1. The ability of the modified Rafs to initiate MAPK signaling was then investigated. All three modified Raf-1 constructs activated MAPK to nearly equivalent levels. The extent of localization of the Raf-l constructs to membrane microdomains known as rafts did not correlate with the level of MAPK activation. Moreover, treatment of cells with the raft disrupting drug methyl-beta -cyclodextrin (M beta CD) caused activation of MAPK to levels equivalent to those achieved with membrane-targeted Raf constructs. The use of pharmacological agents as well as dominant negative mutants revealed that MAPK activation by M beta CD proceeds via a phosphoinositide 3-kinase-dependent mechanism that is Ras/Raf-independent. We conclude that cholesterol depletion from the plasma membrane by M beta CD constitutes an alternative pathway for activating MAPK.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Grad Program Biochem & Struct Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.			Resh, Marilyn/0000-0001-6118-9466; chen, xu/0000-0003-2524-4979	NIGMS NIH HHS [GM 57966] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li XL, 2000, EUR J IMMUNOL, V30, P1576, DOI 10.1002/1521-4141(200006)30:6<1576::AID-IMMU1576>3.0.CO;2-0; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yu WG, 1998, AM J PATHOL, V152, P759; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	43	39	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34617	34623		10.1074/jbc.M103995200	http://dx.doi.org/10.1074/jbc.M103995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457834	hybrid			2022-12-25	WOS:000171024600038
J	Dhamija, S; Krebsbach, PH				Dhamija, S; Krebsbach, PH			Role of Cbfa1 in ameloblastin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL ROOT SHEATH; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; TOOTH DEVELOPMENT; OSTEOCLAST DIFFERENTIATION; EXTRACELLULAR-MATRIX; PROTEIN INTERACTIONS; OSTEOCALCIN GENE; DENTAL ENAMEL; RAT INCISORS	Ameloblastin is a tooth-specific extracellular matrix protein that is thought to play a role in enamel crystal formation in the developing dentition. The murine ameloblastin promoter functions in a cell type-specific manner and contains cas-acting elements that function both to enhance and to suppress transcription. The objective of this study was to determine whether the transcription factor Cbfa1, known to be essential for transcription of other mineralized tissue genes, is also required for ameloblastin transcription. Site-directed mutagenesis of the Cbfa1-binding site (-248 base pairs) termed osteoblast-specific element 2 (OSE2) decreased ameloblastin promoter activity by greater than 50% in ameloblast-like cells. No differences in promoter activity were observed in two other oral tissue-derived cell lines transfected with similar constructs. Nuclear factor binding to the ameloblastin promoter was also shown to be cell type-specific and was altered by site-specific mutations in the OSE2 site. Cbfa1 was specifically shown to participate in the DNA-protein complexes between nuclear factors and the ameloblastin OSE2 site by supershift electrophoretic mobility shift assays. The findings that Cbfa1 interacts with functionally important regions of the ameloblastin promoter while promoter activity is diminished in constructs containing site-directed mutations in the Cbfa1 site indicate that Cbfa1 possesses an important function in transcription of the ameloblastin gene.	Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Biorestorat Oral Hlth, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Krebsbach, PH (corresponding author), Univ Michigan, Sch Dent, Dept Oral Med Pathol & Oncol, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.		Krebsbach, Paul H./AAC-4765-2021		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE012502] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12502] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; BROOKES SJ, 1995, ARCH ORAL BIOL, V40, P1, DOI 10.1016/0003-9969(94)00135-X; CHEN LS, 1992, ARCH ORAL BIOL, V37, P771, DOI 10.1016/0003-9969(92)90110-T; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; Deutsch D, 1995, CONNECT TISSUE RES, V32, P97, DOI 10.3109/03008209509013710; Dhamija S, 1999, J BIOL CHEM, V274, P20738, DOI 10.1074/jbc.274.29.20738; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Fincham AG, 1995, CONNECT TISSUE RES, V32, P119, DOI 10.3109/03008209509013713; Fong CD, 2000, ORAL SURG ORAL MED O, V90, P218, DOI 10.1067/moe.2000.107052; Fong CD, 1998, EUR J ORAL SCI, V106, P324, DOI 10.1111/j.1600-0722.1998.tb02193.x; Fong CD, 1996, J BONE MINER RES, V11, P892; Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201; Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hu CC, 1997, J DENT RES, V76, P648, DOI 10.1177/00220345970760020501; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Jiang HP, 1999, MECH DEVELOP, V81, P169, DOI 10.1016/S0925-4773(98)00232-9; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; Kreiborg S, 1999, J CRAN GENET DEV BIO, V19, P75; Lee SK, 1996, INT J DEV BIOL, V40, P1141; Lukinmaa PL, 1995, J CRAN GENET DEV BIO, V15, P212; LUMSDEN AGS, 1988, DEVELOPMENT S, V103, P55; Maas R, 1997, CRIT REV ORAL BIOL M, V8, P4, DOI 10.1177/10454411970080010101; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nanci A, 1998, J HISTOCHEM CYTOCHEM, V46, P911, DOI 10.1177/002215549804600806; OSUMIYAMASHITA N, 1994, DEV BIOL, V164, P409, DOI 10.1006/dbio.1994.1211; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Paine ML, 1998, J DENT RES, V77, P496, DOI 10.1177/00220345980770030901; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Seow W. Kim, 1995, Pediatric Dentistry, V17, P101; SIMMER JP, 1995, CRIT REV ORAL BIOL M, V6, P84, DOI 10.1177/10454411950060020701; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; Thesleff I, 1996, CURR OPIN CELL BIOL, V8, P844, DOI 10.1016/S0955-0674(96)80086-X; Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200; Uchida T, 1997, J HISTOCHEM CYTOCHEM, V45, P1329, DOI 10.1177/002215549704501002; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; YAMAMOTO H, 1989, ORAL SURG ORAL MED O, V68, P195, DOI 10.1016/0030-4220(89)90192-8	47	43	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35159	35164		10.1074/jbc.M010719200	http://dx.doi.org/10.1074/jbc.M010719200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11451945	hybrid			2022-12-25	WOS:000171024600106
J	Belcheva, MM; Szucs, M; Wang, DX; Sadee, W; Coscia, CJ				Belcheva, MM; Szucs, M; Wang, DX; Sadee, W; Coscia, CJ			mu-opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; SMOOTH-MUSCLE CELLS; C6 GLIOMA-CELLS; TYROSINE-KINASE; EGF RECEPTOR; COUPLED RECEPTORS; ANGIOTENSIN-II; SIGNALING CASCADE; RAT HIPPOCAMPUS; PC12 CELLS	Phosphorylation of the MAPK isoform ERK by G protein-coupled receptors involves multiple signaling pathways. One of these pathways entails growth factor receptor transactivation followed by ERK activation. This study demonstrates that a similar signaling pathway is used by the mu -opioid receptor (MOR) expressed in HEK293 cells and involves calmodulin (CaM). Stimulation of MOR resulted in both epidermal growth factor receptor (EGFR) and ERK phosphorylation. Data obtained with inhibitors of EGFR Tyr kinase and membrane metalloproteases support an intermediate role of EGFR activation, involving release of endogenous membrane-bound epidermal growth factor. Previous studies had demonstrated a role for CaM in opioid signaling based on direct CaM binding to MOR. To test whether CaM contributes to EGFR transactivation and ERK phosphorylation by MOR, we compared wild-type MOR with mutant K273A MOR, which binds CaM poorly, but couples normally to G proteins. Stimulation of K273A MOR with [D-Ala(2), MePhe(4), Gly-ol(5)]enkephalin (10-100 nM) resulted in significantly reduced ERK phosphorylation. Furthermore, wild-type MOR stimulated EGFR Tyr phosphorylation 3-fold more than K273A MOR, indicating that direct CaM-MOR interaction plays a key role in the transactivation process. Inhibitors of CaM and protein kinase C also attenuated [D-Ala(2), MePhe(4), Glyol(5)]enkephalin-induced EGFR transactivation in wildtype (but not mutant) MOR-expressing cells. This novel pathway of EGFR transactivation may be shared by other G protein-coupled receptors shown to interact with CaM.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Hungarian Acad Sci, Biol Res Ctr, H-6701 Szeged, Hungary; Univ Calif San Francisco, Dept Biopharmaceut Sci & Pharmaceut Chem, San Francisco, CA 94143 USA	Saint Louis University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of California System; University of California San Francisco	Coscia, CJ (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA.	cosciacc@slu.edu	Wang, Danxin/I-5810-2019	Wang, Danxin/0000-0002-7134-3065	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004166] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05412, DA04166] Funding Source: Medline; NIGMS NIH HHS [GM43102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Belcheva MM, 2000, CELL SIGNAL, V12, P481, DOI 10.1016/S0898-6568(00)00095-4; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Bohn LM, 2000, J NEUROCHEM, V74, P564, DOI 10.1046/j.1471-4159.2000.740564.x; Bohn LM, 2000, J NEUROCHEM, V74, P574, DOI 10.1046/j.1471-4159.2000.740574.x; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER G, 2000, SCI STKE, V15, P1; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Egea J, 2000, MOL CELL BIOL, V20, P1931, DOI 10.1128/MCB.20.6.1931-1946.2000; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Fan GH, 1999, MOL PHARMACOL, V56, P39, DOI 10.1124/mol.56.1.39; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; HANBAUER I, 1979, NEUROPHARMACOLOGY, V18, P859, DOI 10.1016/0028-3908(79)90082-0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Iacovelli L, 1999, FASEB J, V13, P1; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Koch T, 1997, J NEUROCHEM, V69, P1767; Kramer HK, 2000, BIOCHEM PHARMACOL, V60, P781, DOI 10.1016/S0006-2952(00)00400-7; LAW PY, 1993, MOL PHARMACOL, V43, P684; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; Lou LG, 1999, MOL PHARMACOL, V55, P557; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; NEHMAD R, 1982, MOL PHARMACOL, V22, P389; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHULMAN H, 1992, CELL CALCIUM, V13, P401, DOI 10.1016/0143-4160(92)90053-U; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wang DX, 2000, J NEUROCHEM, V74, P1418, DOI 10.1046/j.1471-4159.2000.0741418.x; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	60	107	122	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33847	33853		10.1074/jbc.M101535200	http://dx.doi.org/10.1074/jbc.M101535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11457825	hybrid			2022-12-25	WOS:000170910200076
J	Cho, SY; Tian, Y; Benjamin, TL				Cho, SY; Tian, Y; Benjamin, TL			Binding of p300/CBP co-activators by polyoma large T antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; PROTEIN PHOSPHATASE-2A; COACTIVATORS P300; TUMOR-INDUCTION; MIDDLE-T; TRANSCRIPTIONAL COACTIVATORS; HISTONE ACETYLTRANSFERASES; PHOSPHORYLATED CREB; RAT FIBROBLASTS; E6 ONCOPROTEIN	Small DNA tumor viruses such as simian virus 40 (SV40) and polyomavirus (Py) take advantage of host cell proteins to transcribe and replicate their DNA. Interactions between the viral T antigens and host proteins result in cell transformation and tumor induction. Large T antigen of SV40 interacts with p53, pRb/p107/ p130 family members, and the cyclic AMP-responsive element-binding protein (CREB)-binding protein (CBP)/ p300. Py large T antigen is known to interact only with pRb and p300 among these proteins. Here we report that Py large T binds to CBP in vivo and in vitro. In cotransfection assays, Py large T inhibits the co-activation functions of CBP/p300 in CREB-mediated transactivation but not in NF-kappaB-mediated transactivation. p53 appears not to be involved in the functions of CREB-mediated transactivation and is not essential for large T:CBP interaction. Mutations introduced into a region of Py large T with homology to adenovirus EIA and SV40 large T prevent binding to the co-activators. These mutant large T antigens fail to inhibit CREB-mediated transactivation. The CBP/p300-binding Py mutants are able to transform established rat embryo fibroblasts but are restricted in their ability to induce tumors in the newborn mouse, indicating that interaction of large T with the co-activators may be essential for virus replication and spread in the intact host.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Benjamin, TL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA050661, R35CA044343] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44343, P01 CA50661] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexiadis V, 1997, CHROMOSOMA, V105, P324; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen YC, 1999, ONCOGENE, V18, P139, DOI 10.1038/sj.onc.1202272; Cho-Chung YS, 2000, MOL CELL BIOCHEM, V212, P29, DOI 10.1023/A:1007144618589; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAWE CJ, 1987, AM J PATHOL, V127, P243; Dey DC, 2000, CELL GROWTH DIFFER, V11, P231; Doherty J, 1997, ONCOGENE, V14, P1923, DOI 10.1038/sj.onc.1201025; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FREUND R, 1994, J VIROL, V68, P7227, DOI 10.1128/JVI.68.11.7227-7234.1994; FREUND R, 1992, ONCOGENE, V7, P1979; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grand RJA, 1998, VIROLOGY, V244, P330, DOI 10.1006/viro.1998.9102; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LUKACHER AE, 1993, VIROLOGY, V196, P241, DOI 10.1006/viro.1993.1472; Marcellus RC, 1996, CELL GROWTH DIFFER, V7, P1643; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nemethova M, 1999, J VIROL, V73, P1734, DOI 10.1128/JVI.73.2.1734-1739.1999; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETERSON SR, 1995, CANCER RES, V55, P4651; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RONAI Z, 1994, ENVIRON MOL MUTAGEN, V23, P157, DOI 10.1002/em.2850230302; SCHAFFHAUSEN BS, 1976, P NATL ACAD SCI USA, V73, P1092, DOI 10.1073/pnas.73.4.1092; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Van Orden K, 2000, GENE EXPRESSION, V9, P29; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; WHEAT WH, 1994, MOL CELL BIOL, V14, P5881, DOI 10.1128/MCB.14.9.5881; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; ZHENG DQ, 1994, ONCOGENE, V9, P3345; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	57	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33533	33539		10.1074/jbc.M102906200	http://dx.doi.org/10.1074/jbc.M102906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438528	hybrid			2022-12-25	WOS:000170910200034
J	Lilja, L; Yang, SN; Webb, DL; Juntti-Berggren, L; Berggren, PO; Bark, C				Lilja, L; Yang, SN; Webb, DL; Juntti-Berggren, L; Berggren, PO; Bark, C			Cyclin-dependent kinase 5 promotes insulin exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; BRAIN-SPECIFIC ACTIVATOR; DIRECTED PROTEIN-KINASE; PANCREATIC BETA-CELLS; REGULATORY SUBUNIT; MEMBRANE-FUSION; FUNCTIONAL-ROLE; KDA SUBUNIT; SYNTAXIN 1A; SYNAPSIN I	Cyclin-dependent kinase 5 (Cdk5) is widely expressed although kinase activity has been described preferentially in neuronal systems. Cdk5 has an impact on actin polymerization during neuronal migration and neurite outgrowth and deregulation of the kinase has been implicated in the promotion of neurodegeneration. Recently it was shown that Cdk5 modulates dopamine signaling in neurons by regulating DARPP-32 function. In addition, Cdk5 phosphorylates munc-18 and synapsin I, two essential components of the exocytotic machinery. We have shown by reverse transcriptase-polymerase chain reaction, immunocytochemistry, and Western blotting that Cdk5 is present in the insulin-secreting pancreatic beta -cell. Subcellular fractionation of isolated beta -cells revealed a glucose-induced translocation of membrane-bound Cdk5 protein to lower density fractions. Inhibition of Cdk5 with roscovitine reduced insulin secretion with similar to 35% compared with control after glucose stimulation and with similar to 65% after depolarization with glucose and KCl. Capacitance measurements performed on single beta -cells that expressed a dominant-negative Cdk5 mutant showed impaired exocytosis. The effect on exocytosis by Cdk5 appeared to be independent of changes in free cytoplasmic Ca2+ concentration. Taken together these results show that Cdk5 is present in beta -cells and acts as a positive regulator of insulin exocytosis.	Karolinska Hosp, Karolinska Inst, Rolf Luft Ctr Diabet Res L3, Dept Mol Med, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Berggren, PO (corresponding author), Karolinska Hosp, Karolinska Inst, Rolf Luft Ctr Diabet Res L3, Dept Mol Med, S-17176 Stockholm, Sweden.	perolof@enk.ks.se	Tuluc, Petronel/C-2527-2011	Berggren, Per-Olof/0000-0001-8991-413X; Bark, Christina/0000-0002-0724-6017; Webb, Dominic-Luc/0000-0002-6979-9194				Andersson J, 2000, EUR J CELL BIOL, V79, P781, DOI 10.1078/0171-9335-00106; Berwin B, 1998, NEURON, V21, P137, DOI 10.1016/S0896-6273(00)80521-8; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; Brown H, 2000, DIABETES, V49, P383, DOI 10.2337/diabetes.49.3.383; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; Easom RA, 2000, SEMIN CELL DEV BIOL, V11, P253, DOI 10.1006/scdb.2000.0174; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hanson PI, 2000, NAT STRUCT BIOL, V7, P347, DOI 10.1038/75103; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HISANAGA SI, 1995, CELL MOTIL CYTOSKEL, V31, P283, DOI 10.1002/cm.970310405; Humbert S, 2000, J CELL SCI, V113, P975; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Kamal A, 2000, CURR OPIN CELL BIOL, V12, P503, DOI 10.1016/S0955-0674(00)00123-X; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; Krueger KA, 1999, DIABETES, V48, P499, DOI 10.2337/diabetes.48.3.499; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; MARTELL AE, 1971, AMINO ACIDS, V1; MARTELL AE, 1971, AMINES, V2; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murphy LI, 1996, MOL CELL ENDOCRINOL, V117, P195, DOI 10.1016/0303-7207(95)03747-0; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; Nishi A, 2000, P NATL ACAD SCI USA, V97, P12840, DOI 10.1073/pnas.220410397; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Paglini G, 2001, EUR J BIOCHEM, V268, P1528, DOI 10.1046/j.1432-1033.2001.02023.x; Pant AC, 1997, BRAIN RES, V765, P259, DOI 10.1016/S0006-8993(97)00561-1; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Rossetto O, 1996, J CELL BIOL, V132, P167, DOI 10.1083/jcb.132.1.167; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Veeranna GJ, 2000, MOL BRAIN RES, V76, P229, DOI 10.1016/S0169-328X(00)00003-6; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164; Zhang W, 2000, J BIOL CHEM, V275, P41521, DOI 10.1074/jbc.M005479200	74	83	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34199	34205		10.1074/jbc.M103776200	http://dx.doi.org/10.1074/jbc.M103776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443123	hybrid			2022-12-25	WOS:000170910200121
J	Raftery, MJ; Yang, Z; Valenzuela, SM; Geczy, CL				Raftery, MJ; Yang, Z; Valenzuela, SM; Geczy, CL			Novel intra- and inter-molecular sulfinamide bonds in S100A8 produced by hypochlorite oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; IONIZATION MASS-SPECTROMETRY; MURINE CHEMOTACTIC PROTEIN; BIOCHEMICAL-CHARACTERIZATION; SUBCELLULAR-LOCALIZATION; HYDROGEN-PEROXIDE; SULFENIC ACID; CROSS-LINKING; AMINO-ACIDS; IN-VITRO	Hypochlorite is a major oxidant generated when neutrophils and macrophages are activated at inflammatory sites, such as in atherosclerotic lesions. Murine S100A8 (AS) is a major cytoplasmic protein in neutrophils and is secreted by macrophages in response to inflammatory stimuli. After incubation with reagent HOC1 for 10 min, similar to 85% of AS was converted to 4 oxidation products, with electrospay ionization mass spectrometry masses of m/z 10354, 10388, 10354 +/- 1, and 20707 +/- 3. All were resistant to reduction by dithiothreitol. Initial formation of a reactive Cys sulfenic acid intermediate was demonstrated by the rapid conjugation of 5,5-dimethyl-1,3-cyclohexanedione (dimedone) to HOC1-treated AS to form stable adducts. Matrix-assisted laser desorption-reflectron time of flight peptide mass fingerprinting of isolated oxidation products confirmed the mass additions observed in the full-length proteins. Both Met(36/73) were converted to Met(36/73) sulfoxides. An additional product with an unusual mass addition of m/z 14 (+/-0.2) was identified and corresponded to the addition of oxygen to Cys(41), conjugation to various E-amines of Lys(6), Lys(34/35), or Lys(87) with loss of dihydrogen and formation of stable intra- or inter-molecular sulfinamide cross-links. Specific fragmentations identified in matrix-assisted laser desorption-post source decay spectra and low energy collisional-induced dissociation tandem mass spectroscopy spectra of sulfinamide-containing digest peptides confirmed Lys(34/35) to Cys(41) sulfinamide bonds. HOCI oxidation of mutants lacking CyS41. (A1a(41)S100A8) or specific Lys residues (e.g. Lys(34/35), Ala(34/35)S100A8) did not form sulfinamide cross-links. HOCI generated by myeloperoxidase and H2O2 and by phorbol 12-myristate 13-acetate-activated neutrophils also formed these products . In contrast to the disulfide linked dimer, oxidized monomer retained normal chemotactic activity for neutrophils. Sulfinamide bond formation represents a novel oxidative cross-linking process between thiols and e-amines and may be a general consequence of HOCI protein oxidation in inflammation not identified previously. Similar modifications in other proteins could potentially regulate normal and pathological processes during aging, atherogenesis, fibrosis, and neurogenerative diseases.	Univ New S Wales, Sch Pathol, Cytokine Res Unit, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Raftery, MJ (corresponding author), Univ New S Wales, Sch Pathol, Cytokine Res Unit, Sydney, NSW 2052, Australia.	m.raftery@unsw.edu.au	Valenzuela, Stella/R-6387-2019	Valenzuela, Stella/0000-0001-5934-6047; Yang, Zheng/0000-0003-4275-0590				ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; Andersen JS, 2000, FEBS LETT, V480, P25, DOI 10.1016/S0014-5793(00)01773-7; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; BALLARD KD, 1992, J AM CHEM SOC, V114, P64, DOI 10.1021/ja00027a009; BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; Carr AC, 2000, BIOCHEM J, V346, P491, DOI 10.1042/0264-6021:3460491; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chaurand P, 1999, J AM SOC MASS SPECTR, V10, P91, DOI 10.1016/S1044-0305(98)00145-7; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CREMLYN RJ, 1996, INTRO ORGANOSULFUR C, P52; Dean RT, 1997, BIOCHEM J, V324, P1; Deshpande R, 2000, J INVEST DERMATOL, V115, P477, DOI 10.1046/j.1523-1747.2000.00078.x; DEVERY JM, 1994, J IMMUNOL, V152, P1888; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DROZDZ R, 1988, BIOCHIM BIOPHYS ACTA, V957, P47, DOI 10.1016/0167-4838(88)90155-0; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Fang SP, 2000, J AM SOC MASS SPECTR, V11, P345, DOI 10.1016/S1044-0305(99)00153-1; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Fu SL, 2000, J BIOL CHEM, V275, P10851, DOI 10.1074/jbc.275.15.10851; Harrison CA, 1999, J BIOL CHEM, V274, P8561, DOI 10.1074/jbc.274.13.8561; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Hetland G, 1998, J CLIN PATHOL-MOL PA, V51, P143, DOI 10.1136/mp.51.3.143; Hu SP, 1996, BLOOD, V87, P3919, DOI 10.1182/blood.V87.9.3919.bloodjournal8793919; IISMAA SE, 1994, DNA CELL BIOL, V13, P183, DOI 10.1089/dna.1994.13.183; Ishikawa K, 2000, ACTA CRYSTALLOGR D, V56, P559, DOI 10.1107/S0907444900002833; JOHNSSON N, 1990, J BIOL CHEM, V265, P14464; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kocher M, 1996, INFECT IMMUN, V64, P1342, DOI 10.1128/IAI.64.4.1342-1350.1996; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; Kumar RK, 1998, PATHOLOGY, V30, P51, DOI 10.1080/00313029800169665; Kumar RK, 2001, J LEUKOCYTE BIOL, V70, P59; LACKMANN M, 1992, J BIOL CHEM, V267, P7499; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAU W, 1995, J CLIN INVEST, V95, P1957, DOI 10.1172/JCI117879; Lee ISM, 2000, ARCH BIOCHEM BIOPHYS, V374, P137, DOI 10.1006/abbi.1999.1595; McCormick ML, 1998, J BIOL CHEM, V273, P32030, DOI 10.1074/jbc.273.48.32030; Mo WJ, 2000, RAPID COMMUN MASS SP, V14, P2080, DOI 10.1002/1097-0231(20001115)14:21<2080::AID-RCM120>3.0.CO;2-P; Passey RJ, 1999, J LEUKOCYTE BIOL, V66, P549, DOI 10.1002/jlb.66.4.549; Raftery MJ, 1997, RAPID COMMUN MASS SP, V11, P405, DOI 10.1002/(SICI)1097-0231(19970228)11:4<405::AID-RCM823>3.0.CO;2-A; Raftery MJ, 1998, J AM SOC MASS SPECTR, V9, P533, DOI 10.1016/S1044-0305(98)00020-8; Ridinger K, 2000, J BIOL CHEM, V275, P8686, DOI 10.1074/jbc.275.12.8686; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scotto C, 1998, J BIOL CHEM, V273, P3901, DOI 10.1074/jbc.273.7.3901; Steen H, 2001, J AM SOC MASS SPECTR, V12, P228, DOI 10.1016/S1044-0305(00)00219-1; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; Thomas GR, 2000, J IMMUNOL, V164, P3870, DOI 10.4049/jimmunol.164.7.3870; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5; Winterbourn CC, 1997, BIOCHEM J, V326, P87, DOI 10.1042/bj3260087; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; Xu K, 2000, J IMMUNOL, V164, P4916, DOI 10.4049/jimmunol.164.9.4916; Xu K, 2001, J IMMUNOL, V166, P6358, DOI 10.4049/jimmunol.166.10.6358; Yen T, 1997, BLOOD, V90, P4812, DOI 10.1182/blood.V90.12.4812.4812_4812_4821	65	106	108	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33393	33401		10.1074/jbc.M101566200	http://dx.doi.org/10.1074/jbc.M101566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445563	hybrid			2022-12-25	WOS:000170910200016
J	Burgon, PG; Lee, WL; Nixon, AB; Peralta, EG; Casey, PJ				Burgon, PG; Lee, WL; Nixon, AB; Peralta, EG; Casey, PJ			Phosphorylation and nuclear translocation of a regulator of G protein signaling (RGS10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; ALPHA INTERACTING PROTEIN; SACCHAROMYCES-CEREVISIAE; MEDIATED MODULATION; TRANSITION-STATE; PLASMA-MEMBRANE; K+ CURRENTS; MAP KINASE; LOCALIZATION; SUBUNITS	Heterotrimeric G proteins are involved in the transduction of hormonal and sensory signals across plasma membranes of eukaryotic cells. Hence, they are a critical point of control for a variety of agents that modulate cellular function. Activation of these proteins is dependent on GTP binding to their alpha (G alpha) subunits. Regulators of G protein signaling (RGS) bind specifically to activated G alpha proteins, potentiating the intrinsic GTPase activity of the Ga proteins and thus expediting the termination of Ga signaling. Although there are several points in most G protein controlled signaling pathways that are affected by reversible covalent modification, little evidence has been shown addressing whether or not the functions of RGS proteins are themselves regulated by such modifications. We report in this study the acute functional regulation of RGS10 thru the specific and inducible phosphorylation of RGS10 protein at serine 168 by cAMP-dependent kinase A. This phosphorylation nullifies the RGS10 activity at the plasma membrane, which controls the G protein-dependent activation of the inwardly rectifying potassium channel. Surprisingly, the phosphorylation-mediated attenuation of RGS10 activity was not manifested in an alteration of its ability to accelerate GTPase activity of Ga. Rather, the phosphorylation event correlates with translocation of RGS10 from the plasma membrane and cytosol into the nucleus.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Harvard University; Duke University; Duke University	Burgon, PG (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	burgon@fas.harvard.edu	Burgon, Patrick/ABB-1027-2021; Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964; Casey, Patrick/0000-0002-7366-9309; Burgon, Patrick/0000-0003-4771-023X	NCI NIH HHS [F32 CA76711] Funding Source: Medline; NIGMS NIH HHS [R01 GM36259, R01 GM55717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA076711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R01GM055717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Herlitze X, 1999, J PHYSIOL-LONDON, V517, P341, DOI 10.1111/j.1469-7793.1999.0341t.x; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOFFMAN PW, 1994, J NEUROSCI, V14, P4185; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	36	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32828	32834		10.1074/jbc.M100960200	http://dx.doi.org/10.1074/jbc.M100960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11443111	hybrid			2022-12-25	WOS:000170746000062
J	Masuyama, N; Oishi, K; Mori, Y; Ueno, T; Takahama, Y; Gotoh, Y				Masuyama, N; Oishi, K; Mori, Y; Ueno, T; Takahama, Y; Gotoh, Y			Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATION-INDUCED APOPTOSIS; DNA-BINDING DOMAIN; NGFI-B; STEROID-RECEPTOR; TRANSCRIPTION FACTOR; NEGATIVE SELECTION; POSITIVE SELECTION; IN-VIVO; SURVIVAL	Akt is a common mediator of cell survival in a variety of circumstances. Although some candidate Akt targets have been described, the function of Akt is not fully understood, particularly because of the cell type- and context-dependent apoptosis regulation. In this study, we demonstrate that one of the mechanisms by which Akt antagonizes apoptosis involves the inhibition of Nur77, a transcription factor implicated in T-cell receptor-mediated apoptosis. It has been suggested that Akt phosphorylates Nur77 directly, but whether Akt suppresses biological functions of Nur77 remains unknown. We found that Akt inhibited the DNA binding activity of Nur77 and stimulated its association with 14-3-3 in a phosphorylation site-dependent manner. Moreover, we found that expression of Akt suppressed Nur77-induced apoptosis in fibroblasts and activation-induced cell death of T-cell hybridomas. The inhibition of Nur77 by Akt suggests a mechanism that explains how T-cell receptor activation can promote survival in some instances even when Nur77 is induced. Collectively, these results may suggest that Akt is a negative regulator of Nur77 in T-cell apoptosis.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokushima, Inst Genome Res, Tokushima 7708503, Japan	University of Tokyo; Tokushima University	Gotoh, Y (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Takahama, Yousuke/A-5863-2010	Takahama, Yousuke/0000-0002-4992-9174				Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CALNAN BJ, 1995, IMMUNITY, V3, P273; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HIRATA Y, 1995, J NEUROCHEM, V65, P1780; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; KEARSE KP, 1995, J EXP MED, V181, P193, DOI 10.1084/jem.181.1.193; Kuang AA, 1999, EUR J IMMUNOL, V29, P3722, DOI 10.1002/(SICI)1521-4141(199911)29:11<3722::AID-IMMU3722>3.0.CO;2-N; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maruyama K, 1998, INT J ONCOL, V12, P1237; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	35	122	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32799	32805		10.1074/jbc.M105431200	http://dx.doi.org/10.1074/jbc.M105431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438550	hybrid			2022-12-25	WOS:000170746000058
J	Parker, LM; Fierro-Monti, I; Mathews, MB				Parker, LM; Fierro-Monti, I; Mathews, MB			Nuclear factor 90 is a substrate and regulator of the eukaryotic initiation factor 2 kinase double-stranded RNA-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS K3L; BINDING PROTEIN; TRANSCRIPTION FACTOR; CELLULAR ACTIVATOR; T-CELLS; IN-VIVO; PKR; INTERFERON; DOMAINS; IDENTIFICATION	Nuclear factor 90 (NF90) is a member of an expanding family of double-stranded (ds) RNA-binding proteins thought to be involved in gene expression. Originally identified in complex with nuclear factor 45 (NF45) as a sequence-specific DNA-binding protein, NF90 contains two double stranded RNA-binding motifs (dsRBMs) and interacts with highly structured RNAs as well as the dsRNA-activated protein kinase, PKR. In this report, we characterize the biochemical interactions between these two dsRBM containing proteins. NF90 binds to PKR through two independent mechanisms: an RNA-independent interaction occurs between the N terminus of NF90 and the C-terminal region of PKR, and an RNA-dependent interaction is mediated by the dsRBMs of the two proteins. Co-immunoprecipitation analysis demonstrates that NF90, NF45, and PKR form a complex in both nuclear and cytosolic extracts, and both proteins serve as substrates for PKR in vitro. NF90 is phosphorylated by PKR in its RNA-binding domain, and this reaction is partially blocked by the NF90 N-terminal region. The C-terminal region also inhibits PKR function, probably through competitive binding to dsRNA. A model for NF90-PKR interactions is proposed.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Mathews, MB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA.	mathews@umdnj.edu	Fierro-Monti, Ivo/AAH-3595-2020	/0000-0002-5460-2117	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bergeron J, 2000, CANCER RES, V60, P6800; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; Coolidge CJ, 2000, NUCLEIC ACIDS RES, V28, P1407, DOI 10.1093/nar/28.6.1407; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; Gale M, 1996, MOL CELL BIOL, V16, P4172; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; JIMENEZGARCIA LF, 1993, J CELL SCI, V106, P11; KAO PN, 1994, J BIOL CHEM, V269, P20691; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Orford RL, 1998, MOL CELL BIOL, V18, P5557, DOI 10.1128/MCB.18.9.5557; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Pe'ery T, 2000, COLD SPRING HARBOR M, V39, P371; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Petryshyn R, 1996, ARCH BIOCHEM BIOPHYS, V326, P290, DOI 10.1006/abbi.1996.0078; Raine DA, 1998, FEBS LETT, V436, P343, DOI 10.1016/S0014-5793(98)01163-6; Romano PR, 1998, MOL CELL BIOL, V18, P7304, DOI 10.1128/MCB.18.12.7304; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Satoh M, 1999, J BIOL CHEM, V274, P34598, DOI 10.1074/jbc.274.49.34598; SCHUMACHER JM, 1995, J CELL BIOL, V129, P1023, DOI 10.1083/jcb.129.4.1023; Setzer DR, 1996, RNA, V2, P1254; Sharp TV, 1997, EUR J BIOCHEM, V250, P85, DOI 10.1111/j.1432-1033.1997.00085.x; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Xu YH, 1999, MOL GENET METAB, V68, P441, DOI 10.1006/mgme.1999.2934; Xu YH, 2000, MOL GENET METAB, V70, P106, DOI 10.1006/mgme.2000.3010; Zhai G, 2001, BIOCHEMISTRY-US, V40, P2032, DOI 10.1021/bi001941r; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	49	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32522	32530		10.1074/jbc.M104408200	http://dx.doi.org/10.1074/jbc.M104408200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438540	hybrid			2022-12-25	WOS:000170746000021
J	Codony, C; Guil, S; Caudevilla, C; Serra, D; Asins, G; Graessmann, A; Hegardt, FG; Bach-Elias, M				Codony, C; Guil, S; Caudevilla, C; Serra, D; Asins, G; Graessmann, A; Hegardt, FG; Bach-Elias, M			Modulation in vitro of H-ras oncogene expression by trans-splicing	ONCOGENE			English	Article						splicing; c-H-ras; trans-splicing	MESSENGER-RNA; MAMMALIAN-CELLS; EXON; GENE; LIVER; ENHANCER	In man, activated N-, K- and H-ras oncogenes have been found in around 30% of the solid tumours tested, An exon known as IDX, which has been described previously and is located between exon 3 and exon 4A of the c-H-ras pre-mRNA, allows an alternative splicing process that results in the synthesis of the mRNA of a putative protein named p19, It has been suggested that this alternative pathway is less tumorigenic than that which results in the activation of p21, We have used the mammalian trans-splicing mechanism as a tool with which to modulate this particular pre-mRNA processing to produce mRNA similar to that of mature p19 RNA. The E4A exon of the activated H-vas gene was found to be a good target for external trans-splicing. We reprogrammed the rat carnitine octanoyltransferase exon 2 to specifically invade the terminal region of H-ras. Assays performed with this reprogrammed trans-exon showed that the trans-splicing product was obtained in competition with cis-splicing of the D intron of the H-ras gene, and was associated with concomitant downmodulation of D intron cis-splicing. We also found that the exon 4A of the human c-H-ras gene underwent successive trans-splicing rounds with an external exon.	CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, ES-08034 Barcelona, Spain; Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08007 Barcelona, Spain; Free Univ Berlin, Inst Molekularbiol & Biochim, D-14195 Berlin, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Free University of Berlin	Bach-Elias, M (corresponding author), CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, C Jorge Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Guil, Sonia/M-8036-2015; Serra, Dolors/L-3657-2014	Guil, Sonia/0000-0002-2257-3331; Serra, Dolors/0000-0002-4936-4206; Codony Servat, Carles/0000-0001-8928-2312				Akopian AN, 1999, FEBS LETT, V445, P177, DOI 10.1016/S0014-5793(99)00126-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Breen MA, 1997, FEBS LETT, V409, P375, DOI 10.1016/S0014-5793(97)00555-3; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Cicarelli RMB, 1998, BIOCHEM BIOPH RES CO, V247, P204, DOI 10.1006/bbrc.1998.8771; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Frantz SA, 1999, P NATL ACAD SCI USA, V96, P5400, DOI 10.1073/pnas.96.10.5400; Huang MY, 1997, ONCOL RES, V9, P611; Kawasaki T, 1999, PLANT J, V18, P625, DOI 10.1046/j.1365-313x.1999.00493.x; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mansfield SG, 2000, GENE THER, V7, P1885, DOI 10.1038/sj.gt.3301307; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; SHIMIZU A, 1993, FASEB J, V7, P149, DOI 10.1096/fasebj.7.1.7916698; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; Zaphiropoulos PG, 1999, NUCLEIC ACIDS RES, V27, P2585, DOI 10.1093/nar/27.13.2585	24	6	6	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3683	3694		10.1038/sj.onc.1204473	http://dx.doi.org/10.1038/sj.onc.1204473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439331				2022-12-25	WOS:000169400200009
J	Foehr, ED; Raffioni, S; Murray-Rust, J; Bradshaw, RA				Foehr, ED; Raffioni, S; Murray-Rust, J; Bradshaw, RA			The role of tyrosine residues in fibroblast growth factor receptor 1 signaling in PC12 cells - Systematic site-directed mutagenesis in the endodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; POINT MUTATION; CHIMERIC RECEPTORS; ADAPTER PROTEINS; ACTIVATION; DOMAIN; KINASE; TRANSDUCTION; MITOGENESIS; RESPONSES	To assess the contribution of the intracellular domain tyrosine residues to the signaling capacity of fibroblast growth factor receptor 1 (FGFR1), stably transfected chimeras bearing the ectodomain of the platelet-derived growth factor receptor (PDGFR) and the endodomain of FGFR1 were systematically altered by a tyrosine to phenylalanine bloc and individual conversions. The 15 tyrosine residues of the endodomain of this construct (PFR1) were divided into four linear segments (labeled A, B, C, and D) that contained 4, 4, 2, and 5 tyrosine residues, respectively. When stimulated by platelet-derived growth factor, derivatives in which the A, B, or A + B blocs of tyrosines were mutated were about two-thirds as active as the unmodified chimera at 48 h but achieved fun activity by 96 h in a neurite outgrowth assay in transfected PC12 cells. Elimination of only the two activation loop tyrosines (C bloc) also inactivated the receptor. All derivatives in which 4 (or 5) of the D bloc tyrosines were mutated were inactive in producing differentiation but showed low levels of kinase activity in in vitro assays. Derivatives in which 1, 2, or 3 tyrosines of the D bloc Mi different combinations were systematically changed demonstrated that 2 residues (Tyr(677) and Tyr(701), using hF-GFR1 numbering) were essential for bioactivity, but the remaining 3 residues, including Tyr(766), the previously identified site for phospholipase C gamma (PLC gamma) activation, were not. Differentiation activity was paralleled by the activation (phosphorylation) of FRS2, SOS, and ERK1/2. PLC gamma activity was dependent on the presence of Tyr(766) but also required Tyr(677) and/or Tyr(701). Although fully active chimeras did not require PLC gamma, the responses of chimeras showing reduced activation of FRS2 were significantly enhanced by this activity. These results establish that PFR1 does not utilize any tyrosine residues, phosphorylated or not, to activate FRS2. However, it does require Tyr(677) and/or Tyr(701), which may function to stabilize the active conformation directly or indirectly.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94103 USA; Imperial Canc Res Fund, London WC2A 3PX, England	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Francisco; The J David Gladstone Institutes; Cancer Research UK	Bradshaw, RA (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA.		Bradshaw, Ralph A/K-1515-2013		NIA NIH HHS [AG09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Foehr ED, 2000, FASEB J, V14, P973, DOI 10.1096/fasebj.14.7.973; Foehr ED, 1998, IMMUNOL CELL BIOL, V76, P406, DOI 10.1046/j.1440-1711.1998.00775.x; Heldin C.-H., 1996, SIGNAL TRANSDUCTION; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; Vajo Z, 2000, ENDOCR REV, V21, P23, DOI 10.1210/er.21.1.23; WANG J, 1996, ONCOGENE, V34, P721; Wang JK, 1997, ONCOGENE, V14, P1767, DOI 10.1038/sj.onc.1201021; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	23	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37529	37536		10.1074/jbc.M103234200	http://dx.doi.org/10.1074/jbc.M103234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11459840	hybrid			2022-12-25	WOS:000171375700088
J	Kishida, K; Shimomura, I; Kondo, H; Kuriyama, H; Makino, Y; Nishizawa, H; Maeda, N; Matsuda, M; Ouchi, N; Kihara, S; Kurachi, Y; Funahashi, T; Matsuzawa, Y				Kishida, K; Shimomura, I; Kondo, H; Kuriyama, H; Makino, Y; Nishizawa, H; Maeda, N; Matsuda, M; Ouchi, N; Kihara, S; Kurachi, Y; Funahashi, T; Matsuzawa, Y			Genomic structure and insulin-mediated repression of the aquaporin adipose (AQPap), adipose-specific glycerol channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; DEPENDENT DIABETES-MELLITUS; FATTY-ACID TRANSPORT; PROTEIN-KINASE-B; FACTOR FKHR; GENE-EXPRESSION; WATER CHANNEL; MOLECULAR CHARACTERIZATION; RESPONSE SEQUENCE; PROMOTER ACTIVITY	In the current study, we examined the genomic structure of the mouse AQPap gene and its regulation by insulin. The mouse AQPap gene spanned 12 kilobase pairs in chromosome 4 and consisted of 8 exons and 7 introns. The first two exons, designated exon I and exon 1', are alternatively spliced to common exon 2, and thus the AQPap gene possessed two potential promoters. The exon 1-derived transcript is dominant in both adipose tissues and adipocytes on the basis of RNase protection assay and promoter analysis. The mRNA increased after fasting and decreased with refeeding. Insulin deficiency generated by streptozotocin enhanced the mRNA in adipose tissue. Insulin down-regulated AQPap mRNA in 3T3-L1 adipocytes. The AQPap promoter contained heptanucleotide sequences, TGTTTTT at -443/-437, similar to the insulin-response element identified previously in the promoters of insulin-repressed genes. Deletion and single base pair substitution analysis of the promoter revealed that these sequences were required for insulin-mediated repression of AQPap gene transcription. The phosphatidylinositol 3-kinase pathway was involved in this inhibition. We conclude that insulin represses the transcription of AQPap gene via insulin response element in its promoter. Sustained up-regulation of AQPap mRNA in adipose tissue in the insulin-resistant condition may disturb glucose homeostasis by increasing plasma glycerol.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Pharmacol 2, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Shimomura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		OUCHI, Noriyuki/I-7306-2014	Nisihida, Makoto/0000-0002-0309-7106				BABA H, 1995, NUTRITION, V11, P149; Bergman Richard N., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P205; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; EISINGER DP, 1993, GENOMICS, V16, P638, DOI 10.1006/geno.1993.1241; Engel A, 2000, EMBO J, V19, P800, DOI 10.1093/emboj/19.5.800; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hui TY, 1998, J BIOL CHEM, V273, P27420, DOI 10.1074/jbc.273.42.27420; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1998, BBA-GENE STRUCT EXPR, V1399, P62, DOI 10.1016/S0167-4781(98)00094-3; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KINLOCH RA, 1993, METHOD ENZYMOL, V225, P294; Kishida K, 2000, J BIOL CHEM, V275, P20896, DOI 10.1074/jbc.M001119200; KLEIN S, 1990, AM J PHYSIOL, V258, pE32, DOI 10.1152/ajpendo.1990.258.1.E32; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; NURJHAN N, 1992, J CLIN INVEST, V89, P169, DOI 10.1172/JCI115558; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PUHAKAINEN I, 1992, J CLIN ENDOCR METAB, V75, P789, DOI 10.1210/jc.75.3.789; Ramsay TG, 1996, ENDOCRIN METAB CLIN, V25, P847, DOI 10.1016/S0889-8529(05)70358-3; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; TRIEZENBERG SJ, 1987, CURRENT PROTOCOLS MO; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; WINARTASAPUTRA H, 1980, CLIN CHEM, V26, P613; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598	43	98	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36251	36260		10.1074/jbc.M106040200	http://dx.doi.org/10.1074/jbc.M106040200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11457862	hybrid			2022-12-25	WOS:000171194500028
J	Takahashi, H; Honma, M; Ishida-Yamamoto, A; Namikawa, K; Kiyama, H; Iizuka, H				Takahashi, H; Honma, M; Ishida-Yamamoto, A; Namikawa, K; Kiyama, H; Iizuka, H			Expression of human cystatin a by keratinocytes is positively regulated via the Ras/MEKK1/MKK7/JNK signal transduction pathway but negatively regulated via the Ras/Raf-1/MEK1/ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; C-JUN; EPIDERMAL TRANSGLUTAMINASE; CORNIFIED ENVELOPE; MESSENGER-RNA; INVOLUCRIN; RAS; EFFICIENT; PHOSPHORYLATION; DIFFERENTIATION	Cystatin A, a cysteine proteinase inhibitor, is a cornified cell envelope constituent expressed in the upper epidermis. We previously reported that a potent protein kinase C activator, 12-O-tetradecanoylphorbol-13-acetate, increases human cystatin A expression by the activation of AP-1 proteins. Here, we delineate the signaling cascade responsible for this regulation. Co-transfection of the cystatin A promoter into normal human keratinocytes together with a dominant active form of ras increased the promoter activity by 3-fold. In contrast, a dominant negative form of ras suppressed basal cystatin A promoter activity. Further analyses disclosed that transfection of dominant negative forms of raf-1, MEK1, ERK1, ERK2, or wild-type MEKK1 all increased cystatin A promoter activity in normal human keratinocytes, whereas wild-type raf-1, ERK1, ERK2, or dominant negative forms of MEKK1, MKK7, or JNK1 suppressed the promoter activity. The increased or decreased promoter activity reflected the expression of cystatin A on mRNA and protein levels. These effects were not observed when a cystatin A promoter with a T2 (-272 to -278) deletion was used. In contrast, transfection of dominant negative forms of MKK3, MKK4, or p38 did not affect cystatin A promoter activity. Immunohistochemical analyses revealed that phosphorylated active extracellular signal-regulated kinases and c-Jun N-terminal kinase were expressed in the nuclei of basal cells and cells in the suprabasal-granular cell layer, respectively. These results indicate that the expression of cystatin A is regulated via mitogen-activated protein kinase pathways positively by Ras/MEKK1/MKK7/JNK and negatively by Ras/Raf/MEK1/ERK.	Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Anat, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Takahashi, H (corresponding author), Asahikawa Med Coll, Dept Dermatol, 2-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	ht@asahikawa-med.ac.jp	Kiyama, Hiroshi/M-8867-2014	Kiyama, Hiroshi/0000-0001-5963-046X				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; HAWLEYNELSON P, 1998, MOL CARCINOG, V1, P202; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; HSIEH WT, 1991, GENOMICS, V9, P207, DOI 10.1016/0888-7543(91)90241-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishida-Yamamoto A, 1998, EXP DERMATOL, V7, P1, DOI 10.1111/j.1600-0625.1998.tb00295.x; IshidaYamamoto A, 1997, J INVEST DERMATOL, V108, P12, DOI 10.1111/1523-1747.ep12285611; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LOBITZ CJ, 1982, J INVEST DERMATOL, V78, P150, DOI 10.1111/1523-1747.ep12506301; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; MUFSON RA, 1982, CANCER RES, V42, P4600; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Namikawa K, 2000, J NEUROSCI, V20, P2875; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Takahashi H, 1997, J INVEST DERMATOL, V108, P843, DOI 10.1111/1523-1747.ep12292575; Takahashi H, 1996, BRIT J DERMATOL, V134, P1065; Takahashi H, 1998, J BIOL CHEM, V273, P17375, DOI 10.1074/jbc.273.28.17375; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; Terashima T, 1997, ANAT EMBRYOL, V196, P363, DOI 10.1007/s004290050105; TEZUKA T, 1994, DERMATOLOGY, V188, P21, DOI 10.1159/000247079; Torma H, 2000, ACTA DERM-VENEREOL, V80, P4, DOI 10.1080/000155500750012405; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238	52	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36632	36638		10.1074/jbc.M102021200	http://dx.doi.org/10.1074/jbc.M102021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11451947	hybrid			2022-12-25	WOS:000171194500077
J	van de Water, B; Houtepen, F; Huigsloot, M; Tijdens, IB				van de Water, B; Houtepen, F; Huigsloot, M; Tijdens, IB			Suppression of chemically induced apoptosis but not necrosis of renal proximal tubular epithelial (LLC-PK1) cells by focal adhesion kinase (FAK) - Role of FAK in maintaining focal adhesion organization after acute renal cell injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; CASPASE-MEDIATED CLEAVAGE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; C-JUN; SURVIVAL SIGNALS; OXIDATIVE STRESS; KIDNEY-CELLS; IN-VITRO; INTEGRINS	Decreased phosphorylation of focal adhesion kinase (FAK) is associated with loss of focal adhesions and actin stress fibers and precedes the onset of apoptosis in renal epithelial cells caused by nephrotoxicants (Van de Water, B., Nagelkerke, J. F., and Stevens, J. L. (1999) J. Biol. Chem 274, 13328 -13337). The role of FAK in the control of apoptosis caused by nephrotoxicants was further investigated in LLC-PK1 cells that were stably transfected with either green fluorescent protein (GFP)-FAK or dominant negative acting deletion mutants of FAY, GFP-FAT, and GFP-FRNK. GFP-FAT and GFP-FRNK delayed the formation of focal adhesions and prevented the localization of endogenous (phosphorylated) FAK at these sites. GFP-FAT and GFP-FRNK overexpression potentiated the onset of apoptosis caused by the nephrotoxicant dichlorovinyl-cysteine. This was associated with an increased activation of caspase-3. GFP-FAT also potentiated apoptosis caused by doxorubicin but not cisplatin. The potentiation of apoptosis by GFP-FAT was related to an almost complete dephosphorylation of FAK, this did not occur in cells overexpressing only GFP. This dephosphorylation was associated with a pronounced loss of focal adhesion organization in GFP-FAT cells, in association with loss of tyrosine phosphorylation of paxillin. In conclusion, the data indicate an important role of cell-matrix signaling in the control of chemically induced apoptosis; loss of FAK activity caused by toxic chemicals results in perturbations of focal adhesion organization with a subsequent inactivation of associated (signaling) molecules and loss of survival signaling.	Leiden Univ, Div Toxicol, LACDR, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	van de Water, B (corresponding author), Leiden Univ, Div Toxicol, LACDR, POB 9503, NL-2300 RA Leiden, Netherlands.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Brady H.R., 1996, KIDNEY, P1200; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN Q, 1990, J BIOL CHEM, V265, P21603; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEDHAR S, 1990, BIOESSAYS, V12, P583, DOI 10.1002/bies.950121205; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAILIT J, 1993, AM J PHYSIOL, V264, pF149, DOI 10.1152/ajprenal.1993.264.1.F149; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; GOLDSTEIN RS, 1996, TOXICOLOGY, P417; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kreidberg JA, 2000, AM J PHYSIOL-RENAL, V279, pF233, DOI 10.1152/ajprenal.2000.279.2.F233; Kruidering M, 1998, CELL DEATH DIFFER, V5, P601, DOI 10.1038/sj.cdd.4400392; LASH LH, 1986, J BIOL CHEM, V261, P5930; LASH LH, 1986, J BIOL CHEM, V261, P3076; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lieberthal W, 1998, SEMIN NEPHROL, V18, P505; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Norman JT, 1999, EXP NEPHROL, V7, P167; Owen JD, 1999, MOL CELL BIOL, V19, P4806; RACUSEN LC, 1991, LAB INVEST, V64, P546; Raman N, 1999, AM J PHYSIOL-CELL PH, V276, pC1312, DOI 10.1152/ajpcell.1999.276.6.C1312; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; STEVENS JL, 1988, J BIOL CHEM, V263, P3395; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; van de Water B, 2000, J BIOL CHEM, V275, P25805, DOI 10.1074/jbc.M001680200; VANDEWATER B, 1994, AM J PHYSIOL-RENAL, V267, pF888, DOI 10.1152/ajprenal.1994.267.5.F888; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; Zhan Y, 1999, ONCOGENE, V18, P6505, DOI 10.1038/sj.onc.1203060; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	60	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36183	36193		10.1074/jbc.M102091200	http://dx.doi.org/10.1074/jbc.M102091200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11447217	Green Published, hybrid			2022-12-25	WOS:000171194500020
J	Buck, E; Iyengar, R				Buck, E; Iyengar, R			Modular design of G beta as the basis for reversible specificity in effector stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNITS; BINDING; RESOLUTION; PROTEINS	The G protein G beta gamma subunit complex stimulates effectors by direct interactions utilizing extensive G beta regions over the surface of its propeller structure that faces the G alpha subunit. Our previous experiments have shown the resolved functions of signal transfer and general binding for G beta regions involved in stimulation of the effector phospholipase C-beta2, PLC-beta2, within the region G beta-(86-135), which comprises three beta strands arranged in a structurally contiguous fashion (Buck, E., Li, J., Chen, Y., Weng, G., Sacarlata, S., and Iyengar, R. (1999) Science 283, 1332-1335). This raises an important question as to why mutagenesis studies indicate that an extensive set of sites all over the G beta propeller structure and outside the 86-135 region are involved in G beta regulation of PLC-beta2. Using peptides to define functions of these G beta regions, we find that G beta signaling to PLC-beta2 relies on a collection of modular signal transfer and general binding units, each with lower apparent affinity relative to G beta gamma -PLC interactions. G beta-(42-54) functions as a signal transfer region, G beta-(228-249) and G beta-(321-340) function in general binding, and G beta-(64-84) and G beta-(300-313) seem to play a structural role rather than a direct contact with the effector. A substitution within the G beta-(42-54) signal transfer region that increases the K-act of this peptide for PLC-beta2 is accompanied by an increase in the observed maximal extent of signal transfer. We conclude that the lower K-act for individual signal transfer regions may result in a decrease in the maximal effect of signal transfer. The spatial resolution of the signal transfer and general binding regions over a wide surface of GP allow geometrical constraints to achieve specificity even with relatively low affinity interactions.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Iyengar, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215,1 Gustave Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-0745, DK-38761] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; CONA R, 1995, FEBS LETT, V367, P122; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; JIANG HP, 1994, J BIOL CHEM, V269, P7593; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; UEDA N, 1994, J BIOL CHEM, V269, P4388; Yan K, 1997, J BIOL CHEM, V272, P2056; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	14	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					36014	36019		10.1074/jbc.M103228200	http://dx.doi.org/10.1074/jbc.M103228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457830	hybrid			2022-12-25	WOS:000171109300105
J	Hsi, LC; Wilson, L; Nixon, J; Eling, TE				Hsi, LC; Wilson, L; Nixon, J; Eling, TE			15-Lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; HUMAN COLORECTAL-CANCER; HUMAN BREAST-CANCER; PPAR-GAMMA; PROTEIN-KINASE; IN-VITRO; MAMMALIAN LIPOXYGENASES; PROSTATE ADENOCARCINOMA; OXIDIZED LDL; COLON-CANCER	Human colon tumors have elevated levels of 15-lipoxygenase-1 (15-LO-1), suggesting that 15-LO-1 may play a role in the development of colorectal cancer. Also, 15-LO-1 metabolites can up-regulate epidermal growth factor signaling pathways, which results in an increase in mitogenesis. However, metabolites of 15-LO-1 can serve as ligands for peroxisome proliferator-activated receptor gamma (PPAR gamma), and activation of this receptor causes most colon cancer cell lines to undergo a differentiative response and reverse their malignant phenotype. Hence, the role 15-LO-1 plays in colon cancer is not clear. To clarify the role of 15-LO-1 in carcinogenesis, the effect of 15-LO-1 and its metabolites on epidermal growth factor signaling and PPAR gamma was investigated. In HCT-116 cells, exogenously added 15-LO-1 metabolites, 13-(S)-hydroxyoctadecadienoic acid, 13-(S)-hydroxyoctadecadienoic acid, and 13-(S)-hydroperoxyoctadecadienoic acid, up-regulated the MAPK signaling pathway, and an increase in PPAR gamma phosphorylation was observed. Furthermore, in stable overexpressing 15-LO-1 HCT-116 cells, which produce endogenous 15-LO-1 metabolites, an up-regulation in mitogen-activated protein kinase and PPAR gamma phosphorylation was observed. Incubation with a MAPK inhibitor ablated MAPK and PPAR gamma phosphorylation. The 15-LO-1 up-regulates MAPK activity and increases PPAR gamma phosphorylation, resulting in a down-regulation of PPAR gamma activity. Thus, 15-LO-1 metabolites may not only serve as ligands for PPAR gamma but can down-regulate PPAR gamma activity via the MAPK signaling pathway.	NIEHS, NIH, Mol Carcinogenesis Lab, Eicosanoid Biochem Sect, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eling, TE (corresponding author), NIEHS, NIH, Mol Carcinogenesis Lab, Eicosanoid Biochem Sect, POB 12233, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050143] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Camp HS, 1997, J BIOL CHEM, V272, P10811; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; Glasgow WC, 1997, J BIOL CHEM, V272, P19269, DOI 10.1074/jbc.272.31.19269; HENKE DC, 1984, ANAL BIOCHEM, V162, P156; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Ikawa H, 1999, CANCER RES, V59, P360; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kelavkar UP, 2000, CARCINOGENESIS, V21, P1777; Kubota T, 1998, CANCER RES, V58, P3344; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; SIGAL E, 1990, J BIOL CHEM, V265, P5113; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5623; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	37	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34545	34552		10.1074/jbc.M100280200	http://dx.doi.org/10.1074/jbc.M100280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11447213	hybrid			2022-12-25	WOS:000171024600028
J	Liu, C; Xu, ZJ; Gupta, D; Dziarski, R				Liu, C; Xu, ZJ; Gupta, D; Dziarski, R			Peptidoglycan recognition proteins - A novel family of four human innate immunity pattern recognition molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; BACTERIAL; ACTIVATION; COMPONENTS; SECRETION; SILKWORM; SLEEP; TLR4; GENE; CD14	The innate immune system recognizes microorganisms through a series of pattern recognition receptors that are highly conserved in evolution. Insects have a family of 12 peptidoglycan recognition proteins (PGRPs) that recognize peptidoglycan, a ubiquitous component of bacterial cell walls. We report cloning of three novel human PGRPs (PGRP-L, PGRP-I alpha, and PGRP-I beta) that together with the previously cloned PGRP-S, define a new family of human pattern recognition molecules. PGRP-L, PGRP-I alpha, and PGRP-1 beta have 576,341, and 373 amino acids coded by five, seven, and eight exons on chromosomes 19 and 1, and they all have two predicted transmembrane domains. All mammalian and insect PGRPs have at least three highly conserved C-terminal PGRP domains located either in the extracellular or in the cytoplasmic (or in both) portions of the molecules. PGRP-L is expressed in liver, PGRP-I alpha and PGRP-I beta in esophagus (and to a lesser extent in tonsils and thymus), and PGRP-S in bone marrow (and to a lesser extent in neutrophils and fetal liver). All four human PGRPs bind peptidoglycan and Grampositive bacteria. Thus, these PGRPs may play a role in recognition of bacteria in these organs.	Indiana Univ, Sch Med, NW Ctr Med Educ, Gary, IN 46408 USA	Indiana University System; Indiana University Northwest	Dziarski, R (corresponding author), Indiana Univ, Sch Med, NW Ctr Med Educ, 3400 Broadway, Gary, IN 46408 USA.	rdziar@iun.edu			NIAID NIH HHS [AI2879] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ashida M., 1997, MOL MECH IMMUNE RESP, P135; Doyle R.J., 2001, MOL MED MICROBIOLOGY, P137; Du X, 2000, EUR CYTOKINE NETW, V11, P362; DUNN PE, 1985, DEV COMP IMMUNOL, V9, P559, DOI 10.1016/0145-305X(85)90019-9; DZIARSKI R, 1980, J IMMUNOL, V125, P2478; Dziarski R, 2000, CHEM IMMUNOL, V74, P83; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Dziarski R. A., 2000, GLYCOMICROBIOLOGY, P145; GOYAL RK, 2001, HARRISONS PRINCIPLES, P1642; GUPTA D, 1995, J IMMUNOL, V155, P2620; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JONES AL, 1992, CELL TISSUE BIOL, P685; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KRUEGER JM, 1982, J BIOL CHEM, V257, P1664; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; MARTIN SA, 1984, J BIOL CHEM, V259, P2652; MCDONALD GB, 1989, GASTROINTESTINAL DIS, P640; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rehman A, 2001, CYTOKINE, V13, P8, DOI 10.1006/cyto.2000.0800; Sambrook J., 2001, MOL CLONING; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Yoshimura A, 1999, J IMMUNOL, V163, P1	34	287	319	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34686	34694		10.1074/jbc.M105566200	http://dx.doi.org/10.1074/jbc.M105566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11461926	hybrid			2022-12-25	WOS:000171024600047
J	Yeh, GC; Daschner, PJ; Lopaczynska, J; MacDonald, CJ; Ciolino, HP				Yeh, GC; Daschner, PJ; Lopaczynska, J; MacDonald, CJ; Ciolino, HP			Modulation of glucose-6-phosphate dehydrogenase activity and expression is associated with aryl hydrocarbon resistance in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUTRITIONAL REGULATION; DNA-ADDUCTS; REDUCTASE; CELLS; DEHYDROEPIANDROSTERONE; IDENTIFICATION; DETOXIFICATION; PROTEIN; GENE	The mutagenic effect of environmental carcinogens has been well documented in animal models and in human studies but the mechanisms involved in preventing carcinogen insult have not been fully elucidated. In this study we examined the molecular and biochemical changes associated with carcinogen resistance in a series of aryl hydrocarbon-resistant MCF-7 cell lines developed by exposure to benzo[a]pyrene (BP). The cell lines were designated as AH(R40), AH(R100), and AH(R200) to denote their increasing fold resistance to BP compared with wild type cells. These cell lines were also resistant to another aryl hydrocarbon (AH), dimethylbenz[a]anthracene, but not to pleiotropic drugs (doxorubicin, vinblastine, and taxol). The resistant cell lines showed an increase in the level of the primary intracellular antioxidant, reduced glutathione, corresponding to increasing AH resistance. However, there was no change in glutathione reductase activity. The generation of reduced glutathione requires NADPH, and we therefore examined the activity and expression of the rate-limiting enzyme in NADPH production, glucose-6-phosphate dehydrogenase (G6PD). An increase in G6PD specific activity was associated with increasing aryl hydrocarbon resistance. This was due to an increased expression of G6PD in resistant cells, which was demonstrated by increases in both protein and mRNA levels. However, there was no increase in the transcription rate of G6PD in the resistant cell. lines, indicating that the increase G6PD expression is due to a post-transcriptional modulation, which was confirmed by actinomycin D chase experiments. These results demonstrate that modulation of G6PD expression and activity is an important mechanism in AH resistance.	NCI, Frederick Canc Res & Dev Ctr, NIH,Cellular Defense & Carcinogenesis Sect, Basic Res Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Yeh, GC (corresponding author), NCI, Frederick Canc Res & Dev Ctr, NIH,Cellular Defense & Carcinogenesis Sect, Basic Res Lab, Bldg 560,Rm 12-05, Frederick, MD 21702 USA.	yeh@ncifcrf.gov	Daschner, Phil/Q-6473-2019	Daschner, Phil/0000-0002-3390-751X	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amir-Ahmady B, 2001, J BIOL CHEM, V276, P10514, DOI 10.1074/jbc.M010535200; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Beutler E, 1984, RED CELL METABOLISM, P74; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAYEN J, 1986, CELL BIOCHEM FUNCT, V4, P249, DOI 10.1002/cbf.290040404; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Ciolino HP, 1999, J BIOL CHEM, V274, P35186, DOI 10.1074/jbc.274.49.35186; Cramer C T, 1995, J Biochem Toxicol, V10, P293, DOI 10.1002/jbt.2570100603; DEUTSCH J, 1982, ENZYME 1 OXIDOREDUCT, V3, P190; DiMonaco M, 1997, BRIT J CANCER, V75, P589, DOI 10.1038/bjc.1997.102; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; GAETANI GF, 1989, BLOOD, V73, P334; GLATZLE D, 1970, INT Z VITAMINFORSCH, V40, P166; Grove AD, 1997, J BIOL CHEM, V272, P1621, DOI 10.1074/jbc.272.3.1621; Hodge DL, 1997, ARCH BIOCHEM BIOPHYS, V348, P303, DOI 10.1006/abbi.1997.0373; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; Joseph P, 1998, BRIT J CANCER, V77, P709, DOI 10.1038/bjc.1998.117; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Koren R, 2001, CANCER RES, V61, P1439; Long DJ, 2000, CANCER RES, V60, P5913; LUZZATTO L, 1987, CELL BIOCHEM FUNCT, V5, P101, DOI 10.1002/cbf.290050204; MOLERO C, 1994, EXP CELL RES, V210, P26, DOI 10.1006/excr.1994.1004; MOORE M, 1994, J BIOL CHEM, V269, P11751; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; Petruzzelli S, 1998, CANCER RES, V58, P4122; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; PROSTKO CR, 1989, BIOCHEM J, V258, P295, DOI 10.1042/bj2580295; PUISIEUX A, 1991, CANCER RES, V51, P6185; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; See KY, 2000, MUTAT RES-REV MUTAT, V463, P215, DOI 10.1016/S1383-5742(00)00047-8; Stabile LP, 1996, ARCH BIOCHEM BIOPHYS, V332, P269, DOI 10.1006/abbi.1996.0342; Tian WN, 1998, J BIOL CHEM, V273, P10609, DOI 10.1074/jbc.273.17.10609; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Xia H, 1998, ARCH BIOCHEM BIOPHYS, V353, P337, DOI 10.1006/abbi.1998.0668; YEH GC, 1987, CANCER RES, V47, P5994	37	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34708	34713		10.1074/jbc.M105680200	http://dx.doi.org/10.1074/jbc.M105680200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11463792	hybrid			2022-12-25	WOS:000171024600050
J	Planel, E; Yasutake, K; Fujita, SC; Ishiguro, K				Planel, E; Yasutake, K; Fujita, SC; Ishiguro, K			Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABNORMALLY PHOSPHORYLATED-TAU; PAIRED HELICAL FILAMENTS; ALZHEIMER-DISEASE BRAIN; BIOLOGICAL-ACTIVITY; RAT-BRAIN; NEUROFIBRILLARY DEGENERATION; MICROTUBULE-BINDING; GLUCOSE-METABOLISM; OKADAIC ACID; DEPHOSPHORYLATION	Hyperphosphorylated tau is the major component of paired helical filaments in neurofibrillary tangles found in Alzheimer's disease (AD) brain. Starvation of adult mice induces tau hyperphosphorylation at many paired helical filaments sites and with a similar regional selectivity as those in AD, suggesting that a common mechanism may be mobilized. Here we investigated the mechanism of starvation-induced tau hyperphosphorylation in terms of tau kinases and Ser/Thr protein phosphatases (PP), and the results were compared with those reported in AD brain. During starvation, tau hyperphosphorylation at specific epitopes was accompanied by decreases in tau protein kinase I/glycogen synthase kinase 3 beta (TPKI/GSK3 beta), cyclin-dependent kinase 5 (cdk5), and PP2A activities toward tau. These results demonstrate that the activation of TPKI/GSK3 beta and cdk5 is not necessary to obtain hyperphosphorylated tau in vivo, and indicate that inhibition of PP2A is likely the dominant factor in inducing tau hyperphosphorylation in the starved mouse, overriding the inhibition of key tau kinases such as TPKI/GSK3 beta and cdk5. Furthermore, these data give strong support to the hypothesis that PP2A is important for the regulation of tau phosphorylation in the adult brain, and provide in vivo evidence in support of a central role of PP2A in tau hyperphosphorylation in AD.	Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan		Fujita, SC (corresponding author), Mitsubishi Kasei Inst Life Sci, 11 Minamiooya, Machida, Tokyo 1948511, Japan.	fujitac@ls.m-kagaku.co.jp		Planel, Emmanuel/0000-0001-5128-0565				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; CHENG B, 1992, EXP NEUROL, V117, P114, DOI 10.1016/0014-4886(92)90120-F; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1991, METHOD ENZYMOL, V201, P389; FUJITA SC, 1995, NEUROCHEM RES, V20, P327; GARRIGA J, 1992, BRAIN RES, V591, P277, DOI 10.1016/0006-8993(92)91708-M; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; Goedert M, 1996, ANN NY ACAD SCI, V777, P121, DOI 10.1111/j.1749-6632.1996.tb34410.x; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1994, NEUROSCIENCE, V61, P765, DOI 10.1016/0306-4522(94)90400-6; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1994, FEBS LETT, V341, P94, DOI 10.1016/0014-5793(94)80247-5; GONG CX, 1994, J NEUROCHEM, V62, P803; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; HOYER S, 1988, J NEUROL, V235, P143, DOI 10.1007/BF00314304; Hoyer S, 1994, J Neural Transm Suppl, V44, P259; Imahori K, 1997, J BIOCHEM, V121, P179; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; Ishiguro K, 1995, NEUROSCI LETT, V202, P81, DOI 10.1016/0304-3940(95)12206-0; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KORNEYEV A, 1995, NEUROSCI LETT, V191, P19, DOI 10.1016/0304-3940(95)11546-3; Lee KY, 1999, NEUROSCI RES, V34, P21, DOI 10.1016/S0168-0102(99)00026-7; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lovestone S, 1997, NEUROSCIENCE, V78, P309; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MCKINTOSH C, 1993, PROTEIN PHOSPHORYLAT, P197; MERLEVEDE W, 1984, CURR TOP CELL REGUL, V23, P177; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Papasozomenos SC, 1996, J NEUROCHEM, V66, P1140; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Pei JJ, 1997, J NEUROPATH EXP NEUR, V56, P70, DOI 10.1097/00005072-199701000-00007; Pei JJ, 1998, BRAIN RES, V797, P267, DOI 10.1016/S0006-8993(98)00296-0; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; Saito T, 1998, BIOCHEM BIOPH RES CO, V252, P775, DOI 10.1006/bbrc.1998.9739; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Taniguchi S, 2001, FEBS LETT, V489, P46, DOI 10.1016/S0014-5793(00)02431-5; Tomidokoro Y, 2001, NEUROSCI LETT, V299, P169, DOI 10.1016/S0304-3940(00)01767-5; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UCHIDA T, 1994, FEBS LETT, V355, P35, DOI 10.1016/0014-5793(94)01163-X; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; Wang JZ, 1996, MOL BRAIN RES, V38, P200, DOI 10.1016/0169-328X(95)00316-K; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yamaguchi H, 1996, ACTA NEUROPATHOL, V92, P232, DOI 10.1007/s004010050513; Yanagisawa M, 1999, FEBS LETT, V461, P329, DOI 10.1016/S0014-5793(99)01480-5	72	175	187	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34298	34306		10.1074/jbc.M102780200	http://dx.doi.org/10.1074/jbc.M102780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11441005	hybrid			2022-12-25	WOS:000170910200133
J	Rao, RV; Hermel, E; Castro-Obregon, S; del Rio, G; Ellerby, LM; Ellerby, HM; Bredesen, DE				Rao, RV; Hermel, E; Castro-Obregon, S; del Rio, G; Ellerby, LM; Ellerby, HM; Bredesen, DE			Coupling endoplasmic reticulum stress to the cell death program - Mechanism of caspase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; INDUCED APOPTOSIS; OXIDATIVE STRESS; AMYLOID-BETA; CYTOCHROME-C; BREFELDIN-A; PROTEINS; CALCIUM; INDUCTION; GRP78	The endoplasmic reticulum (ER) is the site of assembly of polypeptide chains destined for secretion or routing into various subcellular compartments. It also regulates cellular responses to stress and intracellular Ca2+ levels. A variety of toxic insults can result in ER stress that ultimately leads to apoptosis. Apoptosis is initiated by the activation of members of the caspase family and serves as a central mechanism in the cell death process. The present study was carried out to determine the role of caspases in triggering ER stress-induced cell death. Treatment of cells with ER stress inducers such as brefeldin-A or thapsigargin induces the expression of caspase-12 protein and also leads to translocation of cytosolic caspase-7 to the ER surface. Caspase-12, like most other members of the caspase family, requires cleavage of the prodomain to activate its proapoptotic form. Caspase-7 associates with caspase-12 and cleaves the prodomain to generate active caspase-12, resulting in increased cell death. We propose that any cellular insult that causes prolonged ER stress may induce apoptosis through caspase-7-mediated caspase-12 activation. The data underscore the involvement of ER and caspases associated with it in the ER stress-induced apoptotic process.	Buck Inst Age Res, Novato, CA 94945 USA; Touro Univ, Coll Osteopath Med, Vallejo, CA USA	Buck Institute for Research on Aging; Touro University California	Bredesen, DE (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.		Castro-Obregon, Susana/AAE-5105-2020	Castro-Obregon, Susana/0000-0003-0549-5690	NCI NIH HHS [R01 CA84262] Funding Source: Medline; NIA NIH HHS [T32AG00252, AG12282] Funding Source: Medline; NINDS NIH HHS [NS33376, NS35155] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035155, R01NS033376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282, T32AG000252] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; CHATTERJEE S, 1994, CANCER RES, V54, P4405; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Guo H, 1998, EXP CELL RES, V245, P57, DOI 10.1006/excr.1998.4235; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee J, 1999, J NEUROSCI RES, V57, P48, DOI 10.1002/(SICI)1097-4547(19990701)57:1<48::AID-JNR6>3.0.CO;2-L; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	38	510	563	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33869	33874		10.1074/jbc.M102225200	http://dx.doi.org/10.1074/jbc.M102225200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448953	hybrid			2022-12-25	WOS:000170910200079
J	Soukas, A; Socci, ND; Saatkamp, BD; Novelli, S; Friedman, JM				Soukas, A; Socci, ND; Saatkamp, BD; Novelli, S; Friedman, JM			Distinct transcriptional profiles of adipogenesis in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE GENE-EXPRESSION; PPAR-GAMMA; ADIPOSE-TISSUE; IN-VIVO; DIFFERENTIATION; ENHANCER; PREADIPOCYTES; REGULATOR; MICE	Obesity, defined as an increase in adipose tissue mass, is the most prevalent nutritional disorder in industrialized countries and is a growing problem in developing countries. An increase in adipose tissue mass can be the result of the production of new fat cells through the process of adipogenesis and/or the deposition of increased amounts of cytoplasmic triglyceride per cell. Although much has been learned about the differentiation of adipocytes in vitro, less is known about the molecular basis for the mechanisms regulating adipogenesis in vivo. Here oligonucleotide microarrays have been used to compare the patterns of gene expression in preadipocytes and adipocytes in vitro and in vivo. These data indicate that the cellular programs associated with adipocyte differentiation are considerably more complex than previously appreciated and that a greater number of heretofore uncharacterized gene regulatory events are activated during this process in vitro. In addition, the gene expression changes associated with adipocyte development in vivo and in vitro, while overlapping, are in some respects quite different. These data further suggest that one or more transcriptional programs are activated exclusively in vivo to generate the fall adipocyte phenotype. This gene expression survey now sets the stage for further studies to dissect the molecular differences between in vivo and in vitro adipocytes.	Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Univ Calif Santa Barbara, Inst Theoret Phys, Santa Barbara, CA 93106 USA	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; University of California System; University of California Santa Barbara	Friedman, JM (corresponding author), Rockefeller Univ, Mol Genet Lab, 1230 York Ave,Box 305, New York, NY 10021 USA.				NIGMS NIH HHS [GM07739] Funding Source: Medline; NINDS NIH HHS [NS39662] Funding Source: Medline; PHPPO CDC HHS [PHY99-07949] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039662] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHPPO CDC HHS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Brun RP, 1997, J ENDOCRINOL, V155, P217, DOI 10.1677/joe.0.1550217; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Guo XM, 2000, GENE, V251, P45, DOI 10.1016/S0378-1119(00)00192-X; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Mandrup S, 1997, P NATL ACAD SCI USA, V94, P4300, DOI 10.1073/pnas.94.9.4300; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Rentsch J, 1996, FEBS LETT, V379, P55, DOI 10.1016/0014-5793(95)01485-3; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Soukas A, 2000, GENE DEV, V14, P963; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557	28	321	328	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34167	34174		10.1074/jbc.M104421200	http://dx.doi.org/10.1074/jbc.M104421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445576	hybrid			2022-12-25	WOS:000170910200117
J	Forrest, A; Gabrielli, B				Forrest, A; Gabrielli, B			Cdc25B activity is regulated by 14-3-3	ONCOGENE			English	Article						cdc25; 14-3-3; G2 checkpoint	DNA-DAMAGE CHECKPOINT; MULTIPLE SIGNALING PATHWAYS; HUMAN-CELLS; G2/M PROGRESSION; PHASE-TRANSITION; PROTEIN-KINASE; GROWTH-CONTROL; FISSION YEAST; HELA-CELLS; PHOSPHATASE	In the G2 phase cell cycle checkpoint arrest, the cdc25-dependent activation of cyclin B/cdc2, a critical step in regulating entry into mitosis, is blocked. Studies in yeast have demonstrated that the inhibition of cdc25 function involves 14-3-3 binding to cdc25, In humans, two cdc25 isoforms have roles in G2/M progression, cdc25B and cdc25C, both bind 14-3-3, Abrogating 14-3-3 binding to cdc25C attenuates the G2 checkpoint arrest, but the contribution of 14-3-3 binding to the regulation of cdc25B function is unknown. Here we demonstrate that high level over-expression of cdc25B in G2 checkpoint arrested cells can activate cyclin B/cdc2 and overcome the checkpoint arrest. Mutation of the major 14-3-3 binding site, S323, or removal of the N-terminal regulatory domain are strong activating mutations, increasing the efficiency with which the mutant forms of cdc25B not only overcome the arrest, but also initiate aberrant mitosis, We also demonstrate that 14-3-3 binding to the S323 site on cdc25B blocks access of the substrate cyclin/cdks to the catalytic site of the enzyme, thereby directly inhibiting the activity of cdc25B, This provides direct mechanistic evidence that 14-3-3 binding to cdc25B can regulate its activity, thereby controlling progression into mitosis.	Univ Queensland, Sch Med, Dept Pathol, Joint Oncol Program, Brisbane, Qld 4006, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Joint Oncol Program, Herston Rd, Brisbane, Qld 4006, Australia.		Gabrielli, Brian G/B-3655-2011; Forrest, Alistair/A-6597-2008	Gabrielli, Brian G/0000-0003-3933-1651; Forrest, Alistair/0000-0003-4543-1675				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERZINGER T, 1995, ONCOGENE, V11, P2151; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kovelman R, 1996, MOL CELL BIOL, V16, P86; Lammer C, 1998, J CELL SCI, V111, P2445; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xu X, 1996, J BIOL CHEM, V271, P5118; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	43	88	95	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4393	4401		10.1038/sj.onc.1204574	http://dx.doi.org/10.1038/sj.onc.1204574			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466620				2022-12-25	WOS:000169912600013
J	Keating, KE; Gueven, N; Watters, D; Rodemann, HP; Lavin, MF				Keating, KE; Gueven, N; Watters, D; Rodemann, HP; Lavin, MF			Transcriptional downregulation of ATM by EGF is defective in ataxia-telangiectasia cells expressing mutant protein	ONCOGENE			English	Article						ataxia-telangiectasia ATM; transcriptional downregulation; EGF; Sp1 transcriptional factor	EPIDERMAL GROWTH-FACTOR; DAMAGE-INDUCED PHOSPHORYLATION; CYCLE CHECKPOINT PATHWAY; DOUBLE-STRAND BREAKS; DNA-DAMAGE; GENE-PRODUCT; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; SP1-MEDIATED TRANSCRIPTION; SIGNAL-TRANSDUCTION	There is evidence that ATM plays a wider role in intracellular signalling in addition to DNA damage recognition and cell cycle control, In this report we show that activation of the EGF receptor is defective in ataxia-telangiectasia (A-T) cells and that sustained stimulation of cells with EGF downregulates ATM protein in control cells but not in A-T cells expressing mutant protein, Concomitant with the downregulation of ATM, DNA-binding activity of the transcription factor Spl decreased in controls after EGF treatment but increased from a lower basal level in A-T cells to that in untreated control cells, Mutation in two Spl consensus sequences in the ATM promoter reduced markedly the capacity of the promoter to support luciferase activity in a reporter assay. Overexpression of anti-sense ATM cDNA in control cells decreased the;basal level of Spl, which in turn was increased by subsequent treatment of cells with EGF, similar to that observed in,A-T cells. On the other hand full-length ATM cDNA increased the basal level of Spl binding in A-T cells, and in response to EGF Spl binding decreased, confirming that this is an ATR I-dependent process. Contrary to that observed in control cells there was no radiation-induced change in ATM protein in EGF-treated A-T cells and likewise no alteration in Spl binding activity. The results demonstrate that EGF-induced downregulation of ATM (mutant) protein in A-T cells is defective and this appears to be due to less efficient EGFR activation and abnormal Spl regulation.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Lab, Brisbane, Qld 4029, Australia; Sect Radiobiol & Mol Environm Res, D-72076 Tubingen, Germany; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; University of Queensland	Lavin, MF (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Lab, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Clarke RA, 1998, J CLIN PATHOL-MOL PA, V51, P224, DOI 10.1136/mp.51.4.224; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dittmann KH, 1998, INT J RADIAT BIOL, V74, P225, DOI 10.1080/095530098141609; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELMORE E, 1976, J CELL PHYSIOL, V89, P429, DOI 10.1002/jcp.1040890308; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Fukao T, 1999, BLOOD, V94, P1998; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KHANNA KK, 1997, J BIOL CHEM, V271, P29335; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KONDO N, 1993, SCAND J IMMUNOL, V38, P45, DOI 10.1111/j.1365-3083.1993.tb01692.x; KWOK TT, 1992, INT J RADIAT ONCOL, V22, P525, DOI 10.1016/0360-3016(92)90867-H; KWOK TT, 1991, INT J CANCER, V19, P73; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Lynn WS, 1997, NEUROIMMUNOMODULAT, V4, P277, DOI 10.1159/000097348; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NELSON J, 1989, EUR J CANC CLIN ONCO, V12, P1851; OCONNOR RD, 1980, CLIN IMMUNOL IMMUNOP, V15, P66, DOI 10.1016/0090-1229(80)90021-5; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Rhodes N, 1998, GENE DEV, V12, P3686, DOI 10.1101/gad.12.23.3686; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Saito T, 1998, MAMM GENOME, V9, P769, DOI 10.1007/s003359900861; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1982, CARCINOGENESIS, V3, P815, DOI 10.1093/carcin/3.7.815; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WOLTMAN R, 1994, INT J RADIAT ONCOL, V30, P91; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	70	21	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4281	4290		10.1038/sj.onc.1204527	http://dx.doi.org/10.1038/sj.onc.1204527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466608				2022-12-25	WOS:000169912600001
J	Polanowska, J; Fabbrizio, E; Le Cam, L; Trouche, D; Emiliani, S; Herrera, R; Sardet, C				Polanowska, J; Fabbrizio, E; Le Cam, L; Trouche, D; Emiliani, S; Herrera, R; Sardet, C			The periodic down regulation of Cyclin E gene expression from exit of mitosis to end of G(1) is controlled by a deacetylase- and E2F-associated bipartite repressor element	ONCOGENE			English	Article						cyclin E; E2F; promoter; transcriptional repression; cell cycle	PAPILLOMAVIRUS TYPE-16 E7; IN-VIVO STRUCTURE; CELL-CYCLE; HISTONE DEACETYLASE; TRANSCRIPTION FACTOR; S-PHASE; RETINOBLASTOMA PROTEIN; DNA-REPLICATION; E2F BINDING; PROMOTER	The expression of cyclin E and that of a few other bona fide cell cycle regulatory genes periodically oscillates every cycle in proliferating cells. Although numerous experiments have documented the role of E2F sites and E2F activities in the control of these genes as cells exit from Co to move through the initial G(1)/S phase transition, almost nothing is known on the role of E2Fs during the subsequent cell cycles. Here we show that a variant E2F-site that is part of the Cyclin E Repressor Module (CERM) (Le Cam et al,, 1999b) accounts for the periodic down regulation of the cyclin E promoter observed between the exit from mitosis until the mid/late G(1) phase in exponentially cycling cells. This cell cycle-dependent repression correlates with the periodic binding of an atypical G(1)-specific high molecular weight p107-E2F complex (Cyclin E Repressor Complex: CERC2) that differs in both size and DNA binding behaviors from known p107-E2F complexes. Notably, affinity purified CERC2 displays a TSA-sensitive histone deacetylase activity and, consistent with this, derepression of the cyclin E promoter by trichostatin A depends on the GERM element, Altogether, this shows that the cell cycle-dependent control of cyclin E promoter in cycling cells is embroiled in acetylation pathways via the GERM-like E2F element.	CNRS, IFR24, UMR 5535, Inst Genet Mol, F-34293 Montpellier 5, France; CNRS, UPR 1142, Inst Human Genet, F-34396 Montpellier, France; CNRS, IBCG, LBME, F-31062 Toulouse, France; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Baylor College of Medicine	Sardet, C (corresponding author), CNRS, IFR24, UMR 5535, Inst Genet Mol, 1919 Route Mende, F-34293 Montpellier 5, France.		Le Cam, Laurent/O-1408-2016; Polanowska, Jolanta/P-9117-2016; Trouche, Didier/B-2854-2008	Polanowska, Jolanta/0000-0001-7666-7010; LE CAM, Laurent/0000-0003-0325-878X; Trouche, Didier/0000-0003-1398-6481				ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Bennett JD, 1996, ONCOGENE, V13, P1073; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fajas L, 2000, FEBS LETT, V471, P29, DOI 10.1016/S0014-5793(00)01363-6; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Geng Y, 1996, ONCOGENE, V12, P1173; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Huet X, 1996, MOL CELL BIOL, V16, P3789; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Krude T, 2000, J BIOL CHEM, V275, P13699, DOI 10.1074/jbc.275.18.13699; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Le Cam L, 1999, BIOTECHNIQUES, V26, P840; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li FZ, 1999, CANCER RES, V59, P3143; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Merrill GF, 1998, METHOD CELL BIOL, V57, P229; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; SARDET C, 1997, PROGR GENE EXPRESSIO, V2, P1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; Stiegler P, 1998, CANCER RES, V58, P5049; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Takahashi Y, 2000, GENE DEV, V14, P804; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vogt B, 1999, J GEN VIROL, V80, P2103, DOI 10.1099/0022-1317-80-8-2103; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 1996, MOL CELL BIOL, V16, P634; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, 1997, TRENDS GENET, V1, P3; ZWICKER J, 1996, SCIENCE, V271, P5255	66	25	25	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4115	4127		10.1038/sj.onc.1204514	http://dx.doi.org/10.1038/sj.onc.1204514			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464278				2022-12-25	WOS:000169857200002
J	Munshi, A; Pappas, G; Honda, T; McDonnell, TJ; Younes, A; Li, Y; Meyn, RE				Munshi, A; Pappas, G; Honda, T; McDonnell, TJ; Younes, A; Li, Y; Meyn, RE			TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2	ONCOGENE			English	Article						apoptosis; TRAIL; bcl-2; cycloheximide; prostate	CYTOTOXIC LIGAND TRAIL; CYTOCHROME-C RELEASE; MEDIATED APOPTOSIS; DEATH DOMAIN; PROTEIN EXPRESSION; MELANOMA-CELLS; MYELOMA CELLS; FAS; RECEPTOR; TNF	To determine if TRAIL-induced apoptosis in human prostate tumor cells was suppressed by bcl-2, we compared the levels of apoptosis induced by recombinant human TRAIL in pairs of isogenic cell lines that do or do not express bcl-2, Three human prostate tumor cell lines (PC3, DU145 and LNCaP) and their bcl-2-expressing counterparts were tested for their susceptibility to TRAIL, Cells were exposed to TRAIL in the presence of cycloheximide which acted as a sensitizer. Apoptosis was induced rapidly in PC3 and DU145 neo-control transfected cells, whereas induction in LNCaP required 24 h, All three cell line variants expressing bcl-2 were resistant to the apoptotic effects of TRAIL. Caspase 3 and 8 activation was also detected in the neo control cells after treatment with TRAIL, demonstrating the rapid activation of the caspase cascade similar to that seen with other death receptors, Bcl-2 overexpression in these cells blocked activation of these caspases, suggesting that bcl-2 expression of human cancer cells may be a critical factor in the therapeutic efficacy of TRAIL.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Leukemia, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 066, Houston, TX 77030 USA.				NCI NIH HHS [P30 CA16672, R01 CA69003, P01 CA06294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA069003, P01CA006294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bonavida B, 1999, INT J ONCOL, V15, P793; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fulda S, 2000, CANCER RES, V60, P3947; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; MARIANI SM, 1997, J CELL BIOL, V37, P211; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MIYASHITA T, 1993, BLOOD, V81, P151; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; TANG C, 1994, LEUKEMIA, V8, P1960; Thomas WD, 1998, J IMMUNOL, V161, P2195; TSUCHIDA H, 1995, J IMMUNOL, V154, P2403; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WALLACH D, 1984, J IMMUNOL, V132, P2464; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yamada K, 1999, DIABETES, V48, P478, DOI 10.2337/diabetes.48.3.478; Yu R, 2000, CANCER RES, V60, P2384; Zhang XD, 1999, CANCER RES, V59, P2747	48	96	99	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3757	3765		10.1038/sj.onc.1204504	http://dx.doi.org/10.1038/sj.onc.1204504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439339				2022-12-25	WOS:000169494700001
J	Galvez, BG; Matias-Roman, S; Albar, JP; Sanchez-Madrid, F; Arroyo, AG				Galvez, BG; Matias-Roman, S; Albar, JP; Sanchez-Madrid, F; Arroyo, AG			Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; INTEGRIN ALPHA-V-BETA-3; ANGIOGENESIS; MT1-MMP; EXPRESSION; COLLAGEN; SURFACE; MECHANISMS; MMP-2; DOMAIN	Matrix metalloproteinases are thought to play an important role in endothelial cell migration and matrix remodeling. We have used an in vitro wound healing migration model and newly generated anti-membrane type 1-matrix metalloproteinase (MT1-MMP) monoclonal antibodies (mAbs) to characterize the role of MT1-MMP during this process. First, the expression and shedding of MT1-MMP are up-regulated upon induction of migration in endothelial cells, as demonstrated by flow cytometry and Western blot analysis. Furthermore, MT1-MMP is concentrated at discrete areas in migrating endothelial cells, in contrast to the diffuse pattern observed in confluent cells. Interestingly, migration of endothelial cells results in the stimulation of MT1-MMP activity, as shown by its ability to process pro-MMP-2 and to degrade fibrinogen assessed by zymography. Moreover, MT1-MMP-mediated gelatin degradation is enriched at migration sites. mAbs generated against the MT1-MMP catalytic domain are shown to inhibit MT1-MMP enzymatic activity and to impair both phorbol 12-myristate 13-acetate-induced endothelial migration and invasion of collagen and fibrin gels. Furthermore, a reduction in the formation of capillary tubes in Matrigel is also observed when endothelial cells are pretreated with the blocking anti-MT1-MMP mAbs. Altogether, these data demonstrate that MT1-MMP plays an important role during endothelial cell migration, and its activity can modulate endothelial migration, invasion, and formation of capillary tubes during the angiogenic response.	Hosp Princesa, Dept Inmunol, Madrid 28006, Spain; Ctr Nacl Biotecnol, Pharm Consejo Super Invest Cient, Immunol & Oncol Dept, Madrid 28049, Spain	Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Arroyo, AG (corresponding author), Hosp Princesa, Dept Inmunol, C Diego de Leon 62, Madrid 28006, Spain.	agarciaa@hlpr.insalud.es	Gálvez, Beatriz G./H-1644-2015; Arroyo, Alicia G/M-2507-2018; Arroyo, Alicia G./L-2796-2014; Sanchez-Madrid, Francisco/M-7889-2016	Gálvez, Beatriz G./0000-0002-8082-9323; Arroyo, Alicia G/0000-0002-1536-3846; Arroyo, Alicia G./0000-0002-1536-3846; Sanchez-Madrid, Francisco/0000-0001-5303-0762				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Atkinson SJ, 2001, FEBS LETT, V491, P222, DOI 10.1016/S0014-5793(01)02204-9; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; CROTHWER M, 2000, BRIT J SURG, V87, P1391; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; DOMINGUEZJIMENE.C, 2001, FASEB J         0418; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GARCIAMONZON C, 1995, GASTROENTEROLOGY, V108, P231, DOI 10.1016/0016-5085(95)90029-2; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; KALEBIC T, 1983, SCIENCE, V221, P281, DOI 10.1126/science.6190230; Kazes I, 2000, BLOOD, V96, P3064, DOI 10.1182/blood.V96.9.3064.h8003064_3064_3069; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; LEACH L, 1993, J CELL SCI, V104, P1073; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Preaux AM, 1999, HEPATOLOGY, V30, P944, DOI 10.1002/hep.510300432; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Rajavashisth TB, 1999, CIRCULATION, V99, P3103, DOI 10.1161/01.CIR.99.24.3103; Rajavashisth TB, 1999, J BIOL CHEM, V274, P11924, DOI 10.1074/jbc.274.17.11924; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1997, J CELL SCI, V110, P589; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	55	196	214	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37491	37500		10.1074/jbc.M104094200	http://dx.doi.org/10.1074/jbc.M104094200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11448964	hybrid			2022-12-25	WOS:000171375700083
J	Parra, M; Jardi, M; Koziczak, M; Nagamine, Y; Munoz-Canoves, P				Parra, M; Jardi, M; Koziczak, M; Nagamine, Y; Munoz-Canoves, P			p53 phosphorylation at serine 15 is required for transcriptional induction of the plasminogen activator inhibitor-1 (PAI-1) gene by the alkylating agent N-methyl-N '-nitro-N-nitrosoguanidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-6-METHYLGUANINE-DNA METHYLTRANSFERASE MGMT; DAMAGE-INDUCED PHOSPHORYLATION; INDUCED DNA-DAMAGE; P38 KINASE; C-FOS; DIFFERENTIAL REGULATION; UROKINASE RECEPTOR; GENOTOXIC STRESS; CELLS DEFICIENT; MESSENGER-RNA	The alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) is a widely spread environmental carcinogen that causes DNA lesions leading to cell killing. MNNG can also induce a cell-protective response by inducing the expression of DNA repair/transcription-related genes. We recently demonstrated that urokinase-type plasminogen activator, an extracellular protease to which no DNA repair functions have been assigned, was induced by MNNG. Here, we show that the physiological inhibitor of urokinase-type plasminogen activator, PAI-1, is also induced by MNNG in a p53-dependent fashion, because MNNG induced PAI-1 in p53-expressing cells but not in p53-/- cells. MNNG induced p53 phosphorylation at serine 15, resulting in stabilization of the p53 protein, and this phosphorylation event was central for p53-dependent PAI-1 transcription. Finally, we showed that PAI-1 transcriptional induction,by MNNG required a p53-responsive element located at -136 base pairs in the PAI-1 promoter, because specific mutation of this site abrogated the induction. Because PAI-1 is a prognostic factor in many metastatic cancers, being involved in the control of tumor invasiveness, our finding that a genotoxic agent induces the PAI-1 gene via p53 adds a new feature to the role of the tumor-suppressor p53 protein. Our results also suggest the possibility that genotoxic agents contribute to tumor metastasis by inducing PAI-1 without involving genetic modification.	Ctr Mol Oncol, Inst Rec Oncol, E-08907 Barcelona, Spain; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Munoz-Canoves, P (corresponding author), Ctr Mol Oncol, Inst Rec Oncol, Aut Castelldefels,Km 2-7, E-08907 Barcelona, Spain.	pmunoz@iro.es	Munoz-Canoves, Pura/B-3889-2015; M, Jardi/I-1201-2015	M, Jardi/0000-0002-2058-6606				ANGEL P, 1995, INDUCIBLE GENE EXPRE, P62; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BRDAR B, 1986, CANCER RES, V46, P2282; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CASSLEN B, 1994, EUR J CANCER, V30A, P1302, DOI 10.1016/0959-8049(94)90178-3; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONESE M, 1995, BIOL CHEM H-S, V376, P143; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dosch J, 1996, ONCOGENE, V13, P1927; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Hofmann R, 1996, CANCER, V78, P487; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; JACKMAN J, 1994, CANCER RES, V54, P5656; Kaina B, 1997, CANCER RES, V57, P2721; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KLEIHUES P, 1974, J NATL CANCER I, V53, P1839; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LUETHY JD, 1994, CANCER RES, V54, pS1902; Miralles F, 1998, J BIOL CHEM, V273, P2052, DOI 10.1074/jbc.273.4.2052; Miralles F, 1999, THROMB HAEMOSTASIS, V81, P767, DOI 10.1055/s-0037-1614569; MunozCanoves P, 1997, THROMB HAEMOSTASIS, V77, P526; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; NEKARDA H, 1994, LANCET, V343, P117, DOI 10.1016/S0140-6736(94)90845-1; Ochs K, 1999, CANCER RES, V59, P1544; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Parra M, 2000, BLOOD, V96, P1415, DOI 10.1182/blood.V96.4.1415.h8001415_1415_1424; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; PETO R, 1985, IARC SCI PUBL, V57, P623; Prives C, 1999, J PATHOL, V187, P112; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SIER CFM, 1994, GASTROENTEROLOGY, V107, P1449, DOI 10.1016/0016-5085(94)90549-5; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Singer B, 1975, Prog Nucleic Acid Res Mol Biol, V15, P219, DOI 10.1016/S0079-6603(08)60121-X; Singer B., 1983, MOL BIOL MUTAGENS CA; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; THOMALE J, 1990, P NATL ACAD SCI USA, V87, P9883, DOI 10.1073/pnas.87.24.9883; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TSUJII M, 1995, CARCINOGENESIS, V16, P563, DOI 10.1093/carcin/16.3.563; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yih LH, 2000, CANCER RES, V60, P6346	80	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36303	36310		10.1074/jbc.M103735200	http://dx.doi.org/10.1074/jbc.M103735200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470783	hybrid			2022-12-25	WOS:000171194500035
J	Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, ML; Quon, MJ; Reed, BC; Dikic, I; Farese, RV				Bandyopadhyay, G; Sajan, MP; Kanoh, Y; Standaert, ML; Quon, MJ; Reed, BC; Dikic, I; Farese, RV			Glucose activates protein kinase C-zeta/lambda through proline-rich tyrosine kinase-2, extracellular signal-regulated kinase, and phospholipase D - A novel mechanism for activating glucose transporter translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; INSULIN-INDUCED ACTIVATION; MEMBRANE GLUT4 CONTENT; PHOSPHATIDYLINOSITOL 3-KINASE; ACUTE HYPERGLYCEMIA; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; POTENTIAL ROLE; ADIPOCYTES; ZETA; LAMBDA	Insulin controls glucose uptake by translocating GLUT4 and other glucose transporters to the plasma membrane in muscle and adipose tissues by a mechanism that appears to require protein kinase C (PKC)-zeta/lambda operating downstream of phosphatidylinositol 3-kinase. In diabetes mellitus, insulin-stimulated glucose uptake is diminished, but with hyperglycemia, uptake is maintained but by uncertain mechanisms. Presently, we found that glucose acutely activated PKC-zeta/lambda in rat adipocytes and rat skeletal muscle preparations by a mechanism that was independent of phosphatidylinositol 3-kinase but, interestingly, dependent on the apparently sequential activation of the dantrolene-sensitive, nonreceptor proline-rich tyrosine kinase-2; components of the extracellular signal-regulated kinase (ERK) pathway, including, GRB2, SOS, RAS, RAN, MEK1 and ERK1/2; and, most interestingly, phospholipase D, thus yielding increases in phosphatidic acid, a known activator of PKC-zeta/lambda. This activation of PKC-zeta/lambda, moreover, appeared to be required for glucose-induced increases in GLUT4 translocation and glucose transport in adipocytes and muscle cells. Our findings suggest the operation of a novel pathway for activating PKC-zeta/lambda and glucose transport.	Univ S Florida, Coll Med, James A Haley Vet Hosp, Res Serv, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Ludwig Institute for Cancer Research	Farese, RV (corresponding author), Univ S Florida, Coll Med, James A Haley Vet Hosp, Res Serv, VAR 151,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Dikic, Ivan/O-4650-2015; Farese, Robert/B-3605-2015; Quon, Michael/B-1970-2008	Dikic, Ivan/0000-0001-8156-9511; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NIDDK NIH HHS [R01 DK065969] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000002, Z01AT000002] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065969] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bandyopadhyay G, 2000, J BIOL CHEM, V275, P40817, DOI 10.1074/jbc.M007920200; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Djerdjouri B, 1999, BIOCHEM BIOPH RES CO, V264, P371, DOI 10.1006/bbrc.1999.1533; FARESE RV, 1994, J CLIN INVEST, V93, P1894, DOI 10.1172/JCI117180; GALANTE P, 1995, DIABETES, V44, P646, DOI 10.2337/diabetes.44.6.646; Goodyear LJ, 1996, DIABETES, V45, P1051, DOI 10.2337/diabetes.45.8.1051; Hill MM, 1999, MOL CELL BIOL, V19, P7771; ISHIZUKA T, 1989, FEBS LETT, V249, P234, DOI 10.1016/0014-5793(89)80630-1; Kanoh Y, 2001, ENDOCRINOLOGY, V142, P1595, DOI 10.1210/en.142.4.1595; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Marette A, 1999, ENDOCRINE, V10, P13, DOI 10.1385/ENDO:10:1:13; Mathoo JMR, 1999, DIABETES, V48, P1281, DOI 10.2337/diabetes.48.6.1281; NOLTE LA, 1995, DIABETES, V44, P1345, DOI 10.2337/diabetes.44.11.1345; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Standaert ML, 2001, BIOCHEMISTRY-US, V40, P249, DOI 10.1021/bi0018234; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; VAAG A, 1992, DIABETES, V41, P174, DOI 10.2337/diabetes.41.2.174; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WEBER TM, 1988, RECEPTOR BIOCH MET B, V12, P171; YU BZ, 1992, ENDOCRINOLOGY, V130, P3345, DOI 10.1210/en.130.6.3345; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	36	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35537	35545		10.1074/jbc.M106042200	http://dx.doi.org/10.1074/jbc.M106042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11463795	hybrid			2022-12-25	WOS:000171109300045
J	Dale, LB; Babwah, AV; Bhattacharya, M; Kelvin, DJ; Ferguson, SSG				Dale, LB; Babwah, AV; Bhattacharya, M; Kelvin, DJ; Ferguson, SSG			Spatial-temporal patterning of metabotropic glutamate receptor-mediated inositol 1,4,5-triphosphate, calcium, and protein kinase C oscillations - Protein kinase C-dependent receptor phosphorylation is not required	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; GREEN FLUORESCENT PROTEIN; CA2+ OSCILLATIONS; CULTURED ASTROCYTES; PLASMA-MEMBRANE; LIVING CELLS; MUTANT MICE; IN-VIVO; ACTIVATION; TRANSIENTS	The metabotropic glutamate receptors (mGluR), mGluR1a and mGluR5a, are G protein-coupled receptors that couple via G to the hydrolysis of phosphoinositides, the release of Ca2+ from intracellular stores, and the activation of protein kinase C (PKC). We show here that mGluR1/5 activation results in oscillatory G protein coupling to phospholipase C thereby stimulating oscillations in both inositol 1,4,5-triphosphate formation and intracellular Ca2+ concentrations. The mGluR1/5-stimulated Ca2+ oscillations are translated into the synchronized repetitive redistribution of PKC beta II between the cytosol and plasma membrane. The frequency at which mGluR1a and mGluR5a subtypes stimulate inositol 1,4,5-triphosphate, Ca2+, and PKC beta II oscillations is regulated by the charge of a single amino acid residue localized within their G protein-coupling domains. However, oscillatory mGluR signaling does not involve the repetitive feedback phosphorylation and desensitization of mGluR activity, since mutation of the putative PKC consensus sites within the first and second intracellular loops as well as the carboxyl-terminal tail does not prevent mGluR1a-stimulated PKC beta II oscillations. Furthermore, oscillations in Ca2+ continued in the presence of PKC inhibitors, which blocked PKC beta II redistribution from the plasma membrane back into the cytosol. We conclude that oscillatory mGluR signaling represents an intrinsic receptor/G protein coupling property that does not involve PKC feedback phosphorylation.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON, Canada; Univ Western Ontario, Dept Physiol, London, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), John P Robarts Res Inst, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.							ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; Angenstein F, 1999, NEUROSCIENCE, V93, P1289, DOI 10.1016/S0306-4522(99)00315-2; Carey MB, 1999, DEV BIOL, V215, P298, DOI 10.1006/dbio.1999.9433; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DUPONT G, 1993, CELL CALCIUM, V14, P311, DOI 10.1016/0143-4160(93)90052-8; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Flint AC, 1999, P NATL ACAD SCI USA, V96, P12144, DOI 10.1073/pnas.96.21.12144; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hansel C, 2000, NEURON, V26, P473, DOI 10.1016/S0896-6273(00)81179-4; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Ichise T, 2000, SCIENCE, V288, P1832, DOI 10.1126/science.288.5472.1832; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Nakahara K, 1997, J NEUROCHEM, V69, P1467; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SPITZER NC, 1995, J NEUROBIOL, V26, P316, DOI 10.1002/neu.480260304; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	37	65	81	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35900	35908		10.1074/jbc.M103847200	http://dx.doi.org/10.1074/jbc.M103847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461909	hybrid			2022-12-25	WOS:000171109300090
J	Kaminker, PG; Kim, SH; Taylor, RD; Zebarjadian, Y; Funk, WD; Morin, GB; Yaswen, P; Campisi, J				Kaminker, PG; Kim, SH; Taylor, RD; Zebarjadian, Y; Funk, WD; Morin, GB; Yaswen, P; Campisi, J			TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MATRIX; REPLICATIVE SENESCENCE; TELOMERE LENGTH; HUMAN FIBROBLASTS; TANKYRASE; PROTEIN; INHIBITION; MOUSE; DNA; CENTROSOMES	Tankyrase (TANK1) is a human telomere-associated poly(ADP-ribose) polymerase (PARP) that binds the telomere-binding protein TRF1 and increases telomere length when overexpressed. Here we report characterization of a second human tankyrase, tankyrase 2 (TANK2), which can also interact with TRF1 but has properties distinct from those of TANK1. TANK2 is encoded by a 66-kilobase pair gene (TNKS2) containing 28 exons, which express a 6.7-kilobase pair mRNA and a 1166-amino acid protein. The protein shares 85% amino acid identity with TANK1 in the ankyrin repeat, sterile a-motif, and PARP catalytic domains but has a unique N-terminal domain, which is conserved in the murine TNKS2 gene. TANK2 interacted with TRF1 in yeast and in vitro and localized predominantly to a perinuclear region, similar to the properties of TANK1. In contrast to TANK1, however, TANK2 caused rapid cell death when highly overexpressed. TANK2-induced death featured loss of mitochondrial membrane potential, but not PARP1 cleavage, suggesting that TANK2 kills cells by necrosis. The cell death was prevented by the PARP inhibitor 3-aminobenzamide. lit vivo, TANK2 may differ from TANK1 in its intrinsic or regulated PARP activity or its substrate specificity.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Geron Corp, Menlo Pk, CA 94025 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Geron Corporation	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Mailstop 84-171,1 Cyclotron Rd, Berkeley, CA 94720 USA.		Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374	NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909] Funding Source: NIH RePORTER; NIA NIH HHS [AG09909, AG00266] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi Judith, 1996, P121; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; di Fagagna FD, 1999, NAT GENET, V23, P76; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Kanai M, 2000, BIOCHEM BIOPH RES CO, V278, P385, DOI 10.1006/bbrc.2000.3801; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kuimov AN, 2001, GENES IMMUN, V2, P52, DOI 10.1038/sj.gene.6363722; Lansdorp PM, 2000, MECH AGEING DEV, V118, P23, DOI 10.1016/S0047-6374(00)00151-2; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; MEIER HL, 1998, BIOCH BIOPHY ACTA, V1401, P367; Monz D, 2001, CLIN CANCER RES, V7, P113; Pandita TK, 2000, RADIAT RES, V154, P133; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; Quesada P, 2000, MOL CELL BIOCHEM, V205, P91, DOI 10.1023/A:1007005715848; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Sakkers RJ, 1999, INT J RADIAT BIOL, V75, P875, DOI 10.1080/095530099139935; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 2001, NUCLEIC ACIDS RES, V29, P841, DOI 10.1093/nar/29.3.841; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; YAMANAKA H, 1989, ADV EXP MED BIOL, V253, P259; Zhu LX, 1999, GENOMICS, V57, P320, DOI 10.1006/geno.1999.5771	48	184	198	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35891	35899		10.1074/jbc.M105968200	http://dx.doi.org/10.1074/jbc.M105968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11454873	hybrid			2022-12-25	WOS:000171109300089
J	Nishino, T; Komori, K; Ishino, Y; Morikawa, K				Nishino, T; Komori, K; Ishino, Y; Morikawa, K			Dissection of the regional roles of the archaeal holliday junction resolvase Hjc by structural and mutational analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 ENDONUCLEASE-VII; 4-WAY DNA JUNCTION; ESCHERICHIA-COLI; PYROCOCCUS-FURIOSUS; RUVC RESOLVASE; BRANCHED DNA; ENZYME; RECOGNITION; RECOMBINATION; MANIPULATION	Hjc is an archacal DNA endonuclease, which resolves the Holliday junction in the presence of divalent metals. Combined with mutational analyses, the x-ray structure of the Pyrococcus furiosus Me crystal grown in the presence of ammonium sulfate revealed a positively charged interface, rich in conserved basic residues, and the catalytic center (Nishino, T., Komori, K., Tsuchiya, D., Ishino, Y., and Morikawa, K. (2001) Structure 9,197-204). This structural study also suggested that the N-terminal segment and some loops of Me play crucial roles in the cleavage of DNA. However, a structural view of the interaction between these regions and DNA remains elusive. To clarify the regional roles of Me in the recognition of the Holliday junction, further structural and biochemical analyses were carried out. A new crystal form of Hjc was obtained from a polyethylene glycol solution in the absence of ammonium sulfate, and its structure has been determined at 2.16-Angstrom resolution. A comparison of the two crystal structures has revealed that the N-terminal segment undergoes a serious conformational change. The site-directed mutagenesis of the sulfate-binding site within the segment caused a dramatic decrease in the junction binding, but the mutant was still capable of cleaving DNA with a 20-fold lower efficiency. The kinetic analysis of Hjc-Holliday junction interaction indicated that mutations in the N-terminal segment greatly increased the dissociation rate constants of the Hjc-Holliday junction complex, explaining the decreased stability of the complex. This segment is also responsible for the disruption of base pairs near the junction center, through specific interactions with them. Taken together, these results imply that, in addition to the secondary effects of two basic loops, the flexible N-terminal segment plays predominant roles in the recognition of DNA conformation near the crossover and in correct positioning of the cleavage site to the catalytic center of the Me resolvase.	Biomol Engn Res Ins, Dept Biol Struct, Suita, Osaka 5650874, Japan; Biomol Engn Res Ins, Dept Mol Biol, Suita, Osaka 5650874, Japan		Morikawa, K (corresponding author), Biomol Engn Res Ins, Dept Biol Struct, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.		KOMORI, Kimihiro/M-8870-2014	nishino, tatsuya/0000-0001-8017-8762; Ishino, Yoshizumi/0000-0001-9419-0826				Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; Ariyoshi M, 2000, P NATL ACAD SCI USA, V97, P8257, DOI 10.1073/pnas.140212997; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; Bond CS, 2001, P NATL ACAD SCI USA, V98, P5509, DOI 10.1073/pnas.091613398; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chan SN, 1998, NUCLEIC ACIDS RES, V26, P1560, DOI 10.1093/nar/26.7.1560; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Daiyasu H, 2000, NUCLEIC ACIDS RES, V28, P4540, DOI 10.1093/nar/28.22.4540; Duckett D R, 1993, Eur J Biochem, V211, P285; DUCKETT DR, 1995, J MOL BIOL, V246, P95, DOI 10.1006/jmbi.1994.0069; Giraud-Panis MJE, 1998, J MOL BIOL, V278, P117, DOI 10.1006/jmbi.1998.1681; Hadden JM, 2001, NAT STRUCT BIOL, V8, P62; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HYDE H, 1994, J BIOL CHEM, V269, P5202; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEMPER B, 1997, DNA DAMAGE REPAIR BI, P179; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; Komori K, 2000, NUCLEIC ACIDS RES, V28, P4544, DOI 10.1093/nar/28.22.4544; Komori K, 2000, J BIOL CHEM, V275, P40385, DOI 10.1074/jbc.M006294200; Kvaratskhelia M, 2000, J BIOL CHEM, V275, P25540, DOI 10.1074/jbc.M003420200; Lilley DMJ, 2000, P NATL ACAD SCI USA, V97, P9351, DOI 10.1073/pnas.97.17.9351; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; MORIKAWA K, 1998, NUCL ACID M, V12, P275; Nishino T, 2001, STRUCTURE, V9, P197, DOI 10.1016/S0969-2126(01)00576-7; Pohler JRG, 1996, J MOL BIOL, V260, P678; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Sharples GJ, 2001, MOL MICROBIOL, V39, P823, DOI 10.1046/j.1365-2958.2001.02284.x; White MF, 1997, J MOL BIOL, V269, P647, DOI 10.1006/jmbi.1997.1097; White MF, 1997, J MOL BIOL, V266, P122, DOI 10.1006/jmbi.1996.0795; Yoshikawa M, 2001, J BIOL CHEM, V276, P10432, DOI 10.1074/jbc.M010138200	31	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35735	35740		10.1074/jbc.M104460200	http://dx.doi.org/10.1074/jbc.M104460200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11441015	hybrid			2022-12-25	WOS:000171109300070
J	Partridge, CJ; Beech, DJ; Sivaprasadarao, A				Partridge, CJ; Beech, DJ; Sivaprasadarao, A			Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; PROTEIN TRAFFICKING; INSULIN-SECRETION; CYSTIC-FIBROSIS; XENOPUS OOCYTES; CELL-SURFACE; ATP; HYPOGLYCEMIA; INFANCY; BINDING	Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a genetic disorder characterized by excess secretion of insulin and hypoglycemia. In most patients, the disease is caused by mutations in sulfonylurea receptor-1 (SUR1), which, in association with Kir6.2, constitutes the functional ATP-sensitive potassium (K-ATP) channel of the pancreatic beta -cell. Previous studies reported that coexpression of the PHHI mutant R1394H-SUR1 with Kir6.2 in COS cells produces no functional channels. To investigate if the loss of function could be due to impaired trafficking of mutant channels to the cell membrane, we have cotransfected wild-type and mutant SUR1 subunits with Kir6.2 into HEK293 cells and examined their cellular localization by immunofluorescent staining. Our results show that unlike the wildtype subunits, which showed fluorescence at the cell surface, the mutant subunits displayed fluorescence in punctate structures. Co-immunostaining with antibodies against organelle-specific marker proteins identified these structures as the trans-Golgi network. Limited localization in clathrin-positive, but transferrin receptor-negative vesicles was also observed. The post-endoplasmic reticulum localization suggests that the mutation does not impair the folding and assembly of the channels so as to cause its retention by the endoplasmic reticulum. Diazoxide, a KATP channel opener drug that is used in the treatment of PHHI, restored the surface expression in a manner that could be prevented by the channel blocker glibenclamide. When expressed in Xenopus oocytes, R1394H-SUR1 formed functional channels with Kir6.2, indicating that the primary consequence of the mutation is impairment of trafficking rather than function. Thus, our data uncover a novel mechanism underlying the therapeutic action of diazoxide in the treatment of PHHI, i.e. its ability to recruit channels to the membrane. Furthermore, this is the first report to describe a trafficking disorder effecting retention of mutant proteins in the trans-Golgi network.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Sivaprasadarao, A (corresponding author), Univ Leeds, Sch Biomed Sci, Worsley Bldg, Leeds LS2 9JT, W Yorkshire, England.			Beech, David/0000-0002-7683-9422; Sivaprasadarao, Asipu/0000-0002-6755-3502				Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hough E, 2000, PFLUG ARCH EUR J PHY, V440, P481, DOI 10.1007/s004240000311; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Matsuo M, 2000, J BIOL CHEM, V275, P41184, DOI 10.1074/jbc.M006503200; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Otonkoski T, 1999, DIABETES, V48, P408, DOI 10.2337/diabetes.48.2.408; PERMUTT MA, 1996, DIABETES REV, V4, P347; Sanders CR, 2000, CURR OPIN STRUC BIOL, V10, P438, DOI 10.1016/S0959-440X(00)00112-3; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; SMIT LS, 1995, HUM MOL GENET, V4, P269, DOI 10.1093/hmg/4.2.269; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Towler MC, 2000, EXP CELL RES, V259, P167, DOI 10.1006/excr.2000.4958; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123	40	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35947	35952		10.1074/jbc.M104762200	http://dx.doi.org/10.1074/jbc.M104762200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457841	hybrid			2022-12-25	WOS:000171109300096
J	Tatham, MH; Jaffray, E; Vaughan, OA; Desterro, JMP; Botting, CH; Naismith, JH; Hay, RT				Tatham, MH; Jaffray, E; Vaughan, OA; Desterro, JMP; Botting, CH; Naismith, JH; Hay, RT			Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEINS; NUCLEAR-PORE COMPLEX; KAPPA-B-ALPHA; COVALENT MODIFICATION; SENTRIN FAMILY; PML; ACTIVATION; RANGAP1; P53	Conjugation of the small ubiquitin-like modifier SUMO-1/SMT3C/Sentrin-1 to proteins in vitro is dependent on a heterodimeric El (SAE1/SAE2) and an E2 (Ubc9). Although SUMO-2/SMT3A/Sentrin-3 and SUMO-3/SMT3B/Sentrin-2 share 50% sequence identity with SUMO-1, they are functionally distinct. Inspection of the SUMO-2 and SUMO-3 sequences indicates that they both contain the sequence psi KXE, which represents the consensus SUMO modification site. As a consequence SAE1/SAE2 and Ubc9 catalyze the formation of polymeric chains of SUMO-2 and SUMO-3 on protein substrates in vitro, and SUMO-2 chains are detected in vivo. The ability to form polymeric chains is not shared by SUMO-1 and although all SUMO species use the same conjugation machinery, modification by SUMO-1 and SUMO-2/-3 may have distinct functional consequences.	Univ St Andrews, Inst Biomol Sci, St Andrews KY16 5ST, Fife, Scotland	University of St Andrews	Hay, RT (corresponding author), Univ St Andrews, Inst Biomol Sci, St Andrews KY16 5ST, Fife, Scotland.		Hay, Ronald T/F-9338-2011; Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012; Hay, Ronald/S-3233-2019; Tatham, Michael H/E-9622-2010	Hay, Ronald T/0000-0001-7113-9024; Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Hay, Ronald/0000-0001-7113-9024; Tatham, Michael H/0000-0001-6986-1691; Desterro, Joana/0000-0002-6359-7233				Ahn JH, 2001, J VIROL, V75, P3859, DOI 10.1128/JVI.75.8.3859-3872.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DOUGHERTY WG, 1989, VIROLOGY, V172, P302, DOI 10.1016/0042-6822(89)90132-3; Duprez E, 1999, J CELL SCI, V112, P381; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	34	616	653	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35368	35374		10.1074/jbc.M104214200	http://dx.doi.org/10.1074/jbc.M104214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11451954	hybrid			2022-12-25	WOS:000171109300023
J	Walsh, DE; Greene, CM; Carroll, TP; Taggart, CC; Gallagher, PM; O'Neill, SJ; McElvaney, NG				Walsh, DE; Greene, CM; Carroll, TP; Taggart, CC; Gallagher, PM; O'Neill, SJ; McElvaney, NG			Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYSTIC-FIBROSIS GENE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; IL-8 PRODUCTION; LUNG-DISEASE; RECEPTOR; ACTIVATION; INFLAMMATION; EXPRESSION	Cystic fibrosis is characterized in the lungs by neutrophil-dominated inflammation mediated significantly by neutrophil elastase (NE). Previous work has shown that NE induces interleukin-8 (IL-8) gene expression and protein secretion in bronchial epithelial cells. We sought to determine the intracellular mechanisms by which NE up-regulates IL-8 in bronchial epithelial cells. The data show that stimulation of 16HBE14o(-) cells with NE induced IL-8 protein production and gene expression. Both responses were abrogated by actinomycin D, indicating that regulation is at the transcriptional level. Electrophoretic mobility shift assays demonstrated that nuclear factor kappaB (NF kappaB) was activated in 16HBE14o(-) cells stimulated with NE. Western blot analysis demonstrated that activation of NF kappaB by NE was preceded by phosphorylation and degradation of I kappaB proteins, principally I kappaB beta. In addition, we observed that interleukin-1 receptor-associated kinase (IRAK) was degraded in 16HBE14o(-) cells stimulated with NE. Quantification of IL-8 reporter gene activity by luminometry demonstrated that dominant negative MyD88 (MyD88 Delta) or TRAF-6 (TRAF-6 Delta) inhibited IL-8 reporter gene expression in response to NE. Furthermore, MyD88 Delta inhibited NE-induced IRAK degradation. These results show that NE induces IL-8 gene up-regulation in bronchial epithelial cells through an IRAK signaling pathway involving both MyD88 and TRAF-6, resulting in degradation of I kappaB beta and nuclear translocation of NF kappaB. These findings may have implications for therapeutic treatments in the cystic fibrosis condition.	Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr, Resp Res Div, Dublin 9, Ireland	Royal College of Surgeons - Ireland	McElvaney, NG (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr, Resp Res Div, Dublin 9, Ireland.		Greene, Catherine M/D-3513-2012; Taggart, Clifford C/G-4492-2014; McElvaney, Noel/A-6809-2010	Greene, Catherine M/0000-0003-2549-2569; mcelvaney, Noel/0000-0002-0152-4370; Taggart, Clifford/0000-0002-9930-2978; Carroll, Tomas/0000-0002-0418-1641				BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; BERGER M, 1989, J CLIN INVEST, V84, P1302, DOI 10.1172/JCI114298; Berger SP, 1996, J AM SOC NEPHROL, V7, P694; BIRRER P, 1994, AM J RESP CRIT CARE, V150, P207, DOI 10.1164/ajrccm.150.1.7912987; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUER R, 1989, AM REV RESPIR DIS, V139, P779, DOI 10.1164/ajrccm/139.3.779; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; FICK RB, 1984, J CLIN INVEST, V74, P236, DOI 10.1172/JCI111407; Greene C, 1999, BBA-MOL CELL RES, V1451, P109, DOI 10.1016/S0167-4889(99)00079-8; Griesenbach U, 2000, GENE THER, V7, P306, DOI 10.1038/sj.gt.3301078; Jobin C, 1999, J IMMUNOL, V162, P4447; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P939; Kon Y, 1999, FEMS IMMUNOL MED MIC, V25, P313, DOI 10.1111/j.1574-695X.1999.tb01356.x; KONSTAN MW, 1995, NEW ENGL J MED, V332, P848, DOI 10.1056/NEJM199503303321303; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3; Leavell KJ, 1997, J LEUKOCYTE BIOL, V61, P361, DOI 10.1002/jlb.61.3.361; LeMosy EK, 1999, TRENDS CELL BIOL, V9, P102, DOI 10.1016/S0962-8924(98)01494-9; LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S; McElvaney NG, 1997, LUNG SCI FDN, P2205; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Ralston DR, 1997, J CLIN INVEST, V100, P1416, DOI 10.1172/JCI119662; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Roum JH, 1999, J APPL PHYSIOL, V87, P438, DOI 10.1152/jappl.1999.87.1.438; Scheuren N, 1998, BRIT J PHARMACOL, V123, P645, DOI 10.1038/sj.bjp.0701652; Stuhlmeier KM, 1999, BIOCHEM PHARMACOL, V57, P313, DOI 10.1016/S0006-2952(98)00301-3; Tabary O, 1999, AM J PATHOL, V155, P473, DOI 10.1016/S0002-9440(10)65143-7; Taggart C, 2000, AM J PHYSIOL-LUNG C, V278, pL33, DOI 10.1152/ajplung.2000.278.1.L33; TOSI MF, 1990, J CLIN INVEST, V86, P300, DOI 10.1172/JCI114699; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	52	135	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35494	35499		10.1074/jbc.M103543200	http://dx.doi.org/10.1074/jbc.M103543200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461907	hybrid, Green Published			2022-12-25	WOS:000171109300039
J	Kagawa, W; Kurumizaka, H; Ikawa, S; Yokoyama, S; Shibata, T				Kagawa, W; Kurumizaka, H; Ikawa, S; Yokoyama, S; Shibata, T			Homologous pairing promoted by the human Rad52 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; FORMS RING STRUCTURES; ESCHERICHIA-COLI; RECA-PROTEIN; DNA-REPAIR; GENETIC-RECOMBINATION; MULTIPLE PATHWAYS; SUPERHELICAL DNA; YEAST; EXCHANGE	The Rad52 protein, which is unique to eukaryotes, plays important roles in the Rad51-dependent and the Rad51-independent pathways of DNA recombination. In the present study, we have biochemically characterized the homologous pairing activity of the HsRad52 protein (Homo sapiens Rad52 and found that the presynaptic complex formation with ssDNA is essential in its catalysis of homologous pairing. We have identified an N-terminal fragment (amino acid residues 1-237, HsRad52(1-237)) that is defective in binding to the human Rad51 protein, which catalyzed homologous pairing as efficiently as the wild type HsRad52. Electron microscopic visualization revealed that HsRad52 and HsRad52(1-237) both formed nucleoprotein filaments with single-stranded DNA. These lines of evidence suggest the role of HsRad52 in the homologous pairing step of the Rad51-independent recombination pathway. Our results reveal the striking similarity between HsRad52 and the Escherichia coli RecT protein, which functions in a RecA-independent recombination pathway.	RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN, Harima Inst Spring 8, Cellular Signaling Lab, Sayo, Hyogo 6795143, Japan; RIKEN, Mol & Cellular Biol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; RIKEN; RIKEN; University of Tokyo	Yokoyama, S (corresponding author), RIKEN, Genom Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.		Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kagawa, Wataru/0000-0002-8801-6589; Kurumizaka, Hitoshi/0000-0001-7412-3722				ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; AGUILERA A, 1995, CURR GENET, V27, P298, DOI 10.1007/BF00352096; Asleson EN, 1999, GENETICS, V153, P681; Bartsch S, 2000, MOL CELL BIOL, V20, P1194, DOI 10.1128/MCB.20.4.1194-1205.2000; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BOUNDYMILLS KL, 1993, GENETICS, V133, P39; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; GANESAN AK, 1975, MOL GEN GENET, V141, P189, DOI 10.1007/BF00341799; Gellert M, 1996, GENES CELLS, V1, P269, DOI 10.1046/j.1365-2443.1996.22023.x; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Haber JE, 1998, CURR BIOL, V8, pR832, DOI 10.1016/S0960-9822(07)00524-6; Haber JE, 1999, NATURE, V398, P665, DOI 10.1038/19423; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HOLLOMAN WK, 1975, P NATL ACAD SCI USA, V72, P2394, DOI 10.1073/pnas.72.6.2394; Ivanov EL, 1996, GENETICS, V142, P693; Kang LE, 2000, MOL CELL BIOL, V20, P9162, DOI 10.1128/MCB.20.24.9162-9172.2000; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Lett J T, 1990, Prog Nucleic Acid Res Mol Biol, V39, P305, DOI 10.1016/S0079-6603(08)60630-3; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; MAHAJAN SK, 1988, PATHWAYS HOMOLOGOUS, P87; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; Muyrers JPP, 2000, GENE DEV, V14, P1971; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Parsons CA, 2000, EMBO J, V19, P4175, DOI 10.1093/emboj/19.15.4175; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Ranatunga W, 2001, J BIOL CHEM, V276, P15876, DOI 10.1074/jbc.M011747200; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; ROTHMAN RH, 1975, BASIC LIFE SCI, P283; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P5100, DOI 10.1073/pnas.76.10.5100; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1982, J BIOL CHEM, V257, P370; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; TAKAHASHI NK, 1993, J BACTERIOL, V175, P5176, DOI 10.1128/JB.175.16.5176-5185.1993; THRESHER RJ, 1995, J MOL BIOL, V254, P364, DOI 10.1006/jmbi.1995.0623; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	64	123	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35201	35208		10.1074/jbc.M104938200	http://dx.doi.org/10.1074/jbc.M104938200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454867	hybrid			2022-12-25	WOS:000171024600111
J	Langbein, L; Rogers, MA; Winter, H; Praetzel, S; Schweizer, J				Langbein, L; Rogers, MA; Winter, H; Praetzel, S; Schweizer, J			The catalog of human hair keratins - II. Expression of the six type II members in the hair follicle and the combined catalog of human type I and II keratins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CYTOKERATINS; GENE-EXPRESSION; INTERMEDIATE-FILAMENTS; MAMMALIAN-TISSUES; DIFFERENTIATION; CELLS; SEQUENCE; PATTERNS; TONGUE; SKIN	The human type II hair keratin subfamily consists of six individual members and can be divided into two groups. The group A members hHb1, hHb3, and hHb6 are structurally related, whereas group C members hHb2, hHb4, and hHb5 are rather distinct. Specific antisera against the individual hair keratins were used to establish the two-dimensional catalog of human type II hair keratins. In this catalog, hHb5 showed up as a series of isoelectric variants, well separated from a lower, more acidic, and complex protein streak containing isoelectric variants of hair keratins hHb1, hHb2, hHb3, and hHb6. Both in situ hybridization and immunohistochemistry on anagen hair follicles showed that hHb5 and hHb2 defined early stages of hair differentiation in the matrix (hHb5) and cuticle (hHb5 and hHb2), respectively. Although cuticular differentiation proceeded without the expression of further type II hair keratins, cortex cells simultaneously expressed hHb1, hHb3, and hHb6 at an advanced stage of differentiation. In contrast, hHb4, which is undetectable in hair follicle extracts and sections, could be identified as the largest and most alkaline member of this subfamily in cytoskeletal extracts of dorsal tongue. This hair keratin was localized in the posterior compartment of the tongue filiform papillae. Comparative analysis of type II with the previously published type I hair keratin expression profiles suggested specific, but more likely, random keratin-pairing principles during trichocyte differentiation. Finally, by combining the previously published type I hair keratin catalog with the type II hair keratin catalog and integrating both into the existing catalog of human epithelial keratins, we present a two-dimensional compilation of the presently known human keratins.	German Canc Res Ctr, Div Cell Biol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Tumor Cell Regulat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Langbein, L (corresponding author), German Canc Res Ctr, Div Cell Biol, A0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	Langbein@dkfz.de	Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				Aoki N, 2001, J INVEST DERMATOL, V116, P359, DOI 10.1046/j.1523-1747.2001.01226.x; AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Bawden CS, 2001, J INVEST DERMATOL, V116, P157, DOI 10.1046/j.1523-1747.2001.00215.x; CAMERON IL, 1966, J EXP ZOOL, V163, P271, DOI 10.1002/jez.1401630306; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; COLLIN C, 1992, DIFFERENTIATION, V51, P137, DOI 10.1111/j.1432-0436.1992.tb00690.x; Cribier B, 2001, BRIT J DERMATOL, V144, P977, DOI 10.1046/j.1365-2133.2001.04185.x; DasGupta R, 1999, DEVELOPMENT, V126, P4557; DHOUAILLY D, 1989, EXP CELL RES, V181, P141, DOI 10.1016/0014-4827(89)90189-4; Dunn SM, 1998, J CELL SCI, V111, P3487; FARBMAN AI, 1970, J ANAT, V106, P233; FINK P, 1995, BBA-GENE STRUCT EXPR, V1264, P12, DOI 10.1016/0167-4781(95)00122-W; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HEID HW, 1988, DIFFERENTIATION, V37, P215, DOI 10.1111/j.1432-0436.1988.tb00724.x; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; Hofmann I, 1997, EUR J CELL BIOL, V72, P122; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LANGBEIN L, 1993, DIFFERENTIATION, V55, P57, DOI 10.1111/j.1432-0436.1993.tb00033.x; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Lee D, 1999, DEV BIOL, V208, P362, DOI 10.1006/dbio.1999.9221; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Mercier M, 1998, J INVEST DERMATOL, V111, P169, DOI 10.1046/j.1523-1747.1998.00234.x; Mischke D, 1998, Subcell Biochem, V31, P71; MISCHKE D, 1987, J INVEST DERMATOL, V88, P191, DOI 10.1111/1523-1747.ep12525329; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1998, J BIOL CHEM, V273, P26683, DOI 10.1074/jbc.273.41.26683; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; ROGERS MA, 1995, MOL BIOL REP, V20, P155, DOI 10.1007/BF00990548; Rogers MA, 2000, J INVEST DERMATOL, V114, P464, DOI 10.1046/j.1523-1747.2000.00910.x; Schlake T, 2000, DEV DYNAM, V217, P368, DOI 10.1002/(SICI)1097-0177(200004)217:4<368::AID-DVDY4>3.0.CO;2-Z; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Swensson O, 1998, BRIT J DERMATOL, V139, P767; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; WEISS L, 1977, HISTOLOGY, P647; Winter H, 1998, J INVEST DERMATOL, V111, P955, DOI 10.1046/j.1523-1747.1998.00456.x; Winter H, 1997, J BIOL CHEM, V272, P32345, DOI 10.1074/jbc.272.51.32345; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; Winter H, 2001, HUM GENET, V108, P37, DOI 10.1007/s004390000439; WINTER H, 1994, EXP CELL RES, V212, P190, DOI 10.1006/excr.1994.1134; YOON SJ, 1994, GENOMICS, V24, P502, DOI 10.1006/geno.1994.1659; Zhang JS, 2001, GENE CHROMOSOME CANC, V30, P123, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1070>3.0.CO;2-W; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	45	220	231	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35123	35132		10.1074/jbc.M103305200	http://dx.doi.org/10.1074/jbc.M103305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11445569	hybrid			2022-12-25	WOS:000171024600102
J	Miclet, E; Stoven, V; Michels, PAM; Opperdoes, FR; Lallemand, JY; Duffieux, F				Miclet, E; Stoven, V; Michels, PAM; Opperdoes, FR; Lallemand, JY; Duffieux, F			NMR spectroscopic analysis of the first two steps of the pentose-phosphate pathway elucidates the role of 6-phosphogluconolactonase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PLASMODIUM; PROTEINS	The pentose-phosphate pathway provides reductive power and nucleotide precursors to the cell through oxidative and nonoxidative branches, respectively. 6-Phosphogluconolactonase is the second enzyme of the oxidative branch and catalyzes the hydrolysis of 6-phosphogluconolactones, the products of glucose 6-phosphate oxidation by glucose-6-phosphate dehydrogenase. The role of 6-phosphogluconolactonase was still questionable, because 6-phosphogluconolactones were believed to undergo rapid spontaneous hydrolysis. In this work, nuclear magnetic resonance spectroscopy was used to characterize the chemical scheme and kinetic features of the oxidative branch. We show that 6-phosphogluconolactones have in fact a nonnegligible life. time and are highly electrophilic compounds. The delta form (1-5) of the lactone is the only product of glucose 6-phosphate oxidation. Subsequently, it leads to the gamma form (1-4) by intramolecular rearrangement. However, only the delta form undergoes spontaneous hydrolysis, they form being a "dead end" of this branch. The delta form is the only substrate for 6-phosphogluconolactonase. Therefore, 6-phosphogluconolactonase activity accelerates hydrolysis of the delta form, thus preventing its conversion into the gamma form. Furthermore, 6-phosphogluconolactonase guards against the accumulation of 5-6-phosphogluconolactone, which may be toxic through its reaction with endogenous cellular nucleophiles. Finally, the difference between activity of human, Trypanosoma brucei, and Plasmodium falciparum 6-phosphogluconolactonases is reported and discussed.	Ecole Polytech, Dept Chim, Synth Organ Grp RMN, F-91128 Palaiseau, France; Inst Chim Subst Nat, UMR 2301, F-91198 Gif Sur Yvette, France; Univ Catholique Louvain, Biochem Lab, B-1200 Brussels, Belgium; Univ Catholique Louvain, Christian de Duve Inst Cellular Pathol, Trop Dis Res Unit, B-1200 Brussels, Belgium	Institut Polytechnique de Paris; Universite Catholique Louvain; Universite Catholique Louvain	Duffieux, F (corresponding author), Ecole Polytech, Dept Chim, Synth Organ Grp RMN, F-91128 Palaiseau, France.		Opperdoes, Frederik R/C-8897-2018; Michels, Paul A/A-5637-2009; Opperdoes, Fred/N-9922-2019	Opperdoes, Frederik R/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; Opperdoes, Fred/0000-0003-1984-3764; Miclet, Emeric/0000-0002-6250-1690; Duffieux, Francis/0000-0003-4906-0314				Baca AM, 2000, INT J PARASITOL, V30, P113, DOI 10.1016/S0020-7519(00)00019-9; BARTON P, 1994, J CHEM SOC P1, V2, P2021; BAUER HP, 1983, EUR J BIOCHEM, V133, P163, DOI 10.1111/j.1432-1033.1983.tb07442.x; Beranek M, 2001, MOL CELL BIOCHEM, V218, P35, DOI 10.1023/A:1007280913732; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; Breitmaier E., 1987, CARBON 13 NMR SPECTR; Clarke JL, 2001, EUR J BIOCHEM, V268, P2013, DOI 10.1046/j.1432-1327.2001.02078.x; Collard F, 1999, FEBS LETT, V459, P223, DOI 10.1016/S0014-5793(99)01247-8; Cosgrove MS, 2000, BIOCHEMISTRY-US, V39, P15002, DOI 10.1021/bi0014608; DAVIS BG, 1999, J CHEM SOC PERK T, V1, P3215; Duffieux F, 2000, J BIOL CHEM, V275, P27559; Geoghegan KF, 1999, ANAL BIOCHEM, V267, P169, DOI 10.1006/abio.1998.2990; Hager PW, 2000, J BACTERIOL, V182, P3934, DOI 10.1128/JB.182.14.3934-3941.2000; JARORI GK, 1991, FEBS LETT, V278, P247, DOI 10.1016/0014-5793(91)80127-O; Kim KM, 2001, ACTA CRYSTALLOGR D, V57, P759, DOI 10.1107/S0907444901002918; KUPOR SR, 1972, J BIOL CHEM, V247, P1904; LAURIERE M, 1993, ANAL BIOCHEM, V212, P206, DOI 10.1006/abio.1993.1313; Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224; MEDINAPUERTA MM, 1988, BIOCHEM INT, V16, P571; Mehta A, 2000, BEST PRACT RES CL HA, V13, P21, DOI 10.1053/beha.1999.0055; Murray JD.., 2003, MATH BIOL, DOI DOI 10.1007/B98869; OBRIEN E, 1994, MOL BIOCHEM PARASIT, V64, P313, DOI 10.1016/0166-6851(94)00028-X; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Rakitzis ET, 1998, CHEM-BIOL INTERACT, V113, P205, DOI 10.1016/S0009-2797(98)00026-X; Schmidt TJ, 1997, BIOORGAN MED CHEM, V5, P645, DOI 10.1016/S0968-0896(97)00003-5; SHAHABUDDIN M, 1994, BIOCHIM BIOPHYS ACTA, V219, P191; SNYDER CA, 1986, CANCER LETT, V33, P175, DOI 10.1016/0304-3835(86)90022-4; Swamy-Mruthinti S, 2001, BBA-MOL BASIS DIS, V1536, P64, DOI 10.1016/S0925-4439(01)00031-X; UEBERSCH.KH, 1974, EUR J BIOCHEM, V48, P389, DOI 10.1111/j.1432-1033.1974.tb03780.x; WALSH CT, 1979, ENZYMATIC REACTION M	30	78	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34840	34846		10.1074/jbc.M105174200	http://dx.doi.org/10.1074/jbc.M105174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457850	hybrid			2022-12-25	WOS:000171024600067
J	Waschuk, SA; Elton, EA; Darabie, AA; Fraser, PE; McLaurin, J				Waschuk, SA; Elton, EA; Darabie, AA; Fraser, PE; McLaurin, J			Cellular membrane composition defines A beta-lipid interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; SYNAPTIC PLASMA-MEMBRANES; ALZHEIMERS-DISEASE; AMYLOID PEPTIDES; ULTRASTRUCTURAL EVIDENCE; PHOSPHOLIPID-BILAYERS; ENDOPLASMIC-RETICULUM; LAURDAN FLUORESCENCE; HUMAN BRAIN; DUTCH TYPE	Alzheimer's disease pathology has demonstrated amyloid plaque formation associated with plasma membranes and the presence of intracellular amyloid-beta (A beta) accumulation in specific vesicular compartments. This suggests that lipid composition in different compartments may play a role in A beta aggregation. To test this hypothesis, we have isolated cellular membranes from human brain to evaluate A beta 40/42-lipid interactions. Plasma, endosomal, lysosomal, and Golgi membranes were isolated using sucrose gradients. Electron microscopy demonstrated that A beta fibrillogenesis is accelerated in the presence of plasma and endosomal and lysosomal membranes with plasma membranes inducing an enhanced surface organization. Alternatively, interaction of A beta with Golgi membranes fails to progress to fibril formation, suggesting that A beta -Golgi head group interaction stabilizes A beta. Fluorescence spectroscopy using the environment-sensitive probes 1,6-diphenyl-1,3,5-hexatriene, laurdan, N-epsilon -dansyl-L-lysine, and merocyanine 540 demonstrated variations in the inherent lipid properties at the level of the fatty acyl chains, glycerol backbone, and head groups, respectively. Addition of A beta 40/42 to the plasma and endosomal and lysosomal membranes decreases the fluidity not only of the fatty acyl chains but also the head group space, consistent with AP insertion into the bilayer. In contrast, the Golgi bilayer fluidity is increased by A beta 40/42 binding which appears to result from lipid head group interactions and the production of interfacial packing defects.	Univ Toronto, Dept Med Biophys, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathol, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto	McLaurin, J (corresponding author), Univ Toronto, Dept Med Biophys, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	J.mclaurin@utoronto.ca						Avdulov NA, 1997, J NEUROCHEM, V68, P2086; Bagatolli LA, 1997, BBA-BIOMEMBRANES, V1325, P80, DOI 10.1016/S0005-2736(96)00246-5; Bagatolli LA, 1999, PHOTOCHEM PHOTOBIOL, V70, P557, DOI 10.1562/0031-8655(1999)070<0557:AMFTIO>2.3.CO;2; Bagatolli LA, 1998, BIOPHYS J, V75, P331, DOI 10.1016/S0006-3495(98)77517-4; BARTLETT GR, 1959, BIOCHEMISTRY-US, V342, P466; Bernik DL, 1998, J COLLOID INTERF SCI, V203, P97, DOI 10.1006/jcis.1998.5522; Bernik DL, 1996, CHEM PHYS LIPIDS, V82, P111, DOI 10.1016/0009-3084(96)02568-6; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Ditaranto K, 2001, NEUROBIOL DIS, V8, P19, DOI 10.1006/nbdi.2000.0364; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Eckert GP, 2000, DEMENT GERIATR COGN, V11, P181, DOI 10.1159/000017234; EPAND RM, 1992, BIOCHEMISTRY-US, V31, P1550, DOI 10.1021/bi00120a036; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUMPHRIES GMK, 1984, J MEMBRANE BIOL, V80, P249, DOI 10.1007/BF01868443; HUMPHRIES GMK, 1983, BIOCHEM BIOPH RES CO, V111, P768, DOI 10.1016/0006-291X(83)90370-4; Jao SC, 1997, AMYLOID, V4, P240, DOI 10.3109/13506129709003835; Kremer JJ, 2000, BIOCHEMISTRY-US, V39, P10309, DOI 10.1021/bi0001980; LeBlanc AC, 1999, J NEUROCHEM, V72, P1832, DOI 10.1046/j.1471-4159.1999.0721832.x; Luzardo MD, 1999, ARCH BIOCHEM BIOPHYS, V363, P81; Mason RP, 1999, J BIOL CHEM, V274, P18801, DOI 10.1074/jbc.274.26.18801; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; McLaurin J, 1998, J MOL BIOL, V278, P183, DOI 10.1006/jmbi.1998.1677; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; Natte R, 1999, ACTA NEUROPATHOL, V98, P577, DOI 10.1007/s004010051121; PARASASSI T, 1994, BIOPHYS J, V66, P763, DOI 10.1016/S0006-3495(94)80852-5; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; Roher AE, 1999, AMYLOID, V6, P136, DOI 10.3109/13506129909007315; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Sparks DL, 1996, NEUROBIOL AGING, V17, P291, DOI 10.1016/0197-4580(95)02067-5; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Torp R, 2000, NEUROSCIENCE, V96, P495, DOI 10.1016/S0306-4522(99)00568-0; VANBLITTERSWIJK WJ, 1981, BIOCHIM BIOPHYS ACTA, V644, P323, DOI 10.1016/0005-2736(81)90390-4; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; Yamaguchi H, 2000, J NEUROPATH EXP NEUR, V59, P723, DOI 10.1093/jnen/59.8.723; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yang AJ, 1999, J BIOL CHEM, V274, P20650, DOI 10.1074/jbc.274.29.20650; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7	47	83	86	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33561	33568		10.1074/jbc.M103598200	http://dx.doi.org/10.1074/jbc.M103598200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438533	hybrid			2022-12-25	WOS:000170910200038
J	Gassler, CS; Wiederkehr, T; Brehmer, D; Bukau, B; Mayer, MP				Gassler, CS; Wiederkehr, T; Brehmer, D; Bukau, B; Mayer, MP			Bag-1M accelerates nucleotide release for human Hsc70 and Hsp70 and can act concentration-dependent as positive and negative cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSC70; APOPTOTIC PROTEIN BAG-1; SHOCK COGNATE PROTEIN; DNAK CHAPERONE; INTERDOMAIN COMMUNICATION; PEPTIDE BINDING; ATPASE DOMAIN; GRPE; MECHANISM; KINETICS	The cytosol of mammalian cells contains several Hsp70 chaperones and an arsenal of cochaperones, including the anti-apoptotic Bag-IM protein, which regulate the activities of Hsp70s by controlling their ATPase cycles. To elucidate the regulatory function of Bag-1M, we determined its influence on nucleotide exchange, substrate release, ATPase rate, and chaperone activity of the housekeeping Hsc70 and stress-inducible Hsp70 homologs of humans. Bag-1M and a C-terminal fragment of it are potent nucleotide exchange factors as they stimulated the ADP dissociation rate of Hsc70 and Hsp70 up to 900-fold. The N-terminal domain of Bag-IM decreased the affinity of Bag-IM for Hsc70/Hsp70 by 4-fold, indicating a modulating role of the N terminus in Bag-1M action as nucleotide exchange factor. Bag-1M inhibited Hsc70/Hsp70-dependent refolding of luciferase in the absence of P-i. Surprisingly, under physiological conditions, i.e. low Bag-IM concentrations and presence of P-i, Bag-IM activates the chaperone action of Hsc70/Hsp70 in luciferase refolding. Bag-IM accelerated ATP-triggered substrate release by Hsc70/Hsp70. We propose that Bag-IM acts as substrate discharging factor for Hsc70 and Hsp70.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg	Mayer, MP (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Bukau, Bernd/0000-0003-0521-7199				Barouch W, 1997, BIOCHEMISTRY-US, V36, P4303, DOI 10.1021/bi962727z; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Ha JH, 1997, J BIOL CHEM, V272, P27796, DOI 10.1074/jbc.272.44.27796; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Kanelakis KC, 1999, J BIOL CHEM, V274, P34134, DOI 10.1074/jbc.274.48.34134; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1998, BIOCHEMISTRY-US, V37, P16741, DOI 10.1021/bi981762y; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; THEYSSEN H, 2001, J MOL BIOL, V20, P1033; Thress K, 2001, EMBO J, V20, P1033, DOI 10.1093/emboj/20.5.1033; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	43	129	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32538	32544		10.1074/jbc.M105328200	http://dx.doi.org/10.1074/jbc.M105328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11441021	hybrid			2022-12-25	WOS:000170746000023
J	Quignard, JF; Mironneau, J; Carricaburu, V; Fournier, B; Babich, A; Nurnberg, B; Mironneau, C; Macrez, N				Quignard, JF; Mironneau, J; Carricaburu, V; Fournier, B; Babich, A; Nurnberg, B; Mironneau, C; Macrez, N			Phosphoinositide 3-kinase gamma mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORTAL-VEIN MYOCYTES; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; CA2+ CHANNELS; ACTIVATION; BETA; INSULIN; P85-ALPHA-P110-BETA; TRANSDUCTION	Previous results have shown that in rat portal vein myocytes the beta gamma dimer of the G(13) protein transduces the angiotensin II-induced stimulation of calcium channels and increase in intracellular Ca2+ concentration through activation of phosphoinositide 3-kinase (PI3K). In the present work we determined which class I PI3K isoforms were involved in this regulation. Western blot analysis indicated that rat portal vein myocytes expressed only PI3K alpha and PI3K gamma and no other class I PI3K isoforms. In the intracellular presence of an anti-p110 gamma antibody infused by the patch clamp pipette, both angiotensin II- and G beta gamma -mediated stimulation of Ca2+ channel current were inhibited, whereas intracellular application of an anti-p110 alpha antibody had no effect. The anti-PI3K gamma antibody also inhibited the angiotensin II- and G beta gamma -induced production of phosphatidylinositol 3,4,5-trisphosphate. In Indo-1 loaded cells, the angiotensin II-induced increase in [Ca2+](i) was inhibited by intracellular application of the anti-PI3K gamma antibody, whereas the anti-PI3K alpha antibody had no effect. The specificity of the anti-PI3K gamma antibody used in functional experiments was ascertained by showing that this antibody did not recognize recombinant PI3K alpha in Western blot experiments. Moreover, anti-PI3K gamma antibody inhibited the stimulatory effect of intracellularly infused recombinant PI3K gamma on Ca2+ channel current without altering the effect of recombinant PI3K alpha. Our results show that, although both PI3K gamma and PI3K alpha are expressed in vascular myocytes, the angiotensin II-induced stimulation of vascular L-type calcium channel and increase of [Ca2+](i) involves only the PI3K gamma isoform.	Univ Bordeaux 2, CNRS, UMR 5017, Lab Signalisat & Interact Cellulaires, F-33076 Bordeaux, France; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Ulm, Abt Pharmakol & Toxikol, D-89069 Ulm, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Free University of Berlin; Ulm University	Macrez, N (corresponding author), Univ Bordeaux 2, CNRS, UMR 5017, Lab Signalisat & Interact Cellulaires, 146 Rue Leo Saignat, F-33076 Bordeaux, France.		QUIGNARD, Jean-Francois/M-2837-2014	Nurnberg, Bernd/0000-0002-5995-6555; MACREZ, Nathalie/0000-0002-3844-4403				Bartlett SE, 1999, J NEUROSCI RES, V56, P44, DOI 10.1002/(SICI)1097-4547(19990401)56:1<44::AID-JNR6>3.0.CO;2-6; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Bernstein HG, 1998, CELL MOL BIOL, V44, P973; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARO E, 1993, J NEUROCHEM, V60, P2078, DOI 10.1111/j.1471-4159.1993.tb03492.x; Fujita K, 1996, FEBS LETT, V395, P293, DOI 10.1016/0014-5793(96)01056-3; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Kim S, 2000, PHARMACOL REV, V52, P11; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LEPRETRE N, 1994, J BIOL CHEM, V269, P29546; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MacrezLepretre N, 1996, J PHARMACOL EXP THER, V278, P468; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Morel JL, 1996, BRIT J PHARMACOL, V118, P73, DOI 10.1111/j.1476-5381.1996.tb15368.x; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; Seki T, 1999, PFLUG ARCH EUR J PHY, V437, P317, DOI 10.1007/s004240050785; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; Watts SW, 1998, J PHARMACOL EXP THER, V286, P1431; Xie LH, 1999, J PHYSIOL-LONDON, V514, P655, DOI 10.1111/j.1469-7793.1999.655ad.x	35	87	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32545	32551		10.1074/jbc.M102582200	http://dx.doi.org/10.1074/jbc.M102582200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11443116	hybrid			2022-12-25	WOS:000170746000024
J	Hofmann, JFX; Sykora, M; Redemann, N; Beug, H				Hofmann, JFX; Sykora, M; Redemann, N; Beug, H			G1-Cdk activity is required for both proliferation and viability of cytokine-dependent myeloid and erythroid cells	ONCOGENE			English	Article						apoptosis; caspases; cell cycle; cytokines; hematopoiesis	BCL-X-L; APOPTOSIS; DEATH; SURVIVAL; ERYTHROPOIETIN; DIFFERENTIATION; GROWTH; MICE; RECEPTOR; PHOSPHORYLATION	Hematopoietic cytokines are critically required for survival and cell proliferation of myeloid and erythroid progenitors. It is poorly understood how the apoptotic machinery of progenitor cells senses the absence of specific cytokines, Here we show that G1-Cdk activity is essential for cytokine-mediated viability of myeloid and erythroid progenitors. Cytokine deprivation is associated with rapid downregulation of G1-Cdk activity, cell cycle arrest, and apoptosis, Specific inhibition of G1-Cdk activity results in apoptotic cell death in the presence of saturating cytokine levels. In contrast, specific cell cycle arrest in G2/M does not affect viability. When cell proliferation is arrested by cytokine withdrawal, primary erythroid progenitors expressing v-ErbA maintain G1-Cdk activity and undergo delayed apoptosis, Cdk-inhibitors strongly enhance apoptosis in starved v-ErbA cells, indicating that sustained Cdk activity is required for protection from apoptosis by v-ErbA.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Boehringer Ingelheim GmbH & Co KG, Onkol Forsch A, D-88400 Biberach, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim	Beug, H (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.at						Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; Antoku K, 1998, LEUKEMIA, V12, P682, DOI 10.1038/sj.leu.2400992; Barge RMY, 1997, FEBS LETT, V409, P207, DOI 10.1016/S0014-5793(97)00507-3; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Colussi PA, 1999, IMMUNOL CELL BIOL, V77, P58, DOI 10.1046/j.1440-1711.1999.00788.x; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GANDRILLON O, 1994, ONCOGENE, V9, P749; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KELLEY LL, 1993, BLOOD, V82, P2340; Kieslinger M, 2000, GENE DEV, V14, P232; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Lotem J, 1996, LEUKEMIA, V10, P925; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MARVEL J, 1994, ONCOGENE, V9, P1117; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Vander Heiden MG, 1999, MOL CELL, V3, P159; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VONLINDERN M, 2001, IN PRESS ONCOGENE; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	59	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4198	4208		10.1038/sj.onc.1204550	http://dx.doi.org/10.1038/sj.onc.1204550			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464286				2022-12-25	WOS:000169857200010
J	Gutzke, G; Fischer, B; Mendel, RR; Schwarz, G				Gutzke, G; Fischer, B; Mendel, RR; Schwarz, G			Thiocarboxylation of molybdopterin synthase provides evidence for the mechanism of dithiolene formation in metal-binding pterins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; ESCHERICHIA-COLI; NITRATE REDUCTASE; STRUCTURAL CHARACTERIZATION; THIAMIN BIOSYNTHESIS; CONVERTING FACTOR; SULFITE OXIDASE; EARLY STEPS; PRECURSOR-Z; GENE	Molybdopterin (MPT) is a pyranopterin with a unique dithiolene group coordinating molybdenum (Mo) or tungsten (W) in all Mo- and W-enzymes except nitrogenase. In Escherichia coli, MPT is formed by incorporation of two sulfur atoms into precursor Z, which is catalyzed by MPT synthase. The recently solved crystal structure of MPT synthase (Rudolph, M. J., Wuebbens, M. M., Rajagopalan, K. V., and Schindelin, H. (2000) Nat. Struct. Biol. 8, 42-46) shows the heterotetrameric nature of the enzyme that is composed of two small (MoaD) and two large subunits (MoaE). According to sequence and structural similarities among MoaD, ubiquitin, and ThiS, a thiocarboxylation of the C terminus of MoaD is proposed that would serve as the source of sulfur that is transferred to precursor Z. Here, we describe the in vitro generation of carboxylated and thiocarboxylated MoaD. Both forms of MoaD are monomeric and are able to form a heterotetrameric complex after coincubation in equimolar ratios with MoaE. Only the thiocarboxylated MPT synthase complex was found to be able to convert precursor Z in vitro to MPT. Slight but significant differences between the carboxylated and the thiocarboxylated MPT synthase can be seen using size exclusion chromatography. A two-step reaction of MPT synthesis is proposed where the dithiolene is generated by two thiocarboxylates derived from a single tetrameric MPT synthase.	Tech Univ Braunschweig, Inst Bot, D-38023 Braunschweig, Germany; Ruhr Univ Bochum, Lehtstuhl Analyt Chem, D-44780 Bochum, Germany	Braunschweig University of Technology; Ruhr University Bochum	Mendel, RR (corresponding author), Tech Univ Braunschweig, Inst Bot, D-38023 Braunschweig, Germany.		Schwarz, Guenter/ABE-9643-2021	Schwarz, Guenter/0000-0002-2118-9338; Fischer, Berthold/0000-0003-2840-9812				Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; GLASER JH, 1972, MOL GEN GENET, V116, P1, DOI 10.1007/BF00334254; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOFF T, 1995, J BIOL CHEM, V270, P6100, DOI 10.1074/jbc.270.11.6100; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; Kinsland C, 1998, PROTEIN SCI, V7, P1839, DOI 10.1002/pro.5560070821; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Kletzin A, 1996, FEMS MICROBIOL REV, V18, P5, DOI 10.1016/0168-6445(95)00025-9; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; McMaster J, 1998, CURR OPIN CHEM BIOL, V2, P201, DOI 10.1016/S1367-5931(98)80061-6; Mendel RR, 1999, CRIT REV PLANT SCI, V18, P33, DOI 10.1016/S0735-2689(99)00386-X; Mendel RR, 1997, PLANTA, V203, P399, DOI 10.1007/s004250050206; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; REISS J, 1987, MOL GEN GENET, V206, P352, DOI 10.1007/BF00333594; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; Unkles SE, 1999, J BIOL CHEM, V274, P19286, DOI 10.1074/jbc.274.27.19286; Unkles SE, 1997, J BIOL CHEM, V272, P28381, DOI 10.1074/jbc.272.45.28381; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	35	77	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36268	36274		10.1074/jbc.M105321200	http://dx.doi.org/10.1074/jbc.M105321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11459846	hybrid			2022-12-25	WOS:000171194500030
J	Lawson, VA; Priola, SA; Wehrly, K; Chesebro, B				Lawson, VA; Priola, SA; Wehrly, K; Chesebro, B			N-terminal truncation of prion protein affects both formation and conformation of abnormal protease-resistant prion protein generated in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE NEUROBLASTOMA-CELLS; NEURO-BLASTOMA CELLS; CULTURED-CELLS; BIOCHEMICAL-PROPERTIES; INSERTIONAL MUTATION; SCRAPIE AGENT; PRP 27-30; CONVERSION; SUSCEPTIBILITY; INHIBITION	Transmissible spongiform encephalopathy diseases are characterized by conversion of the normal protease-sensitive host prion protein, PrP-sen, to an abnormal protease-resistant form, PrP-res. In the current study, deletions were introduced into the flexible tail of PrP-sen (23-124) to determine if this region was required for formation of PrP-res in a cell-free assay. PrP-res formation was significantly reduced by deletion of residues 34-94 relative to full-length hamster PrP. Deletion of another nineteen amino acids to residue 113 further reduced the amount of PrP-res formed. Furthermore, the presence of additional proteinase K cleavage sites indicated that deletion to residue 113 generated a protease-resistant product with an altered conformation. Conversion of PrP deletion mutants was also affected by post-translational modifications to PrP-sen. Conversion of unglycosylated PrP-sen appeared to alter both the amount and the conformation of protease-resistant PrP-res produced from N-terminally truncated PrP-sen. The N-terminal region also affected the ability of hamster PrP to block mouse PrP-res formation in scrapie-infected mouse neuroblastoma cells. Thus, regions within the flexible N-terminal tail of PrP influenced interactions required for both generating and disrupting PrP-res formation.	NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chesebro, B (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, 903 S 4th St, Hamilton, MT 59840 USA.		Lawson, Victoria/AAJ-7392-2021	Lawson, Victoria/0000-0002-7362-7176	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000752, Z01AI000074, ZIAAI000752, ZIAAI000074] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; Bossers A, 2000, J VIROL, V74, P1407, DOI 10.1128/JVI.74.3.1407-1414.2000; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; Capellari S, 2000, AM J PATHOL, V157, P613, DOI 10.1016/S0002-9440(10)64572-5; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Chabry J, 1999, J VIROL, V73, P6245, DOI 10.1128/JVI.73.8.6245-6250.1999; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; CHESEBRO B, 1983, VIROLOGY, V127, P134, DOI 10.1016/0042-6822(83)90378-1; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Holscher C, 1998, J VIROL, V72, P1153; HOPE J, 1988, CIBA F SYMP, V135, P146; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1998, P NATL ACAD SCI USA, V95, P8322, DOI 10.1073/pnas.95.14.8322; POCCHIARI M, 1994, MOL ASPECTS MED, V15, P195, DOI 10.1016/0098-2997(94)90042-6; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Priola SA, 2001, J VIROL, V75, P4673, DOI 10.1128/JVI.75.10.4673-4680.2001; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; RACE RE, 1988, J VIROL, V62, P2845, DOI 10.1128/JVI.62.8.2845-2849.1988; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; RACE RE, 1995, NEURON, V15, P1183, DOI 10.1016/0896-6273(95)90105-1; Raymond GJ, 2000, EMBO J, V19, P4425, DOI 10.1093/emboj/19.17.4425; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; ROBERTSON MN, 1992, J VIROL, V66, P3271, DOI 10.1128/JVI.66.6.3271-3277.1992; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zulianello L, 2000, J VIROL, V74, P4351, DOI 10.1128/JVI.74.9.4351-4360.2000	54	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35265	35271		10.1074/jbc.M103799200	http://dx.doi.org/10.1074/jbc.M103799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466311	hybrid			2022-12-25	WOS:000171109300010
J	Xia, B; Etchegaray, JP; Inouye, M				Xia, B; Etchegaray, JP; Inouye, M			Nonsense mutations in cspA cause ribosome trapping leading to complete growth inhibition and cell death at low temperature in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEIN CSPA; MESSENGER-RNA; DOWNSTREAM BOX; TRANSLATION INITIATION; AT-RICH; INDUCTION; GENE; SEQUENCES; PROMOTER; REGION	CspA, the major cold shock protein of Escherichia coli, is dramatically induced immediately after cold shock. CspA production is transient and reduces to a low basal level when cells become adapted. Here we show that expression from multicopy plasmids of mutant cspA mRNAs bearing nonsense mutations in the coding region caused sustained high levels of the mutant mRNAs at low temperature, resulting in complete inhibition of cell growth ultimately leading to cell death. We demonstrate that the observed growth inhibition was caused by largely exclusive occupation of cellular ribosomes by the mutant cspA mRNAs. Such sequestration of ribosomes even occurs without a single peptide bond formation, implying that the robust translatability of the cspA mRNA is determined at the step of initiation. Further analysis demonstrated that the downstream box of the cspA mRNA was dispensable for the effect, whereas the upstream box of the mRNA was essential. Our system may offer a novel means to study sequence or structural elements involved in the translation of the cspA mRNA and may also be utilized to regulate bacterial growth at low temperature.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NIGMS NIH HHS [GM19043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae W, 1997, J BACTERIOL, V179, P7081, DOI 10.1128/jb.179.22.7081-7088.1997; BEA W, 2000, P NATL ACAD SCI USA, V97, P7784; Brandi A, 1999, EMBO J, V18, P1653, DOI 10.1093/emboj/18.6.1653; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Etchegaray JP, 1999, J BACTERIOL, V181, P5852, DOI 10.1128/JB.181.18.5852-5854.1999; Etchegaray JP, 1999, J BIOL CHEM, V274, P10079, DOI 10.1074/jbc.274.15.10079; Etchegaray JP, 1999, MOL MICROBIOL, V33, P438, DOI 10.1046/j.1365-2958.1999.01487.x; Etchegaray JP, 1996, GENES CELLS, V1, P171, DOI 10.1046/j.1365-2443.1996.d01-231.x; Fang L, 1997, MOL MICROBIOL, V23, P355, DOI 10.1046/j.1365-2958.1997.2351592.x; Goldenberg D, 1997, MOL GEN GENET, V256, P282, DOI 10.1007/s004380050571; Goldenberg D, 1996, MOL MICROBIOL, V19, P241, DOI 10.1046/j.1365-2958.1996.363898.x; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HIRASHIMA A, 1973, J MOL BIOL, V79, P373, DOI 10.1016/0022-2836(73)90012-0; Jiang WN, 1996, GENES CELLS, V1, P965, DOI 10.1046/j.1365-2443.1996.d01-219.x; Jiang WN, 1997, J BIOL CHEM, V272, P196; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; La Teana A, 2000, RNA, V6, P1393, DOI 10.1017/S1355838200000595; Mitta M, 1997, MOL MICROBIOL, V26, P321, DOI 10.1046/j.1365-2958.1997.5771943.x; NAKAMURA K, 1979, CELL, V18, P1109, DOI 10.1016/0092-8674(79)90224-1; Nakashima K, 1996, J BACTERIOL, V178, P2994, DOI 10.1128/jb.178.10.2994-2997.1996; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; O'Connor M, 1999, P NATL ACAD SCI USA, V96, P8973, DOI 10.1073/pnas.96.16.8973; Phadtare S, 2000, BACTERIAL STRESS RESPONSES, P33; PLATT T, 1975, P NATL ACAD SCI USA, V72, P2399, DOI 10.1073/pnas.72.6.2399; Resch A, 1996, EMBO J, V15, P4740, DOI 10.1002/j.1460-2075.1996.tb00851.x; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; Sprengart ML, 1996, EMBO J, V15, P665, DOI 10.1002/j.1460-2075.1996.tb00399.x; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; Wang N, 1999, J BACTERIOL, V181, P1603, DOI 10.1128/JB.181.5.1603-1609.1999; Xia B, 2001, MOL MICROBIOL, V40, P179, DOI 10.1046/j.1365-2958.2001.02372.x; Yamanaka K, 1999, J BACTERIOL, V181, P6284, DOI 10.1128/JB.181.20.6284-6291.1999; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x; Yamanaka K, 2001, J BACTERIOL, V183, P2808, DOI 10.1128/JB.183.9.2808-2816.2001; Yamanaka K, 2001, GENES CELLS, V6, P279, DOI 10.1046/j.1365-2443.2001.00424.x; Yamanaka Kunitoshi, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P193; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	24	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35581	35588		10.1074/jbc.M103871200	http://dx.doi.org/10.1074/jbc.M103871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457833	hybrid			2022-12-25	WOS:000171109300051
J	Yates, SP; Merrill, AR				Yates, SP; Merrill, AR			A catalytic loop within Pseudomonas aeruginosa exotoxin A modulates its transferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-III; SECONDARY STRUCTURES; CRYSTAL-STRUCTURE; NICOTINAMIDE; SITE; ACTIVATION; MUTATIONS; TOXIN; ASSAY	Mutagenesis techniques were used to replace two loop regions within the catalytic domain of Pseudomonas aeruginosa exotoxin A (ETA) with functionally silent polyglycine loops. The loop mutant proteins, designated polyglycine Loops N and C, were both less active than the wild-type enzyme. However, the polyglycine Loop C mutant protein, replaced with the Gly(483)-Gly(490) loop, showed a much greater loss of enzymatic activity than the polyglycine Loop N protein. The former mutant enzyme exhibited an 18,000-fold decrease in catalytic turnover number (k(cat)), with only a marginal effect on the K-m value for NAD(+) and the eukaryotic elongation factor-2 binding constant. Furthermore, alanine-scanning mutagenesis of this active-site loop region revealed the specific pattern of a critical region for enzymatic activity. Binding and kinetic data suggest that this loop modulates the transferase activity between ETA and eukaryotic elongation factor-2 and may be responsible for stabilization of the transition state for the reaction. Sequence alignment and molecular modeling also identified a similar loop within diphtheria toxin, a functionally and structurally related class A-B toxin. Based on these results and the similarities between ETA and diphtheria toxin, we propose that this catalytic subregion represents the first report of a diphthamide-specific ribosyltransferase structural motif. We expect these findings to further the development of pharmaceuticals designed to prevent ETA toxicity by disrupting the stabilization of the transition state during the ADP-ribose transfer event.	Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem & Biochem, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry	Merrill, AR (corresponding author), Univ Guelph, Dept Chem & Biochem, Guelph Waterloo Ctr Grad Work Chem & Biochem, Guelph, ON N1G 2W1, Canada.	merrill@chembio.uoguelph.ca	Merrill, Rod/M-8313-2014					ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; Armstrong S, 2001, ANAL BIOCHEM, V292, P26, DOI 10.1006/abio.2001.5052; Armstrong S, 2001, BIOPHYS J, V80, p281A; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Beattie BK, 1999, J BIOL CHEM, V274, P15646, DOI 10.1074/jbc.274.22.15646; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P9042, DOI 10.1021/bi960396k; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P15134, DOI 10.1021/bi961985t; Bell CE, 1997, PROTEIN SCI, V6, P2084; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Donate LE, 1996, PROTEIN SCI, V5, P2600, DOI 10.1002/pro.5560051223; FETROW JS, 1995, FASEB J, V9, P708, DOI 10.1096/fasebj.9.9.7601335; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; KESSLER SP, 1992, J BIOL CHEM, V267, P19107; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LI M, 1995, P NATL ACAD SCI USA, V92, P9308, DOI 10.1073/pnas.92.20.9308; LUKAC M, 1988, BIOCHEMISTRY-US, V27, P7629, DOI 10.1021/bi00420a009; MCGOWAN JL, 1991, J BIOL CHEM, V266, P4911; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Prentice GA, 1999, ANAL BIOCHEM, V272, P216, DOI 10.1006/abio.1999.4188; PRENTICE GA, 2001, PROTEIN SCI, V10, P409; RASPER DM, 1994, BIOCHEMISTRY-US, V33, P12981, DOI 10.1021/bi00248a006; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; STEER BA, 1994, BIOCHEMISTRY-US, V33, P1108, DOI 10.1021/bi00171a009; Van Delden C, 1998, EMERG INFECT DIS, V4, P551, DOI 10.3201/eid0404.980405; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WICK MJ, 1990, MOL MICROBIOL, V4, P527, DOI 10.1111/j.1365-2958.1990.tb00620.x; WICK MJ, 1992, INFECT IMMUN, V60, P1128, DOI 10.1128/IAI.60.3.1128-1139.1992; WOZNIAK DJ, 1988, P NATL ACAD SCI USA, V85, P8880, DOI 10.1073/pnas.85.23.8880	28	22	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35029	35036		10.1074/jbc.M105002200	http://dx.doi.org/10.1074/jbc.M105002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457845	hybrid			2022-12-25	WOS:000171024600091
J	Yin, XY; Gu, SM; Jiang, JX				Yin, XY; Gu, SM; Jiang, JX			The development-associated cleavage of lens connexin 45.6 by caspase-3-like protease is regulated by casein kinase II-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEINS; EMBRYONIC CHICK LENS; PULVERULENT CATARACT; MOLECULAR-CLONING; DIFFERENTIATION; DEGRADATION; EXPRESSION; CELLS; FAMILY; COMMUNICATION	Gap junctions are important in maintaining lens transparency and metabolic homeostasis. In this paper, we report that the gap junction-forming protein, connexin (Cx) 45.6, was specifically truncated during lens development and that the majority of the truncated fragments were located in the differentiated lens fibers. When isolated lens membranes were treated by caspase-3, the truncated fragments of Cx45.6 were reproduced, and this truncation occurred at the COOH terminus of Cx45.6. Moreover, when primary lens cells were treated with apoptosis-inducing reagents, Cx45.6 was cleaved similarly as the in vitro treatment by caspase-3, and this cleavage was blocked by a caspase-3 inhibitor. These results suggest that caspase-3 is responsible for the development-associated cleavage of Cx45.6. The cleavage site of Cx45.6 was identified between amino acid residues Glu(367) and Gly(368). We have shown previously that Ser(368). is an in vivo phosphorylated site by casein kinase II, and this specific phosphorylation leads to a rapid turnover of Cx45.6. Interestingly, we found here that when Ser(363) was phosphorylated by casein kinase II, the cleavage of Cx45.6 catalyzed by caspase-3 was inhibited. This study, for the first time, demonstrates that a connexin can be a direct target of an apoptotic protease and that cleavage by caspase-3-like protease leads to the development-associated truncation of a lens connexin. Finally, caspase-3-mediated cleavage can be regulated by casein kinase II-mediated phosphorylation, suggesting that Cx45.6 turnover and specific cleavage by caspase-3-like protease is alternatively modulated.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu		Jiang, Jean/0000-0002-2185-5716	NATIONAL EYE INSTITUTE [R29EY012085, R01EY012085] Funding Source: NIH RePORTER; NEI NIH HHS [EY-12085] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andersson M, 2000, INVEST OPHTH VIS SCI, V41, P2623; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Berry V, 1999, HUM GENET, V105, P168, DOI 10.1007/s004390051082; Berthoud VM, 1999, EXP EYE RES, V68, P475, DOI 10.1006/exer.1998.0635; Berthoud VM, 2000, METHODS, V20, P180, DOI 10.1006/meth.1999.0935; Cooper K., 1991, BIOPHYSICS GAP JUNCT, P57; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; Gu SM, 1999, MOL BIOL CELL, V10, p405A; Guan XJ, 1996, CARCINOGENESIS, V17, P1791, DOI 10.1093/carcin/17.9.1791; Guan XJ, 1996, MOL CARCINOGEN, V16, P157; He DS, 1999, P NATL ACAD SCI USA, V96, P6495, DOI 10.1073/pnas.96.11.6495; Hertlein B, 1998, J MEMBRANE BIOL, V162, P247, DOI 10.1007/s002329900362; Hossain MZ, 1998, J CELL PHYSIOL, V174, P66; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Jiang J. X., 2000, CONNEXIN METHODS PRO, P159; Jiang JX, 1998, EUR J BIOCHEM, V255, P37, DOI 10.1046/j.1432-1327.1998.2550037.x; Jiang JX, 1998, INVEST OPHTH VIS SCI, V39, P537; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Le ACN, 1998, DEV BIOL, V204, P80, DOI 10.1006/dbio.1998.9030; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; Lin JS, 1997, EUR J CELL BIOL, V73, P141; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Matthews RAJ, 1989, CRYPTOLOGIA, VXIII, P29, DOI [10.1080/0161-118991863745, DOI 10.1080/0161-118991863745]; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; MENKO AS, 1984, DEV BIOL, V103, P129, DOI 10.1016/0012-1606(84)90014-9; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; PIATIGORSKY J, 1973, DEV BIOL, V34, P334, DOI 10.1016/0012-1606(73)90362-X; RAFFERTY NS, 1974, J ULTRA MOL STRUCT R, V46, P239, DOI 10.1016/S0022-5320(74)80059-6; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Shiels A, 1998, AM J HUM GENET, V62, P526, DOI 10.1086/301762; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; White TW, 1998, J CELL BIOL, V143, P815, DOI 10.1083/jcb.143.3.815; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; Yin XY, 2000, J BIOL CHEM, V275, P6850, DOI 10.1074/jbc.275.10.6850	49	53	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34567	34572		10.1074/jbc.M106073200	http://dx.doi.org/10.1074/jbc.M106073200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11448971	hybrid			2022-12-25	WOS:000171024600031
J	Daher, A; Longuet, M; Dorin, D; Bois, F; Segeral, E; Bannwarth, S; Battisti, PL; Purcell, DF; Benarous, R; Vaquero, C; Meurs, EF; Gatignol, A				Daher, A; Longuet, M; Dorin, D; Bois, F; Segeral, E; Bannwarth, S; Battisti, PL; Purcell, DF; Benarous, R; Vaquero, C; Meurs, EF; Gatignol, A			Two dimerization domains in the trans-activation response RNA-binding protein (TRBP) individually reverse the protein kinase R inhibition of HIV-1 long terminal repeat expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VIVO; TRANSLATIONAL CONTROL; TAT TRANSACTIVATION; PKR; INTERFERON; CELLS; MECHANISMS; YEAST	Trans-activation response (TAR) RNA-binding protein (TRBP) is a cellular protein that binds to the human immunodeficiency virus-1 (HIV-1) TAR element RNA. It has two double-stranded RNA binding domains (dsRBDs), but only one is functional for TAR binding. TRBP interacts with the interferon-induced protein kinase R (PKR) and inhibits its activity. We used the yeast two-hybrid assay to map the interaction sites between the two proteins. We show that TRBP and PKR-N (178 first amino acids of PKR) interact with PKR wild type and inhibit the PKR-induced yeast growth defect in this assay. We characterized two independent PKR-binding sites in TRBP. These sites are located in each dsRBD in TRBP, indicating that PKR-TRBP interaction does not require the RNA binding activity present only in dsRBD2. TRBP and its fragments that interact with PKR reverse the PKR-induced suppression of HIV-1 long terminal repeat expression. In addition, TRBP activates the HIV-1 long terminal repeat expression to a larger extent than the addition of each domain. These data suggest that TRBP activates gene expression in PKR-dependent and PKR-independent manners.	McGill AIDS Ctr, Mol Oncol Grp, Lady Davis Inst Med Res, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada; INSERM, U529, Inst Cochin Genet Mol, F-75014 Paris, France; Hop La Pitie Salpetriere, U511, INSERM, F-75013 Paris, France; Macfarlane Burnet Ctr Med Res, Fairfield, Vic 3078, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Inst Pasteur, Unite Virol & Immunol Cellulaire, F-75724 Paris 15, France	Lady Davis Institute; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Melbourne; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gatignol, A (corresponding author), McGill AIDS Ctr, Mol Oncol Grp, Lady Davis Inst Med Res, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	anne.gatignol@mcgill.ca	Gatignol, Anne/AAA-6501-2020; Purcell, Damian F/G-5068-2011	Gatignol, Anne/0000-0002-4553-0836; 				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Blair Edward D., 1995, Journal of Biomedical Science, V2, P322, DOI 10.1007/BF02255219; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Cai RR, 2000, ARCH BIOCHEM BIOPHYS, V373, P361, DOI 10.1006/abbi.1999.1583; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; CLARKE PA, 1990, EUR J BIOCHEM, V193, P635, DOI 10.1111/j.1432-1033.1990.tb19381.x; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Daviet L, 2000, EUR J BIOCHEM, V267, P2419, DOI 10.1046/j.1432-1327.2000.01256.x; Daviet L, 1998, J BIOL CHEM, V273, P28219, DOI 10.1074/jbc.273.43.28219; Duarte M, 2000, J BIOMED SCI, V7, P494; Erard M, 1998, J MOL BIOL, V279, P1085, DOI 10.1006/jmbi.1998.1831; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Francois C, 2000, J VIROL, V74, P5587, DOI 10.1128/JVI.74.12.5587-5596.2000; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Gatignol A, 1996, GENE EXPRESSION, V5, P217; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gatignol A, 2000, Adv Pharmacol, V48, P209; Gatignol Anne, 1994, V4, P18; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; Hatada E, 1999, J VIROL, V73, P2425, DOI 10.1128/JVI.73.3.2425-2433.1999; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; JAGUS R, 1994, BIOCHIMIE, V76, P779, DOI 10.1016/0300-9084(94)90082-5; Jeang KT, 1998, J BIOMED SCI, V5, P24; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOZAK CA, 1995, GENOMICS, V25, P66, DOI 10.1016/0888-7543(95)80110-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; Lee K, 1996, MOL CELL BIOL, V16, P3023; LEE SB, 1994, P NATL ACAD SCI USA, V91, P10551, DOI 10.1073/pnas.91.22.10551; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; Merrick WC., 1996, TRANSLATION CONTROL, P31; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Meurs EF, 1995, VIROLOGY, V214, P653, DOI 10.1006/viro.1995.0080; Meurs EF, 1998, VIROLOGY, V247, P125, DOI 10.1006/viro.1998.9277; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Yankulov K, 1998, CURR BIOL, V8, pR447, DOI 10.1016/S0960-9822(98)70289-1; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684; Zhong J, 1998, MAMM GENOME, V9, P413, DOI 10.1007/s003359900786	62	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33899	33905		10.1074/jbc.M103584200	http://dx.doi.org/10.1074/jbc.M103584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438532	hybrid			2022-12-25	WOS:000170910200083
J	Shaw, RJ; Wilson, JL; Smith, KT; Reines, D				Shaw, RJ; Wilson, JL; Smith, KT; Reines, D			Regulation of an IMP dehydrogenase gene and its overexpression in drug-sensitive transcription elongation mutants of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; INOSINE MONOPHOSPHATE DEHYDROGENASE; T-LYMPHOCYTE ACTIVATION; FACTOR S-II; SACCHAROMYCES-CEREVISIAE; INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE; TRITRICHOMONAS-FETUS; MYCOPHENOLIC-ACID; SHUTTLE VECTORS; SUBUNIT RPB9	IMP dehydrogenase is a rate-limiting enzyme involved in the synthesis of GTP. In mammalian cells it is regulated with respect to growth rate and is the target of numerous therapeutic agents. Mutations in the RNA polymerase II elongation machinery render yeast sensitive to inhibitors of IMP dehydrogenase and defective in inducing transcription of one of the IMP dehydrogenase-encoding genes, IMD2. Here we show that loss of IMD2, but not IMD1, IMD3, or IMD4, conferred upon yeast the same drug sensitivity found in elongation mutants. We tested whether the drug sensitivity of elongation mutants is due to their inability to induce IMD2 by providing them with exogenous copies of the gene. In some elongation mutants, overexpression reversed drug sensitivity and a transcriptional defect. Overexpression in mutants with a more severe phenotype partially suppressed drug sensitivity but was inconsequential in reversing a defect in transcription. These findings suggest that the drug sensitivity of elongation mutants is largely but not solely attributable to defects in the ability to induce IMD2, because transcription is compromised even when IMD2 mRNA levels are adequate. We describe two DNA sequence elements in the promoter of the gene that regulate it. We also found that IMD2 mRNA abundance is coupled to cell growth rate. These findings show that yeast possess a conserved system that gauges nucleotide pools and cell growth rate and responds through a uniquely regulated member of the IMD gene family.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Reines, D (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	dreines@emory.edu	excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490, R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46331, R01 GM046331, T32 GM008490] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Barton AB, 1997, YEAST, V13, P1251; Brodsky JL, 1998, BIOCHEMISTRY-US, V37, P18045, DOI 10.1021/bi980900g; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; COLLART FR, 1990, BLOOD, V75, P570; Costa PJ, 2000, GENETICS, V156, P535; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; DAYTON JS, 1994, J IMMUNOL, V152, P984; Digits JA, 1999, BIOCHEMISTRY-US, V38, P2295, DOI 10.1021/bi982305k; Escobar-Henriques M, 2001, J BIOL CHEM, V276, P1523, DOI 10.1074/jbc.M007926200; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; Franchetti P, 1999, CURR MED CHEM, V6, P599; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLESNE DA, 1991, MOL CELL BIOL, V11, P5417, DOI 10.1128/MCB.11.11.5417; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hemming SA, 2000, J BIOL CHEM, V275, P35506, DOI 10.1074/jbc.M004721200; Huberman E., 1995, PURINE PYRIMIDINE ME, V8, P741; HUETEPEREZ JA, 1995, BIOCHEMISTRY-US, V34, P13889, DOI 10.1021/bi00042a021; Ishiguro A, 2000, MOL CELL BIOL, V20, P1263, DOI 10.1128/MCB.20.4.1263-1270.2000; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; Kohler GA, 1997, J BACTERIOL, V179, P2331; Lecoq K, 2000, GENETICS, V156, P953; Lennon JC, 1998, MOL CELL BIOL, V18, P5771, DOI 10.1128/MCB.18.10.5771; Liu YA, 1998, MOL BIOL CELL, V9, P15, DOI 10.1091/mbc.9.1.15; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shimoaraiso M, 2000, J BIOL CHEM, V275, P29623, DOI 10.1074/jbc.M910371199; SIKORSKI RS, 1989, GENETICS, V122, P19; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Wind-Rotolo M, 2001, J BIOL CHEM, V276, P11531, DOI 10.1074/jbc.M011322200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WU J, 1996, P NATL ACAD SCI USA, V93, P1152; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2; ZIMMERMANN AG, 1995, J BIOL CHEM, V270, P6808, DOI 10.1074/jbc.270.12.6808; Zimmermann AG, 1997, J BIOL CHEM, V272, P22913, DOI 10.1074/jbc.272.36.22913	47	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32905	32916		10.1074/jbc.M105075200	http://dx.doi.org/10.1074/jbc.M105075200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11441018	Green Accepted, hybrid			2022-12-25	WOS:000170746000072
J	Vieira, HLA; Belzacq, AS; Haouzi, D; Bernassola, F; Cohen, I; Jacotot, E; Ferri, KF; El Hamel, C; Bartle, LM; Melino, G; Brenner, C; Goldmacher, V; Kroemer, G				Vieira, HLA; Belzacq, AS; Haouzi, D; Bernassola, F; Cohen, I; Jacotot, E; Ferri, KF; El Hamel, C; Bartle, LM; Melino, G; Brenner, C; Goldmacher, V; Kroemer, G			The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal	ONCOGENE			English	Article						apoptosis; Bcl-2; (V)MIA; mitochondria; permeability transition	PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; MITOCHONDRIAL ADP/ATP CARRIER; CELL-DEATH; INDUCED APOPTOSIS; CYCLOPHILIN-D; BCL-2; BAX; PROTEINS	Nitric oxide (NO), peroxynitrite, and 4-hydroxynonenal (HNE) may be involved in the pathological demise of cells via apoptosis, Apoptosis induced by these agents is inhibited by Bcl-2, suggesting the involvement of mitochondria in the death pathway. In vitro, NO, peroxynitrite and HNE can cause direct permeabilization of mitochondrial membranes, and this effect is inhibited by cyclosporin A, indicating involvement of the permeability transition pore complex (PTPC) in the permeabilization event. NO, peroxynitrite and HNE also permeabilize proteoliposomes containing the adenine nucleotide translocator (ANT), one of the key components of the PTPC, yet have no or little effects on protein-free control liposomes, ANT-dependent, NO-, peroxynitrite- or HNE-induced permeabilization is at least partially inhibited by recombinant Bcl-2 protein, as well as the antioxidants trolox and butylated hydroxytoluene, In vitro, none of the tested agents (NO, peroxynitrite, FINE, and tert-butylhydroperoxide) causes preferential carbonylation HNE adduction, or nitrotyrosylation of ANT. How ever, all these agents induced ANT to undergo thiol oxidation/derivatization. Peroxynitrite and HNE also caused significant lipid peroxidation, which was antagonized by butylated hydroxytoluene but not by recombinant Bcl-2, Transfection-enforced expression of vMIA, a viral apoptosis inhibitor specifically targeted to ANT, largely reduces the mitochondrial and nuclear signs of apoptosis induced by NO, peroxynitrite and HNE in intact cells. Taken together these data suggest that NO, peroxynitrite, and HNE may directly act on ANT to induce mitochondrial membrane permeabilization and apoptosis.	Inst Gustave Roussy, CNRS, UMR1599, F-94805 Villejuif, France; Univ Technol Compiegne, CNRS, UMR6022, F-60205 Compiegne, France; Univ Roma Tor Vergata, Biochem Lab, I-00133 Rome, Italy; Apoptosis Technol Inc, Cambridge, MA 02139 USA	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; University of Rome Tor Vergata	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Vieira, Helena/AAZ-9562-2021; brenner, catherine/AAE-8632-2020; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; /0000-0002-5301-1569; Vieira, Helena/0000-0001-9415-3742				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Allione A, 1999, J IMMUNOL, V163, P4182; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BouHamdan M, 1998, J BIOL CHEM, V273, P8009, DOI 10.1074/jbc.273.14.8009; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Buege J A, 1978, Methods Enzymol, V52, P302; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dorner A, 1999, BBA-BIOMEMBRANES, V1417, P16, DOI 10.1016/S0005-2736(98)00245-4; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Glockzin S, 1999, J BIOL CHEM, V274, P19581, DOI 10.1074/jbc.274.28.19581; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Hashimoto M, 1999, BIOCHEMISTRY-US, V38, P1050, DOI 10.1021/bi9822978; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kruman I, 1997, J NEUROSCI, V17, P5089; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Mossalayi MD, 1999, MOL MED, V5, P812, DOI 10.1007/BF03401994; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Nicotera P, 1999, CELL DEATH DIFFER, V6, P931, DOI 10.1038/sj.cdd.4400583; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	65	202	213	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4305	4316		10.1038/sj.onc.1204575	http://dx.doi.org/10.1038/sj.onc.1204575			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466611				2022-12-25	WOS:000169912600004
J	Weil, MM; Kittrell, FS; Yu, YJ; McCarthy, M; Zabriskie, RC; Ullrich, RL				Weil, MM; Kittrell, FS; Yu, YJ; McCarthy, M; Zabriskie, RC; Ullrich, RL			Radiation induces genomic instability and mammary ductal dysplasia in Atm heterozygous mice	ONCOGENE			English	Article						radiation effects; breast cancer; ataxia-telangiectasia; genomic instability	ATAXIA-TELANGIECTASIA; DEFICIENT MICE; CANCER; SENSITIVITY; BALB/C	Ataxia-telangiectasia (AT) is a genetic syndrome resulting from the inheritance of two defective copies of the ATM gene that includes among its stigmata radiosensitivity and cancer susceptibility. Epidemiological studies have demonstrated that although women with a single defective copy of ATM (AT heterozygotes) appear clinically normal, they may never the less have an increased relative risk of developing breast cancer. Whether they are at increased risk for radiation-induced breast cancer from medical exposures to ionizing radiation is unknown. We have used a murine model of AT to investigate the effect of a single defective Atm allele, the murine homologue of ATM, on the susceptibility of mammary epithelial cells to radiation-induced transformation. Here we report that mammary epithelial cells from irradiated mice with one copy of Atm truncated in the PI-3 kinase domain were susceptible to radiation-induced genomic instability and generated a 10% incidence of dysplastic mammary ducts when transplanted into syngenic recipients, whereas cells from Atm(+/+) mice were stable and formed only normal ducts. Since radiation-induced ductal dysplasia is a precursor to mammary cancer, the results indicate that AT heterozygosity increases susceptibility to radiogenic breast cancer in this murine model system.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Radiat Oncol, Div Biol, Galveston, TX 77555 USA; Colorado State Univ, Dept Radiol Hlth Sci, Ft Collins, CO 80523 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Colorado State University	Weil, MM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA073929, P01CA006294, R01CA043322] Funding Source: NIH RePORTER; NCI NIH HHS [CA43322, CA06294, CA73929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS LM, 1987, CANCER RES, V47, P4425; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; BICEHOUSE HJ, 1975, 7 ANN NATL C RAD CON, P136; BOICE JD, 1992, NEW ENGL J MED, V326, P1357; BRIDGES BA, 1992, NEW ENGL J MED, V326, P1357; CONWAY BJ, 1994, RADIOLOGY, V191, P323, DOI 10.1148/radiology.191.2.8153301; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; HALL EJ, 1992, NEW ENGL J MED, V326, P1358; KULLER LH, 1992, NEW ENGL J MED, V326, P1357; LAND CE, 1992, NEW ENGL J MED, V326, P1359; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; UPTON AC, 1977, J NATL CANCER I, V59, P480; WAGNER LK, 1992, NEW ENGL J MED, V326, P1358	18	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4409	4411		10.1038/sj.onc.1204589	http://dx.doi.org/10.1038/sj.onc.1204589			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466622				2022-12-25	WOS:000169912600015
J	Frasca, F; Vigneri, P; Vella, V; Vigneri, R; Wang, JYJ				Frasca, F; Vigneri, P; Vella, V; Vigneri, R; Wang, JYJ			Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor	ONCOGENE			English	Article						Akt; branching morphogenesis; c-Abl; cell motility; ERK; Met; PDGF receptor	C-KIT RECEPTOR; CARCINOMA CELLS; SCATTER FACTOR; RHO-GTPASES; IN-VITRO; ABL; MET; EXPRESSION; STI-571; PROTOONCOGENE	Met are physiological regulators of cell migration, HGF and Met have also been implicated in tumor progression and metastasis. We show here that the tyrosine kinase inhibitor STI571 has a stimulatory effect on HGF-induced migration and branching morphogenesis in thyroid cancer but not in primary or immortalized thyroid epithelial cells. These stimulatory effects of STI571 are observed at a concentration that is clinically relevant. The STI571-enhanced motile response can be correlated with an increase in the Met receptor tyrosine phosphorylation as well as ERK and Akt activation by HGF, Interestingly, one of the targets of STI571, namely the c-Abl tyrosine kinase, is activated by HGF and is recruited at the migrating edge of thyroid cancer cells, These data suggests that c-Abl and/or STI571-inhibited tyrosine kinases can negatively regulate the Met receptor to restrain the motile response in thyroid cancer cells.	Univ Catania, Ist Med Interna Malattie Endocrine & Metab, Osped Garibaldi, I-95123 Catania, Italy; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Catania; University of California System; University of California San Diego; University of California System; University of California San Diego; Magna Graecia University of Catanzaro	Frasca, F (corresponding author), Univ Catania, Ist Med Interna Malattie Endocrine & Metab, Osped Garibaldi, Piazza S Maria di Gesu, I-95123 Catania, Italy.		Vigneri, Paolo G/K-8504-2016; Frasca, Francesco/J-1332-2018; Vella, Veronica/AAX-5690-2020; Vella, Veronica/N-7977-2018; Vigneri, Riccardo/M-3968-2017	Vigneri, Paolo G/0000-0002-5943-6066; Frasca, Francesco/0000-0002-5556-3201; Vella, Veronica/0000-0002-4968-8550; Vigneri, Riccardo/0000-0002-4401-3140	NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline; NHLBI NIH HHS [HL57900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belfiore A, 1997, J CLIN ENDOCR METAB, V82, P2322, DOI 10.1210/jc.82.7.2322; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Bergstrom JD, 1999, BRIT J CANCER, V80, P650, DOI 10.1038/sj.bjc.6690406; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HELDIN NE, 1991, ENDOCRINOLOGY, V129, P2187, DOI 10.1210/endo-129-4-2187; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Kilic T, 2000, CANCER RES, V60, P5143; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; NATALI PG, 1995, CANCER RES, V55, P1787; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365-2613.2000.00138.x; TANAKA T, 1995, ENDOCR J, V42, P723, DOI 10.1507/endocrj.42.723; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698	32	55	56	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3845	3856		10.1038/sj.onc.1204531	http://dx.doi.org/10.1038/sj.onc.1204531			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439348				2022-12-25	WOS:000169494700010
J	von Lindern, M; Deiner, EM; Dolznig, H; Parren-van Amelsvoort, M; Hayman, MJ; Mullner, EW; Beug, H				von Lindern, M; Deiner, EM; Dolznig, H; Parren-van Amelsvoort, M; Hayman, MJ; Mullner, EW; Beug, H			Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis	ONCOGENE			English	Article						erythropoiesis; signal transduction; cellular transformation	STEM-CELL-FACTOR; GROWTH-FACTOR RECEPTOR; SELF-RENEWAL; IN-VITRO; GLUCOCORTICOID-RECEPTOR; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; KINASE; ROLES	Primary erythroid progenitors can be expanded by the synergistic action of erythropoietin (Epo), stem cell factor (SCF) and glucocorticoids, While Epo is required for erythropoiesis in general, glucocorticoids and SCF mainly contribute to stress erythropoiesis in hypoxic mice, This ability of normal erythroid progenitors to undergo expansion under stress conditions is targeted by the avian erythroblastosis virus (AEV), harboring the oncogenes v-ErbB and v-ErbA, We investigated the signaling pathways required for progenitor expansion under stress conditions and in leukemic transformation. Immortal strains of erythroid progenitors, able to undergo normal, terminal differentiation under appropriate conditions, were established from fetal livers of p53-/- mice. Expression and activation of the EGF-receptor (HER-1/c-ErbB) or its mutated oncogenic version (v-ErbB) in these cells abrogated the requirement for Epo and SCF in expansion of these progenitors and blocked terminal differentiation. Upon inhibition of ErbB function, differentiation into erythrocytes occurred. Signal transducing molecules important for renewal induction, i.e. Stat5- and phosphoinositide 3-kinase (PI3K), are utilized by both EpoR/c-Kit and v/c-ErbB, However, while v-ErbB transformed cells and normal progenitors depended on PI3K signaling for renewal, c-ErbB also induces progenitor expansion by PI3K-independent mechanisms.	Inst Mol Pathol, A-1030 Vienna, Austria; Erasmus MC, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Vienna Bioctr, VBC, Inst Med Biochem, A-1030 Vienna, Austria; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Erasmus University Rotterdam; Erasmus MC; Vienna Biocenter (VBC); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.gt	von Lindern, Marieke/AAH-2350-2020; Dolznig, Helmut/L-7005-2015	Dolznig, Helmut/0000-0002-6063-3585				Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; BEUG H, 1995, METHOD ENZYMOL, V254, P41; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P284; Broudy VC, 1998, BLOOD, V91, P898, DOI 10.1182/blood.V91.3.898.898_898_906; Broudy VC, 1996, BLOOD, V88, P75; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; DOLZNIG H, 2001, IN PRESS FASEB J; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KELLEY MW, 1992, DEV AUDITORY VESTIBU, V2, P139; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; Kieslinger M, 2000, GENE DEV, V14, P232; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; OZBUN MA, 1993, CELL GROWTH DIFFER, V4, P811; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; van Dijk TB, 2000, BLOOD, V96, P3406; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; VONRUDEN T, 1992, BLOOD, V79, P3145; Wessely O, 1997, CELL GROWTH DIFFER, V8, P481; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	49	87	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3651	3664		10.1038/sj.onc.1204494	http://dx.doi.org/10.1038/sj.onc.1204494			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439328				2022-12-25	WOS:000169400200006
J	Gomi, K; Kajiyama, N				Gomi, K; Kajiyama, N			Oxyluciferin, a luminescence product of firefly luciferase, is enzymatically regenerated into luciferin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; PURIFICATION; EXPRESSION; DIKINASE; CLONING; AMP	The activity regenerating luciferin from the luminescent product oxyluciferin was found in the protein fraction of a lantern extract from Photinus pyralis. The protein, luciferin-regenerating enzyme (LRE), was purified to homogeneity by ammonium sulfate precipitation followed by successive column chromatography on Ultrogel AcA34, S-Sepharose FF, Q-Sepharose FF, TSKgel super Q 5pw and TSKgel G3000 SWXL. This enzyme was a single polypeptide with a molecular mass of 38 kDa. LRE converted oxyluciferin to 2-cyano-6-hydroxybenzothiazole and thioglycolic acid. In the presence of D-cysteine, 2-cyano-6-hydroxybenzothiazole was turned over into luciferin. The same activities were detected in the extracts from two Japanese fireflies, Luciola cruciata and Luciola lateralis. We have cloned a cDNA encoding LRE from poly(A)+ RNA of the lantern of P. pyralis using reverse transcription-polymerase chain reaction, 5 ' -RACE (rapid amplification of cDNA ends) and 3 ' -RACE. The primary structure of LRE from P. pyralis deduced from the nucleotide sequence was shown to consist of 308 amino acids with a molecular weight of 33,619. The cDNA was successfully expressed under the control of the tac promoter in Escherichia coli.	Kikkoman Foods Inc, Div Res & Dev, Noda, Chiba 2780037, Japan	Kikkoman Corporation	Kajiyama, N (corresponding author), Kikkoman Foods Inc, Div Res & Dev, 399 Noda, Noda, Chiba 2780037, Japan.							BITLER B, 1957, ARCH BIOCHEM BIOPHYS, V72, P358, DOI 10.1016/0003-9861(57)90212-6; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Eisaki N, 1999, BBA-PROTEIN STRUCT M, V1431, P363, DOI 10.1016/S0167-4838(99)00057-6; Fontes R, 1998, FEBS LETT, V438, P190, DOI 10.1016/S0014-5793(98)01301-5; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GATES BJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P616, DOI 10.1016/0003-9861(75)90205-2; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; KAJIYAMA N, 1992, BIOCHIM BIOPHYS ACTA, V1120, P228, DOI 10.1016/0167-4838(92)90275-I; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; Sakakibara T, 1999, ANAL BIOCHEM, V268, P94, DOI 10.1006/abio.1998.3028; Suzuki N., 1971, TETRAHEDRON LETT, V22, P2021; SUZUKI N, 1974, TETRAHEDRON LETT, V32, P2771; Tatsumi H, 1996, ANAL BIOCHEM, V243, P176, DOI 10.1006/abio.1996.0498; WHITE EH, 1963, J AM CHEM SOC, V85, P337, DOI 10.1021/ja00886a019	15	81	89	1	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36508	36513		10.1074/jbc.M105528200	http://dx.doi.org/10.1074/jbc.M105528200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11457857	hybrid			2022-12-25	WOS:000171194500062
J	Caffarri, S; Croce, R; Breton, J; Bassi, R				Caffarri, S; Croce, R; Breton, J; Bassi, R			The major antenna complex of photosystem II has a xanthophyll binding site not involved in light harvesting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEMTOSECOND TRANSIENT ABSORPTION; CHLOROPHYLL ENERGY-TRANSFER; HIGHER-PLANTS; MUTATION ANALYSIS; PROTEINS; CP29; FLUORESCENCE; CAROTENOIDS; MEMBRANES; ZEAXANTHIN	We have characterized a xanthophyll binding site, called V1, in the major light harvesting complex of photosystem II, distinct from the three tightly binding sites previously described as L1, L2, and N1. Xanthophyll binding to the V1 site can be preserved upon solubilization of the chloroplast membranes with the mild detergent dodecyl-a-D-maltoside, while an IEF purification step completely removes the ligand. Surprisingly, spectroscopic analysis showed that when bound in this site, xanthophylls are unable to transfer absorbed light energy to chlorophyll a. Pigments bound to sites L1, L2, and N1, in contrast, readily transfer energy to chlorophyll a. This result suggests that this binding site is not directly involved in light harvesting function. When violaxanthin, which in normal conditions is the main carotenoid in this site, is depleted by the de-epoxidation in strong light, the site binds other xanthophyll species, including newly synthesized zeaxanthin, which does not induce detectable changes in the properties of the complex. It is proposed that this xanthophyll binding site represents a reservoir of readily available violaxanthin for the operation of the xanthophyll cycle in excess light conditions.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; CEA Saclay, Dept Biol Cellulaire & Mol, Sect Bioenerget, F-91191 Gif Sur Yvette, France	University of Verona; CEA; UDICE-French Research Universities; Universite Paris Saclay	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, Str Le Grazie 15, I-37134 Verona, Italy.	bassi@sci.univr.it	Croce, Roberta/F-1174-2014; Croce, Roberta/N-4067-2014; Caffarri, Stefano/AAX-8913-2021; Croce, Roberta/ABG-3595-2021; Croce, Roberta/HGU-9554-2022	Croce, Roberta/0000-0003-3469-834X; Caffarri, Stefano/0000-0002-4729-7679; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; bassi, roberto/0000-0002-4140-8446				BASSI R, 1985, CARLSBERG RES COMMUN, V50, P145, DOI 10.1007/BF02907142; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; Boekema EJ, 1999, BIOCHEMISTRY-US, V38, P2233, DOI 10.1021/bi9827161; Cinque G, 2000, BIOPHYS J, V79, P1706, DOI 10.1016/S0006-3495(00)76423-X; Connelly JP, 1997, BIOCHEMISTRY-US, V36, P281, DOI 10.1021/bi962467l; Crimi M, 2001, EUR J BIOCHEM, V268, P260, DOI 10.1046/j.1432-1033.2001.01874.x; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; Croce R, 2000, PHOTOSYNTH RES, V64, P221, DOI 10.1023/A:1006455230379; Croce R, 2001, BIOPHYS J, V80, P901, DOI 10.1016/S0006-3495(01)76069-9; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; GILMORE AM, 1993, PHOTOSYNTH RES, V35, P67, DOI 10.1007/BF02185412; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Gradinaru CC, 2000, J PHYS CHEM B, V104, P9330, DOI 10.1021/jp001752i; Gruszecki WI, 1999, BBA-BIOENERGETICS, V1412, P173, DOI 10.1016/S0005-2728(99)00055-9; GRUSZECKI WI, 1990, BIOCHIM BIOPHYS ACTA, V1023, P405, DOI 10.1016/0005-2736(90)90133-9; Harrer R, 1998, EUR J BIOCHEM, V255, P196, DOI 10.1046/j.1432-1327.1998.2550196.x; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; HAWORTH P, 1982, BIOCHIM BIOPHYS ACTA, V679, P428, DOI 10.1016/0005-2728(82)90164-5; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Horton P, 1996, NATO ADV SCI INST SE, V287, P99; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; Peterman EJG, 1997, BIOCHEMISTRY-US, V36, P12208, DOI 10.1021/bi9711689; Polivka T, 1999, P NATL ACAD SCI USA, V96, P4914, DOI 10.1073/pnas.96.9.4914; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Rogl H, 1999, BIOCHEMISTRY-US, V38, P16214, DOI 10.1021/bi990739p; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; RUBAN AV, 1994, PHOTOSYNTH RES, V40, P181, DOI 10.1007/BF00019335; RUBAN AV, 1994, BBA-BIOENERGETICS, V1186, P123, DOI 10.1016/0005-2728(94)90143-0; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; SIEFERMANNHARMS D, 1987, PHYSIOL PLANTARUM, V69, P561, DOI 10.1111/j.1399-3054.1987.tb09240.x; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; Walters RG, 1996, P NATL ACAD SCI USA, V93, P14204, DOI 10.1073/pnas.93.24.14204; Wentworth M, 2000, FEBS LETT, V471, P71, DOI 10.1016/S0014-5793(00)01369-7; Yamamoto HY, 1999, ADV PHOTOSYNTH, V8, P293	51	200	202	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35924	35933		10.1074/jbc.M105199200	http://dx.doi.org/10.1074/jbc.M105199200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11454869	hybrid			2022-12-25	WOS:000171109300093
J	Ferlinz, K; Kopal, G; Bernardo, K; Linke, T; Bar, J; Breiden, B; Neumann, U; Lang, F; Schuchman, EH; Sandhoff, K				Ferlinz, K; Kopal, G; Bernardo, K; Linke, T; Bar, J; Breiden, B; Neumann, U; Lang, F; Schuchman, EH; Sandhoff, K			Human acid ceramidase - Processing, glycosylation, and lysosomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; PROTEIN; SPHINGOMYELIN; PURIFICATION; ENZYMES; SIGNAL; DEGRADATION; PHOSPHATASE; SUFFICIENT; ACTIVATION	The biosynthesis of human acid ceramidase (hAC) starts with the expression of a single precursor polypeptide of similar to 53-55 kDa, which is subsequently processed to the mature, heterodimeric enzyme (40 + 13 kDa) in the endosomes/lysosomes. Secretion of hAC by either fibroblasts or acid ceramidase cDNA-transfected COS cells is extraordinarily low. Both lysosomal targeting and endocytosis critically depend on a functional mannose 6-phosphate receptor as judged by the following criteria: (i) hAC-precursor secretion by NH4Cl-treated fibroblasts and I-cell disease fibroblasts, (ii) inhibition of the formation of mature heterodimeric hAC in NH4Cl-treated fibroblasts or in I-cell disease fibroblasts, and (iii) blocked endocytosis of hAC precursor by mannose 6-phosphate receptor-deficient fibroblasts or the addition of mannose 6-phosphate. The influence of the six individual potential N-glycosylation sites of human acid ceramidase on targeting, processing, and catalytic activity was determined by site-directed mutagenesis. Five glycosylation sites (sites 1-5 from the N terminus) are used. The elimination of sites 2, 4, and 6 has no influence on lysosomal processing or enzymatic activity of recombinant ceramidase. The removal of sites 1, 3, and 5 inhibits the formation of the heterodimeric enzyme form. None of the mutant ceramidases gave rise to an increased rate of secretion, suggesting that lysosomal targeting does not depend on one single carbohydrate chain.	Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Univ Tubingen, Inst Physiol 1, D-72076 Tubingen, Germany; Hannover Sch Vet Med, Clin Poultry, D-30559 Hannover, Germany; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	University of Bonn; Eberhard Karls University of Tubingen; University of Veterinary Medicine Hannover, Foundation; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sandhoff, K (corresponding author), Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.	sandhoff@uni-bonn.de	Breiden, Bernadette/S-3005-2019; Breiden, Bernadette/F-2422-2014	Breiden, Bernadette/0000-0002-4838-4109; Breiden, Bernadette/0000-0002-4838-4109				Bar J, 2001, HUM MUTAT, V17, P199, DOI 10.1002/humu.5; BENYOSEPH Y, 1989, CLIN GENET, V36, P38; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 1997, CHEM PHYS LIPIDS, V88, P1, DOI 10.1016/S0009-3084(97)00040-6; Huwiler A, 2001, FASEB J, V15, P7; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kornfeld R, 1998, J BIOL CHEM, V273, P23203, DOI 10.1074/jbc.273.36.23203; Kornfeld S., 2001, METABOLIC MOL BASES, P3469; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Linke, 2001, METABOLIC MOL BASES, P3573; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MOSER HW, 1983, METABOLIC BASES INHE, P2589; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339, DOI 10.1016/0005-2760(69)90192-1; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; Sandhoff K, 1998, ANN NY ACAD SCI, V845, P139, DOI 10.1111/j.1749-6632.1998.tb09667.x; Segui B, 1999, J BIOL CHEM, V274, P37251, DOI 10.1074/jbc.274.52.37251; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPENCE MW, 1986, BIOCHEM CELL BIOL, V64, P400, DOI 10.1139/o86-056; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; VANDONGEN JM, 1985, EUR J CELL BIOL, V39, P179; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YADA Y, 1995, J BIOL CHEM, V270, P12677, DOI 10.1074/jbc.270.21.12677; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	42	88	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35352	35360		10.1074/jbc.M103066200	http://dx.doi.org/10.1074/jbc.M103066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11451951	hybrid			2022-12-25	WOS:000171109300021
J	Olteanu, H; Banerjee, R				Olteanu, H; Banerjee, R			Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ADENINE-DINUCLEOTIDE PHOSPHATE; COMPLEMENTATION GROUP; HOMOCYSTEINE; CBLG; CLONING; FAD; IDENTIFICATION; OXIDOREDUCTASE; VITAMIN-B-12	Methionine synthase is a key enzyme in the methionine cycle that catalyzes the transmethylation of homocysteine to methionine in a cobalamin-dependent reaction that utilizes methyltetrahydrofolate as a methyl group donor. Cob(I)alamin, a supernucleophilic form of the cofactor, is an intermediate in this reaction, and its reactivity renders the enzyme susceptible to oxidative inactivation. In bacteria, an NADPH-dependent two-protein system comprising flavodoxin reductase and flavodoxin, transfers electrons during reactivation of methionine synthase. Until recently, the physiological reducing system in mammals was unknown. Identification of mutations in the gene encoding a putative methionine synthase reductase in the cblE class of patients with an isolated functional deficiency of methionine synthase suggested a role for this protein in activation (Leclerc, D., Wilson, A., Dumas, R., Gafuik, C., Song, D., Watkins, D., Heng, H. H. Q., Rommens, J. M., Scherer, S. W., Rosenblatt, D. S., and Gravel, R. A (1998) Proc. Natl Acad. Sci. U. S. A. 95,3059-3064). In this study, we have cloned and expressed the cDNA encoding human methionine synthase reductase and demonstrate that it is sufficient for supporting NADPH-dependent activity of methionine synthase at a level that is comparable with that seen in the in vitro assay that utilizes artificial reductants. Methionine synthase reductase is a soluble, monomeric protein with a molecular mass of 78 kDa. It is a member of the family of dual flavoproteins and is isolated with an equimolar concentration of FAD and FMN. Reduction by NADPH results in the formation of an air stable semiquinone similar to that observed with cytochrome P-450 reductase. Methionine synthase reductase reduces cytochrome c in an NADPH-dependent reaction at a rate (0.44 mu mol min(-1) mg(-1) at 25 degreesC) that is comparable with that reported for NR1, a soluble dual flavoprotein of unknown function, but is similar to 100-fold slower than that of P-450 reductase. The K-m for NADPH is 2.6 +/- 0.5 muM, and the K-act for methionine synthase reductase is 80.7 +/- 13.7 nM for NADPH-dependent activity of methionine synthase.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee@unl.edu	Olteanu, Horatiu/AAH-1051-2021	Olteanu, Horatiu/0000-0001-5783-4485	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK045776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BANERJEE R, 2000, MOL BIOL METHIONINE, P291; BEINERT H, 1960, ENZYMES, V2, P339; CHEN Z, 1998, THESIS U NEBRASKA LI; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; Chen ZQ, 1998, J BIOL CHEM, V273, P26248, DOI 10.1074/jbc.273.40.26248; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; FUJII K, 1979, METHIONINE SYNTHASE, P173; Gulati S, 1997, J BIOL CHEM, V272, P19171, DOI 10.1074/jbc.272.31.19171; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; Gutierrez A, 2001, BIOCHEMISTRY-US, V40, P1964, DOI 10.1021/bi001719m; Hall DA, 2000, BIOCHEMISTRY-US, V39, P10711, DOI 10.1021/bi001096c; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; Kim JJP, 1996, METHOD ENZYMOL, V272, P368, DOI 10.1016/S0076-6879(96)72042-6; Klatt P, 1996, METHOD ENZYMOL, V268, P358; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; Miller JW, 1999, NUTR REV, V57, P126; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; OSTROWSKI J, 1989, J BIOL CHEM, V264, P714; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Perrin D.D., 1974, BUFFERS PH METAL ION, P4; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; ROSENBLATT DS, 1995, INHERITED DISORDERS, P2049; Shen AL, 2000, J BIOL CHEM, V275, P41087, DOI 10.1074/jbc.M008380200; SHEVELL MI, 1992, CAN J NEUROL SCI, V19, P472, DOI 10.1017/S0317167100041676; Swanson DA, 2001, MOL CELL BIOL, V21, P1058, DOI 10.1128/MCB.21.4.1058-1065.2001; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WATKINS D, 1989, AM J MED GENET, V34, P427, DOI 10.1002/ajmg.1320340320; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; Wilson A, 1999, HUM MOL GENET, V8, P2009, DOI 10.1093/hmg/8.11.2009; Wilson A, 1998, AM J HUM GENET, V63, P409, DOI 10.1086/301976; Wilson A, 1999, MOL GENET METAB, V67, P317, DOI 10.1006/mgme.1999.2879	43	135	143	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35558	35563		10.1074/jbc.M103707200	http://dx.doi.org/10.1074/jbc.M103707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466310	hybrid			2022-12-25	WOS:000171109300048
J	Peyron, P; Maridonneau-Parini, I; Stegmann, T				Peyron, P; Maridonneau-Parini, I; Stegmann, T			Fusion of human neutrophil phagosomes with lysosomes in vitro - Involvement of tyrosine kinases of the Src family and inhibition by mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; NONOPSONIC PHAGOCYTOSIS; TUBERCULOSIS PHAGOSOME; CELL ACTIVATION; NADPH OXIDASE; IN-VITRO; MACROPHAGES; ENDOSOMES; PROTEINS; GRANULES	The intracellular killing of microorganisms in phagocytes involves the fusion of lysosomes containing bactericidal factors with phagosomes, and several intracellular pathogens are able to inhibit this fusion event. In this study, we report the reconstitution of phagosome-lysosome fusion in vitro, using an assay based on resonance energy transfer between fluorescent phospholipid analogues that were inserted into whole human NB4-neutrophil. membranes from liposomes containing positively charged lipids. Cytosol was required for fusion, and fusion was stimulated 3-fold if this cytosol had been prepared from neutrophils activated by using opsonized zymosan or a combination of the calcium ionophore (A23187) and phorbol myristate acetate (PMA). Fusion was inhibited by the addition of PPI, an inhibitor of Src family protein kinases, or GTP gammaS. We have previously reported that the biogenesis of phagolysosomes in human neutrophils is inhibited by mycobacteria. Here we show that cytosol from cells having internalized live (not heat-killed) Mycobacterium smegmatis or cytosol simply incubated with mycobacteria inhibited fusion, indicating that soluble factors are involved in mycobacterial inhibition of phagosome-lysosome fusion.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Stegmann, T (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.		Maridonneau-Parini, Isabelle/F-1985-2011	Maridonneau-Parini, Isabelle/0000-0003-0189-0976				ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469, DOI 10.1128/IAI.67.2.469-477.1999; Beatty WL, 2000, INFECT IMMUN, V68, P6997, DOI 10.1128/IAI.68.12.6997-7002.2000; Bonnafous P, 2000, J BIOL CHEM, V275, P6160, DOI 10.1074/jbc.275.9.6160; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; FOLCH J, 1957, J BIOL CHEM, V226, P497; Funato K, 1997, J BIOL CHEM, V272, P16147, DOI 10.1074/jbc.272.26.16147; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Gregoire C, 1998, J CELL PHYSIOL, V175, P203; Haas A, 1998, MOL MEMBR BIOL, V15, P103, DOI 10.3109/09687689809074522; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hope MJ, 1998, MOL MEMBR BIOL, V15, P1, DOI 10.3109/09687689809027512; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; LANOTTE M, 1991, BLOOD, V77, P1080; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; Ligeti E, 1999, BIOCHEM PHARMACOL, V57, P1209, DOI 10.1016/S0006-2952(98)00377-3; MarieCardine A, 1996, J BIOL CHEM, V271, P20734, DOI 10.1074/jbc.271.34.20734; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; Mocsai A, 1999, J IMMUNOL, V162, P1120; MOHN H, 1995, BIOCHEM J, V309, P657; N'Diaye EN, 1998, J IMMUNOL, V161, P4983; Orsel JC, 1997, J BIOL CHEM, V272, P3369, DOI 10.1074/jbc.272.6.3369; Peyron P, 2000, J IMMUNOL, V165, P5186, DOI 10.4049/jimmunol.165.9.5186; Shukla A, 2000, RESP MED, V94, P10, DOI 10.1053/rmed.1999.0700; STEGMANN T, 1993, BIOCHEMISTRY-US, V32, P11330, DOI 10.1021/bi00093a009; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Teitelbaum R, 1999, P NATL ACAD SCI USA, V96, P15190, DOI 10.1073/pnas.96.26.15190; Vaissiere C, 1999, J LEUKOCYTE BIOL, V65, P629, DOI 10.1002/jlb.65.5.629; Welch H, 1997, J BIOL CHEM, V272, P102; Welch Heidi, 1996, Methods (Orlando), V9, P607, DOI 10.1006/meth.1996.0067	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35512	35517		10.1074/jbc.M104399200	http://dx.doi.org/10.1074/jbc.M104399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11463789	hybrid			2022-12-25	WOS:000171109300041
J	Wu, QQ; Zhang, Y; Chen, Q				Wu, QQ; Zhang, Y; Chen, Q			Indian hedgehog is an essential component of mechanotransduction complex to stimulate chondrocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; CARTILAGE MATRIX PROTEIN; HORMONE-RELATED PEPTIDE; DISTRACTION OSTEOGENESIS; FRACTURE REPAIR; GROWTH-PLATE; DIFFERENTIATION; EXPRESSION; CELL; RECAPITULATION	Indian hedgehog (Ihh), a member of the vertebrate hedgehog morphogen family, is a key signaling molecule that controls chondrocyte proliferation and differentiation. In this study, we show a novel function of Ihh. Namely, it acts as an essential mediator of mechanotransduction in cartilage. Cyclic mechanical stress greatly induces the expression of Ihh by chondrocytes. This induction is abolished by gadolinium, an inhibitor of stretch-activated channels. This suggests that the IHH gene is mechanoresponsive. The mechano-induction of Ihh is essential for stimulating chondrocyte proliferation by mechanical loading. The presence of an Ihh functional blocking antibody during loading completely abolishes the stimulatory effect of mechanical load on proliferation. Furthermore, Ihh mediates the mechanotransduction process in a bone morphogenic protein (BMP)-dependent and parathyroid hormone-related peptide-independent manner. BMP 2/4 are up-regulated by mechanical stress through the induction of Ihh, and BMP antagonist noggin inhibits mechanical stimulation of chondrocyte proliferation. This suggests BMP lies downstream of Ihh in mechanotransduction pathway. Our data suggest that Ihh may transduce mechanical signals during cartilage growth and repair processes.	Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Musculoskeletal Res Lab, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Cell & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, Q (corresponding author), Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Musculoskeletal Res Lab, Hershey, PA 17033 USA.		Chen, Qian/C-4354-2011	Chen, Qian/0000-0003-4406-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017021, R29AG014399, R01AG014399] Funding Source: NIH RePORTER; NIA NIH HHS [AG00811, AG17021, AG 14399] Funding Source: Medline; NIGMS NIH HHS [P20 GM104937] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHHURST DE, 1986, PHILOS T R SOC B, V313, P271, DOI 10.1098/rstb.1986.0038; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Chung UI, 1998, P NATL ACAD SCI USA, V95, P13030, DOI 10.1073/pnas.95.22.13030; COHEN B, 1992, J ORTHOPAED RES, V10, P263, DOI 10.1002/jor.1100100214; Einhorn TA, 1998, J BONE MINER RES, V13, P10, DOI 10.1359/jbmr.1998.13.1.10; Enomoto-Iwamoto M, 1998, J CELL BIOL, V140, P409, DOI 10.1083/jcb.140.2.409; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2; FIETZ MJ, 1994, DEVELOPMENT, P43; Germiller JA, 1997, J ORTHOP RES, V15, P362, DOI 10.1002/jor.1100150308; HALL BK, 1968, J EXP ZOOL, V168, P283, DOI 10.1002/jez.1401680302; HALL BK, 1990, J MORPHOL, V206, P45, DOI 10.1002/jmor.1052060105; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KIM YJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P1, DOI 10.1006/abbi.1994.1201; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Liu MY, 1999, IN VITRO CELL DEV-AN, V35, P87, DOI 10.1007/s11626-999-0006-8; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; MURRAY PDF, 1969, J EMBRYOL EXP MORPH, V22, P349; Pathi S, 1999, DEV BIOL, V209, P239, DOI 10.1006/dbio.1998.9181; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; Sato M, 1999, J BONE MINER RES, V14, P1084, DOI 10.1359/jbmr.1999.14.7.1084; SCHNEIDERMAN R, 1986, J ORTHOPAED RES, V4, P393, DOI 10.1002/jor.1100040402; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; SUZUKI F, 1992, ADV EXP MED BIOL, V324, P101; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; TURNER CH, 1991, BONE, V12, P203, DOI 10.1016/8756-3282(91)90043-I; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; Welch RD, 1998, J BONE MINER RES, V13, P1, DOI 10.1359/jbmr.1998.13.1.1; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Wu QQ, 2000, EXP CELL RES, V256, P383, DOI 10.1006/excr.2000.4847; Zhang Y, 2000, J BIOL CHEM, V275, P32628, DOI 10.1074/jbc.M002594200; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	39	120	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35290	35296		10.1074/jbc.M101055200	http://dx.doi.org/10.1074/jbc.M101055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466306	hybrid			2022-12-25	WOS:000171109300013
J	Bartleson, C; Graves, DJ				Bartleson, C; Graves, DJ			An inhibitory segment of the catalytic subunit of phosphorylase kinase does not act as a pseudosubstrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GAMMA-SUBUNIT; REGULATORY SUBUNIT; STRUCTURAL BASIS; SUBSTRATE RECOGNITION; AUTOINHIBITORY DOMAIN; CRYSTAL-STRUCTURE; CALMODULIN; BINDING; TWITCHIN	The C terminus of the catalytic gamma subunit of phosphorylase kinase contains two autoinhibitory calmodulin binding domains designated PhK13 and PhK5. These peptides inhibit truncated gamma (1-300). Previous data show that PhK13 (residues 302-326) is a competitive inhibitor with respect to phosphorylase b, with a K-i of 1.8 muM (1). This result suggests that PhK13 may bind to the active site of truncated gamma (1-300). Variants of PhK13 were prepared to localize the determinants for interaction with the catalytic fragment gamma (1-300). PhK13-1, containing residues 302-312, was found to be a competitive inhibitor with respect to phosphorylase b with a K-i of 6.0 muM. PhK13 has been proposed to function as a pseudosubstrate inhibitor with Cys-308 occupying the site that normally accommodates the phosphorylatable serine in phosphorylase b. A PhK13-1 variant, C308S, was synthesized. Kinetic characterization of this peptide reveals that it does not serve as a substrate but is a competitive inhibitor. Additional variants were designed based on previous knowledge of phosphorylase kinase substrate determinants. Variants were analyzed as substrates and as inhibitors for truncated gamma (1-300). Although PhK13-1 does not appear to function as a pseudosubstrate, several specificity determinants employed in the recognition of phosphorylase b as substrate are utilized in the recognition of PhK13-1 as an inhibitor.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Iowa State Univ, Signal Transduct Training Program, Ames, IA 50011 USA	Iowa State University; Iowa State University	Bartleson, C (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, 4214 Mol Biol Bldg, Ames, IA 50011 USA.	cjsuitt@iastate.edu			NIGMS NIH HHS [GM-09587] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; DASGUPTA M, 1995, J BIOL CHEM, V270, P22283, DOI 10.1074/jbc.270.38.22283; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRAVES DJ, 1983, METHOD ENZYMOL, V99, P268; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; HUANG CYF, 1993, MOL CELL BIOCHEM, V128, P7, DOI 10.1007/BF01076753; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; KEE SM, 1987, J BIOL CHEM, V262, P9448; KEE SM, 1986, J BIOL CHEM, V261, P4732; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P13997, DOI 10.1021/bi981311d; LEI JY, 1994, J BIOL CHEM, V269, P21078; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MENDELOW M, 1993, J BIOL CHEM, V268, P12289; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PAUDEL HK, 1993, J BIOL CHEM, V268, P6207; POLLARD TD, 1982, METHOD ENZYMOL, V85, P123; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SMITH MK, 1992, J BIOL CHEM, V267, P1761; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; YUAN CJ, 1993, BIOCH BIOPHYSICS, P151	33	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34560	34566		10.1074/jbc.M102308200	http://dx.doi.org/10.1074/jbc.M102308200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11448955	hybrid			2022-12-25	WOS:000171024600030
J	Bitan, G; Lomakin, A; Teplow, DB				Bitan, G; Lomakin, A; Teplow, DB			Amyloid beta-protein oligomerization - Prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; FIBRIL FORMATION; ALZHEIMERS-DISEASE; IN-VITRO; CONFORMATIONAL-CHANGES; ENHANCED PRODUCTION; CELL-CULTURE; TRANSTHYRETIN; FIBRILLOGENESIS; PEPTIDE	Assembly of the amyloid beta -protein (A beta) into neurotoxic oligomers and fibrils is a seminal event in Alzheimer's disease. Understanding the earliest phases of A beta assembly, including prenucleation and nucleation, is essential for the development of rational therapeutic strategies. We have applied a powerful new method, photoinduced cross-linking of unmodified proteins (PI-CUP), to the study of A beta oligomerization. Significant advantages of this method include an extremely short reaction time, enabling the identification and quantification of short lived metastable assemblies, and the fact that no pre facto structural modification of the native peptide is required. Using PICUP, the distribution of A beta oligomers existing prior to assembly was defined. A rapid equilibrium was observed involving monomer, dimer, trimer, and tetramer. A similar distribution was seen in studies of an unrelated amyloidogenic peptide, whereas nonamyloidogenic peptides yielded distributions indicative of a lack of monomer preassociation. These results suggest that simple nucleation-dependent polymerization models are insufficient to describe the dynamic equilibria associated with prenucleation phases of A beta assembly.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol Neurosci, Boston, MA 02115 USA; MIT, Ctr Mat Sci & Engn, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Mat Proc, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Teplow, DB (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 77 Ave Louis Pasteur HIM 756, Boston, MA 02115 USA.	teplow@cnd.bwh.harvard.edu	Bitan, Gal/U-2204-2019	Bitan, Gal/0000-0001-7046-3754	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038328] Funding Source: NIH RePORTER; NIA NIH HHS [AG14366] Funding Source: Medline; NINDS NIH HHS [NS38328] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chatelier H.L, 1884, COMPTES RENDUS, V99, P786; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 1999, NAT STRUCT BIOL, V6, P380; Colon W, 1996, CIBA F SYMP, V199, P228; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Fancy DA, 2000, CHEM BIOL, V7, P697, DOI 10.1016/S1074-5521(00)00020-X; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Fancy DA, 2000, CURR OPIN CHEM BIOL, V4, P28, DOI 10.1016/S1367-5931(99)00047-2; Fezoui Y, 2000, AMYLOID, V7, P166, DOI 10.3109/13506120009146831; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Goda S, 2000, PROTEIN SCI, V9, P369; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lai ZH, 1997, BIOCHEMISTRY-US, V36, P10230, DOI 10.1021/bi963195p; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 1998, BIOCHEMISTRY-US, V37, P17851, DOI 10.1021/bi981876+; Le Chatelier H. L., 1888, ANN MINES, V13, P157; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LEVINE H, 1995, NEUROBIOL AGING, V16, P755, DOI 10.1016/0197-4580(95)00052-G; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; MCKINLEY MP, 1986, INT REV NEUROBIOL, V28, P1, DOI 10.1016/S0074-7742(08)60105-1; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Tanielian C, 1996, J PHYS CHEM-US, V100, P6555, DOI 10.1021/jp952107s; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; Wilkins DK, 2000, EUR J BIOCHEM, V267, P2609, DOI 10.1046/j.1432-1327.2000.01270.x; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yutani K, 2000, BIOCHEMISTRY-US, V39, P2769, DOI 10.1021/bi991406v; ZAGORSKI MG, 2000, NEUROBIOL AGING, V21, pS10; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288; ZHANG XY, 1995, J PHYS CHEM-US, V99, P12797, DOI 10.1021/j100034a018	55	345	353	1	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35176	35184		10.1074/jbc.M102223200	http://dx.doi.org/10.1074/jbc.M102223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11441003	hybrid			2022-12-25	WOS:000171024600108
J	Jump, DB; Thelen, AP; Mater, MK				Jump, DB; Thelen, AP; Mater, MK			Functional interaction between sterol regulatory element-binding protein-1c, nuclear factor Y, and 3,5,3 '-triiodothyronine nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S14 GENE-TRANSCRIPTION; POLYUNSATURATED FATTY-ACIDS; THYROID-HORMONE; RAT-LIVER; MESSENGER-RNAS; SYNTHASE GENE; ADIPOCYTE DETERMINATION; SYNERGISTIC ACTIVATION; HEPATIC EXPRESSION; CULTURED-CELLS	Sterol regulatory element binding protein-1c (SREBP-1c) is a key hepatic transcription factor involved in lipogenic gene expression. In an effort to understand the role SREBP-1c plays in lipogenic gene transcription, we have examined the functional interaction between SREBP-1c, nuclear factor Y, 3,5,3'-triiodothyronine (T-3) receptors, and co-activators using the S14 gene promoter as a model. T-3, glucose, and insulin rapidly induce S14 gene transcription in rat liver and in primary hepatocytes. Linker scanning analyses of the S14 promoter showed that an SIZE at -139/-131 base pairs (bp) binding SREBP-1c and a Y-box at -104/-99 bp binding NF-Y are indispensable for both T-3- and SREBP-1c-mediated induction of S14 promoter activity in rat primary hepatocytes. T-3 and glucose/insulin induce S14 gene transcription through separate enhancers. Enhancer substitution studies reveal a preferential interaction between SREBP-1c.NF-Y and the T-3 regulatory region (-2.8/-2.5 kb) binding thyroid hormone receptor/RXR heterodimers. Elevating hepatocellular levels of specific co-activators (CBP, p/CAF, or GCN5) induced S14 promoter activity 2-3-fold, while SREBP-1c induced promoter activity 10-fold. The combination of these treatments induced S14 promoter activity (20-35-fold). However, this additive effect was lost when the Ts regulatory region was deleted. Based on these results, we suggest that the SREBP-1c.NF-Y complex facilitates the interaction between co-activators that are recruited to distal hormone-regulated enhancers and the general transcription machinery that binds the S14 proximal promoter.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 115 Giltner Hall, E Lansing, MI 48824 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43220, R01 DK043220] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; BLENNEMANN B, 1995, MOL CELL ENDOCRINOL, V110, P1, DOI 10.1016/0303-7207(95)03509-6; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Clarke SD, 2001, J NUTR, V131, P1129, DOI 10.1093/jn/131.4.1129; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Glass CK, 2000, GENE DEV, V14, P121; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jackson SM, 1998, J LIPID RES, V39, P767; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; JUMP DB, 1989, J BIOL CHEM, V264, P4698; JUMP DB, 1990, MOL ENDOCRINOL, V4, P655; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KINLAW WB, 1993, ENDOCRINOLOGY, V133, P645, DOI 10.1210/en.133.2.645; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Moon YA, 2000, J BIOL CHEM, V275, P30280, DOI 10.1074/jbc.M001066200; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; O'Callaghan BL, 2001, J BIOL CHEM, V276, P16033, DOI 10.1074/jbc.M101557200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Rufo C, 1999, BIOCHEM BIOPH RES CO, V261, P400, DOI 10.1006/bbrc.1999.1034; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yin LY, 2000, BBA-GENE STRUCT EXPR, V1517, P91, DOI 10.1016/S0167-4781(00)00267-0	55	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34419	34427		10.1074/jbc.M105471200	http://dx.doi.org/10.1074/jbc.M105471200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11448969	hybrid			2022-12-25	WOS:000171024600010
J	Lerner, LE; Gribanova, YE; Ji, M; Knox, BE; Farber, DB				Lerner, LE; Gribanova, YE; Ji, M; Knox, BE; Farber, DB			Nrl and Sp nuclear proteins mediate transcription of rod-specific cGMP-phosphodiesterase beta-subunit gene - Involvement of multiple response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSENSE MUTATION; RHODOPSIN GENE; HOMEOBOX GENE; OIL DROPLETS; RD MOUSE; PHOTORECEPTOR; IDENTIFICATION; EXPRESSION; DEGENERATION; RETINA	cGMP-phosphodiesterase (PDE) is the key effector in rod photoreceptor signal transduction. Mutations in the gene encoding its catalytic, beta -subunit (beta -PDE) cause retinal degenerations leading to blindness. We report that the short -93 to +53 sequence in the upstream region of this gene is sufficient for beta -PDE transcription in both Y79 human retinoblastoma cells and Xenopus embryo heads maintained ex vivo. This sequence also functions as a minimal rod-specific promoter in transgenic Xenopus tadpoles. The Nrl transcription factor binds in vitro to the beta Ap1/NRE regulatory element located within this region and transactivates it when overexpressed in non-retinal 293 embryonic kidney cells. We also found a G/C-rich activator element, beta /GC, important for promoter activity in Y79 retinoblastoma cells and Xenopus embryos. Both the ubiquitous Sp1 and the central nervous system-specific Sp4 transcription factors are expressed in retina and interact with this element in vitro. Electrophoretic mobilities of beta /GC-Y79 nuclear protein complexes are altered by antibodies against Sp1 and Sp4. Thus, our results implicate Nr1, Sp1, and Sp4 in transcriptional regulation of the rod-specific minimal beta -PDE promoter. We also conclude that Xenopus laevis is an efficient system for analyzing the human beta -PDE promoter and may be used to study other human retinal genes ex vivo and in vivo.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Boyer Ctr Mol Med, Los Angeles, CA 90095 USA; SUNY Upstate Med Univ, Dept Biochem, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Mol Biol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Ophthalmol, Syracuse, NY 13210 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Farber, DB (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.	farber@jsei.ucla.edu		Farber, Debora/0000-0002-3207-697X	NATIONAL EYE INSTITUTE [R01EY012975, R01EY011256, R37EY002651, R01EY002651] Funding Source: NIH RePORTER; NEI NIH HHS [EY11256, EY02651, EY12975, EY00367] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; Batni S, 2000, METHOD ENZYMOL, V316, P50; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BOWMAKER JK, 1977, VISION RES, V17, P755, DOI 10.1016/0042-6989(77)90117-1; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Carey M, 2000, TRANSCRIPTIONAL REGU; DiPolo A, 1997, NUCLEIC ACIDS RES, V25, P3863, DOI 10.1093/nar/25.19.3863; DiPolo A, 1996, INVEST OPHTH VIS SCI, V37, P551; DIPOLO A, 1995, P NATL ACAD SCI USA, V92, P4016, DOI 10.1073/pnas.92.9.4016; FARBER DB, 1992, NEURON, V9, P349, DOI 10.1016/0896-6273(92)90173-B; Farber DB, 1997, CURR OPIN NEUROBIOL, V7, P666, DOI 10.1016/S0959-4388(97)80087-6; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; Knox BE, 1998, FEBS LETT, V423, P117, DOI 10.1016/S0014-5793(98)00018-0; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Lerner LE, 2000, METHOD ENZYMOL, V315, P617; LOLLEY RN, 1977, SCIENCE, V196, P664, DOI 10.1126/science.193183; OHTSUKA T, 1984, NEUROSCI LETT, V52, P241, DOI 10.1016/0304-3940(84)90168-X; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SAXEN L, 1954, ANN ACADEMIAE SCI A, V23, P5; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; ZHANG J, 1994, VISUAL NEUROSCI, V11, P1185, DOI 10.1017/S0952523800006982	34	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34999	35007		10.1074/jbc.M103301200	http://dx.doi.org/10.1074/jbc.M103301200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11438531	hybrid			2022-12-25	WOS:000171024600087
J	McDearmon, EL; Combs, AC; Ervasti, JM				McDearmon, EL; Combs, AC; Ervasti, JM			Differential Vicia villosa agglutinin reactivity identifies three distinct dystroglycan complexes in skeletal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; SYNAPSE-SPECIFIC CARBOHYDRATE; DUCHENNE MUSCULAR-DYSTROPHY; ALPHA-DYSTROGLYCAN; ACETYLCHOLINE-RECEPTORS; SERINE/THREONINE KINASES; ALPHA-7-BETA-1 INTEGRIN; NEUROMUSCULAR-JUNCTIONS; EPSILON-SARCOGLYCAN; CELL-LINES	We present evidence for the expression of three alpha -dystroglycan glycoforms in skeletal muscle cells, including two minor glycoforms marked by either patent or latent reactivity with the N-acetylgalactosamine-specific lectin Vicia villosa agglutinin. Both minor glycoforms co-isolated with beta -dystroglycan, but not with other dystrophin/utrophin-glycoprotein complex components, suggesting that they may perform distinct or modified cellular functions. We also confirmed that both patent and latent V. villosa agglutinin-reactive alpha -dystroglycan glycoforms are expressed in C2C12 myotubes. However, we found that the combined effect of saturating concentrations of V villosa agglutinin and laminin-1 were strictly additive with respect to acetylcholine receptor cluster formation in C2C12 myotubes, which suggests that laminin-1 and V. villosa agglutinin do not compete for the same binding site on the cell surface. Finally, although beta -N-acetylhexosaminidase digestion dramatically inhibited agrin-, V. villosa agglutinin-, and laminin-1-induced acetylcholine receptor clustering in C2C12 myotubes, treatment with this enzyme had no effect on the amount of alpha -dystroglycan that was bound to V. villosa agglutinin-agarose. We conclude that alpha -dystroglycan is not the V. villosa agglutinin receptor implicated in acetylcholine receptor cluster formation. However, our data provide new support for the hypothesis that different glycoforms of alpha -dystroglycan may perform distinct functions even within the same cell.	Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Grad Program Mol & Cellular Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.		Ervasti, James/AAZ-4786-2020		NIAMS NIH HHS [ARO1985] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Burkin DJ, 2000, J CELL SCI, V113, P2877; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Durbeej M, 1999, J BIOL CHEM, V274, P26609, DOI 10.1074/jbc.274.37.26609; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Gautam M, 1999, DEV BRAIN RES, V114, P171, DOI 10.1016/S0165-3806(99)00013-9; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grow WA, 1999, J NEUROBIOL, V40, P356, DOI 10.1002/(SICI)1097-4695(19990905)40:3<356::AID-NEU7>3.3.CO;2-6; Grow WA, 1999, DEV NEUROSCI-BASEL, V21, P436, DOI 10.1159/000017411; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; LAND BR, 1977, J PHYSIOL-LONDON, V269, P155, DOI 10.1113/jphysiol.1977.sp011897; Leschziner A, 2000, J NEUROCHEM, V74, P70, DOI 10.1046/j.1471-4159.2000.0740070.x; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; MAN NT, 1991, J CELL BIOL, V115, P1695; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Montanaro F, 1998, J NEUROSCI, V18, P1250; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Portier GL, 1999, IN VITRO CELL DEV-AN, V35, P219, DOI 10.1007/s11626-999-0030-8; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SONG WK, 1993, J CELL SCI, V106, P1139; Straub V, 1999, J BIOL CHEM, V274, P27989, DOI 10.1074/jbc.274.39.27989; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; Yamada H, 1996, J NEUROCHEM, V66, P1518	43	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35078	35086		10.1074/jbc.M103843200	http://dx.doi.org/10.1074/jbc.M103843200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11459841	hybrid			2022-12-25	WOS:000171024600097
J	Song, XS; Zheng, XL; Malbon, CC; Wang, HY				Song, XS; Zheng, XL; Malbon, CC; Wang, HY			G alpha(i2) enhances in vivo activation of and insulin signaling to GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; N-TERMINAL KINASE; IN-VIVO; ALPHA-SUBUNIT; GLUT4-CONTAINING VESICLES; GLUCOSE TRANSPORTER; SKELETAL-MUSCLE; ANTISENSE RNA; PROTEIN; ADIPOCYTES	Heterotrimeric G-proteins, including G alpha (i2), have been implicated in modulating glucose disposal and insulin signaling. This cross-talk between G-protein-coupled and tyrosine kinase-coupled signaling pathways is a focal point for the study of integration of cell signaling. Herein we study the role of G alpha (i2) in modulating glucose transport, focusing upon linkages to insulin signaling. Utilizing mice harboring a transgene that directs the expression of a constitutively activated, GTPase-deficient mutant of G alpha (i2) (Q205L) in adipose tissue, skeletal muscle, and liver, we demonstrate that G alpha (i2) regulates the translocation of the insulin-sensitive GLUT4 glucose transporter in skeletal muscle and adipose tissue. The expression of Q205L G alpha (i2) increased glucose transport and translocation of GLUT4 to the plasma membrane in vivo in the absence of insulin stimulation. Adipocytes from the Q205L G alpha (i2) mice displayed enhanced insulin-stimulated glucose transport and GLUT4 translocation to the plasma membrane to levels nearly twice that of those from littermate controls. Phosphatidylinositol 3-kinase and Akt activities were constitutively activated in tissues expressing the Q205L G alpha (i2). Studies of adipocytes from wild-type mice displayed short term activation of phosphatidylinositol 3-kinase, Akt, and GLUT4 translocation in response to activation of G alpha (i2) by lysophosphatidic acid, a response sensitive to pertussis toxin. These data provide an explanation for the marked glucose tolerance of the Q205L G alpha (i2) mice and demonstrate a linkage between G alpha (i2) and GLUT4 translocation.	SUNY Stony Brook, Dept Mol Pharmacol, Univ Med Ctr, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Diabet & Metab Dis Res Program, Univ Med Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Wang, HY (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Stony Brook, NY 11794 USA.	wangh@pharm.sunysb.edu	malbon, craig/ABF-3604-2020	Zheng, Xi-Long/0000-0002-0889-1827	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CZECH MP, 1980, J CLIN INVEST, V66, P574, DOI 10.1172/JCI109889; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Hill MM, 1999, MOL CELL BIOL, V19, P7771; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Karoor V, 1998, Adv Pharmacol, V42, P425; MALBON CC, 1980, J BIOL CHEM, V255, P8692; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; Olefsky JM, 1999, J BIOL CHEM, V274, P1863, DOI 10.1074/jbc.274.4.1863; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Wang HY, 2000, METH MOL B, V136, P241; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; Yu SH, 2001, J BIOL CHEM, V276, P19994, DOI 10.1074/jbc.M010313200; Zheng XL, 1998, J BIOL CHEM, V273, P23649, DOI 10.1074/jbc.273.37.23649	30	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34651	34658		10.1074/jbc.M105894200	http://dx.doi.org/10.1074/jbc.M105894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457861	hybrid			2022-12-25	WOS:000171024600042
J	Soulages, JL; Arrese, EL; Chetty, PS; Rodriguez, V				Soulages, JL; Arrese, EL; Chetty, PS; Rodriguez, V			Essential role of the conformational flexibility of helices 1 and 5 on the lipid binding activity of apolipophorin-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; EXCHANGEABLE APOLIPOPROTEINS; ALPHA-HELICES; A-I; DIMYRISTOYLPHOSPHATIDYLCHOLINE; LIPOPROTEINS; SPECTROSCOPY; PROTEINS; VESICLES; INSECTS	It has been recently postulated that the conformational flexibility of helices 1 and 5 of Locusta migratoria apoLp-III could play an important role in early steps of binding of this apolipoprotein to a lipid surface (Soulages, J. L., and Arrese, E. L. (2000) J. Biol. Chem. 275, 17501-17509). To test this model, we have designed a double Cys mutant in which a disulfide bond linking helices 1 and 5 could be formed, resulting in an apolipoprotein with reduced conformational flexibility of its N- and C-terminal helices. Substitution of Thr(18) and Ala(147) by Cys residues provided a protein that under nonreducing conditions was fully oxidized. The far-UV CD spectra of this mutant in the reduced and oxidized states indicated that their secondary structures were identical to the structure of the wild type recombinant apoLp-III, which contains no Cys residues. Near-UV CD studies confirmed the formation of a disulfide bond and the absence of structural perturbations. The lipid binding activity of the reduced mutant, as determined by its ability to form discoidal lipoproteins, was nearly identical to that of the wild type protein. Contrarily, the disulfide form of the mutant was not able to form discoidal lipoproteins with liposomes of either dimirystoylphosphatidylcholine or dimyristoylphosphatidylglycerol. It is concluded that the separation of the helices 1 and 5 constitutes one of the key steps along the complex pathway for the formation of the final apolipoprotein lipid-bound state. It is inferred that the conformational flexibility of helices 1 and 5 is a key property of apoLp-III, allowing the exposure of hydrophobic protein regions and the interaction of the hydrophobic faces of the amphipathic alpha -helices with the lipoprotein lipid surface.	Oklahoma State Univ, Noble Res Ctr 355, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Soulages, JL (corresponding author), Oklahoma State Univ, Noble Res Ctr 355, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055622, R01GM055622] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55622] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Pownall H. J., 1987, PLASMA LIPOPROTEINS, P95; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1992, J LIPID RES, V33, P141; SMITH AF, 1994, J LIPID RES, V35, P1976; Soulages JL, 2000, BIOCHEMISTRY-US, V39, P10574, DOI 10.1021/bi0007223; Soulages JL, 2000, J BIOL CHEM, V275, P17501, DOI 10.1074/jbc.M909661199; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; Weers PMM, 2000, J LIPID RES, V41, P416; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Woody RW, 1996, CIRCULAR DICHROISM C, P109	24	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34162	34166		10.1074/jbc.M105836200	http://dx.doi.org/10.1074/jbc.M105836200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443139	hybrid			2022-12-25	WOS:000170910200116
J	van Oirschot, BA; Stahl, M; Lens, SMA; Medema, RH				van Oirschot, BA; Stahl, M; Lens, SMA; Medema, RH			Protein kinase a regulates expression of p27(kip1) and cyclin D3 to suppress proliferation of leukemic T cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; IMMUNE-RESPONSE; DOWN-REGULATION; G1 PHASE; IDENTIFICATION; LYMPHOCYTES; APOPTOSIS; G(1)	Peripheral homeostasis and tolerance requires the suppression or removal of excessive or harmful T lymphocytes. This can occur either by apoptosis through active antigen-induced death or cytokine withdrawal. Alternatively, T cell activation can be suppressed by agents that activate the cAMP-dependent protein kinase (PKA) signaling pathway, such as prostaglandin E2. Stimulation of PKA inhibits lymphocyte proliferation and immune effector functions. Here we have investigated the mechanism by which activation of PKA induces inhibition of proliferation in human leukemic T cell lines. Using a variety of agents that stimulate PKA, we can arrest Jurkat and H9 leukemic T cells in the G(1) phase of the cell cycle, whereas cell viability is hardly affected. This G(1) arrest is associated with an inhibition of cyclin D/Cdk and cyclin E/Cdk kinase activity. Interestingly, expression of cyclin D3 is rapidly reduced by PKA activation, whereas expression of the Cdk inhibitor p27(kip1) is induced. Ectopic expression of cyclin D3 can override the growth suppression induced by PKA activation to some extent, indicating that growth inhibition of leukemic T cells by PKA activation is partially dependent on down-regulation of cyclin D3 expression. Taken together our data suggest that immunosuppression by protein kinase A involves regulation of both cyclin D3 and p27(kip1) expression.	Netherlands Canc Inst, Dept Mol Biol H8, NL-1066 CX Amsterdam, Netherlands; Utrecht Med Ctr, Jordan Lab Hematooncol, NL-3584 CX Utrecht, Netherlands	Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Netherlands Canc Inst, Dept Mol Biol H8, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011	Medema, Rene/0000-0002-6754-0381				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; NOURSE J, 1992, NATURE, V372, P571; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 2000, CANCER RES, V60, P3689; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	23	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33854	33860		10.1074/jbc.M104395200	http://dx.doi.org/10.1074/jbc.M104395200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11457838	hybrid			2022-12-25	WOS:000170910200077
J	Wuttke, M; Muller, S; Nitsche, DP; Paulsson, M; Hanisch, FG; Maurer, P				Wuttke, M; Muller, S; Nitsche, DP; Paulsson, M; Hanisch, FG; Maurer, P			Structural characterization of human recombinant and bone-derived bone sialoprotein - Functional implications for cell attachment and hydroxyapatite binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; IN-VITRO; OSTEOPONTIN; PROTEIN; GLYCOPROTEINS; PROTEOGLYCAN; SEQUENCE; ACID; OLIGOSACCHARIDES; GLYCOSYLATION	Human bone sialoprotein (BSP) comprises 15% of the total noncollagenous proteins in bone and is thought to be involved in bone mineralization and remodeling. Recent data suggest a role for BSP in breast cancer and the development of bone metastases. We have produced full-length recombinant BSP in a human cell line and purified the protein from human bone retaining the native structure with proper folding and post-translational modifications. Mass spectrometry of bone-derived BSP revealed an average mass of 49 kDa and for recombinant BSP 57 kDa. The post-translational modifications contribute 30-40%. Carbohydrate analysis revealed 10 different complex-type N-glycans on both proteins and eight different O-glycans on recombinant BSP, four of those were found on bone-derived BSP. We could identify eight threonines modified by O-glycans, leaving the C terminus of the protein free of glycans. The recombinant protein showed similar secondary structures as bone-derived BSP. BSP was visualized in electron microscopy as a globule linked to a thread-like structure. The affinity for hydroxyapatite was higher for bone-derived BSP than for recombinant BSP. Cell adhesion assays showed that the binding of BSP to cells can be reversibly diminished by denaturation.	Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany	University of Cologne	Paulsson, M (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	mats.paulsson@uni-koeln.de						ANUMULA KR, 1992, ANAL BIOCHEM, V203, P101, DOI 10.1016/0003-2697(92)90048-C; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CHENU C, 1992, J BONE MINER RES, V7, P47; Diel IJ, 1999, CLIN CANCER RES, V5, P3914; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FISHER LW, 1987, J BIOL CHEM, V262, P9702; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; Hermentin P, 1996, GLYCOBIOLOGY, V6, P217, DOI 10.1093/glycob/6.2.217; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; INGRAM RT, 1993, J BONE MINER RES, V8, P1019; Karmatschek M, 1997, CLIN CHEM, V43, P2076; KASUGAI S, 1992, J CELL PHYSIOL, V152, P467, DOI 10.1002/jcp.1041520305; KELM RJ, 1992, BLOOD, V80, P3112; KINNE RW, 1987, J BIOL CHEM, V262, P10206; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MCQUILLAN DJ, 1995, BONE, V16, P415; Midura RJ, 1996, GLYCOBIOLOGY, V6, P677, DOI 10.1093/glycob/6.7.677; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OLDBERG A, 1989, J CELL BIOL, V109, P3183, DOI 10.1083/jcb.109.6.3183; Packer NH, 1998, GLYCOCONJUGATE J, V15, P737, DOI 10.1023/A:1006983125913; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Woitge HW, 2001, BRIT J CANCER, V84, P344, DOI 10.1054/bjoc.2000.1614; ZHANG R, 1990, J BIOL CHEM, V265, P15375; [No title captured]	48	77	93	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36839	36848		10.1074/jbc.M105689200	http://dx.doi.org/10.1074/jbc.M105689200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11459848	hybrid			2022-12-25	WOS:000171194500104
J	Anders, J; Kjaer, S; Ibanez, CF				Anders, J; Kjaer, S; Ibanez, CF			Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIRSCHSPRUNG-DISEASE; CELL-ADHESION; NEUROTROPHIC FACTOR; MUTATIONAL ANALYSIS; STRUCTURAL BASIS; PROTOONCOGENE; EXPRESSION; GDNF; IDENTIFICATION; SUPERFAMILY	Using bioinformatic tools, mutagenesis, and binding studies, we have investigated the structural organization of the extracellular region of the RET receptor tyrosine kinase, a functional receptor for glial cell line-derived neurotrophic factor (GDNF). Multiple sequence alignments of seven vertebrate sequences and one invertebrate RET sequence delineated four distinct N-terminal domains, each of about 110 residues, containing many of the consensus motifs of the cadherin fold. Based on these alignments and the crystal structures of epithelial and neural cadherins, we have generated molecular models of each of the four cadherin-like domains in the extracellular region of human RET. The modeled structures represent realistic models from both energetic and geometrical points of view and are consistent with previous observations gathered from biochemical analyses of the effects of Hirschsprung's disease mutations affecting the folding and stability of the RET molecule, as well as our own site-directed mutagenesis studies of RET cadherin-like domain 1. We have also investigated the role of Ca2+ in ligand binding by RET and found that Ca2+ ions are required for RET binding to GDNF but not for GDNF binding to the GFR alpha1 co-receptor. In agreement with these results, RET, but not GFR alpha1, was found to bind Ca2+ directly. Our results indicate that the overall architecture of the extracellular region of RET is more closely related to cadherins than previously thought. The models of the cadherin-like domains of human RET represent valuable tools with which to guide future site-directed mutagenesis studies aimed at identifying residues involved in ligand binding and receptor activation.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Retzius Vag 8, S-17177 Stockholm, Sweden.							Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Angrist M, 1996, NAT GENET, V14, P341, DOI 10.1038/ng1196-341; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Bolk S, 2000, P NATL ACAD SCI USA, V97, P268, DOI 10.1073/pnas.97.1.268; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hahn M, 2001, P NATL ACAD SCI USA, V98, P1053, DOI 10.1073/pnas.021558598; Inoue K, 2000, AM J MED GENET, V93, P278, DOI 10.1002/1096-8628(20000814)93:4<278::AID-AJMG5>3.0.CO;2-Q; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Iwashita T, 1996, ONCOGENE, V12, P481; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kusafuka T, 1997, J PEDIATR SURG, V32, P501, DOI 10.1016/S0022-3468(97)90616-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pelet A, 1998, J CLIN INVEST, V101, P1415, DOI 10.1172/JCI375; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Saarma M, 2000, EUR J BIOCHEM, V267, P6968, DOI 10.1046/j.1432-1327.2000.01826.x; Santoro W, 1999, J ENDOCRINOL INVEST, V22, P811, DOI 10.1007/BF03343650; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; Seri M, 1997, HUM MUTAT, V9, P243; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; van Weering DHJ, 1998, J BIOL CHEM, V273, P12077, DOI 10.1074/jbc.273.20.12077; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Yoshida K, 1998, GENOMICS, V49, P458, DOI 10.1006/geno.1998.5271	37	105	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35808	35817		10.1074/jbc.M104968200	http://dx.doi.org/10.1074/jbc.M104968200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11445581	hybrid			2022-12-25	WOS:000171109300079
J	Baron, A; Schaefer, L; Lingueglia, E; Champigny, G; Lazdunski, M				Baron, A; Schaefer, L; Lingueglia, E; Champigny, G; Lazdunski, M			Zn2+ and H+ are coactivators of acid-sensing ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED NA+ CHANNEL; MUTATIONS CAUSING NEURODEGENERATION; MAMMALIAN DEGENERIN MDEG; EXTRACELLULAR PH; HIPPOCAMPAL SLICES; CATION CHANNEL; ATP-RESPONSES; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; SENSORY NEURONS	Acid-sensing ion channels (ASICs) are cationic channels activated by extracellular protons. They are expressed in sensory neurons, where they are thought to be involved in pain perception associated with tissue acidosis. They are also expressed in brain. A number of brain regions, like the hippocampus, contain large amounts of chelatable vesicular Zn2+. This paper shows that Zn2+ potentiates the acid activation of homomeric and heteromeric ASIC2a-containing channels (i.e. ASIC2a, ASIC1a+2a, ASIC2a+3), but not of homomeric ASIC1a and ASIC3. The EC50 for Zn2+ potentiation is 120 and 111 muM for the ASIC2a. and ASIC1a+2a current, respectively. Zn2+ shifts the pH dependence of activation of the ASlCIa+2a current from a pH(0.5) of 5.5 to 6.0. Systematic mutagenesis of the 10 extracellular histidines of ASIC2a leads to the identification of two residues (His-162 and His-339) that are essential for the Zn2+ potentiating effect. Mutation of another histidine residue, His-72, abolishes the pH sensitivity of ASIC2a. This residue, which is located just after the first transmembrane domain, seems to be an essential component of the extracellular pH sensor of ASIC2a.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	BARON, Anne/N-5691-2016; LINGUEGLIA, Eric/F-5509-2013	BARON, Anne/0000-0002-8026-6380; LINGUEGLIA, Eric/0000-0003-3902-3405				Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Adams CM, 1999, J BIOL CHEM, V274, P15500, DOI 10.1074/jbc.274.22.15500; Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Benson CJ, 1999, CIRC RES, V84, P921; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Budde T, 1997, NEUROSCIENCE, V79, P347, DOI 10.1016/S0306-4522(96)00695-1; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; Clarke CE, 2000, J PHYSIOL-LONDON, V523, P697, DOI 10.1111/j.1469-7793.2000.00697.x; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Grunder S, 2000, NEUROREPORT, V11, P1607; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRISON NL, 1994, NEUROPHARMACOLOGY, V33, P935, DOI 10.1016/0028-3908(94)90152-X; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Miles E W, 1977, Methods Enzymol, V47, P431; Olson TH, 1998, NEUROREPORT, V9, P1109, DOI 10.1097/00001756-199804200-00028; Pan HL, 1999, J PHYSIOL-LONDON, V518, P857, DOI 10.1111/j.1469-7793.1999.0857p.x; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079-6123(08)61085-7; SLOMIANKA L, 1992, NEUROSCIENCE, V48, P325, DOI 10.1016/0306-4522(92)90494-M; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; Sutherland S P, 2000, Prog Brain Res, V129, P21; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Wildman SS, 1998, BRIT J PHARMACOL, V123, P1214, DOI 10.1038/sj.bjp.0701717; Wildman SS, 1999, BRIT J PHARMACOL, V128, P486, DOI 10.1038/sj.bjp.0702802; Wildman SS, 1999, BRIT J PHARMACOL, V126, P762, DOI 10.1038/sj.bjp.0702325	51	159	169	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35361	35367		10.1074/jbc.M105208200	http://dx.doi.org/10.1074/jbc.M105208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457851	Green Published, hybrid			2022-12-25	WOS:000171109300022
J	Jethanandani, P; Goldberg, E				Jethanandani, P; Goldberg, E			ldhc expression in non-germ cell nuclei is repressed by NF-I binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-SPECIFIC TRANSCRIPTION; LACTATE-DEHYDROGENASE-C; OVERLAPPING SEQUENCES; GENE PROMOTER; PROTEIN; FAMILY; IDENTIFICATION; SITE	Developmental and testis-specific expression of the mouse lactate dehydrogenase C (mldhc) gene requires mechanisms for activation in germ cells and repression in somatic cells. Promoter activity restricted to the testis has been demonstrated using in vitro transcription assays with a 60-base pair promoter sequence upstream of the transcription initiation site. This promoter fragment has a TATA box and an overlapping 31-base pair palindromic sequence. Here we have explored the role of the palindrome as a silencer of the ldhc gene in somatic tissues. A gel retardation assay detected two sites within the palindrome that were important for protein binding. A member of the NF-I/CTF family was identified as the protein binding to one of the sites. In transiently transfected mouse L cells, a promoter fragment in which the NF-I site was mutated showed a 4-fold greater activity as compared with the wild-type sequence. Overexpression of the four NF-I proteins, NF-IA, -B, -C, or -X, in mouse L cells transiently transfected with an ldhc promoter-reporter construct resulted in a 20-50% decrease in activity of the wild-type promoter but had no effect when the NF-I binding element in the palindrome was mutated. These results indicate a role for the NF-I proteins in regulation of the mldhc gene.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Goldberg, E (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	erv@northwestern.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029099, R01HD005863] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Chaudhry AZ, 1999, J BIOL CHEM, V274, P7072, DOI 10.1074/jbc.274.11.7072; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Clare SE, 1997, J BIOL CHEM, V272, P33028, DOI 10.1074/jbc.272.52.33028; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; Crawford DR, 1998, J BIOL CHEM, V273, P13387, DOI 10.1074/jbc.273.22.13387; CUIF MH, 1993, J BIOL CHEM, V268, P13769; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; Higgy NA, 1997, BBA-GENE STRUCT EXPR, V1351, P313, DOI 10.1016/S0167-4781(96)00221-7; KIM K, 1992, J BIOL CHEM, V267, P15271; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; Li SM, 1998, J BIOL CHEM, V273, P31191, DOI 10.1074/jbc.273.47.31191; Liu YC, 1997, J BIOL CHEM, V272, P10739; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; Osada S, 1997, BIOCHEM BIOPH RES CO, V238, P744, DOI 10.1006/bbrc.1997.7382; Schmidt EE, 1997, J BIOL CHEM, V272, P5326, DOI 10.1074/jbc.272.8.5326; Song CS, 1999, MOL ENDOCRINOL, V13, P1487, DOI 10.1210/me.13.9.1487; SZABO P, 1995, J BIOL CHEM, V270, P10212, DOI 10.1074/jbc.270.17.10212; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; ZHOU W, 1994, THESIS NW U EVANSTON; Zhou WT, 1996, BIOL REPROD, V54, P84, DOI 10.1095/biolreprod54.1.84; ZHOU WT, 1994, BIOL REPROD, V51, P425, DOI 10.1095/biolreprod51.3.425	23	13	17	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35414	35421		10.1074/jbc.M101269200	http://dx.doi.org/10.1074/jbc.M101269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11447215	hybrid			2022-12-25	WOS:000171109300029
J	Tiedemann, K; Batge, B; Muller, PK; Reinhardt, DP				Tiedemann, K; Batge, B; Muller, PK; Reinhardt, DP			Interactions of fibrillin-1 with heparin/heparan sulfate, implications for microfibrillar assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; MARFAN-SYNDROME; EXTRACELLULAR-MATRIX; HEPARAN-SULFATE; CALCIUM-BINDING; PROTEOGLYCAN SYNTHESIS; DERMAL FIBROBLASTS; MOLECULAR-CLONING; CELL-ADHESION; PROTEIN	Fibrillin-1 is a major constituent of the 10-12 nm extracellular microfibrils. Here we identify, characterize, and localize heparin/heparan sulfate-binding sites in fibrillin-1 and report on the role of such glycosaminoglycans in the assembly of fibrillin-1. By using different binding assays, we localize two calcium-independent heparin-binding sites to the N-terminal (Arg(45)-Thr(450)) and C-terminal (Asp(1528)-Arg(2731)) domains of fibrillin-1. A calcium-dependent-binding site was localized to the central (Asp(1028)-Thr(1486)) region of fibrillin-1. Heparin binding to these sites can be inhibited by a highly sulfated and iduronated form of heparan sulfate but not by chondroitin 4-sulfate, chondroitin 6-sulfate, and dermatan sulfate, demonstrating that the heparin binding regions represent binding domains for heparan sulfate. When heparin or heparan sulfate was added to cultures of skin fibroblasts, the assembly of fibrillin-1 into a microfibrillar network was significantly reduced. Western blot analysis demonstrated that this effect was not due to a reduced amount of fibrillin-1 secreted into the culture medium. Inhibition of the attachment of glycosaminoglyeans to core proteins of proteoglycans by beta -D-xylosides resulted in a significant reduction of the fibrillin-1 network. These studies suggest that binding of fibrillin-1 to protcoglycan-associated heparan sulfate chains is an important step in the assembly of microfibrils.	Med Univ Lubeck, Inst Med Mol Biol, D-23538 Lubeck, Germany	University of Lubeck	Reinhardt, DP (corresponding author), Med Univ Lubeck, Inst Med Mol Biol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.		Reinhardt, Dieter P/A-3102-2008; Tiedemann, one/A-9739-2016	Reinhardt, Dieter P/0000-0001-6535-9872; 				AOYAMA T, 1994, J CLIN INVEST, V94, P130, DOI 10.1172/JCI117298; ArroyoYanguas Y, 1997, J CELL BIOCHEM, V64, P595, DOI 10.1002/(SICI)1097-4644(19970315)64:4<595::AID-JCB8>3.0.CO;2-M; Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CAREY DJ, 1987, J CELL BIOL, V105, P1013, DOI 10.1083/jcb.105.2.1013; CHAN FL, 1995, HISTOCHEM CELL BIOL, V104, P369, DOI 10.1007/BF01458131; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; D'Arrigo C, 1998, CONNECT TISSUE RES, V37, P29, DOI 10.3109/03008209809028898; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Engel J, 2000, MATRIX BIOL, V19, P283, DOI 10.1016/S0945-053X(00)00075-5; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HAGGERTY JG, 1994, J CELL PHYSIOL, V158, P39, DOI 10.1002/jcp.1041580106; HAMATI HF, 1989, J CELL BIOL, V108, P2495, DOI 10.1083/jcb.108.6.2495; Hanssen E, 1998, BIOL CELL, V90, P223, DOI 10.1016/S0248-4900(98)80018-X; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; Kielty CM, 1996, FEBS LETT, V386, P169, DOI 10.1016/0014-5793(96)00423-1; KIELTY CM, 1994, MATRIX BIOL, V14, P191, DOI 10.1016/0945-053X(94)90008-6; Klass CM, 2000, J CELL SCI, V113, P493; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Liu WG, 1996, HUM MOL GENET, V5, P1581, DOI 10.1093/hmg/5.10.1581; Lonnqvist L, 1998, HUM MOL GENET, V7, P2039, DOI 10.1093/hmg/7.13.2039; LOW FN, 1961, ANAT RECORD, V139, P105, DOI 10.1002/ar.1091390203; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MATTAI J, 1981, BIOCHIM BIOPHYS ACTA, V677, P302; MAYNE R, 1991, BIOCHEM SOC T, V19, P868, DOI 10.1042/bst0190868; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Pfaff M, 1996, FEBS LETT, V384, P247, DOI 10.1016/0014-5793(96)00325-0; Pyeritz RE, 2000, ANNU REV MED, V51, P481, DOI 10.1146/annurev.med.51.1.481; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Sherratt MJ, 2001, MICRON, V32, P185, DOI 10.1016/S0968-4328(99)00082-7; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	48	134	137	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					36035	36042		10.1074/jbc.M104985200	http://dx.doi.org/10.1074/jbc.M104985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461921	hybrid			2022-12-25	WOS:000171109300108
J	Chakravarty, K; Leahy, P; Becard, D; Hakimi, P; Foretz, M; Ferre, P; Foufelle, F; Hanson, RW				Chakravarty, K; Leahy, P; Becard, D; Hakimi, P; Foretz, M; Ferre, P; Foufelle, F; Hanson, RW			Sterol regulatory element-binding protein-1c mimics the negative effect of insulin on phosphoenolpyruvate carboxykinase (GTP) gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; PEPCK GENE; EXPRESSION; KINASE; SREBP; CAMP; IDENTIFICATION; PROMOTER; LIVERS; GLYCERONEOGENESIS	We have assessed the potential role of sterol regulatory element-binding protein-1c (SREBP-1c) on the transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) (PEPCK-C). SREBP-1c introduced into primary hepatocytes with an adenovirus vector caused a total loss of PEPCK-C mRNA and a marked induction of fatty acid synthase mRNA that directly coincided with the appearance of SREBP-1c in the hepatocytes. It also blocked the induction of PEPCK-C mRNA by cAMP and dexamethasone in these cells. In contrast, a dominant negative form of SREBP-1c (dnSREBP-1c) stimulated the accumulation of PEPCK-C mRNA in these cells. SREBP-1c completely blocked the induction of PEPCK-C gene transcription by the catalytic subunit of protein kinase A (PKA), and increasing concentrations of dnSREBP-1c reversed the negative effect of insulin on transcription from the PEPCK-C gene promoter in WT-IR cells. The more than 10-fold induction of PKA-stimulated PEPCK-C gene transcription caused by the co-activator CBP, was also blocked by SREBP-1c. In addition, dnSREBP-1c reversed the strong negative effect of EIA and NF1 on PKA-stimulated transcription from the PEPCK-C gene promoter. An analysis of the possible site of action of SREBP-1c using stepwise truncations of the PEPCK-C gene promoter indicated that the negative effect of SREBP-1c on transcription is exerted at a site between -355 and -277. We conclude that SREBP-1c is an intermediate in the action of insulin on PEPCK-C gene transcription in the liver and acts by blocking the stimulatory effect cAMP that is mediated via an interaction with cAMP-binding protein.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Ctr Rech Biomed Cordeliers, INSERM, U465, F-75270 Paris 06, France	Case Western Reserve University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Hanson, RW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	hanson@biocserver.cwru.edu	FORETZ, Marc/O-7334-2017; Hakimi, Parvin/AAB-1643-2021; Ferré, Pascal/K-1250-2013	FORETZ, Marc/0000-0001-7017-9032; Ferré, Pascal/0000-0003-0115-7045; FOUFELLE, Fabienne/0000-0002-0752-622X	NIDDK NIH HHS [DK-25541] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BOTION LM, 1995, HORM METAB RES, V27, P310, DOI 10.1055/s-2007-979967; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cournarie F, 1999, FEBS LETT, V460, P527, DOI 10.1016/S0014-5793(99)01407-6; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Goodman RH, 2000, GENE DEV, V14, P1553; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Waltner-Law M, 2000, J BIOL CHEM, V275, P31847, DOI 10.1074/jbc.M003656200; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	50	75	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34816	34823		10.1074/jbc.M103310200	http://dx.doi.org/10.1074/jbc.M103310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11443121	hybrid			2022-12-25	WOS:000171024600064
J	Sonda, S; Ting, LM; Novak, S; Kim, H; Maher, JJ; Farese, RV; Ernst, JD				Sonda, S; Ting, LM; Novak, S; Kim, H; Maher, JJ; Farese, RV; Ernst, JD			Cholesterol esterification by host and parasite is essential for optimal proliferation of Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACYL-COENZYME-A; PARASITOPHOROUS VACUOLE MEMBRANE; RECEPTOR-MEDIATED ENDOCYTOSIS; IN-VITRO; ACYLTRANSFERASE GENE; INTRACELLULAR FATE; BETA-GALACTOSIDASE; MOLECULAR-CLONING; ESCHERICHIA-COLI	Upon host cell invasion the apicomplexan parasite Toxoplasma gondii resides in a specialized compartment termed the parasitophorous vacuole that is derived from the host cell membrane but modified by the parasite. Despite the segregation of the parasitophorous vacuole from the host endocytic network, the intravacuolar parasite has been shown to acquire cholesterol from the host cell. In order to characterize further the role of sterol metabolism in T. gondii biology, we focused our studies on the activity of acyl-CoA:cholesterol acyltransferase (ACAT), a key enzyme for maintaining the intracellular homeostasis of cholesterol through the formation of cholesterol esters. In this study, we demonstrate that ACAT and cholesterol esters play a crucial role in the optimal replication of T. gondii. Moreover, we identified ACAT activity in T. gondii that can be modulated by pharmacological ACAT inhibitors with a consequent detrimental effect on parasite replication.	Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA; Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Div Infect Dis, Bronx, NY 10461 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ernst, JD (corresponding author), Univ Calif San Francisco, Dept Med, Div Infect Dis, Box 0868, San Francisco, CA 94143 USA.			Ernst, Joel/0000-0001-9951-6207	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007810] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00215, AA07810] Funding Source: Medline; NIDDK NIH HHS [P30 DK026743, DK 26743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHBAROU A, 1991, PARASITOLOGY, V103, P321, DOI 10.1017/S0031182000059837; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BOCAN TMA, 1991, ARTERIOSCLER THROMB, V11, P1830, DOI 10.1161/01.ATV.11.6.1830; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; CESBRONDELAUW MF, 1989, P NATL ACAD SCI USA, V86, P7537, DOI 10.1073/pnas.86.19.7537; CHARIF H, 1990, EXP PARASITOL, V71, P114, DOI 10.1016/0014-4894(90)90014-4; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; DUBREMETZ JF, 1993, PARASITOL RES, V79, P402, DOI 10.1007/BF00931830; ERNST JD, 1991, J BIOL CHEM, V266, P6670; FOUSSARD F, 1991, PARASITOLOGY, V102, P367, DOI 10.1017/S0031182000064313; FOUSSARD F, 1991, PARASITOL RES, V77, P475, DOI 10.1007/BF00928412; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; JONES TC, 1972, J EXP MED, V136, P1157, DOI 10.1084/jem.136.5.1157; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; LERICHE MA, 1991, MOL BIOCHEM PARASIT, V45, P249, DOI 10.1016/0166-6851(91)90092-K; McFadden DC, 1997, ANTIMICROB AGENTS CH, V41, P1849, DOI 10.1128/AAC.41.9.1849; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; Meiner V, 1997, J LIPID RES, V38, P1928; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Mordue DG, 1999, EXP PARASITOL, V92, P87, DOI 10.1006/expr.1999.4412; Mordue DG, 1997, J IMMUNOL, V159, P4452; Prattes S, 2000, J CELL SCI, V113, P2977; Rodriguez A, 1999, ARTERIOSCL THROM VAS, V19, P2199, DOI 10.1161/01.ATV.19.9.2199; ROSS AC, 1984, J BIOL CHEM, V259, P815; Rothblat GH, 1999, J LIPID RES, V40, P781; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; Seeber F, 1996, GENE, V169, P39, DOI 10.1016/0378-1119(95)00786-5; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; Simmons T, 1997, J BIOL CHEM, V272, P25531, DOI 10.1074/jbc.272.41.25531; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; Sorensen SW, 1997, EXP PARASITOL, V85, P101, DOI 10.1006/expr.1996.4128; SussToby E, 1996, P NATL ACAD SCI USA, V93, P8413, DOI 10.1073/pnas.93.16.8413; TABAS I, 1986, J BIOL CHEM, V261, P3147; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139	49	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34434	34440		10.1074/jbc.M105025200	http://dx.doi.org/10.1074/jbc.M105025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457847	hybrid			2022-12-25	WOS:000171024600012
J	Lensch, M; Herrmann, RG; Sokolenko, A				Lensch, M; Herrmann, RG; Sokolenko, A			Identification and characterization of SppA, a novel light-inducible chloroplast protease complex associated with thylakoid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDE PEPTIDASE; HEAT-SHOCK PROTEIN; INDUCED D1-PROTEIN DEGRADATION; TERMINAL PROCESSING PROTEASE; CHLOROPHYLL A/B PROTEIN; ATP-DEPENDENT PROTEASE; SERINE-TYPE PROTEASE; II REACTION-CENTER; ESCHERICHIA-COLI; PHOTOSYSTEM-II	A new component of the chloroplast proteolytic machinery from Arabidopsis thaliana was identified as a SppA-type protease. The sequence of the mature protein, deduced from a full-length cDNA, displays 22% identity to the serine-type protease IV (SppA) from Escherichia coli and 27% identity to Synechocystis SppA1 (sll1703) but lacks the putative transmembrane spanning segments predicted from the E. coli sequence. The N-terminal sequence exhibits typical features of a cleavable chloroplast stroma-targeting sequence. The chloroplast localization of SppA was confirmed by in organello import experiments using an in vitro expression system and by immunodetection with antigen-specific antisera. Subfractionation of intact chloroplasts demonstrated that SppA is associated exclusively with thylakoid membranes, predominantly stroma lamellae, and is a part of some high molecular mass complex of about 270 kDa that exhibits proteolytic activity. Treatments with chaotropic salts and proteases showed that SppA is largely exposed to the stroma but that it behaves as an intrinsic membrane protein that may have an unusual monotopic arrangement in the thylakoids. We demonstrate that SppA is a light-inducible protease and discuss its possible involvement in the light-dependent degradation of antenna and photosystem Il complexes that both involve serine-type proteases.	Univ Munich, Inst Bot, D-80638 Munich, Germany	University of Munich	Sokolenko, A (corresponding author), Univ Munich, Inst Bot, Menzingerstr 67, D-80638 Munich, Germany.	anna@botanik.biologie.uni-muenchen.d						Adam Z, 1996, PLANT MOL BIOL, V32, P773, DOI 10.1007/BF00020476; Adamska I, 1996, EUR J BIOCHEM, V236, P591, DOI 10.1111/j.1432-1033.1996.00591.x; ADAMSKA I, 1993, J BIOL CHEM, V268, P5438; ANASTASSIOU R, 1995, PHOTOSYNTH RES, V43, P241, DOI 10.1007/BF00029937; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; Andersson B, 1997, PHYSIOL PLANTARUM, V100, P780, DOI 10.1034/j.1399-3054.1997.1000405.x; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Bolhuis A, 1999, J BIOL CHEM, V274, P24585, DOI 10.1074/jbc.274.35.24585; Chaal BK, 1998, J BIOL CHEM, V273, P689, DOI 10.1074/jbc.273.2.689; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; Eichacker LA, 1996, FEBS LETT, V395, P251, DOI 10.1016/0014-5793(96)01026-5; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; Harlow E., 1988, ANTIBODIES LAB MANUA; ICHIHARA S, 1986, J BIOL CHEM, V261, P9405; Inagaki N, 1996, PLANT MOL BIOL, V30, P39, DOI 10.1007/BF00017801; Itzhaki H, 1998, J BIOL CHEM, V273, P7094, DOI 10.1074/jbc.273.12.7094; Kanervo E, 1998, PHOTOSYNTH RES, V57, P81, DOI 10.1023/A:1006039929839; Karamyshev AL, 1998, J MOL BIOL, V277, P859, DOI 10.1006/jmbi.1997.1617; Karnauchov I, 1997, FEBS LETT, V408, P206, DOI 10.1016/S0014-5793(97)00427-4; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; KYLE DJ, 1984, BIOCHIM BIOPHYS ACTA, V765, P89, DOI 10.1016/0005-2728(84)90001-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legen J, 2001, DNA RES, V8, P53, DOI 10.1093/dnares/8.2.53; LINDAHL M, 1995, EUR J BIOCHEM, V231, P503, DOI 10.1111/j.1432-1033.1995.tb20725.x; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; Lindahl M, 2000, PLANT CELL, V12, P419, DOI 10.1105/tpc.12.3.419; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; Oelmuller R, 1996, J BIOL CHEM, V271, P21848, DOI 10.1074/jbc.271.36.21848; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; PACAUD M, 1982, J BACTERIOL, V149, P6, DOI 10.1128/JB.149.1.6-14.1982; PACAUD M, 1982, J BIOL CHEM, V257, P4333; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; Porankiewicz J, 1999, MOL MICROBIOL, V32, P449, DOI 10.1046/j.1365-2958.1999.01357.x; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; Rosenblum BB, 1997, NUCLEIC ACIDS RES, V25, P4500, DOI 10.1093/nar/25.22.4500; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sarria R, 1998, PLANT CELL, V10, P1217, DOI 10.1105/tpc.10.7.1217; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SLILATY SN, 1991, PROTEIN ENG, V4, P919, DOI 10.1093/protein/4.8.919; Sokolenko A, 1998, PLANTA, V207, P286, DOI 10.1007/s004250050485; Sokolenko A, 1997, PLANT PHYSIOL, V115, P827, DOI 10.1104/pp.115.2.827; Spetea C, 1999, P NATL ACAD SCI USA, V96, P6547, DOI 10.1073/pnas.96.11.6547; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; SUZUKI T, 1987, J BACTERIOL, V169, P2523, DOI 10.1128/jb.169.6.2523-2528.1987; Tziveleka LA, 1998, PLANT PHYSIOL, V117, P961, DOI 10.1104/pp.117.3.961; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VIRGIN I, 1991, FEBS LETT, V287, P125, DOI 10.1016/0014-5793(91)80031-W; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; YAMAMOTO Y, 1981, FEBS LETT, V133, P265, DOI 10.1016/0014-5793(81)80520-0; YAMAMOTO Y, 1995, PHOTOSYNTHESIS LIGHT, V4, P267; Yang DH, 1998, PLANT PHYSIOL, V118, P827, DOI 10.1104/pp.118.3.827	69	62	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33645	33651		10.1074/jbc.M100506200	http://dx.doi.org/10.1074/jbc.M100506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443110	hybrid			2022-12-25	WOS:000170910200049
J	Ligensa, T; Krauss, S; Demuth, D; Schumacher, R; Camonis, J; Jaques, G; Weidner, KM				Ligensa, T; Krauss, S; Demuth, D; Schumacher, R; Camonis, J; Jaques, G; Weidner, KM			A PDZ domain protein interacts with the C-terminal tail of the insulin-like growth factor-1 receptor but not with the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ADAPTER PROTEIN; CYTOPLASMIC DOMAIN; BINDING-PROTEIN; DOCKING SITE; SH2 DOMAIN; ASSOCIATION; CELLS; SUBSTRATE-1; DISTINCT		Roche Diagnost GMBH, Pharma Res, Dept Mol Biol, D-82372 Penzberg, Germany; Inst Curie, INSERM, U248, F-75248 Paris, France; Univ Marburg, Zentrum Innere Med, Hamatol Onkol Abt, D-35033 Marburg, Germany	Roche Holding; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Philipps University Marburg	Weidner, KM (corresponding author), Roche Diagnost GMBH, Pharma Res, Dept Mol Biol, Nonnenwald 2, D-82372 Penzberg, Germany.	michael.weidner@roche.com						Ahmed Z, 1999, BIOCHEM J, V341, P665, DOI 10.1042/0264-6021:3410665; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Cai HB, 1999, J NEUROSCI, V19, P6519; Choi S, 1999, ONCOGENE, V18, P5413, DOI 10.1038/sj.onc.1202917; COOKE M P, 1989, New Biologist, V1, P66; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FARIA TN, 1994, J BIOL CHEM, V269, P13922; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Germani A, 1999, MOL CELL BIOL, V19, P3798; GRANT M, 1987, J CLIN ENDOCR METAB, V65, P370, DOI 10.1210/jcem-65-2-370; GUO CH, 1995, ENDOCRINOLOGY, V136, P3031, DOI 10.1210/en.136.7.3031; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Hongo A, 1996, ONCOGENE, V12, P1231; Iwasaki Y, 1998, J NEUROCHEM, V71, P106; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LONG L, 1995, CANCER RES, V55, P1006; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Manes S, 1999, MOL CELL BIOL, V19, P3125; Marks D C, 1999, Mol Cell Biol Res Commun, V1, P144, DOI 10.1006/mcbr.1999.0123; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Morrione A, 1996, CANCER RES, V56, P3165; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326	59	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33419	33427		10.1074/jbc.M104509200	http://dx.doi.org/10.1074/jbc.M104509200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445579	hybrid			2022-12-25	WOS:000170910200019
J	Noren, NK; Niessen, CM; Gumbiner, BM; Burridge, K				Noren, NK; Niessen, CM; Gumbiner, BM; Burridge, K			Cadherin engagement regulates Rho family GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN CYTOSKELETON; MDCK CELLS; RAC; ACTIVATION; CDC42; JUNCTIONS; COMPLEX	The formation of cell-cell adherens junctions is a cadherin-mediated process associated with reorganization of the actin cytoskeleton. Because Rho family GTPases regulate actin dynamics, we investigated whether cadherin-mediated adhesion regulates the activity of RhoA, Rac1, and Cdc42. Confluent epithelial cells were found to have elevated Rac1 and Cdc42 activity but decreased RhoA activity when compared with low density cultures. Using a calcium switch method to manipulate junction assembly, we found that induction of cell-cell junctions increased Rac1 activity, and this was inhibited by E-cadherin function-blocking antibodies. Using the same calcium switch procedure, we found little effect on RhoA activity during the first hour of junction assembly. However, over several hours, RhoA activity significantly decreased. To determine whether these effects are mediated directly through cadherins or indirectly through engagement of other surface proteins downstream from junction assembly, we used a model system in which cadherin engagement is induced without cell-cell contact. For these experiments, Chinese hamster ovary cells expressing C-cadherin were plated on the extracellular domain of C-cadherin immobilized on tissue culture plates. Whereas direct cadherin engagement did not stimulate Cdc42 activity, it strongly inhibited RhoA activity but increased Rac1 activity. Deletion of the C-cadherin cytoplasmic domain abolished these effects.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Mem Sloan Kettering Canc Ctr, Cellular & Biochem & Biophys Program, New York, NY 10021 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Memorial Sloan Kettering Cancer Center	Noren, NK (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, 108 Taylor Hall,CB 7090, Chapel Hill, NC 27599 USA.		Noren Hooten, Nicole/J-5498-2019	Noren Hooten, Nicole/0000-0002-1683-3838; Niessen, Carien M./0000-0002-4892-9391	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13079] Funding Source: Medline; NIGMS NIH HHS [GM08581-05, GM29860, GM52717] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Lambert M, 2000, J CELL SCI, V113, P2207; Levenberg S, 1998, J CELL SCI, V111, P347; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; YAP AS, 1997, ANN REV CELL BIOL, V11, P549; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	33	354	356	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33305	33308		10.1074/jbc.C100306200	http://dx.doi.org/10.1074/jbc.C100306200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11457821	Green Published, hybrid			2022-12-25	WOS:000170910200004
J	Tian, HH; Kole, R				Tian, HH; Kole, R			Strong RNA splicing enhancers identified by a modified method of cycled selection interact with SR protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SITE SELECTION; EXON SEQUENCES; BINDING; U1; INVITRO; RECOGNITION; DISTINCT; ELEMENT	A modified method of cycled selection was used to characterize splicing enhancers for exon inclusion from a pool of beta -globin-based three exon/two intron pre-mRNAs with a variable number of random nucleotides incorporated in the internal exon. The pre-mRNAs generated by this method contained random sequences ranging from 0 to 18 nucleotides in length. This method was used to isolate particular splicing enhancer motifs from a previously enriched pool of extremely diverse enhancers. After four cycles of selection for mRNA containing the internal exon, a distinct enhancer motif (GACGAC...CAGCAG) was highly enriched. This motif served as strong splicing enhancers in a heterogeneous exon. We have shown here that the selected enhancer motif promotes exon inclusion through specific interaction with SRp30. We have also shown that although present in many of our selected splicing enhancers conforming to this motif, a typical purine-rich enhancer sequence is dispensable for either enhancer activity or binding with SRp30.	Duke Univ, Med Ctr, Dept Genet, Ctr Genet & Cellular Therapies, Durham, NC 27710 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Tian, HH (corresponding author), Duke Univ, Med Ctr, Dept Genet, Ctr Genet & Cellular Therapies, Box 2601, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Cote J, 1999, NUCLEIC ACIDS RES, V27, P2529, DOI 10.1093/nar/27.12.2529; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DOMINSKI Z, 1994, J BIOL CHEM, V269, P23590; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; McNally LM, 1996, J VIROL, V70, P1163, DOI 10.1128/JVI.70.2.1163-1172.1996; NEMEROFF ME, 1992, MOL CELL BIOL, V12, P962, DOI 10.1128/MCB.12.3.962; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN HC, 1995, MOL CELL BIOL, V15, P6291; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; TSANG J, 1994, BIOCHEMISTRY-US, V33, P5966, DOI 10.1021/bi00185a038; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WANG Z, 1995, RNA, V1, P21; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	41	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33833	33839		10.1074/jbc.M102957200	http://dx.doi.org/10.1074/jbc.M102957200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11454855	hybrid, Green Published			2022-12-25	WOS:000170910200074
J	Ogretmen, B; Kraveka, JM; Schady, D; Usta, J; Hannun, YA; Obeid, LM				Ogretmen, B; Kraveka, JM; Schady, D; Usta, J; Hannun, YA; Obeid, LM			Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE GENE; CATALYTIC SUBUNIT HTERT; BREAST-CANCER CELLS; C-MYC; IN-VITRO; PROTEIN PHOSPHATASE; HUMAN FIBROBLASTS; PROMOTER REGION; DNA-BINDING; TUMOR-CELLS	This study was aimed at identifying the molecular mechanisms by which ceramide inhibits telomerase activity in the A549 human lung adenocarcinoma cell line. C-6-ceramide (20 mum) caused a significant reduction of telomerase activity at 24 h as detected using the telomeric repeat amplification protocol, and this inhibition correlated with decreased telomerase reverse transcriptase (hTERT) protein. Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and Northern blot analyses showed that C-6-ceramide significantly decreased hTERT mRNA in a time-dependent manner. Electrophoretic mobility shift and supershift assays demonstrated that the binding activity of c-Myc transcription factor to the E-box sequence on the hTERT promoter was inhibited in response to C.-ceramide at 24 h. These results were also confirmed by transient transfections of A549 cells with pGL3-Basic plasmid constructs containing the functional hTERT promoter and its E-box deleted sequences cloned upstream of a luciferase reporter gene. Further analysis using RT-PCR and Western blotting showed that c-Myc protein but not its mRNA levels were decreased in response to C-6-ceramide at 24 h. The effects of ceramide on the c-Myc protein were shown to be due to a reduction in half-life via increased ubiquitination. Similar results were obtained by increased endogenous ceramide levels in response to nontoxic concentrations of daunorubicin, resulting in the inhibition of telomerase and c-Myc activities. Furthermore, the elevation of endogenous ceramide by overexpression of bacterial sphingomyelinase after transient transfections also induced the inhibition of telomerase activity with concomitant decreased hTERT and c-Myc protein levels. Taken together, these results show for the first time that both exogenons and endogenous ceramides mediate the modulation of telomerase activity via decreased hTERT promoter activity caused by rapid proteolysis of the ubiquitin-conjugated c-Myc transcription factor.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Adm, Dept Med, Charleston, SC 29425 USA; Amer Univ Beirut, Dept Biochem, Beirut, Lebanon	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; American University of Beirut	Ogretmen, B (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, POB 250779, Charleston, SC 29425 USA.			obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG012467, R01AG016583, R55AG012467] Funding Source: NIH RePORTER; NCI NIH HHS [CA87584] Funding Source: Medline; NIA NIH HHS [AG12467, AG16583] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; Devereux TR, 1999, CANCER RES, V59, P6087; Flamigni F, 1997, BIOCHEM J, V324, P783, DOI 10.1042/bj3240783; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Gunes C, 2000, CANCER RES, V60, P2116; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Horikawa I, 1999, CANCER RES, V59, P826; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Katakura Y, 1997, BIOCHEM BIOPH RES CO, V237, P313, DOI 10.1006/bbrc.1997.7104; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM MY, 1991, J BIOL CHEM, V266, P484; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kraveka JM, 2001, ANAL BIOCHEM, V291, P166, DOI 10.1006/abio.2001.5033; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; Lee JC, 1998, LUNG CANCER-J IASLC, V21, P99; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Milas M, 1998, CLIN CANCER RES, V4, P1573; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ogretmen B, 1996, CANCER LETT, V102, P91, DOI 10.1016/0304-3835(96)04170-5; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREDERGAST GC, 1991, SCIENCE, V251, P186; Ramakrishnan S, 1998, CANCER RES, V58, P622; Sarvesvaran J, 1999, CARCINOGENESIS, V20, P1649, DOI 10.1093/carcin/20.8.1649; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Taga S, 1999, ANN SURG, V230, P715, DOI 10.1097/00000658-199911000-00015; Takakura M, 1999, CANCER RES, V59, P551; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu X, 1999, BRIT J CANCER, V80, P453, DOI 10.1038/sj.bjc.6690378; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang P, 1997, J BIOL CHEM, V272, P9609	66	83	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32506	32514		10.1074/jbc.M101350200	http://dx.doi.org/10.1074/jbc.M101350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11441001	hybrid			2022-12-25	WOS:000170746000019
J	Si, XN; Zeng, Q; Ng, CH; Hong, WJ; Pallen, CJ				Si, XN; Zeng, Q; Ng, CH; Hong, WJ; Pallen, CJ			Interaction of farnesylated PRL-2, a protein-tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYLTRANSFERASE INHIBITORS; PLASMA-MEMBRANE; GERANYLGERANYLATED RHOB; ALPHA-SUBUNIT; CDNA CLONING; CELL-GROWTH; CAAX MOTIF; NUDE-MICE; RAS; TRANSFERASE	Protein of regenerating liver (PRL)-1, -2, and -3 comprise a subgroup of closely related protein-tyrosine phosphatases featuring a C-terminal prenylation motif conforming to either the consensus sequence for farnesylation, CAAX, or geranylgeranylation, CCXX. Yeast two-hybrid screening for PRL-2-interacting proteins identified the beta -subunit of Rab geranylgeranyltransferase II (beta GGT II). The specific interaction of beta GGT II with PRL-2 but not with PRL-1 or -3 occurred in yeast and HeLa cells. Chimeric PRL-1/-2 molecules were tested for their interaction with beta GGT II, and revealed that the C-terminal region of PRL-2 is required for interaction, possibly the PRL variable region immediately preceeding the CAAX box. Additionally, PRL-2 prenylation is prequisite for beta GGT II binding. As prenylated PRL-2 is localized to the early endosome, we propose that this is where the interaction occurs. PRL-2 is not a substrate for beta GGT II, as isoprenoid analysis showed that PRL-2 was solely farnesylated in vivo. Co-expression of the a-subunit (a) of GGT II, beta GGT II, and PRL-2 resulted in alpha/beta GGT II heterodimer formation and prevented PRL-2 binding. Expression of PRL-2 alone inhibited the endogenous alpha/beta GGT II activity in HeLa cells. Together, these results indicate that the binding of alpha GGT II and PRL-2 to beta GGT II is mutually exclusive, and suggest that PRL-2 may function as a regulator of GGT II activity.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Pallen, CJ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010; ZENG, Qi/E-9812-2010	Pallen, Catherine/0000-0002-3576-5295; Ng, Chee Hoe/0000-0001-8545-0497				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; Ashburner M, 1999, GENETICS, V153, P179; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Diamond RH, 1996, AM J PHYSIOL-GASTR L, V271, pG121, DOI 10.1152/ajpgi.1996.271.1.G121; Du W, 1999, MOL CELL BIOL, V19, P1831; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Johannes L, 1996, EUR J BIOCHEM, V239, P362, DOI 10.1111/j.1432-1033.1996.0362u.x; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Kong WH, 2000, AM J PHYSIOL-GASTR L, V279, pG613, DOI 10.1152/ajpgi.2000.279.3.G613; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MONTAGNA M, 1995, HUM GENET, V96, P532; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; Peters CS, 2001, J BIOL CHEM, V276, P13718, DOI 10.1074/jbc.M011562200; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Rodriguez-Concepcion M, 1999, EMBO J, V18, P1996, DOI 10.1093/emboj/18.7.1996; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Shack S, 1999, ONCOGENE, V18, P6021, DOI 10.1038/sj.onc.1203002; STERMER BA, 1994, J LIPID RES, V35, P1133; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7; Zhao ZY, 1996, GENOMICS, V35, P172, DOI 10.1006/geno.1996.0336	45	30	42	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32875	32882		10.1074/jbc.M010400200	http://dx.doi.org/10.1074/jbc.M010400200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11447212	hybrid			2022-12-25	WOS:000170746000068
J	Tsuji, M; Inanami, O; Kuwabara, M				Tsuji, M; Inanami, O; Kuwabara, M			Induction of neurite outgrowth in PC12 cells by alpha-phenyl-N-tert-butylnitron through activation of protein kinase C and the Ras-extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; INDUCED NEURONAL DIFFERENTIATION; TRK PROTOONCOGENE PRODUCT; BUTYL NITRONE PBN; MAP KINASE; TYROSINE PHOSPHORYLATION; PHORBOL ESTER; PHEOCHROMOCYTOMA CELLS; FOS EXPRESSION; EGF RECEPTOR	The spin trap alpha -phenyl-N-tert-butylnitron (PBN) is widely used for studies of the biological effects of free radicals. We previously reported the protective effects of PBN against ischemia-reperfusion injury in gerbil hippocampus by its activation of extracellular signal-regulated kinase (ERK) and suppression of both stress-activated protein kinase and p38 mitogen-activated protein kinase. In the present study, we found that PBN induced neurite outgrowth accompanied by ERK activation in PC12 cells in a dose-dependent manner. The induction of neurite outgrowth was inhibited significantly not only by transient transfection of PC12 cells with dominant negative Ras, but also by treatment with mitogen-activated protein kinase/ERK kinase inhibitor PD98059. The activation of receptor tyrosine kinase TrkA was not involved in PBN-induced neurite outgrowth. A protein kinase C (PKC) inhibitor, GF109203X, was found to inhibit neurite outgrowth. The activation of PKC epsilon was observed after PBN stimulation. PBN-induced neurite outgrowth and ERK activation were counteracted by the thiol-based antioxidant N-acetylcysteine. From these results, it was concluded that PBN induced neurite outgrowth in PC12 cells through activation of the Ras-ERK pathway and PKC.	Hokkaido Univ, Grad Sch Vet Med, Radiat Biol Lab, Dept Environm Vet Sci, Sapporo, Hokkaido 0600818, Japan	Hokkaido University	Kuwabara, M (corresponding author), Hokkaido Univ, Grad Sch Vet Med, Radiat Biol Lab, Dept Environm Vet Sci, Sapporo, Hokkaido 0600818, Japan.		Inanami, Osamu/A-5197-2012	Inanami, Osamu/0000-0001-7895-3918				Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Burry RW, 1998, J NEUROSCI RES, V53, P214, DOI 10.1002/(SICI)1097-4547(19980715)53:2<214::AID-JNR10>3.0.CO;2-6; BURSTEIN DE, 1982, BRAIN RES, V247, P115, DOI 10.1016/0006-8993(82)91033-2; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dikalov S, 1996, BIOCHEM BIOPH RES CO, V218, P616, DOI 10.1006/bbrc.1996.0109; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fontecave M, 1998, CELL MOL LIFE SCI, V54, P684, DOI 10.1007/s000180050195; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hohler B, 2000, HISTOCHEM CELL BIOL, V114, P29; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Kalyanaraman B, 1996, ANAL BIOCHEM, V241, P75, DOI 10.1006/abio.1996.0380; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kotake Y, 1999, ARCH BIOCHEM BIOPHYS, V371, P129, DOI 10.1006/abbi.1999.1417; Kruttgen A, 1998, P NATL ACAD SCI USA, V95, P9614, DOI 10.1073/pnas.95.16.9614; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lazarovici P, 1998, MOL PHARMACOL, V54, P547, DOI 10.1124/mol.54.3.547; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; Miyajima T, 1997, FREE RADICAL BIO MED, V22, P463, DOI 10.1016/S0891-5849(96)00391-7; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROIVAINEN R, 1993, BRAIN RES, V624, P85, DOI 10.1016/0006-8993(93)90063-S; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ronn LCB, 2000, J NEUROCHEM, V75, P665, DOI 10.1046/j.1471-4159.2000.0750665.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Saito K, 1998, BIOSCI BIOTECH BIOCH, V62, P275, DOI 10.1271/bbb.62.275; Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666; Sang H, 1999, ARCH BIOCHEM BIOPHYS, V363, P341, DOI 10.1006/abbi.1998.1086; Santus R, 2000, FREE RADICAL RES, V33, P383, DOI 10.1080/10715760000300921; SIGMUND O, 1990, J BIOL CHEM, V265, P2257; SINGH KR, 1994, BIOCHEMISTRY-US, V33, P542, DOI 10.1021/bi00168a020; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; Wakatsuki S, 1999, J BIOCHEM-TOKYO, V126, P1151, DOI 10.1093/oxfordjournals.jbchem.a022561; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yamashita T, 1996, FREE RADICAL BIO MED, V21, P755, DOI 10.1016/0891-5849(96)00222-5	58	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32779	32785		10.1074/jbc.M101403200	http://dx.doi.org/10.1074/jbc.M101403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438521	hybrid			2022-12-25	WOS:000170746000055
J	Yu, CF; Roshan, B; Liu, ZX; Cantley, LG				Yu, CF; Roshan, B; Liu, ZX; Cantley, LG			ERK regulates the hepatocyte growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SUBSTRATE-1 TYROSINE PHOSPHORYLATION; DOCKING PROTEIN; C-MET; PHOSPHOINOSITIDE 3-KINASE; GRB2-ASSOCIATED BINDER-1; EPITHELIAL MORPHOGENESIS; 3T3-L1 ADIPOCYTES; PHOSPHOLIPASE-C; EGF-RECEPTOR	Based on our previous observations that active ERK associates with and phosphorylates Gab1 in response to HGF, and the prediction that the ERK phosphorylation site is adjacent to one of the phosphatidylinositol 3-kinase (PI3K) SH2 binding motifs, we examined the possibility that ERK phosphorylation can regulate the Gab1/PI3K association. The HGF-mediated association of Gab1 with either full-length GST-p85 or its isolated N- or C-terminal SH2 domains was inhibited by similar to 50% in the setting of ERK inhibition, a result confirmed by coimmunoprecipitation of the native proteins. A 14-amino acid peptide encoding (YVPMTP477)-Y-472 (one of the major p85 binding sites in Gab1 and the predicted ERK phosphorylation site) was synthesized with either phosphotyrosine alone (pY), or phosphotyrosine + phosphothreonine (pYT). In both pull-down assays and competition assays, pYT demonstrated a higher affinity for p85 than did pY alone. Finally, examination of the phosphorylation state of Akt after HGF stimulation revealed that ERK inhibition resulted in a decrease in Akt activation at both 5 and 10 min. These results suggest that activated ERK can phosphorylate Gab1 in response to HGF stimulation and thereby potentiate the Gab1/PI3K association and subsequent PI3K activation.	Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, New Haven, CT 06520 USA; Miles City Hlth Care Clin, Miles City, MT 59301 USA	Yale University	Yu, CF (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, 333 Cedar St,LMP 2093, New Haven, CT 06520 USA.	chengfang.yu@yale.edu			NIDDK NIH HHS [DK54911] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054911] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; CANTLEY LG, 1994, AM J PHYSIOL, V267, P271; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Derman MP, 1996, J BIOL CHEM, V271, P4251; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Janez A, 2000, J BIOL CHEM, V275, P26870; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Lu KP, 1996, NATURE, V380, P544; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; RAUCHMAN M, 1993, AM J PHYSIOL, pF416; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; TOKER A, 1994, J BIOL CHEM, V269, P32358; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	37	46	48	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32552	32558		10.1074/jbc.M104493200	http://dx.doi.org/10.1074/jbc.M104493200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11445578	hybrid			2022-12-25	WOS:000170746000025
J	Kozaki, K; Koshikawa, K; Tatematsu, Y; Miyaishi, O; Saito, H; Hida, T; Osada, H; Takahashi, T				Kozaki, K; Koshikawa, K; Tatematsu, Y; Miyaishi, O; Saito, H; Hida, T; Osada, H; Takahashi, T			Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis	ONCOGENE			English	Article						human lung cancer; metastasis; invasion; expression profiling; inflammation	EXPRESSION; ADENOCARCINOMAS; CHEMOKINES	This study established and characterized low-metastatic revertant and parental clones of a highly metastatic human lung cancer cell line, NCI-H460-LNM35 (hereafter referred to as LNM35), Expression-profiling analysis revealed that up-regulation of various proinflammatory cytokines and angiogenic chemotactic chemokines was present in LNM35, Further, while COX-2 itself is known to be inducible in inflammation, COX-2 expression levels correlated well with the capabilities of these clones for not only in vitro motility and invasion but also in vivo metastasis, and COX-2 inhibitors were shown for the first time to reduce lung cancer metastasis in vivo. These findings suggest that lung cancer cells may mimic inflammatory cells in the process of metastasis.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Internal Med, Nagoya, Aichi 4648681, Japan; Natl Inst Longev Sci, Dept Basic Gerontol, Aichi 4748522, Japan	Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Takahashi, Takashi/I-7262-2014; Kozaki, Ken-ichi/M-6281-2014	Takahashi, Takashi/0000-0003-0615-7001; Kozaki, Ken-ichi/0000-0003-3286-819X				Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BANI MR, 1991, JNCI-J NATL CANCER I, V83, P119, DOI 10.1093/jnci/83.2.119; GAZDAR A F, 1990, Current Opinion in Oncology, V2, P321; Hida T, 1998, CANCER RES, V58, P3761; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Kozaki K, 2000, CANCER RES, V60, P2535; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; Sulzer MA, 1998, AM J RESP CRIT CARE, V157, P1319, DOI 10.1164/ajrccm.157.4.9703099; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; Wikenheiser KA, 1997, AM J RESP CELL MOL, V16, P713, DOI 10.1165/ajrcmb.16.6.9191473	20	52	60	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4228	4234		10.1038/sj.onc.1204561	http://dx.doi.org/10.1038/sj.onc.1204561			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464289				2022-12-25	WOS:000169857200013
J	Bjorkhem, I; Andersson, U; Ellis, E; Alvelius, G; Ellegard, L; Diczfalusy, U; Sjovall, J; Einarsson, C				Bjorkhem, I; Andersson, U; Ellis, E; Alvelius, G; Ellegard, L; Diczfalusy, U; Sjovall, J; Einarsson, C			From brain to bile - Evidence that conjugation and omega-hydroxylation are important for elimination of 24S-hydroxycholesterol (cerebrosterol) in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR LXR-ALPHA; CHOLESTEROL HOMEOSTASIS; 24-HYDROXYCHOLESTEROL; OXYSTEROL; METABOLISM; ACIDS; URINE; IDENTIFICATION; CIRCULATION; MECHANISM	The brain is the almost exclusive site of formation of 24S-hydroxycholesterol in man, and there is a continuous flux of this oxysterol across the blood-brain barrier into the circulation. The hepatic metabolism of 24S-hydroxycholesterol was studied here by three different approaches: incubation of tritium-labeled 24S-hydroxycholesterol with human primary hepatocytes, administration of tritium-labeled 24S-hydroxycholesterol to a human volunteer, and quantitation of free and conjugated 24S-hydroxycholesterol and its neutral metabolites in ileocecal fluid from patients with ileal fistulae. 24S-Hydroxycholesterol as well as 24R-hydroxycholesterol were converted into bile acids by human hepatocytes at a rate of about 40% of that of the normal intermediate in bile acid synthesis, 7 alpha -hydroxycholesterol. There was also a conversion of 24S-hydroxycholesterol into conjugate(s) of 5-cholestene-3 beta ,24S,27-triol at a rate similar to the that of conversion into bile acids. When administered to a human volunteer, labeled 24S-hydroxycholesterol was converted into bile acids at about half the rate of simultaneously administered labeled 7 alpha -hydroxycholesterol. Free, sulfated, and glucuronidated 24S-hydroxycholesterol and 5-cholestene-3 beta ,24,27-triol were identified in ileocecal fluid. The excretion of these steroids was about 3.5 mg/24 h, amounting to more than 50% of the total estimated flux of 24S-hydroxycholesterol from the brain. It is concluded that 24S-hydroxycholesterol is a less efficient precursor to bile acids and that about half of it is conjugated and eliminated in bile as such or as a conjugate of a 27-hydroxylated metabolite. The less efficient metabolism of 24S-hydroxycholesterol may explain the surprisingly high levels of this oxysterol in the circulation and is of interest in relation to the suggested role of 24S-hydroxycholesterol as a regulator of cholesterol homeostasis.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Gastroenterol & Hepatol, S-14186 Huddinge, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Div Clin Nutr, SE-41345 Gothenburg, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sahlgrenska University Hospital; University of Gothenburg	Bjorkhem, I (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Chem, S-14186 Huddinge, Sweden.		Ellegard, Lars H/E-6191-2016; Ellis, Ewa C S/D-5370-2014; Diczfalusy, Ulf/A-5336-2008	Ellegard, Lars H/0000-0002-2787-4336; Ellis, Ewa C S/0000-0002-3057-5337; Diczfalusy, Ulf/0000-0001-6643-3763; Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				AXELSON M, 1985, ENTEROHEPATIC CIRCUL, P249; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1983, J LIPID RES, V24, P1451; BJORKHEM I, 1969, EUR J BIOCHEM, V8, P337, DOI 10.1111/j.1432-1033.1969.tb00533.x; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; ELLEGARD L, 1991, EUR J CLIN NUTR, V45, P451; GUSTAFSSON JA, 1969, EUR J BIOCHEM, V8, P467, DOI 10.1111/j.1432-1033.1969.tb00550.x; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KARLAGANIS G, 1984, J LIPID RES, V25, P693; LI AP, 1992, J TISSUE CULT METHOD, V14, P139; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Meaney S, 2001, J LIPID RES, V42, P70; Meng LJ, 1997, J LIPID RES, V38, P926; Meng LJ, 1997, J CHROMATOGR B, V688, P11, DOI 10.1016/S0378-4347(97)88051-6; Norlin M, 2000, J LIPID RES, V41, P1629; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pikuleva IA, 1998, J BIOL CHEM, V273, P18153, DOI 10.1074/jbc.273.29.18153; PRASAD VVK, 1984, J STEROID BIOCHEM, V21, P733, DOI 10.1016/0022-4731(84)90038-4; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; SAUCIER SE, 1993, BIOCHIM BIOPHYS ACTA, V1166, P115, DOI 10.1016/0005-2760(93)90291-G; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; TINT GS, 1978, J LIPID RES, V19, P956; Zhang J, 1997, BIOCHEM J, V322, P175, DOI 10.1042/bj3220175	27	99	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37004	37010		10.1074/jbc.M103828200	http://dx.doi.org/10.1074/jbc.M103828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11463788	hybrid			2022-12-25	WOS:000171375700021
J	Tokita, K; Katsuno, T; Hocart, SJ; Coy, DH; Llinares, M; Martinez, J; Jensen, RT				Tokita, K; Katsuno, T; Hocart, SJ; Coy, DH; Llinares, M; Martinez, J; Jensen, RT			Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROKININ-1 RECEPTOR; PROTEIN-COUPLED RECEPTORS; NEUROMEDIN-B RECEPTOR; SWISS 3T3 CELLS; BOMBESIN RECEPTOR; BINDING-SITES; AGONIST-BINDING; LIGAND-BINDING; AMINO-ACID; EXTRACELLULAR DOMAINS	Few gastrointestinal hormones/neurotransmitters have high affinity peptide receptor antagonists, and little is known about the molecular basis of their selectivity or affinity. The receptor mediating the action of the mammalian bombesin (Bn) peptide, gastrin-releasing peptide receptor (GRPR), is an exception, because numerous classes of peptide antagonists are described. To investigate the molecular basis for their high affinity for the GRPR, two classes of peptide antagonists, a statine analogue, JMV594 ([D-Phe(6),Stat(13)]Bn(6-14)), and a pseudopeptide analogue, JMV641 (D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu psi (CHOH-CH2)-(CH2)(2)-CH3), were studied. Each had high affinity for the GRPR and >3,000-fold selectivity for GRPR over the closely related neuromedin B receptor (NMBR). To investigate the basis for this, we used a chimeric receptor approach to make both GRPR loss of affinity and NMBR gain of affinity chimeras and a site-directed mutagenesis approach. Chimeric or mutated receptors were transiently expressed in Balb/c 3T3. Only substitution of the fourth extracellular (EC) domain of the GRPR by the comparable NMBR domain markedly decreased the affinity for both antagonists. Substituting the fourth EC domain of NMBR into the GRPR resulted in a 300-fold gain in affinity for JMV594 and an 11-fold gain for JMV641. Each of the 11 amino acid differences between the GRPR and NMBR in this domain were exchanged. The substitutions of Thr(297) in GRPR by Pro from the comparable position in NMBR, Phe(302) by Met, and Ser(305) by Thr decreased the affinity of each antagonist. Simultaneous replacement of Thr(297), Phe(302), and Ser(305) in GRPR by the three comparable NMBR amino acids caused a 500-fold decrease in affinity for both antagonists. Replacing the comparable three amino acids in NMBR by those from GRPR caused a gain in affinity for each antagonist. Receptor modeling showed that each of these three amino acids faced inward and was within 5 Angstrom of the putative binding pocket. These results demonstrate that differences in the fourth EC domain of the mammalian Bn receptors are responsible for the selectivity of these two peptide antagonists. They demonstrate that Thr(297), Phe(302), and Ser(305) of the fourth EC domain of GRPR are the critical residues for determining GRPR selectivity and suggest that both receptor-ligand cation-pi interactions and hydrogen bonding are important for their high affinity interaction.	NIDDK, DDB, NIH, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, Peptide Res Labs, Dept Med, New Orleans, LA 70112 USA; Univ Montpellier, Fac Pharm, F-34060 Montpellier, France	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tulane University; Universite de Montpellier	Jensen, RT (corresponding author), NIDDK, DDB, NIH, Bldg 10,Rm 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov	Martinez, Jean/R-9421-2019	Martinez, Jean/0000-0002-9267-4621	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK053100, Z01DK053100] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERS HE, 1991, J NEUROSCI, V11, P846; Azay J, 1996, REGUL PEPTIDES, V65, P91, DOI 10.1016/0167-0115(96)00077-8; Bastian S, 2000, J BIOL CHEM, V275, P6107, DOI 10.1074/jbc.275.9.6107; BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BENYA RV, 1994, MOL PHARMACOL, V46, P235; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BREU V, 1995, EUR J BIOCHEM, V231, P266, DOI 10.1111/j.1432-1033.1995.0266f.x; BROWN MR, 1988, ANN NY ACAD SCI, V547, P174, DOI 10.1111/j.1749-6632.1988.tb23885.x; CASCIERI MA, 1995, MOL PHARMACOL, V47, P660; Chatzistamou I, 2000, BRIT J CANCER, V83, P906, DOI 10.1054/bjoc.2000.1374; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; COY DH, 1988, J BIOL CHEM, V263, P5056; COY DH, 1989, J BIOL CHEM, V264, P14691; deCastiglione R, 1996, CRIT REV ONCOL HEMAT, V24, P117, DOI 10.1016/1040-8428(96)00220-X; Degen LP, 2001, GASTROENTEROLOGY, V120, P361, DOI 10.1053/gast.2001.21174; DELAFUENTE M, 1993, J NEUROIMMUNOL, V48, P143, DOI 10.1016/0165-5728(93)90186-3; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Du P, 1997, PROTEIN ENG, V10, P109, DOI 10.1093/protein/10.2.109; ENDO T, 1991, J ENDOCRINOL, V131, P313, DOI 10.1677/joe.0.1310313; ERSPAMER GF, 1988, REGUL PEPTIDES, V21, P1; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FONG TM, 1992, J BIOL CHEM, V267, P25664; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; GROBLEWSKI T, 1995, BIOCHEM BIOPH RES CO, V209, P153, DOI 10.1006/bbrc.1995.1483; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HILL DJ, 1992, ENDOCRINOLOGY, V130, P2811, DOI 10.1210/en.130.5.2811; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Horwell D C, 1994, Drug Des Discov, V12, P63; HORWELL DC, 1995, TRENDS BIOTECHNOL, V13, P132; Jensen R T, 1993, Recent Results Cancer Res, V129, P87; Jensen RT, 1997, CURRENT CLINICAL TOPICS IN GASTROINTESTINAL PHARMACOLOGY, P144; JENSEN RT, 1988, ANN NY ACAD SCI, V547, P138, DOI 10.1111/j.1749-6632.1988.tb23882.x; JENSEN RT, 1991, TRENDS PHARMACOL SCI, V12, P13, DOI 10.1016/0165-6147(91)90483-9; JENSEN RT, 1994, DIAGNOSTIC THERAPEUT, P1; JI H, 1994, J BIOL CHEM, V269, P16533; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; Ladenheim EE, 1996, AM J PHYSIOL-REG I, V271, pR180, DOI 10.1152/ajpregu.1996.271.1.R180; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; LEBAN JJ, 1993, P NATL ACAD SCI USA, V90, P1922, DOI 10.1073/pnas.90.5.1922; LEE JA, 1994, BIOCHEMISTRY-US, V33, P14543, DOI 10.1021/bi00252a022; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; Llinares M, 1999, J PEPT RES, V53, P275, DOI 10.1034/j.1399-3011.1999.00028.x; MANTEY S, 1993, MOL PHARMACOL, V43, P762; MCCOY JG, 1990, PEPTIDES, V11, P595, DOI 10.1016/0196-9781(90)90064-C; Merali Z, 1999, NEUROPEPTIDES, V33, P376, DOI 10.1054/npep.1999.0054; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; OhkiHamazaki H, 1997, BRAIN RES, V762, P165, DOI 10.1016/S0006-8993(97)00380-6; Padgett KA, 1996, GENE, V168, P31, DOI 10.1016/0378-1119(95)00731-8; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; SEGLEN PO, 1989, CARCINOGENESIS, V10, P21, DOI 10.1093/carcin/10.1.21; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STUITZ CM, 1997, PROTEIN STRUCTURAL B, P447; STULTZ CM, 1993, PROTEIN SCI, V2, P305; SUNDAY ME, 1993, ANAT REC, V236, P25, DOI 10.1002/ar.1092360107; TACHE Y, 1988, ANN NY ACAD SCI, V547, P183, DOI 10.1111/j.1749-6632.1988.tb23886.x; Tokita K, 2001, J BIOL CHEM, V276, P495, DOI 10.1074/jbc.M006059200; VARGA G, 1991, PEPTIDES, V12, P493, DOI 10.1016/0196-9781(91)90090-C; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N; WANG LH, 1990, J BIOL CHEM, V265, P15695; Weigert N, 1997, REGUL PEPTIDES, V69, P33, DOI 10.1016/S0167-0115(97)02127-7; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WHITE JV, 1994, MATH BIOSCI, V119, P35, DOI 10.1016/0025-5564(94)90004-3; WILLEY JC, 1984, EXP CELL RES, V153, P245, DOI 10.1016/0014-4827(84)90466-X	75	37	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36652	36663		10.1074/jbc.M104566200	http://dx.doi.org/10.1074/jbc.M104566200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11463790	hybrid			2022-12-25	WOS:000171194500080
J	Clausen, JD; McIntosh, DB; Woolley, DG; Andersen, JP				Clausen, JD; McIntosh, DB; Woolley, DG; Andersen, JP			Importance of Thr-353 of the conserved phosphorylation loop of the sarcoplasmic reticulum Ca2+-ATPase in MgATP binding and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; FUNCTIONAL CONSEQUENCES; REACTION-MECHANISM; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; CA-2+ TRANSPORT; HIGH-EFFICIENCY; PROTEIN CHEY; CA-2+-ATPASE	Mutants in which Thr-353 of the Ca2+-ATPase of sarcoplasmic reticulum had been replaced with alanine, serine, glutamine, cysteine, valine, aspartate, or tyrosine were analyzed functionally. All the mutations severely affected MgATP binding, whereas ATP binding was close to normal in the alanine, serine, glutamine, and valine mutants. In the serine and valine mutants, the maximum rate of phosphorylation from MgATP was 8- and 600-fold lower, respectively, compared with wild type. Replacement of Mg2+ with Mn2+ led to a 1.5-fold enhancement of the maximum phosphorylation rate in the valine mutant and a 5-fold reduction in the wild type. The turnover of the phosphoenzyme formed from MgATP was slowed 1-2 orders of magnitude relative to wild type in the alanine, serine, and valine mutants, but was close to normal in the aspartate and cysteine mutants. Only the serine mutant formed a phosphoenzyme in the backward reaction with Pi, and the hydrolysis of this intermediate was greatly enhanced. Analysis of the functional changes in the mutants in the light of the recent high resolution structure of the Ca2+-ATPase crystallized without the MgATP substrate suggests that, in the native activated state of the enzyme, the side chain hydroxyl of Thr-353 participates in important interactions with nucleotide and phosphate, possibly in catalysis, whereas the main chain carbonyl of Thr-353, but not the side chain, may coordinate the catalytic Mg2+.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark; Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa	Aarhus University; University of Cape Town	Andersen, JP (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIESI M, 1981, ARCH BIOCHEM BIOPHYS, V208, P586, DOI 10.1016/0003-9861(81)90547-6; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; Hua SM, 2000, J BIOL CHEM, V275, P30546, DOI 10.1074/jbc.M003218200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Lee SY, 2001, NAT STRUCT BIOL, V8, P52; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; McIntosh DB, 2000, NAT STRUCT BIOL, V7, P532, DOI 10.1038/76735; MINTZ E, 1990, J BIOL CHEM, V265, P18762; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLESNER IW, 1986, BIOCHEM J, V239, P175, DOI 10.1042/bj2390175; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; Silversmith RE, 2001, J BIOL CHEM, V276, P18478, DOI 10.1074/jbc.M011418200; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; TAKAKUWA Y, 1982, J BIOL CHEM, V257, P426; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1989, J BIOL CHEM, V264, P21024; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; YAMADA S, 1980, J BIOL CHEM, V255, P3108	42	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35741	35750		10.1074/jbc.M105434200	http://dx.doi.org/10.1074/jbc.M105434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11438551	hybrid			2022-12-25	WOS:000171109300071
J	Sly, LM; Lopez, M; Nauseef, WM; Reiner, NE				Sly, LM; Lopez, M; Nauseef, WM; Reiner, NE			1 alpha,25-dihydroxyvitamin D-3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; VIRULENT MYCOBACTERIUM-TUBERCULOSIS; NEUTROPHIL RESPIRATORY BURST; VITAMIN-D DEFICIENCY; PROTEIN-KINASE-C; MONONUCLEAR PHAGOCYTES; 1,25-DIHYDROXYVITAMIN D-3; PERITONEAL-MACROPHAGES; CULTURED MACROPHAGES; TUBERCLE-BACILLI	We investigated the basis for the induction of monocyte antimycobacterial activity by 1 alpha ,25-dihydroxyvitamin D-3 (D-3). As expected, incubation of Mycobacterium tuberculosis-infected THP-1 cells or human peripheral blood, monocyte-derived macrophages with hormone resulted in the induction of antimycobacterial activity. This effect was significantly abrogated by pretreatment of cells with either of the phosphatidylinositol 3-kinase (PI 3-K) inhibitors, wortmannin or LY294002, or with antisense oligonueleotides to the p110 subunit of PI 3-K alpha. Cells infected with M. tuberculosis alone or incu- bated with D-3 alone produced little or undetectable amounts of superoxide anion (O . (-)(2)). In contrast, exposure of M. tuberculosis-infected cells to D-3 led to significant production of O . (-)(2) and this response was eliminated by either wortmannin, LY294002, or p110 antisense oligonucleotides. As was observed for PI 3-K inactivation, the reactive oxygen intermediate scavenger, 4-hydroxy-TEMPO, and degradative enzymes, polyethylene glycol coupled to either superoxide dismutase or catalase, also abrogated D-3-induced antimycobacterial activity. Superoxide production by THP-1 cells in response to D3 required prior infection with live Al. tuberculosis, since exposure of cells to either killed M. tuberculosis or latex beads did not prime for an oxidative burst in response to subsequent hormone treatment. Consistent with these findings, redistribution of the cytosolic oxidase components p47(phox) and p67(phox) to the membrane fraction was observed in cells incubated with live M. tuberculosis and D-3 but not in response to combined treatment with heat-killed M. tuberculosis followed by D-3. Redistribution of p47(phox) and p67(phox) to the membrane fraction in response to live M. tuberculosis and D-3 was also abrogated under conditions where PI 3-K was inactivated. Taken together, these results indicate that D-3-induced, human monocyte antimycobacterial activity is regulated by PI 3-K and mediated by the NADPH-dependent phagocyte oxidase.	Univ British Columbia, Dept Med, Div Infect Dis, Fac Med,Vancouver Hosp & Hlth Sci Ctr,Res Inst, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Med, Div Infect Dis, Fac Surg,Vancouver Hosp & Hlth Sci Ctr,Res Inst, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Microbiol & Immunol, Fac Surg, Vancouver Hosp & Hlth Sci Ctr,Res Inst, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Microbiol & Immunol, Fac Med, Vancouver Hosp & Hlth Sci Ctr,Res Inst, Vancouver, BC V5Z 3J5, Canada; Univ Iowa, Dept Med, Iowa City, IA 52246 USA; Vet Affairs Med Ctr, Iowa City, IA 52246 USA; Univ Iowa, Inflammat Program, Iowa City, IA 52246 USA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa	Reiner, NE (corresponding author), Univ British Columbia, Div Infect Dis, Rm 452D,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.	ethan@interchange.ubc.ca		Sly, Laura/0000-0002-1673-467X; Nauseef, William/0000-0003-4032-757X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034879, R56AI034879, N01AI075320] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-75320, AI-34879] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ALLEN DM, 1993, J INFECTION, V26, P83, DOI 10.1016/0163-4453(93)97000-N; Allen LAH, 1999, BLOOD, V93, P3521, DOI 10.1182/blood.V93.10.3521.410k21_3521_3530; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614; Berry DM, 1996, J BIOL CHEM, V271, P16090, DOI 10.1074/jbc.271.27.16090; BHATIA M, 1995, J BIOL CHEM, V270, P15962, DOI 10.1074/jbc.270.27.15962; BRETT SJ, 1988, CLIN EXP IMMUNOL, V71, P32; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; CHUSID MJ, 1975, JAMA-J AM MED ASSOC, V233, P1295, DOI 10.1001/jama.233.12.1295; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COHEN MS, 1986, J IMMUNOL, V136, P1049; CROWLE AJ, 1987, INFECT IMMUN, V55, P2945, DOI 10.1128/IAI.55.12.2945-2950.1987; Darwish HM, 1996, PROG NUCLEIC ACID RE, V53, P321, DOI 10.1016/S0079-6603(08)60149-X; DAVIES PDO, 1985, TUBERCLE, V66, P301, DOI 10.1016/0041-3879(85)90068-6; Day M, 1998, NEW SCI, V2127, P21; DeLeo FR, 1996, J IMMUNOL METHODS, V198, P35, DOI 10.1016/0022-1759(96)00144-5; DeLeo FR, 1999, J IMMUNOL, V163, P6732; DUNCAN R, 1982, EUR J BIOCHEM, V123, P535; DurrbaumLandmann I, 1996, INFECT IMMUN, V64, P5384; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Fukui Y, 1998, J BIOCHEM-TOKYO, V124, P1; Gniadecki R, 1998, BIOCHEM PHARMACOL, V56, P1273, DOI 10.1016/S0006-2952(98)00182-8; GONZALEZ B, 1989, PEDIATR INFECT DIS J, V8, P201; GORDON AH, 1994, INFECT IMMUN, V62, P4650, DOI 10.1128/IAI.62.10.4650-4651.1994; HINGLEYWILSON SM, 2000, MOD ASP IMMUNOBIOL, V1, P96; Hmama Z, 1998, J IMMUNOL, V161, P4882; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; Kaufmann S H, 1993, Trends Microbiol, V1, P2, DOI 10.1016/0966-842X(93)90015-J; Keane J, 2000, J IMMUNOL, V164, P2016, DOI 10.4049/jimmunol.164.4.2016; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Kremer L, 1997, EUR J IMMUNOL, V27, P2450, DOI 10.1002/eji.1830270945; KREUTZ M, 1990, BLOOD, V76, P2449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang ML, 1997, BIOCHEM SOC T, V25, pS603, DOI 10.1042/bst025s603; LIU MK, 1994, J IMMUNOL, V153, P2642; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Maiti D, 2001, J BIOL CHEM, V276, P329, DOI 10.1074/jbc.M002650200; Malloy PJ, 1999, AM J MED, V106, P355, DOI 10.1016/S0002-9343(98)00419-7; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; NANDAN D, 1995, INFECT IMMUN, V63, P4495, DOI 10.1128/IAI.63.11.4495-4500.1995; Ohga S, 1997, J INFECTION, V34, P147, DOI 10.1016/S0163-4453(97)92509-3; PHILLIPS WA, 1989, J IMMUNOL, V142, P2445; Placido R, 1997, J PATHOL, V181, P31, DOI 10.1002/(SICI)1096-9896(199701)181:1<31::AID-PATH722>3.0.CO;2-G; REINER NE, 1994, IMMUNOL TODAY, V15, P374, DOI 10.1016/0167-5699(94)90176-7; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536; Santoro P, 1998, ITAL J BIOCHEM, V47, P13; Santucci MB, 2000, J INFECT DIS, V181, P1506, DOI 10.1086/315371; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stokes RW, 1999, CELL IMMUNOL, V197, P1, DOI 10.1006/cimm.1999.1554; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655; Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6; Yang M, 1996, IMMUNOPHARM IMMUNOT, V18, P597, DOI 10.3109/08923979609052756; ZHANG DE, 1994, J IMMUNOL, V153, P3276	65	179	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35482	35493		10.1074/jbc.M102876200	http://dx.doi.org/10.1074/jbc.M102876200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461902	hybrid			2022-12-25	WOS:000171109300038
J	Brock, TG; Maydanski, E; McNish, RW; Peters-Golden, M				Brock, TG; Maydanski, E; McNish, RW; Peters-Golden, M			Co-localization of leukotriene A(4) hydrolase with 5-lipoxygenase in nuclei of alveolar macrophages and rat basophilic leukemia cells but not neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD EOSINOPHILS; ENDOTHELIAL-CELLS; POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-DISEASES; TRANSLOCATION; STIMULATION; EXPRESSION; ADHERENCE; PHOSPHORYLATION; SPECIFICITY	The synthesis of leukotriene B-4 from arachidonic acid requires the sequential action of two enzymes: 5-lipoxygenase and leukotriene A(4) hydrolase. 5-Lipoxygenase is known to be present in the cytoplasm of some leukocytes and able to accumulate in the nucleoplasm of others. In this study, we asked if leukotriene A(4) hydrolase co-localizes with 5-lipoxygenase in different types of leukocytes. Examination of rat basophilic leukemia cells by both immunocytochemistry and immunofluorescence revealed that leukotriene A(4) hydrolase, like 5-lipoxygenase, was most abundant in the nucleus, with only minor occurrences in the cytoplasm. The finding of abundant leukotriene A(4) hydrolase in the soluble nuclear fraction was substantiated by two different cell fractionation techniques. Leukotriene A(4) hydrolase was also found to accumulate together with 5-lipoxygenase in the nucleus of alveolar macrophages. This result was obtained using both in situ and ex vivo techniques. In contrast to these results, peripheral blood neutrophils contained both leukotriene A(4) hydrolase and 5-lipoxygenase exclusively in the cytoplasm. After adherence of neutrophils, 5-lipoxygenase was rapidly imported into the nucleus, whereas leukotriene A(4) hydrolase remained cytosolic. Similarly, 5-lipoxygenase was localized in the nucleus of neutrophils recruited into inflamed appendix tissue, whereas leukotriene A(4) hydrolase remained cytosolic. These results demonstrate for the first time that leukotriene A(4) hydrolase can be accumulated in the nucleus, where it co-localizes with 5-lipoxygenase. As with 5-lipoxygenase, the subcellular distribution of leukotriene A(4) hydrolase is cell-specific and dynamic, but differences in the mechanisms regulating nuclear import must exist. The degree to which these two enzymes are co-localized may influence their metabolic coupling in the conversion of arachidonic acid to leukotriene B-4.	Univ Michigan Hlth Syst, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan Hlth Syst, Dept Internal Med, Div Pulm & Crit Care Med, 6301 MSRB 3, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048141, R29AI043574] Funding Source: NIH RePORTER; NCI NIH HHS [CA46952] Funding Source: Medline; NHLBI NIH HHS [R01 HL50496] Funding Source: Medline; NIAID NIH HHS [R21 AI48141, R29 AI43574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brock TG, 1998, BIOCHEM J, V329, P519; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 1999, J IMMUNOL, V162, P1669; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Byrum RS, 1999, J IMMUNOL, V163, P6810; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CLAESSON HE, 1984, BIOCHIM BIOPHYS ACTA, V804, P52, DOI 10.1016/0167-4889(84)90098-3; Cowburn AS, 1999, J IMMUNOL, V163, P456; CUNNINGHAM FM, 1980, J PHARM PHARMACOL, V32, P377, DOI 10.1111/j.2042-7158.1980.tb12946.x; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; FEINMARK SJ, 1981, FEBS LETT, V136, P141, DOI 10.1016/0014-5793(81)81233-1; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1982, BRIT J PHARMACOL, V76, P215, DOI 10.1111/j.1476-5381.1982.tb09209.x; GIMBRONE MA, 1984, J CLIN INVEST, V74, P1552, DOI 10.1172/JCI111570; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1993, J LIPID MEDIATOR, V6, P1; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Mancuso P, 2001, INFECT IMMUN, V69, P2011, DOI 10.1128/IAI.69.4.2011-2016.2001; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; ORNING L, 1994, J BIOL CHEM, V269, P11269; PETERSGOLDEN M, 1990, J IMMUNOL, V144, P263; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Reiber DC, 2000, ARCH BIOCHEM BIOPHYS, V379, P119, DOI 10.1006/abbi.2000.1851; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; Rybina IV, 1997, J BIOL CHEM, V272, P31865, DOI 10.1074/jbc.272.50.31865; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; TONNESEN MG, 1989, J CLIN INVEST, V83, P637, DOI 10.1172/JCI113928; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889	38	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35071	35077		10.1074/jbc.M105676200	http://dx.doi.org/10.1074/jbc.M105676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11451962	hybrid			2022-12-25	WOS:000171024600096
J	Lee, H; Woodman, SE; Engelman, JA; Volonte, D; Galbiati, F; Kaufman, HL; Lublin, DM; Lisanti, MP				Lee, H; Woodman, SE; Engelman, JA; Volonte, D; Galbiati, F; Kaufman, HL; Lublin, DM; Lisanti, MP			Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase - Targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (Tyr-14)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; PLASMA-MEMBRANE DOMAINS; TRANS-GOLGI-NETWORK; SMOOTH-MUSCLE CELLS; IN-VIVO; GENE FAMILY; PROTEIN; EXPRESSION; COMPLEX; PHOSPHORYLATION	Caveolin-1 was initially identified as a phosphoprotein in Rous sarcoma virus-transformed cells. Previous studies have shown that caveolin-1 is phosphorylated on tyrosine 14 by c-Src and that lipid modification of c-Src is required for this phosphorylation event to occur in vivo. Phosphocaveolin-1 (Tyr(P)-14) localizes within caveolae near focal adhesions and, through its interaction with Grb7, augments anchorage-independent growth and epidermal growth factor-stimulated cell migration. However, the cellular factors that govern the coupling of caveolin-1 to the c-Src tyrosine kinase remain largely unknown. Here, we show that palmitoylation of caveolin-1 at a single site (Cys-156) is required for coupling caveolin-1 to the c-Src tyrosine kinase. Furthermore, upon evaluating a battery of nonreceptor and receptor tyrosine kinases, we demonstrate that the tyrosine phosphorylation of caveolin-1 by c-Src is a highly selective event. We show that Src-induced tyrosine phosphorylation of caveolin-1 can be inhibited or uncoupled by targeting dually acylated proteins (namely carcinoembryonic antigen (CEA), CD36, and the NH2-terminal domain of G alpha (i1)) to the exoplasmic, transmembrane, and cytoplasmic regions of the caveolae membrane, respectively. Conversely, when these proteins are not properly targeted or lipid-modified, the ability of c-Src to phosphorylate caveolin-1 remains unaffected. In addition, when purified caveolae preparations are preincubated with a myristoylated peptide derived from the extreme N terminus of c-Src, the tyrosine phosphorylation of caveolin-1 is abrogated; the same peptide lacking myristoylation has no inhibitory activity. However, an analogous myristoylated peptide derived from c-Yes also has no inhibitory activity. Thus, the inhibitory effects of the myristoylated c-Src peptide are both myristoylation-dependent and sequence-specific. Finally, we investigated whether phosphocaveolin-1 (Tyr(P)-14) interacts with the Src homology 2 and/or phosphotyrosine binding domains of Grb7, the only characterized downstream mediator of its function. Taken together, our data identify a series of novel lipid-lipid-based interactions as important regulatory factors for coupling caveolin-1 to the c-Src tyrosine kinase in vivo.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Surg, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL)	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382	NATIONAL CANCER INSTITUTE [K08CA079881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041297, T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [K08-CA-79881] Funding Source: Medline; NIDDK NIH HHS [T32-DK07513] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288, R01-GM-41297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAN JY, 1983, J CELL SCI, V61, P219; FORBES MS, 1979, J ULTRA MOL STRUCT R, V67, P325, DOI 10.1016/S0022-5320(79)80032-5; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; HARRIS JS, 1995, BIOCHEMISTRY-US, V34, P3851, DOI 10.1021/bi00011a043; KAMPS MP, 1988, ONCOGENE RES, V3, P105; Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Mora R, 1999, J BIOL CHEM, V274, P25708, DOI 10.1074/jbc.274.36.25708; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9	61	97	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35150	35158		10.1074/jbc.M104530200	http://dx.doi.org/10.1074/jbc.M104530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11451957	hybrid			2022-12-25	WOS:000171024600105
J	Li, WQ; Chong, HR; Guan, KL				Li, WQ; Chong, HR; Guan, KL			Function of the Rho family GTPases in Ras-stimulated Raf activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; REQUIRES PHOSPHORYLATION; PAK; IDENTIFICATION; PATHWAYS; SERINE; SITES; ORGANIZATION; COMPLEXITY	Ras plays an essential role in activation of Raf kinase which is directly responsible for activation of the MEK-ERK kinase pathway. A direct protein-protein interaction between Ras and the N-terminal regulatory domain of Raf is critical for Raf activation. However, association with Ras is not sufficient to activate Raf in vitro, indicating that Ras must activate some other biochemical events leading to activation of Raf. We have observed that RasV12Y32F and RasV12T35S mutants fail to activate Raf, yet retain the ability to interact with Raf. In this report, we showed that RasV12Y32F and RasV12T35S can cooperate with members of the Rho family GTPases to activate Raf while alone the Rho family GTPase is not effective in Raf activation. A dominant negative mutant of Rac or RhoA can block Raf activation by Ras. The effect of Rac or Cdc42 can be substituted by the Pak kinase, which is a direct downstream target of Rac/Cdc42. Furthermore, expression of a kinase inactive mutant of Pak or the N-terminal inhibitory domain of Pak1 can block the effect of Rac or Cdc42. In contrast, Pak appears to play no direct role in relaying the signal from RhoA to Raf, indicating that RhoA utilizes a different mechanism than Rac/Cdc42. Membrane-associated but not cytoplasmic Raf can be activated by Rac or RhoA. Our data support a model by which the Rho family small GTPases play an important role to mediate the activation of Raf by Ras. Ras, at least, has two distinct functions in Raf activation, recruitment of Raf to the plasma membrane by direct binding and stimulation of Raf activating kinases via the Rho family GTPases.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	Li, Weiquan/B-4897-2011	Kopera, Huira/0000-0002-8347-5567	NIGMS NIH HHS [5-T32-GM07544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; Sprague GF, 1998, GENE DEV, V12, P2817, DOI 10.1101/gad.12.18.2817; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	48	64	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34728	34737		10.1074/jbc.M103496200	http://dx.doi.org/10.1074/jbc.M103496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457831	hybrid			2022-12-25	WOS:000171024600053
J	Lin, J; Blake, M; Tang, C; Zimmer, D; Rustandi, RR; Weber, DJ; Carrier, F				Lin, J; Blake, M; Tang, C; Zimmer, D; Rustandi, RR; Weber, DJ; Carrier, F			Inhibition of p53 transcriptional activity by the S100B calcium-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; DNA-BINDING; GROWTH; DOMAIN; GENE; S100B(BETA-BETA); IDENTIFICATION; EXPRESSION; PATHWAY; FAMILY	The levels of S100 Ca2+-binding proteins correlate with the progression of certain tumors, but their role, if any, in carcinogenesis is still poorly understood. S100B protein associates with both the p53 oligomerization domain (residues 325-355) and the extreme C terminus of the tumor suppressor p53 (residues 367-392). Consequently, S100B inhibits p53 tetramer formation and p53 phosphorylation mediated by protein kinase C, on p53 C-terminal end. In this report, we show that the S100B protein decreases p53 DNA binding and transcriptional activity. The effect of S100B is reflected in vivo by a reduced accumulation of p53, p21, and MDM2 protein levels in co-transfection assays and in response to bleomycin. The S100B can still interact with p53 in the absence of p53 extreme C-terminal end and reduce the expression of p53 downstream effector genes. These data indicate that S100B does not require p53 extreme C-terminal end to inhibit p53 activity. Collectively, these findings imply that elevated levels of S100B in tumors such as astrocytomas and gliomas could inhibit p53 functions and contribute to cancer progression.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ S Alabama, Dept Pharmacol, Mobile, AL 36688 USA	University System of Maryland; University of Maryland Baltimore; University of South Alabama	Carrier, F (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St,Rm 330, Baltimore, MD 21201 USA.		Weber, David J/B-5349-2011; Carrier, France/C-3063-2008	Weber, David J/0000-0002-8824-1110; Carrier, France/0000-0002-5517-5284; Tang, Chun/0000-0001-6477-6500	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057827, R01GM058888] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058888, 1RO1GM57827-01, R01GM58888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Castets F, 1997, MOL BRAIN RES, V46, P208, DOI 10.1016/S0169-328X(96)00298-7; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; FAN K, 1982, BRAIN RES, V237, P498, DOI 10.1016/0006-8993(82)90462-0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIGORIAN M, 2001, J BIOL CHEM, V5, P5; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; OConnor PM, 1997, CANCER RES, V57, P4285; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Shieh SY, 2000, GENE DEV, V14, P289; TARUNINA M, 1993, ONCOGENE, V8, P3165; VANELDIK LJ, 1988, J BIOL CHEM, V263, P7830; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	29	112	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35037	35041		10.1074/jbc.M104379200	http://dx.doi.org/10.1074/jbc.M104379200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454863	hybrid			2022-12-25	WOS:000171024600092
J	Kobuke, K; Furukawa, Y; Sugai, M; Tanigaki, K; Ohashi, N; Matsumori, A; Sasayama, S; Honjo, T; Tashiro, K				Kobuke, K; Furukawa, Y; Sugai, M; Tanigaki, K; Ohashi, N; Matsumori, A; Sasayama, S; Honjo, T; Tashiro, K			ESDN, a novel neuropilin-like membrane protein cloned from vascular cells with the longest secretory signal sequence among eukaryotes, is up-regulated after vascular injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOTHELIAL GROWTH-FACTOR; DICTYOSTELIUM-DISCOIDEUM; CORONARY ANGIOPLASTY; GENETIC SELECTION; SEMAPHORIN-III; LIGAND-BINDING; ANGIOTENSIN-II; HIGH-AFFINITY; FACTOR-C	A novel cDNA has been isolated from primary culture of human coronary arterial cells by a signal sequence trap method, and designated ESDN ((e) under bar ndothelial and (s) under bar mooth muscle cell-(d) under bar erived (n) under bar europilin-like molecule). ESDN is a type-I transmembrane protein with the longest cleavable secretory signal sequence among eukaryotes. ESDN contains a CUB domain and a coagulation factor V/VIII homology domain, which reminds us of the structure of neuropilins. ESDN also harbors an LCCL domain, which is shared by Limulus factor C and Coch. Mouse and rat counterparts were also identified revealing > 84% amino acid identity with human ESDN. The human ESDN gene was mapped between D3S1552 and D3S1271. Northern blot analysis showed that ESDN mRNA was expressed in various tissues; particularly highly expressed in cultured vascular smooth muscle cells. The ESDN expression was up-regulated in platelet-derived growth factor-BB-stimulated vascular smooth muscle cells in vitro and neointima of the balloon-injured carotid artery in vivo. Overexpression of ESDN in 293T cells suppressed their bromodeoxyuridine uptake. In addition, ESDN protein was strongly expressed in nerve bundles in rodents. Thus, ESDN is considered to play a role in regulation of vascular cell growth and may have a wide variety of functions in other tissues including the nervous system, like neuropilins.	Kyoto Univ, Grad Sch Med, Ctr Mol Biol & Genet,Dept Med Chem, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Tashiro, K (corresponding author), Kyoto Univ, Grad Sch Med, Ctr Mol Biol & Genet,Dept Med Chem, Sakyo Ku, 53 Kawahara Cho1, Kyoto 6068507, Japan.	ktashiro@mfour.med.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016	Sugai, Manabu/0000-0003-1668-7647				Bagnard D, 1998, DEVELOPMENT, V125, P5043; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; BROWN J, 1995, HUM MOL GENET, V4, P1625, DOI 10.1093/hmg/4.9.1625; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; de Kok YJM, 1999, HUM MOL GENET, V8, P361, DOI 10.1093/hmg/8.2.361; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FISHMAN JA, 1975, LAB INVEST, V32, P339; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 2000, J BIOL CHEM, V275, P26690; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; HAMPTON JR, 1993, LANCET, V341, P573; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HAUDENSCHILD CC, 1979, LAB INVEST, V41, P407; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hughes AD, 1996, GEN PHARMACOL-VASC S, V27, P1079, DOI 10.1016/S0306-3623(96)00060-2; Jacobs KA, 1997, GENE, V198, P289, DOI 10.1016/S0378-1119(97)00330-2; Jacobs KA, 1999, METHOD ENZYMOL, V303, P468; Janero DR, 2000, FREE RADICAL BIO MED, V29, P1199, DOI 10.1016/S0891-5849(00)00434-2; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KANE WH, 1988, BLOOD, V71, P539; Kaplan F, 1999, AM J PHYSIOL-LUNG C, V276, pL1027, DOI 10.1152/ajplung.1999.276.6.L1027; KARNOVSKY MJ, 1989, ANN NY ACAD SCI, V556, P268; Kato K, 2000, BLOOD, V96, P362, DOI 10.1182/blood.V96.1.362.013k23_362_364; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lambert-Buisine C, 1998, MOL MICROBIOL, V28, P1283, DOI 10.1046/j.1365-2958.1998.00892.x; LEIMGRUBER PP, 1986, CIRCULATION, V73, P710, DOI 10.1161/01.CIR.73.4.710; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; MUTA T, 1991, J BIOL CHEM, V266, P6554; Nadadur SS, 1999, BBA-GENE STRUCT EXPR, V1489, P433, DOI 10.1016/S0167-4781(99)00189-X; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nakamura T, 1998, GENOMICS, V54, P89, DOI 10.1006/geno.1998.5571; NAKAMURA T, 1988, J BIOCHEM, V103, P370, DOI 10.1093/oxfordjournals.jbchem.a122276; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; Nakaoka T, 1997, J CLIN INVEST, V100, P2824, DOI 10.1172/JCI119830; Naylor SL, 1996, CYTOGENET CELL GENET, V72, P90, DOI 10.1159/000134170; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; OGATA RT, 1993, J IMMUNOL, V150, P2273; Ohashi N, 2000, ARTERIOSCL THROM VAS, V20, P2521, DOI 10.1161/01.ATV.20.12.2521; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; Robertson NG, 1998, NAT GENET, V20, P299, DOI 10.1038/3118; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Shimokawa H, 1996, J CLIN INVEST, V97, P769, DOI 10.1172/JCI118476; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; STEPHENS EB, 1992, VIROLOGY, V190, P569, DOI 10.1016/0042-6822(92)90894-U; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Tashiro K, 1999, METHOD ENZYMOL, V303, P479; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Thielens NM, 1999, J BIOL CHEM, V274, P9149, DOI 10.1074/jbc.274.14.9149; Todaka T, 1999, STROKE, V30, P419, DOI 10.1161/01.STR.30.2.419; Touyz RM, 2000, PHARMACOL REV, V52, P639; Trexler M, 2000, EUR J BIOCHEM, V267, P5751, DOI 10.1046/j.1432-1327.2000.01641.x; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; Yabe D, 1997, J BIOL CHEM, V272, P18232, DOI 10.1074/jbc.272.29.18232	90	52	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34105	34114		10.1074/jbc.M105293200	http://dx.doi.org/10.1074/jbc.M105293200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11447234	hybrid, Green Submitted			2022-12-25	WOS:000170910200109
J	Rubin, JS; Day, RM; Breckenridge, D; Atabey, N; Taylor, WG; Stahl, SJ; Wingfield, PT; Kaufman, JD; Schwall, R; Bottaro, DP				Rubin, JS; Day, RM; Breckenridge, D; Atabey, N; Taylor, WG; Stahl, SJ; Wingfield, PT; Kaufman, JD; Schwall, R; Bottaro, DP			Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-Met interaction facilitates signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; FACTOR ISOFORMS; PROTOONCOGENE PRODUCT; BIOLOGICAL-ACTIVITY; MITOGENIC ACTIVITY; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; NK1 FRAGMENT; DIMERIZATION; ACTIVATION	Hepatocyte growth factor (HGF) is a secreted, heparan sulfate (HS) glycosaminoglycan-binding protein that stimulates mitogenesis, motogenesis, and morphogenesis in a wide array of cellular targets, including hepatocytes and other epithelial cells, melanocytes, endothelial cells, and hematopoietic cells. NK1 is an alternative HGF isoform that consists of the N-terminal (N) and first kringle (K1) domains of full-length HGF and stimulates all major HGF biological activities. Within NK1, the N domain retains the HS binding properties of full-length HGF and mediates HS-stimulated ligand oligomerization but lacks significant mitogenic or motogenic activity. In contrast, K1 does not bind HS, but it stimulates receptor and mitogen-activated protein kinase activation, mitogenesis, and motogenesis, demonstrating that structurally distinct and dissociable domains of HGF are the primary mediators of HS binding and receptor activation. Despite the absence of HS-K1 binding, K1 mitogenic activity in HS-negative cells is strictly dependent on added soluble heparin, whereas K1-stimulated motility is not. We also found that, like the receptors for fibroblast growth factors, the HGF receptor c-Met binds tightly to HS. These data suggest that HS can facilitate HGF signaling through interaction with c-Met that is independent of HGF-HS interaction and that the recruitment of specific intracellular effectors that mediate distinct HGF responses such as mitogenesis and motility is regulated by HS-c-Met interaction at the cell surface.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NIAMS, Prot Express Lab, NIH, Bethesda, MD 20892 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Roche Holding; Genentech	Bottaro, DP (corresponding author), EntreMed Inc, 9640 Med Ctr Dr, Rockville, MD 20850 USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010; Atabey, Nese/A-1853-2018	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Atabey, Nese/0000-0003-4966-2980; Wingfield, Paul/0000-0002-9515-4752	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041115, Z01AR041115] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; FALCO JP, 1988, ONCOGENE, V2, P573; FALETTO DL, 1992, ONCOGENE, V7, P1149; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hsu YR, 1999, BIOCHEMISTRY-US, V38, P2523, DOI 10.1021/bi9821317; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; Lemmon MA, 1998, METH MOL B, V84, P49; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; MARK MR, 1992, J BIOL CHEM, V267, P26166; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Ultsch M, 1998, STRUCT FOLD DES, V6, P1383, DOI 10.1016/S0969-2126(98)00138-5; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; Wadsworth P, 1996, CELL MOTIL CYTOSKEL, V35, P225, DOI 10.1002/(SICI)1097-0169(1996)35:3<225::AID-CM5>3.0.CO;2-7; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Zhou HJ, 1999, BIOCHEMISTRY-US, V38, P14793, DOI 10.1021/bi9908641; Zhou HJ, 1998, STRUCTURE, V6, P109, DOI 10.1016/S0969-2126(98)00012-4; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	43	84	102	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32977	32983		10.1074/jbc.M105486200	http://dx.doi.org/10.1074/jbc.M105486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435444	hybrid			2022-12-25	WOS:000170746000081
J	MacGrogan, D; Alvarez, S; DeBlasio, T; Jhanwar, SC; Nimer, SD				MacGrogan, D; Alvarez, S; DeBlasio, T; Jhanwar, SC; Nimer, SD			Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines	ONCOGENE			English	Article						myeloid leukemia; 20q deletion; loss of heterozygosity	COMMONLY DELETED SEGMENT; MYELOPROLIFERATIVE DISORDERS; MYELODYSPLASTIC SYNDROMES; HEMATOLOGIC DISORDERS; DELETIONS; MAP; REGION; NEUROFIBROMATOSIS; REFINEMENT; ABNORMALITIES	Deletions of the long arm of chromosome 20 have been reported in a wide range of myeloid disorders and may reflect loss of critical tumor suppressor gene(s), To identify such candidate genes, 65 human myeloid cell line DNAs were screened by polymerase chain reaction (PCR) tor evidence of allelic loss at 39 highly polymorphic loci on the long arm of chromosome 20, A mono-allelic pattern was present in eight cell lines at multiple adjacent loci spanning the common deleted regions (CDRs) previously defined in primary hematological samples, suggesting loss of heterozygosity (LOH) at 20q, Fluorescence in situ hybridization (FISH) was then performed using a series of yeast artificial chromosomes (YACs) ordered in the CDR, and in five of eight cell lines, the deletions resulted from cytogenetically detectable whole chromosomal loss or large interstitial deletion, whereas in another cell line deletion was associated with an unbalanced translocation, LOH in the CMK megakaryocytic cell line, which has a hypotetraploid karyotype, was associated with a der(20)t(1;20)(q32;q12)x2 leading to complete deletion of the CDR, Three additional unbalanced translocations were found within the CDR and all three breakpoints mapped to a single YAC, We then used a series of P1 artificial chromosomes (PACs) spanning this YAC clone, and two PACs produced 'split' signals suggesting that they each span one of these breakpoints, Exon trapping using PACs that overlap the breakpoint regions yielded portions of six genes and evaluation of these genes as candidate tumor suppressor genes is underway. The limited information available about these genes suggests that the h-1(3)mbt gene is the most attractive candidate.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Cytogenet Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	MacGrogan, D (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.		MacGrogan, Donal/E-8604-2016; MacGrogan, Donal/AAR-7392-2021	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AATOLA M, 1992, CANCER GENET CYTOGEN, V62, P75, DOI 10.1016/0165-4608(92)90043-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asimakopoulos FA, 1996, BRIT J HAEMATOL, V95, P219; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; Bench AJ, 2000, ONCOGENE, V19, P3902, DOI 10.1038/sj.onc.1203728; Bench AJ, 1998, GENOMICS, V49, P351, DOI 10.1006/geno.1998.5231; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEWALD GW, 1995, SEMIN ONCOL, V22, P341; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; HIRAMA T, 1995, BLOOD, V86, P841; HOLLINGS PE, 1994, BLOOD, V83, P305; HOLLINGS PE, 1995, CANCER GENET CYTOGEN, V79, P32, DOI 10.1016/0165-4608(94)00068-M; KNUUTILA S, 1994, GENE CHROMOSOME CANC, V10, P95, DOI 10.1002/gcc.2870100204; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; Kurtin PJ, 1996, AM J CLIN PATHOL, V106, P680; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; MERTENS F, 1991, LEUKEMIA, V5, P214; MITELMAN F, 1995, CATALOG CHROMOSOME A; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; NACHEVA E, 1995, CANCER GENET CYTOGEN, V80, P87, DOI 10.1016/0165-4608(94)00150-A; NobenTrauth K, 1996, GENOMICS, V35, P610, DOI 10.1006/geno.1996.0408; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Paige AJW, 2000, CANCER RES, V60, P1690; ROULSTON D, 1993, BLOOD, V82, P3424; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; Stoffel M, 1996, P NATL ACAD SCI USA, V93, P3937, DOI 10.1073/pnas.93.9.3937; STRACHAN T, 1996, HUM MOL GENET, P151; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wang PW, 2000, GENOMICS, V67, P28, DOI 10.1006/geno.2000.6215; Wang PW, 1998, GENE CHROMOSOME CANC, V21, P75, DOI 10.1002/(SICI)1098-2264(199802)21:2<75::AID-GCC1>3.0.CO;2-4; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809	38	29	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4150	4160		10.1038/sj.onc.1204540	http://dx.doi.org/10.1038/sj.onc.1204540			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464281				2022-12-25	WOS:000169857200005
J	Cheng, CW; Wu, PE; Yu, JC; Huang, CS; Yue, CT; Wu, CW; Shen, CY				Cheng, CW; Wu, PE; Yu, JC; Huang, CS; Yue, CT; Wu, CW; Shen, CY			Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene	ONCOGENE			English	Article						E-cadherin; breast cancer; two-hit hypothesis; loss of heterozygosity; hypermethylation; snail	TRANSCRIPTION FACTOR SNAIL; LOW-INCIDENCE AREA; HUMAN CANCER; PROMOTER HYPERMETHYLATION; SPORADIC BREAST; GASTRIC-CANCER; ALPHA-CATENIN; GAMMA-CATENIN; BETA-CATENIN; ALLELIC LOSS	Loss of heterozygosity (LOH) allows the expression of recessive mutation in tumor suppressor genes (TSG), Therefore, on the basis of Knudson's 'two-hit' hypothesis for TSG inactivation, the detection of a high LOH frequency in a chromosomal region is considered critical for TSG localization. One of these LOH regions in breast cancer is 16q22.1, which has been suggested to reflect the involvement of E-cadherin (E-cad), a cell-tell adhesion molecule, To confirm the tumorigenic role of Ecad, 81 sporadic invasive ductal carcinomas (IDCs) of the breast were tested for the 'two hits' required to inactivate this gene. A high frequency (37.3%) of LOH was detected in 67 informative tumors, but no mutation was found. To examine the possibility that transcriptional mechanisms serve as the second hit in tumors with LOH, specific pathways, including genetic variant and hypermethylation at the promoter region and abnormal expression of positive (WT1) and negative (Snail) transcription factors, were identified. Of these, promoter hypermethylation and increased expression of Snail were found to be common (> 35%), and to be strongly associated with reduced/negative E-cad expression (P <0.05), However, unexpectedly, a significantly negative association was found between the existence of LOH and promoter hypermethylation (P <0.05), which contradicts the 'two-hit' model, Instead, since they coexisted in a high frequency of tumors, hypermethylation may work in concert with increased Snail to inactivate E-cad expression, Given that Ecad is involved in diverse mechanisms, loss of which is beneficial for tumors to invade but may also trigger apoptosis, this study suggests that maintaining a reversible mechanism, either by controlling the gene at the transcriptional level or by retaining an intact allele subsequent to LOH, might be important for E-cad in IDC and may also be common in TSGs possessing diverse functions, These findings provide clues to explain why certain TSGs identified by LOH cannot fulfil the two-hit hypothesis.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Lib Sci Lib, Taipei 115, Taiwan; Natl Taiwan Univ, Sch Publ Hlth, Grad Inst Epidemiol, Taipei 100, Taiwan; Natl Hlth Res Inst, Taipei 115, Taiwan; Shin Kong Wu Ho Su Mem Hosp, Dept Pathol, Taipei 111, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Triserv Gen Hosp, Dept Surg, Taipei 11490, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Health Research Institutes - Taiwan; Shin Kong Wu Ho Su Memorial Hospital; National Taiwan University; National Taiwan University Hospital; Tri-Service General Hospital	Shen, CY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	bmcys@ccvax.sinica.edu.tw	Shen, CY/F-6271-2010	Huang, Chiun-Sheng/0000-0002-6557-211X				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bindels EMJ, 2000, CANCER RES, V60, P177; Brown MA, 1997, ADV GENET, V36, P45, DOI 10.1016/S0065-2660(08)60307-7; Bukholm IK, 2000, J PATHOL, V190, P15; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Davidson B, 2000, J PATHOL, V192, P460; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fabre A, 1999, HUM PATHOL, V30, P661, DOI 10.1016/S0046-8177(99)90091-6; Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Healey CS, 2000, NAT GENET, V26, P362, DOI 10.1038/81691; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Huang CS, 1999, CANCER RES, V59, P4870; Ilyas M, 2000, J PATHOL, V190, P3, DOI 10.1002/(SICI)1096-9896(200001)190:1<3::AID-PATH490>3.0.CO;2-5; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ku WH, 1997, INT J CANCER, V72, P270, DOI 10.1002/(SICI)1097-0215(19970717)72:2<270::AID-IJC12>3.0.CO;2-K; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788; Li LC, 2000, CANCER RES, V60, P873; LINDBLOM A, 1993, CANCER RES, V53, P3707; Lo YL, 1998, INT J CANCER, V79, P580, DOI 10.1002/(SICI)1097-0215(19981218)79:6<580::AID-IJC5>3.0.CO;2-M; Lou MA, 1997, BRIT J CANCER, V75, P746, DOI 10.1038/bjc.1997.132; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Macleod K, 2000, CURR OPIN GENET DEV, V10, P81, DOI 10.1016/S0959-437X(99)00041-6; Nass SJ, 2000, CANCER RES, V60, P4346; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shen CY, 2000, CANCER RES, V60, P3884; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Tan DSP, 1999, J PATHOL, V189, P20, DOI 10.1002/(SICI)1096-9896(199909)189:1<20::AID-PATH394>3.0.CO;2-2; Tseng SL, 1997, GENE CHROMOSOME CANC, V20, P377; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Woodcock DM, 1999, BRIT J CANCER, V79, P251, DOI 10.1038/sj.bjc.6690041; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang PS, 1997, BRIT J CANCER, V75, P752, DOI 10.1038/bjc.1997.133	60	183	191	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3814	3823		10.1038/sj.onc.1204505	http://dx.doi.org/10.1038/sj.onc.1204505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439345				2022-12-25	WOS:000169494700007
J	Manco, G; Mandrich, L; Rossi, M				Manco, G; Mandrich, L; Rossi, M			Residues at the active site of the esterase 2 from Alicyclobacillus acidocaldarius involved in substrate specificity and catalytic activity at high temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; ARCHAEON ARCHAEOGLOBUS-FULGIDUS; ALPHA/BETA-HYDROLASE FOLD; BACILLUS-ACIDOCALDARIUS; THERMOSTABLE ESTERASE; SEQUENCE SIMILARITY; DIRECTED EVOLUTION; THERMOPHILIC ESTERASE; STRUCTURAL PROTEINS; THERMAL ADAPTATION	The recently solved three-dimensional structure of the thermophilic esterase 2 from Alicyclobacillus acidocaldarius allowed us to have a snapshot of an enzyme-sulfonate complex, which mimics the second stage of the catalytic reaction, namely the covalent acyl-enzyme intermediate. The aim of this work was to design, by structure-aided analysis and to generate by site-directed and saturation mutagenesis, EST2 variants with changed substrate specificity in the direction of preference for monoacylesters whose acyl-chain length is greater than eight carbon atoms. Positions 211 and 215 of the polypeptide chain were chosen to introduce mutations. Among five variants with single and double amino acid substitutions, three were obtained, M211S, R215L, and M211S/R215L, that changed the catalytic efficiency profile in the desired direction. Kinetic characterization of mutants and wild type showed that this change was achieved by an increase in k(cat) and a decrease in K-m values with respect to the parental enzyme. The M211S/ R215L specificity constant for p-nitrophenyl decanoate substrate was 6-fold higher than the wild type. However, variants M211T, M211S, and M211V showed strikingly increased activity as well as maximal activity with monoacylesters with four carbon atoms in the acyl chain, compared with the wild type. In the case of mutant M211T, the k(cat) for p-nitrophenyl butanoate was 2.4-fold higher. Overall, depending on the variant and on the substrate, we observed improved catalytic activity at 70 degreesC with respect to the wild type, which was a somewhat unexpected result for an enzyme with already high k(cat) values at high temperature. In addition, variants with altered specificity toward the acyl-chain length were obtained. The results were interpreted in the context of the EST2 three-dimensional structure and a proposed catalytic mechanism in which k(cat), e.g. the limiting step of the reaction, was dependent on the acyl chain length of the ester substrate.	CNR, Inst Prot Biochem & Enzymol, I-80125 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Manco, G (corresponding author), CNR, Inst Prot Biochem & Enzymol, Via G Marconi 10, I-80125 Naples, Italy.		Manco, Giuseppe/AAL-3777-2020; Mandrich, Luigi/AAH-9328-2020; MANDRICH, Luigi/L-7198-2019	Manco, Giuseppe/0000-0001-6191-3952; Mandrich, Luigi/0000-0002-0025-9544; MANDRICH, Luigi/0000-0002-0025-9544				[Anonymous], 1972, ENZYMES; Arnold FH, 1998, P NATL ACAD SCI USA, V95, P2035, DOI 10.1073/pnas.95.5.2035; Bohlke K, 2000, NUCLEIC ACIDS RES, V28, P3910, DOI 10.1093/nar/28.20.3910; BROCKERHOFF H, 1974, LIPOLYTIC ENZYMES, P194; BROWN WC, 1993, GENE, V127, P99, DOI 10.1016/0378-1119(93)90622-A; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; Cho AR, 2000, FEMS MICROBIOL LETT, V186, P235, DOI 10.1016/S0378-1097(00)00150-6; Cousin X, 1998, NUCLEIC ACIDS RES, V26, P226, DOI 10.1093/nar/26.1.226; D'Auria S, 2000, PROTEINS, V38, P351, DOI 10.1002/(SICI)1097-0134(20000301)38:4<351::AID-PROT1>3.0.CO;2-6; D'Auria S, 2000, PROTEINS, V40, P473, DOI 10.1002/1097-0134(20000815)40:3<473::AID-PROT140>3.0.CO;2-8; DAuria S, 1997, BIOCHEM J, V323, P833, DOI 10.1042/bj3230833; De Simone G, 2000, J MOL BIOL, V303, P761, DOI 10.1006/jmbi.2000.4195; DEREWENDA U, 1994, NAT STRUCT BIOL, V1, P36, DOI 10.1038/nsb0194-36; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; Georis J, 2000, PROTEIN SCI, V9, P466; Gershenson A, 2000, BIOCHEMISTRY-US, V39, P4658, DOI 10.1021/bi992473s; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GUAGLIARDI A, 1989, EUR J BIOCHEM, V183, P25, DOI 10.1111/j.1432-1033.1989.tb14891.x; Haney PJ, 1999, P NATL ACAD SCI USA, V96, P3578, DOI 10.1073/pnas.96.7.3578; HARTLEY BS, 1952, BIOCHEM J, V60, P672; HASAN FB, 1980, J BIOL CHEM, V255, P3898; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; Hirano N, 2000, BIOCHEMISTRY-US, V39, P13285, DOI 10.1021/bi0015008; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; Kim MH, 2000, BIOSCI BIOTECH BIOCH, V64, P280, DOI 10.1271/bbb.64.280; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Lebbink JHG, 2000, BIOCHEMISTRY-US, V39, P3656, DOI 10.1021/bi991483q; Manco G, 1997, PROTEIN PEPTIDE LETT, V4, P375; Manco G, 2000, ARCH BIOCHEM BIOPHYS, V373, P182, DOI 10.1006/abbi.1999.1497; Manco G, 1999, PROTEIN SCI, V8, P1789, DOI 10.1110/ps.8.9.1789; Manco G, 2000, PROTEIN ENG, V13, P197, DOI 10.1093/protein/13.3.197; Manco G, 1998, BIOCHEM J, V332, P203, DOI 10.1042/bj3320203; Manco G, 1998, PROGR BIOTECHNOL, V15, P325; McDonald JH, 1999, MOL BIOL EVOL, V16, P1785, DOI 10.1093/oxfordjournals.molbev.a026090; Merz A, 2000, BIOCHEMISTRY-US, V39, P880, DOI 10.1021/bi992333i; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Niehaus F, 1999, APPL MICROBIOL BIOT, V51, P711, DOI 10.1007/s002530051456; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Sambrook J., 2002, MOL CLONING LAB MANU; SchmidtDannert C, 1997, METHOD ENZYMOL, V284, P194; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; SOMERO GN, 1983, COMP BIOCHEM PHYS A, V76, P621, DOI 10.1016/0300-9629(83)90464-4; Spiller B, 1999, P NATL ACAD SCI USA, V96, P12305, DOI 10.1073/pnas.96.22.12305; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; Wei YY, 1999, NAT STRUCT BIOL, V6, P340; Wintrode PL, 2000, J BIOL CHEM, V275, P31635, DOI 10.1074/jbc.M004503200; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406; Zhang S, 2000, EUR J BIOCHEM, V267, P244, DOI 10.1046/j.1432-1327.2000.00988.x	58	38	40	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37482	37490		10.1074/jbc.M103017200	http://dx.doi.org/10.1074/jbc.M103017200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11447219	hybrid			2022-12-25	WOS:000171375700082
J	Faber, KN; Kram, AM; Ehrmann, M; Veenhuis, M				Faber, KN; Kram, AM; Ehrmann, M; Veenhuis, M			A novel method to determine the topology of peroxisomal membrane proteins in vivo using the tobacco etch virus protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST YARROWIA-LIPOLYTICA; HANSENULA-POLYMORPHA; SACCHAROMYCES-CEREVISIAE; PICHIA-PASTORIS; ENDOPLASMIC-RETICULUM; BIOGENESIS DISORDERS; MATRIX PROTEINS; IMPORT; GENE; COMPLEMENTATION	Most proteins essential for the biogenesis of peroxisomes (peroxins) that are identified to date are associated with or are integral components of the peroxisomal membrane. A prerequisite in elucidating their function is to determine their topology in the membrane. We have developed a novel tool to analyze the topology of peroxisomal membrane proteins in the yeast Hansenula polymorpha in vivo using the 27-kDa NIa protease subunit from the tobacco etch virus (TEVp). TEVp specifically cleaves peptides containing the consensus sequence, EXXYXQ down arrowS (tev). We show that cytosolic TEVp and peroxisomal TEVp.SKL are selectively active on soluble cytosolic and peroxisomal tev-containing proteins in vivo, respectively, without affecting the viability of the yeast cells. The tev sequence was introduced in between the primary sequence of the peroxisomal membrane proteins Pex3p or Pex10p and the reporter protein enhanced green fluorescent protein (eGFP). Co-synthesis of these functional tev-GFP tagged proteins with either cytosolic TEVp or peroxisomal TEVp.SKL revealed that the C termini of Pex3p and Pex10p are exposed to the cytosol. Additional applications of the TEV protease to study peroxisome biogenesis are discussed.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands; Cardiff Univ, Cardiff CF10 3US, S Glam, Wales	University of Groningen; Cardiff University	Veenhuis, M (corresponding author), Univ Groningen, Ctr Biol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	veenhuis@biol.rug.nl	Ehrmann, Michael/A-7307-2012	Ehrmann, Michael/0000-0002-1927-260X				Abe I, 1998, FEBS LETT, V431, P468, DOI 10.1016/S0014-5793(98)00815-1; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DOUGHERTY WG, 1991, VIROLOGY, V183, P449, DOI 10.1016/0042-6822(91)90974-G; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; FABER KN, 1994, P NATL ACAD SCI USA, V91, P12985, DOI 10.1073/pnas.91.26.12985; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; HANNAERT V, 1994, J BIOENERG BIOMEMBR, V26, P205, DOI 10.1007/BF00763069; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; KALISH JE, 1995, MOL CELL BIOL, V15, P6406; KEIZER I, 1992, FEMS MICROBIOL LETT, V93, P7, DOI 10.1016/0378-1097(92)90481-3; Kiel JAKW, 1995, FEBS LETT, V377, P434, DOI 10.1016/0014-5793(95)01385-7; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; Marshall PA, 1996, J CELL BIOL, V135, P123, DOI 10.1083/jcb.135.1.123; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Mondigler M, 1996, J BACTERIOL, V178, P2986, DOI 10.1128/jb.178.10.2986-2988.1996; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; Okumoto K, 1998, HUM MOL GENET, V7, P1399, DOI 10.1093/hmg/7.9.1399; Olsen LJ, 1998, PLANT MOL BIOL, V38, P163, DOI 10.1023/A:1006092830670; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Sagot I, 1999, FEBS LETT, V447, P53, DOI 10.1016/S0014-5793(99)00258-6; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Shulga N, 2000, J CELL BIOL, V149, P1027, DOI 10.1083/jcb.149.5.1027; Smith JJ, 1997, MOL CELL BIOL, V17, P2511, DOI 10.1128/MCB.17.5.2511; SMITH TA, 1991, P NATL ACAD SCI USA, V88, P5159, DOI 10.1073/pnas.88.12.5159; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Titorenko VI, 1998, J CELL BIOL, V142, P403, DOI 10.1083/jcb.142.2.403; van de Kamp M, 1999, ANTON LEEUW INT J G, V75, P41, DOI 10.1023/A:1001775932202; van der Klei IJ, 1997, TRENDS MICROBIOL, V5, P502, DOI 10.1016/S0966-842X(97)01156-6; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Will GK, 1999, MOL CELL BIOL, V19, P2265	60	24	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36501	36507		10.1074/jbc.M105828200	http://dx.doi.org/10.1074/jbc.M105828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11443138	Green Published, hybrid			2022-12-25	WOS:000171194500061
J	Layton, JE; Hall, NE; Connell, F; Venhorst, J; Treutlein, HR				Layton, JE; Hall, NE; Connell, F; Venhorst, J; Treutlein, HR			Identification of ligand-binding site III on the immunoglobulin-like domain of the granulocyte colony-stimulating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; COMPLEX; INTERLEUKIN-6; RECOGNITION; CYTOKINES; GP130; DETERMINANTS; DIMERIZATION	The granulocyte colony-stimulating factor receptor (G-CSF-R) forms a tetrameric complex with G-CSF containing two ligand and two receptor molecules. The N-terminal Ig-like domain of the G-CSF-R is required for receptor dimerization, but it is not known whether it binds G-CSF or interacts elsewhere in the complex. Alanine scanning mutagenesis was used to show that residues in the Ig-like domain of the G-CSF-R (Phe(75), Gln(87), and Gln(91)) interact with G-CSF. This binding site for G-CSF overlapped with the binding site of a neutralizing anti-G-CSF-R antibody. A model of the Ig-like domain showed that the binding site is very similar to the viral interleukin-6 binding site (site III) on the Ig-like domain of gp130, a related receptor. To further characterize the G-CSF-R complex, exposed and inaccessible regions of monomeric and dimeric ligand-receptor complexes were mapped with monoclonal antibodies. The results showed that the E helix of G-CSF was inaccessible in the dimeric but exposed in the monomeric complex, suggesting that this region binds to the Ig-like domain of the G-CSF-R. In addition, the N terminus of G-CSF was exposed to antibody binding in both complexes. These data establish that the dimerization interface of the complete receptor complex is different from that in the x-ray structure of a partial complex. A model of the tetrameric G-CSF.G-CSF-R complex was prepared, based on the viral interleukin-6.gp130 complex, which explains these and previously published data.	Melbourne Tumour Biol Branch, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia	Ludwig Institute for Cancer Research	Layton, JE (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Parkville, Vic 3050, Australia.		Treutlein, Herbert Rudolf/AAC-7648-2021	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Hall, Nathan/0000-0001-8942-0498; Venhorst, Jennifer/0000-0001-6383-9776				Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; CHIZZONITE R, 1991, J IMMUNOL, V147, P1548; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Haman A, 1999, J BIOL CHEM, V274, P34155, DOI 10.1074/jbc.274.48.34155; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Hammacher A, 2000, BIOCHEM J, V345, P25, DOI 10.1042/0264-6021:3450025; Haniu M, 1996, BIOCHEMISTRY-US, V35, P13040, DOI 10.1021/bi960213u; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Hoischen SH, 2000, EUR J BIOCHEM, V267, P3604, DOI 10.1046/j.1432-1327.2000.01389.x; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Horan TP, 1997, J BIOCHEM-TOKYO, V121, P370; Ishibashi M, 2001, PROTEIN EXPRES PURIF, V21, P317, DOI 10.1006/prep.2000.1381; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA N, 1990, J BIOCHEM, V107, P486, DOI 10.1093/oxfordjournals.jbchem.a123072; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurth I, 2000, J IMMUNOL, V164, P273, DOI 10.4049/jimmunol.164.1.273; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Layton JE, 1999, J BIOL CHEM, V274, P17445, DOI 10.1074/jbc.274.25.17445; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; LAYTON JE, 1991, J BIOL CHEM, V266, P23815; Layton JE, 1997, GROWTH FACTORS, V14, P117, DOI 10.3109/08977199709021515; LAYTON JE, 1997, GROW FACT CYTOK  A&B, V2, P557; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moritz RL, 2001, J BIOL CHEM, V276, P8244, DOI 10.1074/jbc.M009979200; Nicola N A, 1987, J Cell Physiol Suppl, VSuppl 5, P9; Olosz F, 2000, J BIOL CHEM, V275, P30100, DOI 10.1074/jbc.M004976200; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; WARD LD, 1994, J BIOL CHEM, V269, P23286; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; Young DC, 1997, PROTEIN SCI, V6, P1228, DOI 10.1002/pro.5560060611	45	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36779	36787		10.1074/jbc.M104787200	http://dx.doi.org/10.1074/jbc.M104787200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11468284	hybrid			2022-12-25	WOS:000171194500096
J	Choudhury, GG				Choudhury, GG			Akt serine threonine kinase regulates platelet-derived growth factor-induced DNA synthesis in glomerular mesangial cells - Regulation of c-fos and p27(kip1) gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; DEPENDENT KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBITOR P27(KIP1); INDUCED PHOSPHORYLATION; PDGF RECEPTOR; CYCLIN D1; SURVIVAL; RAS	Proliferation of mesangial cells requires platelet-derived growth factor receptor beta (PDGFR)-mediated signal transduction. We have previously shown that activation of phosphatidylinositol (PI) 3-kinase is necessary for PDGFR-induced DNA synthesis in these cells. The mechanism by which PI 3-kinase stimulates DNA synthesis is not known. One target of PI 3-kinase, Akt serine threonine kinase, regulates survival of many cells by inhibiting the actions of certain proapoptotic proteins. In this study, we investigated the role of Akt in PDGF-induced DNA synthesis in mesangial cells. PDGF increased Akt serine threonine kinase activity in a time- and PI 3-kinase-dependent manner. Expression of dominant negative Akt by adenovirus-mediated gene transfer blocked PDGF-induced activation of endogenous Akt in mesangial cells, resulting in complete inhibition of DNA synthesis. On the other hand, inhibition of MAPK attenuated PDGF-induced DNA synthesis only partially. Inhibition of Akt also attenuated PDGF-induced c-fos gene transcription, with concomitant inhibition of Elk-1-dependent transcription, indicating positive regulation of this early response gene by Akt. To further determine the role of Akt in PDGF-induced DNA Synthesis, we investigated its effect on cyclin-dependent kinase 2 (CDK2). PDGF stimulated CDK2 activity in mesangial cells and decreased the level of p27(kip1) cyclin kinase inhibitor protein. Expression of dominant negative Akt increased p27(kip1) protein and resulted in inhibition of CDK2 activity. The increase in p27(kip1) expression in response to Akt kinase inhibition was due to increased transcription of the p27(kip1) gene. p27(kip1) transcription similarly was decreased by expression of constitutively active Akt kinase in mesangial cells. These data provide the first evidence that Akt kinase regulates PDGF-induced DNA synthesis by regulating CDK2 activity and define Akt-mediated inhibition of transcription of p27(kip1) as one of the mechanisms for PDGF-induced DNA synthesis in mesangial cells.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Choudhury, GG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	choudhuryg@uthscsa.edu			NIDDK NIH HHS [DK-50190, DK-55815] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050190, R29DK050190, R01DK055815] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud Hanna E., 1995, P573; ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Arar M, 2000, J BIOL CHEM, V275, P9527, DOI 10.1074/jbc.275.13.9527; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Choudhury GG, 2000, KIDNEY INT, V57, P908, DOI 10.1046/j.1523-1755.2000.00907.x; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1998, CANCER RES, V58, P5285; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GESUALDO L, 1991, LAB INVEST, V65, P160; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; GORIN Y, 2001, IN PRESS FASEB J; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; Jefferson JA, 1999, J NEPHROL, V12, P297; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ozes ON, 1999, NATURE, V401, P82; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SINGERLAND J, 2000, J CELL PHYSL, V183, P10; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Treisman R, 1990, Semin Cancer Biol, V1, P47; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	74	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35636	35643		10.1074/jbc.M100946200	http://dx.doi.org/10.1074/jbc.M100946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11470779	hybrid			2022-12-25	WOS:000171109300058
J	Merry, CLR; Bullock, SL; Swan, DC; Backen, AC; Lyon, M; Beddington, RSP; Wilson, VA; Gallagher, JT				Merry, CLR; Bullock, SL; Swan, DC; Backen, AC; Lyon, M; Beddington, RSP; Wilson, VA; Gallagher, JT			The molecular phenotype of heparan sulfate in the Hs2st(-/-) mutant mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FACTOR BINDING; HIGH-AFFINITY; BASIC FGF; EXPRESSION; MICE; IDENTIFICATION; PROTEOGLYCANS; BIOSYNTHESIS; CLONING	Heparan sulfate (HS) is a co-receptor for a number of growth factors, morphogens, and adhesion proteins. HS biosynthetic modifications may determine the strength and outcome of HS-ligand interactions. We previously described the phenotype of mice with a gene-trap mutation in Hs2st, encoding the key HS 2-O-sulfotransferase enzyme in HS polymer modification. In contrast to the early developmental failure of embryos lacking HS, the onset of abnormalities in the Hs2st(-/-) mice occurs only after midgestation, the most dramatic being the complete failure of kidney development. Uronate 2-O-sulfates were not detected in the mutant HS, indicating a complete loss of function of Hs2st. However, the domain structure of the mutant HS is conserved, and compensatory increases in N- and 6-O-sulfation maintain the overall charge density. The apparent affinities of the mutant HS for hepatocyte growth factor/scatter factor and fibronectin were unchanged but were reduced for fibroblast growth factor-1 and -2. Surprisingly, the Hs2st(-/-) cells were able to mount an apparently normal signaling response to fibroblast growth factor-1 and -2 as well as to hepatocyte growth factor/scatter factor.	Natl Inst Med Res, MRC, London NW7 1AA, England; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Christie Hosp NHS Trust, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England	MRC National Institute for Medical Research; University of Edinburgh; Christie NHS Foundation Trust; Christie Hospital	Merry, CLR (corresponding author), Christie Hosp NHS Trust, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England.		Swan, Daniel/A-7167-2008; Wilson, Valerie A/H-5427-2011; Bullock, Simon/K-6885-2012	merry, catherine/0000-0002-3490-2809; , Val/0000-0003-4182-5159; Lyon, Malcolm/0000-0001-9575-6879; Swan, Daniel/0000-0001-8978-8129; Bullock, Simon/0000-0001-9491-4548				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HACKER U, 1997, DEVELOPMENT, V124, P2565; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Wang HM, 1997, BIOCHEM BIOPH RES CO, V235, P369, DOI 10.1006/bbrc.1997.6789; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	140	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35429	35434		10.1074/jbc.M100379200	http://dx.doi.org/10.1074/jbc.M100379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457822	hybrid			2022-12-25	WOS:000171109300031
J	Bauer, PM; Buga, GM; Fukuto, JM; Pegg, AE; Ignarro, LJ				Bauer, PM; Buga, GM; Fukuto, JM; Pegg, AE; Ignarro, LJ			Nitric oxide inhibits ornithine decarboxylase via S-nitrosylation of cysteine 360 in the active site of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; METABOLIC-FATE; POLYAMINES; TARGET; NITROSOGLUTATHIONE; TRANSNITROSATION; PROLIFERATION; GLUTATHIONE; MECHANISM; RESIDUES	Ornithine decarboxylase is the initial and rate-limiting enzyme in the polyamine biosynthetic pathway. Polyamines are found in all mammalian cells and are required for cell growth. We previously demonstrated that N-hydroxyarginine and nitric oxide inhibit tumor cell proliferation by inhibiting arginase and ornithine decarboxylase, respectively, and, therefore, polyamine synthesis. In addition, we showed that nitric oxide inhibits purified ornithine decarboxylase by S-nitrosylation. Herein we provide evidence for the chemical mechanism by which nitric oxide and S-nitrosothiols react with cysteine residues in ornithine decarboxylase to form an S-nitrosothiol(s) on the protein. The diazeniumdiolate nitric oxide donor agent 1-diethyl-2-hydroxy-2-nitroso-hydrazine acts through an oxygen-dependent mechanism leading to formation of the nitrosating agents N2O3 and/or N2O4. S-Nitrosoglutathione inhibits ornithine decarboxylase by an oxygen-independent mechanism likely by S-transnitrosation. In addition, we provide evidence for the S-nitrosylation of 4 cysteine residues per ornithine decarboxylase monomer including cysteine 360, which is critical for enzyme activity. Finally S-nitrosylated ornithine decarboxylase was isolated from intact cells treated with nitric oxide, suggesting that nitric oxide may regulate ornithine decarboxylase activity by S-nitrosylation in vivo.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ignarro, LJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	lignarro@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [R37CA018138, R01CA018138] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040922, R01HL035014] Funding Source: NIH RePORTER; NCI NIH HHS [CA 18138] Funding Source: Medline; NHLBI NIH HHS [HL 40922, HL 35014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bauer PM, 1999, BIOCHEM BIOPH RES CO, V262, P355, DOI 10.1006/bbrc.1999.1210; Blachier F, 1998, BIOCHEM PHARMACOL, V55, P1235, DOI 10.1016/S0006-2952(97)00573-X; Blachier F, 1996, FEBS LETT, V396, P315, DOI 10.1016/0014-5793(96)01122-2; Brune B, 1995, Genet Eng (N Y), V17, P149; Buga GM, 1998, AM J PHYSIOL-REG I, V275, pR1256, DOI 10.1152/ajpregu.1998.275.4.R1256; CELANO P, 1989, J BIOL CHEM, V264, P8922; Coleman C S, 1998, Methods Mol Biol, V79, P41; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DRAGO RS, 1960, J AM CHEM SOC, V82, P96, DOI 10.1021/ja01486a021; GAMET L, 1991, INT J CANCER, V47, P633, DOI 10.1002/ijc.2910470425; GARG UC, 1989, AM J PHYSIOL, V257, pF60, DOI 10.1152/ajprenal.1989.257.1.F60; GINTY DD, 1989, AM J PHYSIOL, V257, pG145, DOI 10.1152/ajpgi.1989.257.1.G145; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Ignarro LJ, 2001, P NATL ACAD SCI USA, V98, P4202, DOI 10.1073/pnas.071054698; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Liu ZG, 1998, J PHARMACOL EXP THER, V284, P526; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MAEDA H, 1994, J LEUKOCYTE BIOL, V56, P588, DOI 10.1002/jlb.56.5.588; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; MCCANN PP, 1987, BIOL SIGNIFICANCE BA; PARK JW, 1993, BIOCHEM MOL BIOL INT, V30, P885; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1995, J CELL BIOCHEM, P132; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; POULIN R, 1992, J BIOL CHEM, V267, P150; Satriano J, 1999, AM J PHYSIOL-CELL PH, V276, pC892, DOI 10.1152/ajpcell.1999.276.4.C892; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Shantz LM, 1996, CANCER RES, V56, P5136; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; WILLIAMSASHMAN HG, 1979, PERSPECT BIOL MED, V22, P421; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g	45	102	106	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34458	34464		10.1074/jbc.M105219200	http://dx.doi.org/10.1074/jbc.M105219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11461922	hybrid			2022-12-25	WOS:000171024600016
J	Garcia-Diaz, M; Bebenek, K; Kunkel, TA; Blanco, L				Garcia-Diaz, M; Bebenek, K; Kunkel, TA; Blanco, L			Identification of an intrinsic 5 '-deoxyribose-5-phosphate lyase activity in human DNA polymerase lambda - A possible role in base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC-APYRIMIDINIC ENDONUCLEASE; MAMMALIAN-CELLS; PHOSPHATE LYASE; ESCHERICHIA-COLI; BETA; MECHANISM; BINDING; FAMILY; DOMAIN; SITE	Base excision repair (BER) is a major repair pathway in eukaryotic cells responsible for repair of lesions that give rise to abasic (AP) sites in DNA. Pivotal to this process is the 5'-deoxyribose-5-phosphate lyase (dRP Iyase) activity of DNA polymerase beta (Pol beta). DNA polymerase lambda (Pol lambda) is a recently identified eukaryotic DNA polymerase that is homologous to Pol beta. We show here that human Pol lambda exhibits dRP, lyase, but not AP lyase, activity in vitro and that this activity is consistent with a beta -elimination mechanism. Accordingly, a single amino acid substitution (K310A) eliminated more than 90% of the wild-type dRP lyase activity, thus suggesting that LyS(310) of Pol lambda is the main nucleophile involved in the reaction. The dRP lyase activity of Pol A, in coordination with its polymerization activity, efficiently repaired uracil-containing DNA in an in vitro reconstituted BER reaction. These results suggest that Pol lambda may participate in "single-nucleotide" base excision repair in mammalian cells.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain; NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Blanco, L (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Campus U Autonoma Madrid,Cantoblanco, Madrid 28049, Spain.		Kunkel, Thomas A./D-5088-2019; Blanco, Luis/I-1848-2015	Kunkel, Thomas A./0000-0002-9900-1788; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065070, Z01ES065070] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Intano GW, 2001, NUCLEIC ACIDS RES, V29, P1366, DOI 10.1093/nar/29.6.1366; KANE CM, 1981, J BIOL CHEM, V256, P3405; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Maciejewski MW, 2000, J MOL BIOL, V296, P229, DOI 10.1006/jmbi.1999.3455; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Nagasawa K, 2000, J BIOL CHEM, V275, P31233, DOI 10.1074/jbc.M004263200; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Ochs K, 1999, CANCER RES, V59, P1544; Oliveros M, 1997, J BIOL CHEM, V272, P30899, DOI 10.1074/jbc.272.49.30899; Olsen AK, 2001, NUCLEIC ACIDS RES, V29, P1781, DOI 10.1093/nar/29.8.1781; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Piersen CE, 2000, MUTAT RES-DNA REPAIR, V459, P43, DOI 10.1016/S0921-8777(99)00054-3; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Pinz KG, 2000, J BIOL CHEM, V275, P12509, DOI 10.1074/jbc.275.17.12509; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; Podlutsky AJ, 2001, BIOCHEMISTRY-US, V40, P809, DOI 10.1021/bi002064s; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SOBEL RW, 1996, NATURE, V379, P183; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	47	209	215	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34659	34663		10.1074/jbc.M106336200	http://dx.doi.org/10.1074/jbc.M106336200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457865	hybrid			2022-12-25	WOS:000171024600043
J	Mukhopadhyay, R; Rosen, BP				Mukhopadhyay, R; Rosen, BP			The phosphatase C(X)(5)R motif is required for catalytic activity of the Saccharomyces cerevisiae Acr2p arsenate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; ARSC PROTEIN; DOMAIN; PURIFICATION; EXPRESSION; RESISTANCE; MECHANISM; CYSTEINE; BINDING	Acr2p detoxifies arsenate by reduction to arsenite in Saccharomyces cerevisiae. This reductase has been shown to require glutathione and glutaredoxin, suggesting that thiol chemistry might be involved in the reaction mechanism. Acr2p has a HC(X)(5)R motif, the signature sequence of the phosphate binding loop of the dual-specific and protein-tyrosine phosphatase family. In Acr2p these are residues His-75, Cys-76, and Arg-82, respectively. Acr2p, has another sequence, (HCR)-H-118, that is absent in phosphatases. Acr2p also has a third cysteine residue at position 106. Each of these cysteine residues was changed individually to serine residues, whereas the histidine and arginine residues were altered to alanines. Cells of Escherichia coli heterologously expressing the majority of the mutant ACR2 genes retained wild type resistance to arsenate, and the purified altered Acr2p proteins exhibited normal enzymatic properties. In contrast, cells expressing either the C76S or R82A mutations lost resistance to arsenate, and the purified proteins were inactive. These results suggest that Acr2p utilizes a phosphatase-like Cys(X)(5)Arg motif as the catalytic center to reduce arsenate to arsenite.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu		Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bhattacharjee H, 1999, SYMP SOC GEN MICROBI, V58, P58; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7288, DOI 10.1021/bi00189a033; GUAN KL, 1991, J BIOL CHEM, V266, P17026; JI GY, 1992, P NATL ACAD SCI USA, V89, P9474, DOI 10.1073/pnas.89.20.9474; JI GY, 1994, BIOCHEMISTRY-US, V33, P7294, DOI 10.1021/bi00189a034; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JY, 1995, BIOCHEMISTRY-US, V34, P13472, DOI 10.1021/bi00041a026; Messens J, 1999, BIOCHEMISTRY-US, V38, P16857, DOI 10.1021/bi9911841; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; Mukhopadhyay R, 1998, FEMS MICROBIOL LETT, V168, P127, DOI 10.1016/S0378-1097(98)00430-3; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; POT DA, 1991, J BIOL CHEM, V266, P19688; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; WISHART MJ, 1995, J BIOL CHEM, V270, P26782, DOI 10.1074/jbc.270.45.26782; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; Xu X, 1996, J BIOL CHEM, V271, P5118; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	30	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34738	34742		10.1074/jbc.M103354200	http://dx.doi.org/10.1074/jbc.M103354200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11461905	hybrid			2022-12-25	WOS:000171024600054
J	Reusch, HP; Zimmermann, S; Schaefer, M; Paul, M; Moelling, K				Reusch, HP; Zimmermann, S; Schaefer, M; Paul, M; Moelling, K			Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GTPASE-ACTIVATING PROTEIN; PHOSPHOINOSITIDE 3-KINASE-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATION; SIGNALING PATHWAYS; BETA-RECEPTOR; SH2 DOMAINS; FACTOR-I; PHOSPHORYLATION	The stimulation of platelet-derived growth factor (PDGF) receptors shifts vascular smooth muscle (VSM) cells toward a more proliferative phenotype. Thrombin activates the same signaling cascades in VSM cells, namely the Ras/Raf/MEK/ERK and the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathways. Nonetheless, thrombin was not mitogenic, but rather increased the expression of the smooth muscle-specific myosin heavy chain (SM-MHC) indicative of an in vitro re-differentiation of VSM cells. A more detailed analysis of the temporal pattern and relative signal intensities revealed marked differences. The strong and biphasic phosphorylation of ERK1/2 in response to thrombin correlated with its ability to increase the activity of the SM-MHC: promoter whereas Akt was only partially and transiently phosphorylated. By contrast, PDGF, a potent mitogen in VSM cells, induced a short-lived ERK1/2 phosphorylation but a complete and sustained phosphorylation of Akt. The phosphorylated form of Akt physically interacted with Raf. Moreover, Akt phosphorylated Raf at Ser(259), resulting in a reduced Raf kinase activity and a termination of MEK and ERK1/2 phosphorylation. Disruption of the PI 3-kinase signaling prevented the PDGF-induced Akt and Raf-Ser(259) phosphorylation. Under these conditions, PDGF elicited a more sustained MEK and ERK phosphorylation and increased SM-MHC promoter activity. Consistently, in cells that express dominant negative Akt, PDGF increased SM MHC promoter activity. Furthermore, expression of constitutively active Akt blocked the thrombin-stimulated SM-MHC promoter activity. Thus, we present evidence that the balance and cross-regulation between the PI 3-kinase/Akt and Ras/Raf/MEK signaling cascades determine the temporal pattern of ERK1/2 phosphorylation and may thereby guide the phenotypic modulation of vascular smooth muscle cells.	Free Univ Berlin, Inst Klin Pharmakol & Toxikol, D-14195 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	Free University of Berlin; Free University of Berlin; University of Zurich	Reusch, HP (corresponding author), Free Univ Berlin, Inst Klin Pharmakol & Toxikol, Garystr 5, D-14195 Berlin, Germany.		Paul, Martin/K-5425-2015					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; ARNQVIST HJ, 1995, METABOLISM, V44, P58, DOI 10.1016/0026-0495(95)90222-8; Bang OS, 2001, J CELL SCI, V114, P81; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DELAFONTAINE P, 1991, HYPERTENSION, V18, P742, DOI 10.1161/01.HYP.18.6.742; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hayashi K, 1998, J BIOL CHEM, V273, P28860, DOI 10.1074/jbc.273.44.28860; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; IVES HE, 1978, J EXP MED, V148, P1400, DOI 10.1084/jem.148.5.1400; JACKSON CL, 1993, ARTERIOSCLER THROMB, V13, P1218, DOI 10.1161/01.ATV.13.8.1218; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Schlesinger TK, 1999, BIOCHEM J, V344, P519, DOI 10.1042/0264-6021:3440519; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shi CS, 2001, J BIOL CHEM, V276, P24293, DOI 10.1074/jbc.M100089200; Soderholm H, 2001, CELL SIGNAL, V13, P95, DOI 10.1016/S0898-6568(00)00141-8; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	56	133	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33630	33637		10.1074/jbc.M105322200	http://dx.doi.org/10.1074/jbc.M105322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443134	hybrid			2022-12-25	WOS:000170910200047
J	Richter, K; Muschler, P; Hainzl, O; Buchner, J				Richter, K; Muschler, P; Hainzl, O; Buchner, J			Coordinated ATP hydrolysis by the Hsp90 dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; DNA-GYRASE; IN-VIVO; SIGNAL-TRANSDUCTION; COMPLEX-FORMATION; BINDING; DIMERIZATION; RECEPTOR	The Hsp90 dimer is a molecular chaperone with an unusual N-terminal ATP binding site. The structure of the ATP binding site makes it a member of a new class of ATP-hydrolyzing enzymes, known as the GHKL family. While for some of the family members structural data on conformational changes occurring after ATP binding are available, these are still lacking for Hsp90. Here we set out to investigate the correlation between dimerization and ATP hydrolysis by Hsp90. The dimerization constant of wild type (WT) Hsp90 was determined to be 60 nm. Heterodimers of WT Hsp90 with fragments lacking the ATP binding domain form readily and exhibit dimerization constants similar to full-length Hsp90. However, the ATPase activity of these heterodimers was significantly lower than that of the wild type protein, indicating cooperative interactions in the N-terminal part of the protein that lead to the activation of the ATPase activity. To further address the contribution of the N-terminal domains to the ATPase activity, we used an Hsp90 point mutant that is unable to bind ATP. Since heterodimers between the WT protein and this mutant showed WT ATPase activity, this mutant, although unable to bind ATP, still has the ability to stimulate the activity in its WT partner domain. Thus, contact formation between the N-terminal domains might not depend on ATP bound to both domains. Together, these results suggest a mechanism for coupling the hydrolysis of ATP to the opening-closing movement of the Hsp90 molecular chaperone.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BARTHOLM.P, 1973, EUR J BIOCHEM, V39, P101, DOI 10.1111/j.1432-1033.1973.tb03108.x; Berr K, 2000, EUR J BIOCHEM, V267, P5413, DOI 10.1046/j.1432-1327.2000.01598.x; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GRENERT JP, 1997, J BIOL CHEM, V272, P23882; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JAKOB U, 1995, J BIOL CHEM, V270, P14412, DOI 10.1074/jbc.270.24.14412; Jibard N, 1999, EXP CELL RES, V247, P461, DOI 10.1006/excr.1998.4375; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kampranis SC, 1998, J BIOL CHEM, V273, P26305, DOI 10.1074/jbc.273.41.26305; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	40	156	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33689	33696		10.1074/jbc.M103832200	http://dx.doi.org/10.1074/jbc.M103832200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11441008	hybrid			2022-12-25	WOS:000170910200055
J	Schuur, ER; Loktev, AV; Sharma, M; Sun, ZJ; Roth, RA; Weigel, RJ				Schuur, ER; Loktev, AV; Sharma, M; Sun, ZJ; Roth, RA; Weigel, RJ			Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; BINDING PROTEIN-1 PROMOTER; PAX3-FKHR FUSION PROTEIN; FACTOR FKHR; ALVEOLAR RHABDOMYOSARCOMA; NUCLEAR EXCLUSION; REGULATED GENES; ER-BETA; PHOSPHORYLATION; EXPRESSION	Estrogen acting through the estrogen receptor (ER) is able to regulate cell growth and differentiation of a variety of normal tissues and hormone-responsive tumors. Ligand-activated DR binds DNA and transactivates the promoters of estrogen target genes. In addition, ligand-activated ER can interact with other factors to alter the physiology and growth of cells. Using a yeast two-hybrid screen, we have identified an interaction between ER alpha and the proapoptotic forkhead transcription factor FKHR. The ER alpha -FKHR interaction depends on beta -estradiol and is reduced significantly in the absence of hormone or the presence of Tamoxifen. A glutathione S-transferase pull-down assay was used to confirm the interaction and localized two interaction sites, one in the forkhead domain and a second in the carboxyl terminus. The FKHR interaction was specific to ER alpha and was not detected with other ligand-activated steroid receptors. The related family members, FKHRL1 and AFX, also bound to ER alpha in the presence of beta -estradiol. FKHR augmented ER alpha transactivation through an estrogen response element. Conversely, ER alpha repressed FKHR-mediated transactivation through an insulin response sequence, and cell cycle arrest induced by FKHRL1 in MCF7 cells was abrogated by estradiol. These results suggest a novel mechanism of estrogen action that involves regulation of the proapoptotic forkhead transcription factors.	Stanford Univ, Sch Med, Dept Surg & Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Weigel, RJ (corresponding author), Stanford Univ, Sch Med, Dept Surg & Mol Pharmacol, Med Sch Lab Surge Room P214,1201 Welch Rd, Stanford, CA 94305 USA.			Weigel, Ronald/0000-0002-9249-0793	NATIONAL CANCER INSTITUTE [R29CA070297, R01CA087767, R01CA077350, R01CA070297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061002, R56DK061002] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA070297-06A1, R01 CA070297-10, R01 CA070297-07, R01 CA070297-11A2, R01 CA070297-09, R29 CA070297-05S1, R01 CA070297, R01 CA087767-03, R01 CA77350, R01 CA087767-01A2, R01 CA070297-08, R29 CA070297, R01 CA087767-05, R01 CA087767, R29 CA070297-05, R01 CA087767-02, R01 CA087767-04, R01 CA070297-12, R29 CA070297-03] Funding Source: Medline; NIDDK NIH HHS [R01 DK061002-03, R01 DK061002-02, R01 DK061002-04, R56 DK061002-06A1, R01 DK061002-05, R01 DK061002-01A1, R56 DK061002, R01 DK061002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BIRGE SJ, 2001, POSTGRAD MED, P11; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAVAILLES V, 1991, BIOCHEM BIOPH RES CO, V174, P816, DOI 10.1016/0006-291X(91)91491-T; Chu YW, 1999, CYTOMETRY, V36, P333, DOI 10.1002/(SICI)1097-0320(19990801)36:4<333::AID-CYTO8>3.0.CO;2-F; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; DAVIS RJ, 1994, CANCER RES, V54, P2869; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Ghosh MG, 2000, CANCER RES, V60, P6367; GOTTLIEB S, 1994, GENETICS, V137, P107; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kim H, 2001, NEUROSCI LETT, V302, P58, DOI 10.1016/S0304-3940(01)01659-7; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SUBLETT JE, 1995, ONCOGENE, V11, P545; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	43	124	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33554	33560		10.1074/jbc.M105555200	http://dx.doi.org/10.1074/jbc.M105555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435445	hybrid			2022-12-25	WOS:000170910200037
J	Purbhoo, MA; Boulter, JM; Price, DA; Vuidepot, AL; Hourigan, CS; Dunbar, PR; Olson, K; Dawson, SJ; Phillips, RE; Jakobsen, BK; Bell, JI; Sewell, AK				Purbhoo, MA; Boulter, JM; Price, DA; Vuidepot, AL; Hourigan, CS; Dunbar, PR; Olson, K; Dawson, SJ; Phillips, RE; Jakobsen, BK; Bell, JI; Sewell, AK			The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; LYMPHOCYTE ACTIVATION; SIGNAL-TRANSDUCTION; LIGAND INTERACTIONS; BETA-CHEMOKINES; PEPTIDE; TCR; AGONIST; BINDING; CTL	Recognition of antigen by cytotoxic T lymphocytes (CTL) is determined by interaction of both the T cell receptor and its CD8 coreceptor with peptide-major histocompatibility complex (pMHC) class I molecules. We examine the relative roles of these receptors in the activation of human CTL using mutations in MHC class I designed to diminish or abrogate the CD8/pMHC interaction. We use surface plasmon resonance to determine that point mutation of the alpha3 loop of HLA A2 abrogates the CD8/pMHC interaction without affecting the affinity of the T cell receptor/pMHC interaction. Antigen-presenting cells expressing HLA A2 which does not bind to CD8 fail to activate CTL at any peptide concentration. Comparison of CTL activation by targets expressing HLA A2 with normal, abrogated, or diminished CD8/pMHC interaction show that the CD8/pMHC interaction enhances sensitivity to antigen. We determine that the biochemical basis for coreceptor dependence is the activation of the 23-kDa phosphoform of the CD3 zeta chain. In addition, we produce mutant MHC class I multimers that specifically stain but do not activate CTL. These reagents may prove useful in circumventing undesirable activation-related perturbation of intracellular processes when pMHC multimers are used to phenotype antigen-specific CD8+ lymphocytes.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Avidex Ltd, Abingdon OX14 4RX, Oxon, England	University of Oxford	Sewell, AK (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Level 7, Oxford OX3 9DU, England.	andy.sewell@ndm.ox.ac.uk	Sewell, Andrew/GPT-4220-2022; Hourigan, Christopher S/C-7588-2012; Price, David A/C-7876-2013; Dunbar, Rod/C-2570-2012	Sewell, Andrew/0000-0003-3194-3135; Hourigan, Christopher S/0000-0002-6189-8067; Price, David A/0000-0001-9416-2737; Dunbar, Rod/0000-0001-9626-2600				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bodinier M, 2000, NAT MED, V6, P707, DOI 10.1038/76292; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; Chen WS, 2000, METH MOL B, V156, P245; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Dunbar PR, 1999, J IMMUNOL, V162, P6959; Gao GF, 2000, J BIOL CHEM, V275, P15232, DOI 10.1074/jbc.275.20.15232; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Gao GF, 2000, IMMUNOL TODAY, V21, P630, DOI 10.1016/S0167-5699(00)01750-3; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Goulder PJR, 1997, J EXP MED, V185, P1423, DOI 10.1084/jem.185.8.1423; Hamad ARA, 1998, J EXP MED, V188, P1633, DOI 10.1084/jem.188.9.1633; Hampl J, 1997, IMMUNITY, V7, P379, DOI 10.1016/S1074-7613(00)80359-3; Howard MC, 1999, IMMUNOL TODAY, V20, P161, DOI 10.1016/S0167-5699(98)01390-5; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Kersh EN, 1999, J EXP MED, V190, P1627, DOI 10.1084/jem.190.11.1627; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; Kessler B, 1998, J IMMUNOL, V161, P6939; KWANLIM GE, 1993, INT IMMUNOL, V5, P1219, DOI 10.1093/intimm/5.10.1219; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Purbhoo MA, 1998, P NATL ACAD SCI USA, V95, P4527, DOI 10.1073/pnas.95.8.4527; Sewell AK, 1997, EUR J IMMUNOL, V27, P2323, DOI 10.1002/eji.1830270929; Sewell AK, 1999, NAT MED, V5, P399, DOI 10.1038/7398; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Sousa CRE, 1996, J EXP MED, V184, P149, DOI 10.1084/jem.184.1.149; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WALLS EV, 1987, LYMPHOCYTES PRACTICA, P149; WAYS JP, 1983, J IMMUNOL, V131, P856; Willcox BE, 1999, PROTEIN SCI, V8, P2418; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Xu XN, 2001, IMMUNITY, V14, P591, DOI 10.1016/S1074-7613(01)00133-9; YOON ST, 1994, IMMUNITY, V1, P563	45	119	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32786	32792		10.1074/jbc.M102498200	http://dx.doi.org/10.1074/jbc.M102498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438524	hybrid			2022-12-25	WOS:000170746000056
J	Dashti, SR; Efimova, T; Eckert, RL				Dashti, SR; Efimova, T; Eckert, RL			MEK6 regulates human involucrin gene expression via a p38 alpha- and p38 delta-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JUN NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; MAP-KINASE; PROMOTER ACTIVITY; PHORBOL ESTER; CROSS-LINKING; SUBSTRATE-SPECIFICITY; SELECTIVE ACTIVATION; CELLULAR STRESSES	A signaling cascade that includes protein kinase C (PKC), Ras, and MEKK1 regulates involucrin (hINV) gene expression in epidermal keratinocytes (Efimova, T., LaCelle, P., Welter, J. F., and Eckert, R. L. (1998) J. Biol. Chem. 273, 24387-24395 and Efimova, T., and Eckert, R. L. (2000) J. Biol. Chem. 275, 1601-1607). Because signal transfer downstream of MEKK1 may involve several MAPK kinases (MEKs), it is important to evaluate the regulatory role of each MEK isoform. In the present study we evaluate the role of MEK6 in transmitting this signal. Constitutively active MEK6 (caMEK6) increases hINV promoter activity and increases endogenous hINV levels. The caMER6-dependent increase in gene expression is inhibited by the p38 MAPK inhibitor, SB203580, and is associated with a marked increase in p38 alpha MAPK activity; JNK and ERK kinases are not activated. In addition, hINV gene expression is inhibited by dominant-negative p38 alpha and increased when caMEK6 and p38 alpha are co-expressed. caMEK6 also activates p38 delta, but p38 delta inhibits the caMEK6-dependent activation. These results suggest that MEK6 increases hINV gene expression by regulating the balance between activation of p38 alpha, which increases gene expression, and p38 delta, which decreases gene expression.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.			Efimova, Tatiana/0000-0002-9869-1545; Dashti, Shervin/0000-0002-1552-9738				Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Balasubramanian S, 2000, BIOCHEM J, V350, P791, DOI 10.1042/0264-6021:3500791; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FEI YJ, 1995, BIOTECHNIQUES, V18, P984; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Green H, 1980, Harvey Lect, V74, P101; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	43	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27214	27220		10.1074/jbc.M100465200	http://dx.doi.org/10.1074/jbc.M100465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11454875	hybrid			2022-12-25	WOS:000169966900066
J	Oya, M; Ohtsubo, M; Takayanagi, A; Tachibana, M; Shimizu, N; Murai, M				Oya, M; Ohtsubo, M; Takayanagi, A; Tachibana, M; Shimizu, N; Murai, M			Constitutive activation of nuclear factor-kappa B prevents TRAIL-induced apoptosis in renal cancer cells	ONCOGENE			English	Article						renal cell carcinoma; TRAIL; NF-kappa B; I kappa B alpha; apoptosis	APO2 LIGAND; FAMILY; EXPRESSION; CARCINOMA; DEATH; RECEPTORS; MEMBER; INDUCTION	TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors, However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the that some cancer cell line! -induced apoptosis despite absence of decoy receptors and the presence of death receptors, This suggested the existance of an inhibitory factor. We herein showed that NF-kappaB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-kappaB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of Ik-Ba, a specific inhibitor of NF-kappaB, in TRAIL-sensitive cell lines with a low NF-kappaB activity result in constitutive activation of NF-kappaB and resistance to TRAIL-induced apoptosis, Adenoviral expression of a stable form of I kappaB alpha in the TRAIL-resistant cell lines induced apoptosis, These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-KB activity and TRAIL-resistant RCC with constitutively activated NF kappaB, In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-kappaB appears to be a promising therapy.	Keio Univ, Sch Med, Dept Urol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University	Oya, M (corresponding author), Keio Univ, Sch Med, Dept Urol, Shinjuku Ku, Tokyo 1608582, Japan.		Oya, Mototsugu/K-8592-2013					Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Frank S, 1999, BIOCHEM BIOPH RES CO, V257, P454, DOI 10.1006/bbrc.1999.0493; Gilmore TD, 1996, ONCOGENE, V13, P1367; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Keane MM, 1999, CANCER RES, V59, P734; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Mulders P, 1997, CANCER RES, V57, P5189; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; RITCHIE AWS, 1983, SEMIN ONCOL, V10, P390; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; Tachibana M, 2000, CELL TISSUE RES, V301, P353, DOI 10.1007/s004410000235; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang XD, 1999, CANCER RES, V59, P2747	29	129	140	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3888	3896		10.1038/sj.onc.1204525	http://dx.doi.org/10.1038/sj.onc.1204525			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439352				2022-12-25	WOS:000169494700014
J	de Magalhaes, JC; Andrade, AA; Silva, PNG; Sousa, LP; Ropert, C; Ferreira, PCP; Kroon, EG; Gazzinelli, RT; Bonjardim, CA				de Magalhaes, JC; Andrade, AA; Silva, PNG; Sousa, LP; Ropert, C; Ferreira, PCP; Kroon, EG; Gazzinelli, RT; Bonjardim, CA			A mitogenic signal triggered at an early stage of vaccinia virus infection - Implication of MEK/ERK and protein kinase in a virus multiplication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; C-FOS PROMOTER; HUMAN PAPILLOMAVIRUS TYPE-11; TRANSCRIPTION FACTOR AP-1; HTLV-I TAX; NEURITE OUTGROWTH; CELL-DEATH; S6 KINASE; ACTIVATION; GENE	Vaccinia virus (VV) triggers a mitogenic signal at an early stage of infection. VV-induced proto-oncogene c-fos mRNA with kinetics paralleling that stimulated by serum. The VV virokine, or vaccinia virus growth factor (VGF), was not crucial for c-fos induction because it was observed upon infection with the virokine-minus mutant VV (VGF(-)). Furthermore, c-fos expression did not require infectious virus particles, as it occurred even with UV-inactivated VV and was equally induced by the different multiplicities of infection, i.e. 1.0, 5.0, and 25.0. c-fos expression was preceded by W-induced DNA binding activity and was mediated via the cis-acting elements serum response element (SRE), activating protein-1 (AP-1), and CAMP-response element (CRE). VV activated the protein kinases p42MAPK/ERK2 and p44MAPK/ERK1 and the transcription factor ATF1 in a time-dependent manner with kinetics that paralleled those of W-stimulated DNA-protein complex formation. The mitogenic signal transmission pathways leading to c-fos activation upon VV infection were apparently mediated by the protein kinases MEK, ERK, and PKA. This assumption was based on the findings that: 1) c-fos transcript was down-regulated; 2) the SRE, AP-1, and CRE binding activities were significantly reduced; and 3) the activation of p42MAPK/ERK2, p44MAPK/ERK1, and ATF1 were drastically affected when the viral infections were carried out in the presence of specific protein kinase inhibitor. Moreover, the mutant VV (VGF-) was also able to activate ERK1/2. It is noteworthy that virus multiplication was equally affected by the same kinase inhibitors. Taken together, our data provide evidence that the early mitogenic signal triggered upon VV infection relies upon the activation of the protein kinases MEK, ERK, and PKA, which are needed for both signal transduction and virus multiplication.	Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Grp Transducao Sinal Lab Virus, BR-31270901 Belo Horizonte, MG, Brazil; Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil; Fdn Oswaldo Cruz, Ctr Pesquisas Rene Rachou, BR-31270901 Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Fundacao Oswaldo Cruz	Bonjardim, CA (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Grp Transducao Sinal Lab Virus, Av Antonio Carlos 6627 Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.		Kroon, Erna Geessien/B-3631-2015; Andrade, Anderson/H-4022-2012; Kroon, Erna/V-5444-2019; Andrade, Anderson Assunção/ABG-9691-2021; Ropert, Catherine/AAL-7302-2021; Ropert, Catherine/G-2463-2012; Bonjardim, Claudio A/J-2601-2014	Kroon, Erna Geessien/0000-0003-2721-3826; Andrade, Anderson/0000-0001-9569-6503; Andrade, Anderson Assunção/0000-0001-9569-6503; Ropert, Catherine/0000-0002-3077-714X; Gazzinelli, Ricardo/0000-0003-2427-7699				Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BOLDOGH I, 1990, SCIENCE, V247, P561, DOI 10.1126/science.1689075; Bonjardim CA, 1997, BRAZ J MED BIOL RES, V30, P41, DOI 10.1590/S0100-879X1997000100007; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; BULLER RML, 1988, VIROLOGY, V164, P182, DOI 10.1016/0042-6822(88)90635-6; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURNET FM, 1936, SPECIAL REPORT SERIE, V220, P4; CAHILL MA, 1995, SIGNALING UPTAKE C F; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Chen SL, 1996, J VIROL, V70, P8558, DOI 10.1128/JVI.70.12.8558-8563.1996; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chow JYC, 2000, J BIOL CHEM, V275, P21169, DOI 10.1074/jbc.M002160200; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER GM, 1995, ONCOGENES, P255; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; da Fonseca FG, 1999, VIRUS GENES, V18, P151, DOI 10.1023/A:1008072720217; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Fanidi A, 1998, J VIROL, V72, P8392, DOI 10.1128/JVI.72.10.8392-8395.1998; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLEMINGTON E, 1990, J VIROL, V64, P4549, DOI 10.1128/JVI.64.9.4549-4552.1990; Fonseca FG, 1998, ARCH VIROL, V143, P1171, DOI 10.1007/s007050050365; Franco GR, 1999, PLACENTA, V20, P189, DOI 10.1053/plac.1998.0364; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJII M, 1995, ONCOGENE, V11, P7; FUJITA M, 1995, ONCOGENE, V11, P15; Gibellini D, 1997, BLOOD, V89, P1654, DOI 10.1182/blood.V89.5.1654.1654_1654_1664; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GREEN DA, 1984, MON NOT R ASTRON SOC, V211, P433, DOI 10.1093/mnras/211.2.433; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; Hirasawa K, 1999, J VIROL, V73, P8541, DOI 10.1128/JVI.73.10.8541-8548.1999; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOKLIK WK, 1962, VIROLOGY, V18, P9, DOI 10.1016/0042-6822(62)90172-1; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KIMURA K, 1994, J BIOL CHEM, V269, P18961; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LIN SQ, 1994, P NATL ACAD SCI USA, V91, P7653, DOI 10.1073/pnas.91.16.7653; Locker JK, 2000, MOL BIOL CELL, V11, P2497, DOI 10.1091/mbc.11.7.2497; MARK R, 1988, J VIROL, V62, P866; MOSS B, 1990, VIROLOGY, V2, P2079; MOSS B, 1996, VIROLOGY, V2, P2637; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NATOLI G, 1995, J HEPATOL, V22, P14; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Oliveira JG, 1997, PLACENTA, V18, P163, DOI 10.1016/S0143-4004(97)90088-6; Rosl F, 1997, J VIROL, V71, P362; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SU ZZ, 1995, ONCOGENE, V10, P2037; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tomas-Zuber M, 2000, J BIOL CHEM, V275, P23549, DOI 10.1074/jbc.M002586200; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	63	82	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38353	38360		10.1074/jbc.M100183200	http://dx.doi.org/10.1074/jbc.M100183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11459835	hybrid			2022-12-25	WOS:000171673200006
J	Kaytor, EN; Zhu, JL; Pao, CI; Phillips, LS				Kaytor, EN; Zhu, JL; Pao, CI; Phillips, LS			Insulin-responsive nuclear proteins facilitate Sp1 interactions with the insulin-like growth factor-I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Joint Meeting of the American-Society-for-Biochemistry-and-Molecular-Biology/American-Society-for-Pharmacology-and-Experimental-Therapeutics	JUN, 2000	BOSTON, MA	Amer Soc Biochem & Molec Biol, Amer Soc Pharmacol & Exptl Therapeut			STREPTOZOTOCIN-DIABETIC RATS; ELEMENT-BINDING PROTEIN; FATTY-ACID SYNTHASE; TRANSCRIPTIONAL REGULATION; DNA-BINDING; IGF-I; STEROL REGULATION; RECEPTOR GENE; PROMOTER; LIVER	The diabetes-induced decrease in insulin-like growth factor-I transcription appears to be mediated by footprint region V in exon 1. Since region V contains both an Sp1 site and an AT-rich element that recognizes an insulin-responsive binding protein (IRBP), we tested the hypothesis that Sp1 interactions are facilitated by an IRBP. Binding of nuclear extracts to region V probes was reduced by mutational or chemical interference with the AT-rich element. Blocking the AT site also reduced interactions of Sp1 with region V in vitro and blunted transactivation of region V reporter constructs by Sp1 in vivo. Sp1 binding was enhanced by small quantities of hepatic nuclear extracts, but enhancement was reduced by the AT mutation and abolished by a 5-base pair insertion between the AT-rich and GC-rich sites, and transactivation by Sp1 in vivo was diminished by inserting bases between the AT-rich and GC-rich elements. However, treating cells with insulin increased the ability of nuclear extracts to enhance Sp1 binding. These findings indicate that the presence of the AT-rich element is essential for the actions of Sp1 in vitro and in vivo, and the combination of both spacing requirements and insulin responsiveness suggests that IRBP may interact directly with Sp1.	Emory Univ, Sch Med, Div Endocrinol, Atlanta, GA 30322 USA	Emory University	Phillips, LS (corresponding author), Emory Univ, Sch Med, Div Endocrinol, 1639 Pierce Dr,1301 WMRB, Atlanta, GA 30322 USA.	medlsp@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033475, F32DK009922] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07298, DK-09922, DK-33475] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BLUNDELL TL, 1983, FED PROC, V42, P2592; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Brown MA, 1999, J ANIM SCI, V77, P25; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GOLDSTEIN S, 1988, MOL ENDOCRINOL, V2, P1093, DOI 10.1210/mend-2-11-1093; GRESH N, 1984, MOL PHARMACOL, V25, P452; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Izumi M, 2000, BBA-GENE STRUCT EXPR, V1492, P341, DOI 10.1016/S0167-4781(00)00117-2; Kaytor EN, 2001, ENDOCRINOLOGY, V142, P1041, DOI 10.1210/en.142.3.1041; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Krishna AY, 1996, J ENDOCRINOL, V151, P215, DOI 10.1677/joe.0.1510215; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; PAO CI, 1995, J BIOL CHEM, V270, P24917, DOI 10.1074/jbc.270.42.24917; PAO CI, 1993, MOL ENDOCRINOL, V7, P1561, DOI 10.1210/me.7.12.1561; PAO CI, 1992, MOL ENDOCRINOL, V6, P969, DOI 10.1210/me.6.6.969; ROBERTS CT, 1986, J BIOL CHEM, V261, P25; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWANDER JC, 1983, ENDOCRINOLOGY, V113, P297, DOI 10.1210/endo-113-1-297; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Zhu JL, 2000, MOL CELL ENDOCRINOL, V164, P205, DOI 10.1016/S0303-7207(00)00207-0; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	38	14	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36896	36901		10.1074/jbc.M104035200	http://dx.doi.org/10.1074/jbc.M104035200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	478YD	11457835	hybrid			2022-12-25	WOS:000171375700007
J	Miyazaki, T; Ohura, T; Kobayashi, M; Shigematsu, Y; Yamaguchi, S; Suzuki, Y; Hata, I; Aoki, Y; Yang, X; Minjares, C; Haruta, I; Uto, H; Ito, Y; Muller, U				Miyazaki, T; Ohura, T; Kobayashi, M; Shigematsu, Y; Yamaguchi, S; Suzuki, Y; Hata, I; Aoki, Y; Yang, X; Minjares, C; Haruta, I; Uto, H; Ito, Y; Muller, U			Fatal propionic acidemia in mice lacking Propionyl-CoA carboxylase and its rescue by postnatal, liver-specific supplementation via a transgene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-THERAPY; FATTY-ACIDS; OXIDATION; DEFICIENCY; EXPRESSION; MUTATIONS; HEPATITIS; VECTORS; PROTEIN; RNA	Propionic acidemia (PA) is an inborn error of metabolism caused by the genetic deficiency of propionyl-CoA carboxylase (PCC). By disrupting the a-subunit gene of PCC, we created a mouse model of PA (PCCA(-/-)), which died in 24-36 h after birth due to accelerated ketoacidosis. A postnatal, liver-specific PCC expression via a transgene in a far lower level than that in wild-type liver, allowed PCCA(-/-) mice to survive the newborn and early infant periods, preventing a lethal fit of ketoacidosis (SAP(+)PCCA(-/-) mice). Interestingly, SAP(+)PCCA(-/-) mice, in which the transgene expression increased after the late infant period, continued to grow normally while mice harboring a persistent low level of PCC died in the late infant period due to severe ketoacidosis, clearly suggesting the requirement of increased PCC supplementation in proportion to the animal growth. Based on these results, we propose a two-step strategy to achieve an efficient PA prevention in human patients: a partial PCC supplementation in the liver during the newborn and early infant periods, followed by a larger amount of supplementation in the late infant period.	Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA; Tohoku Univ, Sch Med, Dept Pediat, Aoba Ku, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Sch Med, Dept Med Genet, Aoba Ku, Sendai, Miyagi 9808574, Japan; Tokyo Womens Med Univ, Dept Pathol, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Womens Med Univ, Inst Gastroenterol, Shinjuku Ku, Tokyo 1628666, Japan; Fukui Med Univ, Sch Med, Dept Pediat, Matsuoka, Fukui 9101193, Japan; Shimane Med Univ, Dept Pediat, Izumo, Shimane 6938501, Japan; Basel Inst Immunol, CH-4005 Basel, Switzerland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tohoku University; Tohoku University; Tokyo Women's Medical University; Tokyo Women's Medical University; University of Fukui; Shimane University	Miyazaki, T (corresponding author), Univ Texas, SW Med Ctr, Ctr Immunol, 6000 Harry Hines Blvd,NA7200, Dallas, TX 75390 USA.	Toru.Miyazaki@UTSouthwestern.edu						Anklesaria P, 2000, CURR OPIN MOL THER, V2, P426; ARAI K, 1982, J BIOCHEM-TOKYO, V91, P11, DOI 10.1093/oxfordjournals.jbchem.a133667; BRANDT IK, 1974, PEDIATRICS, V53, P391; Connelly S, 1999, CURR OPIN MOL THER, V1, P565; Fan X, 2000, GENE THER, V7, P2132, DOI 10.1038/sj.gt.3301352; Fenton W., 1995, METABOLIC MOL BASES, V7th ed., P1423; GLASGOW AM, 1976, PEDIATR RES, V10, P683, DOI 10.1203/00006450-197610070-00010; GRAVEL RA, 1977, AM J HUM GENET, V29, P378; Hackett NR, 2000, CURR OPIN MOL THER, V2, P376; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; Iga M, 2000, J CHROMATOGR B, V746, P75, DOI 10.1016/S0378-4347(00)00123-7; Kozlowski DA, 2001, MOL THER, V3, P256, DOI 10.1006/mthe.2000.0256; LAMHONWAH AM, 1994, GENOMICS, V19, P500, DOI 10.1006/geno.1994.1099; LINSEISEN J, 1993, JPEN-PARENTER ENTER, V17, P522, DOI 10.1177/0148607193017006522; Lundstrom K, 2000, INTERVIROLOGY, V43, P247, DOI 10.1159/000053992; LYLES DS, 1977, BIOCHIM BIOPHYS ACTA, V487, P16, DOI 10.1016/0005-2760(77)90040-6; Miyazaki T, 1999, J EXP MED, V189, P413, DOI 10.1084/jem.189.2.413; Morse MA, 2000, CURR OPIN MOL THER, V2, P448; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; Nowak MA, 1998, ARCH PATHOL LAB MED, V122, P353; Pandha HS, 2000, CURR OPIN MOL THER, V2, P362; Perez-Cerda C, 2000, EUR J HUM GENET, V8, P187, DOI 10.1038/sj.ejhg.5200442; Richard E, 1999, BBA-MOL BASIS DIS, V1453, P351, DOI 10.1016/S0925-4439(99)00008-3; ROSARIO P, 1982, J INHERIT METAB DIS, V5, P59, DOI 10.1007/BF01799756; Saudubray JM, 1999, EUR J PEDIATR, V158, pS65, DOI 10.1007/PL00014325; Smith-Arica J R, 2001, Curr Cardiol Rep, V3, P43, DOI 10.1007/s11886-001-0009-x; Sperl W, 2000, EUR J PEDIATR, V159, P54, DOI 10.1007/s004310050010; TAKASHIMA H, 1992, IMMUNOLOGY, V75, P398; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Tsai SY, 2000, CURR OPIN MOL THER, V2, P515; Ugarte M, 1999, HUM MUTAT, V14, P275, DOI 10.1002/(SICI)1098-1004(199910)14:4<275::AID-HUMU1>3.0.CO;2-N; Wahlfors J, 2001, HISTOCHEM CELL BIOL, V115, P59, DOI 10.1007/s004180000219; Wang FB, 2000, METAB ENG, V2, P126, DOI 10.1006/mben.1999.0144; WENDEL U, 1993, EUR J PEDIATR, V152, P1021, DOI 10.1007/BF01957229; WOLF B, 1981, J PEDIATR-US, V99, P835, DOI 10.1016/S0022-3476(81)80004-2; ZHAO X, 1992, J BIOCHEM-TOKYO, V111, P736, DOI 10.1093/oxfordjournals.jbchem.a123828	36	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35995	35999		10.1074/jbc.M105467200	http://dx.doi.org/10.1074/jbc.M105467200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461925	hybrid			2022-12-25	WOS:000171109300102
J	Nishiyama, R; Sakaguchi, T; Kinugasa, T; Gu, XB; MacDermott, RP; Podolsky, DK; Reinecker, HC				Nishiyama, R; Sakaguchi, T; Kinugasa, T; Gu, XB; MacDermott, RP; Podolsky, DK; Reinecker, HC			Interleukin-2 receptor beta subunit-dependent and -independent regulation of intestinal epithelial tight junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; TYROSINE PHOSPHORYLATION; BARRIER FUNCTION; INTRAEPITHELIAL LYMPHOCYTES; POSSIBLE INVOLVEMENT; DIRECT BINDING; GROWTH-FACTOR; PROTEIN ZO-1; OCCLUDIN; CHAIN	Interleukin (IL)-15 is able to regulate tight junction formation in intestinal epithelial cells. However, the mechanisms that regulate the intestinal barrier function in response to IL-15 and the involved subunits of the IL-15 ligand-receptor system are unknown. We determined the IL-2R beta subunit and IL-15-dependent regulation of tight junction-associated proteins in the human intestinal epithelial cell line T-84. The IL-2R beta subunit was expressed and induced signal transduction in caveolin enriched rafts in intestinal epithelial cells. IL-15-mediated tightening of intestinal epithelial monolayers correlated with the enhanced recruitment of tight junction proteins into Triton X-100-insoluble protein fractions. IL-15-mediated up-regulation of ZO-1 and ZO-2 expression was independent of the IL-2R beta subunit, whereas the phosphorylation of occludin and enhanced membrane association of claudin-1 and claudin-2 by IL-15 required the presence of the IL-2R beta subunit. Recruitment of claudins and hyperphosphorylated occludin into tight junctions resulted in a more marked induction of tight junction formation in intestinal epithelial cells than the up-regulation of ZO-1 and ZO-2 by itself. The regulation of the intestinal epithelial barrier function by IL-15 involves IL-2R beta -dependent and -independent signaling pathways leading to the recruitment of claudins, hyperphosphorylated occludin, ZO-1, and ZO-2 into the tight junctional protein complex.	Massachusetts Gen Hosp, Dept Med, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Albany Med Coll, Div Gastroenterol, Albany, NY 12208 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Albany Medical College	Reinecker, HC (corresponding author), Massachusetts Gen Hosp, Dept Med, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, Jackson Bldg R711,32 Fruit St, Boston, MA 02114 USA.	reinecker@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041557, R37DK041557, P30DK043351, R37DK021474, R01DK021474, R01DK051003, R01DK054427, P01DK033506] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51003, P01 DK 33506, DK 43351, DK 41557, DK 54427, DK 21474] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Andres PG, 2000, J IMMUNOL, V164, P6303, DOI 10.4049/jimmunol.164.12.6303; Badizadegan K, 2000, AM J PHYSIOL-GASTR L, V278, pG895, DOI 10.1152/ajpgi.2000.278.6.G895; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; COLGAN SP, 1994, J IMMUNOL, V153, P2122; Collares-Buzato CB, 1998, EUR J CELL BIOL, V76, P85, DOI 10.1016/S0171-9335(98)80020-4; Ebert EC, 1998, GASTROENTEROLOGY, V115, P1439, DOI 10.1016/S0016-5085(98)70022-8; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hilsden RJ, 1996, GASTROENTEROLOGY, V110, P1395, DOI 10.1053/gast.1996.v110.pm8613043; InagakiOhara K, 1997, EUR J IMMUNOL, V27, P2885, DOI 10.1002/eji.1830271121; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kinugasa T, 2000, GASTROENTEROLOGY, V118, P1001, DOI 10.1016/S0016-5085(00)70351-9; Kirman I, 1996, AM J GASTROENTEROL, V91, P1789; KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514; Lai YG, 1999, J IMMUNOL, V163, P5843; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; Liu ZJ, 2000, J IMMUNOL, V164, P3608, DOI 10.4049/jimmunol.164.7.3608; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; MADARA JL, 1988, CELL, V53, P497, DOI 10.1016/0092-8674(88)90562-4; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; McCarthy KM, 1996, J CELL SCI, V109, P2287; Meijssen MAC, 1998, AM J PHYSIOL-GASTR L, V274, pG472, DOI 10.1152/ajpgi.1998.274.3.G472; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; Nusrat A, 2000, J CELL SCI, V113, P1771; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Peeters M, 1997, GASTROENTEROLOGY, V113, P802, DOI 10.1016/S0016-5085(97)70174-4; REINECKER HC, 1995, P NATL ACAD SCI USA, V92, P8353, DOI 10.1073/pnas.92.18.8353; Reinecker HC, 1996, GASTROENTEROLOGY, V111, P1706, DOI 10.1016/S0016-5085(96)70036-7; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Sakai T, 1998, GASTROENTEROLOGY, V114, P1237, DOI 10.1016/S0016-5085(98)70430-5; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Schmitz H, 1999, GASTROENTEROLOGY, V116, P301, DOI 10.1016/S0016-5085(99)70126-5; SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647, DOI 10.1152/ajplung.1992.262.6.L647; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; STADDON JM, 1995, J CELL SCI, V108, P609; Stevens AC, 1997, AM J PHYSIOL-GASTR L, V272, pG1201, DOI 10.1152/ajpgi.1997.272.5.G1201; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; VANITALLIE CM, 1995, J CELL SCI, V108, P1735; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	70	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35571	35580		10.1074/jbc.M106013200	http://dx.doi.org/10.1074/jbc.M106013200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466322	hybrid			2022-12-25	WOS:000171109300050
J	Weber, J; Senior, AE				Weber, J; Senior, AE			Bi-site catalysis in F-1-ATPase: Does it exist?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; ATP SYNTHASE; NUCLEOTIDE-BINDING; ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL F1-ATPASE; EPSILON-SUBUNIT; ROTATION; ADP; HYDROLYSIS; MECHANISM	The mechanism of action of F1F0-ATP synthase is controversial. Some favor a tri-site mechanism, where substrate must rill all three catalytic sites for activity, others a bi-site mechanism, where one of the three sites is always unoccupied. New approaches were applied to examine this question. First, ITP was used as hydrolysis substrate; lower binding affinities of ITP versus ATP enable more accurate assessment of sites occupancy. Second, distributions of all eight possible enzyme species (with zero, one, two or three sites filled) as fraction of total enzyme population at each ITP concentration were calculated, and compared with measured ITPase activity. Confirming data were obtained with ATP as substrate. Third, we performed a theoretical analysis of possible bi-site mechanisms. The results argue convincingly that bi-site hydrolysis activity is negligible, and may not even exist. Effectively, tri-site hydrolysis is the only mechanism. We argue that only tri-site hydrolysis drives subunit rotation. Theoretical analyses of possible bi-site mechanisms reveal serious flaws, not previously recognized. One is that, in bi-site catalysis, the predicted direction of subunit rotation is the same for both ATP synthesis and hydrolysis; a second is that infrequently occurring enzyme species are required.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; [Anonymous], 2000, J BIOENERG BIOMEMBR; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; DAWSON RMC, 1979, DATA BIOCH RES, P423; Garcia JJ, 1998, J BIOL CHEM, V273, P15940, DOI 10.1074/jbc.273.26.15940; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JAULT JM, 1994, BIOCHEMISTRY-US, V33, P14979, DOI 10.1021/bi00254a005; Jencks WP, 1997, ANNU REV BIOCHEM, V66, P1, DOI 10.1146/annurev.biochem.66.1.1; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KLOTZ IM, 1979, ARCH BIOCHEM BIOPHYS, V193, P314, DOI 10.1016/0003-9861(79)90036-5; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; Milgrom YM, 1998, BIOCHEM J, V330, P1037; MURATALIEV MB, 1994, J BIOL CHEM, V269, P15431; Nadanaciva S, 2000, BIOCHEMISTRY-US, V39, P9583, DOI 10.1021/bi000941o; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Nishizaka T, 2001, BIOPHYS J, V80, p158A; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P25480, DOI 10.1074/jbc.M102200200; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; PETERS F, 1986, METHOD ENZYMOL, V126, P733; RAO R, 1988, J BIOL CHEM, V263, P5569; Ren HM, 2000, J BIOL CHEM, V275, P10057, DOI 10.1074/jbc.275.14.10057; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Weber J, 2000, FEBS LETT, V483, P1, DOI 10.1016/S0014-5793(00)02071-8; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1999, J BIOL CHEM, V274, P19124, DOI 10.1074/jbc.274.27.19124; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; 2000, J EXP BIOL, V203; 2000, BIOCH BIOPHYS ACTA, V1458	43	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35422	35428		10.1074/jbc.M104946200	http://dx.doi.org/10.1074/jbc.M104946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11451960	hybrid			2022-12-25	WOS:000171109300030
J	Zhang, C; Cai, Y; Adachi, MT; Oshiro, S; Aso, T; Kaufman, RJ; Kitajima, S				Zhang, C; Cai, Y; Adachi, MT; Oshiro, S; Aso, T; Kaufman, RJ; Kitajima, S			Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; LOW-DENSITY-LIPOPROTEIN; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; THROMBOGENIC AGENT; HYDROGEN-PEROXIDE; CHOP GADD153; C ACTIVATION; APOPTOSIS; INDUCTION	Severe hyperhomocysteinemia is associated with endothelial cell injury that may contribute to an increased incidence of thromboembolic disease. In this study, homocysteine induced programmed cell death in human umbilical vein endothelial cells as measured by TdT-mediated dUTP nick end labeling assay, DNA ladder formation, induction of caspase 3-like activity, and cleavage of procaspase 3. Homocysteine-induced cell death was specific to homocysteine, was not mediated by oxidative stress, and was mimicked by inducers of the unfolded protein response (UPR), a signal transduction pathway activated by the accumulation of unfolded proteins in the lumen of the endoplasmic reticulum. Dominant negative forms of the endoplasmic reticulum-resident protein kinases IRE1 alpha and -beta, which function as signal transducers of the UPR prevented the activation of glucose-regulated protein 78/immunoglobulin chain-binding protein and C/EBP homologous protein/growth arrest and DNA damage-inducible protein 153 in response to homocysteine. Furthermore, overexpression of the point mutants of IRE1 with defective RNase more effectively suppressed the cell death than the kinase-defective mutant. These results indicate that homocysteine induces apoptosis in human umbilical vein endothelial cells by activation of the UPR and is signaled through IRE1. The studies implicate that the UPR may cause endothelial cell injury associated with severe hyperhomocysteinemia.	Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kitajima, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Longo, Kenneth A/A-5631-2010					Austin RC, 1998, J BIOL CHEM, V273, P30808, DOI 10.1074/jbc.273.46.30808; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chen P, 1999, ADV ENZYME REGUL, V39, P93, DOI 10.1016/S0065-2571(98)00029-6; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; Dimmeler S, 1997, CIRCULATION, V95, P1760; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HARKER LA, 1983, CIRC RES, V53, P731, DOI 10.1161/01.RES.53.6.731; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; Hladovec J, 1997, THROMB RES, V88, P361, DOI 10.1016/S0049-3848(97)00266-1; HLADOVEC J, 1979, BLOOD VESSELS, V16, P202; JORNOT L, 1991, AM J RESP CELL MOL, V5, P265, DOI 10.1165/ajrcmb/5.3.265; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; LENTZ SR, 1993, BLOOD, V81, P683; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; Miyata T, 1998, SEMIN THROMB HEMOST, V24, P285, DOI 10.1055/s-2007-995856; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	49	241	263	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35867	35874		10.1074/jbc.M100747200	http://dx.doi.org/10.1074/jbc.M100747200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11447214	hybrid			2022-12-25	WOS:000171109300086
J	De la Pena, M; Flores, R				De la Pena, M; Flores, R			An extra nucleotide in the consensus catalytic core of a viroid hammerhead ribozyme - Implications for the design of more efficient ribozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROLLING CIRCLE REPLICATION; SELF-CLEAVE INVITRO; SECONDARY STRUCTURE; SATELLITE RNA; FULL-LENGTH; MINUS RNAS; METAL-ION; STEM-II; SEQUENCE; VIRUS	Hammerhead ribozymes catalyze self-cleavage of oligomeric RNAs generated in replication of certain viroid and viroid-like RNAs. Previous studies have defined a catalytic core conserved in most natural hammerheads, but it is still unknown why some present deviations from the consensus. We have addressed this issue in chrysanthemum chlorotic mottle viroid (CChMVd), whose (+) hammerhead has an extra A (A10) between the conserved A9 and the quasi-conserved G10.1. Effects of insertions at this position on hammerhead kinetics have not hitherto been examined. A10 caused a moderate decrease of the trans-cleaving rate constant with respect to the CChMVd (+) hammerhead without this residue, whereas A10 -->C and A10 -->G substitutions had major detrimental effects, likely because they favor catalytically inactive foldings. By contrast, A10 -->U substitution induced a 3-4-fold increase of the rate constant, providing an explanation for the extra U10 present in two natural hammerheads. Because A10 also occupies a singular and indispensable position in the global CChMVd conformation, as revealed by bioassays, these results show that some hammerheads deviate from the consensus due to the involvement of certain residues in critical function(s) other than self-cleavage. Incorporation of the extra U10 into a model hammerhead also caused a similar increase in the rate constant, providing data for a deeper understanding of the hammerhead structural requirements and for designing more efficient ribozymes.	Univ Politecn Valencia, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Flores, R (corresponding author), Univ Politecn Valencia, Inst Biol Mol & Celular Plantas, Ave Naranjos S-N, Valencia 46022, Spain.		De la Peña, Marcos/D-5001-2009; Flores, Ricardo/K-2788-2014	De la Peña, Marcos/0000-0002-7949-8459; Flores, Ricardo/0000-0002-3033-5077				Ambros S, 1998, J VIROL, V72, P7397; Baumstark T, 1997, EMBO J, V16, P599, DOI 10.1093/emboj/16.3.599; BRANCH AD, 1981, P NATL ACAD SCI-BIOL, V78, P6381, DOI 10.1073/pnas.78.10.6381; BRANCH AD, 1988, P NATL ACAD SCI USA, V85, P9128, DOI 10.1073/pnas.85.23.9128; BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; Bussiere F, 1999, J VIROL, V73, P6353; Bussiere F, 2000, J VIROL, V74, P2647, DOI 10.1128/JVI.74.6.2647-2654.2000; BYRAPPA S, 1995, GENOME RES, V5, P404, DOI 10.1101/gr.5.4.404; DAROS JA, 1994, P NATL ACAD SCI USA, V91, P12813, DOI 10.1073/pnas.91.26.12813; DAVIES JW, 1974, VIROLOGY, V61, P281, DOI 10.1016/0042-6822(74)90262-1; De la Pena M, 1999, P NATL ACAD SCI USA, V96, P9960, DOI 10.1073/pnas.96.17.9960; DIENER TO, 1991, FASEB J, V5, P2808, DOI 10.1096/fasebj.5.13.1717335; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; Feldstein PA, 1998, P NATL ACAD SCI USA, V95, P6560, DOI 10.1073/pnas.95.11.6560; Flores R, 2000, ADV VIRUS RES, V55, P271, DOI 10.1016/S0065-3527(00)55006-4; Flores R, 2001, METHOD ENZYMOL, V341, P540, DOI 10.1016/S0076-6879(01)41175-X; Flores R., 2000, VIRUS TAXONOMY, P1009; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FORSTER AC, 1990, METHOD ENZYMOL, V181, P583; GRILL LK, 1978, P NATL ACAD SCI USA, V75, P896, DOI 10.1073/pnas.75.2.896; GROSS HJ, 1978, NATURE, V273, P203, DOI 10.1038/273203a0; HALL TC, 1974, VIROLOGY, V61, P486, DOI 10.1016/0042-6822(74)90284-0; HERNANDEZ C, 1992, NUCLEIC ACIDS RES, V20, P6323, DOI 10.1093/nar/20.23.6323; HERNANDEZ C, 1992, P NATL ACAD SCI USA, V89, P3711, DOI 10.1073/pnas.89.9.3711; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Heus HA, 1997, J MOL BIOL, V271, P147, DOI 10.1006/jmbi.1997.1158; HUTCHINS CJ, 1985, PLANT MOL BIOL, V4, P293, DOI 10.1007/BF02418248; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; KAPER JM, 1988, BIOCHEM BIOPH RES CO, V154, P318, DOI 10.1016/0006-291X(88)90687-0; Liu YH, 1998, RNA, V4, P418; LONG DM, 1994, P NATL ACAD SCI USA, V91, P6977, DOI 10.1073/pnas.91.15.6977; MILLER WA, 1991, VIROLOGY, V183, P711, DOI 10.1016/0042-6822(91)91000-7; Murray JB, 2000, MOL CELL, V5, P279, DOI 10.1016/S1097-2765(00)80423-2; Murray JB, 2000, J MOL BIOL, V296, P33, DOI 10.1006/jmbi.1999.3428; Navarro B, 1997, P NATL ACAD SCI USA, V94, P11262, DOI 10.1073/pnas.94.21.11262; Navarro JA, 1999, VIROLOGY, V253, P77, DOI 10.1006/viro.1998.9497; OWENS RA, 1982, P NATL ACAD SCI-BIOL, V79, P113, DOI 10.1073/pnas.79.1.113; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; ROSSI JJ, 1999, INTRACELLULAR RIBOZY; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SHELDON CC, 1989, NUCLEIC ACIDS RES, V17, P5679, DOI 10.1093/nar/17.14.5679; Song SI, 1999, J MOL BIOL, V293, P781, DOI 10.1006/jmbi.1999.3169; Stage-Zimmermann TK, 1998, RNA, V4, P875, DOI 10.1017/S1355838298980876; Suzumura K, 2000, FEBS LETT, V473, P106, DOI 10.1016/S0014-5793(00)01499-X; SYMONS RH, 1981, NUCLEIC ACIDS RES, V9, P6527, DOI 10.1093/nar/9.23.6527; Thomson JB, 1996, NUCLEIC ACIDS RES, V24, P4401, DOI 10.1093/nar/24.22.4401; TSAGRIS M, 1987, EMBO J, V6, P2173, DOI 10.1002/j.1460-2075.1987.tb02488.x; TUSCHL T, 1993, P NATL ACAD SCI USA, V90, P6991, DOI 10.1073/pnas.90.15.6991; Wang SL, 1999, BIOCHEMISTRY-US, V38, P14363, DOI 10.1021/bi9913202	55	24	24	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34586	34593		10.1074/jbc.M103867200	http://dx.doi.org/10.1074/jbc.M103867200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454858	hybrid			2022-12-25	WOS:000171024600034
J	Kraft, K; Olbrich, H; Majoul, I; Mack, M; Proudfoot, A; Oppermann, M				Kraft, K; Olbrich, H; Majoul, I; Mack, M; Proudfoot, A; Oppermann, M			Characterization of sequence determinants within the carboxyl-terminal domain of chemokine receptor CCR5 that regulate signaling and receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; HIV-1 CORECEPTOR; MEMBRANE RAFTS; PROTEIN-KINASE; DESENSITIZATION; RANTES; CELLS; PALMITOYLATION	The CC chemokine receptor CCR5 mediates chemotaxis of leukocytes and serves as a principal co-receptor for macrophage-tropic human immunodeficiency virus type 1. To identify determinants on the CCR5 carboxyl-terminal domain that regulate receptor signaling and internalization, we generated several CCR5 mutants, which were progressively shortened from the COOH terminus or had carboxyl-terminal serine, cysteine, or leucine residues substituted by alanine and expressed them in RBL-2H3 cells. Using fluorescence resonance energy transfer between beta -arrestin and CCR5 tagged with cyan and yellow variants of green fluorescent protein, we show that high affinity association of the two molecules in living cells requires intact carboxyl-terminal serine phosphorylation sites. Phosphorylation-deficient truncation or Ser/Ala replacement mutants of CCR5 mediated a sustained calcium response and enhanced granular enzyme release in RANTES-stimulated cells. Carboxyl-terminal serine residues are critically involved in CCR5 endocytosis and a dileucine motif, similar to that implicated in the regulation of CXCR2 and CXCR4, contributes to the internalization of CCR5 in a phosphorylation-independent manner. Despite their prominent role in receptor desensitization and internalization, beta -arrestins are dispensable for the CCR5-mediated stimulation of mitogen-activated protein kinase pathways in RBL-2H3 cells. We also show that CCR5 is palmitoylated on carboxyl-terminal cysteine residues. Inhibition of CCR5 palmitoylation by alanine mutagenesis of cysteines or treatment with a palmitate analogue inhibitor profoundly reduces phorbol 12-myristate 13-acetate- and RANTES-induced receptor phosphorylation, homologous desensitization, and internalization. Alanine mutagenesis of serine, cysteine, or leucine residues or the limited carboxyl-terminal truncation of CCR5 did not impair chemokine-stimulated migration of RBL-2H3 cells. Together these results indicate that post-translational modifications of carboxyl-terminal serine and cysteine residues have a significant impact on receptor deactivation and internalization.	Univ Gottingen, Dept Immunol, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Univ Munich, Med Policlin, D-80336 Munich, Germany; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	University of Gottingen; Max Planck Society; University of Munich	Oppermann, M (corresponding author), Univ Gottingen, Dept Immunol, Kreuzbergring 57, D-37075 Gottingen, Germany.		Majoul, Irina V/K-5339-2013					Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; BOUVIER M, 1995, BIOCHEM SOC T, V23, P116, DOI 10.1042/bst0230116; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; JIN H, 1999, REGULATION G PROTEIN, P93; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; MONTZ H, 1990, CELL IMMUNOL, V127, P337, DOI 10.1016/0008-8749(90)90137-G; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Murphy PM, 2000, PHARMACOL REV, V52, P145; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Signoret N, 2000, METH MOL B, V138, P197; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Soskic V, 1999, J BIOL CHEM, V274, P8539, DOI 10.1074/jbc.274.13.8539; Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200	47	137	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34408	34418		10.1074/jbc.M102782200	http://dx.doi.org/10.1074/jbc.M102782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11448957	hybrid, Green Published			2022-12-25	WOS:000171024600009
J	Shalev, A; Valasek, L; Pise-Masison, CA; Radonovich, M; Phan, L; Clayton, J; He, H; Brady, JN; Hinnebusch, AG; Asano, K				Shalev, A; Valasek, L; Pise-Masison, CA; Radonovich, M; Phan, L; Clayton, J; He, H; Brady, JN; Hinnebusch, AG; Asano, K			Saccharomyces cerevisiae protein Pci8p and human protein eIF3e/Int-6 interact with the eIF3 core complex by binding to cognate eIF3b subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; FISSION YEAST HOMOLOG; TRANSLATION INITIATION; RNA-BINDING; COP9 SIGNALOSOME; INT-6; GENE; IDENTIFICATION; EIF2B-EPSILON; INTEGRATION	Mammalian, plant, and Schizosaccharomyces pombe eukaryotic initiation factor-3 (eIF3) contains a protein homologous to the product of int-6 (eIF3e), a frequent integration site of mouse mammary tumor viruses. By contrast, Saccharomyces cerevisiae does not encode a protein closely related to eIF3e/Int-6. Here, we characterize a novel S. cerevisiae protein (Pci8p, Yi1071cp) that contains a PCI (proteasome-COP9 signalosome-eIF3) domain conserved in eIF3e/Int-6. We show that both Pci8p, and human eIF3e/Int-6 expressed in budding yeast interact with the yeast eIF3 complex in vivo and in vitro by binding to a discrete segment of its eIF3b subunit Prt1p and that human eIF3e/Int-6 interacts with the human eIF3b segment homologous to the Pci8p-binding, site of yeast Prt1p. These results refine our understanding of subunit interactions in the eIF3 complex and suggest structural similarity between human eIF3e/Int-6 and yeast Pci8p. However, deletion of PCI8 had no discernible effect on cell growth or translation initiation as judged by polysome analysis, suggesting that Pci8p is not required for the essential function of eIF3 in translation initiation. Motivated by the involvement of Int-6 in transcriptional control, we investigated the effects of deleting PCI8 on the total mRNA expression profile by oligonucleotide microarray analysis and found reduced mRNA levels for a subset of heat shock proteins in the pci8 Delta mutant. We discuss possible dual functions of Pci8p and Int-6 in transcriptional and translational control.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	Kansas State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Asano, K (corresponding author), Kansas State Univ, Div Biol, 109 Ackert Hall, Manhattan, KS 66506 USA.	kasano@ksu.edu	Valášek, Leoš Shivaya/I-5743-2014	Valášek, Leoš Shivaya/0000-0001-8123-8667	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; Chen CR, 1999, P NATL ACAD SCI USA, V96, P517, DOI 10.1073/pnas.96.2.517; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Donahue TF, 2000, COLD SPRING HARBOR M, V39, P487; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P637; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Karniol B, 1998, FEBS LETT, V439, P173, DOI 10.1016/S0014-5793(98)01367-2; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Peng ZH, 2001, MOL BIOL CELL, V12, P383, DOI 10.1091/mbc.12.2.383; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; Treger JM, 1998, BIOCHEM BIOPH RES CO, V243, P13, DOI 10.1006/bbrc.1997.8061; Valasek L, 1999, J BIOL CHEM, V274, P27567, DOI 10.1074/jbc.274.39.27567; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370; Yun DJ, 1997, P NATL ACAD SCI USA, V94, P7082, DOI 10.1073/pnas.94.13.7082; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	47	34	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34948	34957		10.1074/jbc.M102161200	http://dx.doi.org/10.1074/jbc.M102161200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457827	hybrid			2022-12-25	WOS:000171024600081
J	Thibault, P; Logan, SM; Kelly, JF; Brisson, JR; Ewing, CP; Trust, TJ; Guerry, P				Thibault, P; Logan, SM; Kelly, JF; Brisson, JR; Ewing, CP; Trust, TJ; Guerry, P			Identification of the carbohydrate moieties and glycosylation motifs in Campylobacter jejuni flagellin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; STRUCTURAL DETERMINATION; PSEUDOMONAS-AERUGINOSA; ALPHA-GLYCEROPHOSPHATE; NEUB GENES; O-ANTIGEN; BIOSYNTHESIS; SEQUENCE; CLONING; COLI	Flagellins from three strains of Campylobacter jejuni and one strain of Campylobacter coli were shown to be extensively modified by glycosyl residues, imparting an approximate 6000-Da shift from the molecular mass of the protein predicted from the DNA sequence. Tryptic peptides from C. jejuni 81-176 flagellin were subjected to capillary liquid chromatography-electrospray mass spectrometry with a high/low orifice stepping to identify peptide segments of aberrant masses together with their corresponding glycosyl appendages. These modified peptides were further characterized by tandem mass spectrometry and preparative high performance liquid chromatography followed by nano-NMR spectroscopy to identify the nature and precise site of glycosylation. These analyses have shown that there are 19 modified Ser/Thr residues in C. jejuni 81-176 flagellin. The predominant modification found on C. jejuni flagellin was O-linked 5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-manno-nonulosonic acid (pseudaminic acid, Pse5Ac7Ac) with additional heterogeneity conferred by substitution of the acetamido groups with acetamidino and hydroxyproprionyl groups. In C. jejuni 81-176, the gene Cj1316c, encoding a protein of unknown function, was shown to be involved in the biosynthesis and/or the addition of the acetamidino group on Pse5Ac7Ac. Glycosylation is not random, since 19 of the total 107 Ser/Thr residues are modified, and all but one of these are restricted to the central, surface-exposed domain of flagellin when folded in the filament. The mechanism of attachment appears unrelated to a consensus peptide sequence but is rather based on surface accessibility of Ser/Thr residues in the folded protein.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; MIT, Div Comparat Med, Cambridge, MA 02139 USA; USN, Med Res Ctr, Silver Spring, MD 20910 USA	National Research Council Canada; Massachusetts Institute of Technology (MIT); United States Department of Defense; United States Navy	Logan, SM (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	susan.logan@nrc.ca	Guerry, Patricia/A-8024-2011	Thibault, Pierre/0000-0001-5993-0331	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043559] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43559] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANNUNZIATO PW, 1995, J BACTERIOL, V177, P312, DOI 10.1128/jb.177.2.312-319.1995; BAYLEY DP, 1993, ARCH MICROBIOL, V160, P179; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; Brimer CD, 1998, J BACTERIOL, V180, P3209, DOI 10.1128/JB.180.12.3209-3217.1998; CASTRIC P, 1995, MICROBIOL-UK, V141, P1247, DOI 10.1099/13500872-141-5-1247; Castric P, 2001, J BIOL CHEM, V276, P26479, DOI 10.1074/jbc.M102685200; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Edebrink P, 1996, CARBOHYD RES, V287, P225, DOI 10.1016/0008-6215(96)00076-6; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Friedman C.R., 2000, CAMPYLOBACTER, P121; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; Gil-Serrano AM, 1998, BIOCHEM J, V334, P585, DOI 10.1042/bj3340585; Gil-Serrano AM, 1999, BIOCHEM J, V342, P527, DOI 10.1042/0264-6021:3420527; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; GUERRY P, 1991, J BACTERIOL, V173, P4757, DOI 10.1128/jb.173.15.4757-4764.1991; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; Guerry P, 2000, INFECT IMMUN, V68, P6656, DOI 10.1128/IAI.68.12.6656-6662.2000; GUERRY P, 1994, METHOD ENZYMOL, V235, P474; Kenne L, 1988, CARBOHYD RES, V180, P285, DOI 10.1016/0008-6215(88)80085-5; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Knirel YA, 1997, CARBOHYD RES, V304, P77, DOI 10.1016/S0008-6215(97)00211-5; KORLATH JA, 1985, J INFECT DIS, V152, P592, DOI 10.1093/infdis/152.3.592; Leclerc G, 1998, J BACTERIOL, V180, P5010, DOI 10.1128/JB.180.19.5010-5019.1998; Linton D, 2000, MOL MICROBIOL, V35, P1120, DOI 10.1046/j.1365-2958.2000.01780.x; LOGAN SM, 1989, J BACTERIOL, V171, P3031, DOI 10.1128/jb.171.6.3031-3038.1989; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; MANZI AE, 1997, TECHNIQUES GLYCOBIOL, P1; Marceau M, 1998, MOL MICROBIOL, V27, P705, DOI 10.1046/j.1365-2958.1998.00706.x; MARTIN PMV, 1989, INFECT IMMUN, V57, P2542, DOI 10.1128/IAI.57.8.2542-2546.1989; MESSNER P, 1991, Glycobiology, V1, P545, DOI 10.1093/glycob/1.6.545; NACHAMKIN I, 1985, J CLIN MICROBIOL, V21, P33, DOI 10.1128/JCM.21.1.33-38.1985; Oberhelman RA, 2000, CAMPYLOBACTER, V2nd, P139, DOI 10.1016/s0360-3016(00)00774-4; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PLUMMER TH, 1995, J BIOL CHEM, V270, P13192, DOI 10.1074/jbc.270.22.13192; POWER ME, 1994, J BACTERIOL, V176, P3303, DOI 10.1128/jb.176.11.3303-3313.1994; RADEMAKER GJ, 1996, ANAL BIOCHEM, V257, P149; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Stimson E, 1996, BIOCHEM J, V316, P29, DOI 10.1042/bj3160029; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Tsvetkov YE, 2001, CARBOHYD RES, V331, P233, DOI 10.1016/S0008-6215(01)00041-6; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; Virji M, 1997, GENE, V192, P141, DOI 10.1016/S0378-1119(97)00082-6; YAO RJ, 1993, GENE, V130, P127, DOI 10.1016/0378-1119(93)90355-7; Zahringer U, 1995, Prog Clin Biol Res, V392, P113	47	292	314	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34862	34870		10.1074/jbc.M104529200	http://dx.doi.org/10.1074/jbc.M104529200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11461915	hybrid			2022-12-25	WOS:000171024600070
J	Wang, SK; Behan, J; O'Neill, K; Weig, B; Fried, S; Laz, T; Bayne, M; Gustafson, E; Hawes, BE				Wang, SK; Behan, J; O'Neill, K; Weig, B; Fried, S; Laz, T; Bayne, M; Gustafson, E; Hawes, BE			Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, MCH-R2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ALPHA-MSH; RAT; EXPRESSION; GENE; GALANIN; LIGAND; SLC-1; BRAIN; HYPOTHALAMUS	Melanin-concentrating hormone (MCH) is a neuropeptide highly expressed in the brain that regulates several physiological functions mediated by receptors in the G protein-coupled receptor family. Recently an orphan receptor, SLC-1, has been identified as an MCH receptor (MCH-RI). Herein we identify and characterize a novel receptor for human MCH (MCH-R2). The receptor is composed of 340 amino acids encoded by a 1023-base pair cDNA and is 35% homologous to SLC-1. I-125-MCH specifically bound to Chinese hamster ovary cells stably expressing MCH-R2. MCH stimulated dose-dependent increases in intracellular free Ca2+ and inositol phosphate production in these cells but did not affect cAMP production. The pharmacological profile for mammalian MCH, [Phe(13),Tyr(19)]MCH, and salmon MCH at MCH-R2 differed compared with MCH-R1 as assessed by intracellular signaling and radioligand binding assays. The EC50 in signaling assays and the IC50 in radioligand binding assays of salmon MCH was an order of magnitude higher than mammalian MCH at MCH-R2. By comparison, the EC50 and IC50 values of salmon MCH and mammalian MCH at MCH-R1 were relatively similar. Blot hybridization revealed exclusive expression of MCH-R2 m-RNA in several distinct brain regions, particularly in the cortical area, suggesting the involvement of MCH-R2 in the central regulation of MCH-mediated functions.	Schering Plough Corp, Dept Human Genom, Res Inst, Kenilworth, NJ 07033 USA; Schering Plough Corp, Dept CNS Biol, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Hawes, BE (corresponding author), Schering Plough Corp, Dept Human Genom, Res Inst, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	brian.hawes@spcorp.com						Bachner D, 1999, FEBS LETT, V457, P522, DOI 10.1016/S0014-5793(99)01092-3; Bayer L, 2000, NEUROREPORT, V11, P531, DOI 10.1097/00001756-200002280-00021; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Gonzalez MI, 1997, PEPTIDES, V18, P387, DOI 10.1016/S0196-9781(96)00337-3; Hawes BE, 2000, ENDOCRINOLOGY, V141, P4524, DOI 10.1210/en.141.12.4524; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Hervieu G, 1996, ENDOCRINOLOGY, V137, P561, DOI 10.1210/en.137.2.561; Hill J, 2001, J BIOL CHEM, V276, P20125, DOI 10.1074/jbc.M102068200; Huang QL, 1999, NEUROENDOCRINOLOGY, V69, P145, DOI 10.1159/000054413; JEZOVA D, 1992, ENDOCRINOLOGY, V130, P1024, DOI 10.1210/en.130.2.1024; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; Knigge KM, 1997, PEPTIDES, V18, P1095, DOI 10.1016/S0196-9781(97)00036-3; Knigge KM, 1996, PEPTIDES, V17, P1063; Kolakowski LF, 1996, FEBS LETT, V398, P253, DOI 10.1016/S0014-5793(96)01160-X; Lembo PMC, 1999, NAT CELL BIOL, V1, P267, DOI 10.1038/12978; MILLER CL, 1993, PEPTIDES, V14, P431, DOI 10.1016/0196-9781(93)90128-4; Monzon ME, 1999, PEPTIDES, V20, P1517, DOI 10.1016/S0196-9781(99)00164-3; Murray JF, 2000, J NEUROENDOCRINOL, V12, P217; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; NAITO N, 1988, CELL TISSUE RES, V253, P291; PARKES DG, 1993, MELANOTROPIC PEPTIDE, P588; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Rossi M, 1999, BRAIN RES, V846, P164, DOI 10.1016/S0006-8993(99)02005-3; Sahu A, 1998, ENDOCRINOLOGY, V139, P795, DOI 10.1210/en.139.2.795; Sailer AW, 2001, P NATL ACAD SCI USA, V98, P7564, DOI 10.1073/pnas.121170598; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shimomura Y, 1999, BIOCHEM BIOPH RES CO, V261, P622, DOI 10.1006/bbrc.1999.1104; SKOFITSCH G, 1985, PEPTIDES, V6, P509, DOI 10.1016/0196-9781(85)90118-4; Viale A, 1997, MOL BRAIN RES, V46, P243, DOI 10.1016/S0169-328X(97)00018-1	31	85	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34664	34670		10.1074/jbc.M102601200	http://dx.doi.org/10.1074/jbc.M102601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11459838	hybrid			2022-12-25	WOS:000171024600044
J	Thompson, PR; Kurooka, H; Nakatani, Y; Cole, PA				Thompson, PR; Kurooka, H; Nakatani, Y; Cole, PA			Transcriptional coactivator protein p300 - Kinetic characterization of its histone acetyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; CATALYTIC MECHANISM; P300/CBP-ASSOCIATED FACTOR; FACTOR GATA-1; ACETYLATION; CBP; BINDING; SUBSTRATE; SITES; PCAF	The p300/cAMP response element-binding protein-binding protein (CBP) family members include human p300 and cAMP response element-binding protein-binding protein, which are both important transcriptional coactivators and histone acetyltransferases. Although the role of these enzymes in transcriptional regulation has been extensively documented, the molecular mechanisms of p300 and CBP histone acetyltransferase catalysis are poorly understood. Herein, we describe the first detailed kinetic characterization of p300 using full-length purified recombinant enzyme. These studies have employed peptide substrates to systematically examine the substrate specificity requirements and the kinetic mechanism of this enzyme. The importance of nearby positively charged residues in lysine targeting was demonstrated. The strict structural requirement of the lysine side chain was shown. The catalytic mechanism of p300 was shown to follow a ping-pong kinetic pathway and viscosity experiments revealed that product release and/or a conformational change were likely rate-limiting in catalysis. Detailed analysis of the p300 selective inhibitor Lys-CoA showed that it exhibited slow, tight-binding kinetics.	Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Johns Hopkins University; Harvard University; Dana-Farber Cancer Institute	Cole, PA (corresponding author), Johns Hopkins Univ, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.							Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; ANDRES HH, 1983, BIOCHIM BIOPHYS ACTA, V746, P193, DOI 10.1016/0167-4838(83)90074-2; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bergel M, 2000, J BIOL CHEM, V275, P11514, DOI 10.1074/jbc.275.15.11514; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE PA, 1994, J BIOL CHEM, V269, P30880; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luger K, 1999, METHOD ENZYMOL, V304, P3; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Segel IH, 1975, ENZYME KINETICS BEHA; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tan S, 2001, NAT STRUCT BIOL, V8, P8, DOI 10.1038/83098; Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Yamamura ET, 2000, BBA-GEN SUBJECTS, V1475, P10, DOI 10.1016/S0304-4165(00)00038-6; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; ZOETEMAN M, 1990, INORG CHEM, V29, P3487, DOI 10.1021/ic00343a041	51	115	118	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33721	33729		10.1074/jbc.M104736200	http://dx.doi.org/10.1074/jbc.M104736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445580	hybrid			2022-12-25	WOS:000170910200059
J	Yu, X; Warner, JR				Yu, X; Warner, JR			Expression of a micro-protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST RIBOSOMAL-PROTEINS; MESSENGER-RNA TURNOVER; SACCHAROMYCES-CEREVISIAE; IN-SILICO; SEQUENCE; L41; SUBUNIT; COMPLEX; GENOME; DECAY	The smallest known open reading frame encodes the ribosomal protein L41, which in yeast is composed of only 24 amino acids, 17 of which are arginine or lysine. Because of the unique problems that might attend the translation of such a short open reading frame, we have investigated the properties and the translation of the mRNAs encoding L41. In Saccharomyces cerevisiae L41 is encoded by two linked genes, RPL41A and RPL41B. These genes give rise to mRNAs that have short 5' leaders of 18 and 22 nucleotides and rather long 3' leaders of 203 and 210 nucleotides not including their poly(A) tails. The mRNAs are translated exclusively on monosomes, suggesting that ribosomes do not remain attached to the mRNA after termination of translation. Calculations based on the abundance of ribosomes and of L41 mRNA indicate that the entire translation event, from initiation through termination, must occur in similar to2 s. Termination of translation after only 25 codons does not subject the mRNAs encoding L41 to nonsense-mediated decay. Surprisingly, despite the L41 ribosomal protein being conserved from the archaea through the mammalia, S. cerevisiae can grow relatively normally after deletion of both RPL41A and RPL41B.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Warner, JR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIGMS NIH HHS [GM25532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHAN YL, 1995, BIOCHEM BIOPH RES CO, V214, P810, DOI 10.1006/bbrc.1995.2359; CHOLI T, 1993, BIOL CHEM H-S, V374, P377, DOI 10.1515/bchm3.1993.374.1-6.377; Czaplinski K, 1999, BIOESSAYS, V21, P685, DOI 10.1002/(SICI)1521-1878(199908)21:8<685::AID-BIES8>3.0.CO;2-4; DEHOUX P, 1993, EUR J BIOCHEM, V213, P841, DOI 10.1111/j.1432-1033.1993.tb17827.x; FROHMAN MA, 1994, PCR METH APPL, V4, pS40; Graber JH, 1999, P NATL ACAD SCI USA, V96, P14055, DOI 10.1073/pnas.96.24.14055; Guo ZJ, 1996, TRENDS BIOCHEM SCI, V21, P477, DOI 10.1016/S0968-0004(96)10057-8; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HUTTENHOFER A, 1994, EMBO J, V13, P3892, DOI 10.1002/j.1460-2075.1994.tb06700.x; KAWAI S, 1992, J BACTERIOL, V174, P254, DOI 10.1128/jb.174.1.254-262.1992; KLAUDINY J, 1992, BIOCHEM BIOPH RES CO, V187, P901, DOI 10.1016/0006-291X(92)91282-U; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; Li BJ, 1999, MOL CELL BIOL, V19, P5393; LI Z, 1995, MOL CELL BIOL, V15, P6454; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591; OTAKA E, 1984, MOL GEN GENET, V195, P544, DOI 10.1007/BF00341461; SUZUKI K, 1990, CURR GENET, V17, P185, DOI 10.1007/BF00312608; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vilardell J, 2000, RNA, V6, P1773, DOI 10.1017/S135583820000145X; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wheelan SJ, 1999, GENE, V238, P163, DOI 10.1016/S0378-1119(99)00298-X; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	33	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33821	33825		10.1074/jbc.M103772200	http://dx.doi.org/10.1074/jbc.M103772200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11451953	hybrid			2022-12-25	WOS:000170910200072
J	Zhao, YG; Gilmore, R; Leone, G; Coffey, MC; Weber, B; Lee, PWK				Zhao, YG; Gilmore, R; Leone, G; Coffey, MC; Weber, B; Lee, PWK			Hsp90 phosphorylation is linked to its chaperoning function - Assembly of the reovirus cell attachment protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOLECULAR CHAPERONES; IN-VIVO; KINASE; TRIMERIZATION; SIGMA-1; BIOGENESIS; BINDING	Studies on Hsp90 have mainly focused on its involvement in the activation of several families of protein kinases and of steroid hormone receptors. Little is known regarding the role of Hsp90 in the folding of nascent proteins. We previously reported that Hsp90 plays an active role in the posttranslational assembly of the C-terminal globular head of the reovirus attachment protein sigma1. We show here that Hsp90 becomes phosphorylated in this process. However, only the unphosphorylated form of Hsp90 is complexed with sigma1, suggesting that Hsp90 phosphorylation is coupled to the release of the chaperone from the target protein. Geldanamycin, which blocks sigma1 maturation by preventing the release of Hsp90 from sigma1, also inhibits Hsp90 phosphorylation. Taken together, these results demonstrate that Hsp90 phosphorylation is linked to its chaperoning function.	Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Fac Med, Calgary, AB T2N 4N1, Canada; Univ Calgary, Canc Biol Res Grp, Fac Med, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Lee, PWK (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Fac Med, Calgary, AB T2N 4N1, Canada.		Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300				Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; Gilmore R, 1998, J BIOL CHEM, V273, P15227, DOI 10.1074/jbc.273.24.15227; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartson SD, 1998, J BIOL CHEM, V273, P8475, DOI 10.1074/jbc.273.14.8475; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee PWK, 1998, CURR TOP MICROBIOL, V233, P137; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; Leone G, 1996, J BIOL CHEM, V271, P8466, DOI 10.1074/jbc.271.14.8466; MAH DCW, 1990, VIROLOGY, V179, P95, DOI 10.1016/0042-6822(90)90278-Y; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Smith DF, 2000, SEMIN CELL DEV BIOL, V11, P45, DOI 10.1006/scdb.1999.0350; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; Uma S, 1997, J BIOL CHEM, V272, P11648; YEUNG MC, 1989, VIROLOGY, V170, P62, DOI 10.1016/0042-6822(89)90352-8	29	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32822	32827		10.1074/jbc.M105562200	http://dx.doi.org/10.1074/jbc.M105562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438552	hybrid			2022-12-25	WOS:000170746000061
J	Damiens, E; Baratte, B; Marie, D; Eisenbrand, G; Meijer, L				Damiens, E; Baratte, B; Marie, D; Eisenbrand, G; Meijer, L			Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest	ONCOGENE			English	Article						cyclin-dependent kinase; glycogen synthase kinase; GSK-3 beta; indirubin; kinase inhibitor; cancer	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; CHEMICAL INHIBITORS; SODIUM-BUTYRATE; CANCER CELLS; DNA; STAUROSPORINE; APOPTOSIS; MEDICINE; MITOSIS	The bis-indole indirubin is the active ingredient of the Traditional Chinese Medicine recipe Danggui Longhui Wan used against chronic myelocytic leukemia, We have previously shown that indirubins are potent inhibitors of cyclin-dependent kinases and glycogen synthase kinase-3, We here investigated the anti-mitotic properties of this class of compounds using the cell permeable indirubin-3 ' -monoxime and the HBL-100 cell line. Indirubin-3 ' -monoxime reversibly arrests asynchronous HBL-100 cells in G2, This arrest is not accompanied by any significant change in expression of the major cell cycle regulators, However indirubin-3 ' -monoxime inhibits the phosphorylation of consensus CDK phosphorylation sites as well as of nucleolin at a specific CDK1/cyclin B phosphorylation site, suggesting a direct action on the mitotic CDK1/cyclin B, When indirubin-3 ' -monoxime is added to HBL-100 cells synchronized in M phase by nocodazole, cells undergo an endoreplication leading to an 8n DNA content. As soon as indirubin-3 ' -monoxime is washed away, these polyploid cells become aneuploid and later die from necrosis, This mechanism of endoreplication followed by cell death may contribute to the antitumour properties of indirubins.	CNRS, Biol Stn, Cell Cycle Grp, F-29682 Roscoff, France; Univ Kaiserslautern, Div Food Chem & Environm Toxicol, Dept Chem, D-67663 Kaiserslautern, Germany; CNRS, Phytoplankton Ocean Grp, Biol Stn, F-29682 Roscoff, France	Centre National de la Recherche Scientifique (CNRS); University of Kaiserslautern; Centre National de la Recherche Scientifique (CNRS)	Meijer, L (corresponding author), CNRS, Biol Stn, Cell Cycle Grp, BP 74, F-29682 Roscoff, France.		Eisenbrand, Gerhard/AEQ-0284-2022	Eisenbrand, Gerhard/0000-0003-4079-2463; , laurent/0000-0003-3511-4916				Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; [Anonymous], 1992, CHIN DRUGS PLANT ORI; Atienza C, 2000, INT J MOL MED, V6, P55; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bible KC, 1997, CANCER RES, V57, P3375; Borgne A, 1999, M S-MED SCI, V15, P496, DOI 10.4267/10608/1375; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; Chang CN, 1985, ADV CHINESE MED MAT, P369; CHEN DH, 1984, CHINESE TRAD HERBAL, V15, P6; Edamatsu H, 2000, ONCOGENE, V19, P3059, DOI 10.1038/sj.onc.1203625; Hall LL, 1996, CANCER RES, V56, P3551; HAN R, 1994, STEM CELLS, V12, P53, DOI 10.1002/stem.5530120110; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Ikegami Y, 1996, ARZNEIMITTEL-FORSCH, V46, P201; Institute of Haematology Chinese Academy of Medical Sciences, 1979, CHIN J INT MED, V18, P83; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lallemand F, 1999, EXP CELL RES, V247, P432, DOI 10.1006/excr.1998.4370; Ma M Z, 1983, J Tradit Chin Med, V3, P245; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Roberge M, 1998, CANCER RES, V58, P5701; *SICH I TRAD CHIN, 1981, CHIN TRAD HERB DRUGS, V12, P27; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; WANG JH, 1981, ACTA PHARM SINICA, V2, P241; Wu K M, 1985, Yao Xue Xue Bao, V20, P821; WU LM, 1979, COMM CHINESE HERBAL, V9, P6; YAMADA K, 1985, J CELL PHYSIOL, V122, P59, DOI 10.1002/jcp.1041220110; Zhang Z N, 1985, J Tradit Chin Med, V5, P246; ZHU YP, 1995, PHARM WORLD SCI, V17, P103, DOI 10.1007/BF01872386	36	138	157	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3786	3797		10.1038/sj.onc.1204503	http://dx.doi.org/10.1038/sj.onc.1204503			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439342	Bronze			2022-12-25	WOS:000169494700004
J	Wu, CG; Salvay, DM; Forgues, M; Valerie, K; Farnsworth, J; Markin, RS; Wang, XW				Wu, CG; Salvay, DM; Forgues, M; Valerie, K; Farnsworth, J; Markin, RS; Wang, XW			Distinctive gene expression profiles associated with Hepatitis B virus x protein	ONCOGENE			English	Article						hepatitis B virus; cDNA microarray; liver cancer; chronic active hepatitis	HEPATOCELLULAR-CARCINOMA; HBX GENE; CDNA MICROARRAY; LIVER-CANCER; P53 GENE; CELL; APOPTOSIS; ETIOLOGY; TRANSFORMATION; ACCUMULATION	Hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC), HBV encodes the potentially oncogenic HBx protein, which mainly functions as a transcriptional co-activator involving in multiple gene deregulations. However, mechanisms underlying HBx-mediated oncogenicity remain unclear, To determine the role(s) of HBx in the early genesis of HCC, we utilized the NCI Oncochip microarray that contains 2208 human cDNA clones to examine the gene expression profiles in either freshly isolated normal primary adult human hepatocytes (Hhep) or an HCC cell line (SK-Hep-l) ecotopically expressing HBx via an adenoviral system. The gene expression profiles also were determined in liver samples from HBV-infected chronic active hepatitis patients when compared with normal liver samples. The microarray results were validated through Northern blot analysis of the expression of selected genes. Using reciprocally labeling hybridizations, scatterplot analysis of gene expression ratios in human primary hepatocytes expressing HBx demonstrates that microarrays are highly reproducible. The comparison of gene expression profiles between HBx-expressing primary hepatocytes and HBV-infected liver samples shows a consistent alteration of many cellular genes including a subset of oncogenes (such as c-myc and c-myb) and tumor suppressor genes (such as APC, p53, WAF1 and WT1), Furthermore, clustering algorithm analysis showed distinctive gene expression profiles in Hhep and SK-Hep-l cells. Our findings are consistent with the hypothesis that the deregulation of cellular genes by oncogenic HBx may be an early event that favors hepatocyte proliferation during liver carcinogenesis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Virginia Commonwealth University; University of Nebraska System; University of Nebraska Medical Center	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, NIH, MSC 4255,Bldg 37,Room 2C25, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009; Valerie, Kristoffer/AAL-8299-2021	Wang, Xin Wei/0000-0001-9735-606X; 				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Andrisani OM, 1999, INT J ONCOL, V15, P373; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOVA R, 1991, INT J CLIN LAB RES, V21, P190; Bradley DW, 1999, P ASSOC AM PHYSICIAN, V111, P588, DOI 10.1046/j.1525-1381.1999.t01-1-99240.x; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; CASELMANN WH, 1995, J HEPATOL, V22, P34; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; DeRisi J, 1996, NAT GENET, V14, P457; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Han JS, 2000, BIOCHEM BIOPH RES CO, V272, P525, DOI 10.1006/bbrc.2000.2801; HARRIS CC, 1984, CARCINOGENESIS, V5, P697, DOI 10.1093/carcin/5.6.697; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kew MC, 1997, HEPATOLOGY, V25, P1037, DOI 10.1002/hep.510250442; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Kobayashi S, 1997, J SURG RES, V73, P97, DOI 10.1006/jsre.1997.5182; Koike K, 1995, INTERVIROLOGY, V38, P134, DOI 10.1159/000150424; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Ono K, 2000, CANCER RES, V60, P5007; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Robinson WS, 1999, MICROBES AND MALIGNANCY, P232; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; TAO X, 2000, CHUNG HUA KAN TSANG, V8, P161; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Valerie K, 2000, CANCER GENE THER, V7, P879, DOI 10.1038/sj.cgt.7700185; VALERIE K, 1995, MUTAT RES-DNA REPAIR, V336, P91, DOI 10.1016/0921-8777(94)00046-9; Valerie K, 1999, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, P69; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wu CG, 1997, CARCINOGENESIS, V18, P47, DOI 10.1093/carcin/18.1.47; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	56	75	84	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3674	3682		10.1038/sj.onc.1204481	http://dx.doi.org/10.1038/sj.onc.1204481			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439330				2022-12-25	WOS:000169400200008
J	Meinl, E; Derfuss, T; Pirzer, R; Blank, N; Lengenfelder, D; Blancher, A; Le Deist, F; Fleckenstein, B; Hivroz, C				Meinl, E; Derfuss, T; Pirzer, R; Blank, N; Lengenfelder, D; Blancher, A; Le Deist, F; Fleckenstein, B; Hivroz, C			Herpesvirus saimiri replaces ZAP-70 for CD3- and CD2-mediated T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT TRANSCRIPTION FACTORS; PROTEIN-TYROSINE KINASE; HUMAN LYMPHOCYTES-T; SIGNAL-TRANSDUCTION; DOWN-REGULATION; TIP PROTEIN; RECEPTOR; SYK; TRANSFORMATION; P56(LCK)	The protein tyrosine kinase ZAP-70 plays a pivotal role involved in signal transduction through the T cell receptor and CD2. Defects in ZAP-70 result in severe combined immunodeficiency. We report that Herpesvirus saimiri, which does not code for a ZAP-70 homologue, can replace this tyrosine kinase. H. saimiri is an oncogenic virus that transforms human T cells to stable growth based on mutual CD2-mediated activation. Although CD2-mediated proliferation of ZAP-70-deficient uninfected T cells was absent, we could establish H. saimiri-transformed T cell lines from two unrelated patients presenting with ZAP-70 deficiencies. In these cell lines, CD2 and CD3 activation were restored in terms of [Ca2+](i), MAPK activation, cytokine production, and proliferation. Activation-induced tyrosine phosphorylation of remained defective. The transformed cells expressed very high levels of the ZAP-70-related kinase Syk. This increased expression was not observed in the primary T cells from the patients and was not due to the transformation by the virus because transformed cell lines established from control T cells did not present this particularity. In conclusion, wild type H. saimiri can restore CD2- and CD3-mediated activation in signaling-deficient human T cells. It extends our understanding of interactions between the oncogenic H. saimiri and the infected host cells.	Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany; Univ Munich, Inst Clin Neuroimmunol, D-81377 Munich, Germany; Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Clin Immunol, D-91054 Erlangen, Germany; Hop Purpan, F-31059 Toulouse, France; INSERM, U429, F-75015 Paris, France; Inst Curie, INSERM, U520, F-75248 Paris, France	Max Planck Society; University of Munich; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Meinl, E (corresponding author), Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany.		Hivroz, Claire/H-2711-2014	Hivroz, Claire/0000-0002-6794-2890; Meinl, Edgar/0000-0002-2570-6785; Derfuss, Tobias/0000-0001-8656-4250				ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Chu DH, 1999, J IMMUNOL, V163, P2610; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; Fickenscher H, 1997, J VIROL, V71, P2252, DOI 10.1128/JVI.71.3.2252-2263.1997; Gong Q, 1997, IMMUNITY, V7, P369, DOI 10.1016/S1074-7613(00)80358-1; Guo J, 1998, J VIROL, V72, P3698, DOI 10.1128/JVI.72.5.3698-3704.1998; Hartley DA, 2000, VIROLOGY, V276, P339, DOI 10.1006/viro.2000.0570; Hartley DA, 2000, J BIOL CHEM, V275, P16925, DOI 10.1074/jbc.M000709200; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; HIVROZ C, 1994, CURR BIOL, V4, P731, DOI 10.1016/S0960-9822(00)00162-7; HOWARD FD, 1992, J EXP MED, V176, P139, DOI 10.1084/jem.176.1.139; JUNG JU, 1995, J VIROL, V69, P7814, DOI 10.1128/JVI.69.12.7814-7822.1995; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; Knappe A, 2000, BLOOD, V95, P3256; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; Meinl E, 2000, J IMMUNOL, V165, P3578, DOI 10.4049/jimmunol.165.7.3578; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MITTRUCKER HW, 1992, J EXP MED, V176, P909, DOI 10.1084/jem.176.3.909; Noraz N, 2000, J BIOL CHEM, V275, P15832, DOI 10.1074/jbc.M908568199; Taylor N, 1996, J EXP MED, V184, P2031, DOI 10.1084/jem.184.5.2031; Ueno H, 2000, EUR J IMMUNOL, V30, P78; Weil R, 1999, J VIROL, V73, P3709, DOI 10.1128/JVI.73.5.3709-3717.1999; Wiese N, 1996, J BIOL CHEM, V271, P847, DOI 10.1074/jbc.271.2.847; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388	32	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36902	36908		10.1074/jbc.M102668200	http://dx.doi.org/10.1074/jbc.M102668200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11463783	hybrid			2022-12-25	WOS:000171375700008
J	Shimizu, M; Murase, A; Har, M; Shindo, H; Mitchell, AP				Shimizu, M; Murase, A; Har, M; Shindo, H; Mitchell, AP			A C-terminal segment with properties of alpha-helix is essential for DNA binding and in vivo function of zinc finger protein Rme1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; YEAST; REPRESSION; RECOGNITION; MEIOSIS; ACTIVATOR; AFFINITY; SEQUENCES; DOMAIN	Rme1p plays important roles in the control of meiosis and in cell cycle progression through binding to upstream regions of IME1 and CLN2 in Saccharomyces cerevisiae. Rme1p has three zinc finger segments, and two of them are atypical. To determine DNA binding domain of Rme1p, a series of Rme1p derivatives fused with maltose-binding protein were purified and characterized by gel mobility shift assay. We show that not only three zinc fingers, but also the neighboring C-terminal region is essential for DNA binding. Mutational analysis of this region revealed that basic residues Arg-287, Lys-290, and Arg-291 and the hydrophobic residues Phe-288, Leu-292, Ile-295, and Leu-296 are critical for DNA binding. In addition, double substitutions by proline at Asn-289 and Lys-293, each of which was not essential for DNA binding, abolished DNA binding. These results suggest that the C-terminal segment forms an amphipathic helical structure. Furthermore, it was shown that the mutations in the important basic residues abolish or impair Rme1p function in vivo for repression and inhibition of spore formation. Thus, the C-terminal segment is essential and acts as a novel accessory domain for DNA binding by zinc fingers.	Meisei Univ, Dept Chem, Tokyo 1918506, Japan; Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan; Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Inst Canc Res, New York, NY 10032 USA	Meisei University; Tokyo University of Pharmacy & Life Sciences; Columbia University; Columbia University	Shimizu, M (corresponding author), Meisei Univ, Dept Chem, 2-1-1 Hodokubo, Tokyo 1918506, Japan.			Mitchell, Aaron/0000-0002-0868-4000	NIGMS NIH HHS [GM39531] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039531] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arranz V, 1997, MOL CELL BIOL, V17, P2116, DOI 10.1128/MCB.17.4.2116; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; Bowers PW, 1999, NAT STRUCT BIOL, V6, P478; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X; Colomina N, 1999, EMBO J, V18, P320, DOI 10.1093/emboj/18.2.320; COVITZ PA, 1991, GENE DEV, V5, P1982, DOI 10.1101/gad.5.11.1982; COVITZ PA, 1993, GENE DEV, V7, P1598, DOI 10.1101/gad.7.8.1598; COVITZ PA, 1994, GENETICS, V138, P577; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; Dutnall RN, 1996, STRUCTURE, V4, P599, DOI 10.1016/S0969-2126(96)00064-0; Elrod-Erickson M, 1999, J BIOL CHEM, V274, P19281, DOI 10.1074/jbc.274.27.19281; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; Klug A, 1999, J MOL BIOL, V293, P215, DOI 10.1006/jmbi.1999.3007; KUPIEC M, 1997, MOL CELLULAR BIOL YE, V3, P889; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Rose MD., 1990, METHODS YEAST GENETI; Sagee S, 1998, MOL CELL BIOL, V18, P1985, DOI 10.1128/MCB.18.4.1985; Schmiedeskamp M, 1997, BIOCHEMISTRY-US, V36, P14003, DOI 10.1021/bi971364f; Shimizu M, 1998, NUCLEIC ACIDS RES, V26, P2329, DOI 10.1093/nar/26.10.2329; Shimizu M, 1997, P NATL ACAD SCI USA, V94, P790, DOI 10.1073/pnas.94.3.790; SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397; TOONE WM, 1995, EMBO J, V14, P5824, DOI 10.1002/j.1460-2075.1995.tb00270.x; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vershon AK, 2000, CURR OPIN CELL BIOL, V12, P334, DOI 10.1016/S0955-0674(00)00104-6; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183	37	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37680	37685		10.1074/jbc.M105342200	http://dx.doi.org/10.1074/jbc.M105342200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11466318				2022-12-25	WOS:000171375700106
J	Barycki, JJ; O'Brien, LK; Strauss, AW; Banaszak, LJ				Barycki, JJ; O'Brien, LK; Strauss, AW; Banaszak, LJ			Glutamate 170 of human L-3-hydroxyacyl-CoA dehydrogenase is required for proper orientation of the catalytic histidine and structural integrity of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; LARGE ALPHA-SUBUNIT; LACTATE-DEHYDROGENASE; MULTIENZYME COMPLEX; ESCHERICHIA-COLI; A DEHYDROGENASE; RIBONUCLEASE-A; D121A ENZYMES; ACTIVE-SITE; WILD-TYPE	L-3-Hydroxyacyl-CoA dehydrogenase (HAD), the penultimate enzyme in the beta -oxidation spiral, reversibly catalyzes the conversion Of L-3-hydroxyacyl-CoA to the corresponding 3-ketoacyl-CoA. Similar to other dehy-drogenases, HAD contains a general acid/base, His(158), which is within hydrogen bond distance of a carboxylate, Glu(170). To investigate its function in this catalytic dyad, Glu(170) was replaced with glutamine (E170Q), and the mutant enzyme was characterized. Whereas substrate and cofactor binding were unaffected by the mutation, E170Q exhibited diminished catalytic activity. Protonation of the catalytic histidine did not restore wild-type activity, indicating that modulation of the pK(a) of His(158) is not the sole function of Glu(170). The pH profile of charge transfer complex formation, an independent indicator of active site integrity, was unaltered by the amino acid substitution, but the intensity of the charge transfer band was diminished. This observation, coupled with significantly reduced enzymatic stability of the E170Q mutant, implicates Glu(170) in maintenance of active site architecture. Examination of the crystal structure of E170Q in complex with NAD(+) and aceto-acetyl-CoA (R = 21.9%, R-free, = 27.6%, 2.2 Angstrom) reveals that Gln(170) no longer hydrogen bonds to the side chain of His(158). Instead, the imidazole ring is nearly perpendicular to its placement in the comparable native complex and no longer positioned for efficient catalysis.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA	University of Minnesota System; University of Minnesota Twin Cities; Vanderbilt University	Banaszak, LJ (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NIDDK NIH HHS [1F32-DK09759] Funding Source: Medline; NIGMS NIH HHS [GM13925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUER HE, 1980, J BIOL CHEM, V255, P8157; Barycki JJ, 2000, J BIOL CHEM, V275, P27186; Barycki JJ, 1999, BIOCHEMISTRY-US, V38, P5786, DOI 10.1021/bi9829027; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Bernard N, 1997, EUR J BIOCHEM, V244, P213, DOI 10.1111/j.1432-1033.1997.00213.x; BIRKTOFT JJ, 1987, P NATL ACAD SCI USA, V84, P8262, DOI 10.1073/pnas.84.23.8262; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLARKE AR, 1988, BIOCHEMISTRY-US, V27, P1617, DOI 10.1021/bi00405a034; Cleland W W, 1979, Methods Enzymol, V63, P103; Cosgrove MS, 2000, BIOCHEMISTRY-US, V39, P15002, DOI 10.1021/bi0014608; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; ELVING PJ, 1956, ANAL CHEM, V28, P1179, DOI 10.1021/ac60115a034; HARTMANN D, 1991, BIOCHEMISTRY-US, V30, P2782, DOI 10.1021/bi00225a007; He XY, 1996, BIOCHEMISTRY-US, V35, P9625, DOI 10.1021/bi960374y; He XY, 1997, BIOCHEMISTRY-US, V36, P261, DOI 10.1021/bi961841e; IJIST L, 1996, J CLIN INVEST, V98, P1028; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; KOCHHAR S, 1992, J BIOL CHEM, V267, P20298; Kutzenko AS, 1998, FEBS LETT, V423, P105, DOI 10.1016/S0014-5793(98)00074-X; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; NOYES BE, 1973, J BIOL CHEM, V248, P3052; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Quirk DJ, 1999, BIOPHYS J, V76, P1571, DOI 10.1016/S0006-3495(99)77316-9; Roe C. R., 1995, METABOLIC MOL BASES, P1501; Schafer SL, 1996, BIOCHEMISTRY-US, V35, P5662, DOI 10.1021/bi960174m; Schultz LW, 1998, BIOCHEMISTRY-US, V37, P8886, DOI 10.1021/bi972766q; SIMS HF, 1995, P NATL ACAD SCI USA, V92, P841, DOI 10.1073/pnas.92.3.841; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; Strauss AW, 1999, SEMIN PERINATOL, V23, P100, DOI 10.1016/S0146-0005(99)80044-5; Tishkov VI, 1996, FEBS LETT, V390, P104, DOI 10.1016/0014-5793(96)00641-2; YANG SY, 1994, COMP BIOCHEM PHYS B, V109, P557, DOI 10.1016/0305-0491(94)90117-1	32	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36718	36726		10.1074/jbc.M104839200	http://dx.doi.org/10.1074/jbc.M104839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11451959	hybrid			2022-12-25	WOS:000171194500088
J	Lacroix, M; Ebel, C; Kardos, J; Dobo, J; Gal, P; Zavodszky, P; Arlaud, GJ; Thielens, NM				Lacroix, M; Ebel, C; Kardos, J; Dobo, J; Gal, P; Zavodszky, P; Arlaud, GJ; Thielens, NM			Assembly and enzymatic properties of the catalytic domain of human complement protease C1r	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; AMINO-ACID-SEQUENCE; 1ST COMPONENT; FUNCTIONAL-MODEL; SERINE PROTEASES; ACTIVATION; CHAIN; CLR; C(1)OVER-BAR-S; PATHWAY	The catalytic properties of C1r, the protease that mediates activation of the C1 complex of complement, are mediated by its C-terminal region, comprising two complement control protein (CCP) modules followed by a serine protease (SP) domain. Baculovirus-mediated expression was used to produce fragments containing the SP domain and either 2 CCP modules (CCP1/2-SP) or only the second CCP module (CCP2-SP). In each case, the wild-type species and two mutants stabilized in the proenzyme form by mutations at the cleavage site (R446Q) or at the active site serine residue (S637A), were produced. Both wild-type fragments were recovered as two-chain, activated proteases, whereas all mutants retained a single-chain, proenzyme structure, providing the first experimental evidence that Clr activation is an autolytic process. As shown by sedimentation velocity analysis, all CCP1/2-SP fragments were dimers (5.5-5.6 S), and all CCP2-SP fragments were monomers (3.2-3.4 S). Thus, CCP1 is essential to the assembly of the dimer, but formation of a stable dimer is not a prerequisite for self-activation. Activation of the R446Q mutants could be achieved by extrinsic cleavage by thermolysin, which cleaved the CCP2-SP species more efficiently than the CCP1/2-SP species and yielded enzymes with Cls-cleaving activities similar to their active wild-type counterparts. Clr and its activated fragments all cleaved Cls, with relative efficiencies in the order C1r < CCP1/2-SP < CCP2-SP, indicating that CCP1 is not involved in Cls recognition.	Struct Jean Pierre Ebel, Inst Biol, Lab Enzymol Mol, CEA,CNRS, F-38027 Grenoble 1, France; Struct Jean Pierre Ebel, Inst Biol, Mol Biophys Lab, CEA,CNRS, F-38027 Grenoble 1, France; Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1113 Budapest, Hungary	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Thielens, NM (corresponding author), Struct Jean Pierre Ebel, Inst Biol, Lab Enzymol Mol, CEA,CNRS, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	nicole.thielens@ibs.fr	Zavodszky, Peter/C-1214-2008; Kardos, József/J-1035-2017; Gal, Peter/B-5886-2011; Thielens, Nicole M/F-2512-2013; Dobo, Jozsef/C-7331-2014	Kardos, József/0000-0002-2135-2932; Thielens, Nicole M/0000-0002-7354-0302; Ebel, Christine/0000-0002-6912-500X; Dobo, Jozsef/0000-0001-9187-8502				ARLAUD GJ, 1993, METHOD ENZYMOL, V223, P61; ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; ARLAUD GJ, 1986, BIOCHEMISTRY-US, V25, P5177, DOI 10.1021/bi00366a029; Arlaud GJ, 1998, ADV IMMUNOL, V69, P249, DOI 10.1016/S0065-2776(08)60609-4; ARLAUD GJ, 1987, BIOCHEM J, V241, P711, DOI 10.1042/bj2410711; ARLAUD GJ, 1983, BIOCHEMISTRY-US, V22, P1758, DOI 10.1021/bi00277a003; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; BORK P, 1995, TRENDS BIOCH SCI S, V20, pC3; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; Dobo J, 1999, J IMMUNOL, V162, P1108; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Gaboriaud C, 1998, J MOL BIOL, V282, P459, DOI 10.1006/jmbi.1998.2008; Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755; GAL P, COMPLEMENT INFLAMM, V6, P433; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; KING LA, 1992, BACULOVIRUS EXPRESSI, P111; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; LUO C, 1992, BIOCHEMISTRY-US, V31, P4254, DOI 10.1021/bi00132a015; ROSSI V, 1995, BIOCHEMISTRY-US, V34, P7311, DOI 10.1021/bi00022a004; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schuck P, 1999, ANAL BIOCHEM, V272, P199, DOI 10.1006/abio.1999.4172; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; SCHUMAKER VN, 1986, MOL IMMUNOL, V23, P557, DOI 10.1016/0161-5890(86)90119-7; TELLER DC, 1976, NATURE, V260, P729, DOI 10.1038/260729a0; Thielens NM, 1999, J BIOL CHEM, V274, P9149, DOI 10.1074/jbc.274.14.9149; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; VILLIERS CL, 1985, P NATL ACAD SCI USA, V82, P4477, DOI 10.1073/pnas.82.13.4477; Volanakis J., 1998, COMPLEMENT ENZYMES H, P49; WEISS V, 1986, J MOL BIOL, V189, P573, DOI 10.1016/0022-2836(86)90325-6; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; ZACCAI G, 1990, FEBS LETT, V269, P19, DOI 10.1016/0014-5793(90)81108-Z	37	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36233	36240		10.1074/jbc.M105688200	http://dx.doi.org/10.1074/jbc.M105688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11445589	hybrid			2022-12-25	WOS:000171194500026
J	Sriskanda, V; Moyer, RW; Shuman, S				Sriskanda, V; Moyer, RW; Shuman, S			NAD(+)-dependent DNA ligase encoded by a eukaryotic virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; ESCHERICHIA-COLI; ENZYME; NICK; ENTOMOPOXVIRUS; RECOMBINATION; EXPRESSION; MECHANISM	We report the production, purification, and characterization of an NAD(+)-dependent DNA ligase encoded by the Amsacta moorei entomopoxvirus (AmEPV), the first example of an NAD(+) ligase from a source other than eubacteria. AmEPV ligase lacks the zinc-binding tetra-cysteine domain and the BRCT domain that are present in all eubacterial NAD(+) ligases. Nonetheless, the monomeric 532-amino acid AmEPV ligase catalyzed strand joining on a singly nicked DNA in the presence of a divalent cation and NAD(+). Neither ATP, dATP, nor any other nucleoside triphosphate could substitute for NAD(+). Structure probing by limited proteolysis showed that AmEPV ligase is punctuated by a surface-accessible loop between the nucleotidyltransferase domain, which is common to all ligases, and the N-terminal domain Ia, which is unique to the NAD(+) ligases. Deletion of domain la of AmEPV ligase abolished the sealing of 3 ' -OH/5 ' -PO4 nicks and the reaction with NAD(+) to form ligase-adenylate, but had no effect on phosphodiester formation at a pre-adenylated nick. Alanine substitutions at residues within domain Ia either reduced (Tyr(39), Tyr(40), Asp(48), and Asp(52)) or abolished (Tyr(51)) sealing of a 3 ' -OH/5 ' -PO4 nick and adenylyl transfer from NAD(+) without affecting ligation of DNA-adenylate. We conclude that: (i) NAD(+)-dependent ligases exist in the eukaryotic domain of the phylogenetic tree; and (ii) ligase structural domain Ia is a determinant of cofactor specificity and is likely to interact directly with the nicotinamide mononucleotide moiety of NAD(+).	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	Memorial Sloan Kettering Cancer Center; State University System of Florida; University of Florida	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.				NIGMS NIH HHS [GM63611-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afonso CL, 1999, J VIROL, V73, P533, DOI 10.1128/JVI.73.1.533-552.1999; Bawden AL, 2000, VIROLOGY, V274, P120, DOI 10.1006/viro.2000.0449; CHEN JW, 1995, MOL CELL BIOL, V15, P5412; Cheng CH, 1997, NUCLEIC ACIDS RES, V25, P1369, DOI 10.1093/nar/25.7.1369; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; GOTTESMAN MM, 1973, J MOL BIOL, V77, P531, DOI 10.1016/0022-2836(73)90221-0; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; KERR SM, 1991, EMBO J, V10, P4343, DOI 10.1002/j.1460-2075.1991.tb05012.x; KONRAD EB, 1973, J MOL BIOL, V77, P519, DOI 10.1016/0022-2836(73)90220-9; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; PARK UE, 1989, J BACTERIOL, V171, P2173, DOI 10.1128/jb.171.4.2173-2180.1989; Parks RJ, 1998, VIRUS RES, V56, P135, DOI 10.1016/S0168-1702(98)00055-0; Petit MA, 2000, NUCLEIC ACIDS RES, V28, P4642, DOI 10.1093/nar/28.23.4642; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; WEI YF, 1995, MOL CELL BIOL, V15, P3206	31	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36100	36109		10.1074/jbc.M105643200	http://dx.doi.org/10.1074/jbc.M105643200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11459847	hybrid			2022-12-25	WOS:000171194500009
J	Vanderwerf, SM; Cooper, MJ; Stetsenko, IV; Lutsenko, S				Vanderwerf, SM; Cooper, MJ; Stetsenko, IV; Lutsenko, S			Copper specifically regulates intracellular phosphorylation of the Wilson's disease protein, a human copper-transporting ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MENKES DISEASE; FUNCTIONAL EXPRESSION; TRAFFICKING; GENE; IDENTIFICATION; HOMEOSTASIS; MECHANISM; MEMBRANE; ATP7B	Copper is a trace element essential for normal cell homeostasis. The major physiological role of copper is to serve as a cofactor to a number of key metabolic enzymes. In humans, genetic defects of copper distribution, such as Wilson's disease, lead to severe pathologies, including neurodegeneration, liver lesions, and behavior abnormalities. Here, we demonstrate that, in addition to its role as a cofactor, copper can regulate important posttranslational events such as protein phosphorylation. Specifically, in human cells copper modulates phosphorylation of a key copper transporter, the Wilson's disease protein (WNDP). Copper-induced phosphorylation of WNDP is rapid, specific, and reversible and correlates with the intracellular location of this copper transporter. WNDP is found to have at least two phosphorylation sites, a basal phosphorylation site and a site modified in response to increased copper concentration. Comparative analysis of WNDP, the WNDP pineal isoform, and WNDP C-terminal truncation mutants revealed that the basal phosphorylation site is located in the C-terminal Ser(796)-Tyr(1384) region of WNDP. The copper-induced phosphorylation appears to require the presence of the functional N-terminal domain of this protein. The novel physiological role of copper as a modulator of protein phosphorylation could be central to understanding how copper transport is regulated in mammalian cells.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	lutsenko@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055719] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1-DK55719] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Borjigin J, 1999, J NEUROSCI, V19, P1018; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Noll M, 1998, J BIOL CHEM, V273, P21393, DOI 10.1074/jbc.273.33.21393; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453	24	79	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36289	36294		10.1074/jbc.M102055200	http://dx.doi.org/10.1074/jbc.M102055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470780	hybrid			2022-12-25	WOS:000171194500033
J	Randerath, K; Zhou, GD; Somers, RL; Robbins, JH; Brooks, PJ				Randerath, K; Zhou, GD; Somers, RL; Robbins, JH; Brooks, PJ			A P-32-Postlabeling assay for the oxidative DNA lesion 8,5 '-cyclo-2 '-deoxyadenosine in mammalian tissues - Evidence that four type II I-compounds are dinucleotides containing the lesion in the 3 ' nucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER DNA; XERODERMA-PIGMENTOSUM; EXCISION-REPAIR; FERRIC NITRILOTRIACETATE; DIETARY RESTRICTION; PYRIMIDINE DIMERS; RENAL CARCINOGEN; FENTON REACTIONS; DAMAGE; ADDUCTS	8,5 ' -Cyclopurine-2 ' -deoxynuelcotides, which are strong blocks to mammalian DNA and RNA polymerases, represent a novel class of oxidative DNA lesion in that they are specifically repaired by nucleotide excision repair but not by base excision repair or direct enzymatic reversion. Previous studies using thin layer chromatography of P-32-postlabeled DNA digests have detected several bulky oxidative lesions of unknown structure, called I-compounds, in DNA from normal mammalian organs. We investigated whether any of these type II I-compounds contained 8,5 ' -cyclo-2 ' -deoxyadenosine (cA). Two previously detected type II I-compounds were found to be dinucleotides of the sequence pAp-cAp and pCp-cAp. Furthermore, a modification of the technique resulted in detection of two additional I-compounds, pTp-cAp and pGp-eAp. Each I-compound isolated from neonatal rat liver DNA matched authentic P-32-labeled cA-containing chromatographic standards under nine different chromatographic conditions. Their levels increased significantly after normal birth. The P-32-postlabeling technique used here is capable of detecting 1-5 lesions/diploid mammalian cell. Thus, it should now be possible to detect changes of cA levels resulting from low level ionizing radiation and other conditions associated with oxidative stress, and to assess cA levels in tissues from patients with the genetic disease xeroderma pigmentosum who are unable to carry out nucleotide excision repair.	NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Pharmacol, Div Toxicol, Houston, TX 77030 USA; Glen Res Corp, Sterling, VA 20164 USA; NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brooks, PJ (corresponding author), NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.	pjbrooks@diebr.niaaa.nih.gov			NATIONAL CANCER INSTITUTE [R01CA032157, R37CA032157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000083, Z01AA000083] Funding Source: NIH RePORTER; NCI NIH HHS [CA32157] Funding Source: Medline; NIA NIH HHS [AG07550] Funding Source: Medline; NIEHS NIH HHS [ES04917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABELSON PH, 1994, SCIENCE, V265, P1507, DOI 10.1126/science.7832844; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bartsch H, 2000, EUR J CANCER, V36, P1229, DOI 10.1016/S0959-8049(00)00095-2; Beckman KB, 2000, FREE RADICAL BIO MED, V29, P357, DOI 10.1016/S0891-5849(00)00316-6; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Bykov VJ, 1999, J INVEST DERMATOL, V112, P326, DOI 10.1046/j.1523-1747.1999.00523.x; CARMICHAEL PL, 1992, CARCINOGENESIS, V13, P1127, DOI 10.1093/carcin/13.7.1127; CHANG J, 1993, MUTAT RES, V291, P147, DOI 10.1016/0165-1161(93)90154-R; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CONAWAY CC, 1991, CANCER RES, V51, P3143; de Sanctis C, 1932, RIV SPER FRENIATR ME, V56, P269; deVries A, 1996, SEMIN CANCER BIOL, V7, P229, DOI 10.1006/scbi.1996.0031; DIZDAROGLU M, 1986, BIOCHEM J, V238, P247, DOI 10.1042/bj2380247; DIZDAROGLU M, 2001, FREE RADIC BIOL MED, V30, P22; Friedberg EC, 1995, DNA REPAIR MUTAGENES, P24; FUCIARELLI AF, 1976, RADIAT RES, V110, P35; Giese H, 1999, ONCOGENE, V18, P1257, DOI 10.1038/sj.onc.1202404; Hanawalt PC, 1998, MUTAT RES-FUND MOL M, V400, P117, DOI 10.1016/S0027-5107(98)00084-0; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; HART RW, 1977, P NATL ACAD SCI USA, V74, P5574, DOI 10.1073/pnas.74.12.5574; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Henle ES, 1999, J BIOL CHEM, V274, P962, DOI 10.1074/jbc.274.2.962; KECK K, 1968, Z NATURFORSCH PT B, VB 23, P1034; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lloyd DR, 1999, MUTAT RES-FUND MOL M, V424, P23, DOI 10.1016/S0027-5107(99)00005-6; LU LJW, 1986, CANCER RES, V46, P3046; MARIAGGI N, 1976, TETRAHEDRON, V32, P2385, DOI 10.1016/0040-4020(76)87020-2; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; MIASKIEWICZ K, 1995, NUCLEIC ACIDS RES, V23, P515, DOI 10.1093/nar/23.3.515; MU D, 1994, NUCLEIC ACIDS RES, V22, P4869, DOI 10.1093/nar/22.23.4869; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nomoto M, 1999, CARCINOGENESIS, V20, P837, DOI 10.1093/carcin/20.5.837; PETTIJOHN DE, 1963, BIOCHIM BIOPHYS ACTA, V72, P127; RANDERATH E, 1995, MUTAT RES-GENET TOX, V341, P265, DOI 10.1016/0165-1218(95)90098-5; Randerath E, 1997, CARCINOGENESIS, V18, P857, DOI 10.1093/carcin/18.4.859; RANDERATH K, 1981, P NATL ACAD SCI-BIOL, V78, P6126, DOI 10.1073/pnas.78.10.6126; RANDERATH K, 1991, MUTAT RES, V250, P135, DOI 10.1016/0027-5107(91)90169-O; RANDERATH K, 1986, CARCINOGENESIS, V7, P1615, DOI 10.1093/carcin/7.9.1615; RANDERATH K, 1993, MUTAT RES, V295, P247, DOI 10.1016/0921-8734(93)90024-W; Randerath K, 1996, CHEM RES TOXICOL, V9, P247, DOI 10.1021/tx950085v; Randerath K, 1999, MUTAT RES-FUND MOL M, V424, P183, DOI 10.1016/S0027-5107(99)00018-4; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; ROBBINS JH, 1991, BRAIN, V114, P1335, DOI 10.1093/brain/114.3.1335; Rodriguez H, 1997, CANCER RES, V57, P2394; Romieu A, 1999, CHEM RES TOXICOL, V12, P412, DOI 10.1021/tx9802668; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; Scholl TO, 2000, J NUTR, V130, p443S, DOI 10.1093/jn/130.2.443S; SETLOW P, 1975, CRC HDB BIOCH MOL BI, V2, P317; SETLOW RB, 1964, P NATL ACAD SCI USA, V51, P226, DOI 10.1073/pnas.51.2.226; SUH J, 1994, BIOORG CHEM, V22, P318, DOI 10.1006/bioo.1994.1025; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; *US PUHS NIEHS NIH, 2001, 9 US PHS NIEHS NIH, P165; Vilenchik MM, 2000, P NATL ACAD SCI USA, V97, P5381, DOI 10.1073/pnas.090099497; Vulimiri SV, 1998, MUTAT RES-FUND MOL M, V422, P297, DOI 10.1016/S0027-5107(98)00211-5; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; WEATHERALL DJ, 1987, OXFORD TXB MED, V1; WEINFELD M, 1991, BIOCHEMISTRY-US, V30, P1091, DOI 10.1021/bi00218a031; Wijnhoven SWP, 2000, ONCOGENE, V19, P5034, DOI 10.1038/sj.onc.1203844; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; YANO K, 1950, Folia Psychiatr Neurol Jpn, V4, P143; Zhou GD, 1999, NUTR CANCER, V35, P87, DOI 10.1207/S1532791487-95; Zhou GD, 2000, MUTAT RES-FUND MOL M, V447, P137, DOI 10.1016/S0027-5107(99)00211-0; Zhou GD, 2001, MUTAT RES-FUND MOL M, V479, P71, DOI 10.1016/S0027-5107(01)00148-8; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	72	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					36051	36057		10.1074/jbc.M105472200	http://dx.doi.org/10.1074/jbc.M105472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11454870	hybrid			2022-12-25	WOS:000171109300110
J	Strand, J; Nili, M; Homsher, E; Tobacman, LS				Strand, J; Nili, M; Homsher, E; Tobacman, LS			Modulation of myosin function by isoform-specific properties of Saccharomyces cerevisiae and muscle tropomyosins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; THIN FILAMENT REGULATION; TROPONIN-TROPOMYOSIN; COOPERATIVE BINDING; ALPHA-TROPOMYOSIN; F-ACTIN; ESCHERICHIA-COLI; HEAVY-MEROMYOSIN; STRIATED-MUSCLE; COILED COILS	Tropomyosin is an extended coiled-coil protein that influences actin function by binding longitudinally along thin filaments. The present work compares cardiac tropomyosin and the two tropomyosins from Saccharomyces cerevisiae, TPM1 and TPM2, that are much shorter than vertebrate tropomyosins. Unlike cardiac tropomyosin, the phase of the coiled-coil-forming heptad repeat of TPM2 is discontinuous; it is interrupted by a 4-residue deletion. TPM1 has two such deletions, which flank the 38-residue partial gene duplication that causes TPM1 to span five actins instead of the four of TPM2. Each of the three tropomyosin isoforms modulates actin-myosin interactions, with isoform-specific effects on cooperativity and strength of myosin binding. These different properties can be explained by a model that combines opposite effects, steric hindrance between myosin and tropomyosin when the latter is bound to a subset of its sites on actin, and also indirect, favorable interactions between tropomyosin and myosin, mediated by mutually promoted changes in actin. Both of these effects are influenced by which tropomyosin isoform is present. Finally, the tropomyosins have isoform-specific effects on in vitro sliding speed and on the myosin concentration dependence of this movement, suggesting that non-muscle tropomyosin isoforms exist, at least in part, to modulate myosin function.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA	University of Iowa; University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, 200 Hawkins Sr,SE 610-GH, Iowa City, IA 52242 USA.	larry-tobacman@uiowa.edu			NHLBI NIH HHS [HL-38834] Funding Source: Medline; NIAMS NIH HHS [AR-30988] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038834, R01HL038834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Brown JH, 1996, PROTEINS, V26, P134; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Burhop J, 2001, J BIOL CHEM, V276, P20788, DOI 10.1074/jbc.M101110200; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DREES B, 1995, J CELL BIOL, V128, P383, DOI 10.1083/jcb.128.3.383; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; GEEVES MA, 1986, PROC R SOC SER B-BIO, V229, P85, DOI 10.1098/rspb.1986.0076; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HILL LE, 1992, J BIOL CHEM, V267, P16106; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HOLMES KC, 1995, BIOPHYS J, V68, pS2; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; Homsher E, 2000, J PHYSIOL-LONDON, V524, P233, DOI 10.1111/j.1469-7793.2000.00233.x; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; Korman VL, 1999, J BIOL CHEM, V274, P22191, DOI 10.1074/jbc.274.32.22191; Korman VL, 2000, J BIOL CHEM, V275, P22470, DOI 10.1074/jbc.M002939200; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; Landis CA, 1997, J BIOL CHEM, V272, P14051, DOI 10.1074/jbc.272.22.14051; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Luo Y, 1998, BIOPHYS J, V74, P3111, DOI 10.1016/S0006-3495(98)78017-8; Maytum R, 2000, BIOCHEMISTRY-US, V39, P11913, DOI 10.1021/bi000977g; Maytum R, 2001, BIOCHEMISTRY-US, V40, P7334, DOI 10.1021/bi010072i; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; MURRAY JM, 1982, BIOCHEMISTRY-US, V21, P906, DOI 10.1021/bi00534a015; Prochniewicz E, 1999, BIOCHEMISTRY-US, V38, P14860, DOI 10.1021/bi991343g; Rosol M, 2000, BIOPHYS J, V78, P908, DOI 10.1016/S0006-3495(00)76648-3; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; TSUCHIYA T, 1982, BIOPOLYMERS, V21, P979, DOI 10.1002/bip.360210510; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1983, BIOCHEMISTRY-US, V22, P2770, DOI 10.1021/bi00280a027	50	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34832	34839		10.1074/jbc.M104750200	http://dx.doi.org/10.1074/jbc.M104750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457840	hybrid			2022-12-25	WOS:000171024600066
J	Mueller, EG; Palenchar, PM; Buck, CJ				Mueller, EG; Palenchar, PM; Buck, CJ			The role of the cysteine residues of ThiI in the generation of 4-thiouridine in tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI TRANSFER-RNA; PERFORMANCE LIQUID-CHROMATOGRAPHY; SULFUR CLUSTER BIOSYNTHESIS; IN-VITRO BIOSYNTHESIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; THIAMIN BIOSYNTHESIS; NIFS GENE; SULFURTRANSFERASE; PROTEIN	The enzyme Thil is common to the biosynthetic pathways leading to both thiamin and 4-thiouridine in tRNA. We earlier noted the presence of a motif shared with sulfurtransferases, and we reported that the cysteine residue (Cys-456 of Escherichia coli Thil found in this motif is essential for activity (Palenchar, P. M., Buck, C. J., Cheng, H., Larson, T. J., and Mueller, E. G. (2000) J. Biol. Chem 275, 8283-8286). In light of that finding and the report of the involvement of the protein IscS in the reaction (Kambampati, M, and Lauhon, C. T. (1999) Biochemistry 38, 16561-16568), we proposed two mechanisms for the sulfur transfer mediated by Thil, and both suggested possible involvement of the thiol group of another cysteine residue in Thil. We have now substituted each of the cysteine residues with alanine and characterized the effect on activity in vivo and in vitro. Cys-108 and Cys-202 were converted to alanine with no significant effect on Thil activity, and C207A Thil was only mildly impaired. Substitution of Cys-344, the only cysteine residue conserved among all sequenced Thil, resulted in the loss of function in vivo and a 2700-fold reduction in activity measured in vitro. We also examined the possibility that Thil contains an iron-sulfur cluster or disulfide bonds in the resting state, and we found no evidence to support the presence of either species. We propose that Cys-344 forms a disulfide bond with Cys-456 during turnover, and we present evidence that a disulfide bond can form between these two residues in native Thil and that disulfide bonds do form in Thil during turnover. We also discuss the relevance of these findings to the biosynthesis of thiamin and iron-sulfur clusters.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Mueller, EG (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.				NIGMS NIH HHS [GM59636, T32 GM08550] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059636, T32GM008550] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRELL JW, 1971, J BIOL CHEM, V246, P294; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Agar JN, 1999, J INORG BIOCHEM, V74, P61; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BERGSTROM DE, 1971, BIOCHEMISTRY-US, V11, P1; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; CARRE DS, 1974, BIOCHIMIE, V56, P1089, DOI 10.1016/S0300-9084(74)80097-0; Choudens Sandrine Ollagnier-de, 1999, FEBS Letters, V453, P25; DAWSON RMC, 1986, DATA BIOCH RES, P388; FAVRE A, 1969, BIOCHEM BIOPH RES CO, V37, P266, DOI 10.1016/0006-291X(69)90729-3; FAVRE A, 1971, J MOL BIOL, V58, P367, DOI 10.1016/0022-2836(71)90252-X; Flint DH, 1996, J BIOL CHEM, V271, P16068; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; Gibson KJ, 1999, BIOCHEM BIOPH RES CO, V254, P632, DOI 10.1006/bbrc.1998.9991; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; KRAMER GF, 1988, J BACTERIOL, V170, P2344, DOI 10.1128/jb.170.5.2344-2351.1988; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; LIPSETT MN, 1972, J BIOL CHEM, V247, P1458; LIPSETT MN, 1978, J BACTERIOL, V135, P993, DOI 10.1128/JB.135.3.993-997.1978; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Mueller EG, 1999, PROTEIN SCI, V8, P2424; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; PETERKOFSKY A, 1965, BIOCHEM BIOPH RES CO, V20, P780, DOI 10.1016/0006-291X(65)90086-0; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; RAMABHADRAN TV, 1976, P NATL ACAD SCI USA, V73, P59, DOI 10.1073/pnas.73.1.59; Ramamurthy V, 1999, J BIOL CHEM, V274, P22225, DOI 10.1074/jbc.274.32.22225; RYALS J, 1982, J BACTERIOL, V151, P899, DOI 10.1128/JB.151.2.899-904.1982; Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; THOMAS G, 1977, CR ACAD SCI D NAT, V284, P1345; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	40	97	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33588	33595		10.1074/jbc.M104067200	http://dx.doi.org/10.1074/jbc.M104067200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443125	hybrid			2022-12-25	WOS:000170910200042
J	Pages, S; Kester, HCM; Visser, J; Benen, JAE				Pages, S; Kester, HCM; Visser, J; Benen, JAE			Changing a single amino acid residue switches processive and non-processive behavior of Aspergillus niger endopolygalacturonase I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ATTACK; SEQUENCE; FAMILY; GENE; IDENTIFICATION; CLASSIFICATION; CLONING	Processivity, also known as multiple attack on a single chain, is a feature commonly encountered only in enzymes in which the substrate binds in a tunnel. However, of the seven Aspergillus niger endopolygalacturonases, which ba-ve an open substrate binding cleft, four enzymes show processive behavior, whereas the other endopolygalacturonases are randomly acting enzymes. In a previous study (Benen, J.A.E., Kester, H.C.M., and Visser, J. (1999) Eur. J. Biochem. 259, 577-585) we proposed that the high affinity for the substrate of subsite -5 of processive endopolygalacturonase I constitutes the origin of the multiple attack behavior. Based on primary sequence alignments of A. niger endopolygalacturonases and three-dimensional structure analysis of endopolygalacturonase II, an arginine residue was identified in the processive enzymes at a position commensurate with subsite -5, whereas a serine residue was present at this position in the non-processive enzymes. In endopolygalacturonase I mutation R95S was introduced, and in endopolygalacturonase II mutation S91R was introduced. Product progression analysis on polymer substrate and. bond cleavage frequency studies using o1igoga1acturonides of defined chain length for the mutant enzymes revealed that processive/non-processive behavior is indeed interchangeable by one single amino acid substitution at subsite -5, Arg --> Ser or Ser --> Arg.	Wageningen Univ, Sect Mol Genet Ind Microorganisms, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Benen, JAE (corresponding author), Wageningen Univ, Sect Mol Genet Ind Microorganisms, Dreyenlaan 2, NL-6703 HA Wageningen, Netherlands.	jac.benen@algemeen.mgim.wag-ur.nl						ALLEN JD, 1978, CARBOHYD RES, V61, P377, DOI 10.1016/S0008-6215(00)84497-3; Armand S, 2000, J BIOL CHEM, V275, P691, DOI 10.1074/jbc.275.1.691; Benen JAE, 1999, EUR J BIOCHEM, V259, P577, DOI 10.1046/j.1432-1327.1999.00080.x; BUSSINK HJD, 1991, CURR GENET, V20, P301, DOI 10.1007/BF00318519; BUSSINK HJD, 1990, FEBS LETT, V273, P127, DOI 10.1016/0014-5793(90)81066-W; BUSSINK HJD, 1992, EUR J BIOCHEM, V208, P83, DOI 10.1111/j.1432-1033.1992.tb17161.x; DEGRAAFF L, 1992, CURR GENET, V22, P21, DOI 10.1007/BF00351737; FraissinetTachet L, 1995, CURR GENET, V29, P96, DOI 10.1007/BF00313199; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Pages S, 2000, J BIOL CHEM, V275, P29348, DOI 10.1074/jbc.M910112199; Parenicova L, 2000, BIOCHEM J, V345, P637, DOI 10.1042/0264-6021:3450637; Parenicova L, 1998, EUR J BIOCHEM, V251, P72, DOI 10.1046/j.1432-1327.1998.2510072.x; Parenicova L, 2000, FEBS LETT, V467, P333, DOI 10.1016/S0014-5793(00)01173-X; ROBYT JF, 1967, ARCH BIOCHEM BIOPHYS, V122, P8, DOI 10.1016/0003-9861(67)90118-X; ROBYT JF, 1970, ARCH BIOCHEM BIOPHYS, V138, P662, DOI 10.1016/0003-9861(70)90394-2; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; SOMEREN MAK, 1991, CURR GENET, V20, P293, DOI 10.1007/BF00318518; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474; Wubben JP, 1999, APPL ENVIRON MICROB, V65, P1596	21	42	43	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33652	33656		10.1074/jbc.M105770200	http://dx.doi.org/10.1074/jbc.M105770200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445590	hybrid			2022-12-25	WOS:000170910200050
J	Takita, J; Yang, HW; Chen, YY; Hanada, R; Yamamoto, K; Teitz, T; Kidd, V; Hayashi, Y				Takita, J; Yang, HW; Chen, YY; Hanada, R; Yamamoto, K; Teitz, T; Kidd, V; Hayashi, Y			Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma	ONCOGENE			English	Article						allelic imbalance; chromosome 2q; neuroblastoma; caspase 8; caspase 10	TUMOR-SUPPRESSOR GENES; CELL LUNG-CARCINOMA; N-MYC AMPLIFICATION; P16 CDKN2A GENE; P73 GENE; HETEROZYGOSITY; APOPTOSIS; EXPRESSION; DELETION; CANCER	We previously reported a high incidence of loss of heterozygosity (LOH) on chromosome 2q33 in neuroblastoma (NB), observed in various types of human cancers including lung cancer, head and neck cancer and follicular thyroid carcinoma. To better elucidate the role of chromosome 20 aberrations in NE, we examined common allelic imbalance (AI) regions on chromosome 20 in 82 NE patients using 10 polymorphic microsatellite markers. AI on 20 was detected in 26 (32%) of 82 NE cases. There was a distinct common AI region between the D2S115 and D2S307 markers on 2q33, The distance between these markers was about 2.0 cM, Recently, the caspase 8 and caspase 10 genes, both of which encode cystein protease, were mapped to chromosome 2q33, Since the common AI region on 2q33 includes the caspase 8 and caspase 10 genes, the alterations of these genes were examined further. Absent or reduced expression of caspase 8 and caspase 10 were found in 19 (70%) of 27 and two (7%) of 27 NE cell lines by reverse transcription-polymerase chain reaction, respectively. A missense mutation was detected at codon 96, GCT (Alanine) to GTT (Valine), of the caspase 8 gene in one of the NE cell lines lacking caspase 8 expression. Thirteen (68%) of 19 cell lines lacking caspase 8 expression displayed methylation of the CpG island of the caspase 8 gene, whereas only one (13%) of eight cell lines with caspase 8 expression showed caspase 8 methylation (P=0.031), Furthermore, there was significant association between Al at 2q33 and loss of caspase 8 expression (P=0.026), These results indicated that there was a tumor suppressor gene in the common AI region on chromosome 2q33 involved in the pathogenesis of a subset of NE. It is possible that the caspase 8 gene is one of the candidate tumor suppressor genes for NE and inactivation of this gene plays an important role in the tumorigenesis of NE through mainly its methylation.	Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; Saitama Childrens Med Ctr, Div Hematol Oncol, Iwatsuki, Saitama 3390077, Japan; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	University of Tokyo; Saitama Children's Medical Center; St Jude Children's Research Hospital	Hayashi, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hayashiy-tky@umin.ac.jp	Chen, Yuyan/V-7279-2019	Chen, Yuyan/0000-0002-2894-1430	NCI NIH HHS [2RD1 CA67938] Funding Source: Medline; PHS HHS [21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA067938, R01CA067938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CEYNS V, 1998, GENE DEV, V12, P1551; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FERNANDESALNEMR.T, 1909, P NATL ACAD SCI USA, V93, P7464; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Herman JG, 1996, CANCER RES, V56, P722; Inoue A, 1997, INT J CANCER, V72, P1070, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1070::AID-IJC23>3.0.CO;2-7; Kaneko M, 1998, MED PEDIATR ONCOL, V31, P1, DOI 10.1002/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H; Kawano S, 1999, BLOOD, V94, P1113; KOHNO T, 1994, ONCOGENE, V9, P103; Kong XT, 1997, CANCER RES, V57, P3772; Kong XT, 1997, EUR J CANCER, V33, P1962, DOI 10.1016/S0959-8049(97)00209-8; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Muliokandov MR, 1996, CANCER RES, V56, P197; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Ransom DT, 1998, HEAD NECK-J SCI SPEC, V20, P404; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAWAGUCHI S, 1990, CANCER, V66, P1879, DOI 10.1002/1097-0142(19901101)66:9<1879::AID-CNCR2820660905>3.0.CO;2-L; Schor NF, 1999, J NEURO-ONCOL, V41, P159, DOI 10.1023/A:1006171406740; SCHWAB M, 1993, SEMIN CANCER BIOL, V4, P13; Schwemmler W, 1996, ENDOCYT CELL RES, V11, P219; SHISEKI M, 1994, CANCER RES, V54, P5643; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1997, CANCER RES, V57, P907; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Takita J, 2000, EUR J CANCER, V36, P508, DOI 10.1016/S0959-8049(99)00342-1; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Yang HW, 2000, INT J MOL MED, V5, P379; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	45	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4424	4432		10.1038/sj.onc.1204521	http://dx.doi.org/10.1038/sj.onc.1204521			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466626				2022-12-25	WOS:000169912600019
J	Cabeza-Arvelaiz, Y; Sepulveda, JL; Lebovitz, RM; Thompson, TC; Chinault, AC				Cabeza-Arvelaiz, Y; Sepulveda, JL; Lebovitz, RM; Thompson, TC; Chinault, AC			Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22	ONCOGENE			English	Article						prostate cancer; tumor suppressor; human; chromosome 8p; FEZ1; LZTS1	YEAST ARTIFICIAL CHROMOSOME; MAMMALIAN-CELLS; HUMAN GENOME; COLORECTAL-CANCER; BAND 8P22; EXPRESSION; P53; PROMOTER; PROTEIN; REGION	Deletions in the 8p21-22 region of the human genome are among the most common genetic alterations in prostate carcinomas. Several studies in different tumor tissues, including prostate, indicate that there are probably multiple tumor suppressor genes (TSGs) present in this region. To identify candidate TSGs on 8p22 a YAC contig spanning this region was assembled and YAC clones retrofitted with a selectable marker (neo) were transferred into rat prostate AT6,2 cells, Two overlapping YAC clones showed greatly reduced colony-forming efficiency, indicating they may carry a TSG, Two BAC clones encompassing the overlapping region also appeared to exert suppressive effects on the growth of AT6,2 cells, Database searches for genes mapped to the critical region identified a gene known as FEZ1 (LZTS1) as a potential candidate suppressor gene. Subsequent experiments showed that over-expression of LZTS1 cDNA inhibited stable colony-forming efficiencies of AT6,2, HEK-293 and LNCaP cells. In contrast, LZTS1-transfected Rat-1 and RM1 cells were growth-stimulated. Database searches also identified additional isoforms of the LZTS1 mRNA, as well as LZTS1 protein domains reminiscent of those found in transcription factors. Together these data suggest that the LZTS1 gene is involved in the regulation of cell growth and its loss of function may contribute to the development of prostatic carcinomas, as well as other cancers.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Urol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chinault, AC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; Baker A, 1997, NUCLEIC ACIDS RES, V25, P1950, DOI 10.1093/nar/25.10.1950; BALEY PA, 1995, J STEROID BIOCHEM, V52, P403, DOI 10.1016/0960-0760(95)00001-G; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; CHINAULT AC, 1994, CURRENT PROTOCOLS HU, V1; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHUMAKOV IM, 1995, NATURE, V377, P175; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farrington SM, 1996, ONCOGENE, V12, P1803; FOULKES NS, 1996, BIOCHIM BIOPHYS ACTA, V1288, P101; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; ICHIKAWA T, 1994, CANCER RES, V54, P2299; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KAGAN J, 1995, ONCOGENE, V11, P2121; Kirschner LS, 1999, BIOTECHNIQUES, V27, P72; Koreth J, 1999, ONCOGENE, V18, P1157, DOI 10.1038/sj.onc.1202372; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Murakami YS, 1996, CANCER RES, V56, P2157; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; Park BJ, 2000, CANCER RES, V60, P3031; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Reddy DE, 2000, ONCOGENE, V19, P217, DOI 10.1038/sj.onc.1203264; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; TUCK SP, 1989, ONCOGENE RES, V4, P81; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	49	44	47	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4169	4179		10.1038/sj.onc.1204539	http://dx.doi.org/10.1038/sj.onc.1204539			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464283				2022-12-25	WOS:000169857200007
J	Ye, DM; Wei, M; McGuire, M; Huang, K; Kapadia, G; Herzberg, O; Martin, BM; Dunaway-Mariano, D				Ye, DM; Wei, M; McGuire, M; Huang, K; Kapadia, G; Herzberg, O; Martin, BM; Dunaway-Mariano, D			Investigation of the catalytic site within the ATP-grasp domain of Clostridium symbiosum pyruvate phosphate dikinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ALANINE LIGASE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; BINDING SITE; PHOSPHOENOLPYRUVATE FORMATION; GLUTATHIONE SYNTHETASE; NUCLEOTIDE-BINDING; UTILIZING ENZYMES; B-DOMAIN; LOCATION	Pyruvate phosphate dikinase (PPDK) catalyzes the interconversion of ATP, P-i, and pyruvate with AMP, PPi, and phosphoenolpyruvate (PEP) in three partial reactions as follows: 1) E-His + ATP --> E-His-PP-AMP; 2) E-His-PP.AMP + P-i --> E-His-P.AMP.PPi; and 3) E-His-P + pyruvate --> E.PEP using His-455 as the carrier of the transferred phosphoryl groups. The crystal structure of the Clostridium symbiosum PPDK (in the unbound state) reveals a three-domain structure consisting of consecutive N-terminal, central His-455, and C-terminal domains. The N-terminal and central His-455 domains catalyze partial reactions 1 and 2, whereas the C-terminal and central His-455 domains catalyze partial reaction 3. Attempts to obtain a crystal structure of the enzyme with substrate ligands bound at the nucleotide binding domain have been unsuccessful. The object of the present study is to demonstrate Mg(ll) activation of catalysis at the ATP/P-i active site, to identify the residues at the ATP/P-i active site that contribute to catalysis, and to identify roles for these residues based on their positions within the active site scaffold. First, Mg(II) activation studies of catalysis of E + ATP + P-i --> E-P + AMP + PPi partial reaction were carried out using a truncation mutant (Tem533) in which the C-terminal domain is absent. The kinetics show that a minimum of 2 Mg(II) per active site is required for the reaction. The active site residues used for substrate/cofactor binding/activation were identified by site-directed mutagenesis. Lys-22, Arg-92, Asp-321, Glu-323, and Gln-335 mutants were found to be inactive; Arg-337, Glu-279, Asp-280, and Arg-135 mutants were partially active; and Thr-253 and Gln-240 mutants were almost fully active. The participation of the nucleotide ribose 2'-OH and alpha -P in enzyme binding is indicated by the loss of productive binding seen with substrate analogs modified at these positions. The ATP, P-i, and Mg(II) ions were docked into the PPDK N-terminal domain crevice, in an orientation consistent with substrate/cofactor binding modes observed for other members of the ATP-Grasp fold enzyme superfamily and consistent with the structure-function data. On the basis of this docking model, the ATP polyphosphate moiety is oriented/activated for pyrophosphoryl transfer through interaction with Lys-22 (gamma -P), Arg-92 (alpha -P), and the Gly-101 to Met-103 loop (gamma -P) as well as with the Mg(II) cofactors. The P-i is oriented/activated for partial reaction 2 through interaction with Arg-337 and a Mg(II) cofactor. The Mg(II) ions are bound through interaction with Asp-321, Glu-323, and Gln-335 and substrate. Residues Glu-279, Asp-280, and Arg-135 are suggested to function in the closure of an active site loop, over the nucleotide ribose-binding site.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; NIH, Bethesda, MD 20892 USA	University of New Mexico; University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.			Herzberg, Osnat/0000-0003-2823-7627	NIGMS NIH HHS [GM 36260] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002344, Z01MH002344] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; CARROLL LJ, 1989, J AM CHEM SOC, V111, P5965, DOI 10.1021/ja00197a081; CARROLL LJ, 1994, BIOCHEMISTRY-US, V33, P1134, DOI 10.1021/bi00171a012; Cleland W W, 1979, Methods Enzymol, V63, P500; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; Fan C, 1997, BIOCHEMISTRY-US, V36, P2531, DOI 10.1021/bi962431t; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Joyce MA, 2000, BIOCHEMISTRY-US, V39, P17, DOI 10.1021/bi991696f; McGuire M, 1998, BIOCHEMISTRY-US, V37, P13463, DOI 10.1021/bi980920i; McGuire M, 1996, BIOCHEMISTRY-US, V35, P8544, DOI 10.1021/bi960275k; MEHL A, 1994, BIOCHEMISTRY-US, V33, P1093, DOI 10.1021/bi00171a007; MICHAELS G, 1978, J BIOL CHEM, V253, P7656; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; POCALYKO DJ, 1990, BIOCHEMISTRY-US, V29, P10757, DOI 10.1021/bi00500a006; Roussel A., 1989, SILICON GRAPHICS GEO; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; THRALL SH, 1994, BIOCHEMISTRY-US, V33, P1103, DOI 10.1021/bi00171a008; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; WANG HC, 1988, BIOCHEMISTRY-US, V27, P625, DOI 10.1021/bi00402a020; Wang WR, 1998, BIOCHEMISTRY-US, V37, P15647, DOI 10.1021/bi981405n; Wood H G, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P85; XU Y, 1995, BIOCHEMISTRY-US, V34, P2181, DOI 10.1021/bi00007a011; YANKIE L, 1995, BIOCHEMISTRY-US, V34, P2188, DOI 10.1021/bi00007a012	29	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37630	37639		10.1074/jbc.M105631200	http://dx.doi.org/10.1074/jbc.M105631200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11468288	Green Submitted, hybrid			2022-12-25	WOS:000171375700100
J	Bernal-Mendez, E; Leumann, CJ				Bernal-Mendez, E; Leumann, CJ			Conformational diversity versus nucleic acid triplex stability, a combinatorial study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR DNA TRIPLEX; HELIX FORMATION; PSEUDOROTATIONAL EQUILIBRIUM; PENTOFURANOSE MOIETY; SUGAR CONFORMATIONS; CHEMICAL SYNTHESIS; KINETIC-ANALYSIS; 3RD STRAND; DUPLEX DNA; RNA	The stability of a triple helix formed between a DNA duplex and an incoming oligonucleotide strand strongly depends on the solvent conditions and on intrinsic chemical and conformational factors. Attempts to increase triple helix stability in the past included chemical modification of the backbone, sugar ring, and bases in the third strand. However, the predictive power of such modifications is still rather poor. We therefore developed a method that allows for rapid screening of conformationally diverse third strand oligonucleotides for triplex stability in the parallel pairing motif to a given DNA double helix sequence. Combinatorial libraries of oligonucleotides of the requisite (fixed) base composition and length that vary in their sugar unit (ribose or deoxyribose) at each position were generated. After affinity chromatography against their corresponding immobilized DNA target duplex, utilizing a temperature gradient as the selection criterion, the oligonucleotides forming the most stable triple helices were selected and characterized by physicochemical methods. Thus, a series of oligonucleotides were identified that allowed us to define basic rules for triple helix stability in this conformationally diverse system. It was found that ribocytidines in the third strand increase triplex stability relative to deoxyribocytidines independently of the neighboring bases and position along the strand. However, remarkable sequence-dependent differences in stability were found for (deoxy)thymidines and uridines.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Leumann, CJ (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	leumann@ioc.unibe.ch	Leumann, Christian/AAB-5923-2019	Leumann, Christian/0000-0002-7996-7083				*AM PHARM BIOT, US MAN 56 1111 56 GE; Asensio JL, 1999, J AM CHEM SOC, V121, P11063, DOI 10.1021/ja991949s; Bartley JP, 1997, BIOCHEMISTRY-US, V36, P14502, DOI 10.1021/bi970710q; BEIER H, 1991, ESSENTIAL MOL BIOL P, V2, P221; CANTOR CR, 1980, BIOPHYS CHEM, V2, P382; ESCUDE C, 1993, NUCLEIC ACIDS RES, V21, P5547, DOI 10.1093/nar/21.24.5547; FELSENFELD G, 1957, BIOCHIM BIOPHYS ACTA, V26, P457, DOI 10.1016/0006-3002(57)90091-4; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; Gotfredsen CH, 1998, J AM CHEM SOC, V120, P4281, DOI 10.1021/ja973221m; HAN HY, 1993, P NATL ACAD SCI USA, V90, P3806, DOI 10.1073/pnas.90.9.3806; HANDERBOL P, 1995, P NATL ACAD SCI USA, V93, P2811; Hildbrand S, 1997, J AM CHEM SOC, V119, P5499, DOI 10.1021/ja9704904; IMANISHI T, 1999, SYNTH ORG CHEM JPN, V57, P77; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; Leitner D, 2000, BIOCHEMISTRY-US, V39, P5886, DOI 10.1021/bi992630n; LIQUIER J, 1995, NUCLEIC ACIDS RES, V23, P1722, DOI 10.1093/nar/23.10.1722; LIQUIER J, 1991, J BIOMOL STRUCT DYN, V9, P437, DOI 10.1080/07391102.1991.10507927; MACAYA RF, 1992, J AM CHEM SOC, V114, P781, DOI 10.1021/ja00028a067; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NIELSEN PE, 1995, ANNU REV BIOPH BIOM, V24, P167, DOI 10.1146/annurev.bb.24.060195.001123; Noronha A, 1998, NUCLEIC ACIDS RES, V26, P2665, DOI 10.1093/nar/26.11.2665; PEI D, 1991, SCIENCE, V253, P1408, DOI 10.1126/science.1716784; PLAVEC J, 1993, J AM CHEM SOC, V115, P9734, DOI 10.1021/ja00074a046; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; Prakash TP, 2000, TETRAHEDRON LETT, V41, P4855, DOI 10.1016/S0040-4039(00)00703-6; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; SANGER W, 1984, PRINCIPLES NUCL ACID, P271; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHIMIZU M, 1992, FEBS LETT, V302, P155, DOI 10.1016/0014-5793(92)80428-J; SHINDO H, 1993, BIOCHEMISTRY-US, V32, P8963, DOI 10.1021/bi00085a030; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; Sun JS, 1996, CURR OPIN STRUC BIOL, V6, P327, DOI 10.1016/S0959-440X(96)80051-0; Tarkoy M, 1998, BIOCHEMISTRY-US, V37, P5810, DOI 10.1021/bi9728102; Thibaudeau C, 1996, J ORG CHEM, V61, P266, DOI 10.1021/jo951124a; Torigoe H, 1999, BIOCHEMISTRY-US, V38, P14653, DOI 10.1021/bi990832d; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; XODO LE, 1995, EUR J BIOCHEM, V228, P918, DOI 10.1111/j.1432-1033.1995.tb20340.x	44	7	8	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35320	35327		10.1074/jbc.M105794200	http://dx.doi.org/10.1074/jbc.M105794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11441024	hybrid			2022-12-25	WOS:000171109300017
J	Karaiskou, A; Perez, LH; Ferby, I; Ozon, R; Jessus, C; Nebreda, AR				Karaiskou, A; Perez, LH; Ferby, I; Ozon, R; Jessus, C; Nebreda, AR			Differential regulation of Cdc2 and Cdk2 by RINGO and Cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEIOTIC CELL-CYCLE; BRAIN-SPECIFIC ACTIVATOR; B-TYPE CYCLINS; DEPENDENT KINASE; XENOPUS OOCYTES; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; PHOSPHORYLATES CDC2; CATALYTIC SUBUNIT; INHIBITORY KINASE	Cyclin-dependent kinases (Cdks) are key regulators of the eukaryotic cell division cycle. Cdk1 (Cdc2) and Cdk2 should be bound to regulatory subunits named cyclins as well as phosphorylated on a conserved Thr located in the T-loop for full enzymatic activity. Cdc2- and Cdk2-cyclin complexes can be inactivated by phosphorylation on the catalytic cleft-located Thr-14 and Tyr-15 residues or by association with inhibitory subunits such as P21(Cip1). We have recently identified a novel Cdc2 regulator named RINGO that plays an important role in the meiotic cell cycle of Xenopus oocytes. RINGO can bind and activate Cdc2 but has no sequence homology to cyclins. Here we report that, in contrast with Cdc2-cyclin complexes, the phosphorylation of Thr-161 is not required for full activation of Cde2 by RINGO. We also show that RINGO can directly stimulate the kinase activity of Cdk2 independently of Thr-160 phosphorylation. Moreover, RINGO-bound Cdc2 and Cdk2 are both less susceptible to inhibition by p21(cip1), whereas the Thr-14/Tyr-15 kinase Myt1 can negatively regulate the activity of Cdc2-RINGO with reduced efficiency. Our results indicate that Cdk-RINGO complexes may be active under conditions in which cyclin-bound Cdks are inhibited and can therefore play different regulatory roles.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Paris 06, ESA 7080, CNRS, INRA,Lab Physiol Reprod, F-75005 Paris, France	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Sorbonne Universite	Nebreda, AR (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Ferby, Ingvar/B-7895-2008; Nebreda, Angel Rodriguez/R-9594-2019; Perez, Laurent/ABA-4145-2021	Perez, Laurent/0000-0002-8860-7928; Karaiskou, Anthi/0000-0002-1482-7899; Ferby, Ingvar/0000-0002-3435-1728				Adams PD, 1996, MOL CELL BIOL, V16, P6623; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Ferby I, 1999, GENE DEV, V13, P2177, DOI 10.1101/gad.13.16.2177; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Furuno N, 1997, EMBO J, V16, P3860, DOI 10.1093/emboj/16.13.3860; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Karaiskou A, 1999, J CELL SCI, V112, P3747; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; Kumagai A, 1997, METHOD ENZYMOL, V283, P564; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Lenormand JL, 1999, EMBO J, V18, P1869, DOI 10.1093/emboj/18.7.1869; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nakajo N, 2000, GENE DEV, V14, P328; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Ross KE, 2000, MOL BIOL CELL, V11, P1597, DOI 10.1091/mbc.11.5.1597; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; XIANG Y, 1993, NATURE, V366, P701	50	68	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					36028	36034		10.1074/jbc.M104722200	http://dx.doi.org/10.1074/jbc.M104722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461916	Green Published, hybrid			2022-12-25	WOS:000171109300107
J	Lin, SS; Manchester, JK; Gordon, JI				Lin, SS; Manchester, JK; Gordon, JI			Enhanced gluconeogenesis and increased energy storage as hallmarks of aging in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; TRANSCRIPTIONAL ACTIVATOR; CALORIC RESTRICTION; METABOLISM; NAD; CELLS; MIG1; SNF1; SIP4; SIR2	A relationship between life span and cellular glucose metabolism has been inferred from genetic manipulations and caloric restriction of model organisms. In this report, we have used the Snf1p glucose-sensing pathway of Saccharomyces cerevisiae to explore the genetic and biochemical linkages between glucose metabolism and aging. Snf1p is a serine/threonine kinase that regulates cellular responses to glucose deprivation. Loss of Snf4p, an activator of Snf1p, extends generational life span whereas loss of Sip2p, a presumed repressor of the kinase, causes an accelerated aging phenotype. An annotated data base of global age-associated changes in gene expression in isogenic wild-type, sip2 Delta, and snf4 Delta, strains was generated from DNA microarray studies. The transcriptional responses suggested that gluconeogenesis and glucose storage increase as wild-type cells age, that this metabolic evolution is exaggerated in rapidly aging sip2 Delta cells, and that it is attenuated in longer-lived snf4 Delta, cells. To test this hypothesis directly, we applied microanalytic biochemical methods to generation-matched cells from each strain and measured the activities of enzymes and concentrations of metabolites in the gluconeogenic, glycolytic, and glyoxylate pathways, as well as glycogen, ATP, and NAD(+). The sensitivity of the assays allowed comprehensive biochemical profiling to be performed using aliquots of the same cell populations employed for the transcriptional profiling. The results provided additional evidence that aging in S. cerevisiae is associated with a shift away from glycolysis and toward gluconeogenesis and energy storage. They also disclosed that this shift is forestalled by two manipulations that extend life span, caloric restriction and genetic attenuation of the normal age-associated increase in Snf1p activity. Together, these findings indicate that Snf1p activation is not only a marker of aging but also a candidate mediator, because a shift toward energy storage over expenditure could impact myriad aspects of cellular maintenance and repair.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARKING R, 1998, BIOL AGING, P417; Ashrafi K, 2000, GENE DEV, V14, P1872; Ashrafi K, 1999, P NATL ACAD SCI USA, V96, P9100, DOI 10.1073/pnas.96.16.9100; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1111/j.1574-6976.2001.tb00574.x; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HERRERO P, 1995, YEAST, V11, P137, DOI 10.1002/yea.320110205; Jiang JC, 2000, FASEB J, V14, P2135; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Klein CJL, 1998, MICROBIOL-SGM, V144, P13, DOI 10.1099/00221287-144-1-13; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; MCDOUGAL DB, 1990, P NATL ACAD SCI USA, V87, P1357, DOI 10.1073/pnas.87.4.1357; MULLER I, 1971, ARCH MIKROBIOL, V77, P20, DOI 10.1007/BF00407985; PASSONEAU JV, 1993, ENZYMATIC ANAL PRACT; Ramaswamy NT, 1998, GENETICS, V149, P57; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147	27	149	152	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					36000	36007		10.1074/jbc.M103509200	http://dx.doi.org/10.1074/jbc.M103509200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461906	hybrid			2022-12-25	WOS:000171109300103
J	Liu, TF; Kandala, G; Setaluri, V				Liu, TF; Kandala, G; Setaluri, V			PDZ domain protein GIPC interacts with the cytoplasmic tail of melanosomal membrane protein gp75 (tyrosinase-related protein-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN LOCUS PROTEIN; MOLECULAR-BASIS; C-TERMINUS; PIGMENTATION; MOUSE; ALBINISM; GLYCOPROTEIN; FIBROBLASTS; RECOGNITION; RETENTION	Tyrosinase and tyrosinase-related proteins (TRPs) are a family of melanosomal membrane proteins involved in mammalian pigmentation. Whereas the melanogenic functions of TRPs are localized in their amino-terminal domains that reside within the lumen of melanosomes, the sorting and targeting of these proteins to melanosomes is mediated by signals in their cytoplasmic domains. To identify proteins that interact with the cytoplasmic tail of gp75 (TRP-1), the most abundant melanosomal membrane protein, we performed yeast two-hybrid screening of a melanocyte cDNA library. Here, we show that the cytoplasmic domain of gp75 interacts with a PDZ domain-containing protein. The gp75-interacting protein is identical to GIPC, an RGS (regulator of G protein signaling)/GAIP-interacting protein, and to SEMCAP-1, a transmembrane semaphorin-binding protein. Carboxyl-terminal amino acid residues, Ser-Val-Val, of gp75 are necessary and sufficient for interaction of gp75 with the single PDZ domain in GIPC. Although endogenous and transfected GIPCs bind efficiently to transiently expressed gp75, only a small amount of GIPC is found associated with gp75 at steady state. Using a strategy to selectively synchronize the biosynthesis of endogenous gp75, we demonstrate that only newly synthesized gp75 associates with GIPC, primarily in the juxtanuclear Golgi region. Our data suggest that GIPC/SEMCAP-1 plays a role in biosynthetic sorting of proteins, specifically gp75, to melanosomes.	Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Setaluri, V (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041465, R01AR044617] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44617, AR41465] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Boissy RE, 1998, EXP DERMATOL, V7, P198, DOI 10.1111/j.1600-0625.1998.tb00324.x; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; CHEN YT, 1995, P NATL ACAD SCI USA, V92, P8125, DOI 10.1073/pnas.92.18.8125; CHRISTGAU S, 1991, J BIOL CHEM, V266, P21257; d'Addio M, 2000, HUM MOL GENET, V9, P3011, DOI 10.1093/hmg/9.20.3011; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; EIBERG H, 1987, CLIN GENET, V31, P186; Fang D, 1999, BIOCHEM BIOPH RES CO, V256, P657, DOI 10.1006/bbrc.1999.0400; Fang D, 2000, BIOCHEM BIOPH RES CO, V279, P53, DOI 10.1006/bbrc.2000.3894; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; KINGSTON RE, 1999, CURRENT PROTOCOLS MO; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; Park HY, 1999, J BIOL CHEM, V274, P16470, DOI 10.1074/jbc.274.23.16470; PAWLEK JM, 1998, PIGMENTARY SYSTEM PH; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schiaffino MV, 1999, NAT GENET, V23, P108, DOI 10.1038/12715; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; VIJAYASARADHI S, 1995, J INVEST DERMATOL, V105, P113, DOI 10.1111/1523-1747.ep12313414; VIJAYASARADHI S, 1991, EXP CELL RES, V196, P233, DOI 10.1016/0014-4827(91)90256-T; VIJAYASARADHI S, 1991, INT J CANCER, V47, P298, DOI 10.1002/ijc.2910470221; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; Von Kap-Herr C, 2000, CYTOGENET CELL GENET, V89, P234, DOI 10.1159/000015621; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; XU Y, 1997, J INVEST DERMATOL, V110, P324; Youssoufian H, 1998, BIOTECHNIQUES, V24, P198, DOI 10.2144/98242bm05; ZDARSKY E, 1990, GENETICS, V126, P443	42	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35768	35777		10.1074/jbc.M103585200	http://dx.doi.org/10.1074/jbc.M103585200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11441007	hybrid			2022-12-25	WOS:000171109300074
J	Avvakumov, GV; Grishkovskaya, I; Muller, YA; Hammond, GL				Avvakumov, GV; Grishkovskaya, I; Muller, YA; Hammond, GL			Resolution of the human sex hormone-binding globulin dimer interface and evidence for two steroid-binding sites per homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMERIZATION DOMAINS; PROTEIN SBP; PLASMA; TRANSPORT; RECEPTOR; PROGRAM; SHBG	Human sex hormone-binding globulin (SHBG) transports sex steroids in the blood. It functions as a homodimer, but there is little information about the topography of its dimerization domain, and its steroid binding stoichiometry is controversial. The prevailing assumption is that each homodimeric SHBG molecule contains a single steroid-binding site at the dimer interface. However, crystallographic analysis of the aminoterminal Iaminin G-like domain of human SHBG has shown that the dimerization and steroid-binding sites are distinct and that both monomers within a homodimeric complex are capable of binding steroid. To validate our crystallographic model of the SHBG homodimer, we have used site-directed mutagenesis to create SHBG variants in which single amino acid substitutions (V89E and L122E) were introduced to produce steric clashes at critical positions within the proposed dimerization domain. The resulting dimerization-deficient SHBG variants contain a steroid-binding site with an affinity and specificity indistinguishable from wildtype SHBG. Moreover, when equalized in terms of their monomeric subunit content, dimerization-deficient and wild-type SHBGs have essentially identical steroid binding capacities. These data indicate that both subunits of the SHBG homodimer bind steroid and that measurements of the molar concentration of SHBG homodimer in serum samples have been overestimated by 2-fold.	Univ Western Ontario, Dept Obstet & Gynaecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, Canadian Inst Hlth, Res Grp Fetal & Neonatal Hlth & Dev, London, ON N6A 4L6, Canada; Max Delbruck Ctr Mol Med, Forschungsgrp Kristallog, D-13092 Berlin, Germany; Free Univ Berlin, Fachbereich Biol, Grad Sch, D-14195 Berlin, Germany	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin	Hammond, GL (corresponding author), London Reg Canc Ctr, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	ghammond@uwo.ca	Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928; Hammond, Geoffrey/0000-0002-4639-7336				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beck K, 1997, EUR J BIOCHEM, V247, P339, DOI 10.1111/j.1432-1033.1997.00339.x; BOCCHINFUSO WP, 1994, BIOCHEMISTRY-US, V33, P10622, DOI 10.1021/bi00201a008; BOCCHINFUSO WP, 1992, ENDOCRINOLOGY, V131, P2331, DOI 10.1210/en.131.5.2331; Chen CF, 2000, J COMPOS TECH RES, V22, P127, DOI 10.1520/CTR10632J; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; GRENOT C, 1992, BIOCHEMISTRY-US, V31, P7609, DOI 10.1021/bi00148a024; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; Grishkovskaya I, 1999, ACTA CRYSTALLOGR D, V55, P2053, DOI 10.1107/S0907444999012883; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1986, J STEROID BIOCHEM, V24, P815, DOI 10.1016/0022-4731(86)90442-5; Hammond GL, 1995, TRENDS ENDOCRIN MET, V6, P298, DOI 10.1016/1043-2760(95)00162-X; HAMMOND GL, 1990, ENDOCR REV, V11, P65, DOI 10.1210/edrv-11-1-65; HAMMOND GL, 1985, J STEROID BIOCHEM, V23, P451, DOI 10.1016/0022-4731(85)90192-X; HAMMOND GL, 1993, STEROID HORMONE ACTI, P1; HILDEBRAND C, 1995, BIOCHEMISTRY-US, V34, P3231, DOI 10.1021/bi00010a012; HRYB DJ, 1990, J BIOL CHEM, V265, P6048; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACART M, 1982, CLIN CHIM ACTA, V122, P93, DOI 10.1016/0009-8981(82)90100-0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAMKUNG PC, 1990, J BIOL CHEM, V265, P18345; PETRA PH, 1991, J STEROID BIOCHEM, V40, P735, DOI 10.1016/0960-0760(91)90299-K; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; STRELCHYONOK OA, 1990, J STEROID BIOCHEM, V35, P519, DOI 10.1016/0022-4731(90)90195-X; Sui LM, 1996, PROTEIN SCI, V5, P2514, DOI 10.1002/pro.5560051214	26	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34453	34457		10.1074/jbc.M106274200	http://dx.doi.org/10.1074/jbc.M106274200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457864	hybrid			2022-12-25	WOS:000171024600015
J	Ishimi, Y; Komamura-Kohno, Y				Ishimi, Y; Komamura-Kohno, Y			Phosphorylation of Mcm4 at specific sites by cyclin-dependent kinase leads to loss of Mcm4,6,7 helicase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME-MAINTENANCE PROTEINS; REPLICATION FACTOR MCM4; DNA-REPLICATION; S-PHASE; CELL-CYCLE; CHROMATIN BINDING; FISSION YEAST; HETEROHEXAMERIC COMPLEXES; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE	Mcm proteins that play an essential role in eukaryotic DNA replication are phosphorylated in vivo, and cyclin-dependent protein kinase is at least in part responsible for the phosphorylation of Mcm4. Our group reported that the DNA helicase activity of Mcm4,6,7 complex, which may be involved in initiation of DNA replication, is inhibited following phosphorylation by Cdk2/cyclin A in vitro. Here, we further examined the interplay between mouse Mcm4,6,7 complex and cyclin-dependent kinases and determined the sites required for the phosphorylation of Mcm4. Six Ser and Thr residues, in all, were required for the phosphorylation. Inhibition of Mcm4,6,7 helicase activity by Cdk2/cyclin A was largely relieved by introducing mutations in these residues Mcm4. Anti-phosphothreonine antibodies raised against one of these sites reacted with Mcm4 prepared fro HeLa cells at mitotic phase but did not bind to those at G(1) and G(1)/S, suggesting that this site is mainly phosphorylated in the mitotic phase. Mcm4,6,7 complex purified from HeLa cells at the mitotic phase exhibited a low level of DNA helicase activity, compared with the complexes prepared from cells at other phases. These results suggest that phosphorylation of Mcm4 at specific sites leads to loss of Mcm4,6,7 DNA helicase activity.	Mitsubishi Kagaku Inst Life Sci, Tokyo 1948511, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS)	Ishimi, Y (corresponding author), Mitsubishi Kagaku Inst Life Sci, 11 Minamiooya, Tokyo 1948511, Japan.							Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; Coverley D, 2000, J CELL SCI, V113, P1929; Coverley D, 1998, EXP CELL RES, V238, P63, DOI 10.1006/excr.1997.3829; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Detweiler CS, 1998, P NATL ACAD SCI USA, V95, P2384, DOI 10.1073/pnas.95.5.2384; Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fujita M, 1997, J BIOL CHEM, V272, P10928; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jallepalli PV, 1997, CURR OPIN CELL BIOL, V9, P358, DOI 10.1016/S0955-0674(97)80008-7; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kearsey SE, 2000, EMBO J, V19, P1681, DOI 10.1093/emboj/19.7.1681; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 2001, J CELL SCI, V114, P1447; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; You ZY, 1999, MOL CELL BIOL, V19, P8003	56	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34428	34433		10.1074/jbc.M104480200	http://dx.doi.org/10.1074/jbc.M104480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454864	hybrid			2022-12-25	WOS:000171024600011
J	Tammi, R; Rilla, K; Pienimaki, JP; MacCallum, DK; Hogg, M; Luukkonen, M; Hascall, VC; Tammi, M				Tammi, R; Rilla, K; Pienimaki, JP; MacCallum, DK; Hogg, M; Luukkonen, M; Hascall, VC; Tammi, M			Hyaluronan enters keratinocytes by a novel endocytic route catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; ADULT HUMAN-EPIDERMIS; SKIN ORGAN-CULTURE; RAT-LIVER; RECEPTOR CD44; DETERGENT SOLUBILIZATION; HEPARAN-SULFATE; BINDING; DEGRADATION; INTERNALIZATION	Hyaluronan synthesized in the epidermis has an exceptionally short half-life, indicative of its catabolism by epidermal keratinocytes. An intracellular pool of endogenously synthesized hyaluronan, from 1 to 20 fg/cell, inversely related to cell density, was observed in cultured rat epidermal keratinocytes. More than 80% of the intracellular hyaluronan was small (<90 kDa). Approximately 25% of newly synthesized hyaluronan was endocytosed by the keratinocytes and had a half-life of 2-3 h. A biotinylated aggrecan G(1) domain/link protein probe demonstrated hyaluronan in small vesicles of <similar to>100 nm diameter close to the plasma membrane, and in large vesicles and multivesicular bodies up to 1300 nn diameter around the nucleus. Hyaluronan did not co-localize with markers of lysosomes. However, inhibition of lysosomal acidification with NH4Cl or chloroquine, or treating the cells with the hyaluronidase inhibitor apigenin increased intracellular hyaluronan staining, suggesting that it resided in prelysosomal endosomes. Competitive displacement of hyaluronan from surface receptors using hyaluronan decasaccharides, resulted in a rapid disappearance of this endosomal hyaluronan (t(1/2) similar to5 min), indicating its transitory nature. The ultrastructure of the hyaluronan-containing vesicles, co-localization with marker proteins for different vesicle types, and application of specific uptake inhibitors demonstrated that the formation of hyaluronan-containing vesicles did not involve clathrin-coated pits or caveolae. Treatment of rat epidermal keratinocytes with the OX50 monoclonal antibody against the hyaluronan receptor CD44 increased endosomal hyaluronan. However, no CD44-hyaluronan co-localization was observed intracellularly unless endosomal trafficking was retarded by monensin, or cultivation at 20 degreesC, suggesting CD44 recycling. Rat epidermal keratinocytes thus internalize a large proportion of their newly synthesized hyaluronan into non-clathrin-coated endosomes in a receptor mediated way, and rapidly transport it to slower degradation in the endosomal/lysosomal system.	Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland; Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn ND20, Cleveland, OH 44195 USA; Univ Michigan, Dept Anat & Cell Biol, Ann Arbor, MI 48109 USA	University of Eastern Finland; Cleveland Clinic Foundation; University of Michigan System; University of Michigan	Tammi, R (corresponding author), Univ Kuopio, Dept Anat, POB 1627, FIN-70211 Kuopio, Finland.	raija.tammi@uku.fi	Tammi, Markku/AAQ-7878-2021	Kallio, Merja/0000-0003-0799-344X; Rilla, Kirsi/0000-0002-7862-5727				AGREN UM, 1995, J CELL PHYSIOL, V164, P240, DOI 10.1002/jcp.1041640204; Aguiar DJ, 1999, EXP CELL RES, V252, P292, DOI 10.1006/excr.1999.4641; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BERGER M, 1994, J CLIN INVEST, V94, P1113, DOI 10.1172/JCI117426; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Collis L, 1998, FEBS LETT, V440, P444, DOI 10.1016/S0014-5793(98)01505-1; CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209; CULTY M, 1994, J LEUKOCYTE BIOL, V56, P605, DOI 10.1002/jlb.56.5.605; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; Cupers P, 1997, BIOCHEM BIOPH RES CO, V236, P661, DOI 10.1006/bbrc.1997.7033; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DOWRICK P, 1993, EUR J CELL BIOL, V61, P44; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNN WA, 1980, J BIOL CHEM, V255, P5971; Evanko SP, 1999, J HISTOCHEM CYTOCHEM, V47, P1331, DOI 10.1177/002215549904701013; FRASER JRE, 1988, BIOCHEM J, V256, P153, DOI 10.1042/bj2560153; FRASER JRE, 1985, CELL TISSUE RES, V242, P505; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; Gassmann MG, 2000, EXP CELL RES, V258, P23, DOI 10.1006/excr.2000.4904; HOLM PK, 1993, EUR J CELL BIOL, V62, P362; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HUA Q, 1993, J CELL SCI, V106, P365; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; KUPPUSAMY UR, 1990, BIOCHEM PHARMACOL, V40, P397, DOI 10.1016/0006-2952(90)90709-T; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LAURENT UBG, 1991, EXP PHYSIOL, V76, P695, DOI 10.1113/expphysiol.1991.sp003536; LAURENT UBG, 1992, MATRIX, V12, P130, DOI 10.1016/S0934-8832(11)80054-5; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lesley J, 2000, J BIOL CHEM, V275, P26967; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; MACCALLUM D K, 1990, Skin Pharmacology, V3, P86; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGUIRE PG, 1987, J CELL PHYSIOL, V133, P267, DOI 10.1002/jcp.1041330210; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Meyers SA, 1997, MOL REPROD DEV, V46, P392; OKA JA, 1989, J BIOL CHEM, V264, P12016; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Podyma KA, 1997, BIOCHEM BIOPH RES CO, V241, P446, DOI 10.1006/bbrc.1997.7829; POUMAY Y, 1993, EUR J CELL BIOL, V60, P12; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; RIPELLINO JA, 1985, J HISTOCHEM CYTOCHEM, V33, P1060, DOI 10.1177/33.10.4045184; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; SMEDSROD B, 1984, BIOCHEM J, V223, P617, DOI 10.1042/bj2230617; STENBERG PE, 1984, HISTOCHEM J, V16, P983, DOI 10.1007/BF01003853; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; TAMMI R, 1986, J CELL PHYSIOL, V126, P389, DOI 10.1002/jcp.1041260309; Tammi RH, 2000, HISTOCHEM CELL BIOL, V113, P265, DOI 10.1007/s004180000128; Tuhkanen AL, 1997, J INVEST DERMATOL, V109, P213, DOI 10.1111/1523-1747.ep12319402; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; UNDERHILL CB, 1993, DEV BIOL, V155, P324, DOI 10.1006/dbio.1993.1032; WATTS C, 1992, J CELL SCI, V103, P1; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANNARIELLOBROWN J, 1992, BIOCHEMISTRY-US, V31, P576, DOI 10.1021/bi00117a039; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	66	202	208	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35111	35122		10.1074/jbc.M103481200	http://dx.doi.org/10.1074/jbc.M103481200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11451952	hybrid			2022-12-25	WOS:000171024600101
J	Antonyak, MA; Singh, US; Lee, DA; Boehm, JE; Combs, C; Zgola, MM; Page, RL; Cerione, RA				Antonyak, MA; Singh, US; Lee, DA; Boehm, JE; Combs, C; Zgola, MM; Page, RL; Cerione, RA			Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; GTP-BINDING PROTEIN; CELLS; EXPRESSION; LINES; DEATH; IDENTIFICATION; FENRETINIDE; INHIBITION; HYDROLYSIS	Retinoic acid (RA) and its various synthetic analogs affect mammalian cell growth, differentiation, and apoptosis. Whereas treatment of the human leukemia cell line HL60 with RA results in cellular differentiation, addition of the synthetic retinoid, N-(4-hydroxyphenyl) retinamide (HPR), induces HL60 cells to undergo apoptosis. Moreover, pretreatment of HL60 cells as well as other cell lines (i.e. NIH3T3 cells) with RA blocks HPR-induced cell death. In attempting to discover the underlying biochemical activities that might account for these cellular effects, we found that monodansylcadaverine (MDC), which binds to the enzyme (transamidase) active site of tissue transglutaminase (TGase), eliminated RA protection against cell death and in fact caused RA to become an apoptotic factor, suggesting that the ability of RA to protect against apoptosis is linked to the expression of active TGase. Furthermore, it was determined that expression of exogenous TGase in cells exhibited enhanced GTP binding and transamidation activities and mimicked the survival advantage imparted by RA. We tested whether the ability of this dual function enzyme to limit HPR-mediated apoptosis was a result of the ability of TGase to bind GTP and/or catalyze transamidation and found that GTP binding was suffficient for the protective effect. Moreover, excessive transamidation activity did not appear to be detrimental to cell viability. These findings, taken together with observations that the TGase is frequently up-regulated by environmental stresses, suggest that TGase may function to ensure cell survival under conditions of differentiation and cell stress.	Cornell Univ, VMC, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Clin Sci, Ithaca, NY 14853 USA; Texas A&M Univ, Vet Affairs Hosp, Dept Mol Cardiol, Inst Cardiovasc Res, Temple, TX 76504 USA	Cornell University; Cornell University; Texas A&M University System	Cerione, RA (corresponding author), Cornell Univ, VMC, Dept Mol Med, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM061762] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61762, GM208052, GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BERTRAM JS, 1983, CANCER SURV, V2, P243; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; Cocco L, 2001, BBA-MOL CELL BIOL L, V1530, P1, DOI 10.1016/S1388-1981(00)00169-4; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COSTA A, 1994, CANCER RES, V54, pS2032; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Fraij BM, 1996, BIOCHEM BIOPH RES CO, V218, P45, DOI 10.1006/bbrc.1996.0009; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREEN DPL, 1993, HUM REPROD, V8, P91, DOI 10.1093/oxfordjournals.humrep.a137883; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; Kelloff G J, 1994, J Cell Biochem Suppl, V20, P176; KIENTA KJ, 1997, AM J CLIN ONCOL-CANC, V20, P36; KUFE DW, 1984, CANCER RES, V44, P4281; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; MANGELSDORF DJ, 1994, RETINOIDS BIOL CHEM; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; PFAHL M, 1994, VITAM HORM, V49, P327; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; PIACENTINI M, 1988, J BIOL CHEM, V263, P3790; Piredda L, 1997, CELL DEATH DIFFER, V4, P463, DOI 10.1038/sj.cdd.4400267; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SPORN MB, 1983, CANCER RES, V43, P3034; SUGIURA M, 1984, BLOOD, V63, P1153; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou CP, 1998, CLIN CANCER RES, V4, P1345	41	100	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33582	33587		10.1074/jbc.M105318200	http://dx.doi.org/10.1074/jbc.M105318200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438548	hybrid			2022-12-25	WOS:000170910200041
J	Blum, S; Issbruker, K; Willuweit, A; Hehlgans, S; Lucerna, M; Mechtcheriakova, D; Walsh, K; von der Ahe, D; Hofer, E; Clauss, M				Blum, S; Issbruker, K; Willuweit, A; Hehlgans, S; Lucerna, M; Mechtcheriakova, D; Walsh, K; von der Ahe, D; Hofer, E; Clauss, M			An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; ACTIVATES NUCLEAR-FACTOR; NF-KAPPA-B; PROCOAGULANT ACTIVITY; PERMEABILITY FACTOR; FLT-1 VEGFR-1; FACTOR-ALPHA; BLOOD-FLOW; CELLS	Vascular endothelial growth factor (VEGF) is not only essential for vasculogenesis and angiogenesis but is also capable of inducing tissue factor, the prime initiator of coagulation, in endothelial cells. In this study we have analyzed the VEGF-elicited pathways involved in the induction of tissue factor in human umbilical cord vein endothelial cells. Using specific low molecular weight inhibitors we could demonstrate a crucial role of the p38 and Er-k-1/2 mitogen-activated protein (ALA-P) kinases. In contrast, treatment with wortmannin or LY294002, inhibitors of phosphatidylinositol 3 (P13)-kinase, resulted in a strong enhancement of the VEGF-induced tissue factor production, indicating a negative regulatory role of the P13-kinase on tissue factor-inducing pathways. Accordingly, transduction with constitutively active Akt led to a reduction of VEGF-induced tissue factor production. Western blot analyses using antibodies specific, for phosphorylated p38 showed an enhanced activation of this MAP kinase in human umbilical cord vein endotheIial cells when stimulated with VEGF in the presence of wortmannin in comparison to either agent alone. Thus, the negative regulation of the P13-kinase pathway on endotheIial tissue factor activity can be explained at least in part by a suppression of this Map kinase-signaling pathway. This is the first demonstration of a reciprocal relationship between procoagulant activity and the P13-kinase-Akt signaIing pathway, and it reveals a novel mechanism by which tissue factor expression can be controlled in endothelial cells.	Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany; Univ Vienna, Vienna Int Res Cooperat Ctr, Inst Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; WG Kerckhoff Klin, Dept Vasc Genom, D-61231 Bad Nauheim, Germany; St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA	Max Planck Society; University of Vienna; St. Elizabeth's Medical Center	Clauss, M (corresponding author), Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, Pk Str 1, D-61231 Bad Nauheim, Germany.	M.Clauss@kerckhoff.mpg.de	Bieber, Katja/K-8826-2014	Mechtcheriakova, Diana/0000-0002-8737-3592; Clauss, Matthias/0000-0001-5180-3899; Willuweit, Antje/0000-0002-6725-0755				Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; Chavakis E, 2001, CIRCULATION, V103, P2102; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Clauss M, 1996, FEBS LETT, V390, P334, DOI 10.1016/0014-5793(96)00690-4; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CLAUSS M, 1992, TUMOR NECROSIS FACTO, P49; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DAWHIRST MW, 1996, BR J CANC S, V27, P247; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DRAKE TA, 1993, AM J PATHOL, V142, P1458; Fischer S, 1999, AM J PHYSIOL-CELL PH, V276, pC812; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; GRATTON JP, 2001, IN PRESS J BIOL CHEM, V276; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Malek AM, 1999, BIOCHEM BIOPH RES CO, V254, P231, DOI 10.1006/bbrc.1998.9921; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; NAWROTH P, 1988, J EXP MED, V168, P637, DOI 10.1084/jem.168.2.637; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PARK JE, 1994, J BIOL CHEM, V269, P25646; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SEVICK EM, 1989, CANCER RES, V49, P3513; Shen BQ, 2001, J BIOL CHEM, V276, P5281, DOI 10.1074/jbc.M007969200; SHIMOMURA K, 1988, INT J CANCER, V41, P243, DOI 10.1002/ijc.2910410215; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wu HM, 1999, AM J PHYSIOL-HEART C, V276, pH535, DOI 10.1152/ajpheart.1999.276.2.H535; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Zhang YM, 1996, J CLIN INVEST, V97, P2213, DOI 10.1172/JCI118662; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	51	92	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33428	33434		10.1074/jbc.M105474200	http://dx.doi.org/10.1074/jbc.M105474200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445586	hybrid			2022-12-25	WOS:000170910200020
J	Filion, F; Bouchard, N; Goff, AK; Lussier, JG; Sirois, J				Filion, F; Bouchard, N; Goff, AK; Lussier, JG; Sirois, J			Molecular cloning and induction of bovine prostaglandin E synthase by gonadotropins in ovarian follicles prior to ovulation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; HUMAN CHORIONIC-GONADOTROPIN; RAT PREOVULATORY FOLLICLES; G/H SYNTHASE-2; ENDOPEROXIDE SYNTHASE-2; MICE LACKING; ENDOTHELIAL-CELLS; LUTEAL FUNCTION; E-2 SYNTHASE; H SYNTHASE	Prostaglandin E-2 (PGE(2)) is thought to be an ultimate prostaglandin effector during the ovulatory process, and the objectives of this study were to clone bovine PGE synthase (PGES) and to characterize its regulation by gonadotropins in preovulatory follicles in vivo. The bovine PGES complementary DNA (cDNA) was shown to contain a 5 ' -untranslated region of eight base pairs (bp), an open reading frame of 462 bp and a 3 ' -untranslated region of 406 bp. The putative bovine PGES open reading frame encodes a 153-amino acid protein that is 85, 78, and 78% identical to the human, rat, and mouse PGES homologs, respectively. The regulation of PGES during ovulation was studied using three different models in vivo: 1) human chorionic gonadotropin (hCG)-induced ovulation during a normal estrous cycle; 2) hCG-induced ovulation following ovarian hyperstimulation; and 3) spontaneous ovulation during natural estrus. Results from semi-quantitative reverse transcription-polymerase chain reaction/Southern blotting analyses showed that the hCG/luteinizing hormone surge caused a significant increase in PGES mRNA. Levels of PGES transcripts were low or undetectable prior to hCG/luteinizing hormone but increased markedly 18-24 h after hCG in models I and 2, and 18-24 h after the onset of natural estrus in model 3 (p < 0.05). Analyses on isolated preparations of granulosa and theca interna cells indicated that the granulosa cell layer was the predominant site of follicular PGES expression. The regulation of the protein was studied in the same models using a specific antibody raised against a fragment of bovine protein (Delta PGES; from Glu(49) to Val(146)). Results from immunoblots showed an induction of bovine PGES (M-r = 17,000) 18-24 h after hCG treatment or onset of estrus (p < 0.05). The protein was detected in extracts of granulosa cells but not in theca interna. Collectively, these results demonstrate that the ovulatory process is associated with a gonadotropin-dependent induction of PGES in granulosa cells of ovarian follicles in vivo, thus establishing for the first time the regulation of the enzyme in a physiological context.	Univ Montreal, Fac Med Vet, Ctr Rech & Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada; Univ Montreal, Fac Med Vet, Dept Biomed Vet, St Hyacinthe, PQ J2S 7C6, Canada	Universite de Montreal; Universite de Montreal	Sirois, J (corresponding author), Univ Montreal, Fac Med Vet, Ctr Rech & Reprod Anim, CP 5000, St Hyacinthe, PQ J2S 7C6, Canada.	siroisje@medvet.umontreal.ca						AINSWORTH L, 1979, BIOL REPROD, V21, P401, DOI 10.1095/biolreprod21.2.401; ALGIRE JE, 1992, CAN J VET RES, V56, P67; Ando M, 1998, ENDOCRINOLOGY, V139, P2501, DOI 10.1210/en.139.5.2501; ARMSTRONG DT, 1972, PROSTAGL, V1, P21, DOI 10.1016/0090-6980(72)90062-7; ARMSTRONG DT, 1981, J REPROD FERTIL, V62, P283; Boerboom D, 1998, ENDOCRINOLOGY, V139, P1662, DOI 10.1210/en.139.4.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brule S, 2000, BIOL REPROD, V62, P642, DOI 10.1095/biolreprod62.3.642; CURRY TE, 1990, BIOL REPROD, V42, P307, DOI 10.1095/biolreprod42.2.307; CURRY TE, 1987, AM J OBSTET GYNECOL, V157, P537, DOI 10.1016/S0002-9378(87)80003-0; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; DESILVA M, 1985, J REPROD FERTIL, V75, P547, DOI 10.1530/jrf.0.0750547; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Espey Lawrence L., 1994, P725; ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73; Forsberg L, 2000, FEBS LETT, V471, P78, DOI 10.1016/S0014-5793(00)01367-3; Goetz Frederick William, 1991, P127; GUREVICH M, 1993, REPROD FERT DEVELOP, V5, P281, DOI 10.1071/RD9930281; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; HUSLIG RL, 1987, MOL CELL ENDOCRINOL, V50, P237, DOI 10.1016/0303-7207(87)90022-0; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; KILLICK S, 1987, FERTIL STERIL, V47, P773; LAU IF, 1974, J REPROD FERTIL, V40, P467, DOI 10.1530/jrf.0.0400467; LEMAIRE WJ, 1975, PROSTAGLANDINS, V9, P221, DOI 10.1016/0090-6980(75)90027-1; LEMAIRE WJ, 1973, PROSTAGLANDINS, V3, P367, DOI 10.1016/0090-6980(73)90075-0; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu JM, 1998, BIOL REPROD, V58, P1527, DOI 10.1095/biolreprod58.6.1527; Liu JM, 2001, BIOL REPROD, V64, P983, DOI 10.1095/biolreprod64.3.983; Liu JM, 1997, BIOL REPROD, V57, P1524, DOI 10.1095/biolreprod57.6.1524; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Mikuni M, 1998, BIOL REPROD, V59, P1077, DOI 10.1095/biolreprod59.5.1077; MORRIS JK, 1993, ENDOCRINOLOGY, V133, P770, DOI 10.1210/en.133.2.770; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; MURDOCH WJ, 1993, PROSTAG OTH LIPID M, V46, P85, DOI 10.1016/0090-6980(93)90037-8; MURDOCH WJ, 1983, J REPROD FERTIL, V69, P671, DOI 10.1530/jrf.0.0690671; OGRADY JP, 1972, PROSTAGL, V1, P97, DOI 10.1016/0090-6980(72)90072-X; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRIDDY AR, 1993, PROSTAG LEUKOTR ESS, V49, P827, DOI 10.1016/0952-3278(93)90204-A; REICH R, 1991, ENDOCRINOLOGY, V129, P1869, DOI 10.1210/endo-129-4-1869; Richards JS, 1998, MOL CELL ENDOCRINOL, V145, P47, DOI 10.1016/S0303-7207(98)00168-3; Richards JS, 1997, ENDOCRINOLOGY, V138, P4047, DOI 10.1210/en.138.10.4047; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; Sirois J, 2000, SERONO SYMP, P208; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; Sirois J, 1997, ENDOCRINOLOGY, V138, P4427, DOI 10.1210/en.138.10.4427; Smith WL, 1997, ADV EXP MED BIOL, V400, P989; Soler M, 2000, CIRC RES, V87, P504; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Thoren S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432-1327.2000.01735.x; Tilley SL, 1999, J CLIN INVEST, V103, P1539, DOI 10.1172/JCI6579; Tsai SJ, 1996, ENDOCRINOLOGY, V137, P3348, DOI 10.1210/en.137.8.3348; TSANG BK, 1979, PROSTAG OTH LIPID M, V17, P141, DOI 10.1016/0090-6980(79)90086-8; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001	59	87	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34323	34330		10.1074/jbc.M103709200	http://dx.doi.org/10.1074/jbc.M103709200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448962	hybrid			2022-12-25	WOS:000170910200136
J	Wang, X; Bauer, JH; Li, Y; Shao, ZH; Zetoune, FS; Cattaneo, E; Vincenz, C				Wang, X; Bauer, JH; Li, Y; Shao, ZH; Zetoune, FS; Cattaneo, E; Vincenz, C			Characterization of a p75(NTR) apoptotic signaling pathway using a novel cellular model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; ZINC-FINGER PROTEIN; DEATH DOMAIN; NEURONAL APOPTOSIS; MUTATIONAL ANALYSIS; SENSORY NEURONS; FAMILY PROTEINS; NMR STRUCTURE	The p75 neurotrophin receptor (p75(NTR)) belongs to the tumor necrosis factor receptor/nerve growth factor receptor superfamily. In some cells derived from neuronal tissues it causes cell death through a poorly characterized pathway. We developed a neuronal system using conditionally immortalized striatal neurons, in which the expression of p75(NTR) is inducibly controlled by the ecdysone receptor. In these cells p75(NTR) induces apoptosis through its death domain in a nerve growth factor-independent manner. Caspases 9, 6, and 3 are activated by receptor expression indicating the activation of the common effector pathway of apoptosis. Cell death is blocked by a dominant negative form of caspase 9 and Bcl-X-L consistent with a pathway that involves mitochondria. Significantly, the viral flice inhibitory protein E8 protects from p75(NTR). induced cell death indicating that death effector domains are involved. A p75(NTR) construct with a deleted death domain dominantly interferes with p75(NTR) signaling, implying that receptor multimerization is required. However, in contrast to the other receptors of the family, p76(NTR)-mediated apoptosis does not involve the adaptor proteins Fas-associated death domain protein or tumor necrosis factor-associated death domain protein, and the apical caspase 8 is not activated. We conclude that p75(NTR) signals apoptosis by similar mechanisms as other death receptors but uses different adaptors and apical caspases.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; Free Univ Berlin, Dept Biochem, D-14195 Berlin, Germany	University of Michigan System; University of Michigan; University of Milan; Free University of Berlin	Vincenz, C (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Rm 7510 MSRB I,Box 0602,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.			CATTANEO, ELENA/0000-0002-0755-4917; Bauer, Johannes/0000-0001-5539-2601	NIEHS NIH HHS [ES08111] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agerman K, 2000, MOL CELL NEUROSCI, V16, P258, DOI 10.1006/mcne.2000.0875; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Casaccia-Bonnefil P, 1999, MICROSC RES TECHNIQ, V45, P217, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<217::AID-JEMT5>3.0.CO;2-5; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Cattaneo E, 1998, J NEUROSCI RES, V53, P223, DOI 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cheema SS, 1996, J NEUROSCI RES, V46, P239, DOI 10.1002/(SICI)1097-4547(19961015)46:2<239::AID-JNR12>3.0.CO;2-Y; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; Coulson EJ, 1999, J BIOL CHEM, V274, P16387, DOI 10.1074/jbc.274.23.16387; Culmsee C, 2001, J CEREBR BLOOD F MET, V21, P334, DOI 10.1097/00004647-200104000-00002; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Ehrlich ME, 2001, EXP NEUROL, V167, P215, DOI 10.1006/exnr.2000.7551; Frade JM, 1996, NATURE, V383, P166; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Gu CH, 1999, J NEUROSCI, V19, P3043; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; ITOH N, 1993, J BIOL CHEM, V268, P10932; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; Kawaja MD, 1998, J NEUROSCI RES, V52, P295, DOI 10.1002/(SICI)1097-4547(19980501)52:3<295::AID-JNR6>3.0.CO;2-8; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; KISS J, 1989, NEUROSCI LETT, V105, P251, DOI 10.1016/0304-3940(89)90629-0; Kokaia Z, 1998, NEUROSCIENCE, V84, P1113, DOI 10.1016/S0306-4522(97)00579-4; Kong H, 1999, CELL DEATH DIFFER, V6, P1133, DOI 10.1038/sj.cdd.4400587; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Lowry KS, 2001, J NEUROSCI RES, V64, P11, DOI 10.1002/jnr.1048; Majdan M, 1997, J NEUROSCI, V17, P6988; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Orlinick JR, 1997, J BIOL CHEM, V272, P32221, DOI 10.1074/jbc.272.51.32221; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Rodier F, 2000, ONCOGENE, V19, P6261, DOI 10.1038/sj.onc.1204015; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Soilu-Hanninen M, 1999, J NEUROSCI, V19, P4828; Susen K, 1999, FEBS LETT, V463, P231, DOI 10.1016/S0014-5793(99)01628-2; SuterCrazzolara C, 1996, MOL BRAIN RES, V43, P351, DOI 10.1016/S0169-328X(96)00243-4; Suzuki A, 1997, EXP CELL RES, V233, P48, DOI 10.1006/excr.1997.3546; Syroid DE, 2000, J NEUROSCI, V20, P5741, DOI 10.1523/JNEUROSCI.20-15-05741.2000; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; ZHENG DQ, 1994, ONCOGENE, V9, P3345; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	71	85	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33812	33820		10.1074/jbc.M010548200	http://dx.doi.org/10.1074/jbc.M010548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11451944	hybrid			2022-12-25	WOS:000170910200071
J	Zhang, XK; Darnell, JE				Zhang, XK; Darnell, JE			Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-6 RESPONSE ELEMENT; ALPHA(2) MACROGLOBULIN GENE; DNA-BINDING; DOMAIN; PATHWAY; PHOSPHORYLATION; TRANSCRIPTION; TYROSINE; JUN	A tetrameric, Stat3 complex was found to be essential in transfection experiments for maximal interleukin-6-inducible activation of alpha2-macroglobulin gene promoter. Stable tetramer formation of purified phosphorylated Stat3 was dependent on protein.protein interaction involving the N-terminal domain of Stat3. The functional importance of tetramer formation was shown by the decreased levels of transcriptional activation associated with hypomorphic. mutations in N-terminal residues.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA09673] Funding Source: Medline; NIAID NIH HHS [AI34420, AI32489] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034420, R37AI034420, R01AI032489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HOCKE GM, 1992, FOLIA HISTOCHEM CYTO, V30, P137; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; John S, 1999, MOL CELL BIOL, V19, P1910; Murphy TL, 2000, MOL CELL BIOL, V20, P7121, DOI 10.1128/MCB.20.19.7121-7131.2000; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Takeda T, 1998, J ENDOCRINOL, V159, P323, DOI 10.1677/joe.0.1590323; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	22	83	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33576	33581		10.1074/jbc.M104978200	http://dx.doi.org/10.1074/jbc.M104978200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438543	hybrid			2022-12-25	WOS:000170910200040
J	Mukhopadhyay, A; Suttles, J; Stout, RD; Aggarwal, BB				Mukhopadhyay, A; Suttles, J; Stout, RD; Aggarwal, BB			Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; NITRIC-OXIDE SYNTHASE; TNF RECEPTOR; CELL-DEATH; FACTOR-ALPHA; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; APOPTOSIS; MICE; DEFICIENT	Tumor necrosis factor (TNF) is a pleiotropic cytokine known to regulate cell growth, viral replication, inflammation, immune system functioning, angiogenesis, and tumorigenesis. These effects are mediated through two different receptors, TNFR1 and TNFR2 (also called p60 and p80, respectively), with p60 receptor being expressed on all cell types and p80 receptor only on cells of the immune system and on endothelial cells. Although the role of p60 receptor in TNF signaling is well established, the role of p80 is less clear. In this report, by using macrophages derived from wild-type mice (having both receptors) and mice in which the gene for either p60 (p60(-/-)), or p80 (p80(-/-)), or both (p60(-/-) p80(-/-)) receptor have been deleted, we have redefined the, role of these receptors in TNF-induced activation of nuclear factor (NF)-kappaB and of mitogen-activated protein kinases. TNF activated NF-kappaB in a dose- and time-dependent manner in wild-type macrophages but not in p60(-/-), p80(-/-), or p60(-/-) p80(-/-) macrophages. These results correlated with the I kappaB alpha degradation needed for NF-kappaB activation. We also found that TNF activated c-Jun N-terminal protein kinase in a dose- and time-dependent manner in wild-type macrophages but not in p60(-/-), p80(-/-), or p60(-/-) p80(-/-) macrophages. TNF activated p38 MAPK and p44/p42 MAPK in wild-type but not in p60(-/-), p80(-/-), or p60(-/-) p80(-/-) macrophages. TNF induced the proliferation of wild-type macrophages, but for p60(-/-) and p80(-/-) macrophages proliferation was lower, and in p60(-/-) p80(-/-) it was absent. Overall, our studies suggest that both types of TNF receptors are needed in macrophages for optimum TNF cell signaling.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect, Houston, TX 77030 USA; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA	University of Texas System; UTMD Anderson Cancer Center; University of Louisville	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013		NIAID NIH HHS [R01 AI34875] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034875] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; Aggarwal BB, 1996, CANCER RES, V56, P5156; Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; Bonizzi G, 1997, J IMMUNOL, V159, P5264; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Chainy GBN, 1996, J IMMUNOL, V157, P2410; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clemons-Miller AR, 2000, IMMUNOBIOLOGY, V202, P477, DOI 10.1016/S0171-2985(00)80105-9; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dri P, 1999, J IMMUNOL, V162, P460; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; Funk JO, 2000, J IMMUNOL, V165, P4792, DOI 10.4049/jimmunol.165.9.4792; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Haridas V, 1998, J IMMUNOL, V160, P3152; HELLER RA, 1992, CELL, V70, P47; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu XT, 1999, J IMMUNOL, V163, P3106; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MACKAY F, 1994, J IMMUNOL, V153, P5274; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PALEOLOG EM, 1994, BLOOD, V84, P2578; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Riches DWH, 1998, J BIOL CHEM, V273, P22800, DOI 10.1074/jbc.273.35.22800; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TOTPAL K, 1994, J IMMUNOL, V153, P2248; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Weiss T, 1997, J IMMUNOL, V158, P2398; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	50	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31906	31912		10.1074/jbc.M105252200	http://dx.doi.org/10.1074/jbc.M105252200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11438547	hybrid			2022-12-25	WOS:000170613500061
J	Dhakshinamoorthy, S; Jaiswal, AK				Dhakshinamoorthy, S; Jaiswal, AK			Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H : quinone oxidoreductase 1 gene	ONCOGENE			English	Article						NQO1; hARE; Nrf2; INrf2; antioxidant	TRANSCRIPTION FACTOR; NF-E2-RELATED FACTOR-2; COORDINATED INDUCTION; HEME OXYGENASE-1; ACTIN-BINDING; SUBUNIT GENE; C-FOS; NRF2; PROTEIN; ACTIVATION	Antioxidant response element (ARE) and nuclear transcription factor Nrf2 are known to regulate expression and coordinated induction of NQO1 and other detoxifying enzyme genes in response to antioxidants and xenobiotics, A cytosolic inhibitor of Nrf2, INrf2, that retains Nrf2 in the cytoplasm, was cloned and sequenced, Treatment of cells with antioxidants and xenobiotics results in the release of Nrf2 from INrf2, Nrf2 then moves in the nucleus, This leads to the induction of ARE-mediated NQO1 and other detoxifying enzyme genes expression, INrf2 after dissociation from Nrf2 remains in the cytosol, Overexpression of INrf2 repressed ARE-mediated NQO1 gene expression, Deletion mapping of INrf2 revealed the requirement of KELCH domain (amino acid residues 361-597) and C-terminal region (amino acid residues 598-624) in retention of Nrf2 in the cytosol, Both these regions of INrf2 independently retained Nrf2 in the cytosol leading to the repression of ARE-mediated NQO1 gene expression, These results may indicate that two different regions of INrf2 interact with a single molecule of Nrf2 or two or more molecules of Nrf2 interact with a single molecule of INrf2, The transcription of Nrf2 and INrf2 did not change in response to antioxidants and xenobiotics, This indicated that INrf2 and/or Nrf2 might be post-transcriptionally modified in response to antioxidants and xenobiotics leading to the release of Nrf2 from INrf2 and induction of ARE-mediated NQO1 and other detoxifying enzyme genes expression.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NIGMS NIH HHS [GM47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; BERGELSON S, 1994, ONCOGENE, V9, P565; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; JAISWAL AK, 1994, J BIOL CHEM, V269, P14502; Jaiswal AK, 1999, INT CONGR SER, V1172, P103; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Long DJ, 2000, CANCER RES, V60, P5913; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MULKAHY RT, 1997, J BIOL CHEM, V272, P7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; QIAGEN, 2000, QI AEXPRESSIONIST HD; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P597, DOI 10.1016/S0006-2952(99)00143-4; Radjendirane Venugopal, 1997, P441; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT J, 1993, MOL BIOL REP, V18, P223, DOI 10.1007/BF01674434; Schulze-Osthoff Klaus, 1997, P239; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	42	239	246	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3906	3917		10.1038/sj.onc.1204506	http://dx.doi.org/10.1038/sj.onc.1204506			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439354				2022-12-25	WOS:000169494700016
J	Shi, Q; Le, XD; Wang, BL; Abbruzzese, JL; Xiong, QH; He, YJ; Xie, KP				Shi, Q; Le, XD; Wang, BL; Abbruzzese, JL; Xiong, QH; He, YJ; Xie, KP			Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells	ONCOGENE			English	Article						angiogenesis; VEGF; regulation; acidosis; pancreatic cancer	FACTOR MESSENGER-RNA; HUMAN PANCREATIC-CANCER; TUMOR-CELLS; FACTOR GENE; TRANSCRIPTION FACTOR; HYPOXIA; PH; METASTASIS; IDENTIFICATION; ANGIOGENESIS	The influence of acidosis on the expression of the vascular endothelial growth factor (VEGF) gene was determined, FG human pancreatic adenocarcinoma cells were incubated for various time periods in media at a physiologically relevant pH level (6.7-7.4), The expression of VEGF mRNA and protein secretion was inversely correlated with pH in a pH- and time-dependent manner. Transient acidosis also activated the VEGF promoter/enhancer luciferase reporter, which was consistent with an increased VEGF gene transcription rate and VEGF mRNA half-life. These data indicated that acidosis transcriptionally and posttranscriptionally regulates VEGF expression, suggesting that an acidic tumor microenvironment contributes to tumor angiogenesis and progression.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA16672-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; BOUCHER Y, 1990, CANCER RES, V50, P4478; Brooks SE, 1998, CURR EYE RES, V17, P875, DOI 10.1076/ceyr.17.9.875.5134; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; D'Arcangelo D, 2000, CIRC RES, V86, P312, DOI 10.1161/01.RES.86.3.312; Damert A, 1997, CANCER RES, V57, P3860; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Griffiths L, 1997, CANCER RES, V57, P570; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; HUNAG S, 2000, CANCER RES, V60, P5334; INTAGLIETTA M, 1977, MED INSTRUM, V11, P149; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Jang A, 1997, CLIN EXP METASTAS, V15, P469, DOI 10.1023/A:1018470709523; KALLINOWSKI F, 1988, BRIT J CANCER, V58, P314, DOI 10.1038/bjc.1988.210; LADOUX A, 1994, BIOCHEM BIOPH RES CO, V204, P794, DOI 10.1006/bbrc.1994.2529; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; ROTIN D, 1989, CANCER RES, V49, P205; Scott PAE, 1998, INT J CANCER, V75, P706, DOI 10.1002/(SICI)1097-0215(19980302)75:5<706::AID-IJC8>3.0.CO;2-2; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHI Q, 1999, CLIN CANCER RES, V5, P7234; SHI Q, 2000, J INTERFERON CYTOKIN, V20, P1544; SHUBIK P, 1982, J CANCER RES CLIN, V103, P211, DOI 10.1007/BF00409698; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Tannock IF, 1996, J CLIN ONCOL, V14, P3156, DOI 10.1200/JCO.1996.14.12.3156; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAUPEL P, 1989, CANCER RES, V49, P6449; VEZERIDIS MP, 1989, J SURG ONCOL, V40, P261, DOI 10.1002/jso.2930400412; Watanabe Y, 1998, LIFE SCI, V63, P1037, DOI 10.1016/S0024-3205(98)00365-8; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; XIE K, 2001, IN PRESS CYTOKINE GR	39	191	199	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3751	3756		10.1038/sj.onc.1204500	http://dx.doi.org/10.1038/sj.onc.1204500			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439338	Bronze			2022-12-25	WOS:000169400200016
J	Wang, LL; Hiebert, SW				Wang, LL; Hiebert, SW			TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3	ONCOGENE			English	Article						HDAC3; TEL; tumor suppressor; stromelysin-1; mSin3; N-CoR	ACUTE LYMPHOBLASTIC-LEUKEMIA; NUCLEAR RECEPTOR COREPRESSORS; TRANSCRIPTIONAL REPRESSION; N-COR; TUMOR-SUPPRESSOR; ETS-FAMILY; FREQUENT LOSS; CLASS-I; GENE; COMPLEX	TEL (Translocation-ETS-Leukemia or ETV 6) is disrupted by multiple chromosomal translocations in acute leukemia. The loss of heterozygosity at the TEL locus in leukemias and the hemizygous deletion of TEL that is observed in various tumors, suggests that TEL is tumor suppressor, Overexpression of TEL alters cellular morphology and represses the expression of the matrix metalloproteinase stromelysin-1. Based on these studies, deletion analysis was used to define the minimal repression domains of TEL, TEL-mediated repression required both the N-terminal pointed domain and a central region composed of amino acids 268-303, The mSin3A and N-CoR corepressors bind to the pointed domain and the central repression domain of TEL, respectively. Unexpectedly, histone deacetylase-3, but not other histone deacetylases, also associates with the central region of TEL, Histone deacetylase-3 interacts with a TEL mutant that cannot bind N-CoR, suggesting that this is a direct interaction with TEL, In addition, histone H3 was under-acetylated near the TEL-binding sites in the endogenous stromelysin-1 promoter when TEL was expressed. Furthermore, trichostatin A, a potent histone deacetylase inhibitor, impaired TEL-dependent repression of the stromelysin-1 promoter. Finally, while TEL-expression induced cellular aggregation of Ras-transformed cells, Trichostatin A reversed the TEL-induced cellular aggregation phenotype, Thus, the cumulative data suggests that histone deacetylase-3 activity is required for the transcriptional functions of TEL.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Room 512,Med Res Bldg 2, Nashville, TN 37232 USA.		Hiebert, Scott W/C-9979-2010		NCI NIH HHS [CA68465, R01-CA77274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068465, R01CA077274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guarente L, 2000, GENE DEV, V14, P1021; Guenther MG, 2000, GENE DEV, V14, P1048; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Javed A, 2000, J CELL SCI, V113, P2221; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kao HY, 2000, GENE DEV, V14, P55; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mahlknecht U, 1999, CYTOGENET CELL GENET, V86, P237, DOI 10.1159/000015347; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Rao G, 1996, ONCOGENE, V12, P1165; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Romana SP, 1996, LEUKEMIA, V10, P167; SCHOLZ H, 1993, GENETICS, V135, P455; Spirin KS, 1996, CANCER RES, V56, P2400; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wiesen JF, 1996, ENZYME PROTEIN, V49, P174, DOI 10.1159/000468624; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	70	77	79	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3716	3725		10.1038/sj.onc.1204479	http://dx.doi.org/10.1038/sj.onc.1204479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439334				2022-12-25	WOS:000169400200012
J	Hoecker, U; Quail, PH				Hoecker, U; Quail, PH			The phytochrome A-specific signaling intermediate SPA1 interacts directly with COP1, a constitutive repressor of light signaling in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; REGULATED GENE; WD-REPEAT; TRANSDUCTION; PROTEIN; THALIANA; DEFINES; PIF3; PHOTOMORPHOGENESIS; IDENTIFICATION	SPA1 is a phytochrome A (phyA)-specific signaling intermediate that acts as a light-dependent repressor of photomorphogenesis in Arabidopsis seedlings. It contains a WD-repeat domain that shows high sequence similarity to the WD-repeat region of the constitutive repressor of light signaling, COP1. Here, using yeast two-hybrid and in vitro interaction assays, we show that SPA1 strongly and selectively binds to COP1. Domain mapping studies indicate that the putative coiled-coil domain of SPA1 is necessary and sufficient for binding to COP1. Conversely, similar deletion analyses of the COP1 protein suggest that SPA1 interacts with the presumed coiled-coil domain of COP1. To further investigate SPA1 function in the phyA signaling pathway, we tested whether SPA1, like COP1, mediates changes in gene expression in response to light. We show that spa1 mutations increase the photoresponsiveness of certain light-regulated genes within 2 h of light treatment. Taken together, the results suggest that SPA1 may function to link the phytochrome A-specific branch of the light signaling pathway to COP1. Hence, our data provide molecular support for the hypothesis that COP1 is a convergence point for upstream signaling pathways dedicated to individual photoreceptors.	Univ Dusseldorf, Inst Entwicklungs & Mol Biol Pflanzen, D-40225 Dusseldorf, Germany; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; USDA ARS, Ctr Plant Gene Express, Albany, CA 94710 USA	Heinrich Heine University Dusseldorf; University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Hoecker, U (corresponding author), Univ Dusseldorf, Inst Entwicklungs & Mol Biol Pflanzen, Geb 26-03-02, D-40225 Dusseldorf, Germany.			Hoecker, Ute/0000-0002-5636-9777	NIGMS NIH HHS [GM47475] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047475] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; ARMSTRONG GA, 1995, PLANT PHYSIOL, V108, P1505, DOI 10.1104/pp.108.4.1505; Barnes SA, 1996, PLANT J, V10, P1155, DOI 10.1046/j.1365-313X.1996.10061155.x; Bolle C, 2000, GENE DEV, V14, P1269; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; Deng X W, 1998, Symp Soc Exp Biol, V51, P93; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; Deng XW, 1999, SEMIN CELL DEV BIOL, V10, P121, DOI 10.1006/scdb.1999.0287; Dieterle M, 2001, GENE DEV, V15, P939, DOI 10.1101/gad.197201; Fairchild CD, 2000, GENE DEV, V14, P2377; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; Hoecker U, 1999, SCIENCE, V284, P496, DOI 10.1126/science.284.5413.496; Hsieh HL, 2000, GENE DEV, V14, P1958; Hudson M, 1999, GENE DEV, V13, P2017, DOI 10.1101/gad.13.15.2017; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; MATSUI M, 1995, P NATL ACAD SCI USA, V92, P4239, DOI 10.1073/pnas.92.10.4239; MCNELLIS TW, 1995, PLANT CELL, V7, P1749, DOI 10.1105/tpc.7.11.1749; Neff MM, 2000, GENE DEV, V14, P257; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Ni M, 1999, NATURE, V400, P781, DOI 10.1038/23500; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Quail PH, 2000, SEMIN CELL DEV BIOL, V11, P457, DOI 10.1006/scdb.2000.0199; Smith H, 2000, NATURE, V407, P585, DOI 10.1038/35036500; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Soh MS, 1998, PLANT J, V16, P411, DOI 10.1046/j.1365-313x.1998.00307.x; Soh MS, 2000, PLANT CELL, V12, P2061, DOI 10.1105/tpc.12.11.2061; Spiegelman JI, 2000, PLANT CELL, V12, P2485, DOI 10.1105/tpc.12.12.2485; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; vonArnim AG, 1997, PLANT PHYSIOL, V114, P779, DOI 10.1104/pp.114.3.779; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Yamamoto YY, 1998, PLANT CELL, V10, P1083, DOI 10.1105/tpc.10.7.1083; Yamamoto YY, 2001, PLANT CELL, V13, P399, DOI 10.1105/tpc.13.2.399; Zhu YX, 2000, P NATL ACAD SCI USA, V97, P13419, DOI 10.1073/pnas.230433797	37	121	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38173	38178						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11461903				2022-12-25	WOS:000171526500061
J	Holleran, EA; Ligon, LA; Tokito, M; Stankewich, MC; Morrow, JS; Holzbaur, ELF				Holleran, EA; Ligon, LA; Tokito, M; Stankewich, MC; Morrow, JS; Holzbaur, ELF			beta III spectrin binds to the Arp1 subunit of dynactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; GOLGI; COMPLEX; TRANSPORT; IDENTIFICATION; ANKYRIN; PROTEIN; CENTRACTIN; SPECIFICATION; LOCALIZATION	Cytoplasmic dynein is an intracellular motor responsible for endoplasmic reticulum-to-Golgi vesicle trafficking and retrograde axonal transport. The accessory protein dynactin has been proposed to mediate the association of dynein with vesicular cargo. Dynactin contains a 37-nm filament made up of the actin-related protein, Arp1, which may interact with a vesicle-associated spectrin network. Here, we demonstrate that Arp1 binds directly to the Golgi-associated beta III spectrin isoform. We identify two Arp1-binding sites in beta III spectrin, one of which overlaps with the actin-binding site conserved among spectrins. Although conventional actin binds weakly to beta III spectrin, Arp1 binds robustly in the presence of excess F-actin. Dynein, dynactin, and PHI spectrin co-purify on vesicles isolated from rat brain, and beta III spectrin co-immunoprecipitates with dynactin from rat brain cytosol. In interphase cells, beta III spectrin and dynactin both localize to cytoplasmic vesicles, co-localizing most significantly in the perinuclear region of the cell. In dividing cells, beta III spectrin and dynactin co-localize to the developing cleavage furrow and mitotic spindle, a novel localization for beta III spectrin. We hypothesize that the interaction between PHI spectrin and Arp1 recruits dynein and dynactin to intracellular membranes and provides a direct link between the microtubule motor complex and its membrane-bounded cargo.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Dept Cell & Mol Pharmacol, San Francisco, CA 94143 USA; Yale Univ, Dept Pathol, New Haven, CT 06510 USA	University of Pennsylvania; University of California System; University of California San Francisco; Yale University	Holzbaur, ELF (corresponding author), Univ Penn, Dept Anim Biol, 143 Rosenthal Bldg,3800 Spruce St, Philadelphia, PA 19104 USA.			Ligon, Lee/0000-0002-5735-3654	NIGMS NIH HHS [GM48661] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048661] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck KA, 1997, J CELL SCI, V110, P1239; CLARK SW, 1994, MOL BIOL CELL, V5, P1301, DOI 10.1091/mbc.5.12.1301; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; Deng W, 1997, DEV BIOL, V189, P79, DOI 10.1006/dbio.1997.8669; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; HARTWIG JH, 1994, PROTEIN PROFILE, V1, P711; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Holleran EA, 1998, TRENDS CELL BIOL, V8, P26, DOI 10.1016/S0962-8924(97)01195-1; Hoock TC, 1997, J CELL BIOL, V136, P1059, DOI 10.1083/jcb.136.5.1059; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; Karki S, 2000, J BIOL CHEM, V275, P4834, DOI 10.1074/jbc.275.7.4834; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Klopfenstein DR, 2000, CELL, V103, P537, DOI 10.1016/S0092-8674(00)00144-6; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; Lorra C, 1999, NAT CELL BIOL, V1, pE113, DOI 10.1038/12939; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Reese EL, 2000, J CELL BIOL, V151, P155, DOI 10.1083/jcb.151.1.155; Sheterline P, 1998, PROTEIN PROFILE, V4, P1; Skop AR, 1998, CURR BIOL, V8, P1110, DOI 10.1016/S0960-9822(98)70465-8; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tokito MK, 1996, MOL BIOL CELL, V7, P1167, DOI 10.1091/mbc.7.8.1167; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; VAUGHAN PS, 2000, MOL BIOL CELL, V11; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180	38	153	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36598	36605		10.1074/jbc.M104838200	http://dx.doi.org/10.1074/jbc.M104838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11461920	hybrid			2022-12-25	WOS:000171194500073
J	Franzen, R; Pautz, A; Brautigam, L; Geisslinger, G; Pfeilschifter, J; Huwiler, A				Franzen, R; Pautz, A; Brautigam, L; Geisslinger, G; Pfeilschifter, J; Huwiler, A			Interleukin-1 beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FULL-LENGTH CDNA; INDUCED APOPTOSIS; ACID CERAMIDASE; MAPKAP KINASE-2; NITRIC-OXIDE; CELLULAR PROLIFERATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; STRESS	The lipid signaling molecule ceramide is formed by the action of acid and neutral sphingomyelinases and degraded by acid and neutral ceramidases. Short-term stimulation of mesangial cells with the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) leads to a rapid and transient increase in neutral sphingomyelinase activity (Kaszkin, M., Huwiler, A., Scholz, K., van den Bosch, H., and Pfeilschifter, J. (1998) FEBS Lett. 440,163-166). In this study, we report on a second delayed peak of activation occurring after hours of IL-1 beta treatment. This second phase of activation was first detectable after 2 h of treatment and steadily increased over the next 2 h, reaching maximal values after 4 h. In parallel, a pronounced increase in neutral ceramidase activity was observed, accounting for a constant or even decreased level of ceramide after long-term IL-1 beta treatment, despite continuous sphingomyelinase activation. The increase in neutral ceramidase activity was due to expressional up-regulation, as detected by an increase in mRNA levels and enhanced de novo protein synthesis. The increase in neutral ceramidase protein levels and activity could be blocked dose-dependently by the p38 MAPK inhibitor SB 202190, whereas the classical MAPK pathway inhibitor U0126 and the protein kinase C inhibitor Ro 318220 were ineffective. Moreover, cotreatment of cells for 24 h with IL-1 beta and SB 202190 led to an increase in ceramide formation. Interestingly, IL-1 beta -stimulated neutral ceramidase activation was not reduced in mesangial cells isolated from mice deficient in MAPK-activated protein kinase-2, which is a downstream substrate of p38 MAPK, thus suggesting that the p38 MAPK-mediated induction of neutral ceramidase occurs independently of the MAPK-activated protein kinase-2 pathway. In summary, our results suggest a biphasic regulation of sphingomyelin hydrolysis in cytokine-treated mesangial cells with delayed de novo synthesis of neutral ceramidase counteracting sphingomyelinase activity and apoptosis. Neutral ceramidase may thus represent a novel cytoprotective enzyme for mesangial cells exposed to inflammatory stress conditions.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Huwiler, A (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Huwiler@em.uni-frankfurt.de						An SZ, 1998, J CELL BIOCHEM, P147; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Hung WC, 1999, BIOCHEM J, V338, P161, DOI 10.1042/0264-6021:3380161; Huwiler A, 2000, BRIT J PHARMACOL, V129, P612, DOI 10.1038/sj.bjp.0703077; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Huwiler A, 1999, J EXP BIOL, V202, P655; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; KASHGARIAN M, 1992, KIDNEY INT, V41, P524, DOI 10.1038/ki.1992.74; Kaszkin M, 1998, FEBS LETT, V440, P163, DOI 10.1016/S0014-5793(98)01445-8; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kuo ML, 1997, BIOCHEM J, V327, P663, DOI 10.1042/bj3270663; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Machleidt T, 1998, FEBS LETT, V436, P51, DOI 10.1016/S0014-5793(98)01095-3; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PFEILSCHIFTER J, 1989, EUR J CLIN INVEST, V19, P347, DOI 10.1111/j.1365-2362.1989.tb00241.x; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; PFEILSCHIFTER J, 1994, NEWS PHYSIOL SCI, V9, P271, DOI 10.1152/physiologyonline.1994.9.6.271; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sakakura C, 1998, BIOCHEM BIOPH RES CO, V246, P827, DOI 10.1006/bbrc.1998.8719; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Sweeney EA, 1998, FEBS LETT, V425, P61, DOI 10.1016/S0014-5793(98)00198-7; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Tohyama J, 1999, J INHERIT METAB DIS, V22, P649, DOI 10.1023/A:1005590316064; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	49	55	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35382	35389		10.1074/jbc.M102153200	http://dx.doi.org/10.1074/jbc.M102153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457826	hybrid			2022-12-25	WOS:000171109300025
J	Glover, BP; Pritchard, AE; McHenry, CS				Glover, BP; Pritchard, AE; McHenry, CS			tau binds and organizes Escherichia coli replication proteins through distinct domains - Domain III, shared by gamma and tau, oligomerizes DnaX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE HOLOENZYME PARTICLE; POLYMERASE-III; SLIDING CLAMPS; LAGGING-STRAND; SUBUNIT; COMPLEX; IDENTIFICATION; MACHINE; LOADER; PURIFICATION	The tau and gamma proteins of the DNA polymerase III holoenzyme DnaX complex are products of the dnaX gene with gamma being a truncated version Of tau arising from ribosomal frameshifting. tau is comprised of five structural domains, the first three of which are shared by gamma (Gao, D., and McHenry, C. (2001) J. Biol. Chem. 276, 4433-4453). In the absence of the other holoenzyme subunits, DnaX exists as a tetramer. Association of delta, delta ', chi, and psi with domain III of DnaX(4) results in a DnaX complex with a stoichiometry of DnaX(3)delta delta ' chi psi. To identify which domain facilitates DnaX self-association, we examined the properties of purified biotin-tagged DnaX fusion proteins containing domains I-H or III-V. Unlike domain I-II, treatment of domain III-V, gamma, and tau, with the chemical cross-linking reagent BS3 resulted in the appearance of high molecular weight intramolecular cross-linked protein. Gel filtration of domains I-II and III-V demonstrated that domain I-II was monomeric, and domain III-V was an oligomer. Biotin-tagged domain III-V, and not domain I-II, was able to form a mixed DnaX complex by recruiting tau, delta, delta ', chi, and psi onto streptavidin-agarose beads. Thus, domain III not only contains the delta, delta ', chi, and psi binding interface, but also the region that enables DnaX to oligomerize.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,B121, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Carter GJ, 1998, BIOCHEMISTRY-US, V37, P12477, DOI 10.1021/bi980716v; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; Dallmann HG, 2000, J BIOL CHEM, V275, P15512, DOI 10.1074/jbc.M909257199; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FLOWER AM, 1991, J MOL BIOL, V220, P649, DOI 10.1016/0022-2836(91)90107-H; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4447, DOI 10.1074/jbc.M009827200; Gao DX, 2001, J BIOL CHEM, V276, P4441, DOI 10.1074/jbc.M009830200; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Handler CG, 1996, J VIROL, V70, P6067, DOI 10.1128/JVI.70.9.6067-6070.1996; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; Larsen B, 1997, J MOL BIOL, V271, P47, DOI 10.1006/jmbi.1997.1162; Larsen B, 2000, P NATL ACAD SCI USA, V97, P1683, DOI 10.1073/pnas.97.4.1683; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MOK M, 1987, J BIOL CHEM, V262, P16644; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Pritchard AE, 2001, J BIOL CHEM, V276, P35217, DOI 10.1074/jbc.M102735200; Song MS, 2001, J BIOL CHEM, V276, P35165, DOI 10.1074/jbc.M100389200; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024	40	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35842	35846		10.1074/jbc.M103719200	http://dx.doi.org/10.1074/jbc.M103719200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11463787	hybrid			2022-12-25	WOS:000171109300083
J	Planque, N; Leconte, L; Coquelle, FM; Benkhelifa, S; Martin, P; Felder-Schmittbuhl, MP; Saule, S				Planque, N; Leconte, L; Coquelle, FM; Benkhelifa, S; Martin, P; Felder-Schmittbuhl, MP; Saule, S			Interaction of Maf transcription factors with Pax-6 results in synergistic activation of the glucagon promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HOMEODOMAIN PROTEIN; GENE-EXPRESSION; LEUCINE-ZIPPER; CELL-DEVELOPMENT; CRYSTALLIN GENE; PAIRED DOMAIN; BZIP PROTEINS; BASIC DOMAIN; C-MAF	In the endocrine pancreas, a-cell-specific expression of the glucagon gene is mediated by DNA-binding proteins that interact with the G1 proximal promoter element. Among these proteins, the paired domain transcription factor Pax-6 has been shown to bind to G1 and to transactivate glucagon gene expression. Close to the Pax-6-binding site, we observed the presence of a binding site for a basic leucine zipper transcription factor of the Maf family. In the present study, we demonstrate the presence of Maf family members in the endocrine pancreas that bind to G1 and transactivate glucagon promoter expression. In transient transfection experiments, we found that the transactivating effect on the glucagon promoter was greatly enhanced by the simultaneous expression of Maf transcription factors and Pax-6. This enhancement on glucagon transactivation could be correlated with the ability of these proteins to interact together but does not require binding of Maf proteins to the GI element. Furthermore, we found that Maf enhanced the Pax-6 DNA binding capacity. Our data indicate that Maf transcription factors may contribute to glucagon gene expression in the pancreas.	Ctr Univ Orsay, CNRS, UMR 146, Inst Curie,Sect Rech, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Saule, S (corresponding author), Ctr Univ Orsay, CNRS, UMR 146, Inst Curie,Sect Rech, Bat 110, F-91405 Orsay, France.	Simon.Saule@curie.u-psud.fr		Benkhelifa-Ziyyat, Sofia/0000-0002-8088-5288; COQUELLE, Frederic/0000-0002-5483-8787				Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Chau KY, 2000, J BIOL CHEM, V275, P37264, DOI 10.1074/jbc.M002763200; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Chow RL, 1999, DEVELOPMENT, V126, P4213; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Duncan MK, 2000, J CELL SCI, V113, P3173; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Herzig S, 2000, J BIOL CHEM, V275, P27989; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Ishibashi S, 2001, MECH DEVELOP, V101, P155, DOI 10.1016/S0925-4773(00)00585-2; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kerppola TK, 1997, EMBO J, V16, P2907, DOI 10.1093/emboj/16.10.2907; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; Larsson LI, 1998, MECH DEVELOP, V79, P153, DOI 10.1016/S0925-4773(98)00182-8; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; Liu Q, 1996, ONCOGENE, V12, P207; MARTIN P, 1992, ONCOGENE, V7, P1721; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; Planque N, 2001, J BIOL CHEM, V276, P29330, DOI 10.1074/jbc.M101812200; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; Ring BZ, 2000, DEVELOPMENT, V127, P307; Ritz-Laser B, 2000, J BIOL CHEM, V275, P32708, DOI 10.1074/jbc.M005704200; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Sakai M, 2001, NUCLEIC ACIDS RES, V29, P1228, DOI 10.1093/nar/29.5.1228; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	56	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35751	35760		10.1074/jbc.M104523200	http://dx.doi.org/10.1074/jbc.M104523200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457839	Green Published, hybrid			2022-12-25	WOS:000171109300072
J	Yoshioka, K; Fukushima, S; Yamazaki, T; Yoshida, M; Takatsuji, H				Yoshioka, K; Fukushima, S; Yamazaki, T; Yoshida, M; Takatsuji, H			The plant zinc finger protein ZPT2-2 has a unique mode of DNA interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN(2)CYS(6) BINUCLEAR CLUSTER; TARGET-SEQUENCE RECOGNITION; CRYSTAL-STRUCTURE; BINDING PROTEIN; COMPLEX REVEALS; PETUNIA; FAMILY; SITE; GENE; PREFERENCES	ZPT2-2 is a DNA-binding protein of petunia that contains two canonical TFIIIA-type zinc finger motifs separated by a long linker. We previously reported that ZPT2-2 bound to two separate AGT core sites, with each zinc finger making contact with each core site. Here we present our further characterization of ZPT2-2 by using selected and amplified binding sequence imprinting and surface plasmon resonance analyses; together, these assays revealed some unusual features of the interaction between ZPT2-2 and DNA. These experiments allowed us to conclude that 1) the optimal binding sequence for the N-terminal zinc finger is AGC(T), and that of the C-terminal one is CAGT; 2) multiple arrangements of the two core sites accommodate binding; and 3) the spacing between the two core sites affects the binding affinity. In light of these observations, we propose a new model for the DNA-ZPT2-2 interaction. Further, consistent with this model, a high affinity binding site for ZPT2-2 was found in the promoter region of the ZPT2-2 gene. This site may serve as a cis-element for the autoregulation of ZPT2-2 gene expression.	Natl Inst Agrobiol Sci, Dept Biotechnol, Tsukuba, Ibaraki 3058602, Japan; Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan; Natl Inst Agrobiol Sci, Dept Plant Physiol, Tsukuba, Ibaraki 3058602, Japan	National Institute of Agrobiological Sciences - Japan; Tokyo University of Science; National Institute of Agrobiological Sciences - Japan	Takatsuji, H (corresponding author), Natl Inst Agrobiol Sci, Dept Biotechnol, 2-1-2 Kannondai, Tsukuba, Ibaraki 3058602, Japan.							BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kobayashi A, 1998, PLANT J, V13, P571, DOI 10.1046/j.1365-313X.1998.00043.x; Kubo K, 1998, NUCLEIC ACIDS RES, V26, P608, DOI 10.1093/nar/26.2.608; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; TAKATSUJI H, 1992, EMBO J, V11, P241, DOI 10.1002/j.1460-2075.1992.tb05047.x; TAKATSUJI H, 1994, PLANT CELL, V6, P947, DOI 10.1105/tpc.6.7.947; Takatsuji H, 1999, PLANT MOL BIOL, V39, P1073, DOI 10.1023/A:1006184519697; Takatsuji H, 1996, BIOCHEM BIOPH RES CO, V224, P219, DOI 10.1006/bbrc.1996.1010; Takatsuji H, 1996, J BIOL CHEM, V271, P23368, DOI 10.1074/jbc.271.38.23368; van der Krol AR, 1999, PLANT PHYSIOL, V121, P1153, DOI 10.1104/pp.121.4.1153; vanLeeuwen HC, 1997, EMBO J, V16, P2043, DOI 10.1093/emboj/16.8.2043	21	27	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35802	35807		10.1074/jbc.M104079200	http://dx.doi.org/10.1074/jbc.M104079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11454859	hybrid			2022-12-25	WOS:000171109300078
J	Bassler, EL; Ngo-Anh, TJ; Geisler, HS; Ruppersberg, JP; Grunder, S				Bassler, EL; Ngo-Anh, TJ; Geisler, HS; Ruppersberg, JP; Grunder, S			Molecular and functional characterization of acid-sensing ion channel (ASIC) 1b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; ROOT GANGLION-CELLS; NA+ CHANNEL; CONFORMATIONAL CHANGE; MEMBRANE TOPOLOGY; PROTONS ACTIVATE; SENSORY NEURONS; ALPHA-SUBUNIT; SELECTIVITY; ENAC	Acid-sensing ion channels (ASICs) are activated by extracellular protons and are involved in neurotransmission in the central nervous system, in pain perception, as well as in mechanotransduction. Six different ASIC subunits have been cloned to date, which are encoded by four genes (ASIC1-ASIC4). Proton-gated currents have been described in isolated neurons from sensory ganglia as well as from central nervous system. However, it is largely unclear which of the cloned ASIC subunits underlie these native proton-gated currents. Recently, a splice variant, ASIC-beta, has been described for ASIC1a. In this variant about one-third of the protein is exchanged at the N terminus. Here we show that ASIC-beta has a longer N terminus than previously reported, extending the sequence divergence between ASIC1a and this new variant (ASIC1b). We investigated in detail kinetic and selectivity properties of ASIC1b in comparison to ASIC1a. Kinetics is similar for ASIC1b and ASIC1a. Ca2+ permeability of ASIC1a is low, whereas ASIC1b is impermeable to Ca2+. Currents through ASIC1a resemble currents, which have been described in sensory and central neurons, whereas the significance of ASIC1b remains to be established. Moreover, we show that a pre-transmembrane I domain controls the permeability to divalent cations in ASIC1, contributing to our understanding of the pore structure of these channels.	Res Grp Sensory Physiol, Dept Otolaryngol, D-72076 Tubingen, Germany; Dept Physiol 2, D-72076 Tubingen, Germany		Grunder, S (corresponding author), Res Grp Sensory Physiol, Dept Otolaryngol, Rontgenweg 11, D-72076 Tubingen, Germany.	stefan.gruender@uni-tuebingen.de	Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883				Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; AKAIKE N, 1990, J NEUROPHYSIOL, V63, P805, DOI 10.1152/jn.1990.63.4.805; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; DAVIES NW, 1988, J PHYSIOL-LONDON, V400, P159, DOI 10.1113/jphysiol.1988.sp017116; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Grunder S, 2000, NEUROREPORT, V11, P1607; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; KONNERTH A, 1987, J PHYSIOL-LONDON, V386, P603, DOI 10.1113/jphysiol.1987.sp016553; KOVALCHUK YN, 1990, NEUROSCI LETT, V115, P237, DOI 10.1016/0304-3940(90)90461-H; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; RENARD S, 1994, J BIOL CHEM, V269, P12981; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6	33	187	196	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33782	33787		10.1074/jbc.M104030200	http://dx.doi.org/10.1074/jbc.M104030200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448963	hybrid			2022-12-25	WOS:000170910200067
J	Lawler, OA; Miggin, SM; Kinsella, BT				Lawler, OA; Miggin, SM; Kinsella, BT			Protein kinase A-mediated phosphorylation of serine 357 of the mouse prostacyclin receptor regulates its coupling to G(s)-(,) to G(i)-, and to G(q)-coupled effector signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; PROSTANOID RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; DOWN-REGULATION; ALPHA-ISOFORM; DESENSITIZATION; THROMBOXANE	The prostacyclin receptor (IP) is primarily coupled to G alpha (s)-dependent activation of adenylyl cyclase; however, a number of studies indicate that the IP may couple to other secondary effector systems perhaps in a species-specific manner. In the current study, we investigated the specificity of G protein:effector coupling by the mouse (m) IP overexpressed in human embryonic kidney 293 cells, and endogenously expressed in murine, erythroleukemia cells. The mIP exhibited efficient G alpha (s) coupling and concentration-dependent increases in cAMP generation in response to the IP agonist cica-prost; however, mIP also coupled to G alpha (i) decreasing the levels of cAMP in forskolin-treated. cells. mIP coupling to G alpha (i) was pertussis toxin-sensitive and was dependent on protein kinase (PK) A activation status. In addition, the mIP coupled to phospholipase C (PLC) activation in a pertussis toxin-insensitive, G alpha (i)-, G beta gamma-, and PKC-independent but in a G alpha (q)- and PKA-dependent manner. Whole cell phosphorylation assays demonstrated that the mIP undergoes cicaprost-induced PKA phosphorylation. mIP(S357A), a site-directed mutant of mIP, efficiently coupled to G alpha (s) but failed to couple to G alpha (i) or to efficiently couple to G alpha (q):PLC. Moreover, mIP(S357A) did not undergo cicaprost-induced phosphorylation confirming that Ser(357) is the target residue for PKA-dependent phosphorylation. Finally, co-precipitation experiments permitted. the detection of G alpha (S), G alpha (i), and G alpha (q) in the immunoprecipitates of mIP, whereas only G alpha (i) was co-precipitated with mIP(S357A) indicating that Ser (357) of mIP is essential for G alpha (i) and G alpha (q) interaction. Moreover, inhibition of PKA blocked co-precipitation of mIP with G alpha (i) or G alpha (q) Taken together our data indicate that the mIP, in addition to coupling to G alpha (s), couples to G alpha (i) and G alpha (q); however, G alpha (i) and G alpha (q) coupling is dependent on initial cicaprost-induced mIP:G alpha (s) coupling and phosphorylation of mIP by cAMP-dependent PKA where Ser(357) was identified as the target residue for PKA phosphorylation.	Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland	University College Dublin	Kinsella, BT (corresponding author), Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Conway Inst Biomol & Biomed Res, Merville House,Belfield, Dublin 4, Ireland.			Kinsella, B. Therese/0000-0003-3072-941X; Miggin, Sinead/0000-0002-3421-3552				Armstrong RA, 1996, PHARMACOL THERAPEUT, V72, P171, DOI 10.1016/S0163-7258(96)00103-9; Blom N, 1998, NUCLEIC ACIDS RES, V26, P382, DOI 10.1093/nar/26.1.382; BOIE Y, 1994, J BIOL CHEM, V269, P12173; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL W B, 1990, P600; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Dogne JM, 2000, CURR MED CHEM, V7, P609, DOI 10.2174/0929867003374868; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Giovanazzi S, 1997, BIOCHEM J, V325, P71, DOI 10.1042/bj3250071; GODFREY PP, 1992, SIGNAL TRANSDUCTION, P105; Hayes JS, 1999, J BIOL CHEM, V274, P23707, DOI 10.1074/jbc.274.34.23707; HEBERT RL, 1995, AM J PHYSIOL-RENAL, V268, pF145, DOI 10.1152/ajprenal.1995.268.1.F145; Hebert RL, 1998, AM J PHYSIOL-RENAL, V275, pF904, DOI 10.1152/ajprenal.1998.275.6.F904; Kilpartick GJ, 1999, TRENDS PHARMACOL SCI, V20, P294, DOI 10.1016/S0165-6147(99)01355-3; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; Kobayashi H, 2000, J NEUROCHEM, V74, P2167, DOI 10.1046/j.1471-4159.2000.0742167.x; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KRANE A, 1994, BIOCHEM PHARMACOL, V47, P953, DOI 10.1016/0006-2952(94)90405-7; Lawler OA, 2001, BRIT J PHARMACOL, V132, P1639, DOI 10.1038/sj.bjp.0704033; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEIGH PJ, 1985, BRIT J PHARMACOL, V85, P237, DOI 10.1111/j.1476-5381.1985.tb08852.x; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643; NAMBA T, 1994, J BIOL CHEM, V269, P9986; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; OKA M, 1993, CELL SIGNAL, V5, P643, DOI 10.1016/0898-6568(93)90059-U; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; SAKAI A, 1990, LIFE SCI, V47, P711, DOI 10.1016/0024-3205(90)90626-3; SASAKI Y, 1994, BBA-MOL CELL RES, V1224, P601, DOI 10.1016/0167-4889(94)90300-X; SCHWANER I, 1992, BIOCHEM J, V281, P301, DOI 10.1042/bj2810301; SCHWARTSMANN G, 1995, EUR CANCER NEWS, V8, P14; Siegel G, 1989, Eicosanoids, V2, P213; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; Smyth EM, 2000, J BIOL CHEM, V275, P32037, DOI 10.1074/jbc.M003873200; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199; WATANABE T, 1991, BLOOD, V78, P2328; Watson S., 1994, G PROTEIN LINKED REC; Wise H, 1996, TRENDS PHARMACOL SCI, V17, P17, DOI 10.1016/0165-6147(96)81565-3; Zucker TP, 1998, EUR J PHARMACOL, V345, P213, DOI 10.1016/S0014-2999(98)00022-3	47	99	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33596	33607		10.1074/jbc.M104434200	http://dx.doi.org/10.1074/jbc.M104434200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443126	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000170910200043
J	Lu, ZL; Saldanha, JW; Hulme, EC				Lu, ZL; Saldanha, JW; Hulme, EC			Transmembrane domains 4 and 7 of the M-1 muscarinic acetylcholine receptor are critical for ligand binding and the receptor activation switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SCANNING MUTAGENESIS; HORMONE RECEPTOR; RESIDUES; RHODOPSIN; HELIX-7; M3-MUSCARINIC-RECEPTOR; TRANSDUCTION; MUTATION; HELICES	Activation of the muscarinic acetylcholine receptors requires agonist binding followed by a conformational change, but the ligand binding and conformation-switching residues have not been completely identified. Systematic alanine-scanning mutagenesis has been used to assess residues 142-164 in transmembrane helix 4 and 402-421 in transmembrane helix 7 of the M-1 muscarinic acetylcholine receptor. Several inward-facing amino acid side chains in the exofacial parts of transmembrane helices 4 and 7 contribute to acetylcholine binding. Alanine substitution of the aromatic residues in this group reduced signaling efficacy, suggesting that they may form part of a charge-stabilized aromatic cage, which triggers rotation and movement of the transmembrane helices. The mutation of adjacent residues modulated receptor activation, either reducing signaling or causing constitutive activation. In the buried endofacial section of transmembrane helix 7, alanine substitution mutants of the conserved NSXXNPXXY motif displayed strongly reduced signaling efficacy, despite having increased or unchanged acetylcholine affinity. These residues may have dual functions, forming intramolecular contacts that stabilize the receptor in the inactive ground state, but that are broken, allowing them to form new intramolecular bonds in the activated state. This conformational rearrangement is critical to produce a G protein binding site and may represent a key mechanism of receptor activation.	Natl Inst Med Res, MRC, Div Phys Biochem, London NW7 1AA, England; Natl Inst Med Res, MRC, Div Math Biol, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Lu, ZL (corresponding author), Natl Inst Med Res, MRC, Div Phys Biochem, The Ridgeway, London NW7 1AA, England.	zlu@nimr.mrc.ac.uk		Lu, Zhiliang/0000-0002-3442-1415				Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Allman K, 2000, MOL PHARMACOL, V58, P175, DOI 10.1124/mol.58.1.175; Audoly L, 1997, MOL PHARMACOL, V51, P61, DOI 10.1124/mol.51.1.61; BARLOW RB, 1964, INTRODUCTION CHEMICA, P185; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1999, J BIOL CHEM, V274, P35546, DOI 10.1074/jbc.274.50.35546; Furukawa H, 2001, LIFE SCI, V68, P2621; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Heitz F, 1999, EUR J PHARMACOL, V380, P183, DOI 10.1016/S0014-2999(99)00439-2; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; Hulme EC, 1999, EUR J PHARMACOL, V375, P247, DOI 10.1016/S0014-2999(99)00297-6; Hulme EC, 1998, J PHYSIOLOGY-PARIS, V92, P269, DOI 10.1016/S0928-4257(98)80031-4; Jakubik J, 2000, J BIOL CHEM, V275, P18836, DOI 10.1074/jbc.M000112200; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; Konvicka K, 1998, BIOPHYS J, V75, P601, DOI 10.1016/S0006-3495(98)77551-4; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; Lu ZL, 2000, J BIOL CHEM, V275, P5682, DOI 10.1074/jbc.275.8.5682; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; MATSUI H, 1995, MOL PHARMACOL, V47, P88; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perlman JH, 1997, J BIOL CHEM, V272, P11937, DOI 10.1074/jbc.272.18.11937; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Rosendorff A, 2000, MOL BRAIN RES, V84, P90, DOI 10.1016/S0169-328X(00)00227-8; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SCHULMAN JM, 1983, J MED CHEM, V26, P817, DOI 10.1021/jm00360a007; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; Sussman JL, 1998, ACTA CRYSTALLOGR D, V54, P1078, DOI 10.1107/S0907444998009378; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Wang JF, 1997, MOL PHARMACOL, V52, P306, DOI 10.1124/mol.52.2.306; Ward SDC, 1999, MOL PHARMACOL, V56, P1031, DOI 10.1124/mol.56.5.1031; Waugh DJJ, 2000, J BIOL CHEM, V275, P11698, DOI 10.1074/jbc.275.16.11698; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; ZHOU W, 1994, MOL PHARMACOL, V45, P165	39	81	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34098	34104		10.1074/jbc.M104217200	http://dx.doi.org/10.1074/jbc.M104217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11441014	hybrid			2022-12-25	WOS:000170910200108
J	Koyota, S; Ikeda, Y; Miyagawa, S; Ihara, H; Koma, M; Honke, K; Shirakura, R; Taniguchi, N				Koyota, S; Ikeda, Y; Miyagawa, S; Ihara, H; Koma, M; Honke, K; Shirakura, R; Taniguchi, N			Down-regulation of the alpha-Gal epitope expression in N-glycans of swine endothelial cells by transfection with the N-acetylglucosaminyltransferase III gene - Modulation of the biosynthesis of terminal structures by a bisecting GlcNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HUMAN NATURAL ANTIBODIES; GLYCOPROTEIN-SYNTHESIS; SUGAR CHAINS; HUMAN ALPHA-1,2-FUCOSYL-TRANSFERASE; SUBSTRATE-SPECIFICITY; SOLUTION CONFORMATION; PREFERENTIAL TRANSFER; IGA1 IMMUNOGLOBULIN; CARBOHYDRATE MOIETY	The down-regulation of the alpha -Gal epitope (Gal alpha1,3Gal beta -R) in swine tissues would be highly desirable, in terms of preventing hyperacute rejection in pig-to-human xenotransplantation. In an earlier study, we reported that the introduction of the beta1,4-N-acetylglucosaminyltransferase (GnT) III gene into swine endothelial cells resulted in a substantial reduction in the expression of the alpha -Gal epitope. In this study, we report on the mechanism for this down-regulation of the alpha -Gal epitope by means of structural and kinetic analyses. The structural analyses revealed that the amount of N-linked oligosaccharides bearing the alpha -Gal epitopes in the GnT-III-transfected cells was less than 10% that in parental cells, due to the alteration of the terminal structures as well as a decrease in branch formation. In addition, it appeared that the addition of a bisecting GlcNAc, which is catalyzed by GnT-III, leads to a more efficient sialylation rather than alpha -galactosylation. In vitro kinetic analyses showed that the bisecting GlcNAc has an inhibitory effect on alpha -galactosylation, but does not significantly affect the sialylation. These results suggest that the bisecting GlcNAc in the core is capable of modifying the biosynthesis of the terminal structures via its differential effects on the capping glycosyltransferase reactions. The findings may contribute to the development of a novel strategy to eliminate carbohydrate xenoantigens.	Osaka Univ, Dept Biochem, Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Div Organ Transplantat, Sch Med, Biomed Res Ctr, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Dept Biochem, Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				ALLEN SD, 1984, J BIOL CHEM, V259, P6984; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAYARD B, 1983, EUR J BIOCHEM, V137, P319, DOI 10.1111/j.1432-1033.1983.tb07831.x; BLANKEN WM, 1984, J BIOL CHEM, V259, P5131; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; BRISSON JR, 1983, CAN J BIOCHEM CELL B, V61, P1067, DOI 10.1139/o83-135; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3671, DOI 10.1021/bi00284a021; Cohney S, 1997, TRANSPLANTATION, V64, P495, DOI 10.1097/00007890-199708150-00020; Costa C, 1999, FASEB J, V13, P1762, DOI 10.1096/fasebj.13.13.1762; EASTON EW, 1991, J BIOL CHEM, V266, P21674; GALILI U, 1988, J BIOL CHEM, V263, P17755; GLEESON PA, 1983, J BIOL CHEM, V258, P6162; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HARPAZ N, 1980, J BIOL CHEM, V255, P4885; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASE S, 1986, J BIOCHEM-TOKYO, V100, P1; HIRONAKA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P316, DOI 10.1006/abbi.1993.1595; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; Ikeda Y, 2000, J BIOCHEM, V128, P609, DOI 10.1093/oxfordjournals.jbchem.a022793; IWASE H, 1990, ANAL BIOCHEM, V188, P200, DOI 10.1016/0003-2697(90)90552-K; Joziasse DH, 1999, BBA-MOL BASIS DIS, V1455, P403, DOI 10.1016/S0925-4439(99)00056-3; Koma M, 2000, GLYCOBIOLOGY, V10, P745, DOI 10.1093/glycob/10.7.745; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1991, J BIOL CHEM, V266, P2622; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; MELLIS SJ, 1983, J BIOL CHEM, V258, P1546; Miyagawa S, 1999, BIOCHEM BIOPH RES CO, V264, P611, DOI 10.1006/bbrc.1999.1327; MIYAGAWA S, 1994, TRANSPLANTATION, V58, P834, DOI 10.1097/00007890-199410150-00015; Miyagawa S, 1999, J BIOCHEM-TOKYO, V126, P1067, DOI 10.1093/oxfordjournals.jbchem.a022551; MIZUOCHI T, 1982, J IMMUNOL, V129, P2016; MORITA N, 1988, J BIOCHEM-TOKYO, V103, P332, DOI 10.1093/oxfordjournals.jbchem.a122270; NARASIMHAN S, 1985, BIOCHEMISTRY-US, V24, P1694, DOI 10.1021/bi00328a019; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAQUET MR, 1984, J BIOL CHEM, V259, P4716; PLATT JL, 1990, TRANSPLANTATION, V50, P817, DOI 10.1097/00007890-199011000-00015; Platt JL, 1998, NATURE, V392, P11; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SAVVIDOU G, 1984, BIOCHEMISTRY-US, V23, P3736, DOI 10.1021/bi00311a026; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; Seko A, 1997, BBA-GEN SUBJECTS, V1335, P23, DOI 10.1016/S0304-4165(96)00118-3; Sepp A, 1997, J BIOL CHEM, V272, P23104, DOI 10.1074/jbc.272.37.23104; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; Tanemura M, 1997, TRANSPL P, V29, P891, DOI 10.1016/S0041-1345(96)00203-5; Tanemura M, 1998, J BIOL CHEM, V273, P16421, DOI 10.1074/jbc.273.26.16421; Tanemura M, 1997, BIOCHEM BIOPH RES CO, V235, P359, DOI 10.1006/bbrc.1997.6784; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; TSUJI T, 1981, J BIOL CHEM, V256, P497; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; YAMASHITA K, 1983, CANCER RES, V43, P4691; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098	56	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32867	32874		10.1074/jbc.M102371200	http://dx.doi.org/10.1074/jbc.M102371200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11443114	hybrid			2022-12-25	WOS:000170746000067
J	Chang, FM; McCubrey, JA				Chang, FM; McCubrey, JA			P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells	ONCOGENE			English	Article						Raf; p21(Cip1); p27(Kip1); cyclins; Cdks; cytokine independence	DEPENDENT KINASE INHIBITOR; ABROGATE CYTOKINE DEPENDENCY; ACTIVATED PROTEIN-KINASE; B-RAF; MAP KINASE; C-MYC; A-RAF; DIFFERENTIAL ABILITIES; INDUCED PROLIFERATION; TARGETED DISRUPTION		E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Member Leo Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrov I, 1997, FEBS LETT, V414, P465, DOI 10.1016/S0014-5793(97)00992-7; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; BOS JL, 1989, CANCER RES, V49, P4682; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHUANG CF, 1994, FEBS LETT, V346, P229, DOI 10.1016/0014-5793(94)00480-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Frank DA, 1999, MOL MED, V5, P432; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hibi M, 1998, Int Rev Immunol, V17, P75, DOI 10.3109/08830189809084488; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Isaacs JS, 1997, CANCER RES, V57, P2986; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JOHNSON DE, 1998, FRONT BIOSCI, V3, P313; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kim TK, 1997, BIOCHEM BIOPH RES CO, V234, P300, DOI 10.1006/bbrc.1997.6637; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; Kwon EM, 2000, BLOOD, V95, P2552, DOI 10.1182/blood.V95.8.2552.008k30_2552_2558; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee AW, 1999, BLOOD, V93, P537, DOI 10.1182/blood.V93.2.537.402k30_537_553; LEE JE, 1994, GENOMICS, V20, P43, DOI 10.1006/geno.1994.1125; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lin JY, 1996, MOL CELL BIOL, V16, P1786; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mangi MH, 1999, CYTOKINES CELL MOL T, V5, P87; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; May W S Jr, 1997, Adv Pharmacol, V41, P219; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Morisset J, 1999, AM J PHYSIOL-GASTR L, V277, pG953, DOI 10.1152/ajpgi.1999.277.5.G953; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Moye PW, 2000, LEUKEMIA, V14, P1060, DOI 10.1038/sj.leu.2401792; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; Nakanishi M, 1999, BIOCHEM BIOPH RES CO, V263, P35, DOI 10.1006/bbrc.1999.1296; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Ogawa M, 1999, ANN NY ACAD SCI, V872, P17, DOI 10.1111/j.1749-6632.1999.tb08449.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Papin C, 1996, ONCOGENE, V12, P2213; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Steelman LS, 1996, LEUKEMIA, V10, P528; STORM SM, 1990, ONCOGENE, V5, P345; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WADEWITZ AG, 1993, ONCOGENE, V8, P1055; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zou X, 1997, CURR TOP MICROBIOL, V224, P57	99	43	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4354	4364		10.1038/sj.onc.1204564	http://dx.doi.org/10.1038/sj.onc.1204564			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466616				2022-12-25	WOS:000169912600009
J	Hamer, G; Gademan, IS; Kal, HB; de Rooij, DG				Hamer, G; Gademan, IS; Kal, HB; de Rooij, DG			Role for c-Abl and p73 in the radiation response of male germ cells	ONCOGENE			English	Article						c-Abl; p73; p63; cytoplasm; testis; ionizing radiation	TYROSINE KINASE; DNA-DAMAGE; DIFFERENTIATING SPERMATOGONIA; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; X-IRRADIATION; MOUSE TESTIS; P53; EXPRESSION; PROTEIN	p53 plays a central role in the induction of apoptosis of spermatogonia in response to ionizing radiation. In p53(-/) testes, however, spermatogonial apoptosis still can be induced by ionizing radiation, so p53 independent apoptotic pathways must exist in spermatogonia, Here we show that the p53 homologues p63 and p73 are present in the testis and that p73, but not p63, is localized in the cytoplasm of spermatogonia, Unlike p53, neither p63 nor p73 protein levels were found to increase after a dose of 4 Gy of X-rays, Although p73 protein levels did not increase, its interaction with the nonreceptor tyrosine kinase c-Abl and its phosphorylation on tyrosine residues did. c-Abl and p73 co-localize in the cytoplasm of spermatogonia and spermatocytes and in the residual bodies. Furthermore, c-Abl protein levels increase after irradiation. p63 was not found to colocalize or interact with c-Abl neither before nor after irradiation. In conclusion, in the testis ionizing radiation elevates cytoplasmic c-Abl that in turn interacts with p73, This may represent an additional, cytoplasmic, apoptotic pathway. Although less efficient than the p53 route, this pathway may cause spermatogonial apoptosis as observed in p53 deficient mice.	UMCU, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; UMCU, Dept Radiotherapy, NL-3584 CX Utrecht, Netherlands	Unilever; Utrecht University; Utrecht University Medical Center; Unilever; Utrecht University; Utrecht University Medical Center	Hamer, G (corresponding author), UMCU, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		de Rooij, D.G./AAW-1195-2021	de Rooij, Dirk/0000-0003-3932-4419; Hamer, Geert/0000-0002-9583-6796				Agami R, 1999, NATURE, V399, P809; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beumer TL, 1997, MOL REPROD DEV, V47, P240, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;240::AID-MRD2&gt;3.0.CO;2-L; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Blanco-Rodriguez J, 1999, BIOL REPROD, V61, P1541, DOI 10.1095/biolreprod61.6.1541; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Gobe GC, 1999, INT J RADIAT BIOL, V75, P973, DOI 10.1080/095530099139737; Gong JG, 1999, NATURE, V399, P806; Hasegawa M, 1997, RADIAT RES, V147, P457, DOI 10.2307/3579503; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Levrero M, 2000, J CELL SCI, V113, P1661; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; OAKBERG EF, 1960, INT J RADIAT BIOL RE, V2, P196, DOI 10.1080/09553006014550211; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sjoblom T, 1996, ONCOGENE, V12, P2499; Soengas MS, 2000, NAT GENET, V26, P391, DOI 10.1038/82497; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; VANDERMEER Y, 1992, RADIAT RES, V130, P296, DOI 10.2307/3578374; VANDERMEER Y, 1992, RADIAT RES, V130, P289, DOI 10.2307/3578373; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zipfel PA, 2000, J IMMUNOL, V165, P6872, DOI 10.4049/jimmunol.165.12.6872	41	49	56	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4298	4304		10.1038/sj.onc.1204568	http://dx.doi.org/10.1038/sj.onc.1204568			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466610				2022-12-25	WOS:000169912600003
J	Nanbru, C; Prats, AC; Droogmans, L; Defrance, P; Huez, G; Kruys, V				Nanbru, C; Prats, AC; Droogmans, L; Defrance, P; Huez, G; Kruys, V			Translation of the human c-myc P0 tricistronic mRNA involves two independent internal ribosome entry sites	ONCOGENE			English	Article						translation; IRES; proto-oncogene	FACTOR MESSENGER-RNA; TRACT-BINDING-PROTEIN; ALTERNATIVE TRANSLATION; GROWTH-FACTOR; POLIOVIRUS RNA; CELL-CYCLE; POLY(RC) BINDING-PROTEIN-2; INITIATION; TRANSCRIPTION; EXPRESSION	The human c-myc proto-oncogene is transcribed from four alternative promoters (P0, P1, P2, and P3) giving rise to mRNAs having 5 ' leader sequences of various length. The c-myc P0 mRNA contains three open reading frames (ORFs), the last one encoding c-Myc1 and c-Myc2 proteins generated by alternative translation initiated at CUG and AUG codons, The middle ORF (MYCHEX1) and the 5 ' ORF (ORF1) code for proteins 188 and 114 amino acids in length, respectively. We and others previously identified an internal ribosome entry site (IRES) in P0 and P2 c-myc mRNAs, promoting the cap-independent translation of c-Myc1 and c-Myc2, Here, we report the presence of a second IRES (named IRES1) promoting the cap-independent translation of MYCHEX1 in c-myc P0 mRNA, Using deletion analysis, we mapped an 80-nt region essential for IRES1 activity. c-myc P0 mRNA is thus the first eukaryotic polycistronic mRNA described for which translation initiation of two different open reading frames (MYCHEX1 and c-Myc1/c-Myc2) involves internal ribosome entry.	Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; CHU Rangueil, Inst Louis Bugnard, INSERM, Endocrinol & Commun Cellulaire U397, F-31403 Toulouse 04, France; Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Kruys, V (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.		Kruys, Veronique I/N-6613-2018; Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; Kruys, Veronique/0000-0002-3144-5403				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; AUSUBEL FM, 1995, CURR PROTOC MOLEC BI, V31, P10; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; DEDIEU JF, 1988, ONCOGENE, V3, P523; EICK D, 1990, ONCOGENE, V5, P1397; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; Gueydan C, 1996, MOL MED, V2, P479, DOI 10.1007/BF03401907; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hoover R G, 1995, Curr Top Microbiol Immunol, V194, P257; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; RAY D, 1989, ONCOGENE RES, V5, P73; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sella O, 1999, MOL CELL BIOL, V19, P5429; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	49	25	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4270	4280		10.1038/sj.onc.1204548	http://dx.doi.org/10.1038/sj.onc.1204548			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464293				2022-12-25	WOS:000169857200017
J	Scheel, C; Schaefer, KL; Jauch, A; Keller, M; Wai, D; Brinkschmidt, C; van Valen, F; Boecker, W; Dockhorn-Dworniczak, B; Poremba, C				Scheel, C; Schaefer, KL; Jauch, A; Keller, M; Wai, D; Brinkschmidt, C; van Valen, F; Boecker, W; Dockhorn-Dworniczak, B; Poremba, C			Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas	ONCOGENE			English	Article						telomere maintenance; osteosarcomas; telomerase activity; alternative lengthening of telomeres; chromosomal instability	TUMOR-CELLS; P53 GENE; CELLULAR SENESCENCE; CATALYTIC SUBUNIT; IMMORTAL CELLS; BREAST-LESIONS; CANCER; EXPRESSION; MAINTENANCE; IDENTIFICATION	Telomere maintenance is regarded as a key mechanism in overcoming cellular senescence in tumor cells and in most cases is achieved by the activation of telomerase, However there is at least one alternative mechanism of telomere lengthening (ALT) which is characterized by heterogeneous and elongated telomeres in the absence of telomerase activity (TA). We evaluated the prevalence of TA, gene expression of telomerase subunits and ALT in relation to telomere morphology and function in matrix producing bone tumors and in osteosarcoma cell lines and present evidence of a direct association of ALT with telomere dysfunction and chromosomal instability. Telomere fluorescence in situ hybridization (T-FISH) in ALT cells revealed elongated and shortened telomeres, partly in unusual configurations and loci, dicentric marker chromosomes and signal-free chromosome ends, Free ends give rise to end-to-end associations and may induce breakage-fusion-bridge cycles resulting in an increased number of complex chromosomal rearrangements, as detected by multiplex-FISH (M-FISH). We propose that ALT cannot be seen as an equivalent to telomerase activity in telomere maintenance, Its association with telomere dysfunction and chromosomal instability may have major implications for tumor progression.	Univ Munster, Gerhard Domagk Inst Pathol, D-48149 Munster, Germany; Univ Munster, Dept Expt Orthoped, D-48149 Munster, Germany; Univ Heidelberg, Dept Human Genet, Heidelberg, Germany	University of Munster; University of Munster; Ruprecht Karls University Heidelberg	Poremba, C (corresponding author), Univ Munster, Gerhard Domagk Inst Pathol, Domagkstr 17, D-48149 Munster, Germany.							Aue G, 1998, ANN SURG ONCOL, V5, P627, DOI 10.1007/BF02303833; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; Biessmann H, 1997, CHROMOSOMA, V106, P63, DOI 10.1007/s004120050225; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; Brinkschmidt C, 1998, BRIT J CANCER, V77, P2223, DOI 10.1038/bjc.1998.370; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Eils R, 1998, CYTOGENET CELL GENET, V82, P160, DOI 10.1159/000015092; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Ito H, 1998, CLIN CANCER RES, V4, P1603; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Landers JE, 1997, CANCER RES, V57, P3562; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; McClintock B, 1941, GENETICS, V26, P234; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020; Poremba C, 1998, INT J ONCOL, V12, P641; Poremba C, 2000, J CLIN ONCOL, V18, P2582, DOI 10.1200/JCO.2000.18.13.2582; Radig K, 1998, HUM PATHOL, V29, P1310, DOI 10.1016/S0046-8177(98)90263-5; Ramakrishnan S, 1998, CANCER RES, V58, P622; ROMANO JW, 1989, ONCOGENE, V4, P1483; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Sumida T, 1999, INT J CANCER, V80, P1, DOI 10.1002/(SICI)1097-0215(19990105)80:1<1::AID-IJC1>3.0.CO;2-U; Takakura M, 1998, CANCER RES, V58, P1558; Takubo K, 1997, J SURG ONCOL, V66, P88, DOI 10.1002/(SICI)1096-9098(199710)66:2<88::AID-JSO3>3.0.CO;2-H; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wynford-Thomas D, 1999, J PATHOL, V187, P100; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	49	135	137	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3835	3844		10.1038/sj.onc.1204493	http://dx.doi.org/10.1038/sj.onc.1204493			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439347				2022-12-25	WOS:000169494700009
J	Stephen, RL; Shaw, LE; Larsen, C; Corcoran, D; Darbre, PD				Stephen, RL; Shaw, LE; Larsen, C; Corcoran, D; Darbre, PD			Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT REGULATION; SUBSTRATE-1 EXPRESSION; RAT HEPATOCYTES; IGF RECEPTOR; PHENOL RED; IN-VITRO; BINDING; OVEREXPRESSION; PROLIFERATION; ZR-75-1	This work describes a reciprocal relationship between cell density and levels of insulin-like growth factor receptors (IGFR) in MCF7 human breast cancer cells, which adds a new dimension to the mechanism of crosstalk between estrogen and insulin-like growth factors in the regulation of breast cancer cell growth. The reduced binding of both I-125-IGF1 and alpha IR3 anti-IGFR antibody to whole cells showed that IGFR are lost from the surface of MCF7 cells as cell density increases, and this occurred irrespective of the presence or absence of estradiol. Western immunoblotting further confirmed loss of type I IGFR from MCF7 cells with increasing cell density. Long term estrogen deprivation was found to increase the levels of IGFR at all cell densities, such that after 96 weeks of estrogen deprivation, IGFR levels had become similar at the highest cell density in the absence of estradiol to the IGFR levels at the lowest cell density in the estrogen-maintained cells, and the levels of IGFR could be increased still further by estradiol. This overexpression of IGFR in the estrogen-deprived cells correlated with a reversal of response to exogenously added ligand, in that concentrations of insulin, IGFI, and IGFII that had stimulated growth of the estrogen-maintained cells became growth inhibitory to the estrogen-deprived cells. Blockade of the IGFIR with the alpha IR3 anti-IGFR antibody could partially inhibit the growth of the estrogen-deprived cells, suggesting that up-regulation of IGFR in these cells may contribute to the mechanism of adaptation to growth in steroid-deprived conditions which results in progression to estrogen independence of cell growth.	Univ Reading, Sch Anim & Microbial Sci, Div Cell & Mol Biol, Reading RG6 6AJ, Berks, England	University of Reading	Darbre, PD (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Div Cell & Mol Biol, POB 228, Reading RG6 6AJ, Berks, England.	p.d.darbre@reading.ac.uk	Larsen, camilla/C-5346-2009					Abdul-Wahab K, 1999, CELL PROLIFERAT, V32, P271, DOI 10.1046/j.1365-2184.1999.3250271.x; ARTEAGA CL, 1989, CANCER RES, V49, P6237; Bedrin MS, 1997, J CELL PHYSIOL, V172, P126, DOI 10.1002/(SICI)1097-4652(199707)172:1<126::AID-JCP14>3.3.CO;2-N; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; Clayton SJ, 1997, MOL CELL ENDOCRINOL, V128, P57, DOI 10.1016/S0303-7207(96)04016-6; CLEMMONS DR, 1986, J CLIN ENDOCR METAB, V63, P996, DOI 10.1210/jcem-63-4-996; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CULLEN KJ, 1990, CANCER RES, V50, P48; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DALY RJ, 1990, CANCER RES, V50, P5868; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; DARBRE P, 1983, CANCER RES, V43, P349; DARBRE PD, 1990, J STEROID BIOCHEM, V37, P753, DOI 10.1016/0960-0760(90)90416-I; DARBRE PD, 1989, P ROY SOC EDINB B, V95, P119, DOI 10.1017/S0269727000010605; Daws MR, 1996, ENDOCRINOLOGY, V137, P1177, DOI 10.1210/en.137.4.1177; DUBIK D, 1987, CANCER RES, V47, P6517; GLOVER JF, 1988, CANCER RES, V48, P3693; GRONER B, 1996, HORMONE DEPENDENT CA, P255; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HAMBURGER AW, 1991, PATHOBIOLOGY, V59, P329, DOI 10.1159/000163672; HILL DJ, 1989, J ENDOCRINOL, V122, P87, DOI 10.1677/joe.0.1220087; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Jensen BL, 1999, BRIT J CANCER, V79, P386, DOI 10.1038/sj.bjc.6690061; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KOKONTIS J, 1994, CANCER RES, V54, P1566; KULL FC, 1983, J BIOL CHEM, V258, P6561; KUSZYNSKI CA, 1993, IN VITRO CELL DEV-AN, V29, P708, DOI 10.1007/BF02631427; Laulederkind SJF, 2000, EXP CELL RES, V258, P409, DOI 10.1006/excr.2000.4961; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; LICHTNER RB, 1990, J CELL PHYSIOL, V144, P303, DOI 10.1002/jcp.1041440217; LIPPMAN ME, 1990, REGULATORY MECH BREA, P1; Liu WB, 1998, PATHOBIOLOGY, V66, P247, DOI 10.1159/000028030; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCLESKEY SW, 1994, CANCER RES, V54, P523; MILLER WR, 1996, ESTROGEN BREAST CANC, P1; MIZUNO K, 1993, J BIOCHEM-TOKYO, V114, P96, DOI 10.1093/oxfordjournals.jbchem.a124147; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; Oates AJ, 1998, BREAST CANCER RES TR, V47, P269, DOI 10.1023/A:1005959218524; Oh Y, 1998, BREAST CANCER RES TR, V47, P283, DOI 10.1023/A:1005911319432; OSBORNE CK, 1987, BREAST CANCER RES TR, V9, P111, DOI 10.1007/BF01807363; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Parisot JP, 1999, BRIT J CANCER, V79, P693, DOI 10.1038/sj.bjc.6690112; Parnas D, 1997, J MOL NEUROSCI, V8, P115, DOI 10.1007/BF02736777; PERACHIOTTI A, 1994, EXP CELL RES, V213, P404, DOI 10.1006/excr.1994.1216; Petridou S, 2000, INVEST OPHTH VIS SCI, V41, P89; PEYRAT JP, 1992, BREAST CANCER RES TR, V22, P59, DOI 10.1007/BF01833334; POCSIK E, 1994, J CELL BIOCHEM, V54, P453, DOI 10.1002/jcb.240540412; Rasmussen AA, 1998, BREAST CANCER RES TR, V47, P219, DOI 10.1023/A:1005903000777; Richardson TP, 1999, J BIOL CHEM, V274, P13534, DOI 10.1074/jbc.274.19.13534; RIZZINO A, 1988, CANCER RES, V48, P4266; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SCOTT CD, 1987, J CELL PHYSIOL, V133, P532, DOI 10.1002/jcp.1041330314; Stephen R, 2000, BRIT J CANCER, V83, P1183, DOI 10.1054/bjoc.2000.1388; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; VEOMETT G, 1989, BIOCHEM BIOPH RES CO, V159, P694, DOI 10.1016/0006-291X(89)90050-8; WELSHONS WV, 1987, EUR J CANCER CLIN ON, V23, P1935, DOI 10.1016/0277-5379(87)90062-9; Yee D, 1998, BREAST CANCER RES TR, V47, P197, DOI 10.1023/A:1005938615798; YEE D, 1988, CANCER RES, V48, P6691; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338	63	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2001	276	43					40080	40086		10.1074/jbc.M105892200	http://dx.doi.org/10.1074/jbc.M105892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	485XR	11457860	hybrid			2022-12-25	WOS:000171789200078
J	Vidarte, L; Pastor, C; Mas, S; Blazquez, AB; de los Rios, V; Guerrero, R; Vivanco, F				Vidarte, L; Pastor, C; Mas, S; Blazquez, AB; de los Rios, V; Guerrero, R; Vivanco, F			Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT ACTIVATION; IMMUNE-COMPLEXES; ALTERNATIVE PATHWAY; BINDING-SITE; SWISS-MODEL; HEAVY-CHAIN; IMMUNOGLOBULIN; ANTIBODY; REGION; IDENTIFICATION	The covalent binding of C3 (complement component C3) to antigen-antibody complexes (Ag-Ab; immune complexes (ICs)) is a key event in the uptake, transport, presentation, and elimination of Ag in the form of Ag(.)Ab(.)C3b (IC(.)C3b). Upon interaction of C3 with IgG(.)IC, C3b(.)C3b(.)IgG covalent complexes are formed that are detected on SDS-polyacrylamide gel electrophoresis by two bands corresponding to C3b(.)C3b (band A) and C3b(.)IgG (band B) covalent complexes. This allows one to evaluate the covalent binding of C3b to IgG antibodies. It has been described that C3b can attach to both the Fab (on the CHI domain) and the Fc regions of IgG. Here the covalent interaction of C3b to the CH1 domain, a region previously described spanning residues 125-147, has been studied. This region of the CH1 domain is exposed to solvent and contains a cluster of six potential acceptor sites for ester bond formation with C3b (four Ser and two Thr). A set of 10 mutant Abs were generated with the putative acceptor residues substituted by Ala, and we studied their covalent interaction with C3b. Single (Ser-131, Ser-132, Ser-134, Thr-135, Ser-136, and Thr-139), double (positions 131-132), and multiple (positions 134-135-136, 131-132-134-135-136, and 131-132-134-135136-139) mutants were produced. None of the mutants (single, double, or multiple) abolished completely the ability of IgG to bind C3b, indicating the presence of C3b binding regions other than in the CH1 domain. However, all mutant Abs, in which serine at position 132 was replaced by Ala, showed a significant decrease in the ability to form C3b(.)IgG covalent complexes, whereas the remaining mutants had normal activity. In addition we examined ICs using the F(ab')(2) fragment of the mutant Abs, and only those containing Ala at position 132 (instead of Ser) failed to bind C3b. Thus Ser-132 is the binding site for C3b on the CHI domain of the heavy chain, in the Fab region of human IgG.	Fdn Jimenez Diaz, Dept Immunol, Madrid 28040, Spain; Univ Complutense, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain	Complutense University of Madrid	Vivanco, F (corresponding author), Fdn Jimenez Diaz, Dept Immunol, Avda Reyes Catolicos 2, Madrid 28040, Spain.		Mas, S/T-1489-2018; Vivanco, Fernando/Q-6866-2016; Pastor Vargas, Carlos/B-4112-2010	Mas, S/0000-0001-6604-3327; Pastor Vargas, Carlos/0000-0002-4678-7967; Guerrero, Rosa/0000-0002-4138-4667				ALBAR JP, 1981, MOL IMMUNOL, V18, P925, DOI 10.1016/0161-5890(81)90015-8; ANTON LC, 1989, BIOCHEM J, V257, P831, DOI 10.1042/bj2570831; ANTON LC, 1994, EUR J IMMUNOL, V24, P599, DOI 10.1002/eji.1830240316; BARRIO E, 1991, EUR J IMMUNOL, V21, P343, DOI 10.1002/eji.1830210215; Carroll M C, 2000, Adv Immunol, V74, P61; Chacko S, 1996, J BIOL CHEM, V271, P12191, DOI 10.1074/jbc.271.21.12191; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; GADD KJ, 1981, BIOCHEM J, V195, P471, DOI 10.1042/bj1950471; Gomez-Guerrero C, 2000, J IMMUNOL, V164, P2092, DOI 10.4049/jimmunol.164.4.2092; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEX M, 1992, P NATL ACAD SCI USA, V89, P7154; HORGAN C, 1992, J IMMUNOL, V149, P127; Hudson PJ, 1999, CURR OPIN IMMUNOL, V11, P548, DOI 10.1016/S0952-7915(99)00013-8; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Idusogie EE, 2001, J IMMUNOL, V166, P2571, DOI 10.4049/jimmunol.166.4.2571; Kabat E. A., 1991, PROTEINS IMMUNOLOGIC; Kontermann R, 2001, ANTIBODY ENG; Landolfi NF, 2001, J IMMUNOL, V166, P1748, DOI 10.4049/jimmunol.166.3.1748; Laskey R A, 1980, Methods Enzymol, V65, P363; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; Lutz HU, 1996, BLOOD, V88, P184; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MORGAN BP, 1999, COMPLEMENT REGULATOR, P50; Morrison SL, 1998, J IMMUNOL, V160, P2802; Munoz E, 1998, EUR J IMMUNOL, V28, P2591, DOI 10.1002/(SICI)1521-4141(199808)28:08<2591::AID-IMMU2591>3.0.CO;2-P; Munoz E, 1998, INT IMMUNOL, V10, P97, DOI 10.1093/intimm/10.2.97; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; Reddy MP, 2000, J IMMUNOL, V164, P1925, DOI 10.4049/jimmunol.164.4.1925; SAHU A, 1994, BIOCHEM J, V302, P429, DOI 10.1042/bj3020429; SAHU A, 1994, J BIOL CHEM, V269, P28997; SAHU A, 1995, MOL IMMUNOL, V32, P711, DOI 10.1016/0161-5890(95)98933-F; Sahu A, 1996, BIOCHEM PHARMACOL, V51, P797, DOI 10.1016/0006-2952(95)02398-4; SANCHEZCORRAL P, 1989, J IMMUNOL METHODS, V122, P105, DOI 10.1016/0022-1759(89)90340-2; SANCHEZCORRAL P, 1990, MOL IMMUNOL, V27, P891, DOI 10.1016/0161-5890(90)90156-T; SHOHET JM, 1991, J BIOL CHEM, V266, P18520; SHOHET JM, 1993, J BIOL CHEM, V268, P5866; Vivanco F, 1999, MOL IMMUNOL, V36, P843, DOI 10.1016/S0161-5890(99)00105-4; VIVANCO F, 2000, RES AD ALLERGY IMMUN, V1, P1	40	23	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38217	38223						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11447230				2022-12-25	WOS:000171526500067
J	Cheong, CG; Escalante-Semerena, JC; Rayment, I				Cheong, CG; Escalante-Semerena, JC; Rayment, I			Structural investigation of the biosynthesis of alternative lower ligands for cobamides by nicotinate mononucleotide: 5,6-Dimethylbenzimidazole phosphoribosyltransferase from Salmonella enterica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; ANGSTROM RESOLUTION; NUCLEOTIDE LOOP; PHOSPHATE GUANYLYLTRANSFERASE; 3-DIMENSIONAL STRUCTURE; COENZYMIC FUNCTION; DIOL DEHYDRATASE; SPOROMUSA-OVATA; TYPHIMURIUM LT2; VITAMIN-B12	Nicotinate mononucleotide (NaMN):5,6-dimethylbenzimidazole phosphoribosyltransferase (CobT) from Salmonella enterica plays a central role in the synthesis of alpha -ribazole, a key component of the lower ligand of cobalamin. Surprisingly, CobT can phosphoribosylate a wide range of aromatic substrates, giving rise to a wide variety of lower ligands in cobamides. To understand the molecular basis for this lack of substrate specificity, the x-ray structures of CobT complexed with adenine, 5-methylbenzimidazole, 5-methoxybenzimidazole,p-cresol, and phenol were determined. Furthermore, adenine, 5-methylbenzimidazole, 5-methoxybenzimidazole, and 2-hydroxypurine were observed to react with NaMN within the crystal lattice and undergo the phosphoribosyl transfer reaction to form product. Significantly, the stereochemistries of all products are identical to those found in vivo. Interestingly, p-cresol and phenol, which are the lower ligand in Sporomusa ovata, bound to CobT but did not react with NaMN. This study provides a structural explanation for how CobT can phosphoribosylate most of the commonly observed lower ligands found in cobamides with the exception of the phenolic lower ligands observed in S. ovata. This is accomplished with minor conformational changes in the side chains that constitute the 5,6-dimethylbenzimidazole binding site. These investigations are consistent with the implication that the nature of the lower ligand is controlled by metabolic factors rather by the specificity of the phosphoribosyltransferase.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	jcescala@faestaff.wisc.edu; Ivan_Rayment@biochem.wisc.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NIGMS NIH HHS [GM58281, GM40313, R01 GM040313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058281, R01GM040313, R37GM040313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER HA, 1958, P NATL ACAD SCI USA, V44, P1093, DOI 10.1073/pnas.44.11.1093; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; CHEN P, 1995, J BACTERIOL, V177, P1461, DOI 10.1128/jb.177.6.1461-1469.1995; Cheong CG, 1999, BIOCHEMISTRY-US, V38, P16125, DOI 10.1021/bi991752c; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; ESCALANTESEMERENA JC, 1992, J BACTERIOL, V174, P24, DOI 10.1128/jb.174.1.24-29.1992; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; HORIG JA, 1978, J BIOL CHEM, V253, P7410; HORIG JA, 1980, EUR J BIOCHEM, V105, P587, DOI 10.1111/j.1432-1033.1980.tb04536.x; IRION E, 1965, BIOCHEMISTRY-US, V4, P2780, DOI 10.1021/bi00888a031; ISHIDA A, 1993, J NUTR SCI VITAMINOL, V39, P115, DOI 10.3177/jnsv.39.115; JOHNSON MG, 1992, J BIOL CHEM, V267, P13302; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Keck B, 2000, ARCH MICROBIOL, V173, P76, DOI 10.1007/s002030050011; Keck K, 1998, ARCH MICROBIOL, V171, P66, DOI 10.1007/s002030050679; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUTLER B, 1987, EUR J BIOCHEM, V162, P275, DOI 10.1111/j.1432-1033.1987.tb10596.x; KRAUTLER B, 1988, EUR J BIOCHEM, V176, P461, DOI 10.1111/j.1432-1033.1988.tb14303.x; Maggio-Hall LA, 1999, P NATL ACAD SCI USA, V96, P11798, DOI 10.1073/pnas.96.21.11798; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; PERLMAN D, 1958, CAN J MICROBIOL, V4, P9, DOI 10.1139/m58-002; RENZ P, 1970, FEBS LETT, V6, P187, DOI 10.1016/0014-5793(70)80053-9; RENZ P, 1987, EUR J BIOCHEM, V163, P175, DOI 10.1111/j.1432-1033.1987.tb10752.x; RENZ P, 1972, FEBS LETT, V22, P124, DOI 10.1016/0014-5793(72)80236-9; Rondon MR, 1997, PROG NUCLEIC ACID RE, V56, P347, DOI 10.1016/S0079-6603(08)61010-7; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; SCOTT AI, 1993, ANGEW CHEM INT EDIT, V32, P1223, DOI 10.1002/anie.199312233; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; STUPPERICH E, 1988, ARCH MICROBIOL, V149, P268, DOI 10.1007/BF00422016; STUPPERICH E, 1989, EUR J BIOCHEM, V186, P657, DOI 10.1111/j.1432-1033.1989.tb15256.x; STUPPERICH E, 1988, EUR J BIOCHEM, V172, P459, DOI 10.1111/j.1432-1033.1988.tb13910.x; STUPPERICH E, 1989, ADV SPACE RES, V9, P117; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Thomas MG, 2000, J BIOL CHEM, V275, P27576; Thompson TB, 1999, BIOCHEMISTRY-US, V38, P12995, DOI 10.1021/bi990910x; Thompson TB, 1998, BIOCHEMISTRY-US, V37, P7686, DOI 10.1021/bi973178f; TORAYA T, 1994, BBA-PROTEIN STRUCT M, V1204, P169, DOI 10.1016/0167-4838(94)90005-1; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Trzebiatowski JR, 1997, J BIOL CHEM, V272, P17662, DOI 10.1074/jbc.272.28.17662; TRZEBIATOWSKI JR, 1994, J BACTERIOL, V176, P3568, DOI 10.1128/JB.176.12.3568-3575.1994	44	33	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37612	37620		10.1074/jbc.M105390200	http://dx.doi.org/10.1074/jbc.M105390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11441022	hybrid			2022-12-25	WOS:000171375700098
J	Ghayor, C; Chadjichristos, C; Herrouin, JF; Ala-Kokko, L; Suske, G; Pujol, JP; Galera, P				Ghayor, C; Chadjichristos, C; Herrouin, JF; Ala-Kokko, L; Suske, G; Pujol, JP; Galera, P			SP3 represses the SP1-mediated transactivation of the human COL2A1 gene in primary and de-differentiated chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT ARTICULAR CHONDROCYTES; TRANSFORMING GROWTH-FACTOR-BETA-1 TGF-BETA-1; TRANSCRIPTION FACTOR SP1; DNA-BINDING PROTEINS; COLLAGEN TYPE-II; MESSENGER-RNA; SP-FAMILY; C-KROX; EXPRESSION; CARTILAGE	Sp1 and Sp3 effects on the transcription of the human alpha1(II) procollagen gene (COL2A1) were investigated in both differentiated and de-differentiated rabbit articular chondrocytes. Transient transfection with constructs of deleted COL2A1 promoter sequences driving the luciferase reporter gene revealed that the region spanning -266 to +121 base pairs showed Sp1-enhancing effects, whatever the differentiation state. In contrast, Sp3 did not influence COL2A1 gene transcription. Concomitant overexpression of the two Sp proteins demonstrated that Sp3 blocked the Sp1 induction of COL2A1 promoter activity. Moreover, inhibition of Sp1/Sp3 binding to their target DNA sequence decreased both COL2A1 gene transcription and Sp1-enhancing effects. DNase I footprinting and gel retardation assays revealed that Sp1 and Sp3 bind specifically to cis-sequences of the COL2A1 gene promoter whereby they exert their transcriptional effects. Sp1 and Sp3 levels were found to be reduced in de-differentiated chondrocytes, as revealed by DNA-binding and immunochemical study. Sp1 specifically activated collagen neosynthesis whatever the differentiation state of chondrocytes, suggesting that this factor exerts a major role in the expression of collagen type II. However, our data indicate that type II collagen-specific expression in chondrocytes depend on both the Sp1/Sp3 ratio and cooperation of Sp1 with other transcription factors, the amounts of which are also modulated by phenotype alteration.	CHU Niveau 3, Fac Med, Lab Biochim Tissu Conjonctif, F-14032 Caen, France; Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem, SF-90220 Oulu, Finland; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	CHU de Caen NORMANDIE; Universite de Caen Normandie; University of Oulu; University of Oulu; Philipps University Marburg	Galera, P (corresponding author), CHU Niveau 3, Fac Med, Lab Biochim Tissu Conjonctif, Ave Cote de Nacre, F-14032 Caen, France.	Galera.Philippe@wanadoo.fr	Chadjichristos, Christos E/J-4871-2016	Chadjichristos, Christos E/0000-0001-6657-7900; Ghayor, Chafik/0000-0002-3016-3412; Suske, Guntram/0000-0002-4807-0513				AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624; ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BENYA PD, 1977, BIOCHEMISTRY-US, V16, P865, DOI 10.1021/bi00624a009; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bolton MC, 1996, BIOCHEM J, V319, P489, DOI 10.1042/bj3190489; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P105, DOI 10.1016/0014-4827(90)90042-9; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; GALERA P, 1992, J CELL PHYSIOL, V153, P596, DOI 10.1002/jcp.1041530322; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; Ghayor C, 2000, J BIOL CHEM, V275, P27421; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; GOLWASSER M, 1982, CLIN ORTHOP RELAT R, V167, P296; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALL B, 1991, CARTILAGE MOL ASPECT, P1; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HORTON WE, 1992, DNA CELL BIOL, V11, P193, DOI 10.1089/dna.1992.11.193; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; KalffSuske M, 1996, GENOMICS, V37, P410, DOI 10.1006/geno.1996.0582; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LUPARELLO C, 1993, DIFFERENTIATION, V55, P73, DOI 10.1111/j.1432-0436.1993.tb00034.x; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; NIMNI M, 1973, SCIENCE, V181, P751, DOI 10.1126/science.181.4101.751; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PUJOL JP, 1987, LIFE SCI, V41, P1187, DOI 10.1016/0024-3205(87)90196-2; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takaishi H, 1997, BBA-GENE STRUCT EXPR, V1350, P253, DOI 10.1016/S0167-4781(96)00233-3; TAKIGAWA M, 1989, CANCER RES, V49, P3996; TILLER GE, 1990, P NATL ACAD SCI USA, V87, P3889, DOI 10.1073/pnas.87.10.3889; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WANG LQ, 1991, J BIOL CHEM, V266, P19878; Xie WF, 1998, J BIOL CHEM, V273, P5026, DOI 10.1074/jbc.273.9.5026	67	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36881	36895		10.1074/jbc.M105083200	http://dx.doi.org/10.1074/jbc.M105083200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11447232	hybrid			2022-12-25	WOS:000171375700006
J	Hasty, AH; Shimano, H; Osuga, J; Namatame, I; Takahashi, A; Yahagi, N; Perrey, S; Iizuka, Y; Tamura, Y; Amemiya-Kudo, M; Yoshikawa, T; Okazaki, H; Ohashi, K; Harada, K; Matsuzaka, T; Sone, H; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N				Hasty, AH; Shimano, H; Osuga, J; Namatame, I; Takahashi, A; Yahagi, N; Perrey, S; Iizuka, Y; Tamura, Y; Amemiya-Kudo, M; Yoshikawa, T; Okazaki, H; Ohashi, K; Harada, K; Matsuzaka, T; Sone, H; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N			Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; APOLIPOPROTEIN-E; KNOCKOUT MICE; GENE; OBESE; MOUSE; RECOMBINATION; CHOLESTEROL; LESIONS; LIVERS	Leptin-deficient mice (ob/ob) are an excellent murine model for obesity, insulin resistance, and diabetes, all of which are components of a multiple risk factor syndrome that, along with hypercholesterolemia, precipitates a potential high risk for atherosclerosis. In the current study, we show an unexpectedly severe hyperlipidemia in ob/ob mice on a background of low density lipoprotein receptor (LDLR) deficiency (-/-). Doubly mutant mice (LDLR-/-; ob/ob) exhibited striking elevations in both total plasma cholesterol (TC) and triglyceride (TG) levels (1715 +/- 87 and 1016 +/- 172 mg/dl, respectively), at age 3-4 months, resulting in extensive atherosclerotic lesions throughout the aorta by 6 months. Lipoprotein analyses revealed the elevated TC and TG levels to be due to a large increase in an apoB-containing broad-beta remnant lipoprotein fraction. While fasting, diet restriction, and low level leptin treatment significantly lowered TG levels, they caused only slight changes in TC levels. Hepatic cholesterol and triglyceride contents as well as mRNA levels of cholesterologenic and lipogenic enzymes suggest that leptin deficiency increased hepatic triglyceride production but did not change cholesterol production in ob/ob mice regardless of their LDLR genotype. These data provide evidence that the hypertriglyceridemia and hypercholesterolemia in the doubly mutant mice are caused by distinct mechanisms and point to the possibility that leptin might have some impact on plasma cholesterol metabolism, possibly through an LDLR-independent pathway. This model will be an excellent tool for future studies on the relationship between impaired fuel metabolism, increased plasma remnant lipoproteins, diabetes, and atherosclerosis.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Endocrinol & Metab, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Dept Metab Dis, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Endocrinol & Metab, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	slumano-tky@umin.ac.jp	perrey, stephane/B-7483-2008; Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019; Harada, Kenji/J-2230-2016; Hasty, Alyssa/AAA-2757-2020; Sone, Hirohito/ABC-9346-2021; Yahagi, Naoya/D-2360-2014	perrey, stephane/0000-0002-8741-629X; Shimano, Hitoshi/0000-0002-5562-5572; Hasty, Alyssa/0000-0001-7302-8045; Sone, Hirohito/0000-0003-1263-2817; Yahagi, Naoya/0000-0002-1823-1865				COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; Li XH, 1997, J LIPID RES, V38, P1277; MUIR JR, 1967, CLIN CHIM ACTA, V17, P312, DOI 10.1016/0009-8981(67)90139-8; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 1999, J BIOL CHEM, V274, P4140, DOI 10.1074/jbc.274.7.4140; Yagyu H, 1999, J LIPID RES, V40, P1677; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	21	174	181	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37402	37408		10.1074/jbc.M010176200	http://dx.doi.org/10.1074/jbc.M010176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11445560	hybrid			2022-12-25	WOS:000171375700072
J	de Chaves, EP; Bussiere, M; MacInnis, B; Vance, DE; Campenot, RB; Vance, JE				de Chaves, EP; Bussiere, M; MacInnis, B; Vance, DE; Campenot, RB; Vance, JE			Ceramide inhibits axonal growth and nerve growth factor uptake without compromising the viability of sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; NECROSIS-FACTOR-ALPHA; NEUTRAL SPHINGOMYELINASE; ACID SPHINGOMYELINASE; NEUROTROPHIN RECEPTOR; SIGNAL-TRANSDUCTION; RETROGRADE TRANSPORT; DISTINCT POOL; FREE SYSTEM; APOPTOSIS	Ceramide inhibits the axonal growth of cultured rat sympathetic neurons when the ceramide content of distal axons, but not cell bodies, is increased (Posse de Chaves, E. I., Bussiere, M., Vance, D. E., Campenot, R. B., and Vance, J. E. (1997) J. Biol. Chem. 272, 3028-3035). We now report that inhibition of growth does not result from cell death since although ceramide is a known apoptotic agent, C.-ceramide given to the neurons for 24 h did not cause cell death but instead protected the neurons from death induced by deprivation of nerve growth factor (NGF). We also find that a pool of ceramide generated from sphingomyelin in distal axons, but not cell bodies, inhibits axonal growth. Analysis of endogenous sphingomyelinase activities demonstrated that distal axons are rich in neutral sphingomyelinase activity but contain almost no acidic sphingomyelinase, which is concentrated in cell bodies/proximal axons. Together, these observations are consistent with the idea that generation of ceramide from sphingomyelin by a neutral sphingomyelinase in axons inhibits axonal growth. Furthermore, we demonstrate that treatment of distal axons with ceramide inhibits the uptake of NGF and low density lipoproteins by distal axons by similar to 70 and 40%, respectively, suggesting that the inhibition of axonal growth by ceramide might be due, at least in part, to impaired endocytosis of NGF. However, inhibition of endocytosis of NGF by ceramide could not be ascribed to decreased phosphorylation of TrkA.	Univ Alberta, Heritage Med Res Ctr 332, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Heritage Med Res Ctr 332, Dept Med, Edmonton, AB T6G 2S2, Canada.							Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; Brann AB, 1999, J NEUROSCI, V19, P8199; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; CAMPENOT RB, 1994, J NEUROBIOL, V25, P599, DOI 10.1002/neu.480250603; CAMPENOT RB, 1979, METHOD ENZYMOL, V28, P302; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; Carrer DC, 1999, J LIPID RES, V40, P1978; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHAO MV, 1995, MOL CELL NEUROSCI, V6, P91, DOI 10.1006/mcne.1995.1009; Chatterjee S, 1999, J BIOL CHEM, V274, P37407, DOI 10.1074/jbc.274.52.37407; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; CLAUDE P, 1982, J NEUROSCI, V2, P431; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; de Chaves EIP, 2000, J BIOL CHEM, V275, P19883, DOI 10.1074/jbc.275.26.19883; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Edsall LC, 1997, J NEUROSCI, V17, P6952; Folch J., 1959, J BIOL CHEM, V226, P495; Furuya S, 1998, J NEUROCHEM, V71, P366; FURUYA S, 1995, J NEUROCHEM, V65, P1551; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hawrot E, 1979, Methods Enzymol, V58, P574; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Irie F, 1998, J NEUROSCI RES, V54, P475, DOI 10.1002/(SICI)1097-4547(19981115)54:4<475::AID-JNR5>3.0.CO;2-P; ITO A, 1995, J NEUROCHEM, V65, P463; KIM MY, 1991, J BIOL CHEM, V266, P484; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; MacPhee I, 1999, J NEUROCHEM, V72, P1423, DOI 10.1046/j.1471-4159.1999.721423.x; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Nair P, 2000, CELL DEATH DIFFER, V7, P207, DOI 10.1038/sj.cdd.4400628; NIXON RA, 1995, TRENDS NEUROSCI, V18, P489, DOI 10.1016/0166-2236(95)92772-I; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Overly CC, 1996, J NEUROSCI, V16, P6056; PARTON RG, 1993, J NEUROSCI RES, V36, P1, DOI 10.1002/jnr.490360102; Ping SE, 1998, J NEUROSCI RES, V54, P206, DOI 10.1002/(SICI)1097-4547(19981015)54:2<206::AID-JNR8>3.0.CO;2-I; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; SANDHOFF K, 1994, FEBS LETT, V346, P103, DOI 10.1016/0014-5793(94)00282-7; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Schwarz A, 1997, J NEUROSCI, V17, P2929; SHEPHERD J, 1976, CLIN CHIM ACTA, V66, P97, DOI 10.1016/0009-8981(76)90376-4; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Ure DR, 1997, J NEUROSCI, V17, P1282; URE DR, 1994, DEV BIOL, V162, P339, DOI 10.1006/dbio.1994.1091; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Zhang P, 1997, J BIOL CHEM, V272, P9609; ZHOU X, 1992, J LIPID RES, V33, P1233	66	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36207	36214		10.1074/jbc.M104282200	http://dx.doi.org/10.1074/jbc.M104282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11454862	hybrid			2022-12-25	WOS:000171194500023
J	Kantachuvesiri, S; Fleming, S; Peters, J; Peters, B; Brooker, G; Lammie, AG; McGrath, I; Kotelevtsev, Y; Mullins, JJ				Kantachuvesiri, S; Fleming, S; Peters, J; Peters, B; Brooker, G; Lammie, AG; McGrath, I; Kotelevtsev, Y; Mullins, JJ			Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENIN-ANGIOTENSIN SYSTEM; CONFOCAL MICROSCOPY; RATS; ALDOSTERONE; INDUCTION; ARTERIES; PLASMA; DAMAGE	A novel inbred rat model with inducible hypertension has been generated using a renin transgene under the transcriptional control of the cytochrome P450, Cyp1a1 promoter. The degree and duration of hypertension are regulated tightly by administration of the natural xenobiotic indole-3 carbinol and can be readily reversed. Induction experiments reveal distinct temporal and mechanistic responses to hypertensive injury in different vascular beds, which is indicative of differential susceptibility of organs to a hypertensive stimulus. The mesentery and heart exhibited the greatest sensitivity to damage, and the kidney showed an adaptive response prior to the development of malignant hypertensive injury. Quantitative analysis of morphological changes induced in mesenteric resistance arteries suggest eutrophic remodeling of the vessels. Kinetic evidence suggests that locally activated plasma prorenin may play a critical role in mediating vascular injury. This model will facilitate studies of the cellular and genetic mechanisms underlying vascular injury and repair and provide a basis for the identification of novel therapeutic targets for vascular disease.	Univ Edinburgh, Sch Med, Mol Physiol Lab, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Heidelberg, Dept Pharmacol, D-69120 Heidelberg, Germany; Univ Wales Coll Med, Dept Histopathol, Cardiff CF4 2XU, S Glam, Wales; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Edinburgh, Dept Biomed Sci, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; Ruprecht Karls University Heidelberg; Cardiff University; University of Glasgow; University of Edinburgh	Mullins, JJ (corresponding author), Univ Edinburgh, Sch Med, Mol Physiol Lab, Wilkie Bldg,Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		Kotelevtsev, Yuri V/R-1772-2016; McGrath, John C/G-6485-2012	McGrath, John C/0000-0002-5276-0381; Kotelevtsev, Yuri/0000-0002-7255-7794				Arribas SM, 1997, J HYPERTENS, V15, P1685, DOI 10.1097/00004872-199715120-00073; Arribas SM, 1997, HYPERTENSION, V30, P1455, DOI 10.1161/01.HYP.30.6.1455; BLANTZ RC, 1984, KIDNEY INT, V25, P739, DOI 10.1038/ki.1984.84; Bohlender J, 1997, HYPERTENSION, V29, P428, DOI 10.1161/01.HYP.29.1.428; BYROM FB, 1963, LANCET, V1, P516; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUJIIKURIYAMA Y, 1995, PHARMACOGENETICS, V5, P149; GAVRAS H, 1975, CIRC RES, V36, P301; GUYTON AC, 1997, HUMAN PHYSL MECH DIS, P495; GUYTON AC, 1997, HUMAN PHYSL MECH DIS, P142; HELMCHEN U, 1984, HYPERTENSION, V6, P87; HERMANN K, 1988, CLIN CHEM, V34, P1046; Hilbers U, 1999, HYPERTENSION, V33, P1025, DOI 10.1161/01.HYP.33.4.1025; JELLINCK PH, 1993, BIOCHEM PHARMACOL, V45, P1129, DOI 10.1016/0006-2952(93)90258-X; Kantachuvesiri S, 1999, KIDNEY INT, V56, P414, DOI 10.1046/j.1523-1755.1999.00571.x; KANTACHUVESIRI S, 1999, THESIS U EDINBURGH E; LOHMEIER TE, 1984, HYPERTENSION S1, V6, P177; LOUB WD, 1975, J NATL CANCER I, V54, P985; Luft FC, 1999, HYPERTENSION, V33, P212, DOI 10.1161/01.HYP.33.1.212; MEIER G, 1988, CLIN SCI, V75, P551, DOI 10.1042/cs0750551; MULLINS JJ, 1990, J HYPERTENS, V8, pS35; OGG D, 1997, THESIS U EDINBURGH; OSTER P, 1973, EXPERIENTIA, V29, P353, DOI 10.1007/BF01926526; PAUL M, 1994, ANNU REV PHYSIOL, V56, P811, DOI 10.1146/annurev.ph.56.030194.004115; Peters B, 1998, J HISTOCHEM CYTOCHEM, V46, P1215, DOI 10.1177/002215549804601101; PETERS J, 1993, J CLIN INVEST, V91, P742, DOI 10.1172/JCI116292; Peters J, 1996, AM J PHYSIOL-ENDOC M, V271, pE439, DOI 10.1152/ajpendo.1996.271.3.E439; Peters J, 1999, ENDOCRINOLOGY, V140, P675, DOI 10.1210/en.140.2.675; Rocha R, 1999, HYPERTENSION, V33, P232, DOI 10.1161/01.HYP.33.1.232; SCHELLING P, 1980, NEUROENDOCRINOLOGY, V31, P297, DOI 10.1159/000123092; SCHUNKERT H, 1992, AM J PHYSIOL, V263, pE863, DOI 10.1152/ajpendo.1992.263.5.E863; STRESSER DM, 1995, DRUG METAB DISPOS, V23, P965; Veniant M, 1996, J CLIN INVEST, V98, P1966, DOI 10.1172/JCI119000; WHITWORTH CE, 1995, KIDNEY INT, V47, P529, DOI 10.1038/ki.1995.66	34	128	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36727	36733		10.1074/jbc.M103296200	http://dx.doi.org/10.1074/jbc.M103296200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11448960	hybrid			2022-12-25	WOS:000171194500089
J	Sloop, KW; Dwyer, CJ; Rhodes, SJ				Sloop, KW; Dwyer, CJ; Rhodes, SJ			An isoform-specific inhibitory domain regulates the LHX3 LIM homeodomain factor holoprotein and the production of a functional alternate translation form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROENDOCRINE TRANSCRIPTION FACTOR; ALPHA-SUBUNIT PROMOTER; PITUITARY-TUMOR CELLS; CHROMOSOMAL LOCALIZATION; ANTERIOR-PITUITARY; GENOMIC STRUCTURE; HOMEOBOX GENES; DNA-BINDING; HORMONE; ACTIVATION	The LHX3 LIM homeodomain transcription factor is required for pituitary development and motor neuron specification. The Lhx3 gene encodes two isoforms, LHX3a and LHX3b, that differ in their amino-terminal sequences. Humans and mice with defective Lhx3 genes are deficient in gonadotrope, lactotrope, somatotrope, and thyrotrope pituitary cells. We show that, whereas Lhx3b is highly expressed in these Lhx3-dependent cell types, high levels of Lhx3a expression are restricted to a glycoprotein subunit-expressing thyrotropes and gonadotropes. Cross-species comparison reveals the LHX3b-specific domain is more conserved than the LHX3a-specific domain. We demonstrate that the LHX3b-specific domain is a transferable inhibitor that reduces gene activation and DNA binding by homeodomain proteins. In addition, we identify a novel LHX3 protein (M2-LHX3) and determine that this molecule is generated by an internal translation initiation codon. The LHX3a- and LHX3b-specific coding sequences regulate differential usage of this internal start codon. Further, we identify the major activation domain of LHX3 in the carboxyl terminus of the molecule. M2-LHX3 is active because it retains this domain and binds DNA better than LHX3a or LHX3b. Other LIM homeodomain genes, including Lhx4, generate similar truncated proteins. These studies describe how transcriptional regulatory genes can generate multiple functional proteins.	Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Rhodes, SJ (corresponding author), Indiana Univ Purdue Univ, Dept Biol, 723 W Michigan St, Indianapolis, IN 46202 USA.	srhodes@iupui.edu						Alarid ET, 1998, MOL CELL ENDOCRINOL, V140, P25; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Brinkmeier ML, 1998, MOL ENDOCRINOL, V12, P622, DOI 10.1210/me.12.5.622; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Essner JJ, 2000, DEVELOPMENT, V127, P1081; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Hobert O, 2000, TRENDS GENET, V16, P75, DOI 10.1016/S0168-9525(99)01883-1; Howard PW, 2001, J BIOL CHEM, V276, P19020, DOI 10.1074/jbc.M101782200; Kimura N, 1999, J BIOCHEM-TOKYO, V126, P180, DOI 10.1093/oxfordjournals.jbchem.a022420; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Meier BC, 1999, MOL CELL ENDOCRINOL, V147, P65, DOI 10.1016/S0303-7207(98)00213-5; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Netchine I, 2000, NAT GENET, V25, P182, DOI 10.1038/76041; O'Donovan KJ, 1999, MOL CELL BIOL, V19, P4711; Parker GE, 2000, J BIOL CHEM, V275, P23891, DOI 10.1074/jbc.M000377200; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; Rhodes S. J., 1996, J ANIM SCI, V74, P94; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; Schmitt S, 2000, BIOCHEM BIOPH RES CO, V274, P49, DOI 10.1006/bbrc.2000.3038; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; Sloop KW, 2000, MOL CELL ENDOCRINOL, V168, P77, DOI 10.1016/S0303-7207(00)00318-X; Sloop KW, 1999, MOL ENDOCRINOL, V13, P2212, DOI 10.1210/me.13.12.2212; Sloop KW, 2000, GENE, V245, P237, DOI 10.1016/S0378-1119(00)00025-1; SLOOP KW, 2001, GENE, V265, P60; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; VOSS JW, 1991, J BIOL CHEM, V266, P12832; ZHADANOV AB, 1995, GENOMICS, V27, P27, DOI 10.1006/geno.1995.1004	37	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36311	36319		10.1074/jbc.M103888200	http://dx.doi.org/10.1074/jbc.M103888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470784	hybrid			2022-12-25	WOS:000171194500036
J	Swartz, TE; Corchnoy, SB; Christie, JM; Lewis, JW; Szundi, I; Briggs, WR; Bogomolni, RA				Swartz, TE; Corchnoy, SB; Christie, JM; Lewis, JW; Szundi, I; Briggs, WR; Bogomolni, RA			The photocycle of a flavin-binding domain of the blue light photoreceptor phototropin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; HUMAN THIOREDOXIN; FLASH-PHOTOLYSIS; ARABIDOPSIS NPH1; WATER MOLECULE; SCHIFF-BASE; BACTERIORHODOPSIN; ION; MERCAPTIDE; REDUCTION	The plant blue light receptor, phot1, a member of the phototropin family (1), is a plasma membrane-associated flavoprotein that contains two (similar to 110 amino acids) flavin-binding domains, LOV1 and LOV2, within its N terminus and a typical serine-threonine protein kinase domain at its C terminus. The LOV (light, oxygen, and voltage) domains belong to the PAS domain superfamily of sensor proteins. In response to blue light, phototropins undergo autophosphorylation. E. coli-expressed LOV domains bind riboflavin-5 ' -monophosphate, are photochemically active, and have major absorption peaks at 360 and 450 nm, with the 450 nm peak having vibronic structure at 425 and 475 nm. These spectral features correspond to the action spectrum for phototropism in higher plants. Blue light excitation of the LOV2 domain generates, in less than 30 ns, a transient similar to 660 mn-absorbing species that spectroscopically resembles a flavin triplet state. This putative triplet state subsequently decays with a 4-mus time constant into a 390 nm-absorbing metastable form. The LOV2 domain (450 nm) recovers spontaneously with half-times of similar to 50 s. It has been shown that the metastable species is likely a flavin-cysteine (Cys(39) thiol) adduct at the flavin C(4a) position. A LOV2C39A mutant generates the early photoproduct but not the adduct. Titrations of LOV2 using chromophore fluorescence as an indicator suggest that Cys(39) exists as a thiolate.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA	University of California System; University of California Santa Cruz; Carnegie Institution for Science	Bogomolni, RA (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, 1156 High St, Santa Cruz, CA 95064 USA.	bogo@chemistry.ucsc.edu		Christie, John/0000-0002-9976-0055				Briggs WR, 2001, PLANT CELL, V13, P993, DOI 10.1105/tpc.13.5.993; BROWN LS, 1994, BIOCHEMISTRY-US, V33, P12001, DOI 10.1021/bi00206a001; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; FALK MC, 1976, BIOCHEMISTRY-US, V15, P646, DOI 10.1021/bi00648a031; FISCHER WB, 1994, BIOCHEMISTRY-US, V33, P12757, DOI 10.1021/bi00209a005; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; FORMANKAY JD, 1992, BIOCHEMISTRY-US, V31, P3442, DOI 10.1021/bi00128a019; GREEN M, 1968, PHOTOCHEM PHOTOBIOL, V7, P129, DOI 10.1111/j.1751-1097.1968.tb08000.x; GUTMANN F, 1997, CHARGE TRANSFER COMP, P221; HEELIS PF, 1979, PHOTOBIOCH PHOTOBIOP, V1, P63; HOFRICHTER J, 1989, BIOPHYS J, V56, P693, DOI 10.1016/S0006-3495(89)82716-X; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; HUG SJ, 1990, BIOCHEMISTRY-US, V29, P1475, DOI 10.1021/bi00458a019; Jacobi A, 1997, J BIOL CHEM, V272, P21692, DOI 10.1074/jbc.272.35.21692; Kliger DS, 1990, POLARIZED LIGHT OPTI; KNOWLES A, 1968, PHOTOCHEM PHOTOBIOL, V7, P421, DOI 10.1111/j.1751-1097.1968.tb07404.x; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; LEWIS JW, 1993, REV SCI INSTRUM, V64, P2828, DOI 10.1063/1.1144369; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; MAEDA A, 1994, BIOCHEMISTRY-US, V33, P1713, DOI 10.1021/bi00173a013; Maeda A, 1997, J BIOCHEM-TOKYO, V121, P399; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MILLER SM, 1990, BIOCHEMISTRY-US, V29, P2831, DOI 10.1021/bi00463a028; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V2, P1; Nozue K, 1998, P NATL ACAD SCI USA, V95, P15826, DOI 10.1073/pnas.95.26.15826; POLGAR L, 1974, FEBS LETT, V38, P187, DOI 10.1016/0014-5793(74)80110-9; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; SONG PS, 1968, J PHYS CHEM-US, V72, P536, DOI 10.1021/j100848a025; SONG PS, 1968, PHOTOCHEM PHOTOBIOL, V7, P311, DOI 10.1111/j.1751-1097.1968.tb08018.x; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Szundi I, 2001, BIOPHYS J, V80, P469, DOI 10.1016/S0006-3495(01)76029-8; VAISH S P, 1970, Journal of Bioenergetics, V1, P181, DOI 10.1007/BF01515980; WEBER G, 1950, BIOCHEM J, V47, P114, DOI 10.1042/bj0470114; YAGI K, 1980, BIOCHEMISTRY-US, V19, P1553, DOI 10.1021/bi00549a003	38	441	452	2	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36493	36500		10.1074/jbc.M103114200	http://dx.doi.org/10.1074/jbc.M103114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11443119	hybrid			2022-12-25	WOS:000171194500060
J	Flaman, AS; Chen, JM; Van Iderstine, SC; Byers, DM				Flaman, AS; Chen, JM; Van Iderstine, SC; Byers, DM			Site-directed mutagenesis of acyl carrier protein (ACP) reveals amino acid residues involved in ACP structure and acyl-ACP synthetase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; VIBRIO-HARVEYI; BACTERIAL BIOLUMINESCENCE; LUMINESCENT BACTERIA; POLYKETIDE SYNTHASE; PROSTHETIC GROUP; FATTY ACYLATION; LIPID-A; BIOSYNTHESIS; PURIFICATION	Acyl carrier protein (ACP) interacts with many different enzymes during the synthesis of fatty acids, phospholipids, and other specialized products in bacteria. To examine the structural and functional roles of amino acids previously implicated in interactions between the ACP polypeptide and fatty acids attached to the phosphopantetheine prosthetic group, recombinant Vibrio harveyi ACP and mutant derivatives of conserved residues Phe-50, Ile-54, Ala-59, and Tyr-71 were prepared from glutathione S-transferase fusion proteins. Circular dichroism revealed that, unlike Escherichia coli ACP, V. harveyi-derived ACPs are unfolded at neutral pH in the absence of divalent cations; all except F50A and 154A recovered native conformation upon addition of MgCl2. Mutant 154A was not processed to the holo form by ACP synthase. Some mutations significantly decreased catalytic efficiency of ACP fatty acylation by V. harveyi acyl-ACP synthetase relative to recombinant ACP, e.g. F50A (4%), I54L (20%), and I54V (31%), whereas others (V12G, Y71A, and A59G) had less effect. By contrast, all myristoylated ACPs examined were effective substrates for the luminescence-specific V. harveyi myristoyl-ACP thioesterase. Conformationally sensitive gel electrophoresis at pH 9 indicated that fatty acid attachment stabilizes mutant ACPs in a chain length-dependent manner, although stabilization was decreased for mutants F50A and A59G. Our results indicate that (i) residues Ile-54 and Phe-50 are important in maintaining native ACP conformation, (ii) residue Ala-59 may be directly involved in stabilization of ACP structure by acyl chain binding, and (iii) acyl-ACP synthetase requires native ACP conformation and involves interaction with fatty acid binding pocket residues, whereas myristoyl-ACP thioesterase is insensitive to acyl donor structure.	Dalhousie Univ, Atlantic Res Ctr, Clin Res Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	Byers, DM (corresponding author), Dalhousie Univ, Atlantic Res Ctr, Clin Res Ctr, Dept Pediat, Room C-305,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.			Chen, Jeffrey/0000-0001-8431-3802				ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BYERS D, 1985, J BIOL CHEM, V260, P6938; BYERS DM, 1985, P NATL ACAD SCI USA, V82, P6085, DOI 10.1073/pnas.82.18.6085; CAO JG, 1993, J BACTERIOL, V175, P3856, DOI 10.1128/JB.175.12.3856-3862.1993; CRONAN JE, 1982, J BIOL CHEM, V257, P5013; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; delaRoche MA, 1997, ARCH BIOCHEM BIOPHYS, V344, P159, DOI 10.1006/abbi.1997.0203; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERRI SR, 1994, J BIOL CHEM, V269, P6683; FERRI SR, 1991, J BIOL CHEM, V266, P12852; FICE D, 1993, J BACTERIOL, V175, P1865, DOI 10.1128/JB.175.7.1865-1870.1993; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; GUERRA DJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P336, DOI 10.1016/0003-9861(90)90339-Z; GUERRA DJ, 1988, J BIOL CHEM, V263, P4386; Haas JA, 2000, PROTEIN EXPRES PURIF, V20, P274, DOI 10.1006/prep.2000.1293; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P6135, DOI 10.1021/bi00416a046; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JAWORSKI JG, 1989, EUR J BIOCHEM, V184, P603, DOI 10.1111/j.1432-1033.1989.tb15056.x; JONES PJ, 1987, J BIOL CHEM, V262, P8963; JONES PJ, 1987, BIOCHEMISTRY-US, V26, P3493, DOI 10.1021/bi00386a037; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; Keating DH, 1996, J BIOL CHEM, V271, P15905, DOI 10.1074/jbc.271.27.15905; KIM YM, 1990, PROTEINS, V8, P377, DOI 10.1002/prot.340080411; Lambalot RH, 1997, METHOD ENZYMOL, V279, P254; MAYO KH, 1985, BIOCHEMISTRY-US, V24, P7834, DOI 10.1021/bi00347a049; MCLELLAN T, 1982, ANAL BIOCHEM, V126, P94, DOI 10.1016/0003-2697(82)90113-0; MEIGHEN EA, 1994, ANNU REV GENET, V28, P117, DOI 10.1146/annurev.ge.28.120194.001001; Oswood MC, 1997, PROTEINS, V27, P131; Ritsema T, 1998, MOL GEN GENET, V257, P641, DOI 10.1007/s004380050692; Rock C. O., 1996, NEW COMPREHENSIVE BI, V31, P35; ROCK CO, 1979, J BIOL CHEM, V254, P9778; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; ROCK CO, 1983, ARCH BIOCHEM BIOPHYS, V225, P122, DOI 10.1016/0003-9861(83)90014-0; ROCK CO, 1981, J BIOL CHEM, V256, P2669; ROCK CO, 1982, J BIOL CHEM, V257, P10759; RUMLEY MK, 1992, J BIOL CHEM, V267, P11806; Schaefer AL, 1996, P NATL ACAD SCI USA, V93, P9505, DOI 10.1073/pnas.93.18.9505; SCHULZ H, 1975, J BIOL CHEM, V250, P2299; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; Shen ZW, 1996, J BACTERIOL, V178, P571, DOI 10.1128/jb.178.2.571-573.1996; SHEN ZW, 1992, ANAL BIOCHEM, V204, P34, DOI 10.1016/0003-2697(92)90135-T; SHEN ZW, 1994, J BACTERIOL, V176, P77, DOI 10.1128/JB.176.1.77-83.1994; Tang LJ, 1997, J BACTERIOL, V179, P3697, DOI 10.1128/jb.179.11.3697-3705.1997; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	46	48	59	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35934	35939		10.1074/jbc.M101849200	http://dx.doi.org/10.1074/jbc.M101849200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11443113	hybrid			2022-12-25	WOS:000171109300094
J	Zeidner, G; Sadja, R; Reuveny, E				Zeidner, G; Sadja, R; Reuveny, E			Redox-dependent gating of G protein-coupled inwardly rectifying K(+) channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RECTIFIER POTASSIUM CHANNELS; DISULFIDE BOND FORMATION; CYSTEINE RESIDUES; XENOPUS OOCYTES; HIPPOCAMPAL-NEURONS; FAST INACTIVATION; ACH CHANNEL; I-KACH; ACTIVATION	G protein-coupled inwardly rectifying K(+) channels (GIRK) play a major role in inhibitory signaling in excitable and endocrine tissues. The gating mechanism of these channels is mediated by a direct interaction of the G beta gamma subunits of G protein, which are released upon inhibitory neurotransmitter receptor activation. This gating mechanism is further manifested by intracellular factors such as anionic phospholipids and Na(+) and Mg(2+) ions. In addition to the essential role of these components for channel function, phosphorylation events can also modulate channel activity. In this study we ex. plored the involvement of redox modulation on GIRK channel function. Extracellular application of the reducing agent dithiothreitol (DTT), but not reduced glutathione, activated GIRK channels without affecting their permeation or rectification properties. The DTT-dependent activation was found to mimic receptor activation and to act directly on the channel in a membrane delimited fashion. A critical cysteine residue located in the N-terminal cytoplasmic domain was found to be essential for DTT-dependent activation in hetero- and homotetrameric contexts. Interestingly, when mutating this cysteine residue, DTT-dependent activation was abolished, but receptor-mediated channel activation was not affected. These results suggest that intracellular redox potential can play a major role in tuning GIRK channel activity in a receptor-independent manner. This sort of redox modulation can be part of an important cellular protective mechanism against ischemic or hypoxic insults.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Reuveny, E (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	e.reuveny@weizmann.ac.il						Bannister JPA, 1999, FEBS LETT, V458, P393, DOI 10.1016/S0014-5793(99)01096-0; Cho HC, 2000, BIOCHEMISTRY-US, V39, P4649, DOI 10.1021/bi992469g; Cohen MV, 2000, ANNU REV PHYSIOL, V62, P79, DOI 10.1146/annurev.physiol.62.1.79; DiChiara TJ, 1997, J NEUROSCI, V17, P4942; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Haarmann CS, 1999, BIOPHYS J, V77, P3010, DOI 10.1016/S0006-3495(99)77132-8; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Hyllienmark L, 1999, NEUROSCIENCE, V91, P511, DOI 10.1016/S0306-4522(98)00650-2; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Kubo Y, 2001, J PHYSIOL-LONDON, V531, P645, DOI 10.1111/j.1469-7793.2001.0645h.x; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; Leyland ML, 1999, PFLUG ARCH EUR J PHY, V438, P778, DOI 10.1007/s004240051106; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Mark MD, 2000, NEUROPHARMACOLOGY, V39, P2360, DOI 10.1016/S0028-3908(00)00080-0; Medina I, 2000, J BIOL CHEM, V275, P29709, DOI 10.1074/jbc.M004989200; Mullner C, 2000, J GEN PHYSIOL, V115, P547, DOI 10.1085/jgp.115.5.547; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; PEDERSEN SE, 1985, J BIOL CHEM, V260, P4150; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rogalski SL, 2001, J BIOL CHEM, V276, P14855, DOI 10.1074/jbc.M010097200; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; Ruppersberg JP, 1996, NEUROPHARMACOLOGY, V35, P887, DOI 10.1016/0028-3908(96)00092-5; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Sadja R, 2001, NEURON, V29, P669, DOI 10.1016/S0896-6273(01)00242-2; Schultz JE, 1998, AM J PHYSIOL-HEART C, V275, pH495, DOI 10.1152/ajpheart.1998.275.2.H495; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yi BA, 2001, NEURON, V29, P657, DOI 10.1016/S0896-6273(01)00241-0; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	57	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35564	35570		10.1074/jbc.M105189200	http://dx.doi.org/10.1074/jbc.M105189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466316	hybrid			2022-12-25	WOS:000171109300049
J	Kindmark, H; Kohler, M; Brown, G; Branstrom, R; Larsson, O; Berggren, PO				Kindmark, H; Kohler, M; Brown, G; Branstrom, R; Larsson, O; Berggren, PO			Glucose-induced oscillations in cytoplasmic free Ca2+ concentration precede oscillations in mitochondrial membrane potential in the pancreatic beta-cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-CONSUMPTION; INSULIN-SECRETION; HIPPOCAMPAL-NEURONS; ATP CONCENTRATION; CHANNEL ACTIVITY; CYTOSOLIC CA2+; MOUSE ISLETS; B-CELL; CALCIUM; RELEASE	Using dual excitation and fixed emission fluorescence microscopy, we were able to measure changes in cytoplasmic free Ca2+ concentration ([Ca2+](i)) and mitochondrial membrane potential simultaneously in the pancreatic beta -cell. The beta -cells were exposed to a combination of the Ca2+ indicator fura-2/AM and the indicator of mitochondrial membrane potential, rhodamine 123 (Rh123). Using simultaneous measurements of mitochondrial membrane potential and [Ca2+](i) during glucose stimulation, it was possible to measure the time lag between the onset of mitochondrial hyperpolarization and changes in [Ca2+](i). Glucose-induced oscillations in [Ca2+](i) were followed by transient depolarizations of mitochondrial membrane potential. These results are compatible with a model in which nadirs in [Ca2+](i) oscillations are generated by a transient, Ca2+-induced inhibition of mitochondrial metabolism resulting in a temporary fall in the cytoplasmic ATP/ADP ratio, opening of plasma membrane K-ATP channels, repolarization of the plasma membrane, and thus transient closure of voltage-gated L-type Ca2+ channels.	Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Kindmark, H (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden.	henrik.kindmark@ks.se		Branstrom, Robert/0000-0001-6245-7223; Berggren, Per-Olof/0000-0001-8991-413X; Kohler, Martin/0000-0001-6487-4303	NIDDK NIH HHS [DK-35 914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK035914, R37DK035914, R01DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BUNTING JR, 1992, BIOPHYS CHEM, V42, P163, DOI 10.1016/0301-4622(92)85006-P; CHOU HF, 1992, AM J PHYSIOL, V262, pE800, DOI 10.1152/ajpendo.1992.262.6.E800; CHOW RH, 1995, J PHYSIOL-LONDON, V485, P607, DOI 10.1113/jphysiol.1995.sp020756; Civelek VN, 1996, BIOCHEM J, V315, P1015, DOI 10.1042/bj3151015; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; EFENDIC S, 1991, J INTERN MED, V229, P9; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V151, P1299, DOI 10.1016/S0006-291X(88)80503-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLMAN B, 1975, ENDOCRINOLOGY, V97, P392, DOI 10.1210/endo-97-2-392; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Jou MJ, 1996, J PHYSIOL-LONDON, V497, P299, DOI 10.1113/jphysiol.1996.sp021769; Jung SK, 2000, J BIOL CHEM, V275, P6642, DOI 10.1074/jbc.275.9.6642; Jung SK, 1999, BIOCHEM BIOPH RES CO, V259, P331, DOI 10.1006/bbrc.1999.0784; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; KINDMARK H, 1992, FEBS LETT, V303, P85, DOI 10.1016/0014-5793(92)80483-W; Kohler M, 1998, FEBS LETT, V441, P97, DOI 10.1016/S0014-5793(98)01539-7; Krippeit-Drews P, 2000, BIOCHEM BIOPH RES CO, V267, P179, DOI 10.1006/bbrc.1999.1921; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Larsson O, 1996, P NATL ACAD SCI USA, V93, P5161, DOI 10.1073/pnas.93.10.5161; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; Nowicky AV, 1998, J PHYSIOL-LONDON, V507, P131, DOI 10.1111/j.1469-7793.1998.131bu.x; Ortsater H, 2000, DIABETOLOGIA, V43, P1313, DOI 10.1007/s001250051528; Porterfield DM, 2000, DIABETES, V49, P1511, DOI 10.2337/diabetes.49.9.1511; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; White RJ, 1996, J NEUROSCI, V16, P5688; WU EY, 1990, ARCH BIOCHEM BIOPHYS, V282, P358, DOI 10.1016/0003-9861(90)90129-M	38	63	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34530	34536		10.1074/jbc.M102492200	http://dx.doi.org/10.1074/jbc.M102492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11445566	hybrid			2022-12-25	WOS:000171024600026
J	Kim, YS; Han, CY; Kim, SW; Kim, JH; Lee, SK; Jung, DJ; Park, SY; Kang, HJ; Choi, HS; Lee, JW; Pak, YK				Kim, YS; Han, CY; Kim, SW; Kim, JH; Lee, SK; Jung, DJ; Park, SY; Kang, HJ; Choi, HS; Lee, JW; Pak, YK			The orphan nuclear receptor small heterodimer partner as a novel coregulator of nuclear factor-kappa B in oxidized low density lipoprotein-treated macrophage cell line RAW 264.7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PROTEIN-KINASE-C; HORMONE-RECEPTOR; INTERLEUKIN-12 PRODUCTION; GENE-EXPRESSION; BINDING DOMAIN; SHP; LYSOPHOSPHATIDYLCHOLINE; TRANSACTIVATION; SUPERFAMILY	Small heterodimer partner (SHP), specifically expressed in liver and a limited number of other tissues, is an unusual orphan nuclear receptor that lacks the conventional DNA binding domain. In this work, we found that SHP expression is abundant in murine macrophage cell line RAW 264.7 but was suppressed by oxidized low density lipoprotein (oxLDL) and its constituent 13-hydroxyoctadecadienoic acid, a ligand for peroxisome proliferator-activated receptor gamma. Furthermore, SHP acted as a transcription coactivator of nuclear factor-kappaB (NF kappaB) and was essential for the previously described NF kappaB transactivation by palmitoyl lysophosphaticlylcholine, one of the oxLDL constituents. Accordingly NF kappaB, which was transcriptionally active in the beginning, became progressively inert in oxLDL-treated RAW 264.7 cells as oxLDL decreased the SHP expression. Thus, SBP appears to be an important modulatory component to regulate the transcriptional activities of NF kappaB in oxLDL-treated, resting macrophage cells.	Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea; NIH, Dept Biomed Sci, Div Metab Dis, Seoul 122701, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Seoul Natl Univ, Sch Earth & Environm Sci, Seoul 151742, South Korea; Salk Inst Biol Studies, San Diego, CA 92185 USA	Pohang University of Science & Technology (POSTECH); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; Chonnam National University; Seoul National University (SNU); Salk Institute	Lee, JW (corresponding author), Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea.		Pak, Youngmi Kim/AAI-1091-2020	Pak, Youngmi Kim/0000-0001-7424-3484; Kim, Seung-Whan/0000-0001-6983-0481				Burris TP, 1996, RECENT PROG HORM RES, V51, P241; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han CY, 2000, BIOCHEM J, V350, P829, DOI 10.1042/0264-6021:3500829; Han CY, 1999, EXP MOL MED, V31, P165, DOI 10.1038/emm.1999.27; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jang MK, 2001, J BIOL CHEM, V276, P20005, DOI 10.1074/jbc.M010211200; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee SK, 2000, J BIOL CHEM, V275, P33522, DOI 10.1074/jbc.M006418200; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moore DD, 1995, GLOB MOB SURV; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sugiyama S, 1998, ARTERIOSCL THROM VAS, V18, P568, DOI 10.1161/01.ATV.18.4.568; SUGIYAMA S, 1994, CIRC RES, V74, P565, DOI 10.1161/01.RES.74.4.565; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652	30	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33736	33740		10.1074/jbc.M101977200	http://dx.doi.org/10.1074/jbc.M101977200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448950	hybrid			2022-12-25	WOS:000170910200061
J	Barber, AJ; Nakamura, M; Wolpert, EB; Reiter, CEN; Seigel, GM; Antonetti, DA; Gardner, TW				Barber, AJ; Nakamura, M; Wolpert, EB; Reiter, CEN; Seigel, GM; Antonetti, DA; Gardner, TW			Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-B; GROWTH-FACTOR-I; NUCLEAR-LOCALIZATION SEQUENCE; BREAK-INDUCED APOPTOSIS; BLOOD-BRAIN-BARRIER; TRANSCRIPTION FACTOR; P53-INDUCED APOPTOSIS; DIABETIC-RETINOPATHY; MOUSE CEREBELLUM	The ability of insulin to protect neurons from apoptosis was examined in differentiated R28 cells, a neural cell line derived from the neonatal rat retina. Apoptosis was induced by serum deprivation, and the number of pyknotic cells was counted. p53 and Akt were examined by immunoblotting after serum deprivation and insulin treatment, and caspase-3 activation was examined by immunocytochemistry. Serum deprivation for 24 h caused similar to 20% of R28 cells to undergo apoptosis, detected by both pyknosis and activation of caspase-3. 10 nm insulin maximally reduced the amount of apoptosis with a similar potency as 1.3 nm (10 ng/ml) insulin-like growth factor 1, which acted as a positive control. Insulin induced serine phosphorylation of Akt, through the phosphatidylinositol (PI) 3-kinase pathway. Inhibition of PI 3-kinase with wortmannin or LY294002 blocked the ability of insulin to rescue the cells from apoptosis. SN50, a peptide inhibitor of NF-kappaB nuclear translocation, blocked the rescue effect of insulin, but neither insulin or serum deprivation induced phosphorylation of I kappaB. These results suggest that insulin is a survival factor for retinal neurons by activating the PI 3-kinase/Akt pathway and by reducing caspase-3 activation. The rescue effect of insulin does not appear to be mediated by NF-kappaB or p53. These data suggest that insulin provides trophic support for retinal neurons through a PI 3-kinase/Akt-dependent pathway.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA; Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, Penn State Retina Res Grp, Hershey, PA 17033 USA; Univ Rochester, Dept Neurobiol Anat, Rochester, NY 14642 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Rochester	Gardner, TW (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Ophthalmol, H166,500 Univ Dr, Hershey, PA 17033 USA.	tgardner@psu.edu		Barber, Alistair/0000-0003-4235-2293; Gardner, Thomas/0000-0002-5112-5810; antonetti, david/0000-0003-1130-6577; Nakamura, Makoto/0000-0002-6464-4302	NATIONAL EYE INSTITUTE [R01EY012021] Funding Source: NIH RePORTER; NEI NIH HHS [EY12021] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALMIRA EC, 1979, ENDOCRINOLOGY, V104, P205, DOI 10.1210/endo-104-1-205; ANG LC, 1992, J NEUROL SCI, V109, P168, DOI 10.1016/0022-510X(92)90164-G; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Banks WA, 1997, PEPTIDES, V18, P1257, DOI 10.1016/S0196-9781(97)00198-8; Banks WA, 1997, PEPTIDES, V18, P1423, DOI 10.1016/S0196-9781(97)00231-3; Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; BARRES BA, 1993, DEVELOPMENT, V118, P283; Baserga R, 1997, VITAM HORM, V53, P65, DOI 10.1016/S0083-6729(08)60704-9; Bennett MR, 1999, BIOCHEM PHARMACOL, V58, P1089; Benoliel AM, 1997, J CELL SCI, V110, P2089; Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; BUDD GC, 1993, INVEST OPHTH VIS SCI, V34, P463; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen RW, 1999, J NEUROSCI, V19, P9654; CLARKE DW, 1986, J NEUROCHEM, V47, P831; Cregan SP, 1999, J NEUROSCI, V19, P7860; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS GE, 1985, TRENDS NEUROSCI, V8, P528, DOI 10.1016/0166-2236(85)90189-4; DORN A, 1982, HISTOCHEMISTRY, V74, P293, DOI 10.1007/BF00495838; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; FEMAN SS, 1978, AM J OPHTHALMOL, V85, P387, DOI 10.1016/S0002-9394(14)77736-0; FERNYHOUGH P, 1993, BRAIN RES, V607, P117, DOI 10.1016/0006-8993(93)91496-F; Foulstone EJ, 1999, NEUROSCI LETT, V264, P125, DOI 10.1016/S0304-3940(99)00166-4; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; Gardner TW, 2001, INVEST OPHTH VIS SCI, V42, pS664; GUPTA G, 1992, NEUROCHEM INT, V20, P487, DOI 10.1016/0197-0186(92)90027-O; Hanson MG, 1998, J NEUROSCI, V18, P7361; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hetman M, 2000, J NEUROSCI, V20, P2567; HUCK S, 1983, BRAIN RES BULL, V10, P667, DOI 10.1016/0361-9230(83)90036-9; Hughes PE, 1997, NEUROREPORT, V8, pR5; HYNDMAN AG, 1993, DEV BRAIN RES, V75, P289, DOI 10.1016/0165-3806(93)90034-8; Inamura N, 2000, J NEUROSCI RES, V60, P450, DOI 10.1002/(SICI)1097-4547(20000515)60:4<450::AID-JNR3>3.3.CO;2-G; Joo CK, 1999, INVEST OPHTH VIS SCI, V40, P713; KADLE R, 1988, BRAIN RES, V460, P60, DOI 10.1016/0006-8993(88)90429-5; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lieth E, 2000, CLIN EXP OPHTHALMOL, V28, P3, DOI 10.1046/j.1442-9071.2000.00222.x; Lieth E, 2000, EXP EYE RES, V70, P723, DOI 10.1006/exer.2000.0840; Lieth E, 1998, DIABETES, V47, P815, DOI 10.2337/diabetes.47.5.815; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Naeser P, 1997, UPSALA J MED SCI, V102, P35, DOI 10.3109/03009739709178930; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Paterson IA, 1998, J NEUROCHEM, V70, P515; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RODRIGUES M, 1988, BRAIN RES, V443, P389, DOI 10.1016/0006-8993(88)91639-3; ROSENZWEIG SA, 1990, J BIOL CHEM, V265, P18030; Ryu BR, 1999, J NEUROBIOL, V39, P536, DOI 10.1002/(SICI)1097-4695(19990615)39:4<536::AID-NEU7>3.0.CO;2-J; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Seigel G, 1999, MOL VIS, V5; Seigel G M, 1997, Mol Vis, V3, P14; Seigel G M, 1996, Mol Vis, V2, P2; Seigel GM, 1996, IN VITRO CELL DEV-AN, V32, P66; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Tezel G, 1999, INVEST OPHTH VIS SCI, V40, P2660; Torgerson TR, 1998, J IMMUNOL, V161, P6084; WALDBILLIG RJ, 1987, EXP EYE RES, V45, P823, DOI 10.1016/S0014-4835(87)80099-4; Weeks BS, 1999, BIOCHEM BIOPH RES CO, V256, P98, DOI 10.1006/bbrc.1999.0293; WEI L, 1990, J NEUROCHEM, V54, P1661, DOI 10.1111/j.1471-4159.1990.tb01219.x; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	75	248	264	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32814	32821		10.1074/jbc.M104738200	http://dx.doi.org/10.1074/jbc.M104738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11443130	hybrid			2022-12-25	WOS:000170746000060
J	Sheldon, LA; Becker, M; Smith, CL				Sheldon, LA; Becker, M; Smith, CL			Steroid hormone receptor-mediated histone deacetylation and transcription at the mouse mammary tumor virus promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; SODIUM-BUTYRATE; CYCLIC-AMP; ACETYLATION; CHROMATIN; NUCLEOSOME; INDUCTION; BINDING; GENES; DNA	Acetylation of lysines in histones H3 and H4 N-terminal tails is associated with transcriptional activation and deacetylation with repression. Our studies with the mouse mammary tumor virus (MMTV) promoter in chromatin show significant levels of acetylation at promoter proximal and distal regions prior to transactivation. Upon activation with glucocorticoids or progestins, promoter proximal histones become deacetylated within the region of inducible nuclease hypersensitivity. The deacetylation lags behind the initiation of transcription, indicating a role in post-activation regulation. Our results indicate a novel mechanism by which target promoters are regulated by steroid receptors and chromatin modification machinery.	Dartmouth Coll Sch Med, Dept Physiol, Lebanon, NH 03756 USA; NCI, Lab Receptor Biol & Gene Express, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Dartmouth College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sheldon, LA (corresponding author), Dartmouth Coll Sch Med, Dept Physiol, 750W Borwell,1 Med Ctr Dr, Lebanon, NH 03756 USA.				NIDDK NIH HHS [DK03535] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003535] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; CHARRON J, 1989, MOL CELL BIOL, V9, P3127, DOI 10.1128/MCB.9.7.3127; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HONG L, 1993, J BIOL CHEM, V268, P305; MCKNIGHT GS, 1980, CELL, V22, P469; Mizuguchi G, 2001, J BIOL CHEM, V276, P14773, DOI 10.1074/jbc.M100125200; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PLESKO MM, 1983, J BIOL CHEM, V258, P3738; Reinke H, 2001, MOL CELL, V7, P529, DOI 10.1016/S1097-2765(01)00200-3; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217	30	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32423	32426		10.1074/jbc.C100315200	http://dx.doi.org/10.1074/jbc.C100315200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11448945	hybrid			2022-12-25	WOS:000170746000009
J	Chen, WX; Tang, QB; Gonzales, MS; Bowden, GT				Chen, WX; Tang, QB; Gonzales, MS; Bowden, GT			Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes	ONCOGENE			English	Article						UVB; p38; ERK; COX-2; PGE(2)	ACTIVATED PROTEIN-KINASE; CYTOSOLIC PHOSPHOLIPASE A(2); COLON-CANCER CELLS; SKIN-CANCER; MULTISTAGE CARCINOGENESIS; COX-2 EXPRESSION; REGULATED KINASE; MOUSE SKIN; INHIBITION; INDUCTION	The roles of p38 MAP kinases and ERK in UVB induced cox-2 gene expression were studied in a human keratinocyte cell line, HaCaT, UVB significantly increased cox-2 gene expression at both protein and mRNA levels. As we reported previously, p38 and ERK were significantly activated after UVB irradiation in HaCaT cells. In addition, treating the cells with p38 inhibitor SB202190 or MEK inhibitor PD98059 specifically inhibited UVB induced p38 or ERK activation, respectively. In this study, we further examined the roles of p38 and ERK in UVB induced cox-2 gene expression in HaCaT cells. We found that SB202190 strongly inhibited UVB induced COX-2 protein expression at different time points and various UVB doses. Furthermore, SB202190 markedly inhibited UVB induced cox-2 mRNA. Our data indicated that ERK did not play a role in UVB induced cox-2 gene expression in human keratinocytes since suppression of ERK did not significantly alter UVB induced increase of COX-2 protein and mRNA. These results suggested, for the first time, that activation of p38 is required for UVB induced cox-2 gene expression in human keratinocytes, Since cox-2 expression plays an important role in UV carcinogenesis, p38 could be a potential molecular target for chemoprevention of skin cancer.	Univ Arizona, Coll Med, Dept Radiat Oncol, Arizona Canc Ctr, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Dept Radiat Oncol, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA27502, CA23074] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; Barthelman M, 1998, CANCER RES, V58, P711; BENNETT A, 1982, BRIT J CANCER, V46, P888, DOI 10.1038/bjc.1982.298; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 1997, NUTR CANCER, V29, P205, DOI 10.1080/01635589709514625; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 2000, MOL CARCINOGEN, V28, P196, DOI 10.1002/1098-2744(200008)28:4<196::AID-MC2>3.0.CO;2-C; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chulada P. C., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P195; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FURSTENBERGER G, 1990, EICOSANOIDS SKIN, P108; Geijsen N, 2000, FEBS LETT, V471, P83, DOI 10.1016/S0014-5793(00)01373-9; Gresham A, 1996, AM J PHYSIOL-CELL PH, V270, pC1037, DOI 10.1152/ajpcell.1996.270.4.C1037; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Higashi Y, 2000, INT J CANCER, V86, P667, DOI 10.1002/(SICI)1097-0215(20000601)86:5<667::AID-IJC10>3.3.CO;2-P; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; KANGROTONDO CH, 1993, AM J PHYSIOL, V264, P396; Marks F, 2000, EUR J CANCER, V36, P314, DOI 10.1016/S0959-8049(99)00318-4; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Parfenova H, 1998, AM J PHYSIOL-CELL PH, V274, pC72, DOI 10.1152/ajpcell.1998.274.1.C72; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Sheng HM, 1998, CANCER RES, V58, P362; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199	43	151	156	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3921	3926		10.1038/sj.onc.1204530	http://dx.doi.org/10.1038/sj.onc.1204530			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439356				2022-12-25	WOS:000169494700018
J	Rubin, E; Mittnacht, S; Villa-Moruzzi, E; Ludlow, JW				Rubin, E; Mittnacht, S; Villa-Moruzzi, E; Ludlow, JW			Site-specific and temporally-regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1	ONCOGENE			English	Article						retinoblastoma protein; protein phosphatase type 1; pRB dephosphorylation; PP1 activity	CELL-CYCLE; SUSCEPTIBILITY GENE; PHOSPHORYLATION; PRODUCT; PRB; INACTIVATION; PATTERN; BINDING	pRb is dephosphorylated at mitotic exit by the type 1 serine/threonine protein phosphatases (PP1), Here we demonstrate for the first time that mitotic pRb dephosphorylation is a sequential, temporally-regulated event. We also provide evidence that the three mammalian isoforms of PP1, alpha, gamma -1, and delta, differ in their respective preferences for site-specific pRb dephosphorylation and that the mitotic and G(1) PP1-isoform counterparts exhibit differential activities towards mitotic pRb, Finally, the physiological relevance of the striking contrast between the patterns of Thr821 and Thr826 dephosphorylation, sites known to be important for disrupting binding of LXCXE-containing proteins to pRb, is addressed.	Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Pisa, Dept Expt Pathol, Pisa, Italy; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Pisa; University of Rochester	Ludlow, JW (corresponding author), Incara Pharmaceut, POB 14287, Res Triangle Pk, NC 27709 USA.	JLudlow@incara.com			NCI NIH HHS [CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Boylan JF, 1999, EXP CELL RES, V248, P110, DOI 10.1006/excr.1999.4389; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUSSOW AR, 1991, EUR J IMMUNOL, V21, P2297, DOI 10.1002/eji.1830211002; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Puntoni F, 1997, MOL CELL BIOCHEM, V171, P115, DOI 10.1023/A:1006892103306; Tamrakar S, 1999, ONCOGENE, V18, P7803, DOI 10.1038/sj.onc.1203211; Tamrakar S, 2000, J BIOL CHEM, V275, P27784; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; Tognarini M, 1998, METH MOL B, V93, P169; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMSTOTTHALL K, 1999, J BIOL CHEM, V274, P3485; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	38	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3776	3785		10.1038/sj.onc.1204518	http://dx.doi.org/10.1038/sj.onc.1204518			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439341				2022-12-25	WOS:000169494700003
J	Ganiatsas, S; Dow, R; Thompson, A; Schulman, B; Germain, D				Ganiatsas, S; Dow, R; Thompson, A; Schulman, B; Germain, D			A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT	ONCOGENE			English	Article						cyclin D1; SCF; ubiquitination; p27	F-BOX; RETINOBLASTOMA PROTEIN; TRANSGENIC MICE; LIGASE COMPLEX; BREAST-CANCER; HUMAN CUL-1; DEGRADATION; P27(KIP1); P27; ACCUMULATION	Cyclin D1 is an important regulator of the transition from G1 into S phase of the cell cycle. The level to which cyclin D1 accumulates is tightly regulated. One mechanism contributing to the control of cyclin D1 levels is the regulation of its ubiquitination, SK-UT-1B cells are deficient in the degradation of D-type cyclins, We show here that p27, a substrate of the SCFSkp2 ubiquitin Ligase complex, is coordinately stabilized in SK-UT-IB cells. Further, we show that expression of Skp2 in SK-UT-IB cells rescues the cyclin D1 and p27 degradation defect observed in this cell line. These results therefore indicate that the SCFSkp2 ubiquitin ligase complex affects the ubiquitination of cyclin D1, In addition, we show that SK-UT-LB cells express a novel splice variant of Skp2 that localizes to the cytoplasm and that cyclin D1 ubiquitination takes place in the nucleus. We propose that the translocation of Skp2 into the nucleus is required for the ubiquitination of cyclin DI and that the absence of the SCFSkp2 complex in the nucleus of SK-UT-IB cells is the mechanism underlying the ubiquitination defect observed in this cell line, Finally, our data indicates that differential splicing of F-box proteins may represent an additional level of regulation of the F-box mediated ubiquitination pathway.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Peter Maccallum Cancer Center; University of Melbourne; Memorial Sloan Kettering Cancer Center	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.							Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1996, ONCOGENE, V13, P419; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	39	49	53	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3641	3650		10.1038/sj.onc.1204501	http://dx.doi.org/10.1038/sj.onc.1204501			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439327				2022-12-25	WOS:000169400200005
J	Mori, N; Matsumoto, Y; Okumoto, M; Suzuki, N; Yamate, J				Mori, N; Matsumoto, Y; Okumoto, M; Suzuki, N; Yamate, J			Variations in Prkdc encoding the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and susceptibility to radiation-induced apoptosis and lymphomagenesis	ONCOGENE			English	Article						apoptosis susceptibility; susceptibility to radiation lymphomagenesis; genetic variation in DNA-PKcs; DNA double-strand breaks repair	SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; RECOMBINANT CONGENIC STRAINS; V(D)J RECOMBINATION; X-IRRADIATION; NONSENSE MUTATION; SCID MUTATION; BREAK REPAIR; MICE; THYMOCYTES	DNA double-strand breaks (DSBs) induced by ionizing radiation enforce cells to die, if unrepaired; while if misrepaired, DSBs may cause malignant transformation. The DSB repair system predominant in mammals requires DNA-dependent protein kinase (DNA-PK), Previously, we identified the apoptosis susceptibility gene Radiation-induced apoptosis 1 (Rapop1) on mouse chromosome 16, The STS/A (STS) allele at Rapop1 leads to decreased sensitivity to apoptosis in the BALB/cHeA (BALB/c) background. In the present study, we established Rapop1 congenic strains C,S-RI and C.S-R1L, which contain the STS genome in a 0.45 cM interval critical for Rapop1 in common in the BALB/c background. Within the segment critical for Rapop1, Prkdc encoding the catalytic subunit of DNA-PK (DNA-PKcs) was assigned. Two variations T6,418C and G11,530A, which induce amino acid substitutions C2,140R downstream from the putative leucine zipper motif and V3,844M near the kinase domain, respectively, were found between BALB/c and STS for Prkdc. The majority of inbred strains such as C57BL/6J carried the STS allele at Prkdc; a few strains including 129/SvJ and C.B17 carried the BALB/c allele. DNA-PK activity as well as DNA-PKcs expression was profoundly diminished in BALB/c and 129/SvJ mice as compared with C57BL/6 and C.S-R1 mice. In the crosses (C.S-R1 x BALB/c)F-1 x 129/SvJ and (C.S-R1 x BALB/c)F-1 x C.B17, enhanced apoptosis occurred in the absence of the wildtype allele at Prkdc. C.S-R1 and C.S-R1L were both less sensitive to radiation lymphomagenesis than BALB/ c, Our study provides strong evidence for Prkdc as a candidate for Rapop1 and a susceptibility gene for radiation lymphomagenesis as well.	Adv Sci & Technol Res Inst, Dept Appl Biosci, Osaka 5998570, Japan; Univ Osaka Prefecture, Coll Agr, Dept Vet Pathol, Osaka 5998570, Japan; Univ Tokyo, Grad Sch Med, Dept Radiat Oncol, Bunkyo Ku, Tokyo 1130033, Japan	Japan Advanced Institute of Science & Technology (JAIST); Osaka Metropolitan University; University of Tokyo	Mori, N (corresponding author), Adv Sci & Technol Res Inst, Dept Appl Biosci, Osaka 5998570, Japan.		Matsumoto, Yoshihisa/G-3430-2017	Matsumoto, Yoshihisa/0000-0002-0758-290X				Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CUSTER RP, 1985, AM J PATHOL, V120, P464; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Kamisaku H, 1997, INT J RADIAT BIOL, V72, P191, DOI 10.1080/095530097143419; Kienker LJ, 2000, NUCLEIC ACIDS RES, V28, P2752, DOI 10.1093/nar/28.14.2752; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; Lund J, 1999, MAMM GENOME, V10, P438, DOI 10.1007/s003359901019; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; Matsumoto Y, 1999, J RADIAT RES, V40, P183, DOI 10.1269/jrr.40.183; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MORI N, 1991, J RADIAT RES, V32, P277, DOI 10.1269/jrr.32.277; Mori N, 1998, MAMM GENOME, V9, P377, DOI 10.1007/s003359900773; MORI N, 1992, INT J RADIAT BIOL, V62, P153, DOI 10.1080/09553009214551961; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; Okayasu R, 2000, CANCER RES, V60, P4342; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1995, EXP ANIM TOKYO, V44, P43, DOI 10.1538/expanim.44.43; Park YG, 2000, CANCER LETT, V148, P95, DOI 10.1016/S0304-3835(99)00321-3; Peterson SR, 1997, J BIOL CHEM, V272, P10227; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Prise KM, 1998, INT J RADIAT BIOL, V74, P173, DOI 10.1080/095530098141564; SAKATA K, 2000, IN PRESS INT J RAD O; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Weil MM, 1996, RADIAT RES, V146, P646, DOI 10.2307/3579380; Weil MM, 1996, INT J RADIAT BIOL, V70, P579, DOI 10.1080/095530096144789; YAMADA T, 1988, INT J RADIAT BIOL, V53, P65, DOI 10.1080/09553008814550431; YOKORO K, 1986, RAD CARCINOG, P138	42	51	52	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3609	3619		10.1038/sj.onc.1204497	http://dx.doi.org/10.1038/sj.onc.1204497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439324				2022-12-25	WOS:000169400200002
J	Cattaruzza, M; Eberhardt, I; Hecker, M				Cattaruzza, M; Eberhardt, I; Hecker, M			Mechanosensitive transcription factors involved in endothelin B receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; GENE-EXPRESSION; PHOSPHORYLATION; HYPERTENSION; APOPTOSIS; CHOP	Growing evidence suggests an involvement of the endothelin B receptor (ETB-R) in blood pressure-dependent arterial remodeling. To study the molecular mechanisms leading to deformation-induced ETB-R expression, we have cultured rat aortic smooth muscle cells on flexible elastomers and, when grown to 70% confluence, periodically stretched them for 6 h (15% elongation, 0.5 Hz). The cells responded with an increase both in ETB-R mRNA (12-fold compared with control) and protein (4-fold). According to nuclear run-on analysis this increase in ETB-R expression occurred at the level of transcription. Among various kinase pathways, Rho kinase (ROCK) and p38 mitogen-activated protein kinase (p38 MAPK) mediated part of the deformation-induced increase in ETB-R expression, as judged by the inhibitory effect of Y27632 (1 mum, 38% inhibition) and SB202190 (10 mum, 44% inhibition), respectively. Gel shift assaying of the three transcription factors principally activated by these kinases revealed a transient deformation-induced activation of activator protein-1 (AP-1) and CCAAT/enhancer-binding protein (C/EBP), but not activating transcription factor, that was sensitive to both Y27632 and SB212190. The potential role of AP-1 and C/EBP in deformation-induced ETB-R expression was verified both by using decoy oligodeoxynucleotides mimicking the DNA-binding sites of these transcription factors and a nuclear run-on-based assay employing specific antibodies directed against AP-1 and C/EBP. Both techniques unequivocally demonstrated that activation of these transcription factors, namely that of C/EBP beta, contribute to the increase of ETB-R gene expression in response to cyclic stretch.	Univ Goettingen, Dept Cardiovasc Physiol, D-37073 Geottingen, Germany	University of Gottingen	Hecker, M (corresponding author), Univ Goettingen, Dept Cardiovasc Physiol, Humboldtallee 23, D-37073 Geottingen, Germany.	hecker@veg-physiol.med.uni-goettingen.de						Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Cattaruzza M, 2000, FASEB J, V14, P991, DOI 10.1096/fasebj.14.7.991; Cattaruzza M, 2000, BRIT J PHARMACOL, V129, P1155, DOI 10.1038/sj.bjp.0703192; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Cramer H, 1997, BIOCHEMISTRY-US, V36, P13325, DOI 10.1021/bi9708848; Hamet P, 1996, CAN J PHYSIOL PHARM, V74, P850, DOI 10.1139/cjpp-74-7-850; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; HIPPER A, 2001, EUR J PHYSL S, V441, pR255; Iizuka K, 1999, BRIT J PHARMACOL, V128, P925, DOI 10.1038/sj.bjp.0702864; Ito T, 2000, HYPERTENSION, V35, P673, DOI 10.1161/01.HYP.35.2.673; JANAKIDEVI K, 1992, AM J PHYSIOL, V263, pC1295, DOI 10.1152/ajpcell.1992.263.6.C1295; Kyriakis JM, 1999, GENE EXPRESSION, V7, P217; Lauth M, 2000, HYPERTENSION, V35, P648, DOI 10.1161/01.HYP.35.2.648; Morishita R, 1998, CIRC RES, V82, P1023, DOI 10.1161/01.RES.82.10.1023; Pasterkamp G, 2000, CARDIOVASC RES, V45, P843, DOI 10.1016/S0008-6363(99)00377-6; Schenborn E, 1999, MOL BIOTECHNOL, V13, P29, DOI 10.1385/MB:13:1:29; Stefanadis C, 1997, CIRCULATION, V96, P1853, DOI 10.1161/01.CIR.96.6.1853; Wagner AH, 2000, MOL PHARMACOL, V58, P1333, DOI 10.1124/mol.58.6.1333; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; Wang XK, 1996, CIRC RES, V78, P322, DOI 10.1161/01.RES.78.2.322; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Weis M, 1997, CIRCULATION, V96, P2069, DOI 10.1161/01.CIR.96.6.2069; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	26	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36999	37003		10.1074/jbc.M105158200	http://dx.doi.org/10.1074/jbc.M105158200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11457849	hybrid			2022-12-25	WOS:000171375700020
J	Piao, HL; Cui, NR; Xu, HX; Mao, JZ; Rojas, A; Wang, RP; Abdulkadir, L; Li, L; Wu, JP; Jiang, C				Piao, HL; Cui, NR; Xu, HX; Mao, JZ; Rojas, A; Wang, RP; Abdulkadir, L; Li, L; Wu, JP; Jiang, C			Requirement of multiple protein domains and residues for gating K-ATP channels by intracellular pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROMK K(IR)1.1 CHANNELS; PANCREATIC BETA-CELLS; FROG SKELETAL-MUSCLE; POTASSIUM CHANNEL; CONFORMATIONAL-CHANGES; KIR4.1 CHANNELS; C-TERMINUS; B-CELLS; INHIBITION; MODULATION	ATP-sensitive K+ channels (K-ATP) are regulated by pH in addition to ATP, ADP, and phospholipids. In the study we found evidence for the molecular basis of gating the cloned K-ATP by intracellular protons. Systematic constructions of chimerical Kir6.2-Kir1.1 channels indicated that full pH sensitivity required the N terminus, C terminus, and M2 region. Three amino acid residues were identified in these protein domains, which are Thr-71 in the N terminus, Cys-166 in the M2 region, and His-175 in the C terminus. Mutation of any of them to their counterpart residues in Kir1.1 was sufficient to completely eliminate the pH sensitivity. Creation of these residues rendered the mutant channels clear pH-dependent activation. Thus, critical players in gating K-ATP by protons are demonstrated. The pH sensitivity enables the K-ATP to regulate cell excitability in a number of physiological and pathophysiological conditions when pH is low but ATP concentration is normal.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30302 USA.		rojas, asheebo/C-2048-2008	Wu, Jianping/0000-0002-2684-6122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL058410, HL58410] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; Chanchevalap S, 2000, J BIOL CHEM, V275, P7811, DOI 10.1074/jbc.275.11.7811; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Choe H, 1999, BIOPHYS J, V76, P1988, DOI 10.1016/S0006-3495(99)77357-1; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; DAVIES NW, 1990, NATURE, V343, P375, DOI 10.1038/343375a0; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; Dost R, 2000, EPILEPSY RES, V38, P53; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; FAN Z, 1994, AM J PHYSIOL-CELL PH, V267, pC1036; Gramolini A, 1997, AM J PHYSIOL-CELL PH, V272, pC1936, DOI 10.1152/ajpcell.1997.272.6.C1936; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Hughes BA, 2000, AM J PHYSIOL-CELL PH, V279, pC771, DOI 10.1152/ajpcell.2000.279.3.C771; KOYANO T, 1993, J PHYSIOL-LONDON, V463, P747, DOI 10.1113/jphysiol.1993.sp019620; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LIGHT PE, 1994, J PHYSIOL-LONDON, V475, P495, DOI 10.1113/jphysiol.1994.sp020088; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; McNicholas CM, 1998, AM J PHYSIOL-RENAL, V275, pF972, DOI 10.1152/ajprenal.1998.275.6.F972; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; PROKS P, 1994, J PHYSIOL-LONDON, V475, P33, DOI 10.1113/jphysiol.1994.sp020047; Qu ZQ, 2000, J BIOL CHEM, V275, P31573, DOI 10.1074/jbc.M003473200; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Shrivastava IH, 2000, BIOPHYS J, V78, P79, DOI 10.1016/S0006-3495(00)76574-X; Shuck ME, 1997, J BIOL CHEM, V272, P586; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Tucker SJ, 1999, J BIOL CHEM, V274, P33393, DOI 10.1074/jbc.274.47.33393; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; VIVAUDOU M, 1995, J PHYSIOL-LONDON, V486, P629, DOI 10.1113/jphysiol.1995.sp020840; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wei EP, 1998, STROKE, V29, P817, DOI 10.1161/01.STR.29.4.817; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Xu HX, 2000, AM J PHYSIOL-CELL PH, V279, pC1464, DOI 10.1152/ajpcell.2000.279.5.C1464; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x	49	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36673	36680		10.1074/jbc.M106123200	http://dx.doi.org/10.1074/jbc.M106123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11451963	hybrid			2022-12-25	WOS:000171194500082
J	Kramer, W; Girbig, F; Glombik, H; Corsiero, D; Stengelin, S; Weyland, C				Kramer, W; Girbig, F; Glombik, H; Corsiero, D; Stengelin, S; Weyland, C			Identification of a ligand-binding site in the Na+/Bile acid cotransporting protein from rabbit ileum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-VESICLES; TRANSPORT-SYSTEM; RADIATION-INACTIVATION; SUBSTRATE-SPECIFICITY; FUNCTIONAL EXPRESSION; INTESTINAL-ABSORPTION; BILE-ACIDS; RAT-LIVER; ILEAL; CLONING	Reabsorption of bile acids occurs in the terminal ileum by a Na+-dependent transport system composed of several subunits of the ileal bile acid transporter (IBAT) and the ileal lipid-binding protein. To identify the bile acid-binding site of the transporter protein IBAT, ileal brush border membrane vesicles from rabbit ileum were photoaffinity labeled with a radioactive 7-azi-derivative of cholyltaurine followed by enrichment of IBAT protein by preparative SDS gel electrophoresis. Enzymatic fragmentation with chymotrypisin yielded IBAT peptide fragments in the molecular range of 20.4-4 kDa. With epitope-specific antibodies generated against the C terminus a peptide of molecular mass of 6.6-7 kDa was identified as the smallest peptide fragment carrying both the C terminus and the covalently attached radio-labeled bile acid derivative. This clearly indicates that the ileal Na+/bile acid cotransporting protein IBAT contains a bile acid-binding site within the C-terminal 56-67 amino acids. Based on the seven-transmembrane domain model for IBAT, the bile acid-binding site is localized to a region containing the seventh transmembrane domain and the cytoplasmic C terminus. Alternatively, assuming the nine-transmembrane domain model, this bile acid-binding site is localized to the ninth transmembrane domain and the C terminus.	Aventis Pharma Deutschland GmbH, DG Metab Dis, D-65926 Frankfurt, Germany	Sanofi-Aventis	Kramer, W (corresponding author), Aventis Pharma Deutschland GmbH, DG Metab Dis, D-65926 Frankfurt, Germany.							Baringhaus KH, 1999, J LIPID RES, V40, P2158; Carey M.C., 1988, LIVER BIOL PATHOBIOL, V2nd, P573; Dawson Paul A., 1995, Current Opinion in Lipidology, V6, P109, DOI 10.1097/00041433-199504000-00009; ELSNER RH, 1992, J BIOL CHEM, V267, P9788; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; Hallen S, 2000, BIOCHEMISTRY-US, V39, P6743, DOI 10.1021/bi000577t; Hallen S, 1999, BIOCHEMISTRY-US, V38, P11379, DOI 10.1021/bi990554i; KRAMER W, 1992, EUR J BIOCHEM, V204, P923, DOI 10.1111/j.1432-1033.1992.tb16713.x; Kramer W, 1997, EUR J BIOCHEM, V249, P456, DOI 10.1111/j.1432-1033.1997.00456.x; KRAMER W, 1992, BIOCHIM BIOPHYS ACTA, V1111, P93, DOI 10.1016/0005-2736(92)90278-T; Kramer W, 1999, J LIPID RES, V40, P1604; KRAMER W, 1993, J BIOL CHEM, V268, P18035; Kramer W, 2001, J BIOL CHEM, V276, P7291, DOI 10.1074/jbc.M006877200; KRAMER W, 1989, J LIPID RES, V30, P1281; KRAMER W, 1983, J LIPID RES, V24, P910; KRAMER W, 1995, BIOCHEM J, V306, P241, DOI 10.1042/bj3060241; Kramer W, 1998, BIOCHEM J, V333, P335, DOI 10.1042/bj3330335; KRAMER W, 1998, NOVA ACTA LEOPOLDINA, V306, P93; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; RUETZ S, 1988, P NATL ACAD SCI USA, V85, P6147, DOI 10.1073/pnas.85.16.6147; Saeki T, 1999, J BIOCHEM-TOKYO, V125, P846, DOI 10.1093/oxfordjournals.jbchem.a022358; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; WONG MH, 1994, J BIOL CHEM, V269, P1340; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1	28	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					36020	36027		10.1074/jbc.M104665200	http://dx.doi.org/10.1074/jbc.M104665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11447228	hybrid			2022-12-25	WOS:000171109300106
J	Raasi, S; Schmidtke, G; Groettrup, M				Raasi, S; Schmidtke, G; Groettrup, M			The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; ANTIGEN PRESENTATION; GENE-EXPRESSION; PROTEASOME; NECROSIS; FAMILY; CELLS; PA28-ALPHA/BETA; IDENTIFICATION; LACTACYSTIN	FAT10 is a ubiquitin-like protein that is encoded in the major histocompatibility complex class I locus and is synergistically inducible with interferon-gamma and tumor necrosis factor alpha. The molecule consists of two ubiquitin-like domains in tandem arrangement and bears a conserved diglycine motif at its carboxyl terminus commonly used in ubiquitin-like proteins for isopeptide linkage to conjugated proteins. We investigated the function of FAT10 by expressing murine FAT10 in a hemagglutinin-tagged wild type form as well as a diglycine-deficient mutant form in mouse fibroblasts in a tetracycline-repressible manner. FAT10 expression did not affect major histocompatibility complex class I cell surface expression or antigen presentation. However, we found that wild type but not mutant FAT10 caused apoptosis within 24 h of induction in a caspase-dependent manner as indicated by annexin V cell surface staining and DNA fragmentation. Wild type FAT10, but not its diglycine mutant, was covalently conjugated to thus far unidentified proteins, indicating that specific FAT10 activating and conjugating enzymes must be operative in unstimulated fibroblasts. Because FAT10 expression causes apoptosis and is inducible with tumor necrosis factor alpha, it may be functionally involved in the programmed cell death mediated by this cytokine.	Kantonsspital St Gallen, Res Dept, La Forsch Abt, CH-9007 St Gallen, Switzerland	Kantonsspital St. Gallen	Groettrup, M (corresponding author), Kantonsspital St Gallen, Res Dept, La Forsch Abt, Haus 09, CH-9007 St Gallen, Switzerland.	marcus.groettrup@kssg.ch						Allen DJ, 1998, PROCESS SAF PROG, V17, P61, DOI 10.1002/prs.680170112; Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groettrup M, 1996, EUR J IMMUNOL, V26, P863, DOI 10.1002/eji.1830260421; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Ostrowska H, 1997, BIOCHEM BIOPH RES CO, V234, P729, DOI 10.1006/bbrc.1997.6434; PFIZENMAIER K, 1987, J IMMUNOL, V138, P975; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Schmidtke G, 1999, J BIOL CHEM, V274, P35734, DOI 10.1074/jbc.274.50.35734; Schwarz K, 2000, J IMMUNOL, V164, P6147, DOI 10.4049/jimmunol.164.12.6147; Schwarz K, 2000, J IMMUNOL, V165, P768, DOI 10.4049/jimmunol.165.2.768; Schwarz K, 2000, J IMMUNOL METHODS, V237, P199, DOI 10.1016/S0022-1759(99)00236-7; Schwarz K, 2000, EUR J IMMUNOL, V30, P3672, DOI 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sijts AJAM, 2000, J IMMUNOL, V164, P4500, DOI 10.4049/jimmunol.164.9.4500; Tanaka K, 1998, MOL CELLS, V8, P503; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	35	137	146	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35334	35343		10.1074/jbc.M105139200	http://dx.doi.org/10.1074/jbc.M105139200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11445583	Green Submitted, hybrid			2022-12-25	WOS:000171109300019
J	Roh, C; Roduit, R; Thorens, B; Fried, S; Kandror, KV				Roh, C; Roduit, R; Thorens, B; Fried, S; Kandror, KV			Lipoprotein lipase and leptin are accumulated in different secretory compartments in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; INSULIN; CELLS; PROTEINS; MEMBRANE; ADIPSIN; HOMOLOG; ENZYME	Adipose cells produce and secrete several physiologically important proteins, such as lipoprotein lipase (LPL), leptin, adipsin, Aerp30, etc. However, secretory pathways in adipocytes have not been characterized, and vesicular carriers responsible for the accumulation and transport of secreted proteins have not been identified. We have compared the intracellular localization of two proteins secreted from adipose cells: leptin and LPL. Adipocytes accumulate large amounts of both proteins, suggesting that neither of them is targeted to the constitutive secretory pathway. By means of velocity centrifugation in sucrose gradients, equilibrium density centrifugation in iodixanol gradients, and immunofluorescence confocal microscopy, we determined that LPL and leptin were localized in different membrane structures. LPL was found mainly in the endoplasmic reticulum with a small pool being present in low density membrane vesicles that may represent a secretory compartment in adipose cells. Virtually all intracellular leptin was localized in these low density secretory vesicles. Insulin-sensitive Glut4 vesicles did not contain either LPL or leptin. Thus, secretion from adipose cells is controlled both at the exit from the endoplasmic reticulum as well as at the level of "downstream" secretory vesicles.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Rutgers State Univ, New Brunswick, NJ 08901 USA; Univ Lausanne, CH-1005 Lausanne, Switzerland	Boston University; Rutgers State University New Brunswick; University of Lausanne	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K121,715 Albany St, Boston, MA 02118 USA.		Roduit, Raphael/AAC-3890-2021	Roduit, Raphael/0000-0001-7440-2799; Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052057, R01DK052057, R01DK056736] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56736, DK52057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barr VA, 1997, ENDOCRINOLOGY, V138, P4463, DOI 10.1210/en.138.10.4463; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bradley RL, 1999, DIABETES, V48, P272, DOI 10.2337/diabetes.48.2.272; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1984, ENDOCRINOLOGY, V114, P1665, DOI 10.1210/endo-114-5-1665; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; FRIED SK, 1986, LIFE SCI, V39, P2111, DOI 10.1016/0024-3205(86)90363-2; GARFINKEL AS, 1976, BIOCHIM BIOPHYS ACTA, V424, P264, DOI 10.1016/0005-2760(76)90194-6; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Millar CA, 2000, TRAFFIC, V1, P141, DOI 10.1034/j.1600-0854.2000.010206.x; Miller SG, 1990, CURR OPIN CELL BIOL, V2, P642, DOI 10.1016/0955-0674(90)90105-N; MULLER G, 1994, BIOCHEMISTRY-US, V33, P12149; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PRADINESFIGUERES A, 1988, BIOCHEM BIOPH RES CO, V154, P982, DOI 10.1016/0006-291X(88)90236-7; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1467; RODBELL M, 1964, J BIOL CHEM, V239, P375; Roh C, 2000, AM J PHYSIOL-ENDOC M, V279, pE893, DOI 10.1152/ajpendo.2000.279.4.E893; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Thoidis G, 1999, J BIOL CHEM, V274, P14062, DOI 10.1074/jbc.274.20.14062; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	34	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35990	35994		10.1074/jbc.M102791200	http://dx.doi.org/10.1074/jbc.M102791200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11451949	hybrid			2022-12-25	WOS:000171109300101
J	Crespo, JL; Daicho, K; Ushimaru, T; Hall, MN				Crespo, JL; Daicho, K; Ushimaru, T; Hall, MN			The GATA transcription factors GLN3 and GAT1 link TOR to salt stress in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; NITROGEN CATABOLITE REPRESSION; REGULATES GENE-EXPRESSION; SIGNALING PATHWAY; ION HOMEOSTASIS; PHOSPHATASE CALCINEURIN; PLASMA-MEMBRANE; ENA1 GENE; YEAST; RAPAMYCIN	One of the most recent functions assigned to the TOR signaling pathway in yeast is the coordination of the transcription of genes involved in nutrient utilization. Here we show that transcription of ENA1, a gene encoding a lithium and sodium ion transporter essential for salt tolerance in yeast, is controlled by the TOR signaling pathway. First, ENA1 expression is strongly induced under TOR-inactivating conditions. Second, the absence of the TOR-controlled GATA transcription factors GLN3 and GAT1 results in reduced basal and salt-induced expression of ENA1 Third, a gln3 gat1 mutant displays a pronounced sensitivity to high concentrations of lithium and sodium. Fourth, TOR1, similar to ENA1, is required for growth under saline stress conditions. In summary, our results suggest that TOR plays a role in the general response to saline stress by regulating the transcription of ENA1 via GLN3 and GAT1.	Univ Basel, Biozentrum, Div Biochem, CH-4056 Basel, Switzerland; Shizuoka Univ, Fac Sci, Dept Biol, Shizuoka 4228529, Japan	University of Basel; Shizuoka University	Hall, MN (corresponding author), Univ Basel, Biozentrum, Div Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	M.Hall@unibas.ch	Crespo, Jose L/L-3977-2014	Crespo, Jose L/0000-0003-3514-1025; Hall, Michael N/0000-0002-2998-0757				Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chan TF, 2001, J BIOL CHEM, V276, P6463, DOI 10.1074/jbc.M008162200; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Masuda CA, 2000, J BIOL CHEM, V275, P30957, DOI 10.1074/jbc.M004869200; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MORI K, 1993, CELL, V74, P743; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Proft M, 1999, MOL CELL BIOL, V19, P537; Rios G, 1997, YEAST, V13, P515, DOI 10.1002/(SICI)1097-0061(199705)13:6<515::AID-YEA102>3.0.CO;2-X; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STAN R, 1994, J BIOL CHEM, V269, P32027; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Weisman R, 2001, J BIOL CHEM, V276, P7027, DOI 10.1074/jbc.M010446200; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Withee JL, 1998, GENETICS, V149, P865; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463	42	76	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34441	34444		10.1074/jbc.M103601200	http://dx.doi.org/10.1074/jbc.M103601200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457832	hybrid, Green Accepted			2022-12-25	WOS:000171024600013
J	Darman, RB; Flemmer, A; Forbush, B				Darman, RB; Flemmer, A; Forbush, B			Modulation of ion transport by direct targeting of protein phosphatase type 1 to the Na-K-Cl cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; CATALYTIC SUBUNIT; NA+-K+-2CL(-) COTRANSPORTER; AFFINITY-CHROMATOGRAPHY; DIRECT PHOSPHORYLATION; BUMETANIDE BINDING; CALYCULIN-A; IDENTIFICATION; PURIFICATION; INHIBITORS	The specificity of major protein phosphatases is conferred via targeting subunits, each of which binds specifically to the phosphatase and targets it to the vicinity of substrate proteins. In the case of protein phosphatase 1 (PP1), an RVXFXD motif on a targeting subunit binds to a cleft in PP1c, the catalytic subunit. Here we report that a substrate of PPI, the Na-K-Cl cotransporter (NKCC1), bears this motif in its N terminus near sites of regulatory phosphorylation and that direct binding of PP1 to NKCC1 is functionally important in determining the set point for intracellular chloride regulation. NKCC1 mutants in which the motif is destroyed or improved exhibit dramatically shifted activation curves because of a change in the rate of cotransporter dephosphorylation. Furthermore, direct interaction of NKCC1 and PP1c observed by coprecipitation of the two proteins is not seen in a mutant lacking the site. This establishes a new paradigm of phosphatase specificity, one in which a substrate protein containing an RVXFXD motif binds directly to PP1c; we propose that this may be a quite general mechanism.	Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA	Yale University; Mount Desert Island Biological Laboratory	Forbush, B (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	rdarman@caregroup.harvard.edu; andreas.flemmer@kk-i.med.uni-muenchen.de; biff.forbush@yale.edu	W., Andreas Flemmer/AAQ-5654-2021		NIDDK NIH HHS [DK47661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Behnke RD, 1998, FASEB J, V12, pA1013; Brill S., 1995, B MT DESERT ISL BIOL, V34, P53; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Flemmer AW, 1999, FASEB J, V13, pA399; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P376, DOI 10.1007/BF00583938; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HAAS M, 1995, J BIOL CHEM, V270, P28955, DOI 10.1074/jbc.270.48.28955; HEBERT SC, 1984, AM J PHYSIOL, V246, pF745, DOI 10.1152/ajprenal.1984.246.6.F745; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1997, J BIOL CHEM, V272, P15069, DOI 10.1074/jbc.272.24.15069; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; PALFREY HC, 1993, PFLUG ARCH EUR J PHY, V425, P321, DOI 10.1007/BF00374182; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368; Zhao SM, 1997, BIOCHEMISTRY-US, V36, P8318, DOI 10.1021/bi962814r; Zhao SM, 1998, BIOCHEMISTRY-US, V37, P18102, DOI 10.1021/bi982144k; Zhu T, 1999, J BIOL CHEM, V274, P29102, DOI 10.1074/jbc.274.41.29102	37	105	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34359	34362		10.1074/jbc.C100368200	http://dx.doi.org/10.1074/jbc.C100368200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11466303	hybrid			2022-12-25	WOS:000171024600002
J	David, H; Carnero-Diaz, E; Leblanc, N; Monestiez, M; Grosclaude, J; Perrot-Rechenmann, C				David, H; Carnero-Diaz, E; Leblanc, N; Monestiez, M; Grosclaude, J; Perrot-Rechenmann, C			Conformational dynamics underlie the activity of the auxin-binding protein, Nt-abp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOMATAL GUARD-CELLS; ZEA-MAYS-L; ENDOPLASMIC-RETICULUM; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; ROOT GRAVITROPISM; PLASMA-MEMBRANE; HORMONE AUXIN; K+ CHANNELS; C-TERMINUS	The auxin-binding protein 1 (ABP1) has been proposed to be involved in the perception of the phytohormone, at the plasma membrane. Site-directed mutagenesis was performed on highly conserved residues at the C terminus of ABP1 to investigate their relative importance in protein folding and activation of a functional response at the plasma membrane. Detailed analysis of the dynamic interaction of the wild-type ABP1 and mutated proteins with three distinct monoclonal antibodies recognizing conformation-dependent epitopes was performed by surface plasmon resonance. The influence of auxin on these interactions was also investigated. The Cys(177) as well as Asp(175) and Glu(176) were identified as critical residues for ABP1 folding and action at the plasma membrane. On the contrary, the C-terminal KDEL sequence was demonstrated not to be essential for auxin binding, interaction with the plasma membrane, or activation of the transduction cascade although it does appear to be involved in the stability of ABP1. Taken together, the results confirmed that ABP1 conformational change is the critical step for initiating the signal from the plasma membrane.	CNRS, Inst Sci Vegetal, F-91198 Gif Sur Yvette, France; Univ Paris 07, Lab Electrophysiol Membranes, F-75000 Paris, France; INRA, F-78352 Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Perrot-Rechenmann, C (corresponding author), CNRS, Inst Sci Vegetal, F-91198 Gif Sur Yvette, France.	catherine.rechenmann@isv.cnrs-gif.fr		David, Karine/0000-0002-3924-5078				BarbierBrygoo H, 1996, PLANT GROWTH REGUL, V18, P23, DOI 10.1007/BF00028484; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; BLATT MR, 1994, PLANT J, V5, P55, DOI 10.1046/j.1365-313X.1994.5010055.x; CABOCHE M, 1980, PLANTA, V149, P7, DOI 10.1007/BF00386221; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; Choi SY, 1996, PLANT MOL BIOL, V32, P995, DOI 10.1007/BF00020496; Christensen SK, 2000, CELL, V100, P469, DOI 10.1016/S0092-8674(00)80682-0; Deruere J, 1999, PLANT J, V20, P389, DOI 10.1046/j.1365-313x.1999.00607.x; DIEKMANN W, 1995, P NATL ACAD SCI USA, V92, P3425, DOI 10.1073/pnas.92.8.3425; EPHRITIKHINE G, 1987, PLANT PHYSIOL, V83, P801, DOI 10.1104/pp.83.4.801; Gehring CA, 1998, PLANTA, V205, P581, DOI 10.1007/s004250050359; Gertler A, 1996, J BIOL CHEM, V271, P24482, DOI 10.1074/jbc.271.40.24482; GOLDSMITH MHM, 1993, P NATL ACAD SCI USA, V90, P11442, DOI 10.1073/pnas.90.24.11442; Gray WM, 2000, TRENDS BIOCHEM SCI, V25, P133, DOI 10.1016/S0968-0004(00)01544-9; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; HERTEL R, 1995, J EXP BOT, V46, P461, DOI 10.1093/jxb/46.5.461-a; HESSE T, 1989, EMBO J, V8, P2453, DOI 10.1002/j.1460-2075.1989.tb08380.x; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jones AM, 1998, SCIENCE, V282, P1114, DOI 10.1126/science.282.5391.1114; JONES AM, 1994, ANNU REV PLANT PHYS, V45, P393, DOI 10.1146/annurev.pp.45.060194.002141; Lazarus CM, 1996, PLANT MOL BIOL, V31, P267, DOI 10.1007/BF00021789; Leblanc N, 1999, FEBS LETT, V449, P57, DOI 10.1016/S0014-5793(99)00398-1; Leblanc N, 1999, J BIOL CHEM, V274, P28314, DOI 10.1074/jbc.274.40.28314; Leblanc N, 1997, PLANT MOL BIOL, V33, P679, DOI 10.1023/A:1005757815212; Leyser HMO, 1996, PLANT J, V10, P403, DOI 10.1046/j.1365-313x.1996.10030403.x; LOBLER M, 1985, J BIOL CHEM, V260, P9848; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Millner PA, 1996, PLANT GROWTH REGUL, V18, P143, DOI 10.1007/BF00028499; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; NAPIER RM, 1990, PLANTA, V182, P313, DOI 10.1007/BF00197128; NAPIER RM, 1992, J CELL SCI, V102, P261; PALME K, 1992, PLANT CELL, V4, P193, DOI 10.1105/tpc.4.2.193; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; RAY PM, 1977, PLANT PHYSIOL, V59, P357, DOI 10.1104/pp.59.3.357; RONA JP, 1980, J MEMBRANE BIOL, V57, P25, DOI 10.1007/BF01868983; Schouten A, 1997, FEBS LETT, V415, P235, DOI 10.1016/S0014-5793(97)01129-0; Sessions A, 1997, DEVELOPMENT, V124, P4481; SHIMOMURA S, 1986, J BIOCHEM-TOKYO, V99, P1513, DOI 10.1093/oxfordjournals.jbchem.a135621; THIEL G, 1993, P NATL ACAD SCI USA, V90, P11493, DOI 10.1073/pnas.90.24.11493; Tian Q, 1999, DEVELOPMENT, V126, P711; VENIS MA, 1995, J EXP BOT, V46, P463, DOI 10.1093/jxb/46.5.463; VENIS MA, 1995, CRIT REV PLANT SCI, V14, P27, DOI 10.1080/713608065; VENIS MA, 1977, NATURE, V266, P268, DOI 10.1038/266268a0; Warwicker J, 2001, PLANTA, V212, P343, DOI 10.1007/s004250000442	45	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34517	34523		10.1074/jbc.M102783200	http://dx.doi.org/10.1074/jbc.M102783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11438526	hybrid, Green Published			2022-12-25	WOS:000171024600024
J	Tarn, C; Lee, S; Hu, Y; Ashendel, C; Andrisani, OM				Tarn, C; Lee, S; Hu, Y; Ashendel, C; Andrisani, OM			Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; HUMAN-IMMUNODEFICIENCY-VIRUS; SIGNAL-REGULATED KINASE; CELL-CYCLE REGULATION; C-JUN; HBX PROTEIN; GENE-EXPRESSION; MAMMALIAN-CELLS; GAMMA-RADIATION; TRANSCRIPTION	The hepatitis B virus (HBV) X protein (pX) is implicated in hepatocarcinogenesis of chronic HBV patients by an unknown mechanism. Activities of pX likely relevant to hepatocyte transformation include activation of the mitogenic RAS-RAF-MAPK and JNK pathways. To assess the importance of mitogenic pathway activation by pX in transformation, we employed a cellular model system composed of two tetracycline-regulated, pX-expressing cell lines, constructed in AML12-immortalized hepatocytes. This system includes the differentiated 3pX-1 and the de-differentiated 4pX-1 hepatocytes. Our studies have demonstrated that conditional pX expression transforms only 3pX-1 cells. Here, comparative in vitro kinase assays and various in vivo analyses demonstrate that pX affects an inverse activation of RAS-RAF-MAPK and JNK pathways in 3pX-1 versus 4pX-1 cells. Sustained pX-dependent RAS-RAF-MAPK pathway activation is observed in pX-transforming 3pX-1 cells, whereas sustained pX-dependent JNK pathway activation is observed in pX non-transforming 4pX-1 cells. This differential, pX-dependent mitogenic pathway activation affects differential activation of cAMP-response element-binding protein and c-Jun and determines the proliferative response of 3pX-1 and 4pX-1 cells. Furthermore, tetracycline-regulated, pX-NLS-expressing cell lines demonstrate that expression of the nuclear pX-NLS variant minimally activates the RAS-RAF-MAPK pathway and results in markedly reduced transformation. These results link sustained, pX-mediated activation of RAS-RA.F-MAPK pathway to hepatocyte transformation.	Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Andrisani, OM (corresponding author), Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	oma@vet.purdue.edu		Andrisani, Ourania/0000-0002-6230-0303	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044533, R29DK044533] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44533] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andrisani OM, 1999, INT J ONCOL, V15, P373; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; Barnabas S, 2000, J VIROL, V74, P83, DOI 10.1128/JVI.74.1.83-90.2000; BEASLEY RP, 1981, LANCET, V2, P1129; Beier F, 2000, J BIOL CHEM, V275, P12948, DOI 10.1074/jbc.275.17.12948; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Cook SJ, 1999, MOL CELL BIOL, V19, P330; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAIG JR, 1989, ATLAS TUMOR PATHOLOG; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottlob K, 1998, CANCER RES, V58, P3566; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; Hai T, 1999, GENE EXPRESSION, V7, P321; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Huet X, 1996, MOL CELL BIOL, V16, P3789; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Schaefer S, 1998, J GEN VIROL, V79, P767, DOI 10.1099/0022-1317-79-4-767; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	75	69	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34671	34680		10.1074/jbc.M104105200	http://dx.doi.org/10.1074/jbc.M104105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11461911	hybrid			2022-12-25	WOS:000171024600045
J	Couty, JP; Geras-Raaka, E; Weksler, BB; Gershengorn, MC				Couty, JP; Geras-Raaka, E; Weksler, BB; Gershengorn, MC			Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SEQUENCES; SPINDLE CELLS; EXPRESSION; ONCOGENE; HUMAN-HERPESVIRUS-8; DISEASE; HHV-8; GENE	Kaposi's sarcoma-associated herpesvirus (KSHV; human herpesvirus 8) encodes a chemokine-like G protein-coupled receptor (KSHV-GPCR) that is implicated in the pathogenesis of Kaposi's sarcoma (KS). Since endothelial cells appear to be targets for the virus, we developed an in vitro mouse lung endothelial cell model in which KSHV-GPCR is stably expressed and KSHV-GPCR signaling was studied. In mouse lung endothelial cells: 1) HSHV-GPCR does not exhibit basal signaling through the phosphoinositide-specific phospholipase C pathway but inositol phosphate production is stimulated by growth-related oncogene a (Gro-alpha) via a pertussis toxin (PTX) -insensitive pathway; 2) KSHV-GPCR signals basally through a PTX-sensitive pathway leading to a lowering of intracellular cAMP level that can be lowered further by Gro alpha and increased by interferon gamma -inducible protein 10; 3) KSHV-GPCR stimulates phosphatidylinositol 3-kinase via a PTX-insensitive mechanism; and 4) KSHV-GPCR activates nuclear factor-kappaB (NF-kappaB) by a PTX-sensitive GB gamma subunit-mediated pathway. These data show that KSHV-GPCR couples to at least two G proteins and initiates signaling via at least three cascades in endothelial cells thereby increasing the complexity of regulation of endothelial cell function by KSHV-GPCR that may occur during viral infection.	Cornell Univ, Weill Med Coll, Dept Med, Div Mol Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Physiol Biophys & Mol Med, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Gershengorn, MC (corresponding author), NIDDK, Div Intramural Res, NIH, Bldg 10,Rm 9N222,9000 Rockville Pike, Bethesda, MD 20892 USA.		Couty, Jean-Pierre/P-5268-2017	COUTY, Jean-Pierre/0000-0003-3492-9136				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Ganem D, 1998, CURR CLIN TOPICS INF, V18, P237; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; KOCH BD, 1985, J BIOL CHEM, V260, P3138; LODGE PA, 1992, TRANSPLANT P, V24, P2816; Montaner S, 2001, CANCER RES, V61, P2641; Neipel F, 1999, SEMIN CANCER BIOL, V9, P151, DOI 10.1006/scbi.1999.0129; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Sodhi A, 2000, CANCER RES, V60, P4873; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sturzl M, 1997, INT J CANCER, V72, P68, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;68::AID-IJC10&gt;3.0.CO;2-6; VICART P, 1994, EXP CELL RES, V214, P35, DOI 10.1006/excr.1994.1231; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	27	83	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33805	33811		10.1074/jbc.M104631200	http://dx.doi.org/10.1074/jbc.M104631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448967	hybrid			2022-12-25	WOS:000170910200070
J	Pietig, G; Mehrens, T; Hirsch, JR; Cetinkaya, I; Piechota, H; Schlatter, E				Pietig, G; Mehrens, T; Hirsch, JR; Cetinkaya, I; Piechota, H; Schlatter, E			Properties and regulation of organic cation transport in freshly isolated human proximal tubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-KIDNEY; MEMBRANE-VESICLES; CONTRALUMINAL TRANSPORT; SUBSTRATE-SPECIFICITY; BASOLATERAL MEMBRANE; APICAL MEMBRANE; RABBIT KIDNEY; LLC-PK1 CELLS; BRUSH-BORDER	The kidney, and more specifically the proximal tubule, is the main site of elimination of cationic endogenous metabolites and xenobiotics. Although numerous studies exist on renal organic cation transport of rat and rabbit, no information is available from humans. Therefore, we examined organic cation transport and its regulation across the basolateral membrane of isolated human proximal tubules. mRNA for the cation transporters hOCT1 and hOCT2 as well as hOCTN1 and hOCTN2 was detected in these tubules. Organic cation transport across the basolateral membrane of isolated collapsed proximal tubules was recorded with the fluorescent dye 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP(+)). Depolarization of the cells by rising extracellular K+ concentration to 145 mM reduced ASP(+) uptake by 20 +/- 5% (n = 15), indicating its electrogeneity. The substrates of organic cation transport tetraethylammonium (K-i = 63 muM) and cimetidine (K-i = 11 muM) as well as the inhibitor quinine (K-i = 2.9 muM) reduced ASP(+) uptake concentration dependently. Maximal inhibition reached with these substances was similar to 60%. Stimulation of protein kinase C with 1,2-dioctanoyl-sn-glycerol (DOG, 1 muM) or ATP (100 muM) inhibited ASP(+) uptake by 30 +/- 3 (n = 16) and 38 +/- 13% (n = 6), respectively. The effect of DOG could be reduced with calphostin C (0.1 muM, n = 7). Activation of adenylate cyclase by forskolin (1 muM) decreased ASP(+) uptake by 29 +/- 3% (n = 10). hANP (10 nM) or 8-bromo-cGMP (100 muM) also decreased ASP(+) uptake by 17 +/- 3 (n = 9) or 32 +/- 5% (n = 10), respectively. We show for the first time that organic cation transport across the basolateral membrane of isolated human proximal tubules, most likely mediated via hOCT2, is electrogenic and regulated by protein kinase C, the cAMP- and the cGMP-dependent protein kinases.	Univ Klinikum Munster, Med Klin & Poliklin D, D-48149 Munster, Germany; Univ Klinikum Munster, Klin & Poliklin Urol, D-48149 Munster, Germany	University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster	Schlatter, E (corresponding author), Univ Klinikum Munster, Med Klin & Poliklin D, Domagkstr 3A, D-48149 Munster, Germany.							Berkhin EB, 2001, KIDNEY INT, V59, P17, DOI 10.1046/j.1523-1755.2001.00461.x; BOOM SPA, 1992, J PHARMACOL EXP THER, V263, P445; Breidert T, 1998, BRIT J PHARMACOL, V125, P218, DOI 10.1038/sj.bjp.0702065; Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; DAVID C, 1995, PFLUG ARCH EUR J PHY, V430, P477, DOI 10.1007/BF00373884; Derst C, 2001, KIDNEY INT, V59, P2197; Derst C, 2001, FEBS LETT, V491, P305, DOI 10.1016/S0014-5793(01)02202-5; Dresser MJ, 2000, J PHARMACOL EXP THER, V292, P1146; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Grundemann D, 1998, NAT NEUROSCI, V1, P349, DOI 10.1038/1557; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; Hohage H, 1998, J PHARMACOL EXP THER, V286, P305; HOHAGE H, 1994, J PHARMACOL EXP THER, V268, P897; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; Karbach U, 2000, AM J PHYSIOL-RENAL, V279, pF679, DOI 10.1152/ajprenal.2000.279.4.F679; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; Mehrens T, 2000, J AM SOC NEPHROL, V11, P1216, DOI 10.1681/ASN.V1171216; Nagel G, 1997, J BIOL CHEM, V272, P31953, DOI 10.1074/jbc.272.51.31953; PIETRUCK F, 1995, KIDNEY INT, V47, P1647, DOI 10.1038/ki.1995.229; Pritchard JB, 1997, ADV DRUG DELIVER REV, V25, P231, DOI 10.1016/S0169-409X(97)00501-2; Schafer JA, 1997, AM J PHYSIOL-RENAL, V273, pF650, DOI 10.1152/ajprenal.1997.273.4.F650; SCHLATTER E, 1987, PFLUG ARCH EUR J PHY, V409, P81, DOI 10.1007/BF00584753; Stachon A, 1997, CELL PHYSIOL BIOCHEM, V7, P264, DOI 10.1159/000154881; Stachon A, 1996, CELL PHYSIOL BIOCHEM, V6, P72, DOI 10.1159/000154796; Sugawara-Yokoo M, 2000, HISTOCHEM CELL BIOL, V114, P175; Sweet DH, 2000, AM J PHYSIOL-RENAL, V279, pF826, DOI 10.1152/ajprenal.2000.279.5.F826; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Ullrich K, 1999, MEMBRANE TRANSPORTER, P159; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V419, P84, DOI 10.1007/BF00373751; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; WRIGHT SH, 1985, AM J PHYSIOL, V249, pF903, DOI 10.1152/ajprenal.1985.249.6.F903; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Yabuuchi H, 1999, J PHARMACOL EXP THER, V289, P768; Zhang L, 1999, J PHARMACOL EXP THER, V288, P1192; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913; Zhang L, 1998, J PHARMACOL EXP THER, V286, P354	38	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33741	33746		10.1074/jbc.M104617200	http://dx.doi.org/10.1074/jbc.M104617200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11447227	hybrid			2022-12-25	WOS:000170910200062
J	Van Goor, F; Zivadinovic, D; Martinez-Fuentes, AJ; Stojilkovic, SS				Van Goor, F; Zivadinovic, D; Martinez-Fuentes, AJ; Stojilkovic, SS			Dependence of pituitary hormone secretion on the pattern of spontaneus voltage-gated calcium influx - Cell type-specific action potential secretion coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN SECRETION; CYTOPLASMIC CALCIUM; POTASSIUM CHANNELS; CA2+ OSCILLATIONS; RAT LACTOTROPES; PULSE-GENERATOR; NERVE-TERMINALS; EXOCYTOSIS; SOMATOTROPHS; GONADOTROPHS	In excitable cells, voltage-gated calcium influx provides an effective mechanism for the activation of exocytosis. In this study, we demonstrate that although rat anterior pituitary lactotrophs, somatotrophs, and gonadotrophs exhibited spontaneous and extracellular calcium-dependent electrical activity, voltage-gated calcium influx triggered secretion only in lactotrophs and somatotrophs. The lack of action potential-driven secretion in gonadotrophs was not due to the proportion of spontaneously firing cells or spike frequency. Gonadotrophs exhibited calcium signals during prolonged depolarization comparable with signals observed in somatotrophs and lactotrophs. The secretory vesicles in all three cell types also had a similar sensitivity to voltage-gated calcium influx. However, the pattern of action potential calcium influx differed among three cell types. Spontaneous activity in gonadotrophs was characterized by high amplitude, sharp spikes that had a limited capacity to promote calcium influx, whereas lactotrophs and somatotrophs fired plateau-bursting action potentials that generated high amplitude calcium signals. Furthermore, a shift in the pattern of firing from sharp spikes to plateau-like spikes in gonadotrophs triggered luteinizing hormone secretion. These results indicate that the cell type-specific action potential secretion coupling in pituitary cells is determined by the capacity of their plasma membrane oscillator to generate threshold calcium signals.	NICHHD, Sect Cellular Signaling, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHHD, Sect Cellular Signaling, ERRB, NIH, Bldg 49,Rm 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BIALES B, 1977, NATURE, V267, P172, DOI 10.1038/267172a0; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; Bonnefont X, 2000, ENDOCRINOLOGY, V141, P868, DOI 10.1210/en.141.3.868; CHANG JP, 1988, ENDOCRINOLOGY, V123, P87, DOI 10.1210/endo-123-1-87; CHEN C, 1994, NEUROENDOCRINOLOGY, V59, P1, DOI 10.1159/000126631; COTA G, 1990, AM J PHYSIOL, V259, pC949, DOI 10.1152/ajpcell.1990.259.6.C949; DUFY B, 1979, SCIENCE, V204, P309; DYER RG, 1989, J ENDOCRINOL, V123, P1, DOI 10.1677/joe.0.1230001; ENYEART JJ, 1987, J BIOL CHEM, V262, P3154; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; HERRINGTON J, 1994, J NEUROPHYSIOL, V72, P719, DOI 10.1152/jn.1994.72.2.719; HOLL RW, 1988, J BIOL CHEM, V263, P9682; HOLL RW, 1989, AM J PHYSIOL, V256, pE373; HORTA J, 1991, AM J PHYSIOL, V261, pC865, DOI 10.1152/ajpcell.1991.261.5.C865; INGRAM CD, 1986, ENDOCRINOLOGY, V119, P2508, DOI 10.1210/endo-119-6-2508; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; Kehl SJ, 1996, J MEMBRANE BIOL, V150, P219, DOI 10.1007/s002329900046; KIDOKORO Y, 1975, NATURE, V258, P741, DOI 10.1038/258741a0; KNOBIL E, 1990, AM J OBSTET GYNECOL, V163, P1721, DOI 10.1016/0002-9378(90)91435-F; KORN SJ, 1991, J PHYSIOL-LONDON, V439, P423, DOI 10.1113/jphysiol.1991.sp018674; Koshimizu T, 2000, ENDOCRINOLOGY, V141, P4091, DOI 10.1210/en.141.11.4091; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; Kwiecien R, 1998, J PHYSIOL-LONDON, V508, P883, DOI 10.1111/j.1469-7793.1998.883bp.x; Kwiecien R, 1998, NEUROENDOCRINOLOGY, V68, P135, DOI 10.1159/000054360; Li YX, 1997, BIOPHYS J, V72, P1080, DOI 10.1016/S0006-3495(97)78758-7; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; Mansvelder HD, 1998, J NEUROSCI, V18, P81; MARIC D, 1982, J ENDOCRINOL INVEST, V5, P235, DOI 10.1007/BF03348329; MASON WT, 1988, J PHYSIOL-LONDON, V405, P577, DOI 10.1113/jphysiol.1988.sp017349; Mennerick S, 1996, NEURON, V17, P1241, DOI 10.1016/S0896-6273(00)80254-8; MULKEY RM, 1991, NATURE, V350, P153, DOI 10.1038/350153a0; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Sankaranarayanan S, 1996, AM J PHYSIOL-CELL PH, V271, pC1927, DOI 10.1152/ajpcell.1996.271.6.C1927; Sankaranarayanan S, 1998, NEUROENDOCRINOLOGY, V68, P297, DOI 10.1159/000054378; Schafer R, 1999, J PHYSIOL-LONDON, V518, P401, DOI 10.1111/j.1469-7793.1999.0401p.x; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Simasko SM, 1997, AM J PHYSIOL-ENDOC M, V272, pE405, DOI 10.1152/ajpendo.1997.272.3.E405; SIMASKO SM, 1988, AM J PHYSIOL, V254, pE328, DOI 10.1152/ajpendo.1988.254.3.E328; SIMS SM, 1991, J PHYSIOL-LONDON, V441, P615, DOI 10.1113/jphysiol.1991.sp018770; STANLEY EF, 1986, J NEUROSCI, V6, P782; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1994, MOL PHARMACOL, V45, P1013; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P13054; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, 1993, ENDOCRINOLOGY, V132, P1475, DOI 10.1210/en.132.4.1475; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; Van Goor F, 2001, MOL ENDOCRINOL, V15, P1222, DOI 10.1210/me.15.7.1222; VANGOOR F, 2001, IN PRESS J NEUROSCI; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498	52	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33840	33846		10.1074/jbc.M105386200	http://dx.doi.org/10.1074/jbc.M105386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11457854	hybrid			2022-12-25	WOS:000170910200075
J	DeStefano, JJ; Cristofaro, JV; Derebail, S; Bohlayer, WP; Fitzgerald-Heath, MJ				DeStefano, JJ; Cristofaro, JV; Derebail, S; Bohlayer, WP; Fitzgerald-Heath, MJ			Physical mapping of HIV reverse transcriptase to the 5 ' end of RNA primers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RIBONUCLEASE-H DOMAIN; NUCLEOCAPSID PROTEIN; STRAND TRANSFER; NUCLEIC-ACID; CLEAVAGE SPECIFICITY; POLYPURINE TRACT; DNA-SYNTHESIS; BINDING; HYBRIDS	Enzymatic analysis of RNA cleavage products has suggested that human immunodeficiency virus (HIV) reverse transcriptase (RT) binds to the 5' end of RNAs that are recessed on a longer DNA template (RNA primers) yet binds to the 3' end of DNA primers. One concern is that RT molecules bound at the 3' end of RNA would not be easily detected because RT may not catalyze substantial RNA extension or cleavage when bound to the 3' end. We used physical mapping to show that RT binds preferentially to the 5' end of RNA primers. Am HIV-RT that lacked RNase H activity (HIV-RTE478Q) was incubated with the RNA-DNA hybrid followed by the addition of Escherichia coli RNase H. RT protected a similar to 23-base region at the 5' end of the RNA and 4 additional bases on the DNA strand. This footprint correlated well with the crystal structure of HIV-RT. No protection of the RNA 3' end was observed, although when dNTPs were included, low levels of extension occurred, indicating that RT can bind this end. Wildtype HIV-RT cleaved the RNA and then extended a small portion of the cleaved fragments, suggesting that very small RNAs may be bound similar to DNA primers.	Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	DeStefano, JJ (corresponding author), Univ Maryland, Dept Mol Genet & Cell Biol, Bldg 231, College Pk, MD 20742 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051140] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P927, DOI 10.1073/pnas.89.3.927; Cowan JA, 2000, J BIOL INORG CHEM, V5, P67, DOI 10.1007/s007750050009; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOFF SP, 1997, RETROVIRUSES, P121; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HANSEN J, 1987, J BIOL CHEM, V262, P12393; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1989, J BIOL CHEM, V264, P4669; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; Rausch JW, 2000, J BIOL CHEM, V275, P16015, DOI 10.1074/jbc.M909808199; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; Wu TY, 1999, J VIROL, V73, P4794, DOI 10.1128/JVI.73.6.4794-4805.1999	31	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32515	32521		10.1074/jbc.M103958200	http://dx.doi.org/10.1074/jbc.M103958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11441011	hybrid			2022-12-25	WOS:000170746000020
J	Gage, BM; Alroy, D; Shin, CY; Ponomareva, ON; Dhar, S; Sharma, GG; Pandita, TK; Thayer, MJ; Turker, MS				Gage, BM; Alroy, D; Shin, CY; Ponomareva, ON; Dhar, S; Sharma, GG; Pandita, TK; Thayer, MJ; Turker, MS			Spontaneously immortalized cell lines obtained from adult Atm null mice retain sensitivity to ionizing radiation and exhibit a mutational pattern suggestive of oxidative stress	ONCOGENE			English	Article						immortalized Atm null cells; ionizing radiation; mutagenesis oxidative stress	ATAXIA-TELANGIECTASIA; DEFICIENT MICE; POSTCONFLUENCE INHIBITION; TELOMERASE ACTIVITY; MUTATOR PHENOTYPE; END ASSOCIATIONS; MOUSE APRT; RESISTANCE; DEFECTS; CANCER	The study of Ataxia-telangiectasia (A-T) has benefited significantly from mouse models with knockout mutations for the Atm (A-T mutation) locus. While these models have proven useful for in vivo studies, cell cultures from Atm null embryos have been reported to grow poorly and then senesce. In this study, we initiated primary cultures from adult ears and kidneys of Atm homozygous mice and found that these cultures immortalized readily without loss of sensitivity to ionizing radiation and other Atm related cell cycle defects. A mutational analysis for loss of expression of an autosomal locus showed that ionizing radiation had a mutagenic effect, Interestingly, some spontaneous mutants exhibited a mutational pattern that is characteristic of oxidative mutagenesis, This result is consistent with chronic oxidative stress in Atm null cells. In total, the results demonstrate that permanent cell lines can be established from the tissues of adult mice homozygous for Atm and that these cell lines will exhibit expected and novel consequences of this deficiency.	Oregon Hlth Sci Univ, CROET, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA; Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Oregon Health & Science University; Columbia University; Oregon Health & Science University; Oregon Health & Science University	Turker, MS (corresponding author), Oregon Hlth Sci Univ, CROET, Ctr Res Occupat & Environm Toxicol, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Pandita, Tej K/AAM-9188-2020		NCI NIH HHS [CA56383, CA76528] Funding Source: Medline; NIGMS NIH HHS [GM49334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076528, R01CA056383] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; COLE J, 1988, INT J RADIAT BIOL, V54, P929, DOI 10.1080/09553008814552331; COOPER GE, 1992, SOMAT CELL MOLEC GEN, V18, P215, DOI 10.1007/BF01233858; COOPER GE, 1991, SOMAT CELL MOLEC GEN, V17, P105, DOI 10.1007/BF01232969; DICKERMAN LH, 1978, MUTAT RES, V49, P83, DOI 10.1016/0027-5107(78)90080-5; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Freyer GA, 1996, MUTAT RES-FUND MOL M, V357, P237, DOI 10.1016/0027-5107(96)00130-3; Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HEIM RA, 1992, MUTAT RES, V284, P25, DOI 10.1016/0027-5107(92)90022-T; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; Khattar NH, 1997, SOMAT CELL MOLEC GEN, V23, P51, DOI 10.1007/BF02679955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Pandita TK, 1996, RADIAT RES, V145, P730, DOI 10.2307/3579364; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; ROSCHEISEN C, 1994, SOMAT CELL MOLEC GEN, V20, P493, DOI 10.1007/BF02255840; Rose JA, 2000, CANCER RES, V60, P3404; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; TURKER M, 1995, MUTAT RES-FUND MOL M, V329, P97, DOI 10.1016/0027-5107(95)00046-L; Turker MS, 1999, CANCER RES, V59, P1837; Turker MS, 1999, CANCER RES, V59, P4781; Walker KA, 1997, SOMAT CELL MOLEC GEN, V23, P111, DOI 10.1007/BF02679970; Westphal CH, 1998, CANCER RES, V58, P5637; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	34	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4291	4297		10.1038/sj.onc.1204509	http://dx.doi.org/10.1038/sj.onc.1204509			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466609				2022-12-25	WOS:000169912600002
J	Huang, SY; Pettaway, CA; Uehara, H; Bucana, CD; Fidler, IJ				Huang, SY; Pettaway, CA; Uehara, H; Bucana, CD; Fidler, IJ			Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis	ONCOGENE			English	Article						prostate cancer; NF-kappa B; angiogenesis; invasion; metastasis	PROINFLAMMATORY CYTOKINE EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; CONSTITUTIVE ACTIVATION; PERMEABILITY FACTOR; ALPHA PROTEOLYSIS; MELANOMA-CELLS; INHIBITION; TUMORIGENICITY; INTERLEUKIN-8	Since the NF-kappaB/relA transcription factor is constitutively activated in human prostate cancer cells, we determined whether blocking NF-kappaB/relA activity in human prostate cancer cells affected their angiogenesis, growth, and metastasis in an orthotopic nude mouse model. Highly metastatic PC-3M human prostate cancer cells were transfected with a mutated I kappa -B alpha (I kappaB alphaM), which blocks NF-KB activity. Parental (PC3M), control vector-transfected (PC-3M-Neo), and I kappa -B alphaM-transfected (PC-3M-I kappaB alphaM) cells were injected into the prostate gland of nude mice. PC3M and PC-3M-Neo cells produced rapidly growing tumors and regional lymph node metastasis, whereas PC-3M-I kappaB alphaM cells produced slow growing tumors with low metastatic potential. NF-kappaB signaling blockade significantly inhibited in vitro and in vivo expression of three major proangiogenic molecules, VEGF, IL-8, and MMP-9, and hence decreased neoplastic angiogenesis, Inhibition of NF-kappaB activity in PC-3M cells also resulted in the downregulation of MMP-9 mRNA and collagenase activity, resulting in decreased invasion through Matrigel. Collectively, these data suggest that blockade of NF kappaB activity in PC-3M cells inhibits angiogenesis, invasion, and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fidler, IJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	ijfidler@mdanderson.org			NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA42107, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Balbay MD, 1999, CLIN CANCER RES, V5, P783; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Borgstrom P, 1998, PROSTATE, V35, P1; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong G, 1999, CANCER RES, V59, P3495; Duffey DC, 1999, CANCER RES, V59, P3468; Duque JLF, 1999, UROLOGY, V54, P523, DOI 10.1016/S0090-4295(99)00167-3; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; FERRER FA, 1999, J UROLOGY, V6, P2329; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Folkman J, 1992, Semin Cancer Biol, V3, P65; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Gilmore TD, 1996, ONCOGENE, V13, P1367; Giri D, 1999, CLIN CANCER RES, V5, P1063; Greene GF, 1997, AM J PATHOL, V150, P1571; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; Inoue K, 2000, CLIN CANCER RES, V6, P2104; JACKSON MW, 1997, J UROLOGY, V6, P2323; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MELNYK O, 1999, J UROLOGY, V3, P960; Meyskens FL, 1999, CLIN CANCER RES, V5, P1197; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NAKAMOTO T, 1992, CANCER RES, V52, P571; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Puyraimond A, 1999, J CELL SCI, V112, P1283; RAY JM, 1994, EUR RESPIR J, V7, P2062; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227; SATO H, 1993, J BIOL CHEM, V268, P23460; Sehgal G, 1998, AM J PATHOL, V152, P591; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Villarete LH, 1996, AM J PATHOL, V149, P1685; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; YOKOO T, 1996, AM J PHYSIOL, V2, P123; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624	65	488	523	0	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4188	4197		10.1038/sj.onc.1204535	http://dx.doi.org/10.1038/sj.onc.1204535			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464285				2022-12-25	WOS:000169857200009
J	Bradshaw, PC; Jung, DW; Pfeiffer, DR				Bradshaw, PC; Jung, DW; Pfeiffer, DR			Free fatty acids activate a vigorous Ca2+: 2H(+) antiport activity in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; SACCHAROMYCES-CEREVISIAE MITOCHONDRIA; RAT-LIVER MITOCHONDRIA; INORGANIC PYROPHOSPHATASE; ADENINE-NUCLEOTIDES; IONOPHORE A23187; CA2+ TRANSPORT; CALCIUM; MEMBRANE; PHOSPHOLIPASE-A2	The accumulation and retention of Ca2+ by yeast mitochondria (Saccharomyces cerevisiae) mediated by ionophore ETH 129 occurs with a variable efficiency in different preparations. Ineffective Ca2+ transport and a depressed membrane potential occur in parallel, are exacerbated in parallel by exogenous free fatty acids, and are corrected in parallel by the addition of bovine serum albumin. Bovine serum albumin is not required to develop a high membrane potential when either Ca2+ or ETH 129 are absent, and when both are present membrane potential is restored by the addition of EGTA in a concentration-dependant manner. Respiration and swelling data indicate that the permeability transition pore does not open in yeast mitochondria that are treated with Ca2+ and ETH 129, whereas fatty acid concentration studies and the inaction of carboxyatractyloside indicate that fatty acid-derived uncoupling does not underlie the other observations. It is concluded that yeast mitochondria contain a previously unrecognized Ca2+:2H(+) antiporter that is highly active in the presence of free fatty acids and leads to a futile cycle of Ca2+ accumulation and release when exogenous Ca2+ and ETH 129 are available. It is also shown that isolated yeast mitochondria degrade their phospholipids at a relatively rapid rate. The activity responsible is also previously unrecognized. It is Ca2+-independent, little affected by the presence or absence of a respiratory substrate, and leads to the hydrolysis of ester linkages at both the sn-1 and sn-2 positions of the glycerophospholipids. The products of this activity, through their actions on the antiporter, explain the variable behavior of yeast mitochondria treated with Ca2+ plus ETH 129.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Pfeiffer, DR (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 1645 Neil Ave,Hamilton Hall 310A, Columbus, OH 43210 USA.		Bradshaw, Patrick C./AAR-9189-2020	Bradshaw, Patrick C./0000-0002-4591-6798				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; Averet N, 1998, MOL CELL BIOCHEM, V184, P67, DOI 10.1023/A:1006830810440; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; BALCAVAG.WX, 1973, BIOCHIM BIOPHYS ACTA, V305, P41, DOI 10.1016/0005-2728(73)90229-6; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bradshaw PC, 2000, BIOPHYS J, V78, p194A; BRANDOLIN G, 1993, BIOCHEM BIOPH RES CO, V192, P143, DOI 10.1006/bbrc.1993.1393; Broekemeier KM, 1998, BIOCHEMISTRY-US, V37, P13059, DOI 10.1021/bi980820c; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; BROEKEMEIER KM, 1991, J BIOL CHEM, V266, P20700; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; DAUM G, 1982, J BIOL CHEM, V257, P3028; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; DAVIDSON AM, 1989, BIOCHEM J, V258, P817, DOI 10.1042/bj2580817; DUNN T, 1994, J BIOL CHEM, V269, P7273; EIMADHOUN BM, 1998, AM J PHYSIOL-GASTR L, V275, pG638; ERDAHL WL, 1994, BIOPHYS J, V66, P1678, DOI 10.1016/S0006-3495(94)80959-2; FITTON V, 1994, BIOCHEMISTRY-US, V33, P9692, DOI 10.1021/bi00198a039; GUERIN B, 1994, J BIOL CHEM, V269, P25406; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Jung DW, 1997, J BIOL CHEM, V272, P21104, DOI 10.1074/jbc.272.34.21104; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; Litsky ML, 1997, BIOCHEMISTRY-US, V36, P7071, DOI 10.1021/bi970180y; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MANON S, 1992, BIOCHIM BIOPHYS ACTA, V1108, P169, DOI 10.1016/0005-2736(92)90022-E; NICHOLS BJ, 1994, BIOCHEM J, V303, P461, DOI 10.1042/bj3030461; NISSANI E, 1983, ARCH BIOCHEM BIOPHYS, V226, P357, DOI 10.1016/0003-9861(83)90302-8; Norris V, 1996, J BACTERIOL, V178, P3677, DOI 10.1128/jb.178.13.3677-3682.1996; OUHABI R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P293, DOI 10.1016/S0005-2728(05)80319-6; PALMER JW, 1981, ARCH BIOCHEM BIOPHYS, V211, P674, DOI 10.1016/0003-9861(81)90503-8; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; PFEIFFER DR, 1976, BIOCHEMISTRY-US, V15, P2690, DOI 10.1021/bi00657a032; Polcic P, 1997, FEBS LETT, V412, P207, DOI 10.1016/S0014-5793(97)00778-3; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRESTIPINO G, 1993, ANAL BIOCHEM, V210, P119, DOI 10.1006/abio.1993.1160; PRETSCH E, 1980, HELV CHIM ACTA, V63, P191, DOI 10.1002/hlca.19800630117; REED PW, 1972, J BIOL CHEM, V247, P6970; Roucou X, 1997, BBA-BIOMEMBRANES, V1324, P120, DOI 10.1016/S0005-2736(96)00215-5; SCARPA A, 1978, BIOCHEMISTRY-US, V17, P1378, DOI 10.1021/bi00601a004; SCHEFER U, 1986, ANAL CHEM, V58, P2282, DOI 10.1021/ac00124a036; SCHLENK H, 1960, ANAL CHEM, V32, P1412, DOI 10.1021/ac60167a011; SERHAN C, 1981, J BIOL CHEM, V256, P2736; SHARPE MA, 1994, J MEMBRANE BIOL, V141, P21; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Sultan A, 2001, ARCH BIOCHEM BIOPHYS, V386, P52, DOI 10.1006/abbi.2000.2195; Sultan A, 2001, ARCH BIOCHEM BIOPHYS, V386, P37, DOI 10.1006/abbi.2000.2194; Thomas TP, 1997, ARCH BIOCHEM BIOPHYS, V342, P351, DOI 10.1006/abbi.1997.0121; URIBE S, 1992, CELL CALCIUM, V13, P211, DOI 10.1016/0143-4160(92)90009-H; URIBE S, 1993, EUR J BIOCHEM, V217, P657, DOI 10.1111/j.1432-1033.1993.tb18289.x; UTSUMI K, 1985, CELL STRUCT FUNCT, V10, P339, DOI 10.1247/csf.10.339; WANG E, 2001, IN PRESS BIOPHYS J; WEIHUA L, 1992, J BIOL CHEM, V267, P17983; Wojtczak L, 1998, ARCH BIOCHEM BIOPHYS, V357, P76, DOI 10.1006/abbi.1998.0777; Wojtczak L, 1999, J BIOENERG BIOMEMBR, V31, P447, DOI 10.1023/A:1005444322823; YOST RW, 1991, BIOCHEM INT, V24, P199	61	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40502	40509		10.1074/jbc.M105062200	http://dx.doi.org/10.1074/jbc.M105062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11457848	hybrid			2022-12-25	WOS:000171925600020
J	Poullet, P; Gautreau, A; Kadare, G; Girault, JA; Louvard, D; Arpin, M				Poullet, P; Gautreau, A; Kadare, G; Girault, JA; Louvard, D; Arpin, M			Ezrin interacts with focal adhesion kinase and induces its activation independently of cell-matrix adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ACTIN-BASED CYTOSKELETONS; SRC-FAMILY KINASES; PLASMA-MEMBRANE; TERMINAL DOMAIN; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; EPITHELIAL-CELLS; SURVIVAL PATHWAY	Ezrin, a membrane-cytoskeleton linker, is required for cell morphogenesis, motility, and survival through molecular mechanisms that remain to be elucidated. Using the N-terminal domain of ezrin as a bait, we found that p125 focal adhesion kinase (FAR) interacts with ezrin. We show that the two proteins coimmunoprecipitate from cultured cell lysates. However, FAK does not interact with full-length ezrin in vitro, indicating that the FAK binding site on ezrin is cryptic. Mapping experiments showed that the entire N-terminal domain of FAK (amino acids 1-376) is required for optimal ezrin binding. While investigating the role of the ezrin-FAK interaction, we observed that, in suspended kidney-derived epithelial LLC-PK1 cells, overproduction of ezrin promoted phosphorylation of FAK Tyr-397, the major autophosphorylation site, creating a docking site for FAK signaling partners. Treatment of the cells with a Src family kinase inhibitor reduced the phosphorylation of Tyr-577 but not that of Tyr-397, indicating that ezrin-mediated FAK activation does not require the activity of Src kinases. Altogether, these observations indicate that ezrin is able to trigger FAK activation in signaling events that are not elicited by cell-matrix adhesion.	Inst Curie, Lab Morphogenese & Signalisat Cellulaires, CNRS, UMR 144, F-75248 Paris 05, France; Inst Fer Moulin, INSERM, U536, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Arpin, M (corresponding author), Inst Curie, Lab Morphogenese & Signalisat Cellulaires, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Girault, Jean-Antoine/F-7518-2013; Gautreau, Alexis/AAT-2751-2020	Girault, Jean-Antoine/0000-0002-7900-1705; Gautreau, Alexis/0000-0002-2369-4362; Kadare, Gress/0000-0002-8865-5743				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANDREOLI C, 1994, J CELL SCI, V107, P2509; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; CHAN PY, 1994, J BIOL CHEM, V269, P20567; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; FRANCK Z, 1993, J CELL SCI, V105, P219; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; RANKIN S, 1994, J BIOL CHEM, V269, P704; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Toutant M, 2000, BIOCHEM J, V348, P119, DOI 10.1042/0264-6021:3480119; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	49	93	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37686	37691		10.1074/jbc.M106175200	http://dx.doi.org/10.1074/jbc.M106175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11468295	hybrid			2022-12-25	WOS:000171375700107
J	Yamamoto, Y; Kim, DW; Kwak, YT; Prajapati, S; Verma, U; Gaynor, RB				Yamamoto, Y; Kim, DW; Kwak, YT; Prajapati, S; Verma, U; Gaynor, RB			IKK gamma/NEMO facilitates the recruitment of the I kappa B proteins into the I kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; SEVERE LIVER DEGENERATION; X-LINKED DISORDER; TAX PROTEIN; INCONTINENTIA PIGMENTI; DEFICIENT MICE; ALPHA PROTEOLYSIS; UBIQUITIN LIGASE; BETA SUBUNIT; ACTIVATION	IKK gamma /NEMO is an essential regulatory component of the I kappaB kinase complex that is required for NF-kappaB activation in response to various stimuli including tumor necrosis factor-alpha and interleukin-1 beta. To investigate the mechanism by which IKK gamma /NEMO regulates the IKK complex, we examined the ability of IKK gamma /NEMO to recruit the I kappaB proteins into this complex. IKK gamma /NEMO binding to wild-type, but not to a kinase-deficient IKK beta protein, facilitated the association of I kappaB alpha and I kappaB beta with the high molecular weight IKK complex. Following tumor necrosis factor-alpha treatment of HeLa cells, the majority of the phosphorylated form of endogenous I kappaB alpha was associated with the high molecular weight IKK complex in HeLa cells and parental mouse embryo fibroblasts but not in IKK gamma /NEMO-deficient cells. Finally, we demonstrate that IKK gamma /NEMO facilitates the association of the I kappaB proteins and IKK beta and leads to increases in IKK beta kinase activity. These results suggest that an important function of IKK gamma /NEMO is to facilitate the association of both IKK beta and I kappaB in the high molecular weight IKK complex to increase I kappaB phosphorylation.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL CANCER INSTITUTE [R01CA074128] Funding Source: NIH RePORTER; NCI NIH HHS [CA74128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 1999, GENE EXPRESSION, V7, P233; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089/08892220050192994; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Smahi A, 2000, NATURE, V405, P466; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	59	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36327	36336		10.1074/jbc.M104090200	http://dx.doi.org/10.1074/jbc.M104090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470788	hybrid			2022-12-25	WOS:000171194500038
J	Yan, RQ; Han, P; Miao, H; Greengard, P; Xu, HX				Yan, RQ; Han, P; Miao, H; Greengard, P; Xu, HX			The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta-amyloid precursor protein (APP) substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE; MEMBRANE; NETWORK; IDENTIFICATION; GENERATION; CLEAVAGE; FURIN; TRAFFICKING; MATURATION; ENZYME	Release of A beta peptides from beta -amyloid precursor protein (APP) requires sequential cleavage by two endopeptidases, beta- and gamma -secretases. beta -Secretase was recently identified as a novel membrane-bound aspartyl protease, named BACE1, Asp2, or memapsin 2. Employing confocal microscopy and subcellular fractionation, we have found that BACE1 is largely situated in the distal Golgi membrane with a minor presence in the endoplasmic reticulum, endosomes, and plasma membrane in human neuroblastoma SHEP cells and in mouse Neuro-2a cell lines expressing either endogenous mouse BACE1 or additional exogenous human BACE1. The major cellular beta -secretase activity is located in the late Golgi apparatus, consistent with its cellular localization. Furthermore, we demonstrate that the single transmembrane domain of BACE1 alone determines the retention of BACE1 to the Golgi compartments, through examination of recombinant proteins of various BACE1 fragments fused to a reporter green fluorescence protein. In addition, we show that the transmembrane domain of BACE1 is required for the access of BACE1 enzymatic activity to the cellular APP substrate and hence for the optimal generation of the C-terminal fragment of APP (CTF99). The results suggest a molecular and cell biological mechanism for the regulation of beta -secretase activity in vivo.	Pharmacia Corp, Dept Cell & Mol Biol, Kalamazoo, MI 49007 USA; Rockefeller Univ, Fisher Ctr Res Alzheimer Dis, New York, NY 10021 USA	Pfizer; Rockefeller University	Yan, RQ (corresponding author), Pharmacia Corp, Dept Cell & Mol Biol, 301 Henrietta St, Kalamazoo, MI 49007 USA.	ryan@pharmacia.com	Xu, Huaxi/AAV-7177-2021	Yan, Riqiang/0000-0001-7195-7617	NIA NIH HHS [AG09464, P01 AG009464] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Greenfield JP, 2000, FRONT BIOSCI, V5, pD72, DOI 10.2741/Greenfield; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Gruninger-Leitch F, 2000, NAT BIOTECHNOL, V18, P66, DOI 10.1038/71944; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YAN R, 2001, J BIOL CHEM, V10, P1074; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Youkin S. G., 1998, J PHYSIOL-LONDON, V92, P289	40	155	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36788	36796		10.1074/jbc.M104350200	http://dx.doi.org/10.1074/jbc.M104350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11466313	hybrid			2022-12-25	WOS:000171194500097
J	Dal Degan, F; Child, R; Svendsen, I; Ulvskov, P				Dal Degan, F; Child, R; Svendsen, I; Ulvskov, P			The cleavable N-terminal domain of plant endopolygalacturonases from clade B may be involved in a regulated secretion mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-Y; DEHISCENCE ZONE; BRASSICA-NAPUS; PRO REGION; CELL-WALLS; POLYGALACTURONASE; EXPRESSION; PROTEIN; SEQUENCE	Polygalacturonases represent the most abundant carbohydrate hydrolase family in the Arabidopsis thaliana genome, and they are thought to be involved in nearly all of the developmental processes requiring cell wall modifications during the life cycle of the plant. By phylogenetic analysis, plant polygalacturonases fall into at least three groups, one of which is distinguished from the others by the presence of an additional N-terminal domain. We have used RDPG1, the polygalacturonase involved in pod dehiscence in oilseed rape (Brassica napus), as a model to investigate the function of this domain. We have confirmed that this domain is absent in the mature protein by determination of the N-terminal sequence of mature RDPG1 purified from oilseed rape pod. We have furthermore investigated the accumulation and subcellular localization of the precursor containing the N-terminal domain and of the mature protein throughout the development and maturation of the pod. Using recombinant expression in Pichia pastoris, we have produced the RDPG1 precursor, and we present evidence that the N-terminal domain of plant polygalacturonases is not involved in folding or inactivation of the precursor but may play a role in the intracellular transport of this protein family via a novel regulated secretion pathway.	Danish Inst Agr Sci, Biotechnol Grp, DK-1871 Frederiksberg C, Denmark; Univ Bristol, Long Ashton Res Stn, Dept Agr Sci, IACR, Bristol BS18 9AF, Avon, England; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark	Aarhus University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Bristol	Dal Degan, F (corresponding author), Pharmexa, Kogle Alle 6, DK-2970 Horsholm, Denmark.	fdd@pharmexa.com	Ulvskov, Peter/I-1228-2014	Ulvskov, Peter/0000-0003-3776-818X				Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Bassham DC, 2000, CURR OPIN CELL BIOL, V12, P491, DOI 10.1016/S0955-0674(00)00121-6; Bergey DR, 1999, P NATL ACAD SCI USA, V96, P1756, DOI 10.1073/pnas.96.4.1756; Brummell DA, 1999, PLANT CELL, V11, P2203, DOI 10.1105/tpc.11.11.2203; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Chauvaux N, 1997, J EXP BOT, V48, P1423, DOI 10.1093/jxb/48.7.1423; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; DELLAPENNA D, 1988, PLANT PHYSIOL, V86, P1057, DOI 10.1104/pp.86.4.1057; FABRE E, 1992, J BIOL CHEM, V267, P15049; FISCHER RL, 1991, ANNU REV PLANT PHYS, V42, P675, DOI 10.1146/annurev.pp.42.060191.003331; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hadfield KA, 1998, PLANT PHYSIOL, V117, P337, DOI 10.1104/pp.117.2.337; Hadfield KA, 1998, PLANT PHYSIOL, V117, P363, DOI 10.1104/pp.117.2.363; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jenkins ES, 1999, PLANT CELL ENVIRON, V22, P159, DOI 10.1046/j.1365-3040.1999.00372.x; Jenkins ES, 1996, J EXP BOT, V47, P111, DOI 10.1093/jxb/47.1.111; Kalaitzis P, 1997, PLANT PHYSIOL, V113, P1303, DOI 10.1104/pp.113.4.1303; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KNOX JP, 1990, PLANTA, V181, P512, DOI 10.1007/BF00193004; Mahalingam R, 1999, MOL PLANT MICROBE IN, V12, P490, DOI 10.1094/MPMI.1999.12.6.490; Matsuoka K, 1999, J EXP BOT, V50, P165, DOI 10.1093/jexbot/50.331.165; Munoz JA, 1998, P NATL ACAD SCI USA, V95, P9687, DOI 10.1073/pnas.95.16.9687; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Petersen M, 1996, PLANT MOL BIOL, V31, P517, DOI 10.1007/BF00042225; PRESSEY R, 1988, PLANT SCI, V59, P57; Rose JKC, 1998, PLANT PHYSIOL, V117, P345, DOI 10.1104/pp.117.2.345; SEXTON R, 1982, ANNU REV PLANT PHYS, V33, P133, DOI 10.1146/annurev.pp.33.060182.001025; SHEEHY RE, 1987, MOL GEN GENET, V208, P30, DOI 10.1007/BF00330418; Sitrit Y, 1999, PLANT PHYSIOL, V121, P419, DOI 10.1104/pp.121.2.419; SORENSEN P, 1993, BIOCHEMISTRY-US, V32, P12160; SPIERS J, 1989, Journal of Plant Physiology, V135, P576; Torki M, 2000, GENE, V242, P427, DOI 10.1016/S0378-1119(99)00497-7; TRUELSEN TA, 1991, J PLANT PHYSIOL, V139, P129, DOI 10.1016/S0176-1617(11)80596-1; TUCKER GA, 1982, PLANTA, V155, P64, DOI 10.1007/BF00402933; Vitale A, 1999, TRENDS PLANT SCI, V4, P149, DOI 10.1016/S1360-1385(99)01389-8; WATSON CF, 1994, PLANT CELL, V6, P1623, DOI 10.1105/tpc.6.11.1623; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; Whitelaw CA, 1999, J EXP BOT, V50, P335, DOI 10.1093/jexbot/50.332.335; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330	41	33	37	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35297	35304		10.1074/jbc.M102136200	http://dx.doi.org/10.1074/jbc.M102136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466308	hybrid			2022-12-25	WOS:000171109300014
J	Raymond, K; Bergeret, E; Dagher, MC; Breton, R; Griffin-Shea, R; Fauvarque, MO				Raymond, K; Bergeret, E; Dagher, MC; Breton, R; Griffin-Shea, R; Fauvarque, MO			The Rac GTPase-activating protein RotundRacGAP interferes with Drac1 and Dcdc42 signalling in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL KINASE; CELL SHEET MOVEMENT; DORSAL CLOSURE; SIGNALING PATHWAY; RHO-GTPASE; DISTINCT ROLES; GENE-EXPRESSION; MORPHOGENESIS; JNK; JUN	RhoGTPases are negatively regulated by GTPase-activating proteins (GAPs). Here we demonstrate that Drosophila RotundRacGAP is active in vitro on Drac1 and Dcdc42 but not Drho1. Similarly, in yeast, RotundRacGAP interacts specifically with Drac1 and Dcdc42, as well as with their activated V12 forms, showing a particularly strong interaction with Dcdc42V12. In the fly, lowering RotundRacGAP dosage specifically modifies eye defects induced by expressing Drac1 or Dcdc42 but not Drho1, confirming that Drac1 and Dcdc42 are indeed in vivo targets of RotundRacGAP. Furthermore, embryonic-directed expression of either RotundRacGAP, or dominant negative Drac1N17, transgenes induces similar defects in dorsal closure and inhibits Drac1-dependent cytoskeleton assembly at the leading edge. Expression of truncated forms of RotundRacGAP shows that the GAP domain of RotundRacGAP is essential for its function. Unexpectedly, transgenes encoding Drac1N17, Dcdc42N17, or RotundRacGAP do not affect the c-Jun N-terminal kinase-dependent gene expression of decapentaplegic and puckered, indicating that another Drac1-independent signal redundantly activates this pathway. Finally, in a situation where Drac1 is constitutively activated, RotundRacGAP greatly reduces the ectopic expression of decapentaplegic, possibly by negatively regulating Dcdc42.	Univ Grenoble 1, CNRS, CEA, Dept Biol Mol & Struct,UMR 5092, F-38054 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct,UMR 5075, F-38054 Grenoble, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Fauvarque, MO (corresponding author), Univ Grenoble 1, CNRS, CEA, Dept Biol Mol & Struct,UMR 5092, 17 Rue Martyrs, F-38054 Grenoble, France.	mofauvarque@cea.fr	Raymond, Karine/E-2693-2017	Raymond, Karine/0000-0001-5892-8117; Fauvarque, Marie-Odile/0000-0001-5020-3701; DAGHER, Marie-Claire/0000-0001-6878-3169				Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; AGNEL M, 1989, GENE DEV, V3, P85, DOI 10.1101/gad.3.1.85; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Bergeret E, 2001, MOL CELL BIOL, V21, P6280, DOI 10.1128/MCB.21.18.6280-6291.2001; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Byars CL, 1999, DEVELOPMENT, V126, P4913; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CAVENER DR, 1986, GENETICS, V114, P111; Chang HY, 2000, SCIENCE, V290, P1978, DOI 10.1126/science.290.5498.1978; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Deloulme JC, 2000, J BIOL CHEM, V275, P35302, DOI 10.1074/jbc.M003943200; Fanto M, 2000, CURR BIOL, V10, P979, DOI 10.1016/S0960-9822(00)00645-X; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Guichard A, 1997, MECH DEVELOP, V61, P49, DOI 10.1016/S0925-4773(96)00619-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harden N, 1996, MOL CELL BIOL, V16, P1896; Harden N, 1999, J CELL SCI, V112, P273; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hoemann CD, 1996, GENE, V168, P135, DOI 10.1016/0378-1119(95)00747-4; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Hudson JB, 1998, DEVELOPMENT, V125, P1407; INGHAM PW, 1986, NATURE, V324, P592, DOI 10.1038/324592a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Kozma R, 1996, MOL CELL BIOL, V16, P5069; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Magie CR, 1999, DEVELOPMENT, V126, P5353; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Pazman C, 2000, DEVELOPMENT, V127, P1715; Ricos MG, 1999, J CELL SCI, V112, P1225; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; RING JM, 1993, DEVELOPMENT, P251; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sagnier T, 2000, MECH DEVELOP, V94, P267, DOI 10.1016/S0925-4773(00)00291-4; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Simin K, 1998, GENETICS, V148, P801; Sluss HK, 1997, J CELL BIOCHEM, V67, P1; Sotillos S, 2000, DEVELOPMENT, V127, P5427; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Takahashi K, 1998, MECH DEVELOP, V78, P97, DOI 10.1016/S0925-4773(98)00151-8; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Toure A, 1998, J BIOL CHEM, V273, P6019, DOI 10.1074/jbc.273.11.6019; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zeitlinger J, 1997, EMBO J, V16, P7393, DOI 10.1093/emboj/16.24.7393	71	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35909	35916		10.1074/jbc.M105779200	http://dx.doi.org/10.1074/jbc.M105779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11468292	hybrid			2022-12-25	WOS:000171109300091
J	Leimkuhler, S; Wuebbens, MM; Rajagopalan, KV				Leimkuhler, S; Wuebbens, MM; Rajagopalan, KV			Characterization of Escherichia coli MoeB and its involvement in the activation of molybdopterin synthase for the biosynthesis of the molybdenum cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL CHARACTERIZATION; THIAMIN BIOSYNTHESIS; CONVERTING FACTOR; GENE; PROTEIN; PURIFICATION; PROKARYOTES; PRECURSOR; CLONING; SYSTEM	Amino acid sequence comparisons of Escherichia coli MoeB suggested that the MoeB-dependent formation of a C-terminal thiocarboxylate on the MoaD subunit of molybdopterin synthase might resemble the ubiquitin-activating step in the ubiquitin-targeted degradation of proteins in eukaryotes. To determine the exact role of MoeB in molybdopterin biosynthesis, the protein was purified after homologous overexpression. Using purified proteins, we have demonstrated the ATP-dependent formation of a complex of MoeB and MoaD adenylate that is stable to gel filtration. Mass spectrometry of the complex revealed a peak of a molecular mass of 9,073 Da, the expected mass of MoaD adenylate. However, unlike the ubiquitin activation reaction, the formation of a thioester intermediate between MoeB and MoaD could not be observed. There was also no evidence for a MoeB-bound sulfur during the sulfuration of MoaD. Amino acid substitutions were generated in every cysteine residue in MoeB. All of these exhibited activity comparable to the wild type, with the exception of mutations in cysteine residues located in putative Zn-binding motifs. For these cysteines, loss of activity correlated with loss of metal binding.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.			Leimkuhler, Silke/0000-0003-3238-2122	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44283] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleyard MVCL, 1998, J BIOL CHEM, V273, P14869, DOI 10.1074/jbc.273.24.14869; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; BORTHAKUR D, 1990, MOL GEN GENET, V221, P227, DOI 10.1007/BF00261725; Furukawa K, 2000, J BIOL CHEM, V275, P7462, DOI 10.1074/jbc.275.11.7462; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; NOHNO T, 1988, J BACTERIOL, V170, P4097, DOI 10.1128/jb.170.9.4097-4102.1988; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493	20	108	114	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34695	34701		10.1074/jbc.M102787200	http://dx.doi.org/10.1074/jbc.M102787200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11463785	hybrid			2022-12-25	WOS:000171024600048
J	Penketh, PG; Hodnick, WF; Belcourt, MF; Shyam, K; Sherman, DH; Sartorelli, AC				Penketh, PG; Hodnick, WF; Belcourt, MF; Shyam, K; Sherman, DH; Sartorelli, AC			Inhibition of DNA cross-linking by mitomycin C by peroxidase-mediated oxidation of mitomycin C hydroquinone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; ASSAY; RESISTANCE; REDUCTASE; ADJUNCT	Mitomycin C requires reductive activation to crosslink DNA and express anticancer activity. Reduction of mitomycin C (40 muM) by sodium borohydride (200 muM) in 20 nM Tris-HCl, 1 mM EDTA at 37 degreesC, pH 7.4, gives a 50-60% yield of the reactive intermediate mitomycin C hydroquinone. The hydroquinone decays with first order kinetics or pseudo first order kinetics with a t(1/2) of similar to 15 s under these conditions. The cross-linking of T7 DNA in this system followed matching kinetics, with the conversion of mitomycin C hydroquinone to leuco-aziri-dinomitosene appearing to be the rate-determining step. Several peroxidases were found to oxidize mitomycin C hydroquinone to mitomycin C and to block DNA cross-linking to various degrees. Concentrations of the various peroxidases that largely blocked DNA crosslinking, regenerated 10-70% mitomycin C from the reduced material. Thus, significant quantities of products other than mitomycin C were produced by the peroxidase-mediated oxidation of mitomycin C hydroquinone or products derived therefrom. Variations in the sensitivity of cells to mitomycin C have been attributed to differing levels of activating enzymes, export pumps, and DNA repair. Mitomycin C hydroquinone-oxidizing enzymes give rise to a new mechanism by which oxic/hypoxic toxicity differentials and resistance can occur.	Yale Univ, Sch Med, Ctr Canc, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Canc, Dev Therapeut Program, New Haven, CT 06520 USA; Univ Minnesota, Dept Microbiol, St Paul, MN 55108 USA; Univ Minnesota, Biol Proc Technol Inst, St Paul, MN 55108 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	Yale University; Yale University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Sartorelli, AC (corresponding author), Yale Univ, Sch Med, Ctr Canc, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.		Shyam, Krishnamurthy/D-2774-2012		NATIONAL CANCER INSTITUTE [R01CA080845] Funding Source: NIH RePORTER; NCI NIH HHS [CA-80845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agner K., 1941, ACTA PHYSIOL SCAND, V2, P1; AUGUST PR, 1994, J BACTERIOL, V176, P4448, DOI 10.1128/jb.176.14.4448-4454.1994; Belcourt MF, 1998, J BIOL CHEM, V273, P8875, DOI 10.1074/jbc.273.15.8875; Belcourt MF, 1999, P NATL ACAD SCI USA, V96, P10489, DOI 10.1073/pnas.96.18.10489; DENEKAMP J, 1983, BIOL BASIS RADIOTHER, P139; GIAVAZZI R, 1984, CANCER CHEMOTH PHARM, V13, P145; HAFFTY BG, 1993, INT J RADIAT ONCOL, V27, P241, DOI 10.1016/0360-3016(93)90234-M; HODNICK WF, 1993, CANCER RES, V53, P4907; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Kumar GS, 1997, BIOCHEMISTRY-US, V36, P14128, DOI 10.1021/bi971394i; LOWN JW, 1976, CAN J BIOCHEM CELL B, V54, P110, DOI 10.1139/o76-018; MAEHLY AC, 1955, METHOD ENZYMOL, V2, P801, DOI 10.1016/S0076-6879(55)02307-0; MAEHLY AC, 1955, METHOD ENZYMOL, V2, P794, DOI 10.1016/S0076-6879(55)02306-9; Mian IS, 1998, MOL GENET METAB, V63, P230, DOI 10.1006/mgme.1997.2652; MOORE HW, 1981, MED RES REV, V1, P249, DOI 10.1002/med.2610010303; Penketh PG, 1997, ANAL BIOCHEM, V252, P210, DOI 10.1006/abio.1997.9996; Penketh PG, 1996, ANAL BIOCHEM, V238, P46, DOI 10.1006/abio.1996.0248; Penketh PG, 2000, BIOCHEM PHARMACOL, V59, P283, DOI 10.1016/S0006-2952(99)00328-7; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; POLIS BD, 1955, METHOD ENZYMOL, V2, P813; Ren J, 2001, MOL GENET METAB, V72, P54, DOI 10.1006/mgme.2000.3109; Roberts KB, 2000, INT J CANCER, V90, P206, DOI 10.1002/1097-0215(20000820)90:4<206::AID-IJC4>3.0.CO;2-O; SARTORELLI AC, 1994, ONCOL RES, V6, P501; SCHULTZ J, 1958, ANN NY ACAD SCI, V75, P22, DOI 10.1111/j.1749-6632.1958.tb36847.x; SYZBALSKI W, 1964, FED PROC, V23, P946; TOMASZ M, 1995, CHEM BIOL, V2, P575, DOI 10.1016/1074-5521(95)90120-5	26	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34445	34452		10.1074/jbc.M104263200	http://dx.doi.org/10.1074/jbc.M104263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457837	hybrid			2022-12-25	WOS:000171024600014
J	Shen, CH; Clark, DJ				Shen, CH; Clark, DJ			DNA sequence plays a major role in determining nucleosome positions in yeast CUP1 chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-TRANSCRIPTION; MOUSE SATELLITE DNA; BETA-GLOBIN GENE; HISTONE OCTAMER; IN-VITRO; BINDING PROTEIN; TRANSCRIBING POLYMERASE; REMODELING COMPLEX; SWI/SNF COMPLEX; CORE PARTICLE	The role of DNA sequence in determining nucleosome positions in vivo was investigated by comparing the positions adopted by nucleosomes reconstituted on a yeast plasmid in vitro using purified core histones with those in native chromatin containing the same DNA, described previously. Nucleosomes were reconstituted on a 2.5 kilobase pair DNA sequence containing the yeast TRP1ARS1 plasmid with CUP1 as an insert (TAC-DNA). Multiple, alternative, overlapping nucleosome positions were mapped on TAC-DNA. For the 58 positioned nucleosomes identified, the relative positioning strengths and the stabilities to salt and temperature were determined. These positions were, with a few exceptions, identical to those observed in native, remodeled TAC chromatin containing an activated CUP1 gene. Only some of these positions are utilized in native, unremodeled chromatin. These observations suggest that DNA sequence is likely to play a very important role in positioning nucleosomes in vivo. We suggest that events occurring in yeast CUP1 chromatin determine which positions are occupied in vivo and when they are occupied.	NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clark, DJ (corresponding author), NIDDK, Cellular & Dev Biol Lab, NIH, Bldg 50,Rm 3148, Bethesda, MD 20892 USA.	djclark@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015700] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Belikov S, 2000, EMBO J, V19, P1023, DOI 10.1093/emboj/19.5.1023; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; BUCKLE R, 1991, NUCLEIC ACIDS RES, V19, P1219, DOI 10.1093/nar/19.6.1219; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; BUTTINELLI M, 1993, P NATL ACAD SCI USA, V90, P9315, DOI 10.1073/pnas.90.20.9315; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; CULOTTA VC, 1989, P NATL ACAD SCI USA, V86, P8377, DOI 10.1073/pnas.86.21.8377; DAVEY C, 1995, P NATL ACAD SCI USA, V92, P11210, DOI 10.1073/pnas.92.24.11210; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Leblanc BP, 2000, P NATL ACAD SCI USA, V97, P10745, DOI 10.1073/pnas.200365097; LINXWEILER W, 1985, CELL, V42, P281; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Lowary PT, 1997, P NATL ACAD SCI USA, V94, P1183, DOI 10.1073/pnas.94.4.1183; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PUHL HL, 1995, J MOL BIOL, V245, P559, DOI 10.1006/jmbi.1994.0046; RAINBOW M, 1989, BIOCHEMISTRY-US, V28, P7486, DOI 10.1021/bi00444a048; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; ROBERTS MS, 1995, BIOCHEMISTRY-US, V34, P12470, DOI 10.1021/bi00038a046; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Shen CH, 2001, MOL CELL BIOL, V21, P534, DOI 10.1128/MCB.21.2.534-547.2001; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIMPSON RT, 1986, BIOESSAYS, V4, P172, DOI 10.1002/bies.950040408; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; THOMA F, 1985, NATURE, V315, P250, DOI 10.1038/315250a0; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wolffe AP, 1999, CHROMATIN; YENIDUNYA A, 1994, J MOL BIOL, V237, P401, DOI 10.1006/jmbi.1994.1243; ZHANG XY, 1984, J MOL BIOL, V176, P105, DOI 10.1016/0022-2836(84)90384-X	56	33	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35209	35216		10.1074/jbc.M104733200	http://dx.doi.org/10.1074/jbc.M104733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11461917	hybrid			2022-12-25	WOS:000171024600112
J	Chen, JY; Streb, JW; Maltby, KM; Kitchen, CM; Miano, JM				Chen, JY; Streb, JW; Maltby, KM; Kitchen, CM; Miano, JM			Cloning of a novel retinoid-inducible serine carboxypeptidase from vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTIVE PROTEIN; BALLOON ANGIOPLASTY; INTIMAL HYPERPLASIA; IN-VIVO; EXPRESSION; DIFFERENTIATION; PROLIFERATION; RESTENOSIS; INJURY; ATHEROSCLEROSIS	Retinoids block smooth muscle cell (SMC) proliferation and attenuate neointimal formation after vascular injury, presumably through retinoid receptor-mediated changes in gene expression. To identify target genes in SMC whose encoded proteins could contribute to such favorable biological effects, we performed a subtractive screen for retinoid-inducible genes in cultured SMC. Here, we report on the cloning and initial characterization of a novel (r) under bar etinoid-(i) under bar nducible (s) under bar erine (c) under bar arboxypeptidase (RISC). Expression of RISC is low in cultured SMC but progressively increases over a 5-day time-course treatment with all-trans-retinoic acid. A near full-length rat RISC cDNA was cloned and found to have a 452-amino acid open reading frame containing an aminoterminal signal sequence, followed by several conserved domains comprising the catalytic triad common to members of the serine carboxypeptidase family. In vitro transcription and translation experiments showed that the rat RISC cDNA generates a similar to 51-kDa protein. Confocal immunofluorescence microscopy of COS-7 cells transiently transfected with a RISC-His tag plasmid revealed cytosolic localization of the fusion protein. Western blotting studies using conditioned medium from transfected COS-7 cells suggest that RISC is a secreted protein. Tissue Northern blotting studies demonstrated robust expression of RISC in rat aorta, bladder, and kidney with much lower levels in all other tissues analyzed; high level RISC expression was also observed in human kidney. In situ hybridization verified the localization of RISC to medial SMC of the adult rat aorta. Interestingly, expression in kidney was restricted to proximal convoluted tubules; little or no expression was observed in glomerular cells, distal convoluted and collecting tubules, or medullary cells. Radiation hybrid mapping studies placed the rat RISC locus on chromosome 10q. These studies reveal a novel retinoid-inducible protease whose activity may be involved in vascular wall and kidney homeostasis.	Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Miano, JM (corresponding author), Univ Rochester, Med Ctr, Cardiovasc Res Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.		Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007949] Funding Source: NIH RePORTER; NHLBI NIH HHS [1T32HL07949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Axel DI, 2001, CARDIOVASC RES, V49, P851, DOI 10.1016/S0008-6363(00)00312-6; Benson Steve, 2000, Molecular Cell Biology Research Communications, V3, P159, DOI 10.1006/mcbr.2000.0209; CHEM J, 2001, BIOCHEM BIOPH RES CO, V281, P475; Chen JY, 1999, CHINESE MED J-PEKING, V112, P121; Chen SC, 1998, J CLIN INVEST, V102, P653, DOI 10.1172/JCI3483; Claudel T, 2001, P NATL ACAD SCI USA, V98, P2610, DOI 10.1073/pnas.041609298; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; DENG Y, 1992, J BIOCHEM-TOKYO, V112, P168, DOI 10.1093/oxfordjournals.jbchem.a123858; DeRose JJ, 1999, CARDIOVASC SURG, V7, P633, DOI 10.1016/S0967-2109(99)00041-1; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; Gollasch M, 1998, FASEB J, V12, P593, DOI 10.1096/fasebj.12.7.593; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; HANNA WL, 1994, J IMMUNOL, V153, P4663; HAYASHI A, 1995, J BIOCHEM-TOKYO, V117, P132, DOI 10.1093/oxfordjournals.jbchem.a124699; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; ITOH K, 1995, J BIOL CHEM, V270, P515, DOI 10.1074/jbc.270.2.515; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JAMES TW, 1993, J CELL PHYSIOL, V157, P426, DOI 10.1002/jcp.1041570227; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Lee CW, 2000, J KOREAN MED SCI, V15, P31, DOI 10.3346/jkms.2000.15.1.31; Leville CD, 2000, J SURG RES, V90, P183, DOI 10.1006/jsre.2000.5887; LIBBY P, 1992, CIRCULATION, V86, P47; Mangelsdorf David J., 1994, P319; Mentlein R, 1996, PEPTIDES, V17, P709, DOI 10.1016/0196-9781(96)00066-6; Miano JM, 2000, CIRC RES, V87, P355; Miano JM, 1996, CIRCULATION, V93, P1886, DOI 10.1161/01.CIR.93.10.1886; Miano JM, 1998, CIRCULATION, V98, P1219, DOI 10.1161/01.CIR.98.12.1219; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; NAU H, 2000, HDB EXPT PHARM, V139; Neuville P, 1999, ARTERIOSCL THROM VAS, V19, P1430, DOI 10.1161/01.ATV.19.6.1430; Neuville P, 2000, ARTERIOSCL THROM VAS, V20, P1882, DOI 10.1161/01.ATV.20.8.1882; Ou HS, 2000, CIRC RES, V87, P881, DOI 10.1161/01.RES.87.10.881; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pakala R, 2000, J CARDIOVASC PHARM, V35, P302, DOI 10.1097/00005344-200002000-00019; REMINGTON SJ, 1994, METHOD ENZYMOL, V244, P231; Reznik SE, 1998, J HISTOCHEM CYTOCHEM, V46, P1359, DOI 10.1177/002215549804601204; Rottier RJ, 1998, HUM MOL GENET, V7, P1787, DOI 10.1093/hmg/7.11.1787; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SPORN MB, 1976, FED PROC, V35, P1332; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; Takai S, 2001, CLIN CHIM ACTA, V305, P191, DOI 10.1016/S0009-8981(01)00379-5; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; Wiegman PJ, 2000, ARTERIOSCL THROM VAS, V20, P89, DOI 10.1161/01.ATV.20.1.89	43	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34175	34181		10.1074/jbc.M104162200	http://dx.doi.org/10.1074/jbc.M104162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11447226	hybrid			2022-12-25	WOS:000170910200118
J	Ishii, I; Friedman, B; Ye, XQ; Kawamura, S; McGiffert, C; Contos, JJA; Kingsbury, MA; Zhang, GF; Brown, JH; Chun, J				Ishii, I; Friedman, B; Ye, XQ; Kawamura, S; McGiffert, C; Contos, JJA; Kingsbury, MA; Zhang, GF; Brown, JH; Chun, J			Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LPB3/EDG-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID RECEPTORS; PHOSPHOLIPASE-C; SPHINGOSINE-1-PHOSPHATE; EDG-1; GENE; PATHWAYS; CELLS; RECOMBINATION; MOBILIZATION; TRANSDUCTION	Sphingosine 1-phosphate (S1P) exerts diverse physiological actions by activating its cognate G protein-coupled receptors. Five S1P receptors have been identified in mammals: LPB1/EDG-1, LPB2/H218/AGR16/EDG-5, LPB3/EDG-3, LPB4/NRG-1/EDG-8, and LPC1/EDG-6. One of these receptors, LPB1, has recently been shown to be essential for mouse embryonic development. Here we disrupted the lp(B3) gene in mice, resulting in the complete absence of lp(B3) gene, transcript, and LPB3 protein. LPB3-null mice were viable and fertile and developed normally with no obvious phenotypic abnormality. We prepared mouse embryonic fibroblast (MEF) cells to examine effects of LPB3 deletion on S1P-induced signal transduction pathways. Wild-type MEF cells expressed lp(B1), lp(B2), and lp(B3) but neither lp(B4) nor lp(C1), and they were highly responsive to S1P in phospholipase C (PLC) activation, adenylyl cyclase inhibition, and Rho activation. Identically prepared LPB3-null MEF cells showed significant decreases in PLC activation, slight decreases in adenylyl cyclase inhibition, and no change in Rho activation. Retrovirus-mediated rescue of the LPB3 receptor in LP(B3-)null MEF cells restored SIP-dependent PLC activation and adenylyl cyclase inhibition. These results indicate a nonessential role for LPB3, in normal development of mouse but show nonredundant cellular signaling mediated by a single type of S1P receptor.	Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Program Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Program Biomed Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Chun, J (corresponding author), Merck Res Labs, 3535 Gen Atom Ct, San Diego, CA 92121 USA.			Ishii, Isao/0000-0002-5367-205X	NIMH NIH HHS [K02MH01723] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001723] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1999, MOL PHARMACOL, V55, P787; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kimura Y, 2001, J BIOL CHEM, V276, P15208, DOI 10.1074/jbc.M011588200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Weiner JA, 1998, J COMP NEUROL, V398, P587; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Yatomi Y, 1997, J BIOCHEM, V121, P969; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	43	223	229	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33697	33704		10.1074/jbc.M104441200	http://dx.doi.org/10.1074/jbc.M104441200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443127	hybrid			2022-12-25	WOS:000170910200056
J	Iida, KT; Shimano, H; Kawakami, Y; Sone, H; Toyoshima, H; Suzuki, S; Asano, T; Okuda, Y; Yamada, N				Iida, KT; Shimano, H; Kawakami, Y; Sone, H; Toyoshima, H; Suzuki, S; Asano, T; Okuda, Y; Yamada, N			Insulin up-regulates tumor necrosis factor-alpha production in macrophages through an extracellular-regulated kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; PROTEIN-KINASE; MESSENGER-RNA; IN-VITRO; GROWTH; LIPOPOLYSACCHARIDE; ATHEROSCLEROSIS; INHIBITION; EXPRESSION; CYTOKINES	Hyperinsulinemia has recently been reported as a risk factor for atherosclerotic diseases such as coronary heart disease; however, the effect of insulin on the development of atherosclerosis is not well understood. Here we have investigated the direct effect of insulin on macrophages, which are known to be important in the atherosclerotic process. We treated THP-1 macrophages with insulin (10(-7) M) and examined the gene expression using nucleic acid array systems. The results of array analysis showed that insulin stimulated gene expression of tumor necrosis factor-alpha (TNF-alpha) the most among all genes in the analysis. In addition, insulin administration to macrophages enhanced both mRNA expression and protein secretion of TNF-alpha in a dose-dependent manner. To determine the signaling pathway involved in this TNF-alpha response to insulin, we pretreated. the cells with three distinct protein kinase inhibitors: wortmannin, PD98059, and SB203580. Only PD98059, which inhibits extracellular signal-regulated kinases, suppressed insulin-induced production of TNF-alpha mRNA and protein in THP-1 macrophages. These observations indicate that insulin stimulates TNF-alpha production in macrophages by regulating the expression of TNF-alpha mRNA and that the extracellular signal-regulated kinase signaling pathway may have a critical role in stimulating the production of TNF-alpha in response to insulin in macrophages.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Endocrinol & Metab, Tsukuba, Ibaraki 305, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 113, Japan	University of Tsukuba; University of Tokyo	Yamada, N (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Endocrinol & Metab, 1-1-1 tennodai, Tsukuba, Ibaraki 305, Japan.	ymdnbhr@md.tsukuba.ac.jp	Sone, Hirohito/ABC-9346-2021; Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Sone, Hirohito/0000-0003-1263-2817; Shimano, Hitoshi/0000-0002-5562-5572; 				[Anonymous], 1989, DIABETES CARE, V12, P573; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; BONTA IL, 1993, J LEUKOCYTE BIOL, V54, P613, DOI 10.1002/jlb.54.6.613; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GIFFORD GE, 1986, INT J CANCER, V38, P135, DOI 10.1002/ijc.2910380121; Haeffner A, 1997, J IMMUNOL, V158, P1310; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; Hansson GK, 1997, CURR OPIN LIPIDOL, V8, P301, DOI 10.1097/00041433-199710000-00009; HIGASHIMOTO Y, 1995, RESPIRATION, V62, P89, DOI 10.1159/000196398; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; Libby P, 1995, J CARDIOVASC PHARM, V25, pS9, DOI 10.1097/00005344-199500252-00003; LOWE WL, 1986, BIOCHEM BIOPH RES CO, V134, P532, DOI 10.1016/S0006-291X(86)80453-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Means TK, 2000, J LEUKOCYTE BIOL, V67, P885, DOI 10.1002/jlb.67.6.885; Miller L, 1998, J IMMUNOL, V160, P5098; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PFEIFLE B, 1981, DIABETOLOGIA, V20, P155, DOI 10.1007/BF00262020; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; Rayment NB, 1996, CARDIOVASC RES, V32, P1123, DOI 10.1016/S0008-6363(96)00145-9; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REMICK DG, 1988, LAB INVEST, V59, P809; Renier G, 1996, ENDOCRINOLOGY, V137, P4611, DOI 10.1210/en.137.11.4611; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKURAI A, 1985, CANCER IMMUNOL IMMUN, V20, P6; SATO Y, 1989, DIABETES, V38, P91, DOI 10.2337/diabetes.38.1.91; SCHWARTZ CJ, 1985, ANN NY ACAD SCI, V454, P115, DOI 10.1111/j.1749-6632.1985.tb11849.x; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Spiecker M, 1997, J BIOL CHEM, V272, P30969, DOI 10.1074/jbc.272.49.30969; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBERG D, 1990, ANN NY ACAD SCI, V598, P125, DOI 10.1111/j.1749-6632.1990.tb42284.x; STOUT RW, 1975, CIRC RES, V36, P319, DOI 10.1161/01.RES.36.2.319; STOUT RW, 1970, BRIT MED J, V3, P685, DOI 10.1136/bmj.3.5724.685; Taherzadeh S, 1999, AM J PHYSIOL-REG I, V276, pR1289, DOI 10.1152/ajpregu.1999.276.5.R1289; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	42	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32531	32537		10.1074/jbc.M009894200	http://dx.doi.org/10.1074/jbc.M009894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11443108	hybrid			2022-12-25	WOS:000170746000022
J	Langa, F; Lafon, I; Vandormael-Pournin, S; Vidaud, M; Babinet, C; Morello, D				Langa, F; Lafon, I; Vandormael-Pournin, S; Vidaud, M; Babinet, C; Morello, D			Healthy mice with an altered c-myc gene: role of the 3 ' untranslated region revisited	ONCOGENE			English	Article						ARE; Cre/loxP; ES cells; mRNA stability; neomycin; targeted mutagenesis	MESSENGER-RNA STABILITY; MOUSE-LIVER REGENERATION; AU-RICH ELEMENTS; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; PROTEIN-SYNTHESIS; BINDING PROTEIN; TRANSGENIC MICE; HALF-LIFE; DEGRADATION	c-Myc is a protooncogene involved in the control of cellular proliferation, differentiation and apoptosis, Like many other early response genes, regulation of c-myc expression is mainly controlled at the level of mRNA stability. Multiple cls-acting destabilizing elements have been described that are located both in the protein-coding region and in the 3 ' untranslated region (3 ' UTR), However, it is not known when they function during development and whether they act as partly redundant or independent elements to regulate c-myc mRNA level of expression, To begin to address these questions, we created a series of c-myc alleles modified in the 3 ' UTR, using homologous recombination and the Cre/loxP system, and analysed the consequences of these modifications in ES cells and transgenic animals. We found that deletion of the complete 3 ' UTR, including runs of Us and AU-rich elements proposed, on the basis of cell-culture assays, to be involved in the control of c-myc mRNA stability, did not alter the steady-state level of c-myc mRNA in any of the various situations analysed in vivo. Moreover, mice homozygous for the 3 ' UTR-deleted gene were perfectly healthy and fertile, Our results therefore strongly suggest that the 3 ' UTR of c-myc mRNA does not play a major role in the developmental control of c-myc expression.	Univ Toulouse 3, UMR5547, CNRS, Ctr Dev Biol, F-31062 Toulouse 04, France; Inst Pasteur, URA 1960, CNRS, Dev Biol Unit, F-75724 Paris, France; Univ Paris 05, Fac Sci Pharmaceut & Biol, Genet Mol Lab, UPRESS JE 2195, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Morello, D (corresponding author), Univ Toulouse 3, UMR5547, CNRS, Ctr Dev Biol, Batiment 4R3,118 Route Narbonne, F-31062 Toulouse 04, France.		Vidaud, Michel/O-7346-2017					AGHIB DF, 1990, ONCOGENE, V5, P707; ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P901; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Bieche I, 2000, CLIN CANCER RES, V6, P452; BONNIEU A, 1990, ONCOGENE, V5, P1585; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; COLE MD, 1990, ENZYME, V44, P167, DOI 10.1159/000468755; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GIBSON CW, 1986, MOL CELL BIOCHEM, V71, P61; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kress C, 1998, MAMM GENOME, V9, P998, DOI 10.1007/s003359900914; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LAIRDOFFRINGA IA, 1989, NUCLEIC ACIDS RES, V17, P6499, DOI 10.1093/nar/17.16.6499; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORELLO D, 1990, ONCOGENE, V5, P1511; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAUER B, 1990, New Biologist, V2, P441; SOBCZAK J, 1989, ONCOGENE, V4, P1503; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	45	16	17	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4344	4353		10.1038/sj.onc.1204482	http://dx.doi.org/10.1038/sj.onc.1204482			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466615				2022-12-25	WOS:000169912600008
J	Scherl-Mostageer, M; Sommergruber, W; Abseher, R; Hauptmann, R; Ambros, P; Schweifer, N				Scherl-Mostageer, M; Sommergruber, W; Abseher, R; Hauptmann, R; Ambros, P; Schweifer, N			Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer	ONCOGENE			English	Article						representational difference analysis; cDNA chip technology; laser microdissection; CUB domain; CDCP1	REPRESENTATIONAL DIFFERENCE ANALYSIS; HUMAN-CHROMOSOMES; SERIAL ANALYSIS; MESSENGER-RNA; CUB DOMAIN; EXPRESSION; HYBRIDIZATION; REARRANGEMENTS; SEQUENCES; GENOME	We report the identification of a novel human tumor associated gene, CDCP1 (Cub Domain Containing Protein), which was identified using representational difference analysis and cDNA chip technology. The gene consists of eight exons, the upstream region of which neither contains a TATA- nor a CCAAT-box, However, a CpG island is located around the transcription start, which is found in approximately 60% of known genes. The CDCP1 gene was mapped to chromosome 3p21-p23 by fluorescence in situ hybridization, For expression profiling real time quantitative RT - PCR was performed using cell lines and laser capture microdissected colon cancer biopsies. CDCP1 mRNA is approximately 6 kb and highly overexpressed in human colon cancer and lung cancer, CDCP1 represents a putative transmembrane protein, containing three CUB domains in the extracellular part most likely involved in cell adhesion or interacting with the extracellular matrix.	Boehringer Ingelheim KG, Dept Exploratory Res, Res & Dev, A-1121 Vienna, Austria; St Anna Childrens Hosp, CCRI, A-1080 Vienna, Austria	Boehringer Ingelheim; Saint Anna Children's Hospital	Schweifer, N (corresponding author), Boehringer Ingelheim KG, Dept Exploratory Res, Res & Dev, A-1121 Vienna, Austria.	norbert.schweifer@vie.boehringer-ingelheim.com	Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211				ABE K, 1992, MAMM GENOME, V2, P252, DOI 10.1007/BF00355435; Afshari CA, 1999, CANCER RES, V59, P4759; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Bornstein SR, 1998, MED KLIN, V93, P739, DOI 10.1007/BF03044814; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Cross SH, 2000, MAMM GENOME, V11, P373, DOI 10.1007/s003350010071; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; Gerstein M, 2000, CURR OPIN STRUC BIOL, V10, P574, DOI 10.1016/S0959-440X(00)00134-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Ishii M, 2000, GENOMICS, V68, P136, DOI 10.1006/geno.2000.6284; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Knight SJL, 1997, EUR J HUM GENET, V5, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kurian KM, 1999, J PATHOL, V187, P267; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parle-McDermott A, 2000, BRIT J CANCER, V83, P725, DOI 10.1054/bjoc.2000.1330; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stollberg J, 2000, GENOME RES, V10, P1241, DOI 10.1101/gr.10.8.1241; To KY, 2000, COMB CHEM HIGH T SCR, V3, P235; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	42	109	119	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4402	4408		10.1038/sj.onc.1204566	http://dx.doi.org/10.1038/sj.onc.1204566			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466621				2022-12-25	WOS:000169912600014
J	O'Neil, J; Billa, M; Oikemus, S; Kelliher, M				O'Neil, J; Billa, M; Oikemus, S; Kelliher, M			The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice	ONCOGENE			English	Article						Tal-1; E2A; leukemia	LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE II-ALPHA; IN-VIVO; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; ENHANCER-BINDING; TRANSGENIC MICE; ID PROTEINS	Activation of the basic helix-loop-helix (bHLH) gene TAL-1 (or SCL) is the most frequent gain-of-function mutation in pediatric T cell acute lymphoblastic leukemia (T-ALL), Similarly, mis-expression of tal-1 in the thymus of transgenic mice results in the development of clonal T cell lymphoblastic leukemia. To determine the mechanism(s) of tal-1-induced leukemogenesis, we created transgenic mice expressing a DNA binding mutant of tal-1, Surprisingly, these mice develop disease, demonstrating that the DNA binding properties of tal-1 are not required to induce leukemia/lymphoma in mice. However, wild type tal-1 and the DNA binding mutant both form stable complexes with E2A proteins. In addition, tal-1 stimulates differentiation of CDS-single positive thymocytes but inhibits the development of CD4-single positive cells: effects also observed in E2A-deficient mice. Our study suggests that the bHLH protein tal-1 contributes to leukemia by interfering with E2A protein function(s).	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Kelliher, M (corresponding author), BioTech, 373 Plantat St, Worcester, MA 01605 USA.				NATIONAL CANCER INSTITUTE [R01CA096899] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Anderson KP, 1998, J BIOL CHEM, V273, P14347, DOI 10.1074/jbc.273.23.14347; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Begley CG, 1999, BLOOD, V93, P2760; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; Condorelli GL, 1996, CANCER RES, V56, P5113; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DOYLE K, 1994, J BIOL CHEM, V269, P12099; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Littlewood TD., 1998, HELIX LOOP HELIX TRA; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; Vyas P, 1999, DEVELOPMENT, V126, P2799; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	47	49	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3897	3905		10.1038/sj.onc.1204519	http://dx.doi.org/10.1038/sj.onc.1204519			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439353				2022-12-25	WOS:000169494700015
J	Yang, HY; Shao, RP; Hung, MC; Lee, MH				Yang, HY; Shao, RP; Hung, MC; Lee, MH			p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis	ONCOGENE			English	Article						HER2/neu; tetracycline-regulated gene expression; tumor suppression; CDK; p27	DEPENDENT KINASE INHIBITOR; HUMAN-BREAST-CANCER; TUMOR SUPPRESSION; INDUCED APOPTOSIS; GENE-EXPRESSION; NEU ONCOGENE; HER-2/NEU; P27(KIP1); ANTIBODY; TRANSFORMATION	HER2/neu, a receptor tyrosine kinase oncogene, promotes mitogenic growth and transformation of cancer cells. We previously identified that its oncogenic signals down-regulate the cyclin-dependent kinase inhibitor p27 Kip1, which is defined as a haplo-insufficient tumor suppressor. Here, we applied the human p27 gene as a novel anticancer agent for HER2/neu-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system, Overexpression of p27 inhibits HER2/neu-activated CDK2 activity, cell proliferation, and transformation. Most significantly for clinical application, p27 expression in HER2/neu-overexpressing cells can be regulated in vivo and reduce the tumor volume in a tumor model, The findings demonstrate the applicability of employing p27 in HER2/neu-associated cancer gene therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Lee, Mong-Hong/0000-0001-8675-8215	NCI NIH HHS [R01 CA089266, P30 CA016672, R56 CA089266] Funding Source: Medline; NCRR NIH HHS [UL1 RR024148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089266, R56CA089266, P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Baselga J, 1998, CANCER RES, V58, P2825; Clurman BE, 1998, P NATL ACAD SCI USA, V95, P15158, DOI 10.1073/pnas.95.26.15158; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Le XF, 2000, CANCER RES, V60, P3522; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Newman L, 2001, MOL CARCINOGEN, V30, P169, DOI 10.1002/mc.1025; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REARDON DB, 1993, J BIOL CHEM, V268, P18136; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wen Y, 2000, CANCER RES, V60, P42; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	20	46	54	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3695	3702		10.1038/sj.onc.1204472	http://dx.doi.org/10.1038/sj.onc.1204472			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439332				2022-12-25	WOS:000169400200010
J	Haan, C; Is'harc, H; Hermanns, HM; Schmitz-Van de Leur, H; Kerr, IM; Heinrich, PC; Grotzinger, J; Behrmann, I				Haan, C; Is'harc, H; Hermanns, HM; Schmitz-Van de Leur, H; Kerr, IM; Heinrich, PC; Grotzinger, J; Behrmann, I			Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; GROWTH-HORMONE; PROTEIN-KINASE; FERM DOMAIN; BINDING; INTERFERON; INTERLEUKIN-6; ACTIVATION; EXPRESSION; CHAIN	Janus kinase 1 (Jak1) is a cytoplasmic tyrosine kinase that noncovalently associates with a variety of cytokine receptors. Here we show that the in vitro translated N-terminal domains of Jak1 are sufficient for binding to a biotinylated peptide comprising the membrane-proximal 73 amino acids of gp130, the signal-transducing receptor chain of interleukin-6-type cytokines. By the fold recognition approach amino acid residues 36-112 of Jah1 were predicted to adopt a beta -grasp fold, and a structural model was built using ubiquitin as a template. Substitution of Tyr(107) to alanine, a residue conserved Among Jaks and involved in hydrophobic core interactions of the proposed beta -grasp domain, abrogated binding of full-length Jak1 to gp130 in COS-7 transfectants. By further mutagenesis we identified the loop 4 region of the Jak1 beta -grasp domain as essential for gp130 association and gp130-mediated signal transduction. In Jak1-deficient U4C cells reconstituted with the loop 4 Jak1 mutants L80A/Y81A and Delta (Tyr(81)-Ser(84)), the interferon-gamma, interferon-a, and interleukin-6 responses were similarly impaired. Thus, loop 4 of the beta -grasp domain plays a role in the association of Jak1 with both class I and II cytokine receptors. Taken together the structural model and the mutagenesis data provide further insight into the interaction of Janus kinases with cytokine receptors.	Rhein Westfal TH Aachen, Dept Biochem, D-52074 Aachen, Germany; Imperial Canc Res Fund, London WC2A 3PX, England	RWTH Aachen University; Cancer Research UK	Behrmann, I (corresponding author), Rhein Westfal TH Aachen, Dept Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	behrmann@rwth-aachen.de		Behrmann, Iris/0000-0003-3688-3645				Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domingues FS, 1999, PROTEINS, P112; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2000, BIOCHEM J, V349, P261, DOI 10.1042/0264-6021:3490261; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 1999, J IMMUNOL, V163, P6651; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Yan H, 1998, J BIOL CHEM, V273, P4046, DOI 10.1074/jbc.273.7.4046; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	39	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37451	37458		10.1074/jbc.M106135200	http://dx.doi.org/10.1074/jbc.M106135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11468294	hybrid			2022-12-25	WOS:000171375700079
J	Fu, J; Kirk, KL				Fu, J; Kirk, KL			Cysteine substitutions reveal dual functions of the amino-terminal tail in cystic fibrosis transmembrane conductance regulator channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; MEMBRANE-SPANNING SEGMENT; CYTOPLASMIC LOOP; LINING RESIDUES; DOMAIN; PHOSPHORYLATION; IDENTIFICATION; HYDROLYSIS; PERMEATION; MUTATIONS	Previously, we observed that the cystic fibrosis transmembrane conductance regulator (CFTR) channel openings are destabilized by replacing several acidic residues in the amino-terminal tail with alanines (Naren, A. P., Cormet-Boyaka, E., Fu, J., Villain, M., Blalock, J. E., Quick, M. W., and Kirk, K. L. (1999) Science 286, 544-548). Here we determined whether this effect is due to the loss of negative charge at these sites and whether the amino-terminal tail also modulates other aspects of channel gating. We introduced cysteines at two of these positions (E54C/D58C) and tested a series of methanethiosulfonate (NITS) reagents for their effects on the gating properties of these cysteine mutants in intact Xenopus oocytes and excised membrane patches. Covalent modification of these sites with either neutral (MMTS) or charged (2-carboxyethylmethanethiosulfonate (MTSCE) and 2-(trimethylammonium)ethylmethanethiosulfonate (MTSET)) reagents markedly inhibited channel open probability primarily by reducing the rate of channel opening. The MTS reagents had negligible effects on the gating of the wild type channel or a corresponding double alanine mutant (E54A/D58A) under the same conditions. The inhibition of the opening rate of the E54C/D58C mutant channel by MMTS could be reversed by the reducing agent dithiothreitol (200 muM) or by elevating the bath ATP concentration above that required to activate maximally the wild type channel (>1 mM). Interestingly, the three MTS reagents had qualitatively different effects on the duration of channel openings (i.e. channel closing rate), namely the duration of openings was negligibly changed by the neutral MMTS, decreased by the positively charged MTSET, and increased by the negatively charged MTSCE. Our results indicate that the CFTR amino tail modulates both the rates of channel opening and channel closing and that the negative charges at residues 54 and 58 are important for controlling the duration of channel openings.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kirk, KL (corresponding author), Univ Alabama, Dept Physiol & Biophys, 982B MCLM,1918 Univ Blvd, Birmingham, AL 35294 USA.				NIDDK NIH HHS [DK53090, DK56796] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK053090, R56DK056796, R01DK056796] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akabas MH, 1998, BIOCHEMISTRY-US, V37, P12233, DOI 10.1021/bi980969o; Chan KM, 2000, J GEN PHYSIOL, V116, P163, DOI 10.1085/jgp.116.2.163; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; FU J, 2001, IN PRESS J PHYSL LON; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Harrington MA, 1999, J BIOL CHEM, V274, P27536, DOI 10.1074/jbc.274.39.27536; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Lu NT, 2000, ARCH BIOCHEM BIOPHYS, V375, P7, DOI 10.1006/abbi.1999.1656; Mathews CJ, 1998, J PHYSIOL-LONDON, V508, P365, DOI 10.1111/j.1469-7793.1998.365bq.x; McCarty NA, 2000, J EXP BIOL, V203, P1947; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Neville DCA, 1998, BIOCHEMISTRY-US, V37, P2401, DOI 10.1021/bi972021k; Pascual JM, 1997, AM J PHYSIOL-CELL PH, V273, pC1849, DOI 10.1152/ajpcell.1997.273.6.C1849; Quinton Paul M., 1999, Physiological Reviews, V79, pS3; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; RIORDAN JR, 1989, SCIENCE, V245, P1066; Seibert FS, 1996, J BIOL CHEM, V271, P27493, DOI 10.1074/jbc.271.44.27493; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; Tabcharani JA, 1997, J GEN PHYSIOL, V110, P341, DOI 10.1085/jgp.110.4.341; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	25	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35660	35668		10.1074/jbc.M105079200	http://dx.doi.org/10.1074/jbc.M105079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11468285	hybrid			2022-12-25	WOS:000171109300061
J	Schwartzbauer, G; Robbins, J				Schwartzbauer, G; Robbins, J			The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL-3-OH KINASE; 3-KINASE/AKT PATHWAY; PHOSPHATASE-ACTIVITY; GERMLINE MUTATIONS; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; HEART-FAILURE; CELL-SURVIVAL; UP-REGULATION	Cardiac hypertrophy is a complex process involving the coordinated actions of many genes. In a high throughput screen designed to identify transcripts that are actively translated during cardiac hypertrophy, we identified a number of genes with established links to hypertrophy, including those coding for Sp3, e-Jun, annexin II, cathepsin B, and HB-EGF, thus showing the general utility of the screen. Focusing on a candidate transcript that has not been previously linked to hypertrophy, we found that protein levels of the tumor suppressor PTEN (phosphatase and tensin homologue on chromosome ten) were increased in the absence of increased messenger RNA levels. Increased PTEN expression by recombinant adenovirus in cultured neonatal rat primary cardiomyocytes caused cardiomyocyte apoptosis as evidenced by increased caspase-3 activity and cleaved poly(A)DP-ribose polymerase. Expression of PTEN was also able to block growth factor signaling through the phosphatidylinositol 3,4,5-triphosphate pathway. Surprisingly, expression of a catalytically inactive PTEN mutant led to cardiomyocyte hypertrophy, with increased protein synthesis, cell surface area, and atrial natriuretic factor expression. This hypertrophy was accompanied by an increase in Akt activity and improved cell viability in culture.	Childrens Hosp Res Fdn, Dept Pediat, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Robbins, J (corresponding author), Childrens Hosp Res Fdn, Dept Pediat, Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.robbins@chmcc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010350, R01HL060546, R01HL056370, P01HL041496, P50HL052318, R01HL056620] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32HL10350, HL41496, HL60546, HL56620, HL56370, HL52318] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BISHOP SP, 1970, AM J PHYSIOL, V218, P153, DOI 10.1152/ajplegacy.1970.218.1.153; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cai T, 2000, BIOCHEM BIOPH RES CO, V274, P519, DOI 10.1006/bbrc.2000.3177; CRIE JS, 1983, J MOL CELL CARDIOL, V15, P487, DOI 10.1016/0022-2828(83)90324-3; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Hlobilkova A, 2000, EXP CELL RES, V256, P571, DOI 10.1006/excr.2000.4867; Huang H, 1999, DEVELOPMENT, V126, P5365; Jastrzebska B, 2000, J HISTOCHEM CYTOCHEM, V48, P1195, DOI 10.1177/002215540004800903; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kudej RK, 1997, J MOL CELL CARDIOL, V29, P2735, DOI 10.1006/jmcc.1997.0508; Lee J, 1999, EXP MOL MED, V31, P126, DOI 10.1038/emm.1999.21; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MacLellan WR, 2000, CURR OPIN CARDIOL, V15, P128, DOI 10.1097/00001573-200005000-00002; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Moraru II, 1998, ANN NY ACAD SCI, V853, P329, DOI 10.1111/j.1749-6632.1998.tb08292.x; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; PERRELLA MA, 1994, J BIOL CHEM, V269, P27045; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; RABKIN SW, 1993, J CLIN PHARMACOL, V33, P286, DOI 10.1002/j.1552-4604.1993.tb03958.x; Raizis AM, 2000, HUM GENET, V107, P24; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Takao T, 1995, BRAIN BEHAV IMMUN, V9, P276, DOI 10.1006/brbi.1995.1027; Takemoto Y, 1999, J MOL CELL CARDIOL, V31, P2017, DOI 10.1006/jmcc.1999.1033; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	69	120	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35786	35793		10.1074/jbc.M102479200	http://dx.doi.org/10.1074/jbc.M102479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11448956	hybrid			2022-12-25	WOS:000171109300076
J	Candi, E; Oddi, S; Terrinoni, A; Paradisi, A; Ranalli, M; Finazzi-Agro, A; Melino, G				Candi, E; Oddi, S; Terrinoni, A; Paradisi, A; Ranalli, M; Finazzi-Agro, A; Melino, G			Transglutaminase 5 cross-links loricrin, involucrin, and small proline-rich proteins in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ENVELOPE PROTEINS; MOUSE EPIDERMAL-CELLS; RETINOIC ACID; TISSUE TRANSGLUTAMINASE; SUBSTRATE PROPERTIES; HUMAN KERATINOCYTES; IN-SITU; EXPRESSION; FILAMENTS; BINDING	Transglutaminases (TGases) are seven enzymes, cross-linking proteins by gamma -glutamil-epsilon -lysine bonds, four of which are expressed in the skin. A new member of the TGase family, TGase 5, has been identified recently, and in the present study we evaluated its role in keratinocyte differentiation in vitro. In addition to the previously described isoforms, full-length TGase 5 and Delta3 (deletion of exon 3), we identified two new splicing variants, Delta 11 and Delta3 Delta 11 (deletion of exons 11 or 3, 11). We expressed full-length TGase 5, Delta3, Delta 11, and Delta3 Delta 11 isoforms in the keratinocyte and baculovirus systems. The results indicate that both full-length TGase 5 and All are active, whereas Delta3 and Delta3 Delta 11 have very low activity. Expression studies show that full-length TGase 5 is induced during the early stages of keratinocyte differentiation and is differently regulated in comparison with the other epidermal TGases. Kinetic and in vitro crosslinking experiments indicate that full-length TGase 5 is very efficient in using specific epidermal substrates (loricrin, involucrin, and SPR3). In keratinocyte expression system, TGase 5 isoforms are retained in an intermediate filament-enriched fraction, suggesting its association with insoluble proteins. Indeed, TGase 5 co-localize with vimentin and it is able to cross-link vimentin in vitro.	Univ Roma Tor Vergata, IRCCS,Dept Expt Med & Biochem Sci, IDI, Biochem Lab, I-00133 Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata	Melino, G (corresponding author), Univ Roma Tor Vergata, IRCCS,Dept Expt Med & Biochem Sci, IDI, Biochem Lab, Via Tor Vergata 135, I-00133 Rome, Italy.		PARADISI, Andrea/AAN-6404-2020; Oddi, Sergio/B-6668-2009; PARADISI, Andrea/AAE-2293-2020; TERRINONI, Alessandro/J-1533-2012	PARADISI, Andrea/0000-0003-2218-3859; Oddi, Sergio/0000-0002-6217-698X; PARADISI, Andrea/0000-0003-2218-3859; TERRINONI, Alessandro/0000-0002-7442-2252	Telethon [417/BI] Funding Source: Medline	Telethon(Fondazione Telethon)		Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; BARRY ELR, 1990, J BIOL CHEM, V265, P9302; Candi E, 1998, J BIOL CHEM, V273, P13693, DOI 10.1074/jbc.273.22.13693; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; Candi E, 1999, J BIOL CHEM, V274, P7226, DOI 10.1074/jbc.274.11.7226; CHUNG SI, 1970, J BIOL CHEM, V245, P6424; Clement S, 1997, J INVEST DERMATOL, V109, P778, DOI 10.1111/1523-1747.ep12340949; Clement S, 1998, J BIOL CHEM, V273, P7604, DOI 10.1074/jbc.273.13.7604; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FRANKE WW, 1979, DIFFERENTIATION, V14, P35, DOI 10.1111/j.1432-0436.1979.tb01010.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GREENWOOD JA, 1995, EXP CELL RES, V220, P332, DOI 10.1006/excr.1995.1323; JETTEN AM, 1989, J INVEST DERMATOL, V93, P108, DOI 10.1111/1523-1747.ep12277374; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; Lajemi M, 1997, HISTOCHEM J, V29, P593, DOI 10.1023/A:1026484227851; Lee JH, 1996, J BIOL CHEM, V271, P4561; LICHTI U, 1988, CANCER RES, V48, P74; LICHTI U, 1985, J BIOL CHEM, V260, P1422; Melino G, 1998, Results Probl Cell Differ, V24, P175; Melino G, 2000, METHOD ENZYMOL, V322, P433; Nemes Z, 2000, J BIOL CHEM, V275, P2636, DOI 10.1074/jbc.275.4.2636; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; RUBIN AL, 1986, CANCER RES, V46, P2356; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; Steinert PM, 1999, CELL DEATH DIFFER, V6, P916, DOI 10.1038/sj.cdd.4400568; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TREJOSKALLI AV, 1995, P NATL ACAD SCI USA, V92, P8940, DOI 10.1073/pnas.92.19.8940; Tucholski J, 1999, J NEUROCHEM, V73, P1871; ZATLOUKAL K, 1989, LAB INVEST, V61, P603; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	38	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35014	35023		10.1074/jbc.M010157200	http://dx.doi.org/10.1074/jbc.M010157200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11443109	hybrid			2022-12-25	WOS:000171024600089
J	Dilcher, M; Kohler, B; von Mollard, GF				Dilcher, M; Kohler, B; von Mollard, GF			Genetic interactions with the yeast Q-SNARE VTI1 reveal novel functions for the R-SNARE YKT6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT PATHWAYS; SYNTAXIN HOMOLOG; PROTEIN-TRANSPORT; MEMBRANE-FUSION; SHUTTLE VECTORS; SNAP-25 HOMOLOG; T-SNARES; V-SNARES; COMPLEX	SNARE proteins are required for fusion of transport vesicles with target membranes. Previously, we found that the yeast Q-SNARE Vti1p is involved in transport to the cis-Golgi, to the prevacuole/late endosome, and to the vacuole. Here we identified a previously uncharacterized gene, VTS1, and the R-SNARE YKT6 both as multicopy and as low copy suppressors of the growth and vacuolar transport defect in uti1-2 cells. Ykt6p was known to function in retrograde traffic to the cis-Golgi and homotypic vacuolar fusion. We found that VTI1 and YKT6 also interacted in traffic to the prevacuole and vacuole, indicating that these SNARE complexes contain Ykt6p, Vti1p, plus Pep12p and Ykt6p, Vti1p, Vam3p, plus Vam7p, respectively. As Ykt6p was required for several transport steps, R-SNAREs cannot be the sole determinants of specificity. To study the role of the 0 layer in the SNARE motif, we introduced the mutations vti1-Q158R and ykt6-R165Q. SNARE complexes to which Ykt6p contributed a fourth glutamine residue in the 0 layer were nonfunctional, suggesting an essential function for arginine in the 0 layer of these complexes. vti1-Q158R cells had severe defects in several transport steps, indicating that the second arginine in the 0 layer interfered with function.	Univ Gottingen, Biochem Abt 2, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	von Mollard, GF (corresponding author), Univ Gottingen, Biochem Abt 2, Zentrum Biochem & Mol Zellbiol, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	gfische1@gwdg.de	von Mollard, Gabriele Fischer/A-3935-2012; von Mollard, Gabriele Fischer/O-9778-2019	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Dilcher, Meik/0000-0003-1737-6277				Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CARLSON GN, 1982, J PHILOS LOGIC, V11, P145, DOI 10.1007/BF00278382; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; COUVE A, 1994, J BIOL CHEM, V269, P23391; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; Gurunathan S, 2000, MOL BIOL CELL, V11, P3629, DOI 10.1091/mbc.11.10.3629; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz L, 2000, MOL BIOL CELL, V11, P3849, DOI 10.1091/mbc.11.11.3849; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Nichols BJ, 1998, EUR J CELL BIOL, V77, P263, DOI 10.1016/S0171-9335(98)80084-8; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Stone S, 1997, MOL BIOL CELL, V8, P1175, DOI 10.1091/mbc.8.7.1175; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tsui MMK, 2000, J CELL SCI, V113, P145; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Ungermann C, 2000, P NATL ACAD SCI USA, V97, P8889, DOI 10.1073/pnas.160269997; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; von Mollard GF, 1998, J BIOL CHEM, V273, P2624, DOI 10.1074/jbc.273.5.2624; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Wada Y, 1997, J CELL SCI, V110, P1299; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; WEINER MP, 1993, GENE, V126, P35, DOI 10.1016/0378-1119(93)90587-S; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	58	76	84	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34537	34544		10.1074/jbc.M101551200	http://dx.doi.org/10.1074/jbc.M101551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11445562	hybrid			2022-12-25	WOS:000171024600027
J	Pritchard, AE; McHenry, CS				Pritchard, AE; McHenry, CS			Assembly of DNA polymerase III holoenzyme - Co-assembly of gamma and tau is inhibited by DnaX complex accessory proteins but stimulated by DNA polymerase III core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; COORDINATED LEADING-STRAND; ESCHERICHIA-COLI; LAGGING-STRAND; SLIDING CLAMPS; SUBUNIT; FORK; PURIFICATION; PARTICLE; LOADER	Although the two alternative Escherichia coli dnaX gene products, tau and gamma, are found co-assembled in purified DNA polymerase III holoenzyme, the pathway of assembly is not well understood. When the 10 subunits of holoenzyme are simultaneously mixed, they rapidly form a nine-subunit assembly containing tau but not gamma. We developed a new assay based on the binding of complexes containing biotin-tagged tau to streptavidin-coated agarose beads to investigate the effects of various DNA polymerase III holoenzyme subunits on the kinetics of co-assembly of gamma and tau into the same complex. Auxiliary proteins in combination with delta' almost completely blocked co-assembly, whereas chi psi or delta' alone slowed the association only moderately compared with the interaction of tau with gamma alone. In contrast, DNA polymerase III core, in the absence of delta delta' and chi psi, accelerated the coassembly of tau and gamma, suggesting a role for DNA polymerase III' [tau (2)(pol III core)(2)] in the assembly pathway of holoenzyme.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.							Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; FAY PJ, 1981, J BIOL CHEM, V256, P976; Gao DX, 2001, J BIOL CHEM, V276, P4447, DOI 10.1074/jbc.M009827200; Gao DX, 2001, J BIOL CHEM, V276, P4441, DOI 10.1074/jbc.M009830200; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; SONG MS, 2001, J BIOL CHEM     0629; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	27	7	7	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35217	35222		10.1074/jbc.M102735200	http://dx.doi.org/10.1074/jbc.M102735200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11463784	hybrid			2022-12-25	WOS:000171024600113
J	Saidowsky, J; Dodt, G; Kirchberg, K; Wegner, A; Nastainczyk, W; Kunau, WH; Schliebs, W				Saidowsky, J; Dodt, G; Kirchberg, K; Wegner, A; Nastainczyk, W; Kunau, WH; Schliebs, W			The di-aromatic pentapeptide repeats of the human peroxisome import receptor PEX5 are separate high affinity binding sites for the peroxisomal membrane protein PEX14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SIGNAL RECEPTOR; HUMAN PTS1 RECEPTOR; DOCKING SITE; SH3 DOMAIN; IDENTIFICATION; RECOGNITION; BIOGENESIS; INTERACTS; ISOFORM; COMPLEX	PEX5 functions as a mobile import receptor for peroxisomal matrix proteins with a peroxisomal targeting signal 1 (PTS1). A critical step within the PTS1-import pathway is the interaction between PEX5 and the peroxisome membrane-associated protein PEX14. Based on two-hybrid analyses in mammalian cells and complementary in vitro binding assays, we demonstrate that the evolutionarily conserved pentapeptide repeat motifs, WX(E/D/Q/A/S)(E/D/Q)(F/Y), in PEX5 bind to PEX14 with high affinity. The results obtained indicate that each of the seven di-aromatic,pentapeptides of human PEX5 interacts separately at the same binding site in the N terminus of PEX14 with equilibrium dissociation constants in the low nanomolar range. Mutational analysis of the PEX14-binding motifs reveals that the conserved aromatic amino acids at position 1 or 5 are essential for high affinity binding. We propose that the side chains of the aromatic amino acids are in close proximity as part of an amphipathic alpha -helix and together form hydrophobic anchors for binding PEX5 to individual PEX14 molecules.	Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; Univ Saarland, D-66421 Homburg, Germany	Ruhr University Bochum; Saarland University	Schliebs, W (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany.		Kirchberg, Kristina/A-2974-2012	Schliebs, Wolfgang/0000-0003-2762-3403				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Terlecky SR, 2000, TRAFFIC, V1, P465, DOI 10.1034/j.1600-0854.2000.010604.x; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; Will GK, 1999, MOL CELL BIOL, V19, P2265	30	92	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34524	34529		10.1074/jbc.M104647200	http://dx.doi.org/10.1074/jbc.M104647200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11438541	hybrid			2022-12-25	WOS:000171024600025
J	van Rietschoten, JGI; Smits, HH; van de Wetering, D; Westland, R; Verweij, CL; den Hartog, MT; Wierenga, EA				van Rietschoten, JGI; Smits, HH; van de Wetering, D; Westland, R; Verweij, CL; den Hartog, MT; Wierenga, EA			Silencer activity of NFATc2 in the interleukin-12 receptor beta 2 proximal promoter in human T helper cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; HUMAN TH1; IFN-GAMMA; SP-FAMILY; EXPRESSION; SUBSETS; CLONES; GENE; DIFFERENTIATION; COMPONENT	Interleukin 12 (IL-12) is a potent enhancer of interferon gamma production by activated T cells. The high-affinity IL-12 receptor (IL-12R) is a heterodimer of a beta1 and a beta2 subunit. Expression of the signaling IL-12R beta2 chain is usually low, as compared with the more abundant beta1 chain, and may be rate-limiting for IL-12 sensitivity. Little is known about the mechanisms controlling IL-12R beta2 gene expression. Reporter gene assays in IL-12R beta2-expressing Jurkat cells showed that truncation of the region from -151 to -61 abrogated promoter activity. The proximal promoter region does not contain a typical TATA box, suggesting a role for SP-1. Indeed, mutagenesis of the -63 SP-1 consensus site decreased transcription by 50%. Electrophoretic mobility shift experiments confirmed the binding of SP-1 and SP-3 at this site. In contrast, truncation of -252 to -192 increased promoter activity. Likewise, mutagenesis of the consensus nuclear factor of activated T cells site at -206 increased promoter activity by 70%, suggesting silencer activity of this element. Electrophoretic mobility shift experiments with primary Th (T helper) cells showed the formation of a specific, T-cell receptor-inducible complex at this site that is sensitive to cyclosporin A and supershifted with anti-NFATc2 in both Th1 and Th2 cells. Accordingly, cyclosporin A dose-dependently increased IL-12R beta2 mRNA expression. These first data on IL-12R beta2 gene regulation indicate a TATA-less promoter, depending on SP-1/SP-3 transcription factors, and a negative regulatory NFAT element at -206. This element may contribute to the overall low level of IL-12R beta2 expression on Th cells.	Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Free Univ Med Ctr, Dept Mol Cell Biol, NL-1007 MB Amsterdam, Netherlands; Tanox Pharma BV, NL-1098 SM Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Wierenga, EA (corresponding author), Univ Amsterdam, Acad Med Ctr, Meibergdreef 15,POB 22700, NL-1105 AZ Amsterdam, Netherlands.		Smits, Hermelijn/V-4216-2018	Smits, Hermelijn/0000-0001-9279-2890				Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; CHUA AO, 1994, J IMMUNOL, V153, P128; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Hilkens CMU, 1996, J IMMUNOL, V157, P4316; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kraan TCTMV, 1996, J IMMUNOL, V156, P1818; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; MANGER B, 1986, J CLIN INVEST, V77, P1501, DOI 10.1172/JCI112464; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rogge L, 1999, J IMMUNOL, V162, P3926; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Sinigaglia F, 1999, IMMUNOL REV, V170, P65, DOI 10.1111/j.1600-065X.1999.tb01329.x; Smits HH, 2001, EUR J IMMUNOL, V31, P1055, DOI 10.1002/1521-4141(200104)31:4<1055::AID-IMMU1055>3.0.CO;2-7; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; van den Hoff M J, 1995, Methods Mol Biol, V48, P185; van Rietschoten JGI, 2000, IMMUNOGENETICS, V51, P30, DOI 10.1007/s002510050005; Vieira PL, 1998, J IMMUNOL, V161, P5245; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yamamoto K, 1997, CYTOGENET CELL GENET, V77, P257, DOI 10.1159/000134589; Yokoe T, 2001, CELL IMMUNOL, V208, P34, DOI 10.1006/cimm.2001.1759; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	33	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34509	34516		10.1074/jbc.M102536200	http://dx.doi.org/10.1074/jbc.M102536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11438525	hybrid			2022-12-25	WOS:000171024600023
J	Xu, Y; Yu, Q				Xu, Y; Yu, Q			Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; MICROVASCULAR ENDOTHELIAL-CELLS; BLOOD-VESSEL FORMATION; TUMOR ANGIOGENESIS; TIE2 RECEPTOR; OVEREXPRESSING ANGIOPOIETIN-1; GROWTH-FACTORS; IN-VIVO; APOPTOSIS; LIGAND	Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) affect angiogenesis differently during embryogenesis and tumorigenesis. In an attempt to understand the molecular basis underlying the distinct roles of those two homologous molecules, we investigated the association of Ang-1 and Ang-2 with the extracellular matrix (ECM). TA3 murine mammary carcinoma (TA3) and Lewis lung carcinoma cells expressing v5 epitope-tagged Ang-1 and Ang-2 were used in our studies. The results indicated that Ang-1 is secreted and incorporated into the ECM of the tumor cells, whereas Ang-2 is not associated with the ECM. The mutagenesis study indicated the domain that is responsible for the ECM association of Ang-1 is the linker peptide region between the coiled-coil and the fibrinogen-like domains. A weak binding between the coiled-coil domain of Ang-1 and the ECM was observed. Immunocytochemistry study revealed a distinct ECM distribution pattern of Ang-1, which is quite different from that of fibronectin, laminin, and collagen types I and IV. The ECM-associated Ang-1 proteins are released, and Tie-2 receptors are phosphorylated upon the adhesion of human umbilical vein endothelial cells. Implications of the difference in the ECM association of Ang-1 and Ang-2, which are related to the regulation of angiopoietin activity and their roles in local versus distant angiogenesis during tumor metastasis, are discussed.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E,3800 Spruce St, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [R01 HL074117] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2000, BIOCHEM BIOPH RES CO, V269, P361, DOI 10.1006/bbrc.2000.2296; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Klagsbrun M, 1992, Semin Cancer Biol, V3, P81; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; Lauren J, 1998, AM J PATHOL, V153, P1333, DOI 10.1016/S0002-9440(10)65717-3; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Ortega N, 1998, BIOL CELL, V90, P381, DOI 10.1016/S0248-4900(98)80087-7; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yu Q, 2001, AM J PATHOL, V158, P563, DOI 10.1016/S0002-9440(10)63998-3; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	45	84	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34990	34998		10.1074/jbc.M103661200	http://dx.doi.org/10.1074/jbc.M103661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11447223	hybrid			2022-12-25	WOS:000171024600086
J	Bougeret, C; Jiang, SX; Keydar, I; Avraham, H				Bougeret, C; Jiang, SX; Keydar, I; Avraham, H			Functional analysis of Csk and CHK kinases in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SRC FAMILY KINASES; HOMOLOGOUS KINASE; TRASTUZUMAB HERCEPTIN; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; LYN KINASE; C-KIT; RECEPTOR; ASSOCIATION	In this report, we analyzed the expression and kinase activities of Csk and CHK kinases in normal breast tissues and breast tumors and their involvement in HRG-mediated signaling in breast cancer cells. Csk expression and kinase activity were abundant in normal human breast tissues, breast carcinomas, and breast cancer cell lines, whereas CHK expression was negative in normal breast tissues and low in some breast tumors and in the MCF-7 breast cancer cell line. CHK kinase activity was not detected in human breast carcinoma tissues (12 of 12) or in the MCF-7 breast cancer cell line (due to the low level of CHK protein expression), but was significantly induced upon heregulin (HRG) stimulation. We have previously shown that CHK associates with the ErbB-2/neu receptor upon HRG stimulation via its SH2 domain and that it down-regulates the ErbB-2/ neu-activated Src kinases. Our new findings demonstrate that Csk has no effect on ErbB-2/neu-activated Src kinases upon HRG treatment and that its kinase activity is not modulated by HRG. CHK significantly inhibited in vitro cell growth, transformation, and invasion induced upon HRG stimulation. In addition, tumor growth of wt CHK-transfected MCF-7 cells was significantly inhibited in nude mice. Furthermore, CHK downregulated c-Src and Lyn protein expression and kinase activity, and the entry into mitosis was delayed in the wt CH-K-transfected MCF-7 cells upon HRG treatment. These results indicate that CHK, but not Csk, is involved in HRG-mediated signaling pathways, down-regulates ErbB-2/neu-activated Src kinases, and inhibits invasion and transformation of breast cancer cells upon HRG stimulation. These findings strongly suggest that CHK is a novel negative growth regulator of HRG-mediated ErbB-2/neu and Src family kinase signaling pathways in breast cancer cells.	Harvard Univ, Inst Med, Div Expt Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel	Harvard University; Beth Israel Deaconess Medical Center; Tel Aviv University	Avraham, H (corresponding author), Harvard Univ, Inst Med, Div Expt Med, Beth Israel Deaconess Med Ctr, 4 Blackfan Circle, Boston, MA 02115 USA.			Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA 76226, CA 87290] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087290, R01CA076226] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AGBOTOUNOU WK, 1994, MOL PHARMACOL, V45, P922; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; Benistant C, 2001, CANCER RES, V61, P1415; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0; Grgurevich S, 1999, BIOCHEM BIOPH RES CO, V256, P668, DOI 10.1006/bbrc.1999.0398; Grgurevich S, 1997, GROWTH FACTORS, V14, P103, DOI 10.3109/08977199709021514; Hirao A, 1998, J BIOL CHEM, V273, P10004, DOI 10.1074/jbc.273.16.10004; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; Hung MC, 1999, SEMIN ONCOL, V26, P51; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; JHUN BH, 1995, J BIOL CHEM, V270, P9661, DOI 10.1074/jbc.270.16.9661; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; LEVI ADO, 1995, J NEUROSCI, V15, P1329; Levitt ML, 1999, INVEST NEW DRUG, V17, P213, DOI 10.1023/A:1006372102543; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Liu X, 1997, J BIOL CHEM, V272, P11690, DOI 10.1074/jbc.272.18.11690; Maniatis T., 1992, MOL CLONING LAB MANU; MCVICAR DW, 1994, ONCOGENE, V9, P2037; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; MUSSO T, 1994, J EXP MED, V180, P2383, DOI 10.1084/jem.180.6.2383; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PELES E, 1992, J BIOL CHEM, V267, P12266; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; Price DJ, 1999, BIOCHEM BIOPH RES CO, V259, P611, DOI 10.1006/bbrc.1999.0840; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAKANO S, 1994, ONCOGENE, V9, P1155; Schultz Linda B., 1999, Current Opinion in Oncology, V11, P429, DOI 10.1097/00001622-199911000-00002; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Shak S, 1999, SEMIN ONCOL, V26, P71; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; XIE YM, 1995, ONCOGENE, V10, P2409; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422; Zrihan-Licht S, 1998, J BIOL CHEM, V273, P4065, DOI 10.1074/jbc.273.7.4065; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	57	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33711	33720		10.1074/jbc.M104209200	http://dx.doi.org/10.1074/jbc.M104209200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445575	hybrid			2022-12-25	WOS:000170910200058
J	Friebel, A; Ilchmann, H; Aelpfelbacher, M; Ehrbar, K; Machleidt, W; Hardt, WD				Friebel, A; Ilchmann, H; Aelpfelbacher, M; Ehrbar, K; Machleidt, W; Hardt, WD			SopE and SopE2 from Salmonella typhimurium activate different sets of RhoGTPases of the host cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ACTIN STRESS FIBERS; RHO GTPASES; EFFECTOR PROTEINS; SECRETED PROTEIN; CDC42; BINDING; INVASION; DUBLIN; RAC	The bacterial enteropathogen Salmonella typhimurium employs a specialized type III secretion system to inject toxins into host cells, which trigger signaling cascades leading to cell death in macrophages, secretion of pro-inflammatory cytokines, or rearrangements of the host cell cytoskeleton and thus to bacterial invasion. Two of the injected toxins, SopE and the 69% identical protein SopE2, are highly efficient guanine nucleotide exchange factors for the RhoGTPase Cdc42 of the host cell. However, it has been a puzzle why S. typhimurium might employ two toxins with redundant function. We hypothesized that SopE and SopE2 might have different specificities for certain host cellular RhoGTPases. In vitro guanine nucleotide exchange assays and surface plasmon resonance measurements revealed that SopE is an efficient guanine nucleotide exchange factor for Cdc42 and Rac1, whereas SopE2 was interacting efficiently only with Cdc42, but not with Rac1. Affinity precipitation of Cdc42(.)GTP and Rac1(.)GTP from lysates and characteristic cytoskeletal rearrangements of infected tissue culture cells confirmed that SopE is highly efficient at activating Cdc42 and Rac1 in vivo, whereas SopE2 was efficiently activating Cdc42, but not Rac1. We conclude that the translocated effector proteins SopE and SopE2 allow S. typhimurium to specifically activate different sets of RhoGTPase signaling cascades.	Univ Munich, Max Von Pettenkofer Inst, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst Physiol Chem Phys Biochem &, D-80336 Munich, Germany	University of Munich; University of Munich	Hardt, WD (corresponding author), Univ Munich, Max Von Pettenkofer Inst, Pettenkoferstr 9A, D-80336 Munich, Germany.	hardt@m3401.mpk.med.uni-muenchen.de		Hardt, Wolf-Dietrich/0000-0002-9892-6420				Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623; Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x; Azim AC, 2000, METHOD ENZYMOL, V325, P257; Bakshi CS, 2000, J BACTERIOL, V182, P2341, DOI 10.1128/JB.182.8.2341-2344.2000; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen LM, 1999, J EXP MED, V189, P1479, DOI 10.1084/jem.189.9.1479; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Friebel A, 2000, METHOD ENZYMOL, V325, P82; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; Galyov EE, 1997, MOL MICROBIOL, V25, P903, DOI 10.1111/j.1365-2958.1997.mmi525.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Hong KH, 1998, J BACTERIOL, V180, P1793, DOI 10.1128/JB.180.7.1793-1802.1998; Jones MA, 1998, INFECT IMMUN, V66, P5799, DOI 10.1128/IAI.66.12.5799-5804.1998; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Miao EA, 1999, MOL MICROBIOL, V34, P850, DOI 10.1046/j.1365-2958.1999.01651.x; Mirold S, 1999, P NATL ACAD SCI USA, V96, P9845, DOI 10.1073/pnas.96.17.9845; Mirold S, 2001, J BACTERIOL, V183, P2348, DOI 10.1128/JB.183.7.2348-2358.2001; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; Prager R, 2000, INT J MED MICROBIOL, V290, P605; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2000, FR MOLEC B, V24, P89; Rudolph MG, 1999, J BIOL CHEM, V274, P30501, DOI 10.1074/jbc.274.43.30501; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; VAN AL, 1997, GENE DEV, V11, P2295; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x	46	171	180	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34035	34040		10.1074/jbc.M100609200	http://dx.doi.org/10.1074/jbc.M100609200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11440999	hybrid			2022-12-25	WOS:000170910200100
J	Nguyen, H; Ramana, CV; Bayes, J; Stark, GR				Nguyen, H; Ramana, CV; Bayes, J; Stark, GR			Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; EPIDERMAL GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3; CELL ANTIGEN RECEPTOR; C-CBL PROTOONCOGENE; NF-KAPPA-B; TYROSINE PHOSPHORYLATION; IFN-GAMMA; TRANSCRIPTION FACTOR; SIGNALING PATHWAY	STAT1 must be phosphorylated on serine 727 to be fully active in transcription. We show that phosphatidylinositol 3-kinase (PI3K) and its effector kinase Akt play an important role in the serine phosphorylation of STAT1 and in the activation of gene expression in response to interferon-gamma (IFN gamma). IFN gamma activates PI3K as well as Akt in a variety of cell lines. Specific inhibition of PI3K abrogates IFN gamma -induced, but not interleukin-1- or tumor necrosis factor-a-induced, phosphorylation of STAT1. on serine and reduces STAT1-dependent transcription and gene expression by similar to7-fold. Constitutively active forms of PI3K or Akt activate and their dominant-negative derivatives inhibit STAT1-driven transactivation in response to IFN gamma. In addition to PI3K and Akt, JAK1, JAK2, and the tyrosine 440 STAT1 docking residue of IFNGR1 are required for STAT1 to be phospho. rylated on serine. Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org		chilakamarti, ramana/0000-0002-5153-8252	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gamero AM, 2000, J BIOL CHEM, V275, P16574, DOI 10.1074/jbc.M910149199; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gollob JA, 1999, J IMMUNOL, V162, P4472; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meili R, 2000, CURR BIOL, V10, P708, DOI 10.1016/S0960-9822(00)00536-4; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sambrook J., 2002, MOL CLONING LAB MANU; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SEEGERT D, 1994, J BIOL CHEM, V269, P8590; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Su L, 1999, J BIOL CHEM, V274, P31770, DOI 10.1074/jbc.274.45.31770; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	73	199	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33361	33368		10.1074/jbc.M105070200	http://dx.doi.org/10.1074/jbc.M105070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438544	hybrid			2022-12-25	WOS:000170910200012
J	Sauna, ZE; Smith, MM; Muller, M; Ambudkar, SV				Sauna, ZE; Smith, MM; Muller, M; Ambudkar, SV			Evidence for the vectorial nature of drug (substrate)-stimulated ATP hydrolysis by human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC TRANSITION-STATE; MULTIDRUG-RESISTANCE; TRANSPORT; NUCLEOTIDE; MECHANISM; CELLS; SITES; PHOSPHORYLATION; RECONSTITUTION; PURIFICATION	P-glycoprotein (Pgp), the ATP-binding cassette multidrug transporter, exhibits a drug (substrate)-stimulatable ATPase activity, and vanadate (Vi) inhibits this activity by stably trapping the nucleoside diphosphate in the Pgp-ADP-Vi conformation. We recently demonstrated that Vi-induced 8-azido-[alpha-(32)p]ADP trapping into Pgp in the absence of substrate occurs both in the presence of 8-azido-[alpha-P-32]ATP (following 8-azido-ATP hydrolysis) or 8-azido-[alpha-P-32]ADP (without hydrolysis) and, the transition state intermediates generated under either condition are functionally indistinguishable. In this study, we compare the effect of substrates on Vi-induced 8-azido.[alpha-P-32]ADP trapping into Pgp under both non-hydrolysis and hydrolysis conditions. We demonstrate that whereas substrates stimulate the Vi-induced trapping of 8-azido-[alpha-P-32]ADP under hydrolysis conditions, they strongly inhibit Vi-induced trapping under non-hydrolysis conditions. This inhibition is concentration-dependent, follows first order kinetics, and is effected by drastically decreasing the affinity of nucleoside diphosphate for Pgp during trapping. However, substrates do not affect the binding of nucleoside diphosphate in the absence of Vi, indicating that the substrate-induced conformation exerts its effect at a step distinct from nucleoside diphosphate-binding. Our results demonstrate that during the catalytic cycle of Pgp, although the transition state, Pgp.ADP.P-i (Vi), can be generated both via the hydrolysis of ATP or by directly providing ADP to the system, in the presence of substrate the reaction is driven in the forward direction, i.e. hydrolysis of ATP. These data suggest that substrate-stimulated ATP hydrolysis by Pgp is a vectorial process.	NCI, Cell Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Cell Biol Lab, Canc Res Ctr, NIH, Bldg 37, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Sauna, Zuben E./AAA-7149-2019; Ambudkar, Suresh V/B-5964-2008; Ambudkar, Suresh V/L-1317-2016					ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; LELONG IH, 1994, BIOCHEMISTRY-US, V33, P8921, DOI 10.1021/bi00196a009; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P169, DOI 10.1016/S0925-4439(97)00027-6; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; REPKE KRH, 1982, ANN NY ACAD SCI, V402, P272, DOI 10.1111/j.1749-6632.1982.tb25747.x; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Shapiro AB, 1998, EUR J BIOCHEM, V254, P189, DOI 10.1046/j.1432-1327.1998.2540189.x; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; Shepard RL, 1998, BIOCHEM PHARMACOL, V56, P719, DOI 10.1016/S0006-2952(98)00212-3; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; YAMADA S, 1980, J BIOL CHEM, V255, P3108; Zhou TQ, 2001, J BIOL CHEM, V276, P30414, DOI 10.1074/jbc.M103671200	36	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33301	33304		10.1074/jbc.C100369200	http://dx.doi.org/10.1074/jbc.C100369200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11451943	hybrid			2022-12-25	WOS:000170910200003
J	Utton, MA; Gibb, GM; Burdett, IDJ; Anderton, BH; Vandecandelaere, A				Utton, MA; Gibb, GM; Burdett, IDJ; Anderton, BH; Vandecandelaere, A			Functional differences of tau isoforms containing 3 or 4 C-terminal repeat regions and the influence of oxidative stress.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; PAIRED HELICAL FILAMENTS; DYNAMIC INSTABILITY; ALZHEIMERS-DISEASE; INDIVIDUAL MICROTUBULES; FRONTOTEMPORAL DEMENTIA; PRESENILE-DEMENTIA; SELF-ASSOCIATION; BUNDLE FORMATION; BOVINE BRAIN	We report functional differences between tau isoforms with 3 or 4 C-terminal repeats and a difference in susceptibility to oxidative conditions, with respect to the regulation of microtubule dynamics in vitro and tau-microtubule, binding in cultured cells. In the presence of dithiothreitol in vitro, a 3-repeat tau isoform promotes microtubule nucleation, reduces the tubulin critical concentration for microtubule assembly, and suppresses dynamic instability. Under non-reducing conditions, threshold concentrations of 3-repeat tau and tubulin exist below which this isoform still promotes microtubule, nucleation and assembly but fails to reduce the tubulin critical concentration or suppress dynamic instability; above these threshold concentrations, amorphous aggregates of 3-repeat tau and tubulin can be produced at the expense of microtubule formation. A 4-repeat tau isoform is less sensitive to the oxidative potential of the environment, behaving under oxidative conditions similarly to the 3-repeat isoform under reducing conditions. Under conditions of oxidative stress, in Chinese hamster ovary cells stably expressing either 3- or 4-repeat tau, 3-repeat tau disassociates from microtubules more readily than the 4-repeat isoform, and tau-containing high molecular weight aggregates are preferentially observed in lysates from the Chinese hamster ovary cells expressing 3-repeat tau, indicating greater susceptibility of 3-repeat tau to oxidative conditions, compared with 4-repeat tau in vivo.	Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England; Natl Inst Med Res, Div Membrane Biol, London NW7 1AA, England	University of London; King's College London; MRC National Institute for Medical Research; MRC National Institute for Medical Research	Utton, MA (corresponding author), Kings Coll London, Inst Psychiat, Dept Neurosci, De Crespigny Pk, London SE5 8AF, England.	m.utton@iop.kcl.ac.uk						Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Bayley Peter M., 1994, V13, P111; BELLOMO G, 1990, J CELL PHYSIOL, V143, P118, DOI 10.1002/jcp.1041430116; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BRANDT R, 1993, J BIOL CHEM, V268, P3414; BRANDT R, 1993, J NEUROCHEM, V61, P997, DOI 10.1111/j.1471-4159.1993.tb03613.x; BRE MH, 1990, CELL MOTIL CYTOSKEL, V15, P88, DOI 10.1002/cm.970150205; BRION JP, 1993, J NEUROCHEM, V60, P1372, DOI 10.1111/j.1471-4159.1993.tb03298.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CLARK DC, 1981, BIOCHEMISTRY-US, V20, P1924, DOI 10.1021/bi00510a031; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Davis DR, 1997, J NEUROCHEM, V68, P1590; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DEANCOS JG, 1993, J BIOL CHEM, V268, P7976; Delacourte A, 1998, ANN NEUROL, V43, P193, DOI 10.1002/ana.410430209; Di Noto L, 1999, Mol Cell Biol Res Commun, V2, P71, DOI 10.1006/mcbr.1999.0153; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DRUBIN D, 1986, ANN NY ACAD SCI, V466, P257, DOI 10.1111/j.1749-6632.1986.tb38398.x; Epe B, 1996, NUCLEIC ACIDS RES, V24, P1625, DOI 10.1093/nar/24.9.1625; ERICKSON HP, 1981, BIOPHYS J, V34, P293, DOI 10.1016/S0006-3495(81)84850-3; FLAMENTDURAND J, 1979, ACTA NEUROPATHOL, V46, P159, DOI 10.1007/BF00684819; FRANCON J, 1982, EUR J BIOCHEM, V129, P465, DOI 10.1111/j.1432-1033.1982.tb07072.x; Gamblin TC, 1996, BIOCHEMISTRY-US, V35, P12576, DOI 10.1021/bi961135d; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GRAY EG, 1987, NEUROPATH APPL NEURO, V13, P91, DOI 10.1111/j.1365-2990.1987.tb00174.x; Grundke-Iqbal I, 1997, P NATL ACAD SCI USA, V94, P298; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; GUTTMANN RP, 1995, J NEUROCHEM, V64, P1209; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; IKEDA Y, 1978, BIOCHEMISTRY-US, V17, P3454, DOI 10.1021/bi00610a005; ITOH TJ, 1994, CELL STRUCT FUNCT, V19, P279, DOI 10.1247/csf.19.279; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; Ko LW, 1997, BRAIN RES, V760, P118, DOI 10.1016/S0006-8993(97)00292-8; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; KSIEZAKREDING H, 1995, J NEUROSCI RES, V41, P583, DOI 10.1002/jnr.490410504; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; MULOT SFC, 1994, FEBS LETT, V349, P359, DOI 10.1016/0014-5793(94)00702-0; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; NOVELLA IS, 1992, FEBS LETT, V211, P235; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Preuss U, 1997, J CELL SCI, V110, P789; PRYER NK, 1992, J CELL SCI, V103, P965; Revesz T, 1997, J NEUROPATH EXP NEUR, V56, P80; Sambrook J., 1989, MOL CLONING LAB MANU, V3, P18; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCOTT CW, 1991, J NEUROSCI RES, V30, P154, DOI 10.1002/jnr.490300116; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SMITH C, 1994, NEUROPATH APPL NEURO, V20, P322, DOI 10.1111/j.1365-2990.1994.tb00977.x; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; TRONCOSO JC, 1993, BRAIN RES, V613, P313, DOI 10.1016/0006-8993(93)90918-D; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741; Vandecandelaere A, 1996, CELL MOTIL CYTOSKEL, V35, P134, DOI 10.1002/(SICI)1097-0169(1996)35:2<134::AID-CM6>3.0.CO;2-A; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; VERMERSCH P, 1994, ACTA NEUROPATHOL, V87, P572; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; WEISENBERG RC, 1986, ANN NY ACAD SCI, V466, P543, DOI 10.1111/j.1749-6632.1986.tb38431.x; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3	73	18	18	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34288	34297		10.1074/jbc.M011384200	http://dx.doi.org/10.1074/jbc.M011384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438517	hybrid			2022-12-25	WOS:000170910200132
J	Jaburek, M; Varecha, M; Jezek, P; Garlid, KD				Jaburek, M; Varecha, M; Jezek, P; Garlid, KD			Alkylsulfonates as probes of uncoupling protein transport mechanism - Ion pair transport demonstrates that direct H+ translocation by UCP1 is not necessary for uncoupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; FATTY-ACIDS; PROTON TRANSPORT; FLIP-FLOP; COENZYME-Q; MITOCHONDRIA; SITE; RECONSTITUTION; NUCLEOTIDES; MEMBRANES	The mechanism of fatty acid-dependent uncoupling by mitochondrial uncoupling proteins (UCP) is still in debate. We have hypothesized that the anionic fatty acid head group is translocated by UCP, and the proton is transported electroneutrally in the bilayer by flip-flop of the protonated fatty acid. Alkylsulfonates are useful as probes of the UCP transport mechanism. They are analogues of fatty acids, and they are transported by UCP1, UCP2, and UCP3. We show that undecanesulfonate and laurate are mutually competitive inhibitors, supporting the hypothesis that fatty acid anion is transported by UCP1. Alkylsulfonates cannot be protonated because of their low pKa, consequently, they cannot catalyze electroneutral proton transport in the bilayer and cannot support uncoupling by UCP. We report for the first time that propranolol forms permeant ion pairs with the alkylsulfonates, thereby removing this restriction. Because a proton is transported with the neutral ion pair, the sulfonate is able to deliver protons across the bilayer, behaving as if it were a fatty acid. When ion pair transport is combined with UCP1, we now observe electrophoretic proton transport and uncoupling of brown adipose tissue mitochondria. These experiments confirm that the proton transport of UCP-mediated uncoupling takes place in the lipid bilayer and not via UCP itself. Thus, UCP1, like other members of its gene family, translocates anions and does not translocate protons.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Palacky Univ, Dept Expt Phys, Olomouc 77146, Czech Republic; Acad Sci Czech Republ, Inst Physiol, Dept Membrane Transport Biophys, CR-14220 Prague, Czech Republic	Palacky University Olomouc; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Garlid, KD (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	garlid@bmb.ogi.edu	Jezek, Petr/B-9264-2012; Varecha, Miroslav/P-4205-2019; Jaburek, Martin/B-9652-2012; Jabůrek, Martin/H-1114-2019; Varecha, Miroslav/H-4190-2014	Jezek, Petr/0000-0002-2720-9395; Varecha, Miroslav/0000-0002-0236-4241; Jabůrek, Martin/0000-0002-4357-1116; Garlid, Keith/0000-0002-6777-1235	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056273] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56273] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2000, BIOCHEMISTRY-US, V39, P3311, DOI 10.1021/bi992448m; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; GARLID KD, 1983, J BIOL CHEM, V258, P7974; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Hanak P, 2001, FEBS LETT, V495, P137, DOI 10.1016/S0014-5793(01)02338-9; HEATON GM, 1978, EUR J BIOCHEM, V82, P515, DOI 10.1111/j.1432-1033.1978.tb12045.x; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; JEZEK P, 1990, J BIOL CHEM, V265, P19303; Jezek P, 1997, FEBS LETT, V408, P161, DOI 10.1016/S0014-5793(97)00334-7; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1997, J BIOL CHEM, V272, P24272, DOI 10.1074/jbc.272.39.24272; JEZEK P, 1990, J BIOL CHEM, V265, P10522; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; JEZEK P, 1990, J BIOL CHEM, V265, P19296; Jezek P, 1998, INT J BIOCHEM CELL B, V30, P1163, DOI 10.1016/S1357-2725(98)00076-4; JEZEK P, 1989, FEBS LETT, V243, P37, DOI 10.1016/0014-5793(89)81213-X; JEZEK P, 1999, J BIOENERG BIOMEMBR; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kaplan RS, 2001, J MEMBRANE BIOL, V179, P165, DOI 10.1007/s002320010046; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Klingenberg M, 1999, J BIOENERG BIOMEMBR, V31, P419, DOI 10.1023/A:1005440221914; NEDERGAARD J, 1994, BBA-BIOENERGETICS, V1185, P311, DOI 10.1016/0005-2728(94)90246-1; NICHOLLS DG, 1974, EUR J BIOCHEM, V49, P573, DOI 10.1111/j.1432-1033.1974.tb03861.x; NICHOLLS DG, 1973, EUR J BIOCHEM, V37, P523, DOI 10.1111/j.1432-1033.1973.tb03014.x; OROSZ DE, 1993, ANAL BIOCHEM, V210, P7, DOI 10.1006/abio.1993.1143; RAFAEL J, 1969, H-S Z PHYSIOL CHEM, V350, P1121, DOI 10.1515/bchm2.1969.350.2.1121; RICQUIER D, 1976, BIOCHEM BIOPH RES CO, V73, P577, DOI 10.1016/0006-291X(76)90849-4; SIMPSON RB, 1974, J LIPID RES, V15, P415; Varecha M, 2001, BIOPHYS J, V80, p237A	37	37	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31897	31905		10.1074/jbc.M103507200	http://dx.doi.org/10.1074/jbc.M103507200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11468281	hybrid			2022-12-25	WOS:000170613500060
J	Muller, C; Monferran, S; Gamp, AC; Calsou, P; Salles, B				Muller, C; Monferran, S; Gamp, AC; Calsou, P; Salles, B			Inhibition of Ku heterodimer DNA end binding activity during granulocytic differentiation of human promyelocytic cell lines	ONCOGENE			English	Article						double strand breaks; ionizing radiation; DNA repair; non homologous; end joining-differentiation	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; POLY(ADP-RIBOSE) POLYMERASE; CATALYTIC SUBUNIT; LEUKEMIA-CELLS; HL-60; AUTOANTIGEN; APOPTOSIS; RECOMBINATION; SENSITIVITY	The heterodimeric Ku protein (composed of the Ku 86 and Ku 70 sub-units) is a nuclear protein which binds to DNA termini without sequence specificity, Ku is the DNA-targeting component of the large catalytic sub-unit of the DNA-dependent protein kinase complex that is required for the repair of DNA double-strand breaks in mammalian cells. We studied the expression and function of Ku/DNA-PK during granulocytic differentiation of two human promyelocytic cell lines, HL60 and NB4, a process associated to decreased radiation resistance. After 3 days exposure to differentiating agents (either all-trans-retinoic acid or DMSO), Ku binding to double stranded (ds)-DNA ends declined dramatically whereas Ku protein levels remain unchanged, The nuclear, but not cytoplasmic, fraction of differentiated HL60 cells extracts exhibited a heat-sensitive inhibitory activity towards DNA binding of recombinant Ku heterodimer, We further demonstrate that immunoprecipitation of Ku is impaired in extracts from differentiated cells by using two antibodies that recognize epitopes within the C-terminus DNA binding domains of Ku 70 and Ku 86 proteins, These results favor the hypothesis of a protein interacting with Ku that would prevent DNA binding of heterodimerized Ku protein by steric hindrance.	Inst Pharmacol & Biol Struct, CNRS, UPR 9062, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Salles, B (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.		Monferran, Sylvie/M-3445-2014; MULLER, Catherine/M-2185-2018; MULLER, Catherine/E-2060-2011; salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806; Monferran, Sylvie/0000-0002-7062-7437				ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Burgman P, 1997, CANCER RES, V57, P2847; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; COLLINS SJ, 1987, BLOOD, V70, P1233; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; FALZON M, 1993, J BIOL CHEM, V268, P10546; FARNAZEH F, 1987, NUCLEIC ACIDS RES, V15, P3493; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GALLAGHER R, 1979, BLOOD, V54, P713; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; ISLAS AL, 1995, CANCER RES, V55, P336; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; KANAI M, 1982, BIOCHEM BIOPH RES CO, V105, P404, DOI 10.1016/0006-291X(82)91448-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LANOTTE M, 1991, BLOOD, V77, P1080; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; McConnell KR, 1997, J IMMUNOL, V158, P2083; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; MINORI T, 1986, J BIOL CHEM, V261, P10375; Morio T, 1999, IMMUNITY, V11, P339, DOI 10.1016/S1074-7613(00)80109-0; Muller C, 1998, ONCOGENE, V16, P1553, DOI 10.1038/sj.onc.1201676; Muller C, 1999, BIOCHIMIE, V81, P117, DOI 10.1016/S0300-9084(99)80044-3; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; Muller C, 1997, ONCOGENE, V15, P2343, DOI 10.1038/sj.onc.1201402; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PLOEMACHER R, 1992, INT J RADIAT BIOL, V61, P488; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Romero F, 1996, MOL CELL BIOL, V16, P37; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Tai YT, 2000, J IMMUNOL, V165, P6347, DOI 10.4049/jimmunol.165.11.6347; TOFILON PJ, 1988, EXP CELL RES, V174, P502, DOI 10.1016/0014-4827(88)90319-9; Vral A, 2001, INT J RADIAT BIOL, V77, P329, DOI 10.1080/0955300001004237; WAGEMAKER G, 1995, STEM CELLS, V13, P257, DOI 10.1002/stem.5530130731; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; WANG JS, 1994, J CELL SCI, V107, P3223; WHEELER KT, 1983, RADIAT ENVIRON BIOPH, V22, P3, DOI 10.1007/BF01323757; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	63	18	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4373	4382		10.1038/sj.onc.1204571	http://dx.doi.org/10.1038/sj.onc.1204571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466618				2022-12-25	WOS:000169912600011
J	Soubeyran, P; Haglund, K; Garcia, S; Barth, BU; Iovanna, J; Dikic, I				Soubeyran, P; Haglund, K; Garcia, S; Barth, BU; Iovanna, J; Dikic, I			Homeobox gene Cdx1 regulates Ras, Rho and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells	ONCOGENE			English	Article						transformation; intestinal epithelial cells; Cdx1; Ras; PI3 kinase	PROTEIN EXPRESSION; COLORECTAL-CANCER; DOWN-REGULATION; DIFFERENTIATION; ACTIVATION; INHIBITION; ELEMENT; HOMOLOG	The Cdx1 homeobox gene encodes for an intestine-specific transcription factor involved in the control of proliferation and differentiation of epithelial cells. Although it has been indicated that Cdx1 may act as a proto-oncogene in cultured fibroblasts, its direct role in the regulation of intestinal tumorigenesis has not been demonstrated. Here we show that expression of Cdx1 in an intestinal epithelial cell line (IEC-6) induces anchorage-independent growth in soft agar and promotes the formation of adenocarcinoma in vivo, The phenotype of Cdx1-induced tumors was exacerbated when IEC-6/ Cdx1 cells were injected together with matrigel containing mitogens and extracellular matrix components. These changes were correlated with an increase in the GTP-bound form of Ras, modulation of Cdc42 and Rho-A activities, and accumulation of phosphatidyl inositol 3 (PI3) kinase products. Moreover, combined inhibition of Ras/Rho and PI3 kinase signaling by syntethic inhibitors blocked colony formation of IEC-6/Cdx1 cells in soft agar, Taken together, these results demonstrate a direct involvement of Cdx1, and its collaboration with Ras, Rho and PI3 kinase pathways, in transformation and tumorigenesis of intestinal epithelial cells.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; INSERM, Lab Physiol & Pathol Digest, U315, F-13009 Marseille, France; Hop Nord Marseille, F-13915 Marseille, France	Ludwig Institute for Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.	Ivan.Dikic@licr.uu.se	Soubeyran, Philippe/P-1758-2018; Iovanna, Juan/M-9805-2017; Dikic, Ivan/O-4650-2015; Haglund, Kaisa/B-3927-2017	Iovanna, Juan/0000-0003-1822-2237; Dikic, Ivan/0000-0001-8156-9511; Haglund, Kaisa/0000-0002-7946-3299; Soubeyran, Philippe/0000-0002-5876-3217				Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; [Anonymous], 1988, LAB ANIM-UK, V22, P195; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Bell E, 1999, SCIENCE, V284, P2168, DOI 10.1126/science.284.5423.2168; Bijl JJ, 1997, AM J PATHOL, V151, P1067; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Duluc I, 1997, J CELL SCI, V110, P1317; EE HC, 1995, AM J PATHOL, V147, P586; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; JAMES R, 1994, J BIOL CHEM, V269, P15229; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1999, J BIOL CHEM, V274, P7196, DOI 10.1074/jbc.274.11.7196; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ren P, 2000, AM J PATHOL, V156, P621, DOI 10.1016/S0002-9440(10)64766-9; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971	34	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4180	4187		10.1038/sj.onc.1204551	http://dx.doi.org/10.1038/sj.onc.1204551			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464284				2022-12-25	WOS:000169857200008
J	Gross, M; Liu, B; Tan, JA; French, FS; Carey, M; Shuai, K				Gross, M; Liu, B; Tan, JA; French, FS; Carey, M; Shuai, K			Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen signaling; protein inhibitor of activated STAT	NUCLEAR-RECEPTOR; DEPENDENT TRANSCRIPTION; COACTIVATORS; BINDING; DETERMINANTS; SPECIFICITY; COREGULATOR; INHIBITION; REQUIRES; COMPLEX	Androgen signaling influences the development and growth of prostate carcinoma. The transcriptional activity of androgen receptor (AR) is regulated by positive or negative transcriptional cofactors, We report here that PIAS1, PIAS3, and PIASy of the protein inhibitor of activated STAT (PIAS) family, which are expressed in human prostate, display distinct effects on AR-mediated gene activation in prostate cancer cells. While PIAS1 and PIAS3 enhance the transcriptional activity of AR, PIASy acts as a potent inhibitor of AR in prostate cancer cells, The effects of PIAS proteins on AR are competitive. PIASy binds to AR but does not affect the DNA binding activity of AR. An NH2-terminal LXXLL signature motif of PIASy, although not required for PIASy-AR interaction, is essential for the transrepression activity of PIASy, Our results identify PIASy as a transcriptional corepressor of AR and suggest that different PIAS proteins have distinct effects on AR signaling in prostate cancer cells.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ N Carolina, Sch Med, Dept Pediat, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of California System; University of California Los Angeles	Shuai, K (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg,1083 LeConte Ave, Los Angeles, CA 90095 USA.			Gross, Mitchell/0000-0002-1691-921X; Carey, Michael/0000-0003-3899-6280	NIAID NIH HHS [AI43438] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043438, R01AI043438] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Bentel JM, 1996, J ENDOCRINOL, V151, P1, DOI 10.1677/joe.0.1510001; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 2000, GENE DEV, V14, P121; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Kokontis JM, 1999, VITAM HORM, V55, P219; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; McDonald S, 2000, CANCER RES, V60, P2317; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050	30	144	153	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3880	3887		10.1038/sj.onc.1204489	http://dx.doi.org/10.1038/sj.onc.1204489			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439351				2022-12-25	WOS:000169494700013
J	Soncini, C; Berdo, I; Draetta, G				Soncini, C; Berdo, I; Draetta, G			Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease	ONCOGENE			English	Article						de-ubiqitinating enzyme; G3BP; ubiquitin	FACETS DEUBIQUITINATING ENZYME; CHROMOSOMAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; ISOPEPTIDASE-T; DEGRADATION; GENE; INTERACTS; PATHWAY; UNP; PHOSPHORYLATION	Degradation of cellular proteins through ubiquitination is a fundamental strategy for regulating biological pathways. De-ubiquitination, i,e, the removal of ubiquitin from proteins and peptides to which ubiquitin is attached, is catalyzed by processing proteases known as de-ubiquitinating enzymes, We are studying the biology of a family of de-ubiquitinating enzymes, the mammalian ubiquitin-specific proteases (USPs), some of which appear to play a role in growth control. Given the fact that the modes of regulation of USPs and of their substrate specificity are poorly understood, we decided to attempt the identification of USP interacting proteins, Using the yeast two-hybrid system (2HS), we have isolated a cDNA clone whose product specifically interacts with USP10 but not with other USP baits tested. The isolated clone encodes a protein known to interact with the Ras-GTPase activating protein (G3BP), This interaction was further confirmed by performing a 2HS with G3BP, which led to the isolation of USP10 encoding cDNAs. We validated the interaction between the two proteins by performing in vitro binding assays and immunoprecipitations in human cells, G3BP does not appear to be a substrate of USP10; it rather inhibits the ability of USP10 to disassemble ubiquitin chains. The USP10/G3BP complex appears to co-immunoprecipitate with ubiquitinated species that could be substrates of USP10.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Draetta, G (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.			SONCINI, MARIACHIARA/0000-0002-2066-9751				Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; GRAY DA, 1995, ONCOGENE, V10, P2179; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; GUPTA K, 1993, ONCOGENE, V8, P2307; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li QH, 1997, P NATL ACAD SCI USA, V94, P12515, DOI 10.1073/pnas.94.23.12515; Lin HJ, 2000, MOL CELL BIOL, V20, P6568, DOI 10.1128/MCB.20.17.6568-6578.2000; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Parker F, 1996, MOL CELL BIOL, V16, P2561; Sloper-Mould KE, 1999, J BIOL CHEM, V274, P26878, DOI 10.1074/jbc.274.38.26878; STEIN RL, 1995, BIOCHEMISTRY-US, V34, P12616, DOI 10.1021/bi00039a017; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	39	133	142	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3869	3879		10.1038/sj.onc.1204553	http://dx.doi.org/10.1038/sj.onc.1204553			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439350				2022-12-25	WOS:000169494700012
J	Zhou, WL; Carpenter, G				Zhou, WL; Carpenter, G			Heregulin-dependent translocation and hyperphosphorylation of ErbB-2	ONCOGENE			English	Article						ErbB-2; heregulin; detergent-insoluble fraction	LIPID RAFTS; ACTIN CYTOSKELETON; SIGNALING NETWORK; MEMBRANE DOMAINS; RECEPTOR; ONCOGENESIS; TRAFFICKING; RECRUITMENT; ENGAGEMENT; CAVEOLAE	Previous data have shown that in several tumor cells lines the addition of heregulin results in the translocation of ErbB-4 to a detergent-insoluble membrane fraction where it is hypertyrosine phosphorylated, The data herein demonstrate that heregulin or betacellulin, but not EGF, promotes the rapid translocation of ErbB-2, the heterodimerization partner for ErbB-4, to the same detergent-insoluble fraction in T47 D mammary carcinoma cells. The translocation of ErbB-2 and ErbB-4, but not ErbB-3, to this detergent-insoluble fraction is readily detected 2 min after the addition of heregulin, ErbB-2 present in this detergent-insoluble membrane fraction is tyrosine phosphorylated to a level fourfold greater than the majority of cellular ErbB-2 present in the detergent-soluble membrane fraction. These results suggest the ligand-dependent formation of hyperphosphorylated ErbB-4/ErbB-2 dimers coordinate with translocation to a putative membrane microdomain,	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA024071, T32CA009582] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09582, R01 CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Dunbar AJ, 2000, INT J BIOCHEM CELL B, V32, P805, DOI 10.1016/S1357-2725(00)00028-5; Holowka D, 2000, J CELL SCI, V113, P1009; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhao YY, 1999, CIRC RES, V84, P1380; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	17	23	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3918	3920		10.1038/sj.onc.1204517	http://dx.doi.org/10.1038/sj.onc.1204517			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439355				2022-12-25	WOS:000169494700017
J	Savani, RC; Cao, GY; Pooler, PM; Zaman, A; Zhou, Z; DeLisser, HM				Savani, RC; Cao, GY; Pooler, PM; Zaman, A; Zhou, Z; DeLisser, HM			Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; ADHESION MOLECULE; BASEMENT-MEMBRANE; RHAMM; MIGRATION; OLIGOSACCHARIDES; GROWTH; PROTEIN; SURFACE; IDENTIFICATION	Hyaluronan (HA), an important glycosaminoglycan constituent of the extracellular matrix, has been implicated in angiogenesis. It appears to exert its biological effects through binding interactions with at least two cell surface receptors: CD44 and receptor for HA-mediated motility (RHAMM). Recent in vitro studies have suggested potential roles for these two molecules in various aspects of endothelial function. However, the relative contribution of each receptor to endothelial functions critical to angiogenesis and their roles in vivo have not been established. We therefore investigated the endothelial expression of these proteins and determined the effects of antibodies against RHAMM and CD44 on endothelial cell (EC) function and in vivo angiogenesis. Both receptors were detected on vascular endothelium in situ, and on the surface of cultured EC. Further studies with active blocking antibodies revealed that anti-CD44 but not anti-RHAMM antibody inhibited EC adhesion to HA and EC proliferation, whereas anti-RHAMM but not CD44 antibody blocked EC migration through the basement membrane substrate, Matrigel. Although antibodies against both receptor inhibited in vitro endothelial tube formation, only the anti-RHAMM antibody blocked basic fibroblast growth factor-induced neovascularization in mice. These data suggest that RHAMM and CD44, through interactions with their ligands, are both important to processes required for the formation of new blood vessels.	Childrens Hosp Philadelphia, Dept Pediat, Div Neonatol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA; Centocor Inc, Malvern, PA 19355 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	DeLisser, HM (corresponding author), 806 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	delisser@mail.med.upenn.edu	Rashmin C. Savani, MBChB/AAG-2041-2021; DeLisser, Horace/AFM-1942-2022	Rashmin C. Savani, MBChB/0000-0002-9533-5422; 	NHLBI NIH HHS [HL-03382, HL-62868, HL62472, HL-62254] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062868, R01HL062472, K14HL003382, R01HL062254] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; Assmann V, 1999, J CELL SCI, V112, P3943; Assmann V, 1998, J CELL SCI, V111, P1685; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BIRCH M, 1991, CANCER RES, V51, P6660; BOUDREAU N, 1991, DEV BIOL, V143, P235, DOI 10.1016/0012-1606(91)90074-D; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; ChristofidouSolomidou M, 1997, J IMMUNOL, V158, P4872; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FEIBER C, 1999, GENE, V226, P41; FEINBERG RN, 1983, SCIENCE, V220, P1177, DOI 10.1126/science.6857242; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Griffioen AW, 2000, PHARMACOL REV, V52, P237; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; Hofmann M, 1998, J CELL SCI, V111, P1673; Hofmann M, 1998, CELL, V95, P591, DOI 10.1016/S0092-8674(00)81628-1; Ito Y, 1996, INT J CANCER, V67, P148, DOI 10.1002/(SICI)1097-0215(19960703)67:1<148::AID-IJC24>3.3.CO;2-6; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEES VC, 1995, LAB INVEST, V73, P259; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MOUSA SA, 2000, MED INTELL UNIT, V20, P1; Nagy JI, 1998, NEUROSCIENCE, V86, P241, DOI 10.1016/S0306-4522(98)00017-7; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PASSANITI A, 1992, LAB INVEST, V67, P519; Pilarski LM, 1999, BLOOD, V93, P2918; PILARSKI LM, 1993, J IMMUNOL, V150, P4292; Rahmanian M, 1997, EXP CELL RES, V237, P223, DOI 10.1006/excr.1997.3792; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; SAMUEL SK, 1993, J CELL BIOL, V123, P749, DOI 10.1083/jcb.123.3.749; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; SAVANI RC, 1995, J CLIN INVEST, V95, P1158, DOI 10.1172/JCI117764; SAVANI RC, 1995, P W PHARMACOL SOC, V38, P131; Savanti R, 2000, BAS CLIN DERMATOL, P115; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Sneath RJS, 1998, J CLIN PATHOL-MOL PA, V51, P191, DOI 10.1136/mp.51.4.191; THOMAS L, 1993, J INVEST DERMATOL, V100, P115, DOI 10.1111/1523-1747.ep12462776; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; TURLEY EA, 1993, BLOOD, V81, P446; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; YANG BH, 1994, J CELL BIOCHEM, V56, P455, DOI 10.1002/jcb.240560406; Zhou Z, 1999, Angiogenesis, V3, P181, DOI 10.1023/A:1009092107382	55	257	273	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36770	36778		10.1074/jbc.M102273200	http://dx.doi.org/10.1074/jbc.M102273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11448954	hybrid			2022-12-25	WOS:000171194500095
J	Xie, SQ; Wang, Q; Wu, HY; Cogswell, J; Lu, L; Jhanwar-Uniyal, M; Dai, W				Xie, SQ; Wang, Q; Wu, HY; Cogswell, J; Lu, L; Jhanwar-Uniyal, M; Dai, W			Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; XENOPUS EGG EXTRACTS; OXIDATIVE STRESS; PROTEIN-KINASE; SERINE/THREONINE KINASE; GENE; MITOSIS; CELLS; PLX1; CDC5	Upon exposure of cells to hydrogen peroxide (H2O2) phosphorylation of p53 was rapidly induced in human fibroblast GM00637, and this phosphorylation occurred on serine 9, serine 15, serine 20, but not on serine 392. In addition, H2O2-induced phosphorylation of p53 was followed by induction of p21, suggesting functional activation of p53. Induction of phosphorylation of p53 on multiple serine residues by H2O2 was caffeine-sensitive and blocked in ATM(-/-) cells. Polo-like kinase-3 (Plk3) activity was also activated upon H2O2 treatment, and this activation was ATM-dependent. Recombinant His(6)-Plk3 phosphorylated glutathione S-transferase (GST)-p53 fusion protein but not GST alone. When phoshorylated in vitro by His(6)-Plk3, but not by the kinase-defective mutant His6-Plk3(K52R), GST-p53 was recognized by an antibody specifically to serine 20-phosphorylated p53, indicating that serine 20 is an in vitro target of Plk3. Also serine 20-phosphorylated p53 was coimmunoprecipitated with Plk3 in cells treated with H2O2. Furthermore, although H2O2 strongly induced serine 15 phosphorylation of p53, it failed to induce serine 20 phosphorylation in Plk3-difficient Daudi cells. Ectopic expression of a Plk3 dominant negative mutant, Plk3(K52R), in GM00637 cells suppressed H2O2-induced serine 20 phosphorylation. Taken together, our studies strongly suggest that the oxidative stress-induced activation of p53 is at least in part mediated by Plk3.	Amer Hlth Fdn, Lab Cell Cycle Regulat, Valhalla, NY 10595 USA; Glaxo Inc, Res Triangle Pk, NC 27709 USA; Wright State Univ, Dept Physiol & Biophys, Dayton, OH 45435 USA	American Health Foundation; GlaxoSmithKline; University System of Ohio; Wright State University Dayton	Dai, W (corresponding author), Amer Hlth Fdn, Lab Cell Cycle Regulat, 1 Dana Rd, Valhalla, NY 10595 USA.	wei_dai_ny@yahoo.com			NCI NIH HHS [CA47729] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akman SA, 2000, ANN NY ACAD SCI, V899, P88; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Bloecher A, 1999, GENE DEV, V13, P517, DOI 10.1101/gad.13.5.517; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Cavelier G, 2000, MED HYPOTHESES, V54, P95, DOI 10.1054/mehy.1998.0821; Chan TA, 2000, GENE DEV, V14, P1584; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chen QM, 2000, ANN NY ACAD SCI, V908, P111; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; Formichi P, 2000, LIFE SCI, V66, P1893, DOI 10.1016/S0024-3205(00)00515-4; Furuwatari C, 1998, AM J CLIN PATHOL, V110, P368, DOI 10.1093/ajcp/110.3.368; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Haggman MJ, 1997, UROLOGY, V50, P643, DOI 10.1016/S0090-4295(97)00304-X; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; KAGAN J, 1995, ONCOGENE, V11, P2121; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Ouyang B, 1999, DNA SEQUENCE, V10, P109, DOI 10.3109/10425179909008427; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SUNKEL CE, 1988, J CELL SCI, V89, P25; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Uberti D, 1999, MOL BRAIN RES, V65, P167, DOI 10.1016/S0169-328X(98)00339-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1	41	123	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36194	36199		10.1074/jbc.M104157200	http://dx.doi.org/10.1074/jbc.M104157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11447225	hybrid			2022-12-25	WOS:000171194500021
J	Anthonsen, MW; Andersen, S; Solhaug, A; Johansen, B				Anthonsen, MW; Andersen, S; Solhaug, A; Johansen, B			Atypical lambda/iota PKC conveys 5-lipoxygenase-leukotriene B-4-mediated cross-talk between phospholipase A(2)s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; STIMULATED HUMAN PLATELETS; PHOSPHATIDYLINOSITOL 3-KINASE; PI 3-KINASE; INDEPENDENT ACTIVATION; PHOSPHORYLATION SITES; SIGNALING PATHWAY; POTENTIAL ROLE; ZETA ISOFORM	The transcription factor nuclear factor kappaB (NF-kappaB) plays crucial roles in a wide variety of biological functions such as inflammation, stress, and immune responses. We have shown previously that secretory nonpancreatic (snp) and cytosolic (c) phospholipase A(2) (PLA(2)) regulate NF-kappaB activation in response to tumor necrosis factor (TNF)-alpha or interleukin (IL)-1 beta activation and that a functional coupling mediated by the 5-lipoxy-genase (5-LO) metabolite leukotriene B-4 (LTB4) exists between snpPLA(2) and cPLA(2) in human keratinocytes. In this study, we have further investigated the mechanisms of PLA(2)-modulated NF-kappaB activation with respect to specific kinases involved in TNF-alpha /IL-1 beta -stimulated cPLA(2) phosphorylation and NF-KB activation. The protein kinase C (PKC) inhibitors RO 31-8220, Go 6976, and a pseudosubstrate peptide inhibitor of atypical PKCs attenuated arachidonic acid release, cPLA(2) phosphorylation, and NF-kappaB activation induced by TNF-alpha or IL-1 beta, thus indicating atypical PKCs in cPLA(2) regulation and transcription factor activation. Transfection of a kinase-inactive mutant of lambda/iota PKC in NIH-3T3 fibroblasts completely abolished TNF-alpha /IL-1 beta -stimulated cellular arachidonic acid release and cPLA(2) activation assayed in vitro, confirming the role of lambda/iota PKC in cPLA(2) regulation. Furthermore, lambda/iota PKC and cPLA(2) phosphorylation was attenuated by phosphatidyinositol 3-kinase (PI3-kinase) inhibitors, which also reduced NF-kappaB activation in response to TNF-alpha and IL-1 beta, indicating a role for PI3-kinase in these processes in human keratinocytes. TNF-alpha and IL-1 beta -induced phosphorylation of lambda/iota PKC was attenuated by inhibitors toward snpPLA(2) and 5-LO and by an LTB4 receptor antagonist, suggesting lambda/iota PKC as a downstream effector of snpPLA(2) and 5-LO/LTB4 the LTB4 receptor. Hence, lambda/iota PKC regulates snpPLA(2)/LTB4-mediated cPLA(2) activation, cellular arachidonic acid release, and NF-kappaB activation induced by TNF-alpha and IL-1 beta. In addition, our results demonstrate that PI3-kinase and lambda/iota PKC are involved in cytokine-induced cPLA(2) and NF-kappaB activation, thus identifying lambda/iota PKC as a novel regulator of cPLA(2).	Norwegian Univ Sci & Technol, Fac Chem & Biol, UNIGEN Ctr Mol Biol, N-7491 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Anthonsen, MW (corresponding author), Norwegian Univ Sci & Technol, Fac Chem & Biol, UNIGEN Ctr Mol Biol, N-7491 Trondheim, Norway.		Solhaug, Anita/AAJ-1063-2020	Solhaug, Anita/0000-0002-1908-406X				Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ANDERSEN S, 1994, INFLAMMATION, V18, P1, DOI 10.1007/BF01534593; Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V274, pL1030, DOI 10.1152/ajplung.1998.274.6.L1030; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006-2952(98)00353-0; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; Bortuzzo C, 1996, BBA-LIPID LIPID MET, V1300, P240, DOI 10.1016/0005-2760(96)00003-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Castan I, 1999, BIOCHEM J, V339, P281, DOI 10.1042/0264-6021:3390281; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DEJONG EMGJ, 1992, CLIN EXP DERMATOL, V17, P413; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fimiani C, 1999, PROSTAG OTH LIPID M, V57, P23, DOI 10.1016/S0090-6980(98)00068-9; Fonteh AN, 2001, J BIOL CHEM, V276, P1439, DOI 10.1074/jbc.M006551200; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hernandez M, 1999, J NEUROCHEM, V73, P1641, DOI 10.1046/j.1471-4159.1999.0731641.x; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HOUSE C, 1990, CELL SIGNAL, V2, P187, DOI 10.1016/0898-6568(90)90022-3; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; MORICE WG, 1993, J BIOL CHEM, V268, P22737; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; Ozes ON, 1999, NATURE, V401, P82; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; POTTS BCM, 1992, J NAT PROD, V55, P1701, DOI 10.1021/np50090a001; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Samuelsson B, 1997, ADV EXP MED BIOL, V433, P1; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Thommesen L, 1998, J IMMUNOL, V161, P3421; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; Wijkander J, 1997, BIOCHEM J, V325, P405, DOI 10.1042/bj3250405; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053; Yoo MH, 2001, J BIOL CHEM, V276, P24645, DOI 10.1074/jbc.M101975200; Zhang YP, 1999, J BIOL CHEM, V274, P27726, DOI 10.1074/jbc.274.39.27726; Zhu XD, 1999, J IMMUNOL, V163, P3423	91	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35344	35351		10.1074/jbc.M105264200	http://dx.doi.org/10.1074/jbc.M105264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11445585	hybrid			2022-12-25	WOS:000171109300020
J	Boujaoude, LC; Bradshaw-Wilder, C; Mao, CG; Cohn, J; Ogretmen, B; Hannun, YA; Obeid, LM				Boujaoude, LC; Bradshaw-Wilder, C; Mao, CG; Cohn, J; Ogretmen, B; Hannun, YA; Obeid, LM			Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid - Modulation of cellular activity of spingosine 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COUPLED RECEPTOR EDG-1; SACCHAROMYCES-CEREVISIAE; GENE; SPHINGOSINE-1-PHOSPHATE; RESISTANCE; IDENTIFICATION; EXPRESSION; CANCER; CELLS	Sphingolipids have been implicated in the regulation of cell growth, differentiation, and programmed cell death. Sphingosine 1-phosphate (SPP) has recently emerged as an important lipid messenger and a ligand for the endothelial differentiation gene receptor family of proteins through which it mediates its biologic effects. Recent studies in Saccharomyces cerevisiae in our laboratory implicated the yeast oligomycin resistance gene (YOR1), a member of the ATP binding cassette family of proteins, in the transport of SPP. The cystic fibrosis transmembrane regulator is a unique member of the ATP binding cassette transporter family and has high homology with YOR1. We therefore set out to investigate if this member of the family can regulate SPP transport. We demonstrate that C127/cystic fibrosis transmembrane regulator (CFTR) cells, expressing wild type CFTR, exhibited significantly higher uptake of sphingosine 1-phosphate than either cells expressing a mutant CFTR C127/Delta F508 or C127/mock-transfected cells. This effect was specific, dose-dependent, and competed off by dihydrosphingosine 1-phosphate and lysophosphatidic acid. There was no difference in uptake of sphingosine, C16-ceramide, sphingomyelin, lysophingomyelin, phosphatidylcholine, lysophosphatidylcholine, or phosphatidic acid among the different cell lines. Pretreatment with forskolin or isobutylmethylxanthine to stimulate cAMP did not affect the uptake in any of the cell lines. Moreover, we found that mitogen-activated protein kinase activation by SPP was less responsive in C127/CFTR as compared with C127/mock-transfected cells, suggesting that uptake of SPP by CFTR may divert it from interacting with its cell surface receptors and attenuate signaling functions. Taken together, these data implicate CFTR in uptake of SPP and the related phosphorylated lipids dihydrosphingosine 1-phosphate and lysophosphatidic acid. This uptake influences the availability of SPP to modulate biologic activity via endothelial differentiation gene receptors. These studies may have important implications to cystic fibrosis.	Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Div Pediat Gastroenterol & Nutr, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA; Duke Univ, Med Ctr, Dept Internal Med, Durham, NC 27710 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Duke University	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, 114 Doughty St,Rm 604 STB,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM43825, R01-GM62887] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; DECHECCHI MC, 1993, J BIOL CHEM, V268, P11321; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LEIER I, 1994, J BIOL CHEM, V269, P27807; McColley SA, 2000, AM J RESP CRIT CARE, V161, P1877, DOI 10.1164/ajrccm.161.6.9905022; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; OGRETMEN B, 1995, BIOTECHNIQUES, V19, P374; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Pyne S, 1997, BIOCHEM SOC T, V25, P549, DOI 10.1042/bst0250549; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sato K, 2000, MOL BRAIN RES, V85, P151, DOI 10.1016/S0169-328X(00)00262-X; Schwiebert EM, 1998, AM J MED, V104, P576, DOI 10.1016/S0002-9343(98)00119-3; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	29	124	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35258	35264		10.1074/jbc.M105442200	http://dx.doi.org/10.1074/jbc.M105442200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11443135	hybrid			2022-12-25	WOS:000171109300009
J	Gomez-Gonzalo, M; Carretero, M; Rullas, J; Lara-Pezzi, E; Aramburu, J; Berkhout, B; Alcami, J; Lopez-Cabrera, M				Gomez-Gonzalo, M; Carretero, M; Rullas, J; Lara-Pezzi, E; Aramburu, J; Berkhout, B; Alcami, J; Lopez-Cabrera, M			The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals - Functional roles of NF-kappa B/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HBV-ENCODED COACTIVATOR; TATA-BINDING PROTEIN; HOMOSEXUAL MEN; TRANSACTIVATION FUNCTION; SP1 PHOSPHORYLATION; IMMUNE-RESPONSES; TRANS-ACTIVATION; GENE-EXPRESSION; CYCLOSPORINE-A	Co-infection with hepatitis B virus (HBV) and human immunodeficiency virus type-1 (HIV-1) is relatively common. However, the impact of this co-infection on the clinical outcome of HIV infection has not been elucidated. We herein demonstrate that the HBV X protein (HBx) superinduces ongoing HIV-1 replication and HIV-1 long terminal repeat (LTR) transcription by synergizing with Tat protein and with T-cell activation signals. Although HBx cooperated with mitogenic stimuli in the induction of reporter plasmids harboring the HIV-1 kappaB enhancer, in both a NF-kappaB-dependent manner and a NF-AT-dependent manner, deletion of this element from the LTR did not affect the HBx-mediated up-regulation in the presence of Tat and/or mitogens. In contrast, mutation of the proximal LTR Sp1-binding sites abolished the HBx-mediated synergistic activation, but only when it was accompanied by deletion of the kappaB enhancer. When HBx was targeted to the nucleus, its ability to synergize with cellular activation stimuli was maintained. Furthermore, mutations of HBx affecting its interaction with the basal transcription machinery abrogated the synergistic activation by HBx, suggesting that this protein exerts its function by acting as a nuclear co-activator. These results indicate that HBx could contribute to a faster progression to AIDS in HBV-HIV co-infected individuals.	Hosp Univ Princesa, Unidad Biol Mol, Madrid 28006, Spain; Inst Salud Carlos III, Ctr Nacl Microbiol, Majadahonda Madrid 28029, Spain; Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	Hospital de La Princesa; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Pompeu Fabra University; University of Amsterdam; Academic Medical Center Amsterdam	Lopez-Cabrera, M (corresponding author), Hosp Univ Princesa, Unidad Biol Mol, C Diego Leon 62, Madrid 28006, Spain.		Carretero, Marta/C-3842-2017; Aramburu, J/G-8991-2014; Alcami, Pepe/T-2242-2018; Cabrera, Manuel López/AAA-5463-2019; Carretero, Marta/AAF-3380-2021; Lara-Pezzi, Enrique/E-2350-2015	Carretero, Marta/0000-0001-6152-3102; Aramburu, J/0000-0001-9279-9523; Alcami, Pepe/0000-0003-0023-7377; Lara-Pezzi, Enrique/0000-0002-2743-1033; Lopez Cabrera, Manuel/0000-0002-0976-9719				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; ARII M, 1992, ONCOGENE, V7, P397; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; Cheng H, 1998, J VIROL, V72, P6911, DOI 10.1128/JVI.72.8.6911-6916.1998; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Colin JF, 1999, HEPATOLOGY, V29, P1306, DOI 10.1002/hep.510290447; Cron RQ, 2000, CLIN IMMUNOL, V94, P179, DOI 10.1006/clim.1999.4831; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dimitrakopoulos A, 2000, J INFECTION, V40, P127, DOI 10.1053/jinf.1998.0636; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; ESKILD A, 1992, AIDS, V6, P571, DOI 10.1097/00002030-199206000-00008; FRANCO MJD, 1994, J ACQ IMMUN DEF SYND, V10, P1079; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilson RJC, 1997, AIDS, V11, P597, DOI 10.1097/00002030-199705000-00007; HADLER SC, 1991, J INFECT DIS, V163, P454, DOI 10.1093/infdis/163.3.454; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Haviv I, 1998, GENE DEV, V12, P1217, DOI 10.1101/gad.12.8.1217; HO SN, 1994, J BIOL CHEM, V269, P28181; Huang LM, 2001, J BIOL CHEM, V276, P13427, DOI 10.1074/jbc.M011314200; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; LAURE F, 1985, SCIENCE, V229, P561, DOI 10.1126/science.2410981; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Mallardo M, 1996, J BIOL CHEM, V271, P20820, DOI 10.1074/jbc.271.34.20820; MCNAIR ANB, 1992, SEMIN LIVER DIS, V12, P188, DOI 10.1055/s-2007-1007390; MONTE PD, 1997, AIDS, V11, P267; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1994, ONCOGENE, V9, P2836; Ockenga J, 1997, J HEPATOL, V27, P18, DOI 10.1016/S0168-8278(97)80274-7; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Schafer SL, 1996, J VIROL, V70, P6937, DOI 10.1128/JVI.70.10.6937-6946.1996; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Torgeman A, 1999, VIROLOGY, V254, P279, DOI 10.1006/viro.1998.9556; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; TWU JS, 1989, J VIROL, V63, P2857, DOI 10.1128/JVI.63.6.2857-2860.1989; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; ZELDIS JB, 1986, J CLIN INVEST, V78, P411, DOI 10.1172/JCI112591	67	77	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35435	35443		10.1074/jbc.M103020200	http://dx.doi.org/10.1074/jbc.M103020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11457829	hybrid			2022-12-25	WOS:000171109300032
J	Lugardon, K; Chasserot-Golaz, S; Kieffer, AE; Maget-Dana, G; Nullans, G; Kieffer, B; Aunis, D; Metz-Boutigue, MH				Lugardon, K; Chasserot-Golaz, S; Kieffer, AE; Maget-Dana, G; Nullans, G; Kieffer, B; Aunis, D; Metz-Boutigue, MH			Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBACTERIAL ACTIVITY; DODECYLPHOSPHOCHOLINE MICELLES; TERMINAL FRAGMENT; PROTEIN; CELLS; IDENTIFICATION; CALCINEURIN; CALMODULIN; MEMBRANE; LIPIDS	Vasostatin-I, the natural fragment of chromogranin A-(1-76), is a neuropeptide able to kill a large variety of fungi and yeast cells in the micromolar range. We have examined the antifungal properties of synthetic vasostatin-I-related peptides. The most active shortest peptide, named chromofungin, corresponds to the sequence Arg(47)-Leu(66). Extensive H-1 NMR analysis revealed that it adopts a helical structure. The biophysical mechanism implicated in the interaction of chromofungin with fungi and yeast cells was studied, showing the penetration of this peptide with different lipid monolayers. In order to examine thoroughly the antifungal activity of chromofungin, confocal laser microscopy was used to demonstrate the ability of the rhodamine-labeled peptide to interact with the fungal cell wall, to cross the plasma membrane, and to accumulate in Aspergillus fumigatus, Alternaria brassicola, and Candida albicans. Our present data reveal that chromofungin inhibits calcineurin activity, extending a previous observation that the N-terminal region of chromogranin A interacts with calmodulin in the presence of calcium. Therefore, the destabilization of fungal wall and plasma membrane, together with the possible intracellular inhibition of calmodulin-dependent enzymes, is likely to represent the mechanism by which vasostatin-I and chromofungin exert antifungal activity.	INSERM, U338, Biol Commun Cellulaire IFR37, F-67084 Strasbourg, France; CNRS, UPR 2356, Neurotransmiss & Secret Neuroendocrine IFR37, F-67084 Strasbourg, France; CNRS, UPR Cancerogenese & Mutagenese Mol & Struct 9003, F-67400 Illkirch Graffenstaden, France; CNRS, Ctr Biophys Mol, Orleans, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Metz-Boutigue, MH (corresponding author), INSERM, U338, Biol Commun Cellulaire IFR37, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Kieffer, Bruno/AAE-8999-2019; Dominique, Aunis/W-1419-2019; Chasserot-Golaz, Sylvette/K-7625-2017	Chasserot-Golaz, Sylvette/0000-0002-7437-2558; Kieffer, Bruno/0000-0002-2033-4679				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; ARGIOLAS A, 1985, J BIOL CHEM, V260, P1437; Aunis D, 2000, ADV EXP MED BIOL, V482, P21; BARTIZAL K, 1992, ANTIMICROB AGENTS CH, V36, P1648, DOI 10.1128/AAC.36.8.1648; BULET P, 1993, J BIOL CHEM, V268, P14893; CETIN Y, 1993, P NATL ACAD SCI USA, V90, P2360, DOI 10.1073/pnas.90.6.2360; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; Ciesielski-Treska J, 2001, J BIOL CHEM, V276, P13113, DOI 10.1074/jbc.M009711200; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; de Lucca AJ, 1999, ANTIMICROB AGENTS CH, V43, P1, DOI 10.1093/jac/43.1.1; DEBONO M, 1994, ANNU REV MICROBIOL, V48, P471, DOI 10.1146/annurev.mi.48.100194.002351; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; DEMEL RA, 1973, BIOCHIM BIOPHYS ACTA, V311, P507, DOI 10.1016/0005-2736(73)90126-0; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P5894, DOI 10.1073/pnas.77.10.5894; FRIEDMAN KJ, 1980, J MEMBRANE BIOL, V54, P183, DOI 10.1007/BF01870234; FUNAKOSHI A, 1990, BIOCHEM BIOPH RES CO, V168, P741, DOI 10.1016/0006-291X(90)92384-C; Gesell J, 1997, J BIOMOL NMR, V9, P127, DOI 10.1023/A:1018698002314; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; Kanno T, 2000, ADV EXP MED BIOL, V482, P143; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LIANG F, 1995, ACTA PHYSIOL SCAND, V155, P23, DOI 10.1111/j.1748-1716.1995.tb09944.x; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MISHRA P, 1992, BIOCHIM BIOPHYS ACTA, V1127, P1, DOI 10.1016/0005-2760(92)90194-Z; MOL PC, 1987, FEMS MICROBIOL LETT, V41, P95; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prokisch H, 1997, MOL GEN GENET, V256, P104, DOI 10.1007/s004380050551; Ratti S, 2000, J BIOL CHEM, V275, P29257, DOI 10.1074/jbc.M003796200; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SIMON JP, 1989, BIOCHEM J, V262, P1; Stridsberg M, 2000, J ENDOCRINOL, V165, P703, DOI 10.1677/joe.0.1650703; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Suresh K, 1997, FEMS MICROBIOL LETT, V150, P95, DOI 10.1016/S0378-1097(97)00103-1; TARR GE, 1986, METHODS PROTEIN MICR, P162; TAYLOR JW, 1981, J AM CHEM SOC, V103, P6965, DOI 10.1021/ja00413a035; Turquier V, 1999, ENDOCRINOLOGY, V140, P4104, DOI 10.1210/en.140.9.4104; Vignal E, 1998, EUR J BIOCHEM, V253, P221, DOI 10.1046/j.1432-1327.1998.2530221.x; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Yokota T, 1997, Nihon Rinsho, V55, P1155; YOO SH, 1992, BIOCHEMISTRY-US, V31, P6134, DOI 10.1021/bi00141a025; ZAGORSKI MG, 1991, BIOCHEMISTRY-US, V30, P8009, DOI 10.1021/bi00246a019	60	80	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35875	35882		10.1074/jbc.M104670200	http://dx.doi.org/10.1074/jbc.M104670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11451958	hybrid			2022-12-25	WOS:000171109300087
J	Guse, AH; Tsygankov, AY; Weber, K; Mayr, GW				Guse, AH; Tsygankov, AY; Weber, K; Mayr, GW			Transient tyrosine phosphorylation of human ryanodine receptor upon T cell stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; CALCIUM-RELEASE CHANNEL; ANTIGEN-RECEPTOR; SIGNAL-TRANSDUCTION; CA2+ RELEASE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; PROTEIN-KINASE; LYMPHOCYTES; ACTIVATION	The ryanodine receptor of Jurkat T lymphocytes was phosphorylated on tyrosine residues upon stimulation of the cells via the T cell receptor/CD3 complex. The tyrosine phosphorylation was transient, reaching a maximum at 2 min, and rapidly declined thereafter. In co-immunoprecipitates of the ryanodine receptor, the tyrosine kinases p56(lck) and p59(fyn) were detected. However, only p59(fyn) associated with the ryanodine receptor in a stimulation-dependent fashion. Both tyrosine kinases, recombinantly expressed as glutathione S-transferase (GST) fusion proteins, phosphorylated the immunoprecipitated ryanodine receptor in vitro. In permeabilized Jurkat T cells, GST-p59(fyn), but not GST-p56(lck), GST-Grb2, or GST alone, significantly and concentration-dependently enhanced Ca2+ release by cyclic ADP-ribose. The tyrosine kinase inhibitor PP2 specifically blocked the effect of GST-p59(fyn). This indicates that intracellular Ca2+ release via ryanodine receptors may be modulated by tyrosine phosphorylation during T cell activation.	Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Div Cellular Signal Transduct, D-20246 Hamburg, Germany; Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	University of Hamburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Guse, AH (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Div Cellular Signal Transduct, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de	Tsygankov, Alexander Y/K-6205-2017					APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ATHERTON TJ, 1997, RR333 U WARW DEP COM; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Guse AH, 1998, CRIT REV IMMUNOL, V18, P419, DOI 10.1615/CritRevImmunol.v18.i5.20; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 1999, CELL SIGNAL, V11, P309, DOI 10.1016/S0898-6568(99)00004-2; GUSE AH, 1992, BIOCHEM J, V288, P489, DOI 10.1042/bj2880489; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; GUSE AH, 1995, J IMMUNOL, V155, P3353; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HERRMANNFRANK A, 1993, FEBS LETT, V332, P237, DOI 10.1016/0014-5793(93)80640-G; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PETERS DJ, 1990, ONCOGENE, V5, P1313; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; Reyes-Harde M, 1999, P NATL ACAD SCI USA, V96, P4061, DOI 10.1073/pnas.96.7.4061; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34722	34727		10.1074/jbc.M100715200	http://dx.doi.org/10.1074/jbc.M100715200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11466305	hybrid			2022-12-25	WOS:000171024600052
J	Liu, G; Molas, M; Grossmann, GA; Pasumarthy, M; Perales, JC; Cooper, MJ; Hanson, RW				Liu, G; Molas, M; Grossmann, GA; Pasumarthy, M; Perales, JC; Cooper, MJ; Hanson, RW			Biological properties of poly-L-lysine-DNA complexes generated by cooperative binding of the polycation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE DELIVERY; ASIALOGLYCOPROTEIN RECEPTOR; IN-VIVO; EXPRESSION; LIGAND; INVIVO; HEPATOCYTES; PROTEIN; CELLS	We have evaluated the effect of NaCl concentration on the mode of binding Of poly-L-lysine to DNA and the resulting structural and functional features of the condensed DNA particles using DNA precipitation, DNase I resistance, electron microscopy, and receptor-mediated gene transfer assays. At a high concentration of NaCl and in the presence of excess DNA, poly-L-lysine interacted with DNA cooperatively, fully condensing some of the DNA and leaving the rest of the DNA unbound. At low NaCl concentrations, poly-L-lysine molecules interacted with DNA in a noncooperative fashion, i.e. they bind randomly to the whole population of DNA molecules. Cooperative binding Of poly-L-lysine to DNA occurred over a narrow range of NaCl concentrations, and the specific salt concentration depended on the length of the poly-L-lysine. The ability of condensed DNA to withstand digestion by DNase I was correlated with the structural features of the condensed DNA as determined by electron microscopy. Using our condensation procedure, cooperative binding Of poly-L-lysine to DNA is a necessary prerequisite for the preparation of condensed DNA having a spherical shape and a diameter of 15-30 nm. Condensed DNA, containing galactosylated poly-L-lysine, was evaluated further for the extent and specificity of receptor-mediated gene transfer into HuH-7 human hepatoma cells via the asialoglycoprotein receptor. Efficient receptor-mediated transfection. occurred only when condensed DNA complexes had a spherical shape with a diameter of 15-30 nm; asialofetuin, a natural ligand for the asialoglycoprotein receptor, inhibited this process by up to 90%. Our results support the importance of appropriate DNA condensation for the uptake and ultimate expression of DNA in hepatic cells.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Copernicus Therapeut Inc, Cleveland, OH 44106 USA	Case Western Reserve University	Hanson, RW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	rwh@po.cwru.edu	PERALES, JOSE C. C/D-5586-2012; PERALES, JOSE C./AAC-3156-2019; PERALES, JOSE C/J-7457-2017	PERALES, JOSE C. C/0000-0001-7363-2226; PERALES, JOSE C./0000-0001-7363-2226; PERALES, JOSE C/0000-0001-7363-2226; Molas, Maria/0000-0002-3215-515X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541, R01DK021859, R37DK021859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 53672] Funding Source: Medline; NIDDK NIH HHS [DK 21859, DK-25541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CARROLL D, 1972, BIOCHEMISTRY-US, V11, P426, DOI 10.1021/bi00753a020; CHANG C, 1973, BIOCHEMISTRY-US, V12, P3028, DOI 10.1021/bi00740a013; CHENG SY, 1983, NUCLEIC ACIDS RES, V11, P659, DOI 10.1093/nar/11.3.659; CLARK RJ, 1971, NATURE-NEW BIOL, V229, P101, DOI 10.1038/newbio229101a0; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; HAYNES M, 1970, BIOCHEMISTRY-US, V9, P4410, DOI 10.1021/bi00824a600; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; KOWALCZYK T, 2001, 4 ANN M AM SOC GEN T; KUNITZ M, 1950, J GEN PHYSIOL, V33, P349, DOI 10.1085/jgp.33.4.349; KUPFER JM, 1994, HUM GENE THER, V5, P1437, DOI 10.1089/hum.1994.5.12-1437; Lee RJ, 1996, J BIOL CHEM, V271, P8481, DOI 10.1074/jbc.271.14.8481; LEES CW, 1968, BIOCHEMISTRY-US, V7, P2480, DOI 10.1021/bi00847a006; LENG M, 1966, P NATL ACAD SCI USA, V56, P1325, DOI 10.1073/pnas.56.4.1325; LI HJ, 1974, NUCLEIC ACIDS RES, V1, P257, DOI 10.1093/nar/1.2.257; LI HJ, 1974, BIOPOLYMERS, V13, P649, DOI 10.1002/bip.1974.360130402; LI HJ, 1973, BIOCHEMISTRY-US, V12, P1763, DOI 10.1021/bi00733a016; LI HJ, 1974, BIOPOLYMERS, V13, P1681, DOI 10.1002/bip.1974.360130813; LINDBERG U, 1964, BIOCHIM BIOPHYS ACTA, V82, P237, DOI 10.1016/0304-4165(64)90294-6; LINDBERG U, 1967, BIOCHEMISTRY-US, V6, P335, DOI 10.1021/bi00853a050; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; MANIATIS T, 1974, J MOL BIOL, V84, P37, DOI 10.1016/0022-2836(74)90211-3; OLINS DE, 1967, J MOL BIOL, V24, P157, DOI 10.1016/0022-2836(67)90324-5; OLINS DE, 1968, J MOL BIOL, V33, P265, DOI 10.1016/0022-2836(68)90293-3; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; Perales JC, 1997, J BIOL CHEM, V272, P7398, DOI 10.1074/jbc.272.11.7398; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; Perales Jose C., 1996, P105; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPIRO JT, 1969, BIOCHEMISTRY-US, V8, P3219, DOI 10.1021/bi00836a014; STANKOVICS J, 1994, HUM GENE THER, V5, P1095, DOI 10.1089/hum.1994.5.9-1095; TSUBOI M, 1966, J MOL BIOL, V15, P256, DOI 10.1016/S0022-2836(66)80225-5; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WEISKOPF M, 1977, BIOPOLYMERS, V16, P669, DOI 10.1002/bip.1977.360160315; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338; Ziady AG, 1997, AM J PHYSIOL-GASTR L, V273, pG545, DOI 10.1152/ajpgi.1997.273.2.G545	41	142	159	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34379	34387		10.1074/jbc.M105250200	http://dx.doi.org/10.1074/jbc.M105250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11438546	Green Published, hybrid			2022-12-25	WOS:000171024600005
J	Nakamura, K; Bindokas, VP; Kowlessur, D; Elas, M; Milstein, S; Marks, JD; Halpern, HJ; Kang, UJ				Nakamura, K; Bindokas, VP; Kowlessur, D; Elas, M; Milstein, S; Marks, JD; Halpern, HJ; Kang, UJ			Tetrahydrobiopterin scavenges superoxide in dopaminergic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-CYCLOHYDROLASE-I; NITRIC-OXIDE SYNTHASE; GLUTATHIONE DEPLETION; COMPLEX I; PREFERENTIAL RESISTANCE; MITOCHONDRIAL-FUNCTION; TYROSINE-HYDROXYLASE; HYDROGEN-PEROXIDE; RAT-BRAIN; GENERATION	Increased oxidative stresses are implicated in the pathogenesis of Parkinson's disease, and dopaminergic neurons may be intrinsically susceptible to oxidative damage. However, the selective presence of tetrahydrobiopterin (BH4) makes dopaminergic neurons more resistant to oxidative stress caused by glutathione depletion. To further investigate the mechanisms of BH4 protection, we examined the effects of BH4 on superoxide levels in individual living mesencephalic neurons. Dopaminergic neurons have intrinsically lower levels of superoxide than nondopaminergic neurons. In addition, inhibiting BH4 synthesis increased superoxide in dopaminergic neurons, while BH4 supplementation decreased superoxide in nondopaminergic cells. BH4 is also a cofactor in catecholamine and NO production. In order to exclude the possibility that the antioxidant effects of BH4 are mediated by dopamine and NO, we used fibroblasts in which neither catecholamine nor NO production occurs. In fibroblasts, BH4 decreased baseline reactive oxygen species, and attenuated reactive oxygen species increase by rotenone and antimycin A. Physiologic concentrations of BH4 directly scavenged superoxide generated by potassium superoxide in vitro. We hypothesize that BH4 protects dopaminergic neurons from ordinary oxidative stresses generated by dopamine and its metabolites and that environmental insults or genetic defects may disrupt this intrinsic capacity of dopaminergic neurons and contribute to their degeneration in Parkinson's disease.	Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Ctr EPR Imaging In Vivo Physiol, Chicago, IL 60637 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kang, UJ (corresponding author), Univ Chicago, Dept Neurol, Chicago, IL 60637 USA.	u-kang@uchicago.edu	Elas, Martyna/E-3584-2017; Kang, Un/AAV-2858-2020; Marks, Jeremy/W-2087-2019	Elas, Martyna/0000-0001-6296-2844; Kang, Un/0000-0002-5970-6839; Marks, Jeremy/0000-0002-2644-5257	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038547] Funding Source: NIH RePORTER; NIMH NIH HHS [MH11986] Funding Source: Medline; NINDS NIH HHS [R01 NS038547-05, R01 NS038547-02, R01 NS038547-03, R01 NS038547, R01 NS038547-04, R01 NS038547-05S1] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Bencsics C, 1996, J NEUROSCI, V16, P4449; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chen EY, 2000, J COMP NEUROL, V426, P534; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; Furukawa Y, 1998, NEUROLOGY, V51, P632, DOI 10.1212/WNL.51.2.632; GALLOP P M, 1984, Biotechniques, V2, P32; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Haavik J, 1997, J NEUROCHEM, V68, P328; HEALES SJR, 1988, CELL BIOCHEM FUNCT, V6, P191, DOI 10.1002/cbf.290060307; Hensley K, 1998, J NEUROCHEM, V71, P2549; Herrero A, 1997, J BIOENERG BIOMEMBR, V29, P241, DOI 10.1023/A:1022458010266; Hirayama K, 1998, J NEUROCHEM, V70, P164; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Ishii M, 1999, J CARDIOVASC PHARM, V33, P295, DOI 10.1097/00005344-199902000-00018; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; KOJIMA S, 1995, FREE RADICAL RES, V23, P419, DOI 10.3109/10715769509065263; KOJIMA S, 1992, FEBS LETT, V304, P163, DOI 10.1016/0014-5793(92)80610-S; Koshimura K, 1998, J NEUROSCI RES, V54, P664, DOI 10.1002/(SICI)1097-4547(19981201)54:5<664::AID-JNR11>3.0.CO;2-U; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lentz SI, 1996, NEUROCHEM INT, V28, P569, DOI 10.1016/0197-0186(95)00124-7; LEVINE RA, 1981, SCIENCE, V214, P919, DOI 10.1126/science.6117945; LOKESH BR, 1986, TOXICOL LETT, V34, P75, DOI 10.1016/0378-4274(86)90147-5; MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; Nakamura K, 1997, J NEUROCHEM, V69, P1850; Nakamura K, 2000, J NEUROCHEM, V74, P2305, DOI 10.1046/j.1471-4159.2000.0742305.x; Nakamura K, 2000, BRAIN RES, V873, P203, DOI 10.1016/S0006-8993(00)02425-2; PILEBLAD E, 1989, J NEUROCHEM, V52, P978, DOI 10.1111/j.1471-4159.1989.tb02550.x; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; POU S, 1992, J BIOL CHEM, V267, P24173; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; Sawada H, 1996, J NEUROSCI RES, V46, P509, DOI 10.1002/(SICI)1097-4547(19961115)46:4<509::AID-JNR13>3.0.CO;2-T; Sawada H, 1996, J NEUROSCI RES, V43, P503, DOI 10.1002/(SICI)1097-4547(19960215)43:4<503::AID-JNR12>3.0.CO;2-2; SCHAPIRA AHV, 1992, ANN NEUROL, V32, pS116, DOI 10.1002/ana.410320720; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SHEN RS, 1993, ADV EXP MED BIOL, V338, P351; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SMITH GK, 1992, J BIOL CHEM, V267, P5599; Stroes E, 1998, FEBS LETT, V438, P161, DOI 10.1016/S0014-5793(98)01292-7; Toffa S, 1997, J NEURAL TRANSM, V104, P67, DOI 10.1007/BF01271295; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Wullner U, 1996, NEUROREPORT, V7, P921; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Yoshida YI, 2000, BRAIN DEV-JPN, V22, pS45	55	79	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34402	34407		10.1074/jbc.M103766200	http://dx.doi.org/10.1074/jbc.M103766200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11447224	hybrid			2022-12-25	WOS:000171024600008
J	Baek, SJ; Horowitz, JM; Eling, TE				Baek, SJ; Horowitz, JM; Eling, TE			Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter - Basal transcription is mediated by Sp1 and Sp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA SUPERFAMILY; GROWTH-FACTOR-BETA; FUNCTIONAL INTERACTIONS; REPRESS TRANSCRIPTION; MORPHOGENETIC PROTEIN; BINDING PROTEINS; CARCINOMA-CELLS; RB PROTEIN; SP-FAMILY; EXPRESSION	Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is known to be associated with anti-tumorigenic activity and belongs to the transforming growth factor-beta superfamily. In the present study, we cloned the promoter region (-3500 to +41) and investigated the transcriptional regulatory mechanisms of the basal expression of the human NAG-1 gene. Several potential transcription factor-binding sites in this region were identified. Based on the results from clones of nested deletions, the construct between -133 and +41 base pairs contains three Sp1-binding sites (Sp1-A, Sp1-B, and Sp1-C, which confer basal transcription specific activity of NAG-1 expression. When the Spi-C site was mutated (GG to TT), a 60-80% decrease in promoter activity was observed in HCT-116 cells. Gel shift, cotransfection, and chromatin immunoprecipitation assays showed that the Sp transcription factors bind to the Spl-binding sites and transactivate NAG-1 expression. In addition, chicken ovalbumin upstream promoter transcription factor I can interact with the C-terminal region of Sp1 and Sp3 proteins and induce NAG-1 promoter activity through SpI and Sp3 transcription factors. These results identify the critical regulatory regions for the human NAG-1 basal promoter. Furthermore, the results suggest that the level of expression of the NAG-1 gene will depend on the availability of Sp proteins and on co-factors such as chicken ovalbumin upstream promoter-transcription factor 1.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; N Carolina State Univ, Coll Vet Med, Dept Anat Phys Sci & Radiol, Raleigh, NC 27606 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; North Carolina State University	Eling, TE (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.			Baek, Seung/0000-0001-7866-7778	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES010016, Z01ES010016] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Crestani M, 1998, J LIPID RES, V39, P2192; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; FENG ZM, 1989, MOL ENDOCRINOL, V3, P939, DOI 10.1210/mend-3-6-939; Gitelman SE, 1997, MAMM GENOME, V8, P212, DOI 10.1007/s003359900391; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HELMS C, 1987, METHOD ENZYMOL, V153, P69; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Hsiao EC, 2000, MOL CELL BIOL, V20, P3742, DOI 10.1128/MCB.20.10.3742-3751.2000; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; MALIPIERO U, 1990, BIOCHEM BIOPH RES CO, V171, P1145, DOI 10.1016/0006-291X(90)90804-V; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Pabst O, 1999, DEVELOPMENT, V126, P2215; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Schulick AH, 1998, P NATL ACAD SCI USA, V95, P6983, DOI 10.1073/pnas.95.12.6983; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; YokoyamaKobayashi M, 1997, J BIOCHEM-TOKYO, V122, P622; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	41	123	130	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33384	33392		10.1074/jbc.M101814200	http://dx.doi.org/10.1074/jbc.M101814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11445565	hybrid			2022-12-25	WOS:000170910200015
J	Barr, SD; Gedamu, L				Barr, SD; Gedamu, L			Cloning and characterization of three differentially expressed peroxidoxin genes from Leishmania chagasi - Evidence for an enzymatic detoxification of hydroxyl radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; SUPEROXIDE; PROTEIN; PEROXIREDOXIN; REDUCTASE; OVEREXPRESSION; IDENTIFICATION; PROMASTIGOTES; PURIFICATION	Antioxidants have been implicated in protecting cells from oxygen radicals produced as a result of aerobic metabolism and in response to foreign pathogens by phagocytic cells. The mechanisms allowing pathogens to withstand the toxic prooxidant environment within the phagolysosome are poorly understood. We have cloned and characterized three antioxidant genes belonging to the 2-Cys family of peroxidoxins from Leishmania chagasi that may prove to provide these parasites with an enhanced defense mechanism against toxic oxidants. The 5 ' -untranslated regions and coding regions of each gene are highly conserved, whereas the 3 ' -untranslated regions have diverged significantly. L. chagasi peroxidoxin 1 (LcPxn1) is predominantly expressed in the amastigote stage, whereas LcPxn2 and LcPxn3 are expressed mainly in the promastigote stage, with LcPxn3 being far less abundant than LcPxn2. LcPxn2 and LcPxn3 possess a nine-amino acid extension at the carboxyl terminus, which LcPxn1 lacks. LcPxn1 appears to exist as high molecular weight multimers in vivo, and recombinant LcPxn1 was shown to detoxify hydrogen peroxide and alkyl hydroperoxides. We also present strong evidence that recombinant LcPxn1 can enzymatically detoxify hydroxyl radicals, an activity never be. fore clearly demonstrated for a protein.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Gedamu, L (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	lgedamu@ucalgary.ca		Barr, Stephen/0000-0002-0028-7430				Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BRAWN K, 1981, ARCH BIOCHEM BIOPHYS, V206, P414, DOI 10.1016/0003-9861(81)90108-9; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRANE CG, 1991, MOL ASPECTS MED, V12, P137, DOI 10.1016/0098-2997(91)90009-B; DER ES, 2000, STRUCTURE, V8, P605; Dowds B. C., 1994, FEMS MICROBIOL, V124, P155; Eisenstark A, 1996, FREE RADICAL BIO MED, V21, P975, DOI 10.1016/S0891-5849(96)00154-2; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FARR SB, 1988, J BACTERIOL, V170, P1837, DOI 10.1128/jb.170.4.1837-1842.1988; GUTTERIDGE JMC, 1981, FEBS LETT, V128, P343, DOI 10.1016/0014-5793(81)80113-5; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; HALLIWELL B, 1998, ISI ATLAS-BIOCHEM, V1, P48; Halliwell B, 2000, FREE RADICALS BIOL M; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KIM KW, 1988, J BIOL CHEM, V263, P4704; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; Logan C, 2000, J BIOL CHEM, V275, P30019, DOI 10.1074/jbc.M004161200; MASORO EJ, 1991, ANN NY ACAD SCI, V621, P337; Matthews RT, 1997, EXP NEUROL, V143, P282, DOI 10.1006/exnr.1996.6406; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; Ohshima H, 1996, J RADIAT RES, V37, P199, DOI 10.1269/jrr.37.199; Paramchuk WJ, 1997, MOL BIOCHEM PARASIT, V90, P203, DOI 10.1016/S0166-6851(97)00141-2; REED PW, 1969, J BIOL CHEM, V244, P2459; Robinson J M, 1994, Immunol Ser, V60, P159; ROOS D, 1980, J CLIN INVEST, V65, P1515, DOI 10.1172/JCI109817; ROWLEY DA, 1983, BIOCHIM BIOPHYS ACTA, V761, P86, DOI 10.1016/0304-4165(83)90365-3; ROWLEY DA, 1982, FEBS LETT, V138, P33, DOI 10.1016/0014-5793(82)80388-8; SALIN ML, 1974, J CLIN INVEST, V54, P1005, DOI 10.1172/JCI107816; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Shiloh MU, 1999, IMMUNITY, V10, P29, DOI 10.1016/S1074-7613(00)80004-7; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Webb JR, 1998, INFECT IMMUN, V66, P3279, DOI 10.1128/IAI.66.7.3279-3289.1998; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	46	64	65	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34279	34287		10.1074/jbc.M104406200	http://dx.doi.org/10.1074/jbc.M104406200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11438539	hybrid			2022-12-25	WOS:000170910200131
J	Laferriere, J; Houle, F; Taher, MM; Valerie, K; Huot, J				Laferriere, J; Houle, F; Taher, MM; Valerie, K; Huot, J			Transendothelial migration of colon carcinoma cells requires expression of E-selectin by endothelial cells and activation of stress-activated protein kinase-2 (SAPK2/p38) in the tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; P38 MAP KINASE; BREAST-CANCER PATIENTS; ACTIN REORGANIZATION; HEAT-SHOCK; TYROSINE PHOSPHORYLATION; SERUM LEVELS; KAPPA-B; METASTASIS; ICAM-1	Adhesion and migration of tumor cells on and through the vascular endothelium are critical steps of the metastatic invasion. We investigated the roles of E-selectin and of stress-activated protein kinase-2 (SAPK2/p38) in modulating endothelial adhesion and transendothelial migration of HT-29 colon carcinoma cells. Tumor necrosis factor alpha (TNF alpha) strongly increased the expression of E-selectin in human umbilical vein endothelial cells (HUVEC). This effect was independent of the activation of SAPK2/p38 induced by TNF alpha. Adhesion of HT-29 cells on a monolayer of HUVEC pretreated with TNFa was dependent on E-selectin expression but was independent of SAPK2/p38 activity of both HUVEC and tumor cells. The adhesion of HT-29 cells to E-selectin-expressing HUVEC led to the activation of SAPK2/p38 in the tumor cells as reflected by the increased phosphorylation of the actin-polymerizing factor HSP27 by mitogen-activated protein kinase 2/3, a direct target of SAPK2/ p38. Moreover, a recombinant E-selectin/Fc chimera quickly increased the activation of SAPK2/p38 in HT-29 cells. Blocking the increased activity of SAPK2/p38 of HT-29 cells by SB203580 or by expressing a dominant negative form of SAPK2/p38 inhibited their transendothelial migration. Similarly, HeLa cells stably expressing a kinase-inactive mutant of SAPK2/p38 showed a decreased capacity to cross a layer of HUVEC. Overall, our results suggest that the regulation of transendothelial migration of tumor cells involves two essential steps as follows: adhesion to the endothelium through adhesion molecules, such as E-selectin, and increased motogenic potential through adhesion-mediated activation of the SAPK2/p38 pathway.	Univ Laval, Hotel Dieu, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Virginia Commonwealth Univ, Massey Canc Ctr, Dept Radiat Oncol, Richmond, VA 23298 USA	Laval University; Virginia Commonwealth University	Huot, J (corresponding author), Univ Laval, Hotel Dieu, Ctr Rech Cancerol, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca	Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA53199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053199, R29CA053199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aigner S, 1998, FASEB J, V12, P1241, DOI 10.1096/fasebj.12.12.1241; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Aplin AE, 1998, PHARMACOL REV, V50, P197; BANKS RE, 1993, BRIT J CANCER, V68, P122, DOI 10.1038/bjc.1993.298; Benekli M, 1998, BRIT J CANCER, V78, P267, DOI 10.1038/bjc.1998.476; Brodt P, 1997, INT J CANCER, V71, P612, DOI 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D; CHIRIVI RGS, 1994, CELL ADHES COMMUN, V2, P219, DOI 10.3109/15419069409004440; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; GRUSS HJ, 1993, LEUKEMIA, V7, P1245; Guay J, 1997, J CELL SCI, V110, P357; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Haraldsen G, 1996, J IMMUNOL, V156, P2558; Hebbar M, 1999, CLIN CANCER RES, V5, P1427; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Holzmann B, 1998, CURR TOP MICROBIOL, V231, P125; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Jaakkola P, 1998, FASEB J, V12, P959, DOI 10.1096/fasebj.12.11.959; JOHNSON JP, 1992, INT J CLIN LAB RES, V22, P69, DOI 10.1007/BF02591399; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khatib AM, 1999, CANCER RES, V59, P1356; Kobayashi K, 2000, CANCER RES, V60, P3978; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; LANDRY J, 1992, J BIOL CHEM, V267, P794; Landry J, 1999, BIOCHEM SOC SYMP, P79; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Mannori G, 1997, AM J PATHOL, V151, P233; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Matsuura N, 1997, JPN J CLIN ONCOL, V27, P135, DOI 10.1093/jjco/27.3.135; MCEVER RP, 1991, THROMB HAEMOSTASIS, V65, P223; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Ogura M, 1998, J IMMUNOL, V161, P3569; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Smolen JE, 2000, J BIOL CHEM, V275, P15876, DOI 10.1074/jbc.M906232199; Soltesz SA, 1997, INT J CANCER, V71, P645, DOI 10.1002/(SICI)1097-0215(19970516)71:4<645::AID-IJC22>3.0.CO;2-9; St-Pierre Y, 1999, LEUKEMIA LYMPHOMA, V34, P53, DOI 10.3109/10428199909083380; Sun JJ, 1999, J CANCER RES CLIN, V125, P28, DOI 10.1007/s004320050238; TABER MM, 1999, BIOCHEMISTRY-US, V38, P13055; Taher MM, 2000, BIOCHEMISTRY-US, V39, P1709, DOI 10.1021/bi9921079; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; Zhang GJ, 1999, INT J ONCOL, V14, P71	55	93	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33762	33772		10.1074/jbc.M008564200	http://dx.doi.org/10.1074/jbc.M008564200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448946	hybrid			2022-12-25	WOS:000170910200065
J	O'Brien, V; Grindlay, GJ; Campo, MS				O'Brien, V; Grindlay, GJ; Campo, MS			Cell transformation by the E5/E8 protein of bovine papillomavirus type 4 - P27(Kip1), elevated through increased protein synthesis, is sequestered by cyclin D1-DCK4 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); GROWTH-FACTOR RECEPTOR; DEPENDENT KINASE; CDK INHIBITOR; RETINOBLASTOMA PROTEIN; INTERCELLULAR COMMUNICATION; D1 EXPRESSION; TREATED CELLS; MESSENGER-RNA; FACTOR-BETA	The E5/E8 hydrophobic protein of BPV-4 is, at only 42 residues, the smallest transforming protein identified to date. Transformation of NIH-3T3 cells by E5/E8 correlates with up-regulation of both cyclin A-associated kinase activity and, unusually, p27(Kip1) (p27) but does not rely on changes in cyclin E or cyclin E-CDK2 activity. Here we have examined how p27 is prevented from functioning efficiently as a CDK2 inhibitor, and we investigated the mechanisms used to achieve elevated p27 expression in E5/E8 cells. Our results show that normal subcellular targeting of p27 is not subverted in E5/E8 cells, and p27 retains its ability to inhibit both cyclin E-CDK2 and cyclin A-CDK activities upon release from heat-labile complexes. E5/E8 cells also have elevated levels of cyclins D1 and D3, and high levels of nuclear p27 are tolerated because the inhibitor is sequestered within an elevated pool of cyclin D1-CDK4 complexes, a significant portion of which retain kinase activity. In agreement with this, pRB is constitutively hyperphosphorylated in E5/E8 cells in vivo. The increased steady-state level of p27 is achieved largely through an increased rate of protein synthesis and does not rely on changes in p27 mRNA levels or protein half-life. This is the first report of enhanced p27 synthesis as the main mechanism for increasing protein levels in continuously cycling cells. Our results are consistent with a model in which E5/E8 promotes a coordinated elevation of cyclin D1-CDK4 and p27, as well as cyclin A-associated kinase activity, which act in concert to allow continued proliferation in the absence of mitogens.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	O'Brien, V (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			O'Brien, Vincent/0000-0002-2418-7768				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boylan JF, 1999, EXP CELL RES, V248, P110, DOI 10.1006/excr.1999.4389; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Jackson ME, 1996, INT J ONCOL, V9, P1189; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; O'Brien V, 1998, ONCOGENE, V17, P293, DOI 10.1038/sj.onc.1201937; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Russell A, 1999, ONCOGENE, V18, P6454, DOI 10.1038/sj.onc.1203030; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Tan P, 1997, CANCER RES, V57, P1259; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	49	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33861	33868		10.1074/jbc.M100958200	http://dx.doi.org/10.1074/jbc.M100958200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448948	hybrid			2022-12-25	WOS:000170910200078
J	Mathias, JR; Zhong, HL; Jin, HH; Vershon, AK				Mathias, JR; Zhong, HL; Jin, HH; Vershon, AK			Altering the DNA-binding specificity of the yeast Mat alpha 2 homeodomain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ENGRAILED HOMEODOMAIN; TRANSCRIPTION FACTOR; RECOGNITION HELIX; MCM1 PROTEIN; COMPLEX; ALPHA-2; OPERATOR; HETERODIMER; RESOLUTION	Homeodomain proteins are a highly conserved class of DNA-binding proteins that are found in virtually every eukaryotic organism. The conserved mechanism that these proteins use to bind DNA suggests that there may be at least a partial DNA recognition code for this class of proteins. To test this idea, we have investigated the sequence-specific requirements for DNA binding and repression by the yeast alpha2 homeodomain protein in association with its cofactors, Mcm1 and Mata1. We have determined the contribution for each residue in the alpha2 homeodomain that contacts the DNA in the co-crystal structures of the protein. We have also engineered mutants in the alpha2 homeodomain to alter the DNA-binding specificity of the protein. Although we were unable to change the specificity of alpha2 by making substitutions at residues 47, 54, and 55, we were able to alter the DNA-binding specificity by making substitutions at residue 50 in the homeodomain. Since other homeodomain proteins show similar changes in specificity with substitutions at residue 50, this suggests that there is at least a partial DNA recognition code at this position.	Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Vershon, AK (corresponding author), Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.				NIGMS NIH HHS [GM49265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton TB, 1997, MOL CELL BIOL, V17, P1881, DOI 10.1128/MCB.17.4.1881; ADES SE, 1994, BIOCHEMISTRY-US, V33, P9187, DOI 10.1021/bi00197a022; Billeter M, 1996, CELL, V85, P1057, DOI 10.1016/S0092-8674(00)81306-9; BURGLIN TR, 1995, BIODIVERSITY EVOLUTI, P291; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; Grant RA, 2000, BIOCHEMISTRY-US, V39, P8187, DOI 10.1021/bi000071a; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; Jin YS, 1999, MOL CELL BIOL, V19, P585; JIN YS, 1995, SCIENCE, V270, P290, DOI 10.1126/science.270.5234.290; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Li T, 1998, NUCLEIC ACIDS RES, V26, P5707, DOI 10.1093/nar/26.24.5707; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Mead J, 1996, MOL CELL BIOL, V16, P2135; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; Schott O, 1997, J MOL BIOL, V267, P673, DOI 10.1006/jmbi.1997.0905; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; TREISMAN J, 1989, CELL, V59, P553; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Zhong HL, 1997, J BIOL CHEM, V272, P8402, DOI 10.1074/jbc.272.13.8402	38	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32696	32703		10.1074/jbc.M103097200	http://dx.doi.org/10.1074/jbc.M103097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438530	hybrid			2022-12-25	WOS:000170746000044
J	Yamato, K; Hashimoto, S; Imamura, T; Uchida, H; Okahashi, N; Koseki, T; Ishisaki, A; Kizaki, M; Miyazono, K; Ikeda, Y; Nishihara, T				Yamato, K; Hashimoto, S; Imamura, T; Uchida, H; Okahashi, N; Koseki, T; Ishisaki, A; Kizaki, M; Miyazono, K; Ikeda, Y; Nishihara, T			Activation of the p21(CIP1/WAF1) promoter by bone morphogenetic protein-2 in mouse B lineage cells	ONCOGENE			English	Article						BMP; p21(CIP1/WAF1); transcription; promoter; Smad	GROWTH-FACTOR-BETA; SMAD-BINDING-ELEMENT; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL-ANALYSIS; INHIBITOR P21; DNA-DAMAGE; APOPTOSIS; ARREST; DIFFERENTIATION	BMPs exert a negative growth effect on various types of cells. We have previously reported that BMP-2 inhibited the growth of HS-72 mouse hybridoma cells by inducing p21(CIP1/WAF1) expression. In the present study, we demonstrated that BMP-2 activated the mouse p21(CIP1/WAF1) promoter in MS-72 cells, and that a 29-base pair (b) region of the promoter (-1928/-1900 relative to the TATA box), conserved between mice and humans, was responsive to BMP-2 as well as expression of Smad1, Smad4, and constitutively active mutants of BMP type I receptors, Furthermore, an oligonucleotide containing the 29-b region was found to be associated with Smad4 and phosphorylated Smad1 in the nuclear extract of BMP-2-stimulated HS-72 cells, These results suggested that BMP-2 might activate p21(CIP1/WAF1) transcription by inducing a binding of Smad4 and Smad1 to the 29-b region in HS-72 cells.	Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci, Sect Mol Cellular Oncol & Microbiol,Bunkyo Ku, Tokyo 1138549, Japan; Natl Inst Infect Dis, Dept Oral Sci, Tokyo 1628640, Japan; JFCR, Inst Canc, Dept Biochem, Tokyo 1708455, Japan; Keio Univ, Sch Med, Div Hematol, Tokyo 1608582, Japan; Natl Inst Biosci & Human Technol, Biosignaling Dept, Tsukuba, Ibaraki 3058566, Japan; Kyushu Dent Coll, Dept Oral Microbiol, Fukuoka 8038580, Japan	Tokyo Medical & Dental University (TMDU); National Institute of Infectious Diseases (NIID); Japanese Foundation for Cancer Research; Keio University; National Institute of Advanced Industrial Science & Technology (AIST); Kyushu Dental University	Yamato, K (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Div Oral Hlth Sci, Sect Mol Cellular Oncol & Microbiol,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.		okahashi, nobuo/A-4032-2010	okahashi, nobuo/0000-0002-8045-7021; Ishisaki, Akira/0000-0001-6704-4436				Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Jernvall J, 1998, DEVELOPMENT, V125, P161; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Massague J, 2000, GENE DEV, V14, P627; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NISHIHARA T, 1995, J INTERF CYTOK RES, V15, P509, DOI 10.1089/jir.1995.15.509; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Tada K, 1999, GENES CELLS, V4, P731, DOI 10.1046/j.1365-2443.1999.00293.x; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yamato K, 2000, EXP CELL RES, V257, P198, DOI 10.1006/excr.2000.4876; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	41	18	18	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4383	4392		10.1038/sj.onc.1204572	http://dx.doi.org/10.1038/sj.onc.1204572			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466619				2022-12-25	WOS:000169912600012
J	Huo, TI; Wang, XW; Forgues, M; Wu, CG; Spillare, EA; Giannini, C; Brechot, C; Harris, CC				Huo, TI; Wang, XW; Forgues, M; Wu, CG; Spillare, EA; Giannini, C; Brechot, C; Harris, CC			Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis	ONCOGENE			English	Article						HBx; mutation; p53; apoptosis; carcinogenesis	NF-KAPPA-B; HBX PROTEIN; TRANSCRIPTION FACTOR; P53 PROTEIN; TUMOR-ANTIGEN; GENE; LIVER; EXPRESSION; TRANSACTIVATION; ACTIVATION	Chronic hepatitis B virus (HBV) infection and the integration of its X gene (HBx) are closely associated with the development of hepatocellular carcinoma (HCC), The integrated HBx frequently is truncated or contains point mutations, Previous studies indicated that these HBx mutants have a diminished co-transactivational activity. We have compared the effects of wildtype (wt) HBx and its naturally occurring mutants derived from human HCCs on transcriptional co-transactivation, apoptosis and interactive effects with p53. We demonstrated that overexpression of mutant, but not wt HBx, is defective in transcriptional co-transactivation of the NF-kappaB-driven luciferase reporter. By using a microinjection technique, the HBx mutants were shown to have an attenuated pro-apoptotic activity. This deficiency may be attributed to multiple mutations in the co-transactivation domain of HBx, that leads to decreased stability of the translated product. However, wt or mutant HBx bind to p53 in vitro and retain their ability to block p53-mediated apoptosis in vivo, which has been implicated as its major tumor suppressor function. The abrogation of p53-mediated apoptosis by integrated HBx mutants may provide a selective clonal advantage for preneoplastic or neoplastic hepatocytes acid contribute to hepatocellular carcinogenesis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Taipei Vet Gen Hosp, Taipei, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; Necker Inst, Paris, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; UDICE-French Research Universities; Universite Paris Cite	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Room 2C05, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Andrisani OM, 1999, INT J ONCOL, V15, P373; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CASELMANN WH, 1995, J HEPATOL, V22, P34; Chen WN, 2000, BIOCHEM BIOPH RES CO, V276, P885, DOI 10.1006/bbrc.2000.3562; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Gottlob K, 1998, CANCER RES, V58, P3566; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; Huang Y, 2000, CANCER RES, V60, P4426; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kew MC, 1996, CLIN LAB MED, V16, P395, DOI 10.1016/S0272-2712(18)30276-2; Kew MC, 1997, HEPATOLOGY, V25, P1037, DOI 10.1002/hep.510250442; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin Y, 1997, CANCER RES, V57, P5137; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAHE Y, 1991, J BIOL CHEM, V266, P13759; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Ogden SK, 2000, J BIOL CHEM, V275, P27806; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sohn S, 2000, MUTAT RES-DNA REPAIR, V460, P17, DOI 10.1016/S0921-8777(00)00010-0; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 2000, MUTAT RES-REV MUTAT, V462, P365, DOI 10.1016/S1383-5742(00)00026-0; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang XW, 1999, ANTICANCER RES, V19, P4759; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yun CW, 2000, ONCOGENE, V19, P5163, DOI 10.1038/sj.onc.1203896	92	66	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3620	3628		10.1038/sj.onc.1204495	http://dx.doi.org/10.1038/sj.onc.1204495			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439325				2022-12-25	WOS:000169400200003
J	Wert, M; Kennedy, S; Palfrey, HC; Hay, N				Wert, M; Kennedy, S; Palfrey, HC; Hay, N			Myc drives apoptosis in PC12 cells in the absence of Max	ONCOGENE			English	Article						c-Myc; apoptosis; growth factors; Akt	NERVE GROWTH-FACTOR; C-MYC; MEDIATED APOPTOSIS; CYCLE PROGRESSION; DIFFERENTIATION; TRANSCRIPTION; FIBROBLASTS; PROTEIN; DIMERIZATION; MECHANISMS	A conditionally active chimeric form of the c-Myc protein fused to the ligand-binding domain of the estrogen receptor (MycER) was expressed in PC12 cells, Induction of Myc activity resulted in a threefold increase in apoptosis after 5 days when cells were maintained in 1% serum, The effect of Myc overexpression was dependent on its DNA-binding domain but not on its heterodimeric binding protein Max, which is absent in PC12 cells, Preincubation of the c-Myc overexpressing cells with either NGF or bFGF, but not EGF, prevented the Myc-mediated increase in apoptosis, although the signaling pathways used by NGF and bFGF to block cell death differed, NGF-mediated rescue was mediated by the phosphatidylinositol 3 ' -OH (P13) kinase/Akt pathway white rescue by bFGF was not affected by P13 kinase inhibitors, These results show that Myc can induce apoptosis in PC12 cells in a Max-independent manner and that alternate signaling pathways exist to mediate cell survival.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Hay, N (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Kennedy, Scott/0000-0002-7974-8155	NCI NIH HHS [CA71874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Bao JX, 1996, ONCOGENE, V12, P2171; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Crowder RJ, 1998, J NEUROSCI, V18, P2933; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; MARUYAMA K, 1987, ONCOGENE, V1, P361; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RIBON V, 1994, MOL CELL NEUROSCI, V5, P277, DOI 10.1006/mcne.1994.1032; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SPANDIDOS DA, 1989, INT J DEV NEUROSCI, V7, P1, DOI 10.1016/0736-5748(89)90039-7; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	27	9	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3746	3750		10.1038/sj.onc.1204466	http://dx.doi.org/10.1038/sj.onc.1204466			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439337				2022-12-25	WOS:000169400200015
J	Kim, KY; Jeong, SY; Won, J; Ryu, PD; Nam, MJ				Kim, KY; Jeong, SY; Won, J; Ryu, PD; Nam, MJ			Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; TGF-BETA; CANCER CELLS; KDR/FLK-1 RECEPTOR; SKIN TUMORS; IN-VITRO; TGF-BETA-1; GROWTH-FACTOR-BETA-1; GENE; PROGRESSION	The biological effect of transforming growth factor-beta (TGF-beta) is cell type-specific and complex. The precise role of TGF-beta is not clear in vivo. To elucidate the regulation mechanism of endogenous TGF-beta on hepatoma progression, we modified the MH129F mouse hepatoma cell with a retroviral vector encoding the extracellular region of type II TGF-beta receptor (TRII). Soluble TRII (TRIIs) blocked TGF-beta binding to TRII on the membrane of hepatoma cells. Growth of MH129F cells was inhibited by TGF-beta1 treatment; however, soluble TRII-overexpressing cells (MH129F/TRIIs) did not show any change in proliferation after TGF-beta1 treatment. MH129F/TRIIs cells also increased vascular endothelial growth factor (VEGF) expression, endothelial cell migration, and tube formation. Implantation of MH129F/TRIIs cells into C3H/He mice showed the significantly enhanced tumor formation. According to Western blot and protein kinase C assay, the expression of VEGF, KDR/flk-1 receptor, and endothelial nitric-oxide synthase was enhanced, and the phosphorylation activity of protein kinase C was increased up to 3.7-fold in MH129F/TRIIs tumors. Finally, a PECAM-1-stained intratumoral vessel was shown to be 4.2-fold higher in the MH129F/TRIIs tumor. These results indicate that VEGF expression is up-regulated by a blockade of endogenous TGF-beta signaling in TGF-beta -sensitive hepatoma cells and then stimulates angiogenesis and tumorigenicity. Therefore, we suggest that endogenous TGF-beta is a major regulator of the VEGF/flk-1-mediated angiogenesis pathway in hepatoma progression.	Natl Inst Hlth, Div Canc Res, Dept Biomed Sci, Cent Genome Ctr, Seoul 122701, South Korea; Mogam Biotechnol Res Inst, Kyonggi Do 449910, South Korea; Seoul Natl Univ, Dept Pharmacol, Coll Vet Med, Suwon 441744, South Korea	Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Seoul National University (SNU)	Nam, MJ (corresponding author), Natl Inst Hlth, Div Canc Res, Dept Biomed Sci, Cent Genome Ctr, 5 Nopbun Dong, Seoul 122701, South Korea.	genetx@hanmail.net	Ryu, Pan Dong/AGX-5700-2022	Won, Jonghwa/0000-0003-2853-8948				ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; CAPOCASALE RJ, 1995, P NATL ACAD SCI USA, V92, P5501, DOI 10.1073/pnas.92.12.5501; CHANG HL, 1993, CANCER RES, V53, P4391; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; HADDOW S, 1991, ONCOGENE, V6, P1465; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KOCH AE, 1994, J IMMUNOL, V152, P4149; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LIN JK, 1992, CANCER RES, V52, P385; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matsuzaki K, 2000, CANCER RES, V60, P1394; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nakashio T, 1997, INT J CANCER, V70, P612, DOI 10.1002/(SICI)1097-0215(19970304)70:5<612::AID-IJC20>3.3.CO;2-Y; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; ORTEGA N, 1994, FRONT BIOSCI, V4, pD141; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Pepper MS, 1996, CURR TOP MICROBIOL, V213, P31; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shen BQ, 1997, AM J PHYSIOL-LUNG C, V272, pL1115, DOI 10.1152/ajplung.1997.272.6.L1115; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Suzuki K, 1996, CANCER RES, V56, P3004; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; UEKI N, 1993, JPN J CANCER RES, V84, P589, DOI 10.1111/j.1349-7006.1993.tb02017.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Won JW, 1999, CANCER RES, V59, P1273; Wu HM, 1999, AM J PHYSIOL-HEART C, V276, pH535, DOI 10.1152/ajpheart.1999.276.2.H535	44	28	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2001	276	42					38781	38786		10.1074/jbc.M104944200	http://dx.doi.org/10.1074/jbc.M104944200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	484CT	11457844	hybrid			2022-12-25	WOS:000171673200061
J	Christmas, P; Jones, JP; Patten, CJ; Rock, DA; Zheng, YM; Cheng, SM; Weber, BM; Carlesso, N; Scadden, DT; Rettie, AE; Soberman, RJ				Christmas, P; Jones, JP; Patten, CJ; Rock, DA; Zheng, YM; Cheng, SM; Weber, BM; Carlesso, N; Scadden, DT; Rettie, AE; Soberman, RJ			Alternative splicing determines the function of CYP4F3 by switching substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-4 OMEGA-HYDROXYLASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN SEMINAL-VESICLES; 20-HYDROXYEICOSATETRAENOIC ACID; MESSENGER-RNA; HUMAN LIVER; MOLECULAR-CLONING; ARACHIDONIC-ACID; CDNA CLONING; HUMAN KIDNEY	Diversity of cytochrome P450 function is determined by the expression of multiple genes, many of which have a high degree of identity. We report that the use of alternate exons, each coding for 48 amino acids, generates isoforms of human CYP4F3 that differ in substrate specificity, tissue distribution, and biological function. Both isoforms contain a total of 520 amino acids. CYP4F3A, which incorporates exon 4, inactivates LTB4 by omega -hydroxylation (K-m = 0.68 mum) but has low activity for arachidonic acid (K-m = 185 mum); it is the only CYP4F isoform expressed in myeloid cells in peripheral blood and bone marrow. CYP4F3B incorporates exon 3 and is selectively expressed in liver and kidney; it is also the predominant CYP4F isoform in trachea and tissues of the gastrointestinal tract. CYP4F3B has a 30-fold higher K-m for LTB4 compared with CYP4F3A, but it utilizes arachidonic acid as a substrate for omega -hydroxylation (K-m = 22 mum) and generates 20-HETE, an activator of protein kinase C and Ca2+/calmodulin-dependent kinase II. Homology modeling demonstrates that the alternative exon has a position in the molecule which could enable it to contribute to substrate interactions. The results establish that tissue-specific alternative splicing of pre-mRNA can be used as a mechanism for changing substrate specificity and increasing the functional diversity of cytochrome P450 genes.	Massachusetts Gen Hosp E, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, AIDS Res Ctr, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02129 USA; Washington State Univ, Dept Chem, Pullman, WA 99164 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Gentest Corp, Woburn, MA 01801 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Washington State University; University of Washington; University of Washington Seattle	Christmas, P (corresponding author), Massachusetts Gen Hosp E, Ctr Immunol & Inflammatory Dis, 149 Navy Yard,13th St, Boston, MA 02129 USA.	christma@helix.mgh.harvard.edu			NHLBI NIH HHS [5R01HL55718] Funding Source: Medline; NIDDK NIH HHS [5R01DK52234, 1K01DK59991-01] Funding Source: Medline; NIEHS NIH HHS [ES09122] Funding Source: Medline; NIGMS NIH HHS [5R01GM9054-09, 5R01GM-61823] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061823] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amlal H, 1998, AM J PHYSIOL-CELL PH, V274, pC1047, DOI 10.1152/ajpcell.1998.274.4.C1047; Bylund J, 2000, J BIOL CHEM, V275, P21844, DOI 10.1074/jbc.M001712200; Bylund J, 1999, BIOCHEM BIOPH RES CO, V261, P169, DOI 10.1006/bbrc.1999.1011; Bylund J, 2001, BIOCHEM BIOPH RES CO, V280, P892, DOI 10.1006/bbrc.2000.4191; Chang YT, 1999, PROTEINS, V34, P403, DOI 10.1002/(SICI)1097-0134(19990215)34:3<403::AID-PROT12>3.0.CO;2-D; Chen W, 1998, BIOCHEMISTRY-US, V37, P4420, DOI 10.1021/bi972940a; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Cui XM, 2000, GENOMICS, V68, P161, DOI 10.1006/geno.2000.6276; Desrochers M, 1996, BIOCHEM PHARMACOL, V52, P1311, DOI 10.1016/0006-2952(96)00502-3; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GOTOH O, 1992, J BIOL CHEM, V267, P83; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; Hashizume T, 2001, BIOCHEM BIOPH RES CO, V280, P1135, DOI 10.1006/bbrc.2000.4238; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; Hoch U, 2000, J BIOL CHEM, V275, P26952; Huang ZQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P101, DOI 10.1006/abbi.1997.0153; Jacobs ER, 1999, AM J PHYSIOL-LUNG C, V276, pL280, DOI 10.1152/ajplung.1999.276.2.L280; Kikuta Y, 1999, DNA CELL BIOL, V18, P723, DOI 10.1089/104454999315006; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; Kikuta Y, 1998, DNA CELL BIOL, V17, P221, DOI 10.1089/dna.1998.17.221; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; Lewis DFV, 1999, XENOBIOTICA, V29, P763, DOI 10.1080/004982599238227; Loughran PA, 2000, BIOCHEMISTRY-US, V39, P15110, DOI 10.1021/bi001522u; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; MACICA C, 1993, AM J PHYSIOL, V265, pG735, DOI 10.1152/ajpgi.1993.265.4.G735; McGiff JC, 1999, AM J PHYSIOL-REG I, V277, pR607, DOI 10.1152/ajpregu.1999.277.3.R607; MIGLIORISI G, 1987, AM J PATHOL, V127, P157; MILES JS, 1989, NUCLEIC ACIDS RES, V17, P8241, DOI 10.1093/nar/17.20.8241; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; Muthalif MM, 1998, P NATL ACAD SCI USA, V95, P12701, DOI 10.1073/pnas.95.21.12701; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Nowicki S, 1997, J CLIN INVEST, V99, P1224, DOI 10.1172/JCI119279; PALMER CNA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P161, DOI 10.1016/0167-4781(93)90285-L; Powell PK, 1998, J PHARMACOL EXP THER, V285, P1327; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SHAK S, 1984, J BIOL CHEM, V259, P181; Simpson ER, 1997, FASEB J, V11, P29, DOI 10.1096/fasebj.11.1.9034163; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; SOBERMAN RJ, 1985, P NATL ACAD SCI USA, V82, P2292, DOI 10.1073/pnas.82.8.2292	42	106	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38166	38172						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11461919				2022-12-25	WOS:000171526500060
J	Zhang, ZM; Zhu, LY; Lin, DH; Chen, FQ; Chen, DJ; Chen, Y				Zhang, ZM; Zhu, LY; Lin, DH; Chen, FQ; Chen, DJ; Chen, Y			The three-dimensional structure of the C-terminal DNA-binding domain of human Ku70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NUCLEAR-MAGNETIC-RESONANCE; TRANSFER-RNA-SYNTHETASE; ENDONUCLEASE-VII; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NMR STRUCTURE; J-COUPLINGS; LIGASE-IV; COMPLEX	The proteins Ku70 (69.8 kDa) and Ku80 (82.7 kDa) form a heterodimeric complex that is an essential component of the nonhomologous end joining DNA double-strand break repair pathway in mammalian cells. Interaction of Ku with DNA is central for the functions of Ku. Ku70, which is mainly responsible for the DNA binding activity of the Ku heterodimer, contains two DNA-binding domains. We have solved the solution structure of the Ku80-independent DNA-binding domain of Ku70 encompassing residues 536-609 using nuclear magnetic resonance spectroscopy. Residues 536-560 are highly flexible and have a random structure but form specific interactions with DNA. Residues 561-609 of Ku70 form a well defined structure with 3 alpha -helices and also interact with DNA. The three-dimensional structure indicates that all conserved hydrophobic residues are in the hydrophobic core and therefore may be important for structural integrity. Most of the conserved positively charged residues are likely to be critical for DNA recognition. The C-terminal DNA-binding domain of Ku70 contains a helix-extended strand-helix motif, which occurs in other nucleic acid-binding proteins and may represent a common nucleic acid binding motif.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Grad Program Biol Sci, Duarte, CA 91010 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Cell & Mol Biol, Div Life Sci, Berkeley, CA 94720 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.				NCI NIH HHS [CA 50519] Funding Source: Medline; NIGMS NIH HHS [GM 54190] Funding Source: Medline; NLM NIH HHS [1G08LM06722-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA050519, R01CA050519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054190] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [G08LM006722] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BAX A, 1994, METHOD ENZYMOL, V239, P79; Birkenbihl RP, 1998, EMBO J, V17, P4527, DOI 10.1093/emboj/17.15.4527; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Golz S, 1997, EUR J BIOCHEM, V245, P573, DOI 10.1111/j.1432-1033.1997.00573.x; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORE PJ, 1983, J MAGN RESON, V55, P283, DOI 10.1016/0022-2364(83)90240-8; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; Koike M, 1999, EXP CELL RES, V250, P401, DOI 10.1006/excr.1999.4507; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; REEVES WH, 1991, J IMMUNOL, V146, P2678; Rost B, 1996, METHOD ENZYMOL, V266, P525; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034	36	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38231	38236						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11457852				2022-12-25	WOS:000171526500069
J	Craig, R; Wagner, M; McCardle, T; Craig, AG; Glembotski, CC				Craig, R; Wagner, M; McCardle, T; Craig, AG; Glembotski, CC			The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LEUKEMIA INHIBITORY FACTOR; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE KINASE; RAT CARDIAC MYOCYTES; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; DEPENDENT TRANSCRIPTION; CELL HYPERTROPHY; GENE-EXPRESSION	Many cell types mount elaborate, compensatory responses to stress that enhance survival; however, the intracellular signals that govern these responses are poorly understood. Cardiotrophin-1 (CT-1), a stress-induced cytokine, belongs to the interleukin-6/glycoprotein 130 receptor-coupled cytokine family. CT-1 is released from the heart in response to hypoxic stress, and it protects cardiac myocytes from hypoxia-induced apoptosis, thus establishing a central role for this cytokine in the cardiac stress response. In the present study, CT-1 activated p38 and ERK MAPKs as well as Akt in cultured cardiac myocytes; these three pathways were activated in a parallel manner. CT-1 also induced the degradation of the NF-kappaB cytosolic anchor, I kappaB, as well as the translocation of the p65 subunit of NF-kappaB to the nucleus and increased expression of an NF-kappaB-dependent reporter gene. Inhibitors of the p38, ERK, or ARt pathways each partially reduced CT-1-mediated NF-kappaB activation, as well as the cytoprotective effects of CT-1 against hypoxic stress. Together, the inhibitors completely blocked CT-1-dependent NF-kappaB activation and cytoprotection. A cell-permeable peptide that selectively disrupted NF-kappaB activation also completely inhibited the cytoprotective effects of CT-1. These results indicate that CT-1 signals through p38, ERK, and Akt in a parallel manner to activate NF-kappaB and that NF-kappaB is required for CT-1 to mediate its full cytoprotective effects in cardiac myocytes.	San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	California State University System; San Diego State University; California State University System; San Diego State University; Salk Institute	Glembotski, CC (corresponding author), San Diego State Univ, Inst Heart, San Diego, CA 92182 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056861, P01HL046345, R01HL063975] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345, HL-56861, HL-63975] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asai S, 2000, BIOCHEM BIOPH RES CO, V279, P320, DOI 10.1006/bbrc.2000.3932; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Giordano V, 1997, J IMMUNOL, V158, P4097; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Habecker BA, 1997, J BIOL CHEM, V272, P30421, DOI 10.1074/jbc.272.48.30421; Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hishinuma S, 1999, BIOCHEM BIOPH RES CO, V264, P436, DOI 10.1006/bbrc.1999.1535; Jin HK, 1996, CYTOKINE, V8, P920, DOI 10.1006/cyto.1996.0123; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kubin T, 1999, AM J PHYSIOL-HEART C, V276, pH2179, DOI 10.1152/ajpheart.1999.276.6.H2179; Kuwahara K, 2000, J MOL CELL CARDIOL, V32, P1385, DOI 10.1006/jmcc.2000.1177; Kuwahara K, 1999, CIRCULATION, V100, P1116, DOI 10.1161/01.CIR.100.10.1116; Latchman DS, 2000, PHARMACOL THERAPEUT, V85, P29, DOI 10.1016/S0163-7258(99)00049-2; Mackay K, 2000, J MOL CELL CARDIOL, V32, P1585, DOI 10.1006/jmcc.2000.1194; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Ozes ON, 1999, NATURE, V401, P82; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Richards CD, 2000, CYTOKINE, V12, P613, DOI 10.1006/cyto.1999.0635; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Saraste A, 1997, CIRCULATION, V95, P320; SETH A, 1992, J BIOL CHEM, V267, P24796; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Thier M, 1999, J NEUROSCI RES, V55, P411; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang DC, 1996, LAB INVEST, V75, P809; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Wollert KC, 1997, J MOL MED-JMM, V75, P492, DOI 10.1007/s001090050134; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	71	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37621	37629		10.1074/jbc.M103276200	http://dx.doi.org/10.1074/jbc.M103276200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11448959	hybrid			2022-12-25	WOS:000171375700099
J	Hausmann, S; Ho, CK; Schwer, B; Shuman, S				Hausmann, S; Ho, CK; Schwer, B; Shuman, S			An essential function of Saccharomyces cerevisiae RNA triphosphatase Cet1 is to stabilize RNA guanylyltransferase Ceg1 against thermal inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; CAPPING ENZYME SUBUNITS; PRE-MESSENGER-RNA; POLYMERASE-II; IN-VIVO; COMPONENT; PHOSPHORYLATION; MECHANISM; ASSOCIATION; MUTANTS	Saccharomyces cerevisiae RNA triphosphatase (Cet1) and RNA guanylyltransferase (Ceg1) interact in vivo and in vitro to form a bifunctional mRNA capping enzyme complex. Here we show that the guanylyltransferase activity of Ceg1 is highly thermolabile in vitro (98% loss of activity after treatment for 10 min at 35 degreesC) and that binding to recombinant Cet1 protein, or a synthetic peptide Cet1(232-265), protects Ceg1 from heat inactivation at physiological temperatures. Candida albicans guanylyltransferase Cgt1 is also thermolabile and is stabilized by binding to Cet1(232-265). In contrast, Schizosaccharomyces pombe and mammalian guanylyltransferases are intrinsically thermostable in vitro and they are unaffected by Cet1(232-265). We show that the requirement for the Ceg1-binding domain of Cet1 for yeast cell growth can be circumvented by overexpression in high gene dosage of a catalytically active mutant lacking the Ceg1-binding site (Cet1(269-549)) provided that Ceg1 is also overexpressed. However, such cells are unable to grow at 37 degreesC. In contrast, cells overexpressing Cet1(269-549) in single copy grow at all temperatures if they express either the S. pombe or mammalian guanylyltransferase in lieu of Ceg1. Thus, the cell growth phenotype correlates with the inherent thermal stability of the guanylyltransferase. We propose that an essential function of the Cet1-Ceg1 interaction is to stabilize Ceg1 guanylyltransferase activity rather than to allosterically regulate its activity. We used protein-affinity chromatography to identify the COOH-terminal segment of Ceg1 (from amino acids 245-459) as an autonomous Cet1-binding domain. Genetic experiments implicate two peptide segments, (KPVSLYVW295)-K-287 and (337)WQNLKNLEQPLN(348), as likely constituents of the Cet1-binding site on Ceg1.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Ho, KIong/GPP-6051-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Fresco LD, 1996, RNA, V2, P584; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lehman K, 2001, J BIOL CHEM, V276, P14996, DOI 10.1074/jbc.M100588200; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; PAI Y, 2001, NUCLEIC ACIDS RES, V29, P387; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schwer B, 1996, RNA, V2, P574; Schwer B, 2001, J BIOL CHEM, V276, P1857, DOI 10.1074/jbc.M006072200; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Takase Y, 2000, MOL CELL BIOL, V20, P9307, DOI 10.1128/MCB.20.24.9307-9316.2000; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; YAMAGISHI M, 1995, MOL GEN GENET, V249, P147, DOI 10.1007/BF00290360; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	28	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36116	36124		10.1074/jbc.M105856200	http://dx.doi.org/10.1074/jbc.M105856200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11463793	hybrid			2022-12-25	WOS:000171194500011
J	Thirunavukkarasu, K; Miles, RR; Halladay, DL; Yang, XH; Galvin, RJS; Chandrasekhar, S; Martin, TJ; Onyia, JE				Thirunavukkarasu, K; Miles, RR; Halladay, DL; Yang, XH; Galvin, RJS; Chandrasekhar, S; Martin, TJ; Onyia, JE			Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta) - Mapping of the OPG promoter region that mediates TGF-beta effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTOGENESIS-INHIBITORY FACTOR; N-TERMINAL KINASE; TRANSCRIPTION FACTOR OSF2/CBFA1; SMAD BINDING-ELEMENT; DIFFERENTIATION FACTOR; MATURE OSTEOCLASTS; RECEPTOR ACTIVATOR; OSTEOBLASTIC CELLS; BONE-RESORPTION; KAPPA-B	Transforming growth factor-beta (TGF-beta) regulates osteoclastogenesis and osteoclast survival, in part through the induction of osteoprotegerin (OPG), a protein known to inhibit osteoclast formation and function. To explore the molecular basis of TGF-beta regulation of OPG expression, we evaluated the effects of TGF-beta on osteoclast formation, OPG protein secretion, mRNA expression, and gene transcription. The marked inhibitory effect of TGF-beta on osteoclast differentiation was confirmed in a co-culture model utilizing murine stromal/osteoblastic BALC cells and bone marrow hematopoietic precursors. This inhibition in osteoclast differentiation was preceded by a decrease in RANKL mRNA expression (5-fold) and a reciprocal increase in OPG mRNA (6.1-fold) and protein (7.1-fold) expression in BALC cells. At the promoter/transcriptional level, TGF-beta treatment resulted in a 3-10-fold increase in reporter gene activity directed by a 5.9-kilobase fragment of the human OPG promoter in transfection assays performed in UMR106 cells. The effect of TGF-beta was mimicked by TGF-beta2 and -beta3 but not by BMP-4, suggesting a TGF-beta signal-specific effect. Deletion analysis revealed that a 183-base pair region (-372 to -190) in the promoter was required for TGF-beta responsiveness, and this region was sufficient to confer TGF-beta inducibility to a heterologous (osteocalcin) minimal promoter. Substitution mutations that disrupted the Cbfal- and/or Smad-binding elements present in the 183-base pair region resulted in a decrease in baseline expression and in the responsiveness to TGF-beta and Cbfa1. Collectively, these studies indicate the involvement and possible interaction of Cbfa1 and Smad proteins in mediating the effects of TGF-beta on OPG transcription.	Eli Lilly & Co, Lilly Res Labs, Gene Regulat Bone & Inflammat Res, Indianapolis, IN 46285 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Eli Lilly; St. Vincent's Institute of Medical Research	Onyia, JE (corresponding author), Eli Lilly & Co, Lilly Res Labs, Gene Regulat Bone & Inflammat Res, Drop Code 0403, Indianapolis, IN 46285 USA.							Akatsu T, 1998, BONE, V23, P495, DOI 10.1016/S8756-3282(98)00141-0; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; DUCY P, 1995, MOL CELL BIOL, V15, P1858; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Galvin RJS, 1998, BONE, V23, P233, DOI 10.1016/S8756-3282(98)00096-9; Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632; Grimm SL, 1999, BIOTECHNIQUES, V27, P220, DOI 10.2144/99272bm01; Hakeda Y, 1998, BIOCHEM BIOPH RES CO, V251, P796, DOI 10.1006/bbrc.1998.9523; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394; Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743; John V, 1996, ENDOCRINOLOGY, V137, P2457, DOI 10.1210/en.137.6.2457; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Morinaga T, 1998, EUR J BIOCHEM, V254, P685, DOI 10.1046/j.1432-1327.1998.2540685.x; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Nagai M, 1999, BIOCHEM BIOPH RES CO, V257, P719, DOI 10.1006/bbrc.1999.0524; Onyia JE, 2000, J BONE MINER RES, V15, P863, DOI 10.1359/jbmr.2000.15.5.863; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; QUINN JM, 2001, IN PRESS J BONE MIN; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Shi MJ, 1998, J IMMUNOL, V161, P6751; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091; Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200; Thirunavukkarasu K, 2000, BIOTECHNIQUES, V28, P506, DOI 10.2144/00283st09; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Wan M, 2001, J BIOL CHEM, V276, P10119, DOI 10.1074/jbc.M006918200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	50	109	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36241	36250		10.1074/jbc.M104319200	http://dx.doi.org/10.1074/jbc.M104319200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11451955	hybrid			2022-12-25	WOS:000171194500027
J	Sandrock, B; Egly, JM				Sandrock, B; Egly, JM			A yeast four-hybrid system identifies Cdk-activating kinase as a regulator of the XPD helicase, a subunit of transcription factor IIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; FACTOR TFIIH; XERODERMA-PIGMENTOSUM; SUBSTRATE-SPECIFICITY; DNA-REPAIR; MAT1; PHOSPHORYLATION; PROTEIN; GENE; RECEPTOR	To understand the role of the various components of TFIIH, a DNA repair/transcription factor, a yeast four-hybrid system was designed. When the ternary Cdk-activating kinase (CAK) complex composed of Cdk7, cyclin H, and MAT1 was used as bait, the xeroderma pigmentosum (XP) D helicase of transcription factor IIH (TFIIH), among other proteins, was identified as an interacting partner. Deletion mutant analyses demonstrated that the coiled-coil and the hydrophobic domains of MAT1 interlink the CAK complex directly with the N-terminal domain of XPD. Using immunoprecipitates from cells coinfected with baculoviruses, we further validated the bridging function of XPD, which anchors CAK to the core TFIIH. In addition we show that upon interaction with MAT1, CAK inhibits the helicase activity of XPD. This inhibition is overcome upon binding to p44, a subunit of the core TFIIH. It is not surprising that under these conditions some XPD mutations affect interactions not only with p44, but also with MAT1, thus preventing either the CAK inhibitory function within CAK(.)XPD and/or the role of CAK within TFIIH and, consequently, explaining the variety of the XP phenotypes.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Egly, JM (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.	egly@igbmc.u-strasbg.fr						Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Brachmann RK, 1997, CURR OPIN BIOTECH, V8, P561, DOI 10.1016/S0958-1669(97)80029-8; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Feaver WJ, 2000, J BIOL CHEM, V275, P5941, DOI 10.1074/jbc.275.8.5941; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Gaudon C, 1999, EMBO J, V18, P2229, DOI 10.1093/emboj/18.8.2229; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Holstege FCP, 1999, P NATL ACAD SCI USA, V96, P2, DOI 10.1073/pnas.96.1.2; ICHIHASHI M, 1988, ARCH DERMATOL, V124, P256, DOI 10.1001/archderm.124.2.256; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KERIEL A, 2001, CDK ACTIVATING KINAS; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; Marinoni JC, 1997, METHODS, V12, P235, DOI 10.1006/meth.1997.0476; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Riedl T, 2000, GENE EXPRESSION, V9, P3; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rose MD., 1990, METHODS YEAST GENETI; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; SANDROCK B, 2000, METH MOL B, V177, P271; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Seroz T, 2000, J BIOL CHEM, V275, P33260, DOI 10.1074/jbc.M004764200; STEFANINI M, 1992, MUTAT RES, V273, P119, DOI 10.1016/0921-8777(92)90073-C; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAKAYAMA K, 1995, CANCER RES, V55, P5656; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638	50	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35328	35333		10.1074/jbc.M105570200	http://dx.doi.org/10.1074/jbc.M105570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11445587	hybrid			2022-12-25	WOS:000171109300018
J	Stevens, PA; Pediani, J; Carrillo, JJ; Milligan, G				Stevens, PA; Pediani, J; Carrillo, JJ; Milligan, G			Coordinated agonist regulation of receptor and G protein palmitoylation and functional rescue of palmitoylation-deficient mutants of the G protein G(11)alpha following fusion to the alpha(1b)-adrenoreceptor - Palmitoylation of G(11 alpha) is not required for interaction with beta-gamma complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDASE-C; SIGNAL-TRANSDUCTION; ALPHA-SUBUNITS; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; HORMONE RECEPTOR; ACTIVATION; BINDING; G(Q); DEPALMITOYLATION	Transfection of either the alb-adrenoreceptor or Gall into a fibroblast cell line derived from a G alpha (q)/G alpha (11) double knockout mouse failed to produce elevation of intracellular [Ca2+] upon the addition of agonist. Co-expression of these two polypeptides, however, produced a significant stimulation. Co-transfection of the alpha (1b)-adrenoreceptor with the palmitoylation-resistant C9S,C10S G alpha (11) also failed to produce a signal, and much reduced and kinetically delayed signals were obtained using either C9S G alpha (11) or C10S G alpha (11). Expression of a fusion protein between the alpha (1b)-adrenoreceptor and G alpha (11) allowed [Ca2+](i) elevation, and this was also true for a fusion protein between the alpha (1b)-adrenoreceptor and C9S,C10S G alpha (11), since this strategy ensures proximity of the two polypeptides at the cell membrane. For both fusion proteins, co-expression of transducin alpha, as a beta . gamma -sequestering agent, fully attenuated the Ca2+ signal. Both of these fusion proteins and one in which an acylation-resistant form of the receptor was linked to wild type G alpha (11) were also targets for agonist-regulated [H-3]palmitoylation and bound [S-35]guanosine 5 ' -3-O-(thio)triphosphate (GTP gammaS) in an agonist concentration-dependent manner. The potency of agonist to stimulate [S-35]GTP gammaS binding was unaffected by the palmitoylation potential of either receptor or G protein. These studies provide clear evidence for coordinated, agonist-mediated regulation of the post-translational acylation of both a receptor and partner G protein and demonstrate the capacity of such fusions to bind and then release beta . gamma complex upon agonist stimulation whether or not the G protein can be palmitoylated. They also demonstrate that Ca2+ signaling in EF88 cells by such fusion proteins is mediated via release of the G protein beta . gamma complex.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011; Pediani, John/F-2708-2019	Milligan, Graeme/0000-0002-6946-3519; Pediani, John/0000-0001-6615-537X				Beck HI, 1997, NEUROREPORT, V8, P937, DOI 10.1097/00001756-199703030-00024; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grassie MA, 1998, METH MOL B, V88, P241; Groarke DA, 2001, MOL PHARMACOL, V59, P375, DOI 10.1124/mol.59.2.375; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haley JE, 2000, J NEUROSCI, V20, P3973; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Johnson GJ, 1996, BIOCHEM J, V318, P1023, DOI 10.1042/bj3181023; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; KIM GD, 1994, J BIOL CHEM, V269, P19933; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lee TW, 1999, BIOCHEMISTRY-US, V38, P13801, DOI 10.1021/bi9908282; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Loisel TP, 1999, J BIOL CHEM, V274, P31014, DOI 10.1074/jbc.274.43.31014; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; MILLIGAN G, 1993, J NEUROCHEM, V61, P845, DOI 10.1111/j.1471-4159.1993.tb03595.x; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MILLIGAN G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P208, DOI 10.1016/0167-4889(93)90143-D; MILLIGAN G, 2000, HANDB EXP PHARM, V148, P363; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; Moffett S, 2001, J NEUROCHEM, V76, P269, DOI 10.1046/j.1471-4159.2001.00005.x; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; Small KM, 2000, BIOCHEMISTRY-US, V39, P2815, DOI 10.1021/bi992497z; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Stevens PA, 2000, MOL PHARMACOL, V58, P438, DOI 10.1124/mol.58.2.438; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Wise A, 1997, FEBS LETT, V407, P257, DOI 10.1016/S0014-5793(97)00300-1; Wise A, 1997, BIOCHEMISTRY-US, V36, P10620, DOI 10.1021/bi9702997; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745; Zywietz A, 2001, J BIOL CHEM, V276, P3840, DOI 10.1074/jbc.M007819200	58	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35883	35890		10.1074/jbc.M103816200	http://dx.doi.org/10.1074/jbc.M103816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461908	hybrid			2022-12-25	WOS:000171109300088
J	Tanaka, T; Fukui, T; Imanaka, T				Tanaka, T; Fukui, T; Imanaka, T			Different cleavage specificities of the dual catalytic domains in chitinase from the hyperthermophilic archaeon Thermococcus kodakaraensis KOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXA-N-ACETYLCHITOHEXAOSE; BACILLUS-CIRCULANS WL-12; GENE; SYSTEM; CHITOHEXAOSE; HYDROLYSIS; EXPRESSION; SEQUENCE; LYSOZYME; CHIA	The chitinase from the hyperthermophilic archaeon Thermococcus kodakaraensis KOD1, Th-ChiA, has an interesting multidomain structure containing dual catalytic domains and triple chitin-binding domains. To determine the biochemical properties of each domain, we constructed deletion mutant genes corresponding to the individual catalytic domains and purified the recombinant proteins. A synergistic effect was observed when chitin was degraded in the presence of both catalytic domains, suggesting different cleavage specificity of these domains. Analyses of degradation products from N-acetyl-chitooligosaccharides and their chromogenic derivatives with thin layer chromatography indicated that the N-terminal catalytic domain mainly hydrolyzed the second glycosidic bond from the nonreducing end of the oligomers, whereas the C-terminal domain randomly hydrolyzed glycosidic bonds other than the first bond from the nonreducing end. Both catalytic domains formed diacetyl-chitobiose as a major end product and possessed transglycosylation activity. Further analysis of degradation products from colloidal chitin with high performance liquid chromatography showed that the N-terminal catalytic domain exclusively liberated diacetyl-chitobiose, whereas reactions with the C-terminal domain led to N-acetyl-chitooligosaccharides of various lengths. These results demonstrated that the N-terminal and C-terminal catalytic domains functioned as exo- and endochitinases, respectively. The biochemical results provide a physiological explanation for the presence of two catalytic domains with different specificity and suggest a cooperative function between the two on a single polypeptide in the degradation of chitin.	Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Kyoto 6068501, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol Program CREST, Kawaguchi, Saitama 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Imanaka, T (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Sakyo Ku, Kyoto 6068501, Japan.	imanaka@sbchem.kyoto-u.ac.jp	Fukui, Toshiaki/S-6882-2019; Tanaka, Takeshi/C-2921-2012; 福居, 俊昭/K-5056-2012	Fukui, Toshiaki/0000-0003-4557-6284; Tanaka, Takeshi/0000-0001-7547-7928; 福居, 俊昭/0000-0003-4557-6284				Alam MM, 1996, J FERMENT BIOENG, V82, P28, DOI 10.1016/0922-338X(96)89450-5; AUSTIN PR, 1988, METHOD ENZYMOL, V161, P403; Boisset C, 2000, APPL ENVIRON MICROB, V66, P1444, DOI 10.1128/AEM.66.4.1444-1452.2000; Brurberg MB, 1996, MICROBIOL-SGM, V142, P1581, DOI 10.1099/13500872-142-7-1581; Driskill LE, 1999, APPL ENVIRON MICROB, V65, P893; Ezaki S, 1999, J BIOSCI BIOENG, V88, P130, DOI 10.1016/S1389-1723(99)80190-X; FUKAMIZO T, 1985, INSECT BIOCHEM, V15, P141, DOI 10.1016/0020-1790(85)90001-0; Gaudin C, 2000, J BACTERIOL, V182, P1910, DOI 10.1128/JB.182.7.1910-1915.2000; Gooday Graham W., 1994, P279; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hiramatsu S, 1999, VIROLOGY, V260, P308, DOI 10.1006/viro.1999.9824; Honda Y, 2000, FEBS LETT, V476, P194, DOI 10.1016/S0014-5793(00)01729-4; HUBER R, 1995, ARCH MICROBIOL, V164, P255, DOI 10.1007/s002030050262; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; Morimoto K, 1999, APPL MICROBIOL BIOT, V51, P340, DOI 10.1007/s002530051400; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; OWUSU RK, 1989, ENZYME MICROB TECH, V11, P568, DOI 10.1016/0141-0229(89)90084-7; Sambrook J, 2001, MOL CLONING LAB MANU; Shiro M, 1996, BBA-GENE STRUCT EXPR, V1305, P44, DOI 10.1016/0167-4781(95)00213-8; Sugiyama J, 1999, J MOL BIOL, V286, P247, DOI 10.1006/jmbi.1998.2458; Sun LW, 1999, VIROLOGY, V263, P376, DOI 10.1006/viro.1999.9958; SUZUKI K, 1986, CARBOHYD RES, V151, P403, DOI 10.1016/S0008-6215(00)90359-8; Suzuki K, 1999, BIOCHEM J, V343, P587, DOI 10.1042/0264-6021:3430587; Tanaka T, 1999, APPL ENVIRON MICROB, V65, P5338; Techkarnjanaruk S, 1999, MICROBIOL-SGM, V145, P925, DOI 10.1099/13500872-145-4-925; TOKORO A, 1988, CHEM PHARM BULL, V36, P784; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Tsujibo H, 1999, FEMS MICROBIOL LETT, V181, P83, DOI 10.1016/S0378-1097(99)00517-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Watanabe T, 2001, FEBS LETT, V494, P74, DOI 10.1016/S0014-5793(01)02317-1; WEI W, 1991, INT J BIOL MACROMOL, V13, P281, DOI 10.1016/0141-8130(91)90027-R	31	80	87	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35629	35635		10.1074/jbc.M105919200	http://dx.doi.org/10.1074/jbc.M105919200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11468293	hybrid			2022-12-25	WOS:000171109300057
J	Harris, JL; Niles, A; Burdick, K; Maffitt, M; Backes, BJ; Ellman, JA; Kuntz, I; Haak-Frendscho, M; Craik, CS				Harris, JL; Niles, A; Burdick, K; Maffitt, M; Backes, BJ; Ellman, JA; Kuntz, I; Haak-Frendscho, M; Craik, CS			Definition of the extended substrate specificity determinants for beta-tryptases I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; HUMAN-LUNG TRYPTASE; NUCLEIC-ACIDS; FORCE-FIELD; ANGIOGENESIS; THROMBIN; PURIFICATION; INHIBITORS; LIBRARIES; PROTEINS	Tryptases betaI and beta II were heterologously expressed and purified in yeast to functionally characterize the substrate specificity of each enzyme. Three positional scanning combinatorial tetrapeptide substrate libraries were used to determine the primary and extended substrate specificity of the proteases. Both enzymes have a strict primary preference for cleavage after the basic amino acids, lysine and arginine, with only a slight preference for lysine over arginine. betaI and beta II tryptase share similar extended substrate specificity, with preference for proline at P4, preference for arginine or lysine at P3, and P2 showing a slight preference for asparagine. Measurement of kinetic constants with multiple substrates designed for beta -tryptases reveal that selectivity is highly dependent on ground state substrate binding. Coupled with the functional determinants, structural determinants of tryptase substrate specificity were identified. Molecular docking of the preferred substrate sequence to the three-dimensional tetrameric tryptase structure reveals a novel extended substrate binding mode that involves interactions from two adjacent protomers, including P4 Thr-96', P3 Asp-60B' and Glu-217, and P1 Asp-189. Based on the determined substrate information, a mechanism-based tetrapeptide-chloromethylketone inhibitor was designed and shown to be a potent tryptase inhibitor. Finally, the cleavage sites of several physiologically relevant substrates of beta -tryptases show consistency with the specificity data presented here.	Univ Calif San Francisco, Dept Pharmaceut Chem, Program Chem & Chem Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Promega Corp, Dept Neurobiol & Immunol, Madison, WI 53711 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Promega Corporation; University of California System; University of California Berkeley	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Program Chem & Chem Biol, San Francisco, CA 94143 USA.		Ellman, Jonathan A/C-7732-2013					Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; Burgess LE, 1999, P NATL ACAD SCI USA, V96, P8348, DOI 10.1073/pnas.96.15.8348; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Lamb ML, 2001, PROTEINS, V42, P296, DOI 10.1002/1097-0134(20010215)42:3<296::AID-PROT20>3.0.CO;2-F; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Niles AL, 1998, BIOTECHNOL APPL BIOC, V28, P125; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Ribatti D, 2000, INT J CANCER, V85, P171, DOI 10.1002/(SICI)1097-0215(20000115)85:2<171::AID-IJC4>3.0.CO;2-W; Rice KD, 1998, CURR PHARM DESIGN, V4, P381; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; STACK MS, 1994, J BIOL CHEM, V269, P9416; Takanami I, 2000, CANCER, V88, P2686, DOI 10.1002/1097-0142(20000615)88:12<2686::AID-CNCR6>3.0.CO;2-6; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; TANAKA T, 1983, J BIOL CHEM, V258, P3552; Toth T, 2000, HUM PATHOL, V31, P955; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216	26	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34941	34947		10.1074/jbc.M102997200	http://dx.doi.org/10.1074/jbc.M102997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11438529	hybrid			2022-12-25	WOS:000171024600080
J	Kumar, JK; Tabor, S; Richardson, CC				Kumar, JK; Tabor, S; Richardson, CC			Role of the C-terminal residue of the DNA polymerase of bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID POLYMERASE; I KLENOW FRAGMENT; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; EXONUCLEASE ACTIVITIES; REPLICATION FIDELITY; KINETIC MECHANISM; GENE-5 PROTEIN; PROCESSIVITY; THIOREDOXIN	The crystal structure of the DNA polymerase encoded by gene 5 of bacteriophage T7, in a complex with its processivity factor, Escherichia coli thioredoxin, a primer-template, and an incoming deoxynucleoside triphosphate reveals a putative hydrogen bond between the C-terminal residue, histidine 704 of gene 5 protein, and an oxygen atom on the penultimate phosphate diester of the primer strand. Elimination of this electrostatic interaction by replacing His(704) with alanine renders the phage nonviable, and no DNA synthesis is observed in vivo. Polymerase activity of the genetically altered enzyme on primed M13 DNA is only 12% of the wild-type enzyme, and its processivity is drastically reduced. Kinetic parameters for binding a primer-template (K-D(app)), nucleotide binding (K-m), and k(off) for dissociation of the altered polymerase from a primer-template are not significantly different from that of wild-type T7 DNA polymerase. However, the decrease in polymerase activity is concomitant with increased hydrolytic activity, judging from the turnover of nucleoside triphosphate into the corresponding nucleoside monophosphate (percentage of turnover, 65%) during DNA synthesis. Biochemical data along with structural observations imply that the terminal amino acid residue of T7 DNA polymerase plays a critical role in partitioning DNA between the polymerase and exonuclease sites.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.				NIGMS NIH HHS [GM-54397] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CARVER TE, 1994, P NATL ACAD SCI USA, V91, P10670, DOI 10.1073/pnas.91.22.10670; Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; HERSHFIELD MS, 1972, J BIOL CHEM, V247, P3393; HORI K, 1979, J BIOL CHEM, V254, P1598; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JOVIN TM, 1969, J BIOL CHEM, V244, P2996; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; NAKAI H, 1986, J BIOL CHEM, V261, P5217; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SAITO H, 1981, J VIROL, V37, P343, DOI 10.1128/JVI.37.1.343-351.1981; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; TABOR S, 1986, THIOREDOXIN GLUTARED; VONHIPPEL PH, 1994, ANN NY ACAD SCI, V726, P118; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	46	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34905	34912		10.1074/jbc.M104151200	http://dx.doi.org/10.1074/jbc.M104151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454860	hybrid, Green Published			2022-12-25	WOS:000171024600075
J	Wang, DX; Quillan, JM; Winans, K; Lucas, JL; Sadee, W				Wang, DX; Quillan, JM; Winans, K; Lucas, JL; Sadee, W			Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INBRED MOUSE STRAINS; MORPHINE PREFERENCE; OPIATE RECEPTOR; CANDIDATE GENE; DEPENDENCE; CELLS; TOLERANCE; MICE; OP3; PHOSPHORYLATION	The mu opioid receptor (MOR) plays a central role in mediating acute and chronic effects of narcotic drugs. Three rare single nucleotide polymorphisms in the hMOR gene have been identified that cause amino acid substitutions in the third intracellular (i3) loop of MOR (R260H, R265H, and S268P). Genotyping 252 individuals of the Coriell collection identified one allele encoding the R265H-MOR variant and a new variant encoding D274N-MOR. Variants R260H-, R265H-, and S268P-MOR were constructed and transfected into HEK293 cells. Morphine stimulated G protein coupling of the three receptor variants to a maximal level approaching that of wild type MOR. In contrast, spontaneous, agonist-independent (basal) MOR signaling, proposed to play a role in opioid tolerance and dependence, was significantly reduced for R260H- and R265H-MOR. Moreover, domains within the i3 loop of MOR have been shown to interact with both G proteins and calmodulin (CaM). CaM binding was deficient for variants R265H- and S268P-MOR, suggesting that domains for G protein coupling and CaM binding overlap partially. Morphine pretreatment significantly enhanced basal G protein coupling of wild type MOR, which is thought to result from release of CaM. In contrast basal G protein coupling activity of the three variants was unaffected by morphine pretreatment consistent with diminished CaM regulation, low basal activity, or both. In conclusion, each of the three single nucleotide polymorphisms mapping to the i3 loop of MOR caused substantial changes in basal G protein coupling, CaM binding, or both. Carriers of the mutant alleles might display altered responses to narcotic analgesics.	Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci & Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Wheeler Ctr Neurobiol Addict, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94721 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Sadee, W (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci & Pharmaceut Chem, Box 0446, San Francisco, CA 94143 USA.		Wang, Danxin/I-5810-2019	Wang, Danxin/0000-0002-7134-3065; Lucas, Julie/0000-0001-6094-1740				ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Berrettini W. H., 1994, Psychiatric Genetics, V4, P81, DOI 10.1097/00041444-199422000-00003; Berrettini WH, 1997, ADDICT BIOL, V2, P303, DOI 10.1080/13556219772598; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; Bilsky EJ, 1996, J PHARMACOL EXP THER, V277, P484; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Burford NT, 2000, BIOCHEM J, V348, P531, DOI 10.1042/0264-6021:3480531; Burford NT, 1998, EUR J PHARMACOL, V342, P123, DOI 10.1016/S0014-2999(97)01556-2; Claeysen S, 2000, MOL PHARMACOL, V58, P136, DOI 10.1124/mol.58.1.136; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556; HOEHE M, 1988, PSYCHONEUROENDOCRINO, V13, P397, DOI 10.1016/0306-4530(88)90046-7; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Liu JG, 2001, MOL PHARMACOL, V60, P53, DOI 10.1124/mol.60.1.53; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; Uhl GR, 1999, P NATL ACAD SCI USA, V96, P7752, DOI 10.1073/pnas.96.14.7752; Wade SM, 1996, MOL PHARMACOL, V50, P351; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wang DX, 2000, J NEUROCHEM, V75, P763, DOI 10.1046/j.1471-4159.2000.0750763.x; Wang DX, 2000, J NEUROCHEM, V74, P1418, DOI 10.1046/j.1471-4159.2000.0741418.x; Wang DX, 2001, J NEUROCHEM, V77, P1590, DOI 10.1046/j.1471-4159.2001.00362.x; WANG Z, 1994, LIFE SCI, V54, P339; Wang ZJ, 1999, EUR J PHARMACOL, V371, P1, DOI 10.1016/S0014-2999(99)00131-4; WONG YH, 1994, METHOD ENZYMOL, V238, P81; YU VC, 1990, J NEUROCHEM, V55, P1390, DOI 10.1111/j.1471-4159.1990.tb03151.x	30	59	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34624	34630		10.1074/jbc.M104083200	http://dx.doi.org/10.1074/jbc.M104083200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457836	hybrid			2022-12-25	WOS:000171024600039
J	Blanchette, F; Rivard, N; Rudd, P; Grondin, F; Attisano, L; Dubois, CM				Blanchette, F; Rivard, N; Rudd, P; Grondin, F; Attisano, L; Dubois, CM			Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor beta 1-induced furin gene transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; PROCESSING ENDOPROTEASE FURIN; PROPROTEIN CONVERTASES; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; EPITHELIAL-CELLS; ONCOGENIC RAS; PROTEIN; EXPRESSION; ACTIVATION	Furin, a predominant convertase of the cellular constitutive secretory pathway, is known to be involved in the maturation of a number of growth/differentiation factors, but the mechanisms governing its expression remain elusive. We have previously demonstrated that transforming growth factor (TGF) beta1, through the activation of Smad transducers, regulates its own converting enzyme, furin, creating a unique activation/regulation loop of potential importance in a variety of cell fate and functions. Here we studied the involvement of the p42/p44 MAPK pathway in such regulation. Using HepG2 cells transfected with fur P1 LUC (luciferase) promoter construct, we observed that forced expression of a dominant negative mutant form of the small G protein p21(ras) (RasN17) inhibited TGF beta1-induced far gene transcription, suggesting the involvement of the p42/p44 MAPK cascade. In addition, TGF beta induced sustained activation/phosphorylation of endogenous p42/p44 MAPK. Further-more, the role of MAPK cascade in far gene transcription was highlighted by the use of the MEK1/2 inhibitors, PD98059 or U0126, or co-expression of a p44 antisense construct that repressed the induction of fur promoter transactivation. Conversely, overexpression of a constitutively active form of MEK1 increased unstimulated, TGF beta1-stimulated, and Smad2-stimulated promoter P1 transactivation, and the universal Smad inhibitor, Smad7, inhibited this effect. Activation of Smad2 by MEK1 or TGF beta1 resulted in an enhanced nuclear localization of Smad2, which was inhibited upon blocking MEK1 activity. Our findings clearly show that the activation of the p42/p44 MAPK pathway is involved in far gene expression and led us to propose a co-operative model whereby TGF beta1-induced receptor activation stimulates not only a Smad pathway but also a parallel p42/p44 MAPK pathway that targets Smad2 for an increased nuclear translocation and enhanced fur gene transactivation. Such an uncovered mechanism may be a key determinant for the regulation of furin in embryogenesis and growth-related physiopathological conditions.	Univ Sherbrooke, Fac Med, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada; Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada	University of Sherbrooke; University of Sherbrooke; University of Toronto	Dubois, CM (corresponding author), Univ Sherbrooke, Fac Med, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Blanchette F, 2001, J CELL PHYSIOL, V188, P264, DOI 10.1002/jcp.1116; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; BRUNET A, 1994, ONCOGENE, V9, P3379; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; Constam DB, 2000, DEVELOPMENT, V127, P245; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hoshino H, 1997, FEBS LETT, V419, P9, DOI 10.1016/S0014-5793(97)01409-9; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kaestner KH, 2000, GENE DEV, V14, P142; Kayo T, 1996, ENDOCRINOLOGY, V137, P5126, DOI 10.1210/en.137.11.5126; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Lebman DA, 1999, MICROBES INFECT, V1, P1297, DOI 10.1016/S1286-4579(99)00254-3; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; Letterio JJ, 2000, CYTOKINE GROWTH F R, V11, P81, DOI 10.1016/S1359-6101(99)00031-3; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yu SJ, 1999, BIOCHEM BIOPH RES CO, V259, P544, DOI 10.1006/bbrc.1999.0808; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	65	102	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33986	33994		10.1074/jbc.M100093200	http://dx.doi.org/10.1074/jbc.M100093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448947	hybrid			2022-12-25	WOS:000170910200094
J	Nishi, T; Kawasaki-Nishi, S; Forgac, M				Nishi, T; Kawasaki-Nishi, S; Forgac, M			Expression and localization of the mouse homologue of the yeast V-ATPase 21-kDa subunit c '' (Vma16p)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; VESICLE PROTON PUMP; PROTEOLIPID SUBUNIT; ESCHERICHIA-COLI; PREFERENTIAL EXPRESSION; CAENORHABDITIS-ELEGANS; LUMINAL ACIDIFICATION; ELECTRON-MICROSCOPY; STRUCTURAL-CHANGES; PAPILLOMAVIRUS E5	We have identified a cDNA encoding the mouse homologue of the yeast V-ATPase 21-kDa subunit c " (Vma16p). The encoded protein contains 205 amino acid residues with five putative membrane spanning segments and shows 48% identity and 64% similarity to the yeast protein. Despite this homology, however, the mouse cDNA does not complement the phenotype of a yeast strain in which the VMA16 gene has been disrupted. Northern blot analysis demonstrated that the 21-kDa subunit is expressed in most tissues examined and showed an expression pattern almost identical to that of the 16-kDa proteolipid subunit (subunit c). The presence of multiple m-RNA species suggests the existence of alternatively spliced forms of the 21-kDa subunit which, from Southern blot analysis, are derived from a single gene. Promoter analysis using the luciferase reporter gene revealed that a region 186 bases upstream of the initiation site is sufficient to show a low level of transcriptional activity but that transcription is significantly enhanced by inclusion of the region -186 to -706. The 21-kDa protein was Myc-tagged and the 16-kDa protein was HA-tagged and the tagged proteins were co-expressed in COS-1 cells in order to study their intracellular localization by immunofluorescence microscopy. Both proteins showed significant punctate and perinuclear staining and were predominantly co-localized throughout the cell, consistent with their presence in the sn me V-0 complexes. Selective permeabilization of cells with digitonin (to permeabilize the plasma membrane) or Triton X-100 (to permeabilize both intracellular and plasma membranes) followed by immunofluorescence microscopy revealed that the carboxyl terminus of the 21-kDa subunit is exposed on the cytoplasmic side of the membrane whereas the carboxyl terminus of the 16-kDa subunit is located on the lumenal side of the membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM034478, R01 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; APPERSON M, 1990, BIOCHEM BIOPH RES CO, V168, P574, DOI 10.1016/0006-291X(90)92359-8; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1988, J BIOL CHEM, V263, P8796; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brown D, 2000, J EXP BIOL, V203, P137; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GILLESPIE GAJ, 1991, P NATL ACAD SCI USA, V88, P4289, DOI 10.1073/pnas.88.10.4289; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Graham LA, 2000, J EXP BIOL, V203, P61; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 1997, J BIOCHEM, V121, P922; Nishigori H, 1998, GENOMICS, V50, P222, DOI 10.1006/geno.1998.5310; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Oka T, 2000, J BIOL CHEM, V275, P29556, DOI 10.1074/jbc.M002756200; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Zhang SQ, 2000, BIOCHEM J, V348, P621, DOI 10.1042/0264-6021:3480621; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	63	20	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34122	34130		10.1074/jbc.M104682200	http://dx.doi.org/10.1074/jbc.M104682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11441017	hybrid			2022-12-25	WOS:000170910200111
J	Venkatachalam, K; Ma, HT; Ford, DL; Gill, DL				Venkatachalam, K; Ma, HT; Ford, DL; Gill, DL			Expression of functional receptor-coupled TRPC3 channels in DT40 triple receptor InsP3 knockout cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; OPERATED HTRP3 CHANNELS; STORE DEPLETION; CA2+ ENTRY; SIGNAL-TRANSDUCTION; PROTEIN; INFLUX; ACTIVATION; DROSOPHILA	The TRPC3 channel, an intensively studied member of the widely expressed transient receptor potential (TRP) family, is a Ca2+-conducting channel activated in response to phospholipase C-coupled receptors. Despite scrutiny, the receptor-induced mechanism to activate TRPC3 channels remains unclear. Evidence indicates TRPC3 channels interact directly with intracellular inositol 1,4,5-trisphosphate receptors (InsP(3)Rs) and that channel activation is mediated through coupling to InsP(3)Rs. TRPC3 channels were expressed in DT40 chicken B lymphocytes in which all three InsP(3)R genes were deleted (DT40InsP(3)R-k/o). Endogenous B-cell receptors (BCR) coupled through Syk kinase to phospholipase C-gamma (PLC-gamma) activated the expressed TRPC3 channels in both DT40w/t and DT40InsP(3)R-k/o cells. The diacylglycerol (DAG) analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG) also activated TRPC3 channels independently of InsP(3)Rs. BCR-induced TRPC3 activation was blocked by the PLC enzymic inhibitor, U-73122, and also blocked by wortmannin-induced PLC substrate depletion. Neither U-73122 nor wortmannin modified either OAG-induced TRPC3 activation or store-operated channel activation in DT40 cells. Cotransfection of cells with both G protein-coupled M5 muscarinic receptors and TRPC3 channels resulted in successful M5 coupling to open TRPC3 channels mediated by PLC-beta. We conclude that TRPC3 channels are activated independently of InsP(3)Rs through DAG production resulting from receptor-mediated activation of either PLC-gamma or PLC-beta.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene ST, Baltimore, MD 21201 USA.		Venkatachalam, Kaliyamurthi/GXM-4890-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Chorna-Ornan I, 2001, J NEUROSCI, V21, P2622, DOI 10.1523/JNEUROSCI.21-08-02622.2001; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Mery L, 2001, FEBS LETT, V487, P377, DOI 10.1016/S0014-5793(00)02362-0; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	39	124	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33980	33985		10.1074/jbc.C100321200	http://dx.doi.org/10.1074/jbc.C100321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11466302	hybrid			2022-12-25	WOS:000170910200093
J	Liu, XX; Schrager, JA; Lange, GD; Marsh, JW				Liu, XX; Schrager, JA; Lange, GD; Marsh, JW			HIV Nef-mediated cellular phenotypes are differentially expressed as a function of intracellular NEF concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; VIRUS TYPE-1 NEF; CD4 DOWN-REGULATION; CLASS-I MOLECULES; IMMUNODEFICIENCY-VIRUS; T-CELLS; DILEUCINE MOTIF; SURFACE CD4; MHC-I; GENE	Nef is a regulatory protein encoded by the genome of both human and simian immunodeficiency virus. Its expression in T cells leads to CD4 and major histocompatibility complex class I modulation and either enhancement or suppression of T cell activation. How this viral protein achieves multiple and at times opposing activities has been unclear. Through direct measurements of Nef and the Nef-GFP fusion protein, we find that these events are mediated by different Nef concentrations. Relative to the intracellular concentration that down-modulates surface CD4, an order of magnitude increase in Nef-GFP expression is required for a comparable modulation of major histocompatibility complex class I, and a further 3-fold increase is necessary to suppress T cell activation.	NINDS, Instrumentat & Comp Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Marsh, JW (corresponding author), NIMH, Mol Biol Lab, Bldg 36,Rm 1B08,36 Convent Dr,MSC 4034, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002629, Z01MH002629] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Alexander L, 1997, J VIROL, V71, P6094, DOI 10.1128/JVI.71.8.6094-6099.1997; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; Collette Y, 1996, J IMMUNOL, V156, P360; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; Marsh JW, 1999, ARCH BIOCHEM BIOPHYS, V365, P192, DOI 10.1006/abbi.1999.1208; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Page KA, 1997, AIDS RES HUM RETROV, V13, P1077, DOI 10.1089/aid.1997.13.1077; Palm GJ, 1997, NAT STRUCT BIOL, V4, P361, DOI 10.1038/nsb0597-361; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; RHEE SS, 1994, J IMMUNOL, V152, P5128; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; Riggs NL, 1999, VIROLOGY, V258, P203, DOI 10.1006/viro.1999.9736; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Walk SF, 2001, J VIROL, V75, P834, DOI 10.1128/JVI.75.2.834-843.2001; Wang CF, 2000, IEEE T PARALL DISTR, V11, P97, DOI 10.1109/71.841747; WEISS A, 1984, J IMMUNOL, V133, P123; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502	45	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32763	32770		10.1074/jbc.M101025200	http://dx.doi.org/10.1074/jbc.M101025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438519	hybrid			2022-12-25	WOS:000170746000053
J	Giannakakou, P; Robey, R; Fojo, T; Blagosklonny, MV				Giannakakou, P; Robey, R; Fojo, T; Blagosklonny, MV			Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity	ONCOGENE			English	Article						paclitaxel; G1 arrest; mitosis; p53; p21; Bcl-2	HUMAN CANCER-CELLS; INHIBITOR-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; SV40-TRANSFORMED CELLS; ANTICANCER AGENTS; G(1) ARREST; G2/M ARREST; HUMAN HEAD; TAXOL; OVARIAN	Paclitaxel (PTX), a microtubule-active agent, blocks cell proliferation by inhibiting mitotic progression leading to mitotic and postmitotic arrest and cell death. Here we demonstrate for the first time that very low concentrations of PTX (3-6 nM) can completely inhibit cell proliferation without arresting cells at mitosis, At these low concentrations that are insufficient to inhibit mitotic progression, PTX induced both p53 and p21 causing CI and G2 arrest in A549. In contrast, low PTX concentrations failed to induce G1 and G2 arrest in A549/E6 cells, that do not express p53, Furthermore, we observed that the levels of p53 and p21 induced by adriamycin and by low concentrations of PTX in A549 cells were comparable. This observation led us to conclude that tow concentrations of PTX can induce p53 and p21 sufficiently to cause G1 and G2, Many other cell lines, including HCT116 cells, do not readily upregulate p53 in response to PTX, and therefore undergo exclusively mitotic and postmitotic arrest after PTX treatment. At low concentrations that do not cause mitotic arrest, PTX did not significantly inhibit proliferation of these cells. In HCT116 cells, loss of p53 (HCT/p53(-/-)) or p21 (HCT/p21(-/-)) affects both Bax and Bcl-2 expression. In cells lacking p53, levels of Bax and p21 were decreased. In cells lacking p21, levels of wt p53 were highly increased to compensate for the loss of p21, This in turn results in upregulation of Bax and downregulation of Bcl-2 resulting in an increase of the apoptotic Bax/Bcl2 ratio consistent with increased sensitivity of these cells to apoptotic stimuli, High levels of p53 and Bax/Bcl-2 ratio can also explain why loss of p21 is rarely found in human cancer.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; Emory Univ, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emory University	Blagosklonny, MV (corresponding author), NCI, Med Branch, NIH, Bldg 10,R 12N226, Bethesda, MD 20892 USA.			Giannakakou, Paraskevi/0000-0001-7378-262X; Robey, Rob/0000-0002-0857-3650				An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; De Feudis P, 2000, NEOPLASIA, V2, P202, DOI 10.1038/sj.neo.7900086; Debernardis D, 1997, CANCER RES, V57, P870; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gan YB, 1996, CANCER RES, V56, P2086; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Khan SH, 1998, CANCER RES, V58, P396; Koutcher JA, 2000, CLIN CANCER RES, V6, P1498; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LONG BH, 1994, CANCER RES, V54, P4355; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maurer BJ, 1999, MOL PHARMACOL, V55, P938; MIYASHITA T, 1995, CELL, V80, P293; Motwani M, 2000, CLIN CANCER RES, V6, P924; Nielsen LL, 1998, CLIN CANCER RES, V4, P835; OConnor PM, 1997, CANCER RES, V57, P4285; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Safran H, 1996, CANCER, V78, P1203, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1203::AID-CNCR6>3.0.CO;2-A; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stewart ZA, 1999, CANCER RES, V59, P3831; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Torres K, 1998, CANCER RES, V58, P3620; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WALDMAN T, 1995, CANCER RES, V55, P5187; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zaffaroni N, 1998, BRIT J CANCER, V77, P1378, DOI 10.1038/bjc.1998.230; Zeng S, 2000, CLIN CANCER RES, V6, P3766; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	56	185	203	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3806	3813		10.1038/sj.onc.1204487	http://dx.doi.org/10.1038/sj.onc.1204487			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439344				2022-12-25	WOS:000169494700006
J	Razani, B; Engelman, JA; Wang, XB; Schubert, W; Zhang, XL; Marks, CB; Macaluso, F; Russell, RG; Li, MM; Pestell, RG; Di Vizio, D; Hou, H; Kneitz, B; Lagaud, G; Christ, GJ; Edelmann, W; Lisanti, MP				Razani, B; Engelman, JA; Wang, XB; Schubert, W; Zhang, XL; Marks, CB; Macaluso, F; Russell, RG; Li, MM; Pestell, RG; Di Vizio, D; Hou, H; Kneitz, B; Lagaud, G; Christ, GJ; Edelmann, W; Lisanti, MP			Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NITRIC-OXIDE SYNTHASE; TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; ROUS-SARCOMA VIRUS; ONCOGENICALLY TRANSFORMED-CELLS; GIRDLE MUSCULAR-DYSTROPHY; RECEPTOR TYROSINE KINASE; CYCLIN-DEPENDENT KINASES; RICH MEMBRANE DOMAINS; IN-VIVO	Caveolin-1 is the principal structural protein of caveolae membranes in fibroblasts and endothelia. Recently, we have shown that the human CAV-1 gene is localized to a suspected tumor suppressor locus, and mutations in Cav-1 have been implicated in human cancer. Here, we created a eaveolin-1 null (CAV-1 -/-) mouse model, using standard homologous recombination techniques, to assess the role of caveolin-1 in caveolae biogenesis, endocytosis, cell proliferation, and endothelial nitric-oxide synthase (eNOS) signaling. Surprisingly, Cav-1 null mice are viable. We show that these mice lack caveolin-1 protein expression and plasmalemmal caveolae. In addition, analysis of cultured fibroblasts from Cav-1 null embryos reveals the following: W a loss of caveolin-2 protein expression; (ii) defects in the endocytosis of a known caveolar ligand, i.e. fluorescein isothiocyanate-albumin; and (iii) a hyperproliferative phenotype. Importantly, these phenotypic changes are reversed by recombinant expression of the caveolin-1 cDNA. Furthermore, examination of the lung parenchyma (an endothelial-rich tissue) shows hypercellularity with thickened alveolar septa and an increase in the number of vascular endothelial growth factor receptor (Flk-1)-positive endothelial cells. As predicted, endothelial cells from Cav-1 null mice lack caveolae membranes. Finally, we examined eNOS signaling by measuring the physiological response of aortic rings to various stimuli. Our results indicate that eNOS activity is up-regulated in Cav-1 null animals, and this activity can be blunted by using a specific NOS inhibitor, nitro-L-arginine methyl ester. These findings are in accordance with previous in vitro studies showing that caveolin-1 is an endogenous inhibitor of eNOS. Thus, caveolin-1 expression is required to stabilize the caveolin-2 protein product, to mediate the caveolar endocytosis of specific ligands, to negatively regulate the proliferation of certain cell types, and to provide tonic inhibition of eNOS activity in endothelial cells.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Analyt Imaging Facil, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Inst Anim Studies, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Urol, Inst Smooth Muscle Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol, Inst Smooth Muscle Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biophys, Inst Smooth Muscle Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Razani, Babak/0000-0002-7172-9240	NCI NIH HHS [R01-CA70897, R01-CA86072, R01-CA75503] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075503, R01CA070897, R01CA086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achille A, 1996, CANCER RES, V56, P3808; Bagnoli M, 2000, ONCOGENE, V19, P4754, DOI 10.1038/sj.onc.1203839; Bender FC, 2000, CANCER RES, V60, P5870; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRAB M, 2001, IN PRESS SCIENCE; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GERDES J, 1991, AM J PATHOL, V138, P867; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Hailstones D, 1998, J LIPID RES, V39, P369; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hayashi K, 2001, CANCER RES, V61, P2361; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HUANG H, 1998, GENE CHROMOSOME CANC, V21, P162; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Jenkins RB, 1998, CANCER RES, V58, P759; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Mora R, 1999, J BIOL CHEM, V274, P25708, DOI 10.1074/jbc.274.36.25708; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razani B, 2000, BIOCHEMISTRY-US, V39, P13916, DOI 10.1021/bi001489b; Razani B, 2000, J CELL SCI, V113, P2103; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Suzuki T, 1998, J BIOCHEM-TOKYO, V124, P383, DOI 10.1093/oxfordjournals.jbchem.a022123; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamamoto M, 1999, EXP CELL RES, V247, P380, DOI 10.1006/excr.1998.4379; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	108	960	983	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38121	38138						18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11457855				2022-12-25	WOS:000171526500055
J	Schiffler, B; Kiefer, M; Wilken, A; Hannemann, F; Adolph, HW; Bernhardt, R				Schiffler, B; Kiefer, M; Wilken, A; Hannemann, F; Adolph, HW; Bernhardt, R			The interaction of bovine adrenodoxin with CYP11A1 (cytochrome P450(scc)) and CYP11B1 (cytochrome P450(11 beta)) - Acceleration of reduction and substrate conversion by site-directed mutagenesis of adrenodoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL STEROID HYDROXYLASES; ELECTRON-TRANSFER FUNCTION; SIDE-CHAIN CLEAVAGE; ESCHERICHIA-COLI; CARBOXYLATE GROUPS; HUMAN FERREDOXIN; AFFECT BINDING; PUTIDAREDOXIN; EXPRESSION; IDENTIFICATION	The kinetics of protein-protein interaction and heme reduction between adrenodoxin wild type as well as eight mutants and the cytochromes P450 CYP11A1 and CYP11B1 was studied in detail. Rate constants for the formation of the reduced CYP11A1(.)CO and CYP11B1(.)CO complexes by wild type adrenodoxin, the adrenodoxin mutants Adx-(4-108), Adx-(4-114), T54S, T54A, and S112W, and the double mutants Y82F/S112W, Y82L/ S112W, and Y82S/S112W (the last four mutants are Delta 113-128) are presented. The rate constants observed differ by a factor of up to 10 among the respective adrenodoxin mutants for CYP11A1 but not for CYP11B1. According to their apparent rate constants for CYP11A1, the adrenodoxin mutants can be grouped into a slow (wild type, T54A, and T54S) and a fast group (all the other mutants). The adrenodoxin mutants forming the most stable complexes with CYP11A1 show the fastest rates of reduction and the highest rate constants for cholesterol to pregnenolone conversion. This strong correlation suggests that C-terminal truncation of adrenodoxin in combination with the introduction of a C-terminal tryptophan residue enables a modified protein-protein interaction rendering the system almost as effective as the bacterial putidaredoxin/CYP101 system. Such a variation of the adrenodoxin structure resulted in a mutant protein (S112W) showing a 100-fold increased efficiency in conversion of cholesterol to pregnenolone.	Univ Saarland, Biochem FR 8 8, D-66041 Saarbrucken, Germany	Saarland University	Bernhardt, R (corresponding author), Univ Saarland, Biochem FR 8 8, POB 151150, D-66041 Saarbrucken, Germany.	ritabern@mx.uni-saarland.de	Adolph, Hans W/A-2104-2008	Hannemann, Frank/0000-0001-7991-9033				Adolph HW, 1997, BIOCHEMISTRY-US, V36, P8743, DOI 10.1021/bi970398k; BECKERT V, 1995, EUR J BIOCHEM, V231, P226, DOI 10.1111/j.1432-1033.1995.tb20691.x; BECKERT V, 1994, J BIOL CHEM, V269, P2568; Beckert V, 1997, J BIOL CHEM, V272, P4883, DOI 10.1074/jbc.272.8.4883; Bernhardt R, 1996, REV PHYSIOL BIOCH P, V127, P137, DOI 10.1007/BFb0048267; Burova TV, 1996, PROTEIN SCI, V5, P1890, DOI 10.1002/pro.5560050915; CHU JW, 1973, J BIOL CHEM, V248, P2089; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; DAVIES MD, 1992, BIOCHEMISTRY-US, V31, P11383, DOI 10.1021/bi00161a016; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; ESTABROOK RW, 1973, IRON SULPHUR PROTEIN, V1, P193; GEREN L, 1986, J BIOL CHEM, V261, P5491; GEREN LM, 1984, J BIOL CHEM, V259, P2155; Grinberg AV, 1998, PROTEIN ENG, V11, P1057, DOI 10.1093/protein/11.11.1057; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; Hannemann F, 2001, J BIOL CHEM, V276, P1369, DOI 10.1074/jbc.M007589200; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; HOLDEN HM, 1994, J BIOENERG BIOMEMBR, V26, P67, DOI 10.1007/BF00763220; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; HUI BON HOA G, 1978, Biochemistry, V17, P2835; Imai T, 1998, BIOCHEMISTRY-US, V37, P8097, DOI 10.1021/bi9802768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1983, J BIOL CHEM, V258, P5596; LAMBETH JD, 1985, J BIOL CHEM, V260, P8810; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; LAMBETH JD, 1990, FRONTIERS BIOTRANSFO, V3, P68; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; Miller WL, 1995, J STEROID BIOCHEM, V55, P607, DOI 10.1016/0960-0760(95)00212-X; Muller A, 1998, STRUCTURE, V6, P269, DOI 10.1016/S0969-2126(98)00031-8; OMURA T, 1964, J BIOL CHEM, V239, P2370; PEDERSON TC, 1976, MICROSOMES DRUG OXID, P275; Pikuleva IA, 2000, ARCH BIOCHEM BIOPHYS, V373, P44, DOI 10.1006/abbi.1999.1536; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; SAGARA Y, 1993, BIOL PHARM BULL, V16, P627; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIKITA M, 1974, P NATL ACAD SCI USA, V71, P1441, DOI 10.1073/pnas.71.4.1441; SLIGAR SG, 1979, BIOCHEMISTRY-US, V18, P2290, DOI 10.1021/bi00578a024; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; SUGANO S, 1989, ANAL BIOCHEM, V182, P327, DOI 10.1016/0003-2697(89)90603-9; TAKIKAWA O, 1978, ARCH BIOCHEM BIOPHYS, V190, P300, DOI 10.1016/0003-9861(78)90279-5; TULS J, 1987, J BIOL CHEM, V262, P10020; TYSON CA, 1972, J BIOL CHEM, V247, P5777; UHLMANN H, 1994, J BIOL CHEM, V269, P22557; UHLMANN H, 1995, J BIOL CHEM, V270, P29959; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; Uhlmann H, 1997, EUR J BIOCHEM, V248, P897, DOI 10.1111/j.1432-1033.1997.00897.x; VIJAYAKUMAR S, 1992, BIOCHIM BIOPHYS ACTA, V1160, P281, DOI 10.1016/0167-4838(92)90089-V; WADA A, 1992, J BIOL CHEM, V267, P22877; WILSON GS, 1973, J BIOL CHEM, V248, P6059	50	38	40	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36225	36232		10.1074/jbc.M102320200	http://dx.doi.org/10.1074/jbc.M102320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11459837	hybrid			2022-12-25	WOS:000171194500025
J	Cernuda-Morollon, E; Pineda-Molina, E; Canada, FJ; Perez-Sala, D				Cernuda-Morollon, E; Pineda-Molina, E; Canada, FJ; Perez-Sala, D			15-deoxy-Delta (12,14)-prostaglandin J(2) inhibition of NF-kappa B-DNA binding through covalent modification of the p50 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ACTIVATED RECEPTOR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS; CYCLOOXYGENASE-2 EXPRESSION; INTRACELLULAR GLUTATHIONE; PPAR-GAMMA; PHOSPHORYLATION; INFLAMMATION; PATHWAY	Cyclopentenone prostaglandins display anti-inflammatory activities and interfere with the signaling pathway that leads to activation of transcription factor NF kappaB. Here we explore the possibility that the NF-kappaB subunit p50 may be a target for the cyclopentenone 15-deoxy-Delta (12,14) -prostaglandin J(2) (15d-PGJ(2)). This prostaglandin inhibited the DNA binding ability of recombinant p50 in a dose-dependent manner. The inhibition required the cyclopentenone moiety and could be prevented but not reverted by glutathione and dithiothreitol. Moreover, a p50 mutant with a C62S mutation was resistant to inhibition, indicating that the effect of 15d-PGJ(2) was probably due to its interaction with eysteine 62 in p50. The covalent modification of p50 by 15d-PGJ2 was demonstrated by reverse-phase high pressure liquid chromatography and mass spectrometry analysis that showed an increase in retention time and in the molecular mass of 15d-PGJ(2)-treated p50, respectively. The interaction between p50 and 15d-PGJ2 was relevant in intact cells. 15d-PGJ2 effectively inhibited cytokine-elicited NF-kappaB activity in HeLa without reducing I kappaB alpha degradation or nuclear translocation of NF-kappaB subunits. 15d-PGJ2 reduced NF-kappaB DNA binding activity in isolated nuclear extracts, suggesting a direct effect on NF-kappaB proteins. Finally, treatment of HeLa with biotinylated-15d-PGJ(2) resulted in the formation of a 15d-PGJ(2)-p50 adduct as demonstrated by neutravidin binding and immunoprecipitation. These results clearly show that p50 is a target for covalent modification by 15d-PGJ2 that results in inhibition of DNA binding.	CSIC, Inst Reina Sofia Invest Nefrol, Dept Estructura & Func Prot, Ctr Invest Biol, E-28006 Madrid, Spain; CSIC, Inst Quim Organ Gen, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG)	Perez-Sala, D (corresponding author), CSIC, Inst Reina Sofia Invest Nefrol, Dept Estructura & Func Prot, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.	dperezsala@cib.csic.es	Perez-Sala, Dolores/L-5969-2014; Cañada, Francisco J./D-5837-2014; Pineda-Molina, Estela/K-9969-2014	Perez-Sala, Dolores/0000-0003-0600-665X; Cañada, Francisco J./0000-0003-4462-1469; Pineda-Molina, Estela/0000-0002-4266-0192				Appleton I, 1996, Adv Pharmacol, V35, P27, DOI 10.1016/S1054-3589(08)60274-4; ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Diaz-Cazorla M, 1999, J AM SOC NEPHROL, V10, P943; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1989, ADV PROSTAG THROMB L, V19, P415; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Inoue H, 2000, J BIOL CHEM, V275, P28028; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; Klatt P, 2000, BIOCHEM J, V349, P567, DOI 10.1042/0264-6021:3490567; LI CCH, 1994, J BIOL CHEM, V269, P30089; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Parker J, 1995, PROSTAGLANDINS, V50, P359, DOI 10.1016/0090-6980(95)00136-0; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	39	274	285	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35530	35536		10.1074/jbc.M104518200	http://dx.doi.org/10.1074/jbc.M104518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466314	hybrid, Green Published			2022-12-25	WOS:000171109300044
J	Stehr, M; Schneider, G; Aslund, F; Holmgren, A; Lindqvist, Y				Stehr, M; Schneider, G; Aslund, F; Holmgren, A; Lindqvist, Y			Structural basis for the thioredoxin-like activity profile of the glutaredoxin-like NrdH-redoxin from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; NMR STRUCTURE; CRYSTAL-STRUCTURE; MIXED DISULFIDE; PROTEIN; MUTANT; RESOLUTION; SITE; GLUTATHIONE; REPLACEMENT	NrdH-redoxin is a representative of a class of small redox proteins that contain a conserved CXXC motif and are characterized by a glutaredoxin-like amino acid sequence and thioredoxin-like activity profile. The crystal structure of recombinant Escherichia coli NrdH-redoxin in the oxidized state has been determined at 1.7 Angstrom resolution by multiwavelength anomalous diffraction. NrdH-redoxin belongs to the thioredoxin superfamily and is structurally most similar to E. coli glutaredoxin 3 and phage T4 glutaredoxin. The angle between the C-terminal helix alpha3 and strand beta4, which differs between thioredoxin and glutaredoxin, has an intermediate value in NrdH-redoxin. The orientation of this helix is to a large extent determined by an extended hydrogen-bond network involving the highly conserved sequence motif (61)WSG-FRP(D/E)(67), which is unique to this subclass of the thioredoxin superfamily. Residues that bind glutathione in glutaredoxins are in general not conserved in NrdH-redoxin, and no glutathione-binding cleft is present. Instead, NrdH-redoxin contains a wide hydrophobic pocket at the surface, similar to thioredoxin. Modeling studies suggest that NrdH-redoxin can interact with E. coli thioredoxin reductase at this pocket and also via a loop that is complementary to a crevice in the reductase in a similar manner as observed in the E. coli thioredoxin-thioredoxin reductase complex.	Karolinska Inst, Div Mol Struct Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Lindqvist, Y (corresponding author), Karolinska Inst, Div Mol Struct Biol, S-17177 Stockholm, Sweden.		Lindqvist, Ylva/F-9009-2010	Lindqvist, Ylva/0000-0003-3162-8661; Schneider, Gunter/0000-0003-0622-5713				Andersen JF, 1997, BIOCHEMISTRY-US, V36, P13979, DOI 10.1021/bi971004s; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; Cave JW, 2001, PROTEIN SCI, V10, P384, DOI 10.1110/ps.35101; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dillet V, 1998, BIOCHEMISTRY-US, V37, P10298, DOI 10.1021/bi980333x; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; EKLUND H, 1992, J MOL BIOL, V228, P596, DOI 10.1016/0022-2836(92)90844-A; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1981, J BIOL CHEM, V256, P3118; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DY, 2000, BIOCHEMISTRY-US, V39, P6652, DOI 10.1021/bi000035b; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Monje-Casas F, 2001, J BIOL CHEM, V276, P18031, DOI 10.1074/jbc.M011728200; Mossner E, 1999, J BIOL CHEM, V274, P25254, DOI 10.1074/jbc.274.36.25254; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Nordstrand K, 2000, J MOL BIOL, V303, P423, DOI 10.1006/jmbi.2000.4145; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reinemer P, 1996, J MOL BIOL, V255, P289, DOI 10.1006/jmbi.1996.0024; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH K, 1995, BIOCHEM J, V312, P465, DOI 10.1042/bj3120465; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Torrents E, 2000, CURR MICROBIOL, V41, P346, DOI 10.1007/s002840010147; XIA TH, 1992, PROTEIN SCI, V1, P310	46	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35836	35841		10.1074/jbc.M105094200	http://dx.doi.org/10.1074/jbc.M105094200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11441020	hybrid			2022-12-25	WOS:000171109300082
J	Gilleron, M; Ronet, C; Mempel, M; Monsarrat, B; Gachelin, G; Puzo, G				Gilleron, M; Ronet, C; Mempel, M; Monsarrat, B; Gachelin, G; Puzo, G			Acylation state of the phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette Guerin and ability to induce granuloma and recruit natural killer T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL ANCHOR; NMR-SPECTROSCOPY; NKT CELLS; MULTIACYLATED FORMS; LIPOGLYCAN ANTIGENS; ALPHA-CHAIN; TUBERCULOSIS; CD1; BCG; LIPOARABINOMANNAN	Previous studies have found that, when injected into mice, glycolipidic fractions of mycobacterial cell walls containing phosphatidylinositol mannosides (PIM) induced a granuloma and recruitment of Natural Killer T cells in the lesions. The dimannoside (PIM(2)) and the hexamannoside (PIM(6)) PIM were isolated from Mycobacterium bovis bacillus Calmette Guerin and shown to act alike, but the activity was found to be dependent on the presence of the lipidic part. The chemical structure of PIM was then re-evaluated, focusing on the characterization of their lipidic part, defining mono- to tetra-acylated PIM(2). The structure of these acyl forms was elucidated using a sophisticated combination of chemical degradations and analytical tools including electrospray ionization/mass spectrometry, electrospray ionization/mass spectrometry/mass spectrometry, and two-dimensional NMR. Finally, the acyl forms were purified by hydrophobic interaction chromatography and tested for their capacity to induce the granuloma and Natural Killer T cell recruitment. We found that there is an absolute requirement for the molecules to possess at least one fatty acyl chain, but the number, location, and size of the acyl chains was without effect. Moreover, increasing the complexity of the carbohydrate moiety did not lead to significant differences in the biological responses.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Inst Pasteur, Unite Biol Mol Gene, F-75284 Paris 15, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gilleron, M (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.	gilleron@ipbs.fr	Ronet, Catherine/O-6866-2017	Ronet, Catherine/0000-0003-1479-2873; GILLERON, Martine/0000-0002-2581-3302				Apostolou I, 2000, J IMMUNOL, V165, P2481, DOI 10.4049/jimmunol.165.5.2481; Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141; BALLOU CE, 1963, J BIOL CHEM, V238, P69; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; Brossay L, 1998, J IMMUNOL, V161, P5124; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chen HJ, 1997, J IMMUNOL, V159, P2240; DEBELDER AN, 1968, CARBOHYD RES, V8, P1, DOI 10.1016/S0008-6215(00)81685-7; Ernst WA, 1998, IMMUNITY, V8, P331, DOI 10.1016/S1074-7613(00)80538-5; FOURNIE JJ, 1987, J BIOL CHEM, V262, P3174; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; GILLERON M, 1993, J BIOL CHEM, V268, P3168; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Hsu FF, 2000, J AM SOC MASS SPECTR, V11, P986, DOI 10.1016/S1044-0305(00)00172-0; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; KHULLER GK, 1968, EXPERIENTIA, V24, P851, DOI 10.1007/BF02144914; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEE YC, 1964, J BIOL CHEM, V239, P1316; LEE YC, 1965, BIOCHEMISTRY-US, V4, P1395, DOI 10.1021/bi00883a026; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Matsuda JL, 2001, CURR OPIN IMMUNOL, V13, P19, DOI 10.1016/S0952-7915(00)00176-X; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; NOJIMA S, 1959, J BIOCHEM, V46, P607, DOI 10.1093/jb/46.5.607; PANGBORN MC, 1966, J LIPID RES, V7, P627; Porcelli SA, 1998, IMMUNOL TODAY, V19, P362, DOI 10.1016/S0167-5699(98)01289-4; Prigozy TI, 2001, SCIENCE, V291, P664, DOI 10.1126/science.291.5504.664; Ronet C, 2001, J IMMUNOL, V166, P1755, DOI 10.4049/jimmunol.166.3.1755; Severn WB, 1998, CARBOHYD RES, V308, P397, DOI 10.1016/S0008-6215(98)00108-6; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Shamshiev A, 2000, IMMUNITY, V13, P255, DOI 10.1016/S1074-7613(00)00025-X; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; VERCELLONE A, 1989, J BIOL CHEM, V264, P7447; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149; WANG Y, 1995, ANAL BIOCHEM, V225, P242, DOI 10.1006/abio.1995.1149; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	47	131	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34896	34904		10.1074/jbc.M103908200	http://dx.doi.org/10.1074/jbc.M103908200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11441009	Green Published, hybrid			2022-12-25	WOS:000171024600074
J	Hege, T; Feltzer, RE; Gray, RD; Baumann, U				Hege, T; Feltzer, RE; Gray, RD; Baumann, U			Crystal structure of a complex between Pseudomonas aeruginosa alkaline protease and its cognate inhibitor - Inhibition by a zinc-NH2 coordinative bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERRATIA-MARCESCENS METALLOPROTEASE; ERWINIA-CHRYSANTHEMI; SNAKE-VENOM; SECRETION; BINDING; PROTEINASE; ASTACINS	Serralysins are a family of metalloproteases secreted by Gram-negative bacteria into the medium in the form of inactive zymogens. Usually, all serralysin secretors have on the same operon a gene coding for a periplasmic 10-kDa protein, which is an inhibitor of the secreted protease. The recent characterization of the inhibitor of the alkaline protease from Pseudomonas aeruginosa revealed a surprisingly low dissociation constant of 4 pM, contrary to earlier studies on homologous systems, where inhibition constants in the muM range were reported. To approach a more accurate understanding, the crystal structure of the complex between inhibitor and protease from P. aeruginosa was determined at 1.74 Angstrom resolution and refined to R-free = 0.204. The structure reported here shows clearly that the N terminus of the inhibitor forms a coordinative bond to the catalytic Zn2+ ion with a nitrogen-zinc distance of 2.17 Angstrom. We conclude that this interaction adds substantially to the complex stability and show also that similar interactions are found in other metzincin-inhibitor complexes.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA	University of Bern; University of Louisville	Baumann, U (corresponding author), Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland.	ulrich.baumann@ibc.unibe.ch	Baumann, Ulrich/B-1220-2013					Bae KH, 1998, ARCH BIOCHEM BIOPHYS, V352, P37, DOI 10.1006/abbi.1997.0561; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DELEPELAIRE P, 1989, J BIOL CHEM, V264, P9083; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; DUONG F, 1992, GENE, V121, P47, DOI 10.1016/0378-1119(92)90160-Q; Feltzer RE, 2000, J BIOL CHEM, V275, P21002, DOI 10.1074/jbc.M002088200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM KS, 1995, APPL ENVIRON MICROB, V61, P3035, DOI 10.1128/AEM.61.8.3035-3041.1995; Kluytmans J, 1997, PREVENTION CONTROL N, P841; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LETOFFE S, 1989, MOL MICROBIOL, V3, P79, DOI 10.1111/j.1365-2958.1989.tb00106.x; LIU PV, 1974, J INFECT DIS, V130, pS94, DOI 10.1093/infdis/130.Supplement.S94; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORIHARA K, 1963, BIOCHIM BIOPHYS ACTA, V73, P113; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pollack M, 1998, INFECT DIS, P1824; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WIRBLIN RT, 1997, PREVENTION CONTROL N, P807	32	44	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35087	35092		10.1074/jbc.M104020200	http://dx.doi.org/10.1074/jbc.M104020200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11445573	hybrid			2022-12-25	WOS:000171024600098
J	Pham, AS; Reinhart, GD				Pham, AS; Reinhart, GD			Pre-steady state quantification of the allosteric influence of Escherichia coli phosphofructokinese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SUBSTRATE-BINDING; PH-DEPENDENCE; FLUORESCENCE	Stopped-flow kinetics was utilized to determine how allosteric activators and inhibitors of wild-type Escherichia coli phosphofructokinase influenced the kinetic rate and equilibrium constants of the binding of substrate fructose 6-phosphate. Monitoring pre-steady state fluorescence intensity emission changes upon an addition of a ligand to the enzyme was possible by a unique tryptophan per subunit of the enzyme. Binding of fructose 6-phosphate to the enzyme displayed a two-step process, with a fast complex formation step followed by a relatively slower isomerization step. Systematic addition of fructose 6-phosphate to phosphofructokinase in the absence and presence of several fixed concentrations of phosphoenolpyruvate indicated that the inhibitor binds to the enzyme concurrently with the substrate, forming a ternary complex and inducing a conformational change, rather than a displacement of the equilibrium as predicted by the classical two-state model (Monod, J., Wyman, J., and Changeux, J. P. (1965) J. Mol. Biol. 12, 88-118). The activator, MgADP, also altered the affinity of fructose 6-phosphate to the enzyme by forming a ternary complex. Furthermore, both phosphoenolpyruvate and MgADP act by influencing the fast complex formation step while leaving the slower enzyme isomerization step essentially unchanged.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station	Pham, AS (corresponding author), 1515 Holcombe Blvd,Box 84, Houston, TX 77030 USA.				NIGMS NIH HHS [GM33216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUZAT I, 1995, J MOL BIOL, V246, P248, DOI 10.1006/jmbi.1994.0080; AUZAT I, 1992, PROTEIN SCI, V1, P254; AUZAT I, 1995, J MOL BIOL, V249, P478, DOI 10.1006/jmbi.1995.0310; BERGER SA, 1991, BIOCHEMISTRY-US, V30, P8477, DOI 10.1021/bi00098a027; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; BRAXTON BL, 1994, J BIOL CHEM, V269, P47; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; DEVILLEBONNE D, 1991, FEBS LETT, V290, P173, DOI 10.1016/0014-5793(91)81253-5; DEVILLEBONNE D, 1991, BIOCHEMISTRY-US, V30, P5750, DOI 10.1021/bi00237a017; DEVILLEBONNE D, 1992, BIOCHEMISTRY-US, V31, P1695, DOI 10.1021/bi00121a017; HIROMI K, 1979, KINETICS FAST ENZYME, P255; JOHNSON JL, 1992, BIOCHEMISTRY-US, V31, P11510, DOI 10.1021/bi00161a032; JOHNSON JL, 1994, BIOCHEMISTRY-US, V33, P2635, DOI 10.1021/bi00175a036; Johnson JL, 1997, BIOCHEMISTRY-US, V36, P12814, DOI 10.1021/bi970942p; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; Johnson ML, 1997, METHOD ENZYMOL, V278, P570; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; LAU FTK, 1987, NATURE, V326, P811; LEBRAS G, 1989, BIOCHEMISTRY-US, V28, P6836, DOI 10.1021/bi00443a009; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PETERMAN BF, 1979, BIOCHIM BIOPHYS ACTA, V577, P314, DOI 10.1016/0005-2795(79)90035-7; Pham AS, 2001, BIOCHEMISTRY-US, V40, P4140, DOI 10.1021/bi001768z; Pham AS, 2001, BIOCHEMISTRY-US, V40, P4150, DOI 10.1021/bi001769r; PHAM TC, 1999, THESIS TEXAS A M U; REINHART GD, 1988, BIOPHYS CHEM, V30, P159, DOI 10.1016/0301-4622(88)85013-0; REINHART GD, 1983, ARCH BIOCHEM BIOPHYS, V224, P389, DOI 10.1016/0003-9861(83)90225-4; SERRE MC, 1990, EUR J BIOCHEM, V189, P487, DOI 10.1111/j.1432-1033.1990.tb15513.x; TANAKA A, 1982, BIOCHEMISTRY-US, V21, P107, DOI 10.1021/bi00530a019; TESCHNER W, 1990, BIOCHIMIE, V72, P403, DOI 10.1016/0300-9084(90)90064-N; TESCHNER W, 1989, BIOCHEMISTRY-US, V28, P1912, DOI 10.1021/bi00430a072; VALDEZ BC, 1989, J BIOL CHEM, V264, P131	32	4	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34388	34395		10.1074/jbc.M102785200	http://dx.doi.org/10.1074/jbc.M102785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11443117	hybrid			2022-12-25	WOS:000171024600006
J	Samuelson, JC; Jiang, FL; Yi, L; Chen, MY; de Gier, JW; Kuhn, A; Dalbey, RE				Samuelson, JC; Jiang, FL; Yi, L; Chen, MY; de Gier, JW; Kuhn, A; Dalbey, RE			Function of YidC for the insertion of M13 Procoat protein in Escherichia coli - Translocation of mutants that show differences in their membrane potential dependence and Sec requirement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; POSITIVELY CHARGED RESIDUES; INNER MEMBRANE; CYTOPLASMIC MEMBRANE; TARGETING PATHWAY; POLYTOPIC PROTEIN; LEADER PEPTIDE; OXA1P; EXPORT; INTEGRATION	The membrane insertion of the Sec-independent M13 Procoat protein in bacteria requires the membrane electrochemical potential and the integral membrane protein YidC. We show here that YidC is involved in the translocation but not in the targeting of the Procoat protein, because we found the protein was partitioned into the membrane in the absence of YidC. YidC can function also to promote membrane insertion of Procoat mutants that insert independently of the membrane potential, proving that the effect of YidC depletion is not due to a dissipation of the membrane potential. We also found that YidC is absolutely required for Sec-dependent translocation of a long periplasmic loop of a mutant Procoat in which the periplasmic region has been extended from 20 to 194 residues. Furthermore, when Sec-dependent membrane proteins with large periplasmic domains were overproduced under YidC-limited conditions, we found that the exported proteins pro-OmpA and pre-peptidoglycan-associated lipoprotein accumulated in the cytoplasm. This suggests for Sec-dependent proteins that YidC functions at a late stage in membrane insertion, after the See translocase interacts with the translocating membrane protein. These studies are consistent with the understanding that YidC cooperates with the See translocase for membrane translocation and that YidC is required for clearing the protein-conducting channel.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Stockholm Univ, Arrhenius Lab, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Univ Hohenheim, Inst Microbiol & Mol Biol, D-70599 Stuttgart, Germany	University System of Ohio; Ohio State University; Stockholm University; University Hohenheim	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, 120 W 18th Ave, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu			NIGMS NIH HHS [GM63862] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063862] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Cristobal S, 1999, J BIOL CHEM, V274, P20068, DOI 10.1074/jbc.274.29.20068; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Hellman J, 2000, INFECT IMMUN, V68, P2566, DOI 10.1128/IAI.68.5.2566-2572.2000; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; ITO K, 1980, J BIOL CHEM, V255, P2123; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; KUHN A, 1985, J BIOL CHEM, V260, P5914; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Schuenemann TA, 1999, J BIOL CHEM, V274, P6855, DOI 10.1074/jbc.274.11.6855; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	45	115	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34847	34852		10.1074/jbc.M105793200	http://dx.doi.org/10.1074/jbc.M105793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11457858	hybrid			2022-12-25	WOS:000171024600068
J	Salvador, LM; Mukherjee, S; Kahn, RA; Lamm, MLG; Fazleabas, AT; Maizels, ET; Bader, MF; Hamm, H; Rasenick, MM; Casanova, JE; Hunzicker-Dunn, M				Salvador, LM; Mukherjee, S; Kahn, RA; Lamm, MLG; Fazleabas, AT; Maizels, ET; Bader, MF; Hamm, H; Rasenick, MM; Casanova, JE; Hunzicker-Dunn, M			Activation of the luteinizing hormone/choriogonadotropin hormone receptor promotes ADP ribosylation factor 6 activation in porcine ovarian follicular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; THYROTROPIN-RELEASING-HORMONE; CHOLERA-TOXIN; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; HORMONE/CHORIOGONADOTROPIN RECEPTOR; CHROMAFFIN CELLS; G-PROTEINS; REGULATED EXOCYTOSIS; ADRENERGIC-RECEPTOR	Previously we demonstrated in a cell-free ovarian follicular plasma membrane model that agonist-dependent desensitization of the luteinizing hormone/choriogonadotropin receptor (LH/CG R) is GTP-dependent, mimicked by the addition of ADP-ribosylation factor (ARF) nucleotide binding site opener, which acts as a guanine nucleotide exchange factor for ARFs 1 and 6, and selectively inhibited by synthetic N-terminal ARF6 peptides. We therefore sought direct evidence that activation of the LH/CG R promotes activation of ARF1 and/or ARF6. Using a classic ARF activation assay, the cholera toxin-catalyzed ADP-ribosylation of G alpha (s), results show that LH/CG R activation stimulates an ARF protein by a brefeldin A-independent mechanism. Synthetic N-terminal inhibitory ARF6 but not ARF1 peptide blocks LH/CG R-stimulated ARF activity. LH/CG R activation also promotes the binding of a photoaffinity GTP analog to a protein that migrates on one- and two-dimensional polyacrylamide gel electrophoresis with ARF6. These results suggest that ARF6 is the predominant ARF activated by the LH/CG R. To activate ARF6, the LH/CG R does not appear to signal through the C-terminal regions of G alpha (i) or G alpha (q) or through the second or third intracellular loops or the N terminus of the cytoplasmic tail of the LH/CG R. Although exogenous recombinant ARNO promotes only a small increase in ARF6 activation in the presence of activated LH/CG R, hCG-stimulated ARF6 activation is reduced to basal levels by catalytically inactive ARF nucleotide binding-site opener. These results provide direct evidence that LH/CG R activation leads to the activation of membrane-delimited ARF6.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60611 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; INSERM, U338, F-67084 Strasbourg, France; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Obstet & Gynecol, Chicago, IL 60612 USA; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA	Northwestern University; Northwestern University; Northwestern University; Emory University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Virginia	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	mhd@northwestern.edu	Bader, Marie-France/O-2098-2016; Hamm, Heidi E/G-2374-2014	Maizels, Evelyn/0000-0001-9072-1095	NIAID NIH HHS [R01 AI 32991] Funding Source: Medline; NIA NIH HHS [AG15482] Funding Source: Medline; NICHD NIH HHS [R01 HD/DK 38060] Funding Source: Medline; NIMH NIH HHS [R01 MH39595] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BENDER FE, 1982, STAT METHODS FOOD AG; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BORNANCIN F, 1993, J BIOL CHEM, V268, P17026; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; GILL DM, 1991, METHOD ENZYMOL, V195, P267; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; HUNZICKERDUNN M, 1991, J BIOL CHEM, V266, P7166; IIRI T, 1989, J BIOL CHEM, V264, P21394; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; JAMES SR, 1994, BIOCHEM J, V304, P359, DOI 10.1042/bj3040359; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Lamm MLG, 1999, ENDOCRINOLOGY, V140, P29, DOI 10.1210/en.140.1.29; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Le Stunff H, 2000, BIOCHEM J, V352, P491, DOI 10.1042/0264-6021:3520491; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Mukherjee S, 2001, J BIOL CHEM, V276, P6524, DOI 10.1074/jbc.C000725200; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Rajagopalan-Gupta RM, 1999, ENDOCRINOLOGY, V140, P1612, DOI 10.1210/en.140.4.1612; Rajagopalan-Gupta RM, 1998, ENDOCRINOLOGY, V139, P4547, DOI 10.1210/en.139.11.4547; RajagopalanGupta RM, 1997, MOL ENDOCRINOL, V11, P538, DOI 10.1210/me.11.5.538; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; RASENICK MM, 1994, METHOD ENZYMOL, V237, P100; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; SHENKER A, 1991, J BIOL CHEM, V266, P9309; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; TSAI SC, 1991, J BIOL CHEM, V266, P8213; VANDOP C, 1984, J BIOL CHEM, V259, P696; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	74	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33773	33781		10.1074/jbc.M101498200	http://dx.doi.org/10.1074/jbc.M101498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448949	hybrid			2022-12-25	WOS:000170910200066
J	Veenendaal, AKJ; van der Does, C; Driessen, AJM				Veenendaal, AKJ; van der Does, C; Driessen, AJM			Mapping the sites of interaction between SecY and SecE by cysteine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION MACHINERY; COLI PREPROTEIN TRANSLOCASE; VIVO CROSS-LINKING; ESCHERICHIA-COLI; MEMBRANE TRANSLOCATION; CATALYTIC CYCLE; PRLA; COMPONENT; COMPLEX; DOMAINS	In Escherichia coli, the SecYEG complex mediates the translocation and membrane integration of proteins. Both genetic and biochemical data indicate interactions of several transmembrane segments (TMSs) of SecY with SecE. By means of cysteine scanning mutagenesis, we have identified intermolecular sites of contact between TMS7 of SecY and TMS3 of SecE. The cross-linking of SecY to SecE demonstrates that these subunits are present in a one-to-one stoichiometry within the SecYEG complex. Sites in TMS3 of SecE involved in SecE dimerization are confined to a specific a-helical interface and occur in an oligomeric SecYEG complex. Although crosslinking reversibly inactivates translocation, the contact between TMS7 of SecY and TMS3 of SecE remains unaltered upon insertion of the preprotein into the translocation channel. These data support a model for an oligomeric translocation channel in which pairs of SecYEG complexes contact each other via SecE.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@biol.rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANADA M, 1994, J BIOL CHEM, V269, P23625; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manting EH, 1997, J BACTERIOL, V179, P5699, DOI 10.1128/jb.179.18.5699-5704.1997; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 1999, J BIOL CHEM, V274, P23868, DOI 10.1074/jbc.274.34.23868; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Nagamori S, 2000, J BIOCHEM-TOKYO, V128, P129, DOI 10.1093/oxfordjournals.jbchem.a022723; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; TANJI Y, 1991, J BACTERIOL, V173, P1997, DOI 10.1128/jb.173.6.1997-2005.1991; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Voorst F, 1998, BIOCHEMISTRY-US, V37, P12261, DOI 10.1021/bi9809021; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Yahr TL, 2000, EMBO J, V19, P4393, DOI 10.1093/emboj/19.16.4393	43	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32559	32566		10.1074/jbc.M103912200	http://dx.doi.org/10.1074/jbc.M103912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11445571	hybrid, Green Published			2022-12-25	WOS:000170746000026
J	Ma, XR; Karra, S; Lindner, DJ; Hu, JB; Reddy, SPM; Kimchi, A; Yodoi, J; Kalvakolanu, DD				Ma, XR; Karra, S; Lindner, DJ; Hu, JB; Reddy, SPM; Kimchi, A; Yodoi, J; Kalvakolanu, DD			Thioredoxin participates in a cell death pathway induced by interferon and retinoid combination	ONCOGENE			English	Article						cytokines; vitamin-A; apoptosis; redox control; tumor growth	ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; MOLECULAR-CLONING; INDUCED APOPTOSIS; REDOX REGULATION; MAMMALIAN THIOREDOXIN; MEDIATED APOPTOSIS; CYTOCHROME-C; CYCLE ARREST; VITAMIN-A	Interferons (IFNs) and retinoids are potent tumor growth suppressors, We have shown earlier that the IFN-P and all-trans retinoic acid combination, but not the single agents, induces death in several tumor cell lines. Employing a genetic approach we have recently identified several Genes associated with Retinoid-IFN induced Mortality (GRIM) that mediate the cell death effect of IFN/RA combination. One of the GRIMs, GRIM-12, was identical to human thioredoxin reductase (TR), an enzyme that controls intracellular redox state. To define the participants of TR mediated death pathway we have examined the role of thioredoxin (Trx), its downstream substrate, and its influence on IFN/RA-induced death regulation. Inhibition of the thioredoxin expression by antisense RNA suppressed cell death. Similarly, a mutant Trx1 lacking the critical cysteine residues blocked cell death. In contrast, overexpression of wildtype thioredoxin augmented cell death. This effect of Trx1 was in part due to its ability to augment cell death via caspase-8, The redox inactive Trx1 mutant inhibits the cell death induced by caspase-8 but not caspase-3, These studies identify a novel mechanism of cell death regulation by IFN/RA combination involving redox enzymes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Mol & Cellular Biol Program,Greenebaun Canc Ctr, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD 21218 USA; Weizmann Inst Sci, Dept Mol Genet & Virol, IL-76100 Rehovot, Israel; Inst Virus Res, Dept Biol Responses, Shogin, Japan	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Weizmann Institute of Science	Kalvakolanu, DD (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Mol & Cellular Biol Program,Greenebaun Canc Ctr, Baltimore, MD 21201 USA.		Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 71401, CA 78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071401, R01CA078282] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; Gallegos A, 1996, CANCER RES, V56, P5765; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; PellicenaPalle A, 1997, MECH DEVELOP, V62, P61, DOI 10.1016/S0925-4773(96)00650-8; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SALZ HK, 1994, GENETICS, V136, P1075; Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 2000, CLIN CANCER RES, V6, P1563; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Ueda S, 1998, J IMMUNOL, V161, P6689; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang ZG, 1998, SCIENCE, V279, P1547; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	84	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3703	3715		10.1038/sj.onc.1204477	http://dx.doi.org/10.1038/sj.onc.1204477			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439333				2022-12-25	WOS:000169400200011
J	Boulares, AH; Zoltoski, AJ; Yakovlev, A; Xu, M; Smulson, ME				Boulares, AH; Zoltoski, AJ; Yakovlev, A; Xu, M; Smulson, ME			Roles of DNA fragmentation factor and poly(ADP-ribose) polymerase in an amplification phase of tumor necrosis factor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CASPASE-ACTIVATED DNASE; CELL-DEATH; CYTOCHROME-C; NUCLEAR EVENTS; NITRIC-OXIDE; HISTONE H1; TNF-ALPHA; CLEAVAGE; ENDONUCLEASE	During apoptosis, endonucleases cleave DNA into 50-300-kb fragments and subsequently into internucleosomal fragments. DNA fragmentation factor (DFF) is implicated in apoptotic DNA cleavage; this factor comprises DFF45 and DFF40 subunits, the former of which acts as a chaperone and inhibitor of the catalytic subunit and whose cleavage by caspase-3 results in DFF activation. Disruption of the DFF45 gene blocks internucleosomal DNA fragmentation and confers resistance to apoptosis in primary thymocytes. The role of DFF-mediated DNA fragmentation in apoptosis was investigated in primary fibroblasts from DFF45(-/-) and control (DFF45(+/+)) mice. DFF45 deficiency rendered fibroblasts resistant to apoptosis induced by tumor necrosis factor (TNF). TNF induced rapid cleavage of DNA into similar to 50-kb fragments in DFF45(+/+) fibroblasts but not in DFF45(-/-) cells, indicating that DFF mediates this initial step in DNA processing. The TNF-induced activation of poly(ADP-ribose) polymerase (PARP), which requires PARP binding to DNA strand breaks, and the consequent depletion of the PARP substrate NAD were markedly delayed in DFF45(-/-) cells, suggesting a role for DFF in PARP activation. The activation of caspase-3 and mitochondrial events important in apoptotic signaling, including the loss of mitochondrial membrane potential and the release of cytochrome c, induced by TNF were similarly delayed in DFF45(-/-) fibroblasts. DFF45(-/-) and DFF45(+/+) cells were equally sensitive to the DNA-damaging agent and PARP activator N-methyl-N'-nitro-N-nitrosoguanidine. Inhibition of PARP by 3-aminobenzamide partially protected DFF45(+/+) cells against TNF-induced death and inhibited the associated release of cytochrome c and activation of caspase-3. These results suggest that the generation of 50-kb DNA fragments by DFF, together with the activation of PARP, mitochondrial dysfunction, and caspase-3 activation, contributes to an amplification loop in the death process.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC 20007 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Georgetown University; Georgetown University; University System of Ohio; University of Cincinnati	Smulson, ME (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Basic Sci Bldg,Rm 351,3900 Reservoir Rd,NW, Washington, DC 20007 USA.	smulson@bc.georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA013195] Funding Source: NIH RePORTER; NCI NIH HHS [CA13195, CA25344] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL S, 1988, J IMMUNOL, V140, P4187; Alvarez-Gonzalez R, 1999, MOL CELL BIOCHEM, V193, P19, DOI 10.1023/A:1006979220009; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Boulares AH, 1996, VIROLOGY, V218, P71, DOI 10.1006/viro.1996.0167; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cao Z, 1999, COLD SPRING HARB SYM, V64, P473, DOI 10.1101/sqb.1999.64.473; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN GM, 1994, J IMMUNOL, V153, P507; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Giardina C, 1999, BBA-MOL CELL RES, V1448, P425, DOI 10.1016/S0167-4889(98)00156-6; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Halappanavar SS, 1999, J BIOL CHEM, V274, P37097, DOI 10.1074/jbc.274.52.37097; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; Jacobson EL, 1997, METHOD ENZYMOL, V280, P221; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Kumari SR, 1998, CANCER RES, V58, P5075; Kupper JH, 1999, BIOCHEM BIOPH RES CO, V265, P525, DOI 10.1006/bbrc.1999.1690; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LegrandPoels S, 1997, FREE RADICAL RES, V27, P301, DOI 10.3109/10715769709065768; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Piette J, 1997, BIOL CHEM, V378, P1237; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; SimibulanRosenthal CMG, 1996, PROG NUCLEIC ACID RE, V55, P135; SMULSON ME, 1984, METHOD ENZYMOL, V106, P438; Smulson ME, 1998, CANCER RES, V58, P3495; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; VAKOVLEV AG, 2001, MOL MED, V7, P205; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; Yakovlev AG, 1999, NUCLEIC ACIDS RES, V27, P1999, DOI 10.1093/nar/27.9.1999; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122	63	58	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38185	38192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11461900				2022-12-25	WOS:000171526500063
J	Pfannschmidt, T; Schutze, K; Brost, M; Oelmuller, R				Pfannschmidt, T; Schutze, K; Brost, M; Oelmuller, R			A novel mechanism of nuclear photosynthesis gene regulation by redox signals from the chloroplast during photosystem stoichiometry adjustment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CHLOROPHYLL PRECURSORS; ELECTRON-TRANSPORT; SPINACH PSAD; EXPRESSION; SUBUNIT; TRANSCRIPTION; FERREDOXIN; IDENTIFICATION; PLASTOCYANIN	Photosynthetic organisms acclimate to long term changes in the environmental light quality by an adjustment of their photosystem stoichiometry to maintain photosynthetic efficiency. By using light sources that predominantly excite either photosystem I (PSI) or photosystem II (PSII), we studied the effects of excitation imbalances between both photosystems on nuclear PSI gene transcription in transgenic tobacco seedlings with promoter::beta -glucuronidase gene fusions. Shifts from PSI to PSII light sources (and vice versa) induced changes in the reduction/oxidation state of intersystem redox components, and acclimation of tobacco seedlings to such changes were monitored by changes in chlorophyll alb ratios and in vivo chlorophyll a fluorescence. The ferredoxin-NADP(+)-oxidoreductase gene promoter did not respond to these treatments, those from the genes for subunits PsaD and PsaF of PSI are activated by a reduction signal, and the plastocyanin promoter responded to both reduction and oxidation signals. Additional experiments with photosynthetic electron transport inhibitors 3-(3 ' ,4 ' -dichlorophenyl)-1,1 ' -dimethyl urea and 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone demonstrated that the redox state of the plastoquinone pool controls the activity of the plastocyanin promoter, whereas subunit PsaD and PsaF gene transcription is regulated by other photosynthesis-derived signals. Thus, the expression of nuclear-encoded PSI genes is controlled by diverse light quality-dependent redox signals from the plastids during photosystem stoichiometry adjustment.	Univ Jena, Dept Plant Physiol, Inst Gen Bot, D-07743 Jena, Germany	Friedrich Schiller University of Jena	Pfannschmidt, T (corresponding author), Univ Jena, Dept Plant Physiol, Inst Gen Bot, Dornburger Str 159, D-07743 Jena, Germany.	Thomas.Pfannschmidt@uni-jena.de	Pfannschmidt, Thomas/AAH-5916-2021					Alfonso M, 2000, PLANT PHYSIOL, V122, P505, DOI 10.1104/pp.122.2.505; Allen JF, 2000, PHILOS T R SOC B, V355, P1351, DOI 10.1098/rstb.2000.0697; Allen JF, 1996, J MOL EVOL, V42, P482, DOI 10.1007/BF02352278; ALLEN JF, 1995, PHYSIOL PLANTARUM, V93, P196, DOI 10.1034/j.1399-3054.1995.930128.x; Anderson JM, 1999, AUST J PLANT PHYSIOL, V26, P625, DOI 10.1071/PP99070; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOLLE C, 1994, PLANT PHYSIOL, V105, P1355, DOI 10.1104/pp.105.4.1355; Bolle C, 1996, PLANT J, V10, P919, DOI 10.1046/j.1365-313X.1996.10050919.x; Chitnis PR, 1996, PLANT PHYSIOL, V111, P661, DOI 10.1104/pp.111.3.661; Durnford DG, 1997, PHOTOSYNTH RES, V53, P229, DOI 10.1023/A:1005815725371; Durnford DG, 1998, METHOD ENZYMOL, V297, P220; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; FLIEGER K, 1993, PLANT J, V4, P9, DOI 10.1046/j.1365-313X.1993.04010009.x; FLIEGER K, 1994, PLANT J, V6, P359, DOI 10.1046/j.1365-313X.1994.06030359.x; GENTY B, 1989, BIOCHIM BIOPHYS ACTA, V990, P87, DOI 10.1016/S0304-4165(89)80016-9; GoldschmidtClermont M, 1998, INT REV CYTOL, V177, P115; Gray MW, 1999, CURR OPIN GENET DEV, V9, P678, DOI 10.1016/S0959-437X(99)00030-1; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; JOHANNINGMEIER U, 1988, EUR J BIOCHEM, V177, P417, DOI 10.1111/j.1432-1033.1988.tb14391.x; Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627; Karpinski S, 1999, SCIENCE, V284, P654, DOI 10.1126/science.284.5414.654; Kovacs L, 2000, PHOTOSYNTH RES, V65, P231, DOI 10.1023/A:1010650532693; Kropat J, 2000, PLANT J, V24, P523, DOI 10.1046/j.1365-313x.2000.00898.x; Kusnetsov V, 1996, MOL GEN GENET, V252, P631, DOI 10.1007/BF02173968; LELONG C, 1994, J BIOL CHEM, V269, P10034; Leon P, 1998, ANNU REV PLANT PHYS, V49, P453, DOI 10.1146/annurev.arplant.49.1.453; LINK G, 1999, ADV PHOTOSYNTHESIS, P1; LUBBERSTEDT T, 1994, MOL GEN GENET, V242, P602, DOI 10.1007/BF00285284; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; MAXWELL DP, 1995, PLANT PHYSIOL, V109, P787, DOI 10.1104/pp.109.3.787; Mochizuki N, 2001, P NATL ACAD SCI USA, V98, P2053, DOI 10.1073/pnas.98.4.2053; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; OELMULLER R, 1986, PLANTA, V168, P482, DOI 10.1007/BF00392267; OELMULLER R, 1993, MOL GEN GENET, V237, P261, DOI 10.1007/BF00282808; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; Oswald O, 2001, P NATL ACAD SCI USA, V98, P2047, DOI 10.1073/pnas.021449998; Petracek ME, 1998, P NATL ACAD SCI USA, V95, P9009, DOI 10.1073/pnas.95.15.9009; Petracek ME, 1997, PLANT CELL, V9, P2291, DOI 10.1105/tpc.9.12.2291; Pfannschmidt T, 1999, IUBMB LIFE, V48, P271, DOI 10.1080/713803507; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Pfannschmidt T, 1997, MOL GEN GENET, V257, P35, DOI 10.1007/s004380050621; Pfannschmidt T, 2001, PHYSIOL PLANTARUM, V112, P1, DOI 10.1034/j.1399-3054.2001.1120101.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RAPP JC, 1991, PLANT MOL BIOL, V17, P813, DOI 10.1007/BF00037063; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; Smeekens S, 2000, ANNU REV PLANT PHYS, V51, P49, DOI 10.1146/annurev.arplant.51.1.49; Streatfield SJ, 1999, PLANT CELL, V11, P1609, DOI 10.1105/tpc.11.9.1609; Sugita M, 1996, PLANT MOL BIOL, V32, P315, DOI 10.1007/BF00039388; Sullivan JA, 1999, PLANT CELL, V11, P901, DOI 10.1105/tpc.11.5.901; Surpin M, 1997, ESSAYS BIOCHEM, V32, P113; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V46, P445; Trebst A., 1980, METH ENZYMOL, V69, P675, DOI DOI 10.1016/S0076-6879(80)69067-3; Tullberg A, 2000, PLANT CELL PHYSIOL, V41, P1045, DOI 10.1093/pcp/pcd031; Vinti G, 2000, PLANT J, V24, P883, DOI 10.1046/j.1365-313x.2000.00936.x; WYNN RM, 1989, PLANT PHYSIOL, V91, P445, DOI 10.1104/pp.91.1.445; XU Q, 1994, J BIOL CHEM, V269, P21512; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	59	166	178	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36125	36130		10.1074/jbc.M105701200	http://dx.doi.org/10.1074/jbc.M105701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11468291	hybrid			2022-12-25	WOS:000171194500012
J	Banno, Y; Takuwa, Y; Akao, Y; Okamoto, H; Osawa, Y; Naganawa, T; Nakashima, S; Suh, PG; Nozawa, Y				Banno, Y; Takuwa, Y; Akao, Y; Okamoto, H; Osawa, Y; Naganawa, T; Nakashima, S; Suh, PG; Nozawa, Y			Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHOSPHATIDIC-ACID; PHOSPHOINOSITIDE 3-KINASE; CALCIUM MOBILIZATION; LYSOPHOSPHATIDIC ACID; VESICULAR TRAFFICKING; KINASE ACTIVATION; HUMAN NEUTROPHILS; EPITHELIAL-CELLS; MAMMALIAN-CELLS	Phospholipase D (PLD), phosphatidylinositol 3-kinase (PI3K), and Akt are known to be involved in cellular signaling related to proliferation and cell survival. In this report, we provide evidence that PLD links sphingosine 1-phosphate (S1P)-induced activation of the G protein-coupled EDG3 receptor to stimulation of PI3K and its downstream effector Akt in Chinese hamster ovary (CHO) cells. SIP stimulation of EDG3-overexpressing CHO cells but not vector-transfected cells induced activation of PLD, PI3K, and Akt in a time- an dose-dependent manner. Akt phosphorylation was prevented by the PI3K inhibitors wortmannin and LY294002 (2-(4-monrpholinyl)-8-phenyl-4H-1-benzopyran-4-one), indicating that Akt activation was dependent on PI3K. SIP-induced activation of PI3K and Akt was abrogated by 1-butanol, which inhibited S1P-induced accumulation of phosphatidic acid by serving as a phosphatidyl group acceptor in the transphosphatidylation reaction catalyzed by PLD, whereas both PI3K and Akt activation were not inhibited by 2-butanol without such reaction. Co-expression of wild-type PLD2 with myc-Akt resulted in increased Akt activation in response to SIP. In contrast, co-expression of a catalytically inactive mutant of PLD2 eliminated the S1P-induced A-kt activation. The treatment of EDG3-expressing CHO cells with exogenous Streptomyces chromofuscus PLD, which caused an accumulation of phosphatidic acid, resulted in increases in PI3K activity and the phosphorylation of Akt, the latter of which was completely abolished by LY294002. Furthermore, S1P-induced membrane ruffling, which was dependent on P13K and Rac, was inhibited by I-butanol, but not by 2-butanol. These results demonstrate that PLD participates in the activation of PI3K and Akt stimulation of EDG3 receptor.	Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Internal Med, Gifu 5008705, Japan; Kanazawa Univ, Sch Med, Dept Pathol, Kanazawa, Ishikawa 9208640, Japan; Gifu Int Inst Biotechnol, Gifu 5050116, Japan; Inst Appl Biochem, Gifu 5050116, Japan; Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 790784, South Korea	Gifu University; Gifu University; Kanazawa University; Pohang University of Science & Technology (POSTECH)	Banno, Y (corresponding author), Gifu Univ, Sch Med, Dept Biochem, Tsukasamachi 40, Gifu 5008705, Japan.	banno@cc.gifu-u.ac.jp	Suh, Pann-Ghill/F-3610-2010					An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; An SZ, 2000, ANN NY ACAD SCI, V905, P25; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Cissel DS, 1998, J PHARMACOL EXP THER, V285, P110; DATA SR, 1997, CELL, V91, P231; Emoto M, 2000, J BIOL CHEM, V275, P7144, DOI 10.1074/jbc.275.10.7144; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gillooly DJ, 1999, BIOCHEM J, V344, P605, DOI 10.1042/0264-6021:3440605; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Igarashi Y, 1998, ANN NY ACAD SCI, V845, P19, DOI 10.1111/j.1749-6632.1998.tb09659.x; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; JONES GA, 1993, J BIOL CHEM, V268, P20845; JUST L, 1995, NATURE, V375, P500; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kirsch C, 2001, BIOCHEM BIOPH RES CO, V282, P691, DOI 10.1006/bbrc.2001.4623; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; KOH J, 1999, J BIOL CHEM, V274, P23940; Kozawa O, 1997, EUR J BIOCHEM, V248, P149, DOI 10.1111/j.1432-1033.1997.00149.x; LAUENER R, 1995, BIOCHEM BIOPH RES CO, V215, P8, DOI 10.1006/bbrc.1995.2427; Lavie Y, 1996, J NEUROCHEM, V66, P811; Lee SD, 2000, J NEUROCHEM, V75, P1053, DOI 10.1046/j.1471-4159.2000.0751053.x; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Litosch I, 2000, BIOCHEMISTRY-US, V39, P7736, DOI 10.1021/bi000022y; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lucas L, 2000, ONCOGENE, V19, P431, DOI 10.1038/sj.onc.1203323; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Meier KE, 1999, BBA-MOL CELL BIOL L, V1439, P199, DOI 10.1016/S1388-1981(99)00095-5; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nakamura M, 1997, BIOCHEM PHARMACOL, V53, P1929, DOI 10.1016/S0006-2952(97)00169-X; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Ohguchi K, 1997, BBA-LIPID LIPID MET, V1346, P301, DOI 10.1016/S0005-2760(97)00043-X; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Orlati S, 2000, ARCH BIOCHEM BIOPHYS, V375, P69, DOI 10.1006/abbi.1999.1589; Palicz A, 2001, J BIOL CHEM, V276, P3090, DOI 10.1074/jbc.M007759200; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sergeant S, 2001, J BIOL CHEM, V276, P4737, DOI 10.1074/jbc.M006571200; Siddiqui RA, 2000, BBA-MOL CELL BIOL L, V1483, P161, DOI 10.1016/S1388-1981(99)00172-9; Siddiqui RA, 1997, BBA-LIPID LIPID MET, V1349, P81, DOI 10.1016/S0005-2760(97)00085-4; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Steele-Mortimer O, 2000, J BIOL CHEM, V275, P37718, DOI 10.1074/jbc.M008187200; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; Takuwa Y, 2001, MOL CELL ENDOCRINOL, V177, P3, DOI 10.1016/S0303-7207(01)00441-5; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Yamakawa H, 2000, NEUROREPORT, V11, P3647, DOI 10.1097/00001756-200011090-00049; YANO H, 1993, J BIOL CHEM, V268, P25846; Zhang Y, 2000, J BIOL CHEM, V275, P35224, DOI 10.1074/jbc.M003329200	66	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35622	35628		10.1074/jbc.M105673200	http://dx.doi.org/10.1074/jbc.M105673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11468290	hybrid			2022-12-25	WOS:000171109300056
J	Fischle, W; Dequiedt, F; Fillion, M; Hendzel, MJ; Voelter, W; Verdin, E				Fischle, W; Dequiedt, F; Fillion, M; Hendzel, MJ; Voelter, W; Verdin, E			Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR COREPRESSORS; MEF2 TRANSCRIPTION FACTOR; REPRESSION PATHWAY; CO-REPRESSOR; IN-VIVO; N-COR; CHROMATIN; YEAST; COMPLEX; ACETYLATION	Histone deacetylases (HDACs) are part of transcriptional corepressor complexes and play key roles in regulating chromatin structure. Three different classes of human HDACs have been defined based on their homology to HDACs found in Saccharomyces cerevisiae: RPD3 (class I), HDA1 (class II), and SIR2 (class III). Here we describe the identification and functional characterization of HDAC7, a new member of the human class II HDAC family. Although HDAC7 is localized mostly to the cell nucleus, it is also found in the cytoplasm, suggesting nucleocytoplasmic shuttling. The HDAC activity of HDAC7 maps to a carboxyl-terminal domain and is dependent on the interaction with the class I HDAC, HDAC3, in the cell nucleus. Cytoplasmic HDAC7 that is not bound to HDAC3 is enzymatically inactive. We provide evidence that the transcriptional corepressors SMRT and N-CoR could serve as critical mediators of HDAC7 activity by binding class II HDACs and HDAC3 by two distinct repressor domains. Different class II HDACs reside in the cell nucleus in stable and autonomous complexes with enzymatic activity, but the enzymatic activities associated with HDAC7 and HDAC4 rely on shared cofactors, including HDAC3 and SMRT/N-CoR.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany; Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of California System; University of California San Francisco; The J David Gladstone Institutes; Eberhard Karls University of Tubingen; University of Alberta	Verdin, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.	everdin@gladstone.ucsf.edu	Hendzel, Michael/C-3391-2009; Verdin, Eric/AAB-7999-2019	Hendzel, Michael/0000-0002-9603-7945; Dequiedt, Franck/0000-0003-1234-7477; Verdin, Eric/0000-0003-3703-3183	NIGMS NIH HHS [GM51671] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Davie JR, 1999, J CELL BIOCHEM, P141; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guenther MG, 2000, GENE DEV, V14, P1048; Harlow E., 1988, ANTIBODIES LAB MANUA; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang EY, 2000, GENE DEV, V14, P45; Huynh KD, 2000, GENE DEV, V14, P1810; Jones KA, 2000, GENE DEV, V14, P1992; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kao HY, 2000, GENE DEV, V14, P55; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Moore DD, 1995, GLOB MOB SURV; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SOLOVYEV V, 1997, ISMB, V5, P294; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Stewart S, 2000, NATURE, V408, P46, DOI 10.1038/35040690; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; VANHOLDE KE, 1988, CHROMATIN, P111; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wolffe A., 1998, CHROMATIN STRUCTURE; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	69	159	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35826	35835		10.1074/jbc.M104935200	http://dx.doi.org/10.1074/jbc.M104935200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11466315	hybrid			2022-12-25	WOS:000171109300081
J	Hernandez-Torres, J; Yunta, M; Lazo, PA				Hernandez-Torres, J; Yunta, M; Lazo, PA			Differential cooperation between regulatory sequences required for human CD53 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; PROTEIN-1 MRP-1/CD9; KAI1/CD82 EXPRESSION; MOLECULAR-CLONING; GENOMIC STRUCTURE; MYELOID CELLS; ANTIGEN; PU.1; PROMOTER; MOTILITY	CD53 is a tetraspanin protein mostly expressed in to the lymphoid-myeloid lineage. We have characterized the human CD53 gene regulatory region. Within the proximal 2 kilobases, and with opposite transcriptional orientation, is located the promoter-enhancer of a second gene, which does not affect CD53. Twenty-four copies of a CA dinucleotide repeat separate these two gene promoters. The proximal enhanceosome of the human CD53 gene is comprised between residues -266 and +84, and can be subdivided into four major subregions, two of them within exon 1. Mutational analysis identified several cooperating sequences. An Sp1 and an ets-1 site, at positions - 115 and + 62, respectively, are essential for transcriptional competence in all cell lines. Five other regulatory sequences have a dual role, activator or down-regulator, depending on the cell line. At the end of the non-coding exon 1, + 64 to + 83, there is a second ets-1 regulatory element, which is required for high level of transcription, in cooperation with the Sp1 site, in K562 and Molt-4, but not in Namalwa cells, where it functions as a repressor. This Sp1 site also cooperates with another ets-1/PU.1 site at -172. Different cell types use different regulatory sequences in the enhanceosome for the expression of the same gene.	Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain; Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Genet & Med Mol, E-28220 Majadahonda, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Instituto de Salud Carlos III	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	plazozbi@usal.es	Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025; Yunta, Monica/0000-0002-8060-9582				Adachi M, 1996, CANCER RES, V56, P1751; Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397; Anderson DC, 1995, METABOLIC MOL BASES, P3955; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BOSCA L, 1994, J EXP MED, V179, P1119, DOI 10.1084/jem.179.4.1119; Cao L, 1997, IMMUNOBIOLOGY, V197, P70, DOI 10.1016/S0171-2985(97)80058-7; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dong JT, 1996, CANCER RES, V56, P4387; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; FEDUCHI E, 1994, INT J CANCER, V58, P855; Feng X, 2000, J BIOL CHEM, V275, P8331, DOI 10.1074/jbc.275.12.8331; Ferrer M, 1998, LEUKEMIA, V12, P773, DOI 10.1038/sj.leu.2400969; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; GALLEGO MI, 1995, J BIOL CHEM, V270, P24321, DOI 10.1074/jbc.270.41.24321; GONZALEZ ME, 1993, GENOMICS, V18, P725; Guo XZ, 1998, CANCER RES, V58, P753; Guo XZ, 1996, CANCER RES, V56, P4876; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Higashiyama M, 1997, INT J CANCER, V74, P205, DOI 10.1002/(SICI)1097-0215(19970422)74:2<205::AID-IJC12>3.0.CO;2-C; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1992, BIOCHEM BIOPH RES CO, V185, P436, DOI 10.1016/S0006-291X(05)81004-6; HOTTA H, 1988, CANCER RES, V48, P2955; HOTTA H, 1989, JPN J CANCER RES, V80, P1186, DOI 10.1111/j.1349-7006.1989.tb01653.x; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KORINEK V, 1993, IMMUNOGENETICS, V38, P272, DOI 10.1007/BF00188803; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lazo PA, 1997, CELL IMMUNOL, V178, P132, DOI 10.1006/cimm.1997.1139; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LeNaour F, 1997, LEUKEMIA, V11, P1290, DOI 10.1038/sj.leu.2400721; LeNaour F, 1996, ONCOGENE, V13, P481; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Lloberas J, 1999, IMMUNOL TODAY, V20, P184, DOI 10.1016/S0167-5699(99)01442-5; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; MIYAKE M, 1995, CANCER RES, V55, P4127; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; Mollinedo F, 1997, CLIN DIAGN LAB IMMUN, V4, P229, DOI 10.1128/CDLI.4.2.229-231.1997; Muller S, 1999, BIOCHEM BIOPH RES CO, V259, P364, DOI 10.1006/bbrc.1999.0677; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; OLWEUS J, 1993, J IMMUNOL, V151, P707; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; Rubinstein E, 1997, EUR J IMMUNOL, V27, P1919, DOI 10.1002/eji.1830270815; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Sacristan MP, 1999, ONCOGENE, V18, P5836, DOI 10.1038/sj.onc.1202963; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; TAKAHASHI N, 1991, JPN J CANCER RES, V82, P1239, DOI 10.1111/j.1349-7006.1991.tb01787.x; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666	69	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35405	35413		10.1074/jbc.M104723200	http://dx.doi.org/10.1074/jbc.M104723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11443129	hybrid			2022-12-25	WOS:000171109300028
J	Kopitz, J; von Reitzenstein, C; Andre, S; Kaltner, H; Uhl, J; Ehemann, V; Cantz, M; Gabius, HJ				Kopitz, J; von Reitzenstein, C; Andre, S; Kaltner, H; Uhl, J; Ehemann, V; Cantz, M; Gabius, HJ			Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-SPECIFIC LECTINS; GANGLIOSIDE SIALIDASE; ANIMAL LECTINS; IN-VITRO; ENDOGENOUS LECTIN; VERTEBRATE LECTIN; PLASMA-MEMBRANE; GLIOMA-CELLS; T-CELLS; EXPRESSION	The cell density-dependent growth inhibition of human SK-N-MC neuroblastoma cells is initiated by increased ganglioside sialidase activity leading to elevated cell surface presentation of ganglioside GM1, a ligand of galectin-1. We herein show that the extent of the cell surface expression of the galectin coincides with marked increases of the sialidase activity. Reverse transcriptase-polymerase chain reaction analysis excludes a regulation at the transcriptional level. Exposure of cells to purified galectin-1 reveals its carbohydrate-dependent activity to reduce cell proliferation. Assays to detect DNA fragmentation biochemically and cytometrically and to block caspases render it unlikely that galectin-1 acts as a classical proapoptotic factor on these cells. Because the chimeric galectin-3 shares binding sites and binding parameters with galectin-1 for these cells, we tested whether this galectin will elicit the same response as the homodimeric cross-linking galectin-1. Evidently, galectin-3 fails to affect cell growth by itself but interferes with galectin-1 upon coincubation. Its proteolytically truncated variant, the C-terminal lectin domain with impaired capacity to form aggregates when surface bound, has only weak binding properties. Thus, the way in which the galectin-1 interacts topologically with an apparently common set of ligands relative to galectin-3 is crucial for eliciting post-binding events. We conclude that galectin-1 is a probable effector in the sialidase-dependent growth control in this system. Moreover, the experiments with galectin-3 reveal functional divergence, most probably based on different topologies of presentation of homologous carbohydrate-binding sites.	Heidelberg Univ, Klinikum, Inst Pathol, D-69120 Heidelberg, Germany; Univ Munich, Tierarztliche Fak, Inst Physiol Chem, D-80539 Munich, Germany	Ruprecht Karls University Heidelberg; University of Munich	Cantz, M (corresponding author), Heidelberg Univ, Inst Pathochem & Neurochem, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	michael_cantz@med.uni-heidelberg.de		Andre, Sabine/0000-0003-0850-0432; Kaltner, Herbert/0000-0003-4680-8411; Gabius, Hans-Joachim/0000-0003-3467-3900				Abad-Rodriguez J, 1998, GLIA, V23, P156, DOI 10.1002/(SICI)1098-1136(199806)23:2<156::AID-GLIA7>3.0.CO;2-4; Adams L, 1996, BBA-MOL CELL RES, V1312, P137, DOI 10.1016/0167-4889(96)00031-6; AGRWAL N, 1993, J BIOL CHEM, V268, P14932; Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Andre S, 1997, BIOCONJUGATE CHEM, V8, P845, DOI 10.1021/bc970164d; BAO Q, 1995, J CELL SCI, V108, P2791; Barboni EAM, 1999, GLYCOCONJUGATE J, V16, P365, DOI 10.1023/A:1007004330048; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; Camby I, 2001, BRAIN PATHOL, V11, P12; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Douglas RS, 1995, J IMMUNOL METHODS, V188, P219, DOI 10.1016/0022-1759(95)00216-2; Ehemann V, 1999, CANCER LETT, V138, P101, DOI 10.1016/S0304-3835(98)00383-8; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Gabius HJ, 2000, NATURWISSENSCHAFTEN, V87, P108, DOI 10.1007/s001140050687; GABIUS HJ, 1991, HISTOCHEMISTRY, V95, P269; GABIUS HJ, 1990, ANAL BIOCHEM, V189, P91, DOI 10.1016/0003-2697(90)90050-J; Gabius HJ, 2001, ANAT HISTOL EMBRYOL, V30, P3, DOI 10.1046/j.1439-0264.2001.00305.x; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Gabius HJ, 1997, CANCER INVEST, V15, P454, DOI 10.3109/07357909709047585; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; Gunnersen JM, 2000, GLIA, V32, P146, DOI 10.1002/1098-1136(200011)32:2<146::AID-GLIA40>3.3.CO;2-V; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P5526, DOI 10.1021/bi00184a022; Hakamori S, 1998, ACTA ANAT, V161, P79; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HO MK, 1982, J IMMUNOL, V128, P1221; HSU DK, 1992, J BIOL CHEM, V267, P14167; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Kaltner H, 1998, ACTA ANAT, V161, P162; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; Kopitz J, 2001, FEBS LETT, V491, P233, DOI 10.1016/S0014-5793(01)02207-4; KOPITZ J, 1997, GLYCOSCIENCES STATUS, P163; Kuklinski S, 1998, J NEUROCHEM, V70, P814; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; Laine R. A., 1997, GLYCOSCIENCES STATUS, P1; Lingwood CA, 1999, BIOSCIENCE REP, V19, P345, DOI 10.1023/A:1020299819637; LIPSICK JS, 1980, BIOCHEM BIOPH RES CO, V97, P56, DOI 10.1016/S0006-291X(80)80133-1; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; Loo DT, 1998, METHOD CELL BIOL, V57, P251; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDAL DK, 1992, BIOCHEMISTRY-US, V31, P8465, DOI 10.1021/bi00151a012; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MEHUL B, 1994, J BIOL CHEM, V269, P18250; Moiseeva EP, 2000, CARDIOVASC RES, V45, P493, DOI 10.1016/S0008-6363(99)00276-X; Nagai Y, 1998, PURE APPL CHEM, V70, P49, DOI 10.1351/pac199870010049; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; OHANNESIAN DW, 1997, GLYCOSCIENCES STATUS, P459; Openo KP, 2000, EXP CELL RES, V255, P278, DOI 10.1006/excr.1999.4782; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PETTMANN B, 1988, J NEUROSCI RES, V20, P442, DOI 10.1002/jnr.490200406; PITTS MJ, 1981, BIOCHEM J, V195, P435, DOI 10.1042/bj1950435; Rabinovich GA, 1997, J BIOCHEM-TOKYO, V122, P365; Remmelink M, 1999, J CANCER RES CLIN, V125, P275, DOI 10.1007/s004320050274; Reuter G, 1999, CELL MOL LIFE SCI, V55, P368, DOI 10.1007/s000180050298; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; SANDHOFF K, 1995, NATURWISSENSCHAFTEN, V82, P403, DOI 10.1007/BF01133673; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SATO S, 1994, J BIOL CHEM, V269, P4424; SCHNELLER M, 1995, CELL IMMUNOL, V166, P35, DOI 10.1006/cimm.1995.0005; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; WIESER RJ, 1995, GLYCOCONJUGATE J, V12, P672, DOI 10.1007/BF00731264; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	74	247	250	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35917	35923		10.1074/jbc.M105135200	http://dx.doi.org/10.1074/jbc.M105135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11451961	hybrid			2022-12-25	WOS:000171109300092
J	Lien, S; Gustafsson, A; Andersson, AK; Mannervik, B				Lien, S; Gustafsson, A; Andersson, AK; Mannervik, B			Human glutathione transferase Al-1 demonstrates both half-of-the-sites and all-of-the-sites reactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOSOL; S-TRANSFERASE; ACTIVE-SITE; CATALYTIC ACTIVITY; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; DIRECTED MUTAGENESIS; PRODUCT COMPLEXES; ESCHERICHIA-COLI; MALIC ENZYME	A study of the kinetics of a heterodimeric variant of glutathione transferase (GST) A1-1 has led to the conclusion that, although the wild-type enzyme displays all-of-the-sites reactivity in nucleophilic aromatic substitution reactions, it demonstrates half-of-the-sites reactivity in addition reactions. The heterodimer, designed to be essentially catalytically inactive in one subunit due to a single point mutation (D101K), and the two parental homodimers were analyzed with seven different substrates, exemplifying three types of reactions catalyzed by glutathione transferases (nucleophilic aromatic substitution, addition, and double-bond isomerization reactions). Stopped-flow kinetic results suggested that the wild-type GST A1-1 behaved with half-of-the-sites reactivity in a nucleophilic aromatic substitution reaction, but steady-state kinetic analyses of the GST A1-D101K heterodimer revealed that this was presumably due to changes to the extinction coefficient of the enzyme-bound product. In contrast, steady-state kinetic analysis of the heterodimer with three different substrates of addition reactions provided evidence that the wild-type enzyme displayed half-of-the-sites reactivity in association with these reactions. The half-of-the-sites reactivity was shown not to be dependent on substrate size, the level of saturation of the enzyme with glutathione, or relative catalytic rate.	Uppsala Univ, Dept Biochem, Biomed Ctr, SE-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Dept Biochem, Biomed Ctr, Box 576, SE-75123 Uppsala, Sweden.							Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOOTH J, 1961, BIOCHEM J, V79, P516, DOI 10.1042/bj0790516; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; Caccuri AM, 2001, J BIOL CHEM, V276, P5432, DOI 10.1074/jbc.M002818200; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; GRAZI E, 1977, ARCH BIOCHEM BIOPHYS, V179, P131, DOI 10.1016/0003-9861(77)90095-9; Gustafsson A, 1999, J MOL BIOL, V288, P787, DOI 10.1006/jmbi.1999.2712; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1981, BIOCHEM J, V197, P491, DOI 10.1042/bj1970491; HERSH LB, 1981, J BIOL CHEM, V256, P1732; HERSH LB, 1982, J BIOL CHEM, V257, P1633; HOLBROOK JJ, 1973, BIOCHEM J, V135, P901, DOI 10.1042/bj1350901; HSU RY, 1980, BIOCHEMISTRY-US, V19, P962, DOI 10.1021/bi00546a021; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; JAKOBSON I, 1979, J BIOL CHEM, V254, P7085; JAKOBSON I, 1977, EUR J BIOCHEM, V77, P253, DOI 10.1111/j.1432-1033.1977.tb11664.x; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; Johansson AS, 1998, J MOL BIOL, V278, P687, DOI 10.1006/jmbi.1998.1708; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; KONG KH, 1993, PROTEIN ENG, V6, P93, DOI 10.1093/protein/6.1.93; LAZDUNSKI M, 1971, EUR J BIOCHEM, V20, P124, DOI 10.1111/j.1432-1033.1971.tb01370.x; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1982, J BIOL CHEM, V257, P9909; Mannervik B., 1978, CONJUGATION REACTION, P101; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MIOSGA T, 1993, YEAST, V9, P1241, DOI 10.1002/yea.320091111; Nanduri B, 1996, ARCH BIOCHEM BIOPHYS, V335, P305, DOI 10.1006/abbi.1996.0511; Neet K E, 1980, Methods Enzymol, V64, P139; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Pettersson PL, 2001, J BIOL CHEM, V276, P11698, DOI 10.1074/jbc.M009146200; PRY TA, 1980, BIOCHEMISTRY-US, V19, P951, DOI 10.1021/bi00546a020; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sayed Y, 2000, FEBS LETT, V465, P169, DOI 10.1016/S0014-5793(99)01747-0; Schorken U, 1998, FEBS LETT, V441, P247, DOI 10.1016/S0014-5793(98)01521-X; SEELIG GF, 1980, J BIOL CHEM, V255, P9589; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; TAHIR MK, 1986, J BIOL CHEM, V261, P1048; TAKAHASHI K, 1980, J BIOL CHEM, V255, P8206; Ubarretxena-Belandia I, 1999, EUR J BIOCHEM, V260, P794, DOI 10.1046/j.1432-1327.1999.00221.x; Wallace LA, 1998, BIOCHEMISTRY-US, V37, P5320, DOI 10.1021/bi972936z; WANG RW, 1992, J BIOL CHEM, V267, P19866; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; Xiao B, 1999, BIOCHEMISTRY-US, V38, P11887, DOI 10.1021/bi990468i	59	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35599	35605		10.1074/jbc.M103789200	http://dx.doi.org/10.1074/jbc.M103789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11468282	hybrid			2022-12-25	WOS:000171109300053
J	Liochev, SI; Fridovich, I				Liochev, SI; Fridovich, I			Copper,zinc superoxide dismutase as a univalent NO- oxidoreductase and as a dichlorofluorescin peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; NITRIC-OXIDE SYNTHASE; HYDROGEN-PEROXIDE; NITROXYL ANION; IN-VITRO; PEROXYNITRITE; OXYGEN; BICARBONATE; CONVERSION; NEUROTOXICITY	Nitroxyl (NO-) may be produced by nitric-oxide synthase and by the reduction of NO by reduced Cu,Zn-SOD. The ability of NO- to cause oxidations and of SOD to inhibit such oxidations was therefore explored. The decomposition of Angeli's salt (AS) produces NO- and that in turn caused the aerobic oxidation of NADPH, directly or indirectly. O-2(.)- was produced concomitant with the aerobic oxidation of NADPH by AS, as evidenced by the SOD-inhibitable reduction of cytochrome c. Both Cu,Zn-SOD and Mn-SOD inhibited the aerobic oxidation of NADPH by AS, but the amounts required were similar to 100-fold greater than those needed to inhibit the reduction of cytochrome c. This inhibition was not due to a nonspecific protein effect or to an effect of those large amounts of the SODs on the rate of decomposition of AS. NO- caused the reduction of the Cu(II) of Cu,Zn-SOD, and in the presence of O-2(.)-, SOD could catalyze the oxidation of NO- to NO. The reverse reaction, i.e. the reduction of NO to NO- by Cu(I), Zn-SOD, followed by the reaction of NO- with O-2 would yield ONOO- and that could explain the oxidation of dichlorofluorescin (DCF) by Cu(I),Zn-SOD plus NO. Cu,Zn-SOD plus H2O2 caused the HCO3--dependent oxidation of DCF, casting doubt on the validity of using DCF oxidation as a reliable measure of intracellular H2O2 production.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, 231 Naaanaline H Duke,Box 3711, Durham, NC 27710 USA.							Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Ahmed MS, 2000, J NEUROL SCI, V176, P88, DOI 10.1016/S0022-510X(00)00317-8; Crow JP, 1997, J NEUROCHEM, V69, P1936; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FUKUTO JM, 1993, BIOCHEM BIOPH RES CO, V196, P707, DOI 10.1006/bbrc.1993.2307; Fukuto JM, 1999, MET IONS BIOL SYST, V36, P547; Goto JJ, 2000, J BIOL CHEM, V275, P1007, DOI 10.1074/jbc.275.2.1007; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HORECKER BL, 1948, J BIOL CHEM, V175, P385; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; Jay-Gerin JP, 2000, BIOCHIMIE, V82, P161, DOI 10.1016/S0300-9084(00)00062-6; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; Kirsch M, 1999, J BIOL CHEM, V274, P24664, DOI 10.1074/jbc.274.35.24664; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liochev SI, 1999, IUBMB LIFE, V48, P157, DOI 10.1080/152165499307161; LIOCHEV SI, 1991, ARCH BIOCHEM BIOPHYS, V291, P379, DOI 10.1016/0003-9861(91)90149-D; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; McBride AG, 1999, BBA-MOL BASIS DIS, V1454, P275, DOI 10.1016/S0925-4439(99)00046-0; Miranda KM, 2001, J BIOL CHEM, V276, P1720, DOI 10.1074/jbc.M006174200; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; Okado-Matsumoto A, 2000, FREE RADICAL RES, V33, P65, DOI 10.1080/10715760000300621; Reif A, 2001, FREE RADICAL BIO MED, V30, P803, DOI 10.1016/S0891-5849(01)00477-4; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Stoyanovsky DA, 1999, J AM CHEM SOC, V121, P5093, DOI 10.1021/ja990318v; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; WILKINSON F, 1995, J PHYS CHEM REF DATA, V24, P663, DOI 10.1063/1.555965; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; YIM MB, 1993, J BIOL CHEM, V268, P4099; Ying WH, 2000, J CEREBR BLOOD F MET, V20, P359, DOI 10.1097/00004647-200002000-00018; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038	37	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35253	35257		10.1074/jbc.M104237200	http://dx.doi.org/10.1074/jbc.M104237200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461912	hybrid			2022-12-25	WOS:000171109300008
J	Carter, AB; Tephly, LA; Hunninghake, GW				Carter, AB; Tephly, LA; Hunninghake, GW			The absence of activator protein 1-dependent gene expression in THP-1 macrophages stimulated with phorbol esters is due to lack of p38 mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; HUMAN ALVEOLAR MACROPHAGES; SIGNAL-TRANSDUCTION PATHWAY; JUN NH2-TERMINAL KINASE; RNA-POLYMERASE-II; C-JUN; TRANSCRIPTION FACTORS; HA-RAS; TERMINAL PHOSPHORYLATION; BASAL TRANSCRIPTION	Activator protein 1 (AP-1) binds to the promoters of many genes involved in immune and inflammatory responses. We have previously shown that the p38 mitogen-activated protein (MAP) kinase regulates NF-kappaB-dependent gene expression by modulating the phosphorylation and subsequent activation of TATA-binding protein (TBP). In this study, we asked whether the p38 MAP kinase regulated the transcriptional activity of AP-1. We found that phorbol 12-myristate 13-acetate (PMA) was unable to drive the AP-1-dependent reporter gene in THP-1 cells. PMA activated both the extracellular signal-regulated kinase and e-Jun NH2-terminal kinase MAP kinases, but it did not activate the p38 MAP kinase. We found that cells expressing ALA-P kinase kinase 6(Glu), which is the upstream kinase that activates the p38 MAP kinase, had significantly increased AP-1-dependent gene expression alone and when stimulated with PMA. These cells also had increased phosphorylation of native c-Jun, suggesting that both c-Jun NH2-terminal kinase and p38 ALA-P kinases phosphorylate c-Jun. More importantly, expression of a constitutive active MAP kinase kinase 6(Glu) resulted in the phosphorylation of a His-TBP fusion protein and increased direct interaction of TBP with c-Jun. These findings suggest that in macrophages, the p38 MAP kinase regulates AP-1-driven transcription by modulating the activation of TBP.	Univ Iowa, Coll Med, Iowa City, IA 52242 USA; Iowa City Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Carter, AB (corresponding author), Univ Iowa, Coll Med, Iowa City, IA 52242 USA.				NHLBI NIH HHS [HL03860, HL60316] Funding Source: Medline; NIAID NIH HHS [AI35018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Carter AB, 1998, AM J RESP CELL MOL, V18, P384, DOI 10.1165/ajrcmb.18.3.2972; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Carter KB, 2000, J BIOL CHEM, V275, P27858; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; Monick MM, 1999, J IMMUNOL, V162, P3005; Nick JA, 1996, J IMMUNOL, V156, P4867; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x	44	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33826	33832		10.1074/jbc.M100209200	http://dx.doi.org/10.1074/jbc.M100209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11454854	hybrid			2022-12-25	WOS:000170910200073
J	Li, B; Reese, JC				Li, B; Reese, JC			Ssn6-Tup1 regulates RNR3 by positioning nucleosomes and affecting the chromatin structure at the upstream repression sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL TRANSCRIPTIONAL REGULATORS; CELL-SPECIFIC GENE; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; RIBONUCLEOTIDE REDUCTASE; REMODELING COMPLEX; CYC8-TUP1 COREPRESSOR; HISTONE ACETYLATION; SWI/SNF COMPLEX; DISTINCT ROLES	The DNA damage inducible gene ribonucleotide reductase (RNR3) is regulated by a transcriptional repression mechanism by the recruitment of the Ssn6-Tup1 corepressor complex to its promoter by the sequence-specific DNA-binding protein Crt1. Ssn6-Tup1 is reported to represses transcription by interfering with transcription factors, recruiting histone deacetylases, and positioning nucleosomes at the promoter of its target genes. Two of the three mechanisms involve effects on chromatin structure, and therefore, we have delineated the nucleosomal structure of RNR3 in the repressed and derepressed state using multiple nuclease mapping strategies. A regular array of positioned nucleosomes is detected over the repressed RNR3 promoter that extends into the coding sequence. Treating cells with DNA damaging agents or deleting CRT1, SSN6, or TUP1 derepresses RNR3 transcription, and causes a dramatic disruption of nucleosome positioning over its promoter. Furthermore, derepression of RNR3 correlated with changes in nuclease sensitivity within the upstream repression sequence (URS) region. Specifically, the loss of a MNase-hypersensitive site, and the appearance of strong DNase I hypersensitivity, was observed over the URS. Interestingly, we find that the binding of Crt1 to the promoter in the absence of Ssn6 or Tup1 is insufficient for nucleosome positioning or regulating chromatin structure at the URS; thus, these two functions are strictly dependent upon Ssn6-Tup1. We propose that RNR3 is regulated by changes in nucleosome positioning and chromatin structure that are mediated by Ssn6, Tup1, and CAI.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Reese, JC (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 203 Althouse Lab, University Pk, PA 16802 USA.	jcr8@psu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058672] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058672, GM58672] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basrai MA, 1999, MOL CELL BIOL, V19, P7041; Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5; BRUIN DD, 2001, NATURE, V409, P109; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Conlan RS, 1999, J BIOL CHEM, V274, P205, DOI 10.1074/jbc.274.1.205; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; Ducker CE, 2000, EMBO J, V19, P400, DOI 10.1093/emboj/19.3.400; Edmondson DG, 1996, FASEB J, V10, P1173, DOI 10.1096/fasebj.10.10.8751719; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Gavin IM, 2000, EMBO J, V19, P5875, DOI 10.1093/emboj/19.21.5875; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Gregory PD, 1999, METHOD ENZYMOL, V304, P365; Gregory PD, 1999, METH MOL B, V119, P417; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Guthrie C, 1991, GUIDE YEAST GENETICS; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Kastaniotis AJ, 2000, MOL CELL BIOL, V20, P7088, DOI 10.1128/MCB.20.19.7088-7098.2000; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Kiser GL, 1996, MOL BIOL CELL, V7, P703, DOI 10.1091/mbc.7.5.703; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; Lee M, 2000, GENETICS, V155, P1535; Li B, 2000, EMBO J, V19, P4091, DOI 10.1093/emboj/19.15.4091; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Mai X, 2000, MOL CELL BIOL, V20, P6668, DOI 10.1128/MCB.20.18.6668-6676.2000; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Moreira JMA, 2000, EMBO J, V19, P6804, DOI 10.1093/emboj/19.24.6804; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; PATTERSON HG, 1994, MOL CELL BIOL, V14, P4002, DOI 10.1128/MCB.14.6.4002; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; Ryan MP, 1999, METHOD ENZYMOL, V304, P376; Sidorova JM, 1997, GENE DEV, V11, P3032, DOI 10.1101/gad.11.22.3032; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; Simpson RT, 1998, METHODS, V15, P283, DOI 10.1006/meth.1998.0632; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Weiss K, 1997, EMBO J, V16, P4352, DOI 10.1093/emboj/16.14.4352; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Whitehouse I, 2000, BIOCHEM SOC T, V28, P376, DOI 10.1042/0300-5127:0280376; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Wu L, 1997, NUCLEIC ACIDS RES, V25, P4230, DOI 10.1093/nar/25.21.4230; ZHOU Z, 1992, GENETICS, V131, P851	70	54	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33788	33797		10.1074/jbc.M104220200	http://dx.doi.org/10.1074/jbc.M104220200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11448965	hybrid			2022-12-25	WOS:000170910200068
J	McMahon, GA; Petitclerc, E; Stefansson, S; Smith, E; Wong, MKK; Westrick, RJ; Ginsburg, D; Brooks, PC; Lawrence, DA				McMahon, GA; Petitclerc, E; Stefansson, S; Smith, E; Wong, MKK; Westrick, RJ; Ginsburg, D; Brooks, PC; Lawrence, DA			Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; UROKINASE RECEPTOR; CELL-MIGRATION; CANCER INVASION; MOUSE MODEL; IN-VITRO; VITRONECTIN; BINDING; TYPE-1; TISSUE	Elevated expression of plasminogen activator inhibitor-1 (PAI-1) in tumors is associated with a poor prognosis in many cancers. Reduced tumor growth and angiogenesis have also been reported in mice deficient in PAI-1. These results suggest that PAI-1 may be required for efficient angiogenesis and tumor growth. In the present study, we demonstrate that PAI-1 can both enhance and inhibit the growth of M21 human melanoma tumors in nude mice and that this appears to be due to PAI-1 regulation of angiogenesis. Quantitative analysis of angiogenesis in a Matrigel implant assay indicated that in PAI-1 null mice angiogenesis was reduced similar to 60% compared with wild-type mice, while in mice overexpressing PAI-1, angiogenesis was increased nearly 3-fold. Furthermore, addition of PAI-1 to implants in wild-type mice enhanced angiogenesis up to 3-fold at low concentrations but inhibited angiogenesis nearly completely at high concentrations. Together, these data demonstrate that PAI-1 is a potent regulator of angiogenesis and hence of tumor growth and suggest that understanding the mechanism of this activity may lead to the development of important new therapeutic agents for controlling pathologic angiogenesis.	Amer Red Cross, Dept Vasc Biol, Holland Lab, Rockville, MD 20855 USA; Univ Laval, Ctr Rech, Hotel Dieu, Quebec City, PQ G1R 2J6, Canada; Univ Pittsburgh, Pittsburgh Canc Inst, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; NYU, Sch Med, Kaplan Canc Ctr, Dept Radiat Oncol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, Dept Cell Biol, New York, NY 10016 USA	American Red Cross; Laval University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; New York University; New York University	Lawrence, DA (corresponding author), Amer Red Cross, Dept Vasc Biol, Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.			Lawrence, Daniel/0000-0003-3126-1935	NCI NIH HHS [CA74132, CA83090] Funding Source: Medline; NHLBI NIH HHS [HL55374, HL55747, HL57346-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074132, R01CA083090] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, P01HL057346, R01HL055747] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Eitzman DT, 1996, BLOOD, V87, P4718; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; Fibbi G, 1998, LAB INVEST, V78, P1109; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GIGLI I, 1968, J IMMUNOL, V100, P1154; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; Gutierrez LS, 2000, CANCER RES, V60, P5839; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; NEKARDA H, 1994, LANCET, V343, P117, DOI 10.1016/S0140-6736(94)90845-1; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PASSANITI A, 1992, LAB INVEST, V67, P519; PEDERSEN H, 1994, CANCER RES, V54, P4671; Petitclerc E, 1999, CANCER RES, V59, P2724; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Webb DJ, 2000, J CELL SCI, V113, P123; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Yepes M, 2000, BLOOD, V96, P569	36	233	242	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33964	33968		10.1074/jbc.M105980200	http://dx.doi.org/10.1074/jbc.M105980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11441025	hybrid			2022-12-25	WOS:000170910200091
J	Coppola, T; Magnin-Luthi, S; Perret-Menoud, V; Gattesco, S; Schiavo, G; Regazzi, R				Coppola, T; Magnin-Luthi, S; Perret-Menoud, V; Gattesco, S; Schiavo, G; Regazzi, R			Direct interaction of the Rab3 effector RIM with Ca2+ channels, SNAP-25, and synaptotagmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; SYNAPTIC-VESICLE FUSION; PANCREATIC BETA-CELLS; MEMBRANE-FUSION; C2B DOMAIN; ALPHA-1 SUBUNIT; BINDING-PROTEIN; CA2+-DEPENDENT EXOCYTOSIS; REGULATED EXOCYTOSIS; SNARE INTERACTIONS	To define the role of the Rab3-interacting molecule RIM in exocytosis we searched for additional binding partners of the protein. We found that the two C-2 domains of RIM display properties analogous to those of the C2B domain of synaptotagmin-I. Thus, RIM-C(2)A and RIM-C2B bind in a Ca2+-independent manner to alpha 1B, the pore-forming subunit of N-type Ca2+ channels (EC50 = similar to 20 nM). They also weakly interact with the alpha 1C but not the alpha 1D subunit of L-type Ca2+ channels. In addition, the C-2 domains of RIM associate with SNAP-25 and synaptotagmin-I. The binding affinities for these two proteins are 203 and 24 nM, respectively, for RIM-C(2)A and 224 and 16 nM for RIM-C2B. The interactions of the C-2 domains of RIM with SNAP-25 and synaptotagmin-I are modulated by Ca2+. Thus, in the presence of Ca2+ (EC50 = similar to 75 mum) the interaction with synaptotagmin-I is increased, whereas SNAP-25 binding is reduced. Synaptotagmin-I binding is abolished by mutations in two positively charged amino acids in the C-2 domains of RIM and by the addition of inositol polyphosphates. We propose that the Rab3 effector RIM is a scaffold protein that participates through its multiple binding partners in the docking and fusion of secretory vesicles at the release sites.	Univ Lausanne, Inst Biol Cellulaire & Morphol, CH-1005 Lausanne, Switzerland; Imperial Canc Res Fund, London WC2A 3PX, England	University of Lausanne; Cancer Research UK	Regazzi, R (corresponding author), Univ Lausanne, Inst Biol Cellulaire & Morphol, Rue Bugnon 9, CH-1005 Lausanne, Switzerland.		Coppola, Thierry/I-5036-2016	Coppola, Thierry/0000-0003-1018-722X; Schiavo, Giampietro/0000-0002-4319-8745; Regazzi, Romano/0000-0002-9773-2915				Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; COPPOLA T, 1994, FEBS LETT, V338, P1, DOI 10.1016/0014-5793(94)80105-3; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GALLI T, 1995, NEUROPHARMACOLOGY, V34, P1351, DOI 10.1016/0028-3908(95)00113-K; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Gerst JE, 1999, CELL MOL LIFE SCI, V55, P707, DOI 10.1007/s000180050328; Grote E, 1999, MOL BIOL CELL, V10, P4149, DOI 10.1091/mbc.10.12.4149; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Han SY, 2000, BIOCHEM J, V352, P165, DOI 10.1042/0264-6021:3520165; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MA WJ, 1992, J BIOL CHEM, V267, P22728; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; OharaImaizumi M, 1997, P NATL ACAD SCI USA, V94, P287, DOI 10.1073/pnas.94.1.287; Ohnishi H, 1997, J CLIN INVEST, V100, P3044, DOI 10.1172/JCI119859; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	52	140	150	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32756	32762		10.1074/jbc.M100929200	http://dx.doi.org/10.1074/jbc.M100929200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11438518	hybrid			2022-12-25	WOS:000170746000052
J	Oka, T; Toyomura, T; Honjo, K; Wada, Y; Futai, M				Oka, T; Toyomura, T; Honjo, K; Wada, Y; Futai, M			Four subunit a isoforms of Caenorhabditis elegans vacuolar H+-ATPase - Cell-specific expression during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; SECRETORY-EXCRETORY SYSTEM; C-ELEGANS; V-ATPASE; PREFERENTIAL EXPRESSION; LUMINAL ACIDIFICATION; MOLECULAR-CLONING; GENE-EXPRESSION; 116-KDA SUBUNIT; 3 ISOFORMS	We have identified four genes (vha-5, vha-6, vha-7, and unc-32) coding for vacuolar-type proton-translocating ATPase (V-ATPase) subunit a in Caenorhabditis elegans, the first example of four distinct isoforms in eukaryotes. Their products had nine putative transmembrane regions, exhibited 43-60% identity and 62-84% similarity with the bovine subunit al isoform, and retained 11 amino acid residues essential for yeast V-ATPase activity (Leng, X. H., Manolson, M. F., and Forgac, M. (1998) J. Biol. Chem. 273, 6717-6723). The similarities, together with the results of immunoprecipitation, suggest that these isoforms are components of V-ATPase. Transgenic and immunofluorescence analyses revealed that these genes were strongly expressed in distinct cells; vha-5 was strongly expressed in an H-shaped excretory cell, vha-6 was strongly expressed in intestine, vha-7 was strongly expressed in hypodermis, and unc-32 was strongly expressed in nerve cells. Furthermore, the vha-7 and unc-32 genes were also expressed in the uteri of hermaphrodites. RNA interference analysis showed that the double-stranded RNA for unc-32 caused embryonic lethality similar to that seen with other subunit genes (vha-1, vha-4, and vha-11) (Oka, T., and Futai, M. (2000) J. Biol. Chem. 275, 29556-29561). The progenies of worms injected with the vha-5 or vha-6 double-stranded RNA became died at a specific larval stage, whereas the vha-7 double-stranded RNA showed no effect on development. These results suggest that V-ATPases with these isoforms generate acidic compartments essential for worm development in a cell-specific manner.	Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Ibaraki, Osaka 5670047, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Ibaraki, Osaka 5670047, Japan	Osaka University; Japan Science & Technology Agency (JST)	Futai, M (corresponding author), Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, 8-1 Mihogaoka, Ibaraki, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; APPS DK, 1989, BIOCHEM J, V263, P81, DOI 10.1042/bj2630081; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Brady KP, 1999, GENOMICS, V56, P254, DOI 10.1006/geno.1998.5722; BRENNER S, 1974, GENETICS, V77, P71; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; BROEKS A, 1995, EMBO J, V14, P1858, DOI 10.1002/j.1460-2075.1995.tb07178.x; Brown D, 2000, J EXP BIOL, V203, P137; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Futai M, 2000, J EXP BIOL, V203, P107; Graham LA, 2000, J EXP BIOL, V203, P61; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hird SN, 1996, DEVELOPMENT, V122, P1303; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; LEE CK, 1990, MOL IMMUNOL, V27, P1137; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Oka T, 2000, J BIOL CHEM, V275, P29556, DOI 10.1074/jbc.M002756200; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; PENG SB, 1994, J BIOL CHEM, V269, P17262; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Pujol N, 2001, J BIOL CHEM, V276, P11913, DOI 10.1074/jbc.M009451200; SCHEDL T, 1997, C ELEGANS, V2, P241; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Tomochika K, 1997, FEBS LETT, V404, P61, DOI 10.1016/S0014-5793(97)00090-2; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; WHITE J, 1998, NEMATODE CAENORHABDI, P81; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	45	103	112	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33079	33085		10.1074/jbc.M101652200	http://dx.doi.org/10.1074/jbc.M101652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11441002	hybrid			2022-12-25	WOS:000170746000093
J	Saunders, LR; Perkins, DJ; Balachandran, S; Michaels, R; Ford, R; Mayeda, A; Barber, GN				Saunders, LR; Perkins, DJ; Balachandran, S; Michaels, R; Ford, R; Mayeda, A; Barber, GN			Characterization of two evolutionarily conserved, alternatively spliced nuclear phosphoproteins, NFAR-1 and -2, that function in mRNA processing and interact with the double-stranded RNA-dependent protein kinase, PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; VIRUS-INFECTED CELLS; ACTIVATED T-CELLS; NF-KAPPA-B; VACCINIA VIRUS; BINDING-PROTEIN; INDUCED APOPTOSIS; GENE-PRODUCT; ADENOSINE-DEAMINASE; CATALYTIC DOMAIN	We report here the isolation and characterization of two proteins, NFAR-1 and -2, which were isolated through their ability to interact with the dsRNA-dependent protein kinase, PKR. The NFAR proteins, of 90 and 110 kDa, are derived from a single gene through alternative splicing and are evolutionarily conserved nuclear phosphoproteins that interact with double-stranded RNA. Both NFAR-1 and -2 are phosphorylated by PHR, reciprocally co-immunoprecipitate with PKR, and colocalize with the kinase in a diffuse nuclear pattern within the cell. Transfection studies indicate that the NFARs regulate gene expression at the level of transcription, probably during the processing of pre-mRNAs, an activity that was increased in fibroblasts lacking PKR. Subsequent functional analyses indicated that amino acids important for NFAR's activity were localized to the C terminus of the protein, a region that was found to specifically interact with FUS and SMN, proteins also known as regulators of RNA processing. Accordingly, both NFARs were found to associate with both pre-mRNAs and spliced mRNAs in post-transcriptional studies, similar to the known splicing factor ASF/SF-2. Collectively, our data indicate that the NFARs may facilitate double-stranded RNA-regulated gene expression at the. level of post-transcription and possibly contribute to host defense-related mechanisms in the cell.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, Rm 511,Papanicolaou Bldg,1550 NW 10th AveM710, Miami, FL 33136 USA.		Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X	NATIONAL CANCER INSTITUTE [R21CA083166, R01CA084247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER; NCI NIH HHS [CA84247, CA83166] Funding Source: Medline; NIGMS NIH HHS [T32 GM008490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Besse S, 1998, EXP CELL RES, V239, P379, DOI 10.1006/excr.1997.3908; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHOI SY, 1992, J BIOL CHEM, V267, P286; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Coolidge CJ, 2000, NUCLEIC ACIDS RES, V28, P1407, DOI 10.1093/nar/28.6.1407; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DUBOIS MF, 1990, VIROLOGY, V179, P591, DOI 10.1016/0042-6822(90)90126-C; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Hanamura A, 1998, RNA, V4, P430; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; JIMENEZGARCIA LF, 1993, J CELL SCI, V106, P11; KAO PN, 1994, J BIOL CHEM, V269, P20691; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Polson AG, 1996, NATURE, V380, P454; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RICE AP, 1984, J VIROL, V50, P229, DOI 10.1128/JVI.50.1.229-236.1984; Sakamoto S, 1999, BIOCHEMISTRY-US, V38, P3355, DOI 10.1021/bi982099g; Samuel C E, 1994, Hokkaido Igaku Zasshi, V69, P1339; Saunders LR, 2001, GENOMICS, V71, P256, DOI 10.1006/geno.2000.6423; SCHWEMMLE M, 1992, P NATL ACAD SCI USA, V89, P10292, DOI 10.1073/pnas.89.21.10292; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zinszner H, 1997, J CELL SCI, V110, P1741	83	108	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32300	32312		10.1074/jbc.M104207200	http://dx.doi.org/10.1074/jbc.M104207200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11438536	hybrid			2022-12-25	WOS:000170613500112
J	Yui, D; Yoneda, T; Oono, K; Katayama, T; Imaizumi, K; Tohyama, M				Yui, D; Yoneda, T; Oono, K; Katayama, T; Imaizumi, K; Tohyama, M			Interchangeable binding of Bcl10 to TRAF2 and cIAPs regulates apoptosis signaling	ONCOGENE			English	Article						Bcl10; TRAF2; cIAPs; phosphorylation; apoptosis	NECROSIS-FACTOR-ALPHA; CELL-DEATH; PROTEINS; GENE; LYMPHOMA; CASPASES; KINASE; RECRUITMENT; ACTIVATION; MUTATIONS	Bcl10 was identified as a candidate gene responsible for low grade B cell lymphomas of mucosa-associated lymphoid tissue. Overexpression of Bcl10 in cultured cells was reported to promote apoptosis, however, the mechanism of regulation of apoptosis mediated by Bcl10 has not been demonstrated. In the present study, we analysed the apoptosis signaling pathway mediated by Bcl10, focusing on phosphorylation of Bcl10 and the dynamic interaction with its binding partners during apoptosis, Previously, we have demonstrated that Bcl10 potentially interacts with the other apoptosis regulator, TNF receptor associated factor-2 (TRAF2) and inhibitor of apoptosis proteins (cIAPs), The present results showed that the complex formation of these molecules was regulated by phosphorylation of Bcl10, that is, phosphorylation of Bcl10 resulted in binding of Bcl10 to cIAPs and the dissociation of it from TRAFZ. Moreover, hyperphosphorylation of Bcl10 enhanced apoptosis, suggesting that changes in the binding partners of Bcl10 were correlated to the promotion of apoptosis as mediated by Bcl10, Indeed, the mutant which was deleted from the binding site of Bcl10 for cIAPs, could not induce apoptosis, These findings indicate that Bcl10 is a mediator of apoptosis signaling, by switching over binding to cIAPs from TRAFZ through the events of Bcl10 phosphorylation.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cellular & Struct Biol, Nara 6300101, Japan; JST, Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Nara Institute of Science & Technology; Japan Science & Technology Agency (JST)	Yui, D (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Bertoni F, 1999, ANN ONCOL, V10, P1259, DOI 10.1023/A:1008309631480; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Du MQ, 2000, BLOOD, V95, P3885; HOFFMAN K, 1997, TRENDS BIOCHEM SCI, V22, P155; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; KIZAKI H, 1989, J BIOCHEM-TOKYO, V105, P673, DOI 10.1093/oxfordjournals.jbchem.a122724; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Laouar A, 1999, J BIOL CHEM, V274, P23526, DOI 10.1074/jbc.274.33.23526; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simms LA, 2000, CELL DEATH DIFFER, V7, P236, DOI 10.1038/sj.cdd.4400650; Takada Y, 1999, J BIOL CHEM, V274, P28286, DOI 10.1074/jbc.274.40.28286; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamamoto H, 2000, CELL DEATH DIFFER, V7, P238, DOI 10.1038/sj.cdd.4400651; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoneda T, 2000, J BIOL CHEM, V275, P11114, DOI 10.1074/jbc.275.15.11114; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	27	21	26	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4317	4323		10.1038/sj.onc.1204576	http://dx.doi.org/10.1038/sj.onc.1204576			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466612				2022-12-25	WOS:000169912600005
J	Feng, L; Lee, KAW				Feng, L; Lee, KAW			A repetitive element containing a critical tyrosine residue is required for transcriptional activation by the EWS/ATF1 oncogene	ONCOGENE			English	Article						EWS/ATF1 oncogene; transcription; activation domain; tyrosine	TUMOR-SUPPRESSOR GENE; EWS/FLI-1 FUSION GENE; RNA-POLYMERASE-II; EWINGS-SARCOMA; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; CHIMERIC PROTEIN; BINDING DOMAIN; SOFT PARTS; EWS	Chromosomal fusion of the N-terminal region of the Ewings Sarcoma Oncogene (EWS-activation-domain, EAD) to the DNA-binding domains of a variety of cellular transcription factors produce oncogenic proteins (EWS-fusion proteins (EFPs)) that cause distinct malignancies. In EFPs, the EAD acts as a potent transcriptional activation domain and this ability is repressed in the context of normal, non-tumorigenic, EWS, Trans-activation by the EAD is therefore a specific characteristic of EFPs and it is thought that EFPs induce tumorigenesis via improper transcriptional activation of cellular genes. Functional elements required for transcriptional activation are dispersed throughout the EAD, as are thirty-one copies of a Degenerate Hexapeptide Repeat (DHR, consensus SYCQQS), This suggests that the EAD contains a highly reiterated functional element related to DHRs. Here we show that in the context of EWS/ATF1, the EFP that causes malignant melanoma of soft parts, trans-cooperation by small regions of the EAD (similar to 30 residues) results in potent transcriptional activation dependent on the conserved tyrosine residues present in DHRs, These findings provide the first evidence for a role of DHRs in EAD-mediated trans-activation and demonstrate that the EAD represents a novel tyrosine-dependent transcriptional activation domain.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Lee, KAW (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bokaw@usthk.ust.hk						Benuck ML, 1999, J BIOL CHEM, V274, P25419, DOI 10.1074/jbc.274.36.25419; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROWN AD, 1995, ONCOGENE, V10, P1749; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; Fujimura Y, 1996, ONCOGENE, V12, P159; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; Kovar Heinrich, 1999, Current Opinion in Oncology, V11, P275, DOI 10.1097/00001622-199907000-00007; KRAJEWSKI W, 1994, MOL CELL BIOL, V14, P7204, DOI 10.1128/MCB.14.11.7204; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LESSNICK SL, 1995, ONCOGENE, V10, P423; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nyanguile O, 1997, P NATL ACAD SCI USA, V94, P13402, DOI 10.1073/pnas.94.25.13402; OHNO T, 1993, CANCER RES, V53, P5859; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Pollock R, 1997, P NATL ACAD SCI USA, V94, P13388, DOI 10.1073/pnas.94.25.13388; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RIBEIRO A, 1994, J BIOL CHEM, V269, P31124; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; Zhou HQ, 2001, ONCOGENE, V20, P1519, DOI 10.1038/sj.onc.1204135; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	45	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4161	4168		10.1038/sj.onc.1204522	http://dx.doi.org/10.1038/sj.onc.1204522			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464282				2022-12-25	WOS:000169857200006
J	Hoffmann, L; Maury, S; Bergdoll, M; Thion, L; Erard, M; Legrand, M				Hoffmann, L; Maury, S; Bergdoll, M; Thion, L; Erard, M; Legrand, M			Identification of the enzymatic active site of tobacco caffeoyl-coenzyme a O-methyltransferase by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN BIOSYNTHESIS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PHENYLPROPANOID METABOLISM; COA 3-O-METHYLTRANSFERASE; HYDROXYCINNAMOYL-COENZYME; SUBSTRATE SPECIFICITIES; HYPERSENSITIVE REACTION; ANTIOXIDANT ACTIVITY; CDNA CLONING	Animal catechol O-methyltransferases and plant caffeoyl-coenzyme A O-methyltransferases share about 20% sequence identity and display common structural features. The crystallographic structure of rat liver catechol O-methyltransferase was used as a template to construct a homology model for tobacco caffeoyl-coenzyme A O-methyltransferase. Integrating substrate specificity data, the three-dimensional model identified several amino acid residues putatively involved in substrate binding. These residues were mutated by a polymerase chain reaction method and wild-type and mutant enzymes were each expressed in Escherichia coli and purified. Substitution of Arg-220 with Thr resulted in the total loss of enzyme activity, thus indicating that Arg-220 is involved in the electrostatic interaction with the coenzyme A moiety of the substrate. Changes of Asp-58 to Ala and Gln-61 to Ser were shown to increase K-m values for caffeoyl coenzyme A and to decrease catalytic activity. Deletions of two amino acid sequences specific for plant enzymes abolished activity. The secondary structures of the mutants, as measured by circular dichroism, were essentially unperturbed as compared with the wild type. Similar changes in circular dichroism spectra were observed after addition of caffeoyl coenzyme A to the wild-type enzyme and the substitution mutants but not in the case of deletion mutants, thus revealing the importance of these sequences in substrate-enzyme interactions.	Univ Strasbourg, CNRS, Inst Biol Mol Plantes, F-67000 Strasbourg, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Legrand, M (corresponding author), Univ Strasbourg, CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67000 Strasbourg, France.	michel.legrand@ibmp-ulp.u-strasbg.fr		Maury, Stephane/0000-0003-0481-0847				ASSICOT M, 1970, European Journal of Biochemistry, V12, P490, DOI 10.1111/j.1432-1033.1970.tb00877.x; AXELROD J, 1958, J BIOL CHEM, V233, P702; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bonifati V, 1999, PHARMACOL THERAPEUT, V81, P1, DOI 10.1016/S0163-7258(98)00032-1; BOUDET AM, 1995, NEW PHYTOL, V129, P203, DOI 10.1111/j.1469-8137.1995.tb04292.x; Bugl H, 2000, MOL CELL, V6, P349, DOI 10.1016/S1097-2765(00)00035-6; BUGOS RC, 1991, PLANT MOL BIOL, V17, P1203, DOI 10.1007/BF00028736; Burns J, 2000, J AGR FOOD CHEM, V48, P220, DOI 10.1021/jf9909757; Chen CY, 2000, PLANT PHYSIOL, V123, P853, DOI 10.1104/pp.123.3.853; COLLAZO P, 1992, PLANT MOL BIOL, V20, P857, DOI 10.1007/BF00027157; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Douglas CJ, 1996, TRENDS PLANT SCI, V1, P171, DOI 10.1016/1360-1385(96)10019-4; Frick S, 1999, PLANT J, V17, P329, DOI 10.1046/j.1365-313X.1999.00379.x; GEOFFROY P, 1990, MOL PLANT MICROBE IN, V3, P327, DOI 10.1094/MPMI-3-327; Ibrahim RK, 1998, PLANT MOL BIOL, V36, P1, DOI 10.1023/A:1005939803300; Inoue K, 1998, PLANT PHYSIOL, V117, P761, DOI 10.1104/pp.117.3.761; JAECK E, 1992, MOL PLANT MICROBE IN, V5, P294, DOI 10.1094/MPMI-5-294; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; JONES TA, 1989, CRYSTALLOGRAPHIC MOD, P189; Joshi CP, 1998, PLANT MOL BIOL, V37, P663, DOI 10.1023/A:1006035210889; Kaakkola S, 2000, DRUGS, V59, P1233, DOI 10.2165/00003495-200059060-00004; Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l; LEGRAND M, 1978, PLANTA, V144, P101, DOI 10.1007/BF00385014; LUDERITZ T, 1982, EUR J BIOCHEM, V123, P583; Martz F, 1998, PLANT MOL BIOL, V36, P427, DOI 10.1023/A:1005969825070; Maury S, 1999, PLANT PHYSIOL, V121, P215, DOI 10.1104/pp.121.1.215; NEGREL J, 1984, PHYTOCHEMISTRY, V23, P31, DOI 10.1016/0031-9422(84)83072-1; PELLEGRINI L, 1993, PLANT PHYSIOL, V103, P509, DOI 10.1104/pp.103.2.509; Ruottinen HM, 1998, J NEUROL, V245, pP25, DOI 10.1007/PL00007743; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHMITT D, 1991, J BIOL CHEM, V266, P17416; Skinner MM, 2000, STRUCTURE, V8, P1189, DOI 10.1016/S0969-2126(00)00522-0; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029	40	25	31	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36831	36838		10.1074/jbc.M104977200	http://dx.doi.org/10.1074/jbc.M104977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11459845	hybrid			2022-12-25	WOS:000171194500103
J	Miller, BS; Zandi, E				Miller, BS; Zandi, E			Complete reconstitution of human I kappa B kinase (IKK) complex in yeast - Assessment of its stoichiometry and the role of IKK gamma on the complex activity in the absence of stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; MICE LACKING; ACTIVATION; PHOSPHORYLATION; ALPHA; BETA; EXPRESSION; INHIBITOR; APOPTOSIS	The I kappaB kinase (IKK) complex, composed of two catalytic subunits (IKK alpha and IKK beta) and a regulatory subunit (IKK gamma), is the key enzyme in activation of nuclear factor kappaB (NF-kappaB). To study the mechanism and structure of the complex, we wanted to recombinantly express IKK in a model organism that lacks IKK. For this purpose, we have recombinantly reconstituted all three subunits together in yeast and have found that it is biochemically similar to IKK isolated from human cells. We show that there is one regulatory subunit per kinase subunit. Thus, the core subunit composition of IKK alpha . beta . gamma complex is alpha (1)beta (1)gamma (2), and the core subunit composition of IKK beta . gamma is beta (2)gamma (2). The activity of the IKK complex (alpha+beta+gamma or beta+gamma) expressed in yeast (which lack NF-kappaB and IKK) is 4-5-fold higher than an equivalent amount of IKK from nonstimulated HeLa cells. In the absence of IKK gamma, IKK beta shows a level of activity similar to that of IKK from nonstimulated HeLa cells. Thus, IKK gamma activates IKK complex in the absence of upstream stimuli. Deleting the gamma binding domain of IKK beta or IKK alpha prevented IKK gamma induced activation of IKK complex in yeast, but it did not prevent the incorporation of IKK gamma into IKK and large complex formation. The possibility of IKK complex being under negative control in mammalian cells is discussed.	Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Zandi, E (corresponding author), Univ So Calif, Keck Sch Med, Norris Canc Ctr, 1441 Eastlake Ave,6429 MS 73, Los Angeles, CA 90089 USA.							BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Epinat JC, 1997, YEAST, V13, P599, DOI 10.1002/(SICI)1097-0061(19970615)13:7<599::AID-YEA109>3.0.CO;2-H; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nomura F, 2000, GENES CELLS, V5, P191; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547	30	52	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36320	36326		10.1074/jbc.M104051200	http://dx.doi.org/10.1074/jbc.M104051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11470787	hybrid			2022-12-25	WOS:000171194500037
J	Moller-Jensen, J; Franch, T; Gerdes, K				Moller-Jensen, J; Franch, T; Gerdes, K			Temporal translational control by a metastable RNA structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HOK MESSENGER-RNA; HEPATITIS-DELTA VIRUS; PRE-RIBOSOMAL-RNA; SELF-SPLICING RNA; ANTISENSE RNA; PLASMID R1; SECONDARY STRUCTURE; GENETIC ALGORITHM; KINETICS	Programmed cell death by the hok/sok locus of plasmid R1 relies on a complex translational control mechanism. The highly stable hok mRNA is activated by 3 ' -end exonucleolytical processing. Removal of the mRNA 3 ' end releases a 5 ' -end sequence that triggers refolding of the mRNA. The refolded hok mRNA is translatable but can also bind the inhibitory Sok antisense RNA. Binding of Sok RNA leads to irreversible mRNA inactivation by an RNase III-dependent mechanism. A coherent model predicts that during transcription hok mRNA must be refractory to translation and antisense RNA binding. Here we provide genetic evidence for the existence of a 5 ' metastable structure in kok mRNA that locks the nascent transcript in an inactive configuration in vivo. Consistently, the metastable structure reduces the rate of Sok RNA binding and completely blocks hok translation in vitro. Structural analyses of native RNAs strongly support that the 5 ' metastable structure exists in the nascent transcript. Further structural analyses reveal that the mRNA Wend triggers refolding of the mRNA 5 ' end into the more stable tac-stem conformation. These results provide a profound understanding of an unusual and intricate posttranscriptional control mechanism.	Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	University of Southern Denmark	Gerdes, K (corresponding author), Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark.		Møller-Jensen, Jakob/AAO-8480-2020; Gerdes, Kenn/AAS-5548-2021; Gerdes, Kenn/M-2420-2014	Møller-Jensen, Jakob/0000-0002-6008-3771; Gerdes, Kenn/0000-0002-7462-4612; Gerdes, Kenn/0000-0002-7462-4612				BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BELINKY A, 1992, BIOPHYS CHEM, V42, P1, DOI 10.1016/0301-4622(92)80001-L; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BIEBRICHER CK, 1992, EMBO J, V11, P5129, DOI 10.1002/j.1460-2075.1992.tb05620.x; Brion P, 1997, ANNU REV BIOPH BIOM, V26, P113, DOI 10.1146/annurev.biophys.26.1.113; Cao Y, 1998, RNA, V4, P901, DOI 10.1017/S1355838298980621; Chadalavada DM, 2000, J MOL BIOL, V301, P349, DOI 10.1006/jmbi.2000.3953; DAM MN, 1997, MOL MICROBIOL, V26, P311; Draper DE, 1996, TRENDS BIOCHEM SCI, V21, P145; Draper DE, 1996, NAT STRUCT BIOL, V3, P397, DOI 10.1038/nsb0596-397; EMERICK VL, 1993, BIOCHEMISTRY-US, V32, P14062, DOI 10.1021/bi00213a040; Fernandez A, 1996, BIOPHYS CHEM, V61, P101, DOI 10.1016/S0301-4622(96)02189-8; Franch T, 1997, J MOL BIOL, V273, P38, DOI 10.1006/jmbi.1997.1294; Franch T, 1996, MOL MICROBIOL, V21, P1049, DOI 10.1046/j.1365-2958.1996.771431.x; Franch T, 1999, J MOL BIOL, V294, P1115, DOI 10.1006/jmbi.1999.3306; GERDES K, 1990, MOL MICROBIOL, V4, P1807, DOI 10.1111/j.1365-2958.1990.tb02029.x; GERDES K, 1985, J BACTERIOL, V161, P292, DOI 10.1128/JB.161.1.292-298.1985; Gerdes K, 1997, ANNU REV GENET, V31, P1, DOI 10.1146/annurev.genet.31.1.1; GULTYAEV AP, 1995, NUCLEIC ACIDS RES, V23, P3718, DOI 10.1093/nar/23.18.3718; Gultyaev AP, 1997, J MOL BIOL, V273, P26, DOI 10.1006/jmbi.1997.1295; GULTYAEV AP, 1995, J MOL BIOL, V250, P37, DOI 10.1006/jmbi.1995.0356; Gultyaev AP, 1998, J MOL BIOL, V276, P43, DOI 10.1006/jmbi.1997.1384; KRAMER FR, 1981, NUCLEIC ACIDS RES, V9, P5109, DOI 10.1093/nar/9.19.5109; LAZINSKI DW, 1995, RNA, V1, P225; LECUYER KA, 1994, P NATL ACAD SCI USA, V91, P3373, DOI 10.1073/pnas.91.8.3373; LECUYER KA, 1993, BIOCHEMISTRY-US, V32, P5301, DOI 10.1021/bi00071a004; LOSS P, 1991, EMBO J, V10, P719, DOI 10.1002/j.1460-2075.1991.tb08002.x; Matysiak M, 1999, J MOL BIOL, V291, P283, DOI 10.1006/jmbi.1999.2955; Miller J.H., 1972, EXPT MOL GENETICS; Nagel JHA, 1999, RNA, V5, P1408, DOI 10.1017/S1355838299990805; Pan J, 1998, J MOL BIOL, V280, P597, DOI 10.1006/jmbi.1998.1901; Pan J, 1997, J MOL BIOL, V273, P7, DOI 10.1006/jmbi.1997.1311; PERSSON C, 1988, EMBO J, V7, P3279, DOI 10.1002/j.1460-2075.1988.tb03195.x; POULSEN LK, 1992, MOL MICROBIOL, V6, P895, DOI 10.1111/j.1365-2958.1992.tb01540.x; Repsilber D, 1999, RNA, V5, P574, DOI 10.1017/S1355838299982018; Song SI, 1999, J MOL BIOL, V293, P781, DOI 10.1006/jmbi.1999.3169; THISTED T, 1994, EMBO J, V13, P1950, DOI 10.1002/j.1460-2075.1994.tb06464.x; THISTED T, 1994, EMBO J, V13, P1960, DOI 10.1002/j.1460-2075.1994.tb06465.x; Tinoco I, 1999, J MOL BIOL, V293, P271, DOI 10.1006/jmbi.1999.3001; VANBATENBURG FHD, 1995, J THEOR BIOL, V174, P269, DOI 10.1006/jtbi.1995.0098; WALSTRUM SA, 1990, BIOCHEMISTRY-US, V29, P10573, DOI 10.1021/bi00498a022; WESTHOF E, 1996, FOLD DES, V1, P78; Woodson SA, 2000, CELL MOL LIFE SCI, V57, P796, DOI 10.1007/s000180050042; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	44	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35707	35713		10.1074/jbc.M105347200	http://dx.doi.org/10.1074/jbc.M105347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11461923	hybrid			2022-12-25	WOS:000171109300067
J	Trujillo, KM; Sung, P				Trujillo, KM; Sung, P			DNA structure-specific nuclease activities in the Saccharomyces cerevisiae Rad50 center dot Mre11 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MRE11; RECOMBINATION; REPAIR; PROTEINS; RAD50; YEAST; MAINTENANCE; MRE11/RAD50; MEIOSIS	Saccharomyces cerevisiae RAD50 and MRE11 genes are required for the nucleolytic processing of DNA double-strand breaks. We have overexpressed Rad50 and Mre11 in yeast cells and purified them to near homogeneity. Consistent with the genetic data, we show that the purified Rad50 and Mre11 proteins form a stable complex. In the Rad50(.)Mre11 complex, the protein components exist in equimolar amounts. Mre11 has a 3 ' to 5 ' exonuclease activity that results in the release of mononucleotides. The addition of Rad50 does not significantly alter the exonucleolytic function of Mre11. Using homopolymeric oligonucleotide-based substrates, we show that the exonuclease activity of Mre11 and Rad50(.)Mre11 is enhanced for substrates with duplex DNA ends. We have examined the endonucleolytic function of Mre11 on defined, radio-labeled hairpin structures that also contain 3 ' and 5 ' single-stranded DNA overhangs. Mre11 is capable of cleaving hairpins and the 3 ' single-stranded DNA tail. These endonuclease activities of Mre11 are enhanced markedly by Rad50 but only in the presence of ATP. Based on these results, we speculate that the Mre11 nuclease complex may mediate the nucleolytic digestion of the 5 ' strand at secondary structures formed upon DNA strand separation.	Univ Texas, Hlth Sci Ctr, San Antonio, TX 78245 USA; Univ Texas, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, 15355 Lambda Dr, San Antonio, TX 78245 USA.	sung@uthscsa.edu			NIEHS NIH HHS [R01 ES07061] Funding Source: Medline; NIGMS NIH HHS [R01 GM57814] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; JOHZUKA K, 1995, GENETICS, V139, P1521; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liu YL, 2000, EMBO REP, V1, P85, DOI 10.1093/embo-reports/kvd002; Liu YL, 1999, CURR BIOL, V9, P975, DOI 10.1016/S0960-9822(99)80427-8; MacPhail SH, 2001, RADIAT RES, V155, P672, DOI 10.1667/0033-7587(2001)155[0672:RFAAWC]2.0.CO;2; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; Moreau S, 1999, MOL CELL BIOL, V19, P556; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Symington LS, 2000, NUCLEIC ACIDS RES, V28, P4649, DOI 10.1093/nar/28.23.4649; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2	21	206	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35458	35464		10.1074/jbc.M105482200	http://dx.doi.org/10.1074/jbc.M105482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11454871	hybrid			2022-12-25	WOS:000171109300035
J	Maeda, K; Yoshimura, K; Shibayama, S; Habashita, H; Tada, H; Sagawa, K; Miyakawa, T; Aoki, M; Fukushima, D; Mitsuya, H				Maeda, K; Yoshimura, K; Shibayama, S; Habashita, H; Tada, H; Sagawa, K; Miyakawa, T; Aoki, M; Fukushima, D; Mitsuya, H			Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; HIGHLY POTENT; CHEMOKINE RECEPTOR; TYPE-1 INFECTION; IN-VITRO; REPLICATION; VARIANTS; THERAPY; CORECEPTOR	Novel low molecular weight spirodiketopiperazine derivatives which potently inhibit R5 human immunodeficiency virus type 1 (HIV-1) infection through their antagonistic effects on CCR5 were identified. One such compound E913 (M-r 484) specifically blocked the binding of macrophage inflammatory protein-1 alpha (MIP-1 alpha) to CCR5 (IC50 0.002 muM) and MIP-1 alpha -elicited cellular Ca2+ mobilization (IC50 similar to 0.02 muM). E913 potently inhibited the replication of laboratory and primary R5 HIV-1 strains as well as various multidrug-resistant monocyte/ macrophage tropic (R5) HIV-1 at IC50 values of 0.03 to 0.06 muM. E913 was inactive against T cell tropic (X4) HIV-1; however, when combined with a CXCR4 antagonist AMD-3100, E913 potently and synergistically inhibited the replication of dualtropic HIV-1 and a 50:50 mixture of R5 and X4 HIV-1. Antagonism in anti-HIV-1 activity was not seen when E913 was combined with the reverse transcriptase inhibitor zidovudine or protease inhibitors. E913 proved to compete with the binding of antibodies to CCR5 which recognize the C-terminal half of the second extracellular loop (ECL2B) of CCR5. E913 and its analogs are acid-resistant and orally bioavailable in rodents. These data warrant that spirodiketopiperazine derivatives be further developed as potential therapeutics for HIV-1 infection.	Kumamoto Univ, Sch Med, Dept Internal Med 2, Kumamoto 8600811, Japan; Ono Pharmaceut Co Ltd, Minase Res Inst, Dept Med Chem, Osaka 6188585, Japan; Ono Pharmaceut Co Ltd, Minase Res Inst, Exploratory Res Labs, Osaka 6188585, Japan; NCI, Expt Retrovirol Sect, Med Branch, NIH, Bethesda, MD 20892 USA	Kumamoto University; Ono Pharmaceutical Co Ltd; Ono Pharmaceutical Co Ltd; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mitsuya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Internal Med 2, 1-1-1 Honjo, Kumamoto 8600811, Japan.		Maeda, Kenji/B-7708-2019	Maeda, Kenji/0000-0002-9424-1491				Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668; Este JA, 1999, J VIROL, V73, P5577; Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Floch V, 1998, BBA-BIOMEMBRANES, V1371, P53, DOI 10.1016/S0005-2736(98)00002-9; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GRECO WR, 1995, PHARMACOL REV, V47, P331; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; Kavlick MF, 2001, ANTIRETROVIRAL THERAPY, P279; Kinter A, 1998, P NATL ACAD SCI USA, V95, P11880, DOI 10.1073/pnas.95.20.11880; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Marechal V, 1999, J VIROL, V73, P3608; Margolis LB, 1998, J CLIN INVEST, V101, P1876, DOI 10.1172/JCI2015; Mitsuya H, 1999, TXB AIDS MED, P751; Moriuchi H, 1998, J EXP MED, V187, P1689, DOI 10.1084/jem.187.10.1689; Mosier DE, 1999, J VIROL, V73, P3544, DOI 10.1128/JVI.73.5.3544-3550.1999; Murai M, 1999, J CLIN INVEST, V104, P49, DOI 10.1172/JCI6642; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; PRICHARD MN, 1993, ANTIMICROB AGENTS CH, V37, P540, DOI 10.1128/AAC.37.3.540; Rusconi S, 2000, J VIROL, V74, P9328, DOI 10.1128/JVI.74.19.9328-9332.2000; Sakai A, 1999, Kansenshogaku Zasshi, V73, P205; Salazar-Mather TP, 1998, J EXP MED, V187, P1, DOI 10.1084/jem.187.1.1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schols D, 1997, J VIROL, V71, P7300, DOI 10.1128/JVI.71.10.7300-7304.1997; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; Singh A, 2000, J VIROL, V74, P10229, DOI 10.1128/JVI.74.21.10229-10235.2000; Tanaka M, 1997, ANTIMICROB AGENTS CH, V41, P1313, DOI 10.1128/AAC.41.6.1313; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; Uchida H, 1997, ANTIVIR RES, V36, P107, DOI 10.1016/S0166-3542(97)00047-8; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; WOITAS RP, 2001, 8 C RETR OPP INF CHI; Yoshimura K, 1999, P NATL ACAD SCI USA, V96, P8675, DOI 10.1073/pnas.96.15.8675; Zhou YH, 1998, J IMMUNOL, V160, P4018	44	124	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35194	35200		10.1074/jbc.M105670200	http://dx.doi.org/10.1074/jbc.M105670200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11454872	hybrid			2022-12-25	WOS:000171024600110
J	Maney, T; Wagenbach, M; Wordeman, L				Maney, T; Wagenbach, M; Wordeman, L			Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR PROTEIN; DOMAIN; DIRECTION; MOVEMENT; DYNAMICS; MITOSIS; XKCM1; NECK; NCD; ATP	Mitotic centromere-associated kinesin (MCAK) is a microtubule depolymerizer that is consistent with its role in promoting chromosome segregation during mitosis. Here we show that the conserved motor domain of MCAK is necessary but not sufficient for microtubule depolymerization in cells or in vitro. The addition of only 30 amino acids N-terminal to the motor restores depolymerization activity. Furthermore, dimerization studies revealed that the smallest functional MCAK deletion constructs are monomers. These results define a highly conserved domain within MCAK and related (KIN I) kinesins that is critical for depolymerization activity and show that this depolymerization is not dependent on MCAK dimerization.	Univ Washington, Sch Med, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wordeman, L (corresponding author), Univ Washington, Sch Med, Dept Physiol & Biophys, Seattle, WA 98195 USA.			Wordeman, Linda/0000-0002-9444-0650	NIGMS NIH HHS [GM53654A] Funding Source: Medline; PHS HHS [T326M07270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Coy DL, 1999, J BIOL CHEM, V274, P3667, DOI 10.1074/jbc.274.6.3667; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Endow SA, 2000, NATURE, V406, P913, DOI 10.1038/35022617; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Jordan MA, 1996, CANCER RES, V56, P816; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Thormahlen M, 1998, J STRUCT BIOL, V122, P30, DOI 10.1006/jsbi.1998.3986; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Watts NR, 2000, J CELL BIOL, V150, P349, DOI 10.1083/jcb.150.2.349; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; Wordeman L, 1999, CELL BIOL INT, V23, P275, DOI 10.1006/cbir.1999.0359	21	120	126	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34753	34758		10.1074/jbc.M106626200	http://dx.doi.org/10.1074/jbc.M106626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11466324	hybrid			2022-12-25	WOS:000171024600056
J	Spencer, J; Clarke, AR; Walsh, TR				Spencer, J; Clarke, AR; Walsh, TR			Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; XANTHOMONAS-MALTOPHILIA; AEROMONAS-HYDROPHILA; SEQUENCE-ANALYSIS; INHIBITORS; CATALYSIS; SCHEME; POTENT; CCRA	Stopped-flow tryptophan fluorescence under single turnover and pseudo-first-order conditions has been used to investigate the kinetic mechanism of beta -lactam hydrolysis by the Stenotrophomonas maltophilia L1 metallo-beta -lactamase. For the cephalosporin substrates nitrocefin and cefaclor and the carbapenem meropenem, a substantial quench of fluorescence is observed on association of substrate with enzyme. We have assigned this to a rearrangement event subsequent to formation of an initial collision complex. For the colorimetric compound nitrocefin, decay of this dark intermediate represents the overall rate-determining step for the reaction and is equivalent to decay of a previously observed state in which the beta -lactam amide bond has already been cleaved. For both cefaclor and meropenem, the rate-determining step for hydrolysis is loss of a second, less quenched state, in which, however, the beta -lactam amide bond remains intact. We suggest, therefore, that the mechanism of hydrolysis of nitrocefin by binuclear metallo-beta -lactamases may be atypical and that cleavage of the-lactam amide bond is the rate-determining step for breakdown of the majority of beta -lactam substrates by the L1 enzyme.	Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol	Spencer, J (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Univ Walk, Bristol BS8 1TD, Avon, England.	Jim.Spencer@bristol.ac.uk	Walsh, Timothy R/F-6519-2010	Walsh, Timothy/0000-0003-4315-4096				AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; BICKNELL R, 1986, BIOCHEMISTRY-US, V25, P7208, DOI 10.1021/bi00370a066; BICKNELL R, 1985, BIOCHEMISTRY-US, V24, P6876, DOI 10.1021/bi00345a021; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; CURTIS AR, 1985, 1171 HMSO AERER; Fast W, 2001, BIOCHEMISTRY-US, V40, P1640, DOI 10.1021/bi001860v; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P192, DOI 10.1128/AAC.39.1.192; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Hirakata Y, 1998, ANTIMICROB AGENTS CH, V42, P2006, DOI 10.1128/AAC.42.8.2006; Huntley JJA, 2000, BIOCHEMISTRY-US, V39, P13356, DOI 10.1021/bi001210r; ITO H, 1995, ANTIMICROB AGENTS CH, V39, P824, DOI 10.1128/AAC.39.4.824; LEATHERBARROW RJ, 1994, GRAFIT VERSION 3 0; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; Quinn JP, 1998, CLIN INFECT DIS, V27, pS117, DOI 10.1086/514912; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; VARTIVARIAN S, 1994, ANTIMICROB AGENTS CH, V38, P624, DOI 10.1128/AAC.38.3.624; WALSH TR, 1994, BBA-GENE STRUCT EXPR, V1218, P199, DOI 10.1016/0167-4781(94)90011-6; Walsh TR, 1997, ANTIMICROB AGENTS CH, V41, P1460, DOI 10.1128/AAC.41.7.1460; Walter MW, 1996, BIOORG MED CHEM LETT, V6, P2455, DOI 10.1016/0960-894X(96)00453-2; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524; Yang YJ, 1999, J BIOL CHEM, V274, P15706, DOI 10.1074/jbc.274.22.15706	42	84	88	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33638	33644		10.1074/jbc.M105550200	http://dx.doi.org/10.1074/jbc.M105550200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11443136	hybrid			2022-12-25	WOS:000170910200048
J	Arai, A; Kanda, E; Nosaka, Y; Miyasaka, N; Miura, O				Arai, A; Kanda, E; Nosaka, Y; Miyasaka, N; Miura, O			CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEIN; CELL-LINE; KINASE; ASSOCIATION; ACTIVATION; BINDING; SHIP	The erythropoietin (Epo) receptor transduces its signals by activating physically associated tyrosine kinases, mainly Jak2 and Lyn, and thereby inducing tyrosine phosphorylation of various substrates including the Epo receptor (EpoR) itself. We previously demonstrated that, in Epo-stimulated cells, an adapter protein, CrkL, becomes tyrosine-phosphorylated, physically associates with Shc, SHP-2, and Cb1, and plays a role in activation of the Ras/Erk signaling pathway. Here, we demonstrate that Epo induces binding of CrkL to the tyrosine-phosphorylated EpoR and SHIP1 in 32D/EpoR-Wt cells overexpressing CrkL. In vitro binding studies showed that the CrkL SH2 domain directly mediates the EpoR binding, which was specifically inhibited by a synthetic phosphopeptide corresponding to the amino acid sequences at Tyr(460) in the cytoplasmic domain of EpoR. The CrkL SH2 domain was also required for tyrosine phosphorylation of CrkL in Epo-stimulated cells. Overexpression of Lyn induced constitutive phosphorylation of CrkL and activation of Erk, whereas that of a Lyn mutant lacking the tyrosine kinase domain attenuated the Epo-induced phosphorylation of CrkL and activation of Erk. Furthermore, Lyn, but not Jak2, phosphorylated CrkL on tyrosine in in vitro kinase assays. Together, the present study suggests that, upon Epo stimulation, CrkL is recruited to the EpoR through interaction between the CrkL SH2 domain and phosphorylated Tyr(460) in the EpoR cytoplasmic domain and undergoes tyrosine phosphorylation by receptor-associated Lyn to activate the downstream signaling pathway leading to the activation of Erk and Elk-1.	Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 113, Japan; Tokyo Med & Dent Univ, Dept Bioregulatory Med & Rheumatol, Bunkyo Ku, Tokyo 113, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.	miura.med1@med.tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Chin H, 1998, BLOOD, V91, P3734; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; FELLER SM, 1995, ONCOGENE, V10, P1465; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; HERMINE O, 1992, BLOOD, V80, P3060; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KOMATSU N, 1991, CANCER RES, V51, P341; Krystal G, 1999, INT J BIOCHEM CELL B, V31, P1007, DOI 10.1016/S1357-2725(99)00072-2; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Oda A, 1996, BLOOD, V88, P4304; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park RK, 1999, BLOOD, V94, P2112; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TENHOEVE J, 1994, CANCER RES, V54, P2563; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, CANCER RES, V61, P2453; Tilbrook PA, 1999, INT J BIOCHEM CELL B, V31, P1001, DOI 10.1016/S1357-2725(99)00071-0; Uemura N, 1999, ONCOGENE, V18, P3343, DOI 10.1038/sj.onc.1202689; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187	39	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33282	33290		10.1074/jbc.M102924200	http://dx.doi.org/10.1074/jbc.M102924200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11443118	hybrid			2022-12-25	WOS:000170746000115
J	Wiethoff, CM; Smith, JG; Koe, GS; Middaugh, CR				Wiethoff, CM; Smith, JG; Koe, GS; Middaugh, CR			The potential role of proteoglycans in cationic lipid-mediated gene delivery - Studies of the interaction of cationic lipid-DNA complexes with model glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; IN-VITRO; RELEASE; VIRUS; TRANSFECTION; MECHANISM; BINDING	Recent evidence supports a role for proteoglycans in polycation-mediated gene delivery. Therefore, the interaction of glycosaminoglycans with cationic lipid-DNA complexes (CLDCs) has been characterized using a combination of biophysical approaches. At low ionic strength, CLDCs bind to heparin-derivatized Sepharose particles, with the ratio of cationic lipid to DNA controlling the binding. Incorporation of the helper lipids cholesterol or 1,2-dioleoyl-phosphatidylethanolamine increases the amount of bound CLDC. Heparin also induces the aggregation of CLDCs, with cholesterol reducing this effect. Isothermal titration calorimetry demonstrates an endothermic heat for the binding of heparin to CLDCs at low ionic strength, whereas circular dichroism studies suggest a heparin-stimulated release of DNA from CLDCs at a greater than 20-fold charge excess. Increasing the ionic strength to 0.11 reduces CLDC binding to heparin beads, and greatly enhances the release of DNA from CLDCs by heparin. The ability of the cell surface glycosaminoglycan heparan sulfate to release DNA from CLDCs is more sensitive than heparin to the incorporation of the cholesterol or 1,2-dioleoyl-phosphatidylethanolamine. Titration calorimetry reveals an exothermic heat for the interaction glycosaminoglycans with CLDCs at higher ionic strength. These results are consistent with the direct involvement of proteoglycans in transfection.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Valentis Inc, Burlingame, CA 94010 USA	University of Kansas	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.	middaugh@ukans.edu						Belting M, 1999, BIOCHEM J, V342, P281, DOI 10.1042/0264-6021:3420281; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; CHAKRABARTI B, 1980, CRC CR REV BIOCH MOL, V8, P225, DOI 10.3109/10409238009102572; CHU B, 1974, LASER LIGHT SCATTERI, P201; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COTTER MA, 1977, J CHEM PHYS, V66, P1098, DOI 10.1063/1.434044; Dechecchi MC, 2000, VIROLOGY, V268, P382, DOI 10.1006/viro.1999.0171; Edward Conrad H, 1998, HEPARIN BINDING PROT, P7, DOI [10.1016/B978-012186060-8/50003-6, DOI 10.1016/B978-012186060-8/50003-6]; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; Fasbender A, 1997, GENE THER, V4, P716, DOI 10.1038/sj.gt.3300459; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; Hunter RJ, 1993, INTRO MODERN COLLOID; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kennedy MT, 2000, BIOPHYS J, V78, P1620, DOI 10.1016/S0006-3495(00)76714-2; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; LASIC DD, 1997, LIPOSOMES GENE DELIV, P295; LEDLEY FD, 1995, HUM GENE THER, V6, P1129, DOI 10.1089/hum.1995.6.9-1129; Lobo B A, 2001, Methods Mol Med, V65, P319, DOI 10.1385/1-59259-139-6:319; Lobo BA, 2001, ARCH BIOCHEM BIOPHYS, V386, P95, DOI 10.1006/abbi.2000.2196; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; MOHRI H, 1993, ARCH BIOCHEM BIOPHYS, V303, P27, DOI 10.1006/abbi.1993.1251; Mounkes LC, 1998, J BIOL CHEM, V273, P26164, DOI 10.1074/jbc.273.40.26164; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; Ruponen M, 1999, BBA-BIOMEMBRANES, V1415, P331, DOI 10.1016/S0005-2736(98)00199-0; Smith JG, 1998, PHARMACEUT RES, V15, P1356, DOI 10.1023/A:1011937218418; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Trubetskoy VS, 1999, BIOCONJUGATE CHEM, V10, P624, DOI 10.1021/bc9801530; Tseng WC, 1997, J BIOL CHEM, V272, P25641, DOI 10.1074/jbc.272.41.25641; Wong FMP, 1999, ARCH BIOCHEM BIOPHYS, V366, P31, DOI 10.1006/abbi.1999.1201; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; Xu YH, 1999, BIOPHYS J, V77, P341, DOI 10.1016/S0006-3495(99)76894-3; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493; Zelphati O, 1998, BBA-LIPID LIPID MET, V1390, P119, DOI 10.1016/S0005-2760(97)00169-0	36	85	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32806	32813		10.1074/jbc.M007940200	http://dx.doi.org/10.1074/jbc.M007940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11443107	hybrid			2022-12-25	WOS:000170746000059
J	Celiker, MY; Wang, M; Atsidaftos, E; Liu, X; Liu, YE; Jiang, Y; Valderrama, E; Goldberg, ID; Shi, YE				Celiker, MY; Wang, M; Atsidaftos, E; Liu, X; Liu, YE; Jiang, Y; Valderrama, E; Goldberg, ID; Shi, YE			Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA	ONCOGENE			English	Article						TIMP-4; Wilms' tumor; gene therapy; growth inhibition; tumorigenesis	IN-VIVO; PROGELATINASE-A; GENE-TRANSFER; PROMOTING ACTIVITY; STROMAL CELLS; EXPRESSION; CANCER; METASTASIS; OVEREXPRESSION; SUPPRESSION	Extracellular matrix (ECM) degrading matrix metalloproteinases (MMPs) lead to ECM turnover, a key event in cancer growth and progression. The tissue inhibitors of matrix metalloproteinases (TIMPs) Limit the activity of MMPs, which suggests their use for cancer gene therapy. Here we report that systemic administration of naked TIMP-4 DNA significantly inhibited Wilms' tumor growth in nude mice. TIMP-4, whose expression was lost in Wilms' tumor, inhibited the growth of G401 Wilms' tumor tells at a concentration lower than those required for MMP inhibition. This inhibition was associated with internalization of exogenous recombinant TIMP-4, Electroporation-mediated intramuscular injection of TIMP-4 expression plasmid resulted in sustained plasma TIMP-4 levels and significant tumor suppression. Our data demonstrate a tumor suppressive effect of TIMP-4 against Wilms' tumor and the potential utility of intramuscular delivery of TIMP gene for treatment of kidney derived cancers.	Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Schneider Childrens Hosp, Long Isl Jewish Med Ctr, Div Pediat Hematol Oncol, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Med, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Long Isl Jewish Med Ctr, Dept Pathol, New Hyde Park, NY 11040 USA	Northwell Health; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Northwell Health; Northwell Health; Northwell Health	Shi, YE (corresponding author), Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, New Hyde Park, NY 11040 USA.				NCI NIH HHS [CA68064-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; BACCALAO R, 1995, HDB BIOL CONFOCAL MI, P311; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRANCINI G, 1993, CANCER EPIDEM BIOMAR, V2, P125; GARVIN AJ, 1993, AM J PATHOL, V142, P375; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Heppner KJ, 1996, AM J PATHOL, V149, P273; Imren S, 1996, CANCER RES, V56, P2891; Jiang YF, 2001, CANCER RES, V61, P2365; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; Liu YLE, 1997, J BIOL CHEM, V272, P20479, DOI 10.1074/jbc.272.33.20479; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; Nemeth JA, 1996, EXP CELL RES, V224, P110, DOI 10.1006/excr.1996.0117; PYKE C, 1993, AM J PATHOL, V142, P359; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	33	51	60	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4337	4343		10.1038/sj.onc.1204508	http://dx.doi.org/10.1038/sj.onc.1204508			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466614				2022-12-25	WOS:000169912600007
J	Obexer, P; Certa, U; Kofler, R; Helmberg, A				Obexer, P; Certa, U; Kofler, R; Helmberg, A			Expression profiling of glucocorticoid-treated T-ALL cell lines: rapid repression of multiple genes involved in RNA-, protein- and nucleotide synthesis	ONCOGENE			English	Article						chemotherapy; gene chip; glucocorticoid; leukemia; pathophysiology	SPINAL MUSCULAR-ATROPHY; RECEPTOR MESSENGER-RNA; KAPPA-B ACTIVITY; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; FK506-BINDING IMMUNOPHILIN; REGULATED APOPTOSIS; DOWN-REGULATION; COMPLETE CDNA; DNA-BINDING	To arrive at a better understanding of the effects of the glucocorticoid component of chemotherapy protocols on lymphocytic leukemia cells, we analysed early responses of T-lymphocytic leukemia cell lines Jurkat and CEM-C7, both of which undergo apoptosis in response to dexamethasone, via gene chips. Among genes identified as repressed, a notable cluster seemed to be of importance for the processes of transcription, mRNA splicing and protein synthesis. Consequently, we assessed time-resolved uptake of uridine and methionine to monitor RNA and protein synthesis, along with parameters quantifying apoptosis, Repression of uptake to about 65% of that in untreated cells preceded the first sign of apoptosis by several hours in both cell lines, In addition to this general repression of RNA and protein synthesis, several genes were found to be regulated that may contribute to synergistic action of glucocorticoids with other components of frequently used chemotherapy protocols such as antimetabolites, methotrexate and alkylating agents.	Univ Innsbruck, Sch Med, Inst Pathophysiol, A-6020 Innsbruck, Austria; F Hoffmann La Roche & Co Ltd, Roche Genet, CH-4070 Basel, Switzerland	University of Innsbruck; Roche Holding	Helmberg, A (corresponding author), Univ Innsbruck, Sch Med, Inst Pathophysiol, A-6020 Innsbruck, Austria.	arno.helmberg@uibk.ac.at						ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; ANTAKLY T, 1989, CANCER RES, V49, pS2230; ASHRAF J, 1991, J STEROID BIOCHEM, V38, P561, DOI 10.1016/0960-0760(91)90313-T; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baxter J D, 2000, Adv Intern Med, V45, P317; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Chabncr BA, 1996, PHARMACOL BASIS THER, P1233; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; Chen QF, 1998, GENOMICS, V48, P121, DOI 10.1006/geno.1997.5141; CRUZEN ME, 1994, DNA SEQUENCE, V4, P243, DOI 10.3109/10425179409020847; DAYAN A, 1995, GENE, V165, P307, DOI 10.1016/0378-1119(95)00321-V; DENTON RR, 1993, ENDOCRINOLOGY, V133, P248, DOI 10.1210/en.133.1.248; EISEN LP, 1988, J BIOL CHEM, V263, P12044; ELISEI R, 1993, J ENDOCRINOL INVEST, V16, P533, DOI 10.1007/BF03348900; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FOLEY GE, 1967, BIOCHEM PHARMACOL, V16, P659, DOI 10.1016/0006-2952(67)90078-0; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Godowski P.J., 1989, UCLA S MOL CELLULAR, P197; GOMI M, 1990, CANCER RES, V50, P1873; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HELMBERG A, 1990, J IMMUNOL, V145, P4332; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HONORE B, 1995, J BIOL CHEM, V270, P28780; HORTSCH M, 1988, NUCLEIC ACIDS RES, V16, P361, DOI 10.1093/nar/16.1.361; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; HUANG SH, 1994, DNA CELL BIOL, V13, P461, DOI 10.1089/dna.1994.13.461; Iwahana H, 1996, BIOCHEM BIOPH RES CO, V219, P249, DOI 10.1006/bbrc.1996.0213; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Lipsitt DR, 1999, GEN HOSP PSYCHIAT, V21, P1; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MITA K, 1995, GENE, V159, P285, DOI 10.1016/0378-1119(95)00081-G; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Ramdas J, 1999, CANCER RES, V59, P1378; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 1998, MOL CELL ENDOCRINOL, V146, P1, DOI 10.1016/S0303-7207(98)00208-1; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHIMMER BP, 1996, PHARMACOL BASIS THER, P1465; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; SIBLEY CH, 1974, CELL, V2, P213, DOI 10.1016/0092-8674(74)90013-0; SILLEKENS PTG, 1988, NUCLEIC ACIDS RES, V16, P8307, DOI 10.1093/nar/16.17.8307; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; THULASI R, 1993, J BIOL CHEM, V268, P18306; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; TSUI FWL, 1987, NUCLEIC ACIDS RES, V15, P3349, DOI 10.1093/nar/15.8.3349; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; Yoon JB, 1996, MOL CELL BIOL, V16, P1; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	74	47	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4324	4336		10.1038/sj.onc.1204573	http://dx.doi.org/10.1038/sj.onc.1204573			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466613				2022-12-25	WOS:000169912600006
J	Krueger, JS; Keshamouni, VG; Atanaskova, N; Reddy, KB				Krueger, JS; Keshamouni, VG; Atanaskova, N; Reddy, KB			Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion	ONCOGENE			English	Article						MAPK; MEK; cell motility; breast cancer; cell signaling	HUMAN BREAST-CANCER; EPIDERMAL GROWTH-FACTOR; FACTOR SCATTER FACTOR; TYROSINE KINASE; EGF RECEPTOR; SIGNAL-TRANSDUCTION; MIGRATION; EXPRESSION; LINES; RAS	We have shown that ER-negative and invasive human breast cancer cell lines MDA-MB-468 and MDA-MB-231 have constitutively higher mitogen activated protein kinase (ERK1&2/MAPK) when compared to the ER-positive and non-invasive MCF-7 human breast cancer cells. In MCF-7 cells, TGF alpha stimulation induced only transient MAPK activation, leading to a transient increase in cell migration. However, MDA 231 and MDA 468 cells, TCF alpha stimulation induced sustained MAPK activation, which correlated with enhanced cell motility and in vitro invasion, Serum stimulation activates ERK/MAPK activity persistently ire both ER-positive and ER-negative breast cancer cells, leading to enhanced and sustained cell migration. Inhibition of MAPK activation by anti-sense MEK expression in MDA-MB-468 cells significantly inhibits cell migration and in vitro invasion. In contrast, MCF-7 cells expressing constitutively activated MEK show a significant increase in MAPK activity and cell migration, but this failed to enhance in vitro invasion. The kinetic profiles of MAPK activation and inhibition show a relationship between the duration and magnitude of MAPK activation and cell migration in both ER-positive and ER-negative human breast cancer cells. These studies show that cell motility is modulated by the magnitude and the duration of MAPK activation; but increased activation of MAPK may not be sufficient to allow in vitro invasion in noninvasive MCF-7 breast cancer cells.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.			Keshamouni, Venkateshwar/0000-0003-1947-791X	NCI NIH HHS [CA 64248, CA 83964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083964, R29CA064248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Fan W H, 1998, Cell Res, V8, P63; FRIEDL P, 1995, CANCER RES, V55, P4557; Gilhooly EM, 1999, INT J ONCOL, V15, P267; Gopalakrishna R, 1999, CANCER LETT, V136, P143, DOI 10.1016/S0304-3835(98)00315-2; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSKE M, 1994, INT REV CYTOL, V155, P49, DOI 10.1016/S0074-7696(08)62096-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MISHRA S, 1993, BIOCHEM BIOPH RES CO, V191, P1066, DOI 10.1006/bbrc.1993.1325; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; Reddy KB, 1999, INT J ONCOL, V15, P301; Rigot V, 1998, J CELL SCI, V111, P3119; SATO C, 1995, J INVEST DERMATOL, V104, P958, DOI 10.1111/1523-1747.ep12606221; SEGER R, 1995, J BIOL CHEM, V270, P28325; Shao ZM, 1998, ANTICANCER RES, V18, P1435; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slack JK, 1999, J BIOL CHEM, V274, P27177, DOI 10.1074/jbc.274.38.27177; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Xie H, 1998, J CELL SCI, V111, P615; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	41	145	161	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4209	4218		10.1038/sj.onc.1204541	http://dx.doi.org/10.1038/sj.onc.1204541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464287				2022-12-25	WOS:000169857200011
